

A Carcinogenic Potency Database of the Standardized Results of Animal Bioassays

Lois Swirsky Gold,^{*‡} Charles B. Sawyer,^{*} Renae Magaw,^{*} Georganne M. Backman,^{*} Margarita de Veciana,^{*} Robert Levinson,^{*} N. Kim Hooper,[†] William R. Havender,^{*} Leslie Bernstein,[§] Richard Peto^{**}, Malcolm C. Pike[§], and Bruce N. Ames^{†‡}

The preceding paper described our numerical index of carcinogenic potency, the TD₅₀ and the statistical procedures adopted for estimating it from experimental data. This paper presents the Carcinogenic Potency Database, which includes results of about 3000 long-term, chronic experiments of 770 test compounds. Part II is a discussion of the sources of our data, the rationale for the inclusion of particular experiments and particular target sites, and the conventions adopted in summarizing the literature. Part III is a guide to the plot of results presented in Part IV. A number of appendices are provided to facilitate use of the database. The plot includes information about chronic cancer tests in mammals, such as dose and other aspects of experimental protocol, histopathology and tumor incidence, TD₅₀ and its statistical significance, dose response, author's opinion and literature reference. The plot readily permits comparisons of carcinogenic potency and many other aspects of cancer tests; it also provides quantitative information about negative tests. The range of carcinogenic potency is over 10 million-fold.

Part I: Introduction

This paper presents the Carcinogenic Potency Database, which includes data on approximately 3000 long-term, chronic animal experiments with about 770 chemicals. The preceding paper (1) described our numerical index of carcinogenic potency, the TD₅₀, and the statistical procedures adopted for estimating it from experimental data. In a simplified way, TD₅₀ may be defined as follows: for a given target site(s), if there are no tumors in control animals, then TD₅₀ is that chronic dose rate in mg/kg body weight/day which would induce tumors in half the test animals at the end of a standard lifespan for the species. Since the tumor(s) of interest often does occur in control animals, TD₅₀ is more precisely defined as: that dose rate (in mg/kg body

weight/day) which, if administered chronically for the standard lifespan of the species, will halve the probability of remaining tumorless throughout that period. A TD₅₀ can be computed for any particular type of neoplasm, for any particular tissue, or for any combination of these.

Part II of this paper discusses the sources of bioassay results and the rationale for including particular experiments and particular target sites in the database. The conventions adopted in summarizing and standardizing the literature are also described. In Part IV we present a plot of the database. In order for the reader to use this plot most effectively, Part III includes a full description of the contents, variable by variable. Several appendices which define codes and give additional details about particular tests are included after the plot.

Efforts to use animal bioassays in the evaluation of the potential health risks of chemicals to humans have been hampered by the lack of a standardized method to compare experimental results. Experimental protocols as well as the type of information reported in the literature are quite diverse. Moreover, quantitative estimates of carcinogenic potency have not yet been applied to the results of tests on a broad range of chemicals.

Our Carcinogenic Potency Database is an attempt to quantify and standardize the animal bioassay literature

*Biology and Medicine Division, Lawrence Berkeley Laboratory, Berkeley, CA 94720.

†Department of Biochemistry, University of California, Berkeley, CA 94720.

‡Authors to whom correspondence should be addressed, at the Department of Biochemistry, University of California, Berkeley, CA 94720. Copies of this issue are available from the U. S. Government Printing Office.

§Department of Preventive Medicine, University of Southern California School of Medicine, Los Angeles, CA 90033.

**I.C.R.F. Cancer Studies Unit, Nuffield Department of Clinical Medicine, Radcliffe Infirmary, Oxford OX2 6HE, United Kingdom.

and to organize it systematically. It has become clear that the dose levels of different chemicals which induce tumors in rats and mice vary enormously, i.e., some chemicals are observed to be more powerful carcinogens than others. Moreover, the total number of known and suspected carcinogens, both natural and man-made, to which humans are exposed is much larger than previously thought (2). Therefore, quantifying the carcinogenic potency of various chemicals is one important aspect of developing a policy response to the problem of chemical hazards to humans.

Ideally, for human risk assessment and regulatory policy, one would like to have quantitative information about the potency of various chemicals in man, but with rare exceptions this information is not available. The next best source of information is the extensive literature on animal bioassays. Although it is clear that animal models are not a completely satisfactory model for man, it is essential to examine the published animal literature in a more organized and quantitative way.

We would like to emphasize the complexities of animal bioassay results, and to caution that no single number such as the TD_{50} fully describes the data. We have included in the database presented in Part IV, information about a variety of factors which are important in the interpretation of bioassays, such as: the TD_{50} and its statistical significance, the species and strains which have been tested chronically, the route and duration of compound administration, the tumor types, the proportion of animals with specific types of tumors in dosed and control groups, the shape of the dose-response curve and the author's opinion about carcinogenicity.

Future analyses of this database should help to identify similarities and differences in response among strains and species. In addition, quantitative estimates of carcinogenic potency should be useful in determining the extent to which potency in animals is predictable from mutagenic potency calculated from short-term tests.

A word of caution is necessary about the limitations of the database. We have not attempted to evaluate whether or not a compound is a carcinogen; rather, we report the opinions of the authors whose data we present, as well as the statistical significance of the TD_{50} calculated from their results. Moreover, the database contains only long-term tests which fit a set of criteria designed to measure potency, and therefore does not cover all cancer tests or all carcinogens. The limitations and criteria are discussed further in Part II.

Part II: Materials and Methods of the Carcinogenic Potency Database

Sources of Data

One major goal of the Carcinogenic Potency Database has been to obtain data which would give the best estimates of carcinogenic potency, i.e., experiments for

which detailed time-to-tumor data would permit adjustment for the gross effects of intercurrent mortality (see preceding paper). Full lifetable information was available for the calculations of potency from the Carcinogenesis Bioassay Program of the National Cancer Institute (NCI)/National Toxicology Program (NTP) and from a set of bioassays of aromatic amines (3-5). For all other estimates of potency from the published literature, we have calculated TD_{50} using the final proportions of animals with tumors, since only this summary information is consistently published. A description of each of these two sources of data, (1) NCI/NTP Bioassays and (2) bioassays in the published literature, is given below.

NCI/NTP Bioassays. The Carcinogenesis Bioassay Program of the NCI/NTP was designed to use a similar experimental protocol for a large number of compounds, and to report results in a consistent format including full histopathology. We obtained computer tapes containing the individual animal pathology tables from the Chemical Package Report of the Carcinogenesis Bioassay Data System (6) for which Technical Reports were published prior to July 1980. These tapes contain information about the time of death (in weeks) and full histopathology for each animal in each experiment. By using the tapes in combination with the series of technical reports (Appendix 15) published by NCI/NTP we have been able to estimate a TD_{50} for each site which was evaluated as treatment-related, as well as for each site found to be statistically significant but not considered evidence for carcinogenicity, in the text of the technical report.

The Carcinogenesis Bioassay Program protocol recommends that tests be conducted in two species of rodents (rats and mice) with both sexes tested individually at the maximally tolerated dose and half that dose, and includes a control group (vehicle control where appropriate) (7). The actual conduct of the bioassays published prior to July 1980 varied from one experiment to another, and details about each are given in the plot in Part IV. (An experiment is defined here as the dose groups and control group for one sex in one species from a single research report.) Comparisons of results from the 776 NCI/NTP experiments are particularly useful for the following reasons: our analyses utilized full lifetable data; each compound was usually tested in both sexes of rats and mice; the same mouse hybrid, B6C3F1, was used throughout; the rat bioassays utilized mostly the Fischer F344 strain, and less frequently either the Osborne-Mendel or Sprague-Dawley stocks; test agents were usually administered by an oral route, and dosing continued for the majority of the animals' lives (18-24 months); and terminal sacrifice was usually performed after 21 to 25 months on test. For many of the reports, the quality of the pathology was monitored by a detailed review system (8). For the others, target sites were always selectively reviewed to verify the conclusions in the Report.

Bioassays in the Published Literature. In the literature at large, experimental designs as well as the

authors' choice of information to report, are quite diverse. For the Carcinogenic Potency Database, we have developed a set of standard criteria, and experiments from the literature have been included only if they meet all of the following conditions: (A) animals on test were mammals; (B) administration was begun early in life (100 days of age or less for rats, mice and hamsters); (C) route of administration was diet, water, gavage, inhalation, intravenous or intraperitoneal injection (i.e., where the whole body was more likely to have been exposed rather than only a specific site, as with subcutaneous injection or skin painting); (D) test agent was administered alone, rather than in combination with other chemicals; (E) exposure was chronic, with not more than 7 days between administrations; (F) duration of exposure was at least one-fourth the standard lifespan for that species; (G) duration of experiment was at least half the standard lifespan for that species; (H) research design included a control group; (I) research design included at least 5 animals per group; (J) surgical intervention was not performed; (K) pathology data were reported for the number of animals with tumors rather than the total number of tumors; (L) results reported were original data, rather than secondary analyses of experiments already reported by other authors.

A search of the published literature through July 1981 was conducted for all bioassays which met the standard criteria, whether or not the authors considered the test agent related to tumor induction. The literature search covered the Public Health Service publication, *Survey of Compounds Which Have Been Tested for Carcinogenic Activity 1948-1973 and 1978* (9). Since the years 1974-1977 and 1979-1981 are not covered by the PHS Survey, a search of the cancer journals which contain most of the bioassay literature was conducted for those years, including *Carcinogenesis Abstracts* and the following journals through July 1981: *British Journal of Cancer*, *Cancer Letters*, *Cancer Research*, *Carcinogenesis*, *Chemosphere*, *Environmental Health Perspectives*, *European Journal of Cancer*, *Food and Cosmetics Toxicology*, *Gann*, *International Journal of Cancer*, *Journal of Cancer Research and Clinical Oncology* (formerly *Zeitschrift für Krebsforschung und Klinische Onkologie*), *Journal of Environmental Pathology and Toxicology*, *Journal of Toxicology and Environmental Health*, *Journal of the National Cancer Institute*, and *Toxicology and Applied Pharmacology*. The monographs on chemical carcinogens prepared by the International Agency for Research on Cancer (1972-1981) and *Current Contents* (1976-1981) were also used.

From the literature search, more than 2000 experiments on approximately 600 chemicals met the inclusion criteria and are in the database. Most experiments used rats or mice, many used hamsters, and a small number used dogs, monkeys, tree shrews or bush babies. For any single chemical, the number of experiments in the database may vary. For example, some chemicals may

have only one test in one sex of one species, while others may have multiple tests including both sexes of a few strains of rats and mice, utilizing different protocols. Similarly, the number of TD_{50} values reported for an experiment may vary, depending upon the results of the test and what the author reported.

Because we have adhered quite strictly to the standard inclusion criteria and the publication date of July 1981, a number of well-known carcinogens are not in the database. There are no single injection or skin painting tests, and no experiments on initiation-promotion. Bioassays of particulate or fibrous matters are not included, e.g., asbestos, cigarette smoke and dusts. For a few carcinogens, the only tests which met the inclusion rules were negative, and therefore no positive results are given in the plot*.

Although we have excluded mixtures of chemicals from the database, some commercial preparations such as pesticides and drugs to which humans are frequently exposed have been included. A few exceptions have been made about the cutoff date of July 1981, either because partial results were published before that date or because the data were relevant for our own analyses already in progress.

For the relatively small literature on the long-lived nonhuman primates, we have relaxed some of our standard rules in order to include the maximum number of experiments (see Appendix 13).

Selection of Tissue and Tumor Types for Calculation of Carcinogenic Potency

In order to standardize the very diverse bioassay literature, a great many decisions have had to be made in the construction of the database. Such decisions were based on two major considerations: to provide the most accurate estimates of TD_{50} and to provide a large resource with comparable data to facilitate the analysis of the results of animal cancer tests.

Our choice of which sites and pathology to report from the published literature is limited by what individual authors have reported, and this varied considerably from paper to paper. The precision of pathology analyses has increased over the years, and nomenclature has changed, thus creating further differences in the literature.

For reasons of both accuracy and consistency throughout the database, our general approach has been to calculate a TD_{50} for each category of neoplasm, benign or malignant, which an author evaluated as treatment-related, regardless of the statistical or biological basis for the evaluation. (Hyperplasia and non-neoplastic

*For seven chemicals evaluated as having sufficient evidence for carcinogenicity by IARC, only negative tests met the inclusion rules: cadmium chloride, cadmium sulfate, epichlorohydrin, glycidaldehyde, isosafrole, mestranol, 2-nitropropane (10). These are flagged in the plot of the database with a double asterisk (**) after the chemical name.

lesions are not included in the database.) In addition, a TD_{50} has been estimated for the category "all tumor-bearing animals" (TBA) wherever this was reported.

In order to provide information which would permit comparisons of target sites across experiments, an additional category of histopathology was developed for the database—"mandatory sites." Whenever there is adequate documentation in the published paper or report, a TD_{50} is estimated for tumors of the liver in rats and mice, and for tumors of the lung in mice. These tissues were selected as mandatory because they occurred most often in a frequency count of the positive sites in the NCI/NTP bioassays. From the general literature, whenever possible, we have also taken both the liver and lung as mandatory sites in hamsters, dogs and monkeys.

In summary, for each experiment in the database, a TD_{50} is calculated whenever documentation is adequate for the following categories: (1) each target site evaluated by the author as treatment-related; (2) mandatory sites; (3) all tumor-bearing animals (TBA).

Some special considerations about selection of pathology for the calculation of TD_{50} from each source of data are as follows.

NCI/NTP Bioassays. From the NCI/NTP Technical Reports, TD_{50} values have been calculated for all categories of tissues and tumors listed in the Tables of Analyses of Primary Tumors as positively related to dose. (See description of statistical tests in Technical Reports.) For our plot we always report a target site when there was a positive evaluation in the text of the report; however, in the absence of a positive evaluation, sites that are reported in the statistical tables but that are not considered treatment-related, are included only if the TD_{50} itself is significant at the $p < 0.05$ level (two-tailed p -value for the test that the slope of the dose response is different from zero). We refer to these cases as "statistical sites" to indicate that the report did not evaluate them as evidence for carcinogenicity.[†]

Because the computer tapes from the Individual Animal Pathology Tables of the NCI/NTP contain individual pathology results, it has been possible to calculate a TD_{50} for a composite category of all tumors which the report evaluated as associated with administration of the test compound. For purposes of risk assessment this seems prudent, despite the bias which this can, in principle, cause. It has not been possible to formulate such a composite category for other experiments in the database.

[†]In a few cases, a compound was evaluated in the Technical Report as negative in rats and mice of both sexes, yet the statistical significance associated with a TD_{50} "statistical site" is $p < 0.01$. For these cases which raise questions about the evaluation of the compound, we have forwarded our findings to the NTP. For the NCI bioassay of Kepone, the Technical Report's positive evaluation of hepatocellular carcinomas in male and female rats was based on pooled controls. No TD_{50} values were calculated for these sites however, because the lifetable data for the pooled controls were not available. Therefore, on the plot the negative opinion for male and female rats reflects only the evaluation for matched controls.

In the NCI/NTP data, for each mandatory site, a TD_{50} is estimated for a specific combination of tumors. These were selected because they are the common histopathology reported for the specified tissue by the NCI/NTP. For the liver, neoplastic nodule, hepatocellular adenoma, and hepatocellular carcinoma are combined in the mandatory TD_{50} . For the lung, alveolar/bronchiolar adenoma and alveolar/bronchiolar carcinoma are combined. In all cases, the incidence represents the proportion of animals with any of the tumors; animals with multiple tumors of the given tissue are counted only once. For the category TBA, we have excluded interstitial-cell tumors of the testis for Fischer 344 rats, since these tumors occur spontaneously in nearly all male animals by the end of their standard lifespan.

Bioassays in the Published Literature. Authors of papers published in the general literature rarely indicate which animals were diagnosed as having more than one tumor. Therefore, it has been generally impossible for us to combine data on various tumors within a single tissue, or to specify particular tumor types which should be included in mandatory sites. To attempt to combine incidence data would risk multiple counting of animals.

For the mandatory sites from the published literature, a TD_{50} is estimated for individual tumor types reported in the mandatory tissue, as well as for any combination of tumors which is reported or could be created for that tissue without risking multiple counting.

In the interest of completeness, we have added to the database results for tissues and tumors in the literature which the authors did not consider treatment-related, but which we calculate as statistically significant (standard chi-square test, one-sided $p < 0.05$).

Throughout the database, when we report results separately for benign and malignant tumors at a given site in a single experiment, we often do not know whether the author counted animals only for the most malignant tumor. For example, we may not know whether the proportion of animals with adenomas represents only those animals which did not have carcinomas.

Estimation of Average Daily Dose Level

Because a variety of routes of administration, dosing schedules, species, strains, and sexes are used in carcinogenesis bioassays, some standardization of dose is required for a single index of potency. Our convention in estimating TD_{50} is to determine for each dose group in an experiment the daily dose rate (in mg/kg of body weight) averaged over the duration of the experiment. It may be that a different measure of dose (such as mg/cm² surface area) will prove to be most similar across species (11).

To convert parts per million (ppm) or percent in the food, water or air, into milligrams per kilo body weight during the dosing period, we assume 100% absorption and then use a set of standard values for each sex of

each species, including body weight and average intake per day (Table 1). Using standard values, the daily dose rate is calculated as follows:

$$\text{Dose rate} = \frac{\text{dose} \times \text{intake/day} \times \text{number of doses/week}}{\text{animal weight} \times 7 \text{ days/week}}$$

or, equivalently,

$$\text{Dose rate} = \text{dose} \times \text{intake/day as a proportion of body weight} \times \text{proportion of week dose is administered}$$

In an experiment where the animals were dosed the entire time on test this value would equal the average daily dose level. For example, in a bioassay of male mice fed 50 ppm of some test agent in the diet for the entire time on test, the calculation would be:

$$\begin{aligned} \text{Dose rate} &= 50 \text{ ppm} \times 0.12 \times 1 \\ &= 6 \text{ mg/kg body weight/day} \end{aligned}$$

In this example, the exposure time is equal to the experiment time.

In using standard values we recognize that there is no single factor which precisely reflects the entire experimental literature. For example, strains within a species will vary in weight; younger animals have lower body weight and food intake than adults; some test agents will reduce appetite due to taste; or illness may result in loss of appetite. However, the values used here are

within reasonable limits of those usually found in the published literature and are unlikely to produce substantial error.

In many experiments the administration of the test compound is stopped before the terminal sacrifice or before the death of the last animal. In such cases, averaging the dose over the course of the experiment will lower the daily dose level. By convention we take the total dose administered and spread this over the entire experimental period; thus, for male mice which are dosed at 50 ppm in the feed for 70 weeks and then continued on test to 100 weeks, the dose is considered as equivalent to 35 ppm for the entire 100 weeks, (i.e., 50 ppm \times 70/100), resulting in a 4.2 mg/kg body weight/day average dose. In calculating the dose, we utilize the concept of exposure time (the period of active treatment) and experiment time (the actual time on test). When terminal sacrifice is performed, the experiment time is the length of time from the start of the experiment to sacrifice. When, however, animals are permitted to survive to natural death, we define experiment time by using the time of the death of the last dosed animal.

Extrapolation of TD₅₀ to the Standard Lifespan

TD₅₀ is defined in terms of the dose rate that will halve the probability of remaining tumor-free at the end of a standard lifespan. For each species the assumed value for the standard lifespan is given in Table 1; these values are within reasonable limits usually found in the

Table 1. Standard values for dose calculation: animal lifespans, weights, and intake by diet, water, and inhalation.^a

Experimental animal	Sex	Standard lifespan, yr ^b	Weight kg ^c	Food/day, g ^c	Food as % body weight/day	Water, mL/day ^d	Inhalation volume, L/min ^e
Rodents							
Mouse	Male	2	0.03	3.6	12.00	5	0.03
	Female	2	0.025	3.25	13.00	5	0.03
Rat	Male	2	0.5	20	4.00	25	0.10
	Female	2	0.35	17.5	5.00	20	0.10
Hamster	Male	2	0.125	11.5	9.20	15	0.06
	Female	2	0.110	11.5	10.45	15	0.06
Monkeys							
African green (<i>Cercopithecus aethiops</i>)	Both	20					
Cynomolgus (<i>Macaca fascicularis</i>)	Both	20					
Rhesus (<i>Macaca mulatta</i>)	Both	20					
Prosimians							
Bush babies (<i>Galago crassicaudatus</i>)	Both	10					
Tree shrews (<i>Pupaia glis</i>)	Both	4.5					
Dog	Both	11	16	400	2.50	500	

^a Although values sometimes vary depending on the source, those given here are within reasonable limits of those usually found in the published literature. No value is given when this information was not necessary for our dose calculation.

^b Rat and mouse: data based on NCI trichloroethylene bioassay (12); hamster: data of Williams (13); nonhuman primates: data of S. M. Sieber (Laboratory of Chemical Pharmacology, NCI, National Institute of Health, Bethesda, MD.), personal communication; bush babies: ages adapted from Dittmer (14); tree shrews: data of D. J. Reddy (Northwestern University, Chicago, IL.) personal communication; dog: data of M. S. Redfearn (Division of Animal Resources, University of California, Berkeley, CA.) personal communication.

^c Rat and mouse: data based on NCI trichloroethylene bioassay (12); hamster and dog: data of D. Brooks (University of California, Davis) personal communication.

^d Mouse, rat and dog: data from NIOSH (15); hamster: data from Hoeltge, Inc. (16).

^e Mouse: data of Sanoskij (17); rat: data of Baker et al. (18); hamsters: data of Guyton (19).

published literature. The use of two years as standard for rats and mice reflects both the standard NCI/NTP protocol and values that appear frequently in the literature.

When an experiment is terminated before the standard lifespan, animals are not at risk of developing tumors later in life. Thus the number of tumors found will be reduced, and the TD_{50} will be greater than the true TD_{50} , i.e., the compound will appear to be less potent than it actually is. Because tumor incidence increases markedly with age, our convention has been to adopt as a correction factor f^2 , where f = experiment time/standard lifespan. The basis for selecting f^2 is discussed in the preceding paper (1).

Note that the correction factor f^2 is based on the time the animals are on test, rather than upon age. In an experiment which began when the animals were 6 weeks of age and which terminated when the animals were 100 weeks of age, the experiment time is 94 weeks. Thus, TD_{50} is defined in terms of the dose rate which would be administered throughout life, from birth to death, or the entire standard lifespan.

By omitting from the database any experiments lasting less than half the standard lifespan for that species, the necessity for great extrapolation has been reduced. Few bioassays in any species are continued for much longer than the period we have adopted for a standard lifespan, so the reverse correction is minimal.

Taking the example above of male mice fed some test agent at 50 ppm for 70 weeks and then continued on test for 30 more weeks, the experiment time would be 100 weeks. The standard lifespan for mice is 104 weeks, so the extrapolation factor would be $(100/104)^2$, or 0.92. Further details about the estimation of TD_{50} can be found in the preceding paper (1).

We have made an exception to the experiment-length rule by including in the database bioassays of four compounds in nonhuman primates for which the results were positive in a short time and the standard lifespan is quite long. For these experiments, considerable extrapolation has been required, thus making the estimate of TD_{50} less reliable (see Appendix 13).

Range of Carcinogenic Potency

The TD_{50} values we have estimated according to the rules and conventions just described are presented in Part IV. The plot format provides a systematic means of distinguishing among the carcinogenic potencies of a variety of chemicals. The range of TD_{50} values is more than 10 million-fold.

For male rats, the range of carcinogenic potency is shown in Figure 1, where we present the most potent TD_{50} values for a selected group of compounds which were evaluated as tumorigens in either an NCI/NTP Technical Report or the general literature. In each case, we have indicated the value for the most potent TD_{50} for a target site(s) which was considered positive, and for which the statistical significance of TD_{50} is less than

0.01. At the two extremes are the most potent TD_{50} values for 2,3,7,8-tetrachlorodibenzo-*p*-dioxin (TCDD), $TD_{50} = 101$ ng, and for FD&C Green No. 1, $TD_{50} = 5.98$ g.

It is our intention to present analyses of potency in future publications which will discuss such issues as comparisons of potency across species and strains, and among different bioassays of the same chemical.

Part III: Guide to the Plot of the Carcinogenic Potency Database

The results of our estimates of TD_{50} and the standardization of the bioassay literature are summarized and presented graphically below in the plot of the database. This plot includes information on many aspects of the 2944 experiments it summarizes. The following description of the plot, in conjunction with the appendices, is intended as a guide for the reader to facilitate use of the data. Because so much information is included in the




FIGURE 1. Range of carcinogenic potency in male rats.

output, the reader may find it helpful to go over the description once and to refer back to specific variables when using the plot.

The plot covers two facing pages and is organized alphabetically by chemical name. The left side includes a logarithmic scale of TD₅₀ values on which is plotted the TD₅₀ for the most potent site in each experiment. Experiments are listed under the name of the test agent, and each experiment can be identified by a unique number in the plot.

Figures 2 and 3 show an example from the plot of one experiment on 1,2-dibromoethane from the NCI/NTP bioassays, which will be used to describe the variables included in the plot, the codes and conventions, and the appendices. At the top of the example, as at the top of the plot of the entire database, is a two-line header describing the type of information in each field. The header should be read across using both lines together, first top line "Spe," then bottom line "Sex," then top line "Strain," etc. Each title in the header begins where the data it describes begins, with the exception of "AuOp" and "Brkly Code" which are in the last column on each side. Immediately beneath the header in this example, we have inserted a set of numbers (1)-(28) which will be used in the text to give details of the information in each field; this set of numbers does not appear in the actual output.

(1) The chemical name in capitals is indicated under (1) in the top line for a set of experiments. An alphabetical list of all chemicals in the plot is given in Appendix 1. Common synonyms are also provided which refer the reader to the compound name used in the plot e.g., ethylene dibromide (see 1,2-dibromoethane). A list of the chemicals sorted by Chemical Abstracts Service (CAS) registry number is presented in Appendix 2. Also under the number (1), immediately

below the chemical name, is the unique plot number for each experiment, i.e., one sex of one species from one research report. Since only one experiment is used in this example, it is assigned the number one. In the larger output, each new number indicates a separate experiment. A set of lower case letters—in the example "a" through "f"—identifies each TD₅₀ calculated for that same experiment using a different set of sites and/or histopathology; only the most potent site is plotted on the graph.

(2) The species used in this experiment is indicated in the column headed by "Spe." The letter "M" refers to mice, "R" to rats, "H" to hamsters and "D" to dogs. Other test animals are indicated by an "N" for prosimians and a "P" for monkeys.

(3) The sex is indicated by "f" for female, "m" for male. Occasionally an author will report data only for both sexes together, and in these cases the notecode "b" for both is used.

(4) The strain or stock of animal is reported as a three-letter code under "Strain"; a list of all strain codes and definitions appears in Appendix 3. Strains are coded just as they are referred to in the original publication. No attempt has been made to standardize the strain names; therefore, if different nomenclature is used by two authors who actually tested the same strain, then two different codes are used in the database. For monkeys and prosimians, this column is used for the species code, e.g., "rhe" for rhesus.

(5) The route of administration is indicated in the header line by "Route" and reported as a three-letter code. In the example, "gav" stands for gavage. Other routes are listed in Appendix 4 and use mnemonic codes like "eat" for administration in the diet.

(6,7) The site and histopathology used in the calculation of the TD₅₀ are reported in these columns, and are

Spe Strain Site Xpo+Xpt										TD50	2Tailpvl					
Sex Route Hist Notes										DR	AuOp					
(1)	(2)	(3)	(4)	(5)	(6)	(7)	(8)	(9)	(10)	(11)	(12)	(13)	(14)	(15)	(16)	
1,2-DIBROMOETHANE										100.....1ug.....10.....100.....1mg.....10.....100.....1g.....10						
1	M	f	b6c	gav	MXB	MXB	53w78	sv				3.74mg	*	P<.0005		
a	M	f	b6c	gav	ato	sqc	53w78	sv				4.07mg	*	P<.0005c		
b	M	f	b6c	gav	lun	MXA	53w78	sv				15.4mg	*	P<.04	c	
c	M	f	b6c	gav	lun	a/a	53w78	sv				17.3mg	*	P<.03	c	
d	M	f	b6c	gav	TBA	MXB	53w78	sv				3.52mg	*	P<.0005		
e	M	f	b6c	gav	liv	MXB	53w78	sv				no dre		P=1.		
f	M	f	b6c	gav	lun	MXB	53w78	sv				15.4mg	*	P<.04		

FIGURE 2. Left side of database plot.

RefNum	LoConf	UpConf	Cntrl	1Dose	1Inc	2Dose	2Inc	Citation or Pathology		Brkly Code	
(17)	(18)	(19)	(20)	(21)	(22)	(23)	(24)	(25)	(26)	(27)	(28)
1,2-DIBROMOETHANE (ethylene dibromide, EDB. c00522 is NCI TR# 86; c00523 is NCI/NTP TR# 210) 106-93-4											
1	c00522	2.58mg	6.93mg	0/20	26.0mg	46/50	52.0mg	30/50		lun:a/a,a/c; sto:sqc. C	
a	c00522	2.81mg	8.09mg	0/20	26.0mg	46/50	52.0mg	28/50			
b	c00522	8.06mg	n.s.s.	0/20	26.0mg	11/50	52.0mg	6/50		lun:a/a,a/c.	
c	c00522	8.85mg	n.s.s.	0/20	26.0mg	10/50	52.0mg	6/50			
d	c00522	2.42mg	6.31mg	0/20	26.0mg	47/50	52.0mg	31/50			
e	c00522	n.s.s.	n.s.s.	0/20	26.0mg	1/50	52.0mg	0/50		liv:hpa,hpc,nnd.	
f	c00522	8.06mg	n.s.s.	0/20	26.0mg	11/50	52.0mg	6/50		lun:a/a,a/c.	

FIGURE 3. Right side of database plot.

marked in the header line by "Site" and "Hist." Each is indicated by a three-letter code, and the respective codes and definitions are provided in Appendices 5 and 6. Three-letter codes have been created so that they are similar to the words they represent; for example line 1a reports "sto sqc" which stands for stomach, squamous-cell carcinoma; and line 1c reports "lun a/a" for lung, alveolar/bronchiolar adenoma.

For the NCI/NTP bioassays, the pathology nomenclature is identical to that reported in the Technical Reports and/or on the computer tapes. For the general literature, the nomenclature reflects exactly the terminology employed by the original authors in their published papers. The operational rule has been to retain what is in the published paper and not to reinterpret or rename any diagnostic categories. Thus, when authors use different nomenclature for the same tissue or morphologic type of tumor, two different codes are used in the database. Occasionally it has been necessary to replace an adjective used for a tissue with a noun, e.g., the database uses kidney when renal is used in a paper. Some special considerations about the reporting of site and histopathology information from each source of data are as follows.

NCI/NTP Bioassays. In the 1,2-dibromoethane example (Figs. 2 and 3), certain tissue and tumor codes are given in capital letters; these denote particular mixes of sites or tumor types from the NCI/NTP bioassays; capital letters are not used for other sources of data. When these capitals appear, additional information about the specific pathology is presented on the right side of the plot, where the header line reads "Citation or Pathology" in field (27). These special capitalized codes are used in the plot when the calculation of TD_{50} is based on special mixes of tissue and tumor types from the NCI/NTP bioassays.

1. The mandatory sites are denoted by "MXB" (for "Mix Berkeley") to indicate that the site was created especially for the database and is not based upon the NCI/NTP evaluations in the Technical Reports. For every NCI/NTP experiment, the same sites are given per species: liv MXB (liver mandatory), lun MXB (lung mandatory) and TBA MXB (all tumor-bearing animals) for mice; liv MXB and TBA MXB for rats. For the NCI/NTP bioassays, these mandatory sites are always listed as the last TD_{50} values for the experiment, in the order TBA, liv, and lun. Thus in the example given here, lines 1d, e, and f, report for mice the TBA MXB, liv MXB, and then lun MXB. The specific pathology is given for liv MXB and lun MXB under column (27).

2. "MXA" (for "Mix Author") is used to denote a combination of sites or pathologies which is taken directly from the Technical Report Tables of Analyses of Primary Tumors, and denotes a mix of tissues or tumors created in those tables. In the example, the site and histopathology for line 16, "lun MXA" are listed in column (27). Whenever MXA appears, as in line 1b "lun MXA," the sites and/or histopathology which were combined are listed in column (27).

3. "MXB MXB" denotes that a combination of tissues and tumors has been created for the database, which consists of the aggregate of all sites and histopathology considered to be treatment-related in the NCI/NTP Technical Reports. In the example, in field (27) of line 1, MXB MXB is described as a combination of "lun: a/a, a/c; sto: sqc." (This stands for lung alveolar/bronchiolar adenoma, lung alveolar/bronchiolar carcinoma, and stomach squamous-cell carcinoma.)

Bioassays in the Published Literature. The site and pathology information from the literature experiments is given in the plot for individual tissues and tumors just as it is for the NCI/NTP bioassays. As described earlier, it is usually not possible to combine sites from the published literature because, unlike the data available from the NCI/NTP bioassays, information is seldom reported about multiple tumor incidence in the same animal. When an author does give information about aggregated tissue or tumor types, the code "mix" is used in the plot to denote that the specific sites or tumors are described in the paper. When the tumor types are not specified, the code "tum" is used. Mandatory sites from experiments in the literature are included in the database for the same tissues as the NCI/NTP bioassays. A TD_{50} is calculated for any mix of tumors reported in the mandatory site and for individual tumor types as well;* see, for example, "hydrazine sulfate" for female mice, lines 1434 and 1434a and b in the large plot. All codes are in lower case letters. Whenever an author reported results for all animals with malignant tumors separately from all animals with benign tumors, we have included a TD_{50} for each category of "tba".

(8,9) The exposure and experiment times are indicated in the header line by "Xpo + Xpt." Exposure time is the period over which the test agent is administered; if administration was once a week for 40 weeks, for example, the exposure time is 40 weeks. Experiment time is the total time on test; it is not the age of the animals. It is measured from the start of the experiment to the time of death of the last dosed animal. Within a single experiment, all TD_{50} values have the same exposure time and the same experiment time. Both times are always reported in the same units. When both are less than 100 weeks, exposure and experiment times are reported as "w" for weeks; when greater than this, "m" for months is used. For tests in long-lived experimental animals like dogs and nonhuman primates, "y" for years may also be used. When exposure time and experiment time are equal, then the duration of dosing was for the entire experiment. In Figure 2 lines 1a-1f, the mice were dosed for 53 weeks, and the experiment lasted a total of 78 weeks.

(10) Notes, indicated in the header line in (10), pro-

*If an author reported many individual types of tumors in a mandatory tissue, and all are statistically nonsignificant, we have calculated TD_{50} values for the tumor types with the highest incidence among dosed animals.

vide additional information about the experiment in single-letter codes which are defined in Appendix 7. This supplementary information is helpful in evaluating the experimental data. In the example, for instance, the notecode "s" is used to denote that survival was poor due to toxicity or disease and the notecode "v" that dosing was variable or irregular, e.g., dose level changed during the course of the experiment.

(11) The logarithmic scale is used for presenting the values of TD_{50} and its confidence limits (in units/kilogram body weight/day). The plot extends from 100 nanograms to 10 grams. On the scale itself, the location of 100 ng, 1 μ g, 10 μ g, etc., is indicated by under-scoring; the points for 5, 50, 500 are denoted by a colon (":"). For each experiment, only the TD_{50} for the "most potent site" is plotted; this TD_{50} is listed first. For other sites within an experiment, the TD_{50} is not plotted, but all other information about it is given in the plot.

The "most potent site" is determined by ordering the TD_{50} values in each experiment by statistical significance. If any TD_{50} values are significant at the $p < 0.01$ level, then these are listed first, in order of potency; then follow all TD_{50} values with $p < 0.10$ sorted in order of potency. Last, all other TD_{50} values are listed in order of potency. We have excluded the category TBA from this sorting of the target sites and have listed it last. For the NCI/NTP bioassays, the mandatory sites are also excluded from this sorted order, and are listed at the end in the order TBA MXB, liv MXB, and lun MXB.

In the example of 1,2-dibromoethane (Fig. 2), there are two TD_{50} values (excluding TBA) with statistical significance of $p < 0.01$. The TD_{50} for MXB MXB is the more potent and thus appears first. The plotted point for this most potent site lies between 1 mg and 10 mg on the scale, and the estimated TD_{50} , 3.74 mg, appears in the column to the right of the scale under the header title " TD_{50} ." These results indicate that 3.74 mg/kg body weight/day would halve the proportion of tumorless survivors at the end of a standard lifespan for mice (in the absence of all other causes of death).

(12) The TD_{50} value on the plot is indicated by one of three symbols: "+" "±" or ">", depending upon the p -value associated with the TD_{50} for the most potent site. In an experiment where the statistical significance of the TD_{50} is $p < 0.01$, the symbol "+" is used, and the plotted point is the most potent estimate of TD_{50} , i.e., the smallest value of TD_{50} from among those with $p < 0.01$. In an experiment where the statistical significance is between 0.01 and 0.10 a "±" symbol is used to plot the most potent site. If there is no evidence for any statistical association, i.e., for all TD_{50} values, $p > 0.10$, then the symbol ">" appears just to the right of the lower confidence limit. For these statistically nonsignificant experiments, the symbol ">" provides a lower bound for TD_{50} , i.e., it is extremely unlikely that TD_{50} could be less than (more potent than) the value plotted.

A special symbol "<+" is used for cases where 100% of all dosed animals had the tumor(s) of interest and the TD_{50} was calculated with summary data; the "<+"

appears at the upper confidence limit. With summary data, only an upper bound, but no TD_{50} , can be estimated in such cases.

Occasionally, the symbol for the most potent TD_{50} is plotted with parentheses around it to indicate that the test did not meet our standard criteria; usually the experiment time was too short. All NCI/NTP bioassays have been included in the database, and some do not meet the criteria. For experiments in nonhuman primates, the criteria have been relaxed. (See Appendix 13.) For an example of such a case, see C.I. Direct Brown 95 for female rats, line 404 in the large plot.

The plot symbol is a convenient way to determine quickly the number of experiments reported for any particular test agent, since each experiment will have one symbol for its most potent TD_{50} .

Since there are both statistical and nonstatistical uncertainties in the estimation of TD_{50} , we have calculated 99% confidence intervals for it. A discussion is given in the preceding paper (1). Whenever the TD_{50} calculation is based on lifetable data, as in the NCI/NTP bioassays and a set of experiments on aromatic amines, the symbol ":" denotes the confidence limits. When the TD_{50} calculation is based on summary data, then the symbol "." denotes the confidence limits.

In an experiment where the statistical significance of TD_{50} is $p < 0.01$, both the lower and upper confidence limits are plotted. The calculated values for these intervals are presented on the right side of the plot in columns (20) and (21) (Fig. 3), where the header line reads "LoConf" and "UpConf" for lower confidence and upper confidence limits. In the example, the plotted confidence interval is 2.58–6.93 mg (Fig. 3), suggesting that the lower value would not reduce the proportion of tumorless survivors by half, while 5.55 mg/kg body weight/day would more than halve it.

In an experiment where the statistical significance of TD_{50} is $p > 0.01$, the confidence interval will be open at the upper end. In such a case, the lower limit dose rate would be unlikely to halve the proportion of tumor-free survivors, but no statement can be made about the carcinogenic effect of higher doses. In such cases, there is no ":" or "." to the right of the TD_{50} on the plot.

When the plotted symbol is "<+" because 100% of the animals had tumors and we estimated TD_{50} with summary data, the "<+" appears at the upper confidence limit. In such cases, the upper limit dose rate would induce tumors in all animals and the rate which would reduce the proportion of tumorless survivors by half cannot be estimated with only summary information.

Occasionally, for a TD_{50} with statistical significance $p < 0.01$, the upper confidence limit is too large to be printed within the range up to 10 grams; in such rare instances the symbol for the upper confidence level also will not appear, although the value will be printed in the field headed UpConf (21).

(13) The value of each TD_{50} is presented just to the right of the plot range (13) and includes the appropriate

units (per kg) of body weight per day. The symbol "no TD₅₀" appears instead of a numerical value whenever 100% of the dosed animals had the tumor(s) of interest and the TD₅₀ was calculated with summary data. The symbol "no dre," for no dose-related effect, indicates that TD₅₀ is not estimable for some other reason. For statistically non-significant TD₅₀ values the numerical value may be impossibly large.

(14) The shape of the dose-response curve for each TD₅₀ appears in column (14) under the header "DR." The codes and definitions for the curvatures are listed in Appendix 8. The shape of the dose-response has been determined by a test for departure from linearity. If there was no significant departure from a linear dose response, then the curve shape is listed as linear, and the asterisk symbol "*" appears. For experiments with three groups of animals including controls, a significant departure from linearity with upward curvature is denoted by a bar slanting to the right (the symbol "/"). If there was a significant departure from linearity with downward curvature, then the TD₅₀ is calculated without the data from the highest dose group, and a bar slanting to the left (the symbol "\") appears. We have adopted this convention to obtain the best estimate of TD₅₀ by using only the linear portion of the dose-response curve in the calculation.

When there are more than three dose groups (including controls) in the TD₅₀ calculation and there is a significant departure from linearity, the symbol "Z" is listed in column (14). When there is a blank space for the shape of the dose-response, there are two possible reasons. First, there may be only one dose group and a control group in the experiment, in which case there is not enough information to determine a curve shape. Most tests in the general literature have only a control and one dose group. Second, there may be no dose-related effect, in which case the code "no dre" appears in column (13) and "P = 1." appears in column (15).

(15) The two-tailed *p*-value appears in column (15), under the header "2Tailpvl." This value indicates the statistical significance associated with testing whether the slope of the dose-response curve is different from zero. All values are given to one significant figure. When there is no dose-related effect or the slope is negative, then "P = 1." appears in column (15). Due to rounding, the lowest *p*-value reported is $p < 0.0005$; a calculated *p*-value which is > 0.0005 and < 0.001 is reported as $p < 0.001$. Note that the significance level listed in this column determines which symbol will be plotted for the most potent site in each experiment.

(16) The opinion of the original author, as to the tumorigenicity of the test agent at the site for which the TD₅₀ was calculated, is given in the last column on the left side of the plot (16) under the heading "AuOp" for author's opinion. Our rule for reporting opinions from all sources of data has been to record all clearly stated evaluations of tumorigenicity at the site(s) included in a TD₅₀ calculation. Some special considerations about our codes for the opinions of authors from various sources are as follows.

NCI/NTP Bioassays. Our conventions for coding the author's opinions from the NCI/NTP Technical Reports are based upon the text of the Report, including the evaluation of the Clearinghouse on Environmental Carcinogens (Data Evaluation/Risk Assessment Subgroup), and the Tables of Analyses of Primary Tumors. An author's opinion is listed for all target sites except: Berkeley Mixes (MXB) and the statistical sites, i.e., those included in the Tables of Analyses but not considered evidence for carcinogenicity in the text of the Technical Report. For these cases, the opinion column is blank, as in lines 1, 1d, 1e, and 1f of the 1,2-dibromoethane example (Fig. 2).

A "c" in the author's opinion column indicates that the Clearinghouse evaluation or the text of the Report stated that at the site(s) on which TD₅₀ is based, the compound was carcinogenic under the conditions of the bioassay. See for example, the opinion column in the example for lines 1a, 1b, and 1c. An "a" indicates an opinion that the incidence of tumors at that site(s) was associated with administration of the compound under the conditions of the bioassay, or that the evidence for carcinogenicity was suggestive.

The symbol "-" will appear in the opinion column for the most potent site in an NCI/NTP bioassay to denote the evaluation that the compound was not carcinogenic in that sex of that species under the conditions of the bioassay. In most cases, the "-" appears for the TD₅₀ calculated for TBA, which is our convention whenever there is no evidence for carcinogenicity. For experiments evaluated as inadequate in the Technical Report, the opinion column is always blank. For a list of experiments evaluated as inadequate, see Appendix 12.

There are some cases when the "-" appears for a statistical site, i.e., one not evaluated as evidence for carcinogenicity in the Report, but which was statistically significant according to the Tables of Analyses of Primary Tumors and also had a TD₅₀ significance level of $p < 0.05$. When this TD₅₀ is the only evidence for a treatment-related effect, and thus the most potent site, we have indicated this by placing a "-" in the opinion column and flagging the TD₅₀ with a # sign in the plot just to the left of the TD₅₀ value. For example, refer to "calcium cyanamide," for female mice, line 697 in the large graphic output. Note that the *p*-value associated with the TD₅₀ determines the symbol plotted for the TD₅₀; this is independent of the author's opinion.

For bioassays in which some target sites were evaluated as treatment-related, the statistical sites are also reported but the opinion column is left blank. In order to make it clear that the Report itself did not contain positive evaluations of any statistical sites, we put an "S" for statistical in the last column on the right side of the plot, column (28), under the header "Brkly Code."*

*For some chemicals, the NCI/NTP Technical Report indicated that experiments in one or more sex-species groups were inadequate carcinogenesis bioassays, primarily based on the insufficient survival of the animals on test. We have indicated this opinion by placing an asterisk (**) after the chemical name on the left side of the plot. See Appendix 12 for a list of the particular sex-species groups.

Bioassays in the Published Literature. In the general literature whenever the author evaluated the proportion of animals with tumors at a particular site as treatment-related, a "+" will appear in the opinion column (16) for the TD_{50} calculated for that site. Such stated opinions as "positive," "carcinogenic," "active," and "tumorigenic," fit this category. The symbol "+" will only appear in the opinion column for a TD_{50} in one of the following two cases: either, the author gave a positive opinion for the particular target sites included in the TD_{50} , or in the occasional case where an author evaluated the compound as carcinogenic without specifying the target site, and we have indicated this with a "+" symbol in the opinion column for the category "all tumor bearing animals (tba)."

Similarly, the opinion column will contain a "-" only when either the author stated an opinion that the particular sites included in the TD_{50} are negative, or the author concluded that there was no treatment-related effect in the experiment, in which case all sites reported for the experiment have a "-" in the opinion column.

Target sites which an author did not evaluate as positive are included in the database only when the statistical significance associated with an increased percentage of dosed animals with tumors is $p < 0.05$ (standard chi-square test, one-sided p -value), or when the tissue is a mandatory site (liver and lung for mice and hamsters; liver for rats).

When no opinion about carcinogenicity is stated for sites which are nevertheless used for TD_{50} calculations, the author's opinion column is left blank. This may occur either for mandatory sites, or for included sites which were not unequivocally evaluated by the author. In those rare cases where the author provided enough information to permit the combining of tissues and tumors into a mandatory site, the author's opinion column is also blank, since the mix was created especially for the database.

In summary, the symbol for the author's opinion column in the general literature reflects what the author actually stated in the paper. Sites evaluated as positive are given a "+". Sites evaluated as negative are given a "-". A "+" is used for tba when the compound was evaluated as positive, and no specific target site was evaluated as positive. For all other opinions the author's opinion column is blank.

Occasionally, when there is a "c" or an "a" in the opinion column for an NCI/NTP bioassay, or a "+" for a test from the general literature, the positive evaluation was made because the incidence among dosed animals was high in comparison to historical control incidences; this occurs, for example, when there is a rare tumor among the dosed animals. The actual numbers of animals bearing such tumors may be quite low, thus making the estimate of TD_{50} unreliable. In such cases, we have indicated that the author's opinion was based on historical control comparisons by putting the words "+ historical" in the TD_{50} column. See, for example, "allyl chloride" for female mice, line 152 in the large plot.

(17,18) The plot continues on the right side (Fig.3), by first repeating the identification numbers given for each line on the left side of the output, e.g., 1, 1a, 1b, etc. In field (17) the chemical name is also repeated, followed by common synonyms, in some cases. In the example, "ethylene dibromide" and "EDB" are given as synonyms for 1,2-dibromoethane. The Chemical Abstracts Service registry number (CAS#) is reported in field (18); in the example, 106-93-4 (Fig.3).

(19) Under the header "RefNum", is the unique reference number assigned to each paper in the database. For NCI/NTP bioassays, this is the number used in the computer tapes; here, c00522. In the case of 1,2-dibromoethane, NCI/NTP conducted two bioassays: in one, the compound was administered by gavage and in the other, by inhalation. In such cases, we have assigned a consecutive number to distinguish the second bioassay and have included the appropriate Technical Report number. NCI/NTP uses a single number for both bioassays.

(20, 21) The lower and upper confidence limits for each TD_{50} are presented in (20) "LoConf" and (21) "UpConf," respectively. When the abbreviation "n.s.s." appears for either the lower or upper confidence limit, it denotes "not statistically significant." Whenever the statistical significance of TD_{50} is $p > 0.01$, then the upper 99% confidence limit will not be calculated; see, for example, line 1f for 1,2-dibromoethane (Fig.3). When the lower confidence limit is "n.s.s." this usually indicates that there were no tumors or only one tumor of the specified type in the experiment, and the lower confidence limit was not estimable; most often this occurs for mandatory sites as in 1e in the 1,2-dibromoethane example. Occasionally the n.s.s. occurs for the lower confidence limit because 100% of dosed animals had the tumor(s) of interest and hence no lower confidence limit could be estimated with summary data.

(22-26) Beginning in (22) on the right side, and extending through (26), we report the proportion of animals with tumors and the average dose level in mg/kg body weight/day which we have calculated for each dose group in the experiment. The proportion of animals with tumors for TD_{50} values which have been calculated with lifetable data are presented here in summary form, i.e., the number of animals with tumors by the end of the experiment.

Reading across (22)-(26), under "Cntrl" (22), we list the proportion of control animals with the tumor types in the TD_{50} calculation; the average dose in the lowest dose group is given under "1Dose" (23); the proportion of animals in that group with the tumor(s) is listed under "1Inc," for incidence, (24); the next highest average dose "2Dose" (25) and the proportion of those animals with the tumor(s) "2Inc" (26) is given next, etc., for as many dose groups as there are in the experiment.

Whenever the TD_{50} was calculated without the data from the high dose group (i.e., there was a significant downward departure from linearity), we have indicated this fact with parentheses around the data which were omitted from the final calculation. Thus, whenever the

shape of the dose-response on the left side of the plot is “\” column (14), the parentheses appear on the right side around the appropriate data. See, for example, 2-aminoanthraquinone for male rats, line 202 in the large plot. Whenever there were more than three groups (including controls), and the dose-response was non-linear, there is a “Z” in column (14) on the left side; if the departure from linearity in such cases was downward, then this fact is indicated by parentheses around the group that was excluded from the TD_{50} calculation.

NCI/NTP Bioassays. For the data on the proportion of animals with tumors, the number of animals in each group is the number at the start of the experiment. In the example, there were 20 in the control group, and 50 in both the low and high dose groups. When pooled controls have been used as evidence for carcinogenicity in the Technical Report, we have calculated TD_{50} values with those controls as well as the matched controls. (This convention has also been followed for the lifetable calculations of the experiments of aromatic amines.) Data using the pooled controls are indicated by the letter “p” following the control incidence in column (22); see, for example, “aldrin” for male mice in the large plot, line 135. The use of pooled controls is also reflected on the left side of the output by the word “pool” following the notes in column (10) and by assigning a different line number to the pooled data.

In the conduct of several of the NCI/NTP bioassays, the dose level administered to the high dose group was sufficiently toxic to necessitate starting a new dose group and a new control group. For some of the bioassays in which this was done, the statistical analysis in the Technical Report was performed separately for the control and dose groups which were started later. For these cases, we compared the proportion of animals with tumors in the earlier and later control groups, and since we found no significant difference, we combined the data from the control groups and analyzed the experiment as one dose response, using both the high and low dose groups. Appendix 10, “NCI/NTP Bioassays with Combined Controls,” lists all such cases.

In some instances, the data for the proportion of animals with tumors is slightly different from what is reported in the Technical Report because the pathology diagnoses were updated after the Report was published; the revised data were on the computer tapes provided to us. These cases are listed in Appendix 11, “NCI/NTP Bioassays with Revised Data.”

Bioassays in the Published Literature. The proportion of animals with tumors presented here reflects exactly the number of animals used in the TD_{50} calculation. Many authors have reported only the starting number of animals. Whenever additional information was given, i.e., number of animals alive at the time of appearance of the first tumor, or number examined histologically, then this number is used in the denominator of the proportion of animals with tumor. This is a more accurate description of the number of animals at risk of tumor. These data were used in the TD_{50} calculation and are reflected in columns (22), (24) and

(26). In these cases, the notecode “e” for “effective number” appears on the left side of the plot under “Notes” in column (10). Otherwise, the data reflect the number of animals started in each group. Since experimental designs vary in the literature, the incidence and dose-rate data may include a control and only one dose group or perhaps, a control and several dose groups.

In the general literature, pooled control data reported by the author are used in TD_{50} calculations only when no matched data were reported. Our conventions for plotting pooled data are the same as those described for the NCI/NTP bioassays.

(27) Reading across the right side of the plot, under “Citation or Pathology” for the NCI/NTP bioassays, we present the three-letter codes for all of the sites and histopathology which are “Author’s Mix” (MXA) or “Berkeley Mix” (MXB). This includes the MXB mandatory liver and lung pathologies, our combinations of sites which were individually evaluated as positive in the Report (MXB), the statistical sites which included more than one site in the Tables of Analyses (MXA), and any combination of sites evaluated as treatment-related in the Technical Report (MXA). The three-letter code for each tissue in the TD_{50} calculation is followed by a “:” and then by the three-letter codes for each category of neoplasm included in the calculation. A “.” follows the last three-letter tumor code in each mix. The definitions for these codes are given in Appendices 5 and 6.

For the published literature, a citation to the paper is provided, giving the first author, code for the journal or book title, volume number, pages, and year. The full titles of the four-letter codes for the names of references are listed in Appendix 9, “Reference Codes and Definitions.” The abbreviation “pers.comm.” indicates that additional data for the TD_{50} calculation were acquired through personal communication with the author(s). On the plot a new citation for a published paper is listed whenever there is a change in paper. When the following experiment is an NCI/NTP bioassay, then codes for pathology appear in field (27) instead of a citation. In Appendices 14 and 15 we have provided a complete bibliography of all papers in the database. Appendix 14 includes the articles, books, and reports in the general literature; Appendix 15 lists the NCI/NTP Technical Reports.

(28) The last column of the plot, is used only for NCI/NTP bioassays. Under the header “Brkly Code,” we indicate that a TD_{50} has been included in the database because of a decision by the Carcinogenic Potency Project (Berkeley) rather than because the sites were evaluated as treatment-related in the NCI/NTP Technical Report.

The letters “C,” “A” and “T” are used in the Berkeley Code column for Berkeley Mixes (MXB). The letter “C” denotes a TD_{50} calculated for all sites evaluated in the Technical Report as evidence for carcinogenicity. (Fig. 3). The letter “A” denotes a combination of tumors evaluated as associated with administration of the compound. The letter “T,” for together, denotes a

combination of all sites evaluated as "C" or "A" in a bioassay where the weaker "associated" opinion and the stronger "carcinogenic" opinion were both reported. The letter "S" indicates that the TD₅₀ has been included in the plot because the sites were statistically significant in the Tables of Analyses of Primary Tumors and the TD₅₀ was significant at the $p < 0.05$ level; however, no positive opinion was provided in the Report. An "S" may appear for either a mix of sites or a single site. For all mandatory sites, the column for "Brkly Code" is blank.

The information in the plot is ordered systematically to facilitate use of the data. All bioassays of a particular chemical are organized under the chemical name, and these names are ordered alphabetically. Within each compound, the bioassays are ordered alphabetically by species code, so that dogs would appear first, then hamsters, mice, prosimians, monkeys, and finally rats. Within a species, the bioassays are ordered by the code for the strain or stock. (For monkeys and prosimians, the tests are ordered by the code for the species.) If there is an NCI/NTP bioassay of the chemical, then all experiments using that strain are reported first, followed by the strain used in any other experiments providing lifetable data, and finally by any remaining strains ordered alphabetically. Within the strain, the bioassays of females are reported first. Thus, when there is an NCI/NTP bioassay, "b6c" mice will appear first, and all experiments using "b6c" female mice would be reported before any experiments using "b6c" males.

The reader may find it convenient, when utilizing the plot, to refer back to this guide. Abbreviations and symbols are defined in detail in the Appendices. When using the database, readers may find that we have not identified an experiment which does meet the standard inclusion criteria. Therefore, we welcome information about additional tests, as well as corrections of any errors in the database.

We wish to thank Jerrold Ward and Kenneth Chu for their valuable and consistent expertise in pathology and toxicology during the course of our work. For their significant contributions we would like to acknowledge Cathy St. Hilaire and Robert Harris in the early stages of this project, and Mary Argus, Susan Sieber, and Joan Staats more recently. Numerous experimentalists have assisted us in the interpretation and details of their published papers, and we are grateful for their time and work.

This work was completed with the assistance also of D. Ang, J. Bertucelli, M. Blumenthal, M. DaCosta, A. Friedman, K. Gould, T. Haggin, E. Higgins, H. Hurd, P. Kato, T. Liou, P. M. MacLeod, M. Needels, M. Nichols, M. Rosenfeld, W. E. Rouse and M. Smith.

This work was supported by NIEHS/DOE Interagency Agreement 222-Y01-AS-10066 and EPA-NCI/DOE Interagency Agreement Y01-CP-15791 through the Lawrence Berkeley Laboratory, and by DOE Contract DE-AT03-80EV70156 to B.N.A.

REFERENCES

1. Peto, R., Pike, M. C., Bernstein, L., Gold, L. S., and Ames, B. A. The TD₅₀: a proposed general convention for the numerical description of the carcinogenic potency of chemicals in chronic-exposure animal experiments. *Environ. Health Perspect.* 58: 1-8 (1984).
2. Ames, B. N. Dietary carcinogens and anti-carcinogens. *Science* 221: 1256-1264 (1983).
3. Russfield, A. B., Homburger, F., Boger, E., Van Dongen, C. G., Weisburger, E. K., and Weisburger, J. H. The carcinogenic effect of 4,4'-methylene-bis-(2-chloroaniline) in mice and rats. *Toxicol. Appl. Pharmacol.* 31: 47-54 (1975).
4. Russfield, A. B., Homburger, F., Boger, E., Van Dongen, C. G., Weisburger, E. K., and Weisburger, J. H. Carcinogenicity of Chemicals Present in Man's Environment. Final Report, Contract No. NIH-NCI-E-68-1311. Bio-Research Consultants Inc., Cambridge, MA, 1973.
5. Weisburger, E. K., Russfield, A. B., Homburger, F., Weisburger, J. H., Boger, E., Van Dongen, C. G., and Chu, K. Testing of twenty-one aromatic amines or derivatives for long-term toxicity or carcinogenicity. *J. Environ. Pathol. Toxicol.* 2: 325-356 (1978).
6. Linhart, M., Cooper, J., Martin, R., Page, N., and Peters, J. Carcinogenesis bioassay data system. *Comp. Biomed. Res.* 7: 230-248 (1974).
7. Sontag, J. A., Page, N. P., and Saffiotti, U. Guidelines for carcinogen bioassay in small rodents. Carcinogenesis Technical Reports Series 1, DHEW Pub. No. (NIH) 76-801 Bethesda, MD, 1976.
8. Ward, J. M., Goodman, D. G., Griesmer, R. A., Hardisty, J. F., Schueler, J. D., Squire, R. A., and Strandberg, J. D. Quality assurance for pathology in rodent carcinogenesis tests. *J. Environ. Pathol. Toxicol.* 2:371-378 (1978).
9. U. S. Public Health Service. Survey of Compounds Which Have Been Tested for Carcinogenic Activity, 1948-1973. Shubik and Hartwell, DHEW Pub. No. (NIH) 75 P.H.S. Pub. No. 149 (NIH Pub. No. 80-453, formerly P.H.S. 149), 1978.
10. IARC Monographs. Evaluation of the Carcinogenic Risk of Chemicals to Humans. Chemicals, Industrial Processes and Industries Associated with Cancer in Humans, Supplement 4. IARC, Lyon, France, 1982, pp. 267-270.
11. Freireich, E. J., Gehan, E. A., Rall, D. P., Schmidt, L. H., and Skipper, H. E. Quantitative comparison of toxicity of anticancer agents in mouse, rat, hamster, dog, monkey, and man. *Cancer Chemotherapy Reports* 50: 219-244 (1966).
12. National Cancer Institute. Carcinogenesis Bioassay of Trichloroethylene. Technical Report Series No. 2. DHEW Pub. No. (NIH) 76-802, 1976.
13. Williams, C. S. F. Practical Guide to Laboratory Animals. C. V. Mosby, St. Louis, 1976.
14. Dittmer, D. S. Biology Data Book, 2nd ed., Vol. I (P. Altman, Ed.), Federation of American Societies for Experimental Biology, Bethesda, MD, 1973.
15. NIOSH. Registry of Toxic Effects of Chemical Substances, Publication 79-100 (R. Lewis and R. Tatken, Eds.), National Institute for Occupational Safety and Health, Cincinnati, OH 1980, p. xxxii.
16. Hoeltge Inc. Animal Care Equipment Catalog. Cincinnati, OH, p. 15.
17. Sanockij, I. V. (Ed.) Methods for Determining Toxicity and Hazards of Chemicals. Medicina, Moscow, 1970, pp. 62-63 (in Russian); cited in Principles and Methods for Evaluating the Toxicity of Chemicals, Part I. World Health Organization, Geneva, 1971.
18. Baker, H. J., Lindsey, J. R., and Weisbroth, S. H. (Eds.) Selected normative data. In: The Laboratory Rat, Vol. I., Academic Press, New York, 1979.
19. Guyton, A. C. Measurement of the respiratory volumes of laboratory animals. *Am J. Physiol.* 150:70-77 (1947).
20. Maltoni, C. Vinyl chloride carcinogenicity: an experimental model for carcinogenesis studies. In: Origins of Human Cancer, Book A, Vol. 4 (H. H. Hiatt, J. D. Watson and J. A. Winsten, Eds.), Cold Spring Harbor Laboratory, Cold Spring Harbor, NY, 1977, pp. 119-146.

1. Peto, R., Pike, M. C., Bernstein, L., Gold, L. S., and Ames, B. A. The TD₅₀: a proposed general convention for the numerical de-

Part IV: Plot of the Carcinogenic Potency Database

Spe	Strain	Site	Xpo + Xpt		TD50	2Tailpvl
Sex	Route	Hist	Notes		DR	AuOp
ACETAMIDE						
1	M f	cb6 eat	lun a/a 52w69 e	100ng...1ug...10...100...1mg...10...100...1g...10		
			pool		>	no dre P=1. -
a	M f	cb6 eat	liv hpc 52w69 e			no dre P=1. -
2	M m	cb6 eat	ato sqp 52w69 e	pool	+	1.89gm \ P<.0005
a	M m	cb6 eat	mln mno 52w69 e			2.66gm \ P<.002
b	M m	cb6 eat	--- mix 52w69 e			3.01gm * P<.0005+
c	M m	cb6 eat	--- mno 52w69 e			3.05gm \ P<.002
d	M m	cb6 eat	--- mlh 52w69 e			6.24gm * P<.002
e	M m	cb6 eat	mln mlh 52w69 e			9.52gm * P<.02
f	M m	cb6 eat	liv hpc 52w69 e			57.5gm * P<.7 -
g	M m	cb6 eat	lun a/a 52w69 e			no dre P=1. -
3	R f	f34 eat	liv hpc 52w69 e		+	230.mg P<.0005+
a	R f	f34 eat	liv nnd 52w69 e			4.15gm P<.04 +
4	R m	f34 eat	liv hpc 52w69 ea		+	104.mg P<.0005+
a	R m	f34 eat	liv nnd 52w69 ea			9.96gm P<.3 +
5	R m	wis eat	liv hpt 52w65 ek		±	372.mg P<.02 +
ACETAMINOPHEN						
6	M f	swi eat	--- leu 32w52 v	100ng...1ug...10...100...1mg...10...100...1g...10		
a	M f	swi eat	liv tum 32w52 v		>	no dre P=1. -
b	M f	swi eat	lun tum 32w52 v			no dre P=1. -
7	R m	sda eat	liv tum 27m27		>	no dre P=1. -
ACETONEXAMIDE						
8	M f	b6c eat	TBA MXB 24m25 sv	100ng...1ug...10...100...1mg...10...100...1g...10		
a	M f	b6c eat	liv MXB 24m25 sv		>	no dre P=1. -
b	M f	b6c eat	lun MXB 24m25 sv			no dre P=1. -
9	M m	b6c eat	TBA MXB 24m25 v		>	2.37gm \ P<.7 -
a	M m	b6c eat	liv MXB 24m25 v			no dre P=1. -
b	M m	b6c eat	lun MXB 24m25 v			no dre P=1. -
10	R f	f34 eat	TBA MXB 24m25		>	no dre P=1. -
a	R f	f34 eat	liv MXB 24m25			no dre P=1. -
11	R m	f34 eat	--- leu 24m24		+	527.mg \ P<.008 -
a	R m	f34 eat	TBA MXB 24m24			2.12gm * P<.6
b	R m	f34 eat	liv MXB 24m24			16.6gm * P<.4
ACETONE [4-(5-NITRO-2-FURYL)-2-THIAZOLYL]HYDRAZONE						
12	R f	hza eat	for sqp 36w54 ea	100ng...1ug...10...100...1mg...10...100...1g...10		
a	R f	hza eat	liv tum 36w54 ea		±	11.0mg P<.05
13	R f	hza eat	for sqp 44w60 ea		+	no dre P=1. -
a	R f	hza eat	liv tum 44w60 ea			6.05mg P<.0005+
						no dre P=1. -
1'-ACETOXYSAFROLE						
14	M m	cd1 eat	liv car 56w69 s	100ng...1ug...10...100...1mg...10...100...1g...10		
a	M m	cd1 eat	lun tum 56w69 s		>	no dre P=1. -
b	M m	cd1 eat	tba mix 56w69 s			no dre P=1. -
15	M m	cd1 eat	liv car 30w69 s		>	no dre P=1. -
a	M m	cd1 eat	lun tum 30w69 s			no dre P=1. -
b	M m	cd1 eat	tba mix 30w69 s			no dre P=1. -
16	R m	cdr eat	for pam 47w69 sv		+	30.7mg P<.0005+
a	R m	cdr eat	liv car 47w69 sv			no dre P=1. -
b	R m	cdr eat	tba mix 47w69 sv			32.4mg P<.0005
17	R m	cdr eat	for pam 36w52 s		+	21.1mg P<.0005+
a	R m	cdr eat	liv hpc 36w52 s			348.mg P<.3 -
b	R m	cdr eat	tba mix 36w52 s			21.1mg P<.0005
N'-ACETYL-4-(HYDROXYMETHYL)PHENYLHYDRAZINE						
18	M f	swa eat	blv mix 27m27 e	100ng...1ug...10...100...1mg...10...100...1g...10		
a	M f	swa eat	lun mix 27m27 e		+	287.mg P<.0005+
b	M f	swa eat	liv tum 27m27			329.mg P<.004 +
19	M m	swa eat	lun mix 27m27 e		+	no dre P=1. -
a	M m	swa eat	blv mix 27m27 e			208.mg P<.003 +
b	M m	swa eat	liv hpt 27m27 e			252.mg P<.0005+
						no dre P=1. -
1-ACETYL-2-ISONICOTINOYLHYDRAZINE						
20	M f	swa eat	lun mix 94w94 e	100ng...1ug...10...100...1mg...10...100...1g...10		
a	M f	swa eat	liv mix 94w94 e		+	319.mg P<.0005+
21	M m	swa eat	lun mix 92w92 e		+	55.7gm P<.9
a	M m	swa eat	liv hem 92w92 e			342.mg P<.0005+
						no dre P=1. -
3-ACETYL-6-METHYL-2,4-PYRAN-2(1H)-ONE						
22	M f	b6a orl	liv hpt 76w76 evx	100ng...1ug...10...100...1mg...10...100...1g...10		
a	M f	b6a orl	lun ade 76w76 evx		>	no dre P=1. -
b	M f	b6a orl	tba mix 76w76 evx			no dre P=1. -
23	M m	b6a orl	lun ade 76w76 evx		>	no dre P=1. -
a	M m	b6a orl	liv hpt 76w76 evx			no dre P=1. -
b	M m	b6a orl	tba mix 76w76 evx			no dre P=1. -
24	M f	b6c orl	liv hpt 76w76 evx		>	no dre P=1. -
a	M f	b6c orl	lun mix 76w76 evx			no dre P=1. -
b	M f	b6c orl	tba tum 76w76 evx			no dre P=1. -

RefNum	LoConf	UpConf	Cntrl	1Dose	1Inc	2Dose	2Inc	Citation or Pathology	Brkly Code
ACETAMIDE 60-35-5									
1	1343	2.22gm	n.s.s.	2/89p	1.15gm	0/34	2.31gm	0/28	Fleischman;jept,3,149-170;1980
a	1343	6.96gm	n.s.s.	1/89p	1.15gm	2/41	2.31gm	0/46	
2	1343	717.mg	7.92gm	0/82p	1.07gm	5/32	(2.13gm)	0/22)	
a	1343	1.01gm	13.2gm	0/74p	1.07gm	5/44	(2.13gm)	0/39)	
b	1343	1.62gm	6.73gm	0/95p	1.07gm	7/50	2.13gm	7/46	
c	1343	1.16gm	14.1gm	0/95p	1.07gm	5/50	(2.13gm)	1/46)	
d	1343	2.70gm	23.9gm	0/95p	1.07gm	2/50	2.13gm	5/46	
e	1343	3.29gm	n.s.s.	0/79p	1.07gm	1/44	2.13gm	3/39	
f	1343	6.31gm	n.s.s.	2/91p	1.07gm	0/50	2.13gm	2/46	
g	1343	1.55gm	n.s.s.	1/87p	1.07gm	0/24	2.13gm	0/24	
3	1343	147.mg	382.mg	0/49	888.mg	33/48			
a	1343	1.26gm	n.s.s.	0/49	888.mg	3/48			
4	1343	65.2mg	171.mg	0/50	710.mg	41/47			
a	1343	1.62gm	n.s.s.	0/50	710.mg	1/47			
5	2	158.mg	n.s.s.	0/7	800.mg	7/16			Weisburger;txap,14,163-175;1969
ACETAMINOPHEN (Tylenol, paracetamol) 103-90-2									
6	1118	805.mg	n.s.s.	1/30	863.mg	1/30			Cohen;canr,38,1398-1405;1978
a	1118	1.33gm	n.s.s.	0/30	863.mg	0/30			
b	1118	1.33gm	n.s.s.	0/30	863.mg	0/30			
7	1459	1.65gm	n.s.s.	0/30	214.mg	0/30			Johansson;ijcn,27,521-529;1981
ACETOHEXAMIDE 968-81-0									
8	c03247	939.mg	n.s.s.	2/15	568.mg	7/35	1.14gm	3/35	
a	c03247	1.78gm	n.s.s.	1/15	568.mg	1/35	1.14gm	1/35	Liv:hpa,hpc,nnd.
b	c03247	n.s.s.	n.s.s.	0/15	568.mg	1/35	1.14gm	0/35	Lun:a/a,s/c.
9	c03247	348.mg	n.s.s.	6/15	525.mg	14/35	(1.05gm)	5/35)	
a	c03247	3.66gm	n.s.s.	3/15	525.mg	2/35	1.05gm	1/35	Liv:hpa,hpc,nnd.
b	c03247	2.34gm	n.s.s.	2/15	525.mg	3/35	1.05gm	2/35	Lun:a/a,s/c.
10	c03247	751.mg	n.s.s.	9/15	348.mg	23/35	694.mg	18/35	
a	c03247	n.s.s.	n.s.s.	0/15	348.mg	0/35	694.mg	0/35	Liv:hpa,hpc,nnd.
11	c03247	256.mg	7.11gm	0/15	278.mg	10/35	(561.mg)	4/35)	S
a	c03247	386.mg	n.s.s.	7/15	278.mg	19/35	561.mg	21/35	
b	c03247	2.70gm	n.s.s.	0/15	278.mg	0/35	561.mg	1/35	Liv:hpa,hpc,nnd.
ACETONE 4-(5-NITRO-2-FURYL)-2-THIAZOLYL HYDRAZONE 18523-69-8									
12	1063n	3.23mg	n.s.s.	0/5	33.3mg	3/7			Morris;canr,29,2145-2156;1969
a	1063n	13.0mg	n.s.s.	0/5	33.3mg	0/7			
13	1063n	3.10mg	13.3mg	0/16	36.8mg	15/20			
a	1063n	50.5mg	n.s.s.	0/16	36.8mg	0/20			
1'-ACETOXYSAFROLE 34627-78-6									
14	1042b	92.9mg	n.s.s.	3/35	29.3mg	0/35			Borchert;canr,33,590-600;1973
a	1042b	92.9mg	n.s.s.	0/35	29.3mg	0/35			
b	1042b	92.9mg	n.s.s.	3/35	29.3mg	0/35			
15	1042c	83.3mg	n.s.s.	3/35	26.3mg	0/35			
a	1042c	83.3mg	n.s.s.	0/35	26.3mg	0/35			
b	1042c	83.3mg	n.s.s.	3/35	26.3mg	0/35			
16	1042b	14.2mg	81.2mg	0/18	112.mg	10/15			
a	1042b	152.mg	n.s.s.	0/18	112.mg	0/15			
b	1042b	14.5mg	107.mg	1/18	112.mg	10/15			
17	1042c	10.2mg	52.6mg	0/18	116.mg	11/18			
a	1042c	56.7mg	n.s.s.	0/18	116.mg	1/18			
b	1042c	10.2mg	52.6mg	0/18	116.mg	11/18			
N'-ACETYL-4-(HYDROXYMETHYL)PHENYLHYDRAZINE 65734-38-5									
18	410	143.mg	950.mg	8/96	125.mg	16/44			Toth;canr,38,177-180;1978
a	410	148.mg	3.05gm	15/96	125.mg	17/44			
b	410	1.57gm	n.s.s.	0/99	125.mg	0/50			
19	410	98.6mg	1.38gm	22/92	104.mg	24/48			
a	410	127.mg	762.mg	5/88	104.mg	15/45			
b	410	997.mg	n.s.s.	2/62	104.mg	0/38			
1-ACETYL-2-ISONICOTINOYLHYDRAZINE 1078-38-2									
20	1055	196.mg	567.mg	14/104	800.mg	37/47			Toth;ejca,9,285-289;1973
a	1055	2.66gm	n.s.s.	3/73	800.mg	2/41			
21	1055	202.mg	664.mg	11/91	667.mg	29/42			
a	1055	968.mg	n.s.s.	2/40	667.mg	0/9			
3-ACETYL-6-METHYL-2,4-PYRANDIONE (dehydroacetic acid) 520-46-5									
22	1294	67.2mg	n.s.s.	0/17	33.9mg	0/18			Innes;ntis,1968/1969
a	1294	67.2mg	n.s.s.	1/17	33.9mg	0/18			
b	1294	32.0mg	n.s.s.	2/17	33.9mg	2/18			
23	1294	38.9mg	n.s.s.	2/18	31.6mg	1/17			
a	1294	59.1mg	n.s.s.	1/18	31.6mg	0/17			
b	1294	41.6mg	n.s.s.	3/18	31.6mg	1/17			
24	1294	67.2mg	n.s.s.	0/16	33.9mg	0/18			
a	1294	67.2mg	n.s.s.	0/16	33.9mg	0/18			
b	1294	67.2mg	n.s.s.	0/16	33.9mg	0/18			

Spe	Strain	Site	Xpo+Xpt			TD50	2Tailpvl
Sex	Route	Hist	Notes			DR	AuOp
25	M m	b6c orl	liv hpt	76w76 evx	->	no dre	P=1. -
a	M m	b6c orl	lun mix	76w76 evx		no dre	P=1. -
b	M m	b6c orl	tba mix	76w76 evx		202.mg	P<.3 -
1-ACETYL-2-PHENYLHYDRAZINE				100ng.....1ug.....10.....100.....1mg.....10.....100.....1g.....10			
26	M f	swa wat	liv mix	26m26 e	. + .	44.8mg	P<.0005+
a	M f	swa wat	blv mix	26m26 e		49.0mg	P<.0005+
b	M f	swa wat	liv agm	26m26 e		105.mg	P<.0005
c	M f	swa wat	liv ang	26m26 e		105.mg	P<.0005
d	M f	swa wat	blv ang	26m26 e		117.mg	P<.005
e	M f	swa wat	blv agm	26m26 e		117.mg	P<.005
f	M f	swa wat	lun ade	26m26 e		413.mg	P<.5 -
g	M f	swa wat	lun mix	26m26 e		no dre	P=1.
27	M m	swa wat	blv mix	25m25 e	. + .	59.8mg	P<.0005+
a	M m	swa wat	liv mix	25m25 e		62.1mg	P<.0005+
b	M m	swa wat	blv agm	25m25 e		113.mg	P<.01
c	M m	swa wat	liv agm	25m25 e		128.mg	P<.01
d	M m	swa wat	liv ang	25m25 e		146.mg	P<.008
e	M m	swa wat	blv ang	25m25 e		161.mg	P<.03
f	M m	swa wat	lun adc	25m25 e		no dre	P=1. -
g	M m	swa wat	lun ade	25m25 e		no dre	P=1. -
h	M m	swa wat	lun mix	25m25 e		no dre	P=1.
4-ACETYLAMINOBIIPHENYL				100ng.....1ug.....10.....100.....1mg.....10.....100.....1g.....10			
28	R f	nss eat	agl adc	43w65	. + .	1.18mg	P<.0005+
a	R f	nss eat	liv tum	43w65		no dre	P=1.
1-ACETYLAMINOFLUORENE				100ng.....1ug.....10.....100.....1mg.....10.....100.....1g.....10			
29	R f	buf eat	pit ade	47w88 e	->	43.5mg	P<.6
a	R f	buf eat	--- ile	47w88 e		54.8mg	P<.3
b	R f	buf eat	ova gcc	47w88 e		54.8mg	P<.3
c	R f	buf eat	ute cas	47w88 e		54.8mg	P<.3
d	R f	buf eat	adr car	47w88 e		54.8mg	P<.3
2-ACETYLAMINOFLUORENE				100ng.....1ug.....10.....100.....1mg.....10.....100.....1g.....10			
30	H m	nss eat	liv bdc	32w56	. + .	17.4mg	P<.04 +
31	H m	nss ipj	smi adc	34w69	->	7.26mg	P<.3
a	H m	nss ipj	par sar	34w69		no dre	P=1.
b	H m	nss ipj	for pem	34w69		no dre	P=1.
32	H f	syg eat	liv cac	26w68 e	. + .	17.3mg	P<.03
33	H m	syg eat	liv cac	40w84 e	. + .	15.3mg	P<.003
34	H m	syg eat	liv cac	26w80 e	->	31.5mg	P<.2
35	M f	asw eat	tba mix	84w84 e	->	no dre	P=1. +
a	M f	asw eat	tba mal	84w84 e		51.1mg	P<.3
36	M m	asw eat	tba mal	84w84 e	. + .	17.4mg	P<.006
a	M m	asw eat	tba mix	84w84 e		21.7mg	P<.2 +
37	M f	bcn eat	ubl tcc	65w78 ekr	. + .	66.5mg Z	P<.0005+
a	M f	bcn eat	liv hpc	65w78 ekr		120.mg *	P<.0005+
38	M f	bcn eat	liv hpc	15m24 ekr	. + .	30.6mg *	P<.0005+
a	M f	bcn eat	ubl tcc	15m24 ekr		95.5mg Z	P<.0005+
39	M f	bcn eat	ubl tcc	52w52 ekr	. + .	150.mg Z	P<.0005+
a	M f	bcn eat	liv hpc	52w52 ekr		226.mg *	P<.2 +
40	M f	bcn eat	ubl tcc	60w60 ekr	. + .	68.8mg Z	P<.0005+
a	M f	bcn eat	liv hpc	60w60 ekr		747.mg *	P<.2 +
41	M f	bcn eat	ubl tcc	65w65 ekr	. + .	45.8mg Z	P<.0005+
a	M f	bcn eat	liv hpc	65w65 ekr		199.mg *	P<.07 +
42	M f	bcn eat	ubl tcc	69w69 ekr	. + .	62.1mg Z	P<.0005+
a	M f	bcn eat	liv hpc	69w69 ekr		218.mg *	P<.05 +
43	M f	bcn eat	ubl tcc	73w73 ekr	. + .	64.1mg Z	P<.0005+
a	M f	bcn eat	liv hpc	73w73 ekr		147.mg *	P<.05 +
44	M f	bcn eat	ubl tcc	78w78 ekr	. + .	101.mg Z	P<.0005+
a	M f	bcn eat	liv hpc	78w78 ekr		154.mg *	P<.0005+
45	M f	bcn eat	liv hpc	24m24 ekr	. + .	41.7mg Z	P<.0005+
a	M f	bcn eat	ubl tcc	24m24 ekr		96.0mg Z	P<.0005+
46	M f	bcn eat	liv hpc	33m33 ekr	. + .	19.6mg *	P<.008 +
a	M f	bcn eat	ubl tcc	33m33 ekr		82.1mg Z	P<.0005+
47	M f	bcn eat	liv hpc	39w78 ekr	. + .	110.mg *	P<.002 +
a	M f	bcn eat	ubl tcc	39w78 ekr		142.mg *	P<.004 +
48	M f	bcn eat	liv hpc	9m24 ekr	. + .	19.1mg *	P<.0005+
a	M f	bcn eat	ubl tcc	9m24 ekr		97.2mg Z	P<.0005+
49	M f	bcn eat	ubl tcc	52w78 ekr	. + .	82.8mg Z	P<.0005+
a	M f	bcn eat	liv hpc	52w78 ekr		156.mg Z	P<.009 +

Spe	Strain	Site	Xpo + Xpt	Notes	TD50	2Tailpvl
Sex	Route	Hist			DR	AuOp
50	M f bcn	eat liv	hpc 12m24	ekr	. + .	24.3mg * P<.0005+
a	M f bcn	eat ubl	tcc 12m24	ekr		101.mg Z P<.0005+
51	M f cd1	eat liv	hpt 78w78	e	. + .	21.3mg P<.0005
a	M f cd1	eat liv	nod 78w78	e		76.2mg P<.0005
b	M f cd1	eat lun	ade 78w78	e		354.mg P<.6
52	M m cd1	eat liv	hpt 78w78	e	. + .	22.5mg P<.0005
a	M m cd1	eat lun	ade 78w78	e		no dre P=1.
53	M f cf1	eat mgl	car 52w52	e	. + .	14.6mg P<.0005
a	M f cf1	eat liv	lcc 52w52	e		16.5mg P<.0005+
b	M f cf1	eat lun	tum 52w52	e		no dre P=1.
54	M m cf1	eat liv	lcc 52w52	e	. + .	31.4mg P<.006 +
a	M m cf1	eat lun	ade 52w52	e		149.mg P<.5
55	M f ifc	eat liv	mix 64w64	e	. + .	4.78mg P<.0005+
a	M f ifc	eat liv	hpt 64w64	e		5.95mg P<.0005
b	M f ifc	eat ubl	car 64w64	e		565.mg P<.4 +
c	M f ifc	eat ubl	pam 64w64	e		565.mg P<.4 +
56	M m ifc	eat liv	mix 64w64	e	. + .	36.1mg P<.005 +
a	M m ifc	eat ubl	car 64w64	e		36.1mg P<.005 +
b	M m ifc	eat liv	hpt 64w64	e		43.7mg P<.01
c	M m ifc	eat ubl	pam 64w64	e		69.8mg P<.04 +
57	M f ifm	eat liv	mix 60w60	e	. + .	19.6mg P<.0005+
a	M f ifm	eat liv	hpt 60w60	e		31.5mg P<.0005
b	M f ifm	eat ubl	mix 60w60	e		44.9mg P<.0005+
58	M f ifm	eat liv	ade 60w60	e	. >	91.2mg P<.2
59	M m ifm	eat liv	mix 60w60	e	. + .	42.9mg P<.002 +
a	M m ifm	eat liv	hpt 60w60	e		77.8mg P<.004
60	M m ifm	eat ubl	mix 60w60	e	. + .	12.9mg P<.0005+
a	M m ifm	eat liv	mix 60w60	e		57.2mg P<.3
61	M f r3m	eat ubl	mix 60w60	e	. ±	104.mg P<.07 +
a	M f r3m	eat liv	mix 60w60	e		no dre P=1.
62	M m r3m	eat ubl	mix 60w60	e	. ±	51.0mg P<.04 +
a	M m r3m	eat ubl	car 60w60	e		86.0mg P<.1
b	M m r3m	eat liv	mix 60w60	e		no dre P=1. +
63	R f cdr	eat mgl	mix 15m24	ae	. + .	4.75mg * P<.0005+
a	R f cdr	eat liv	hpc 15m24	ae		26.9mg * P<.02 +
64	R m cdr	eat liv	hpc 15m24	ae	. + .	3.78mg * P<.0005+
65	R f hza	eat mem	tum 36w54	es	. + .	.841mg P<.0005+
a	R f hza	eat eac	car 36w54	es		13.8mg P<.4
b	R f hza	eat tiv	tum 36w54	es		no dre P=1.
66	R f hza	eat mem	tum 44w60	es	. + .	.981mg P<.0005+
a	R f hza	eat eac	car 44w60	es		8.75mg P<.02
b	R f hza	eat liv	tum 44w60	es		no dre P=1.
4-ACETYLAMINOFLUORENE				100ng.....1ug.....10.....100.....1mg.....10.....100.....1g.....10		
67	R f buf	eat ---	ile 62w97	e	. >	59.4mg P<.2
a	R f buf	eat mgl	adf 62w97	e		59.4mg P<.2
b	R f buf	eat ute	sar 62w97	e		59.4mg P<.2
ACETYLATED DIAMYOPECTIN PHOSPHATE			1ug.....10.....100.....1mg.....10.....100.....1g.....10		
68	R f wis	eat liv	tum 24m24	e		no dre P=1. -
a	R f wis	eat tba	mix 24m24	e		no dre P=1. -
69	R m wis	eat liv	tum 24m24	e		no dre P=1. -
a	R m wis	eat tba	mix 24m24	e		no dre P=1. -
ACETYLATED DISTARCH ADIPATE				100ng.....1ug.....10.....100.....1mg.....10.....100.....1g.....10		
70	R f ofs	eat liv	tum 24m24	eg		no dre P=1. -
a	R f ofs	eat tba	mix 24m24	eg		no dre P=1. -
71	R m ofs	eat liv	hem 24m24	e		no dre P=1. -
a	R m ofs	eat tba	mix 24m24	e		14.0gm P<.06 -
ACETYLATED DISTARCH GLYCEROL				100ng.....1ug.....10.....100.....1mg.....10.....100.....1g.....10		
72	R f ofs	eat liv	tum 24m24	eg		no dre P=1. -
a	R f ofs	eat tba	mix 24m24	eg		no dre P=1. -
73	R m ofs	eat liv	hem 24m24	e		no dre P=1. -
a	R m ofs	eat tba	mix 24m24	e		26.1gm P<.3 -
ACETYLATED DISTARCH PHOSPHATE				100ng.....1ug.....10.....100.....1mg.....10.....100.....1g.....10		
74	R f wis	eat liv	tum 24m24	e		no dre P=1. -
a	R f wis	eat tba	mix 24m24	e		20.4gm P<.4 -
75	R m wis	eat liv	tum 24m24	e		no dre P=1. -
a	R m wis	eat tba	mix 24m24	e		37.6gm P<.8 -
ACRONYCINE*				100ng.....1ug.....10.....100.....1mg.....10.....100.....1g.....10		
76	M f b6c	ipj TBA	MXB 48w78	as	. >	no dre P=1.
a	M f b6c	ipj liv	MXB 48w78	as		2.46mg * P<.3
b	M f b6c	ipj lun	MXB 48w78	as		2.46mg * P<.3
77	M m b6c	ipj TBA	MXB 66w78	as	. >	no dre P=1.
a	M m b6c	ipj liv	MXB 66w78	as		no dre P=1.
b	M m b6c	ipj lun	MXB 66w78	as		no dre P=1.

78	Spe	Strain	Site	Xpo+Xpt	Notes	DR	2Tailpvl	AuOp	
									Sex
	R	f sda	ipj mgl	MXA 52w80	e				
	R	f sda	ipj mgl	fbA 52w80	e				
	R	f sda	ipj MXB	MXB 52w80	e				
	R	f sda	ipj per	MXA 52w80	e				
	R	f sda	ipj per	srn 52w80	e				
	R	f sda	ipj TBA	MXB 52w80	e				
	R	f sda	ipj Liv	MXB 52w80	e				
79	R	m sda	ipj MXB	MXB 51w80	ee				
	R	m sda	ipj ---	ost 51w80	ee				
	R	m sda	ipj MXA	MXA 51w80	ee				
	R	m sda	ipj per	MXA 51w80	ee				
	R	m sda	ipj adr	coa 51w80	ee				
	R	m sda	ipj TBA	MXB 51w80	ee				
	R	m sda	ipj Liv	MXB 51w80	ee				
ACRYLONITRILE									
						100ng.....1ug.....10.....100.....1mg.....10.....100.....1g.....10			
80	R	f sss	inh cns	ast 24m24	ees				
	R	f sss	inh ccx	ast 24m24	ees				
	R	f sss	inh zym	mix 24m24	ees				
	R	f sss	inh zym	sac 24m24	ees				
	R	f sss	inh brs	ast 24m24	ees				
	R	f sss	inh ntu	rsc 24m24	ees				
	R	f sss	inh mgl	adc 24m24	ees				
	R	f sss	inh liv	cho 24m24	ees				
	R	f sss	inh liv	clc 24m24	ees				
	R	f sss	inh mgl	aff 24m24	ees				
	R	f sss	inh tba	mix 24m24	ees				
81	R	f sss	wat cns	ast 24m25	eesv				
	R	f sss	wat smi	muc 24m25	eesv				
	R	f sss	wat brs	ast 24m25	eesv				
	R	f sss	wat stn	mix 24m25	eesv				
	R	f sss	wat ccx	ast 24m25	eesv				
	R	f sss	wat stn	sqp 24m25	eesv				
	R	f sss	wat zym	mix 24m25	eesv				
	R	f sss	wat zym	sac 24m25	eesv				
	R	f sss	wat mgl	mal 24m25	eesv				
	R	f sss	wat stn	sqc 24m25	eesv				
	R	f sss	wat crl	ast 24m25	eesv				
	R	f sss	wat spd	ast 24m25	eesv				
	R	f sss	wat zym	ade 24m25	eesv				
	R	f sss	wat liv	mix 24m25	eesv				
	R	f sss	wat mgl	mix 24m25	eesv				
	R	f sss	wat tba	mix 24m25	eesv				
82	R	f sss	wat ton	mix 22m25	esv				
	R	f sss	wat ton	sqc 22m25	esv				
83	R	m sss	inh cns	ast 24m24	ees				
	R	m sss	inh itl	mix 24m24	ees				
	R	m sss	inh ccx	ast 24m24	ees				
	R	m sss	inh zym	sac 24m24	ees				
	R	m sss	inh zym	mix 24m24	ees				
	R	m sss	inh stn	mix 24m24	ees				
	R	m sss	inh liv	hpc 24m24	ees				
	R	m sss	inh tba	mix 24m24	ees				
84	R	m sss	inh smi	muc 24m24	ees				
	R	m sss	inh ton	sqp 24m24	ees				
	R	m sss	inh ton	mix 24m24	ees				
85	R	m sss	wat stn	mix 24m25	eesv				
	R	m sss	wat cns	ast 24m25	eesv				
	R	m sss	wat ccx	ast 24m25	eesv				
	R	m sss	wat stn	sqp 24m25	eesv				
	R	m sss	wat stn	sqc 24m25	eesv				
	R	m sss	wat brs	ast 24m25	eesv				
	R	m sss	wat zym	sac 24m25	eesv				
	R	m sss	wat smi	muc 24m25	eesv				
	R	m sss	wat liv	hpc 24m25	eesv				
	R	m sss	wat tba	mix 24m25	eesv				
86	R	m sss	wat ton	mix 96w96	eesv				
	R	m sss	wat ton	sqc 96w96	eesv				
ACTINOMYCIN C									
						100ng.....1ug.....10.....100.....1mg.....10.....100.....1g.....10			
87	R	m b46	ivj tba	mix 12m24	ees				
	R	m b46	ivj tba	ben 12m24	ees				
	R	m b46	ivj tba	mal 12m24	ees				
ACTINOMYCIN D									
						100ng.....1ug.....10.....100.....1mg.....10.....100.....1g.....10			
88	R	f cdr	ipj per	sar 26w78	e				
	R	f cdr	ipj lun	ade 26w78	e				
	R	f cdr	ipj Liv	tum 26w78	e				
	R	f cdr	ipj tba	mal 26w78	e				

Spe	Strain	Site	Xpo+Xpt	Notes	TD50	2Tailpvl
Sex	Route	Hist			DR	AuOp
d	R f cdr	ipj	tba mix 26w78	e	1.45ug *	P<.003
e	R f cdr	ipj	tba ben 26w78	e	no dre	P=1.
89	R m cdr	ipj	per sar 26w78	e	769.ng	P<.0005+
a	R m cdr	ipj	--- plc 26w78	e	20.1ug	P<.008
b	R m cdr	ipj	--- lys 26w78	e	20.1ug	P<.008
c	R m cdr	ipj	liv hem 26w78	e	40.7ug	P<.06
d	R m cdr	ipj	tba mix 26w78	e	501.ng	P<.0005
e	R m cdr	ipj	tba mal 26w78	e	708.ng	P<.0005
f	R m cdr	ipj	tba ben 26w78	e	no dre	P=1.
ADIPAMIDE					100ng...1ug...10...100...1mg...10...100...1g...10	
90	M f cb6	eat	lun a/a 52w69	e	pool	> 8.55gm \ P<.2 -
a	M f cb6	eat	liv hpc 52w69	e	pool	no dre P=1. -
91	M m cb6	eat	liv hpc 52w69	e	pool	> no dre P=1. -
a	M m cb6	eat	lun a/a 52w69	e		no dre P=1. -
92	R f f34	eat	liv tum 52w69	e		> no dre P=1. -
93	R m f34	eat	liv hpc 52w69	e		+ 6.42gm * P<.007
AF-2					100ng...1ug...10...100...1mg...10...100...1g...10	
94	H f syg	eat	for mix 94w94	e		59.1mg * P<.0005
a	H f syg	eat	for sqc 94w94	e		2.34gm * P<.3 +
b	H f syg	eat	oes pam 94w94	e		2.34gm * P<.3 +
c	H f syg	eat	liv tum 94w94	e		no dre P=1.
d	H f syg	eat	lun tum 94w94	e		no dre P=1.
95	H m syg	eat	for mix 94w94	e		30.5mg * P<.0005
a	H m syg	eat	for sqc 94w94	e		164.mg * P<.0005+
b	H m syg	eat	oes mix 94w94	e		328.mg * P<.003
c	H m syg	eat	oes sqc 94w94	e		2.18gm * P<.3 +
d	H m syg	eat	liv tum 94w94	e		no dre P=1.
e	H m syg	eat	lun tum 94w94	e		no dre P=1.
96	M f cdf	eat	for pam 18m24	e		714.mg * P<.0005+
a	M f cdf	eat	for sqc 18m24	e		2.54gm * P<.002 +
b	M f cdf	eat	lun tum 18m24	e		16.4gm * P<.7
97	M m cdf	eat	for pam 18m24	e		753.mg * P<.0005+
a	M m cdf	eat	for sqc 18m24	e		928.mg * P<.0005+
b	M m cdf	eat	lun tum 18m24	e		9.27gm * P<.5
98	M m ddy	eat	for mix 44w80	e		60.8mg P<.005
a	M m ddy	eat	for sqc 44w80	e		72.9mg P<.002 +
b	M m ddy	eat	lun ade 44w80	e		299.mg P<.09
c	M m ddy	eat	liv tum 44w80	e		no dre P=1.
d	M m ddy	eat	tba mix 44w80	e		60.8mg P<.005
99	M f icr	eat	for mix 62w62	e		95.0mg * P<.0005+
a	M f icr	eat	for sqc 62w62	e		225.mg / P<.0005+
b	M f icr	eat	--- leu 62w62	e		1.80gm * P<.3
c	M f icr	eat	liv tum 62w62	e		no dre P=1.
100	M f icr	eat	liv hct 24m24	e		7.07gm * P<.9 ~
101	M m icr	eat	for mix 62w62	e		90.3mg * P<.0005+
a	M m icr	eat	for sqc 62w62	e		208.mg / P<.0005+
b	M m icr	eat	liv tum 62w62	e		no dre P=1.
102	M m icr	eat	liv hct 24m24	e		no dre P=1. -
103	R f sda	eat	mgl mix 46w66	e		11.4mg P<.0005+
a	R f sda	eat	mgl adc 46w66	e		26.4mg P<.0005+
104	R f wis	eat	mgl mix 18m24	e		74.7mg * P<.0005+
a	R f wis	eat	for pam 18m24	e		424.mg * P<.0005
b	R f wis	eat	liv has 18m24	e		2.00gm * P<.02
105	R m wis	eat	for pam 18m24	e		409.mg * P<.0005
a	R m wis	eat	mgl mix 18m24	e		1.20gm * P<.05 +
b	R m wis	eat	liv has 18m24	e		1.60gm * P<.02
AFLATOXICOL					100ng...1ug...10...100...1mg...10...100...1g...10	
106	R m f34	eat	liv hpc 12m24	e		2.47ug * P<.0005+
a	R m f34	eat	kid adc 12m24	e		32.9ug * P<.06
AFLATOXIN B1					100ng...1ug...10...100...1mg...10...100...1g...10	
107	M b tat	eat	liv hpc 40w40	er		26.9ug P<.0005+
108	P b cym	mix	g/b adc 14y14	emuw		.107mg P<.06 +
a	P b cym	mix	liv has 14y14	emuw		.145mg P<.03 +
b	P b cym	mix	--- ost 14y14	emuw		.301mg P<.2 +
c	P b cym	mix	tba mal 14y14	emuw		43.8ug P<.002
109	P b rhe	mix	liv has 14y14	emuw		71.4ug P<.003 +
a	P b rhe	mix	g/b adc 14y14	emuw		.108mg P<.06 +
b	P b rhe	mix	pan adc 14y14	emuw		.194mg P<.06 +
c	P b rhe	mix	liv hpc 14y14	emuw		.194mg P<.06 +
d	P b rhe	mix	--- ost 14y14	emuw		.398mg P<.2 +
e	P b rhe	mix	tba mal 14y14	emuw		30.2ug P<.0005
110	R m buf	eat	liv hpc 35w65	ekr		noTD50 P<.004 +
a	R m buf	eat	liv mix 35w65	ekr		noTD50 P<.004 +
b	R m buf	eat	liv nnd 35w65	ekr		noTD50 P<.004 +
111	R m cdr	eat	liv mix 24m24	r		4.19ug P<.0005+

Spe	Strain	Site	Xpo+Xpt	Notes	TD50	2Tailpvl
Sex	Route	Hist			DR	AuOp
112	R f f34 eat col mix 75w75 e				.148mg	P<.05 +
113	R m f34 eat liv hpc 12m24				1.34ug	P<.0005 +
	a R m f34 eat kid adc 12m24				13.4ug	P<.3
114	R m f34 eat col mix 75w75 e				55.8ug	P<.06 +
115	R f fis eat liv hpt 24m24 e				9.93ug	P<.3 +
116	R m fis eat liv hpt 24m24 e				1.13ug	P<.003 +
117	R m fis eat liv hpc 22m24 ae				932.ng	* P<.0005+
118	R f por eat liv hpc 24m24 e				12.5ug	* P<.0005+
119	R m por eat liv hpc 24m24 e				3.52ug	* P<.0005+
120	R b sde eat liv sar 95w95 e				12.0ug	P<.3
	a R b sde eat tba mal 95w95 e				+historical	P<.03 +
121	R m wag eat liv hpt 69w69 er				noTD50	P<.0005+
122	R f wio eat liv hpt 24m24 e				7.49ug	* P<.0005+
123	R m wio eat liv hpt 24m24 e				6.76ug	* P<.0005+
124	R m wis eat kid car 55w55 er				36.6ug	* P<.006 +
AFLATOXIN, CRUDE					100ng.....1ug.....10.....100.....1mg.....10.....100.....1g.....10	
125	M m swi gav --- lyk 52w52 e				.343mg	P<.002 +
	a M m swi gav liv hpt 52w52 e				no dre	P=1.
126	R m cdr eat liv tum 52w52 e				7.48ug	P<.002 +
127	R m chm eat liv car 68w68				1.87ug	P<.0005+
	a R m chm eat liv nod 68w68				6.96ug	P<.002 +
128	R m lev eat ktu ade 58w78				3.44mg	* P<.0005
	a R m lev eat liv nod 58w78				6.18mg	* P<.002
	b R m lev eat liv hpc 58w78				14.5mg	* P<.05
ALDICARB					100ng.....1ug.....10.....100.....1mg.....10.....100.....1g.....10	
129	M f b6c eat TBA MXB 24m24				no dre	P=1. -
	a M f b6c eat liv MXB 24m24				52.7mg	/ P<.9
	b M f b6c eat lun MXB 24m24				no dre	P=1.
130	M m b6c eat TBA MXB 24m24				1.74mg	* P<.3 -
	a M m b6c eat liv MXB 24m24				2.83mg	* P<.4
	b M m b6c eat lun MXB 24m24				14.8mg	* P<.8
131	R f f34 eat TBA MXB 24m24				no dre	P=1. -
	a R f f34 eat liv MXB 24m24				no dre	P=1.
132	R m f34 eat TBA MXB 24m24				10.4mg	/ P<.1. -
	a R m f34 eat liv MXB 24m24				1.33mg	* P<.2
ALDRIN					100ng.....1ug.....10.....100.....1mg.....10.....100.....1g.....10	
133	M f b6c eat TBA MXB 80w90 s				no dre	P=1. -
	a M f b6c eat liv MXB 80w90 s				no dre	P=1.
	b M f b6c eat lun MXB 80w90 s				9.02mg	* P<.6
134	M m b6c eat liv hpc 80w90				.741mg	* P<.007 c
	a M m b6c eat lun MXA 80w90				3.20mg	* P<.05
	b M m b6c eat TBA MXB 80w90				1.01mg	* P<.08
	c M m b6c eat liv MXB 80w90				.741mg	* P<.007
	d M m b6c eat lun MXB 80w90				3.20mg	* P<.05
135	M m b6c eat liv hpc 80w89	pool			.861mg	* P<.0005c
136	M b c3e eat liv hpa 24m24 e				4.41mg	P<.0005+
	a M b c3e eat lun car 24m24 e				129.mg	P<.3
	b M b c3e eat lun ade 24m24 e				no dre	P=1.
137	M b c3h eat liv hpt 24m24				3.45mg	P<.0005
	a M b c3h eat liv hpc 24m24				no dre	P=1.
	b M b c3h eat tba ben 24m24				4.25mg	P<.0005
	c M b c3h eat tba mal 24m24				no dre	P=1.
138	R b osm eat lun lys 24m24 es				42.3mg	* P<.5
	a R b osm eat tba mix 24m24 es				no dre	P=1. +
139	R f osm eat TBA MXB 19m26				no dre	P=1. -
	a R f osm eat liv MXB 19m26				466.mg	* P<.1.
140	R f osm eat adr coe 19m25	pool			#3.12mg	\ P<.0005-
141	R f osm eat liv tum 26m27 ev				no dre	P=1. -
	a R f osm eat tba mix 26m27 ev				no dre	P=1. -
142	R f osm eat lnr tum 24m24 es				4.35mg	\ P<.03 -
	a R f osm eat liv tum 24m24 es				no dre	P=1. -
	b R f osm eat tba tum 24m24 es				1.69mg	\ P<.3
	c R f osm eat tba mal 24m24 es				no dre	P=1.
143	R f osm eat liv tum 25m25				no dre	P=1. -
	a R f osm eat tba mix 25m25				no dre	P=1. -
144	R m osm eat TBA MXB 17m26				16.4mg	* P<.9 -
	a R m osm eat liv MXB 17m26				no dre	P=1.
145	R m osm eat liv hem 29m31 ev				no dre	P=1. -
	a R m osm eat tba mix 29m31 ev				no dre	P=1. -
146	R m osm eat liv tum 25m25				no dre	P=1. -
	a R m osm eat tba mix 25m25				4.21mg	P<.6 -
147	R f nss eat tba tum 24m24				no dre	P=1. -
148	R m nss eat tba tum 24m24				no dre	P=1. -

Spe	Strain	Site	Xpo+Xpt	Notes	TD50	2Tailpvl	DR	AuOp
Sex	Route	Hist						
149	R f sde eat	liv tum	24m24	es	>	no dre	P=1.	-
a	R f sde eat	tba tum	24m24	es		no dre	P=1.	
b	R f sde eat	tba mal	24m24	es		no dre	P=1.	
ALKYLBENZENESULFONATE, LINEAR					100ng...1ug...10...100...1mg...10...100...1g...10			
150	R f sls eat	pre mix	33m34	er	>	no dre	P=1.	-
151	R a sls eat	pre mix	29m32	er	>	no dre	P=1.	-
ALLYL CHLORIDE*					100ng...1ug...10...100...1mg...10...100...1g...10			
152	M f b6c gav	sto MXA	78w91	dv	>	+historical	* P<.2	a
a	M f b6c gav	TBA MXB	78w91	dv		343.mg	* P<.3	
b	M f b6c gav	liv MXB	78w91	dv		2.18gm	* P<.4	
c	M f b6c gav	lun MXB	78w91	dv		1.25gm	* P<.6	
153	M a b6c gav	sto MXA	67w91	adsv	>	+historical	* P<.4	a
a	M a b6c gav	TBA MXB	67w91	adsv		184.mg	* P<.4	
b	M a b6c gav	liv MXB	67w91	adsv		457.mg	* P<.6	
c	M a b6c gav	lun MXB	67w91	adsv		no dre	P=1.	
154	R f oam gav	TBA MXB	18m26	sv	>	35.2mg	* P<.2	
a	R f oam gav	liv MXB	18m26	sv		no dre	P=1.	
155	R a oam gav	TBA MXB	18m26	sv	>	28.1mg	* P<.2	
a	R a oam gav	liv MXB	18m26	sv		no dre	P=1.	
ALLYLHYDRAZINE.HCl					100ng...1ug...10...100...1mg...10...100...1g...10			
156	M f swa wat	lun mix	24m24	e	+	38.4mg	P<.0005+	
a	M f swa wat	lun ade	24m24	e		46.1mg	P<.002	
b	M f swa wat	lun adc	24m24	e		96.0mg	P<.003	
c	M f swa wat	blv mix	24m24	e		119.ng	P<.02	+
d	M f swa wat	blv agm	24m24	e		163.mg	P<.02	
e	M f swa wat	liv mix	24m24	e		234.mg	P<.09	
157	M a swa wat	lun ade	93w93	e	+	28.9mg	P<.0005	
a	M a swa wat	lun mix	93w93	e		30.9mg	P<.005	+
b	M a swa wat	liv hpt	93w93	e		274.mg	P<.04	-
c	M a swa wat	liv mix	93w93	e		no dre	P=1.	
ALUMINUM POTASSIUM SULFATE					100ng...1ug...10...100...1mg...10...100...1g...10			
158	M f cd1 wat	lkm	31m31	e	+	5.32mg	P<.02	-
a	M f cd1 wat	lun tum	31m31	e		11.4mg	P<.4	-
b	M f cd1 wat	tba mal	31m31	e		4.42mg	P<.02	-
c	M f cd1 wat	tba mix	31m31	e		4.23mg	P<.2	-
159	M a cd1 wat	lun tum	35m35	e	>	11.4mg	P<.4	-
a	M a cd1 wat	tba mal	35m35	e		6.29mg	P<.03	-
b	M a cd1 wat	tba mix	35m35	e		10.7mg	P<.5	-
160	R f leb wat	tba mix	38m38	e	>	4.68mg	P<.9	-
a	R f leb wat	tba mal	38m38	e		no dre	P=1.	-
161	R a leb wat	tba mix	36m36	e	+	.663mg	P<.006	-
a	R a leb wat	tba mal	36m36	e		1.93mg	P<.2	-
3-AMINO-1,4-DIMETHYL-5H-PYRIDO[4,3-b]INDOLE ACETATE					10...100...1mg...10...100...1g...10			
162	M f cdf eat	liv mix	88w88		+	25.0mg	P<.0005+	
a	M f cdf eat	liv hpc	88w88			29.6mg	P<.0005+	
b	M f cdf eat	lun adc	88w88			no dre	P=1.	
c	M f cdf eat	lun ade	88w88			no dre	P=1.	
163	M a cdf eat	liv mix	88w88		+	109.mg	P<.08	+
a	M a cdf eat	liv hpc	88w88			112.mg	P<.02	+
b	M a cdf eat	lun adc	88w88			no dre	P=1.	
c	M a cdf eat	lun ade	88w88			no dre	P=1.	
3-AMINO-4-ETHOXYACETANILIDE					100ng...1ug...10...100...1mg...10...100...1g...10			
164	M f b6c eat	pit MXA	78w93		+	#1.05gm	\ P<.009	-
a	M f b6c eat	TBA MXB	78w93			569.mg	\ P<.02	
b	M f b6c eat	liv MXB	78w93			no dre	P=1.	
c	M f b6c eat	lun MXB	78w93			8.63gm	* P<.4	
165	M a b6c eat	thy MXA	78w93		+	2.07gm	/ P<.0005c	
a	M a b6c eat	thy fcc	78w93			3.77gm	/ P<.0005c	
b	M a b6c eat	thy MXA	78w93			4.02gm	* P<.02	c
c	M a b6c eat	TBA MXB	78w93			no dre	P=1.	
d	M a b6c eat	liv MXB	78w93			8.99gm	\ P<.9	
e	M a b6c eat	lun MXB	78w93			no dre	P=1.	
166	R f f34 eat	adr MXA	18m25		+	#415.mg	\ P<.005	-
a	R f f34 eat	TBA MXB	18m25			no dre	P=1.	
b	R f f34 eat	liv MXB	18m25			717.mg	\ P<.002	
167	R a f34 eat	thy ccr	18m25		+	#610.mg	\ P<.05	-
a	R a f34 eat	TBA MXB	18m25			no dre	P=1.	
b	R a f34 eat	liv MXB	18m25			no dre	P=1.	
3-AMINO-9-ETHYLCARBAZOLE.HCl					100ng...1ug...10...100...1mg...10...100...1g...10			
168	M f b6c eat	liv hpc	78w95		+	33.0mg	P<.0005c	
a	M f b6c eat	TBA MXB	78w95			41.8mg	P<.0005	
b	M f b6c eat	liv MXB	78w95			33.0mg	P<.0005	
c	M f b6c eat	lun MXB	78w95			1.78gm	P<.6	

	Spe	Strain	Site	Xpo+Xpt	Notes		TD50	
							DR	2Tailpvl AuOp
169	M m	b6c	eat liv	hpc	78w95		46.4mg	P<.0005c
a	M m	b6c	eat liv	MXA	78w95	: + :	49.8mg	P<.0005c
b	M m	b6c	eat TBA	MXB	78w95		70.6mg	P<.005
c	M m	b6c	eat liv	MXB	78w95		49.8mg	P<.0005
d	M m	b6c	eat lun	MXB	78w95		no dre	P=1.
170	R f	f34	eat MXB	MXB	18m25	: + :	55.1mg	P<.0005
a	R f	f34	eat ute	ecn	18m25		106.mg	P<.0005c
b	R f	f34	eat zym	MXA	18m25		151.mg	P<.0005c
c	R f	f34	eat zym	sqc	18m25		212.mg	P<.0005c
d	R f	f34	eat liv	MXA	18m25		237.mg	P<.002 c
e	R f	f34	eat TBA	MXB	18m25		44.7mg	P<.007
f	R f	f34	eat liv	MXB	18m25		237.mg	P<.002
171	R m	f34	eat MXB	MXB	18m25	: + :	28.1mg	P<.0005
a	R m	f34	eat liv	MXA	18m25		39.2mg	P<.0005c
b	R m	f34	eat liv	hpc	18m25		156.mg	P<.007 c
c	R m	f34	eat MXA	MXA	18m25		203.mg	P<.003 c
d	R m	f34	eat zym	MXA	18m25		240.mg	P<.003 c
e	R m	f34	eat MXA	MXA	18m25		257.mg	P<.007 c
f	R m	f34	eat TBA	MXB	18m25		42.7mg	P<.03
g	R m	f34	eat liv	MXB	18m25		39.2mg	P<.0005
3-AMINO-9-ETHYLCARBAZOLE MIXTURE 100ng...1ug.....10.....100.....1mg.....10.....100.....1g.....10								
172	M f	b6c	eat liv	hpc	78w95	:+ :	30.5mg	P<.0005c
a	M f	b6c	eat TBA	MXB	78w95		59.7mg	P<.008
b	M f	b6c	eat liv	MXB	78w95		30.5mg	P<.0005
c	M f	b6c	eat lun	MXB	78w95		7.49gm	P<1.
173	M m	b6c	eat liv	hpc	78w94	: + :	50.4mg	P<.0005c
a	M m	b6c	eat TBA	MXB	78w94		64.9mg	P<.007
b	M m	b6c	eat liv	MXB	78w94		50.4mg	P<.0005
c	M m	b6c	eat lun	MXB	78w94		4.13gm	P<1.
174	R f	f34	eat zym	MXA	18m24	: + :	58.0mg	P<.0005c
a	R f	f34	eat zym	sqc	18m24		95.4mg	P<.006 c
b	R f	f34	eat zym	can	18m24		148.mg	P<.01 c
c	R f	f34	eat TBA	MXB	18m24		18.2mg	P<.04
d	R f	f34	eat liv	MXB	18m24		no dre	P=1.
175	R m	f34	eat MXB	MXB	18m24	: + :	11.8mg	P<.0005
a	R m	f34	eat liv	MXA	18m24		17.1mg	P<.0005c
b	R m	f34	eat liv	hpc	18m24		42.6mg	P<.002 c
c	R m	f34	eat ski	MXA	18m24		45.0mg	P<.0005c
d	R m	f34	eat ski	MXA	18m24		62.8mg	P<.003 c
e	R m	f34	eat zym	MXA	18m24		104.mg	P<.009 c
f	R m	f34	eat TBA	MXB	18m24		10.6mg	P<.0005
g	R m	f34	eat liv	MXB	18m24		17.1mg	P<.0005
3-AMINO-1-METHYL-5H-PYRIDO[4,3-b]INDOLE ACETATE.....10.....100.....1mg.....10.....100.....1g.....10								
176	M f	cdf	eat liv	hpc	88w88 e	. + .	6.81mg	P<.0005+
a	M f	cdf	eat lun	adc	88w88		no dre	P=1.
b	M f	cdf	eat lun	ade	88w88		no dre	P=1.
177	M m	cdf	eat lun	adc	88w88	. ±	81.1mg	P<.1
a	M m	cdf	eat liv	hpc	88w88 e		88.2mg	P<.04 +
b	M m	cdf	eat liv	mix	88w88 e		83.2mg	P<.2 +
c	M m	cdf	eat lun	ade	88w88		224.mg	P<.3
178	R f	aci	eat liv	nnd	29m29 e	. + .	5.32mg	P<.0005+
a	R f	aci	eat liv	mix	29m29 e		5.32mg	P<.0005+
b	R f	aci	eat liv	hms	29m29 e		46.2mg	P<.1 +
c	R f	aci	eat jaj	adc	29m29 e		46.2mg	P<.1 +
d	R f	aci	eat ilm	ade	29m29 e		46.2mg	P<.1 +
179	R m	aci	eat liv	tum	29m29 e	>	no dre	P=1.
1-AMINO-2-METHYLANTHRAQUINONE 100ng...1ug.....10.....100.....1mg.....10.....100.....1g.....10								
180	M f	b6c	eat liv	MXA	70w97 aeesv	: ±	174.mg *	P<.07 c
a	M f	b6c	eat TBA	MXB	70w97 aeesv		no dre	P=1.
b	M f	b6c	eat liv	MXB	70w97 aeesv		174.mg *	P<.07
c	M f	b6c	eat lun	MXB	70w97 aeesv		no dre	P=1.
181	M m	b6c	eat TBA	MXB	70w97 aeesv	:>	no dre	P=1. -
a	M m	b6c	eat liv	MXB	70w97 aeesv		no dre	P=1.
b	M m	b6c	eat lun	MXB	70w97 aeesv		no dre	P=1.
182	R f	f34	eat liv	MXA	18m24 v	: + :	115.mg *	P<.003 c
a	R f	f34	eat liv	hpc	18m24 v		182.mg *	P<.002 c
b	R f	f34	eat TBA	MXB	18m24 v		no dre	P=1.
c	R f	f34	eat liv	MXB	18m24 v		115.mg *	P<.003
183	R m	f34	eat MXB	MXB	18m24 v	: + :	34.1mg *	P<.0005
a	R m	f34	eat liv	MXA	18m24 v		39.9mg *	P<.0005c
b	R m	f34	eat kid	MXA	18m24 v		131.mg *	P<.0005c
c	R m	f34	eat pit	MXA	18m24 v		136.mg *	P<.006
d	R m	f34	eat liv	hpc	18m24 v		150.mg *	P<.008 c
e	R m	f34	eat kid	tla	18m24 v		196.mg *	P<.003
f	R m	f34	eat thy	MXA	18m24 v		283.mg *	P<.007
g	R m	f34	eat kid	MXA	18m24 v		441.mg *	P<.02

Spe	Strain	Site	Xpo+Xpt	TD50	2Tailpvl
Sex	Route	Hist	Notes	DR	AnOp
h	R m f34 eat	TBA	MXB 18m24 v	64.4mg *	P<.07
i	R m f34 eat	liv	MXB 18m24 v	39.9mg *	P<.0005
2-AMINO-5-(5-NITRO-2-FURYL)-1,3,4-OXADIAZOLE10.....100.....1mg.....10.....100.....1g.....10					
184	R f sda eat	mgl mix	46w66 ev	3.67mg	P<.0005+
a	R f sda eat	mgl adc	46w66 ev	7.98mg	P<.0005
b	R f sda eat	for sqp	46w66 ev	37.0mg	P<.009 +
c	R f sda eat	k/p tcc	46w66 ev	+historical	P<.02 +
d	R f sda eat	lun alc	46w66 ev	242.mg	P<.3 +
e	R f sda eat	liv tum	46w66 ev	no dre	P=1.
f	R f sda eat	tba mix	46w66 ev	2.74mg	P<.0005
2-AMINO-5-(5-NITRO-2-FURYL)-1,3,4-THIADIAZOLE10.....100.....1mg.....10.....100.....1g.....10					
185	R f sda eat	mgl mix	45w66 ev	.662mg	P<.0005+
a	R f sda eat	mgl adc	45w66 ev	1.20mg	P<.0005
b	R f sda eat	for sqp	45w66 ev	23.7mg	P<.07 +
c	R f sda eat	lun alc	45w66 ev	73.4mg	P<.3 +
d	R f sda eat	k/p tcc	45w66 ev	+historical	P<.3 +
e	R f sda eat	liv tum	45w66 ev	no dre	P=1.
f	R f sda eat	tba mix	45w66 ev	.662mg	P<.0005
2-AMINO-4-(5-NITRO-2-FURYL)THIAZOLE10.....100.....1mg.....10.....100.....1g.....10					
186	M f swi eat	for mix	46w55 e	7.87mg	P<.0005+
a	M f swi eat	for sqp	46w55 e	11.5mg	P<.0005
b	M f swi eat	liv tum	46w55 e	no dre	P=1.
c	M f swi eat	lun tum	46w55 e	no dre	P=1.
d	M f swi eat	tba mix	46w55 e	6.83mg	P<.0005
4-AMINO-2-NITROPHENOL 100ng.....1ug.....10.....100.....1mg.....10.....100.....1g.....10					
187	M f b6c eat	TBA	MXB 24m24	>	no dre P=1. -
a	M f b6c eat	liv	MXB 24m24	3.65mg *	P<.3
b	M f b6c eat	lun	MXB 24m24	no dre	P=1.
188	M m b6c eat	TBA	MXB 24m24	>	no dre P=1. -
a	M m b6c eat	liv	MXB 24m24	2.25mg *	P<.7
b	M m b6c eat	lun	MXB 24m24	no dre	P=1.
189	R f f34 eat	ubl tcc	24m24	>	+historical * P<.3 a
a	R f f34 eat	TBA	MXB 24m24	no dre	P=1.
b	R f f34 eat	liv	MXB 24m24	no dre	P=1.
190	R m f34 eat	ubl tcc	24m24	: + :	309.mg / P<.002 c
a	R m f34 eat	TBA	MXB 24m24	270.mg /	P<.4
b	R m f34 eat	liv	MXB 24m24	no dre	P=1.
2-AMINO-4-(p-NITROPHENYL)THIAZOLE 100ng.....1ug.....10.....100.....1mg.....10.....100.....1g.....10					
191	M f swi eat	--- lle	46w66 e	9.95mg	P<.03 +
a	M f swi eat	liv tum	46w66 e	no dre	P=1.
b	M f swi eat	lun tum	46w66 e	no dre	P=1.
c	M f swi eat	tba mix	46w66 e	9.95mg	P<.03
2-AMINO-5-NITROTHIAZOLE 100ng.....1ug.....10.....100.....1mg.....10.....100.....1g.....10					
192	M f b6c eat	TBA	MXB 24m24	>	no dre P=1. -
a	M f b6c eat	liv	MXB 24m24	109.mg *	P<.4
b	M f b6c eat	lun	MXB 24m24	63.5mg *	P<.09
193	M m b6c eat	TBA	MXB 24m24	>	no dre P=1. -
a	M m b6c eat	liv	MXB 24m24	no dre	P=1.
b	M m b6c eat	lun	MXB 24m24	no dre	P=1.
194	R f f34 eat	ute esp	26m26	: ±	#57.2mg \ P<.03 -
a	R f f34 eat	TBA	MXB 26m26	326.mg *	P<.9
b	R f f34 eat	liv	MXB 26m26	no dre	P=1.
195	R m f34 eat	--- MXA	26m26	: + :	27.6mg * P<.003 a
a	R m f34 eat	MXB	MXB 26m26	27.6mg *	P<.003
b	R m f34 eat	mul grl	26m26	90.2mg *	P<.02 a
c	R m f34 eat	MXA	MXA 26m26	445.mg *	P<.7 a
d	R m f34 eat	TBA	MXB 26m26	32.3mg *	P<.2
e	R m f34 eat	liv	MXB 26m26	318.mg *	P<.2
196	R f sda eat	mgl mix	46w66 ev	. ±	44.6mg P<.03 +
a	R f sda eat	k/p tcc	46w66 v	+historical	P<.09 +
b	R f sda eat	lun alc	46w66 v	157.mg	P<.09 +
c	R f sda eat	liv tum	46w66 v	no dre	P=1.
d	R f sda eat	tba mix	46w66 v	32.5mg	P<.006
2-AMINO-5-PHENYL-2-OXAZOLIN-4-ONE + Mg(OH)2 1ug.....10.....100.....1mg.....10.....100.....1g.....10					
197	R f sda eat	liv tum	46w66 e	>	no dre P=1.
a	R f sda eat	tba mix	46w66 e	3.01mg	P<.04 -
198	R f sda eat	liv tum	46w66 e	>	no dre P=1.
a	R f sda eat	tba mix	46w66 e	no dre	P=1. -
2-AMINOANTHRAQUINONE 100ng.....1ug.....10.....100.....1mg.....10.....100.....1g.....10					
199	M f b6c eat	MXB	MXB 79w94	: + :	1.49gm * P<.0005
a	M f b6c eat	liv	hpc 79w94	2.82gm *	P<.004 c

CARCINOGENIC POTENCY DATABASE

RefNum	LoConf	UpConf	Cntrl	1Dose	1Inc	2Dose	2Inc	Citation or Pathology	Brkly Code
h	c01901	26.1mg	n.s.s.	26/50	30.4mg	42/50	60.0mg	35/50	
i	c01901	25.8mg	83.7mg	3/50	30.4mg	25/50	60.0mg	24/50	Liv:hpa,hpc,nnd.
2-AMINO-5-(5-NITRO-2-FURYL)-1,3,4-OXADIAZOLE 3775-55-1									
184	1126	2.06mg	7.05mg	2/24	26.9mg	29/33			Cohen;jnci,54,841-850;1975
a	1126	4.59mg	15.4mg	0/24	26.9mg	20/33			
b	1126	15.1mg	855.mg	0/24	26.9mg	6/33			
c	1126	17.1mg	n.s.s.	0/24	26.9mg	5/33			
d	1126	39.3mg	n.s.s.	0/24	26.9mg	1/33			
e	1126	73.8mg	n.s.s.	0/24	26.9mg	0/33			
f	1126	1.41mg	5.35mg	2/24	26.9mg	31/33			
2-AMINO-5-(5-NITRO-2-FURYL)-1,3,4-THIADIAZOLE 712-68-5									
185	1126	.293mg	1.36mg	2/24	8.18mg	32/33			Cohen;jnci,54,841-850;1975
a	1126	.695mg	2.16mg	0/24	8.18mg	28/33			
b	1126	7.17mg	n.s.s.	0/24	8.18mg	3/33			
c	1126	11.9mg	n.s.s.	0/24	8.18mg	1/33			
d	1126	11.9mg	n.s.s.	0/24	8.18mg	1/33			
e	1126	22.4mg	n.s.s.	0/24	8.18mg	0/33			
f	1126	.293mg	1.36mg	2/24	8.18mg	32/33			
2-AMINO-4-(5-NITRO-2-FURYL)THIAZOLE 38514-71-5									
186	1076	4.20mg	15.3mg	0/29	90.2mg	24/27			Cohen;canr,33,1593-1597;1973
a	1076	6.42mg	22.3mg	0/29	90.2mg	21/27			
b	1076	140.mg	n.s.s.	0/29	90.2mg	0/27			
c	1076	140.mg	n.s.s.	0/29	90.2mg	0/27			
d	1076	3.40mg	14.0mg	2/29	90.2mg	25/27			
4-AMINO-2-NITROPHENOL 119-34-6									
187	c03963	558.mg	n.s.s.	8/20	159.mg	17/50	319.mg	16/50	
a	c03963	1.26gm	n.s.s.	0/20	159.mg	2/50	319.mg	2/50	Liv:hpa,hpc,nnd.
b	c03963	1.73gm	n.s.s.	2/20	159.mg	3/50	319.mg	2/50	Lun:a/a,e/c.
188	c03963	301.mg	n.s.s.	12/20	147.mg	32/50	294.mg	28/50	
a	c03963	336.mg	n.s.s.	6/20	147.mg	18/50	294.mg	19/50	Liv:hpa,hpc,nnd.
b	c03963	863.mg	n.s.s.	5/20	147.mg	10/50	294.mg	7/50	Lun:a/a,e/c.
189	c03963	563.mg	n.s.s.	0/20	61.3mg	1/49	123.mg	2/50	
a	c03963	140.mg	n.s.s.	13/20	61.3mg	34/49	123.mg	28/50	
b	c03963	n.s.s.	n.s.s.	0/20	61.3mg	0/49	123.mg	0/50	Liv:hpa,hpc,nnd.
190	c03963	155.mg	1.14gm	0/20	49.0mg	0/50	98.1mg	11/50	
a	c03963	71.2mg	n.s.s.	12/20	49.0mg	22/50	98.1mg	35/50	
b	c03963	604.mg	n.s.s.	0/20	49.0mg	1/50	98.1mg	0/50	Liv:hpa,hpc,nnd.
2-AMINO-4-(p-NITROPHENYL)THIAZOLE 2104-09-8									
191	1076	3.42mg	n.s.s.	1/28	9.06mg	5/20			Cohen;canr,33,1593-1597;1973
a	1076	15.0mg	n.s.s.	0/28	9.06mg	0/20			
b	1076	15.0mg	n.s.s.	0/28	9.06mg	0/20			
c	1076	3.42mg	n.s.s.	1/28	9.06mg	5/20			
2-AMINO-5-NITROTHIAZOLE 121-66-4									
192	c03065	15.3mg	n.s.s.	26/50	6.50mg	31/50	13.0mg	28/50	
a	c03065	29.0mg	n.s.s.	2/50	6.50mg	6/50	13.0mg	5/50	Liv:hpa,hpc,nnd.
b	c03065	24.6mg	n.s.s.	2/50	6.50mg	4/50	13.0mg	8/50	Lun:a/a,e/c.
193	c03065	10.5mg	n.s.s.	39/50	6.00mg	32/50	12.0mg	34/50	
a	c03065	19.5mg	n.s.s.	20/50	6.00mg	16/50	12.0mg	15/50	Liv:hpa,hpc,nnd.
b	c03065	20.8mg	n.s.s.	14/50	6.00mg	12/50	12.0mg	12/50	Lun:a/a,e/c.
194	c03065	22.8mg	n.s.s.	2/50	14.9mg	9/50 (29.7mg	3/50)		S
a	c03065	21.1mg	n.s.s.	40/50	14.9mg	44/50	29.7mg	44/50	
b	c03065	n.s.s.	n.s.s.	0/50	14.9mg	0/50	29.7mg	0/50	Liv:hpa,hpc,nnd.
195	c03065	14.6mg	147.mg	13/50	11.9mg	19/50	23.8mg	28/50	---:leu,lym.
a	c03065	14.6mg	147.mg	13/50	11.9mg	19/50	23.8mg	28/50	---:leu,lle,lym,my; mul:grl,ule. A
b	c03065	40.1mg	n.s.s.	2/50	11.9mg	4/50	23.8mg	9/50	
c	c03065	56.5mg	n.s.s.	6/50	11.9mg	4/50	23.8mg	6/50	---:lle,my; mul:ule.
d	c03065	11.7mg	n.s.s.	36/50	11.9mg	37/50	23.8mg	39/50	
e	c03065	78.3mg	n.s.s.	0/50	11.9mg	1/50	23.8mg	1/50	Liv:hpa,hpc,nnd.
196	1126	17.4mg	n.s.s.	2/39	33.4mg	8/35			Cohen;jnci,54,841-850;1975
a	1126	38.6mg	n.s.s.	0/39	33.4mg	2/35			
b	1126	38.6mg	n.s.s.	0/39	33.4mg	2/35			
c	1126	97.1mg	n.s.s.	0/39	33.4mg	0/35			
d	1126	14.2mg	371.mg	2/39	33.4mg	10/35			
2-AMINO-5-PHENYL-2-OXAZOLIN-4-ONE + Mg(OH)2 (magnesium pemoline) 18968-99-5									
197	200an	8.10mg	n.s.s.	0/35	2.79mg	0/35			Cohen;jnci,51,403-417;1973
a	200an	1.18mg	n.s.s.	4/35	2.79mg	11/35			
198	200an	162.mg	n.s.s.	0/35	55.8mg	0/35			
a	200an	122.mg	n.s.s.	4/35	55.8mg	1/35			
2-AMINOANTHRAQUINONE 117-79-3									
199	c01876	805.mg	4.96gm	11/100	539.mg	9/50	1.08gm	23/50	---:lym; Liv:hpc. C
a	c01876	1.33gm	23.7gm	5/100	539.mg	5/50	1.08gm	12/50	

Spe	Strain	Site	Xpo + Xpt	Notes	TD50	2Tailpvl
Sex	Route	Hist			DR	AuOp
b	M f	b6c eat	---	lym 79w94	3.16gm	* P<.02 c
c	M f	b6c eat	TBA	MXB 79w94	1.62gm	/ P<.02
d	M f	b6c eat	liv	MXB 79w94	2.82gm	* P<.004
e	M f	b6c eat	lun	MXB 79w94	33.4gm	* P<.7
200	M m	b6c eat	liv	hpc 79w93	755.mg	* P<.0005c
a	M m	b6c eat	liv	MXA 79w93	798.mg	* P<.0005c
b	M m	b6c eat	TBA	MXB 79w93	952.mg	/ P<.008
c	M m	b6c eat	liv	MXB 79w93	798.mg	* P<.0005
d	M m	b6c eat	lun	MXB 79w93	19.4gm	* P<.8
201	R f	f34 eat	TBA	MXB 18m25 s	124.mg	P<.6 -
a	R f	f34 eat	liv	MXB 18m25 s	no dre	P=1.
202	R m	f34 eat	liv	MXA 18m25 v	101.mg	\ P<.0005c
a	R m	f34 eat	liv	hpc 18m25 v	268.mg	\ P<.002 c
b	R m	f34 eat	TBA	MXB 18m25 v	759.mg	* P<.6
c	R m	f34 eat	liv	MXB 18m25 v	101.mg	\ P<.0005
o-AMINOAZOTOLUENE					100ng...1ug...10...100...1mg...10...100...1g...10	
203	M m	cf1 eat	lun	ade 26w65 e	80.2mg	P<.6
a	M m	cf1 eat	liv	mix 26w65 e	no dre	P=1.
204	R f	alb eat	liv	mix 63w63 ems	3.70mg	P<.002 +
a	R f	alb eat	liv	hpn 63w63 ems	8.49mg	P<.02 +
b	R f	alb eat	liv	lca 63w63 ems	21.4mg	P<.2 +
205	R m	alb eat	liv	mix 67w67 ems	4.46mg	P<.005 +
a	R m	alb eat	liv	hpn 67w67 ems	11.5mg	P<.06 +
b	R m	alb eat	liv	lca 67w67 ems	15.2mg	P<.1 +
4-AMINODIPHENYL					100ng...1ug...10...100...1mg...10...100...1g...10	
206	M f	abi gav	ubl	car 39w94	5.94mg	P<.05 +
a	M f	abi gav	liv	hpt 39w94 e	no dre	P=1. -
207	M m	abi gav	liv	hpt 39w94 e	3.84mg	P<.5 -
a	M m	abi gav	ubl	car 39w94 e	11.6mg	P<.4 +
208	M f	cif gav	liv	mix 50w70 r	.993mg	P<.0005
a	M f	cif gav	liv	mhp 50w70 r	3.05mg	P<.0005
209	M m	cif gav	liv	mix 50w70 r	3.91mg	P<.002 +
a	M m	cif gav	liv	mhp 50w70 r	7.50mg	P<.02
b	M m	cif gav	ubl	car 50w70 r	32.5mg	P<.3 +
2-AMINODIPHENYLENE OXIDE					100ng...1ug...10...100...1mg...10...100...1g...10	
210	M f	cif eat	liv	mhp 52w58 r	noTD50	P<.0005
a	M f	cif eat	liv	mix 52w58 r	noTD50	P<.0005+
211	M m	cif eat	liv	mix 52w67 r	5.73mg	P<.0005+
a	M m	cif eat	liv	mhp 52w67 r	8.67mg	P<.0005
b	M m	cif eat	ubl	car 52w67 r	22.3mg	P<.004 +
3-AMINOTRIAZOLE					100ng...1ug...10...100...1mg...10...100...1g...10	
212	M f	b6a orl	liv	hpt 59w59 evx	24.5mg	P<.0005+
a	M f	b6a orl	lun	mix 59w59 evx	no dre	P=1.
b	M f	b6a orl	tba	mix 59w59 evx	25.6mg	P<.0005
213	M m	b6a orl	liv	hpt 52w52 evx	26.0mg	P<.0005+
a	M m	b6a orl	lun	ade 52w52 evx	no dre	P=1.
b	M m	b6a orl	tba	mix 52w52 evx	28.0mg	P<.0005
214	M f	b6c orl	liv	hpt 57w57 evx	noTD50	P<.0005
a	M f	b6c orl	lun	ade 57w57 evx	no dre	P=1.
b	M f	b6c orl	tba	mix 57w57 evx	noTD50	P<.0005
215	M m	b6c orl	liv	hpt 53w53 evx	25.4mg	P<.0005+
a	M m	b6c orl	lun	ade 53w53 evx	no dre	P=1.
b	M m	b6c orl	tba	mix 53w53 evx	30.8mg	P<.002
216	R b	nss eat	thy	ade 24m24 er	3.74mg	* P<.0005
217	R f	wis wat	tyf	mal 16m24 r	102.mg	P<.002
AMMONIUM CHLORIDE					100ng...1ug...10...100...1mg...10...100...1g...10	
218	M f	ifc wat	ubl	car 93w93 r	no dre	P=1.
219	M f	ifc wat	ubl	tum 52w52 ekr	>	no dre P=1.
AMMONIUM CITRATE					100ng...1ug...10...100...1mg...10...100...1g...10	
220	R m	wis eat	liv	tum 52w65 ek	>	no dre P=1. -
AMMONIUM HYDROXIDE					100ng...1ug...10...100...1mg...10...100...1g...10	
221	M f	c3h wat	mgl	adc 24m24	>	no dre P=1. -
222	M f	swi wat	lun	mix 28m28 ee	>	no dre P=1. -
a	M f	swi wat	liv	mix 28m28 ee	no dre	P=1.
223	M m	swi wat	lun	adc 28m29 ee	± 7.33gm	* P<.03 -
a	M m	swi wat	liv	mix 28m29 ee	15.3gm	* P<.7 -
b	M m	swi wat	liv	mix 28m29 ee	26.7gm	* P<.7
1-AMYL-1-NITROSOUREA					100ng...1ug...10...100...1mg...10...100...1g...10	
224	R f	don wat	eso	tum 65w65	.967mg	Z P<.0005
a	R f	don wat	dgt	mix 65w65	1.15mg	* P<.0005+
b	R f	don wat	for	tum 65w65	1.35mg	* P<.0005

CARCINOGENIC POTENCY DATABASE

RefNum	LoConf	UpConf	Cntrl	1Dose	1Inc	2Dose	2Inc	Citation or Pathology	Brkly Code
b	c01876	1.38gm n.s.s.	7/100	539.mg	6/50	1.08gm	12/50		
c	c01876	742.mg n.s.s.	27/100	539.mg	16/50	1.08gm	29/50		
d	c01876	1.33gm 23.7gm	5/100	539.mg	5/50	1.08gm	12/50		
e	c01876	3.75gm n.s.s.	4/100	539.mg	2/50	1.08gm	3/50		liv:hpa,hpc,nnd. lun:a/a,a/c.
200	c01876	449.mg 1.83gm	18/100	498.mg	20/50	1.01gm	36/50		
a	c01876	463.mg 2.11gm	20/100	498.mg	20/50	1.01gm	36/50		liv:hpa,hpc.
b	c01876	458.mg 20.0gm	41/100	498.mg	28/50	1.01gm	42/50		
c	c01876	463.mg 2.11gm	20/100	498.mg	20/50	1.01gm	36/50		liv:hpa,hpc,nnd. lun:a/a,a/c.
d	c01876	1.94gm n.s.s.	17/100	498.mg	8/50	1.01gm	11/50		
201	c01876	18.9mg n.s.s.	19/25	71.0mg	17/50				
a	c01876	89.0mg n.s.s.	2/25	71.0mg	1/50				liv:hpa,hpc,nnd. liv:hpc,nnd.
202	c01876	57.8mg 204.mg	0/50	102.mg	18/50	(203.mg 18/50)			
a	c01876	121.mg 1.13gm	0/50	102.mg	8/50	(203.mg 5/50)			
b	c01876	145.mg n.s.s.	20/50	102.mg	26/50	203.mg 30/50			
c	c01876	57.8mg 204.mg	0/50	102.mg	18/50	(203.mg 18/50)			liv:hpa,hpc,nnd.
o-AMINAZOTOLUENE 97-56-3									
203	103	11.5mg n.s.s.	95/288	28.8mg	9/23			Walker;fctx,11,415-432;1973	
a	103	22.7mg n.s.s.	58/288	28.8mg	4/23				
204	30	1.16mg 16.9mg	0/5	28.6mg	6/7			Waters;yjba,10,179-184;1937	
a	30	2.77mg n.s.s.	0/5	28.6mg	4/7				
b	30	5.18mg n.s.s.	0/5	28.6mg	2/7				
205	30	1.91mg 27.7mg	0/4	21.7mg	9/12				
a	30	4.27mg n.s.s.	0/4	21.7mg	5/12				
b	30	5.20mg n.s.s.	0/4	21.7mg	4/12				
4-AMINODIPHENYL 92-67-1									
206	1165	.957mg n.s.s.	0/28	2.37mg	1/5			Clayson;bjca,19,297-310;1965/Williams 1962	
a	1165	1.99mg n.s.s.	4/26	2.37mg	0/5				
207	1165	.761mg n.s.s.	5/13	1.97mg	7/13				
a	1165	1.88mg n.s.s.	0/5	1.97mg	1/11				
208	31	.544mg 1.94mg	1/31	6.12mg	24/28			Clayson;bjca,21,755-762;1967	
a	31	1.58mg 6.92mg	0/31	6.12mg	13/28				
209	31	1.67mg 16.2mg	0/19	5.10mg	7/21				
a	31	2.58mg n.s.s.	0/19	5.10mg	4/21				
b	31	5.28mg n.s.s.	0/19	5.10mg	1/21				
2-AMINODIPHENYLENE OXIDE 3693-22-9									
210	31	n.s.s. 3.31mg	0/31	35.0mg	30/30			Clayson;bjca,21,755-762;1967	
a	31	n.s.s. 3.36mg	1/31	35.0mg	30/30				
211	31	2.94mg 12.6mg	0/19	27.9mg	15/20				
a	31	4.32mg 20.7mg	0/19	27.9mg	12/20				
b	31	9.02mg 126.mg	0/19	27.9mg	6/20				
3-AMINOTRIAZOLE (amitrol) 61-82-5									
212	35a	9.88mg 58.2mg	0/17	321.mg	17/18			Innes;ntis,1968/1969	
a	35a	384.mg n.s.s.	0/17	321.mg	0/18				
b	35a	10.0mg 66.8mg	2/17	321.mg	17/18				
213	35a	11.5mg 72.3mg	3/18	306.mg	16/18				
a	35a	283.mg n.s.s.	2/18	306.mg	0/18				
b	35a	11.8mg 98.4mg	5/18	306.mg	16/18				
214	35a	n.s.s. 37.3mg	0/18	323.mg	18/18				
a	35a	359.mg n.s.s.	1/18	323.mg	0/18				
b	35a	n.s.s. 42.2mg	3/18	323.mg	18/18				
215	35a	11.6mg 61.4mg	1/17	305.mg	16/18				
a	35a	294.mg n.s.s.	2/17	305.mg	0/18				
b	35a	12.5mg 146.mg	6/17	305.mg	16/18				
216	1513	2.17mg 8.86mg	0/5	.450mg	1/10	2.25mg 2/15	4.50mg 17/26	Jukes;scie,132,296-297;1960	
217	35	58.9mg 299.mg	0/10	96.2mg	19/40			Tsuda;jnci,57,861-864;1976	
AMMONIUM CHLORIDE 12125-02-9									
218	142a	8.57gm n.s.s.	0/26	2.00gm	0/26			Flaks;bjca,31,585-587;1975	
219	142b	2.68gm n.s.s.	0/26	2.00gm	0/26			Flaks;jnci,51,2007-2008;1973	
AMMONIUM CITRATE 3012-65-5									
220	2	2.10gm n.s.s.	0/7	1.54gm	0/17			Weisburger;txap,14,163-175;1969	
AMMONIUM HYDROXIDE 1336-21-6									
221	1117	264.mg n.s.s.	23/30	200.mg	24/40			Toth;jcn,9,109-118;1972/1969a	
222	1117	2.78gm n.s.s.	14/109	200.mg	12/50	400.mg 8/48	600.mg 4/42		
a	1117	7.33gm n.s.s.	3/89	200.mg	1/47	400.mg 2/41	600.mg 0/42		
223	1117	2.99gm n.s.s.	0/86	167.mg	2/49	333.mg 2/48	500.mg 2/44		
a	1117	2.36gm n.s.s.	10/86	167.mg	5/49	333.mg 5/48	500.mg 7/44		
b	1117	3.47gm n.s.s.	2/67	167.mg	1/46	333.mg 3/28	500.mg 1/43		
1-AMYL-1-NITROSUREA 10589-74-9									
224	1328	.559mg 1.86mg	0/20	3.06mg	20/35	(6.12mg 15/33)	12.2mg 18/33)	Fujii;gann,71,464-470;1980	
a	1328	.835mg 1.77mg	0/20	3.06mg	24/35	6.12mg 27/33	12.2mg 27/33		
b	1328	.982mg 2.17mg	0/20	3.06mg	21/35	6.12mg 27/33	12.2mg 25/33		

Spe	Strain	Site	Xpo+Xpt	Notes	TD50	2Tailpvl
Sex	Route	Hist			DR	AuOp
c	R f don wat	liv hpa	65w65		13.3mg *	P<.0005
d	R f don wat	---	mye 65w65		19.9mg *	P<.005 +
e	R f don wat	mgl mix	65w65		11.9mg *	P<.3 +
f	R f don wat	tba mix	65w65		1.93mg *	P<.002
225	R m don wat	for tum	65w65	. + .	.532mg Z	P<.0005
a	R m don wat	dgt mix	65w65		.532mg Z	P<.0005+
b	R m don wat	eso tum	65w65		1.44mg Z	P<.0005
c	R m don wat	---	mye 65w65		9.17mg *	P<.005 +
d	R m don wat	liv hpa	65w65		no dre	P=1.
e	R m don wat	tba mix	65w65		.541mg Z	P<.0005
ANHYDROGLUCOCHLORAL					100ng...1ug...10...100...1mg...10...100...1g...10	
226	M f b6a orl	lun ade	76w76 evx	>	19.5mg	P<.6 -
a	M f b6a orl	liv hpt	76w76 evx		no dre	P=1. -
b	M f b6a orl	tba mix	76w76 evx		17.3mg	P<.6 -
227	M m b6a orl	lun ade	76w76 evx	>	no dre	P=1. -
a	M m b6a orl	liv hpt	76w76 evx		no dre	P=1. -
b	M m b6a orl	tba mix	76w76 evx		no dre	P=1. -
228	M f b6c orl	liv hpt	76w76 evx	>	no dre	P=1. -
a	M f b6c orl	lun mix	76w76 evx		no dre	P=1. -
b	M f b6c orl	tba tum	76w76 evx		no dre	P=1. -
229	M m b6c orl	liv hpt	76w76 evx	. +	7.27mg	P<.05 -
a	M m b6c orl	lun ade	76w76 evx		11.2mg	P<.2 -
b	M m b6c orl	tba mix	76w76 evx		4.07mg	P<.009 -
ANILAZINE					100ng...1ug...10...100...1mg...10...100...1g...10	
230	M f b6c eat	TBA MXB	24m25	: +	99.2mg \	P<.02 -
a	M f b6c eat	liv MXB	24m25		2.55gm *	P<.5 -
b	M f b6c eat	lun MXB	24m25		1.69gm *	P<.2 -
231	M m b6c eat	TBA MXB	24m25	>	no dre	P=1. -
a	M m b6c eat	liv MXB	24m25		no dre	P=1. -
b	M m b6c eat	lun MXB	24m25		no dre	P=1. -
232	R f f34 eat	TBA MXB	24m24	>	no dre	P=1. -
a	R f f34 eat	liv MXB	24m24		1.05gm *	P<.5 -
233	R m f34 eat	TBA MXB	24m24	>	246. mg *	P<.7 -
a	R m f34 eat	liv MXB	24m24		no dre	P=1. -
ANILINE					100ng...1ug...10...100...1mg...10...100...1g...10	
234	R m wis wat	for pam	80w80	>	587. mg *	P<.2 -
a	R m wis wat	ubl tum	80w80		no dre	P=1. -
ANILINE.HCL					100ng...1ug...10...100...1mg...10...100...1g...10	
235	M f b6c eat	TBA MXB	24m25	>	9.15gm *	P<.6 -
a	M f b6c eat	liv MXB	24m25		8.85gm *	P<.2 -
b	M f b6c eat	lun MXB	24m25		no dre	P=1. -
236	M m b6c eat	TBA MXB	24m25	>	no dre	P=1. -
a	M m b6c eat	liv MXB	24m25		no dre	P=1. -
b	M m b6c eat	lun MXB	24m25		no dre	P=1. -
237	R f f34 eat	MXA MXA	24m25	: +	1.74gm *	P<.02 c
a	R f f34 eat	TBA MXB	24m25		no dre	P=1. -
b	R f f34 eat	liv MXB	24m25		13.0gm *	P<.4
238	R m f34 eat	MXB MXB	24m25	++ :	88.0mg *	P<.0005
a	R m f34 eat	MXA MXA	24m25		146. mg *	P<.0005c
b	R m f34 eat	spl hes	24m25		160. mg *	P<.0005c
c	R m f34 eat	MXA MXA	24m25		263. mg *	P<.0005c
d	R m f34 eat	spl MXA	24m25		451. mg *	P<.006 c
e	R m f34 eat	MXA MXA	24m25		572. mg *	P<.002 c
f	R m f34 eat	adr MXA	24m25		556. mg *	P<.05
g	R m f34 eat	TBA MXB	24m25		124. mg *	P<.0005
h	R m f34 eat	liv MXB	24m25		no dre	P=1. -
o-ANISIDINE.HCL					100ng...1ug...10...100...1mg...10...100...1g...10	
239	M f b6c eat	ubl MXA	24m24	: + :	1.00gm /	P<.0005c
a	M f b6c eat	ubl tcc	24m24		1.34gm /	P<.0005c
b	M f b6c eat	TBA MXB	24m24		21.1gm *	P<.1
c	M f b6c eat	liv MXB	24m24		no dre	P=1. -
d	M f b6c eat	lun MXB	24m24		no dre	P=1. -
240	M m b6c eat	ubl MXA	24m24	: + :	935. mg /	P<.0005c
a	M m b6c eat	ubl tcc	24m24		1.62gm /	P<.0005c
b	M m b6c eat	TBA MXB	24m24		no dre	P=1. -
c	M m b6c eat	liv MXB	24m24		no dre	P=1. -
d	M m b6c eat	lun MXB	24m24		no dre	P=1. -
241	R f f34 eat	ubl MXA	22m24 as	: + :	27.8mg /	P<.0005c
a	R f f34 eat	ubl tcc	22m24 as		29.1mg /	P<.0005c
b	R f f34 eat	ubl tpp	22m24 as		693. mg *	P<.002
c	R f f34 eat	TBA MXB	22m24 as		37.0mg /	P<.0005
d	R f f34 eat	liv MXB	22m24 as		no dre	P=1. -
242	R m f34 eat	MXB MXB	22m24 as	: + :	31.9mg /	P<.0005
a	R m f34 eat	ubl MXA	22m24 as		31.9mg /	P<.0005c

RefNum	LoConf	UpConf	Cntrl	1Dose	1Inc	2Dose	2Inc	Citation or Pathology	Brkly Code	
c	1328	7.01mg	37.2mg	0/20	3.06mg	0/35	6.12mg	5/33	12.2mg	8/33
d	1328	9.35mg	172.mg	0/20	3.06mg	1/35	6.12mg	2/33	12.2mg	6/33
e	1328	3.80mg	n.s.s.	6/20	3.06mg	12/35	6.12mg	15/33	12.2mg	15/33
f	1328	1.01mg	10.2mg	8/20	3.06mg	27/35	6.12mg	28/33	12.2mg	28/33
225	1328	.367mg	.840mg	0/14	2.14mg	29/35	4.29mg	27/35	(8.57mg)	20/35)
a	1328	.367mg	.840mg	0/14	2.14mg	29/35	4.29mg	27/35	(8.57mg)	22/35)
b	1328	.926mg	3.19mg	0/14	2.14mg	13/35	4.29mg	18/35	(8.57mg)	13/35)
c	1328	4.93mg	69.6mg	0/14	2.14mg	1/35	4.29mg	6/35	8.57mg	7/35
d	1328	21.7mg	n.s.s.	0/14	2.14mg	5/35	4.29mg	0/35	8.57mg	0/35
e	1328	.359mg	1.03mg	1/14	2.14mg	29/35	4.29mg	28/35	(8.57mg)	26/35)
ANHYROGLUCOCHLORAL (alpha-chloralose) 15879-93-3										
226	1297	2.86mg	n.s.s.	1/17	3.89mg	2/16				Innes;ntis,1968/1969
a	1297	6.85mg	n.s.s.	0/17	3.89mg	0/16				
b	1297	2.41mg	n.s.s.	2/17	3.89mg	3/16				
227	1297	4.75mg	n.s.s.	2/18	3.62mg	1/18				
a	1297	7.17mg	n.s.s.	1/18	3.62mg	0/18				
b	1297	3.75mg	n.s.s.	3/18	3.62mg	2/18				
228	1297	7.28mg	n.s.s.	0/16	3.89mg	0/17				
a	1297	7.28mg	n.s.s.	0/16	3.89mg	0/17				
b	1297	7.28mg	n.s.s.	0/16	3.89mg	0/17				
229	1297	2.19mg	n.s.s.	0/16	3.62mg	3/18				
a	1297	2.76mg	n.s.s.	0/16	3.62mg	2/18				
b	1297	1.54mg	89.3mg	0/16	3.62mg	5/18				
ANILAZINE 101-05-3										
230	c08684	47.6mg	n.s.s.	4/25	62.0mg	22/50	(124.mg)	18/50)		
a	c08684	628.mg	n.s.s.	0/25	62.0mg	1/50	124.mg	1/50		liv:hpa,hpc,nnd.
b	c08684	511.mg	n.s.s.	0/25	62.0mg	1/50	124.mg	2/50		lun:a/a,a/c.
231	c08684	224.mg	n.s.s.	15/25	57.7mg	20/50	114.mg	25/50		
a	c08684	365.mg	n.s.s.	9/25	57.7mg	6/50	114.mg	12/50		liv:hpa,hpc,nnd.
b	c08684	391.mg	n.s.s.	4/25	57.7mg	7/50	114.mg	6/50		lun:a/a,a/c.
232	c08684	32.9mg	n.s.s.	22/25	25.0mg	42/50	50.0mg	43/50		
a	c08684	257.mg	n.s.s.	0/25	25.0mg	1/50	50.0mg	1/50		liv:hpa,hpc,nnd.
233	c08684	34.2mg	n.s.s.	12/25	20.0mg	26/50	40.0mg	28/50		
a	c08684	n.s.s.	n.s.s.	0/25	20.0mg	0/50	40.0mg	0/50		liv:hpa,hpc,nnd.
ANILINE 62-53-3										
234	1460	144.mg	n.s.s.	0/28	15.0mg	0/28	30.0mg	1/28	60.0mg	1/28
a	1460	29.3mg	n.s.s.	0/28	15.0mg	0/28	30.0mg	0/28	60.0mg	0/28
ANILINE.HCl 142-04-1										
235	c03736	1.61gm	n.s.s.	21/50	741.mg	22/50	1.50gm	28/49		
a	c03736	3.27gm	n.s.s.	1/50	741.mg	5/50	1.50gm	5/49		liv:hpa,hpc,nnd.
b	c03736	n.s.s.	n.s.s.	0/50	741.mg	0/50	1.50gm	0/49		lun:a/a,a/c.
236	c03736	2.45gm	n.s.s.	24/50	693.mg	27/50	1.39gm	22/50		
a	c03736	5.78gm	n.s.s.	12/50	693.mg	9/50	1.39gm	7/50		liv:hpa,hpc,nnd.
b	c03736	5.15gm	n.s.s.	4/50	693.mg	8/50	1.39gm	3/50		lun:a/a,a/c.
237	c03736	786.mg	248.gm	0/25	144.mg	1/50	286.mg	7/50		mul:fbs,ern; spl:fbs,ern.
a	c03736	265.mg	n.s.s.	17/25	144.mg	32/50	286.mg	35/50		
b	c03736	2.12gm	n.s.s.	0/25	144.mg	0/50	286.mg	1/50		liv:hpa,hpc,nnd.
238	c03736	64.2mg	133.mg	0/25	115.mg	27/50	229.mg	38/50		bod:men; mul:fbs,hes,ern; spl:fbs,hes,ern. C
a	c03736	99.9mg	277.mg	0/25	115.mg	19/50	229.mg	23/50		bod:men; mul:hes; spl:hes.
b	c03736	108.mg	344.mg	0/25	115.mg	19/50	229.mg	20/50		
c	c03736	168.mg	565.mg	0/25	115.mg	11/50	229.mg	18/50		bod:men; mul:fbs,ern; spl:fbs,ern.
d	c03736	251.mg	4.10gm	0/25	115.mg	7/50	229.mg	9/50		spl:fbs,ern.
e	c03736	312.mg	2.01gm	0/25	115.mg	4/50	229.mg	11/50		bod:men; mul:fbs,ern.
f	c03736	249.mg	n.s.s.	2/25	115.mg	6/50	229.mg	12/50		adr:phe,pha. S
g	c03736	65.9mg	1.25gm	10/25	115.mg	42/50	229.mg	45/50		
h	c03736	2.38gm	n.s.s.	1/25	115.mg	0/50	229.mg	0/50		liv:hpa,hpc,nnd.
o-ANISIDINE.HCl (NCI uses CAS# 134-29-0) 134-29-2										
239	c03747	611.mg	1.81gm	0/55	319.mg	1/55	638.mg	22/55		ubl:tcc, tpp.
a	c03747	771.mg	2.64gm	0/55	319.mg	0/55	638.mg	18/55		
b	c03747	761.mg	n.s.s.	34/55	319.mg	20/55	638.mg	33/55		
c	c03747	4.37gm	n.s.s.	11/55	319.mg	1/55	638.mg	4/55		liv:hpa,hpc,nnd.
d	c03747	4.67gm	n.s.s.	4/55	319.mg	2/55	638.mg	1/55		lun:a/a,a/c.
240	c03747	575.mg	1.67gm	0/55	297.mg	2/55	589.mg	22/55		ubl:tcc, tpp.
a	c03747	888.mg	3.46gm	0/55	297.mg	0/55	589.mg	15/55		
b	c03747	1.14gm	n.s.s.	43/55	297.mg	27/55	589.mg	30/55		
c	c03747	1.08gm	n.s.s.	28/55	297.mg	13/55	(589.mg)	7/55)		liv:hpa,hpc,nnd.
d	c03747	824.mg	n.s.s.	12/55	297.mg	9/55	(589.mg)	2/55)		lun:a/a,a/c.
241	c03747	11.0mg	48.6mg	0/55	248.mg	46/55	500.mg	50/55		ubl:tcc, tpp.
a	c03747	11.2mg	52.9mg	0/55	248.mg	41/55	500.mg	50/55		
b	c03747	208.mg	3.85gm	0/55	248.mg	5/55	500.mg	0/55		S
c	c03747	21.0mg	62.0mg	52/55	248.mg	50/55	500.mg	51/55		
d	c03747	n.s.s.	n.s.s.	1/55	248.mg	0/55	500.mg	0/55		liv:hpa,hpc,nnd.
242	c03747	20.6mg	48.8mg	0/55	198.mg	52/55	400.mg	52/55		k/p:tcc; thy:cyn,fca,fcc,pcn,pcy; tyf:pcn,pcy; ubl:tcc, tpp. C
a	c03747	20.6mg	48.8mg	0/55	198.mg	52/55	400.mg	52/55		ubl:tcc, tpp.

Spe	Strain	Site	Xpo + Xpt	Notes	TD50	2Tailpvi
Sex	Route	Hist			DR	AuOp
b	R m f34 eat ubl tcc	22m24	as		32.7mg	P<.0005c
c	R m f34 eat thy MXA	22m24	as		235.mg	P<.0005c
d	R m f34 eat MXA MXA	22m24	as		535.mg *	P<.0005c
e	R m f34 eat k/p tcc	22m24	as		1.04gm *	P<.002 c
f	R m f34 eat TBA MXB	22m24	as		30.9mg	P<.0005
g	R m f34 eat liv MXB	22m24	as		483.mg *	P<.002
p-ANISIDINE.HCl				100ng...1ug...10...100...1mg...10...100...1g...10		
243	M f b6c eat TBA MXB	24m24			no dre	P=1. -
a	M f b6c eat liv MXB	24m24			no dre	P=1. -
b	M f b6c eat lun MXB	24m24			no dre	P=1. -
244	M m b6c eat TBA MXB	24m24			no dre	P=1. -
a	M m b6c eat liv MXB	24m24			no dre	P=1. -
b	M m b6c eat lun MXB	24m24			12.6gm *	P<.6
245	R f f34 eat TBA MXB	24m24			no dre	P=1. -
a	R f f34 eat liv MXB	24m24			6.83gm *	P<.5
246	R m f34 eat pre MXA	24m24			493.mg \	P<.02 a
a	R m f34 eat MXB MXB	24m24			942.mg *	P<.05
b	R m f34 eat lun a/e	24m24			3.59gm *	P<.06 a
c	R m f34 eat ski sqc	24m24			3.72gm *	P<.06 a
d	R m f34 eat TBA MXB	24m24			no dre	P=1. -
e	R m f34 eat liv MXB	24m24			1.56gm *	P<.03
ANTHRANILIC ACID				100ng...1ug...10...100...1mg...10...100...1g...10		
247	M f b6c eat TBA MXB	18m24			68.4gm *	P<.9 -
a	M f b6c eat liv MXB	18m24			26.4gm *	P<.4
b	M f b6c eat lun MXB	18m24			80.7gm *	P<.4
248	M m b6c eat TBA MXB	18m24			no dre	P=1. -
a	M m b6c eat liv MXB	18m24			no dre	P=1. -
b	M m b6c eat lun MXB	18m24			no dre	P=1. -
249	R f f34 eat TBA MXB	18m24			no dre	P=1. -
a	R f f34 eat liv MXB	18m24			no dre	P=1. -
250	R m f34 eat TBA MXB	18m24			no dre	P=1. -
a	R m f34 eat liv MXB	18m24			no dre	P=1. -
9,10-ANTHRAQUINONE				100ng...1ug...10...100...1mg...10...100...1g...10		
251	M f b6a orl lun ade	76w76	evx		847.mg	P<.6 -
a	M f b6a orl liv hpt	76w76	evx		no dre	P=1. -
b	M f b6a orl tba mix	76w76	evx		749.mg	P<.6 -
252	M m b6a orl liv hpt	76w76	evx		no dre	P=1. -
a	M m b6a orl lun ade	76w76	evx		no dre	P=1. -
b	M m b6a orl tba mix	76w76	evx		no dre	P=1. -
253	M f b6c orl lun ade	76w76	evx		494.mg	P<.1 -
a	M f b6c orl liv hpt	76w76	evx		no dre	P=1. -
b	M f b6c orl tba mix	76w76	evx		494.mg	P<.1 -
254	M m b6c orl liv hpt	76w76	evx		460.mg	P<.1 -
a	M m b6c orl lun mix	76w76	evx		no dre	P=1. -
b	M m b6c orl tba mix	76w76	evx		460.mg	P<.1 -
ANTIMONY POTASSIUM TARTRATE				100ng...1ug...10...100...1mg...10...100...1g...10		
255	M b cd1 wat lun tum	33m33	e		no dre	P=1. -
a	M b cd1 wat liv tum	33m33	e		no dre	P=1. -
b	M b cd1 wat tba tum	33m33	e		no dre	P=1. -
c	M b cd1 wat tba mal	33m33	e		no dre	P=1. -
ARAMITE				100ng...1ug...10...100...1mg...10...100...1g...10		
256	M f b6a orl lun ade	80w80	evx		432.mg	P<.3
a	M f b6a orl liv hpt	80w80	evx		no dre	P=1. -
b	M f b6a orl tba mix	80w80	evx		391.mg	P<.4
257	M m b6a orl liv hpt	77w77	evx		15.9gm	P<.1
a	M m b6a orl lun ade	77w77	evx		no dre	P=1. -
b	M m b6a orl tba mix	77w77	evx		no dre	P=1. -
258	M f b6c orl liv hpt	77w77	evx		973.mg	P<.3
a	M f b6c orl lun ade	77w77	evx		973.mg	P<.3
b	M f b6c orl tba mix	77w77	evx		92.7gm	P<.0005
259	M m b6c orl liv mix	80w80	evx		126.mg	P<.003
a	M m b6c orl liv hpt	80w80	evx		158.mg	P<.006 +
b	M m b6c orl lun mix	80w80	evx		no dre	P=1. -
c	M m b6c orl tba mix	80w80	evx		103.mg	P<.002
260	R b cfn eat liv hnd	24m24			61.8mg *	P<.0005+
a	R b cfn eat bil ade	24m24			1.01gm *	P<.05 +
261	R b fds eat liv mix	22m24	agre		430.mg *	P<.002 +
262	R f osm eat liv hem	27m27			256.mg	P<.3 -
a	R f osm eat tba mix	27m27			no dre	P=1. -
263	R f osm eat liv tum	24m24	e		no dre	P=1. -
a	R f osm eat tba ben	24m24	e		31.5mg	P<.6 -
b	R f osm eat tba mal	24m24	e		no dre	P=1. -
264	R m osm eat liv tum	27m27			no dre	P=1. -
a	R m osm eat tba mal	27m27			101.mg	P<.1 -
b	R m osm eat tba mix	27m27			198.mg	P<.6 -

RefNum	LoConf	UpConf	Cntrl	1Dose	1Inc	2Dose	2Inc	Citation or Pathology	Brkly Code	
b	c03747	21.0mg	50.4mg	0/55	198.mg	50/55	400.mg	51/55		
c	c03747	98.9mg	595.mg	0/55	198.mg	7/55	400.mg	6/55	thy:cyn,fca,fcc,pcn,pcy.	
d	c03747	191.mg	1.90gm	0/55	198.mg	4/55	400.mg	4/55	thy:fca; tyf:pcn,pcy.	
e	c03747	304.mg	5.61gm	0/55	198.mg	2/55	400.mg	4/55		
f	c03747	20.3mg	49.2mg	39/55	198.mg	53/55	400.mg	53/55		
g	c03747	148.mg	3.15gm	0/55	198.mg	4/55	400.mg	0/55	liv:hpa,hpc,nnd.	
p-ANISIDINE.HCl 20265-97-8										
243	c03758	2.32gm	n.s.s.	34/55	638.mg	33/55	1.28gm	24/55		
a	c03758	4.69gm	n.s.s.	11/55	638.mg	10/55	1.28gm	6/55	liv:hpa,hpc,nnd.	
b	c03758	5.15gm	n.s.s.	4/55	638.mg	5/55	1.28gm	3/55	lun:a/a,a/c.	
244	c03758	2.19gm	n.s.s.	43/55	589.mg	29/55	1.18gm	36/55		
a	c03758	2.78gm	n.s.s.	28/55	589.mg	22/55	1.18gm	23/55	liv:hpa,hpc,nnd.	
b	c03758	2.35gm	n.s.s.	12/55	589.mg	8/55	1.18gm	17/55	lun:a/a,a/c.	
245	c03758	568.mg	n.s.s.	52/55	146.mg	38/55	291.mg	42/55		
a	c03758	1.41gm	n.s.s.	1/55	146.mg	1/55	291.mg	3/55	liv:hpa,hpc,nnd.	
246	c03758	202.mg	n.s.s.	1/55	118.mg	8/55	(233.mg)	3/55	pre:adn,cen.	
a	c03758	428.mg	n.s.s.	1/55	118.mg	8/55	233.mg	7/55	lun:a/a; pre:adn,cen; ski:sgc. A	
b	c03758	1.09gm	n.s.s.	0/55	118.mg	0/55	233.mg	3/55		
c	c03758	1.12gm	n.s.s.	0/55	118.mg	0/55	233.mg	3/55		
d	c03758	424.mg	n.s.s.	39/55	118.mg	36/55	233.mg	31/55		
e	c03758	673.mg	n.s.s.	0/55	118.mg	3/55	233.mg	4/55	liv:hpa,hpc,nnd.	
ANTHRANILIC ACID 118-92-3										
247	c01730	4.53gm	n.s.s.	1/15	1.73gm	5/35	3.45gm	5/35		
a	c01730	7.83gm	n.s.s.	0/15	1.73gm	1/35	3.45gm	2/35	liv:hpa,hpc,nnd.	
b	c01730	13.1gm	n.s.s.	0/15	1.73gm	0/35	3.45gm	1/35	lun:a/a,a/c.	
248	c01730	1.48gm	n.s.s.	0/15	1.59gm	13/35	3.18gm	6/35		
a	c01730	1.79gm	n.s.s.	0/15	1.59gm	6/35	3.18gm	5/35	liv:hpa,hpc,nnd.	
b	c01730	n.s.s.	n.s.s.	0/15	1.59gm	5/35	(3.18gm)	0/35	lun:a/a,a/c.	
249	c01730	361.mg	n.s.s.	10/15	402.mg	19/35	(804.mg)	11/35		
a	c01730	n.s.s.	n.s.s.	0/15	402.mg	0/35	804.mg	0/35	liv:hpa,hpc,nnd.	
250	c01730	867.mg	n.s.s.	6/15	318.mg	14/35	643.mg	11/35		
a	c01730	n.s.s.	n.s.s.	0/15	318.mg	0/35	643.mg	0/35	liv:hpa,hpc,nnd.	
9,10-ANTHRAQUINONE 84-65-1										
251	1229	124.mg	n.s.s.	1/17	169.mg	2/16			Innes;ntis,1968/1969	
a	1229	297.mg	n.s.s.	0/17	169.mg	0/16				
b	1229	104.mg	n.s.s.	2/17	169.mg	3/16				
252	1229	312.mg	n.s.s.	1/18	157.mg	0/18				
a	1229	312.mg	n.s.s.	2/18	157.mg	0/18				
b	1229	312.mg	n.s.s.	3/18	157.mg	0/18				
253	1229	121.mg	n.s.s.	0/16	169.mg	2/17				
a	1229	316.mg	n.s.s.	0/16	169.mg	0/17				
b	1229	121.mg	n.s.s.	0/16	169.mg	2/17				
254	1229	113.mg	n.s.s.	0/16	157.mg	2/17				
a	1229	294.mg	n.s.s.	0/16	157.mg	0/17				
b	1229	113.mg	n.s.s.	0/16	157.mg	2/17				
ANTIMONY POTASSIUM TARTRATE 28300-74-5										
255	1036	9.12mg	n.s.s.	15/71	.877mg	10/76			Kanisawa;canr,29,892-895;1969	
a	1036	19.7mg	n.s.s.	4/71	.877mg	1/76				
b	1036	6.83mg	n.s.s.	24/71	.877mg	18/76				
c	1036	9.91mg	n.s.s.	8/71	.877mg	6/76				
ARAMITE 140-57-8										
256	40a	99.0mg	n.s.s.	1/17	157.mg	3/16			Innes;ntis,1968/1969	
a	40a	305.mg	n.s.s.	0/17	157.mg	0/16				
b	40a	85.9mg	n.s.s.	2/17	157.mg	4/16				
257	40a	166.mg	n.s.s.	1/18	146.mg	1/17				
a	40a	281.mg	n.s.s.	2/18	146.mg	0/17				
b	40a	145.mg	n.s.s.	3/18	146.mg	2/17				
258	40a	158.mg	n.s.s.	0/16	157.mg	1/17				
a	40a	158.mg	n.s.s.	0/16	157.mg	1/17				
b	40a	41.1mg	295.mg	0/16	157.mg	8/17				
259	40a	50.7mg	617.mg	0/16	146.mg	6/16				
a	40a	59.4mg	1.56gm	0/16	146.mg	5/16				
b	40a	285.mg	n.s.s.	0/16	146.mg	0/16				
c	40a	43.6mg	375.mg	0/16	146.mg	7/16				
260	42	38.4mg	122.mg	5/180	4.50mg	3/93	9.00mg	10/90	18.0mg	22/96
a	42	248.mg	n.s.s.	0/180	4.50mg	0/93	9.00mg	0/90	18.0mg	2/96
261	1133	202.mg	1.99gm	0/22	22.5mg	1/20	71.1mg	2/21	225.mg	6/20
262	21	41.7mg	n.s.s.	0/30	10.0mg	1/30				
a	21	16.1mg	n.s.s.	13/30	10.0mg	12/30				
263	84a	24.7mg	n.s.s.	1/30	4.00mg	0/30				
a	84a	5.40mg	n.s.s.	6/30	4.00mg	8/30				
b	84a	13.0mg	n.s.s.	6/30	4.00mg	3/30				
264	21	62.6mg	n.s.s.	0/30	8.00mg	0/30				
a	21	24.7mg	n.s.s.	0/30	8.00mg	2/30				
b	21	27.2mg	n.s.s.	1/30	8.00mg	2/30				

Spe	Strain	Site	Xpo+Xpt	Notes	TD50	2Tailpvl
Sex	Route	Hist			DR	AuOp
265	R m osm eat	liv tum	24m24	e	>	no dre P=1. -
a	R m osm eat	tba ben	24m24	e		64.7mg P<.3 -
b	R m osm eat	tba mal	24m24	e		no dre P=1. -
266	R b ada eat	liv hnd	24m24		>	760.mg * P<.3 -
267	R b wid eat	liv hnd	24m24		. + .	79.9mg Z P<.0005+
a	R b wid eat	bil ade	24m24			397.mg * P<.002 +
b	R b wid eat	liv hpc	24m24			+historical * P<.04 +
AROCLOR 1254				100ng...1ug...10...100...1mg...10...100...1g...10		
268	M m baj eat	liv hpt	47w47	e	(+)	9.58mg P<.0005+
269	M m baj eat	liv hpt	26w47	e	(. >)	64.6mg P<.2 -
270	R f f34 eat	liv adn	24m24	a	: ±	+historical * P<.07 a
a	R f f34 eat	MXB MXB	24m24	a		21.7mg * P<.2 -
b	R f f34 eat	sto ecn	24m24	a		+historical P=1. a
c	R f f34 eat	TBA MXB	24m24	a		no dre P=1. -
d	R f f34 eat	liv MXB	24m24	a		no dre P=1. -
271	R m f34 eat	--- MXA	24m24		: + :	5.94mg * P<.004
a	R m f34 eat	--- lau	24m24			6.75mg * P<.009
b	R m f34 eat	MXB MXB	24m24			10.4mg * P<.004
c	R m f34 eat	liv MXA	24m24			+historical * P<.008 a
d	R m f34 eat	MXA MXA	24m24			+historical * P<.3 a
e	R m f34 eat	TBA MXB	24m24			3.23mg * P<.004
f	R m f34 eat	liv MXB	24m24			20.8mg * P<.03
AROCLOR 1260				100ng...1ug...10...100...1mg...10...100...1g...10		
272	R f shc eat	liv mix	89w95	e	. + .	1.04mg P<.0005+
a	R f shc eat	liv nnd	89w95	e		1.76mg P<.0005+
b	R f shc eat	liv hpc	89w95	e		18.3mg P<.0005+
ARSENATE, SODIUM				100ng...1ug...10...100...1mg...10...100...1g...10		
273	R b osm eat	tba mal	24m24	s	>	no dre P=1. -
a	R b osm eat	tba mix	24m24	s		no dre P=1. -
ARSENIUS OXIDE				100ng...1ug...10...100...1mg...10...100...1g...10		
274	M b cbl wat	liv tum	23m23	av	>	no dre P=1. -
a	M b cbl wat	tba mix	23m23	av		no dre P=1. -
275	M m ssa wat	sbq pem	24m24		>	54.8mg P<.3 -
276	M f swi wat	lun ade	65w65	e	>	215.mg P<.9 -
a	M f swi wat	liv hpt	65w65	e		no dre P=1. -
277	M m swi wat	lun ade	65w65	e	. *	31.4mg P<.06 -
a	M m swi wat	liv hpt	65w65	e		no dre P=1. -
ARSENITE, SODIUM				100ng...1ug...10...100...1mg...10...100...1g...10		
278	M b cd1 wat	lun mix	24m24	e	>	no dre P=1. -
a	M b cd1 wat	liv mix	24m24	e		no dre P=1. -
b	M b cd1 wat	tba mal	24m24	e		no dre P=1. -
c	M b cd1 wat	tba mix	24m24	e		no dre P=1. -
d	M b cd1 wat	tba ben	24m24	e		no dre P=1. -
279	R b leb wat	liv tum	39m39	e	>	10.6mg P<.2 -
a	R b leb wat	tba mal	39m39	e		no dre P=1. -
b	R b leb wat	tba tum	39m39	e		no dre P=1. -
280	R b osm eat	tba mal	24m24	s	>	626.mg Z P<.1. -
a	R b osm eat	tba mix	24m24	s		no dre P=1. -
ASPARTAME				100ng...1ug...10...100...1mg...10...100...1g...10		
281	R f sls eat	bra tum	52w52	ekr	>	no dre P=1. -
282	R f sls eat	bra mix	24m24	er		no dre P=1. -
283	R m sls eat	bra tum	52w52	ekr	>	no dre P=1. -
284	R m sls eat	bra mix	24m24	er		7.43gm * P<.5 -
ASPIRIN				100ng...1ug...10...100...1mg...10...100...1g...10		
285	M f cb6 eat	liv tum	77w77	e	>	no dre P=1. -
286	M m cb6 eat	liv tum	77w77	e	>	no dre P=1. -
ASPIRIN, PHENACETIN, AND CAFFEINE				100ng...1ug...10...100...1mg...10...100...1g...10		
287	M f b6c eat	TBA MXB	78w94		>	no dre P=1. -
a	M f b6c eat	liv MXB	78w94			18.0gm * P<.4 -
b	M f b6c eat	lun MXB	78w94			no dre P=1. -
288	M m b6c eat	TBA MXB	78w94		>	3.01gm * P<.3 -
a	M m b6c eat	liv MXB	78w94			44.5gm * P<.9 -
b	M m b6c eat	lun MXB	78w94			3.68gm * P<.07 -
289	M f cb6 eat	liv hnd	77w77	e	>	8.76gm P<.3 -
a	M f cb6 eat	liv hpc	77w77	e		no dre P=1. -
290	M m cb6 eat	liv hnd	77w77	e	>	9.54gm P<.3 -
a	M m cb6 eat	liv hpc	77w77	e		no dre P=1. -
291	R f f34 eat	TBA MXB	18m25		>	no dre P=1. -
a	R f f34 eat	liv MXB	18m25			3.05gm * P<.07

CARCINOGENIC POTENCY DATABASE

RefNum	LoConf	UpConf	Cntrl	1Dose	1Inc	2Dose	2Inc	Citation or Pathology				Brkly Code			
265	84a	19.8mg	n.s.s.	0/30	3.20mg	0/30		Radomski;txap,7,652-656;1965							
a	84a	10.5mg	n.s.s.	0/30	3.20mg	1/30									
b	84a	10.6mg	n.s.s.	3/30	3.20mg	2/30									
266	42	187.mg	n.s.s.	0/82	4.50mg	0/46	9.00mg	1/41	18.0mg	1/92	Popper;canc,13,1035-1046;1960				
267	42	48.2mg	155.mg	2/193	4.50mg	2/93	9.00mg	3/100	18.0mg	20/90					
a	42	151.mg	1.86gm	0/193	4.50mg	0/93	9.00mg	0/100	18.0mg	5/90					
b	42	246.mg	n.s.s.	0/193	4.50mg	0/93	9.00mg	0/100	18.0mg	2/90					
AROCFLOR 1254 (PCB) 27323-18-8															
268	1029	4.46mg	26.3mg	0/58	36.0mg	9/22		Kimbrough;jnci,53,547-549;1974							
269	1029	10.5mg	n.s.s.	0/58	19.6mg	1/24									
270	c02664	10.5mg	n.s.s.	0/24	1.30mg	0/24	2.50mg	1/24	5.00mg	2/24	Liv:adn; sto:acn. A				
a	c02664	8.23mg	n.s.s.	0/24	1.30mg	1/24	2.50mg	2/24	5.00mg	2/24					
b	c02664	15.2mg	n.s.s.	0/24	1.30mg	1/24	2.50mg	1/24	5.00mg	0/24					
c	c02664	4.25mg	n.s.s.	11/24	1.30mg	18/24	2.50mg	13/24	5.00mg	12/24					
d	c02664	n.s.s.	n.s.s.	0/24	1.30mg	0/24	2.50mg	0/24	5.00mg	0/24	Liv:hpa,hpc,ndd.				
271	c02664	2.78mg	52.3mg	3/24	1.00mg	2/24	2.00mg	5/24	4.00mg	9/24	---:leu,lym. S				
a	c02664	3.01mg	275.mg	3/24	1.00mg	2/24	2.00mg	5/24	4.00mg	8/24	S				
b	c02664	4.19mg	36.4mg	0/24	1.00mg	0/24	2.00mg	3/24	4.00mg	3/24	cec:acn; jej:acn; liv:adn,hpc; sto:acn. A				
c	c02664	5.21mg	338.mg	0/24	1.00mg	0/24	2.00mg	1/24	4.00mg	3/24	Liv:adn,hpc.				
d	c02664	8.40mg	n.s.s.	0/24	1.00mg	0/24	2.00mg	2/24	4.00mg	0/24	cec:acn; jej:acn; sto:acn.				
e	c02664	1.60mg	23.4mg	7/24	1.00mg	7/24	2.00mg	12/24	4.00mg	13/24					
f	c02664	6.29mg	n.s.s.	0/24	1.00mg	0/24	2.00mg	1/24	4.00mg	2/24	Liv:hpa,hpc,ndd.				
AROCFLOR 1260 (PCB) 11096-82-5															
272	1320	.804mg	1.35mg	0/173	4.69mg	170/184		Kimbrough;jnci,55,1453-1456;1975							
a	1320	1.39mg	2.24mg	0/173	4.69mg	144/184									
b	1320	11.3mg	34.3mg	1/173	4.69mg	26/184									
ARSENATE, SODIUM 7631-89-2															
273	1507	116.mg	n.s.s.	8/50	1.41mg	14/50	2.81mg	8/50	5.63mg	10/50	11.3mg	6/50	18.0mg	5/50	Byron;
a	1507	121.mg	n.s.s.	17/50	1.41mg	21/50	2.81mg	15/50	5.63mg	16/50	11.3mg	13/50	18.0mg	6/50	txap,10,132-147;1967
ARSENIUS OXIDE 1327-53-3															
274	1505	39.4mg	n.s.s.	0/50	4.13mg	0/50		Hueper;aenh,5,445-462;1962							
a	1505	39.4mg	n.s.s.	1/50	4.13mg	0/50									
275	1506	12.1mg	n.s.s.	1/50	3.33mg	3/50		Sanderson;becc,39,628-629;1961							
276	1509	8.52mg	n.s.s.	34/137	20.0mg	4/15		Baroni;aenh,7,668-674;1963/Shubik 1962							
a	1509	24.2mg	n.s.s.	4/137	20.0mg	0/15									
277	1509	11.4mg	n.s.s.	18/133	16.7mg	15/60									
a	1509	80.5mg	n.s.s.	2/133	16.7mg	0/60									
ARSENITE, SODIUM 7784-46-5															
278	1512	14.2mg	n.s.s.	26/170	.877mg	3/103		Kanisawa;canr,27,1192-1195;1967							
a	1512	14.6mg	n.s.s.	7/170	.877mg	1/103									
b	1512	7.97mg	n.s.s.	15/170	.877mg	6/103									
c	1512	10.9mg	n.s.s.	55/170	.877mg	11/103									
d	1512	14.5mg	n.s.s.	29/170	.877mg	3/103									
279	1036	3.35mg	n.s.s.	1/82	.265mg	5/91		Kanisawa;canr,29,892-895;1969							
a	1036	8.08mg	n.s.s.	9/82	.265mg	3/91									
b	1036	2.90mg	n.s.s.	31/82	.265mg	25/91									
280	1507	13.8mg	n.s.s.	8/50	.703mg	8/50	1.41mg	9/50	2.81mg	15/50	5.63mg	7/50	(11.3mg	1/50)	Byron;
a	1507	60.2mg	n.s.s.	16/50	.703mg	14/50	1.41mg	15/50	2.81mg	18/50	5.63mg	15/50	11.3mg	6/50	txap,10,132-147;1967
ASPARTAME 22839-47-0															
281	1327m	23.6mg	n.s.s.	0/16	50.0mg	0/16	100.mg	0/16	200.mg	0/16	Ishii;txlt,7,433-437;1981				
282	1327n	2.29gm	n.s.s.	1/60	50.0mg	0/60	100.mg	2/60	200.mg	0/60					
283	1327m	18.8mg	n.s.s.	0/16	40.0mg	0/16	80.0mg	0/16	160.mg	0/16					
284	1327n	1.41gm	n.s.s.	0/59	40.0mg	1/59	80.0mg	0/60	160.mg	1/60					
ASPIRIN 50-78-2															
285	1028	1.77gm	n.s.s.	0/36	382.mg	0/41		Macklin;dact,3,135-163;1980							
286	1028	1.94gm	n.s.s.	0/35	382.mg	0/45									
ASPIRIN, PHENACETIN, AND CAFFEINE (APC) 8003-03-0															
287	c02697	2.92gm	n.s.s.	20/50	755.mg	17/50	1.51gm	14/50							
a	c02697	4.46gm	n.s.s.	1/50	755.mg	2/50	1.51gm	3/50			Liv:hpa,hpc,ndd.				
b	c02697	3.65gm	n.s.s.	4/50	755.mg	7/50	1.51gm	4/50			Lun:a/a,a/c.				
288	c02697	975.mg	n.s.s.	17/50	697.mg	24/50	1.39gm	21/50							
a	c02697	2.35gm	n.s.s.	7/50	697.mg	11/50	1.39gm	6/50			Liv:hpa,hpc,ndd.				
b	c02697	1.46gm	n.s.s.	6/50	697.mg	9/50	1.39gm	12/50			Lun:a/a,a/c.				
289	1028	1.43gm	n.s.s.	0/36	696.mg	1/34		Macklin;dact,3,135-163;1980							
a	1028	2.67gm	n.s.s.	0/36	696.mg	0/34									
290	1028	1.55gm	n.s.s.	0/35	696.mg	1/37									
a	1028	2.91gm	n.s.s.	0/35	696.mg	0/37									
291	c02697	222.mg	n.s.s.	42/50	245.mg	41/50	(485.mg	32/49)							
a	c02697	1.32gm	n.s.s.	0/50	245.mg	4/50	485.mg	3/49			Liv:hpa,hpc,ndd.				

Spe	Strain	Site	Xpo + Xpt	Notes	TD50	2Tailpvl	DR	AnOp
292	R m f34 eat	TBA	MXB	18m25			no dre	P=1. -
a	R m f34 eat	liv	MXB	18m25			no dre	P=1. -
ATRAZINE					100ng...1ug...10...100...1mg...10...100...1g...10			
293	M f b6a orl	lun	ade	76w76 evx			no dre	P=1. -
a	M f b6a orl	liv	hpt	76w76 evx			no dre	P=1. -
b	M f b6a orl	tba	mix	76w76 evx			58.8mg	P<.7 -
294	M m b6a orl	lun	ade	76w76 evx			28.2mg	P<.4 -
a	M m b6a orl	liv	hpt	76w76 evx			no dre	P=1. -
b	M m b6a orl	tba	mix	76w76 evx			54.6mg	P<.7 -
295	M f b6c orl	liv	hpt	76w76 evx			no dre	P=1. -
a	M f b6c orl	lun	mix	76w76 evx			no dre	P=1. -
b	M f b6c orl	tba	mix	76w76 evx			71.0mg	P<.3 -
296	M m b6c orl	liv	hpt	76w76 evx			15.0mg	P<.02 -
a	M m b6c orl	lun	mix	76w76 evx			no dre	P=1. -
b	M m b6c orl	tba	mix	76w76 evx			9.29mg	P<.004 -
ATROPINE					100ng...1ug...10...100...1mg...10...100...1g...10			
297	R f sda ipj	tba	mal	24m24 e			90.7mg	P<.1. -
298	R m sda ipj	liv	hae	24m24 e			no dre	P=1. -
a	R m sda ipj	tba	mal	24m24 e			no dre	P=1. -
AURAMINE-O					100ng...1ug...10...100...1mg...10...100...1g...10			
299	M f alb eat	liv	hpt	52w79 e			94.3mg	P<.08 +
300	M m alb eat	liv	hpt	52w84 e			39.2mg	P<.008 +
301	M f cba eat	liv	hpt	52w99 e			67.7mg	P<.0005+
302	M m cba eat	liv	hpt	52w79 e			77.5mg	P<.004 +
303	R m wsw eat	liv	hpt	20m29 e			11.0mg	P<.0005+
5-AZACYTIDINE*					100ng...1ug...10...100...1mg...10...100...1g...10			
304	M f b6c ipj	MXA	MXA	52w81			.256mg	* P<.0005a
a	M f b6c ipj	mul	MXA	52w81			.520mg	* P<.008 a
b	M f b6c ipj	---	lym	52w81			.615mg	* P<.03 a
c	M f b6c ipj	TBA	MXB	52w81			.219mg	* P<.003
d	M f b6c ipj	liv	MXB	52w81			no dre	P=1. -
e	M f b6c ipj	lun	MXB	52w81			no dre	P=1. -
305	M m b6c ipj	TBA	MXB	52w81 s			1.05mg	* P<.2
a	M m b6c ipj	liv	MXB	52w81 s			15.7mg	* P<.9
b	M m b6c ipj	lun	MXB	52w81 s			61.4mg	* P<.1
306	R f sda ipj	TBA	MXB	34w80 s			.487mg	/ P<.09
a	R f sda ipj	liv	MXB	34w80 s			no dre	P=1. -
307	R m sda ipj	TBA	MXB	34w80 s			.328mg	* P<.004
a	R m sda ipj	liv	MXB	34w80 s			no dre	P=1. -
AZASERINE					100ng...1ug...10...100...1mg...10...100...1g...10			
308	R b wis ipj	paе	сar	26w78 e			.793mg	P<.0005+
a	R b wis ipj	kid	tum	26w78 e			.942mg	P<.0005
b	R b wis ipj	liv	tum	26w78 e			3.02mg	P<.03
AZIDE, SODIUM					100ng...1ug...10...100...1mg...10...100...1g...10			
309	R f cdr eat	mgl	tum	18m24 e			3.01mg	\ P<.003
a	R f cdr eat	pit	cra	18m24 e			16.1mg	* P<.5 -
310	R m cdr eat	pit	cra	18m24 e			no dre	P=1. -
AZINPHOSMETHYL					100ng...1ug...10...100...1mg...10...100...1g...10			
311	M f b6c eat	TBA	MXB	80w92			2.58gm	/ P<.1. -
a	M f b6c eat	liv	MXB	80w92			no dre	P=1. -
b	M f b6c eat	lun	MXB	80w92			118.4mg	* P<.3
312	M m b6c eat	liv	hpc	80w92			#14.3mg	* P<.007 -
a	M m b6c eat	TBA	MXB	80w92			46.6mg	* P<.8
b	M m b6c eat	liv	MXB	80w92			12.6mg	* P<.2
c	M m b6c eat	lun	MXB	80w92			no dre	P=1. -
313	R f osm eat	TBA	MXB	19m27			no dre	P=1. -
a	R f osm eat	liv	MXB	19m27			164.4mg	/ P<.9
314	R f osm eat	pit	acn	19m25	pool		#6.93mg	\ P<.0005-
a	R f osm eat	thy	MXA	19m25			15.9mg	* P<.004
b	R f osm eat	adr	coa	19m25			16.4mg	* P<.02
315	R m osm eat	pni	MXA	19m27 v			22.9mg	* P<.04 a
a	R m osm eat	TBA	MXB	19m27 v			5.42mg	* P<.3
b	R m osm eat	liv	MXB	19m27 v			52.7mg	* P<.6
316	R m osm eat	pit	MXA	19m25 v	pool		3.99mg	\ P<.008
a	R m osm eat	pit	cra	19m25 v			3.99mg	\ P<.008
b	R m osm eat	thy	MXA	19m25 v			6.06mg	* P<.0005a
c	R m osm eat	thy	---	19m25 v			7.87mg	* P<.003
d	R m osm eat	thy	MXA	19m25 v			10.5mg	* P<.006 a
e	R m osm eat	adr	MXA	19m25 v			15.3mg	* P<.006
f	R m osm eat	pit	MXA	19m25 v			7.43mg	* P<.02
g	R m osm eat	liv	hpa	19m25 v			23.3mg	* P<.02
h	R m osm eat	pni	MXA	19m25 v			30.6mg	* P<.03 a
i	R m osm eat	adr	acn	19m25 v			44.3mg	* P<.02

CARCINOGENIC POTENCY DATABASE

RefNum	LoConf	UpConf	Cntrl	1Dose	1Inc	2Dose	2Inc	Citation or Pathology	Brkly Code
292	c02697	406.mg n.s.s.	30/50	196.mg	37/50	388.mg	33/50		
a	c02697	2.75gm n.s.s.	5/50	196.mg	4/50	388.mg	1/50		liv:hpa,hpc,nnd.
ATRAZINE 1912-24-9									
293	1244	12.4mg n.s.s.	1/17	11.1mg	1/17				Innes;ntis,1968/1969
a	1244	20.7mg n.s.s.	0/17	11.1mg	0/17				
b	1244	7.41mg n.s.s.	2/17	11.1mg	3/17				
294	1244	5.90mg n.s.s.	2/18	10.3mg	4/18				
a	1244	20.4mg n.s.s.	1/18	10.3mg	0/18				
b	1244	6.40mg n.s.s.	3/18	10.3mg	4/18				
295	1244	22.0mg n.s.s.	0/16	11.1mg	0/18				
a	1244	22.0mg n.s.s.	0/16	11.1mg	0/18				
b	1244	11.6mg n.s.s.	0/16	11.1mg	1/18				
296	1244	5.16mg n.s.s.	0/16	10.3mg	4/18				
a	1244	20.4mg n.s.s.	0/16	10.3mg	0/18				
b	1244	3.75mg 56.8mg	0/16	10.3mg	6/18				
ATROPINE 51-55-8									
297	1134	2.23mg n.s.s.	3/33	.857mg	3/31			Schmahl;zkk0,86,77-84;1976	
298	1134	5.30mg n.s.s.	1/36	.857mg	0/30				
a	1134	5.30mg n.s.s.	1/36	.857mg	0/30				
AURAMINE-O 2465-27-2									
299	45	28.2mg n.s.s.	0/6	85.0mg	3/10			Williams;bjca,16,87-91;1962	
300	45	12.8mg 860.mg	0/7	74.3mg	4/7				
301	45	30.5mg 197.mg	3/41	136.mg	11/15				
302	45	30.3mg 666.mg	1/14	157.mg	7/12				
303	45	4.06mg 31.2mg	0/12	27.7mg	11/12				
5-AZACYTIDINE* 320-67-2									
304	c01569	.138mg .716mg	0/14	.610mg	17/35	1.60mg	0/35	---	lym; mul:grl,gss.
a	c01569	.243mg 6.56mg	0/14	.610mg	10/35	1.60mg	0/35		mul:grl,gss.
b	c01569	.249mg n.s.s.	0/14	.610mg	7/35	1.60mg	0/35		
c	c01569	.112mg 1.35mg	2/14	.610mg	22/35	1.60mg	1/35		
d	c01569	n.s.s. n.s.s.	0/14	.610mg	0/35	1.60mg	0/35	liv:hpa,hpc,nnd.	
e	c01569	1.65mg n.s.s.	2/14	.610mg	0/35	1.60mg	0/35		lun:a/s,a/c.
305	c01569	.360mg n.s.s.	2/16	.600mg	6/35	1.20mg	5/35		
a	c01569	.919mg n.s.s.	1/16	.600mg	1/35	1.20mg	1/35	liv:hpa,hpc,nnd.	
b	c01569	1.36mg n.s.s.	1/16	.600mg	0/35	1.20mg	1/35		lun:a/s,a/c.
306	c01569	.164mg n.s.s.	7/15	.470mg	15/35	1.68mg	3/35		
a	c01569	n.s.s. n.s.s.	0/15	.470mg	0/35	1.68mg	0/35	liv:hpa,hpc,nnd.	
307	c01569	.156mg 2.32mg	1/15	.470mg	11/35	1.72mg	1/35		
a	c01569	n.s.s. n.s.s.	0/15	.470mg	0/35	1.72mg	0/35	liv:hpa,hpc,nnd.	
AZASERINE 115-02-6									
308	1172	.342mg 2.54mg	0/76	.475mg	7/34			Longnecker;canc,47,1562-1572;1981	
a	1172	.384mg 3.38mg	0/76	.475mg	6/34				
b	1172	.742mg n.s.s.	0/76	.475mg	2/34				
AZIDE, SODIUM 26628-22-8									
309	1112	1.45mg 19.1mg	3/16	3.75mg	17/26	(7.50mg)	10/26)	Weisburger;jnci,67,75-88;1981	
a	1112	3.92mg n.s.s.	6/16	3.75mg	19/26	7.50mg	14/26		
310	1112	13.5mg n.s.s.	3/16	3.00mg	6/26	6.00mg	3/26		
AZINPHOSMETHYL (Gusethion) 86-50-0									
311	c00066	18.2mg n.s.s.	5/10	7.02mg	10/50	14.3mg	17/50		
a	c00066	96.3mg n.s.s.	1/10	7.02mg	0/50	14.3mg	1/50	liv:hpa,hpc,nnd.	
b	c00066	40.6mg n.s.s.	0/10	7.02mg	1/50	14.3mg	3/50		lun:a/s,a/c.
312	c00066	7.82mg 169.mg	0/10	3.24mg	3/50	6.48mg	12/50		S
a	c00066	4.69mg n.s.s.	4/10	3.24mg	23/50	6.48mg	23/50		
b	c00066	5.18mg n.s.s.	2/10	3.24mg	11/50	6.48mg	19/50	liv:hpa,hpc,nnd.	
c	c00066	16.8mg n.s.s.	2/10	3.24mg	8/50	6.48mg	4/50		lun:a/s,a/c.
313	c00066	2.58mg n.s.s.	7/10	2.17mg	37/49	4.34mg	26/50		
a	c00066	12.0mg n.s.s.	2/10	2.17mg	2/49	4.34mg	5/50	liv:hpa,hpc,nnd.	
314	c00066	3.14mg 20.4mg	0/105p	2.17mg	8/49	(4.34mg)	1/50)		S
a	c00066	7.20mg 123.mg	1/105p	2.17mg	6/49	4.34mg	4/50	thy:adn,cyn.	S
b	c00066	6.72mg n.s.s.	5/105p	2.17mg	4/49	4.34mg	8/50		S
315	c00066	9.81mg n.s.s.	0/10	2.18mg	1/50	4.35mg	6/50		pni:isa,isc.
a	c00066	1.68mg n.s.s.	7/10	2.18mg	40/50	4.35mg	41/50		
b	c00066	10.5mg n.s.s.	1/10	2.18mg	3/50	4.35mg	5/50	liv:hpa,hpc,nnd.	
316	c00066	1.77mg 90.0mg	15/105p	2.18mg	21/50	(4.35mg)	15/50)		S
a	c00066	1.77mg 90.0mg	15/105p	2.18mg	21/50	(4.35mg)	13/50)		S
b	c00066	3.69mg 11.0mg	0/105p	2.18mg	10/50	4.35mg	13/50	thy:adn,cyn,pch.	
c	c00066	3.98mg 44.0mg	8/105p	2.18mg	14/50	4.35mg	14/50		S
d	c00066	4.92mg 143.mg	7/105p	2.18mg	10/50	4.35mg	12/50	thy:adn,cyn,fc.	
e	c00066	6.93mg 183.mg	4/105p	2.18mg	4/50	4.35mg	10/50	adr:adn,coa.	S
f	c00066	3.32mg n.s.s.	20/105p	2.18mg	21/50	4.35mg	20/50	pit:adn,cra,crc,cyn.	S
g	c00066	9.63mg n.s.s.	1/105p	2.18mg	3/50	4.35mg	5/50		S
h	c00066	11.3mg n.s.s.	2/105p	2.18mg	1/50	4.35mg	6/50		S
i	c00066	15.3mg n.s.s.	0/105p	2.18mg	1/50	4.35mg	3/50	pni:isa,isc.	S

Spe	Strain	Site	Xpo+Xpt	Notes	TD50	2Tailpvl
Sex	Route	Hist			DR	AuOp
AZOBEZENE						
					100ng...1ug...10...100...1mg...10...100...1g...10	
317	M f	b6c eat	TBA MXB 24m24 v			no dre P=1. -
a	M f	b6c eat	liv MXB 24m24 v			no dre P=1. -
b	M f	b6c eat	lun MXB 24m24 v			no dre P=1. -
318	M f	b6c orl	lun ade 76w76 evx	>		47.3mg P<.3
a	M f	b6c orl	liv hpt 76w76 evx			no dre P=1. -
b	M f	b6c orl	tba mix 76w76 evx			47.3mg P<.3
319	M m	b6c eat	TBA MXB 24m24	>		no dre P=1. -
a	M m	b6c eat	liv MXB 24m24			no dre P=1. -
b	M m	b6c eat	lun MXB 24m24			no dre P=1. -
320	M m	b6c orl	liv mix 76w76 evx	- + -		3.85mg P<.0005
a	M m	b6c orl	liv hpt 76w76 evx			4.54mg P<.0005
b	M m	b6c orl	lun mix 76w76 evx			no dre P=1. -
c	M m	b6c orl	tba mix 76w76 evx			3.85mg P<.0005
321	M f	b6a orl	lun ade 76w76 evx	>		39.3mg P<.6
a	M f	b6a orl	liv hpt 76w76 evx			no dre P=1. -
b	M f	b6a orl	tba mix 76w76 evx			34.3mg P<.1
322	M m	b6a orl	liv hpt 76w76 evx	>		44.1mg P<.6
a	M m	b6a orl	lun ade 76w76 evx			no dre P=1. -
b	M m	b6a orl	tba mix 76w76 evx			no dre P=1. -
323	R f	f34 eat	MXA MXA 24m24	: + :		32.3mg * P<.0005c
a	R f	f34 eat	MXB MXB 24m24			32.3mg * P<.0005
b	R f	f34 eat	spl eat 24m24			90.5mg * P<.008 c
c	R f	f34 eat	spl fbs 24m24			102.mg * P<.02 c
d	R f	f34 eat	TBA MXB 24m24			51.5mg * P<.5
e	R f	f34 eat	liv MXB 24m24			276. mg * P<.3
324	R m	f34 eat	MXA MXA 24m24 a	: + :		19.2mg / P<.0005c
a	R m	f34 eat	MXB MXB 24m24 a			19.2mg / P<.0005
b	R m	f34 eat	mul fbs 24m24 a			43.9mg / P<.0005
c	R m	f34 eat	spl fbs 24m24 a			44.4mg / P<.004 c
d	R m	f34 eat	TBA MXB 24m24 a			11.4mg / P<.0005
e	R m	f34 eat	liv MXB 24m24 a			122. mg * P<.07
BARIUM ACETATE						
					100ng...1ug...10...100...1mg...10...100...1g...10	
325	M f	cd1 wat	--- lkm 27m27 e	.		4.28mg P<.05 -
a	M f	cd1 wat	lun tum 27m27 e			no dre P=1. -
b	M f	cd1 wat	tba mal 27m27 e			7.21mg P<.3 -
c	M f	cd1 wat	tba mix 27m27 e			no dre P=1. -
326	M m	cd1 wat	lun tum 27m27 e	>		no dre P=1. -
a	M m	cd1 wat	tba mix 27m27 e			14.6mg P<.8 -
b	M m	cd1 wat	tba mal 27m27 e			5.98mg P<.2 -
327	R f	leb wat	tba mix 37m37 e	>		no dre P=1. -
a	R f	leb wat	tba mal 37m37 e			no dre P=1. -
328	R m	leb wat	tba mix 37m37 e	>		2.87mg P<.4 -
a	R m	leb wat	tba mal 37m37 e			2.87mg P<.2 -
BENZENE						
					100ng...1ug...10...100...1mg...10...100...1g...10	
329	M m	aks inh	--- mly 72w72 e	>		114. mg P<.3 -
330	M m	c56 inh	thm lym 69w69	.		no dre P=1. -
a	M m	c56 inh	--- mix 69w69			+historical P<.04 +
b	M m	c56 inh	--- lcl 69w69			+historical P<.2 +
331	R f	sda gav	zym car 12m33 e	.		+historical * P<.0005+
a	R f	sda gav	ski car 12m33 e			+historical * P<.06 +
b	R f	sda gav	mgl car 12m33 e			545. mg * P<.2 +
c	R f	sda gav	liv hpt 12m33 e			no dre P=1. -
d	R f	sda gav	--- leu 12m33 e			no dre P=1. -
332	R m	sda gav	mam fib 12m33 e	.		77.5mg \ P<.007
a	R m	sda gav	--- leu 12m33 e			697. mg * P<.009 +
b	R m	sda gav	liv hpt 12m33 e			+historical * P<.2 +
c	R m	sda gav	sub ang 12m33 e			+historical * P<.2 +
d	R m	sda gav	zym car 12m33 e			no dre P=1. -
333	R m	sda inh	liv tum 98w98	>		no dre P=1. -
a	R m	sda inh	tba tum 98w98			no dre P=1. -
BENZENESULPHONOHYDRAZIDE						
					100ng...1ug...10...100...1mg...10...100...1g...10	
334	M f	awi gav	liv lct 50w60 ev	.		46.6mg P<.1
a	M f	awi gav	lun tum 50w60 ev			46.6mg P<.1
BENZIADINE						
					100ng...1ug...10...100...1mg...10...100...1g...10	
335	R b	alb inh	--- myl 20m28 e	.		2.08mg P<.02 +
a	R b	alb inh	mgl car 20m28 e			5.51mg P<.2 +
b	R b	alb inh	liv hpt 20m28 e			11.2mg P<.3 +
c	R b	alb inh	tba mix 20m28 e			1.73mg P<.1 +
BENZO(a)PYRENE						
					100ng...1ug...10...100...1mg...10...100...1g...10	
336	M f	alb eat	for pam 60w60 ev	.		1.86mg P<.05
337	M m	cf1 wat	eso pam 95w95	.		11.0mg P<.0005+
a	M m	cf1 wat	for pam 95w95			12.4mg P<.03
b	M m	cf1 wat	eso car 95w95			119. mg P<.3 +

RefNum	LoConf	UpConf	Cntrl	1Dose	1Inc	2Dose	2Inc	Citation or Pathology	Brkly Code	
AZOBENZENE 103-33-3										
317	c02926	78.4mg	n.s.s.	9/20	27.0mg	20/50	70.8mg	12/50		
a	c02926	247.mg	n.s.s.	0/20	27.0mg	2/50	70.8mg	0/50		
b	c02926	232.mg	n.s.s.	2/20	27.0mg	2/50	70.8mg	2/50		
318	1104	7.70mg	n.s.s.	0/16	7.84mg	1/17				
a	1104	14.7mg	n.s.s.	0/16	7.84mg	0/17				
b	1104	7.70mg	n.s.s.	0/16	7.84mg	1/17				
319	c02926	34.6mg	n.s.s.	13/20	24.0mg	25/50	(48.0mg)	20/50		
a	c02926	43.6mg	n.s.s.	8/20	24.0mg	16/50	(48.0mg)	2/50		
b	c02926	287.mg	n.s.s.	2/20	24.0mg	4/50	48.0mg	1/50		
320	1104	1.78mg	11.1mg	0/16	7.30mg	9/18				
a	1104	2.02mg	14.9mg	0/16	7.30mg	8/18				
b	1104	14.5mg	n.s.s.	0/16	7.30mg	0/18				
c	1104	1.78mg	11.1mg	0/16	7.30mg	9/18				
321	1104	5.76mg	n.s.s.	1/17	7.84mg	2/16				
a	1104	13.8mg	n.s.s.	0/17	7.84mg	0/16				
b	1104	6.39mg	n.s.s.	2/17	7.84mg	2/16				
322	1104	6.12mg	n.s.s.	1/18	7.30mg	2/18				
a	1104	9.58mg	n.s.s.	2/18	7.30mg	1/18				
b	1104	5.74mg	n.s.s.	3/18	7.30mg	3/18				
323	c02926	19.8mg	69.9mg	0/20	10.0mg	5/50	20.0mg	19/50		
a	c02926	19.8mg	69.9mg	0/20	10.0mg	5/50	20.0mg	19/50		
b	c02926	42.7mg	1.39um	0/20	10.0mg	1/50	20.0mg	8/50		
c	c02926	46.2mg	n.s.s.	0/20	10.0mg	1/50	20.0mg	7/50		
d	c02926	13.0mg	n.s.s.	10/20	10.0mg	32/50	20.0mg	33/50		
e	c02926	83.5mg	n.s.s.	0/20	10.0mg	1/50	20.0mg	2/50		
324	c02926	11.4mg	39.1mg	0/20	8.00mg	6/50	16.0mg	16/50		
a	c02926	11.4mg	39.1mg	0/20	8.00mg	6/50	16.0mg	16/50		
b	c02926	22.9mg	110.mg	0/20	8.00mg	0/50	16.0mg	13/50		
c	c02926	20.8mg	121.mg	0/20	8.00mg	2/50	16.0mg	7/50		
d	c02926	6.61mg	37.1mg	10/20	8.00mg	19/50	16.0mg	43/50		
e	c02926	41.4mg	n.s.s.	0/20	8.00mg	1/50	16.0mg	3/50		
BARIUM ACETATE 543-80-6										
325	1395	1.34mg	n.s.s.	3/47	1.00mg	5/21				
a	1395	2.63mg	n.s.s.	9/47	1.00mg	3/21				
b	1395	1.65mg	n.s.s.	4/47	1.00mg	4/21				
c	1395	2.10mg	n.s.s.	14/47	1.00mg	5/21				
326	1395	3.28mg	n.s.s.	5/38	.833mg	4/37				
a	1395	1.53mg	n.s.s.	11/38	.833mg	12/37				
b	1395	1.88mg	n.s.s.	2/38	.833mg	6/37				
327	1456	1.14mg	n.s.s.	17/24	.286mg	15/33				
a	1456	1.18mg	n.s.s.	8/24	.286mg	9/33				
328	1456	.738mg	n.s.s.	4/26	.250mg	8/30				
a	1456	.844mg	n.s.s.	2/26	.250mg	6/30				
BENZENE 71-43-2										
329	1048	32.4mg	n.s.s.	24/50	83.7mg	29/49				
330	1048	190.mg	2.81um	0/40	251.mg	6/40				
a	1048	167.mg	n.s.s.	2/40	251.mg	8/40				
b	1048	212.mg	n.s.s.	2/40	251.mg	6/40				
331	1047	125.mg	916.mg	0/30	11.6mg	2/30	58.0mg	8/32		
a	1047	347.mg	n.s.s.	0/30	11.6mg	0/30	58.0mg	2/32		
b	1047	156.mg	n.s.s.	3/30	11.6mg	4/30	58.0mg	7/32		
c	1047	116.mg	n.s.s.	0/30	11.6mg	0/30	58.0mg	0/32		
d	1047	425.mg	n.s.s.	1/30	11.6mg	2/30	58.0mg	1/32		
332	1047	29.4mg	1.11gm	0/28	11.6mg	5/28	(58.0mg)	2/33		
a	1047	241.mg	27.4gm	0/28	11.6mg	0/28	58.0mg	4/33		
b	1047	473.mg	n.s.s.	0/28	11.6mg	0/28	58.0mg	1/33		
c	1047	473.mg	n.s.s.	0/28	11.6mg	0/28	58.0mg	1/33		
d	1047	110.mg	n.s.s.	0/28	11.6mg	0/28	58.0mg	0/33		
333	518	415.mg	n.s.s.	0/27	50.4mg	0/45				
a	518	415.mg	n.s.s.	0/27	50.4mg	0/45				
BENZENESULPHONOHYDRAZIDE (BSH) 5351-65-5										
334	1060	13.7mg	n.s.s.	1/29	30.1mg	4/24				
a	1060	13.7mg	n.s.s.	1/29	30.1mg	4/24				
BENZIDINE 92-87-5										
335	598	.786mg	n.s.s.	0/21	.440mg	5/28				
a	598	1.35mg	n.s.s.	0/21	.440mg	2/28				
b	598	1.83mg	n.s.s.	0/21	.440mg	1/28				
c	598	.610mg	n.s.s.	2/21	.440mg	8/28				
BENZO(a)PYRENE 50-32-8										
336	1274	.707mg	n.s.s.	0/40	.520mg	5/81				
337	1129	5.37mg	29.3mg	0/67	3.34mg	10/63				
a	1129	5.10mg	n.s.s.	5/67	3.34mg	13/63				
b	1129	19.4mg	n.s.s.	0/67	3.34mg	1/63				

Spe	Strain	Site	Xpo+Xpt		TD50	2Tailpvl
Sex	Route	Hist	Notes		DR	AuQp
BENZOATE, SODIUM				100ng...1ug...10...100...1mg...10...100...1g...10		
338	R f f34	eat tba	mix 24m25 e	>	24.9gm	* P<.9 -
	a	R f f34	eat tba	mal 24m25 e		104.gm * P<.1. -
339	R m f34	eat tba	mix 24m25 e	>	no dre	P=1. -
	a	R m f34	eat tba	mal 24m25 e		no dre P=1. -
BENZOGUANAMINE				100ng...1ug...10...100...1mg...10...100...1g...10		
340	M f chi	eat liv	mix 77w94	>	2.04gm	* P<.3 -
	a	M f chi	eat lun	mix 77w94		9.34gm * P<.9 -
	b	M f chi	eat tba	mix 77w94		932.mg * P<.5 -
341	M m chi	eat lun	mix 73w94 a	:	304.mg	* P<.03 -
	a	M m chi	eat liv	mix 73w94 a		3.20gm * P<.7 -
	b	M m chi	eat tba	mix 73w94 a		439.mg * P<.2 -
342	R m cdr	eat liv	mix 77w94	>	no dre	P=1. -
	a	R m cdr	eat tba	mix 77w94		16.3mg \ P<.2 -
1,2-BENZOPYRONE				100ng...1ug...10...100...1mg...10...100...1g...10		
343	H f syg	eat liv	tum 22m24 ae	>	no dre	P=1. -
	a	H f syg	eat tba	mix 22m24 ae		5.52gm * P<.9 -
344	H m syg	eat liv	tum 24m24 e	>	no dre	P=1. -
	a	H m syg	eat tba	mix 24m24 e		603.mg * P<.04 -
BENZOTHIAZYL DISULFIDE				100ng...1ug...10...100...1mg...10...100...1g...10		
345	M f b6a	orl lun	ade 76w76 evx	>	no dre	P=1. -
	a	M f b6a	orl liv	hpt 76w76 evx		no dre P=1. -
	b	M f b6a	orl tba	mix 76w76 evx		1.38gm P<.7 -
346	M m b6a	orl lun	ade 76w76 evx	>	1.13gm	P<.7 -
	a	M m b6a	orl liv	hpt 76w76 evx		no dre P=1. -
	b	M m b6a	orl tba	mix 76w76 evx		511.mg P<.5 -
347	M f b6c	orl lun	ade 76w76 evx	>	669.mg	P<.2 -
	a	M f b6c	orl liv	hpt 76w76 evx		no dre P=1. -
	b	M f b6c	orl tba	mix 76w76 evx		432.mg P<.05 -
348	M m b6c	orl liv	hpt 76w76 evx	>	621.mg	P<.2 -
	a	M m b6c	orl lun	mix 76w76 evx		no dre P=1. -
	b	M m b6c	orl tba	mix 76w76 evx		401.mg P<.05 -
1H-BENZOTRIAZOLE				100ng...1ug...10...100...1mg...10...100...1g...10		
349	M f b6c	eat lun	MXA 24m25 v	:	3.89gm \	P<.0005a
	a	M f b6c	eat lun	a/c 24m25 v		4.39gm \ P<.002 a
	b	M f b6c	eat TBA	MXB 24m25 v		18.9gm \ P<.8
	c	M f b6c	eat liv	MXB 24m25 v		no dre P=1. -
	d	M f b6c	eat lun	MXB 24m25 v		3.89gm \ P<.0005
350	M m b6c	eat TBA	MXB 24m25 v	>	no dre	P=1. -
	a	M m b6c	eat liv	MXB 24m25 v		no dre P=1. -
	b	M m b6c	eat lun	MXB 24m25 v		no dre P=1. -
351	R f f34	eat bra	gln 18m24 v		+historical	* P<.3 a
	a	R f f34	eat TBA	MXB 18m24 v		no dre P=1. -
	b	R f f34	eat liv	MXB 18m24 v		10.1gm * P<.2
352	R m f34	eat liv	nnd 18m24 v	:	2.72gm	* P<.02
	a	R m f34	eat bra	MXA 18m24 v		+historical P=1. a
	b	R m f34	eat TBA	MXB 18m24 v		no dre P=1. -
	c	R m f34	eat liv	MXB 18m24 v		2.72gm * P<.02
BENZOYL HYDRAZINE				100ng...1ug...10...100...1mg...10...100...1g...10		
353	M f swa	wat lun	ade 26m26 e	.	13.4mg	P<.0005
	a	M f swa	wat lun	mix 26m26 e		13.8mg P<.0005+
	b	M f swa	wat lun	adc 26m26 e		39.0mg P<.0005
	c	M f swa	wat ---	mly 26m26 e		52.1mg P<.004 +
	d	M f swa	wat liv	mix 26m26 e		no dre P=1. -
354	M m swa	wat lun	mix 92w92 e	.	7.35mg	P<.0005+
	a	M m swa	wat lun	ade 92w92 e		8.52mg P<.0005
	b	M m swa	wat lun	adc 92w92 e		24.1mg P<.0005
	c	M m swa	wat ---	mly 92w92 e		52.0mg P<.07 +
	d	M m swa	wat liv	hem 92w92 e		no dre P=1. -
355	M f swi	gav lun	tum 40w55	>	no dre	P=1. -
BENZYLHYDRAZINE, 2HCl				100ng...1ug...10...100...1mg...10...100...1g...10		
356	M f swa	wat lun	mix 28m28 e	.	85.3mg	P<.02 +
	a	M f swa	wat liv	ang 28m28 e		252.mg P<.2 -
	b	M f swa	wat liv	mix 28m28 e		304.mg P<.3
357	M m swa	wat liv	mix 23m23 e	.	86.2mg	P<.08
	a	M m swa	wat lun	ade 23m23 e		711.mg P<.8 -
	b	M m swa	wat lun	mix 23m23 e		no dre P=1. -
BERYLLIUM SULFATE				100ng...1ug...10...100...1mg...10...100...1g...10		
358	M f cd1	wat lun	tum 33m33 e	>	no dre	P=1. -
	a	M f cd1	wat tba	mix 33m33 e		9.42mg P<.4 -
	b	M f cd1	wat tba	mal 33m33 e		36.9mg P<.7 -

RefNum	LoConf	UpConf	Cntrl	1Dose	1Inc	2Dose	2Inc	Citation or Pathology	Brkly Code
BENZOATE, SODIUM 532-32-1									
338	1319	2.03gm	n.s.s.	8/43	480.mg	16/52	960.mg	11/52	Sodemoto;jept,4,87-95;1980
a	1319	4.00gm	n.s.s.	3/43	480.mg	5/52	960.mg	4/52	
339	1319	2.78gm	n.s.s.	9/25	384.mg	7/50	768.mg	11/50	
a	1319	7.17gm	n.s.s.	0/25	384.mg	1/50	768.mg	0/50	
BENZOGUANAMINE 91-76-9									
340	381	503.mg	n.s.s.	0/20	223.mg	1/17	446.mg	1/18	Weisburger;jept,2,325-356;1978/pers.comm./Russfield 1973
a	381	433.mg	n.s.s.	6/20	223.mg	2/17	446.mg	3/18	
b	381	200.mg	n.s.s.	17/20	223.mg	8/17	446.mg	9/18	
341	381	119.mg	n.s.s.	5/18	240.mg	2/13	411.mg	7/14	
a	381	378.mg	n.s.s.	3/18	240.mg	0/13	411.mg	2/14	
b	381	131.mg	n.s.s.	12/18	240.mg	3/13	411.mg	9/14	
342	381	144.mg	n.s.s.	1/22	17.1mg	0/20	34.3mg	0/21	
a	381	5.02mg	n.s.s.	14/22	17.1mg	13/20	34.3mg	9/21	
1,2-BENZOPYRONE (coumarin) 91-64-5									
343	1340	222.mg	n.s.s.	0/12	105.mg	0/13	523.mg	0/10	Ueno;fctx,19,353-355;1981
a	1340	350.mg	n.s.s.	5/12	105.mg	3/13	523.mg	4/10	
344	1340	174.mg	n.s.s.	0/12	92.0mg	0/11	460.mg	0/11	
a	1340	212.mg	n.s.s.	1/12	92.0mg	2/11	460.mg	5/11	
BENZOTHAZYL DISULFIDE (Altax) 120-78-5									
345	1301	256.mg	n.s.s.	1/17	215.mg		1/18		Innes;ntis,1968/1969
a	1301	426.mg	n.s.s.	0/17	215.mg		0/18		
b	1301	155.mg	n.s.s.	2/17	215.mg		3/18		
346	1301	142.mg	n.s.s.	2/18	200.mg		3/18		
a	1301	396.mg	n.s.s.	1/18	200.mg		0/18		
b	1301	102.mg	n.s.s.	3/18	200.mg		5/18		
347	1301	164.mg	n.s.s.	0/16	215.mg		2/18		
a	1301	426.mg	n.s.s.	0/16	215.mg		0/18		
b	1301	130.mg	n.s.s.	0/16	215.mg		3/18		
348	1301	153.mg	n.s.s.	0/16	200.mg		2/18		
a	1301	396.mg	n.s.s.	0/16	200.mg		0/18		
b	1301	121.mg	n.s.s.	0/16	200.mg		3/18		
1H-BENZOTRIAZOLE 95-14-7									
349	c03521	2.21gm	7.77gm	0/50	1.50gm	10/50	(2.99gm	4/50)	Lun:a/a,a/c.
a	c03521	2.43gm	9.15gm	0/50	1.50gm	9/50	(2.99gm	3/50)	
b	c03521	2.21gm	n.s.s.	21/50	1.50gm	25/50	(2.99gm	14/50)	
c	c03521	25.8gm	n.s.s.	1/50	1.50gm	2/50	2.99gm	1/50	Liv:hpa,hpc,nnnd.
d	c03521	1.89gm	11.6gm	0/50	1.50gm	10/50	(2.99gm	4/50)	Lun:a/a,a/c.
350	c03521	1.68gm	n.s.s.	24/50	1.38gm	23/50	(2.76gm	18/50)	
a	c03521	9.88gm	n.s.s.	12/50	1.38gm	12/50	2.76gm	7/50	Liv:hpa,hpc,nnnd.
b	c03521	7.62gm	n.s.s.	4/50	1.38gm	7/50	2.76gm	5/50	Lun:a/a,a/c.
351	c03521	3.31gm	n.s.s.	0/50	250.mg	0/50	450.mg	1/50	
a	c03521	535.mg	n.s.s.	27/50	250.mg	27/50	450.mg	30/50	
b	c03521	2.48gm	n.s.s.	0/50	250.mg	0/50	450.mg	2/50	Liv:hpa,hpc,nnnd.
352	c03521	1.03gm	n.s.s.	0/50	202.mg	0/50	360.mg	5/50	
a	c03521	n.s.s.	n.s.s.	0/50	202.mg	3/50	360.mg	0/50	bra:gln,oli.
b	c03521	368.mg	n.s.s.	28/50	202.mg	20/50	(360.mg	18/50)	
c	c03521	1.03gm	n.s.s.	0/50	202.mg	0/50	360.mg	5/50	Liv:hpa,hpc,nnnd.
BENZOYL HYDRAZINE 613-94-5									
353	48	8.18mg	24.9mg	12/89	20.0mg		34/47		Toth;ejca,8,341-345;1972/1969a
a	48	8.29mg	26.1mg	14/89	20.0mg		34/47		
b	48	21.0mg	89.4mg	2/89	20.0mg		16/47		
c	48	23.6mg	463.mg	16/106	20.0mg		18/49		
d	48	145.mg	n.s.s.	3/88	20.0mg		1/47		
354	48	4.40mg	13.7mg	10/86	16.7mg		31/42		
a	48	5.05mg	16.5mg	10/86	16.7mg		29/42		
b	48	12.7mg	54.5mg	0/86	16.7mg		13/42		
c	48	16.4mg	n.s.s.	2/40	16.7mg		5/25		
d	48	67.2mg	n.s.s.	2/40	16.7mg		0/25		
355	1095	10.8mg	n.s.s.	8/85	10.4mg		1/25		Roe;natu,216,375-376;1967
BENZYLHYDRAZINE.2HCL 20570-96-1									
356	1056	36.8mg	n.s.s.	21/90	30.0mg		21/47		Toth;zkko,87,267-273;1976/1974
a	1056	61.4mg	n.s.s.	2/56	30.0mg		3/22		
b	1056	63.8mg	n.s.s.	3/56	30.0mg		3/22		
357	1056	24.8mg	n.s.s.	6/71	25.0mg		5/21		
a	1056	59.5mg	n.s.s.	15/99	25.0mg		8/47		
b	1056	70.9mg	n.s.s.	23/99	25.0mg		9/47		
BERYLLIUM SULFATE 13510-49-1									
358	1395	9.07mg	n.s.s.	9/47	1.00mg		5/52		Schroeder;jnut,105,452-458;1975
a	1395	2.34mg	n.s.s.	14/47	1.00mg		20/52		
b	1395	5.36mg	n.s.s.	4/47	1.00mg		6/52		

Spe	Strain	Site	Xpo+Xpt	Notes		TD50	2Tailpvl	
							DR	AuOp
359	M m cd1 wat	lun tum	41m41 e		>	98.8mg	P<.9	-
a	M m cd1 wat	tba mix	41m41 e			17.1mg	P<.6	-
b	M m cd1 wat	tba mal	41m41 e			49.6mg	P<.6	-
360	R f leb wat	tba mix	47m47 e		>	1.48mg	P<.4	-
a	R f leb wat	tba mal	47m47 e			3.24mg	P<.4	-
361	R m leb wat	tba mix	38m38 e		>	2.78mg	P<.3	-
a	R m leb wat	tba mal	38m38 e			8.56mg	P<.6	-
BIPHENYL						100ng.....1ug.....10.....100.....1mg.....10.....100.....1g.....10		
362	M f b6a orl	liv hpt	76w76 evx		>	no dre	P=1.	-
a	M f b6a orl	lun ade	76w76 evx			no dre	P=1.	-
b	M f b6a orl	tba mix	76w76 evx			187.mg	P<.4	-
363	M m b6a orl	liv hpt	76w76 evx		>	182.mg	P<.3	-
a	M m b6a orl	lun ade	76w76 evx			no dre	P=1.	-
b	M m b6a orl	tba mix	76w76 evx			290.mg	P<.7	-
364	M f b6c orl	lun ade	76w76 evx		>	467.mg	P<.3	-
a	M f b6c orl	liv hpt	76w76 evx			no dre	P=1.	-
b	M f b6c orl	tba mix	76w76 evx			227.mg	P<.2	-
365	M m b6c orl	lun ade	76w76 evx		±	128.mg	P<.04	-
a	M m b6c orl	liv hpt	76w76 evx			199.mg	P<.1	-
b	M m b6c orl	tba mix	76w76 evx			71.5mg	P<.007	-
BIS(2-CHLORO-1-METHYLETHYL) ETHER						100ng.....1ug.....10.....100.....1mg.....10.....100.....1g.....10		
366	R f f34 gav	TBA MXB	24m24 s		± +	65.6mg /	P<.006	-
a	R f f34 gav	liv MXB	24m24 s			no dre	P=1.	-
367	R m f34 gav	TBA MXB	24m24 s		±	101.mg /	P<.02	-
a	R m f34 gav	liv MXB	24m24 s			no dre	P=1.	-
BIS-2-CHLOROETHYLETHER						100ng.....1ug.....10.....100.....1mg.....10.....100.....1g.....10		
368	M f b6a orl	liv hpt	79w79 evx		>	no dre	P=1.	-
a	M f b6a orl	lun mix	79w79 evx			no dre	P=1.	-
b	M f b6a orl	tba mix	79w79 evx			no dre	P=1.	-
369	M m b6a orl	liv hpt	79w79 evx		. + .	20.2mg	P<.0005+	-
a	M m b6a orl	lun ade	79w79 evx			no dre	P=1.	-
b	M m b6a orl	tba mix	79w79 evx			21.6mg	P<.01	-
370	M f b6c orl	liv hpt	79w79 evx		±	65.0mg	P<.02	-
a	M f b6c orl	lun ade	79w79 evx			no dre	P=1.	-
b	M f b6c orl	tba mix	79w79 evx			122.mg	P<.4	-
371	M m b6c orl	liv hpt	79w79 evx		. + .	8.19mg	P<.0005+	-
a	M m b6c orl	lun ade	79w79 evx			no dre	P=1.	-
b	M m b6c orl	tba mix	79w79 evx			noTD50	P<.007	-
BIS-1,4-(CHLOROMETHOXY)BUTANE						100ng.....1ug.....10.....100.....1mg.....10.....100.....1g.....10		
372	M f hic ipj	abd sar	81w81		>	no dre	P=1.	-
BIS-1,2-(CHLOROMETHOXY)ETHANE						100ng.....1ug.....10.....100.....1mg.....10.....100.....1g.....10		
373	M f hic ipj	abd mix	78w78		±	4.62mg	P<.02	+
BIS-1,6-(CHLOROMETHOXY)HEXANE						100ng.....1ug.....10.....100.....1mg.....10.....100.....1g.....10		
374	M f hic ipj	abd sar	81w81		>	no dre	P=1.	-
BIS-1,4-(CHLOROMETHOXY)-p-XYLENE						100ng.....1ug.....10.....100.....1mg.....10.....100.....1g.....10		
375	M f hic ipj	abd sar	77w77		±	3.11mg	P<.1	+
BIS-(CHLOROMETHYL) ETHER						100ng.....1ug.....10.....100.....1mg.....10.....100.....1g.....10		
376	M f hic ipj	abd sar	60w60		±	.182mg	P<.02	+
377	M m hic inh	lun mix	6m25 es		>	1.16mg *	P<.4	+
a	M m hic inh	lun ade	6m25 es			1.26mg *	P<.3	+
b	M m hic inh	liv mix	6m25 es			no dre	P=1.	-
c	M m hic inh	liv hpc	6m25 es			no dre	P=1.	-
378	R m sss inh	nap ene	6m28 e		±.	3.57ug Z	P<.0005+	-
a	R m sss inh	lun ade	6m28 e			.196mg *	P<.002	+
b	R m sss inh	nap car	6m28 e			.795mg *	P<.2	+
c	R m sss inh	liv bht	6m28 e			no dre	P=1.	-
d	R m sss inh	tba mix	6m28 e			2.34ug *	P<.0005	-
4-BIS(2-HYDROXYETHYL)AMINO-2-(5-NITRO-2-THIENYL)QUINAZOLINE.....100.....1mg.....10.....100.....1g.....10								
379	R m sda eat	smi sar	50w52 e		. + .	3.14mg	P<.0005+	-
a	R m sda eat	smi lei	50w52 e			3.60mg	P<.0005	-
b	R m sda eat	mg1 mix	50w52 e			6.45mg	P<.0005+	-
c	R m sda eat	mg1 adc	50w52 e			11.5mg	P<.007	+
d	R m sda eat	tba mix	50w52 e			1.10mg	P<.0005	-
4-BIS(2-HYDROXYETHYL)AMINO-2-(2-THIENYL)QUINAZOLINE ..10.....100.....1mg.....10.....100.....1g.....10								
380	R f sda eat	tba mix	46w66 e		>	60.1mg	P<.3	-
BIS-2-HYDROXYETHYLDITHIOCARBAMIC ACID, POTASSIUM.....10.....100.....1mg.....10.....100.....1g.....10								
381	M f b6a orl	liv hpt	79w79 evx		±	298.mg	P<.04	-
a	M f b6a orl	lun ade	79w79 evx			850.mg	P<.6	-
b	M f b6a orl	tba mix	79w79 evx			138.mg	P<.04	-

RefNum	LoConf	UpConf	Cntrl	1Dose	1Inc	2Dose	2Inc	Citation or Pathology	Brkly Code
359	1395	6.34mg	n.s.s.	5/38	.833mg	7/48			
a	1395	3.29mg	n.s.s.	11/38	.833mg	17/48			
b	1395	7.70mg	n.s.s.	2/38	.833mg	4/48			
360	1456	.298mg	n.s.s.	17/24	.286mg	14/17		Schroeder; jnut, 105,421-427; 1975	
a	1456	.689mg	n.s.s.	8/24	.286mg	8/17			
361	1456	.768mg	n.s.s.	4/26	.250mg	9/33			
a	1456	1.33mg	n.s.s.	2/26	.250mg	4/33			
BIPHENYL 92-52-4									
362	1307	137.mg	n.s.s.	0/17	73.0mg	0/17		Innes;ntis, 1968/1969	
a	1307	137.mg	n.s.s.	1/17	73.0mg	0/17			
b	1307	39.1mg	n.s.s.	2/17	73.0mg	4/17			
363	1307	41.6mg	n.s.s.	1/18	68.0mg	3/17			
a	1307	83.7mg	n.s.s.	2/18	68.0mg	1/17			
b	1307	39.1mg	n.s.s.	3/18	68.0mg	4/17			
364	1307	76.1mg	n.s.s.	0/16	73.0mg	1/18			
a	1307	145.mg	n.s.s.	0/16	73.0mg	0/18			
b	1307	55.7mg	n.s.s.	0/16	73.0mg	2/18			
365	1307	38.7mg	n.s.s.	0/16	68.0mg	3/17			
a	1307	48.8mg	n.s.s.	0/16	68.0mg	2/17			
b	1307	26.9mg	966.mg	0/16	68.0mg	5/17			
BIS(2-CHLORO-1-METHYLETHYL) ETHER 108-60-1									
366	c50044	30.7mg	907.mg	39/50	70.1mg	32/50	140.mg	15/50	
a	c50044	n.s.s.	n.s.s.	0/50	70.1mg	0/50	140.mg	0/50	Liv:hpa,hpc,nd.
367	c50044	45.3mg	n.s.s.	30/50	70.7mg	30/50	141.mg	18/50	
a	c50044	366.mg	n.s.s.	1/50	70.7mg	1/50	141.mg	0/50	Liv:hpa,hpc,nd.
BIS-2-CHLOROETHYLETHER 111-44-4									
368	1227	88.4mg	n.s.s.	0/15	41.3mg	0/18		Innes;ntis, 1968/1969	
a	1227	88.4mg	n.s.s.	0/15	41.3mg	0/18			
b	1227	53.7mg	n.s.s.	1/15	41.3mg	1/18			
369	1227	9.25mg	56.1mg	0/18	38.4mg	9/17			
a	1227	40.0mg	n.s.s.	3/18	38.4mg	2/17			
b	1227	8.80mg	1.09gm	3/18	38.4mg	10/17			
370	1227	22.4mg	n.s.s.	0/18	41.3mg	4/18			
a	1227	88.4mg	n.s.s.	1/18	41.3mg	0/18			
b	1227	25.6mg	n.s.s.	2/18	41.3mg	4/18			
371	1227	3.46mg	27.6mg	3/15	38.4mg	14/16			
a	1227	73.1mg	n.s.s.	2/15	38.4mg	0/16			
b	1227	n.s.s.	12.7mg	5/15	38.4mg	16/16			
BIS-1,4-(CHLOROMETHOXY)BUTANE ---									
372	582	2.14mg	n.s.s.	0/30	.571mg	0/30		Van Duuren;canr,35,2553-2557;1975	
BIS-1,2-(CHLOROMETHOXY)ETHANE 13483-18-6									
373	582	1.59mg	n.s.s.	0/30	1.71mg	4/30		Van Duuren;canr,35,2553-2557;1975	
BIS-1,6-(CHLOROMETHOXY)HEXANE ---									
374	582	6.43mg	n.s.s.	0/30	1.71mg	0/30		Van Duuren;canr,35,2553-2557;1975	
BIS-1,4-(CHLOROMETHOXY)-p-XYLENE 56894-91-8									
375	582	.765mg	n.s.s.	0/30	.571mg	2/30		Van Duuren;canr,35,2553-2557;1975	
BIS-(CHLOROMETHYL) ETHER (BCME) 542-88-1									
376	582	62.8ug	n.s.s.	0/30	.114mg	4/30		Van Duuren;canr,35,2553-2557;1975	
377	1086	.253mg	n.s.s.	10/157	295.ng	7/138	2.95ug	3/143	33.6ug 10/144
a	1086	.291mg	n.s.s.	6/157	295.ng	4/138	2.95ug	2/143	33.6ug 7/144
b	1086	1.17mg	n.s.s.	4/157	295.ng	1/138	2.95ug	0/143	33.6ug 0/144
c	1086	1.17mg	n.s.s.	3/157	295.ng	1/138	2.95ug	0/143	33.6ug 0/144
378	1086	2.63ug	4.90ug	0/104	52.8ng	0/105	528.ng	0/103	7.78ug 96/103
a	1086	67.7ug	1.09mg	0/104	52.8ng	0/105	528.ng	0/103	7.78ug 4/103
b	1086	.129mg	n.s.s.	0/104	52.8ng	0/105	528.ng	0/103	7.78ug 1/103
c	1086	.234mg	n.s.s.	0/104	52.8ng	1/105	528.ng	0/103	7.78ug 0/103
d	1086	1.43ug	3.88ug	56/104	52.8ng	48/105	528.ng	43/103	7.78ug 102/103
4-BIS(2-HYDROXYETHYL)AMINO-2-(5-NITRO-2-THIENYL)QUINAZOLINE ---									
379	1390	1.59mg	7.25mg	0/20	19.2mg	13/20		Cohen;jnci,57,277-282;1976	
a	1390	1.79mg	8.58mg	0/20	19.2mg	12/20			
b	1390	2.88mg	20.4mg	0/20	19.2mg	8/20			
c	1390	4.32mg	132.mg	0/20	19.2mg	5/20			
d	1390	.452mg	2.52mg	0/20	19.2mg	19/20			
4-BIS(2-HYDROXYETHYL)AMINO-2-(2-THIENYL)QUINAZOLINE ---									
380	1390	12.7mg	n.s.s.	6/84	17.4mg	4/28		Cohen;jnci,57,277-282;1976	
BIS-2-HYDROXYETHYLDITHIOCARBAMIC ACID, POTASSIUM 23746-34-1									
381	1217	90.0mg	n.s.s.	0/17	157.mg	3/16		Innes;ntis, 1968/1969	
a	1217	124.mg	n.s.s.	1/17	157.mg	2/16			
b	1217	49.5mg	n.s.s.	2/17	157.mg	7/16			

Spe	Strain	Site	Xpo+Xpt	Notes	TD50	2Tailpvl
Sex	Route	Hist	Notes		DR	AuOp
382	M m b6a	orl liv	hpt 79w79	evx . + .	41.5mg	P<.0005+
a	M m b6a	orl lun	ade 79w79	evx	no dre	P=1.
b	M m b6a	orl tba	mix 79w79	evx	45.6mg	P<.0005
383	M f b6c	orl liv	hpt 79w79	evx . + .	56.4mg	P<.0005
a	M f b6c	orl lun	ade 79w79	evx	1.08gm	P<.3
b	M f b6c	orl tba	mix 79w79	evx	48.4mg	P<.0005
384	M m b6c	orl liv	hpt 79w79	evx . + .	34.5mg	P<.0005+
a	M m b6c	orl lun	mix 79w79	evx	no dre	P=1.
b	M m b6c	orl tba	mix 79w79	evx	27.8mg	P<.0005
BISMUTH DIMETHYLDITHIOCARBAMATE					100ng...1ug...10...100...1mg...10...100...1g...10	
385	M f b6a	orl lun	ade 76w76	evx .>	26.3mg	P<.6 -
a	M f b6a	orl liv	hpt 76w76	evx	no dre	P=1. -
b	M f b6a	orl tba	mix 76w76	evx	no dre	P=1. -
386	M m b6a	orl lun	ade 76w76	evx .>	no dre	P=1. -
a	M m b6a	orl liv	hpt 76w76	evx	no dre	P=1. -
b	M m b6a	orl tba	mix 76w76	evx	no dre	P=1. -
387	M f b6c	orl liv	hpt 76w76	evx .>	no dre	P=1. -
a	M f b6c	orl lun	mix 76w76	evx	no dre	P=1. -
b	M f b6c	orl tba	tum 76w76	evx	no dre	P=1. -
388	M m b6c	orl lun	ade 76w76	evx . ±	12.6mg	P<.1 -
a	M m b6c	orl liv	adm 76w76	evx	26.0mg	P<.3 -
b	M m b6c	orl tba	mix 76w76	evx	4.53gm	P<.007 -
BISMUTH OXYCHLORIDE					100ng...1ug...10...100...1mg...10...100...1g...10	
389	R b bdr	eat mgl	fa 24m28		150. gm *	P<.8 -
a	R b bdr	eat mgl	car 24m28		no dre	P=1. -
b	R b bdr	eat hpl	ade 24m28		no dre	P=1. -
BLACK PN					100ng...1ug...10...100...1mg...10...100...1g...10	
390	M f cws	eat liv	tum 80w80	e .>	no dre	P=1. -
a	M f cws	eat lun	ade 80w80	e	no dre	P=1. -
391	M m cws	eat lun	ade 80w80	e .>	3.66gm *	P<.3 -
a	M m cws	eat liv	tum 80w80	e	no dre	P=1. -
392	R f cfe	eat liv	tum 24m24	es .>	no dre	P=1. -
393	R m cfe	eat liv	tum 24m24	es .>	no dre	P=1. -
C.I. DIRECT BLACK 38					100ng...1ug...10...100...1mg...10...100...1g...10	
394	R f f34	eat liv	nnd 13w13	: (+) :	2.61mg *	P<.003 c
a	R f f34	eat TBA	MXB 13w13		2.61mg *	P<.003
b	R f f34	eat liv	MXB 13w13		2.61mg *	P<.003
395	R m f34	eat liv	MXA 13w13	: (+) :	.945mg Z	P<.0005c
a	R m f34	eat liv	hpc 13w13		2.22mg *	P<.004
b	R m f34	eat TBA	MXB 13w13		.945mg Z	P<.0005
c	R m f34	eat liv	MXB 13w13		.945mg Z	P<.0005
C.I. DIRECT BLUE 6					100ng...1ug...10...100...1mg...10...100...1g...10	
396	R f f34	eat liv	MXA 13w13	: (+) :	3.21mg Z	P<.0005c
a	R f f34	eat liv	hpc 13w13		5.97mg *	P<.003
b	R f f34	eat TBA	MXB 13w13		3.21mg Z	P<.0005
c	R f f34	eat liv	MXB 13w13		3.21mg Z	P<.0005
397	R m f34	eat liv	MXA 13w13	: (+) :	1.18mg Z	P<.0005c
a	R m f34	eat TBA	MXB 13w13		1.18mg Z	P<.0005
b	R m f34	eat liv	MXB 13w13		1.18mg Z	P<.0005
FD & C BLUE NO. 1					100ng...1ug...10...100...1mg...10...100...1g...10	
398	R b osm	eat liv	hpt 24m24		62.1gm *	P<.2
a	R b osm	eat tba	mix 24m24		no dre	P=1. -
FD & C BLUE NO. 2					100ng...1ug...10...100...1mg...10...100...1g...10	
399	M f cd1	eat liv	nod 84w84	es .>	no dre	P=1. -
a	M f cd1	eat lun	ade 84w84	es	no dre	P=1. -
400	M m cd1	eat liv	nod 84w84	es .>	20.2gm *	P<.4 -
a	M m cd1	eat lun	ade 84w84	es	no dre	P=1. -
401	R b osm	eat tba	mix 24m24		5.43gm *	P<.06 -
BROMATE, POTASSIUM					100ng...1ug...10...100...1mg...10...100...1g...10	
402	M f the	eat liv	hem 80w80	e .>	347. mg *	P<.6 -
403	M m the	eat liv	tum 80w80	e .>	no dre	P=1. -
a	M m the	eat tba	mal 80w80	e	no dre	P=1. -
C.I. DIRECT BROWN 95					100ng...1ug...10...100...1mg...10...100...1g...10	
404	R f f34	eat liv	MXA 13w13	: (+) :	2.07mg Z	P<.002 c
a	R f f34	eat TBA	MXB 13w13		2.07mg Z	P<.002
b	R f f34	eat liv	MXB 13w13		2.07mg Z	P<.002
405	R m f34	eat TBA	MXB 13w13		no dre	P=1. -
a	R m f34	eat liv	MXB 13w13		no dre	P=1. -

Spe	Strain	Site	Xpo+Xpt	Notes	TD50	2Tailpvl
Sex	Route	Hist			DR	AuOp
2-sec-BUTYL-4,6-DINITROPHENOL 100ng....1ug.....10.....100.....1mg.....10.....100.....1g.....10						
406	M f b6a	orl lun	ade	76w76 evx	>	no dre P=1. -
a	M f b6a	orl liv	hpt	76w76 evx		no dre P=1. -
b	M f b6a	orl tba	mix	76w76 evx		no dre P=1. -
407	M m b6a	orl lun	ade	76w76 evx	>	2.17mg P<.4 -
a	M m b6a	orl liv	hpt	76w76 evx		94.1mg P<.1 -
b	M m b6a	orl tba	mix	76w76 evx		1.29mg P<.3 -
408	M f b6c	orl lun	ade	76w76 evx	>	6.14mg P<.3 -
a	M f b6c	orl liv	hpt	76w76 evx		no dre P=1. -
b	M f b6c	orl tba	mix	76w76 evx		6.14mg P<.3 -
409	M m b6c	orl liv	hpt	76w76 evx	*	1.30mg P<.02 -
a	M m b6c	orl lun	ade	76w76 evx		2.77mg P<.2 -
b	M m b6c	orl tba	mix	76w76 evx		.662mg P<.002 -
M-N-BUTYL-N-FORMYLHYDRAZINE 100ng....1ug.....10.....100.....1mg.....10.....100.....1g.....10						
410	M f swa	wat lun	mix	92w92 e	+	19.4mg P<.0005+
a	M f swa	wat cli	mix	92w92 e		252.mg P<.004 +
b	M f swa	wat cli	sqc	92w92 e		321.mg P<.01
c	M f swa	wat liv	mix	92w92 e		no dre P=1.
411	M m swa	wat lun	mix	90w90 e	+	19.2mg P<.0005+
a	M m swa	wat pre	mix	90w90 e		28.2mg P<.0005+
b	M m swa	wat pre	sqc	90w90 e		35.6mg P<.0005
c	M m swa	wat pre	fsa	90w90 e		304.mg P<.002
d	M m swa	wat pre	ang	90w90 e		519.mg P<.02
e	M m swa	wat liv	agm	90w90 e		no dre P=1. -
N-BUTYL-N-(4-HYDROXYBUTYL)NITROSAMINE1ug.....10.....100.....1mg.....10.....100.....1g.....10						
412	R m sda	wat ubl	car	24m24	+	3.30mg P<.0005+
a	R m sda	wat liv	lcc	24m24		271.mg P<.3
DI-tert-BUTYL-4-HYDROXYMETHYL PHENOL1ug.....10.....100.....1mg.....10.....100.....1g.....10						
413	R f nbw	eat mgl	fa	24m24	>	3.71gm * P<.3 -
a	R f nbw	eat liv	tum	24m24		no dre P=1.
b	R f nbw	eat tba	mix	24m24		3.71gm * P<.3 -
414	R m nbw	eat liv	tum	24m24	>	no dre P=1.
a	R m nbw	eat tba	tum	24m24		no dre P=1. -
N-BUTYL-N'-NITRO-N-NITROSOGUANIDINE1ug.....10.....100.....1mg.....10.....100.....1g.....10						
415	R m wis	wat stg	tum	52w78 er	>	no dre P=1. -
BUTYLATED HYDROXYTOLUENE 100ng....1ug.....10.....100.....1mg.....10.....100.....1g.....10						
416	M f b6c	eat lun	MXA	25m25 a	*	#715.mg \ P<.02 -
a	M f b6c	eat TBA	MXB	25m25 a		no dre P=1.
b	M f b6c	eat liv	MXB	25m25 a		10.7gm * P<.6
c	M f b6c	eat lun	MXB	25m25 a		715.mg \ P<.02
417	M m b6c	eat TBA	MXB	25m25 a	>	no dre P=1. -
a	M m b6c	eat liv	MXB	25m25 a		no dre P=1.
b	M m b6c	eat lun	MXB	25m25 a		no dre P=1.
418	M f bal	eat lun	tum	69w69	>	no dre P=1.
a	M f bal	eat liv	tum	69w69		no dre P=1.
419	M m bal	eat lun	tum	69w69	>	7.33gm P<.8
a	M m bal	eat liv	mix	69w69		no dre P=1.
420	M m bal	eat lun	ppa	69w69 e	*	368.mg P<.03 +
a	M m bal	eat sto	sqc	69w69 e		2.03gm P<.09 -
b	M m bal	eat ---	rts	69w69 e		no dre P=1. -
c	M m bal	eat liv	tum	69w69 e		no dre P=1. -
421	R f f34	eat TBA	MXB	24m24	>	no dre P=1. -
a	R f f34	eat liv	MXB	24m24		no dre P=1.
422	R m f34	eat TBA	MXB	24m24	>	no dre P=1. -
a	R m f34	eat liv	MXB	24m24		2.30gm * P<.4
423	R f wis	eat pit	ade	24m24 e	*	613.mg \ P<.02 -
a	R f wis	eat liv	hnd	24m24 e		5.99gm * P<.4 -
b	R f wis	eat tba	mix	24m24 e		2.31gm * P<.5 -
424	R m wis	eat liv	hnd	24m24 e	>	no dre P=1. -
a	R m wis	eat tba	mix	24m24 e		no dre P=1. -
1,1-DI-N-BUTYLHYDRAZINE 100ng....1ug.....10.....100.....1mg.....10.....100.....1g.....10						
425	M f swa	wat lun	ade	25m25 es	+	51.5mg P<.0005
a	M f swa	wat lun	mix	25m25 es		55.5mg P<.0005+
b	M f swa	wat for	mix	25m25 es		71.5mg P<.0005+
c	M f swa	wat for	sqc	25m25 es		95.9mg P<.0005
d	M f swa	wat lun	adc	25m25 es		133.mg P<.0005
e	M f swa	wat for	sqc	25m25 es		152.mg P<.0005
f	M f swa	wat liv	agm	25m25 es		no dre P=1. -
426	M m swa	wat lun	mix	25m25 es	+	38.1mg P<.0005+
a	M m swa	wat lun	ade	25m25 es		44.9mg P<.0005
b	M m swa	wat lun	adc	25m25 es		82.3mg P<.0005
c	M m swa	wat for	mix	25m25 es		84.2mg P<.0005+
d	M m swa	wat liv	mix	25m25 es		105.mg P<.0005+

RefNum	LoConf	UpConf	Cntrl	1Dose	1Inc	2Dose	2Inc	Citation or Pathology	Brkly Code
2-sec-BUTYL-4,6-DINITROPHENOL 88-85-7									
406	1289	1.07mg n.s.s.	1/17	.959mg	1/17			Innes;ntis,1968/1969	
a	1289	1.79mg n.s.s.	0/17	.959mg	0/17				
b	1289	.843mg n.s.s.	2/17	.959mg	2/17				
407	1289	.475mg n.s.s.	2/18	.891mg	4/17				
a	1289	.987mg n.s.s.	1/18	.891mg	1/17				
b	1289	.351mg n.s.s.	3/18	.891mg	6/17				
408	1289	.999mg n.s.s.	0/16	.959mg	1/18				
a	1289	1.90mg n.s.s.	0/16	.959mg	0/18				
b	1289	.999mg n.s.s.	0/16	.959mg	1/18				
409	1289	.446mg n.s.s.	0/16	.891mg	4/18				
a	1289	.680mg n.s.s.	0/16	.891mg	2/18				
b	1289	.282mg 2.70mg	0/16	.891mg	7/18				
N-N-BUTYL-N-FORMYLHYDRAZINE ---									
410	1057	11.2mg 35.3mg	25/99	80.0mg	45/49			Toth;carc,1,589-593;1980	
a	1057	95.7mg 1.78gm	0/40	80.0mg	5/32				
b	1057	111. mg 25.8gm	0/40	80.0mg	4/32				
c	1057	184. mg n.s.s.	6/47	80.0mg	5/41				
411	1057	11.4mg 35.8mg	26/100	66.7mg	42/48				
a	1057	18.0mg 47.0mg	0/85	66.7mg	33/47				
b	1057	22.4mg 60.9mg	0/85	66.7mg	29/47				
c	1057	115. mg 1.44gm	0/85	66.7mg	5/47				
d	1057	157. mg n.s.s.	0/85	66.7mg	3/47				
e	1057	123. mg n.s.s.	7/70	66.7mg	2/23				
N-BUTYL-N-(4-HYDROXYBUTYL)NITROSAMINE 3817-11-6									
412	1192	1.98mg 5.64mg	0/40	10.0mg	35/40			Schmahl;arzn,28,49-51;1978	
a	1192	44.1mg n.s.s.	0/40	10.0mg	1/40				
DI-tert-BUTYL-4-HYDROXYMETHYL PHENOL ---									
413	127	604. mg n.s.s.	0/20	100. mg	0/20	175. mg	1/20	Decre;txap,17,669-678;1970	
a	127	262. mg n.s.s.	0/20	100. mg	0/20	175. mg	0/20		
b	127	604. mg n.s.s.	0/20	100. mg	0/20	175. mg	1/20		
414	127	210. mg n.s.s.	0/20	80.0mg	0/20	140. mg	0/20		
a	127	210. mg n.s.s.	0/20	80.0mg	0/20	140. mg	0/20		
N-BUTYL-N'-NITRO-N-NITROSOGUANIDINE 13010-08-7									
415	1082	1.99mg n.s.s.	0/9	2.14mg	0/8			Matsukura;gann,70,181-185;1979	
BUTYLATED HYDROXYTOLUENE (BMT) 128-37-0									
416	c03598	357. mg n.s.s.	1/20	390. mg	16/50	(780. mg	7/50)	Lun;a/a,a/c. S	
a	c03598	336. mg n.s.s.	14/20	390. mg	32/50	(780. mg	23/50)		
b	c03598	2.18gm n.s.s.	1/20	390. mg	4/50	780. mg	5/50	Liv:hpa,hpc,nnd.	
c	c03598	357. mg n.s.s.	1/20	390. mg	16/50	(780. mg	7/50)	Lun;a/a,a/c.	
417	c03598	355. mg n.s.s.	17/20	360. mg	39/50	(720. mg	32/50)		
a	c03598	531. mg n.s.s.	11/20	360. mg	23/50	(720. mg	13/50)	Liv:hpa,hpc,nnd.	
b	c03598	1.23gm n.s.s.	7/20	360. mg	21/50	720. mg	17/50	Lun;a/a,a/c.	
418	1006	1.15gm n.s.s.	13/50	975. mg	11/50			Clapp;jnci,61,177-180;1978	
a	1006	4.42gm n.s.s.	0/50	975. mg	0/50				
419	1006	711. mg n.s.s.	45/100	900. mg	47/100				
a	1006	8.16gm n.s.s.	2/100	900. mg	0/100				
420	53	122. mg n.s.s.	6/25	900. mg	7/11			Clapp;fctx,12,367-371;1974	
a	53	330. mg n.s.s.	0/25	900. mg	1/8				
b	53	509. mg n.s.s.	14/25	900. mg	1/8				
c	53	898. mg n.s.s.	0/25	900. mg	0/11				
421	c03598	374. mg n.s.s.	12/20	150. mg	36/50	300. mg	26/50		
a	c03598	n.s.s. n.s.s.	0/20	150. mg	0/50	300. mg	0/50	Liv:hpa,hpc,nnd.	
422	c03598	210. mg n.s.s.	17/20	120. mg	36/50	240. mg	35/50		
a	c03598	796. mg n.s.s.	0/20	120. mg	2/50	240. mg	2/50	Liv:hpa,hpc,nnd.	
423	1087	250. mg 171. gm	0/32	125. mg	6/46	(500. mg	3/51)	Hirose;fctx,19,147-151;1981	
a	1087	1.45gm n.s.s.	0/32	125. mg	3/46	500. mg	3/51		
b	1087	476. mg n.s.s.	11/32	125. mg	25/46	500. mg	25/51		
424	1087	2.23gm n.s.s.	2/26	100. mg	2/43	400. mg	1/38		
a	1087	1.12gm n.s.s.	6/26	100. mg	13/43	400. mg	10/51		
1,1-DI-n-BUTYLHYDRAZINE ---									
425	1438	30.3mg 107. mg	20/99	62.5mg	34/50			Toth;carc,2,651-654;1981	
a	1438	31.5mg 128. mg	25/99	62.5mg	34/50				
b	1438	41.4mg 147. mg	4/71	62.5mg	23/45				
c	1438	52.5mg 227. mg	4/71	62.5mg	19/45				
d	1438	69.3mg 371. mg	6/99	62.5mg	17/50				
e	1438	77.9mg 355. mg	0/71	62.5mg	12/45				
f	1438	474. mg n.s.s.	5/71	62.5mg	1/45				
426	1438	21.7mg 84.7mg	26/96	52.1mg	34/46				
a	1438	26.1mg 93.8mg	16/96	52.1mg	30/46				
b	1438	43.3mg 235. mg	12/96	52.1mg	21/46				
c	1438	46.7mg 174. mg	0/96	52.1mg	16/43				
d	1438	39.4mg 437. mg	0/40	52.1mg	5/16				

Spe	Strain	Site	Xpo + Xpt		TD50	2Tailpvl
Sex	Route	Hist	Notes		DR	AuOp
e	M m swa wat	for sqp	25m25 es		109. mg	P<.0005
f	M m swa wat	liv bhp	25m25 es		189. mg	P<.006
g	M m swa wat	for sqc	25m25 es		317. mg	P<.0005
1,2-DI-n-BUTYLHYDRAZINE.2HCl				100ng.....1ug.....10.....100.....1mg.....10.....100.....1g.....10		
427	M f swa wat	lun mix	93w93 e	.	69.8mg	P<.0005+
a	M f swa wat	--- mly	93w93 e	.	198. mg	P<.003 +
b	M f swa wat	liv ang	93w93 e	.	no dre	P=1. -
c	M f swa wat	liv agm	93w93 e	.	no dre	P=1. -
428	M m swa wat	lun mix	87w87 e	.	34.5mg	P<.0005+
a	M m swa wat	kid mix	87w87 e	.	449. mg	P<.004 +
b	M m swa wat	--- mly	87w87 e	.	886. mg	P<.4 +
c	M m swa wat	liv agm	87w87 e	.	no dre	P=1. -
d	M m swa wat	liv ang	87w87 e	.	no dre	P=1. -
n-BUTYLHYDRAZINE.HCl				100ng.....1ug.....10.....100.....1mg.....10.....100.....1g.....10		
429	M f swa wat	lun mix	28m28 e	.	18.4mg	P<.0005+
a	M f swa wat	lun ade	28m28 e	.	19.3mg	P<.0005
b	M f swa wat	lun adc	28m28 e	.	50.6mg	P<.0005
c	M f swa wat	liv mix	28m28 e	.	no dre	P=1. -
430	M m swa wat	lun ade	23m23 e	.	8.40mg	P<.0005
a	M m swa wat	lun mix	23m23 e	.	9.03mg	P<.0005+
b	M m swa wat	liv mix	23m23 e	.	no dre	P=1. -
N-BUTYLUREA				100ng.....1ug.....10.....100.....1mg.....10.....100.....1g.....10		
431	M f cb6 eat	liv hpc	52w69 e	.	no dre	P=1. -
a	M f cb6 eat	lun ade	52w69 e	.	no dre	P=1. -
b	M f cb6 eat	tba mix	52w69 e	.	no dre	P=1. -
432	M m cb6 eat	lun ade	52w69 e	.	5.51gm	P<.4 -
a	M m cb6 eat	liv hpc	52w69 e	.	no dre	P=1. -
b	M m cb6 eat	tba mix	52w69 e	.	699. mg	P<.02 -
433	R f f34 eat	liv tum	52w69 e	.	no dre	P=1. -
a	R f f34 eat	tba mix	52w69 e	.	no dre	P=1. -
434	R m f34 eat	liv tum	52w69 e	.	no dre	P=1. -
a	R m f34 eat	tba mix	52w69 e	.	no dre	P=1. -
BETA-BUTYROLACTONE				100ng.....1ug.....10.....100.....1mg.....10.....100.....1g.....10		
435	R f esd gav	for sqc	70w70	.	13.8mg	P<.02 +
CADMIUM ACETATE				100ng.....1ug.....10.....100.....1mg.....10.....100.....1g.....10		
436	M f cd1 wat	lun car	30m30 e	.	no dre	P=1. -
a	M f cd1 wat	tba tum	30m30 e	.	no dre	P=1. -
437	M m cd1 wat	lun car	28m28 e	.	no dre	P=1. -
a	M m cd1 wat	tba tum	28m28 e	.	no dre	P=1. -
438	R b leb wat	liv tum	41m41 es	.	37.7mg	P<.8 -
a	R b leb wat	tba tum	41m41 es	.	1.81mg	P<.2 -
b	R b leb wat	tba mal	41m41 es	.	5.10mg	P<.2 -
CADMIUM CHLORIDE MONOHYDRATE**				100ng.....1ug.....10.....100.....1mg.....10.....100.....1g.....10		
439	R f wws eat	liv hpt	24m24 e	.	no dre	P=1. -
a	R f wws eat	tba mix	24m24 e	.	21.6mg *	P<.7 -
b	R f wws eat	tba ben	24m24 e	.	44.0mg *	P<.8 -
c	R f wws eat	tba mal	24m24 e	.	124. mg *	P<.9 -
440	R m wws eat	adr phe	24m24 e	.	1.33mg Z	P<.04 -
a	R m wws eat	liv hpt	24m24 e	.	no dre	P=1. -
b	R m wws eat	tba mal	24m24 e	.	47.4mg *	P<.5 -
c	R m wws eat	tba ben	24m24 e	.	no dre	P=1. -
d	R m wws eat	tba mix	24m24 e	.	no dre	P=1. -
CADMIUM DIETHYLDITHIOCARBAMATE				100ng.....1ug.....10.....100.....1mg.....10.....100.....1g.....10		
441	M f b6a orl	lun ade	76w76 evx	.	no dre	P=1. -
a	M f b6a orl	liv hpt	76w76 evx	.	no dre	P=1. -
b	M f b6a orl	tba mix	76w76 evx	.	47.5mg	P<.7 -
442	M m b6a orl	liv hpt	76w76 evx	.	no dre	P=1. -
a	M m b6a orl	lun ade	76w76 evx	.	no dre	P=1. -
b	M m b6a orl	tba mix	76w76 evx	.	no dre	P=1. -
443	M f b6c orl	lun ade	76w76 evx	.	57.4mg	P<.3 -
a	M f b6c orl	liv hpt	76w76 evx	.	no dre	P=1. -
b	M f b6c orl	tba mix	76w76 evx	.	18.0mg	P<.05 -
444	M m b6c orl	liv hpt	76w76 evx	.	16.7mg	P<.05 -
a	M m b6c orl	lun ade	76w76 evx	.	25.9mg	P<.2 -
b	M m b6c orl	tba mix	76w76 evx	.	6.20mg	P<.002 -
CADMIUM SULPHATE**				100ng.....1ug.....10.....100.....1mg.....10.....100.....1g.....10		
445	M m swi gav	lun mix	78w78 e	.	1.78mg *	P<.6 -
a	M m swi gav	liv mix	78w78 e	.	no dre	P=1. -
446	R m cbo gav	liv lca	24m26	.	1.17mg *	P<.07 -

	RefNum	LoConf	UpConf	Cntrl	1Dose	1Inc	2Dose	2Inc	Citation or Pathology	Brkly Code			
e	1438	57.2mg	246.mg	0/96	52.1mg	13/43							
f	1438	56.9mg	2.40gm	0/40	52.1mg	3/16							
g	1438	120.mg	1.37gm	0/96	52.1mg	5/43							
1,2-DI-n-BUTYLHYDRAZINE.2HCL 7422-80-2													
427	1116	40.5mg	149.mg	25/99	125.mg	36/50			Toth;expa,37,773-775;1981				
a	1116	93.2mg	1.29gm	18/100	125.mg	21/50							
b	1116	379.mg	n.s.s.	3/47	125.mg	2/36							
c	1116	517.mg	n.s.s.	3/47	125.mg	1/36							
428	1116	20.2mg	67.3mg	26/100	104.mg	38/46							
a	1116	155.mg	3.51gm	0/70	104.mg	4/38							
b	1116	186.mg	n.s.s.	8/100	104.mg	6/46							
c	1116	416.mg	n.s.s.	5/70	104.mg	1/38							
d	1116	420.mg	n.s.s.	3/80	104.mg	1/42							
n-BUTYLHYDRAZINE.HCL 56795-65-4													
429	252	10.7mg	37.6mg	21/90	25.0mg	34/44			Nagel;ejca,11,473-478;1975/Toth 1974				
a	252	11.3mg	38.5mg	18/90	25.0mg	33/44							
b	252	27.2mg	121.mg	4/90	25.0mg	17/44							
c	252	101.mg	n.s.s.	3/56	25.0mg	0/15							
430	252	4.21mg	19.9mg	15/92	20.8mg	19/23							
a	252	4.36mg	24.1mg	23/92	20.8mg	19/23							
b	252	47.6mg	n.s.s.	6/71	20.8mg	1/18							
N-BUTYLUREA 592-31-4													
431	1361	1.24gm	n.s.s.	1/92	567.mg	0/24			Murthy;jcn,23,253-259;1979				
a	1361	1.24gm	n.s.s.	2/92	567.mg	0/24							
b	1361	501.mg	n.s.s.	17/92	567.mg	4/24							
432	1361	682.mg	n.s.s.	1/95	523.mg	1/26							
a	1361	1.23gm	n.s.s.	2/95	523.mg	0/26							
b	1361	244.mg	n.s.s.	8/95	523.mg	7/26							
433	1361	317.mg	n.s.s.	0/44	218.mg	0/16							
a	1361	127.mg	n.s.s.	20/44	218.mg	5/16							
434	1361	253.mg	n.s.s.	0/50	175.mg	0/16							
a	1361	84.4mg	n.s.s.	30/50	175.mg	7/16							
beta-BUTYROLACTONE 3068-88-0													
435	55	3.85mg	n.s.s.	0/5	40.8mg	3/5			Van Duuren;jnci,37,825-838;1966				
CADMIUM ACETATE 543-90-8													
436	56	4.71mg	n.s.s.	9/60	1.00mg	5/39			Schroeder;jnut,83,239-250;1964				
a	56	4.14mg	n.s.s.	22/60	1.00mg	10/39							
437	56	11.0mg	n.s.s.	8/44	.833mg	0/48							
a	56	9.55mg	n.s.s.	11/44	.833mg	1/48							
438	1036	3.29mg	n.s.s.	1/34	.265mg	2/47			Kanisawa;canr,29,892-895;1969				
a	1036	.668mg	n.s.s.	10/34	.265mg	22/47							
b	1036	1.56mg	n.s.s.	2/34	.265mg	7/47							
CADMIUM CHLORIDE MONOHYDRATE** 35658-65-2													
439	1139	.343mg	n.s.s.	0/94	49.5ug	0/48	.149mg	0/48	.495mg	0/48	2.48mg	0/46	Losler;clot,9,191-198;1980
a	1139	2.74mg	n.s.s.	54/94	49.5ug	23/48	.149mg	17/48	.495mg	31/48	2.48mg	25/46	
b	1139	3.56mg	n.s.s.	46/94	49.5ug	19/48	.149mg	16/48	.495mg	22/48	2.48mg	21/46	
c	1139	6.66mg	n.s.s.	10/94	49.5ug	6/48	.149mg	7/48	.495mg	11/48	2.48mg	6/46	
440	1139	.432mg	n.s.s.	2/98	39.6ug	0/50	.119mg	5/50	.396mg	2/50	1.98mg	2/50	
a	1139	24.2mg	n.s.s.	0/98	39.6ug	1/50	.119mg	0/50	.396mg	0/50	1.98mg	0/50	
b	1139	7.94mg	n.s.s.	4/98	39.6ug	4/50	.119mg	2/50	.396mg	1/50	1.98mg	4/50	
c	1139	6.32mg	n.s.s.	40/98	39.6ug	18/50	.119mg	25/50	.396mg	23/50	1.98mg	15/50	
d	1139	5.23mg	n.s.s.	43/98	39.6ug	21/50	.119mg	26/50	.396mg	24/50	1.98mg	18/50	
CADMIUM DIETHYLTHIOCARBAMATE (ethyl cadmate) 14239-68-0													
441	1140	9.99mg	n.s.s.	1/17	8.96mg	1/17			Innes;ntis,1968/1969				
a	1140	16.8mg	n.s.s.	0/17	8.96mg	0/17							
b	1140	5.99mg	n.s.s.	2/17	8.96mg	3/17							
442	1140	16.3mg	n.s.s.	1/18	8.34mg	0/18							
a	1140	16.5mg	n.s.s.	2/18	8.34mg	0/18							
b	1140	11.7mg	n.s.s.	3/18	8.34mg	1/18							
443	1140	9.34mg	n.s.s.	0/16	8.96mg	1/18							
a	1140	17.8mg	n.s.s.	0/16	8.96mg	0/18							
b	1140	5.43mg	n.s.s.	0/16	8.96mg	3/18							
444	1140	5.05mg	n.s.s.	0/16	8.34mg	3/18							
a	1140	6.36mg	n.s.s.	0/16	8.34mg	2/18							
b	1140	2.64mg	25.2mg	0/16	8.34mg	7/18							
CADMIUM SULPHATE** 7790-84-3													
445	1044	.307mg	n.s.s.	33/149	62.9ug	14/50	.126mg	9/50	.250mg	14/49	Levy;ano,17,213-220;1975		
a	1044	.492mg	n.s.s.	50/149	62.9ug	18/50	.126mg	18/50	.250mg	11/49			
446	1045	.359mg	n.s.s.	1/90	26.2ug	2/30	52.3ug	0/30	.105mg	3/30	Levy;ano,17,205-211;1975		

Spe	Strain	Site	Xpo + Xpt	Notes	TD50	2Tailpvl	DR	AuOp
Sex	Route	Hist						
CAFFEINE					100ng...1ug...10...100...1mg...10...100...1g...10			
447	M f	cb6 eat	liv tum	77w77 e	>	no dre	P=1.	-
448	M m	cb6 eat	liv hnd	77w77 e	>	775.mg	P<.3	-
449	R m	sds eat	liv tum	25m25 s	>	no dre	P=1.	-
CAPTAN					100ng...1ug...10...100...1mg...10...100...1g...10			
450	M f	b6c eat	TBA MXB	80w91	>	no dre	P=1.	-
	a	M f	b6c eat	liv MXB	80w91		no dre	P=1.
	b	M f	b6c eat	lun MXB	80w91		no dre	P=1.
451	M f	b6c eat	duo ace	80w90	pool	:	21.6gm *	P<.03 e
452	M f	b6c orl	liv hpt	76w76 evx	>	no dre	P=1.	-
	a	M f	b6c orl	lun mix	76w76 evx		no dre	P=1.
	b	M f	b6c orl	tba mix	76w76 evx		244.mg	P<.2 -
453	M m	b6c eat	TBA MXB	80w91	>	no dre	P=1.	-
	a	M m	b6c eat	liv MXB	80w91		no dre	P=1.
	b	M m	b6c eat	lun MXB	80w91		no dre	P=1.
454	M m	b6c eat	duo adm	80w90	pool	:	7.39gm *	P<.003 e
	a	M m	b6c eat	duo ace	80w90		15.1gm *	P<.03 e
455	M m	b6c orl	liv hpt	76w76 evx	.	86.1mg	P<.02	-
	a	M m	b6c orl	lun ade	76w76 evx	.	187.mg	P<.09 -
	b	M m	b6c orl	tba mix	76w76 evx		42.5mg	P<.0005-
456	M f	b6a orl	liv hpt	76w76 evx	>	no dre	P=1.	-
	a	M f	b6a orl	lun ade	76w76 evx		no dre	P=1.
	b	M f	b6a orl	tba mix	76w76 evx		no dre	P=1.
457	M m	b6a orl	liv hpt	76w76 evx	>	195.mg	P<.3	-
	a	M m	b6a orl	lun ade	76w76 evx		3.62gm	P<.1 -
	b	M m	b6a orl	tba mix	76w76 evx		161.mg	P<.4 -
458	R f	osm eat	TBA MXB	19m26 v	>	no dre	P=1.	-
	a	R f	osm eat	liv MXB	19m26 v		no dre	P=1.
459	R f	osm eat	adr MXA	19m25 v	pool	:	253.mg \	P<.02 -
460	R m	osm eat	TBA MXB	19m26 v	>	4.78gm *	P<.1.	-
	a	R m	osm eat	liv MXB	19m26 v		no dre	P=1.
CARBANYL HYDRAZINE.HCl					100ng...1ug...10...100...1mg...10...100...1g...10			
461	M f	swa wat	lun mix	27m27 e	.	223.mg	P<.002 +	
	a	M f	swa wat	lun ade	27m27 e		333.mg	P<.007
	b	M f	swa wat	blv mix	27m27 e		395.mg	P<.003 +
	c	M f	swa wat	liv mix	27m27 e		798.mg	P<.04
	d	M f	swa wat	blv ang	27m27 e		798.mg	P<.04
	e	M f	swa wat	blv agm	27m27 e		975.mg	P<.05
462	M m	swa wat	liv hpt	27m27 e	.	1.42gm	P<.03 -	
	a	M m	swa wat	lun ade	27m27 e		745.mg	P<.2
	b	M m	swa wat	lun mix	27m27 e		833.mg	P<.4 +
	c	M m	swa wat	liv mix	27m27 e		933.mg	P<.2
1-CARBANYL-2-PHENYLHYDRAZINE					100ng...1ug...10...100...1mg...10...100...1g...10			
463	M f	swa wat	lun ade	79w79 e	.	150.mg	P<.0005	
	a	M f	swa wat	lun mix	79w79 e		155.mg	P<.0005+
	b	M f	swa wat	lun adc	79w79 e		1.25gm	P<.007
	c	M f	swa wat	liv ang	79w79 e		1.98gm	P<.03 -
	d	M f	swa wat	liv agm	79w79 e		2.67gm	P<.06 -
464	M m	swa wat	lun ade	79w79 e	.	158.mg	P<.0005	
	a	M m	swa wat	lun mix	79w79 e		176.mg	P<.0005+
	b	M m	swa wat	liv mix	79w79 e		1.79gm	P<.3
	c	M m	swa wat	liv ang	79w79 e		2.00gm	P<.3 -
CARBARSONE					100ng...1ug...10...100...1mg...10...100...1g...10			
465	R f	fdr eat	--- lyk	22m24 aes	>	4.59gm *	P<.4 -	
466	R m	fdr eat	thm rts	22m24 aes	>	4.50gm *	P<.4 -	
CARBARYL					100ng...1ug...10...100...1mg...10...100...1g...10			
467	M f	b6a orl	lun ade	76w76 evx	>	no dre	P=1.	-
	a	M f	b6a orl	liv hpt	76w76 evx		no dre	P=1.
	b	M f	b6a orl	tba mix	76w76 evx		no dre	P=1.
468	M m	b6a orl	liv hpt	76w76 evx	>	no dre	P=1.	-
	a	M m	b6a orl	lun ade	76w76 evx		no dre	P=1.
	b	M m	b6a orl	tba mix	76w76 evx		no dre	P=1.
469	M f	b6c orl	liv hpt	76w76 evx	>	no dre	P=1.	-
	a	M f	b6c orl	lun mix	76w76 evx		no dre	P=1.
	b	M f	b6c orl	tba mix	76w76 evx		12.4mg	P<.3 -
470	M m	b6c orl	liv hpt	76w76 evx	.	3.39mg	P<.04 -	
	a	M m	b6c orl	lun ade	76w76 evx		3.39mg	P<.04 -
	b	M m	b6c orl	tba mix	76w76 evx		1.51mg	P<.003 -
471	R b	mgr gav	liv tum	22m24 e	>	no dre	P=1.	-
	a	R b	mgr gav	tba mix	22m24 e		14.1mg	P<.003 +
CARBON TETRACHLORIDE					100ng...1ug...10...100...1mg...10...100...1g...10			
472	M f	b6c gav	liv hpc	78w91 ers pool	.	165.mg *	P<.0005+	
473	M m	b6c gav	liv hpc	78w84 ers pool	.	114.mg *	P<.0005+	

CARCINOGENIC POTENCY DATABASE

RefNum	LoConf	UpConf	Cntrl	1Dose	1Inc	2Dose	2Inc	Citation or Pathology	Brkly Code	
CAFFEINE 58-08-2										
447	1028	230.mg	n.s.s.	0/36	55.0mg	0/37		Macklin;dact,3,135-163;1980		
448	1028	126.mg	n.s.s.	0/35	55.0mg	1/38				
449	1459	267.mg	n.s.s.	0/30	40.8mg	0/30		Johansson;ijcn,27,521-529;1981		
CAPTAN 133-06-2										
450	c00077	4.11gm	n.s.s.	3/10	914.mg	5/50	1.83gm	8/50		
a	c00077	11.0gm	n.s.s.	1/10	914.mg	1/50	1.83gm	1/50	Liv:hpa,hpc,nnd, Lun:a/a,a/c.	
b	c00077	n.s.s.	n.s.s.	0/10	914.mg	0/50	1.83gm	0/50		
451	c00077	6.53gm	n.s.s.	0/79p	914.mg	0/50	1.83gm	3/50		
452	1092	155.mg	n.s.s.	0/16	78.4mg	0/18			Innes;ntis,1968/1969	
a	1092	155.mg	n.s.s.	0/16	78.4mg	0/18				
b	1092	59.8mg	n.s.s.	0/16	78.4mg	2/18				
453	c00077	3.94gm	n.s.s.	5/10	844.mg	7/50	1.69gm	10/50		
a	c00077	8.87gm	n.s.s.	3/10	844.mg	1/50	1.69gm	3/50	Liv:hpa,hpc,nnd, Lun:a/a,a/c.	
b	c00077	3.04gm	n.s.s.	2/10	844.mg	3/50	(1.69gm	1/50)		
454	c00077	3.35gm	38.5gm	0/80p	844.mg	3/50	1.69gm	5/50		
a	c00077	5.22gm	n.s.s.	0/80p	844.mg	1/50	1.69gm	3/50		
455	1092	29.5mg	n.s.s.	0/16	73.0mg	4/15			Innes;ntis,1968/1969	
a	1092	45.8mg	n.s.s.	0/16	73.0mg	2/15				
b	1092	18.0mg	149.mg	0/16	73.0mg	7/15				
456	1092	147.mg	n.s.s.	0/17	78.4mg	0/17				
a	1092	147.mg	n.s.s.	1/17	78.4mg	0/17				
b	1092	97.0mg	n.s.s.	2/17	78.4mg	1/17				
457	1092	44.6mg	n.s.s.	1/18	73.0mg	3/17				
a	1092	63.5mg	n.s.s.	2/18	73.0mg	2/17				
b	1092	34.3mg	n.s.s.	3/18	73.0mg	5/17				
458	c00077	170.mg	n.s.s.	8/10	89.0mg	39/50	212.mg	36/50		
a	c00077	888.mg	n.s.s.	0/10	89.0mg	3/50	212.mg	1/50	Liv:hpa,hpc,nnd, adr:coa,coc, S	
459	c00077	109.mg	n.s.s.	4/75p	89.0mg	13/50	(212.mg	7/50)		
460	c00077	124.mg	n.s.s.	5/10	71.2mg	32/50	170.mg	25/50		
a	c00077	798.mg	n.s.s.	1/10	71.2mg	1/50	170.mg	1/50	Liv:hpa,hpc,nnd.	
CARBAMYL HYDRAZINE.HCL 563-41-7										
461	60	111.mg	950.mg	21/90	125.mg	25/47			Toth;ejca,11,17-22;1975/1974	
a	60	149.mg	5.61gm	18/90	125.mg	20/47				
b	60	164.mg	2.88gm	5/81	125.mg	9/31				
c	60	256.mg	n.s.s.	3/81	125.mg	5/31				
d	60	256.mg	n.s.s.	3/81	125.mg	5/31				
e	60	292.mg	n.s.s.	2/81	125.mg	4/31				
462	60	350.mg	n.s.s.	0/87	104.mg	2/32				
a	60	224.mg	n.s.s.	15/99	104.mg	12/48				
b	60	207.mg	n.s.s.	23/99	104.mg	15/48				
c	60	240.mg	n.s.s.	6/87	104.mg	5/32				
1-CARBAMYL-2-PHENYLHYDRAZINE 103-03-7										
463	60a	92.1mg	273.mg	18/100	500.mg	39/50			Toth;jnci,52,241-251;1974	
a	60a	93.7mg	289.mg	21/100	500.mg	39/50				
b	60a	513.mg	19.6gm	4/100	500.mg	9/50				
c	60a	682.mg	n.s.s.	0/34	500.mg	4/42				
d	60a	807.mg	n.s.s.	0/34	500.mg	3/42				
464	60a	94.8mg	305.mg	15/96	417.mg	33/47				
a	60a	101.mg	388.mg	23/96	417.mg	33/47				
b	60a	429.mg	n.s.s.	3/40	417.mg	5/32				
c	60a	477.mg	n.s.s.	2/40	417.mg	4/32				
CARBARSONE 121-59-5										
465	65	747.mg	n.s.s.	0/89	25.0mg	0/43	50.0mg	1/45	69.2mg	0/49
466	65	732.mg	n.s.s.	0/85	25.0mg	0/39	50.0mg	1/43	69.2mg	0/50
CARBARYL (Sevin) 63-25-2										
467	1228	2.30mg	n.s.s.	1/17	1.93mg	1/18				Innes;ntis,1968/1969
a	1228	3.82mg	n.s.s.	0/17	1.93mg	0/18				
b	1228	1.82mg	n.s.s.	2/17	1.93mg	2/18				
468	1228	2.12mg	n.s.s.	1/18	1.80mg	1/18				
a	1228	2.36mg	n.s.s.	2/18	1.80mg	1/18				
b	1228	1.86mg	n.s.s.	3/18	1.80mg	2/18				
469	1228	3.82mg	n.s.s.	0/16	1.93mg	0/18				
a	1228	3.82mg	n.s.s.	0/16	1.93mg	0/18				
b	1228	2.01mg	n.s.s.	0/16	1.93mg	1/18				
470	1228	1.02mg	n.s.s.	0/16	1.80mg	3/17				
a	1228	1.02mg	n.s.s.	0/16	1.80mg	3/17				
b	1228	.609mg	8.19mg	0/16	1.80mg	6/17				
471	1426	19.5mg	n.s.s.	0/46	7.88mg	0/12				Andrianova;vpit,29,71-74;1970
a	1426	4.62mg	139.mg	1/46	7.88mg	4/12				
CARBON TETRACHLORIDE 56-23-5										
472	1469	101.mg	258.mg	1/80p	824.mg	40/40	1.52gm	43/45		National Cancer Institute;bccr;1976
473	1469	63.7mg	188.mg	5/77p	824.mg	49/49	1.65gm	47/48		

Spe	Strain	Site	Xpo+Xpt				TD50	2Tailpvl
Sex	Route	Hist	Notes				DR	AuOp
474	R f nss ivj	liv tum	47w69				.877mg	P<.1
a	R f nss ivj	mgl mix	47w69		±		.765mg	P<.3 +
b	R f nss ivj	tba mix	47w69				.176mg	P<.007
475	R f osm gav	liv hpc	18m26 er	pool			365. mg	\ P<.004
a	R f osm gav	liv nnd	18m26 er				1.46gm	* P<.3
476	R m osm gav	liv nnd	18m26 er	pool			900. mg	* P<.08
a	R m osm gav	liv hpc	18m26 er		±		952. mg	* P<.2
CARBOXYMETHYLNITROSOUREA				100ng.....1ug.....10.....100.....1mg.....10.....100.....1g.....10				
477	R m mrw wat	api mix	17m30		±		34.8mg	P<.02 +
a	R m mrw wat	liv tum	17m30				no dre	P=1.
b	R m mrw wat	tba mix	17m30				13.1mg	P<.09
CARBROMAL				100ng.....1ug.....10.....100.....1mg.....10.....100.....1g.....10				
478	M f b6c eat	Lun MXA	18m24			±	#553. mg	* P<.05 -
a	M f b6c eat	TBA MXB	18m24				5.32gm	* P<.1
b	M f b6c eat	liv MXB	18m24				1.95gm	* P<.09
c	M f b6c eat	Lun MXB	18m24				553. mg	* P<.05
479	M m b6c eat	TBA MXB	18m24			>	no dre	P=1. -
a	M m b6c eat	liv MXB	18m24				1.58gm	* P<.6
b	M m b6c eat	Lun MXB	18m24				no dre	P=1.
480	R f f34 eat	TBA MXB	24m24			>	no dre	P=1. -
a	R f f34 eat	liv MXB	24m24				no dre	P=1.
481	R m f34 eat	TBA MXB	24m24			>	1.03gm	* P<.8 -
a	R m f34 eat	liv MXB	24m24				no dre	P=1.
CARRAGEENAN, ACID-DEGRADED				100ng.....1ug.....10.....100.....1mg.....10.....100.....1g.....10				
482	R b sda wat	clr mix	65w65 er				2.20gm	P<.0005+
a	R b sda gav	clr mix	65w65 er				5.16gm	* P<.0005+
CARRAGEENAN, NATIVE				100ng.....1ug.....10.....100.....1mg.....10.....100.....1g.....10				
483	H f syg eat	liv hem	78w78			>	no dre	P=1. -
a	H f syg eat	tba mix	78w78				177. gm	* P<.9 -
484	H m syg eat	liv hem	25m26 a			>	no dre	P=1. -
a	H m syg eat	tba mix	25m26 a				54.1gm	* P<.3 -
485	R f mrc eat	pns tum	33m34 a				35.4gm	* P<.03 -
a	R f mrc eat	ski tum	33m34 a				no dre	P=1. -
486	R m mrc eat	tba mix	32m33 a			>	no dre	P=1. -
CHENODEOXYCHOLIC ACID				100ng.....1ug.....10.....100.....1mg.....10.....100.....1g.....10				
487	M b cba eat	itn tum	54w54 r			>	no dre	P=1. -
CHLORAMBEN				100ng.....1ug.....10.....100.....1mg.....10.....100.....1g.....10				
488	M f b6c eat	TBA MXB	80w91			>	3.62gm	* P<.2 -
a	M f b6c eat	liv MXB	80w91				3.97gm	* P<.2
b	M f b6c eat	Lun MXB	80w91				58.0gm	* P<.8
489	M f b6c eat	liv hpc	80w90	pool		+	5.23gm	* P<.006 c
490	M m b6c eat	TBA MXB	80w91			>	9.80gm	* P<.7 -
a	M m b6c eat	liv MXB	80w91				no dre	P=1.
b	M m b6c eat	Lun MXB	80w91				18.0gm	* P<.1
491	M m b6c eat	liv hpc	80w90	pool		±	4.96gm	* P<.07 a
492	R f osm eat	TBA MXB	19m26			>	no dre	P=1. -
a	R f osm eat	liv MXB	19m26				no dre	P=1.
493	R m osm eat	TBA MXB	19m26			>	1.28gm	* P<.5 -
a	R m osm eat	liv MXB	19m26				no dre	P=1.
494	R m osm eat	--- hem	19m25	pool		±	#3.03gm	* P<.02 -
CHLORAMBUCIL				100ng.....1ug.....10.....100.....1mg.....10.....100.....1g.....10				
495	M f swi ipj	Lun mix	26w78 e		+		97.0ug	* P<.0005+
a	M f swi ipj	--- lys	26w78 e				.709mg	* P<.003
b	M f swi ipj	liv lys	26w78 e				no dre	P=1.
c	M f swi ipj	tba mix	26w78 e				30.6ug	* P<.0005
d	M f swi ipj	tba mal	26w78 e				60.4ug	* P<.0005
e	M f swi ipj	tba ben	26w78 e				3.60mg	* P<.7
496	M m swi ipj	Lun mix	26w78 e		+		.210mg	* P<.0005+
a	M m swi ipj	--- lys	26w78 e				.435mg	* P<.0005+
b	M m swi ipj	liv mix	26w78 e				no dre	P=1.
c	M m swi ipj	tba mix	26w78 e				.102mg	* P<.0005
d	M m swi ipj	tba mal	26w78 e				.126mg	* P<.0005
e	M m swi ipj	tba ben	26w78 e				no dre	P=1.
497	R m cdr ipj	--- lau	26w78 e		+		1.41mg	* P<.004 +
a	R m cdr ipj	--- lys	26w78 e				1.73mg	* P<.0005
b	R m cdr ipj	liv tum	26w78 e				no dre	P=1.
c	R m cdr ipj	tba mix	26w78 e				.603mg	* P<.07
d	R m cdr ipj	tba mal	26w78 e				.712mg	* P<.03
e	R m cdr ipj	tba ben	26w78 e				no dre	P=1.
CHLORAMPHENICOL				100ng.....1ug.....10.....100.....1mg.....10.....100.....1g.....10				
498	R f sda eat	liv hpt	66w75 e			>	278. mg	P<.2 -
a	R f sda eat	tba mix	66w75 e				no dre	P=1. -

RefNum	LoConf	UpConf	Cntrl	1Dose	1Inc	2Dose	2Inc	Citation or Pathology	Brkly Code	
474	1515	.265mg	n.s.s.	0/34	.157mg	3/57		Tourkevitch;ijcn,20,1446-1449;1964		
a	1515	.214mg	n.s.s.	1/34	.157mg	5/57				
b	1515	87.0ug	2.27mg	2/34	.157mg	16/57				
475	1469	126.mg	2.57mg	0/98p	40.5mg	4/49	(81.0mg	National Cancer Institute;bccr;1976	1/49)	
a	1469	383.mg	n.s.s.	2/98p	40.5mg	2/49	81.0mg		3/49	
476	1469	272.mg	n.s.s.	0/99p	23.8mg	2/50	47.6mg		1/50	
a	1469	251.mg	n.s.s.	1/99p	23.8mg	2/50	47.6mg	2/50		
CARBOXYMETHYLNITROSOUREA (CMNU) 60391-92-6										
477	1246	14.2mg	n.s.s.	0/26	5.29mg			Bulay;jnci,62,1523-1528;1979		
a	1246	68.1mg	n.s.s.	0/26	5.29mg	0/40				
b	1246	5.06mg	n.s.s.	10/26	5.29mg	24/40				
CARBROMAL (bromodiethylacetylurea) 77-65-6										
478	c03805	314.mg	n.s.s.	0/20	122.mg	8/50	244.mg		9/49 lun:a/a,a/c. S	
a	c03805	210.mg	n.s.s.	7/20	122.mg	30/50	244.mg	25/49		
b	c03805	739.mg	n.s.s.	0/20	122.mg	1/50	244.mg	4/49	liv:hpa,hpc,nnd.	
c	c03805	314.mg	n.s.s.	0/20	122.mg	8/50	244.mg	9/49	lun:a/a,a/c.	
479	c03805	344.mg	n.s.s.	12/20	112.mg	16/49	225.mg	21/50		
a	c03805	321.mg	n.s.s.	4/20	112.mg	8/49	225.mg	13/50	liv:hpa,hpc,nnd.	
b	c03805	748.mg	n.s.s.	7/20	112.mg	4/49	225.mg	8/50	lun:a/a,a/c.	
480	c03805	138.mg	n.s.s.	10/20	61.9mg	24/50	124.mg	26/50		
a	c03805	n.s.s.	n.s.s.	0/20	61.9mg	0/50	124.mg	0/50	liv:hpa,hpc,nnd.	
481	c03805	125.mg	n.s.s.	8/20	49.5mg	14/50	99.0mg	24/50		
a	c03805	886.mg	n.s.s.	1/20	49.5mg	0/50	99.0mg	1/50	liv:hpa,hpc,nnd.	
CARRAGEENAN, ACID-DEGRADED ---										
482	611	1.10gm	5.92gm	0/30	2.65gm	11/40		Wakabayashi;clot,4,171-176;1978		
a	611	2.33gm	15.2gm	0/30	1.00gm	0/30	5.00gm		8/29	
CARRAGEENAN, NATIVE 9000-07-1										
483	1330	1.40gm	n.s.s.	1/100	523.mg	0/30	2.61gm	0/30	5.23gm 0/30 Rustia;clot,11,1-10;1980	
a	1330	11.0gm	n.s.s.	5/100	523.mg	0/30	2.61gm	3/30	5.23gm 1/30	
484	1330	2.49gm	n.s.s.	1/100	460.mg	0/30	2.30gm	0/30	4.60gm 0/30	
a	1330	12.8gm	n.s.s.	6/100	460.mg	2/30	2.30gm	2/30	4.60gm 4/30	
485	1330	11.7gm	n.s.s.	2/100	250.mg	1/30	1.25gm	1/30	2.50gm 4/30	
a	1330	35.2gm	n.s.s.	1/100	250.mg	3/30	1.25gm	0/30	2.50gm 0/30	
486	1330	6.34gm	n.s.s.	56/100	200.mg	15/30	1.00gm	19/30	2.00gm 12/30	
CHEMODOXYCHOLIC ACID 474-25-9										
487	1445	17.4mg	n.s.s.	0/10	31.3mg	0/10		Martin;bjca,43,884-886;1981		
CHLORAMBEN 133-90-4										
488	c00055	1.80gm	n.s.s.	0/10	1.14gm	12/50	2.26gm	13/50		
a	c00055	2.28gm	n.s.s.	0/10	1.14gm	8/50	2.26gm	10/50	liv:hpa,hpc,nnd.	
b	c00055	9.57gm	n.s.s.	0/10	1.14gm	1/50	2.26gm	1/50	lun:a/a,a/c.	
489	c00055	2.58gm	57.4gm	2/69p	1.14gm	7/50	2.26gm	10/50		
490	c00055	1.53gm	n.s.s.	2/10	1.05gm	20/50	2.09gm	20/50		
a	c00055	2.26gm	n.s.s.	2/10	1.05gm	18/50	2.09gm	14/50	liv:hpa,hpc,nnd.	
b	c00055	6.22gm	n.s.s.	0/10	1.05gm	0/50	2.09gm	4/50	lun:a/a,a/c.	
491	c00055	2.01gm	n.s.s.	9/70p	1.05gm	16/50	2.09gm	14/50		
492	c00055	616.mg	n.s.s.	6/10	354.mg	36/50	708.mg	34/50		
a	c00055	2.90gm	n.s.s.	0/10	354.mg	2/50	708.mg	1/50	liv:hpa,hpc,nnd.	
493	c00055	339.mg	n.s.s.	2/10	286.mg	25/50	566.mg	24/50		
a	c00055	1.79gm	n.s.s.	0/10	286.mg	4/50	566.mg	1/50	liv:hpa,hpc,nnd.	
494	c00055	1.31gm	n.s.s.	0/75p	286.mg	4/50	566.mg	3/50	S	
CHLORAMBUCIL 305-03-3										
495	1336	51.4ug	.225mg	20/154	.213mg	16/19	.426mg	4/8	Skipper;srfr;1976/Weisburger 1977/Prejean pers.comm.	
a	1336	.229mg	8.39mg	3/154	.213mg	1/19	.426mg	3/8		
b	1336	.215mg	n.s.s.	1/154	.213mg	0/19	.426mg	0/8		
c	1336	11.8ug	77.2ug	42/154	.213mg	18/19	.426mg	8/8		
d	1336	30.9ug	.136mg	29/154	.213mg	16/19	.426mg	7/8		
e	1336	.350mg	n.s.s.	13/154	.213mg	2/19	.426mg	1/8		
496	1336	.108mg	.567mg	9/101	.213mg	10/26	.426mg	7/12		
a	1336	.194mg	1.61mg	2/101	.213mg	6/26	.426mg	3/12		
b	1336	.308mg	n.s.s.	2/101	.213mg	0/26	.426mg	0/12		
c	1336	54.3ug	.256mg	28/101	.213mg	18/26	.426mg	10/12		
d	1336	67.7ug	.305mg	19/101	.213mg	14/26	.426mg	10/12		
e	1336	.535mg	n.s.s.	9/101	.213mg	4/26	.426mg	0/12		
497	1336	.456mg	19.3mg	2/177	.314mg	2/21	.643mg	2/12		
a	1336	.524mg	12.4mg	0/177	.314mg	1/21	.643mg	2/12		
b	1336	.412mg	n.s.s.	0/177	.314mg	0/21	.643mg	0/12		
c	1336	.198mg	n.s.s.	59/177	.314mg	9/21	.643mg	7/12		
d	1336	.252mg	n.s.s.	32/177	.314mg	5/21	.643mg	6/12		
e	1336	.681mg	n.s.s.	27/177	.314mg	4/21	.643mg	1/12		
CHLORAMPHENICOL (Chloromycetin) 56-75-7										
498	200a	45.3mg	n.s.s.	0/71	22.0mg	1/36		Cohen;jnci,51,403-417;1973		
a	200a	22.2mg	n.s.s.	18/71	22.0mg	9/36				

Spe	Strain	Site	Xpo+Xpt	Notes	TD50	2Tailpvl
Sex	Route	Hist			DR	AuOp
CHLORANIL 100ng...1ug...10...100...1mg...10...100...1g...10						
499	M f	b6a orl	lun ade	76w76 evx	>	no dre P=1.
a	M f	b6a orl	liv hpt	76w76 evx		no dre P=1.
b	M f	b6a orl	tba mix	76w76 evx		no dre P=1.
500	M m	b6a orl	lun ade	76w76 evx	>	no dre P=1.
a	M m	b6a orl	liv hpt	76w76 evx		no dre P=1.
b	M m	b6a orl	tba mix	76w76 evx		440. mg P<.7
501	M f	b6c orl	liv hpt	76w76 evx	.	261. mg P<.1
a	M f	b6c orl	lun mix	76w76 evx		no dre P=1.
b	M f	b6c orl	tba mix	76w76 evx		261. mg P<.1
502	M m	b6c orl	liv hpt	76w76 evx	.	57.2 mg P<.002
a	M m	b6c orl	lun ade	76w76 evx		113. mg P<.02
b	M m	b6c orl	tba mix	76w76 evx		34.2 mg P<.0005
CHLORDANE 100ng...1ug...10...100...1mg...10...100...1g...10						
503	M f	b6c eat	liv hpc	80w90 v	:+ :	4.89 mg / P<.0005c
a	M f	b6c eat	TBA MXB	80w90 v		5.16 mg / P<.0005
b	M f	b6c eat	liv MXB	80w90 v		4.89 mg / P<.0005
c	M f	b6c eat	lun MXB	80w90 v		228. mg * P<.4
504	M f	b6c eat	liv hpc	80w89 v	pool	5.28 mg / P<.0005c
505	M m	b6c eat	liv hpc	80w90 ev		2.15 mg / P<.0005c
a	M m	b6c eat	TBA MXB	80w90 ev		2.31 mg * P<.0005
b	M m	b6c eat	liv MXB	80w90 ev		2.15 mg / P<.0005
c	M m	b6c eat	lun MXB	80w90 ev		656. mg * P<.1
506	M m	b6c eat	liv hpc	80w89 ev	pool	2.48 mg / P<.0005c
507	M f	cd1 eat	liv nod	78w78 e	.	1.78 mg Z P<.0005
a	M f	cd1 eat	liv hpt	78w78 e		71.8 mg * P<.2
b	M f	cd1 eat	lun ade	78w78 e		no dre P=1.
508	M m	cd1 eat	liv nod	78w78 e	.	1.45 mg * P<.0005
a	M m	cd1 eat	liv hpt	78w78 e		no dre P=1.
b	M m	cd1 eat	lun mix	78w78 e		no dre P=1.
509	R f	osm eat	TBA MXB	19m25 ev	>	18.4 mg * P<.5 -
a	R f	osm eat	liv MXB	19m25 ev		121. mg * P<.9
510	R f	osm eat	ute MXA	19m25 ev	pool	#101. mg * P<.05 -
511	R m	osm eat	thy MXA	19m25 v		#41.6 mg * P<.04 -
a	R m	osm eat	--- fih	19m25 v		42.5 mg * P<.03
b	R m	osm eat	TBA MXB	19m25 v		21.6 mg * P<.4
c	R m	osm eat	liv MXB	19m25 v		no dre P=1.
512	R m	osm eat	--- fih	19m25 v	pool	#60.4 mg * P<.05 -
CHLORINE 100ng...1ug...10...100...1mg...10...100...1g...10						
513	R b	bd2 wat	tba mix	35m35 g	>	no dre P=1. -
a	R b	bd2 wat	tba mal	35m35 g		no dre P=1. -
b	R b	bd2 wat	tba ben	35m35 g		no dre P=1. -
CHLORMADINONE ACETATE 100ng...1ug...10...100...1mg...10...100...1g...10						
514	M f	c3h eat	nam tum	24m24 er	>	3.77 mg * P<.5 -
515	M f	crf eat	nam tum	24m24 er	pool	no dre P=1. -
516	M f	r3m eat	nam tum	24m24 er		no dre P=1. -
4-CHLORO-4'-AMINODIPHENYLETHER 100ng...1ug...10...100...1mg...10...100...1g...10						
517	M f	chi eat	liv mix	68w86 av	.	905. mg * P<.05
a	M f	chi eat	lun mix	68w86 av		no dre P=1.
b	M f	chi eat	tba mix	68w86 av		598. mg * P<.4
518	M f	chi eat	--- vac	68w86 av	pool	346. mg * P<.0005+
a	M f	chi eat	ubl mix	68w86 av		1.13 gm * P<.0005+
519	M m	chi eat	liv mix	51w55 v		no dre P=1. -
a	M m	chi eat	lun mix	51w55 v		no dre P=1. -
b	M m	chi eat	tba mix	51w55 v		no dre P=1. -
520	R m	cdr eat	liv hpt	77w98 v	.	37.9 mg \ P<.005 +
a	R m	cdr eat	liv mix	77w98 v		37.9 mg \ P<.005 +
b	R m	cdr eat	tba mix	77w98 v		25.1 mg * P<.004
521	R m	cdr eat	liv hpt	77w98 v	pool	37.6 mg \ P<.0005+
2-CHLORO-5-(3,5-DIMETHYLPYPERIDINOSULPHONYL)BENZOIC ACID ...100...1mg...10...100...1g...10						
522	R m	f34 eat	liv hpc	70w71 erv	.	4.85 mg P<.0005+
1-CHLORO-2,4-DINITROBENZENE 100ng...1ug...10...100...1mg...10...100...1g...10						
523	M f	chi eat	lun mix	77w94 v	.	150. mg \ P<.007 -
a	M f	chi eat	liv mix	77w94 v		1.52 gm * P<.3 -
b	M f	chi eat	tba mix	77w94 v		124. mg * P<.004 -
524	M m	chi eat	liv mix	77w94 v	.	365. mg * P<.03 -
a	M m	chi eat	lun mix	77w94 v		541. mg * P<.06 -
b	M m	chi eat	tba mix	77w94 v		255. mg \ P<.09 -
525	R m	cdr eat	liv mix	18m24 v	>	no dre P=1. -
a	R m	cdr eat	tba mix	18m24 v		12.3 mg \ P<.01 -
1-CHLORO-2-NITROBENZENE 100ng...1ug...10...100...1mg...10...100...1g...10						
526	M f	chi eat	liv hpt	77w98 v	.	289. mg \ P<.007 +
a	M f	chi eat	liv mix	77w98 v		289. mg \ P<.007

RefNum	LoConf	UpConf	Cntrl	1Dose	1Inc	2Dose	2Inc	Citation or Pathology	Brkly Code	
CHLORANIL (tetrachloro-p-benzoquinone) 118-75-2										
499	1241	106.mg	n.s.s.	1/17	89.1mg	1/18		Innes;ntis,1968/1969		
a	1241	177.mg	n.s.s.	0/17	89.1mg	0/18				
b	1241	84.1mg	n.s.s.	2/17	89.1mg	2/18				
500	1241	77.5mg	n.s.s.	2/18	82.9mg	2/18				
a	1241	98.0mg	n.s.s.	1/18	82.9mg	1/18				
b	1241	51.5mg	n.s.s.	3/18	82.9mg	4/18				
501	1241	64.0mg	n.s.s.	0/16	89.1mg	2/17				
a	1241	167.mg	n.s.s.	0/16	89.1mg	0/17				
b	1241	64.0mg	n.s.s.	0/16	89.1mg	2/17				
502	1241	24.3mg	220.mg	0/16	82.9mg	7/17				
a	1241	38.9mg	n.s.s.	0/16	82.9mg	4/17				
b	1241	16.1mg	89.9mg	0/16	82.9mg	10/17				
CHLORDANE 57-74-9										
503	c00099	3.28mg	7.88mg	0/20	3.51mg	3/50	7.41mg	34/50		
a	c00099	3.28mg	11.7mg	2/20	3.51mg	6/50	7.41mg	35/50		
b	c00099	3.28mg	7.88mg	0/20	3.51mg	3/50	7.41mg	34/50	liv:hpa,hpc,nnd.	
c	c00099	37.1mg	n.s.s.	0/20	3.51mg	0/50	7.41mg	1/50	lun:a/a,a/c.	
504	c00099	3.41mg	9.30mg	3/80p	3.51mg	3/50	7.41mg	34/50		
505	c00099	1.45mg	4.08mg	2/18	3.12mg	16/50	6.00mg	43/50		
a	c00099	1.47mg	5.55mg	4/18	3.12mg	19/50	6.00mg	43/50		
b	c00099	1.45mg	4.08mg	2/18	3.12mg	16/50	6.00mg	43/50	liv:hpa,hpc,nnd.	
c	c00099	9.98mg	n.s.s.	1/18	3.12mg	6/50	6.00mg	3/50	lun:a/a,a/c.	
506	c00099	1.61mg	4.44mg	17/95p	3.12mg	16/50	6.00mg	43/50		
507	66a	1.15mg	2.94mg	0/57	.650mg	0/62	3.25mg	32/51 (6.50mg	36/51) Epstein(review) {irdc};stev,6,103-154;1976	
a	66a	19.0mg	n.s.s.	1/57	.650mg	0/62	3.25mg	2/51	6.50mg	2/51
b	66a	13.1mg	n.s.s.	6/57	.650mg	2/62	3.25mg	2/51	(6.50mg	0/51)
508	66a	1.07mg	2.05mg	1/47	.600mg	6/58	3.00mg	34/52	6.00mg	38/50
a	66a	14.5mg	n.s.s.	4/47	.600mg	6/58	3.00mg	10/52	6.00mg	2/50
b	66a	32.7mg	n.s.s.	8/47	.600mg	7/58	3.00mg	2/52	6.00mg	2/50
509	c00099	4.46mg	n.s.s.	7/10	4.40mg	34/50	8.90mg	29/50		
a	c00099	11.2mg	n.s.s.	1/10	4.40mg	11/50	8.90mg	6/50		liv:hpa,hpc,nnd.
510	c00099	30.4mg	n.s.s.	0/60p	4.40mg	1/50	8.90mg	2/50		ute:adc,sar. S
511	c00099	17.9mg	n.s.s.	0/10	5.96mg	1/50	11.9mg	6/50		thy:fca,fcc. S
a	c00099	18.9mg	n.s.s.	0/10	5.96mg	1/50	11.9mg	7/50		S
b	c00099	6.13mg	n.s.s.	3/10	5.96mg	21/50	11.9mg	23/50		
c	c00099	40.9mg	n.s.s.	0/10	5.96mg	2/50	11.9mg	0/50		liv:hpa,hpc,nnd.
512	c00099	22.3mg	n.s.s.	2/60p	5.96mg	1/50	11.9mg	7/50		S
CHLORINE 7782-50-5										
513	1421	52.6mg	n.s.s.	3/20	5.29mg	5/60		Druckrey;fctx,6,147-154;1968		
a	1421	64.6mg	n.s.s.	2/20	5.29mg	3/60				
b	1421	69.1mg	n.s.s.	1/20	5.29mg	2/60				
CHLORMADINONE ACETATE 302-22-7										
514	1175	.713mg	n.s.s.	54/92	.104mg	28/43	1.04mg	24/36		Rudali;Jnci,49,813-819;1972
515	1175	.966mg	n.s.s.	161/167p	.104mg	45/46	1.04mg	34/40		
516	1175	1.11mg	n.s.s.	50/73	.104mg	10/19	1.04mg	18/30		
4-CHLORO-4'-AMINODIPHENYLETHER 101-79-1										
517	381	225.mg	n.s.s.	1/15	287.mg	1/17	624.mg	2/18		Weisburger;jept,2,325-356;1978/pers.comm./Russfield 1973
a	381	286.mg	n.s.s.	5/15	287.mg	2/17	624.mg	0/18		
b	381	126.mg	n.s.s.	10/15	287.mg	7/17	624.mg	5/18		
518	381	130.mg	1.49gm	8/102p	287.mg	5/17	624.mg	3/18		
a	381	389.mg	5.82gm	0/102p	287.mg	0/17	624.mg	4/18		
519	381	n.s.s.	n.s.s.	1/14	300.mg	0/16	600.mg	0/9		
a	381	n.s.s.	n.s.s.	3/14	300.mg	0/16	600.mg	0/9		
b	381	110.mg	n.s.s.	7/14	300.mg	3/16	600.mg	0/9		
520	381	11.8mg	381.mg	0/16	38.2mg	4/13	(84.0mg	1/23)		
a	381	11.8mg	381.mg	0/16	38.2mg	4/13	(84.0mg	1/23)		
b	381	8.14mg	248.mg	10/16	38.2mg	9/13	84.0mg	9/23		
521	381	12.1mg	258.mg	2/111p	38.2mg	4/13	(84.0mg	1/23)		
2-CHLORO-5-(3,5-DIMETHYLPYPERIDINOSULPHONYL)BENZOIC ACID ---										
522	1331	2.15mg	9.78mg	0/30	52.1mg	30/31		Reddy;natu,283,397-398;1980		
1-CHLORO-2,4-DINITROBENZENE 97-00-7										
523	381	51.7mg	2.37gm	3/13	169.mg	5/19	(306.mg	5/16)		Weisburger;jept,2,325-356;1978/pers.comm./Russfield 1973
a	381	247.mg	n.s.s.	0/13	169.mg	0/19	306.mg	1/16		
b	381	57.4mg	1.03gm	9/13	169.mg	9/19	306.mg	11/16		
524	381	138.mg	n.s.s.	2/16	207.mg	2/15	354.mg	4/21		
a	381	203.mg	n.s.s.	2/16	207.mg	3/15	354.mg	3/21		
b	381	79.2mg	n.s.s.	9/16	207.mg	6/15	(354.mg	10/21)		
525	381	66.5mg	n.s.s.	1/17	17.6mg	2/18	32.2mg	0/18		
a	381	5.05mg	1.78gm	13/17	17.6mg	12/18	(32.2mg	14/18)		
1-CHLORO-2-NITROBENZENE 88-73-3										
526	381	109.mg	3.78gm	0/20	241.mg	5/22	(461.mg	5/19)		Weisburger;jept,2,325-356;1978/pers.comm./Russfield 1973
a	381	109.mg	3.78gm	0/20	241.mg	5/22	(461.mg	7/19)		

Spe	Strain	Site	Xpo+Xpt	Notes	TD50	2Tailpv1
Sex	Route	Hist			DR	AuOp
b	M f chi eat	lun mix	77w98 v		10.9gm	* P<.1 -
c	M f chi eat	tba mix	77w98 v		287.mg	\ P<.2
527	M f chi eat	liv hpt	77w98 v	pool	289.mg	\ P<.0005+
528	M m chi eat	liv mix	73w81 av		113.mg	* P<.003
a	M m chi eat	lun mix	73w81 av		no dre	P=1.
b	M m chi eat	tba mix	73w81 av		186.mg	* P<.07
529	M m chi eat	liv hpt	73w81 av	pool	108.mg	* P<.0005+
530	R m cdr eat	liv mix	77w98 v		no dre	P=1. -
a	R m cdr eat	tba mix	77w98 v		no dre	P=1.
1-CHLORO-4-NITROBENZENE					100ng...1ug...10...100...1mg...10...100...1g...10	
531	M f chi eat	--- vsc	73w90 a		526.mg	* P<.0005+
a	M f chi eat	lun mix	73w90 a		539.mg	* P<.08 -
b	M f chi eat	liv mix	73w90 a		1.44gm	* P<.04 -
c	M f chi eat	tba mix	73w90 a		125.mg	* P<.0005
532	M f chi eat	--- vsc	73w90 a	pool	634.mg	* P<.0005+
533	M m chi eat	--- vsc	73w86 a		430.mg	* P<.006 +
a	M m chi eat	liv mix	73w86 a		262.mg	* P<.03
b	M m chi eat	lun mix	73w86 a		1.69gm	/ P<.4 -
c	M m chi eat	tba mix	73w86 a		215.mg	* P<.02
534	M m chi eat	--- vac	73w86 a	pool	483.mg	* P<.0005+
a	M m chi eat	liv hpt	73w86 a		558.mg	* P<.02 +
535	R m cdr eat	liv mix	77w98 v		no dre	P=1. -
a	R m cdr eat	tba mix	77w98 v		60.4mg	* P<.5 -
4-CHLORO-m-PHENYLENEDIAMINE					100ng...1ug...10...100...1mg...10...100...1g...10	
536	M f b6c eat	liv MXA	78w95 v		1.23gm	\ P<.0005c
a	M f b6c eat	liv hpc	78w95 v		1.78gm	\ P<.002 c
b	M f b6c eat	TBA MXB	78w95 v		15.4gm	* P<.8
c	M f b6c eat	liv MXB	78w95 v		1.23gm	\ P<.0005
d	M f b6c eat	lun MXB	78w95 v		no dre	P=1.
537	M m b6c eat	TBA MXB	78w94 v		7.32gm	* P<.7 -
a	M m b6c eat	liv MXB	78w94 v		7.05gm	* P<.5
b	M m b6c eat	lun MXB	78w94 v		no dre	P=1.
538	R f f34 eat	ute esp	18m24		#175.mg	\ P<.007 -
a	R f f34 eat	TBA MXB	18m24		479.mg	* P<.5
b	R f f34 eat	liv MXB	18m24		2.68gm	* P<.1
539	R m f34 eat	adr phe	18m24		315.mg	* P<.03 c
a	R m f34 eat	TBA MXB	18m24		422.mg	/ P<.5
b	R m f34 eat	liv MXB	18m24		1.57gm	* P<.2
4-CHLORO-o-PHENYLENEDIAMINE					100ng...1ug...10...100...1mg...10...100...1g...10	
540	M f b6c eat	liv MXA	78w95 v		2.24gm	* P<.0005c
a	M f b6c eat	liv hpc	78w95 v		5.06gm	* P<.006 c
b	M f b6c eat	TBA MXB	78w95 v		4.09gm	* P<.4
c	M f b6c eat	liv MXB	78w95 v		2.24gm	* P<.0005
d	M f b6c eat	lun MXB	78w95 v		no dre	P=1.
541	M m b6c eat	liv MXA	78w95 v		957.mg	* P<.002 c
a	M m b6c eat	liv hpc	78w95 v		1.37gm	* P<.002 c
b	M m b6c eat	TBA MXB	78w95 v		905.mg	* P<.005
c	M m b6c eat	liv MXB	78w95 v		957.mg	* P<.002
d	M m b6c eat	lun MXB	78w95 v		21.3gm	* P<.8
542	R f f34 eat	MXB MXB	18m24		212.mg	/ P<.0005
a	R f f34 eat	ubl MXA	18m24		212.mg	/ P<.0005c
b	R f f34 eat	ubl MXA	18m24		429.mg	/ P<.0005c
c	R f f34 eat	thy MXA	18m24		2.16gm	* P<.02
d	R f f34 eat	sto sqp	18m24		5.27gm	* P<.04 c
e	R f f34 eat	TBA MXB	18m24		351.mg	* P<.03
f	R f f34 eat	liv MXB	18m24		6.50gm	* P<.08
543	R m f34 eat	MXB MXB	18m24		197.mg	* P<.0005
a	R m f34 eat	ubl MXA	18m24		216.mg	* P<.0005c
b	R m f34 eat	ubl tcc	18m24		363.mg	* P<.0005c
c	R m f34 eat	sto MXA	18m24		+historical	* P<.02 c
d	R m f34 eat	thy MXA	18m24		3.38gm	* P<.04
e	R m f34 eat	ubl sqc	18m24		3.78gm	* P<.04 c
f	R m f34 eat	TBA MXB	18m24		362.mg	* P<.07
g	R m f34 eat	liv MXB	18m24		1.24gm	* P<.02
2-CHLORO-p-PHENYLENEDIAMINE SULFATE					...1ug...10...100...1mg...10...100...1g...10	
544	M f b6c eat	TBA MXB	22m24 a		1.43gm	* P<.5 -
a	M f b6c eat	liv MXB	22m24 a		1.59gm	* P<.07
b	M f b6c eat	lun MXB	22m24 a		3.33gm	* P<.2
545	M m b6c eat	TBA MXB	22m24 a		4.38gm	/ P<.8 -
a	M m b6c eat	liv MXB	22m24 a		1.31gm	* P<.2
b	M m b6c eat	lun MXB	22m24 a		no dre	P=1.
546	R f f34 eat	TBA MXB	24m24 a		no dre	P=1. -
a	R f f34 eat	liv MXB	24m24 a		3.60gm	* P<.6
547	R m f34 eat	TBA MXB	24m24 a		244.mg	* P<.2 -
a	R m f34 eat	liv MXB	24m24 a		665.mg	* P<.4

Spe	Strain	Site	Xpo + Xpt	Notes	TD50	2Tailpvl	AuOp
Sex	Route	Hist				DR	
3-CHLORO-p-TOLUIDINE				<u>100ng</u> <u>1ug</u> <u>10</u> <u>100</u> <u>1mg</u> <u>10</u> <u>100</u> <u>1g</u> <u>10</u>			
548	M f	b6c eat	TBA MXB 78w90		:>	1.98gm * P<.8	-
a	M f	b6c eat	liv MXB 78w90			919.mg * P<.6	
b	M f	b6c eat	lun MXB 78w90			5.11gm / P<.8	
549	M m	b6c eat	TBA MXB 78w90		:>	3.11gm * P<.1	-
a	M m	b6c eat	liv MXB 78w90			no dre P=1.	
b	M m	b6c eat	lun MXB 78w90			733.mg * P<.3	
550	R f	f34 eat	ute eap 18m24 v		: ±	#406.mg * P<.02	-
a	R f	f34 eat	TBA MXB 18m24 v			365.mg * P<.4	
b	R f	f34 eat	liv MXB 18m24 v			5.68gm * P<.4	
551	R m	f34 eat	TBA MXB 18m24 v		:>	no dre P=1.	-
a	R m	f34 eat	liv MXB 18m24 v			no dre P=1.	
5-CHLORO-o-TOLUIDINE				<u>100ng</u> <u>1ug</u> <u>10</u> <u>100</u> <u>1mg</u> <u>10</u> <u>100</u> <u>1g</u> <u>10</u>			
552	M f	b6c eat	MXB MXB 78w91		: + :	143.mg * P<.0005	
a	M f	b6c eat	liv MXA 78w91			180.mg * P<.0005c	
b	M f	b6c eat	liv hpc 78w91			217.mg * P<.0005c	
c	M f	b6c eat	--- has 78w91			373.mg / P<.0005c	
d	M f	b6c eat	TBA MXB 78w91			164.mg * P<.0005	
e	M f	b6c eat	liv MXB 78w91			180.mg * P<.0005	
f	M f	b6c eat	lun MXB 78w91			7.48gm * P<.5	
553	M m	b6c eat	MXB MXB 78w91		: + :	134.mg / P<.0005	
a	M m	b6c eat	--- has 78w91			213.mg / P<.0005c	
b	M m	b6c eat	liv MXA 78w91			249.mg * P<.0005c	
c	M m	b6c eat	liv hpc 78w91			271.mg * P<.002 c	
d	M m	b6c eat	TBA MXB 78w91			132.mg / P<.0005	
e	M m	b6c eat	liv MXB 78w91			249.mg * P<.0005	
f	M m	b6c eat	lun MXB 78w91			no dre P=1.	
554	R f	f34 eat	TBA MXB 18m24		:>	no dre P=1.	-
a	R f	f34 eat	liv MXB 18m24			no dre P=1.	
555	R m	f34 eat	adr phe 18m24		: ±	#714.mg * P<.03	-
a	R m	f34 eat	TBA MXB 18m24			1.02gm * P<.7	
b	R m	f34 eat	liv MXB 18m24			3.34gm * P<.6	
4-CHLORO-o-TOLUIDINE.HCL				<u>100ng</u> <u>1ug</u> <u>10</u> <u>100</u> <u>1mg</u> <u>10</u> <u>100</u> <u>1g</u> <u>10</u>			
556	M f	b6c eat	--- MXA 95w99 as		: + :	40.0mg / P<.0005c	
a	M f	b6c eat	--- has 95w99 as			42.3mg / P<.0005c	
b	M f	b6c eat	TBA MXB 95w99 as			38.8mg / P<.0005	
c	M f	b6c eat	liv MXB 95w99 as			754.mg * P<.3	
d	M f	b6c eat	lun MXB 95w99 as			798.mg * P<.01	
557	M m	b6c eat	--- MXA 99w99 s		: + :	743.mg / P<.0005c	
a	M m	b6c eat	--- has 99w99 s			911.mg / P<.0005c	
b	M m	b6c eat	TBA MXB 99w99 s			537.mg / P<.0005	
c	M m	b6c eat	liv MXB 99w99 s			3.26gm * P<.03	
d	M m	b6c eat	lun MXB 99w99 s			no dre P=1.	
558	M f	chi eat	--- vac 51w60 e		: + :	15.7mg * P<.0005+	
a	M f	chi eat	liv mix 51w60 e			139.mg * P<.02	-
b	M f	chi eat	lun mix 51w60 e			153.mg * P<.06	-
c	M f	chi eat	tba mix 51w60 e			15.6mg * P<.0005	
559	M f	chi eat	--- vac 51w60 e pool		: + :	18.4mg * P<.0005+	
560	M m	chi eat	lun mix 55w60		: + :	8.85mg \ P<.0005-	
a	M m	chi eat	--- vac 55w60			15.4mg * P<.0005+	
b	M m	chi eat	liv mix 55w60			95.7mg * P<.04	-
c	M m	chi eat	tba mix 55w60			7.72mg * P<.0005	
561	M m	chi eat	--- vac 55w60 pool		: + :	15.4mg * P<.0005+	
562	R f	f34 eat	TBA MXB 25m25		:>	no dre P=1.	-
a	R f	f34 eat	liv MXB 25m25			no dre P=1.	
563	R m	f34 eat	pit cra 25m25		: ±	#576.mg * P<.05	-
a	R m	f34 eat	TBA MXB 25m25			no dre P=1.	
b	R m	f34 eat	liv MXB 25m25			6.18gm * P<.8	
564	R m	cdr eat	liv mix 77w98 v		:>	123.mg * P<.2	-
a	R m	cdr eat	tba mix 77w98 v			24.9mg * P<.03	-
[4-CHLORO-6-(2,3-XYLIDINO)-2-PYRIMIDINYLTHIO]ACETIC ACID <u>100</u> <u>1mg</u> <u>10</u> <u>100</u> <u>1g</u> <u>10</u>							
565	R m	f34 eat	liv hpc 65w65 e		<	noTD50	P<.0005+
a	R m	f34 eat	tba mix 65w65 e			noTD50	P<.005
4-CHLORO-6-(2,3-XYLIDINO)-2-PYRIMIDINYLTHIO(N-beta-HYDROXYETHYL)ACETAMIDE <u>1mg</u> <u>10</u> <u>100</u> <u>1g</u> <u>10</u>							
566	M f	cab eat	liv hpc 82w82 ar		+ +	44.6mg	P<.0005+
567	R m	f34 eat	liv hpc 75w82 eer		. + .	6.49mg	* P<.0005+
CHLOROACETALDEHYDE				<u>100ng</u> <u>1ug</u> <u>10</u> <u>100</u> <u>1mg</u> <u>10</u> <u>100</u> <u>1g</u> <u>10</u>			
568	M f	hic gav	for tum 90w90		>	13.6mg	P<.4
569	M m	hic gav	for tum 90w90		>	no dre	P=1.
4'-(CHLOROACETYL)-ACETANILIDE				<u>100ng</u> <u>1ug</u> <u>10</u> <u>100</u> <u>1mg</u> <u>10</u> <u>100</u> <u>1g</u> <u>10</u>			
570	M f	b6c eat	liv hpc 21m24 v		: ±	4.70gm * P<.02	a
a	M f	b6c eat	TBA MXB 21m24 v			3.50gm \ P<.7	
b	M f	b6c eat	liv MXB 21m24 v			4.70gm * P<.02	
c	M f	b6c eat	lun MXB 21m24 v			3.02gm \ P<.09	

Spe	Strain	Site	Xpo + Xpt	Notes	TD50	2Tailpvl	DR	AuOp
Sex	Route	Hist						
571	M m b6c eat	TBA	MXB 21m24	v		>	no dre	P=1. -
a	M m b6c eat	liv	MXB 21m24	v			no dre	P=1.
b	M m b6c eat	lun	MXB 21m24	v			no dre	P=1.
572	R f f34 eat	TBA	MXB 20m24	v		>	no dre	P=1. -
a	R f f34 eat	liv	MXB 20m24	v			no dre	P=1.
573	R m f34 eat	TBA	MXB 20m24	v		>	325.mg *	P<.7 -
a	R m f34 eat	liv	MXB 20m24	v			2.47gm *	P<.8
p-CHLORANILINE					100ng.....1ug.....10.....100.....1mg.....10.....100.....1g.....10			
574	M f b6c eat	---	MXA 78w91			:	1.48gm *	P<.01 a
a	M f b6c eat	---	has 78w91				1.65gm *	P<.02 a
b	M f b6c eat	liv	MXA 78w91				2.35gm *	P<.02
c	M f b6c eat	TBA	MXB 78w91				889.mg *	P<.05
d	M f b6c eat	liv	MXB 78w91				2.35gm *	P<.02
e	M f b6c eat	lun	MXB 78w91				no dre	P=1.
575	M m b6c eat	---	MXA 78w91			>	+historical *	P<.2 a
a	M m b6c eat	TBA	MXB 78w91				no dre	P=1.
b	M m b6c eat	liv	MXB 78w91				no dre	P=1.
c	M m b6c eat	lun	MXB 78w91				no dre	P=1.
576	R f f34 eat	TBA	MXB 18m24			>	60.7mg *	P<.4 -
a	R f f34 eat	liv	MXB 18m24				867.mg *	P<.4
577	R m f34 eat	spl	MXA 18m24			:	+historical /	P<.009 a
a	R m f34 eat	MXA	MXA 18m24				72.0mg /	P<.03
b	R m f34 eat	spl	fib 18m24				101.mg *	P<.02
c	R m f34 eat	TBA	MXB 18m24				31.4mg *	P<.09
d	R m f34 eat	liv	MXB 18m24				609.mg *	P<.4
CHLOROBENZILATE					100ng.....1ug.....10.....100.....1mg.....10.....100.....1g.....10			
578	M f b6c eat	liv	hpc 78w90	dv		:	848.mg *	P<.004 c
a	M f b6c eat	TBA	MXB 78w90	dv			3.93gm *	P<.7
b	M f b6c eat	liv	MXB 78w90	dv			848.mg *	P<.004
c	M f b6c eat	lun	MXB 78w90	dv			no dre	P=1.
579	M f b6c orl	lun	ade 82w82	evx		>	621.mg	P<.3
a	M f b6c orl	liv	hpt 82w82	evx			no dre	P=1.
b	M f b6c orl	tba	mix 82w82	evx			302.mg	P<.2
580	M m b6c eat	liv	hpc 78w90	dv		:	235.mg \	P<.03 c
a	M m b6c eat	TBA	MXB 78w90	dv			256.mg \	P<.05
b	M m b6c eat	liv	MXB 78w90	dv			235.mg \	P<.03
c	M m b6c eat	lun	MXB 78w90	dv			no dre	P=1.
581	M m b6c orl	liv	hpt 82w82	evx		.	43.8mg	P<.0005+
a	M m b6c orl	lun	mix 82w82	evx			no dre	P=1.
b	M m b6c orl	tba	mix 82w82	evx			31.7mg	P<.0005
582	M f b6a orl	lun	ade 82w82	evx		>	621.mg	P<.6
a	M f b6a orl	liv	hpt 82w82	evx			no dre	P=1.
b	M f b6a orl	tba	mix 82w82	evx			621.mg	P<.7
583	M m b6a orl	liv	hpt 82w82	evx		.	69.8mg	P<.01 +
a	M m b6a orl	lun	ade 82w82	evx			no dre	P=1.
b	M m b6a orl	tba	mix 82w82	evx			72.8mg	P<.06
584	R f osm eat	adr	coa 18m26	dv		:	#490.mg *	P<.01 -
a	R f osm eat	TBA	MXB 18m26	dv			no dre	P=1.
b	R f osm eat	liv	MXB 18m26	dv			no dre	P=1.
585	R m osm eat	adr	coa 18m26	dv		:	#186.mg \	P<.007 -
a	R m osm eat	TBA	MXB 18m26	dv			no dre	P=1.
b	R m osm eat	liv	MXB 18m26	dv			1.60gm *	P<.4
586	R f cwf eat	agl	adf 24m24			>	no dre	P=1. -
(2-CHLOROETHYL)TRIMETHYLAMMONIUM CHLORIDE					100ng.....1ug.....10.....100.....1mg.....10.....100.....1g.....10			
587	M f b6c eat	TBA	MXB 24m24			>	no dre	P=1. -
a	M f b6c eat	liv	MXB 24m24				no dre	P=1.
b	M f b6c eat	lun	MXB 24m24				no dre	P=1.
588	M f b6c orl	liv	hpt 76w76	evx		>	no dre	P=1.
a	M f b6c orl	lun	mix 76w76	evx			no dre	P=1.
b	M f b6c orl	tba	mix 76w76	evx			57.4mg	P<.3
589	M m b6c eat	TBA	MXB 24m24			>	3.24gm *	P<.9 -
a	M m b6c eat	liv	MXB 24m24				599.mg *	P<.2
b	M m b6c eat	lun	MXB 24m24				no dre	P=1.
590	M m b6c orl	liv	hpt 76w76	evx		.	9.38mg	P<.009
a	M m b6c orl	lun	mix 76w76	evx			no dre	P=1.
b	M m b6c orl	tba	mix 76w76	evx			5.19mg	P<.0005
591	M f b6a orl	liv	hpt 76w76	evx		>	no dre	P=1.
a	M f b6a orl	lun	ade 76w76	evx			no dre	P=1.
b	M f b6a orl	tba	mix 76w76	evx			33.5mg	P<.6
592	M m b6a orl	liv	hpt 76w76	evx		.	11.4mg	P<.07
a	M m b6a orl	lun	ade 76w76	evx			no dre	P=1.
b	M m b6a orl	tba	mix 76w76	evx			21.3mg	P<.5
593	R f f34 eat	TBA	MXB 25m25			>	no dre	P=1. -
a	R f f34 eat	liv	MXB 25m25				8.09gm *	P<.4
594	R m f34 eat	pni	isa 25m25			:	#458.mg *	P<.02 -
a	R m f34 eat	TBA	MXB 25m25				3.36gm *	P<.1
b	R m f34 eat	liv	MXB 25m25				no dre	P=1.

Spe	Strain	Site	Xpo + Xpt	Notes	TD50	ZTailpvl	DR	AuOp
Sex	Route	Hist						
CHLOROFORM					100ng.....1ug.....10.....100.....1mg.....10.....100.....1g.....10			
595	D f	beg eat	liv tum	87m92 e	>	no dre	P=1.	-
a	D f	beg eat	tba mix	87m92 e	>	10.0mg \	P<.3	-
596	D m	beg eat	liv tum	87m92 e	>	no dre	P=1.	-
a	D m	beg eat	tba mix	87m92 e		13.3mg *	P<.008	-
597	M f	b6c gav	liv hpc	78w92 v	++	48.0mg *	P<.0005c	-
a	M f	b6c gav	TBA MXB	78w92 v		54.1mg *	P<.0005	-
b	M f	b6c gav	liv MXB	78w92 v		48.0mg *	P<.0005	-
c	M f	b6c gav	lun MXB	78w92 v		no dre	P=1.	-
598	M m	b6c gav	liv hpc	78w92 v	++	56.2mg /	P<.0005c	-
a	M m	b6c gav	TBA MXB	78w92 v		71.1mg *	P<.004	-
b	M m	b6c gav	liv MXB	78w92 v		56.2mg /	P<.0005	-
c	M m	b6c gav	lun MXB	78w92 v		no dre	P=1.	-
599	M m	c5l gav	lun mix	19m24 e	>	728.mg	P<.5	-
a	M m	c5l gav	liv tum	19m24 e		no dre	P=1.	-
b	M m	c5l gav	tba mix	19m24 e		no dre	P=1.	-
600	M m	cba gav	liv mix	19m24 e	>	no dre	P=1.	-
a	M m	cba gav	lun mix	19m24 e		no dre	P=1.	-
b	M m	cba gav	tba mix	19m24 e		no dre	P=1.	-
601	M m	cfl gav	lun mix	80w93 e	>	376.mg	P<.6	-
a	M m	cfl gav	liv tum	80w93 e		1.43gm	P<.9	-
b	M m	cfl gav	tba mix	80w93 e		140.mg	P<.4	-
602	M m	cfl gav	kid mix	19m24 e	+. .	153.mg	P<.0005+	-
a	M m	cfl gav	lun tum	19m24 e		4.35gm	P<.1	-
b	M m	cfl gav	liv tum	19m24 e		no dre	P=1.	-
c	M m	cfl gav	tba mix	19m24 e		no dre	P=1.	-
603	M f	ici gav	lun tum	80w96 e	>	316.mg *	P<.3	-
a	M f	ici gav	liv tum	80w96 e		no dre	P=1.	-
b	M f	ici gav	tba mix	80w96 e		no dre	P=1.	-
604	M m	ici gav	kid mix	80w96 e	+. .	139.mg *	P<.0005+	-
a	M m	ici gav	liv tum	80w96 e		324.mg *	P<.4	-
b	M m	ici gav	lun tum	80w96 e		9.83gm *	P<.1	-
c	M m	ici gav	tba mix	80w96 e		45.4mg *	P<.006	-
605	M m	ici gav	kid mix	80w98 e	. *	278.mg	P<.08	+
a	M m	ici gav	lun mix	80w98 e		336.mg	P<.3	+
b	M m	ici gav	liv mix	80w98 e		437.mg	P<.6	-
c	M m	ici gav	tba mix	80w98 e		88.5mg	P<.2	-
606	M m	ici gav	kid mix	80w98 e	+. .	95.5mg	P<.0005+	-
a	M m	ici gav	liv mix	80w98 e		no dre	P=1.	-
b	M m	ici gav	lun mix	80w98 e		no dre	P=1.	-
c	M m	ici gav	tba mix	80w98 e		no dre	P=1.	-
607	R f	osm gav	thy MXA	18m26 v	+. .	#126.mg *	P<.004	-
a	R f	osm gav	TBA MXB	18m26 v		68.2mg *	P<.05	-
b	R f	osm gav	liv MXB	18m26 v		1.13gm *	P<.7	-
608	R m	osm gav	kid MXA	18m26	+. .	119.mg /	P<.0005c	-
a	R m	osm gav	TBA MXB	18m26		194.mg *	P<.5	-
b	R m	osm gav	liv MXB	18m26		455.mg *	P<.08	-
609	R f	ada gav	liv cye	80w95 e	>	1.20gm	P<.3	-
a	R f	ada gav	tba mix	80w95 e		78.3mg	P<.2	-
b	R f	ada gav	tba mal	80w95 e		276.mg	P<.2	-
610	R m	sda gav	liv tum	80w95 e	>	no dre	P=1.	-
a	R m	sda gav	tba mix	80w95 e		no dre	P=1.	-
b	R m	sda gav	tba mal	80w95 e		no dre	P=1.	-
CHLOROMETHYL METHYL ETHER					100ng.....1ug.....10.....100.....1mg.....10.....100.....1g.....10			
611	H m	syg inh	mix mix	26m29	. *	16.4mg	P<.1	+
a	H m	syg inh	lun adc	26m29		32.9mg	P<.3	-
612	R m	sda inh	mix mix	26m28	. *	5.50mg	P<.1	+
2-(CHLOROMETHYL)PYRIDINE.HCl					100ng.....1ug.....10.....100.....1mg.....10.....100.....1g.....10			
613	M f	b6c gav	TBA MXB	23m24	>	9.79gm *	P<.1	-
a	M f	b6c gav	liv MXB	23m24		no dre	P=1.	-
b	M f	b6c gav	lun MXB	23m24		2.17gm *	P<.6	-
614	M m	b6c gav	TBA MXB	23m24	>	no dre	P=1.	-
a	M m	b6c gav	liv MXB	23m24		no dre	P=1.	-
b	M m	b6c gav	lun MXB	23m24		2.94gm *	P<.9	-
615	R f	f34 gav	TBA MXB	23m24	>	114.mg *	P<.4	-
a	R f	f34 gav	liv MXB	23m24		no dre	P=1.	-
616	R m	f34 gav	sub fib	23m24	+. *	#515.mg *	P<.03	-
a	R m	f34 gav	TBA MXB	23m24		671.mg *	P<.9	-
b	R m	f34 gav	liv MXB	23m24		no dre	P=1.	-
3-(CHLOROMETHYL)PYRIDINE.HCl					100ng.....1ug.....10.....100.....1mg.....10.....100.....1g.....10			
617	M f	b6c gav	sto MXA	21m24 es	. *	+historical *	P<.04	c
a	M f	b6c gav	TBA MXB	21m24 es		141.mg *	P<.2	-
b	M f	b6c gav	liv MXB	21m24 es		16.3gm *	P<.1	-
c	M f	b6c gav	lun MXB	21m24 es		1.97gm *	P<.7	-
618	M m	b6c gav	sto MXA	21m24 es	+. .	161.mg /	P<.003	c
a	M m	b6c gav	TBA MXB	21m24 es		64.9mg *	P<.02	-

CARCINOGENIC POTENCY DATABASE

75

RefNum	LoConf	UpConf	Cntrl	1Dose	1Inc	2Dose	2Inc	Citation or Pathology	Brkly Code
CHLOROFORM 67-66-3									
595	1003	6.52mg	n.s.s.	0/16	12.2mg	0/8	24.4mg	0/8	Keywood; jept, 2, 835-851; 1979
a	1003	2.22mg	n.s.s.	4/16	12.2mg	4/8	(24.4mg)	0/8	
596	1003	6.52mg	n.s.s.	0/16	12.2mg	0/8	24.4mg	0/8	
a	1003	5.39mg	230.mg	0/16	12.2mg	4/8	24.4mg	2/8	
597	c02686	35.2mg	68.0mg	0/20	144.mg	36/50	289.mg	39/50	
a	c02686	37.8mg	91.8mg	2/20	144.mg	37/50	289.mg	39/50	
b	c02686	35.2mg	68.0mg	0/20	144.mg	36/50	289.mg	39/50	liv:hpa,hpc,nnd.
c	c02686	n.s.s.	n.s.s.	0/20	144.mg	1/50	289.mg	0/50	lun:a/a,a/c.
598	c02686	38.7mg	118.mg	1/20	83.6mg	19/50	168.mg	44/50	
a	c02686	40.4mg	491.mg	4/20	83.6mg	26/50	168.mg	44/50	
b	c02686	38.7mg	118.mg	1/20	83.6mg	19/50	168.mg	44/50	liv:hpa,hpc,nnd.
c	c02686	490.mg	n.s.s.	1/20	83.6mg	3/50	168.mg	2/50	lun:a/a,a/c.
599	710m	134.mg	n.s.s.	2/46	39.6mg	4/51			Roe; jept, 2, 799-819; 1979
a	710m	416.mg	n.s.s.	2/46	39.6mg	0/51			
b	710m	112.mg	n.s.s.	16/46	39.6mg	13/51			
600	710m	70.7mg	n.s.s.	37/51	39.6mg	29/51			
a	710m	155.mg	n.s.s.	13/51	39.6mg	8/51			
b	710m	64.7mg	n.s.s.	42/51	39.6mg	33/51			
601	710m	64.2mg	n.s.s.	9/45	44.2mg	12/48			
a	710m	111.mg	n.s.s.	4/45	44.2mg	5/48			
b	710m	37.2mg	n.s.s.	16/45	44.2mg	22/48			
602	710m	66.6mg	613.mg	6/240	39.6mg	9/49			
a	710m	65.8mg	n.s.s.	102/240	39.6mg	21/49			
b	710m	189.mg	n.s.s.	69/240	39.6mg	8/49			
c	710m	68.4mg	n.s.s.	170/240	39.6mg	30/49			
603	710m	81.3mg	n.s.s.	5/59	12.1mg	2/35	42.9mg	6/38	
a	710m	59.2mg	n.s.s.	1/59	12.1mg	0/35	42.9mg	0/38	
b	710m	71.5mg	n.s.s.	29/59	12.1mg	10/35	42.9mg	15/38	
604	710m	62.8mg	407.mg	0/72	12.1mg	0/37	42.9mg	8/38	
a	710m	73.5mg	n.s.s.	5/72	12.1mg	6/37	42.9mg	5/38	
b	710m	95.4mg	n.s.s.	7/72	12.1mg	7/37	42.9mg	4/38	
c	710m	21.0mg	643.mg	20/72	12.1mg	20/37	42.9mg	21/38	
605	710n	91.2mg	n.s.s.	1/49	42.0mg	5/47			
a	710n	83.7mg	n.s.s.	4/49	42.0mg	7/47			
b	710n	78.3mg	n.s.s.	7/49	42.0mg	9/47			
c	710n	31.8mg	n.s.s.	17/49	42.0mg	24/47			
606	710o	47.1mg	325.mg	1/50	42.0mg	12/48			
a	710o	105.mg	n.s.s.	9/50	42.0mg	8/48			
b	710o	182.mg	n.s.s.	5/50	42.0mg	3/48			
c	710o	66.8mg	n.s.s.	24/50	42.0mg	20/48			
607	c02686	65.8mg	936.mg	1/20	50.2mg	8/50	100.mg	11/50	thy:cca,ccr,fca,fcc. S
a	c02686	28.8mg	n.s.s.	12/20	50.2mg	24/50	100.mg	25/50	
b	c02686	156.mg	n.s.s.	2/20	50.2mg	4/50	100.mg	3/50	liv:hpa,hpc,nnd.
608	c02686	65.5mg	334.mg	0/20	45.2mg	4/50	90.3mg	12/50	kid:tla,uac.
a	c02686	43.5mg	n.s.s.	9/20	45.2mg	24/50	90.3mg	20/50	
b	c02686	157.mg	n.s.s.	0/20	45.2mg	1/50	90.3mg	3/50	liv:hpa,hpc,nnd.
609	711	196.mg	n.s.s.	0/50	43.3mg	1/49			Palmer; jept, 2, 821-833; 1979
a	711	27.1mg	n.s.s.	22/50	43.3mg	29/49			
b	711	86.0mg	n.s.s.	2/50	43.3mg	6/49			
610	711	365.mg	n.s.s.	0/48	43.3mg	0/49			
a	711	115.mg	n.s.s.	12/48	43.3mg	9/49			
b	711	195.mg	n.s.s.	6/48	43.3mg	3/49			
CHLOROMETHYL METHYL ETHER (CMME) 107-30-2									
611	348	4.02mg	n.s.s.	0/88	.377mg	2/90			Laskin;aenh,30,70-72;1975
a	348	5.36mg	n.s.s.	0/88	.377mg	1/90			
612	348	1.35mg	n.s.s.	0/74	.160mg	2/74			
2-(CHLOROMETHYL)PYRIDINE.HCl 6959-47-3									
613	c03907	174.mg	n.s.s.	5/20	51.0mg	11/50	102.mg	10/50	
a	c03907	n.s.s.	n.s.s.	0/20	51.0mg	1/50	102.mg	0/50	liv:hpa,hpc,nnd.
b	c03907	368.mg	n.s.s.	1/20	51.0mg	1/50	102.mg	3/50	lun:a/a,a/c.
614	c03907	162.mg	n.s.s.	9/20	51.0mg	18/50	102.mg	13/50	
a	c03907	266.mg	n.s.s.	3/20	51.0mg	6/50	102.mg	4/50	liv:hpa,hpc,nnd.
b	c03907	210.mg	n.s.s.	2/20	51.0mg	5/50	102.mg	5/50	lun:a/a,a/c.
615	c03907	32.8mg	n.s.s.	12/20	30.3mg	35/50	60.6mg	39/50	
a	c03907	n.s.s.	n.s.s.	0/20	30.3mg	0/50	60.6mg	0/50	liv:hpa,hpc,nnd.
616	c03907	194.mg	n.s.s.	0/20	30.3mg	0/50	60.6mg	5/49	S
a	c03907	54.0mg	n.s.s.	13/20	30.3mg	28/50	60.6mg	29/49	
b	c03907	743.mg	n.s.s.	3/20	30.3mg	0/50	60.6mg	0/49	liv:hpa,hpc,nnd.
3-(CHLOROMETHYL)PYRIDINE.HCl 6959-48-4									
617	c03838	161.mg	n.s.s.	0/20	42.0mg	1/50	66.8mg	5/50	sto:sgc,sgp.
a	c03838	56.8mg	n.s.s.	5/20	42.0mg	15/50	66.8mg	20/50	
b	c03838	376.mg	n.s.s.	1/20	42.0mg	0/50	66.8mg	2/50	liv:hpa,hpc,nnd.
c	c03838	269.mg	n.s.s.	1/20	42.0mg	1/50	66.8mg	3/50	lun:a/a,a/c.
618	c03838	81.9mg	683.mg	0/20	42.0mg	2/50	66.8mg	10/50	sto:sgc,sgp.
a	c03838	32.3mg	n.s.s.	7/20	42.0mg	20/50	66.8mg	28/50	

Spe	Strain	Site	Xpo+Xpt	Notes	TD50	2Tailpvl
Sex	Route	Hist			DR	AuOp
b	M m b6c	gav liv	MXB 21m24	as	324.mg	* P<.4
c	M m b6c	gav lun	MXB 21m24	as	624.mg	* P<.6
619	R f f34	gav TBA	MXB 22m24	as	160.mg	* P<.6 -
e	R f f34	gav liv	MXB 22m24	as	no dre	P=1.
620	R m f34	gav sto	MXA 22m24	as	+historical	* P<.07 c
a	R m f34	gav TBA	MXB 22m24	as	no dre	P=1.
b	R m f34	gav liv	MXB 22m24	as	no dre	P=1.
p-CHLOROPHENYL-p-CHLOROBENZENE SULFONATE101001mg101001g10						
621	M f b6a	orl lun	ade 76w76	evx	>	no dre P=1. -
a	M f b6a	orl liv	hpt 76w76	evx		no dre P=1. -
b	M f b6a	orl tba	mix 76w76	evx		no dre P=1. -
622	M m b6a	orl lun	ade 76w76	evx	>	no dre P=1. -
a	M m b6a	orl liv	hpt 76w76	evx		no dre P=1. -
b	M m b6a	orl tba	mix 76w76	evx		no dre P=1. -
623	M f b6c	orl liv	hpt 76w76	evx	>	931.mg P<.3 -
a	M f b6c	orl lun	mix 76w76	evx		no dre P=1. -
b	M f b6c	orl tba	mix 76w76	evx		931.mg P<.3 -
624	M m b6c	orl liv	hpt 76w76	evx	>	422.mg P<.2 -
a	M m b6c	orl lun	ade 76w76	evx		869.mg P<.3 -
b	M m b6c	orl tba	mix 76w76	evx		84.5mg P<.0005-
3-(p-CHLOROPHENYL)-1,1-DIMETHYLUREA101001mg101001g10						
625	M f b6a	orl lun	ade 76w76	evx	>	414.mg P<.6
a	M f b6a	orl liv	hpt 76w76	evx		no dre P=1.
b	M f b6a	orl tba	mix 76w76	evx		387.mg P<.7
626	M m b6a	orl lun	ade 76w76	evx	.	70.7mg P<.07
a	M m b6a	orl liv	hpt 76w76	evx	.	no dre P=1.
b	M m b6a	orl tba	mix 76w76	evx		86.6mg P<.2
627	M f b6c	orl liv	hpt 76w76	evx	>	no dre P=1.
a	M f b6c	orl lun	mix 76w76	evx		no dre P=1.
b	M f b6c	orl tba	tum 76w76	evx		no dre P=1.
628	M m b6c	orl liv	hpt 76w76	evx	.	112.mg P<.04
a	M m b6c	orl lun	ade 76w76	evx	.	174.mg P<.09
b	M m b6c	orl tba	mix 76w76	evx		39.6mg P<.0005
1-(4-CHLOROPHENYL)-1-PHENYL-2-PROPYNYL CARBAMATE101001mg101001g10						
629	R m hrl	eat jej	adc 72w94	ae	.	8.78mg * P<.0005+
a	R m hrl	eat duo	adc 72w94	ae	.	24.9mg * P<.0005+
b	R m hrl	eat liv	mix 72w94	ae	.	58.5mg * P<.2
c	R m hrl	eat bra	mix 72w94	ae	.	+historical * P<.8 +
d	R m hrl	eat tba	mix 72w94	ae	.	3.88mg * P<.0005
p-CHLOROPHENYL-2,4,5-TRICHLOROPHENYL SULFIDE101001mg101001g10						
630	R f wis	eat liv	tum 27m27		>	no dre P=1. -
631	R f wis	eat liv	tum 24m24		>	no dre P=1. -
632	R m wis	eat liv	hpt 27m27		>	4.59gm * P<.2 -
633	R m wis	eat liv	tum 24m24		>	no dre P=1. -
CHLOROPICRIN* 100ng1ug101001mg101001g10						
634	M f b6c	gav TBA	MXB 78w91	v	>	82.0mg * P<.2 -
a	M f b6c	gav liv	MXB 78w91	v		no dre P=1.
b	M f b6c	gav lun	MXB 78w91	v		111.mg * P<.06
635	M m b6c	gav TBA	MXB 78w91	v	>	no dre P=1. -
a	M m b6c	gav liv	MXB 78w91	v		no dre P=1.
b	M m b6c	gav lun	MXB 78w91	v		no dre P=1.
636	R f osm	gav TBA	MXB 18m26	dsv	>	no dre P=1.
a	R f osm	gav liv	MXB 18m26	dsv		no dre P=1.
637	R m osm	gav TBA	MXB 18m26	dsv	>	no dre P=1.
a	R m osm	gav liv	MXB 18m26	dsv		no dre P=1.
2-CHLOROPROPANAL 100ng1ug101001mg101001g10						
638	M f hic	gav for	tum 89w89		.	12.9mg P<.004 +
639	M m hic	gav for	tum 89w89		.	22.7mg * P<.04
1-CHLOROPROPENE 100ng1ug101001mg101001g10						
640	M f hic	gav for	tum 89w89		.	5.05mg P<.0005+
641	M m hic	gav for	tum 89w89		.	16.7mg P<.02
CHLOROTHALONIL 100ng1ug101001mg101001g10						
642	M f b6c	eat TBA	MXB 80w91	v	>	no dre P=1. -
a	M f b6c	eat liv	MXB 80w91	v		no dre P=1.
b	M f b6c	eat lun	MXB 80w91	v		no dre P=1.
643	M m b6c	eat TBA	MXB 80w91	v	>	no dre P=1. -
a	M m b6c	eat liv	MXB 80w91	v		no dre P=1.
b	M m b6c	eat lun	MXB 80w91	v		no dre P=1.
644	R f osm	eat TBA	MXB 19m26	v	>	1.58gm * P<.7 -
a	R f osm	eat liv	MXB 19m26	v		no dre P=1.
645	R f osm	eat kid	MXA 19m25	v	.	2.51gm * P<.009 c
a	R f osm	eat kid	MXA 19m25	v	.	4.97gm * P<.04 c

RefNum	LoConf	UpConf	Cntrl	1Dose	1Inc	2Dose	2Inc	Citation or Pathology	Briely Code
b	c03838	93.6mg	n.s.s.	3/20	42.0mg	3/50	66.8mg 9/50		liv:hpa,hpc,nnd.
c	c03838	122.mg	n.s.s.	2/20	42.0mg	4/50	66.8mg 5/50		lun:a/a,a/c.
619	c03838	32.3mg	n.s.s.	14/20	31.8mg	31/49	51.3mg 23/50		
a	c03838	n.s.s.	n.s.s.	0/20	31.8mg	0/49	51.3mg 0/50		liv:hpa,hpc,nnd.
620	c03838	148.mg	n.s.s.	0/20	31.8mg	1/50	51.3mg 3/50		sto:sqc,ssp.
a	c03838	70.7mg	n.s.s.	14/20	31.8mg	21/50	51.3mg 11/50		
b	c03838	377.mg	n.s.s.	1/20	31.8mg	1/50	51.3mg 0/50		liv:hpa,hpc,nnd.
p-CHLOROPHENYL-p-CHLOROBENZENE SULFONATE (ovex) 80-53-1									
621	1287	162.mg	n.s.s.	1/17	145.mg	1/17		Innes;ntis,1968/1969	
a	1287	272.mg	n.s.s.	0/17	145.mg	0/17			
b	1287	128.mg	n.s.s.	2/17	145.mg	2/17			
622	1287	127.mg	n.s.s.	2/18	136.mg	2/18			
a	1287	160.mg	n.s.s.	1/18	136.mg	1/18			
b	1287	107.mg	n.s.s.	3/18	136.mg	3/18			
623	1287	152.mg	n.s.s.	0/16	145.mg	1/18			
a	1287	288.mg	n.s.s.	0/16	145.mg	0/18			
b	1287	152.mg	n.s.s.	0/16	145.mg	1/18			
624	1287	104.mg	n.s.s.	0/16	136.mg	2/18			
a	1287	141.mg	n.s.s.	0/16	136.mg	1/18			
b	1287	37.6mg	278.mg	0/16	136.mg	8/18			
3-(p-CHLOROPHENYL)-1,1-DIMETHYLUREA (Telvar, monuron) 150-68-5									
625	1278	57.6mg	n.s.s.	1/17	73.0mg	2/17		Innes;ntis,1968/1969	
a	1278	137.mg	n.s.s.	0/17	73.0mg	0/17			
b	1278	48.8mg	n.s.s.	2/17	73.0mg	3/17			
626	1278	23.3mg	n.s.s.	2/18	68.0mg	6/16			
a	1278	120.mg	n.s.s.	1/18	68.0mg	0/16			
b	1278	24.5mg	n.s.s.	3/18	68.0mg	6/16			
627	1278	145.mg	n.s.s.	0/16	73.0mg	0/18			
a	1278	145.mg	n.s.s.	0/16	73.0mg	0/18			
b	1278	145.mg	n.s.s.	0/16	73.0mg	0/18			
628	1278	33.6mg	n.s.s.	0/16	68.0mg	3/15			
a	1278	42.7mg	n.s.s.	0/16	68.0mg	2/15			
b	1278	16.7mg	139.mg	0/16	68.0mg	7/15			
1-(4-CHLOROPHENYL)-1-PHENYL-2-PROPYNYL CARBAMATE 10473-70-8									
629	1348	4.78mg	18.3mg	0/10	10.0mg	6/10	20.0mg 5/10 40.0mg 10/10	Harris;txap,21,414-418;1972	
a	1348	12.2mg	65.5mg	0/10	10.0mg	1/10	20.0mg 2/10 40.0mg 8/10		
b	1348	23.8mg	n.s.s.	0/10	10.0mg	2/10	20.0mg 2/10 40.0mg 2/10		
c	1348	39.7mg	n.s.s.	0/10	10.0mg	2/10	20.0mg 0/10 40.0mg 1/10		
d	1348	1.73mg	10.9mg	2/10	10.0mg	9/10	20.0mg 9/10 40.0mg 10/10		
p-CHLOROPHENYL-2,4,5-TRICHLOROPHENYL SULFIDE (tetrasul) 2227-13-6									
630	281m	15.6mg	n.s.s.	0/32	2.50mg	0/32	10.0mg 0/32 50.0mg 0/32 150.mg 0/32	Verschuuren;txcy,1,63-78;1973	
631	281n	2.36mg	n.s.s.	0/32	.500mg	0/32	1.25mg 0/32		
632	281m	747.mg	n.s.s.	0/32	2.00mg	0/32	8.00mg 0/32 40.0mg 0/32 120.mg 1/32		
633	281n	1.88mg	n.s.s.	0/32	.400mg	0/32	1.00mg 0/32		
CHLOROPICRIN* 76-06-2									
634	c00533	29.9mg	n.s.s.	4/20	20.0mg	9/50	40.0mg 10/50		
a	c00533	n.s.s.	n.s.s.	0/20	20.0mg	0/50	40.0mg 0/50	liv:hpa,hpc,nnd.	
b	c00533	44.2mg	n.s.s.	1/20	20.0mg	3/50	40.0mg 6/50	lun:a/a,a/c.	
635	c00533	36.5mg	n.s.s.	5/20	20.0mg	7/50	34.0mg 9/50		
a	c00533	63.8mg	n.s.s.	2/20	20.0mg	4/50	34.0mg 2/50	liv:hpa,hpc,nnd.	
b	c00533	67.7mg	n.s.s.	3/20	20.0mg	1/50	34.0mg 5/50	lun:a/a,a/c.	
636	c00533	7.12mg	n.s.s.	11/20	10.0mg	14/50	11.0mg 9/50		
a	c00533	n.s.s.	n.s.s.	0/20	10.0mg	0/50	11.0mg 0/50	liv:hpa,hpc,nnd.	
637	c00533	9.97mg	n.s.s.	5/20	12.4mg	3/50	(13.0mg 0/50)		
a	c00533	n.s.s.	n.s.s.	0/20	12.4mg	0/50	13.0mg 0/50	liv:hpa,hpc,nnd.	
2-CHLOROPROPANAL 683-50-1									
638	1011	5.23mg	73.7mg	0/30	5.71mg	6/30		Van Duuren;jnci,63,1433-1439;1979	
639	1011	6.86mg	n.s.s.	0/30	4.76mg	3/30			
1-CHLOROPROPENE 590-21-6									
640	1011	2.63mg	11.5mg	0/30	5.71mg	13/30		Van Duuren;jnci,63,1433-1439;1979	
641	1011	5.76mg	n.s.s.	0/30	4.76mg	4/30			
CHLOROTHALDNIL 1897-45-6									
642	c00102	1.38gm	n.s.s.	3/10	343.mg	6/50	679.mg 8/50		
a	c00102	n.s.s.	n.s.s.	0/10	343.mg	0/50	679.mg 0/50	liv:hpa,hpc,nnd.	
b	c00102	2.16gm	n.s.s.	1/10	343.mg	2/50	679.mg 3/50	lun:a/a,a/c.	
643	c00102	460.mg	n.s.s.	3/10	283.mg	9/50	(560.mg 1/50)		
a	c00102	1.42gm	n.s.s.	2/10	283.mg	1/50	(560.mg 1/50)	liv:hpa,hpc,nnd.	
b	c00102	634.mg	n.s.s.	1/10	283.mg	4/50	(560.mg 0/50)	lun:a/a,a/c.	
644	c00102	240.mg	n.s.s.	5/10	184.mg	25/49	368.mg 34/50		
a	c00102	1.19gm	n.s.s.	0/10	184.mg	3/49	368.mg 2/50	liv:hpa,hpc,nnd.	
645	c00102	1.02gm	58.1gm	0/65p	184.mg	1/49	368.mg 5/50	kid:adn,can,tla,uac.	
a	c00102	1.50gm	n.s.s.	0/65p	184.mg	0/49	368.mg 3/50	kid:adn,tia.	

Spe	Strain	Site	Xpo+Xpt				TD50	2Tailpvl	
Sex	Route	Hist	Notes				DR	AuOp	
646	R m osm eat	TBA MXB	19m26 v						
a	R m osm eat	liv MXB	19m26 v						
647	R m osm eat	kid MXA	19m25 v	pool					
a	R m osm eat	kid MXA	19m25 v						
b	R m osm eat	sub fih	19m25 v						
CHLOROZOTOCIN									
648	R f sde ipj	pec mix	20m26 aes						
a	R f sde ipj	tba mal	20m26 aes						
649	R m sde ipj	pec mix	18m23 aes						
a	R m sde ipj	tba mal	18m23 aes						
CHLORPROPAMIDE									
650	M f b6c eat	TBA MXB	24m24 sv						
a	M f b6c eat	liv MXB	24m24 sv						
b	M f b6c eat	lun MXB	24m24 sv						
651	M m b6c eat	TBA MXB	24m24 sv						
a	M m b6c eat	liv MXB	24m24 sv						
b	M m b6c eat	lun MXB	24m24 sv						
652	R f f34 eat	TBA MXB	24m24 a						
a	R f f34 eat	liv MXB	24m24 a						
653	R m f34 eat	TBA MXB	24m24 a						
a	R m f34 eat	liv MXB	24m24 a						
CHOCOLATE BROWN FB									
654	M f cws eat	liv tum	80w80 e						
a	M f cws eat	lun ade	80w80 e						
655	M m cws eat	lun ade	80w80 e						
a	M m cws eat	liv tum	80w80 e						
656	R f cfe eat	liv tum	24m24 e						
657	R m cfe eat	liv tum	24m24 e						
CHOCOLATE BROWN HT									
658	M f tf1 eat	--- lys	80w80 e						
a	M f tf1 eat	liv hnd	80w80 e						
b	M f tf1 eat	lun ade	80w80 e						
659	M m tf1 eat	liv hnd	80w80 e						
a	M m tf1 eat	liv lca	80w80 e						
b	M m tf1 eat	lun ade	80w80 e						
CHROMIC OXIDE PIGMENT									
660	R b bdr eat	mgl fba	20m43						
a	R b bdr eat	mgl car	20m43						
b	R b bdr eat	hpl ade	20m43						
CHROMIUM (III) ACETATE									
661	M f cd1 wat	lun tum	34m34 e						
a	M f cd1 wat	tba tum	34m34 e						
662	M m cd1 wat	lun tum	32m32 e						
a	M m cd1 wat	tba tum	32m32 e						
663	R b leb wat	liv tum	42m42 e						
a	R b leb wat	tba tum	42m42 e						
b	R b leb wat	tba mal	42m42 e						
CLIVORINE									
664	R b aci wat	liv mix	48w68 e						
a	R b aci wat	liv nnd	48w68 e						
b	R b aci wat	liv has	48w68 e						
CLOFIBRATE									
665	R m f34 eat	liv hpc	28m28 e						
a	R m f34 eat	pan acc	28m28 e						
CLOMIPHENE CITRATE									
666	M f cac gav	lun tum	69w69 ek						
a	M f cac gav	tba mix	69w69 ek						
667	M f cac gav	tba mix	69w82 ek						
CLONITRALID*									
668	M f b6c eat	TBA MXB	78w91 sv						
a	M f b6c eat	liv MXB	78w91 sv						
b	M f b6c eat	lun MXB	78w91 sv						
669	M m b6c eat	TBA MXB	78w91 sv						
a	M m b6c eat	liv MXB	78w91 sv						
b	M m b6c eat	lun MXB	78w91 sv						
670	R f osm eat	ute esp	18m26 v						
a	R f osm eat	thy MXA	18m26 v						
b	R f osm eat	TBA MXB	18m26 v						
c	R f osm eat	liv MXB	18m26 v						

Spe	Strain	Site	Xpo+Xpt		TD50	2Tailpvl	
Sex	Route	Hist	Notes		DR	AuOp	
671	R m	osm eat	TBA MXB 18m26 v			P=1.	-
a	R m	osm eat	liv MXB 18m26 v			P=1.	-
COLCEMID				100ng...1ug...10...100...1mg...10...100...1g...10			
672	R m	b46 ivj	tba mix 12m24 es		78.7ug	P<.5	-
a	R m	b46 ivj	tba mal 12m24 es		.129mg	P<.6	-
b	R m	b46 ivj	tba bon 12m24 es		.248mg	P<.7	-
COPPER DIMETHYLDITHIOCARBAMATE				100ng...1ug...10...100...1mg...10...100...1g...10			
673	M f	b6a orl	liv hpt 76w76 evx		146.mg	P<.3	-
a	M f	b6a orl	liv hpt 76w76 evx		no dre	P=1.	-
b	M f	b6a orl	tba mix 76w76 evx		no dre	P=1.	-
674	M m	b6a orl	liv hpt 76w76 evx		655.mg	P<.9	-
a	M m	b6a orl	liv hpt 76w76 evx		no dre	P=1.	-
b	M m	b6a orl	tba mix 76w76 evx		no dre	P=1.	-
675	M f	b6c orl	liv hpt 76w76 evx		no dre	P=1.	-
a	M f	b6c orl	liv hpt 76w76 evx		no dre	P=1.	-
b	M f	b6c orl	liv hpt 76w76 evx		70.8mg	P<.2	-
676	M m	b6c orl	liv hpt 76w76 evx		34.7mg	P<.04	-
a	M m	b6c orl	liv hpt 76w76 evx		112.mg	P<.3	-
b	M m	b6c orl	tba mix 76w76 evx		19.1mg	P<.005	-
COPPER-B-HYDROXYQUINOLINE				100ng...1ug...10...100...1mg...10...100...1g...10			
677	M f	b6a orl	liv hpt 76w76 evx		no dre	P=1.	-
a	M f	b6a orl	liv hpt 76w76 evx		no dre	P=1.	-
b	M f	b6a orl	tba mix 76w76 evx		2.49gm	P<.7	-
678	M m	b6a orl	liv hpt 76w76 evx		967.mg	P<.3	-
a	M m	b6a orl	liv hpt 76w76 evx		no dre	P=1.	-
b	M m	b6a orl	tba mix 76w76 evx		11.2gm	P<.1	-
679	M f	b6c orl	liv hpt 76w76 evx		no dre	P=1.	-
a	M f	b6c orl	liv hpt 76w76 evx		no dre	P=1.	-
b	M f	b6c orl	tba mix 76w76 evx		2.49gm	P<.3	-
680	M m	b6c orl	liv hpt 76w76 evx		no dre	P=1.	-
a	M m	b6c orl	liv hpt 76w76 evx		no dre	P=1.	-
b	M m	b6c orl	tba mix 76w76 evx		2.05gm	P<.3	-
COUMAPHOS				100ng...1ug...10...100...1mg...10...100...1g...10			
681	M f	b6c eat	TBA MXB 24m24		10.1mg *	P<.5	-
a	M f	b6c eat	liv MXB 24m24		11.6mg *	P<.08	-
b	M f	b6c eat	liv MXB 24m24		42.6mg *	P<.7	-
682	M m	b6c eat	TBA MXB 24m24		no dre	P=1.	-
a	M m	b6c eat	liv MXB 24m24		no dre	P=1.	-
b	M m	b6c eat	liv MXB 24m24		no dre	P=1.	-
683	R f	f34 eat	TBA MXB 24m24		98.1mg *	P<.1	-
a	R f	f34 eat	liv MXB 24m24		6.99mg *	P<.2	-
684	R m	f34 eat	TBA MXB 24m24		1.58mg *	P<.3	-
a	R m	f34 eat	liv MXB 24m24		12.3mg *	P<.4	-
m-CRESIDINE*				100ng...1ug...10...100...1mg...10...100...1g...10			
685	M f	b6c gav	liv MXA 53w93 sv		#206.mg *	P<.02	-
a	M f	b6c gav	TBA MXB 53w93 sv		69.2mg *	P<.03	-
b	M f	b6c gav	liv MXB 53w93 sv		206.mg *	P<.02	-
c	M f	b6c gav	liv MXB 53w93 sv		250.mg *	P<.08	-
686	M m	b6c gav	TBA MXB 53w93 sv		72.2mg *	P<.6	-
a	M m	b6c gav	liv MXB 53w93 sv		no dre	P=1.	-
b	M m	b6c gav	liv MXB 53w93 sv		no dre	P=1.	-
687	R f	f34 gav	ubl fba 18m25		52.7mg \	P<.03	-
a	R f	f34 gav	ubl tcc 18m25		+historical *	P<.2	c
b	R f	f34 gav	TBA MXB 18m25		51.5mg \	P<.3	-
c	R f	f34 gav	liv MXB 18m25		1.10gm *	P<.4	-
688	R m	f34 gav	ubl tcc 18m25		470.mg *	P<.02	c
a	R m	f34 gav	TBA MXB 18m25		368.mg *	P<.7	-
b	R m	f34 gav	liv MXB 18m25		506.mg *	P<.4	-
p-CRESIDINE				100ng...1ug...10...100...1mg...10...100...1g...10			
689	M f	b6c eat	ubl MXA 97w97 sv		69.0mg /	P<.0005c	-
a	M f	b6c eat	MXB MXB 97w97 sv		69.0mg /	P<.0005	-
b	M f	b6c eat	ubl MXA 97w97 sv		70.1mg /	P<.0005c	-
c	M f	b6c eat	liv MXA 97w97 sv		301.mg *	P<.0005c	-
d	M f	b6c eat	liv hpc 97w97 sv		315.mg *	P<.0005c	-
e	M f	b6c eat	TBA MXB 97w97 sv		75.0mg /	P<.0005	-
f	M f	b6c eat	liv MXB 97w97 sv		301.mg *	P<.0005	-
g	M f	b6c eat	liv MXB 97w97 sv		3.81gm *	P<.6	-
690	M m	b6c eat	ubl MXA 97w97 sv		44.7mg /	P<.0005c	-
a	M m	b6c eat	TBA MXB 97w97 sv		46.4mg /	P<.0005	-
b	M m	b6c eat	liv MXB 97w97 sv		255.mg *	P<.01	-
c	M m	b6c eat	liv MXB 97w97 sv		1.17gm /	P<.4	-
691	R f	f34 eat	ubl MXA 24m24 s		110.mg /	P<.0005c	-
a	R f	f34 eat	MXB MXB 24m24 s		110.mg /	P<.0005	-
b	R f	f34 eat	ute esp 24m24 s		913.mg *	P<.007	-

RefNum	LoConf	UpConf	Cntrl	1Dose	1Inc	2Dose	2Inc	Citation or Pathology	Brkly Code
671	c00431	1.44gm	n.s.s.	10/20	403.mg	20/50	799.mg	20/50	
a	c00431	n.s.s.	n.s.s.	0/20	403.mg	0/50	799.mg	0/50	Liv:hpa,hpc,nnd.
COLCEMID 477-30-5									
672	1017	14.2ug	n.s.s.	7/65	7.86ug	5/30			Schmahl;arzn,20,1461-1467;1970
a	1017	18.4ug	n.s.s.	4/65	7.86ug	3/30			
b	1017	22.4ug	n.s.s.	3/65	7.86ug	2/30			
COPPER DIMETHYLDITHIOCARBAMATE (cumate) 137-29-1									
673	1203	23.8mg	n.s.s.	0/17	22.8mg	1/18			Innes;ntis,1968/1969
a	1203	45.2mg	n.s.s.	0/17	22.8mg	0/18			
b	1203	30.1mg	n.s.s.	2/17	22.8mg	1/18			
674	1203	20.4mg	n.s.s.	1/18	21.2mg	1/15			
a	1203	22.6mg	n.s.s.	2/18	21.2mg	1/15			
b	1203	17.4mg	n.s.s.	3/18	21.2mg	2/15			
675	1203	45.2mg	n.s.s.	0/16	22.8mg	0/18			
a	1203	45.2mg	n.s.s.	0/16	22.8mg	0/18			
b	1203	17.4mg	n.s.s.	0/16	22.8mg	2/18			
676	1203	10.5mg	n.s.s.	0/16	21.2mg	3/15			
a	1203	18.3mg	n.s.s.	0/16	21.2mg	1/15			
b	1203	7.18mg	151.mg	0/16	21.2mg	5/15			
COPPER-8-HYDROXYQUINOLINE 10380-28-6									
677	1295	771.mg	n.s.s.	0/17	389.mg	0/18			Innes;ntis,1968/1969
a	1295	771.mg	n.s.s.	1/17	389.mg	0/18			
b	1295	279.mg	n.s.s.	2/17	389.mg	3/18			
678	1295	221.mg	n.s.s.	1/18	362.mg	3/17			
a	1295	677.mg	n.s.s.	2/18	362.mg	0/17			
b	1295	263.mg	n.s.s.	3/18	362.mg	3/17			
679	1295	771.mg	n.s.s.	0/16	389.mg	0/18			
a	1295	771.mg	n.s.s.	0/16	389.mg	0/18			
b	1295	405.mg	n.s.s.	0/16	389.mg	1/18			
680	1295	638.mg	n.s.s.	0/16	362.mg	0/16			
a	1295	638.mg	n.s.s.	0/16	362.mg	0/16			
b	1295	334.mg	n.s.s.	0/16	362.mg	1/16			
COUMAPHOS 56-72-4									
681	c08662	2.50mg	n.s.s.	8/25	1.30mg	20/50	2.60mg	24/50	
a	c08662	5.46mg	n.s.s.	0/25	1.30mg	4/50	2.60mg	5/50	Liv:hpa,hpc,nnd. Lun:a/a,a/c.
b	c08662	7.02mg	n.s.s.	1/25	1.30mg	4/50	2.60mg	4/50	
682	c08662	3.31mg	n.s.s.	15/25	1.20mg	26/50	2.40mg	22/50	
a	c08662	5.22mg	n.s.s.	7/25	1.20mg	14/50	2.40mg	9/50	Liv:hpa,hpc,nnd. Lun:a/a,a/c.
b	c08662	6.82mg	n.s.s.	4/25	1.20mg	4/50	2.40mg	6/50	
683	c08662	.635mg	n.s.s.	17/23	.500mg	41/50	1.00mg	38/50	
a	c08662	2.65mg	n.s.s.	0/23	.500mg	2/50	1.00mg	3/50	Liv:hpa,hpc,nnd.
684	c08662	.471mg	n.s.s.	12/25	.400mg	32/50	.800mg	32/50	
a	c08662	3.02mg	n.s.s.	0/25	.400mg	1/50	.800mg	1/50	Liv:hpa,hpc,nnd.
m-CRESIDINE* 102-50-1									
685	c02993	83.9mg	n.s.s.	0/25	22.6mg	1/50	45.3mg	5/50	Liv:hpa,hpc, S
a	c02993	32.9mg	n.s.s.	3/25	22.6mg	10/50	45.3mg	15/50	
b	c02993	83.9mg	n.s.s.	0/25	22.6mg	1/50	45.3mg	5/50	Liv:hpa,hpc,nnd.
c	c02993	95.1mg	n.s.s.	0/25	22.6mg	2/50	45.3mg	3/50	Lun:a/a,a/c.
686	c02993	12.5mg	n.s.s.	9/25	22.9mg	10/50	54.6mg	0/50	
a	c02993	23.8mg	n.s.s.	5/25	22.9mg	3/50	54.6mg	0/50	Liv:hpa,hpc,nnd.
b	c02993	26.9mg	n.s.s.	4/25	22.9mg	4/50	54.6mg	0/50	Lun:a/a,a/c.
687	c02993	24.9mg	n.s.s.	3/25	40.4mg	21/49	80.0mg	8/50	S
a	c02993	232.mg	n.s.s.	0/25	40.4mg	1/49	80.0mg	2/50	
b	c02993	17.1mg	n.s.s.	12/25	40.4mg	38/49	80.0mg	20/50	
c	c02993	270.mg	n.s.s.	0/25	40.4mg	1/49	80.0mg	1/50	Liv:hpa,hpc,nnd.
688	c02993	178.mg	n.s.s.	0/25	40.4mg	0/50	80.0mg	5/50	
a	c02993	56.4mg	n.s.s.	14/25	40.4mg	30/50	80.0mg	21/50	
b	c02993	191.mg	n.s.s.	0/25	40.4mg	4/50	80.0mg	1/50	Liv:hpa,hpc,nnd.
p-CRESIDINE 120-71-8									
689	c02982	49.9mg	97.7mg	0/50	281.mg	42/50	563.mg	45/50	ubl:can,nen,npw,sgc,tcc.
a	c02982	49.9mg	97.7mg	0/50	281.mg	42/50	563.mg	45/50	Liv:hpa,hpc; ubl:can,nen,npw,sgc,tcc. C
b	c02982	50.5mg	99.5mg	0/50	281.mg	41/50	563.mg	44/50	ubl:can,sgc,tcc.
c	c02982	172.mg	587.mg	0/50	281.mg	14/50	563.mg	6/50	Liv:hpa,hpc.
d	c02982	177.mg	627.mg	0/50	281.mg	13/50	563.mg	6/50	
e	c02982	51.5mg	117.mg	14/50	281.mg	45/50	563.mg	45/50	
f	c02982	172.mg	587.mg	0/50	281.mg	14/50	563.mg	6/50	Liv:hpa,hpc,nnd.
g	c02982	573.mg	n.s.s.	4/50	281.mg	4/50	563.mg	1/50	Lun:a/a,a/c.
690	c02982	28.7mg	70.9mg	0/50	260.mg	40/50	552.mg	31/50	ubl:sgc,tcc.
a	c02982	29.3mg	78.2mg	22/50	260.mg	42/50	552.mg	32/50	
b	c02982	95.5mg	32.7gm	15/50	260.mg	11/50	552.mg	3/50	Liv:hpa,hpc,nnd.
c	c02982	207.mg	n.s.s.	7/50	260.mg	2/50	552.mg	1/50	Lun:a/a,a/c.
691	c02982	79.6mg	157.mg	0/50	245.mg	31/50	491.mg	43/50	ubl:nen,ppc,sgc,tcc.
a	c02982	79.6mg	157.mg	0/50	245.mg	31/50	491.mg	43/50	nas:oln; ubl:nen,ppc,sgc,tcc. C
b	c02982	401.mg	14.2gm	2/50	245.mg	8/50	491.mg	4/50	S

Spe	Strain	Site	Xpo+Xpt	Notes	TD50	2Tailpvl
Sex	Route	Hist			DR	AuOp
c	R f	f34 eat nas	oln 24m24	s	1.19gm /	P<.0005c
d	R f	f34 eat adr	coa 24m24	s	1.49gm *	P<.02
e	R f	f34 eat TBA	MXB 24m24	s	93.8mg /	P<.0005
f	R f	f34 eat liv	MXB 24m24	s	2.18gm *	P<.06
692	R m	f34 eat MXB	MXB 24m24	s	76.3gm /	P<.0005
					:+ :	
a	R m	f34 eat ubl	MXA 24m24	s	88.4mg /	P<.0005c
b	R m	f34 eat tea	ict 24m24	s	165. mg /	P<.006
c	R m	f34 eat nas	MXA 24m24	s	397. mg /	P<.0005c
d	R m	f34 eat liv	MXA 24m24	s	406. mg *	P<.0005c
e	R m	f34 eat nas	MXA 24m24	s	450. mg /	P<.0005c
f	R m	f34 eat MXA	MXA 24m24	s	3.51gm /	P<.02
g	R m	f34 eat MXA	MXA 24m24	s	4.62gm *	P<.03 c
h	R m	f34 eat TBA	MXB 24m24	s	98.0mg /	P<.0005
i	R m	f34 eat liv	MXB 24m24	s	443. mg *	P<.0005
CUPFERRON					100ng.....1ug.....10.....100.....1mg.....10.....100.....1g.....10	
693	M f	b6c eat MXB	MXB 78w95	v	253. mg *	P<.0005
a	M f	b6c eat liv	MXA 78w95	v	413. mg *	P<.0005c
b	M f	b6c eat ---	MXA 78w95	v	419. mg \	P<.003 c
c	M f	b6c eat liv	hpc 78w95	v	564. mg *	P<.0005c
d	M f	b6c eat hag	adn 78w95	v	1.27gm *	P<.002 c
e	M f	b6c eat lun	MXA 78w95	v	798. mg *	P<.04
f	M f	b6c eat ---	has 78w95	v	1.33gm *	P<.03
g	M f	b6c eat zym	MXA 78w95	v	3.93gm *	P<.04 c
h	M f	b6c eat TBA	MXB 78w95	v	211. mg *	P<.0005
i	M f	b6c eat liv	MXB 78w95	v	413. mg *	P<.0005
j	M f	b6c eat lun	MXB 78w95	v	798. mg *	P<.04
694	M m	b6c eat ---	has 78w95	v	1.00gm *	P<.005 c
a	M m	b6c eat hag	adn 78w95	v	1.04gm *	P<.004
b	M m	b6c eat TBA	MXB 78w95	v	252. mg *	P<.004
c	M m	b6c eat liv	MXB 78w95	v	5.45gm *	P<.9
d	M m	b6c eat lun	MXB 78w95	v	2.39gm *	P<.6
695	R f	f34 eat MXB	MXB 18m25	s	14.1mg *	P<.0005
a	R f	f34 eat ---	has 18m25	s	17.4mg /	P<.0005c
b	R f	f34 eat liv	MXA 18m25	s	17.7mg *	P<.0005c
c	R f	f34 eat liv	hpc 18m25	s	20.1mg *	P<.0005c
d	R f	f34 eat sto	MXA 18m25	s	27.8mg /	P<.0005c
e	R f	f34 eat sto	sqc 18m25	s	31.3mg /	P<.0005c
f	R f	f34 eat zym	MXA 18m25	s	historical *	P<.002 c
g	R f	f34 eat TBA	MXB 18m25	s	11.2mg /	P<.0005
h	R f	f34 eat liv	MXB 18m25	s	17.7mg *	P<.0005
696	R m	f34 eat MXB	MXB 18m24	s	5.33gm /	P<.0005
a	R m	f34 eat ---	has 18m24	s	5.49mg /	P<.0005c
b	R m	f34 eat sto	MXA 18m24	s	6.28mg /	P<.0005c
c	R m	f34 eat sto	sqc 18m24	s	6.94mg /	P<.0005c
d	R m	f34 eat liv	MXA 18m24	s	9.28mg *	P<.0005c
e	R m	f34 eat sub	fib 18m24	s	10.5mg *	P<.0005
f	R m	f34 eat liv	hpc 18m24	s	30.7mg *	P<.0005c
g	R m	f34 eat bod	MXA 18m24	s	139. mg *	P<.002
h	R m	f34 eat TBA	MXB 18m24	s	8.85mg /	P<.0005
i	R m	f34 eat liv	MXB 18m24	s	9.28mg *	P<.0005
CYANAMIDE, CALCIUM					100ng.....1ug.....10.....100.....1mg.....10.....100.....1g.....10	
697	M f	b6c eat ---	MXA 23m23	s	478. mg *	P<.03 -
a	M f	b6c eat TBA	MXB 23m23	s	no dre	P=1.
b	M f	b6c eat liv	MXB 23m23	s	no dre	P=1.
c	M f	b6c eat lun	MXB 23m23	s	4.04gm /	P<.6
698	M f	b6c orl liv	hpt 76w76	evx	no dre	P=1.
a	M f	b6c orl lun	mix 76w76	evx	no dre	P=1.
b	M f	b6c orl tba	mix 76w76	evx	68.0mg	P<.05
699	M m	b6c eat ---	has 23m23	s	766. mg *	P<.009 -
a	M m	b6c eat TBA	MXB 23m23	s	909. mg *	P<.6
b	M m	b6c eat liv	MXB 23m23	s	no dre	P=1.
c	M m	b6c eat lun	MXB 23m23	s	no dre	P=1.
700	M m	b6c orl ---	rts 76w76	evx	30.9mg	P<.006
a	M m	b6c orl liv	hpt 76w76	evx	55.7mg	P<.04
b	M m	b6c orl lun	mix 76w76	evx	no dre	P=1.
c	M m	b6c orl tba	mix 76w76	evx	16.7mg	P<.0005
701	M f	b6a orl liv	hpt 76w76	evx	no dre	P=1.
a	M f	b6a orl lun	ade 76w76	evx	no dre	P=1.
b	M f	b6a orl tba	mix 76w76	evx	no dre	P=1.
702	M m	b6a orl liv	hpt 76w76	evx	191. mg	P<.6
a	M m	b6a orl lun	ade 76w76	evx	no dre	P=1.
b	M m	b6a orl tba	mix 76w76	evx	no dre	P=1.
703	R f	f34 eat TBA	MXB 25m25	s	267. mg *	P<.9 -
a	R f	f34 eat liv	MXB 25m25	s	no dre	P=1.
704	R m	f34 eat ---	MXA 25m25	s	7.45mg \	P<.05 -
a	R m	f34 eat TBA	MXB 25m25	s	no dre	P=1.
b	R m	f34 eat liv	MXB 25m25	s	no dre	P=1.

Spe	Strain	Site	Xpo + Xpt	Notes	TD50	2Tailpvt	DR	AuOp
Sex	Route	Hist						
CYCLAMATE, SODIUM					100ng.....1ug.....10.....100.....1mg.....10.....100.....1g.....10			
705	M f	asp eat	rel lys	80w82 e			16.7gm	* P<.04 -
a	M f	asp eat	lun ade	80w82 e			228.gm	* P<.1. -
b	M f	asp eat	liv tum	80w82 e			no dre	P=1. -
706	M m	asp eat	liv tum	80w82 e		>	no dre	P=1. -
a	M m	asp eat	lun ade	80w82 e			no dre	P=1. -
707	M f	c3h wat	liv tum	24m24 e		>	no dre	P=1. -
a	M f	c3h wat	lun tum	24m24 e			no dre	P=1. -
b	M f	c3h wat	tba mix	24m24 e			no dre	P=1. -
708	M m	c3h wat	liv mix	24m24 e		>	no dre	P=1. -
a	M m	c3h wat	lun mix	24m24 e			no dre	P=1. -
b	M m	c3h wat	tba mix	24m24 e			no dre	P=1. -
709	M f	cd1 eat	liv tum	24m24 e			no dre	P=1. -
a	M f	cd1 eat	lun tum	24m24 e			no dre	P=1. -
b	M f	cd1 eat	tba mix	24m24 e			no dre	P=1. -
710	M m	crf wat	liv mix	24m24 e		.	1.42gm	P<.09 +
a	M m	crf wat	lun mix	24m24 e			4.38gm	P<.2
b	M m	crf wat	tba mix	24m24 e			772.mg	P<.03 +
711	M m	r3m wat	lun mix	24m24 e		.	4.67gm	P<.05 +
a	M m	r3m wat	liv tum	24m24 e			no dre	P=1. -
b	M m	r3m wat	tba mix	24m24 e			4.67gm	P<.05
712	M f	awa eat	liv hpt	76w76 e			no dre	P=1. -
713	M f	swi eat	ubl apc	91w91 eg			no dre	P=1. -
714	M m	swi eat	ubl tum	91w91 e			no dre	P=1. -
715	M f	xvi wat	lun mix	24m24 e		.	587.mg	P<.0005
a	M f	xvi wat	liv mix	24m24 e		.	16.0gm	P<.3
b	M f	xvi wat	tba mix	24m24 e			587.mg	P<.0005+
716	R b	sda eat	ubl pam	30m30 e			no dre	P=1. -
a	R b	sda eat	ubl tcc	30m30 e			no dre	P=1. -
b	R b	sda eat	tba mal	30m30 e			30.7gm	* P<.3 -
717	R b	wis eat	ubl tum	24m24 er			83.9gm	* P<.2
CYCLOCHLOROTINE					100ng.....1ug.....10.....100.....1mg.....10.....100.....1g.....10			
718	M m	ddn eat	liv mix	37m37 e		.	23.6mg	* P<.1 +
a	M m	ddn eat	liv lca	37m37 e			48.6mg	* P<.2 +
b	M m	ddn eat	liv lcc	37m37 e			98.9mg	* P<.4 +
c	M m	ddn eat	liv hpt	37m37 e			99.5mg	* P<.9 +
N-CYCLOHEXYL-2-BENZOTHAZOLE SULFENAMIDE					100ng.....1ug.....10.....100.....1mg.....10.....100.....1g.....10			
719	M f	b6a orl	liv hpt	76w76 evx		>	no dre	P=1. -
a	M f	b6a orl	lun ade	76w76 evx			no dre	P=1. -
b	M f	b6a orl	tba mix	76w76 evx			no dre	P=1. -
720	M m	b6a orl	liv hpt	76w76 evx		>	no dre	P=1. -
a	M m	b6a orl	lun ade	76w76 evx			no dre	P=1. -
b	M m	b6a orl	tba mix	76w76 evx			no dre	P=1. -
721	M f	b6c orl	liv hpt	76w76 evx		>	no dre	P=1. -
a	M f	b6c orl	lun mix	76w76 evx			no dre	P=1. -
b	M f	b6c orl	tba mix	76w76 evx			243.mg	P<.09 -
722	M m	b6c orl	liv hpt	76w76 evx		.	92.7mg	P<.007 -
a	M m	b6c orl	lun ade	76w76 evx			532.mg	P<.3 -
b	M m	b6c orl	tba mix	76w76 evx			50.8mg	P<.0005-
CYCLOHEXYLAMINE.HCl					100ng.....1ug.....10.....100.....1mg.....10.....100.....1g.....10			
723	M f	asp eat	lun ade	80w84 e		>	no dre	P=1. -
a	M f	asp eat	liv nod	80w84 e			no dre	P=1. -
b	M f	asp eat	tba mix	80w84 e			no dre	P=1. -
724	M m	asp eat	liv nod	80w84 e		.	231.mg	Z P<.02 -
a	M m	asp eat	lun adc	80w84 e			no dre	P=1. -
b	M m	asp eat	lun ade	80w84 e			no dre	P=1. -
c	M m	asp eat	tba mix	80w84 e			no dre	P=1. -
725	R b	fdr eat	liv mix	24m24 g		>	no dre	P=1. -
a	R b	fdr eat	tba mix	24m24 g			no dre	P=1. -
726	R b	sda eat	liv lca	30m30 e		>	14.5gm	P<.2 -
a	R b	sda eat	ubl tum	30m30 e			no dre	P=1. -
b	R b	sda eat	tba mal	30m30 e			no dre	P=1. -
727	R f	wis eat	liv hem	24m24 e		.	1.33gm	Z P<.04 -
728	R m	wis eat	liv nod	24m24 e		>	47.0gm	* P<.1. -
a	R m	wis eat	liv hem	24m24 e			no dre	P=1. -
CYCLOHEXYLAMINE SULFATE					100ng.....1ug.....10.....100.....1mg.....10.....100.....1g.....10			
729	M f	swi eat	ubl apc	91w91 eg		>	no dre	P=1. -
730	M m	swi eat	ubl tum	91w91 e		>	no dre	P=1. -
731	R f	csa eat	ubl tum	24m24 r		>	no dre	P=1. -
732	R m	csa eat	ubl tcc	24m24 r		>	280.mg	* P<.2
CYCLOPHOSPHAMIDE					100ng.....1ug.....10.....100.....1mg.....10.....100.....1g.....10			
733	M f	swi ipj	--- lys	26w79 e		.	7.09gm	* P<.003 +
a	M f	swi ipj	ski sqc	26w79 e		.	11.1gm	* P<.002
b	M f	swi ipj	lun mix	26w79 e		.	6.15gm	* P<.06 +

Spe	Strain	Site	Xpo+Xpt	Notes	TD50	2Tailpvl
Sex	Route	Hist			DR	AuOp
c	M f swi ipj	liv lys	26w79	e	no dre	P=1.
d	M f swi ipj	tba mix	26w79	e	1.78mg *	P<.0005
e	M f swi ipj	tba mal	26w79	e	1.78mg *	P<.0005
f	M f swi ipj	tba ben	26w79	e	no dre	P=1.
734	M m swi ipj	---	leu	26w79 e	8.69mg *	P<.004
a	M m swi ipj	lun mix	26w79	e	5.78mg *	P<.07 +
b	M m swi ipj	liv mix	26w79	e	40.9mg *	P<.5
c	M m swi ipj	tba mix	26w79	e	3.66mg *	P<.09
d	M m swi ipj	tba mal	26w79	e	3.77mg *	P<.05
e	M m swi ipj	tba ben	26w79	e	no dre	P=1.
735	R m b46 ivj	tba mix	12m24	es	3.01mg	P<.04 +
a	R m b46 ivj	tba mal	12m24	es	5.36mg	P<.1 +
b	R m b46 ivj	tba ben	12m24	es	9.02mg	P<.3
736	R f sda ipj	mem mal	24m24	es	1.70mg	P<.05
a	R f sda ipj	tba mal	24m24	es	1.26mg	P<.02 +
737	R m sda ipj	liv haa	25m25	es	no dre	P=1.
a	R m sda ipj	tba mal	25m25	es	2.87mg	P<.06 +
DACARBAZINE					100ng...1ug...10...100...1mg...10...100...1g...10	
738	M f swi ipj	lun mix	26w61	e	.595mg	P<.0005+
a	M f swi ipj	ute adc	26w61	e	3.20mg	P<.0005+
b	M f swi ipj	---	lys	26w61 e	8.00mg	P<.05 +
c	M f swi ipj	spl haa	26w61	e	14.5mg	P<.03 +
d	M f swi ipj	liv lys	26w61	e	no dre	P=1.
e	M f swi ipj	tba mal	26w61	e	.807mg	P<.0005
f	M f swi ipj	tba ben	26w61	e	7.03mg	P<.2
g	M f swi ipj	tba mix	26w61	e	noTD50	P<.2
739	M m swi ipj	lun mix	26w78	e	2.57mg	P<.0005+
a	M m swi ipj	spl mix	26w78	e	5.17mg	P<.0005+
b	M m swi ipj	---	lyk	26w78 e	13.0mg	P<.004 +
c	M m swi ipj	---	lys	26w78 e	16.1mg	P<.07 +
d	M m swi ipj	liv mix	26w78	e	98.8mg	P<.7
e	M m swi ipj	tba mix	26w78	e	.813mg	P<.0005
f	M m swi ipj	tba mal	26w78	e	1.54mg	P<.0005
g	M m swi ipj	tba ben	26w78	e	10.6mg	P<.2
740	R f sda eat	mpl adf	46w60		.710mg	P<.0005+
a	R f sda eat	thm lys	46w60		4.21mg	P<.02 +
b	R f sda eat	ute lei	46w60		6.55mg	P<.05 +
DAMINOZIDE					100ng...1ug...10...100...1mg...10...100...1g...10	
741	M f b6c eat	TBA MXB	24m24		56.4gm *	P<.1. -
a	M f b6c eat	liv MXB	24m24		6.82gm \	P<.5
b	M f b6c eat	lun MXB	24m24		2.92gm *	P<.06
742	M m b6c eat	liv hpc	24m24		2.15gm *	P<.005 a
a	M m b6c eat	liv MXA	24m24		2.45gm *	P<.05 a
b	M m b6c eat	TBA MXB	24m24		1.50gm *	P<.2
c	M m b6c eat	liv MXB	24m24		2.45gm *	P<.05
d	M m b6c eat	lun MXB	24m24		3.40gm *	P<.4
743	M f swa wat	blv mix	92w92	e	1.24gm	P<.0005+
a	M f swa wat	lun mix	92w92	e	1.37gm	P<.0005+
b	M f swa wat	liv tum	92w92	e	no dre	P=1.
744	M m swa wat	blv mix	81w81	e	880. mg	P<.0005+
a	M m swa wat	lun mix	81w81	e	1.11gm	P<.0005+
b	M m swa wat	kid ade	81w81	e	10.9gm	P<.002 +
c	M m swa wat	liv hpt	81w81	e	38.8gm	P<.3 -
745	R f f34 eat	lun a/e	24m24		4.89gm *	P<.05
a	R f f34 eat	MXB MXB	24m24		1.84gm *	P<.2
b	R f f34 eat	utm acn	24m24		+historical *	P<.3 c
c	R f f34 eat	ute lei	24m24		+historical *	P<.2 c
d	R f f34 eat	TBA MXB	24m24		3.45gm *	P<.8
e	R f f34 eat	liv MXB	24m24		9.64gm *	P<.5
746	R m f34 eat	TBA MXB	24m24		no dre	P=1. -
a	R m f34 eat	liv MXB	24m24		no dre	P=1.
DAPSONE					100ng...1ug...10...100...1mg...10...100...1g...10	
747	M f b6c eat	TBA MXB	18m25		no dre	P=1. -
a	M f b6c eat	liv MXB	18m25		no dre	P=1.
b	M f b6c eat	lun MXB	18m25		no dre	P=1.
748	M m b6c eat	TBA MXB	18m25		no dre	P=1. -
a	M m b6c eat	liv MXB	18m25		no dre	P=1.
b	M m b6c eat	lun MXB	18m25		no dre	P=1.
749	R f f34 eat	TBA MXB	18m24		no dre	P=1. -
a	R f f34 eat	liv MXB	18m24		no dre	P=1.
750	R m f34 eat	apl MXA	18m24		22.4mg *	P<.0005c
a	R m f34 eat	apl fib	18m24		28.5mg *	P<.004 c
b	R m f34 eat	TBA MXB	18m24		22.4mg *	P<.1
c	R m f34 eat	liv MXB	18m24		no dre	P=1.
751	R m f34 eat	apl MXA	18m24	pool	22.4mg *	P<.0005c
a	R m f34 eat	apl fib	18m24		28.5mg *	P<.0005c

RefNum	LoConf	UpConf	Cntrl	1Dose	1Inc	2Dose	2Inc	Citation or Pathology	Brkly Code
c	1336	2.43mg	n.s.s.	1/154	1.69mg	0/19	3.52mg	0/16	
d	1336	.815mg	8.25mg	42/154	1.69mg	9/19	3.52mg	11/16	
e	1336	.858mg	5.93mg	29/154	1.69mg	7/19	3.52mg	11/16	
f	1336	6.99mg	n.s.s.	13/154	1.69mg	2/19	3.52mg	0/16	
734	1336	2.63mg	84.8mg	0/101	1.72mg	2/22	3.52mg	1/9	
a	1336	1.78mg	n.s.s.	9/101	1.72mg	5/22	3.52mg	2/9	
b	1336	4.60mg	n.s.s.	2/101	1.72mg	0/22	3.52mg	1/9	
c	1336	1.15mg	n.s.s.	28/101	1.72mg	8/22	3.52mg	5/9	
d	1336	1.27mg	n.s.s.	19/101	1.72mg	7/22	3.52mg	4/9	
e	1336	4.42mg	n.s.s.	9/101	1.72mg	1/22	3.52mg	1/9	
735	1017	1.12mg	n.s.s.	7/65	.929mg	10/36			Schmahl;arzn,20,1461-1467;1970
a	1017	1.62mg	n.s.s.	4/65	.929mg	6/36			
b	1017	2.12mg	n.s.s.	3/65	.929mg	4/36			
736	1134	.660mg	n.s.s.	3/33	.571mg	10/36			Schmahl;zkko,86,77-84;1976
a	1134	.549mg	n.s.s.	3/33	.571mg	12/36			
737	1134	3.91mg	n.s.s.	1/36	.571mg	0/32			
a	1134	.956mg	n.s.s.	1/36	.571mg	5/32			
DACARBAZINE (DIC) 4342-03-4									
738	1336	.249mg	1.74mg	20/154	4.56mg	12/14			Skipper;srfr;1976/Waisburger 1977/Prejean pers.com.
a	1336	1.09mg	16.5mg	0/154	4.56mg	4/14			
b	1336	1.76mg	n.s.s.	3/154	4.56mg	2/14			
c	1336	2.36mg	n.s.s.	0/154	4.56mg	1/14			
d	1336	4.53mg	n.s.s.	1/154	4.56mg	0/14			
e	1336	.336mg	2.84mg	29/154	4.56mg	11/14			
f	1336	1.50mg	n.s.s.	13/154	4.56mg	3/14			
g	1336	n.s.s.	n.s.s.	42/154	4.56mg	14/14			
739	1336	1.26mg	7.71mg	9/101	3.56mg	14/30			
a	1336	2.23mg	16.6mg	0/101	3.56mg	7/30			
b	1336	3.94mg	114.mg	0/101	3.56mg	3/30			
c	1336	4.16mg	n.s.s.	2/101	3.56mg	3/30			
d	1336	7.22mg	n.s.s.	2/101	3.56mg	1/30			
e	1336	.419mg	1.86mg	28/101	3.56mg	26/30			
f	1336	.796mg	4.06mg	19/101	3.56mg	20/30			
g	1336	2.97mg	n.s.s.	9/101	3.56mg	6/30			
740	1412	.316mg	2.38mg	4/28	3.83mg	12/16			Beal;jnci,54,951-957;1975
a	1412	1.27mg	n.s.s.	0/28	3.83mg	3/16			
b	1412	1.61mg	n.s.s.	0/28	3.83mg	2/16			
DAMINOZIDE (succinic acid 2,2-dimethyl hydrazide, DMSA) 1596-84-5									
741	c03827	1.04gm	n.s.s.	13/20	644.mg	27/50	1.29gm	25/50	
a	c03827	1.36gm	n.s.s.	1/20	644.mg	4/50	(1.29gm	0/50)	Liv:hpa,hpc,nnd.
b	c03827	1.35gm	n.s.s.	1/20	644.mg	8/50	1.29gm	10/50	lun:a/a,a/c.
742	c03827	1.26gm	14.9gm	0/20	594.mg	7/50	1.19gm	13/50	
a	c03827	1.20gm	n.s.s.	1/20	594.mg	9/50	1.19gm	14/50	Liv:hpa,hpc.
b	c03827	588.mg	n.s.s.	8/20	594.mg	28/50	1.19gm	37/50	
c	c03827	1.20gm	n.s.s.	1/20	594.mg	9/50	1.19gm	14/50	Liv:hpa,hpc,nnd.
d	c03827	1.01gm	n.s.s.	4/20	594.mg	15/50	1.19gm	18/50	lun:a/a,a/c.
743	401	757.mg	2.16gm	8/96	4.00gm	36/43			Toth;canr,37,3497-3500;1977
a	401	831.mg	2.47gm	15/99	4.00gm	37/45			
b	401	29.0gm	n.s.s.	0/71	4.00gm	0/45			
744	401	552.mg	1.49gm	5/89	3.33gm	37/46			
a	401	649.mg	2.21gm	22/92	3.33gm	36/46			
b	401	4.15gm	51.1gm	0/77	3.33gm	5/42			
c	401	7.39gm	n.s.s.	1/77	3.33gm	2/42			
745	c03827	1.69gm	n.s.s.	0/20	248.mg	0/50	495.mg	4/50	S
a	c03827	922.mg	n.s.s.	0/20	248.mg	6/50	495.mg	5/50	ute:lci; utm:acn. C
b	c03827	1.13gm	n.s.s.	0/20	248.mg	5/50	495.mg	3/50	
c	c03827	1.81gm	n.s.s.	0/20	248.mg	1/50	495.mg	3/50	
d	c03827	404.mg	n.s.s.	11/20	248.mg	32/50	495.mg	28/50	
e	c03827	2.37gm	n.s.s.	0/20	248.mg	1/50	495.mg	1/50	Liv:hpa,hpc,nnd.
746	c03827	771.mg	n.s.s.	10/20	198.mg	21/50	396.mg	19/50	
a	c03827	3.37gm	n.s.s.	0/20	198.mg	1/50	396.mg	0/50	Liv:hpa,hpc,nnd.
DAPSONE 80-08-0									
747	c01718	45.8mg	n.s.s.	6/14	33.8mg	4/35	(67.6mg	2/36)	
a	c01718	n.s.s.	n.s.s.	0/14	33.8mg	0/35	67.6mg	0/36	Liv:hpa,hpc,nnd.
b	c01718	262.mg	n.s.s.	1/14	33.8mg	0/35	67.6mg	0/36	lun:a/a,a/c.
748	c01718	67.2mg	n.s.s.	0/14	31.2mg	11/35	62.4mg	5/34	
a	c01718	106.mg	n.s.s.	0/14	31.2mg	6/35	62.4mg	2/34	Liv:hpa,hpc,nnd.
b	c01718	133.mg	n.s.s.	0/14	31.2mg	5/35	62.4mg	1/34	lun:a/a,a/c.
749	c01718	35.7mg	n.s.s.	8/15	16.0mg	15/35	32.0mg	14/35	
a	c01718	n.s.s.	n.s.s.	0/15	16.0mg	0/35	32.0mg	0/35	Liv:hpa,hpc,nnd.
750	c01718	13.1mg	61.0mg	0/15	12.8mg	6/35	25.6mg	14/35	spl:fb, fib,arn.
a	c01718	15.7mg	157.mg	0/15	12.8mg	6/35	25.6mg	10/35	
b	c01718	8.91mg	n.s.s.	6/15	12.8mg	23/35	25.6mg	24/35	
c	c01718	n.s.s.	n.s.s.	0/15	12.8mg	0/35	25.6mg	0/35	Liv:hpa,hpc,nnd.
751	c01718	13.1mg	42.8mg	0/45p	12.8mg	6/35	25.6mg	14/35	spl:fb, fib,arn.
a	c01718	15.7mg	62.2mg	0/45p	12.8mg	6/35	25.6mg	10/35	

Spe	Strain	Site	Xpo+Xpt	Notes	TD50	2Tailpvl	
Sex	Route	Hist			DR	AuOp	
b	R m f34	eat	---	lym 18m24	50.1mg	\ P<.008	
c	R m f34	eat	per	MXA 18m24	56.3mg	* P<.002 c	
d	R m f34	eat	per	srn 18m24	91.3mg	* P<.02	
e	R m f34	eat	per	fbs 18m24	148.mg	* P<.03 c	
f	R m f34	eat	spl	fbs 18m24	167.mg	* P<.03 c	
g	R m f34	eat	spl	srn 18m24	170.mg	* P<.03 c	
o,p'-DDD					100ng.....1ug.....10.....100.....1mg.....10.....100.....1g.....10		
752	M f b6a	orl	lun	ade 76w76 evx	>	236.mg P<.4	
a	M f b6a	orl	liv	hpt 76w76 evx		no dre P=1.	
b	M f b6a	orl	tba	mix 76w76 evx		102.mg P<.2	
753	M m b6a	orl	lun	ade 76w76 evx	>	414.mg P<.7	
a	M m b6a	orl	lun	car 76w76 evx		467.mg P<.3	
b	M m b6a	orl	liv	hpt 76w76 evx		no dre P=1.	
c	M m b6a	orl	tba	mix 76w76 evx		187.mg P<.5	
754	M f b6c	orl	liv	hpt 76w76 evx	>	no dre P=1.	
a	M f b6c	orl	lun	mix 76w76 evx		no dre P=1.	
b	M f b6c	orl	tba	tum 76w76 evx		no dre P=1.	
755	M m b6c	orl	---	rts 76w76 evx	.	82.1mg P<.009	
a	M m b6c	orl	liv	hpt 76w76 evx	.	147.mg P<.05	
b	M m b6c	orl	lun	ade 76w76 evx		467.mg P<.3	
c	M m b6c	orl	tba	mix 76w76 evx		38.5mg P<.0005	
p,p'-DDD					100ng.....1ug.....10.....100.....1mg.....10.....100.....1g.....10		
756	M f b6c	eat	TBA	MXB 78w90 v	>	108.mg \ P<.2	
a	M f b6c	eat	liv	MXB 78w90 v		493.mg * P<.1	
b	M f b6c	eat	lun	MXB 78w90 v		no dre P=1.	
757	M f b6c	orl	lun	ade 76w76 evx	>	250.mg P<.3	
a	M f b6c	orl	liv	hpt 76w76 evx		no dre P=1.	
b	M f b6c	orl	tba	mix 76w76 evx		250.mg P<.3	
758	M m b6c	eat	TBA	MXB 78w90 v	>	997.mg * P<.9	
a	M m b6c	eat	liv	MXB 78w90 v		116.mg * P<.2	
b	M m b6c	eat	lun	MXB 78w90 v		no dre P=1.	
759	M m b6c	orl	liv	hpt 76w76 evx	.	43.3mg P<.009	
a	M m b6c	orl	lun	ade 76w76 evx	.	120.mg P<.2	
b	M m b6c	orl	tba	mix 76w76 evx		34.8mg P<.004	
760	M f b6a	orl	lun	ade 76w76 evx	>	73.0mg P<.2	
a	M f b6a	orl	liv	hpt 76w76 evx		no dre P=1.	
b	M f b6a	orl	tba	mix 76w76 evx		37.4mg P<.05	
761	M m b6a	orl	lun	ade 76w76 evx	>	82.9mg P<.3	
a	M m b6a	orl	liv	hpt 76w76 evx		no dre P=1.	
b	M m b6a	orl	tba	mix 76w76 evx		49.0mg P<.2	
762	M f cf1	eat	lun	mix 29m29	.	39.9mg P<.0005+	
a	M f cf1	eat	liv	hpt 29m29	.	4.83gm P<.8	
b	M f cf1	eat	tba	mix 29m29		67.1mg P<.3	
763	M m cf1	eat	lun	mix 29m29	.	24.9mg P<.0005+	
a	M m cf1	eat	liv	hpt 29m29	.	86.8mg P<.02 +	
b	M m cf1	eat	tba	mix 29m29		33.2mg P<.2	
764	R f osm	eat	TBA	MXB 18m26	>	no dre P=1.	
a	R f osm	eat	liv	MXB 18m26		2.08gm * P<.7	
765	R m osm	eat	thy	MXA 18m26 v	:	75.8mg \ P<.05	
a	R m osm	eat	TBA	MXB 18m26 v		82.6mg \ P<.4	
b	R m osm	eat	liv	MXB 18m26 v		no dre P=1.	
p,p'-DDE					100ng.....1ug.....10.....100.....1mg.....10.....100.....1g.....10		
766	M f b6c	eat	liv	hpc 78w92 dv	+: :	9.45mg / P<.0005c	
a	M f b6c	eat	TBA	MXB 78w92 dv		11.9mg / P<.0005	
b	M f b6c	eat	liv	MXB 78w92 dv		9.45mg / P<.0005	
c	M f b6c	eat	lun	MXB 78w92 dv		no dre P=1.	
767	M m b6c	eat	liv	hpc 78w92 dsv	:	11.1mg * P<.03 c	
a	M m b6c	eat	TBA	MXB 78w92 dsv		7.48mg * P<.05	
b	M m b6c	eat	liv	MXB 78w92 dsv		11.1mg * P<.03	
c	M m b6c	eat	lun	MXB 78w92 dsv		119.mg * P<.5	
768	M f cf1	eat	liv	hpt 25m25	.	10.5mg P<.0005+	
a	M f cf1	eat	lun	mix 25m25	.	no dre P=1.	
b	M f cf1	eat	tba	mix 25m25		14.8mg P<.0005	
769	M m cf1	eat	liv	hpt 25m25	.	33.9mg P<.0005+	
a	M m cf1	eat	lun	mix 25m25	.	no dre P=1.	
b	M m cf1	eat	tba	mix 25m25		no dre P=1.	
770	R f osm	eat	thy	MXA 18m26 dev	:	#33.2mg * P<.04	
a	R f osm	eat	TBA	MXB 18m26 dev		58.0mg * P<.7	
b	R f osm	eat	liv	MXB 18m26 dev		no dre P=1.	
771	R m osm	eat	TBA	MXB 18m26 dv	>	48.1mg * P<.4	
a	R m osm	eat	liv	MXB 18m26 dv		no dre P=1.	
DDT					100ng.....1ug.....10.....100.....1mg.....10.....100.....1g.....10		
772	H f syg	eat	liv	tum 28m28 e	>	no dre P=1.	
a	H f syg	eat	tba	mix 28m28 e		639.mg * P<.4	
773	H f syg	eat	tba	mix 48w88 e	>	no dre P=1.	

RefNum	LoConf	UpConf	Cntri	1Dose	1Inc	2Dose	2Inc	Citation or Pathology	Brkly Code
b	c01718	16.9mg	1.09gm	0/45p	12.8mg	4/35	(25.6mg 0/35)		S
c	c01718	27.8mg	202.mg	0/45p	12.8mg	5/35	25.6mg 6/35	per:fb, srn.	S
d	c01718	38.7mg	n.s.s.	0/45p	12.8mg	4/35	25.6mg 3/35		
e	c01718	50.0mg	n.s.s.	0/45p	12.8mg	1/35	25.6mg 3/35		
f	c01718	50.0mg	n.s.s.	0/45p	12.8mg	0/35	25.6mg 3/35		
g	c01718	50.7mg	n.s.s.	0/45p	12.8mg	0/35	25.6mg 3/35		
o,p'-DDD 53-19-0									
752	1202	51.4mg	n.s.s.	1/17	78.4mg	3/18		Innes;ntis,1968/1969	
a	1202	155.mg	n.s.s.	0/17	78.4mg	0/18			
b	1202	31.8mg	n.s.s.	2/17	78.4mg	6/18			
753	1202	52.0mg	n.s.s.	2/18	73.0mg	3/18			
a	1202	76.1mg	n.s.s.	0/18	73.0mg	1/18			
b	1202	86.3mg	n.s.s.	1/18	73.0mg	1/18			
c	1202	37.2mg	n.s.s.	3/18	73.0mg	5/18			
754	1202	155.mg	n.s.s.	0/16	78.4mg	0/18			
a	1202	155.mg	n.s.s.	0/16	78.4mg	0/18			
b	1202	155.mg	n.s.s.	0/16	78.4mg	0/18			
755	1202	30.9mg	1.80gm	0/16	73.0mg	5/18			
a	1202	44.2mg	n.s.s.	0/16	73.0mg	3/18			
b	1202	76.1mg	n.s.s.	0/16	73.0mg	1/18			
c	1202	17.8mg	111.mg	0/16	73.0mg	9/18			
p,p'-DDD (TDE) 72-56-8									
756	c00475	40.9mg	n.s.s.	2/20	45.5mg	13/50	(89.7mg 6/50)		
a	c00475	201.mg	n.s.s.	0/20	45.5mg	2/50	89.7mg 4/50	liv:hpa,hpc,nnd. lun:a/a,a/c.	
b	c00475	240.mg	n.s.s.	0/20	45.5mg	4/50	89.7mg 1/50		
757	79	40.7mg	n.s.s.	0/16	41.4mg	1/17		Innes;ntis,1968/1969	
a	79	77.4mg	n.s.s.	0/16	41.4mg	0/17			
b	79	40.7mg	n.s.s.	0/16	41.4mg	1/17			
758	c00475	53.0mg	n.s.s.	8/20	42.0mg	19/50	84.0mg 19/50		
a	c00475	48.5mg	n.s.s.	2/20	42.0mg	12/50	84.0mg 14/50	liv:hpa,hpc,nnd. lun:a/a,a/c.	
b	c00475	173.mg	n.s.s.	1/20	42.0mg	4/50	84.0mg 2/50	Innes;ntis,1968/1969	
759	79	16.3mg	950.mg	0/16	38.5mg	5/18			
a	79	29.4mg	n.s.s.	0/16	38.5mg	2/18			
b	79	14.0mg	212.mg	0/16	38.5mg	6/18			
760	79	20.7mg	n.s.s.	1/17	41.4mg	4/17			
a	79	77.4mg	n.s.s.	0/17	41.4mg	0/17			
b	79	13.2mg	n.s.s.	2/17	41.4mg	7/17			
761	79	19.0mg	n.s.s.	2/18	38.5mg	4/16			
a	79	67.8mg	n.s.s.	1/18	38.5mg	0/16			
b	79	13.9mg	n.s.s.	3/18	38.5mg	6/16			
762	80	21.8mg	115.mg	37/97	32.5mg	43/60		Tomatis;jnci,52,883-891;1974	
a	80	328.mg	n.s.s.	1/97	32.5mg	1/60			
b	80	18.5mg	n.s.s.	79/97	32.5mg	53/60			
763	80	13.5mg	68.6mg	53/101	30.0mg	51/60			
a	80	37.6mg	n.s.s.	33/101	30.0mg	31/60			
b	80	9.92mg	n.s.s.	89/101	30.0mg	57/60			
764	c00475	59.0mg	n.s.s.	17/20	29.0mg	35/50	59.0mg 36/50	liv:hpa,hpc,nnd.	
a	c00475	295.mg	n.s.s.	1/20	29.0mg	0/50	59.0mg 3/50	thy:fca,fcc.	
765	c00475	35.9mg	n.s.s.	1/20	45.6mg	16/50	(91.2mg 11/50)		
a	c00475	25.3mg	n.s.s.	7/20	45.6mg	33/50	(91.2mg 25/50)	liv:hpa,hpc,nnd.	
b	c00475	450.mg	n.s.s.	1/20	45.6mg	1/50	91.2mg 2/50		
p,p'-DDE 72-55-9									
766	c00555	6.69mg	14.3mg	0/20	15.6mg	19/50	28.6mg 34/50		
a	c00555	7.31mg	32.8mg	5/20	15.6mg	25/50	28.6mg 35/50		
b	c00555	6.69mg	14.3mg	0/20	15.6mg	19/50	28.6mg 34/50	liv:hpa,hpc,nnd. lun:a/a,a/c.	
c	c00555	n.s.s.	n.s.s.	0/20	15.6mg	0/50	28.6mg 0/50		
767	c00555	6.68mg	n.s.s.	0/20	15.6mg	7/50	26.4mg 17/50		
a	c00555	4.86mg	n.s.s.	0/20	15.6mg	15/50	26.4mg 22/50	liv:hpa,hpc,nnd. lun:a/a,a/c.	
b	c00555	6.68mg	n.s.s.	0/20	15.6mg	7/50	26.4mg 17/50		
c	c00555	35.8mg	n.s.s.	0/20	15.6mg	1/50	26.4mg 2/50		
768	80	6.80mg	16.3mg	1/97	32.5mg	54/60		Tomatis;jnci,52,883-891;1974	
a	80	231.mg	n.s.s.	37/97	32.5mg	9/60			
b	80	8.34mg	32.3mg	48/97	32.5mg	54/60			
769	80	18.4mg	103.mg	33/101	30.0mg	39/60			
a	80	136.mg	n.s.s.	53/101	30.0mg	19/60			
b	80	35.9mg	n.s.s.	89/101	30.0mg	48/60			
770	c00555	15.5mg	n.s.s.	2/20	8.40mg	9/50	14.4mg 12/50	thy:fca,fcc.	S
a	c00555	9.00mg	n.s.s.	16/20	8.40mg	36/50	14.4mg 29/50		
b	c00555	n.s.s.	n.s.s.	0/20	8.40mg	0/50	14.4mg 0/50	liv:hpa,hpc,nnd.	
771	c00555	13.6mg	n.s.s.	9/20	12.0mg	21/50	23.2mg 20/50		
a	c00555	n.s.s.	n.s.s.	0/20	12.0mg	0/50	23.2mg 0/50	liv:hpa,hpc,nnd.	
DDT 50-29-3									
772	1179	59.9mg	n.s.s.	0/39	13.1mg	0/28	26.1mg 0/28	52.3mg 0/40	Cabral;tumo,68,5-10;1982
a	1179	154.mg	n.s.s.	5/39	13.1mg	3/28	26.1mg 2/28	52.3mg 8/40	
773	1400	34.8mg	n.s.s.	3/6	28.5mg	3/17		Agthe;pseb,134,113-116;1970	

	Spe	Strain	Site	Xpo+Xpt				TD50	2Tailpvl
	Sex	Route	Hist	Notes				DR	AuOp
774	H m	syg eat	liv mix	28m28 e	.	±	311.mg	Z	P<.03
a	H m	syg eat	tba mix	28m28 e	.	±	145.mg	*	P<.02 -
775	H m	syg eat	tba mix	48m85 e	.	>	113.mg		P<.2 -
776	M f	b6c eat	--- lym	78w92 v	.	±	#61.2mg	*	P<.02 -
a	M f	b6c eat	TBA MXB	78w92 v	.	±	59.2mg	*	P<.2 -
b	M f	b6c eat	liv MXB	78w92 v	.	±	151.mg	*	P<.09 -
c	M f	b6c eat	lun MXB	78w92 v	.	±	no dre		P=1.
777	M f	b6c orl	liv hpt	80w80 evx	.	±	31.1mg		P<.02 -
a	M f	b6c orl	lun mix	80w80 evx	.	±	no dre		P=1.
b	M f	b6c orl	tba mix	80w80 evx	.	±	24.0mg		P<.009 -
778	M m	b6c eat	TBA MXB	78w91 sv	.	>	2.04mg	\	P<.4 -
a	M m	b6c eat	liv MXB	78w91 sv	.	>	no dre		P=1.
b	M m	b6c eat	lun MXB	78w91 sv	.	>	no dre		P=1.
779	M m	b6c orl	liv hpt	80w80 evx	.	+ .	8.95mg		P<.0005+
a	M m	b6c orl	lun ade	80w80 evx	.	+ .	127.mg		P<.3
b	M m	b6c orl	lun car	80w80 evx	.	+ .	127.mg		P<.3
c	M m	b6c orl	tba mix	80w80 evx	.	+ .	7.69mg		P<.0005
780	M f	b6a orl	--- rts	80w80 evx	.	+ .	19.3mg		P<.003 +
a	M f	b6a orl	liv hpt	80w80 evx	.	+ .	137.mg		P<.3
b	M f	b6a orl	lun ade	80w80 evx	.	+ .	no dre		P=1.
c	M f	b6a orl	tba mix	80w80 evx	.	+ .	21.3mg		P<.07
781	M m	b6a orl	liv hpt	80w80 evx	.	±	16.7mg		P<.02 +
a	M m	b6a orl	lun ade	80w80 evx	.	±	no dre		P=1.
b	M m	b6a orl	tba mix	80w80 evx	.	±	17.9mg		P<.07
782	M f	bal eat	liv lct	31m31 eg	.	+ .	59.5mg	*	P<.0005+
a	M f	bal eat	lun ade	31m31 g	.	+ .	no dre		P=1. -
b	M f	bal eat	tba mix	31m31 g	.	+ .	no dre		P=1. -
783	M f	cf1 eat	liv hpt	7m28	.	+ .	34.2mg		P<.0005+
a	M f	cf1 eat	tba tum	7m28	.	+ .	no dre		P=1. -
784	M f	cf1 eat	liv hpt	30w95	.	+ .	26.3mg		P<.0005+
a	M f	cf1 eat	tba tum	30w95	.	+ .	17.9mg		P<.4
785	M f	cf1 eat	liv hpt	30w65	.	+	52.2mg		P<.01 +
a	M f	cf1 eat	tba tum	30w65	.	+	150.mg		P<.9
786	M f	cf1 eat	liv mix	26m26 e	.	+ .	9.11mg	*	P<.0005+
a	M f	cf1 eat	liv lpb	26m26 e	.	+ .	76.5mg	*	P<.007
b	M f	cf1 eat	lun ade	26m26 e	.	+ .	no dre		P=1. -
c	M f	cf1 eat	lun car	26m26 e	.	+ .	no dre		P=1. -
787	M f	cf1 eat	liv mix	26m26 e	.	+ .	5.82mg		P<.0005+
a	M f	cf1 eat	liv lct	26m26 e	.	+ .	20.0mg		P<.0005+
b	M f	cf1 eat	lun tum	26m26 e	.	+ .	no dre		P=1. -
788	M f	cf1 eat	liv hpt	31m31 eg	.	+ .	43.0mg	*	P<.0005+
a	M f	cf1 eat	lun tum	31m31 eg	.	+ .	121.mg	*	P<.04 -
b	M f	cf1 eat	ute tum	31m31 eg	.	+ .	no dre		P=1. -
c	M f	cf1 eat	tba mix	31m31 eg	.	+ .	106.mg	*	P<.5
789	M m	cf1 eat	liv hpt	7m28	.	+ .	12.5mg		P<.002 +
a	M m	cf1 eat	tba tum	7m28	.	+ .	no dre		P=1. -
790	M m	cf1 eat	liv hpt	30w95	.	+ .	6.70mg		P<.0005+
a	M m	cf1 eat	tba tum	30w95	.	+ .	4.59mg		P<.02
791	M m	cf1 eat	liv hpt	30w65	.	+	4.55mg		P<.0005+
a	M m	cf1 eat	tba tum	30w65	.	+	5.35mg		P<.02
792	M m	cf1 eat	liv mix	26m26 e	.	+	15.0mg	*	P<.0005+
a	M m	cf1 eat	liv lpb	26m26 e	.	+	72.6mg	*	P<.02
b	M m	cf1 eat	lun ade	26m26 e	.	+	49.3mg	*	P<.4 -
c	M m	cf1 eat	lun car	26m26 e	.	+	no dre		P=1. -
793	M m	cf1 eat	liv mix	26m26 e	.	+	8.04mg		P<.0005+
a	M m	cf1 eat	liv lct	26m26 e	.	+	30.3mg		P<.003 +
b	M m	cf1 eat	lun tum	26m26 e	.	+	no dre		P=1. -
794	M m	cf1 eat	liv hpt	29m31 e	.	+ .	34.7mg	*	P<.0005+
a	M m	cf1 eat	lun tum	29m31 e	.	+ .	no dre		P=1. -
b	M m	cf1 eat	tba mix	29m31 e	.	+ .	no dre		P=1. -
795	R f	osm eat	TBA MXB	18m26 v	.	>	no dre		P=1. -
a	R f	osm eat	liv MXB	18m26 v	.	>	no dre		P=1. -
796	R f	osm eat	liv hpt	27m27	.	>	256.mg		P<.3 -
a	R f	osm eat	tba mix	27m27	.	>	no dre		P=1. -
797	R f	osm eat	liv mal	24m24	.	>	no dre		P=1. -
798	R m	osm eat	TBA MXB	18m26 v	.	>	no dre		P=1. -
a	R m	osm eat	liv MXB	18m26 v	.	>	no dre		P=1. -
799	R m	osm eat	liv tum	27m27	.	>	no dre		P=1. -
a	R m	osm eat	tba mix	27m27	.	>	no dre		P=1. -
800	R m	osm eat	liv mal	24m24	.	>	no dre		P=1. -
801	R b	alb eat	liv tum	60w60 k	.	>	no dre		P=1. -
802	R f	por eat	liv lct	33m33	.	+ .	140.mg	*	P<.002 +
a	R f	por eat	tba mix	33m33	.	+ .	no dre		P=1. -
803	R m	por eat	liv lct	33m33	.	>	902.mg	*	P<.4 -
a	R m	por eat	tba mix	33m33	.	>	90.1mg	*	P<.3
804	R f	wis eat	liv hpt	34m34 ev	.	+ .	57.2mg		P<.0005+
a	R f	wis eat	tba mix	34m34 v	.	+ .	116.mg		P<.4
805	R m	wis eat	liv hpt	34m34 e	.	+ .	92.6mg		P<.0005+
a	R m	wis eat	tba mix	34m34	.	+ .	no dre		P=1. -

CARCINOGENIC POTENCY DATABASE

RefNum	LoConf	UpConf	Cntrl	1Dose	1Inc	2Dose	2Inc		Citation or Pathology	Brkly Code
774	1179	94.1mg	n.s.s.	0/40	11.5mg	0/30	23.0mg	3/31 (46.0mg	0/39)	Cabral;tumo,68,5-10;1982
a	1179	68.7mg	n.s.s.	3/40	11.5mg	5/30	23.0mg	8/31	46.0mg	11/39
775	1400	34.1mg	n.s.s.	0/11	26.0mg	3/30			Agthe;psob,134,113-116;1970	
776	c00464	29.8mg	n.s.s.	0/20	9.50mg	3/50	19.5mg	7/50		S
a	c00464	22.4mg	n.s.s.	2/20	9.50mg	8/50	19.5mg	10/50		
b	c00464	52.1mg	n.s.s.	0/20	9.50mg	1/50	19.5mg	3/50		liv:hpa,hpc,nnnd.
c	c00464	n.s.s.	n.s.s.	0/20	9.50mg	1/50	19.5mg	0/50		lun:a/a,a/c.
777	133	10.7mg	n.s.s.	0/16	19.3mg	4/18			Innes;ntis,1968/1969	
a	133	42.3mg	n.s.s.	0/16	19.3mg	0/18				
b	133	9.05mg	526.mg	0/16	19.3mg	5/18				
778	c00464	.345mg	n.s.s.	4/20	2.30mg	6/50 (4.40mg	4/50)			
a	c00464	4.67mg	n.s.s.	2/20	2.30mg	1/50	4.40mg	1/50		liv:hpa,hpc,nnnd.
b	c00464	4.67mg	n.s.s.	1/20	2.30mg	1/50	4.40mg	0/50		lun:a/a,a/c.
779	133	4.24mg	23.7mg	0/16	17.9mg	10/18			Innes;ntis,1968/1969	
a	133	20.7mg	n.s.s.	0/16	17.9mg	1/18				
b	133	20.7mg	n.s.s.	0/16	17.9mg	1/18				
c	133	3.72mg	19.2mg	0/16	17.9mg	11/18				
780	133	7.78mg	106.mg	0/17	19.3mg	6/18				
a	133	22.2mg	n.s.s.	0/17	19.3mg	1/18				
b	133	42.3mg	n.s.s.	1/17	19.3mg	0/18				
c	133	7.42mg	n.s.s.	2/17	19.3mg	7/18				
781	133	6.56mg	n.s.s.	1/18	17.9mg	7/18				
a	133	18.5mg	n.s.s.	2/18	17.9mg	2/18				
b	133	6.21mg	n.s.s.	3/18	17.9mg	8/18				
782	88	37.8mg	101.mg	0/50	.260mg	0/58	2.60mg	1/50	32.5mg	28/57
a	88	238.mg	n.s.s.	20/62	.260mg	20/63	2.60mg	20/61	32.5mg	14/63
b	88	73.1mg	n.s.s.	56/62	.260mg	51/63	2.60mg	48/61	32.5mg	48/63
783	1012	16.7mg	99.9mg	1/90	8.13mg	11/54			Tomatis;zkko,82,25-35;1974	
a	1012	13.0mg	n.s.s.	77/90	8.13mg	41/54				
784	1012m	13.2mg	64.3mg	0/72	10.3mg	11/55				
a	1012m	4.65mg	n.s.s.	52/72	10.3mg	44/55				
785	1012n	18.0mg	5.13gm	0/69	15.0mg	4/54				
a	1012n	9.20mg	n.s.s.	27/69	15.0mg	22/54				
786	103	5.53mg	18.6mg	8/47	6.50mg	15/30	13.0mg	24/32		
a	103	31.2mg	895.mg	0/47	6.50mg	2/30	13.0mg	4/32	Welker;fctx,11,415-432;1973	
b	103	52.1mg	n.s.s.	19/47	6.50mg	6/30	13.0mg	7/32		
c	103	48.8mg	n.s.s.	3/47	6.50mg	5/30	13.0mg	1/32		
787	89	3.06mg	13.0mg	10/44	12.6mg	26/30			Thorpe;fctx,11,433-442;1973	
a	89	10.2mg	47.1mg	0/44	12.6mg	12/30				
b	89	40.4mg	n.s.s.	27/44	12.6mg	9/30				
788	90	28.1mg	71.8mg	2/56	.260mg	3/56	1.30mg	2/59	6.50mg	7/55
a	90	47.7mg	n.s.s.	13/56	.260mg	17/56	1.30mg	22/59	6.50mg	23/55
b	90	334.mg	n.s.s.	2/56	.260mg	8/56	1.30mg	3/59	6.50mg	4/55
c	90	20.1mg	n.s.s.	45/56	.260mg	50/56	1.30mg	52/59	6.50mg	48/55
789	1012	6.40mg	53.1mg	33/98	7.50mg	37/60			Tomatis;zkko,82,25-35;1974	
a	1012	8.22mg	n.s.s.	83/98	7.50mg	49/60				
790	1012m	3.86mg	15.9mg	24/83	9.47mg	41/60				
a	1012m	1.90mg	n.s.s.	65/83	9.47mg	56/60				
791	1012n	2.76mg	9.13mg	12/70	13.8mg	38/60				
a	1012n	2.39mg	n.s.s.	42/70	13.8mg	48/60				
792	103	8.40mg	43.3mg	6/47	6.00mg	12/32	12.0mg	17/32		
a	103	29.6mg	n.s.s.	0/47	6.00mg	3/32	12.0mg	3/32	Welker;fctx,11,415-432;1973	
b	103	12.9mg	n.s.s.	18/47	6.00mg	13/32	12.0mg	16/32		
c	103	30.6mg	n.s.s.	0/47	6.00mg	0/32	12.0mg	0/32		
793	89	4.17mg	21.3mg	11/45	11.7mg	23/30			Thorpe;fctx,11,433-442;1973	
a	89	13.1mg	195.mg	2/45	11.7mg	9/30				
b	89	29.5mg	n.s.s.	27/45	11.7mg	11/30				
794	90	19.4mg	86.6mg	12/55	.240mg	25/58	1.20mg	28/53	6.00mg	24/53
a	90	151.mg	n.s.s.	23/55	.240mg	38/58	1.20mg	29/53	6.00mg	27/53
b	90	24.9mg	n.s.s.	46/55	.240mg	53/58	1.20mg	48/53	6.00mg	49/53
795	c00464	16.8mg	n.s.s.	16/20	7.40mg	38/50	15.0mg	27/50		
a	c00464	n.s.s.	n.s.s.	0/20	7.40mg	0/50	15.0mg	0/50		liv:hpa,hpc,nnnd.
796	21	41.7mg	n.s.s.	0/30	10.0mg	1/30			Deichmann;txap,11,88-103;1967	
a	21	24.3mg	n.s.s.	13/30	10.0mg	9/30				
797	84a	24.7mg	n.s.s.	1/30	4.00mg	0/30			Radomski;txap,7,652-656;1965	
798	c00464	14.2mg	n.s.s.	10/20	8.80mg	29/50	18.4mg	32/50		
a	c00464	n.s.s.	n.s.s.	0/20	8.80mg	0/50	18.4mg	0/50		liv:hpa,hpc,nnnd.
799	21	62.6mg	n.s.s.	0/30	8.00mg	0/30			Deichmann;txap,11,88-103;1967	
a	21	37.8mg	n.s.s.	1/30	8.00mg	1/30				
800	84a	19.8mg	n.s.s.	0/30	3.20mg	0/30			Radomski;txap,7,652-656;1965	
801	1457	.148mg	n.s.s.	0/6	.360mg	0/6			Cameron;bmj1,2,819-821;1951	
802	1178	74.0mg	552.mg	0/38	6.25mg	2/30	12.5mg	4/30	25.0mg	7/38
a	1178	47.0mg	n.s.s.	32/38	6.25mg	26/30	12.5mg	27/30	25.0mg	27/38
803	1178	174.mg	n.s.s.	1/38	5.00mg	0/30	10.0mg	1/30	20.0mg	2/38
a	1178	24.5mg	n.s.s.	20/38	5.00mg	19/30	10.0mg	18/30	20.0mg	25/38
804	85	31.1mg	122.mg	0/32	25.0mg	15/34			Rossi;ijcn,19,179-185;1977	
a	85	29.5mg	n.s.s.	19/35	25.0mg	23/35				
805	85	43.5mg	272.mg	0/35	20.0mg	9/36				
a	85	42.6mg	n.s.s.	19/36	20.0mg	19/37				

Spe	Strain	Site	Xpo+Xpt	Notes	TD50	2Tailpvl
Sex	Route	Hist			DR	AuOp
DESERPIDINE 100ng...1ug...10...100...1mg...10...100...1g...10						
806	R b wis	eat mix	mix	78w78 r	>	1.28mg P<.6 -
N-1-DIACETAMIDOFLOURENE 100ng...1ug...10...100...1mg...10...100...1g...10						
807	R f buf	eat pit	ade	53w93 e	.	8.63mg P<.03
a	R f buf	eat mgl	adc	53w93 e	.	19.0mg P<.03 +
b	R f buf	eat liv	hem	53w93 e	.	61.2mg P<.3
c	R f buf	eat edu	sqc	53w93 e	.	61.2mg P<.3 +
DIALLATE 100ng...1ug...10...100...1mg...10...100...1g...10						
808	M f b6a	orl liv	hpt	85w85 evx	.	516.mg P<.3
a	M f b6a	orl lun	ade	85w85 evx	.	4.26gm P<.1.
b	M f b6a	orl tba	mix	85w85 evx	.	1.99gm P<.9
809	M m b6a	orl liv	hpt	84w84 evx	.	43.0mg P<.002 +
a	M m b6a	orl lun	ade	84w84 evx	.	243.mg P<.4
b	M m b6a	orl tba	mix	84w84 evx	.	35.4mg P<.003
810	M f b6c	orl liv	mix	83w83 evx	.	164.mg P<.04
a	M f b6c	orl lun	ade	83w83 evx	.	255.mg P<.09
b	M f b6c	orl tba	mix	83w83 evx	.	90.8mg P<.006
811	M m b6c	orl liv	hpt	84w84 evx	.	19.4mg P<.0005+
a	M m b6c	orl lun	ade	84w84 evx	.	113.mg P<.02
b	M m b6c	orl tba	mix	84w84 evx	.	15.6mg P<.0005
4,6-DIAMINO-2-(5-NITRO-2-FURYL)-s-TRIAZINE 1ug...10...100...1mg...10...100...1g...10						
812	R f sda	eat mgl	mix	46w66 e	.	1.71mg P<.0005+
a	R f sda	eat mgl	adc	46w66 e	.	4.49mg P<.0005
b	R f sda	eat liv	tum	46w66 e	.	no dre P=1.
c	R f sda	eat tba	mix	46w66 e	.	1.71mg P<.0005
2,4-DIAMINODANISOLE SULFATE 100ng...1ug...10...100...1mg...10...100...1g...10						
813	M f b6c	eat ---	lym	78w96	.	262.mg \ P<.005
a	M f b6c	eat thy	MXA	78w96	.	1.06gm / P<.0005c
b	M f b6c	eat thy	fca	78w96	.	1.45gm * P<.002 c
c	M f b6c	eat TBA	MXB	78w96	.	311.mg * P<.02
d	M f b6c	eat liv	MXB	78w96	.	7.35gm * P<.6
e	M f b6c	eat lun	MXB	78w96	.	10.9gm * P<.9
814	M m b6c	eat thy	fca	78w96	.	791.mg / P<.0005c
a	M m b6c	eat TBA	MXB	78w96	.	354.mg * P<.04
b	M m b6c	eat liv	MXB	78w96	.	926.mg * P<.2
c	M m b6c	eat lun	MXB	78w96	.	2.56gm / P<.5
815	R f f34	eat MXB	MXB	18m25 v	.	301.mg * P<.0005
a	R f f34	eat MXA	MXA	18m25 v	.	408.mg * P<.0005
b	R f f34	eat cli	MXA	18m25 v	.	416.mg * P<.003
c	R f f34	eat thy	MXA	18m25 v	.	425.mg * P<.0005c
d	R f f34	eat zym	sec	18m25 v	.	665.mg * P<.0005c
e	R f f34	eat TBA	MXB	18m25 v	.	181.mg * P<.09
f	R f f34	eat liv	MXB	18m25 v	.	14.5gm * P<.8
816	R f f34	eat cli	mix	83w86 ae	.	113.mg Z P<.0005+
a	R f f34	eat cli	ssc	83w86 ae	.	162.mg Z P<.0005+
b	R f f34	eat thy	mix	83w86 ae	.	162.mg Z P<.0005+
c	R f f34	eat thy	fca	83w86 ae	.	296.mg Z P<.0005
d	R f f34	eat mgl	mix	83w86 ae	.	1.29gm * P<.5 +
e	R f f34	eat tba	mix	83w86 ae	.	67.3mg * P<.0005
817	R m f34	eat MXB	MXB	18m25 v	.	72.6mg * P<.0005
a	R m f34	eat thy	MXA	18m25 v	.	192.mg * P<.0005c
b	R m f34	eat thy	scn	18m25 v	.	252.mg * P<.0005c
c	R m f34	eat thy	MXA	18m25 v	.	319.mg * P<.0005c
d	R m f34	eat pre	MXA	18m25 v	.	351.mg * P<.0005c
e	R m f34	eat ski	MXA	18m25 v	.	358.mg * P<.0005c
f	R m f34	eat pre	MXA	18m25 v	.	530.mg * P<.002 c
g	R m f34	eat MXA	MXA	18m25 v	.	709.mg * P<.0005c
h	R m f34	eat TBA	MXB	18m25 v	.	135.mg * P<.03
i	R m f34	eat liv	MXB	18m25 v	.	1.61gm * P<.3
2,4-DIAMINOTOLUENE 100ng...1ug...10...100...1mg...10...100...1g...10						
818	M f b6c	eat MXB	MXB	23m23	.	7.18mg \ P<.002
a	M f b6c	eat ---	MXA	23m23	.	10.6mg \ P<.004 a
b	M f b6c	eat liv	hpc	23m23	.	26.7mg * P<.002 c
c	M f b6c	eat TBA	MXB	23m23	.	8.64mg \ P<.01
d	M f b6c	eat liv	MXB	23m23	.	26.7mg * P<.002
e	M f b6c	eat lun	MXB	23m23	.	no dre P=1.
819	M m b6c	eat lun	a/c	23m23	.	#35.8mg \ P<.02 -
a	M m b6c	eat TBA	MXB	23m23	.	105.mg * P<.7
b	M m b6c	eat liv	MXB	23m23	.	no dre P=1.
c	M m b6c	eat lun	MXB	23m23	.	35.8mg \ P<.02
820	R f f34	eat MXB	MXB	22m24 asv	.	1.43mg / P<.0005
a	R f f34	eat mgl	ade	22m24 asv	.	1.46mg * P<.0005c
b	R f f34	eat mgl	MXA	22m24 asv	.	5.54mg * P<.0005c

RefNum	LoConf	UpConf	Cntrl	1Dose	1Inc	2Dose	2Inc	Citation or Pathology	Brkly Code
DESERPIDINE 131-01-1									
806	1188	.272mg	n.s.s.	17/130	100.ug	36/230		Tuchmann-Duplessis;adsc,254,1535-1537;1962	
N-1-DIACETAMIDOFLOURENE ---									
807	144	3.14mg	n.s.s.	2/18	7.21mg	7/16		Morris;jnci,24,149-180;1960	
a	144	5.74mg	n.s.s.	0/18	7.21mg	3/16			
b	144	9.96mg	n.s.s.	0/18	7.21mg	1/16			
c	144	9.96mg	n.s.s.	0/18	7.21mg	1/16			
DIALATE (Avadex) 2303-16-4									
808	1219	84.0mg	n.s.s.	0/17	77.8mg	1/15		Innes;ntis,1968/1969	
a	1219	94.1mg	n.s.s.	1/17	77.8mg	1/15			
b	1219	73.2mg	n.s.s.	2/17	77.8mg	2/15			
809	1219	19.5mg	172.mg	1/18	72.5mg	10/18			
a	1219	50.7mg	n.s.s.	2/18	72.5mg	4/18			
b	1219	15.6mg	210.mg	3/18	72.5mg	12/18			
810	1219	49.4mg	n.s.s.	0/16	77.9mg	3/16			
a	1219	62.5mg	n.s.s.	0/16	77.9mg	2/16			
b	1219	34.1mg	898.mg	0/16	77.9mg	5/16			
811	1219	9.11mg	46.4mg	0/16	72.5mg	13/16			
a	1219	38.7mg	n.s.s.	0/16	72.5mg	4/16			
b	1219	7.03mg	37.3mg	0/16	72.5mg	14/16			
4,6-DIAMINO-2-(5-NITRO-2-FURYL)-S-TRIAZINE 720-69-4									
812	200a	.895mg	3.23mg	2/39	17.4mg	33/35		Cohen;jnci,51,403-417;1973	
a	200a	2.66mg	8.28mg	0/39	17.4mg	23/35			
b	200a	50.6mg	n.s.s.	0/39	17.4mg	0/35			
c	200a	.895mg	3.23mg	2/39	17.4mg	33/35			
2,4-DIAMINODANISOLE SULFATE (NCI uses CAS# 615-05-4) 39156-41-7									
813	c01989	116.mg	2.51gm	7/100	126.mg	14/50	(253.mg 9/50)		S
a	c01989	480.mg	3.18gm	0/100	126.mg	0/50	253.mg 8/50	thy:fca,fcc.	
b	c01989	591.mg	5.87gm	0/100	126.mg	0/50	253.mg 6/50		
c	c01989	145.mg	n.s.s.	30/100	126.mg	25/50	253.mg 30/50		
d	c01989	1.03gm	n.s.s.	2/100	126.mg	1/50	253.mg 2/50	liv:hpa,hpc,nnd.	
e	c01989	716.mg	n.s.s.	7/100	126.mg	5/50	253.mg 4/50	lun:a/a,a/c.	
814	c01989	383.mg	2.47gm	1/100	116.mg	0/50	234.mg 11/50		
a	c01989	148.mg	n.s.s.	39/100	116.mg	24/50	234.mg 33/50	liv:hpa,hpc,nnd.	
b	c01989	296.mg	n.s.s.	15/100	116.mg	14/50	234.mg 12/50	lun:a/a,a/c.	
c	c01989	480.mg	n.s.s.	16/100	116.mg	3/50	234.mg 12/50		
815	c01989	155.mg	785.mg	3/100	44.0mg	1/50	182.mg 14/50	thy:acn,fcc,pcn; zym:sec. C	
a	c01989	191.mg	1.11gm	0/100	44.0mg	4/50	182.mg 5/50	cli:can; utm:acn,can,ppc. S	
b	c01989	184.mg	2.88gm	3/100	44.0mg	5/50	182.mg 8/50	cli:adn,can,cyn,sgc,sgp. S	
c	c01989	195.mg	1.62gm	3/100	44.0mg	1/50	182.mg 10/50	thy:acn,fcc,pcn.	
d	c01989	284.mg	2.08gm	0/100	44.0mg	0/50	182.mg 7/50		
e	c01989	65.1mg	n.s.s.	70/100	44.0mg	44/50	182.mg 37/50		
f	c01989	773.mg	n.s.s.	2/100	44.0mg	0/50	182.mg 1/50	liv:hpa,hpc,nnd.	
816	1027	68.8mg	206.mg	0/37	60.0mg	8/47	120.mg 15/33 (250.mg 9/40)	Evarts;jnci,65,197-204;1980	
a	1027	91.4mg	266.mg	0/37	60.0mg	5/47	120.mg 12/33 (250.mg 9/40)		
b	1027	107.mg	267.mg	1/37	60.0mg	2/47	120.mg 3/33 250.mg 31/40		
c	1027	178.mg	545.mg	0/37	60.0mg	0/47	120.mg 1/33 250.mg 21/40		
d	1027	297.mg	n.s.s.	2/37	60.0mg	7/47	120.mg 8/33 250.mg 5/40		
e	1027	47.3mg	103.mg	3/37	60.0mg	14/47	120.mg 19/33 250.mg 36/40		
817	c01989	48.0mg	123.mg	4/99	35.2mg	11/50	146.mg 36/50	eac:sec,sgc; ear:sgc; pre:adn,can,cyn,ppa; ski:bcc,sec;	
								thy:acn,ccr,fcc,pac,pcn; zym:sec. C	
a	c01989	107.mg	430.mg	2/99	35.2mg	2/50	146.mg 17/50	thy:acn,fcc,pac,pcn.	
b	c01989	131.mg	648.mg	2/99	35.2mg	1/50	146.mg 14/50		
c	c01989	154.mg	1.27gm	2/99	35.2mg	4/50	146.mg 10/50	thy:cca,ccr.	
d	c01989	171.mg	954.mg	0/99	35.2mg	2/50	146.mg 8/50	pre:adn,can,cyn,ppa.	
e	c01989	177.mg	875.mg	0/99	35.2mg	2/50	146.mg 9/50	ski:bcc,sec,sgc.	
f	c01989	228.mg	2.44gm	0/99	35.2mg	2/50	146.mg 5/50	pre:adn,cyn,ppa.	
g	c01989	305.mg	2.51gm	0/99	35.2mg	1/50	146.mg 6/50	eac:sec,sgc; ear:sgc; zym:sec.	
h	c01989	57.5mg	n.s.s.	52/99	35.2mg	35/50	146.mg 41/50		
i	c01989	356.mg	n.s.s.	1/99	35.2mg	2/50	146.mg 2/50	liv:hpa,hpc,nnd.	
2,4-DIAMINOTOLUENE 95-80-7									
818	c02302	4.32mg	24.3mg	2/20	13.0mg	36/50	(26.0mg 24/50)	---:leu,lym; liv:hpc. T	
a	c02302	5.93mg	75.5mg	2/20	13.0mg	29/50	(26.0mg 11/50)	---:leu,lym.	
b	c02302	17.3mg	99.8mg	0/20	13.0mg	13/50	26.0mg 18/50		
c	c02302	4.52mg	629.mg	5/20	13.0mg	40/50	(26.0mg 26/50)		
d	c02302	17.3mg	99.8mg	0/20	13.0mg	13/50	26.0mg 18/50	liv:hpa,hpc,nnd.	
e	c02302	134.mg	n.s.s.	0/20	13.0mg	2/50	26.0mg 0/50	lun:a/a,a/c.	
819	c02302	16.9mg	n.s.s.	0/20	12.0mg	9/50	(24.0mg 6/50)		S
a	c02302	17.4mg	n.s.s.	10/20	12.0mg	31/50	24.0mg 30/50		
b	c02302	34.9mg	n.s.s.	5/20	12.0mg	17/50	24.0mg 13/50	liv:hpa,hpc,nnd.	
c	c02302	16.9mg	n.s.s.	0/20	12.0mg	9/50	(24.0mg 6/50)	lun:a/a,a/c.	
820	c02302	.984mg	2.24mg	1/20	3.95mg	34/50	8.55mg 41/50	liv:hpc,nnd; mgl:ade,ade,car. C	
a	c02302	1.00mg	2.33mg	1/20	3.95mg	34/50	8.55mg 38/50		
b	c02302	3.14mg	11.5mg	0/20	3.95mg	11/50	8.55mg 14/50	mgl:ade,car.	

Spe	Strain	Site	Xpo+Xpt	Notes	TD50	2Tailpvt
Sex	Route	Hist			DR	AuOp
c	R f f34 eat	mgl car	22m24	asv	8.98mg	* P<.002
d	R f f34 eat	sub fib	22m24	asv	16.4mg	* P<.002
e	R f f34 eat	liv MXA	22m24	asv	58.0mg	* P<.02 c
f	R f f34 eat	TBA MXB	22m24	asv	1.46mg	/ P<.0005
g	R f f34 eat	liv MXB	22m24	asv	58.0mg	* P<.02
821	R m f34 eat	sub fib	21m24	asv	2.52mg	/ P<.0005
a	R m f34 eat	--- mso	21m24	asv	6.81mg	/ P<.0005
b	R m f34 eat	liv MXA	21m24	asv	8.11mg	/ P<.0005c
c	R m f34 eat	sub lip	21m24	asv	13.2mg	* P<.002
d	R m f34 eat	TBA MXB	21m24	asv	.991mg	/ P<.0005
e	R m f34 eat	liv MXB	21m24	asv	8.11mg	/ P<.0005
2,4-DIAMINOTOLUENE.2HCL					100ng...1ug.....10.....100.....1mg.....10.....100.....1g.....10	
822	M f chi eat	lun mix	77w90		72.0mg	\ P<.007 -
a	M f chi eat	liv mix	77w90		180. mg	* P<.09
b	M f chi eat	tba mix	77w90		100. mg	\ P<.4
823	M f chi eat	liv hpt	77w90	pool	206. mg	* P<.006 +
824	M m chi eat	liv mix	77w90		191. mg	* P<.2
a	M m chi eat	lun mix	77w90		no dre	P=1. -
b	M m chi eat	tba mix	77w90		no dre	P=1. -
825	M m chi eat	liv hpt	77w90	pool	201. mg	* P<.1 +
a	M m chi eat	--- vac	77w90		317. mg	* P<.2 +
826	R m cdr eat	sub fib	64w73	av	5.42mg	/ P<.0005+
a	R m cdr eat	liv mix	64w73	av	26.2mg	* P<.02
b	R m cdr eat	tba mix	64w73	av	2.98mg	/ P<.0005
827	R m cdr eat	sub fib	64w73	av pool	4.42mg	/ P<.0005+
a	R m cdr eat	liv hpt	64w73	av	22.2mg	* P<.003 +
2,5-DIAMINOTOLUENE SULFATE					100ng...1ug.....10.....100.....1mg.....10.....100.....1g.....10	
828	M f b6c eat	lun MXA	78w94		#364. mg	* P<.03 -
a	M f b6c eat	TBA MXB	78w94		33.2gm	* P<.1
b	M f b6c eat	liv MXB	78w94		1.96gm	* P<.6
c	M f b6c eat	lun MXB	78w94		364. mg	* P<.03
829	M m b6c eat	TBA MXB	78w94		272. mg	* P<.3 -
a	M m b6c eat	liv MXB	78w94		288. mg	/ P<.06
b	M m b6c eat	lun MXB	78w94		3.56gm	* P<.9
830	R f f34 eat	TBA MXB	18m25	v	no dre	P=1. -
a	R f f34 eat	liv MXB	18m25	v	no dre	P=1. -
831	R m f34 eat	TBA MXB	18m25	v	no dre	P=1. -
a	R m f34 eat	liv MXB	18m25	v	233. mg	\ P<.09
DIAZINON					100ng...1ug.....10.....100.....1mg.....10.....100.....1g.....10	
832	M f b6c eat	TBA MXB	24m24		230. mg	* P<.7 -
a	M f b6c eat	liv MXB	24m24		no dre	P=1. -
b	M f b6c eat	lun MXB	24m24		6.23gm	* P<.1
833	M m b6c eat	TBA MXB	24m24		no dre	P=1. -
a	M m b6c eat	liv MXB	24m24		26.8mg	\ P<.2
b	M m b6c eat	lun MXB	24m24		no dre	P=1. -
834	R f f34 eat	TBA MXB	24m24		51.3mg	* P<.4 -
a	R f f34 eat	liv MXB	24m24		no dre	P=1. -
835	R m f34 eat	--- MXA	24m24		#20.4mg	\ P<.03 -
a	R m f34 eat	TBA MXB	24m24		53.4mg	\ P<.7
b	R m f34 eat	liv MXB	24m24		no dre	P=1. -
DIBENZ(a,h)ANTHRACENE					100ng...1ug.....10.....100.....1mg.....10.....100.....1g.....10	
836	M m dba eat	lun alc	60w60		5.88mg	P<.0005+
DIBENZO-p-DIOXIN					100ng...1ug.....10.....100.....1mg.....10.....100.....1g.....10	
837	M f b6c eat	TBA MXB	90w91	s	no dre	P=1. -
a	M f b6c eat	liv MXB	90w91	s	no dre	P=1. -
b	M f b6c eat	lun MXB	90w91	s	8.09gm	* P<.2
838	M m b6c eat	lun a/c	88w92	as	#2.84gm	\ P<.01 -
a	M m b6c eat	TBA MXB	88w92	as	no dre	P=1. -
b	M m b6c eat	liv MXB	88w92	as	no dre	P=1. -
c	M m b6c eat	lun MXB	88w92	as	no dre	P=1. -
839	R f oas eat	TBA MXB	26m26	s	no dre	P=1. -
a	R f oas eat	liv MXB	26m26	s	5.37gm	* P<.08
840	R m oas eat	TBA MXB	26m26		no dre	P=1. -
a	R m oas eat	liv MXB	26m26		no dre	P=1. -
3-DIBENZOFURANAMINE					100ng...1ug.....10.....100.....1mg.....10.....100.....1g.....10	
841	R m wis eat	liv hpt	89w89	e	9.44mg	P<.3
a	R m wis eat	tba ben	89w89	e	1.57mg	P<.06
b	R m wis eat	tba mal	89w89	e	2.48mg	P<.02 +
1,2-DIBROMO-3-CHLOROPROPANE					100ng...1ug.....10.....100.....1mg.....10.....100.....1g.....10	
842	M f b6c gav	sto sqc	53w59	av	4.29mg	/ P<.0005c
a	M f b6c gav	TBA MXB	53w59	av	4.29mg	/ P<.0005
b	M f b6c gav	liv MXB	53w59	av	1.42gm	* P<.3
c	M f b6c gav	lun MXB	53w59	av	150. mg	* P<.04

RefNum	LoConf	UpConf	Cntrl	1Dose	1Inc	2Dose	2Inc	Citation or Pathology	Brkly Code	
c	c02302	4.53mg	32.3mg	0/20	3.95mg	9/50	8.55mg	8/50		S
d	c02302	7.85mg	55.9mg	0/20	3.95mg	4/50	8.55mg	10/50		S
e	c02302	23.6mg	n.s.s.	0/20	3.95mg	0/50	8.55mg	6/50		S
f	c02302	.918mg	2.96mg	13/20	3.95mg	49/50	8.55mg	49/50	liv:hpc, nnd.	
g	c02302	23.6mg	n.s.s.	0/20	3.95mg	0/50	8.55mg	6/50	liv:hpa, hpc, nnd.	
821	c02302	1.50mg	4.48mg	0/20	3.20mg	15/50	7.00mg	19/50		S
a	c02302	3.13mg	18.9mg	0/20	3.20mg	5/50	7.00mg	8/50		S
b	c02302	3.81mg	21.2mg	0/20	3.20mg	5/50	7.00mg	10/50	liv:hpc, nnd.	
c	c02302	5.48mg	49.3mg	0/20	3.20mg	3/50	7.00mg	8/50		S
d	c02302	.627mg	1.85mg	13/20	3.20mg	42/50	7.00mg	44/50		S
e	c02302	3.81mg	21.2mg	0/20	3.20mg	5/50	7.00mg	10/50	liv:hpa, hpc, nnd.	
2,4-DIAMINOTOLUENE, 2HCL (2,4-toluenediamine, 2HCL) 636-23-7										
822	381	29.3mg	894.mg	5/22	58.5mg	6/19	(111.mg	2/17)	Waisburger; jept, 2,325-356; 1978/pers.com./Russfield 1973	
a	381	58.7mg	n.s.s.	1/22	58.5mg	1/19	111.mg	5/17		
b	381	24.6mg	n.s.s.	18/22	58.5mg	12/19	(111.mg	10/17)		
823	381	65.9mg	3.37gm	1/102p	58.5mg	1/19	111.mg	3/17		
824	381	54.2mg	n.s.s.	1/18	54.0mg	2/22	103.mg	4/17		
a	381	118.mg	n.s.s.	8/18	54.0mg	1/22	(103.mg	2/17)		
b	381	45.1mg	n.s.s.	13/18	54.0mg	7/22	103.mg	11/17		
825	381	54.8mg	n.s.s.	7/99p	54.0mg	2/22	103.mg	4/17		
a	381	76.7mg	n.s.s.	5/99p	54.0mg	0/22	103.mg	4/17		
826	381	2.81mg	10.7mg	0/24	12.4mg	6/19	25.7mg	15/24		
a	381	6.43mg	n.s.s.	0/24	12.4mg	1/19	25.7mg	3/24		
b	381	1.58mg	7.35mg	7/24	12.4mg	12/19	25.7mg	20/24		
827	381	2.27mg	10.2mg	14/111p	12.4mg	6/19	25.7mg	15/24		
a	381	5.70mg	263.mg	2/111p	12.4mg	1/19	25.7mg	3/24		
2,5-DIAMINOTOLUENE SULFATE (2,5-toluenediamine sulfata) 6369-59-1										
828	c01832	152.mg	n.s.s.	5/100	64.7mg	6/50	104.mg	8/50		Lun:a/a,e/c. S
a	c01832	128.mg	n.s.s.	42/100	64.7mg	15/50	104.mg	22/50		
b	c01832	307.mg	n.s.s.	5/100	64.7mg	2/50	104.mg	4/50	liv:hpa, hpc, nnd.	
c	c01832	152.mg	n.s.s.	5/100	64.7mg	6/50	104.mg	8/50	Lun:a/a,e/c.	
829	c01832	83.9mg	n.s.s.	38/100	59.8mg	19/50	96.5mg	27/50		
a	c01832	113.mg	n.s.s.	17/100	59.8mg	8/50	96.5mg	18/50	liv:hpa, hpc, nnd.	
b	c01832	211.mg	n.s.s.	17/100	59.8mg	6/50	96.5mg	10/50	Lun:a/a,e/c.	
830	c01832	27.0mg	n.s.s.	51/75	21.9mg	34/50	(71.6mg	33/50)		
a	c01832	520.mg	n.s.s.	4/75	21.9mg	1/50	71.6mg	1/50	liv:hpa, hpc, nnd.	
831	c01832	102.mg	n.s.s.	36/75	17.1mg	20/50	57.8mg	25/50		
a	c01832	57.1mg	n.s.s.	0/75	17.1mg	2/50	(57.8mg	0/50)	liv:hpa, hpc, nnd.	
DIAZINON 333-41-5										
832	c08673	33.4mg	n.s.s.	9/25	12.7mg	14/50	25.5mg	21/50		
a	c08673	143.mg	n.s.s.	2/25	12.7mg	0/50	25.5mg	3/50	liv:hpa, hpc, nnd.	
b	c08673	139.mg	n.s.s.	1/25	12.7mg	1/50	25.5mg	2/50	Lun:a/a,e/c.	
833	c08673	29.6mg	n.s.s.	12/25	11.8mg	30/50	23.5mg	24/50		
a	c08673	9.56mg	n.s.s.	5/25	11.8mg	20/50	(23.5mg	13/50)	liv:hpa, hpc, nnd.	
b	c08673	126.mg	n.s.s.	2/25	11.8mg	3/50	23.5mg	1/50	Lun:a/a,e/c.	
834	c08673	14.7mg	n.s.s.	20/25	19.8mg	44/50	39.6mg	41/50		
a	c08673	231.mg	n.s.s.	1/25	19.8mg	1/50	39.6mg	0/50	liv:hpa, hpc, nnd.	
835	c08673	9.49mg	n.s.s.	5/25	15.7mg	25/50	(31.4mg	12/50)	---:lou,lym. S	
a	c08673	7.64mg	n.s.s.	20/25	15.7mg	41/50	(31.4mg	33/50)		
b	c08673	203.mg	n.s.s.	1/25	15.7mg	2/50	31.4mg	0/50	liv:hpa, hpc, nnd.	
DIBENZ(a,h)ANTHRACENE 53-70-3										
836	1128	3.03mg	13.2mg	0/25	28.3mg	14/21			Snell; jnci, 28, 1043-1051; 1962	
DIBENZO-p-DIOXIN 262-12-4										
837	c03656	1.74gm	n.s.s.	15/50	636.mg	12/50	1.29gm	9/50		
a	c03656	n.s.s.	n.s.s.	0/50	636.mg	1/50	1.29gm	0/50	liv:hpa, hpc, nnd.	
b	c03656	2.28gm	n.s.s.	3/50	636.mg	2/50	1.29gm	5/50	Lun:a/a,e/c.	
838	c03656	1.08gm	289.gm	0/50	557.mg	5/50	(1.12gm	1/50)		S
a	c03656	1.67gm	n.s.s.	19/50	557.mg	19/50	1.12gm	16/50		
b	c03656	3.33gm	n.s.s.	8/50	557.mg	8/50	1.12gm	5/50	liv:hpa, hpc, nnd.	
c	c03656	2.58gm	n.s.s.	8/50	557.mg	11/50	1.12gm	6/50	Lun:a/a,e/c.	
839	c03656	500.mg	n.s.s.	26/35	250.mg	19/35	500.mg	13/35		
a	c03656	1.32gm	n.s.s.	0/35	250.mg	0/35	500.mg	2/35	liv:hpa, hpc, nnd.	
840	c03656	1.13gm	n.s.s.	21/35	200.mg	11/35	400.mg	11/35		
a	c03656	3.52gm	n.s.s.	1/35	200.mg	0/35	400.mg	0/35	liv:hpa, hpc, nnd.	
3-DIBENZOFURANAMINE 4106-66-5										
841	1420	1.53mg	n.s.s.	0/6	3.43mg	1/6			Heckmann; zkk, 61, 45-54; 1956	
a	1420	.329mg	n.s.s.	0/3	3.43mg	2/3				
b	1420	.825mg	n.s.s.	0/6	3.43mg	4/8				
1,2-DIBROMO-3-CHLOROPROPANE (DBCP. NCI uses CAS# 1836-75-5. c00500 is the NCI TR# 28; c00501 is NCI/MTP TR# 206) 96-12-8										
842	c00500	2.79mg	6.57mg	0/20	79.0mg	50/50	149.mg	47/50		
a	c00500	2.79mg	6.57mg	0/20	79.0mg	50/50	149.mg	47/50		
b	c00500	231.mg	n.s.s.	0/20	79.0mg	0/50	149.mg	1/50	liv:hpa, hpc, nnd.	
c	c00500	29.4mg	n.s.s.	0/20	79.0mg	1/50	149.mg	2/50	Lun:a/a,e/c.	

	Spe	Strain	Site	Xpo+ Xpt	Notes		TD50	2Tailpvi
							DR	AuOp
843	M	f b6c inh	MXB MXB	21m24	a	: + :	1.28mg / P<.0005	
a	M	f b6c inh	MXA MXA	21m24	a		2.13mg / P<.0005c	
b	M	f b6c inh	MXA MXA	21m24	a		2.27mg / P<.0005c	
c	M	f b6c inh	Lun MXA	21m24	a		5.21mg / P<.0005c	
d	M	f b6c inh	nas can	21m24	a		6.49mg / P<.0005c	
e	M	f b6c inh	Lun a/a	21m24	a		7.89mg / P<.0005c	
f	M	f b6c inh	hag adn	21m24	a		8.21mg * P<.003	
g	M	f b6c inh	nas MXA	21m24	a		10.2mg * P<.0005c	
h	M	f b6c inh	nas acn	21m24	a		14.5mg * P<.0005c	
i	M	f b6c inh	nas sqc	21m24	a		19.0mg * P<.0005c	
j	M	f b6c inh	nas cas	21m24	a		40.0mg * P<.003 c	
k	M	f b6c inh	nas fbs	21m24	a		46.8mg * P<.003 c	
l	M	f b6c inh	l/b ppc	21m24	a		72.2mg * P<.02 a	
m	M	f b6c inh	TBA MXB	21m24	a		.945mg / P<.0005	
n	M	f b6c inh	Liv MXB	21m24	a		9.84mg * P<.02	
o	M	f b6c inh	Lun MXB	21m24	a		5.21mg / P<.0005	
844	M	m b6c gav	sto sqc	53w59	av	: + :	4.62mg / P<.0005c	
a	M	m b6c gav	TBA MXB	53w59	av		4.64mg / P<.0005	
b	M	m b6c gav	Liv MXB	53w59	av		no dre P=1.	
c	M	m b6c gav	Lun MXB	53w59	av		1.11gm * P<.3	
845	M	m b6c inh	MXB MXB	76w76		: + :	1.44mg * P<.0005	
a	M	m b6c inh	MXB MXB	76w76			1.44mg * P<.0005	
b	M	m b6c inh	MXA MXA	76w76			1.82mg * P<.0005c	
c	M	m b6c inh	MXB MXB	76w76			2.05mg * P<.0005	
d	M	m b6c inh	Lun --	76w76			2.48mg * P<.0005a	
e	M	m b6c inh	Lun MXA	76w76			3.95mg * P<.002 c	
f	M	m b6c inh	nas apn	76w76			4.75mg * P<.002 c	
g	M	m b6c inh	nas can	76w76			6.09mg * P<.0005c	
h	M	m b6c inh	nas sqc	76w76			7.05mg * P<.002 c	
i	M	m b6c inh	Lun a/a	76w76			7.38mg * P<.003 c	
j	M	m b6c inh	nas hes	76w76			16.3mg * P<.02 a	
k	M	m b6c inh	sto MXA	76w76			16.8mg * P<.02 a	
l	M	m b6c inh	sto sqp	76w76			21.5mg * P<.05 a	
m	M	m b6c inh	TBA MXB	76w76			1.32mg * P<.0005	
n	M	m b6c inh	Liv MXB	76w76			32.4mg * P<.7	
o	M	m b6c inh	Lun MXB	76w76			3.95mg * P<.002	
846	R	f f34 inh	MXB MXB	22m24	a	: + :	.199mg / P<.0005	
a	R	f f34 inh	MXA MXA	22m24	a		.252mg / P<.0005c	
b	R	f f34 inh	mgl --	22m24	a		.727mg / P<.0005	
c	R	f f34 inh	mgl fba	22m24	a		.896mg * P<.0005	
d	R	f f34 inh	nas sqp	22m24	a		.948mg * P<.0005c	
e	R	f f34 inh	adr coa	22m24	a		1.20mg * P<.0005c	
f	R	f f34 inh	nas adn	22m24	a		1.51mg * P<.0005c	
g	R	f f34 inh	nas apn	22m24	a		1.70mg * P<.0005c	
h	R	f f34 inh	ton MXA	22m24	a		1.80mg * P<.0005c	
i	R	f f34 inh	nas can	22m24	a		1.83mg / P<.0005c	
j	R	f f34 inh	ntu apn	22m24	a		2.08mg * P<.002	
k	R	f f34 inh	ton sqp	22m24	a		2.46mg * P<.0005c	
l	R	f f34 inh	nas sqc	22m24	a		2.90mg / P<.0005c	
m	R	f f34 inh	nas acn	22m24	a		3.53mg * P<.0005c	
n	R	f f34 inh	phr MXA	22m24	a		4.70mg / P<.0005c	
o	R	f f34 inh	phr sqp	22m24	a		5.86mg / P<.0005c	
p	R	f f34 inh	ton sqc	22m24	a		6.75mg * P<.003 c	
q	R	f f34 inh	TBA MXB	22m24	a		.164mg / P<.0005	
r	R	f f34 inh	Liv MXB	22m24	a		5.52mg * P<.4	
847	R	m f34 inh	MXB MXB	22m24	a	: + :	.106mg / P<.0005	
a	R	m f34 inh	MXA MXA	22m24	a		.107mg / P<.0005c	
b	R	m f34 inh	nas apn	22m24	a		.567mg * P<.0005c	
c	R	m f34 inh	nas adn	22m24	a		.837mg * P<.0005c	
d	R	m f34 inh	nas acn	22m24	a		.864mg * P<.0005c	
e	R	m f34 inh	ntu apn	22m24	a		.976mg * P<.002	
f	R	m f34 inh	nas sqp	22m24	a		.978mg * P<.0005c	
g	R	m f34 inh	nas can	22m24	a		1.15mg / P<.0005c	
h	R	m f34 inh	nas sqc	22m24	a		1.44mg / P<.0005c	
i	R	m f34 inh	ton MXA	22m24	a		2.08mg / P<.0005c	
j	R	m f34 inh	tnv aso	22m24	a		2.73mg * P<.002	
k	R	m f34 inh	ton sqp	22m24	a		2.75mg * P<.0005c	
l	R	m f34 inh	ski tri	22m24	a		3.25mg / P<.0005	
m	R	m f34 inh	tnv men	22m24	a		3.70mg * P<.0005	
n	R	m f34 inh	tnv men	22m24	a		3.70mg * P<.0005	
o	R	m f34 inh	ton sqc	22m24	a		9.14mg * P<.005 c	
p	R	m f34 inh	TBA MXB	22m24	a		.112mg / P<.0005	
q	R	m f34 inh	Liv MXB	22m24	a		5.65mg * P<.03	
848	R	f osm gav	MXB MXB	68w72	av	: + :	.855mg / P<.0005	
a	R	f osm gav	sto sqc	68w72	av		.909mg / P<.0005c	
b	R	f osm gav	mgl MXA	68w72	av		2.33mg / P<.0005c	

Spe	Strain	Site	Xpo+Xpt	Notes	TD50	2Tailpvl
Sex	Route	Hist			DR	AuOp
c	R f osm	gav	mgl acn	68w72 av		2.37mg * P<.0005c
d	R f osm	gav	sto sqp	68w72 av		30.1mg / P<.002 c
e	R f osm	gav	TBA MXB	68w72 av		.892mg / P<.0005
f	R f osm	gav	liv MXB	68w72 av		90.3mg * P<.4
849	R m osm	gav	sto sqc	71w83 av	: + :	.967mg / P<.0005c
a	R m osm	gav	--- MXA	71w83 av		4.23mg * P<.02
b	R m osm	gav	TBA MXB	71w83 av		.988mg / P<.0005
c	R m osm	gav	liv MXB	71w83 av		no dre P=1.
DIBROMODULCITOL				100ng...1ug...10...100...1mg...10...100...1g...10		
850	M f swi	ipj	lun mix	26w78 e		9.23mg * P<.003 +
a	M f swi	ipj	--- lys	26w78 e		12.2mg * P<.0005+
b	M f swi	ipj	--- leu	26w78 e		46.3mg * P<.006
c	M f swi	ipj	liv lys	26w78 e		no dre P=1.
d	M f swi	ipj	tba mix	26w78 e		2.45mg * P<.0005
e	M f swi	ipj	tba mal	26w78 e		4.75mg * P<.0005
f	M f swi	ipj	tba ben	26w78 e		24.5mg * P<.09
851	M m swi	ipj	--- lys	26w78 e	. + .	17.6mg * P<.002 +
a	M m swi	ipj	--- lyk	26w78 e		32.4mg * P<.002 +
b	M m swi	ipj	lun mix	26w78 e		13.5mg \ P<.05 +
c	M m swi	ipj	liv mix	26w78 e		no dre P=1.
d	M m swi	ipj	tba mix	26w78 e		12.7mg * P<.06
e	M m swi	ipj	tba mal	26w78 e		15.2mg * P<.04
f	M m swi	ipj	tba ben	26w78 e		no dre P=1.
852	R m cdr	ipj	ski mix	26w78 e	. + .	8.37mg * P<.0005+
a	R m cdr	ipj	per sar	26w78 e		59.2mg * P<.002
b	R m cdr	ipj	mgl sqc	26w78 e		182. mg * P<.04
c	R m cdr	ipj	--- lys	26w78 e		182. mg * P<.04
d	R m cdr	ipj	liv tum	26w78 e		no dre P=1.
e	R m cdr	ipj	tba mix	26w78 e		3.13mg * P<.0005
f	R m cdr	ipj	tba mal	26w78 e		5.05mg * P<.0005
g	R m cdr	ipj	tba ben	26w78 e		no dre P=1.
1,2-DIBROMOETHANE				100ng...1ug...10...100...1mg...10...100...1g...10		
853	M f b6c	gav	MXB MXB	53w78 av	:+ :	3.74mg * P<.0005
a	M f b6c	gav	sto sqc	53w78 av		4.07mg * P<.0005c
b	M f b6c	gav	lun MXA	53w78 av		15.4mg * P<.04 c
c	M f b6c	gav	lun a/a	53w78 av		17.3mg * P<.03 c
d	M f b6c	gav	TBA MXB	53w78 av		3.52mg * P<.0005
e	M f b6c	gav	liv MXB	53w78 av		no dre P=1.
f	M f b6c	gav	lun MXB	53w78 av		15.4mg * P<.04
854	M f b6c	inh	MXB MXB	22m24 s	:+ :	9.60mg / P<.0005
a	M f b6c	inh	lun MXA	22m24 s		18.4mg / P<.0005c
b	M f b6c	inh	lun MXA	22m24 s		18.7mg / P<.0005c
c	M f b6c	inh	--- MXA	22m24 s		24.1mg / P<.0005c
d	M f b6c	inh	--- hes	22m24 s		25.7mg / P<.0005c
e	M f b6c	inh	mgl acn	22m24 s		26.2mg * P<.0005c
f	M f b6c	inh	lun a/c	22m24 s		30.3mg / P<.0005c
g	M f b6c	inh	lun a/a	22m24 s		38.6mg / P<.0005c
h	M f b6c	inh	sub fbs	22m24 s		90.7mg * P<.0005c
i	M f b6c	inh	l/b MXA	22m24 s		169. mg * P<.0005
j	M f b6c	inh	nas ---	22m24 s		187. mg / P<.0005c
k	M f b6c	inh	--- hem	22m24 s		245. mg * P<.0005
l	M f b6c	inh	l/b can	22m24 s		259. mg * P<.002
m	M f b6c	inh	l/b MXA	22m24 s		272. mg / P<.0005
n	M f b6c	inh	nas MXA	22m24 s		337. mg * P<.0005c
o	M f b6c	inh	nas MXA	22m24 s		353. mg * P<.0005c
p	M f b6c	inh	l/b adn	22m24 s		361. mg * P<.0005
q	M f b6c	inh	nas can	22m24 s		443. mg * P<.0005c
r	M f b6c	inh	nas apn	22m24 s		470. mg * P<.004 c
s	M f b6c	inh	TBA MXB	22m24 s		6.83mg / P<.0005
t	M f b6c	inh	liv MXB	22m24 s		107. mg * P<.07
u	M f b6c	inh	lun MXB	22m24 s		18.7mg / P<.0005
855	M m b6c	gav	MXB MXB	53w78 eav	: + :	2.34mg * P<.0005
a	M m b6c	gav	sto MXA	53w78 eav		2.36mg * P<.0005c
b	M m b6c	gav	sto sqc	53w78 eav		2.38mg * P<.0005c
c	M m b6c	gav	lun a/a	53w78 eav		13.4mg * P<.003 c
d	M m b6c	gav	TBA MXB	53w78 eav		2.66mg * P<.0005
e	M m b6c	gav	liv MXB	53w78 eav		no dre P=1.
f	M m b6c	gav	lun MXB	53w78 eav		13.4mg * P<.003
856	M m b6c	inh	MXB MXB	78w78	: + :	18.0mg * P<.0005
a	M m b6c	inh	lun ---	78w78		18.2mg * P<.0005c
b	M m b6c	inh	lun MXA	78w78		21.0mg * P<.0005c
c	M m b6c	inh	lun a/c	78w78		24.7mg * P<.0005c
d	M m b6c	inh	lun a/a	78w78		60.1mg * P<.0005c
e	M m b6c	inh	l/b MXA	78w78		124. mg * P<.02
f	M m b6c	inh	MXA MXA	78w78		124. mg * P<.02
g	M m b6c	inh	--- MXA	78w78		200. mg * P<.03 c

Spe	Strain	Site	Xpo+Xpt					
Sex	Route	Hist	Notes					
h	M m b6c inh	L/b	apn	78w78				
i	M m b6c inh	TBA	MXB	78w78				
j	M m b6c inh	Liv	MXB	78w78				
k	M m b6c inh	Lun	MXB	78w78				
857	R f f34 inh	MXB	MXB	23m24	as			
a	R f f34 inh	nas	---	23m24	as			
b	R f f34 inh	mgl	fbn	23m24	as			
c	R f f34 inh	nas	acn	23m24	as			
d	R f f34 inh	pit	adn	23m24	as			
e	R f f34 inh	nas	adn	23m24	as			
f	R f f34 inh	nas	can	23m24	as			
g	R f f34 inh	nas	apn	23m24	as			
h	R f f34 inh	nas	sqc	23m24	as			
i	R f f34 inh	Liv	hpc	23m24	as			
j	R f f34 inh	Lun	MXA	23m24	as			
k	R f f34 inh	spl	hes	23m24	as			
l	R f f34 inh	---	hes	23m24	as			
m	R f f34 inh	Lun	a/c	23m24	as			
n	R f f34 inh	sub	MXA	23m24	as			
o	R f f34 inh	sub	fib	23m24	as			
p	R f f34 inh	mgl	acn	23m24	as			
q	R f f34 inh	TBA	MXB	23m24	as			
r	R f f34 inh	Liv	MXB	23m24	as			
858	R m f34 inh	MXB	MXB	22m24	as			
a	R m f34 inh	MXA	MXA	22m24	as			
b	R m f34 inh	nas	acn	22m24	as			
c	R m f34 inh	nas	apn	22m24	as			
d	R m f34 inh	tnv	mso	22m24	as			
e	R m f34 inh	tnv	men	22m24	as			
f	R m f34 inh	nas	adn	22m24	as			
g	R m f34 inh	pit	adn	22m24	as			
h	R m f34 inh	spl	hes	22m24	as			
i	R m f34 inh	nas	can	22m24	as			
j	R m f34 inh	mul	mnm	22m24	as			
k	R m f34 inh	sig	ser	22m24	as			
l	R m f34 inh	thy	MXA	22m24	as			
m	R m f34 inh	TBA	MXB	22m24	as			
n	R m f34 inh	Liv	MXB	22m24	as			
859	R f osm gav	MXB	MXB	50w61	ades			
a	R f osm gav	sto	sqc	50w61	ades			
b	R f osm gav	Liv	MXA	50w61	ades			
c	R f osm gav	Liv	hpc	50w61	ades			
d	R f osm gav	adr	MXA	50w61	ades			
e	R f osm gav	TBA	MXB	50w61	ades			
f	R f osm gav	Liv	MXB	50w61	ades			
860	R m osm gav	MXB	MXB	40w49	adsv			
a	R m osm gav	sto	sqc	40w49	adsv			
b	R m osm gav	---	hes	40w49	adsv			
c	R m osm gav	thy	MXA	40w49	adsv			
d	R m osm gav	TBA	MXB	40w49	adsv			
e	R m osm gav	Liv	MXB	40w49	adsv			
861	R f cdr inh	nas	tum	78w78	e			
a	R f cdr inh	nas	ben	78w78	e			
b	R f cdr inh	nas	mal	78w78	e			
c	R f cdr inh	mgl	car	78w78	e			
d	R f cdr inh	Liv	hpc	78w78	e			
e	R f cdr inh	spl	hes	78w78	e			
862	R m cdr inh	nas	tum	78w78	e			
a	R m cdr inh	nas	ben	78w78	e			
b	R m cdr inh	nas	mal	78w78	e			
c	R m cdr inh	spl	hes	78w78	e			
d	R m cdr inh	bra	mng	78w78	e			
e	R m cdr inh	Liv	hpc	78w78	e			

DIBROMOMANNITOL

100ng.....1ug.....10.....100.....1mg.....10.....100.....1g.....10

863	M f swi ipj	Lun	mix	26w78	e			
a	M f swi ipj	---	lys	26w78	e			
b	M f swi ipj	sub	car	26w78	e			
c	M f swi ipj	---	lyk	26w78	e			
d	M f swi ipj	adr	coe	26w78	e			
e	M f swi ipj	Liv	lys	26w78	e			
f	M f swi ipj	tba	mix	26w78	e			
g	M f swi ipj	tba	mal	26w78	e			
h	M f swi ipj	tba	ben	26w78	e			
864	M m swi ipj	Lun	mix	26w78	e			
a	M m swi ipj	Liv	mix	26w78	e			
b	M m swi ipj	tba	mix	26w78	e			
c	M m swi ipj	tba	mal	26w78	e			
d	M m swi ipj	tba	ben	26w78	e			

Spe	Strain	Site	Xpo + Xpt	Notes	TD50	2Tailpvl	AuOp
Sex	Route	Hist			DR		
865	R f cdr ipj	mgf adc	26w78 e	.	24.9mg	P<.003	+
a	R f cdr ipj	per sar	26w78 e	.	79.2mg	P<.004	+
b	R f cdr ipj	lun car	26w78 e	.	84.6mg	P<.03	
c	R f cdr ipj	liv tum	26w78 e	.	no dre	P=1.	
d	R f cdr ipj	tba mal	26w78 e	.	11.5mg	P<.002	
e	R f cdr ipj	tba mix	26w78 e	.	12.5mg	P<.08	
f	R f cdr ipj	tba ben	26w78 e	.	no dre	P=1.	
866	R m cdr ipj	per sar	26w78 e	.	30.9mg	P<.0005+	
a	R m cdr ipj	ski mix	26w78 e	.	103.mg	* P<.03	+
b	R m cdr ipj	mgf fba	26w78 e	.	255.mg	* P<.2	
c	R m cdr ipj	liv tum	26w78 e	.	no dre	P=1.	
d	R m cdr ipj	tba mix	26w78 e	.	7.95mg	\ P<.0005	
e	R m cdr ipj	tba ben	26w78 e	.	16.6mg	\ P<.003	
f	R m cdr ipj	tba mal	26w78 e	.	no dre	P=1.	
1,3-DIBUTYL-1-NITROSOUREA					100ng.....1ug.....10.....100.....1mg.....10.....100.....1g.....10		
867	R f don wat	mam fba	75w75 e	.	2.23mg	Z P<.0005	
a	R f don wat	mam mix	75w75 e	.	4.28mg	* P<.002	+
b	R f don wat	mgf adc	75w75 e	.	22.7mg	* P<.002	
c	R f don wat	ute mix	75w75 e	.	15.3mg	Z P<.03	
d	R f don wat	--- leu	75w75 e	.	32.0mg	* P<.06	+
e	R f don wat	liv ade	75w75 e	.	303.mg	* P<.6	
f	R f don wat	tba mix	75w75 e	.	2.67mg	* P<.0005	
DIBUTYLIN DIACETATE*					100ng.....1ug.....10.....100.....1mg.....10.....100.....1g.....10		
868	M f b6c eat	liv hpa	78w92 ev	.	#31.6mg	* P<.006	-
a	M f b6c eat	TBA MXB	78w92 ev	.	29.6mg	* P<.07	
b	M f b6c eat	liv MXB	78w92 ev	.	31.6mg	* P<.006	
c	M f b6c eat	lun MXB	78w92 ev	.	no dre	P=1.	
869	M m b6c eat	TBA MXB	78w92 v	.	178.mg	* P<.9	-
a	M m b6c eat	liv MXB	78w92 v	.	29.2mg	* P<.06	
b	M m b6c eat	lun MXB	78w92 v	.	no dre	P=1.	
870	R f f34 eat	TBA MXB	18m24 v	.	no dre	P=1.	
a	R f f34 eat	liv MXB	18m24 v	.	94.4mg	* P<.5	
871	R m f34 eat	TBA MXB	18m24 v	.	no dre	P=1.	-
a	R m f34 eat	liv MXB	18m24 v	.	no dre	P=1.	
2,3-DICHLORO-p-DIOXANE					100ng.....1ug.....10.....100.....1mg.....10.....100.....1g.....10		
872	M f hic ipj	lun ptm	64w64	.	7.04mg	P<.6	
alpha,beta-DICHLORO-beta-FORMYLACRYLIC ACID					1ug.....10.....100.....1mg.....10.....100.....1g.....10		
873	M f b6a orl	liv hpt	76w76 evx	.	no dre	P=1.	-
a	M f b6a orl	lun ade	76w76 evx	.	no dre	P=1.	-
b	M f b6a orl	tba mix	76w76 evx	.	no dre	P=1.	-
874	M m b6a orl	lun mix	76w76 evx	.	17.8mg	P<.4	-
a	M m b6a orl	liv hpt	76w76 evx	.	771.mg	P<.1	-
b	M m b6a orl	tba mix	76w76 evx	.	16.1mg	P<.4	-
875	M f b6c orl	liv hpt	76w76 evx	.	no dre	P=1.	-
a	M f b6c orl	lun mix	76w76 evx	.	no dre	P=1.	-
b	M f b6c orl	tba mix	76w76 evx	.	24.4mg	P<.2	-
876	M m b6c orl	liv hpt	76w76 evx	.	44.1mg	P<.3	-
a	M m b6c orl	lun ade	76w76 evx	.	44.1mg	P<.3	-
b	M m b6c orl	tba mix	76w76 evx	.	5.03mg	P<.002	-
3,4'-DICHLORO-2-METHYLACRYLANILIDE				1ug.....10.....100.....1mg.....10.....100.....1g.....10		
877	M f b6a orl	liv hpt	76w76 evx	.	no dre	P=1.	-
a	M f b6a orl	lun ade	76w76 evx	.	no dre	P=1.	-
b	M f b6a orl	tba mix	76w76 evx	.	no dre	P=1.	-
878	M m b6a orl	liv hpt	76w76 evx	.	27.1mg	P<.3	-
a	M m b6a orl	lun ade	76w76 evx	.	no dre	P=1.	-
b	M m b6a orl	tba mix	76w76 evx	.	49.1mg	P<.7	-
879	M f b6c orl	liv hpt	76w76 evx	.	no dre	P=1.	-
a	M f b6c orl	lun mix	76w76 evx	.	no dre	P=1.	-
b	M f b6c orl	tba tum	76w76 evx	.	no dre	P=1.	-
880	M m b6c orl	liv hpt	76w76 evx	.	15.2mg	P<.04	-
a	M m b6c orl	lun ade	76w76 evx	.	23.7mg	P<.09	-
b	M m b6c orl	tba mix	76w76 evx	.	5.39mg	P<.0005-	
2,3-DICHLORO-1,4-NAPHTHOQUINONE					100ng.....1ug.....10.....100.....1mg.....10.....100.....1g.....10		
881	M f b6a orl	liv hpt	76w76 evx	.	26.5mg	P<.3	-
a	M f b6a orl	lun ade	76w76 evx	.	no dre	P=1.	-
b	M f b6a orl	tba mix	76w76 evx	.	no dre	P=1.	-
882	M m b6a orl	liv hpt	76w76 evx	.	no dre	P=1.	-
a	M m b6a orl	lun ade	76w76 evx	.	no dre	P=1.	-
b	M m b6a orl	tba mix	76w76 evx	.	no dre	P=1.	-
883	M f b6c orl	liv hpt	76w76 evx	.	26.5mg	P<.3	-
a	M f b6c orl	lun ade	76w76 evx	.	no dre	P=1.	-
b	M f b6c orl	tba mix	76w76 evx	.	8.31mg	P<.05	-

	RefNum	LoConf	UpConf	Cntrl	1Dose	1Inc	2Dose	2Inc	Citation or Pathology	Brkly Code
865	1336n	9.35mg	232.mg	12/182	17.9mg	7/24				
a	1336n	19.5mg	1.19gm	0/182	17.9mg	2/24				
b	1336n	19.8mg	n.s.s.	1/182	17.9mg	2/24				
c	1336n	49.8mg	n.s.s.	0/182	17.9mg	0/24				
d	1336n	4.92mg	68.1mg	44/182	17.9mg	14/24				
e	1336n	3.95mg	n.s.s.	103/182	17.9mg	18/24				
f	1336n	27.8mg	n.s.s.	59/182	17.9mg	4/24				
866	1336n	11.7mg	129.mg	0/177	17.9mg	5/25 (53.0mg)	0/12)			
a	1336n	32.5mg	n.s.s.	4/177	17.9mg	4/25	53.0mg	1/12		
b	1336n	52.7mg	n.s.s.	1/177	17.9mg	2/25	53.0mg	0/12		
c	1336n	30.4mg	n.s.s.	0/177	17.9mg	0/25	53.0mg	0/12		
d	1336n	3.57mg	34.3mg	59/177	17.9mg	18/25 (53.0mg)	2/12)			
e	1336n	6.83mg	125.mg	27/177	17.9mg	11/25 (53.0mg)	1/12)			
f	1336n	44.3mg	n.s.s.	32/177	17.9mg	7/25	53.0mg	1/12		
1,3-DIBUTYL-1-NITROSOUREA				56654-52-5						
867	1216	1.31mg	4.93mg	5/25	5.71mg	21/26	11.4mg	19/24 (22.9mg)	11/19)	Ogiu;zkko,96,35-41;1980
a	1216	2.26mg	18.1mg	8/25	5.71mg	21/26	11.4mg	20/24	22.9mg	15/19
b	1216	11.7mg	86.6mg	0/25	5.71mg	1/26	11.4mg	7/24	22.9mg	4/19
c	1216	7.22mg	n.s.s.	0/25	5.71mg	6/26	11.4mg	3/24 (22.9mg)	2/19)	
d	1216	13.0mg	n.s.s.	1/25	5.71mg	3/26	11.4mg	5/24	22.9mg	4/19
e	1216	49.4mg	n.s.s.	0/25	5.71mg	0/26	11.4mg	1/24	22.9mg	0/19
f	1216	1.45mg	7.88mg	10/25	5.71mg	23/26	11.4mg	22/24	22.9mg	17/19
DIBUTYLIN DIACETATE*				1067-33-0						S
868	c02028	16.1mg	313.mg	1/20	8.30mg	4/50	16.8mg	12/50		
a	c02028	12.8mg	n.s.s.	3/20	8.30mg	12/50	16.8mg	13/50		
b	c02028	16.1mg	313.mg	1/20	8.30mg	4/50	16.8mg	12/50		liv:hpa,hpc,nnd.
c	c02028	69.4mg	n.s.s.	2/20	8.30mg	4/50	16.8mg	0/50		lun:s/a,s,e/c.
869	c02028	15.4mg	n.s.s.	6/20	7.70mg	19/50	15.5mg	16/50		
a	c02028	13.3mg	n.s.s.	2/20	7.70mg	11/50	15.5mg	15/50		liv:hpa,hpc,nnd.
b	c02028	47.6mg	n.s.s.	2/20	7.70mg	8/50	15.5mg	2/50		lun:s/a,s,e/c.
870	c02028	3.35mg	n.s.s.	12/19	2.50mg	26/50 (5.00mg)	13/50)			
a	c02028	23.2mg	n.s.s.	0/19	2.50mg	1/50	5.00mg	1/50		liv:hpa,hpc,nnd.
871	c02028	5.12mg	n.s.s.	8/20	2.00mg	20/50	4.00mg	11/50		
a	c02028	n.s.s.	n.s.s.	0/20	2.00mg	2/50	4.00mg	0/50		liv:hpa,hpc,nnd.
2,3-DICHLORO-p-DIOXANE				3883-43-0						
872	1143	1.11mg	n.s.s.	10/30	2.86mg	12/30				Van Duuren;jnci,53,695-700;1974
alpha,beta-DICHLORO-beta-FORMYLACRYLIC ACID (mucochloric acid)				87-56-9						
873	1296	15.5mg	n.s.s.	0/17	7.84mg	0/18				Innes;ntis,1968/1969
a	1296	15.5mg	n.s.s.	1/17	7.84mg	0/18				
b	1296	10.3mg	n.s.s.	2/17	7.84mg	1/18				
874	1296	3.89mg	n.s.s.	2/18	7.30mg	4/17				
a	1296	8.09mg	n.s.s.	1/18	7.30mg	1/17				
b	1296	3.43mg	n.s.s.	3/18	7.30mg	5/17				
875	1296	15.5mg	n.s.s.	0/16	7.84mg	0/18				
a	1296	15.5mg	n.s.s.	0/16	7.84mg	0/18				
b	1296	5.98mg	n.s.s.	0/16	7.84mg	2/18				
876	1296	7.17mg	n.s.s.	0/16	7.30mg	1/17				
a	1296	7.17mg	n.s.s.	0/16	7.30mg	1/17				
b	1296	2.14mg	19.3mg	0/16	7.30mg	7/17				
3,4'-DICHLORO-2-METHYLACRYLANILIDE (dicryl)				2164-09-2						
877	1279	18.6mg	n.s.s.	0/17	9.96mg	0/17				Innes;ntis,1968/1969
a	1279	18.6mg	n.s.s.	1/17	9.96mg	0/17				
b	1279	18.6mg	n.s.s.	2/17	9.96mg	0/17				
878	1279	6.05mg	n.s.s.	1/18	9.26mg	3/18				
a	1279	18.3mg	n.s.s.	2/18	9.26mg	0/18				
b	1279	5.75mg	n.s.s.	3/18	9.26mg	4/18				
879	1279	19.7mg	n.s.s.	0/16	9.96mg	0/18				
a	1279	19.7mg	n.s.s.	0/16	9.96mg	0/18				
b	1279	19.7mg	n.s.s.	0/16	9.96mg	0/18				
880	1279	4.58mg	n.s.s.	0/16	9.26mg	3/15				
a	1279	5.81mg	n.s.s.	0/16	9.26mg	2/15				
b	1279	2.28mg	18.9mg	0/16	9.26mg	7/15				
2,3-DICHLORO-1,4-NAPHTHOQUINONE (dichlone)				117-80-6						
881	1240	4.31mg	n.s.s.	0/17	4.14mg	1/18				Innes;ntis,1968/1969
a	1240	4.92mg	n.s.s.	1/17	4.14mg	1/18				
b	1240	3.91mg	n.s.s.	2/17	4.14mg	2/18				
882	1240	7.63mg	n.s.s.	1/18	3.85mg	0/18				
a	1240	7.63mg	n.s.s.	2/18	3.85mg	0/18				
b	1240	7.63mg	n.s.s.	3/18	3.85mg	0/18				
883	1240	4.31mg	n.s.s.	0/16	4.14mg	1/18				
a	1240	8.20mg	n.s.s.	0/16	4.14mg	0/18				
b	1240	2.51mg	n.s.s.	0/16	4.14mg	3/18				

Spe	Strain	Site	Xpo + Xpt	Notes	TD50	2Tailpvl	DR	AuOp
	Sex	Route	Hist					
884	M m	b6c orl	lun ade	76w76 evx		7.26mg	P<.04	-
a	M m	b6c orl	liv hpt	76w76 evx		23.2mg	P<.3	-
b	M m	b6c orl	tba mix	76w76 evx		3.24mg	P<.003	-
2,6-DICHLORO-4-NITROANILINE 100ng.....1ug.....10.....100.....1mg.....10.....100.....1g.....10								
885	M f	b6a orl	lun ade	76w76 evx		no dre	P=1.	-
a	M f	b6a orl	liv hpt	76w76 evx		no dre	P=1.	-
b	M f	b6a orl	tba mix	76w76 evx		182.mg	P<.3	-
886	M f	b6a orl	liv hpt	76w76 evx		no dre	P=1.	-
a	M f	b6a orl	lun ade	76w76 evx		no dre	P=1.	-
b	M f	b6a orl	tba mix	76w76 evx		no dre	P=1.	-
887	M m	b6a orl	liv hpt	76w76 evx		no dre	P=1.	-
a	M m	b6a orl	lun ade	76w76 evx		no dre	P=1.	-
b	M m	b6a orl	tba mix	76w76 evx		no dre	P=1.	-
888	M m	b6a orl	liv hpt	76w76 evx		471.mg	P<.6	-
a	M m	b6a orl	lun ade	76w76 evx		no dre	P=1.	-
b	M m	b6a orl	tba mix	76w76 evx		no dre	P=1.	-
889	M f	b6c orl	lun ade	76w76 evx		602.mg	P<.3	-
a	M f	b6c orl	liv hpt	76w76 evx		no dre	P=1.	-
b	M f	b6c orl	tba mix	76w76 evx		188.mg	P<.04	-
890	M f	b6c orl	lun ade	76w76 evx		506.mg	P<.3	-
a	M f	b6c orl	liv hpt	76w76 evx		no dre	P=1.	-
b	M f	b6c orl	tba mix	76w76 evx		114.mg	P<.02	-
891	M m	b6c orl	liv mix	76w76 evx		104.mg	P<.009	-
a	M m	b6c orl	lun ade	76w76 evx		594.mg	P<.3	-
b	M m	b6c orl	tba mix	76w76 evx		57.7mg	P<.0005	-
892	M m	b6c orl	liv agm	76w76 evx		499.mg	P<.3	-
a	M m	b6c orl	liv hpt	76w76 evx		499.mg	P<.3	-
b	M m	b6c orl	lun ade	76w76 evx		499.mg	P<.3	-
c	M m	b6c orl	tba mix	76w76 evx		156.mg	P<.05	-
3,3'-DICHLOROBENZIDINE 100ng.....1ug.....10.....100.....1mg.....10.....100.....1g.....10								
893	D f	beg cap	liv mix	86m86 ev		noTD50	P<.008	+
a	D f	beg cap	ubi mix	86m86 ev		noTD50	P<.008	+
b	D f	beg cap	tba mix	86m86 ev		noTD50	P<.6	-
894	R f	cdr eat	agl adc	69w69		18.3mg	P<.0005	+
a	R f	cdr eat	liv tum	69w69		no dre	P=1.	-
895	R m	cdr eat	zys sqc	69w69		60.1mg	P<.002	+
a	R m	cdr eat	agl adc	69w69		69.6mg	P<.002	+
b	R m	cdr eat	--- grl	69w69		66.2mg	P<.03	+
c	R m	cdr eat	liv tum	69w69		no dre	P=1.	-
trans-1,4-DICHLOROBUTENE-2 100ng.....1ug.....10.....100.....1mg.....10.....100.....1g.....10								
896	M f	hic ipj	abd ear	76w76		1.52mg	P<.1	+
2,7-DICHLORODIBENZO-p-DIOXIN 100ng.....1ug.....10.....100.....1mg.....10.....100.....1g.....10								
897	M f	b6c eat	TBA MXB	90w91		no dre	P=1.	-
a	M f	b6c eat	liv MXB	90w91		no dre	P=1.	-
b	M f	b6c eat	lun MXB	90w91		no dre	P=1.	-
898	M m	b6c eat	MXB MXB	90w92		640.mg \	P<.003	
a	M m	b6c eat	--- MXA	90w92		1.92gm \	P<.003	a
b	M m	b6c eat	--- MXA	90w92		2.75gm \	P<.01	a
c	M m	b6c eat	liv MXA	90w92		2.12gm *	P<.07	a
d	M m	b6c eat	TBA MXB	90w92		2.91gm *	P<.4	
e	M m	b6c eat	liv MXB	90w92		2.12gm *	P<.07	
f	M m	b6c eat	lun MXB	90w92		no dre	P=1.	-
899	R f	osm eat	TBA MXB	26m26		no dre	P=1.	-
a	R f	osm eat	liv MXB	26m26		no dre	P=1.	-
900	R m	osm eat	TBA MXB	26m26		no dre	P=1.	-
a	R m	osm eat	liv MXB	26m26		12.9gm *	P<.8	
1,1-DICHLOROETHANE 100ng.....1ug.....10.....100.....1mg.....10.....100.....1g.....10								
901	M f	b6c gav	TBA MXB	78w90		8.40gm /	P<.5	-
a	M f	b6c gav	liv MXB	78w90		no dre	P=1.	-
b	M f	b6c gav	lun MXB	78w90		no dre	P=1.	-
902	M f	b6c gav	ute esp	78w90	sv pool	11.2gm *	P<.004	a
903	M m	b6c gav	TBA MXB	78w90	esv	1.37gm *	P<.07	-
a	M m	b6c gav	liv MXB	78w90	esv	2.04gm *	P<.05	
b	M m	b6c gav	lun MXB	78w90	esv	7.32gm *	P<.04	
904	R f	osm gav	MXB MXB	18m26	dsv	535.mg *	P<.005	
a	R f	osm gav	agl adc	18m26	dsv	986.mg *	P<.04	a
b	R f	osm gav	--- hes	18m26	dsv	1.35gm *	P<.05	a
c	R f	osm gav	TBA MXB	18m26	dsv	336.mg *	P<.2	
d	R f	osm gav	liv MXB	18m26	dsv	4.65gm *	P<.4	
905	R f	osm gav	--- hes	18m26	dsv pool	1.36gm *	P<.02	a
906	R m	osm gav	TBA MXB	18m26	dsv	no dre	P=1.	-
a	R m	osm gav	liv MXB	18m26	dsv	no dre	P=1.	-

RefNum	LoConf	UpConf	Cntrl	1Dose	1Inc	2Dose	2Inc	Citation or Pathology	Brkly Code
884	1240	2.19mg	n.s.s.	0/16	3.85mg	3/17			
a	1240	3.78mg	n.s.s.	0/16	3.85mg	1/17			
b	1240	1.31mg	17.6mg	0/16	3.85mg	6/17			
2,6-DICHLORO-4-NITROANILINE (Botran) 99-30-9									
885	1291	119.mg	n.s.s.	1/17	99.7mg	1/18		Innes;ntis,1968/1969	
a	1291	198.mg	n.s.s.	0/17	99.7mg	0/18			
b	1291	47.7mg	n.s.s.	2/17	99.7mg	5/18			
886	1292	157.mg	n.s.s.	0/17	83.8mg	0/17			
a	1292	157.mg	n.s.s.	1/17	83.8mg	0/17			
b	1292	157.mg	n.s.s.	2/17	83.8mg	0/17			
887	1291	184.mg	n.s.s.	1/18	92.7mg	0/18			
a	1291	184.mg	n.s.s.	2/18	92.7mg	0/18			
b	1291	130.mg	n.s.s.	3/18	92.7mg	1/18			
888	1292	65.3mg	n.s.s.	1/18	78.0mg	2/18			
a	1292	102.mg	n.s.s.	2/18	78.0mg	1/18			
b	1292	61.3mg	n.s.s.	3/18	78.0mg	3/18			
889	1291	98.0mg	n.s.s.	0/16	99.7mg	1/17			
a	1291	187.mg	n.s.s.	0/16	99.7mg	0/17			
b	1291	56.7mg	n.s.s.	0/16	99.7mg	3/17			
890	1292	82.3mg	n.s.s.	0/16	83.8mg	1/17			
a	1292	157.mg	n.s.s.	0/16	83.8mg	0/17			
b	1292	39.3mg	n.s.s.	0/16	83.8mg	4/17			
891	1291	39.3mg	2.29gm	0/16	92.7mg	5/18			
a	1291	96.6mg	n.s.s.	0/16	92.7mg	1/18			
b	1291	25.7mg	190.mg	0/16	92.7mg	8/18			
892	1292	81.2mg	n.s.s.	0/16	78.0mg	1/18			
a	1292	81.2mg	n.s.s.	0/16	78.0mg	1/18			
b	1292	81.2mg	n.s.s.	0/16	78.0mg	1/18			
c	1292	47.2mg	n.s.s.	0/16	78.0mg	3/18			
3,3'-DICHLOROBENZIDINE (DCB) 91-94-1									
893	1379	n.s.s.	1.78mg	0/6	4.42mg	5/5		Stula;jept,1,475-490;1978	
a	1379	n.s.s.	1.78mg	0/6	4.42mg	5/5			
b	1379	n.s.s.	n.s.s.	5/6	4.42mg	5/5			
894	192	10.8mg	36.6mg	3/44	50.0mg	26/44		Stula;txap,31,159-176;1975/pers.com.	
a	192	200.mg	n.s.s.	0/44	50.0mg	0/44			
895	192	27.2mg	203.mg	0/44	40.0mg	8/44			
a	192	30.0mg	290.mg	0/44	40.0mg	7/44			
b	192	26.9mg	n.s.s.	2/44	40.0mg	9/44			
c	192	160.mg	n.s.s.	0/44	40.0mg	0/44			
trans-1,4-DICHLOROBUTENE-2 110-57-6									
896	582	.373mg	n.s.s.	0/30	.286mg	2/30		Van Duuren;canr,35,2553-2557;1975	
2,7-DICHLORODIBENZO-p-DIOXIN (DCDD) 33857-26-0									
897	c03667	2.30gm	n.s.s.	15/50	636.mg	18/50	1.19gm	9/50	
a	c03667	n.s.s.	n.s.s.	0/50	636.mg	1/50	1.19gm	0/50	liv:hpa,hpc,nnd. lun:a/a,a/c.
b	c03667	8.39gm	n.s.s.	3/50	636.mg	2/50	1.19gm	0/50	
898	c03667	321.mg	4.17gm	8/50	540.mg	26/50	(1.09gm)	20/50	---:hem,hes,leu,lym; liv:hpa,hpc. ---:leu,lym.
a	c03667	831.mg	9.58gm	0/50	540.mg	7/50	(1.09gm)	3/50	---:hem,hes.
b	c03667	1.04gm	281.gm	0/50	540.mg	5/50	(1.09gm)	1/50	liv:hpa,hpc.
c	c03667	885.mg	n.s.s.	8/50	540.mg	20/50	1.09gm	17/50	
d	c03667	787.mg	n.s.s.	19/50	540.mg	30/50	1.09gm	25/50	
e	c03667	885.mg	n.s.s.	8/50	540.mg	20/50	1.09gm	17/50	liv:hpa,hpc,nnd. lun:a/a,a/c.
f	c03667	3.95gm	n.s.s.	8/50	540.mg	5/50	1.09gm	5/50	
899	c03667	456.mg	n.s.s.	26/35	250.mg	22/35	500.mg	16/35	
a	c03667	n.s.s.	n.s.s.	0/35	250.mg	0/35	500.mg	0/35	liv:hpa,hpc,nnd.
900	c03667	131.mg	n.s.s.	21/35	198.mg	14/35	(396.mg)	6/35	
a	c03667	716.mg	n.s.s.	1/35	198.mg	0/35	396.mg	1/35	liv:hpa,hpc,nnd.
1,1-DICHLOROETHANE 75-34-3									
901	c04535	2.03gm	n.s.s.	6/20	1.02gm	6/50	2.04gm	12/50	
a	c04535	10.3gm	n.s.s.	1/20	1.02gm	1/50	2.04gm	0/50	liv:hpa,hpc,nnd. lun:a/a,a/c.
b	c04535	8.16gm	n.s.s.	1/20	1.02gm	2/50	2.04gm	0/50	
902	c04535	3.89gm	86.3gm	0/80p	1.02gm	0/50	2.04gm	4/50	
903	c04535	588.mg	n.s.s.	4/20	883.mg	19/50	1.77gm	15/50	
a	c04535	936.mg	n.s.s.	1/20	883.mg	8/50	1.77gm	8/50	liv:hpa,hpc,nnd. lun:a/a,a/c.
b	c04535	2.67gm	n.s.s.	0/20	883.mg	1/50	1.77gm	4/50	
904	c04535	248.mg	3.68gm	0/20	238.mg	1/50	477.mg	9/50	---:hes; mgl:adc. A
a	c04535	377.mg	n.s.s.	0/20	238.mg	1/50	477.mg	5/50	
b	c04535	450.mg	n.s.s.	0/20	238.mg	0/50	477.mg	4/50	
c	c04535	119.mg	n.s.s.	4/20	238.mg	12/50	477.mg	18/50	
d	c04535	758.mg	n.s.s.	0/20	238.mg	0/50	477.mg	1/50	liv:hpa,hpc,nnd.
905	c04535	456.mg	n.s.s.	0/40p	238.mg	0/50	477.mg	4/50	
906	c04535	258.mg	n.s.s.	6/20	192.mg	6/50	383.mg	5/50	
a	c04535	926.mg	n.s.s.	1/20	192.mg	0/50	383.mg	0/50	liv:hpa,hpc,nnd.

Spe	Strain	Site	Xpo+Xpt	Notes	TD50	2Tailpvi			
Sex	Route	Hist			DR	AuOp			
1,2-DICHLOROETHANE				100ng...:..1ug.....:..10.....:..100.....:..1mg.....:..10.....:..100.....:..1g.....:..10					
907	M f b6c	gav	MXB MXB 78w90	v	:	+	61.2mg / P<.0005		
a	M f b6c	gav	lun a/a 78w90	v			118. mg / P<.0005c		
b	M f b6c	gav	mgl acn 78w90	v			133. mg / P<.0005c		
c	M f b6c	gav	TBA MXB 78w90	v			36.0mg / P<.0005		
d	M f b6c	gav	liv MXB 78w90	v			4.74gm / P<.8		
e	M f b6c	gav	lun MXB 78w90	v			112. mg / P<.0005		
908	M f b6c	gav	lun a/a 78w90	v	pool	:	+	116. mg / P<.0005c	
a	M f b6c	gav	mgl acn 78w90	v			133. mg / P<.0005c		
b	M f b6c	gav	ute MXA 78w90	v			230. mg / P<.0005c		
c	M f b6c	gav	sto sqc 78w90	v			438. mg / P<.003		
909	M m b6c	gav	lun a/a 78w90	v	:	+	:	89.7mg * P<.0005c	
a	M m b6c	gav	liv hpc 78w90	v			133. mg * P<.04		
b	M m b6c	gav	TBA MXB 78w90	v			57.7mg * P<.02		
c	M m b6c	gav	liv MXB 78w90	v			133. mg * P<.04		
d	M m b6c	gav	lun MXB 78w90	v			89.7mg * P<.0005		
910	M m b6c	gav	lun a/a 78w90	v	pool	:	+	:	89.7mg * P<.0005c
a	M m b6c	gav	liv hpc 78w90	v			148. mg * P<.02		
911	M f swi	inh	liv mix 18m25	ev			>	16.9gm * P<.7 -	
a	M f swi	inh	lun ade 18m25	ev				55.4gm * P<.1. -	
b	M f swi	inh	liv ang 18m25	ev				no dre P=1. -	
c	M f swi	inh	liv hpt 18m25	ev				no dre P=1. -	
d	M f swi	inh	tba mix 18m25	ev				no dre P=1. -	
912	M m swi	inh	liv hpt 18m25	ev			>	no dre P=1. -	
a	M m swi	inh	liv ang 18m25	ev				no dre P=1. -	
b	M m swi	inh	liv mix 18m25	ev				no dre P=1. -	
c	M m swi	inh	lun ade 18m25	ev				no dre P=1. -	
d	M m swi	inh	tba mix 18m25	ev				no dre P=1. -	
913	R f osm	gav	mgl MXA 18m26	dsv	:	+	:	5.49mg / P<.0005c	
a	R f osm	gav	mgl fba 18m26	dsv				5.84mg / P<.0005	
b	R f osm	gav	mgl acn 18m26	dsv				74.8mg / P<.0005c	
c	R f osm	gav	TBA MXB 18m26	dsv				3.19mg / P<.0005	
d	R f osm	gav	liv MXB 18m26	dsv				60.6mg * P<.2	
914	R f osm	gav	mgl MXA 18m26	dsv	pool	:	+	:	5.63mg / P<.0005c
a	R f osm	gav	mgl fba 18m26	dsv				6.38mg / P<.0005	
b	R f osm	gav	--- hes 18m26	dsv				19.5mg * P<.0005	
c	R f osm	gav	mgl acn 18m26	dsv				54.0mg / P<.0005c	
915	R m osm	gav	MXB MXB 18m26	dsv	:	+	:	11.5mg / P<.0005	
a	R m osm	gav	--- hes 18m26	dsv				15.0mg * P<.0005c	
b	R m osm	gav	sto sqc 18m26	dsv				46.3mg / P<.0005c	
c	R m osm	gav	TBA MXB 18m26	dsv				3.18mg / P<.0005	
d	R m osm	gav	liv MXB 18m26	dsv				132. mg / P<.07	
916	R m osm	gav	--- hes 18m26	dsv	pool	:	+	:	18.4mg * P<.0005c
a	R m osm	gav	sub fib 18m26	dsv				43.2mg / P<.0005c	
b	R m osm	gav	sto sqc 18m26	dsv				46.3mg / P<.0005c	
917	R f sda	inh	liv mix 18m31	ev			>	no dre P=1. -	
a	R f sda	inh	mam mix 18m31	ev				no dre P=1. -	
b	R f sda	inh	tba mix 18m31	ev				no dre P=1. -	
918	R f sda	inh	mam mix 18m31	ev			.	±	38.1mg Z P<.07 -
a	R f sda	inh	liv mix 18m31	ev				no dre P=1. -	
b	R f sda	inh	tba mix 18m31	ev				48.8mg Z P<.2 -	
919	R m sda	inh	liv mix 18m33	ev			>	no dre P=1. -	
a	R m sda	inh	tba mix 18m33	ev				2.40gm Z P<.1 -	
920	R m sda	inh	liv mix 18m33	ev			>	no dre P=1. -	
a	R m sda	inh	tba mix 18m33	ev				no dre P=1. -	
alpha-(2,4-DICHLOROPHOXY)PROPIONIC ACID				.1ug.....:..10.....:..100.....:..1mg.....:..10.....:..100.....:..1g.....:..10					
921	M f b6a	ort	liv agm 76w76	evx			>	233. mg P<.3 -	
a	M f b6a	ort	lun ade 76w76	evx				no dre P=1. -	
b	M f b6a	ort	tba mix 76w76	evx				66.5mg P<.3 -	
922	M f b6a	ort	lun ade 76w76	evx			>	364. mg P<.1 -	
a	M f b6a	ort	liv hpt 76w76	evx				no dre P=1. -	
b	M f b6a	ort	tba mix 76w76	evx				no dre P=1. -	
923	M m b6a	ort	liv hpt 76w76	evx			>	3.58gm P<.1 -	
a	M m b6a	ort	lun ade 76w76	evx				no dre P=1. -	
b	M m b6a	ort	tba mix 76w76	evx				no dre P=1. -	
924	M m b6a	ort	lun mix 76w76	evx			>	no dre P=1. -	
a	M m b6a	ort	liv hpt 76w76	evx				no dre P=1. -	
b	M m b6a	ort	tba mix 76w76	evx				9.26gm P<.5 -	
925	M f b6c	ort	lun ade 76w76	evx			>	220. mg P<.3 -	
a	M f b6c	ort	liv hpt 76w76	evx				no dre P=1. -	
b	M f b6c	ort	tba mix 76w76	evx				106. mg P<.1 -	
926	M f b6c	ort	liv hpt 76w76	evx			>	no dre P=1. -	
a	M f b6c	ort	lun mix 76w76	evx				no dre P=1. -	
b	M f b6c	ort	tba tum 76w76	evx				no dre P=1. -	
927	M m b6c	ort	liv hpt 76w76	evx			.	±	99.1mg P<.1 -
a	M m b6c	ort	lun mix 76w76	evx				no dre P=1. -	
b	M m b6c	ort	tba mix 76w76	evx				99.1mg P<.1 -	

Spe	Strain	Site	Xpo + Xpt	Notes	TD50		2Tailpvl	
					DR	AuOp		
928	M m b6c	orl liv	hpt 76w76 evx	.	±	4.27mg	P<.02	-
a	M m b6c	orl lun	mix 76w76 evx			no dre	P=1.	-
b	M m b6c	orl tba	mix 76w76 evx			2.59mg	P<.002	-
alpha-(2,5-DICHLOROPHENOXY)PROPIONIC ACID ..1ug.....10.....100.....1mg.....10.....100.....1g.....10								
929	M f b6a	orl lun	ade 76w76 evx		>	no dre	P=1.	-
a	M f b6a	orl liv	hpt 76w76 evx			no dre	P=1.	-
b	M f b6a	orl tba	mix 76w76 evx			no dre	P=1.	-
930	M m b6a	orl lun	ade 76w76 evx		>	no dre	P=1.	-
a	M m b6a	orl liv	hpt 76w76 evx			no dre	P=1.	-
b	M m b6a	orl tba	mix 76w76 evx			no dre	P=1.	-
931	M f b6c	orl liv	hpt 76w76 evx		>	no dre	P=1.	-
a	M f b6c	orl lun	mix 76w76 evx			no dre	P=1.	-
b	M f b6c	orl tba	tum 76w76 evx			no dre	P=1.	-
932	M m b6c	orl liv	hpt 76w76 evx	.	*	36.7mg	P<.1	-
a	M m b6c	orl lun	ade 76w76 evx			36.7mg	P<.1	-
b	M m b6c	orl tba	mix 76w76 evx			10.5mg	P<.003	-
2,4-DICHLOROPHENOXYACETIC ACID 100ng.....1ug.....10.....100.....1mg.....10.....100.....1g.....10								
933	M f b6a	orl lun	ade 76w76 evx		>	2.75gm *	P<.1	-
a	M f b6a	orl liv	hpt 76w76 evx			no dre	P=1.	-
b	M f b6a	orl tba	mix 76w76 evx			1.07gm *	P<.9	-
934	M m b6a	orl liv	hpt 76w76 evx		>	no dre	P=1.	-
a	M m b6a	orl lun	ade 76w76 evx			no dre	P=1.	-
b	M m b6a	orl tba	mix 76w76 evx			no dre	P=1.	-
935	M f b6c	orl liv	hpt 76w76 evx		>	123.mg	P<.3	-
a	M f b6c	orl lun	mix 76w76 evx			no dre	P=1.	-
b	M f b6c	orl tba	mix 76w76 evx			123.mg	P<.3	-
936	M m b6c	orl liv	hpt 76w76 evx		>	no dre	P=1.	-
a	M m b6c	orl lun	mix 76w76 evx			no dre	P=1.	-
b	M m b6c	orl tba	mix 76w76 evx			55.5mg	P<.1	-
2,4-DICHLOROPHENOXYACETIC ACID, n-BUTYL ESTER10.....100.....1mg.....10.....100.....1g.....10								
937	M f b6a	orl liv	hpt 76w76 evx		>	no dre	P=1.	-
a	M f b6a	orl lun	ade 76w76 evx			no dre	P=1.	-
b	M f b6a	orl tba	mix 76w76 evx			no dre	P=1.	-
938	M m b6a	orl lun	ade 76w76 evx		>	no dre	P=1.	-
a	M m b6a	orl liv	hpt 76w76 evx			no dre	P=1.	-
b	M m b6a	orl tba	mix 76w76 evx			no dre	P=1.	-
939	M f b6c	orl liv	hpt 76w76 evx		>	no dre	P=1.	-
a	M f b6c	orl lun	mix 76w76 evx			no dre	P=1.	-
b	M f b6c	orl tba	mix 76w76 evx			29.7mg	P<.02	-
940	M m b6c	orl lun	ade 76w76 evx		>	59.0mg	P<.2	-
a	M m b6c	orl liv	hpt 76w76 evx			122.mg	P<.3	-
b	M m b6c	orl tba	mix 76w76 evx			38.1mg	P<.05	-
2,4-DICHLOROPHENOXYACETIC ACID, ISOOCTYL ESTER10.....100.....1mg.....10.....100.....1g.....10								
941	M f b6a	orl liv	hpt 76w76 evx		>	no dre	P=1.	-
a	M f b6a	orl lun	ade 76w76 evx			no dre	P=1.	-
b	M f b6a	orl tba	mix 76w76 evx			no dre	P=1.	-
942	M m b6a	orl lun	mix 76w76 evx		>	no dre	P=1.	-
a	M m b6a	orl liv	hpt 76w76 evx			no dre	P=1.	-
b	M m b6a	orl tba	mix 76w76 evx			no dre	P=1.	-
943	M f b6c	orl lun	ade 76w76 evx	.	*	34.0mg	P<.04	-
a	M f b6c	orl liv	hpt 76w76 evx			no dre	P=1.	-
b	M f b6c	orl tba	mix 76w76 evx			24.6mg	P<.02	-
944	M m b6c	orl liv	hpt 76w76 evx	.	*	31.7mg	P<.04	-
a	M m b6c	orl lun	mix 76w76 evx			no dre	P=1.	-
b	M m b6c	orl tba	mix 76w76 evx			17.7mg	P<.007	-
2,4-DICHLOROPHENOXYACETIC ACID, ISOPROPYL ESTER.....10.....100.....1mg.....10.....100.....1g.....10								
945	M f b6a	orl liv	hpc 76w76 evx		>	94.7mg	P<.3	-
a	M f b6a	orl lun	ade 76w76 evx			no dre	P=1.	-
b	M f b6a	orl tba	mix 76w76 evx			83.2mg	P<.7	-
946	M m b6a	orl lun	ade 76w76 evx		>	no dre	P=1.	-
a	M m b6a	orl liv	hpt 76w76 evx			no dre	P=1.	-
b	M m b6a	orl tba	mix 76w76 evx			no dre	P=1.	-
947	M f b6c	orl liv	hpt 76w76 evx		>	100.mg	P<.3	-
a	M f b6c	orl lun	ade 76w76 evx			100.mg	P<.3	-
b	M f b6c	orl tba	mix 76w76 evx			48.7mg	P<.2	-
948	M m b6c	orl lun	ade 76w76 evx	.	*	21.3mg	P<.02	-
a	M m b6c	orl liv	hpt 76w76 evx			93.6mg	P<.3	-
b	M m b6c	orl tba	mix 76w76 evx			16.4mg	P<.009	-
3-(3,4-DICHLOROPHENYL)-1,1-DIMETHYLUREA....1ug.....10.....100.....1mg.....10.....100.....1g.....10								
949	M f b6a	orl lun	ade 76w76 evx		>	no dre	P=1.	-
a	M f b6a	orl liv	hpt 76w76 evx			no dre	P=1.	-
b	M f b6a	orl tba	mix 76w76 evx			no dre	P=1.	-

	RefNum	LoConf	UpConf	Cntrl	1Dose	1Inc	2Dose	2Inc	Citation or Pathology	Brkly Code
928	1238	1.46mg	n.s.s.	0/16	3.62mg	4/15				
a	1238	5.98mg	n.s.s.	0/16	3.62mg	0/15				
b	1238	1.04mg	11.7mg	0/16	3.62mg	6/15				
alpha-(2,5-DICHLOROPHENOXY)PROPIONIC ACID 6965-71-5										
929	1231	16.0mg	n.s.s.	1/17	13.4mg	1/18			Innes;ntis,1968/1969	
a	1231	26.6mg	n.s.s.	0/17	13.4mg	0/18				
b	1231	17.7mg	n.s.s.	2/17	13.4mg	1/18				
930	1231	15.4mg	n.s.s.	2/18	12.5mg	1/17				
a	1231	23.5mg	n.s.s.	1/18	12.5mg	0/17				
b	1231	16.5mg	n.s.s.	3/18	12.5mg	1/17				
931	1231	25.1mg	n.s.s.	0/16	13.4mg	0/17				
a	1231	25.1mg	n.s.s.	0/16	13.4mg	0/17				
b	1231	25.1mg	n.s.s.	0/16	13.4mg	0/17				
932	1231	9.00mg	n.s.s.	0/16	12.5mg	2/17				
a	1231	9.00mg	n.s.s.	0/16	12.5mg	2/17				
b	1231	4.25mg	57.2mg	0/16	12.5mg	6/17				
2,4-DICHLOROPHENOXYACETIC ACID (2,4-D) 94-75-7										
933	1232	64.6mg	n.s.s.	1/17	20.4mg	0/16	44.3mg	1/15	Innes;ntis,1968/1969	
a	1232	24.1mg	n.s.s.	0/17	20.4mg	0/16	44.3mg	0/15		
b	1232	43.4mg	n.s.s.	2/17	20.4mg	1/16	44.3mg	2/15		
934	1232	22.2mg	n.s.s.	1/18	19.0mg	0/18	41.2mg	0/12		
a	1232	40.0mg	n.s.s.	2/18	19.0mg	2/18	41.2mg	1/12		
b	1232	45.0mg	n.s.s.	3/18	19.0mg	2/18	41.2mg	1/12		
935	1232	20.1mg	n.s.s.	0/16	20.4mg	1/17				
a	1232	38.2mg	n.s.s.	0/16	20.4mg	0/17				
b	1232	20.1mg	n.s.s.	0/16	20.4mg	1/17				
936	1232	35.5mg	n.s.s.	0/16	19.0mg	0/17				
a	1232	35.5mg	n.s.s.	0/16	19.0mg	0/17				
b	1232	13.6mg	n.s.s.	0/16	19.0mg	2/17				
2,4-DICHLOROPHENOXYACETIC ACID, n-BUTYL ESTER 94-80-4										
937	1237	36.0mg	n.s.s.	0/17	20.4mg	0/16			Innes;ntis,1968/1969	
a	1237	36.0mg	n.s.s.	1/17	20.4mg	0/16				
b	1237	36.0mg	n.s.s.	2/17	20.4mg	0/16				
938	1237	24.9mg	n.s.s.	2/18	19.0mg	1/18				
a	1237	37.6mg	n.s.s.	1/18	19.0mg	0/18				
b	1237	14.9mg	n.s.s.	3/18	19.0mg	3/18				
939	1237	40.5mg	n.s.s.	0/16	20.4mg	0/18				
a	1237	40.5mg	n.s.s.	0/16	20.4mg	0/18				
b	1237	10.2mg	n.s.s.	0/16	20.4mg	4/18				
940	1237	14.5mg	n.s.s.	0/16	19.0mg	2/18				
a	1237	19.8mg	n.s.s.	0/16	19.0mg	1/18				
b	1237	11.5mg	n.s.s.	0/16	19.0mg	3/18				
2,4-DICHLOROPHENOXYACETIC ACID, ISOCTYL ESTER 25168-26-7										
941	1236	33.8mg	n.s.s.	0/17	18.1mg	0/17			Innes;ntis,1968/1969	
a	1236	33.8mg	n.s.s.	1/17	18.1mg	0/17				
b	1236	22.3mg	n.s.s.	2/17	18.1mg	1/17				
942	1236	15.7mg	n.s.s.	2/18	16.8mg	2/18				
a	1236	19.9mg	n.s.s.	1/18	16.8mg	1/18				
b	1236	13.2mg	n.s.s.	3/18	16.8mg	3/18				
943	1236	10.3mg	n.s.s.	0/16	18.1mg	3/17				
a	1236	33.8mg	n.s.s.	0/16	18.1mg	0/17				
b	1236	8.46mg	n.s.s.	0/16	18.1mg	4/17				
944	1236	9.56mg	n.s.s.	0/16	16.8mg	3/17				
a	1236	31.4mg	n.s.s.	0/16	16.8mg	0/17				
b	1236	6.65mg	239.mg	0/16	16.8mg	5/17				
2,4-DICHLOROPHENOXYACETIC ACID, ISOPROPYL ESTER 94-11-1										
945	1235	15.4mg	n.s.s.	0/17	15.7mg	1/17			Innes;ntis,1968/1969	
a	1235	29.3mg	n.s.s.	1/17	15.7mg	0/17				
b	1235	10.5mg	n.s.s.	2/17	15.7mg	3/17				
946	1235	13.7mg	n.s.s.	2/18	14.6mg	2/18				
a	1235	29.0mg	n.s.s.	1/18	14.6mg	0/18				
b	1235	11.5mg	n.s.s.	3/18	14.6mg	3/18				
947	1235	16.3mg	n.s.s.	0/16	15.7mg	1/18				
a	1235	16.3mg	n.s.s.	0/16	15.7mg	1/18				
b	1235	12.0mg	n.s.s.	0/16	15.7mg	2/18				
948	1235	7.32mg	n.s.s.	0/16	14.6mg	4/18				
a	1235	15.2mg	n.s.s.	0/16	14.6mg	1/18				
b	1235	6.20mg	361.mg	0/16	14.6mg	5/18				
3-(3,4-DICHLOROPHENYL)-1,1-DIMETHYLUREA (Karmex, diuron) 330-54-1										
949	1276	215.mg	n.s.s.	1/17	193.mg	1/17			Innes;ntis,1968/1969	
a	1276	361.mg	n.s.s.	0/17	193.mg	0/17				
b	1276	170.mg	n.s.s.	2/17	193.mg	2/17				

Spe	Strain	Site	Xpo + Xpt	Notes	TD50	2Tailpvl
Sex	Route	Hist			DR	AuOp
950	M m b6a	orl lun	ade 76w76	evx	437.mg	P<.4 -
a	M m b6a	orl liv	hpt 76w76	evx	no dre	P=1. -
b	M m b6a	orl tba	mix 76w76	evx	260.mg	P<.3 -
951	M f b6c	orl lun	ade 76w76	evx	600.mg	P<.2 -
a	M f b6c	orl liv	hpt 76w76	evx	no dre	P=1. -
b	M f b6c	orl tba	mix 76w76	evx	388.mg	P<.05 -
952	M m b6c	orl liv	hpt 76w76	evx	1.15gm	P<.3 -
a	M m b6c	orl lun	ade 76w76	evx	1.15gm	P<.3 -
b	M m b6c	orl tba	mix 76w76	evx	361.mg	P<.05 -
2,4-DICHLOROPHENYL BENZENE SULFONATE 100ng.....1ug.....10.....100.....1mg.....10.....100.....1g.....10						
953	M f b6a	orl lun	mix 76w76	evx	1.92gm	P<.6 -
a	M f b6a	orl liv	hpt 76w76	evx	no dre	P=1. -
b	M f b6a	orl tba	mix 76w76	evx	867.mg	P<.4 -
954	M m b6a	orl lun	ade 76w76	evx	866.mg	P<.4 -
a	M m b6a	orl liv	hpt 76w76	evx	no dre	P=1. -
b	M m b6a	orl tba	mix 76w76	evx	1.68gm	P<.7 -
955	M f b6c	orl lun	ade 76w76	evx	1.92gm	P<.3 -
a	M f b6c	orl liv	hpt 76w76	evx	no dre	P=1. -
b	M f b6c	orl tba	mix 76w76	evx	929.mg	P<.09 -
956	M m b6c	orl liv	hpt 76w76	evx	266.mg	P<.003 -
a	M m b6c	orl lun	ade 76w76	evx	924.mg	P<.1 -
b	M m b6c	orl tba	mix 76w76	evx	218.mg	P<.002 -
DICHLORVOS 100ng.....1ug.....10.....100.....1mg.....10.....100.....1g.....10						
957	M f b6c	eat TBA	MXB 80w92	v	7.85gm	* P<.1. -
a	M f b6c	eat liv	MXB 80w92	v	no dre	P=1. -
b	M f b6c	eat lun	MXB 80w92	v	1.53gm	* P<.8 -
958	M m b6c	eat TBA	MXB 80w92	v	40.3mg	\ P<.08 -
a	M m b6c	eat liv	MXB 80w92	v	no dre	P=1. -
b	M m b6c	eat lun	MXB 80w92	v	725.mg	* P<.8 -
959	R f osm	eat TBA	MXB 19m26	v	no dre	P=1. -
a	R f osm	eat liv	MXB 19m26	v	no dre	P=1. -
960	R m osm	eat TBA	MXB 19m26	v	no dre	P=1. -
a	R m osm	eat liv	MXB 19m26	v	no dre	P=1. -
961	R f cfe	inh pit	tum 24m24	e	4.65mg	* P<.009 -
a	R f cfe	inh liv	tum 24m24	e	no dre	P=1. -
b	R f cfe	inh tba	mix 24m24	e	24.5mg	* P<.9 -
962	R m cfe	inh pit	tum 24m24	e	11.3mg	* P<.3 -
a	R m cfe	inh liv	tum 24m24	e	50.0mg	* P<.2 -
b	R m cfe	inh thy	tum 24m24	e	no dre	P=1. -
c	R m cfe	inh tba	mix 24m24	e	no dre	P=1. -
DICOFOL 100ng.....1ug.....10.....100.....1mg.....10.....100.....1g.....10						
963	M f b6c	eat TBA	MXB 78w91	v	no dre	P=1. -
a	M f b6c	eat liv	MXB 78w91	v	no dre	P=1. -
b	M f b6c	eat lun	MXB 78w91	v	no dre	P=1. -
964	M m b6c	eat liv	MXA 78w91	v	32.9mg	* P<.04 c
a	M m b6c	eat liv	hpc 78w91	v	34.8mg	* P<.04 c
b	M m b6c	eat TBA	MXB 78w91	v	59.2mg	* P<.4 -
c	M m b6c	eat liv	MXB 78w91	v	32.9mg	* P<.04 -
d	M m b6c	eat lun	MXB 78w91	v	616.mg	* P<.6 -
965	R f osm	eat TBA	MXB 18m26	v	no dre	P=1. -
a	R f osm	eat liv	MXB 18m26	v	no dre	P=1. -
966	R m osm	eat TBA	MXB 18m26	v	no dre	P=1. -
a	R m osm	eat liv	MXB 18m26	v	517.mg	* P<.7 -
N,N'-DICYCLOHEXYLTHIOUREA 100ng.....1ug.....10.....100.....1mg.....10.....100.....1g.....10						
967	M f b6c	eat TBA	MXB 25m24		122.gm	* P<.1. -
a	M f b6c	eat liv	MXB 25m24		no dre	P=1. -
b	M f b6c	eat lun	MXB 25m24		no dre	P=1. -
968	M m b6c	eat TBA	MXB 25m24		no dre	P=1. -
a	M m b6c	eat liv	MXB 25m24		no dre	P=1. -
b	M m b6c	eat lun	MXB 25m24		no dre	P=1. -
969	R f f34	eat TBA	MXB 25m25		no dre	P=1. -
a	R f f34	eat liv	MXB 25m25		no dre	P=1. -
970	R m f34	eat thy	cca 25m25		5.48gm	* P<.03 -
a	R m f34	eat thy	MXA 25m25		7.41gm	* P<.04 -
b	R m f34	eat ski	bcc 25m25		26.1gm	* P<.04 -
c	R m f34	eat TBA	MXB 25m25		3.91gm	* P<.3 -
d	R m f34	eat liv	MXB 25m25		15.6gm	* P<.09 -
DICYCLOPENTADIENE DIOXIDE 100ng.....1ug.....10.....100.....1mg.....10.....100.....1g.....10						
971	M f chi	eat lun	mix 64w86	a	1.66gm	* P<.2 -
a	M f chi	eat liv	mix 64w86	a	no dre	P=1. -
b	M f chi	eat tba	mix 64w86	a	789.mg	* P<.2 -
972	M m chi	eat lun	mix 77w86		373.mg	\ P<.009 -
a	M m chi	eat liv	mix 77w86		930.mg	* P<.05 -
b	M m chi	eat tba	mix 77w86		149.mg	\ P<.003 -

CARCINOGENIC POTENCY DATABASE

RefNum	LoConf	UpConf	Cntrl	1Dose	1Inc	2Dose	2Inc	Citation or Pathology	Brkly Code
950	1276	95.6mg n.s.s.	2/18	180.mg	4/17				
a	1276	336.mg n.s.s.	1/18	180.mg	0/17				
b	1276	70.7mg n.s.s.	3/18	180.mg	6/17				
951	1276	147.mg n.s.s.	0/16	193.mg	2/18				
a	1276	382.mg n.s.s.	0/16	193.mg	0/18				
b	1276	117.mg n.s.s.	0/16	193.mg	3/18				
952	1276	187.mg n.s.s.	0/16	180.mg	1/18				
a	1276	187.mg n.s.s.	0/16	180.mg	1/18				
b	1276	109.mg n.s.s.	0/16	180.mg	3/18				
2,4-DICHLOROPHENYLBENZENE SULFONATE (Genite-R99) 97-16-5									
953	1288	267.mg n.s.s.	1/17	339.mg	2/17			Innes;ntis,1968/1969	
a	1288	634.mg n.s.s.	0/17	339.mg	0/17				
b	1288	182.mg n.s.s.	2/17	339.mg	4/17				
954	1288	181.mg n.s.s.	2/18	316.mg	4/18				
a	1288	626.mg n.s.s.	1/18	316.mg	0/18				
b	1288	196.mg n.s.s.	3/18	316.mg	4/18				
955	1288	313.mg n.s.s.	0/16	339.mg	1/16				
a	1288	597.mg n.s.s.	0/16	339.mg	0/16				
b	1288	228.mg n.s.s.	0/16	339.mg	2/16				
956	1288	107.mg 1.44gm	0/16	316.mg	6/17				
a	1288	227.mg n.s.s.	0/16	316.mg	2/17				
b	1288	92.7mg 837.mg	0/16	316.mg	7/17				
DICHLORVOS (DDVP, Vapona) 62-73-7									
957	c00113	86.5mg n.s.s.	1/10	35.1mg	11/50	70.2mg	9/50		
a	c00113	n.s.s. n.s.s.	0/10	35.1mg	0/50	70.2mg	0/50	liv:hpa,hpc,nnd.	
b	c00113	277.mg n.s.s.	0/10	35.1mg	1/50	70.2mg	1/50	lun:a/a,a/c.	
958	c00113	20.1mg n.s.s.	1/10	32.4mg	22/50	64.8mg	14/50		
a	c00113	76.1mg n.s.s.	0/10	32.4mg	12/50	64.8mg	7/50	liv:hpa,hpc,nnd.	
b	c00113	103.mg n.s.s.	0/10	32.4mg	7/50	64.8mg	5/50	lun:a/a,a/c.	
959	c00113	5.73mg n.s.s.	8/10	5.50mg	34/50	11.9mg	30/50		
a	c00113	75.7mg n.s.s.	1/10	5.50mg	3/50	11.9mg	1/50	liv:hpa,hpc,nnd.	
960	c00113	8.10mg n.s.s.	6/10	4.40mg	21/50	9.50mg	33/50		
a	c00113	n.s.s. n.s.s.	0/10	4.40mg	0/50	9.50mg	0/50	liv:hpa,hpc,nnd.	
961	96	1.97mg 172.mg	7/47	18.9ug	5/47	.189mg	12/47	1.89mg	16/46
a	96	.165mg n.s.s.	0/47	18.9ug	0/47	.189mg	0/47	1.89mg	0/46
b	96	1.48mg n.s.s.	36/47	18.9ug	28/47	.189mg	36/47	1.89mg	33/46
962	96	2.76mg n.s.s.	4/50	13.3ug	10/50	.133mg	6/50	1.33mg	10/50
a	96	8.14mg n.s.s.	0/50	13.3ug	0/50	.133mg	0/50	1.33mg	1/50
b	96	5.04mg n.s.s.	2/50	13.3ug	9/50	.133mg	5/50	1.33mg	5/50
c	96	1.97mg n.s.s.	18/50	13.3ug	30/50	.133mg	26/50	1.33mg	24/50
DICOFOL (Kethene) 115-32-2									
963	c00486	65.1mg n.s.s.	5/20	13.0mg	6/50	26.0mg	8/50		
a	c00486	309.mg n.s.s.	1/20	13.0mg	0/50	26.0mg	0/50	liv:hpa,hpc,nnd.	
b	c00486	296.mg n.s.s.	1/20	13.0mg	0/50	26.0mg	0/50	lun:a/a,a/c.	
964	c00486	15.9mg n.s.s.	3/20	26.4mg	23/50	54.0mg	36/50		liv:hpa,hpc.
a	c00486	16.8mg n.s.s.	3/20	26.4mg	22/50	54.0mg	35/50		
b	c00486	16.1mg n.s.s.	5/20	26.4mg	34/50	54.0mg	38/50		
c	c00486	15.9mg n.s.s.	3/20	26.4mg	23/50	54.0mg	36/50	liv:hpa,hpc,nnd.	
d	c00486	114.mg n.s.s.	1/20	26.4mg	2/50	54.0mg	5/50	lun:a/a,a/c.	
965	c00486	46.3mg n.s.s.	16/20	13.0mg	27/50	26.0mg	28/50		
a	c00486	n.s.s. n.s.s.	0/20	13.0mg	0/50	26.0mg	0/50	liv:hpa,hpc,nnd.	
966	c00486	13.4mg n.s.s.	10/20	12.6mg	23/50	26.4mg	16/50		
a	c00486	103.mg n.s.s.	0/20	12.6mg	1/50	26.4mg	1/50	liv:hpa,hpc,nnd.	
N,N'-DICYCLOHEXYLTHIOUREA 1212-29-9									
967	c04524	4.84gm n.s.s.	36/49	3.25gm	37/50	6.50gm	37/50		
a	c04524	30.1gm n.s.s.	5/49	3.25gm	2/50	6.50gm	3/50	liv:hpa,hpc,nnd.	
b	c04524	23.9gm n.s.s.	4/49	3.25gm	2/50	6.50gm	4/50	lun:a/a,a/c.	
968	c04524	4.43gm n.s.s.	39/50	3.00gm	37/50	6.00gm	39/50		
a	c04524	6.61gm n.s.s.	26/50	3.00gm	18/50	6.00gm	25/50	liv:hpa,hpc,nnd.	
b	c04524	13.6gm n.s.s.	9/50	3.00gm	5/50	6.00gm	9/50	lun:a/a,a/c.	
969	c04524	3.02gm n.s.s.	48/50	1.25gm	31/50	2.50gm	43/50		
a	c04524	15.2gm n.s.s.	1/50	1.25gm	1/50	2.50gm	1/50	liv:hpa,hpc,nnd.	
970	c04524	2.45gm n.s.s.	4/50	1.00gm	9/50	2.00gm	12/50		S
a	c04524	3.32gm n.s.s.	1/50	1.00gm	7/50	2.00gm	6/50	thy:fca,fcc.	S
b	c04524	7.90gm n.s.s.	0/50	1.00gm	0/50	2.00gm	3/50		S
c	c04524	1.18gm n.s.s.	36/50	1.00gm	36/50	2.00gm	43/50		
d	c04524	5.92gm n.s.s.	0/50	1.00gm	3/50	2.00gm	2/50	liv:hpa,hpc,nnd.	
DICYCLOPENTADIENE DIOXIDE 81-21-0									
971	381	407.mg n.s.s.	3/13	493.mg	2/19	1.04gm	0/15	Weisburger;jept,2,325-356;1978/pers.comm./Russfield 1973	
a	381	n.s.s. n.s.s.	0/13	493.mg	0/19	1.04gm	0/15		
b	381	232.mg n.s.s.	9/13	493.mg	7/19	1.04gm	1/15		
972	381	140.mg 12.1gm	2/16	455.mg	5/15	909.mg	2/16		
a	381	380.mg n.s.s.	2/16	455.mg	3/15	909.mg	3/16		
b	381	66.5mg 962.mg	9/16	455.mg	13/15	909.mg	8/16		

Spe	Strain	Site	Xpo+Xpt		TD50	2Tailpvl
Sex	Route	Hist	Notes		DR	AuOp
973	R m cdr eat liv mix 18m25				3.91gm *	P<.8 -
a	R m cdr eat tba mix 18m25				176.mg *	P<.03 -
DIELDRIN						
				100ng.....1ug.....10.....100.....1mg.....10.....100.....1g.....10		
974	H f syg eat liv hpt 23m26 e				176.mg *	P<.3 -
a	H f syg eat lun tum 23m26 e				no dre	P=1. -
b	H f syg eat tba mix 23m26 e				355.mg *	P<.6 -
975	H m syg eat liv hpt 26m26 e				198.mg *	P<.4 -
a	H m syg eat lun ade 26m26 e				732.mg *	P<.2 -
b	H m syg eat tba mix 26m26 e				69.9mg *	P<.05 -
976	M f b6c eat TBA MXB 80w91 s				no dre	P=1. -
a	M f b6c eat liv MXB 80w91 s				1.09mg \	P<.06
b	M f b6c eat lun MXB 80w91 s				5.05mg *	P<.4
977	M m b6c eat TBA MXB 80w91 s				1.06mg *	P<.2 -
a	M m b6c eat liv MXB 80w91 s				1.04mg *	P<.2
b	M m b6c eat lun MXB 80w91 s				24.7mg *	P<.9
978	M m b6c eat liv hpc 80w89 s	pool			1.35mg *	P<.08 a
979	M b c3e eat liv hpa 24m24 e				4.09mg	P<.0005+
a	M b c3e eat lun ade 24m24 e				no dre	P=1. -
b	M b c3e eat lun car 24m24 e				no dre	P=1. -
980	M b c3h eat liv hpt 24m24				3.08mg	P<.0005
a	M b c3h eat liv hpc 24m24				167.mg	P<.8
b	M b c3h eat tba ben 24m24				3.10mg	P<.0005
c	M b c3h eat tba mal 24m24				no dre	P=1. -
981	M f cf1 eat lun ade 28m32 ee				.606mg Z	P<.002 -
a	M f cf1 eat liv mix 28m32 ee				.642mg *	P<.0005+
b	M f cf1 eat liv lpb 28m32 ee				1.96mg Z	P<.0005
c	M f cf1 eat lun car 28m32 ee				1.78mg Z	P<.06 -
982	M f cf1 eat liv mix 25m30 aea				1.49mg *	P<.0005+
a	M f cf1 eat liv lpb 25m30 aea				9.72mg *	P<.0005
b	M f cf1 eat lun ade 25m30 aea				no dre	P=1. -
c	M f cf1 eat lun car 25m30 aea				no dre	P=1. -
983	M f cf1 eat liv lpb 90w90 e				2.59mg	P<.007
a	M f cf1 eat liv mix 90w90 e				1.05mg	P<.02 +
b	M f cf1 eat lun ade 90w90 e				no dre	P=1. -
c	M f cf1 eat lun car 90w90 e				no dre	P=1. -
984	M f cf1 eat liv mix 30m30 e				3.11mg	P<.02 +
a	M f cf1 eat liv lpb 30m30 e				12.1mg	P<.06
b	M f cf1 eat lun ade 30m30 e				no dre	P=1. -
c	M f cf1 eat lun car 30m30 e				no dre	P=1. -
985	M f cf1 eat liv mix 25m25 e				1.16mg	P<.002 +
a	M f cf1 eat liv lpb 25m25 e				3.96mg	P<.007
b	M f cf1 eat lun ade 25m25 e				5.69mg	P<.4 -
c	M f cf1 eat lun car 25m25 e				no dre	P=1. -
986	M f cf1 eat liv mix 26m26 e				.567mg	P<.0005+
a	M f cf1 eat liv lct 26m26 e				1.59mg	P<.0005+
b	M f cf1 eat lun tum 26m26 e				no dre	P=1. -
987	M m cf1 eat liv mix 28m31 ee				.547mg *	P<.0005+
a	M m cf1 eat liv lpb 28m31 ee				1.68mg *	P<.0005
b	M m cf1 eat lun ade 28m31 ee				2.13mg Z	P<.5 -
c	M m cf1 eat lun car 28m31 ee				3.71mg Z	P<.4 -
988	M m cf1 eat liv mix 26m30 aea				1.12mg Z	P<.0005+
a	M m cf1 eat liv lpb 26m30 aea				4.66mg *	P<.0005
b	M m cf1 eat lun ade 26m30 aea				no dre	P=1. -
c	M m cf1 eat lun car 26m30 aea				no dre	P=1. -
989	M m cf1 eat liv mix 30m30 e				.913mg	P<.002 +
a	M m cf1 eat liv lpb 30m30 e				5.12mg	P<.04
b	M m cf1 eat lun ade 30m30 e				no dre	P=1. -
c	M m cf1 eat lun car 30m30 e				no dre	P=1. -
990	M m cf1 eat liv mix 30m30 e				1.91mg	P<.04 +
a	M m cf1 eat liv lpb 30m30 e				6.58mg	P<.2
b	M m cf1 eat lun ade 30m30 e				no dre	P=1. -
c	M m cf1 eat lun car 30m30 e				no dre	P=1. -
991	M m cf1 eat liv mix 26m29 e				.713mg	P<.002 +
a	M m cf1 eat liv lpb 26m29 e				4.02mg	P<.006
b	M m cf1 eat lun ade 26m29 e				no dre	P=1. -
c	M m cf1 eat lun car 26m29 e				no dre	P=1. -
992	M m cf1 eat liv mix 26m26 e				noTD50	P<.0005+
a	M m cf1 eat liv lct 26m26 e				1.28mg	P<.0005+
b	M m cf1 eat lun tum 26m26 e				no dre	P=1. -
993	R f f34 eat TBA MXB 24m24 a				489.mg *	P<.1. -
a	R f f34 eat liv MXB 24m24 a				no dre	P=1. -
994	R m f34 eat TBA MXB 24m24 a				7.28mg *	P<.4 -
a	R m f34 eat liv MXB 24m24 a				no dre	P=1. -
995	R b osm eat lun lys 24m24 es				no dre	P=1. -
a	R b osm eat tba mix 24m24 es				no dre	P=1. +
996	R f osm eat TBA MXB 21m26 sv				no dre	P=1. -
a	R f osm eat liv MXB 21m26 sv				38.4mg *	P<.8

Spe	Strain	Site	Xpo+Xpt	Notes	TD50	2Tailpvl
Sex	Route	Hist			DR	AuOp
997	R f osm eat	edr MXA	21m25	sv pool		#4.42mg \ P<.003 -
998	R f osm eat	liv tum	28m29	ev		no dre P=1. -
a	R f osm eat	tba mix	28m29	ev		no dre P=1. -
999	R m osm eat	TBA MXB	21m26	sv	>	3.34mg * P<.6 -
a	R m osm eat	liv MXB	21m26	sv		no dre P=1. -
1000	R m osm eat	liv hem	29m29	ev	>	no dre P=1. -
a	R m osm eat	tba mix	29m29	ev		no dre P=1. -
1001	R f cfe eat	tba mix	24m24	e	>	no dre P=1. -
1002	R m cfe eat	tba mix	24m24	e	>	2.01mg * P<.5 -
1003	R f nss eat	tba tum	24m24		>	57.2mg * P<.9 -
1004	R m nss eat	tba tum	24m24		>	40.5mg * P<.8 -
DIELDRIN, PHOTO- 100ng...1ug...10...100...1mg...10...100...1g...10						
1005	M f b6c eat	TBA MXB	80w92		>	.743mg * P<.6 -
a	M f b6c eat	liv MXB	80w92			2.53mg * P<.4 -
b	M f b6c eat	lun MXB	80w92			6.78mg * P<.9 -
1006	M m b6c eat	TBA MXB	80w93		>	.494mg * P<.7 -
a	M m b6c eat	liv MXB	80w93			1.96mg * P<.1 -
b	M m b6c eat	lun MXB	80w93			.465mg * P<.09 -
1007	R f osm eat	mgl MXA	16m26	ev	: ±	#.612mg * P<.04 -
a	R f osm eat	TBA MXB	16m26	ev		.327mg * P<.4 -
b	R f osm eat	liv MXB	16m26	ev		no dre P=1. -
1008	R m osm eat	TBA MXB	19m26		>	no dre P=1. -
a	R m osm eat	liv MXB	19m26			7.72mg * P<.4 -
1009	R m osm eat	--- hem	19m25	pool	: ±	#2.89mg * P<.02 -
D,L-DIEPOXYBUTANE 100ng...1ug...10...100...1mg...10...100...1g...10						
1010	R f esd gav	sto tum	52w52		>	no dre P=1. -
DIETHYL-beta,gamma-EPOXYPROPYLPHOSPHONATE .1ug...10...100...1mg...10...100...1g...10						
1011	M f hic ipj	lun ptm	64w64		: ±	12.4mg P<.02
N,N-DIETHYL-4-(4'-[PYRIDYL-1'-OXIDE]AZO)ANILINE...10...100...1mg...10...100...1g...10						
1012	R m sda eat	liv tum	52w52	bfr	<	noTD50 P<.0005+
O,O-DIETHYL-O-(3,5,6-TRICHLORO-2-PYRIDYL)PHOSPHOROTHIOATE...100...1mg...10...100...1g...10						
1013	R f she eat	liv tum	24m24	e	>	no dre P=1. -
a	R f she eat	tba mix	24m24	e		no dre P=1. -
1014	R m she eat	liv bda	24m24	e	>	70.6mg * P<.4 -
a	R m she eat	tba mix	24m24	e		203.mg * P<.1. -
DIETHYLACETAMIDE 100ng...1ug...10...100...1mg...10...100...1g...10						
1015	R m wis gav	kid ptc	73w73	e	>	8.85mg P<.5 +
a	R m wis gav	liv tum	73w73	e		no dre P=1. -
b	R m wis gav	tba mix	73w73	e		11.8mg P<.9 -
DIETHYLENE GLYCOL 100ng...1ug...10...100...1mg...10...100...1g...10						
1016	R m osm eat	ubl mix	24m24	r		1.66gm * P<.002 +
DIETHYLFORMAMIDE 100ng...1ug...10...100...1mg...10...100...1g...10						
1017	R m wis gav	liv tum	73w73	e	>	no dre P=1. -
a	R m wis gav	tba mix	73w73	e		no dre P=1. -
DIETHYLSTILBESTROL 100ng...1ug...10...100...1mg...10...100...1g...10						
1018	M m c3c eat	mgl car	24m24	er	.+	35.9ug * P<.0005+
1019	M m c3c eat	mgl car	24m24	er	. + .	42.1ug \ P<.0005+
1020	M m c3c eat	mgl car	24m24	er	. + .	78.9ug * P<.0005+
1021	M f c3h eat	mgl car	85w85	r	. + .	29.2ug * P<.0005+
1022	M f c3h eat	mgl adc	24m24	r	. + .	26.0ug P<.0005+
1023	M f c3j eat	mgl adc	52w52	ek	. ±	82.5ug * P<.03
1024	M f c3j eat	ova tua	78w78	ek	>	22.2ug * P<.3
a	M f c3j eat	mgl adc	78w78	ek		no dre P=1. -
1025	M f c3j eat	mgl adc	24m24	ek	>	14.2mg * P<.1
a	M f c3j eat	ova tua	24m24	ek		no dre P=1. -
1026	M f cbj eat	mgl tum	52w52	ek	>	no dre P=1. -
1027	M f cbj eat	mgl adc	78w78	ek	. ±	.295mg * P<.04
a	M f cbj eat	ova tua	78w78	ek		.329mg * P<.3
1028	M f cbj eat	ova tua	24m24	ek	>	.597mg * P<.8
1029	M f cbj eat	ova tua	30m30	ek	>	no dre P=1. -
a	M f cbj eat	mgl adc	30m30	ek		no dre P=1. -
1030	R f cdr eat	liv hpt	21m24	ses	. ±	.130mg \ P<.1 -
1031	R m cdr eat	liv tum	21m24	ses	>	no dre P=1. -
1032	R m cdr eat	pit cra	66w66		. + .	.114mg P<.002 +
a	R m cdr eat	adr coa	66w66			.390mg P<.07 +
b	R m cdr eat	liv nod	66w66			.390mg P<.07
c	R m cdr eat	liv car	66w66			1.21mg P<.3

Spe	Strain	Site	Xpo+Xpt	Notes	TD50	2Tailpvl
Sex	Route	Hist			DR	AuOp
N,N'-DIETHYLTHIOUREA				100ng...1ug...10...100...1mg...10...100...1g...10		
1033	M f	b6c eat	TBA MXB 24m24		>	no dre P=1. -
a	M f	b6c eat	liv MXB 24m24			687.mg * P<.3
b	M f	b6c eat	lun MXB 24m24			no dre P=1.
1034	M m	b6c eat	TBA MXB 24m24		>	no dre P=1. -
a	M m	b6c eat	liv MXB 24m24			no dre P=1.
b	M m	b6c eat	lun MXB 24m24			no dre P=1.
1035	R f	f34 eat	thy MXA 24m24	: + :		23.8mg * P<.0005c
a	R f	f34 eat	thy fcc 24m24			57.9mg * P<.008 c
b	R f	f34 eat	TBA MXB 24m24			21.5mg * P<.3
c	R f	f34 eat	liv MXB 24m24			no dre P=1.
1036	R m	f34 eat	thy MXA 24m24	: + :		24.3mg / P<.0005c
a	R m	f34 eat	thy fcc 24m24			33.6mg * P<.003 c
b	R m	f34 eat	TBA MXB 24m24			12.9mg * P<.04
c	R m	f34 eat	liv MXB 24m24			no dre P=1.
1,2-DIFORMYLHYDRAZINE				100ng...1ug...10...100...1mg...10...100...1g...10		
1037	M f	swa wat	lun ade 83w83 e		.	561.mg P<.0005
a	M f	swa wat	lun mix 83w83 e		.	571.mg P<.0005+
b	M f	swa wat	lun adc 83w83 e			2.17gm P<.0005
c	M f	swa wat	liv hpt 83w83 e			7.82gm P<.07 -
d	M f	swa wat	liv mix 83w83 e			89.2gm P<.8
1038	M m	swa wat	lun ade 83w83 e		.	779.mg P<.0005
a	M m	swa wat	lun mix 83w83 e			806.mg P<.0005+
b	M m	swa wat	lun adc 83w83 e			4.53gm P<.0005
c	M m	swa wat	liv mix 83w83 e			8.14gm P<.02
d	M m	swa wat	liv hpt 83w83 e			11.3gm P<.02 -
1,2-DIHYDRO-2-(5-NITRO-2-THIENYL)QUINAZOLIN-4(3H)-ONE				10...100...1mg...10...100...1g...10		
1039	R f	sda eat	agl adc 46w66 e		.	13.3mg P<.0005
a	R f	sda eat	tba mix 46w66 e		.	1.53mg P<.0005+
3,6-DIHYDRO-2-NITROSO-2H-1,2-OXAZINE				...1ug...10...100...1mg...10...100...1g...10		
1040	R b	sda wat	liv hpt 20m23		>	417.mg P<.3 -
a	R b	sda wat	tba mal 20m23			90.6mg P<.07 +
b	R b	sda wat	tba mix 20m23			110.mg P<.3
DIHYDROSAFROLE				100ng...1ug...10...100...1mg...10...100...1g...10		
1041	M f	b6a orl	sto pam 81w81 evx		.	84.7mg P<.0005
a	M f	b6a orl	lun ade 81w81 evx		.	739.mg P<.6
b	M f	b6a orl	liv agm 81w81 evx			1.40gm P<.3
c	M f	b6a orl	liv hpt 81w81 evx			no dre P=1.
d	M f	b6a orl	tba mix 81w81 evx			305.mg P<.2
1042	M m	b6a orl	liv hpt 81w81 evx		.	117.mg P<.0005+
a	M m	b6a orl	lun ade 81w81 evx			323.mg P<.2
b	M m	b6a orl	lun mix 81w81 evx			448.mg P<.4
c	M m	b6a orl	tba mix 81w81 evx			86.6mg P<.004
1043	M f	b6c orl	lun ade 81w81 evx		.	230.mg P<.006 +
a	M f	b6c orl	liv hpt 81w81 evx			no dre P=1.
b	M f	b6c orl	tba mix 81w81 evx			170.mg P<.02
1044	M m	b6c orl	liv hpt 81w81 evx		.	90.0mg P<.0005+
a	M m	b6c orl	lun ade 81w81 evx			358.mg P<.2
b	M m	b6c orl	tba mix 81w81 evx			107.mg P<.09
1045	R b	osm eat	eso mix 24m24		.	143.mg * P<.0005+
DIMETHOATE				100ng...1ug...10...100...1mg...10...100...1g...10		
1046	M f	b6c eat	TBA MXB 80w93		>	no dre P=1. -
a	M f	b6c eat	liv MXB 80w93			no dre P=1.
b	M f	b6c eat	lun MXB 80w93			222.mg * P<.4
1047	M m	b6c eat	TBA MXB 69w93		>	no dre P=1. -
a	M m	b6c eat	liv MXB 69w93			no dre P=1.
b	M m	b6c eat	lun MXB 69w93			no dre P=1.
1048	R f	osm eat	TBA MXB 19m26 sv		>	92.4mg * P<.8 -
a	R f	osm eat	liv MXB 19m26 sv			126.mg * P<.3
1049	R m	osm eat	TBA MXB 19m26 sv		>	no dre P=1. -
a	R m	osm eat	liv MXB 19m26 sv			215.mg * P<.8
DIMETHOXANE				100ng...1ug...10...100...1mg...10...100...1g...10		
1050	R m	wis wat	liv hpt 20m23 e		.	716.mg P<.005 +
a	R m	wis wat	kid ptc 20m23 e			6.77gm P<.4 +
b	R m	wis wat	--- mlk 20m23 e			6.77gm P<.4 +
c	R m	wis wat	ski epc 20m23 e			6.77gm P<.4 +
d	R m	wis wat	sub fba 20m23 e			6.77gm P<.4 +
e	R m	wis wat	--- lys 20m23 e			29.8gm P<.1 +
f	R m	wis wat	lun tum 20m23 e			no dre P=1.
g	R m	wis wat	tba mix 20m23 e			419.mg P<.004
2,5-DIMETHOXY-4'-AMINOSTILBENE				100ng...1ug...10...100...1mg...10...100...1g...10		
1051	M f	chi eat	lun mix 77w90		.	152.mg \ P<.09 -
a	M f	chi eat	liv mix 77w90		.	no dre P=1. -

RefNum	LoConf	UpConf	Cntrl	1Dose	1Inc	2Dose	2Inc	Citation or Pathology	Brkly Code
M,N'-DIETHYLTHIOUREA 105-55-5									
1033	c03816	102.mg	n.s.s.	11/20	32.2mg	23/50	64.3mg 15/50		
a	c03816	208.mg	n.s.s.	0/20	32.2mg	1/50	64.3mg 2/50	liv:hpa,hpc,nnd.	
b	c03816	472.mg	n.s.s.	1/20	32.2mg	1/50	64.3mg 0/50	lun:a/a,a/c.	
1034	c03816	77.7mg	n.s.s.	8/19	29.8mg	21/50	59.4mg 23/50		
a	c03816	94.1mg	n.s.s.	5/19	29.8mg	7/50	(59.4mg 3/50)	liv:hpa,hpc,nnd.	
b	c03816	163.mg	n.s.s.	2/19	29.8mg	4/50	59.4mg 6/50	lun:a/a,a/c.	
1035	c03816	14.2mg	55.0mg	0/20	6.20mg	4/50	12.4mg 17/50		thy:fca,fcc.
a	c03816	27.3mg	774.mg	0/20	6.20mg	1/50	12.4mg 8/50		
b	c03816	6.90mg	n.s.s.	13/20	6.20mg	33/50	12.4mg 41/50		
c	c03816	n.s.s.	n.s.s.	0/20	6.20mg	0/50	12.4mg 0/50	liv:hpa,hpc,nnd.	thy:fca,fcc.
1036	c03816	13.5mg	50.0mg	0/20	5.00mg	1/50	9.90mg 15/50		
a	c03816	17.3mg	136.mg	0/20	5.00mg	1/50	9.90mg 11/50		
b	c03816	6.15mg	n.s.s.	5/20	5.00mg	23/50	9.90mg 31/50		
c	c03816	n.s.s.	n.s.s.	0/20	5.00mg	0/50	9.90mg 0/50	liv:hpa,hpc,nnd.	
1,2-DIFORMYLHYDRAZINE 628-36-4									
1037	491	307.mg	987.mg	10/100	4.00gm		48/50	Toth;zkko,92,11-16;1978	
a	491	310.mg	1.02gm	15/100	4.00gm		48/50		
b	491	1.33gm	3.98gm	6/100	4.00gm		29/50		
c	491	1.26gm	n.s.s.	0/19	4.00gm		1/5		
d	491	7.47gm	n.s.s.	3/46	4.00gm		3/36		
1038	491	469.mg	1.38gm	17/98	3.33gm		41/47		
a	491	479.mg	1.48gm	22/98	3.33gm		41/47		
b	491	2.25gm	14.5gm	6/98	3.33gm		15/47		
c	491	2.86gm	n.s.s.	3/69	3.33gm		6/30		
d	491	3.62gm	n.s.s.	1/69	3.33gm		4/30		
1,2-DIHYDRO-2-(5-NITRO-2-THIENYL)QUINAZOLIN-4(3H)-ONE 33389-33-2									
1039	1390	5.76mg	48.5mg	2/84	17.4mg		8/25	Cohen;jnci,57,277-282;1976	
a	1390	.647mg	3.36mg	6/84	17.4mg		24/25		
3,6-DIHYDRO-2-NITROSO-2H-1,2-OXAZINE (N-nitroso-3,6-dihydrooxazine-1,2) 3276-41-3									
1040	1417	67.9mg	n.s.s.	0/20	33.1mg		1/20	Wiessler;zkko,79,114-117;1973	
a	1417	29.7mg	n.s.s.	1/20	33.1mg		5/20		
b	1417	28.5mg	n.s.s.	3/20	33.1mg		6/20		
DIHYDROSAFROLE 94-58-6									
1041	111	41.0mg	212.mg	0/15	192.mg		11/18	Innes;ntis,1968/1969	
a	111	128.mg	n.s.s.	2/15	192.mg		4/18		
b	111	228.mg	n.s.s.	0/15	192.mg		1/18		
c	111	263.mg	n.s.s.	1/15	192.mg		1/18		
d	111	89.7mg	n.s.s.	2/15	192.mg		6/18		
1042	111	51.9mg	358.mg	0/18	179.mg		8/17		
a	111	89.7mg	n.s.s.	2/18	179.mg		5/17		
b	111	95.6mg	n.s.s.	3/18	179.mg		5/17		
c	111	37.0mg	685.mg	3/18	179.mg		11/17		
1043	111	86.5mg	2.37gm	0/17	192.mg		5/17		
a	111	409.mg	n.s.s.	0/17	192.mg		0/17		
b	111	66.8mg	n.s.s.	1/17	192.mg		7/17		
1044	111	40.6mg	352.mg	1/17	179.mg		10/17		
a	111	101.mg	n.s.s.	1/17	179.mg		4/17		
b	111	36.1mg	n.s.s.	7/17	179.mg		12/17		
1045	110	98.5mg	215.mg	0/20	225.mg	37/50	450.mg 15/20	Hagan;txap,7,18-24;1965	
DIMETHOATE 60-51-5									
1046	c00135	85.1mg	n.s.s.	3/10	28.0mg	15/50	55.4mg 12/50		
a	c00135	632.mg	n.s.s.	1/10	28.0mg	0/50	55.4mg 0/50	liv:hpa,hpc,nnd.	
b	c00135	102.mg	n.s.s.	0/10	28.0mg	4/50	55.4mg 5/50	lun:a/a,a/c.	
1047	c00135	48.0mg	n.s.s.	6/7	22.3mg	11/50	(38.3mg 11/50)		
a	c00135	51.0mg	n.s.s.	4/7	22.3mg	8/50	(38.3mg 6/50)	liv:hpa,hpc,nnd.	
b	c00135	101.mg	n.s.s.	3/7	22.3mg	2/50	(38.3mg 1/50)	lun:a/a,a/c.	
1048	c00135	9.18mg	n.s.s.	7/10	6.70mg	30/50	13.4mg 21/50		
a	c00135	35.8mg	n.s.s.	1/10	6.70mg	1/50	13.4mg 5/50	liv:hpa,hpc,nnd.	
1049	c00135	9.62mg	n.s.s.	7/10	4.30mg	23/50	8.60mg 24/50		
a	c00135	39.5mg	n.s.s.	0/10	4.30mg	1/50	8.60mg 1/50	liv:hpa,hpc,nnd.	
DIMETHOXANE 828-00-2									
1050	112	322.mg	4.88gm	0/14	436.mg		8/25	Hoch-Ligetij;nci,53,791-793;1974	
a	112	1.10gm	n.s.s.	0/14	436.mg		1/25		
b	112	1.10gm	n.s.s.	0/14	436.mg		1/25		
c	112	1.10gm	n.s.s.	0/14	436.mg		1/25		
d	112	1.10gm	n.s.s.	0/14	436.mg		1/25		
e	112	946.mg	n.s.s.	1/14	436.mg		2/25		
f	112	2.08gm	n.s.s.	0/14	436.mg		0/25		
g	112	203.mg	2.46gm	1/14	436.mg		13/25		
2,5-DIMETHOXY-4'-AMINOSTILBENE 5803-51-0									
1051	381	39.1mg	n.s.s.	5/15	234.mg	6/16	(468.mg 3/17)	Weinburger;jept,2,325-356;1978/pers.comm./Russfield 1973	
a	381	n.s.s.	n.s.s.	1/15	234.mg	0/16	468.mg 0/17		

Spe	Strain	Site	Xpo+Xpt	Notes	TD50	2Tailpvl
Sex	Route	Hist			DR	AuOp
b	M f chi eat	tba mix	77w90		118.mg \	P<.06 -
1052	M m chi eat	lun mix	77w90	: ±	95.9mg \	P<.02 +
a	M m chi eat	liv mix	77w90		329.mg \	P<.04
b	M m chi eat	tba mix	77w90		126.mg \	P<.09
1053	M m chi eat	lun mix	77w90	pool : + :	115.mg \	P<.0005+
a	M m chi eat	liv hpt	77w90		376.mg \	P<.005 +
1054	R m cdr eat	sto mix	47w51 v	: (+) :	.721mg *	P<.0005+
a	R m cdr eat	smi mix	47w51 v		.866mg *	P<.0005+
b	R m cdr eat	ear mix	47w51 v		1.45mg *	P<.0005+
c	R m cdr eat	liv mix	47w51 v		2.61mg *	P<.02
d	R m cdr eat	tba mix	47w51 v		.269mg *	P<.0005
1055	R m cdr eat	sto mix	47w51 v	pool : (+) :	.721mg *	P<.0005+
a	R m cdr eat	smi mix	47w51 v		.866mg *	P<.0005+
b	R m cdr eat	ski mix	47w51 v		1.48mg *	P<.0005+
c	R m cdr eat	ear mix	47w51 v		1.54mg *	P<.0005+
2,4-DIMETHOXYANILINE.HCl 100ng...1ug...10...100...1mg...10...100...1g...10						
1056	M f b6c eat	TBA MXB	24m24	: ±	986.mg *	P<.08 -
a	M f b6c eat	liv MXB	24m24		2.79gm *	P<.4
b	M f b6c eat	lun MXB	24m24		50.6gm *	P<.9
1057	M m b6c eat	TBA MXB	24m24	: >	1.65gm /	P<.3 -
a	M m b6c eat	liv MXB	24m24		1.39gm /	P<.09
b	M m b6c eat	lun MXB	24m24		no dre	P=1.
1058	R f f34 eat	TBA MXB	24m24	: >	no dre	P=1. -
a	R f f34 eat	liv MXB	24m24		no dre	P=1.
1059	R m f34 eat	TBA MXB	24m24	: >	no dre	P=1. -
a	R m f34 eat	liv MXB	24m24		no dre	P=1.
3,3'-DIMETHOXYBENZIDINE-4,4'-DIISOCYANATE .1ug...10...100...1mg...10...100...1g...10						
1060	M f b6c eat	TBA MXB	18m24	: >	32.8gm *	P<.8 -
a	M f b6c eat	liv MXB	18m24		no dre	P=1.
b	M f b6c eat	lun MXB	18m24		no dre	P=1.
1061	M m b6c eat	TBA MXB	18m24	: >	24.0gm *	P<.7 -
a	M m b6c eat	liv MXB	18m24		12.1gm *	P<.2
b	M m b6c eat	lun MXB	18m24		87.9gm *	P<.9
1062	R f f34 orl	MXB MXB	18m24 v	: + :	1.21gm *	P<.0005
a	R f f34 orl	MXB MXB	18m24 v		1.45gm *	P<.0005
b	R f f34 orl	--- MXA	18m24 v		2.28gm *	P<.004 c
c	R f f34 orl	ute esp	18m24 v		2.74gm *	P<.003 c
d	R f f34 orl	MXA MXA	18m24 v		2.59gm \	P<.02 a
e	R f f34 orl	TBA MXB	18m24 v		773.mg *	P<.006
f	R f f34 orl	liv MXB	18m24 v		17.1gm *	P<.2
1063	R m f34 orl	MXB MXB	18m24 ev	: + :	662.mg *	P<.0005
a	R m f34 orl	MXB MXB	18m24 ev		742.mg *	P<.0005
b	R m f34 orl	--- MXA	18m24 ev		1.27gm *	P<.0005c
c	R m f34 orl	MXA MXA	18m24 ev		1.33gm *	P<.002 c
d	R m f34 orl	MXA MXA	18m24 ev		1.77gm *	P<.006 c
e	R m f34 orl	MXB MXB	18m24 ev		7.01gm *	P<.02
f	R m f34 orl	MXA MXA	18m24 ev		7.01gm *	P<.02 a
g	R m f34 orl	TBA MXB	18m24 ev		809.mg *	P<.005
h	R m f34 orl	liv MXB	18m24 ev		6.60gm *	P<.5
5,7-DIMETHOXYCYCLOPENTENE c COUMARIN .1ug...10...100...1mg...10...100...1g...10						
1064	R m fis gav	liv tum	52w87 r	: >	no dre	P=1. -
5,7-DIMETHOXYCYCLOPENTENONE 2,3-c COUMARIN.1ug...10...100...1mg...10...100...1g...10						
1065	R m fis gav	liv tum	52w74 r	: >	no dre	P=1. -
5,7-DIMETHOXYCYCLOPENTENONE 3,2-c COUMARIN.1ug...10...100...1mg...10...100...1g...10						
1066	R m fis gav	liv tum	52w87 r	: >	no dre	P=1. -
N,N-DIMETHYL-4-AMINOAZOBENZENE 100ng...1ug...10...100...1mg...10...100...1g...10						
1067	R f wal eat	liv hpt	33w56 fv	: + :	3.31mg	P<.002 +
a	R f wal eat	liv bdt	33w56 fv		4.90mg	P<.006 +
b	R f wal eat	liv cca	33w56 fv		7.42mg	P<.03 +
N,N'-DIMETHYL-N,N'-DINITROSPHTHALAMIDE...1ug...10...100...1mg...10...100...1g...10						
1068	R m wis gav	liv tum	67w67 ev	: >	no dre	P=1. -
a	R m wis gav	tba mix	67w67 ev		no dre	P=1. -
4,6-DIMETHYL-2-(5-NITRO-2-FURYL)PYRIMIDINE.1ug...10...100...1mg...10...100...1g...10						
1069	R f sda eat	for sqc	42w59 e	: <	noTD50	P<.0005+
a	R f sda eat	itn sar	42w59 e		2.61mg	P<.0005+
b	R f sda eat	itn has	42w59 e		3.43mg	P<.0005+
c	R f sda eat	mgl adc	42w59 e		6.45mg	P<.0005+
d	R f sda eat	kid tcc	42w59 e		45.5mg	P<.03 +
e	R f sda eat	tba mix	42w59 e		noTD50	P<.0005

Spe	Strain	Site	Xpo+Xpt	Notes	TD50	2Tailpvl
Sex	Route	Hist			DR	AuOp
1,2-DIMETHYL-5-NITROIMIDAZOLE 100ng...1ug...10...100...1mg...10...100...1g...10						
1070	R f	sda eat	mgl fba	46w66 e	.	17.0mg P<.0005+
a	R f	sda eat	liv tum	46w66 e	.	no dre P=1.
b	R f	sda eat	tba mix	46w66 e	.	17.0mg P<.0005
DIMETHYL TEREPHTHALATE 100ng...1ug...10...100...1mg...10...100...1g...10						
1071	M f	b6c eat	TBA MXB	24m24	.	4.34gm / P<.7 -
a	M f	b6c eat	liv MXB	24m24	.	no dre P=1.
b	M f	b6c eat	lun MXB	24m24	.	44.0gm \ P<.1.
1072	M m	b6c eat	lun MXA	24m24	.	#1.16gm * P<.002 -
a	M m	b6c eat	TBA MXB	24m24	.	no dre P=1.
b	M m	b6c eat	liv MXB	24m24	.	no dre P=1.
c	M m	b6c eat	lun MXB	24m24	.	1.16gm * P<.002
1073	R f	f34 eat	TBA MXB	24m24	.	342.mg \ P<.5 -
a	R f	f34 eat	liv MXB	24m24	.	no dre P=1.
1074	R m	f34 eat	TBA MXB	24m24	.	no dre P=1. -
a	R m	f34 eat	liv MXB	24m24	.	no dre P=1.
trans-2-[(DIMETHYLAMINO)METHYLIMINO]-5-[2-(5-NITRO-2-FURYL)VINYL]-1,3,4-OXADIAZOLE 10...100...1g...10						
1075	R f	sda eat	mgl adc	46w66 e	.	20.4mg P<.0005
a	R f	sda eat	mgl mix	46w66 e	.	22.4mg P<.0005+
b	R f	sda eat	for sqp	46w66 e	.	221.mg P<.08 +
c	R f	sda eat	duo adp	46w66 e	.	336.mg P<.2 +
d	R f	sda eat	duo adc	46w66 e	.	336.mg P<.2 +
e	R f	sda eat	lun atc	46w66 e	.	+historical P<.4 +
f	R f	sda eat	liv tum	46w66 e	.	no dre P=1.
g	R f	sda eat	tba mix	46w66 e	.	20.6mg P<.0005
4-DIMETHYLAMINO-3,5-XYLENOL 100ng...1ug...10...100...1mg...10...100...1g...10						
1076	M f	b6a orl	lun ade	76w76 evx	.	no dre P=1. -
a	M f	b6a orl	liv hpt	76w76 evx	.	no dre P=1. -
b	M f	b6a orl	tba mix	76w76 evx	.	220.mg P<.7 -
1077	M m	b6a orl	liv hpt	76w76 evx	.	207.mg P<.6 -
a	M m	b6a orl	lun ade	76w76 evx	.	no dre P=1. -
b	M m	b6a orl	tba mix	76w76 evx	.	1.19gm P<.1. -
1078	M f	b6c orl	lun ade	76w76 evx	.	265.mg P<.3 -
a	M f	b6c orl	liv hpt	76w76 evx	.	no dre P=1. -
b	M f	b6c orl	tba mix	76w76 evx	.	265.mg P<.3 -
1079	M m	b6c orl	lun ade	76w76 evx	.	56.1mg P<.02 -
a	M m	b6c orl	liv hpt	76w76 evx	.	247.mg P<.3 -
b	M m	b6c orl	tba mix	76w76 evx	.	34.8mg P<.004 -
DIMETHYLARSINIC ACID 100ng...1ug...10...100...1mg...10...100...1g...10						
1080	M f	b6a orl	lun ade	76w76 evx	.	108.mg P<.3 -
a	M f	b6a orl	liv hpt	76w76 evx	.	no dre P=1. -
b	M f	b6a orl	tba mix	76w76 evx	.	34.0mg P<.04 -
1081	M m	b6a orl	lun ade	76w76 evx	.	95.2mg P<.3 -
a	M m	b6a orl	liv hpt	76w76 evx	.	no dre P=1. -
b	M m	b6a orl	tba mix	76w76 evx	.	no dre P=1. -
1082	M f	b6c orl	liv hpt	76w76 evx	.	no dre P=1. -
a	M f	b6c orl	lun ade	76w76 evx	.	no dre P=1. -
b	M f	b6c orl	tba mix	76w76 evx	.	no dre P=1. -
1083	M m	b6c orl	liv hpt	76w76 evx	.	no dre P=1. -
a	M m	b6c orl	lun mix	76w76 evx	.	no dre P=1. -
b	M m	b6c orl	tba mix	76w76 evx	.	no dre P=1. -
7,12-DIMETHYLBENZ(a)ANTHRACENE 100ng...1ug...10...100...1mg...10...100...1g...10						
1084	M f	alb eat	mei ane	60w60 er	.	84.0ug P<.0005+
a	M f	alb eat	for pam	60w60 er	.	.287mg P<.0005
DIMETHYLCARBAMYL CHLORIDE 100ng...1ug...10...100...1mg...10...100...1g...10						
1085	M m	syg inh	nas sqc	26m26 er	.	+historical P<.0005+
1086	M f	hic ipj	abd mix	64w64	.	4.59mg P<.004
a	M f	hic ipj	abd ear	64w64	.	5.37mg P<.008 +
b	M f	hic ipj	lun ptm	64w64	.	6.65mg P<.3
DIMETHYLDITHIOCARBAMIC ACID, DIMETHYLAMINE 1ug...10...100...1mg...10...100...1g...10						
1087	M f	b6a orl	liv agm	76w76 evx	.	233.mg P<.3 -
a	M f	b6a orl	lun ade	76w76 evx	.	no dre P=1. -
b	M f	b6a orl	tba mix	76w76 evx	.	no dre P=1. -
1088	M m	b6a orl	liv hpt	76w76 evx	.	99.1mg P<.3 -
a	M m	b6a orl	lun ade	76w76 evx	.	no dre P=1. -
b	M m	b6a orl	tba mix	76w76 evx	.	180.mg P<.7 -
1089	M f	b6c orl	liv hpt	76w76 evx	.	233.mg P<.3 -
a	M f	b6c orl	lun mix	76w76 evx	.	no dre P=1. -
b	M f	b6c orl	tba mix	76w76 evx	.	113.mg P<.2 -
1090	M m	b6c orl	lun ade	76w76 evx	.	63.9mg P<.04 -
a	M m	b6c orl	liv hpt	76w76 evx	.	99.1mg P<.1 -
b	M m	b6c orl	tba mix	76w76 evx	.	19.5mg P<.0005-

RefNum	LoConf	UpConf	Cntrl	1Dose	1Inc	2Dose	2Inc	Citation or Pathology	Brkly Code
1,2-DIMETHYL-5-NITROIMIDAZOLE 551-92-8									
1070	200a	9.67mg	35.9mg	4/35	69.7mg	25/35		Cohen; Jnci, 51, 403-417; 1973	
a	200a	202. mg	n.s.s.	0/35	69.7mg	0/35			
b	200a	9.67mg	35.9mg	4/35	69.7mg	25/35			
DIMETHYL TEREPHTHALATE (DMT) 120-61-6									
1071	c50055	660. mg	n.s.s.	29/50	319. mg	20/50	638. mg	32/50	
a	c50055	2.21gm	n.s.s.	5/50	319. mg	1/50	(638. mg)	0/50	liv:hpa,hpc, nnd. lun:a/a, a/c.
b	c50055	926. mg	n.s.s.	4/50	319. mg	5/50	(638. mg)	0/50	lun:a/a, a/c. S
1072	c50055	640. mg	5.49gm	1/50	294. mg	8/50	589. mg	13/50	
a	c50055	731. mg	n.s.s.	36/50	294. mg	33/50	589. mg	34/50	
b	c50055	1.33gm	n.s.s.	19/50	294. mg	13/50	589. mg	16/50	liv:hpa,hpc, nnd. lun:a/a, a/c.
c	c50055	640. mg	5.49gm	1/50	294. mg	8/50	589. mg	13/50	
1073	c50055	75.7mg	n.s.s.	38/50	123. mg	38/50	(245. mg)	29/50	
a	c50055	2.03gm	n.s.s.	1/50	123. mg	1/50	245. mg	0/50	liv:hpa,hpc, nnd.
1074	c50055	168. mg	n.s.s.	40/50	98.2mg	28/50	(196. mg)	26/50	
a	c50055	1.91gm	n.s.s.	4/50	98.2mg	0/50	196. mg	1/50	liv:hpa,hpc, nnd.
trans-2-[(DIMETHYLAMINO)METHYLIMINO]-5-[2-(5-NITRO-2-FURYL)VINYL]-1,3,4-OXADIAZOLE 55738-54-0									
1075	1126	12.0mg	37.9mg	0/24	69.7mg	22/36		Cohen; Jnci, 54, 841-850; 1975	
a	1126	12.6mg	53.5mg	2/24	69.7mg	22/36			
b	1126	66.9mg	n.s.s.	0/24	69.7mg	3/36			
c	1126	82.7mg	n.s.s.	0/24	69.7mg	2/36			
d	1126	82.7mg	n.s.s.	0/24	69.7mg	2/36			
e	1126	111. mg	n.s.s.	0/24	69.7mg	1/36			
f	1126	208. mg	n.s.s.	0/24	69.7mg	0/36			
g	1126	11.7mg	46.8mg	2/24	69.7mg	23/36			
4-DIMETHYLAMINO-3,5-XYLENOL 6120-10-1									
1076	1248	46.1mg	n.s.s.	1/17	41.4mg	1/17		Innes; ntis, 1968/1969	
a	1248	77.4mg	n.s.s.	0/17	41.4mg	0/17			
b	1248	27.7mg	n.s.s.	2/17	41.4mg	3/17			
1077	1248	30.2mg	n.s.s.	1/18	38.5mg	2/17			
a	1248	47.4mg	n.s.s.	2/18	38.5mg	1/17			
b	1248	28.0mg	n.s.s.	3/18	38.5mg	3/17			
1078	1248	43.1mg	n.s.s.	0/16	41.4mg	1/18			
a	1248	82.0mg	n.s.s.	0/16	41.4mg	0/18			
b	1248	43.1mg	n.s.s.	0/16	41.4mg	1/18			
1079	1248	19.3mg	n.s.s.	0/16	38.5mg	4/18			
a	1248	40.1mg	n.s.s.	0/16	38.5mg	1/18			
b	1248	14.0mg	212. mg	0/16	38.5mg	6/18			
DIMETHYLARSINIC ACID (cacodylic acid) 75-60-5									
1080	1198	17.6mg	n.s.s.	0/18	16.9mg	1/18		Innes; ntis, 1968/1969	
a	1198	33.5mg	n.s.s.	0/18	16.9mg	0/18			
b	1198	10.3mg	n.s.s.	0/18	16.9mg	3/18			
1081	1198	15.5mg	n.s.s.	0/18	15.8mg	1/17			
a	1198	29.5mg	n.s.s.	1/18	15.8mg	0/17			
b	1198	19.4mg	n.s.s.	2/18	15.8mg	1/17			
1082	1198	33.5mg	n.s.s.	0/18	16.9mg	0/18			
a	1198	33.5mg	n.s.s.	1/18	16.9mg	0/18			
b	1198	33.5mg	n.s.s.	2/18	16.9mg	0/18			
1083	1198	17.1mg	n.s.s.	3/14	15.8mg	1/14			
a	1198	24.3mg	n.s.s.	0/14	15.8mg	0/14			
b	1198	10.3mg	n.s.s.	4/14	15.8mg	3/14			
7,12-DIMETHYLBENZ(a)ANTHRACENE 57-97-6									
1084	1274	58.2ug	.126mg	0/40	.390mg	49/75		Chouroulinkov; bdca, 54, 67-78; 1967	
a	1274	.169mg	.563mg	0/40	.390mg	20/75			
DIMETHYLCARBAMYL CHLORIDE 79-44-7									
1085	1142	.439mg	.928mg	0/50	.553mg	50/99		Sellakumar; jept, 4, 107-115; 1980	
1086	1143	2.02mg	34.7mg	1/30	5.71mg	9/30		Van Duuren; jnci, 53, 695-700; 1974	
a	1143	2.25mg	134. mg	1/30	5.71mg	8/30			
b	1143	1.76mg	n.s.s.	10/30	5.71mg	14/30			
DIMETHYLDITHIOCARBAMIC ACID, DIMETHYLAMINE 598-64-1									
1087	1222	37.9mg	n.s.s.	0/17	36.4mg	1/18		Innes; ntis, 1968/1969	
a	1222	43.3mg	n.s.s.	1/17	36.4mg	1/18			
b	1222	36.4mg	n.s.s.	2/17	36.4mg	2/18			
1088	1222	22.1mg	n.s.s.	1/18	33.9mg	3/18			
a	1222	44.5mg	n.s.s.	2/18	33.9mg	1/18			
b	1222	21.1mg	n.s.s.	3/18	33.9mg	4/18			
1089	1222	37.9mg	n.s.s.	0/16	36.4mg	1/18			
a	1222	72.1mg	n.s.s.	0/16	36.4mg	0/18			
b	1222	27.8mg	n.s.s.	0/16	36.4mg	2/18			
1090	1222	19.3mg	n.s.s.	0/16	33.9mg	3/17			
a	1222	24.3mg	n.s.s.	0/16	33.9mg	2/17			
b	1222	8.66mg	62.1mg	0/16	33.9mg	8/17			

Spe	Strain	Site	Xpo+Xpt	Notes	TD50	ZTailpvl
Sex	Route	Hist			DR	AuOp
1,1-DIMETHYLHYDRAZINE				<u>100ng</u> ... <u>1ug</u> ... <u>10</u> ... <u>100</u> ... <u>1mg</u> ... <u>10</u> ... <u>100</u> ... <u>1g</u> ... <u>10</u>		
1091	H f	syg wat cec mix	79w79 e	.	104.mg	P<.0005+
	a	H f	syg wat blv mix	79w79 e	620.mg	P<.04
	b	H f	syg wat liv mix	79w79 e	620.mg	P<.04
	c	H f	syg wat lun tum	79w79 e	no dre	P=1.
1092	H m	syg wat cec mix	91w91 e	.	155.mg	P<.0005+
	a	H m	syg wat liv mix	91w91 e	183.mg	P<.0005
	b	H m	syg wat blv mix	91w91 e	183.mg	P<.0005
	c	H m	syg wat liv ang	91w91 e	242.mg	P<.0005
	d	H m	syg wat cec adc	91w91 e	322.mg	P<.0005
	e	H m	syg wat cec pla	91w91 e	372.mg	P<.0005
	f	H m	syg wat liv adm	91w91 e	975.mg	P<.02
	g	H m	syg wat lun tum	91w91 e	no dre	P=1.
1093	M f	sua wat blv ang	72w72 e	.	3.57mg	P<.0005+
	a	M f	sua wat blv mix	72w72 e	3.65mg	P<.0005+
	b	M f	sua wat lun ade	72w72 e	5.58mg	P<.0005
	c	M f	sua wat lun mix	72w72 e	5.69mg	P<.0005+
	d	M f	sua wat lun adc	72w72 e	51.6mg	P<.007
	e	M f	sua wat kid ade	72w72 e	148.mg	P<.2
	f	M f	sua wat liv tum	72w72 e	no dre	P=1.
1094	M m	sua wat blv ang	62w62 e	.	2.09mg	P<.0005+
	a	M m	sua wat blv mix	62w62 e	2.11mg	P<.0005+
	b	M m	sua wat lun ade	62w62 e	2.62mg	P<.0005
	c	M m	sua wat lun mix	62w62 e	2.62mg	P<.0005+
	d	M m	sua wat kid ade	62w62 e	19.5mg	P<.0005
	e	M m	sua wat liv hpt	62w62 e	30.4mg	P<.005 +
	f	M m	sua wat lun adc	62w62 e	46.6mg	P<.005
1095	M f	awi gav	lun tum 40w55	.	16.0mg	P<.2 +
1,2-DIMETHYLHYDRAZINE.2HCl				<u>100ng</u> ... <u>1ug</u> ... <u>10</u> ... <u>100</u> ... <u>1mg</u> ... <u>10</u> ... <u>100</u> ... <u>1g</u> ... <u>10</u>		
1096	H f	syg wat blv ang	67w67 e	.	.156mg	P<.0005+
	a	H f	syg wat liv ang	67w67 e	.156mg	P<.0005+
	b	H f	syg wat lun ang	67w67 e	.395mg	P<.0005+
	c	H f	syg wat cec mix	67w67 e	.864mg	P<.0005+
	d	H f	syg wat liv mix	67w67 e	.917mg	P<.0005+
	e	H f	syg wat mus ang	67w67 e	1.03mg	P<.0005+
	f	H f	syg wat liv hpt	67w67 e	1.40mg	P<.003
	g	H f	syg wat cec pla	67w67 e	2.08mg	P<.004
	h	H f	syg wat hea ang	67w67 e	2.13mg	P<.004 +
	i	H f	syg wat cec adc	67w67 e	2.84mg	P<.02
	j	H f	syg wat pan ang	67w67 e	18.4mg	P<.4 +
1097	H m	syg wat blv ang	71w71 e	.	.211mg	P<.0005+
	a	H m	syg wat liv ang	71w71 e	.211mg	P<.0005+
	b	H m	syg wat lun ang	71w71 e	.685mg	P<.0005+
	c	H m	syg wat mus ang	71w71 e	1.36mg	P<.0005+
	d	H m	syg wat liv mix	71w71 e	2.05mg	P<.006 +
	e	H m	syg wat hea ang	71w71 e	2.49mg	P<.008 +
	f	H m	syg wat cec pla	71w71 e	2.42mg	P<.02 +
	g	H m	syg wat pan ang	71w71 e	18.6mg	P<.4 +
1098	M f	sua wat blv ang	52w52 e	.	noTD50	P<.0005+
	a	M f	sua wat lun ade	52w52 e	.559mg	P<.0005+
	b	M f	sua wat liv hpt	52w52 e	13.9mg	P<.5
1099	M m	sua wat blv ang	52w52 e	.	.102mg	P<.0005+
	a	M m	sua wat prn ang	52w52 e	.180mg	P<.0005
	b	M m	sua wat mus ang	52w52 e	.203mg	P<.0005
	c	M m	sua wat fat ang	52w52 e	.215mg	P<.0005
	d	M m	sua wat pep ang	52w52 e	.337mg	P<.0005
	e	M m	sua wat liv ang	52w52 e	.377mg	P<.0005
	f	M m	sua wat sub ang	52w52 e	.781mg	P<.0005
	g	M m	sua wat lyd ang	52w52 e	1.02mg	P<.0005
	h	M m	sua wat lun mix	52w52 e	1.81mg	P<.06 +
2-(2,2-DIMETHYLHYDRAZINO)-4-(5-NITRO-2-FURYL)THIAZOLE				<u>10</u> ... <u>100</u> ... <u>1mg</u> ... <u>10</u> ... <u>100</u> ... <u>1g</u> ... <u>10</u>		
1100	R f	sda eat mgl mix	46w66 e	.	noTD50	P<.0005+
	a	R f	sda eat mgl adc	46w66 e	.391mg	P<.0005
	b	R f	sda eat --- lbl	46w66 e	+historical	P<.09 +
	c	R f	sda eat liv tum	46w66 e	no dre	P=1.
	d	R f	sda eat tbe mix	46w66 e	noTD50	P<.0005
DIMETHYLNITRAMINE				<u>100ng</u> ... <u>1ug</u> ... <u>10</u> ... <u>100</u> ... <u>1mg</u> ... <u>10</u> ... <u>100</u> ... <u>1g</u> ... <u>10</u>		
1101	R f	nzd wat liv tum	12w24	.	.256mg	P<.0005+
	a	R f	nzd wat bil ade	12w24	1.65mg	P<.0005-
	b	R f	nzd wat tbe mix	12w24	.321mg	P<.002
1102	R m	nzd wat liv tum	12w24	.	.322mg	P<.0005+
	a	R m	nzd wat tbe mix	12w24	.403mg	P<.002
DINITRO(1-METHYLHEPTYL)PHENYL CROTONATE				<u>10</u> ... <u>100</u> ... <u>1mg</u> ... <u>10</u> ... <u>100</u> ... <u>1g</u> ... <u>10</u>		
1103	M f	b6a orl liv hpt	76w76 evx	.	no dre	P=1. -
	a	M f	b6a orl lun ade	76w76 evx	no dre	P=1. -
	b	M f	b6a orl tbe mix	76w76 evx	no dre	P=1. -

RefNum	LoConf	UpConf	Cntrl	1Dose	1Inc	2Dose	2Inc	Citation or Pathology	Brkly Code
1,1-DIMETHYLHYDRAZINE 57-14-7									
1091	367	49.0mg	301.mg	1/50	136.mg	10/24		Toth;canc,40,2427-2431;1977	
a	367	152.mg	n.s.s.	0/50	136.mg	2/24			
b	367	152.mg	n.s.s.	0/50	136.mg	2/24			
c	367	519.mg	n.s.s.	0/100	136.mg	0/32			
1092	367	84.8mg	329.mg	0/64	120.mg	15/45			
a	367	98.0mg	399.mg	0/85	120.mg	14/48			
b	367	98.0mg	399.mg	0/85	120.mg	14/48			
c	367	121.mg	592.mg	0/85	120.mg	11/48			
d	367	145.mg	957.mg	0/64	120.mg	8/45			
e	367	161.mg	1.25gm	0/64	120.mg	7/45			
f	367	295.mg	n.s.s.	0/85	120.mg	3/48			
g	367	909.mg	n.s.s.	0/88	120.mg	0/48			
1093	117	2.23mg	5.94mg	0/47	20.0mg	37/44		Toth;jnci,50,181-194;1973	
a	117	2.26mg	6.17mg	4/104	20.0mg	37/44			
b	117	3.38mg	10.3mg	12/104	20.0mg	32/44			
c	117	3.41mg	10.7mg	14/104	20.0mg	32/44			
d	117	19.2mg	1.11gm	2/104	20.0mg	6/44			
e	117	24.1mg	n.s.s.	0/32	20.0mg	1/23			
f	117	94.8mg	n.s.s.	0/109	20.0mg	0/48			
1094	117	1.33mg	3.37mg	0/50	16.7mg	42/49			
a	117	1.34mg	3.44mg	2/91	16.7mg	42/49			
b	117	1.63mg	4.53mg	10/86	16.7mg	39/48			
c	117	1.63mg	4.53mg	10/86	16.7mg	39/48			
d	117	9.19mg	59.3mg	0/45	16.7mg	9/48			
e	117	12.4mg	218.mg	0/45	16.7mg	6/48			
f	117	16.1mg	391.mg	0/86	16.7mg	4/48			
1095	1095	4.00mg	n.s.s.	8/85	10.4mg	5/25		Roe;natu,216,375-376;1967	
1,2-DIMETHYLHYDRAZINE.2HCL 306-37-6									
1096	1108	94.9ug	.258mg	0/32	1.36mg	44/48		Toth;canr,32,804-807;1972/1967a	
a	1108	94.9ug	.258mg	0/32	1.36mg	44/48			
b	1108	.250mg	.670mg	0/32	1.36mg	30/48			
c	1108	.487mg	1.76mg	0/32	1.36mg	17/47			
d	1108	.444mg	2.51mg	0/25	1.36mg	10/29			
e	1108	.566mg	2.27mg	0/32	1.36mg	15/48			
f	1108	.604mg	6.57mg	0/25	1.36mg	7/29			
g	1108	.940mg	11.0mg	0/32	1.36mg	8/47			
h	1108	.962mg	11.8mg	0/32	1.36mg	8/48			
i	1108	1.16mg	n.s.s.	0/32	1.36mg	6/47			
j	1108	3.00mg	n.s.s.	0/32	1.36mg	1/48			
1097	1108	.135mg	.342mg	0/31	1.20mg	41/49			
a	1108	.135mg	.342mg	0/31	1.20mg	41/49			
b	1108	.406mg	1.28mg	0/31	1.20mg	21/49			
c	1108	.701mg	3.69mg	0/31	1.20mg	12/49			
d	1108	.883mg	18.3mg	0/28	1.20mg	7/41			
e	1108	1.07mg	37.5mg	0/31	1.20mg	7/49			
f	1108	.987mg	n.s.s.	0/28	1.20mg	6/41			
g	1108	3.03mg	n.s.s.	0/31	1.20mg	1/49			
1098	119	n.s.s.	.128mg	4/109	2.00mg	49/49		Toth;ajpa,64,585-600;1971	
a	119	.334mg	1.11mg	0/18	2.00mg	22/48			
b	119	2.26mg	n.s.s.	0/15	2.00mg	1/41			
1099	119	60.3ug	.171mg	0/40	1.67mg	46/49			
a	119	.116mg	.291mg	0/40	1.67mg	39/49			
b	119	.131mg	.330mg	0/40	1.67mg	37/49			
c	119	.139mg	.351mg	0/40	1.67mg	36/49			
d	119	.211mg	.580mg	0/40	1.67mg	28/49			
e	119	.233mg	.662mg	0/40	1.67mg	26/49			
f	119	.427mg	1.66mg	0/40	1.67mg	15/49			
g	119	.522mg	2.49mg	0/40	1.67mg	12/49			
h	119	.655mg	n.s.s.	11/95	1.67mg	12/49			
2-(2,2-DIMETHYLHYDRAZINO)-4-(5-NITRO-2-FURYL)THIAZOLE 26049-69-4									
1100	200a	n.s.s.	.410mg	2/39	3.48mg	35/35		Cohan;jnci,51,403-417;1973	
a	200a	.219mg	.707mg	0/39	3.48mg	32/35			
b	200a	4.02mg	n.s.s.	0/39	3.48mg	2/35			
c	200a	10.1mg	n.s.s.	0/39	3.48mg	0/35			
d	200a	n.s.s.	.410mg	2/39	3.48mg	35/35			
DIMETHYLNITRAMINE 4164-28-7									
1101	119a	89.8ug	.796mg	0/107	.860mg	9/10		Goodall;clet,1,295-298;1976	
a	119a	.494mg	11.9mg	0/107	.860mg	3/10			
b	119a	96.7ug	2.35mg	40/107	.860mg	9/10			
1102	119a	.126mg	1.02mg	1/107	.753mg	8/10			
a	119a	.137mg	3.12mg	30/107	.753mg	8/10			
DINITRO(1-METHYLHEPTYL)PHENYL CROTONATE (Karathane) 6119-92-2									
1103	1290	.774mg	n.s.s.	0/17	.414mg	0/17		Innes;ntis,1968/1969	
a	1290	.774mg	n.s.s.	1/17	.414mg	0/17			
b	1290	.774mg	n.s.s.	2/17	.414mg	0/17			

Spe	Strain	Site	Xpo+Xpt	Notes	TD50	2Tailpvl
Sex	Route	Hist			DR	AuOp
1104	M m b6a	orl liv	hpt 76w76	evx		2.07mg P<.6 -
a	M m b6a	orl lun	ade 76w76	evx	>	19.1mg P<.1 -
b	M m b6a	orl tba	mix 76w76	evx		11.9mg P<.1 -
1105	M f b6c	orl liv	hpt 76w76	evx		2.50mg P<.3 -
a	M f b6c	orl lun	mix 76w76	evx	>	no dre P=1. -
b	M f b6c	orl tba	mix 76w76	evx		1.21mg P<.1 -
1106	M m b6c	orl liv	hpt 76w76	evx		2.32mg P<.3 -
a	M m b6c	orl lun	mix 76w76	evx	>	no dre P=1. -
b	M m b6c	orl tba	mix 76w76	evx		.405mg P<.007 -
2,4-DINITROPHENOL					100ng...1ug...10...100...1mg...10...100...1g...10	
1107	M b c5l	eat pit	ade 73w73	er	>	no dre P=1.
DINITROSOHOMOPIPERAZINE					100ng...1ug...10...100...1mg...10...100...1g...10	
1108	R f f34	wat ugi	car 7m31	es	.	.240mg Z P<.0005+
a	R f f34	wat eso	mix 7m31	es	.	.253mg Z P<.0005+
b	R f f34	wat ugi	mix 7m31	es	.	.708mg Z P<.0005+
c	R f f34	wat liv	mix 7m31	es	.	no dre P=1. +
d	R f f34	wat nes	olc 7m31	es	.	no dre P=1. +
1109	R f f34	wat ugi	mix 60w82	es	.	29.7ug P<.0005+
a	R f f34	wat ugi	car 60w82	es	.	46.9ug P<.0005+
b	R f f34	wat eso	mix 60w82	es	.	55.3ug P<.0005+
c	R f f34	wat nes	olc 60w82	es	.	.207mg P<.002 +
1110	R f f34	wat ugi	mix 28m31	es	.	91.4ug * P<.0005+
a	R f f34	wat liv	mix 28m31	es	.	97.3ug \ P<.006 +
b	R f f34	wat eso	mix 28m31	es	.	.105mg * P<.0005+
c	R f f34	wat ton	bcp 28m31	es	.	.630mg * P<.004 +
N,N-DINITROSOPIPERAZINE					100ng...1ug...10...100...1mg...10...100...1g...10	
1111	R m cbr	ipj liv	hpt 6m23	e	>	no dre P=1. -
DINITROSOPIPERAZINE					100ng...1ug...10...100...1mg...10...100...1g...10	
1112	M f c17	gav for	sqc 9m24	e	.	4.66mg P<.003 +
a	M f c17	gav ute	rna 9m24	e	.	4.13mg P<.02
1113	M m c17	gav for	sqc 9m24	e	.	2.01mg P<.0005+
1114	M f swi	wat lun	ade 12m23	e	.	no dre P=1.
a	M f swi	wat liv	hpc 12m23	e	.	no dre P=1.
b	M f swi	wat tba	mix 12m23	e	.	no dre P=1. +
1115	M m swi	wat lun	ade 12m23	e	.	8.70mg P<.0005
a	M m swi	wat liv	hpc 12m23	e	.	51.9mg P<.2
b	M m swi	wat tba	mix 12m23	e	.	8.24mg P<.02 +
2,4-DINITROTOLUENE					100ng...1ug...10...100...1mg...10...100...1g...10	
1116	M f b6c	eat TBA	MXB 78w93		>	no dre P=1. -
a	M f b6c	eat liv	MXB 78w93			no dre P=1.
b	M f b6c	eat lun	MXB 78w93			68.0mg \ P<.2
1117	M m b6c	eat TBA	MXB 78w92		>	no dre P=1. -
a	M m b6c	eat liv	MXB 78w92			no dre P=1.
b	M m b6c	eat lun	MXB 78w92			no dre P=1.
1118	R f f34	eat mgl	tba 18m25	v	:	12.7mg * P<.02 a
a	R f f34	eat TBA	MXB 18m25	v	:	no dre P=1.
b	R f f34	eat liv	MXB 18m25	v	:	no dre P=1.
1119	R m f34	eat MXA	MXA 18m25	v	:	9.35mg * P<.0005a
a	R m f34	eat TBA	MXB 18m25	v	:	43.7mg * P<.8
b	R m f34	eat liv	MXB 18m25	v	:	31.1mg * P<.04
1,4-DIOXANE					100ng...1ug...10...100...1mg...10...100...1g...10	
1120	M f b6c	wat liv	MXA 90w90		:+	594.ug * P<.0005c
a	M f b6c	wat liv	hpc 90w90		:+	938.ug / P<.0005c
b	M f b6c	wat TBA	MXB 90w90		:+	847.ug * P<.0005
c	M f b6c	wat liv	MXB 90w90		:+	594.ug * P<.0005
d	M f b6c	wat lun	MXB 90w90		:+	71.9ug * P<.8
1121	M m b6c	wat liv	hpc 90w91		:+	1.42gm * P<.0005c
a	M m b6c	wat liv	MXA 90w91		:+	1.46gm * P<.0005c
b	M m b6c	wat ---	MXA 90w91		:+	3.15gm \ P<.005
c	M m b6c	wat ---	lym 90w91		:+	3.93gm \ P<.009
d	M m b6c	wat TBA	MXB 90w91		:+	1.88gm * P<.03
e	M m b6c	wat liv	MXB 90w91		:+	1.46gm * P<.0005
f	M m b6c	wat lun	MXB 90w91		:+	no dre P=1.
1122	R f osm	wat MXB	MXB 26m26		:+	126.ug * P<.0005
a	R f osm	wat liv	hpa 26m26		:+	160.ug * P<.0005c
b	R f osm	wat ntu	sqc 26m26		:+	476.ug * P<.0005c
c	R f osm	wat TBA	MXB 26m26		:+	40.5mg \ P<.0005
d	R f osm	wat liv	MXB 26m26		:+	124.ug * P<.0005

RefNum	LoConf	UpConf	Cntrl	1Dose	1Inc	2Dose	2Inc	Citation or Pathology	Brkly Code
1104	1290	.302mg n.s.s.	1/18	.385mg	2/17				
a	1290	.335mg n.s.s.	2/18	.385mg	2/17				
b	1290	.280mg n.s.s.	3/18	.385mg	3/17				
1105	1290	.407mg n.s.s.	0/16	.414mg	1/17				
a	1290	.774mg n.s.s.	0/16	.414mg	0/17				
b	1290	.297mg n.s.s.	0/16	.414mg	2/17				
1106	1290	.378mg n.s.s.	0/16	.385mg	1/17				
a	1290	.721mg n.s.s.	0/16	.385mg	0/17				
b	1290	.152mg 5.47mg	0/16	.385mg	5/17				
2,4-DINITROPHENOL 51-28-5									
1107	257	241.mg n.s.s.	0/28	62.5mg	0/38			King;pseb,112,365-366;1963	
DINITROSOHOMOPIPERAZINE 55557-00-1									
1108	1375m	.144mg .501mg	0/20	10.1ug	1/20	26.4ug	3/20	72.0ug 7/20 .269mg 13/20 (1.18mg 10/20)	
a	1375m	.151mg .538mg	0/20	10.1ug	1/20	26.4ug	3/20	72.0ug 6/20 .269mg 13/20 (1.18mg 10/20)	Lijinsky;eas,6,513-527;1982/pers.comm.
b	1375m	.398mg 1.43mg	0/20	10.1ug	1/20	26.4ug	4/20	72.0ug 9/20 .269mg 16/20 1.18mg 15/20	
c	1375m	29.3mg n.s.s.	1/20	10.1ug	6/20	26.4ug	4/20	72.0ug 1/20 .269mg 0/20 1.18mg 0/20	
d	1375m	26.8mg n.s.s.	0/20	10.1ug	0/20	26.4ug	0/20	72.0ug 7/20 .269mg 0/20 1.18mg 0/20	
1109	1375n	12.2ug 68.1ug	0/20	.209mg	19/20				
a	1375n	23.4ug .102mg	0/20	.209mg	17/20				
b	1375n	28.2ug .120mg	0/20	.209mg	16/20				
c	1375n	88.4ug .783mg	0/20	.209mg	7/20				
1110	1375o	52.8ug .173mg	0/20	39.9ug	5/20	.116mg	17/20		
a	1375o	40.6ug 1.20mg	1/20	39.9ug	8/20	(.116mg 6/20)			
b	1375o	59.4ug .203mg	0/20	39.9ug	3/20	.116mg	17/20		
c	1375o	.239mg 4.43mg	0/20	39.9ug	0/20	.116mg	5/20		
N,N-DINITROSOPENTAMETHYLENETETRAMINE 101-25-7									
1111	1258	4.93mg n.s.s.	1/22	1.86mg	1/23			Boylard;ejca,4,233-239;1968	
DINITROSOPIPERAZINE 140-79-4									
1112	1347	1.59mg 28.1mg	0/22	3.08mg	4/11			Pai;carc,2,175-177;1981	
a	1347	1.36mg n.s.s.	2/22	3.08mg	5/11				
1113	1347	.831mg 7.00mg	0/12	2.56mg	7/12				
1114	1250	11.7mg n.s.s.	7/29	10.4mg	3/14			Borzsonyi;canr,40,2925-2927;1980	
a	1250	27.8mg n.s.s.	4/29	10.4mg	0/14				
b	1250	5.26mg n.s.s.	25/29	10.4mg	10/14				
1115	1250	4.07mg 27.6mg	3/50	8.67mg	11/22				
a	1250	12.2mg n.s.s.	2/50	8.67mg	3/22				
b	1250	3.17mg n.s.s.	19/50	8.67mg	15/22				
2,4-DINITROTOLUENE 121-14-2									
1116	c01865	18.6mg n.s.s.	39/100	8.80mg	14/50	(44.2mg 11/50)			
a	c01865	234.mg n.s.s.	8/100	8.80mg	1/50	44.2mg 1/50			liv:hpa,hpc,ndd. Lun:a/a,a/c.
b	c01865	18.6mg n.s.s.	2/100	8.80mg	4/50	(44.2mg 0/50)			
1117	c01865	86.7mg n.s.s.	40/100	8.20mg	13/50	40.8mg 13/50			
a	c01865	86.7mg n.s.s.	22/100	8.20mg	6/50	40.8mg 9/50			liv:hpa,hpc,ndd. Lun:a/a,a/c.
b	c01865	39.4mg n.s.s.	18/100	8.20mg	3/50	(40.8mg 2/50)			
1118	c01865	5.78mg n.s.s.	13/75	3.00mg	12/50	7.50mg 23/50			
a	c01865	5.97mg n.s.s.	57/75	3.00mg	41/50	7.50mg 40/50			
b	c01865	35.0mg n.s.s.	3/75	3.00mg	0/50	7.50mg 2/50			liv:hpa,hpc,ndd.
1119	c01865	5.49mg 19.1mg	0/75	2.40mg	7/50	6.00mg 13/50			ski:fib; sub:fib.
a	c01865	4.84mg n.s.s.	40/75	2.40mg	29/50	6.00mg 35/50			
b	c01865	12.6mg n.s.s.	0/75	2.40mg	3/50	6.00mg 3/50			liv:hpa,hpc,ndd.
1,4-DIOXANE (p-dioxane) 123-91-1									
1120	c03689	426.mg 861.mg	0/50	984.mg	21/50	1.99gm 35/50			liv:hpa,hpc.
a	c03689	639.mg 1.45gm	0/50	984.mg	12/50	1.99gm 29/50			
b	c03689	501.mg 2.19gm	15/50	984.mg	31/50	1.99gm 35/50			
c	c03689	426.mg 861.mg	0/50	984.mg	21/50	1.99gm 35/50			liv:hpa,hpc,ndd.
d	c03689	6.34mg n.s.s.	3/50	984.mg	0/50	1.99gm 3/50			Lun:a/a,a/c.
1121	c03689	863.mg 3.66gm	4/50	820.mg	18/50	1.65gm 24/50			
a	c03689	833.mg 5.11gm	8/50	820.mg	19/50	1.65gm 28/50			liv:hpa,hpc.
b	c03689	1.29gm 22.1gm	0/50	820.mg	6/50	(1.65gm 3/50)			---hem,hes. S
c	c03689	1.49gm 16.3gm	0/50	820.mg	5/50	(1.65gm 2/50)			S
d	c03689	841.mg n.s.s.	19/50	820.mg	28/50	1.65gm 33/50			
e	c03689	833.mg 5.11gm	8/50	820.mg	19/50	1.65gm 28/50			liv:hpa,hpc,ndd.
f	c03689	8.27gm n.s.s.	8/50	820.mg	3/50	1.65gm 3/50			Lun:a/a,a/c.
1122	c03689	69.7mg 218.mg	0/35	284.mg	18/35	569.mg 18/35			liv:hpa; ntu:sgc. C
a	c03689	79.1mg 323.mg	0/35	284.mg	10/35	569.mg 11/35			
b	c03689	249.mg 970.mg	0/35	284.mg	10/35	569.mg 8/35			
c	c03689	20.0mg 108.mg	26/35	284.mg	28/35	(569.mg 22/35)			
d	c03689	60.1mg 263.mg	0/35	284.mg	10/35	569.mg 12/35			liv:hpa,hpc,ndd.

Spe	Strain	Site	Xpo+Xpt	Notes	TD50	2Tailpvl
Sex	Route	Hist			DR	AuOp
1123	R m	osm wat	ntu sqc	26m26		168.mg * P<.0005c
a	R m	osm wat	TBA MXB	26m26	: + :	114.mg * P<.0005
b	R m	osm wat	liv MXB	26m26		796.mg * P<.2
1124	R m	cdr wat	nas sqc	56w69 r		. ±+historical * P<.07 +
1125	R b	she wat	liv mix	24m24 e		. + . 2.12gm * P<.0005+
a	R b	she wat	liv hpc	24m24 e		2.50gm * P<.0005+
b	R b	she wat	ntu sqc	24m24 e		15.9gm * P<.006 +
c	R b	she wat	tba mix	24m24 e		no dre P=1.
1126	R b	wis wat	liv hpt	63w64		515.mg P<.05 +
a	R b	wis wat	tba mix	63w64	. ±	690.mg P<.4
DIOXATHION						
					100ng.....1ug.....10.....100.....1mg.....10.....100.....1g.....10	
1127	M f	b6c eat	TBA MXB	78w90 v		2.59gm * P<.9 -
a	M f	b6c eat	liv MXB	78w90 v	>	no dre P=1.
b	M f	b6c eat	lun MXB	78w90 v		1.82gm * P<.5
1128	M m	b6c eat	TBA MXB	78w90 v		no dre P=1. -
a	M m	b6c eat	liv MXB	78w90 v	>	no dre P=1.
b	M m	b6c eat	lun MXB	78w90 v		628.mg * P<.5
1129	R f	osm eat	TBA MXB	18m26 v		no dre P=1. -
a	R f	osm eat	liv MXB	18m26 v	>	no dre P=1.
1130	R m	osm eat	TBA MXB	18m26 v		no dre P=1. -
a	R m	osm eat	liv MXB	18m26 v	>	no dre P=1.
DIPENTAMETHYLENETHIURAM HEXASULFIDE						
				1ug.....10.....100.....1mg.....10.....100.....1g.....10	
1131	M f	b6a orl	lun ade	76w76 evx		no dre P=1. -
a	M f	b6a orl	liv hpt	76w76 evx	>	no dre P=1. -
b	M f	b6a orl	tba mix	76w76 evx		120.mg P<.5 -
1132	M m	b6a orl	lun ade	76w76 evx		no dre P=1. -
a	M m	b6a orl	liv hpt	76w76 evx	>	no dre P=1. -
b	M m	b6a orl	tba mix	76w76 evx		no dre P=1. -
1133	M f	b6c orl	lun ade	76w76 evx		83.1mg P<.05 -
a	M f	b6c orl	liv hpt	76w76 evx	. ±	no dre P=1. -
b	M f	b6c orl	tba mix	76w76 evx		83.1mg P<.05 -
1134	M m	b6c orl	liv hpt	76w76 evx		113.mg P<.1 -
a	M m	b6c orl	lun ade	76w76 evx	. ±	113.mg P<.1 -
b	M m	b6c orl	tba mix	76w76 evx		52.5mg P<.02 -
DIPHENYL-p-PHENYLENEDIAMINE						
					100ng.....1ug.....10.....100.....1mg.....10.....100.....1g.....10	
1135	M f	b6a orl	lun ade	76w76 evx		2.79gm P<.3 -
a	M f	b6a orl	liv hpt	76w76 evx	>	no dre P=1. -
b	M f	b6a orl	tba mix	76w76 evx		2.79gm P<.3 -
1136	M m	b6a orl	lun ade	76w76 evx		1.33gm P<.09 -
a	M m	b6a orl	liv hpt	76w76 evx	. ±	no dre P=1. -
b	M m	b6a orl	tba mix	76w76 evx		no dre P=1. -
1137	M f	b6c orl	liv hpt	76w76 evx		no dre P=1. -
a	M f	b6c orl	lun ade	76w76 evx	>	no dre P=1. -
b	M f	b6c orl	tba mix	76w76 evx		no dre P=1. -
1138	M m	b6c orl	liv hpt	76w76 evx		no dre P=1. -
a	M m	b6c orl	lun ade	76w76 evx	>	no dre P=1. -
b	M m	b6c orl	tba mix	76w76 evx		4.11gm P<.9 -
DIPHENYLACETONITRILE						
					100ng.....1ug.....10.....100.....1mg.....10.....100.....1g.....10	
1139	M f	b6a orl	lun ade	76w76 evx		no dre P=1. -
a	M f	b6a orl	liv hpt	76w76 evx	>	no dre P=1. -
b	M f	b6a orl	tba mix	76w76 evx		no dre P=1. -
1140	M m	b6a orl	lun ade	76w76 evx		3.62gm P<.1. -
a	M m	b6a orl	liv hpt	76w76 evx	>	no dre P=1. -
b	M m	b6a orl	tba mix	76w76 evx		no dre P=1. -
1141	M f	b6c orl	lun mix	76w76 evx		229.mg P<.1 -
a	M f	b6c orl	liv hpt	76w76 evx	. ±	no dre P=1. -
b	M f	b6c orl	tba mix	76w76 evx		148.mg P<.04 -
1142	M m	b6c orl	lun ade	76w76 evx		129.mg P<.04 -
a	M m	b6c orl	liv hpt	76w76 evx	. ±	200.mg P<.09 -
b	M m	b6c orl	tba mix	76w76 evx		46.4mg P<.002 -
DIPHENYLCARBONATE						
					100ng.....1ug.....10.....100.....1mg.....10.....100.....1g.....10	
1143	M f	b6a orl	lun ade	76w76 evx		206.mg P<.6 -
a	M f	b6a orl	liv hpt	76w76 evx	>	no dre P=1. -
b	M f	b6a orl	tba mix	76w76 evx		no dre P=1. -
1144	M m	b6a orl	lun ade	76w76 evx		no dre P=1. -
a	M m	b6a orl	liv hpt	76w76 evx	>	no dre P=1. -
b	M m	b6a orl	tba mix	76w76 evx		no dre P=1. -
1145	M f	b6c orl	liv hem	76w76 evx		233.mg P<.3 -
a	M f	b6c orl	lun ade	76w76 evx	>	233.mg P<.3 -
b	M f	b6c orl	tba mix	76w76 evx		73.1mg P<.05 -
1146	M m	b6c orl	liv hpt	76w76 evx		68.0mg P<.05 -
a	M m	b6c orl	lun ade	76w76 evx	. ±	217.mg P<.3 -
b	M m	b6c orl	tba mix	76w76 evx		25.2mg P<.002 -

CARCINOGENIC POTENCY DATABASE

RefNum	LoConf	UpConf	Cntrl	1Dose	1Inc	2Dose	2Inc	Citation or Pathology		Brkly Code
1123	c03689	94.3mg	304.mg	0/35	250.mg	12/35	500.mg	16/35		
a	c03689	59.3mg	339.mg	21/35	250.mg	18/35	500.mg	27/35		
b	c03689	190.mg	n.s.s.	1/35	250.mg	2/35	500.mg	1/35		
1124	124	1.20gm	n.s.s.	0/30	305.mg	1/30	406.mg	1/30	569.mg	2/30 731.mg 2/30
1125	125	1.08gm	5.36gm	2/106	5.29mg	0/110	52.9mg	1/106	529.mg	12/66
a	125	1.22gm	6.73gm	1/106	5.29mg	0/110	52.9mg	1/106	529.mg	10/66
b	125	4.82gm	231.gm	0/120	5.29mg	0/120	52.9mg	0/120	529.mg	3/120
c	125	4.33gm	n.s.s.	31/120	5.29mg	34/120	52.9mg	28/120	529.mg	21/120
1126	104	209.mg	n.s.s.	0/9	521.mg	6/26				Argus; jnci, 35, 949-958; 1965
a	104	206.mg	n.s.s.	1/9	521.mg	7/26				
DIOXATHION 78-34-2										
1127	c00395	207.mg	n.s.s.	2/20	52.5mg	6/50	105.mg	6/50		
a	c00395	623.mg	n.s.s.	0/20	52.5mg	1/50	105.mg	0/50		liv:hpa,hpc,nnd.
b	c00395	447.mg	n.s.s.	0/20	52.5mg	1/50	105.mg	1/50		lun:a/a,a/c.
1128	c00395	77.0mg	n.s.s.	7/20	29.5mg	10/50	58.8mg	13/50		
a	c00395	128.mg	n.s.s.	4/20	29.5mg	4/50	58.8mg	6/50		liv:hpa,hpc,nnd.
b	c00395	141.mg	n.s.s.	1/20	29.5mg	1/50	58.8mg	4/50		lun:a/a,a/c.
1129	c00395	3.98mg	n.s.s.	36/50	1.60mg	27/50	3.00mg	29/50		
a	c00395	36.3mg	n.s.s.	1/50	1.60mg	0/50	3.00mg	0/50		liv:hpa,hpc,nnd.
1130	c00395	6.81mg	n.s.s.	28/50	2.40mg	23/50	4.80mg	21/50		
a	c00395	n.s.s.	n.s.s.	0/50	2.40mg	0/50	4.80mg	0/50		liv:hpa,hpc,nnd.
DIPENTAMETHYLENETHIURAM HEXASULFIDE (sulfada) ---										
1131	1221	49.2mg	n.s.s.	1/17	41.4mg	1/18				Innes;ntis,1968/1969
a	1221	82.0mg	n.s.s.	0/17	41.4mg	0/18				
b	1221	23.9mg	n.s.s.	2/17	41.4mg	4/18				
1132	1221	47.4mg	n.s.s.	2/18	38.5mg	1/17				
a	1221	72.1mg	n.s.s.	1/18	38.5mg	0/17				
b	1221	50.7mg	n.s.s.	3/18	38.5mg	1/17				
1133	1221	25.1mg	n.s.s.	0/16	41.4mg	3/18				
a	1221	82.0mg	n.s.s.	0/16	41.4mg	0/18				
b	1221	25.1mg	n.s.s.	0/16	41.4mg	3/18				
1134	1221	27.6mg	n.s.s.	0/16	38.5mg	2/17				
a	1221	27.6mg	n.s.s.	0/16	38.5mg	2/17				
b	1221	18.1mg	n.s.s.	0/16	38.5mg	4/17				
DIPHENYL-p-PHENYLENEDIAMINE (Agerite DPPD) 74-31-7										
1135	1158	454.mg	n.s.s.	0/18	462.mg	1/17				Innes;ntis,1968/1969
a	1158	864.mg	n.s.s.	0/18	462.mg	0/17				
b	1158	454.mg	n.s.s.	0/18	462.mg	1/17				
1136	1158	328.mg	n.s.s.	0/18	430.mg	2/18				
a	1158	851.mg	n.s.s.	1/18	430.mg	0/18				
b	1158	401.mg	n.s.s.	2/18	430.mg	2/18				
1137	1158	915.mg	n.s.s.	0/18	462.mg	0/18				
a	1158	915.mg	n.s.s.	1/18	462.mg	0/18				
b	1158	915.mg	n.s.s.	2/18	462.mg	0/18				
1138	1158	306.mg	n.s.s.	3/14	430.mg	3/16				
a	1158	756.mg	n.s.s.	0/14	430.mg	0/16				
b	1158	213.mg	n.s.s.	4/14	430.mg	5/16				
DIPHENYLACETONITRILE 86-29-3										
1139	1311	93.2mg	n.s.s.	1/17	78.4mg	1/18				Innes;ntis,1968/1969
a	1311	155.mg	n.s.s.	0/17	78.4mg	0/18				
b	1311	74.0mg	n.s.s.	2/17	78.4mg	2/18				
1140	1311	63.5mg	n.s.s.	2/18	73.0mg	2/17				
a	1311	137.mg	n.s.s.	1/18	73.0mg	0/17				
b	1311	70.3mg	n.s.s.	3/18	73.0mg	2/17				
1141	1311	56.3mg	n.s.s.	0/16	78.4mg	2/17				
a	1311	147.mg	n.s.s.	0/16	78.4mg	0/17				
b	1311	44.6mg	n.s.s.	0/16	78.4mg	3/17				
1142	1311	38.8mg	n.s.s.	0/16	73.0mg	3/16				
a	1311	49.1mg	n.s.s.	0/16	73.0mg	2/16				
b	1311	19.7mg	170.mg	0/16	73.0mg	7/16				
DIPHENYLCARBONATE 102-09-0										
1143	1313	28.7mg	n.s.s.	1/17	36.4mg	2/17				Innes;ntis,1968/1969
a	1313	68.1mg	n.s.s.	0/17	36.4mg	0/17				
b	1313	32.0mg	n.s.s.	2/17	36.4mg	2/17				
1144	1313	38.9mg	n.s.s.	2/18	33.9mg	1/16				
a	1313	59.7mg	n.s.s.	1/18	33.9mg	0/16				
b	1313	41.6mg	n.s.s.	3/18	33.9mg	1/16				
1145	1313	37.9mg	n.s.s.	0/16	36.4mg	1/18				
a	1313	37.9mg	n.s.s.	0/16	36.4mg	1/18				
b	1313	22.0mg	n.s.s.	0/16	36.4mg	3/18				
1146	1313	20.5mg	n.s.s.	0/16	33.9mg	3/18				
a	1313	35.3mg	n.s.s.	0/16	33.9mg	1/18				
b	1313	10.7mg	103.mg	0/16	33.9mg	7/18				

Spe	Strain	Site	Xpo+Xpt	Notes	TD50	2Tailpvl	
Sex	Route	Hist			DR	AuOp	
5,5-DIPHENYLHYDANTOIN 100ng...1ug...10...100...1mg...10...100...1g...10							
1147	R f	hza eat	---	mly 60w60 es	>	422.mg	P<.3 -
a	R f	hza eat	---	liv tum 60w60 es		no dre	P=1. -
b	R f	hza eat	---	mam tum 60w60 es		no dre	P=1. -
N,N-DIPROPYL-4-(4'-[PYRIDYL-1'-OXIDE]AZO)ANILINE ...10...100...1mg...10...100...1g...10							
1148	R m	sda eat	---	liv tum 52w52 bfr	>	no dre	P=1. -
2,5-DITHIOBIUREA 100ng...1ug...10...100...1mg...10...100...1g...10							
1149	M f	b6c eat	---	liv hpc 94w94		: ± 5.67gm * P<.03	a -
a	M f	b6c eat	---	TBA MXB 94w94		4.35gm * P<.2	
b	M f	b6c eat	---	liv MXB 94w94		5.67gm * P<.03	
c	M f	b6c eat	---	lun MXB 94w94		22.9gm * P<.6	
1150	M m	b6c eat	---	TBA MXB 94w94		:> 20.0gm * P<.8	-
a	M m	b6c eat	---	liv MXB 94w94		no dre	P=1. -
b	M m	b6c eat	---	lun MXB 94w94		no dre	P=1. -
1151	R f	f34 eat	---	TBA MXB 25m25		:> 842.mg * P<.3	-
a	R f	f34 eat	---	liv MXB 25m25		131.gm * P<.1	-
1152	R m	f34 eat	---	pit can 25m25		: ± #2.62gm * P<.02	-
a	R m	f34 eat	---	TBA MXB 25m25		960.mg / P<.4	-
b	R m	f34 eat	---	liv MXB 25m25		5.01gm * P<.09	-
DITHIOOXAMIDE 100ng...1ug...10...100...1mg...10...100...1g...10							
1153	R f	cdr eat	---	mgl tum 18m24 av		: ± 12.6mg \ P<.02	-
n-DODECYLGUANIDINE ACETATE 100ng...1ug...10...100...1mg...10...100...1g...10							
1154	M f	b6a orl	---	liv hpt 76w76 evx	>	no dre	P=1. -
a	M f	b6a orl	---	lun ade 76w76 evx		no dre	P=1. -
b	M f	b6a orl	---	tba mix 76w76 evx		no dre	P=1. -
1155	M m	b6a orl	---	lun mix 76w76 evx	>	41.9gm P<.6	-
a	M m	b6a orl	---	liv hpt 76w76 evx		no dre	P=1. -
b	M m	b6a orl	---	tba mix 76w76 evx		149.mg P<.9	-
1156	M f	b6c orl	---	liv hpt 76w76 evx	>	54.7gm P<.3	-
a	M f	b6c orl	---	lun mix 76w76 evx		no dre	P=1. -
b	M f	b6c orl	---	tba mix 76w76 evx		54.7gm P<.3	-
1157	M m	b6c orl	---	liv hpt 76w76 evx		: ± 19.4gm P<.04	-
a	M m	b6c orl	---	lun ade 76w76 evx		30.1gm P<.1	-
b	M m	b6c orl	---	tba mix 76w76 evx		10.8gm P<.007	-
EDIFAS A 100ng...1ug...10...100...1mg...10...100...1g...10							
1158	M f	aps eat	---	liv tum 23m23 e	>	no dre	P=1. -
a	M f	aps eat	---	lun ade 23m23 e		no dre	P=1. -
b	M f	aps eat	---	tba mix 23m23 e		no dre	P=1. -
1159	M m	aps eat	---	liv hpt 23m23 e		254.gm * P<.9	-
a	M m	aps eat	---	lun ade 23m23 e		no dre	P=1. -
b	M m	aps eat	---	tba mix 23m23 e		19.4gm * P<.4	-
1160	R f	aps eat	---	lun ade 24m24 e		161.gm * P<.2	-
a	R f	aps eat	---	liv mix 24m24 e		375.gm * P<.7	-
b	R f	aps eat	---	tba mix 24m24 e		113.gm * P<.9	-
1161	R m	aps eat	---	liv tum 24m24 e	>	no dre	P=1. -
a	R m	aps eat	---	lun ade 24m24 e		no dre	P=1. -
b	R m	aps eat	---	tba mix 24m24 e		27.3gm * P<.4	-
EDIFAS B 100ng...1ug...10...100...1mg...10...100...1g...10							
1162	M f	aps eat	---	liv hpt 23m23 e		538.gm * P<.7	-
a	M f	aps eat	---	lun ade 23m23 e		no dre	P=1. -
b	M f	aps eat	---	tba mix 23m23 e		no dre	P=1. -
1163	M m	aps eat	---	lun ade 23m23 e		no dre	P=1. -
a	M m	aps eat	---	liv hpt 23m23 e		no dre	P=1. -
b	M m	aps eat	---	tba mix 23m23 e		132.gm * P<.9	-
1164	R f	aps eat	---	liv tum 24m24 e	>	no dre	P=1. -
a	R f	aps eat	---	tba mix 24m24 e		7.79gm * P<.2	-
1165	R m	aps eat	---	liv hpt 24m24 e		133.gm * P<.2	-
a	R m	aps eat	---	tba mix 24m24 e		no dre	P=1. -
EDTA, TRISODIUM SALT TRIHYDRATE 100ng...1ug...10...100...1mg...10...100...1g...10							
1166	M f	b6c eat	---	TBA MXB 24m24	>	no dre	P=1. -
a	M f	b6c eat	---	liv MXB 24m24		18.8gm * P<.5	-
b	M f	b6c eat	---	lun MXB 24m24		5.29gm * P<.2	-
1167	M m	b6c eat	---	TBA MXB 24m24	>	4.92gm * P<.7	-
a	M m	b6c eat	---	liv MXB 24m24		12.3gm * P<.8	-
b	M m	b6c eat	---	lun MXB 24m24		3.19gm * P<.2	-
1168	R f	f34 eat	---	TBA MXB 24m24	>	no dre	P=1. -
a	R f	f34 eat	---	liv MXB 24m24		no dre	P=1. -
1169	R m	f34 eat	---	TBA MXB 24m24	>	1.86gm * P<.7	-
a	R m	f34 eat	---	liv MXB 24m24		6.59gm * P<.6	-
EMETINE.2HCl* 100ng...1ug...10...100...1mg...10...100...1g...10							
1170	M f	b6c ipj	---	TBA MXB 40w78 es		: ± 1.20gm * P<.03	-
a	M f	b6c ipj	---	liv MXB 40w78 es		no dre	P=1. -

RefNum	LoConf	UpConf	Cntrl	1Dose	1Inc	2Dose	2Inc	Citation or Pathology	Brkly Code	
5,5-DIPHENYLHYDANTOIN 57-41-0										
1147	1063	68.7mg	n.s.s.	0/16	100.mg	1/19		Morris;canr,29,2145-2156;1969		
a	1063	130.mg	n.s.s.	0/16	100.mg	0/19				
b	1063	93.9mg	n.s.s.	3/16	100.mg	1/19				
N,N-DIPROPYL-4-(4'-PYRIDYL-1'-OXIDE)ANILINE ---										
1148	1176	6.18mg	n.s.s.	0/10	12.0mg	0/10		Brown;jnci,37,365-367;1966		
2,5-DITHIOBIUREA 142-46-1										
1149	c03009	2.60gm	n.s.s.	2/50	1.08gm	8/50	2.16gm	9/50		
a	c03009	1.58gm	n.s.s.	12/50	1.08gm	24/50	2.16gm	20/50		
b	c03009	2.60gm	n.s.s.	2/50	1.08gm	8/50	2.16gm	9/50	liv:hpa,hpc,nnd.	
c	c03009	4.47gm	n.s.s.	4/50	1.08gm	5/50	2.16gm	6/50	lun:a/a,a/c.	
1150	c03009	1.94gm	n.s.s.	20/50	996.mg	23/50	1.99gm	18/50		
a	c03009	5.70gm	n.s.s.	15/50	996.mg	9/50	1.99gm	7/50	liv:hpa,hpc,nnd.	
b	c03009	3.98gm	n.s.s.	7/50	996.mg	13/50	1.99gm	4/50	lun:a/a,a/c.	
1151	c03009	262.mg	n.s.s.	31/50	215.mg	36/50	429.mg	32/50		
a	c03009	3.07gm	n.s.s.	1/50	215.mg	0/50	429.mg	1/50	liv:hpa,hpc,nnd.	
1152	c03009	905.mg	n.s.s.	0/50	172.mg	0/50	343.mg	4/50	S	
a	c03009	251.mg	n.s.s.	31/50	172.mg	28/50	343.mg	30/50		
b	c03009	1.46gm	n.s.s.	0/50	172.mg	1/50	343.mg	2/50	liv:hpa,hpc,nnd.	
DITHIOXAMIDE 79-40-3										
1153	1112	5.72mg	n.s.s.	3/16	12.0mg	15/26	(24.0mg)	9/27)	Weisburger;jnci,67,75-88;1981	
n-DODECYLGUANIDINE ACETATE 2439-10-3										
1154	1293	22.0mg	n.s.s.	0/17	11.1mg	0/18			Innes;ntis,1968/1969	
a	1293	22.0mg	n.s.s.	1/17	11.1mg	0/18				
b	1293	10.5mg	n.s.s.	2/17	11.1mg	2/18				
1155	1293	6.32mg	n.s.s.	2/18	10.3mg	3/16				
a	1293	18.1mg	n.s.s.	1/18	10.3mg	0/16				
b	1293	6.90mg	n.s.s.	3/18	10.3mg	3/16				
1156	1293	8.90mg	n.s.s.	0/16	11.1mg	1/14				
a	1293	17.1mg	n.s.s.	0/16	11.1mg	0/14				
b	1293	8.90mg	n.s.s.	0/16	11.1mg	1/14				
1157	1293	5.85mg	n.s.s.	0/16	10.3mg	3/17				
a	1293	7.39mg	n.s.s.	0/16	10.3mg	2/17				
b	1293	4.07mg	146.mg	0/16	10.3mg	5/17				
EDIFAS A (methyl ethyl cellulose) 9004-59-5										
1158	127a	5.78gm	n.s.s.	0/35	1.30gm	0/25	13.0gm	0/35	McElligott;fctx,6,449-460;1968	
a	127a	38.9gm	n.s.s.	1/35	1.30gm	3/25	13.0gm	2/35		
b	127a	12.6gm	n.s.s.	16/35	1.30gm	16/25	13.0gm	18/35		
1159	127a	14.8gm	n.s.s.	4/29	1.20gm	6/24	12.0gm	4/20		
a	127a	18.3gm	n.s.s.	8/29	1.20gm	2/24	12.0gm	4/20		
b	127a	4.17gm	n.s.s.	18/29	1.20gm	16/24	12.0gm	15/20		
1160	127a	26.2gm	n.s.s.	0/43	500.mg	0/44	5.00gm	1/43		
a	127a	28.3gm	n.s.s.	1/43	500.mg	0/44	5.00gm	1/43		
b	127a	5.18gm	n.s.s.	22/43	500.mg	26/44	5.00gm	24/43		
1161	127a	3.26gm	n.s.s.	0/46	400.mg	0/43	4.00gm	0/49		
a	127a	3.26gm	n.s.s.	1/46	400.mg	0/43	4.00gm	0/49		
b	127a	6.71gm	n.s.s.	6/46	400.mg	10/43	4.00gm	12/49		
EDIFAS B (cellulose carboxymethyl ether, sodium) 9004-32-4										
1162	127a	42.9gm	n.s.s.	0/23	1.30gm	1/32	13.0gm	1/35	McElligott;fctx,6,449-460;1968	
a	127a	44.7gm	n.s.s.	1/23	1.30gm	5/32	13.0gm	2/35		
b	127a	17.3gm	n.s.s.	12/23	1.30gm	25/32	13.0gm	18/35		
1163	127a	18.9gm	n.s.s.	5/31	1.20gm	9/27	12.0gm	7/31		
a	127a	51.1gm	n.s.s.	3/31	1.20gm	1/27	12.0gm	1/31		
b	127a	9.17gm	n.s.s.	18/31	1.20gm	14/27	12.0gm	18/31		
1164	127a	4.46gm	n.s.s.	0/43	500.mg	0/48	5.00gm	0/44		
a	127a	2.57gm	n.s.s.	27/43	500.mg	29/48	5.00gm	33/44		
1165	127a	21.7gm	n.s.s.	0/49	400.mg	0/42	4.00gm	1/45		
a	127a	8.70gm	n.s.s.	21/49	400.mg	14/42	4.00gm	15/45		
EDTA, TRISODIUM SALT TRIHYDRATE (EDTA) 150-38-9										
1166	c03974	1.22gm	n.s.s.	12/20	483.mg	24/50	966.mg	23/50		
a	c03974	4.62gm	n.s.s.	0/20	483.mg	1/50	966.mg	1/50	liv:hpa,hpc,nnd.	
b	c03974	2.29gm	n.s.s.	0/20	483.mg	3/50	966.mg	4/50	lun:a/a,a/c.	
1167	c03974	739.mg	n.s.s.	9/20	446.mg	24/50	891.mg	27/50		
a	c03974	1.41gm	n.s.s.	3/20	446.mg	10/50	891.mg	10/50	liv:hpa,hpc,nnd.	
b	c03974	1.16gm	n.s.s.	2/20	446.mg	8/50	891.mg	12/50	lun:a/a,a/c.	
1168	c03974	563.mg	n.s.s.	14/20	186.mg	28/50	371.mg	27/50		
a	c03974	2.96gm	n.s.s.	0/20	186.mg	1/50	371.mg	0/50	liv:hpa,hpc,nnd.	
1169	c03974	263.mg	n.s.s.	9/20	149.mg	25/50	297.mg	30/50		
a	c03974	1.62gm	n.s.s.	0/20	149.mg	1/50	297.mg	1/50	liv:hpa,hpc,nnd.	
EMETINE 2HCL* (NCI uses CAS# 483-18-1) 316-42-7										
1170	c01605	.298mg	n.s.s.	0/25	.460mg	2/35	1.40mg	0/35	2.70mg	1/35
a	c01605	n.s.s.	n.s.s.	0/25	.460mg	0/35	1.40mg	0/35	2.70mg	0/35
									liv:hpa,hpc,nnd.	

Spe	Strain	Site	Xpo+Xpt	Notes	TD50	2Tailpvl
Sex	Route	Hist			DR	AuOp
b	M f b6c	ipj	Lun	MXB 40w78 as	49.4mg	* P<.2
1171	M m b6c	ipj	TBA	MXB 44w78 as	.552mg	* P<.09
a	M m b6c	ipj	Liv	MXB 44w78 as	1.30mg	* P<.3
b	M m b6c	ipj	Lun	MXB 44w78 as	1.19mg	* P<.2
1172	R f sda	ipj	TBA	MXB 52w83 s	.235mg	* P<.3
a	R f sda	ipj	Liv	MXB 52w83 s	no dre	P=1.
1173	R m sda	ipj	TBA	MXB 52w83 s	.382mg	* P<.5
a	R m sda	ipj	Liv	MXB 52w83 s	no dre	P=1.
EMULSIFIER YN				100ng...1ug...10...100...1mg...10...100...1g...10		
1174	M f nas	eat	liv	tum 80w80 e	no dre	P=1. -
a	M f nas	eat	Lun	ade 80w80 e	no dre	P=1. -
1175	M m nas	eat	Lun	ade 80w80 e	no dre	P=1. -
a	M m nas	eat	Liv	ade 80w80 e	no dre	P=1. -
1176	R f wis	eat	pit	cra 24m24 e	5.54gm	* P<.009 -
a	R f wis	eat	liv	nod 24m24 e	511.gm	* P<.9 -
1177	R m wis	eat	liv	cho 24m24 e	no dre	P=1. -
ENDOSULFAN*				100ng...1ug...10...100...1mg...10...100...1g...10		
1178	M f b6c	eat	TBA	MXB 78w91 v	no dre	P=1. -
a	M f b6c	eat	liv	MXB 78w91 v	15.9mg	* P<.4
b	M f b6c	eat	Lun	MXB 78w91 v	no dre	P=1. -
1179	M f b6c	orl	liv	hpt 76w76 evx	no dre	P=1. -
a	M f b6c	orl	Lun	ade 76w76 evx	no dre	P=1. -
b	M f b6c	orl	tba	mix 76w76 evx	.425mg	\ P<.02 -
1180	M m b6c	eat	TBA	MXB 78w91 ev	6.36mg	* P<.9
a	M m b6c	eat	liv	MXB 78w91 ev	no dre	P=1. -
b	M m b6c	eat	Lun	MXB 78w91 ev	1.70mg	* P<.2
1181	M m b6c	orl	liv	hpt 76w76 evx	.584mg	\ P<.03 -
a	M m b6c	orl	Lun	ade 76w76 evx	.914mg	\ P<.08 -
b	M m b6c	orl	tba	mix 76w76 evx	.319mg	\ P<.004 -
1182	M f b6a	orl	liv	hpt 76w76 evx	no dre	P=1. -
a	M f b6a	orl	Lun	ade 76w76 evx	no dre	P=1. -
b	M f b6a	orl	tba	mix 76w76 evx	no dre	P=1. -
1183	M m b6a	orl	liv	hpt 76w76 evx	no dre	P=1. -
a	M m b6a	orl	Lun	ade 76w76 evx	no dre	P=1. -
b	M m b6a	orl	tba	mix 76w76 evx	no dre	P=1. -
1184	R f osm	eat	TBA	MXB 18m26 dv	no dre	P=1. -
a	R f osm	eat	liv	MXB 18m26 dv	224.mg	* P<.4
1185	R m osm	eat	TBA	MXB 70w74 advs	no dre	P=1. -
a	R m osm	eat	liv	MXB 70w74 advs	no dre	P=1. -
ENDRIN				100ng...1ug...10...100...1mg...10...100...1g...10		
1186	M f b6c	eat	TBA	MXB 80w90	6.88mg	* P<.8 -
a	M f b6c	eat	liv	MXB 80w90	no dre	P=1. -
b	M f b6c	eat	Lun	MXB 80w90	67.0mg	* P<.1
1187	M m b6c	eat	TBA	MXB 80w90 dsv	.546mg	* P<.04 -
a	M m b6c	eat	liv	MXB 80w90 dsv	.854mg	* P<.2
b	M m b6c	eat	Lun	MXB 80w90 dsv	1.27mg	* P<.08
1188	R f osm	eat	TBA	MXB 19m26 ev	no dre	P=1. -
a	R f osm	eat	liv	MXB 19m26 ev	7.44mg	* P<.8
1189	R f osm	eat	adr	MXA 19m25 ev	pool	#.227mg \ P<.003 -
a	R f osm	eat	pit	adn 19m25 ev	.579mg	* P<.02
1190	R f osm	eat	liv	hem 27m28 ev	42.3mg	* P<.4 -
a	R f osm	eat	tba	mix 27m28 ev	no dre	P=1. -
1191	R m osm	eat	TBA	MXB 19m26	.776mg	* P<.8 -
a	R m osm	eat	liv	MXB 19m26	no dre	P=1. -
1192	R m osm	eat	adr	MXA 19m26	pool	#.553mg * P<.04 -
a	R m osm	eat	adr	adn 19m26	.660mg	* P<.04
b	R m osm	eat	---	hem 19m26	.661mg	* P<.03
c	R m osm	eat	pn1	isc 19m26	1.75mg	* P<.04
1193	R m osm	eat	liv	hem 28m29 ev	no dre	P=1. -
a	R m osm	eat	tba	mix 28m29 ev	no dre	P=1. -
ENOVID				100ng...1ug...10...100...1mg...10...100...1g...10		
1194	M f aah	eat	Lun	tum 24m24 g	4.62mg	P<.6 -
a	M f aah	eat	liv	hpt 24m24 g	25.2mg	P<.3 -
1195	M f aah	eat	Lun	tum 24m24	4.31mg	P<.2 -
a	M f aah	eat	liv	hpt 24m24	no dre	P=1. -
1196	M f aah	eat	Lun	tum 24m24	no dre	P=1. -
1197	M f bal	eat	mix	sqc 86w86 r	2.00mg	P<.1 -
1198	M f bca	eat	Lun	tum 24m24 g	no dre	P=1. -
1199	M f bca	eat	Lun	tum 24m24 g	no dre	P=1. -
1200	M f bca	eat	Lun	tum 24m24	no dre	P=1. -
1201	M f c7l	gav	pit	tum 89w89 e	.151mg	* P<.0005+
1202	M f cfl	eat	liv	hct 78w78 er	no dre	P=1. -
1203	M m cfl	eat	liv	hct 78w78 er	no dre	P=1. -
1204	M f che	eat	Lun	tum 24m24 g	20.7mg	P<.3 -
1205	M f che	eat	hpl	cra 24m24	1.75mg	P<.008

RefNum	LoConf	UpConf	Cntrl	1Dose	1Inc	2Dose	2Inc		Citation or Pathology	Brkly Code	
b	c01605	8.05mg	n.s.s.	0/25	.460mg	0/35	1.40mg	0/35	2.70mg	1/35	Lun:a/a,a/c.
1171	c01605	.175mg	n.s.s.	3/25	.460mg	7/35	1.00mg	0/35	2.70mg	0/35	
a	c01605	.293mg	n.s.s.	1/25	.460mg	3/35	1.00mg	0/35	2.70mg	0/35	Liv:hpa,hpc,nnd.
b	c01605	.279mg	n.s.s.	1/25	.460mg	3/35	1.00mg	0/35	2.70mg	0/35	Lun:a/a,a/c.
1172	c01605	71.5ug	n.s.s.	6/10	.130mg	26/35	.270mg			22/35	
a	c01605	n.s.s.	n.s.s.	0/10	.130mg	0/35	.270mg			0/35	Liv:hpa,hpc,nnd.
1173	c01605	96.7ug	n.s.s.	3/10	.130mg	13/35	.270mg			5/35	
a	c01605	n.s.s.	n.s.s.	0/10	.130mg	2/35	.270mg			0/35	Liv:hpa,hpc,nnd.
EMULSIFIER YN 55965-13-4											
1174	425	10.1gm	n.s.s.	0/41	2.60gm	0/41	7.80gm			0/47	Gaunt;fctx,15,1-5;1977
a	425	n.s.s.	n.s.s.	1/41	2.60gm	0/41	7.80gm			1/47	
1175	425	15.8gm	n.s.s.	2/25	2.40gm	4/34	7.20gm			2/37	
a	425	32.5gm	n.s.s.	1/25	2.40gm	1/34	7.20gm			0/37	
1176	1359	2.58gm	214.gm	13/47	1.00gm	9/45	3.00gm			23/44	Brantom;fctx,11,755-769;1973
a	1359	21.7gm	n.s.s.	1/47	1.00gm	0/45	3.00gm			1/44	
1177	1359	14.7gm	n.s.s.	0/41	800.mg	1/39	2.40gm			0/39	
EMDOSULFAN* (Thiodan) 115-29-7											
1178	c00566	.250mg	n.s.s.	7/20	.210mg	18/50	(.430mg)			8/50)	
a	c00566	2.59mg	n.s.s.	0/20	.210mg	0/50	.430mg			1/50	Liv:hpa,hpc,nnd.
b	c00566	.497mg	n.s.s.	2/20	.210mg	5/50	(.430mg)			0/50)	Lun:a/a,a/c.
1179	283	.353mg	n.s.s.	0/16	.414mg	0/10	.834mg			0/17	Innes;ntis,1968/1969
a	283	1.09mg	n.s.s.	0/16	.414mg	1/10	.834mg			0/17	
b	283	.127mg	n.s.s.	0/16	.414mg	3/10	(.834mg)			0/17)	
1180	c00566	.364mg	n.s.s.	4/20	.350mg	8/50	.700mg			7/50	
a	c00566	.408mg	n.s.s.	1/20	.350mg	6/50	.700mg			2/50	Liv:hpa,hpc,nnd.
b	c00566	.576mg	n.s.s.	0/20	.350mg	2/50	.700mg			2/50	Lun:a/a,a/c.
1181	283	.176mg	n.s.s.	0/16	.385mg	3/14	(.776mg)			0/16)	Innes;ntis,1968/1969
a	283	.224mg	n.s.s.	0/16	.385mg	2/14	(.776mg)			0/16)	
b	283	.120mg	2.11mg	0/16	.385mg	5/14	(.776mg)			0/16)	
1182	283	.506mg	n.s.s.	0/17	.414mg	0/16	.834mg			0/18	
a	283	1.68mg	n.s.s.	1/17	.414mg	1/16	.834mg			0/18	
b	283	1.29mg	n.s.s.	2/17	.414mg	3/16	.834mg			0/18	
1183	283	.433mg	n.s.s.	1/18	.385mg	0/16	.776mg			0/14	
a	283	.620mg	n.s.s.	2/18	.385mg	4/16	.776mg			1/14	
b	283	.637mg	n.s.s.	3/18	.385mg	5/16	.776mg			1/14	
1184	c00566	10.5mg	n.s.s.	15/20	6.60mg	30/50	15.6mg			24/50	
a	c00566	55.0mg	n.s.s.	0/20	6.60mg	1/50	15.6mg			1/50	Liv:hpa,hpc,nnd.
1185	c00566	15.3mg	n.s.s.	12/20	15.7mg	8/50	(32.9mg)			3/50)	
a	c00566	n.s.s.	n.s.s.	0/20	15.7mg	0/50	32.9mg			0/50	Liv:hpa,hpc,nnd.
ENDRIN 72-20-8											
1186	c00157	.956mg	n.s.s.	2/10	.290mg	5/50	.570mg			8/50	
a	c00157	.973mg	n.s.s.	2/10	.290mg	3/50	(.570mg)			1/50)	Liv:hpa,hpc,nnd.
b	c00157	1.83mg	n.s.s.	0/10	.290mg	2/50	.570mg			1/50	Lun:a/a,a/c.
1187	c00157	.261mg	n.s.s.	1/10	.170mg	3/50	.340mg			14/50	
a	c00157	.335mg	n.s.s.	1/10	.170mg	3/50	.340mg			10/50	Liv:hpa,hpc,nnd.
b	c00157	.520mg	n.s.s.	0/10	.170mg	1/50	.340mg			5/50	Lun:a/a,a/c.
1188	c00157	.214mg	n.s.s.	8/10	.110mg	37/50	.210mg			33/50	
a	c00157	1.21mg	n.s.s.	0/10	.110mg	1/50	.210mg			1/50	Liv:hpa,hpc,nnd.
1189	c00157	.110mg	1.27mg	4/60p	.110mg	16/50	(.210mg)			6/50)	adr:adn,can. S
a	c00157	.277mg	n.s.s.	4/60p	.110mg	11/50	.210mg			13/50	S
1190	1004	6.88mg	n.s.s.	0/88	95.6ug	0/48	.287mg			1/45	.575mg 0/49
a	1004	1.77mg	n.s.s.	60/88	95.6ug	37/48	.287mg			26/45	.575mg 27/49
1191	c00157	.101mg	n.s.s.	5/10	70.0ug	25/50	.140mg			27/50	
a	c00157	n.s.s.	n.s.s.	0/10	70.0ug	0/50	.140mg			0/50	Liv:hpa,hpc,nnd.
1192	c00157	.233mg	n.s.s.	2/60p	70.0ug	4/50	.140mg			8/50	adr:adn,can. S
a	c00157	.265mg	n.s.s.	2/60p	70.0ug	2/50	.140mg			8/50	S
b	c00157	.298mg	n.s.s.	0/60p	70.0ug	5/50	.140mg			3/50	S
c	c00157	.529mg	n.s.s.	0/60p	70.0ug	0/50	.140mg			3/50	S
1193	1004	.706mg	n.s.s.	1/75	76.5ug	0/47	.230mg			0/44	.461mg 0/42
a	1004	2.08mg	n.s.s.	19/75	76.5ug	11/47	.230mg			6/44	.461mg 10/42
ENOVID (norethynodrel/mestranol [66:1]) 8015-30-3											
1194	1367m	.763mg	n.s.s.	28/61	.650mg	29/57					Heston;jnci,51,209-224;1973
a	1367m	4.10mg	n.s.s.	0/61	.650mg	1/57					
1195	1367n	1.42mg	n.s.s.	21/59	1.30mg	30/63					
a	1367n	16.9mg	n.s.s.	1/59	1.30mg	0/63					
1196	1367o	6.12mg	n.s.s.	17/49	2.60mg	16/54					
1197	1472	.492mg	n.s.s.	0/20	.450mg	2/20					Munoz;canr,38,1504-1508;1973/Dunn 1969
1198	1367m	4.21mg	n.s.s.	18/52	.650mg	6/55					Heston;jnci,51,209-224;1973
1199	1367n	3.77mg	n.s.s.	15/53	1.30mg	11/50					
1200	1367o	19.8mg	n.s.s.	12/55	2.60mg	3/55					
1201	230	52.7ug	.995mg	1/8	.200mg	6/11	2.00mg			7/7	Poel;scie,154,402-403;1966
1202	1453	23.8mg	n.s.s.	0/39	.125mg	1/40	1.50mg			1/40	5.00mg 0/38
1203	1453	17.8mg	n.s.s.	6/39	.125mg	4/40	1.50mg			5/39	5.00mg 1/40
1204	1367m	3.37mg	n.s.s.	0/50	.650mg	1/47					Heston;jnci,51,209-224;1973
1205	1367n	.830mg	40.3mg	17/50	1.30mg	32/53					

Spe	Strain	Site	Xpo+Xpt	Notes	TD50	2Tailpvl
Sex	Route	Hist			DR	AuOp
1206	M f che	eat hpl cra	24m24	. + .	1.82mg	P<.0005+
a	M f che	eat liv hpt	24m24		no dre	P=1. -
1207	M f chf	eat --- fbs	24m24 g	. + .	3.93mg	P<.005 -
a	M f chf	eat lun tum	24m24 g		27.6mg	P<.8 -
b	M f chf	eat liv hpt	24m24 g		no dre	P=1. -
1208	M f chf	eat lun tum	24m24 g	>	no dre	P=1. -
a	M f chf	eat liv hpt	24m24 g		no dre	P=1. -
1209	M f chf	eat lun tum	24m24	>	no dre	P=1. -
a	M f chf	eat liv hpt	24m24		no dre	P=1. -
1210	M f chh	eat liv hpt	24m24 g	>	no dre	P=1. -
1211	M f cac	gav lun tum	69w69 ek	>	no dre	P=1. -
a	M f cac	gav tba mix	69w69 ek		no dre	P=1. -
1212	M f cac	gav tba mix	69w82 ek	>	.332mg	P<.8 -
1213	M f r3m	eat mam tum	24m24 r	>	no dre	P=1. -
ENOVID-E					100ng...1ug...10...100...1mg...10...100...1g...10	
1214	M f cfl	eat liv hct	78w78 er	>	143.mg *	P<.8 -
1215	M m cfl	eat liv hct	78w78 er	>	no dre	P=1. -
1216	M f sww	gav liv hct	65w80 er	>	20.8mg	P<.6 -
EPICHLOROHYDRIN**					100ng...1ug...10...100...1mg...10...100...1g...10	
1217	M f hic	ipj lun ptm	64w64	>	28.9mg	P<.8
1218	R m sda	inh --- mly	30m32 as	>	462.mg *	P<.4 -
a	R m sda	inh liv tum	30m32 as		no dre	P=1.
ESTRADIOL					100ng...1ug...10...100...1mg...10...100...1g...10	
1219	M f c3h	eat mgl adc	24m24 r	>	.282mg	P<.7 +
1220	M f c3j	eat mgl adc	52w52 ek	. ±	.904mg *	P<.02
1221	M f c3j	eat ova tua	78w78 ek	>	no dre	P=1.
1222	M f c3j	eat mgl adc	24m24 ek	>	2.75mg *	P<.6
ESTRADIOL MUSTARD					100ng...1ug...10...100...1mg...10...100...1g...10	
1223	M f b6c	gav MXB MXB	52w84 s	: + :	.682mg *	P<.0005
a	M f b6c	gav lun MXA	52w84 s		1.14mg *	P<.0005c
b	M f b6c	gav --- lym	52w84 s		2.34mg *	P<.0005c
c	M f b6c	gav myc srn	52w84 s		3.01mg *	P<.006 c
d	M f b6c	gav sto sqc	52w84 s		+historical *	P<.009 c
e	M f b6c	gav mgl MXA	52w84 s		13.4mg *	P<.02
f	M f b6c	gav TBA MXB	52w84 s		.562mg *	P<.0005
g	M f b6c	gav liv MXB	52w84 s		no dre	P=1.
h	M f b6c	gav lun MXB	52w84 s		1.14mg *	P<.0005
1224	M f b6c	gav lun MXA	52w82 s	pool : + :	1.28mg *	P<.0005c
a	M f b6c	gav --- lym	52w82 s		2.23mg *	P<.0005c
b	M f b6c	gav lun a/c	52w82 s		2.87mg *	P<.002
c	M f b6c	gav myc srn	52w82 s		3.22mg *	P<.0005c
d	M f b6c	gav mgl MXA	52w82 s		12.8mg *	P<.007
1225	M m b6c	gav MXB MXB	52w83 s	: + :	4.10mg *	P<.0005
a	M m b6c	gav --- MXA	52w83 s		4.39mg *	P<.0005c
b	M m b6c	gav sto sqc	52w83 s		+historical *	P<.08 c
c	M m b6c	gav TBA MXB	52w83 s		1.96mg *	P<.0005
d	M m b6c	gav liv MXB	52w83 s		no dre	P=1.
e	M m b6c	gav lun MXB	52w83 s		2.34mg \	P<.02
1226	M m b6c	gav lun MXA	52w81 s	pool : + :	1.99mg \	P<.0005c
a	M m b6c	gav lun a/c	52w81 s		3.61mg \	P<.0005c
b	M m b6c	gav --- MXA	52w81 s		4.31mg *	P<.0005c
c	M m b6c	gav myc srn	52w81 s		5.55mg \	P<.003 c
1227	R f sda	gav TBA MXB	52w85	>	.189mg *	P<.2 -
a	R f sda	gav liv MXB	52w85		no dre	P=1.
1228	R m sda	gav TBA MXB	52w85	>	3.85mg *	P<.9 -
a	R m sda	gav liv MXB	52w85		no dre	P=1.
1229	R m sda	gav mgl fba	52w85	pool : ±	#.756mg *	P<.02 -
ETHIONAMIDE					100ng...1ug...10...100...1mg...10...100...1g...10	
1230	M f b6c	eat TBA MXB	18m24 s	>	450.mg *	P<.5 -
a	M f b6c	eat liv MXB	18m24 s		no dre	P=1.
b	M f b6c	eat lun MXB	18m24 s		no dre	P=1.
1231	M m b6c	eat TBA MXB	18m24 s	>	no dre	P=1. -
a	M m b6c	eat liv MXB	18m24 s		no dre	P=1.
b	M m b6c	eat lun MXB	18m24 s		no dre	P=1.
1232	M f bal	gav thy car	50w69 e	. +	.69.3mg	P<.01 +
a	M f bal	gav lun ade	50w69 e		124.mg	P<.4 -
b	M f bal	gav liv ppc	50w69 e		240.mg	P<.2 -
1233	R f f34	eat TBA MXB	18m24 s	>	no dre	P=1. -
a	R f f34	eat liv MXB	18m24 s		508.mg *	P<.2
1234	R m f34	eat TBA MXB	18m24	>	no dre	P=1. -
a	R m f34	eat liv MXB	18m24		623.mg *	P<.5
ETHIONINE					100ng...1ug...10...100...1mg...10...100...1g...10	
1235	R m wis	eat liv car	34w52 a	<	noTD50	P<.0005+

RefNum	LoConf	UpConf	Cntrl	1Dose	1Inc	2Dose	2Inc	Citation or Pathology	Brkly Code		
1206	1367o	1.03mg	4.55mg	15/51	2.60mg	36/49					
a	1367o	26.3mg	n.s.s.	1/51	2.60mg	0/49					
1207	1367m	1.60mg	26.9mg	0/54	.650mg	6/56					
a	1367m	2.21mg	n.s.s.	5/54	.650mg	6/56					
b	1367m	4.36mg	n.s.s.	46/54	.650mg	13/56					
1208	1367n	10.2mg	n.s.s.	3/52	1.30mg	1/53					
a	1367n	11.4mg	n.s.s.	34/52	1.30mg	4/53					
1209	1367o	12.5mg	n.s.s.	6/50	2.60mg	4/52					
a	1367o	24.0mg	n.s.s.	37/50	2.60mg	3/52					
1210	1367o	28.4mg	n.s.s.	2/55	2.60mg	0/53					
1211	585m	.194mg	n.s.s.	0/15	.143mg	0/15		Pool; canr, 28, 845-859; 1968			
a	585m	83.4ug	n.s.s.	4/15	.143mg	3/15					
1212	585n	36.7ug	n.s.s.	8/15	.120mg	9/15					
1213	1463	1.93mg	n.s.s.	50/73	1.95mg	12/21		Rudali; gmcr, 17, 243-252; 1975			
ENOVID-E (norethynodrel/mestranol [25:1]) ---											
1214	1453m	9.95mg	n.s.s.	0/39	.130mg	1/39	1.56mg	0/38	2.60mg	1/39	Barrows; jtxe, 3, 219-230; 1977
1215	1453m	8.87mg	n.s.s.	6/39	.130mg	8/40	1.56mg	7/40	2.60mg	1/39	
1216	1453n	2.84mg	n.s.s.	1/50	1.06mg	2/50					
EPICHLOROHYDRIN** 106-89-8											
1217	1143	2.54mg	n.s.s.	10/30	5.71mg	11/30					Van Duuren; jnci, 53, 695-700; 1974
1218	1167	114. mg	n.s.s.	0/100	1.98mg	1/100	5.95mg	1/100			Laskin; jnci, 65, 751-757; 1980
a	1167	52.4mg	n.s.s.	0/100	1.98mg	0/100	5.95mg	0/100			
ESTRADIOL (estradiol-17beta) 50-28-2											
1219	1131	38.1ug	n.s.s.	11/23	56.8ug	12/22					Gass; obgy, 5, 477; 1977
1220	1468	.338mg	n.s.s.	2/43	13.0ug	1/34	.130mg	1/34	.650mg	7/45	Highman; jept, 4, 81-95; 1980/pers. comm.
1221	1468m	.525mg	n.s.s.	2/14	13.0ug	0/5	.130mg	2/16	.650mg	0/7	
1222	1468n	.368mg	n.s.s.	4/24	13.0ug	5/23	.130mg	5/18	.650mg	2/7	
ESTRADIOL MUSTARD 22966-79-6											
1223	c01570	.330mg	1.38mg	0/16	3.98mg	21/36	8.80mg	14/35			---:lym; Lun:a/a,a/c; myc:arn; sto:sgc. C Lun:a/a,a/c.
a	c01570	.409mg	5.29mg	0/16	3.98mg	7/36	8.80mg	1/35			
b	c01570	.991mg	5.45mg	0/16	3.98mg	9/36	8.80mg	11/35			
c	c01570	.925mg	35.0mg	0/16	3.98mg	8/36	8.80mg	1/35			
d	c01570	1.43mg	178. mg	0/16	3.98mg	2/36	8.80mg	2/35			
e	c01570	2.93mg	n.s.s.	0/16	3.98mg	0/36	8.80mg	3/35			mgl:acn, can. S
f	c01570	.298mg	.998mg	0/16	3.98mg	25/36	8.80mg	20/35			
g	c01570	n.s.s.	n.s.s.	0/16	3.98mg	0/36	8.80mg	0/35			liv:hpa,hpc,nnd.
h	c01570	.409mg	5.29mg	0/16	3.98mg	7/36	8.80mg	1/35			Lun:a/a,a/c.
1224	c01570	.442mg	6.82mg	1/31p	3.98mg	7/36	8.80mg	1/35			Lun:a/a,a/c.
a	c01570	.944mg	4.65mg	0/31p	3.98mg	9/36	8.80mg	11/35			
b	c01570	.807mg	22.7mg	0/31p	3.98mg	4/36	8.80mg	0/35			S
c	c01570	1.09mg	11.0mg	0/31p	3.98mg	8/36	8.80mg	1/35			
d	c01570	2.79mg	272. mg	0/31p	3.98mg	0/36	8.80mg	3/35			mgl:acn, can. S
1225	c01570	2.41mg	8.00mg	0/14	3.98mg	6/34	8.20mg	18/35			---:leu,lym; sto:sgc. C
a	c01570	2.56mg	8.90mg	0/14	3.98mg	6/34	8.20mg	17/35			---:leu,lym.
b	c01570	7.13mg	n.s.s.	0/14	3.98mg	0/34	8.20mg	2/35			
c	c01570	1.12mg	6.77mg	4/14	3.98mg	26/34	8.20mg	23/35			
d	c01570	5.23mg	n.s.s.	2/14	3.98mg	5/34	8.20mg	1/35			liv:hpa,hpc,nnd.
e	c01570	1.01mg	n.s.s.	2/14	3.98mg	12/34	(8.20mg)	5/35			Lun:a/a,a/c.
1226	c01570	.929mg	7.16mg	2/29p	3.98mg	12/34	(8.20mg)	5/35			Lun:a/a,a/c.
a	c01570	1.46mg	12.7mg	0/29p	3.98mg	6/34	(8.20mg)	1/35			
b	c01570	2.54mg	7.89mg	0/29p	3.98mg	6/34	8.20mg	17/35			---:leu,lym.
c	c01570	2.18mg	27.4mg	0/29p	3.98mg	6/34	(8.20mg)	2/35			
1227	c01570	65.7ug	n.s.s.	5/10	.160mg	27/35	.330mg	26/35			
a	c01570	n.s.s.	n.s.s.	0/10	.160mg	0/35	.330mg	0/35			liv:hpa,hpc,nnd.
1228	c01570	.234mg	n.s.s.	4/10	.160mg	10/35	.330mg	10/35			
a	c01570	n.s.s.	n.s.s.	0/10	.160mg	0/35	.330mg	0/35			liv:hpa,hpc,nnd.
1229	c01570	.327mg	n.s.s.	0/20p	.160mg	2/35	.330mg	5/35			S
ETHIONAMIDE 536-33-4											
1230	c01694	113. mg	n.s.s.	4/15	70.2mg	7/35	139. mg	14/35			
a	c01694	n.s.s.	n.s.s.	0/15	70.2mg	0/35	139. mg	0/35			liv:hpa,hpc,nnd.
b	c01694	650. mg	n.s.s.	1/15	70.2mg	0/35	139. mg	1/35			Lun:a/a,a/c.
1231	c01694	101. mg	n.s.s.	7/15	64.8mg	16/35	128. mg	10/34			
a	c01694	159. mg	n.s.s.	3/15	64.8mg	6/35	128. mg	4/34			liv:hpa,hpc,nnd.
b	c01694	192. mg	n.s.s.	2/15	64.8mg	5/35	128. mg	2/34			Lun:a/a,a/c.
1232	1014	29.9mg	7.42gm	0/20	49.7mg	7/36					Biancifiori; lapp, 24, 145-165; 1964
a	1014	31.8mg	n.s.s.	2/18	49.7mg	7/33					
b	1014	58.9mg	n.s.s.	0/18	49.7mg	2/33					
1233	c01694	49.5mg	n.s.s.	12/15	40.0mg	26/35	81.0mg	25/35			
a	c01694	175. mg	n.s.s.	0/15	40.0mg	1/35	81.0mg	3/35			liv:hpa,hpc,nnd.
1234	c01694	33.4mg	n.s.s.	10/15	32.0mg	16/35	(64.8mg)	4/34			
a	c01694	153. mg	n.s.s.	0/15	32.0mg	1/35	64.8mg	1/34			liv:hpa,hpc,nnd.
ETHIONINE 13073-35-3											
1235	1373	n.s.s.	4.97mg	0/30	65.4mg	30/30					Argus; zkk0, 75, 201-208; 1971

Spe	Strain	Site	Xpo+Xpt	Notes	TD50	ZTailpvi	
Sex	Route	Hist			DR	AuOp	
ETHYL ALCOHOL					100ng...1ug...10...100...1mg...10...100...1g...10		
1236	R f nbr	wat	liv tum	64w64		.no dre P=1.	
1237	R m nbr	wat	liv tum	64w64		.>no dre P=1.	
1238	R b sda	wat	tba mal	26w26 e		no dre P=1. -	
ETHYL BROMOACETATE					100ng...1ug...10...100...1mg...10...100...1g...10		
1239	M f hic	ipj	lun ptm	64w64		no dre P=1.	
S-ETHYL-L-CYSTEINE					100ng...1ug...10...100...1mg...10...100...1g...10		
1240	R m wis	eat	abd lps	58w89 aev		3.63gm * P<.4 -	
a	R m wis	eat	liv tum	58w89 aev		no dre P=1. -	
b	R m wis	eat	tba mix	58w89 aev		3.63gm * P<.4 -	
p,p'-ETHYL-DDD					100ng...1ug...10...100...1mg...10...100...1g...10		
1241	M f b6c	eat	liv MXA	24m24 v		2.67gm * P<.04 a	
a	M f b6c	eat	liv hpc	24m24 v		3.16gm * P<.04 a	
b	M f b6c	eat	TBA MXB	24m24 v		2.36gm * P<.4	
c	M f b6c	eat	liv MXB	24m24 v		2.67gm * P<.04	
d	M f b6c	eat	lun MXB	24m24 v		no dre P=1.	
1242	M f b6c	orl	liv hpt	76w76 evx		665.mg P<.3	
a	M f b6c	orl	lun mix	76w76 evx		no dre P=1.	
b	M f b6c	orl	tba mix	76w76 evx		322.mg P<.1	
1243	M m b6c	eat	lun a/a	24m24		#1.64gm * P<.02 -	
a	M m b6c	eat	TBA MXB	24m24		no dre P=1.	
b	M m b6c	eat	liv MXB	24m24		9.16gm * P<.9	
c	M m b6c	eat	lun MXB	24m24		5.07gm * P<.6	
1244	M m b6c	orl	liv hpt	76w76 evx		65.1mg P<.002	
a	M m b6c	orl	lun ade	76w76 evx		581.mg P<.3	
b	M m b6c	orl	tba mix	76w76 evx		56.1mg P<.0005	
1245	M f b6a	orl	liv hpt	76w76 evx		no dre P=1.	
a	M f b6a	orl	lun ade	76w76 evx		no dre P=1.	
b	M f b6a	orl	tba mix	76w76 evx		no dre P=1.	
1246	M m b6a	orl	lun ade	76w76 evx		581.mg P<.7	
a	M m b6a	orl	liv hpt	76w76 evx		no dre P=1.	
b	M m b6a	orl	tba mix	76w76 evx		543.mg P<.7	
1247	R f f34	eat	TBA MXB	24m24		no dre P=1. -	
a	R f f34	eat	liv MXB	24m24		8.54gm * P<.8	
1248	R m f34	eat	TBA MXB	24m24		no dre P=1. -	
a	R m f34	eat	liv MXB	24m24		no dre P=1.	
N-ETHYL-N-FORMYLHYDRAZINE					100ng...1ug...10...100...1mg...10...100...1g...10		
1249	M f sww	wat	blv mix	61w61 e		2.49mg P<.0005+	
a	M f sww	wat	lun mix	61w61 e		2.52mg P<.0005+	
b	M f sww	wat	liv tum	61w61 e		no dre P=1.	
1250	M m sww	wat	lun mix	60w60 e		3.19mg P<.0005+	
a	M m sww	wat	blv mix	60w60 e		3.55mg P<.0005+	
b	M m sww	wat	liv mix	60w60 e		17.7mg P<.0005+	
c	M m sww	wat	gal mix	60w60 e		47.4mg P<.005 +	
d	M m sww	wat	pre mix	60w60 e		50.8mg P<.003 +	
N-ETHYL-N'-NITRO-N-NITROSOGUANIDINE					...1ug...10...100...1mg...10...100...1g...10		
1251	M b cbh	wat	duo mix	43w69 e		2.84mg P<.0005+	
a	M b cbh	wat	eso mix	43w69 e		3.85mg P<.0005+	
b	M b cbh	wat	duo adc	43w69 e		4.20mg P<.0005+	
c	M b cbh	wat	eso aqc	43w69 e		5.60mg P<.0005+	
d	M b cbh	wat	sto mix	43w69 e		8.03mg P<.002	
e	M b cbh	wat	liv hms	43w69 e		70.3mg P<.3	
f	M b cbh	wat	lun ade	43w69 e		no dre P=1.	
g	M b cbh	wat	liv hpt	43w69 e		no dre P=1.	
h	M b cbh	wat	tba mix	43w69 e		284.mg P<.1.	
ETHYL TELLURAC					100ng...1ug...10...100...1mg...10...100...1g...10		
1252	M f b6c	eat	TBA MXB	25m25 v		1.03gm * P<.3 -	
a	M f b6c	eat	liv MXB	25m25 v		2.27gm * P<.2	
b	M f b6c	eat	lun MXB	25m25 v		3.40gm * P<.5	
1253	M f b6c	orl	lun ade	76w76 evx		131.mg P<.3	
a	M f b6c	orl	liv hpt	76w76 evx		no dre P=1.	
b	M f b6c	orl	tba mix	76w76 evx		63.5mg P<.2	
1254	M m b6c	eat	eye adn	25m25 v		201.mg \ P<.002 a	
a	M m b6c	eat	lun MXA	25m25 v		228.mg \ P<.002	
b	M m b6c	eat	lun a/c	25m25 v		260.mg \ P<.003	
c	M m b6c	eat	TBA MXB	25m25 v		902.mg * P<.5	
d	M m b6c	eat	liv MXB	25m25 v		no dre P=1.	
e	M m b6c	eat	lun MXB	25m25 v		228.mg \ P<.002	
1255	M m b6c	orl	liv hpt	76w76 evx		24.2mg P<.02	
a	M m b6c	orl	lun mix	76w76 evx		52.1mg P<.09	
b	M m b6c	orl	lun car	76w76 evx		108.mg P<.3	
c	M m b6c	orl	lun ade	76w76 evx		108.mg P<.3	
d	M m b6c	orl	tba mix	76w76 evx		8.41mg P<.0005	

RefNum	LoConf	UpConf	Cntrl	1Dose	1Inc	2Dose	2Inc	Citation or Pathology	Brkly Code
ETHYL ALCOHOL 64-17-5									
1236	162a	8.92gm	n.s.s.	0/20	5.71gm	0/20		Yamamoto;ijcn,2,337-343;1967	
1237	162a	7.80gm	n.s.s.	0/20	5.00gm	0/20			
1238	1264	39.9gm	n.s.s.	4/48	9.45gm	4/48		Schmahl;clot,1,215-218;1976	
ETHYL BROMOACETATE 105-36-2									
1239	1143	.390mg	n.s.s.	12/30	.571mg	9/30		Van Duuren;jnci,53,695-700;1974	
S-ETHYL-L-CYSTEINE 2629-59-6									
1240	1373	592.mg	n.s.s.	0/30	116.mg	0/30	127.mg	1/30	Argus;zkko,75,201-208;1971
a	1373	275.mg	n.s.s.	0/30	116.mg	0/30	127.mg	0/30	
b	1373	592.mg	n.s.s.	0/30	116.mg	0/30	127.mg	1/30	
p,p'-ETHYL-DDD (Perthane) 72-56-0									
1241	c02868	1.23gm	n.s.s.	1/20	368.mg	3/50	806.mg	11/50	liv:hpa,hpc.
a	c02868	1.39gm	n.s.s.	1/20	368.mg	2/50	806.mg	10/50	
b	c02868	617.mg	n.s.s.	7/20	368.mg	24/50	806.mg	26/50	
c	c02868	1.23gm	n.s.s.	1/20	368.mg	3/50	806.mg	11/50	liv:hpa,hpc,nnd.
d	c02868	2.94gm	n.s.s.	0/20	368.mg	3/50	806.mg	1/50	lun:a/a,a/c.
1242	1098	108.mg	n.s.s.	0/16	110.mg	1/17			Innes;ntis,1968/1969
a	1098	206.mg	n.s.s.	0/16	110.mg	0/17			
b	1098	79.1mg	n.s.s.	0/16	110.mg	2/17			
1243	c02868	866.mg	n.s.s.	0/20	300.mg	4/50	600.mg	9/50	S
a	c02868	430.mg	n.s.s.	11/20	300.mg	38/50	600.mg	33/50	liv:hpa,hpc,nnd.
b	c02868	508.mg	n.s.s.	8/20	300.mg	27/50	600.mg	25/50	lun:a/a,a/c.
c	c02868	988.mg	n.s.s.	4/20	300.mg	5/50	600.mg	12/50	Innes;ntis,1968/1969
1244	1098	27.6mg	238.mg	0/16	102.mg	7/16			
a	1098	94.5mg	n.s.s.	0/16	102.mg	1/16			
b	1098	23.9mg	167.mg	0/16	102.mg	8/16			
1245	1098	218.mg	n.s.s.	0/17	110.mg	0/18			
a	1098	218.mg	n.s.s.	1/17	110.mg	0/18			
b	1098	104.mg	n.s.s.	2/17	110.mg	2/18			
1246	1098	72.9mg	n.s.s.	2/18	102.mg	3/18			
a	1098	121.mg	n.s.s.	1/18	102.mg	1/18			
b	1098	63.6mg	n.s.s.	3/18	102.mg	4/18			
1247	c02868	166.mg	n.s.s.	15/20	175.mg	32/50	(350.mg)	21/50)	
a	c02868	1.59gm	n.s.s.	0/20	175.mg	2/50	350.mg	1/50	liv:hpa,hpc,nnd.
1248	c02868	286.mg	n.s.s.	13/20	140.mg	36/50	280.mg	30/50	
a	c02868	1.59gm	n.s.s.	0/20	140.mg	2/50	280.mg	0/50	liv:hpa,hpc,nnd.
N-ETHYL-N-FORNILHYDRAZINE 74920-78-8									
1249	1052	1.17mg	4.67mg	8/96	40.0mg	47/48			Toth;carc,1,61-65;1980
a	1052	1.17mg	4.76mg	15/99	40.0mg	49/50			
b	1052	142.mg	n.s.s.	0/21	40.0mg	0/50			
1250	1052	1.76mg	6.03mg	22/98	33.3mg	39/42			
a	1052	2.04mg	6.45mg	5/88	33.3mg	32/36			
b	1052	9.07mg	45.6mg	1/52	33.3mg	13/36			
c	1052	16.4mg	452.mg	0/44	33.3mg	4/27			
d	1052	19.3mg	290.mg	0/52	33.3mg	5/36			
N-ETHYL-N'-NITRO-N-NITROSOGUANIDINE ---									
1251	600	1.64mg	5.50mg	0/38	5.48mg	19/43			Nakamura;jnci,52,519-522;1974
a	600	2.10mg	8.18mg	0/38	5.48mg	15/43			
b	600	2.25mg	9.20mg	0/38	5.48mg	14/43			
c	600	2.80mg	14.3mg	0/38	5.48mg	11/43			
d	600	3.63mg	29.5mg	0/38	5.48mg	8/43			
e	600	11.4mg	n.s.s.	0/38	5.48mg	1/43			
f	600	21.4mg	n.s.s.	3/38	5.48mg	0/43			
g	600	13.8mg	n.s.s.	19/38	5.48mg	5/43			
h	600	2.37mg	n.s.s.	22/38	5.48mg	25/43			
ETHYL TELLURAC 20941-65-5									
1252	c02857	325.mg	n.s.s.	8/20	277.mg	36/50	639.mg	36/50	
a	c02857	908.mg	n.s.s.	1/20	277.mg	7/50	639.mg	10/50	liv:hpa,hpc,nnd.
b	c02857	856.mg	n.s.s.	3/20	277.mg	9/50	639.mg	12/50	lun:a/a,a/c.
1253	132	21.3mg	n.s.s.	0/16	20.4mg	1/18			Innes;ntis,1968/1969
a	132	40.5mg	n.s.s.	0/16	20.4mg	0/18			
b	132	15.6mg	n.s.s.	0/16	20.4mg	2/18			
1254	c02857	112.mg	617.mg	0/20	151.mg	16/50	(376.mg)	10/50)	
a	c02857	127.mg	706.mg	0/20	151.mg	16/50	(376.mg)	11/50)	liv:hpa,hpc,nnd.
b	c02857	140.mg	1.02gm	0/20	151.mg	14/50	(376.mg)	11/50)	S
c	c02857	198.mg	n.s.s.	10/20	151.mg	39/50	376.mg	35/50	
d	c02857	518.mg	n.s.s.	8/20	151.mg	15/50	376.mg	16/50	liv:hpa,hpc,nnd.
e	c02857	127.mg	706.mg	0/20	151.mg	16/50	(376.mg)	11/50)	lun:a/a,a/c.
1255	132	8.30mg	n.s.s.	0/16	19.0mg	4/16			Innes;ntis,1968/1969
a	132	12.8mg	n.s.s.	0/16	19.0mg	2/16			
b	132	17.5mg	n.s.s.	0/16	19.0mg	1/16			
c	132	17.5mg	n.s.s.	0/16	19.0mg	1/16			
d	132	3.84mg	23.6mg	0/16	19.0mg	9/16			

Spe	Strain	Site	Xpo + Xpt	Notes	TD50	2Tailpvl
Sex	Route	Hist			DR	AuOp
1256	M f b6a	orl lun	ade 76w76	evx	28.2mg	P<.08
a	M f b6a	orl liv	hpt 76w76	evx	no dre	P=1.
b	M f b6a	orl tba	mix 76w76	evx	26.7mg	P<.2
1257	M m b6a	orl liv	hpt 76w76	evx	55.5mg	P<.3
a	M m b6a	orl lun	ade 76w76	evx	no dre	P=1.
b	M m b6a	orl tba	mix 76w76	evx	31.2mg	P<.3
1258	R f f34	eat pit	adn 24m24		#12.3mg	P<.04 -
a	R f f34	eat T8A	MXB 24m24		no dre	P=1.
b	R f f34	eat liv	MXB 24m24		650.mg *	P<.4
1259	R m f34	eat ---	men 24m24		77.6mg *	P<.009 a
a	R m f34	eat MXB	MXB 24m24		77.6mg *	P<.009
b	R m f34	eat bod	men 24m24		181.mg *	P<.05 a
c	R m f34	eat T8A	MXB 24m24		no dre	P=1.
d	R m f34	eat liv	MXB 24m24		no dre	P=1.
ETHYLENE GLYCOL					100ng.....1ug.....10.....100.....1mg.....10.....100.....1g.....10	
1260	M f hic	ipj lun	ptm 64w64		no dre	P=1.
ETHYLENE IMINE					100ng.....1ug.....10.....100.....1mg.....10.....100.....1g.....10	
1261	M f b6a	orl lun	ade 76w76	evx	.283mg	P<.0005+
a	M f b6a	orl liv	hpt 76w76	evx	3.29mg	P<.05
b	M f b6a	orl tba	mix 76w76	evx	noTD50	P<.003
1262	M m b6a	orl lun	ade 76w76	evx	.485mg	P<.0005
a	M m b6a	orl liv	hpt 76w76	evx	.800mg	P<.002 +
b	M m b6a	orl lun	bro 76w76	evx	2.14mg	P<.02
c	M m b6a	orl tba	mix 76w76	evx	noTD50	P<.002
1263	M f b6c	orl lun	ade 76w76	evx	noTD50	P<.0005+
a	M f b6c	orl liv	hpt 76w76	evx	.500mg	P<.0005
b	M f b6c	orl tba	mix 76w76	evx	noTD50	P<.0005
1264	M m b6c	orl liv	hpt 77w77	evx	.295mg	P<.0005+
a	M m b6c	orl lun	mix 77w77	evx	.295mg	P<.0005+
b	M m b6c	orl lun	ade 77w77	evx	.364mg	P<.0005
c	M m b6c	orl tba	mix 77w77	evx	.223mg	P<.0005
ETHYLENE THIOUREA					100ng.....1ug.....10.....100.....1mg.....10.....100.....1g.....10	
1265	M f b6a	orl liv	hpt 81w81	evx	44.7mg	P<.0005
a	M f b6a	orl lun	ade 81w81	evx	no dre	P=1.
b	M f b6a	orl tba	mix 81w81	evx	29.3mg	P<.0005
1266	M m b6a	orl liv	hpt 81w81	evx	noTD50	P<.0005
a	M m b6a	orl lun	ade 81w81	evx	no dre	P=1.
b	M m b6a	orl tba	mix 81w81	evx	noTD50	P<.0005
1267	M f b6c	orl liv	hpt 81w81	evx	noTD50	P<.0005
a	M f b6c	orl lun	ade 81w81	evx	203.mg	P<.05
b	M f b6c	orl tba	mix 81w81	evx	noTD50	P<.0005
1268	M m b6c	orl liv	hpt 82w82	evx	16.9mg	P<.0005+
a	M m b6c	orl lun	ade 82w82	evx	545.mg	P<.3
b	M m b6c	orl tba	mix 82w82	evx	16.9mg	P<.0005
1269	R b cdr	eat ---	fbs 24m24	e	13.2mg	Z P<.003
a	R b cdr	eat thy	mix 24m24	e	16.6mg	Z P<.0005+
b	R b cdr	eat thy	ade 24m24	e	33.9mg	Z P<.0005+
c	R b cdr	eat liv	hpt 24m24	e	330.mg *	P<.04 +
d	R b cdr	eat mgl	adc 24m24	e	no dre	P=1.
e	R b cdr	eat tba	mix 24m24	e	7.23mg *	P<.0005
f	R b cdr	eat tba	mal 24m24	e	13.4mg	Z P<.0005
1270	R f cdr	eat thy	fcc 18m24	e	39.8mg *	P<.03 +
1271	R f cdr	eat thy	car 18m24	e	34.4mg *	P<.002 +
a	R f cdr	eat thy	sca 18m24	e	98.9mg *	P<.2 +
b	R f cdr	eat liv	hnd 18m24	e	304.mg *	P<.6
1272	R m cdr	eat thy	fcc 18m24	e	12.8mg	/ P<.0005+
1273	R m cdr	eat thy	car 18m24	e	10.8mg	/ P<.0005+
a	R m cdr	eat liv	hnd 18m24	e	79.1mg *	P<.2
ETHYLENE UREA					100ng.....1ug.....10.....100.....1mg.....10.....100.....1g.....10	
1274	M f b6a	orl lun	ade 76w76	evx	505.mg	P<.6 -
a	M f b6a	orl liv	hpt 76w76	evx	no dre	P=1. -
b	M f b6a	orl tba	mix 76w76	evx	473.mg	P<.7 -
1275	M m b6a	orl liv	hpt 76w76	evx	500.mg	P<.6 -
a	M m b6a	orl lun	ade 76w76	evx	no dre	P=1. -
b	M m b6a	orl tba	mix 76w76	evx	no dre	P=1. -
1276	M f b6c	orl liv	hpt 76w76	evx	no dre	P=1. -
a	M f b6c	orl lun	mix 76w76	evx	no dre	P=1. -
b	M f b6c	orl tba	tum 76w76	evx	no dre	P=1. -
1277	M m b6c	orl liv	hpt 76w76	evx	242.mg	P<.1 -
a	M m b6c	orl lun	ade 76w76	evx	242.mg	P<.1 -
b	M m b6c	orl tba	mix 76w76	evx	87.1mg	P<.007 -
ETHYLENEBISDITHIOCARBAMATE, DISODIUM				1ug.....10.....100.....1mg.....10.....100.....1g.....10	
1278	M f b6a	orl liv	hpt 76w76	evx	no dre	P=1. -

RefNum	LoConf	UpConf	Cntrl	1Dose	1Inc	2Dose	2Inc	Citation or Pathology	Brkly Code		
1256	132	9.17mg n.s.s.	1/17	20.4mg	5/18						
a	132	40.5mg n.s.s.	0/17	20.4mg	0/18						
b	132	8.28mg n.s.s.	2/17	20.4mg	6/18						
1257	132	12.4mg n.s.s.	1/18	19.0mg	3/18						
a	132	17.8mg n.s.s.	2/18	19.0mg	2/18						
b	132	8.12mg n.s.s.	3/18	19.0mg	6/18						
1258	c02857	5.78mg n.s.s.	2/20	7.50mg	19/50	(15.0mg	9/50)		S		
a	c02857	11.7mg n.s.s.	15/20	7.50mg	40/50	15.0mg	39/50				
b	c02857	106.mg n.s.s.	0/20	7.50mg	0/50	15.0mg	1/50				
1259	c02857	37.1mg 2.43gm	0/20	12.0mg	2/50	24.0mg	8/50		Liv:hpa,hpc,nnD.		
a	c02857	37.1mg 2.43gm	0/20	12.0mg	2/50	24.0mg	8/50		---:men; bod:men. A		
b	c02857	61.8mg n.s.s.	0/20	12.0mg	0/50	24.0mg	4/50				
c	c02857	12.7mg n.s.s.	17/20	12.0mg	43/50	24.0mg	39/50				
d	c02857	119.mg n.s.s.	1/20	12.0mg	2/50	24.0mg	0/50		Liv:hpa,hpc,nnD.		
ETHYLENE GLYCOL (glycol sulfate) 1072-53-3											
1260	1143	.169mg n.s.s.	10/30	.286mg	9/30				Van Duuren;jnci,53,695-700;1974		
ETHYLENE IMINE 151-56-4											
1261	1245	.100mg .900mg	1/17	1.81mg	10/11						
a	1245	.806mg n.s.s.	0/17	1.81mg	2/11				Innes;ntis,1968/1969		
b	1245	n.s.s. .551mg	2/17	1.81mg	11/11						
1262	1245	.219mg 1.59mg	2/18	1.68mg	12/16						
a	1245	.349mg 3.45mg	1/18	1.68mg	9/16						
b	1245	.734mg n.s.s.	0/18	1.68mg	4/16						
c	1245	n.s.s. .419mg	3/18	1.68mg	16/16						
1263	1245	n.s.s. .409mg	0/16	1.81mg	15/15						
a	1245	.233mg 1.27mg	0/16	1.81mg	11/15						
b	1245	n.s.s. .409mg	0/16	1.81mg	15/15						
1264	1245	.135mg .688mg	0/16	1.68mg	15/17						
a	1245	.135mg .688mg	0/16	1.68mg	15/17						
b	1245	.174mg .847mg	0/16	1.68mg	14/17						
c	1245	88.7ug .540mg	0/16	1.68mg	16/17						
ETHYLENE THIOUREA (ETU) 96-45-7											
1265	1141	20.4mg 124.mg	0/17	88.8mg	9/16						
a	1141	178.mg n.s.s.	1/17	88.8mg	0/16				Innes;ntis,1968/1969		
b	1141	13.2mg 99.9mg	2/17	88.8mg	12/16						
1266	1141	n.s.s. 20.0mg	1/18	82.6mg	18/18						
a	1141	87.7mg n.s.s.	2/18	82.6mg	2/18						
b	1141	n.s.s. 21.8mg	3/18	82.6mg	18/18						
1267	1141	n.s.s. 20.7mg	0/16	88.8mg	18/18						
a	1141	61.1mg n.s.s.	0/16	88.8mg	3/18						
b	1141	n.s.s. 20.7mg	0/16	88.8mg	18/18						
1268	1141	7.63mg 40.5mg	0/16	82.5mg	14/16						
a	1141	88.7mg n.s.s.	0/16	82.5mg	1/16						
b	1141	7.63mg 40.5mg	0/16	82.5mg	14/16						
1269	139	5.00mg 75.7mg	0/72	.225mg	0/75	1.13mg	5/73 (5.63mg	4/73	11.3mg 5/69	22.5mg 3/70)	Graham; fctx,13,493-499;1975
a	139	12.5mg 22.9mg	2/72	.225mg	2/75	1.13mg	1/73	5.63mg	2/73	11.3mg 16/69	22.5mg 62/70
b	139	20.0mg 70.6mg	2/72	.225mg	0/75	1.13mg	5/73	5.63mg	1/73	11.3mg 21/69	(22.5mg 3/70)
c	139	117.mg n.s.s.	1/72	.225mg	1/75	1.13mg	1/73	5.63mg	2/73	11.3mg 1/69	22.5mg 5/70
d	139	100.mg n.s.s.	2/72	.225mg	14/75	1.13mg	4/73	5.63mg	2/73	11.3mg 5/69	(22.5mg 0/70)
e	139	4.58mg 13.5mg	51/72	.225mg	49/75	1.13mg	45/73	5.63mg	54/73	11.3mg 61/69	22.5mg 68/70
f	139	9.62mg 19.9mg	15/72	.225mg	23/75	1.13mg	13/73	5.63mg	16/73	11.3mg 31/69	22.5mg 63/70
1270	1112	18.0mg n.s.s.	0/10	6.56mg	2/26	13.1mg	6/26				Weisburger;jnci,67,75-88;1981
1271	141m	15.6mg 149.mg	0/32	6.56mg	3/26	13.1mg	5/21				Ulland;jnci,49,583-584;1972
a	141m	29.9mg n.s.s.	0/32	6.56mg	2/26	13.1mg	1/21				
b	141m	49.4mg n.s.s.	0/32	6.56mg	1/26	13.1mg	0/21				
1272	1112	7.21mg 28.7mg	0/10	5.25mg	2/26	10.5mg	15/26				Weisburger;jnci,67,75-88;1981
1273	141m	6.03mg 21.8mg	0/32	5.25mg	3/26	10.5mg	14/21				Ulland;jnci,49,583-584;1972
a	141m	23.9mg n.s.s.	0/32	5.25mg	2/26	10.5mg	1/21				
ETHYLENE UREA (2-imidazolidinone) 120-93-4											
1274	1197	70.3mg n.s.s.	1/17	89.1mg	2/17						Innes;ntis,1968/1969
a	1197	167.mg n.s.s.	0/17	89.1mg	0/17						
b	1197	59.5mg n.s.s.	2/17	89.1mg	3/17						
1275	1197	69.5mg n.s.s.	1/18	82.9mg	2/18						
a	1197	109.mg n.s.s.	2/18	82.9mg	1/18						
b	1197	65.2mg n.s.s.	3/18	82.9mg	3/18						
1276	1197	167.mg n.s.s.	0/16	89.1mg	0/17						
a	1197	167.mg n.s.s.	0/16	89.1mg	0/17						
b	1197	167.mg n.s.s.	0/16	89.1mg	0/17						
1277	1197	59.5mg n.s.s.	0/16	82.9mg	2/17						
a	1197	59.5mg n.s.s.	0/16	82.9mg	2/17						
b	1197	32.8mg 1.18gm	0/16	82.9mg	5/17						
ETHYLENEBISDITHIOCARBAMATE, DISODIUM (Dithane, nabem) 142-59-6											
1278	1215	19.7mg n.s.s.	0/17	9.96mg	0/18						Innes;ntis,1968/1969

Spe	Strain	Site	Xpo+Xpt	Notes	TD50	2Tailpvl
Sex	Route	Hist			DR	AuOp
a	M f	b6a orl	lun mix	76w76 evx	no dre	P=1. -
b	M f	b6a orl	tba mix	76w76 evx	no dre	P=1. -
1279	M m	b6a orl	lun ade	76w76 evx	no dre	P=1. -
a	M m	b6a orl	liv hpt	76w76 evx	no dre	P=1. -
b	M m	b6a orl	tba mix	76w76 evx	no dre	P=1. -
1280	M f	b6c orl	liv hpt	76w76 evx	no dre	P=1. -
a	M f	b6c orl	lun ade	76w76 evx	no dre	P=1. -
b	M f	b6c orl	tba mix	76w76 evx	no dre	P=1. -
1281	M m	b6c orl	liv hpt	76w76 evx	866.mg	P<1. -
a	M m	b6c orl	lun ade	76w76 evx	no dre	P=1. -
b	M m	b6c orl	tba mix	76w76 evx	no dre	P=1. -
1-ETHYLENEOXY-3,4-EPOXYCYCLOHEXANE					100ng.....1ug.....10.....100.....1mg.....10.....100.....1g.....10	
1282	R f	ead gav	sto tum	84w84	no dre	P=1. -
ETHYLHYDRAZINE.HCl					100ng.....1ug.....10.....100.....1mg.....10.....100.....1g.....10	
1283	M f	swa wat	lun mix	82w82 e	5.22mg	P<.0005+
a	M f	swa wat	lun ade	82w82 e	5.62mg	P<.0005
b	M f	swa wat	blv mix	82w82 e	11.6mg	P<.0005+
c	M f	swa wat	liv mix	82w82 e	13.0mg	P<.0005
d	M f	swa wat	lun adc	82w82 e	14.0mg	P<.0005
e	M f	swa wat	blv ang	82w82 e	27.6mg	P<.0005
f	M f	swa wat	liv ang	82w82 e	27.6mg	P<.0005
g	M f	swa wat	liv agm	82w82 e	42.9mg	P<.0005
h	M f	swa wat	blv agm	82w82 e	42.9mg	P<.0005
1284	M m	swa wat	lun ade	72w72 e	7.82mg	P<.0005
a	M m	swa wat	lun mix	72w72 e	8.81mg	P<.0005+
b	M m	swa wat	blv mix	72w72 e	38.6mg	P<.09 +
c	M m	swa wat	blv ang	72w72 e	46.9mg	P<.08
d	M m	swa wat	liv ang	72w72 e	46.9mg	P<.08
e	M m	swa wat	liv mix	72w72 e	48.1mg	P<.2
ETHYLNITROSOCYANAMIDE					100ng.....1ug.....10.....100.....1mg.....10.....100.....1g.....10	
1285	R f	mrw wat	res tum	52w90	2.91mg	P<.0005+
a	R f	mrw wat	liv tum	52w90	no dre	P=1.
b	R f	mrw wat	tba mix	52w90	3.17mg	P<.2
1286	R m	mrw wat	res tum	52w90	4.99mg	P<.005 +
a	R m	mrw wat	liv tum	52w90	no dre	P=1.
b	R m	mrw wat	tba mix	52w90	no dre	P=1.
4-ETHYLSULPHONYLNAPHTHALENE-1-SULFONAMIDE					100ng.....1ug.....10.....100.....1mg.....10.....100.....1g.....10	
1287	M f	aif eat	ubl car	23w23 e	34.2mg	P<.0005+
a	M f	aif eat	lun ade	23w23 e	53.4mg	P<.005
1288	M f	ifc eat	ubl car	92w92 r	15.3mg	P<.0005+
ETHYNODIOL DIACETATE					100ng.....1ug.....10.....100.....1mg.....10.....100.....1g.....10	
1289	M f	crf eat	mam tum	24m24 er	no dre	P=1. -
EUCALYPTOL					100ng.....1ug.....10.....100.....1mg.....10.....100.....1g.....10	
1290	M m	cfl gav	lun tum	19m24 e	no dre	P=1.
a	M m	cfl gav	liv tum	19m24 e	no dre	P=1.
b	M m	cfl gav	tba mix	19m24 e	119.mg	* P<.7
c	M m	cfl gav	tba mol	19m24 e	no dre	P=1.
FENAMINOSULF, FORMULATED					100ng.....1ug.....10.....100.....1mg.....10.....100.....1g.....10	
1291	M f	b6c eat	liv MXA	78w95 v	152.mg	\ P<.02 -
a	M f	b6c eat	TBA MXB	78w95 v	259.mg	* P<.2
b	M f	b6c eat	liv MXB	78w95 v	152.mg	\ P<.02
c	M f	b6c eat	lun MXB	78w95 v	1.75gm	* P<.7
1292	M m	b6c eat	TBA MXB	78w94 v	no dre	P=1. -
a	M m	b6c eat	liv MXB	78w94 v	no dre	P=1.
b	M m	b6c eat	lun MXB	78w94 v	no dre	P=1.
1293	R f	f34 eat	TBA MXB	18m24 v	no dre	P=1. -
a	R f	f34 eat	liv MXB	18m24 v	no dre	P=1.
1294	R m	f34 eat	TBA MXB	18m24 v	no dre	P=1. -
a	R m	f34 eat	liv MXB	18m24 v	no dre	P=1.
FENTHION					100ng.....1ug.....10.....100.....1mg.....10.....100.....1g.....10	
1295	M f	b6c eat	TBA MXB	24m24	17.8mg	* P<.7 -
a	M f	b6c eat	liv MXB	24m24	no dre	P=1.
b	M f	b6c eat	lun MXB	24m24	no dre	P=1.
1296	M m	b6c eat	MXA MXA	24m24	6.12mg	* P<.02 a
a	M m	b6c eat	TBA MXB	24m24	1.03mg	\ P<.02
b	M m	b6c eat	liv MXB	24m24	9.44mg	* P<.5
c	M m	b6c eat	lun MXB	24m24	13.3mg	* P<.3
1297	R f	f34 eat	TBA MXB	24m24	29.4mg	* P<.1. -
a	R f	f34 eat	liv MXB	24m24	no dre	P=1.
1298	R m	f34 eat	TBA MXB	24m24	no dre	P=1. -
a	R m	f34 eat	liv MXB	24m24	10.3mg	* P<.7

CARCINOGENIC POTENCY DATABASE

RefNum	LoConf	UpConf	Cntrl	1Dose	1Inc	2Dose	2Inc	Citation or Pathology	Brkly Code
a	1215	19.7mg	n.s.s.	0/17	9.96mg	0/18			
b	1215	19.7mg	n.s.s.	2/17	9.96mg	0/18			
1279	1215	12.2mg	n.s.s.	2/18	9.26mg	1/18			
a	1215	18.3mg	n.s.s.	3/18	9.26mg	0/18			
b	1215	14.1mg	n.s.s.	5/18	9.26mg	1/18			
1280	1215	17.5mg	n.s.s.	0/18	9.96mg	0/16			
a	1215	17.5mg	n.s.s.	1/18	9.96mg	0/16			
b	1215	17.5mg	n.s.s.	3/18	9.96mg	0/16			
1281	1215	9.63mg	n.s.s.	1/17	9.26mg	1/16			
a	1215	10.7mg	n.s.s.	2/17	9.26mg	1/16			
b	1215	10.1mg	n.s.s.	6/17	9.26mg	2/16			
1-ETHYLENEOXY-3,4-EPOXYCYCLOHEXANE				106-87-6					
1282	55	27.4mg	n.s.s.	0/5	40.8mg	0/5		Van Duuren; jnci, 37, 825-838; 1966	
ETHYLHYDRAZINE.HCL				18413-14-4					
1283	142	3.11mg	9.34mg	21/97	25.0mg	44/49		Shimizu; jcn, 13, 500-505; 1974	
a	142	3.40mg	9.90mg	18/97	25.0mg	43/49			
b	142	7.37mg	19.6mg	0/43	25.0mg	30/50			
c	142	8.13mg	22.3mg	0/43	25.0mg	28/50			
d	142	8.54mg	25.8mg	4/97	25.0mg	27/49			
e	142	15.4mg	57.0mg	0/43	25.0mg	16/50			
f	142	15.4mg	57.0mg	0/43	25.0mg	16/50			
g	142	21.5mg	111.1mg	0/43	25.0mg	11/50			
h	142	21.5mg	111.1mg	0/43	25.0mg	11/50			
1284	142	4.62mg	15.7mg	15/100	20.8mg	31/48			
a	142	4.93mg	21.1mg	23/100	20.8mg	31/48			
b	142	13.7mg	n.s.s.	2/28	20.8mg	8/36			
c	142	16.3mg	n.s.s.	1/28	20.8mg	6/36			
d	142	16.3mg	n.s.s.	1/28	20.8mg	6/36			
e	142	15.4mg	n.s.s.	2/28	20.8mg	7/36			
ETHYLNITROSOCYANAMIDE (nitrosoethanecarbamonitrile)				38434-77-4					
1285	1246	1.35mg	8.02mg	0/25	3.40mg	9/20		Bulay; jnci, 62, 1523-1528; 1979	
a	1246	10.5mg	n.s.s.	0/25	3.40mg	0/20			
b	1246	.981mg	n.s.s.	12/25	3.40mg	14/20			
1286	1246	1.88mg	36.2mg	0/22	2.97mg	5/19			
a	1246	8.71mg	n.s.s.	0/22	2.97mg	0/19			
b	1246	1.67mg	n.s.s.	12/22	2.97mg	10/19			
4-ETHYLSULPHONYLNAPHTHALENE-1-SULFONAMIDE				842-00-2					
1287	142c	16.1mg	102.1mg	0/40	13.0mg	9/42		Flaks; b]ca, 28, 227-231; 1973	
a	142c	21.8mg	360.1mg	0/40	13.0mg	6/42			
1288	142a	8.89mg	31.0mg	0/26	13.0mg	19/52		Flaks; b]ca, 31, 585-587; 1975	
ETHYNYDIOL DIACETATE				297-76-7					
1289	1175	.190mg	n.s.s.	161/167p	9.75ug	30/32	.130mg	46/56	Rudeli; jnci, 49, 813-819; 1972
EUCALYPTOL				470-82-6					
1290	710	38.5mg	n.s.s.	102/240	5.27mg	30/52	21.1mg	18/47	Roe; jept, 2, 799-819; 1979
a	710	72.8mg	n.s.s.	69/240	5.27mg	5/52	21.1mg	12/47	
b	710	16.2mg	n.s.s.	170/240	5.27mg	36/52	21.1mg	35/47	
c	710	67.8mg	n.s.s.	75/240	5.27mg	18/52	21.1mg	11/47	
FENAMINOSULF, FORMULATED (methyl orange B)				140-56-7					
1291	c03010	47.6mg	n.s.s.	2/100	54.3mg	4/50	(103.1mg	3/49)	liv:hpa,hpc, S
a	c03010	82.6mg	n.s.s.	26/100	54.3mg	10/50	103.1mg	16/49	
b	c03010	47.6mg	n.s.s.	2/100	54.3mg	4/50	(103.1mg	3/49)	liv:hpa,hpc,nnd.
c	c03010	210.1mg	n.s.s.	8/100	54.3mg	3/50	103.1mg	4/49	lun:a/a,a/c.
1292	c03010	137.1mg	n.s.s.	20/50	94.7mg	20/50	189.1mg	3/50	
a	c03010	265.1mg	n.s.s.	15/50	94.7mg	9/50	189.1mg	2/50	liv:hpa,hpc,nnd.
b	c03010	249.1mg	n.s.s.	7/50	94.7mg	7/50	189.1mg	1/50	lun:a/a,a/c.
1293	c03010	36.7mg	n.s.s.	31/50	19.3mg	33/50	34.4mg	30/50	
a	c03010	325.1mg	n.s.s.	1/50	19.3mg	1/50	34.4mg	0/50	liv:hpa,hpc,nnd.
1294	c03010	19.3mg	n.s.s.	31/50	15.4mg	18/50	(27.5mg	17/50)	
a	c03010	n.s.s.	n.s.s.	0/50	15.4mg	1/50	27.5mg	0/50	liv:hpa,hpc,nnd.
FENTHION				55-38-9					
1295	c08651	2.57mg	n.s.s.	12/25	1.30mg	22/50	2.60mg	24/50	
a	c08651	11.0mg	n.s.s.	2/25	1.30mg	4/50	2.60mg	2/50	liv:hpa,hpc,nnd.
b	c08651	11.2mg	n.s.s.	3/25	1.30mg	3/50	2.60mg	3/50	lun:a/a,a/c.
1296	c08651	3.34mg	n.s.s.	0/25	1.20mg	7/50	2.40mg	8/50	ski: fbs, orn; sub: fbs, rhb, orn.
a	c08651	.500mg	n.s.s.	10/25	1.20mg	35/50	(2.40mg	26/50)	
b	c08651	2.37mg	n.s.s.	6/25	1.20mg	17/50	2.40mg	17/50	liv:hpa,hpc,nnd.
c	c08651	4.15mg	n.s.s.	2/25	1.20mg	5/50	2.40mg	8/50	lun:a/a,a/c.
1297	c08651	.581mg	n.s.s.	18/25	.500mg	44/50	1.00mg	39/50	
a	c08651	9.77mg	n.s.s.	1/25	.500mg	0/50	1.00mg	0/50	liv:hpa,hpc,nnd.
1298	c08651	1.04mg	n.s.s.	17/25	.400mg	32/50	.800mg	26/50	
a	c08651	2.82mg	n.s.s.	0/25	.400mg	2/50	.800mg	1/50	liv:hpa,hpc,nnd.

Spe	Strain	Site	Xpo+Xpt					TD50	2Tailpvl			
Sex	Route	Hist	Notes					DR	AuOp			
FERRIC DIMETHYLDITHIOCARBAMATE 100ng...1ug...10...100...1mg...10...100...1g...10												
1299	M	f	b6a	orl	liv	hpt	76w76	evx	>	no dre	P=1.	-
a	M	f	b6a	orl	lun	ade	76w76	evx		no dre	P=1.	-
b	M	f	b6a	orl	tba	mix	76w76	evx		no dre	P=1.	-
1300	M	m	b6a	orl	lun	ade	76w76	evx	>	11.2mg	P<.4	-
a	M	m	b6a	orl	liv	hpt	76w76	evx		no dre	P=1.	-
b	M	m	b6a	orl	tba	mix	76w76	evx		21.6mg	P<.7	-
1301	M	f	b6c	orl	lun	ade	76w76	evx	>	26.9mg	P<.3	-
a	M	f	b6c	orl	liv	hpt	76w76	evx		no dre	P=1.	-
b	M	f	b6c	orl	tba	mix	76w76	evx		12.0mg	P<.09	-
1302	M	m	b6c	orl	liv	hpt	76w76	evx	.	5.57mg	P<.02	-
a	M	m	b6c	orl	lun	ade	76w76	evx	.	11.9mg	P<.1	-
b	M	m	b6c	orl	tba	mix	76w76	evx	.	2.81mg	P<.002	-
N-(2-FLUORENYL)-2,2,2-TRIFLUOROACETAMIDE ...1ug...10...100...1mg...10...100...1g...10												
1303	R	f	buf	eat	mgl	adc	53w54	e	.	1.62mg	P<.0005+	-
a	R	f	buf	eat	liv	hpt	53w54	e	.	1.90mg	P<.0005+	-
b	R	f	buf	eat	edu	sqc	53w54	e	.	4.94mg	P<.002	+
FLUORIDE, SODIUM 100ng...1ug...10...100...1mg...10...100...1g...10												
1304	M	b	cd1	wat	lun	tum	30m30	e	>	no dre	P=1.	-
a	M	b	cd1	wat	liv	tum	30m30	e		no dre	P=1.	-
b	M	b	cd1	wat	tba	tum	30m30	e		no dre	P=1.	-
c	M	b	cd1	wat	tba	mal	30m30	e		no dre	P=1.	-
4'-FLUORO-4-AMINODIPHENYL 100ng...1ug...10...100...1mg...10...100...1g...10												
1305	M	f	cba	gav	liv	hpt	6m24	e	.	1.09mg	P<.0005+	-
1306	M	m	cba	gav	liv	hpt	6m24	e	.	1.19mg	P<.005	+
a	M	m	cba	gav	liv	mix	6m24	e	.	1.19mg	P<.005	-
N-4-(4'-FLUOROBIPHENYL)ACETAMIDE 100ng...1ug...10...100...1mg...10...100...1g...10												
1307	R	m	f34	eat	kid	adc	52w52	ekr	.	1.01mg	P<.0005+	-
5-FLUOROURACIL 100ng...1ug...10...100...1mg...10...100...1g...10												
1308	R	m	b46	ivj	liv	ade	12m24	es	.	34.7mg	P<.1	-
a	R	m	b46	ivj	tba	ben	12m24	es	.	16.3mg	P<.2	-
b	R	m	b46	ivj	tba	mix	12m24	es	.	18.6mg	P<.4	-
c	R	m	b46	ivj	tba	mal	12m24	es	.	no dre	P=1.	-
FORMIC ACID 2-[4-(2-FURYL)-2-THIAZOLYL]HYDRAZIDE ...10...100...1mg...10...100...1g...10												
1309	R	f	ada	eat	liv	tum	46w64	ev	>	no dre	P=1.	-
a	R	f	ada	eat	tba	mix	46w64	ev		no dre	P=1.	-
FORMIC ACID 2-(4-METHYL-2-THIAZOLYL)HYDRAZIDE ...10...100...1mg...10...100...1g...10												
1310	R	f	ada	eat	mgl	adf	46w64	ev	.	14.4mg	P<.03	+
a	R	f	ada	eat	liv	tum	46w64	ev	.	no dre	P=1.	-
b	R	f	ada	eat	tba	mix	46w64	ev	.	14.4mg	P<.03	-
FORMIC ACID 2-[4-(5-NITRO-2-FURYL)-2-THIAZOLYL]HYDRAZIDE ...100...1mg...10...100...1g...10												
1311	M	m	syg	eat	ubl	tcc	48w70	e	.	16.6mg	P<.0005+	-
a	M	m	syg	eat	for	sqp	48w70	e	.	25.1mg	P<.0005+	-
b	M	m	syg	eat	lun	tum	48w70	e	.	no dre	P=1.	-
c	M	m	syg	eat	liv	tum	48w70	e	.	no dre	P=1.	-
1312	M	f	awi	eat	for	sqp	33w52	e	.	8.85mg	P<.0005+	-
a	M	f	awi	eat	---	lle	33w52	e	.	11.4mg	P<.0005+	-
b	M	f	awi	eat	lun	alc	33w52	e	.	67.1mg	P<.06	-
c	M	f	awi	eat	liv	tum	33w52	e	.	no dre	P=1.	-
d	M	f	awi	eat	tba	mix	33w52	e	.	2.42mg	P<.0005	-
1313	M	f	awi	eat	for	pam	33w52	e	.	13.8mg	P<.0005+	-
a	M	f	awi	eat	---	leu	33w52	e	.	25.6mg	P<.008	-
b	M	f	awi	eat	liv	tum	33w52	e	.	no dre	P=1.	-
c	M	f	awi	eat	lun	tum	33w52	e	.	no dre	P=1.	-
1314	R	f	buf	eat	mgl	mix	46w64	e	.	5.54mg	P<.0005+	-
a	R	f	buf	eat	mgl	adc	46w64	e	.	13.1mg	P<.0005+	-
b	R	f	buf	eat	kid	mix	46w64	e	.	17.5mg	P<.0005+	-
c	R	f	buf	eat	liv	cye	46w64	e	.	39.1mg	P<.0005+	-
d	R	f	buf	eat	kid	uac	46w64	e	.	44.1mg	P<.0005+	-
e	R	f	buf	eat	mgl	adf	46w64	e	.	80.5mg	P<.003	+
f	R	f	buf	eat	kid	tue	46w64	e	.	98.6mg	P<.007	+
g	R	f	buf	eat	tba	mix	46w64	e	.	noTD50	P<.0005	-
1315	R	f	hza	eat	mam	tum	44w60	es	.	5.50mg	P<.0005+	-
a	R	f	hza	eat	kid	ade	44w60	es	.	17.6mg	P<.0005+	-
b	R	f	hza	eat	smi	adc	44w60	es	.	78.5mg	P<.03	+
c	R	f	hza	eat	kid	car	44w60	es	.	78.5mg	P<.03	+
d	R	f	hza	eat	ec	sqc	44w60	es	.	+historical	P<.05	+
e	R	f	hza	eat	cec	adc	44w60	es	.	210.mg	P<.2	+
f	R	f	hza	eat	liv	hms	44w60	es	.	428.mg	P<.4	-
1316	R	f	ada	eat	mgl	mix	46w64	e	.	5.85mg	P<.0005+	-
a	R	f	ada	eat	kid	mix	46w64	e	.	9.96mg	P<.0005+	-

RefNum	LoConf	UpConf	Cntrl	1Dose	1Inc	2Dose	2Inc	Citation or Pathology	Brkly Code
FERRIC DIMETHYLDITHIOCARBAMATE (ferbam) 14484-64-1									
1299	1209	8.21mg n.s.s.	0/17	4.39mg	0/17				Innes;ntis,1968/1969
a	1209	8.21mg n.s.s.	1/17	4.39mg	0/17				
b	1209	5.43mg n.s.s.	2/17	4.39mg	1/17				
1300	1209	2.34mg n.s.s.	2/18	4.08mg	4/18				
a	1209	4.82mg n.s.s.	1/18	4.08mg	1/18				
b	1209	2.54mg n.s.s.	3/18	4.08mg	4/18				
1301	1209	4.05mg n.s.s.	0/16	4.39mg	1/16				
a	1209	7.73mg n.s.s.	0/16	4.39mg	0/16				
b	1209	2.95mg n.s.s.	0/16	4.39mg	2/16				
1302	1209	1.91mg n.s.s.	0/16	4.08mg	4/17				
a	1209	2.93mg n.s.s.	0/16	4.08mg	2/17				
b	1209	1.20mg 10.8mg	0/16	4.08mg	7/17				
N-(2-FLUORENYL)-2,2,2-TRIFLUOROACETAMIDE 363-17-7									
1303	144	.800mg 3.71mg	0/18	13.2mg	14/18			Morris;jnci,24,149-180;1960	
a	144	.940mg 4.44mg	0/18	13.2mg	13/18				
b	144	2.11mg 18.4mg	0/18	13.2mg	7/18				
FLUORIDE, SODIUM 7681-49-4									
1304	1036	11.0mg n.s.s.	15/71	1.75mg	12/72			Kanisawa;canr,29,892-895;1969	
a	1036	15.3mg n.s.s.	4/71	1.75mg	4/72				
b	1036	7.10mg n.s.s.	24/71	1.75mg	22/72				
c	1036	17.4mg n.s.s.	8/71	1.75mg	5/72				
4'-FLUORO-4-AMINODIPHENYL 324-93-6									
1305	1165	.663mg 1.96mg	0/18	1.30mg	25/40			Clayson;b]ca,19,297-310;1965/Williams 1962	
1306	1165	.601mg 8.97mg	2/15	1.19mg	18/32				
a	1165	.601mg 8.97mg	2/15	1.19mg	18/32				
N-4-(4'-FLUOROBIPHENYL)ACETAMIDE 398-32-3									
1307	1150	.392mg 2.58mg	0/15	16.0mg	14/15			Hinton;bect,23,464-469;1979	
5-FLUOROURACIL 51-21-8									
1308	1017	5.65mg n.s.s.	0/65	2.36mg	1/22			Schwehl;arzn,20,1461-1467;1970	
a	1017	3.65mg n.s.s.	3/65	2.36mg	3/22				
b	1017	3.37mg n.s.s.	7/65	2.36mg	4/22				
c	1017	6.96mg n.s.s.	4/65	2.36mg	1/22				
FORMIC ACID 2-[4-(2-FURYL)-2-THIAZOLYL]HYDRAZIDE 31873-81-1									
1309	1073	52.9mg n.s.s.	0/29	29.5mg	0/23			Erturk;jnci,47,437-445;1971/1970a	
a	1073	52.9mg n.s.s.	2/29	29.5mg	0/23				
FORMIC ACID 2-(4-METHYL-2-THIAZOLYL)HYDRAZIDE 32852-21-4									
1310	1073	5.54mg n.s.s.	2/29	14.7mg	8/28			Erturk;jnci,47,437-445;1971/1970a	
a	1073	32.1mg n.s.s.	0/29	14.7mg	0/28				
b	1073	5.54mg n.s.s.	2/29	14.7mg	8/28				
FORMIC ACID 2-[4-(5-NITRO-2-FURYL)-2-THIAZOLYL]HYDRAZIDE (FNT) 3570-75-0									
1311	1077	7.32mg 46.9mg	0/17	63.1mg	9/13			Croft;jnci,51,941-949;1973	
a	1077	12.9mg 57.3mg	0/24	63.1mg	13/24				
b	1077	141.mg n.s.s.	0/24	63.1mg	0/24				
c	1077	141.mg n.s.s.	0/24	63.1mg	0/24				
1312	1076	4.33mg 21.9mg	0/29	41.3mg	11/20			Cohen;canr,33,1593-1597;1973	
a	1076	5.09mg 47.4mg	2/29	41.3mg	10/20				
b	1076	16.5mg n.s.s.	0/29	41.3mg	2/20				
c	1076	42.5mg n.s.s.	0/29	41.3mg	0/20				
d	1076	.980mg 5.76mg	2/29	41.3mg	19/20				
1313	1118	7.06mg 32.6mg	0/30	41.3mg	12/30			Cohen;canr,38,1398-1405;1978	
a	1118	10.7mg 639.mg	1/30	41.3mg	8/30				
b	1118	63.8mg n.s.s.	0/30	41.3mg	0/30				
c	1118	63.8mg n.s.s.	0/30	41.3mg	0/30				
1314	1073	2.43mg 11.4mg	0/30	71.9mg	28/29			Erturk;jnci,47,437-445;1971/1970a	
a	1073	7.48mg 25.0mg	0/30	71.9mg	22/29				
b	1073	9.87mg 34.5mg	0/30	71.9mg	19/29				
c	1073	19.5mg 96.4mg	0/30	71.9mg	11/29				
d	1073	21.3mg 116.mg	0/30	71.9mg	10/29				
e	1073	32.7mg 434.mg	0/30	71.9mg	6/29				
f	1073	37.3mg 1.20gm	0/30	71.9mg	5/29				
g	1073	n.s.s. 8.39mg	0/30	71.9mg	29/29				
1315	1063	2.28mg 13.1mg	3/16	73.6mg	25/26			Morris;canr,29,2145-2156;1969	
a	1063	9.51mg 37.0mg	0/16	73.6mg	16/26				
b	1063	29.7mg n.s.s.	0/16	73.6mg	5/26				
c	1063	29.7mg n.s.s.	0/16	73.6mg	5/26				
d	1063	34.6mg n.s.s.	0/16	73.6mg	4/26				
e	1063	51.5mg n.s.s.	0/16	73.6mg	2/26				
f	1063	69.6mg n.s.s.	0/16	73.6mg	1/26				
1316	1073	2.49mg 12.8mg	2/29	71.9mg	25/26			Erturk;jnci,47,437-445;1971/1970a	
a	1073	5.42mg 19.5mg	0/29	71.9mg	22/26				

Spe	Strain	Site	Xpo+Xpt						
Sex	Route	Hist	Notes					TD50	2Tailpvl DR AuOp
b	R f sda eat mgl adc 46w64 e							19.5mg	P<.0005+
c	R f sda eat liv mix 46w64 e							30.1mg	P<.0005+
d	R f sda eat kid uac 46w64 e							33.9mg	P<.0005+
e	R f sda eat liv cye 46w64 e							43.9mg	P<.0005+
f	R f sda eat kid tua 46w64 e							50.7mg	P<.0005+
g	R f sda eat mgl adf 46w64 e							52.8mg	P<.009 +
h	R f sda eat tba mix 46w64 e							noTD50	P<.0005
1317	R f sda eat mgl adc 45w75 ev			.	+	.		3.54mg	P<.0005+
a	R f sda eat kid rcc 45w75 ev							65.4mg	P<.0005
b	R f sda eat for eqp 45w75 ev							65.4mg	P<.0005
c	R f sda eat k/p tcc 45w75 ev							+historical	P<.008 +
d	R f sda eat --- lbl 45w75 ev							+historical	P<.03 +
e	R f sda eat liv tum 45w75 ev							no dre	P=1. -
f	R f sda eat tba mix 45w75 ev							3.79mg	P<.0005
1318	R m sda eat kid mix 46w64 er			.	+	.		5.82mg	P<.0005+
a	R m sda eat kid uac 46w64 er							19.3mg	P<.0005+
b	R m sda eat liv cye 46w64 e							35.3mg	P<.0005+
c	R m sda eat mgl adf 46w64 e							+historical	P<.0005+
d	R m sda eat kid tua 46w64 er							47.6mg	P<.002 +
e	R m sda eat k/p tcc 46w64 er							69.9mg	P<.006 +
f	R m sda eat tba mix 46w64 e							noTD50	P<.0005
1-FORMYL-3-THIOSEMICARBAZIDE				100ng.....1ug.....10.....100.....1mg.....10.....100.....1g.....10					
1319	R f sda eat liv tum 46w64 e							no dre	P=1. -
a	R f sda eat tba mix 46w64 e							140.mg	P<.2 -
FORMYLHYDRAZINE				100ng.....1ug.....10.....100.....1mg.....10.....100.....1g.....10					
1320	M f sda eat lun mix 83w83 e			.	+	.		36.0mg	P<.0005+
a	M f sda eat liv mix 83w83 e							6.86gm	P<.9
1321	M m sda eat lun mix 83w83 e							noTD50	P<.0005+
a	M m sda eat liv mix 83w83 e							1.15gm	P<.2
2-FURALDEHYDE SEMICARBAZONE				100ng.....1ug.....10.....100.....1mg.....10.....100.....1g.....10					
1322	R f sda eat mgl tba 46w66 er							48.8mg	P<.2 -
FURFURAL				100ng.....1ug.....10.....100.....1mg.....10.....100.....1g.....10					
1323	M f sda eat liv tum 52w81 ev							no dre	P=1. -
a	M f sda eat lun tum 52w81 ev							no dre	P=1. -
1324	M m sda eat liv tum 52w81 ev							no dre	P=1. -
a	M m sda eat lun tum 52w81 ev							no dre	P=1. -
GERMANATE, SODIUM				100ng.....1ug.....10.....100.....1mg.....10.....100.....1g.....10					
1325	M b cd1 eat lun mix 24m24 e							no dre	P=1. -
a	M b cd1 eat liv mix 24m24 e							no dre	P=1. -
b	M b cd1 eat tba mix 24m24 e							no dre	P=1. -
c	M b cd1 eat tba ben 24m24 e							no dre	P=1. -
d	M b cd1 eat tba mal 24m24 e							no dre	P=1. -
1326	R b leb eat liv tum 35m35 e							no dre	P=1. -
a	R b leb eat tba tum 35m35 e							no dre	P=1. -
b	R b leb eat tba mal 35m35 e							no dre	P=1. -
GIBBERELIC ACID				100ng.....1ug.....10.....100.....1mg.....10.....100.....1g.....10					
1327	M f b6a eat liv hpt 76w76 evx							no dre	P=1. -
a	M f b6a eat lun ade 76w76 evx							no dre	P=1. -
b	M f b6a eat tba mix 76w76 evx							no dre	P=1. -
1328	M m b6a eat liv hpt 76w76 evx							316.mg	P<.2 -
a	M m b6a eat lun mix 76w76 evx							460.mg	P<.4 -
b	M m b6a eat tba mix 76w76 evx							151.mg	P<.07 -
1329	M f b6c eat liv hpt 76w76 evx							no dre	P=1. -
a	M f b6c eat lun mix 76w76 evx							no dre	P=1. -
b	M f b6c eat tba mix 76w76 evx							1.15gm	P<.3 -
1330	M m b6c eat liv hpt 76w76 evx							460.mg	P<.09 -
a	M m b6c eat lun ade 76w76 evx							952.mg	P<.3 -
b	M m b6c eat tba mix 76w76 evx							214.mg	P<.02 -
GLYCEROL alpha-MONOCHLOROHYDRIN				100ng.....1ug.....10.....100.....1mg.....10.....100.....1g.....10					
1331	R f cdr gav pty ade 17m24 ev							no dre	P=1. -
1332	R m cdr gav pty ade 17m24 ev							116.mg *	P<.06
GLYCIDALDEHYDE**				100ng.....1ug.....10.....100.....1mg.....10.....100.....1g.....10					
1333	R f ead gav sto tum 70w70							no dre	P=1. -
GLYCOL SULFITE				100ng.....1ug.....10.....100.....1mg.....10.....100.....1g.....10					
1334	M f h1c ipj lun ptm 64w64							1.03mg	P<.07
FD & C GREEN NO. 1				100ng.....1ug.....10.....100.....1mg.....10.....100.....1g.....10					
1335	M f cbj eat liv mix 24m24							146.gm *	P<.6 -
a	M f cbj eat lun ade 24m24							146.gm *	P<.6 -
b	M f cbj eat tba mal 24m24							18.4gm \	P<.1 -
c	M f cbj eat tba mix 24m24							no dre	P=1. -

RefNum	LoConf	UpConf	Cntrl	1Dose	1Inc	2Dose	2Inc	Citation or Pathology	Brkly Code
b	1073	10.6mg	41.0mg	0/29	71.9mg	16/26			
c	1073	15.3mg	71.1mg	0/29	71.9mg	12/26			
d	1073	16.8mg	83.4mg	0/29	71.9mg	11/26			
e	1073	20.5mg	123.mg	0/29	71.9mg	9/26			
f	1073	22.8mg	157.mg	0/29	71.9mg	8/26			
g	1073	22.0mg	2.37gm	2/29	71.9mg	9/26			
h	1073	n.s.s.	9.13mg	2/29	71.9mg	26/26			
1317	200a	1.95mg	6.19mg	6/71	31.3mg	49/51		Cohen;jnci,51,403-417;1973	
a	200a	29.6mg	196.mg	0/71	31.3mg	8/51			
b	200a	29.6mg	196.mg	0/71	31.3mg	8/51			
c	200a	47.2mg	3.07gm	0/71	31.3mg	4/51			
d	200a	55.7mg	n.s.s.	0/71	31.3mg	3/51			
e	200a	171.mg	n.s.s.	0/71	31.3mg	0/51			
f	200a	2.02mg	7.04mg	18/71	31.3mg	49/51			
1318	1073	2.92mg	11.7mg	0/28	57.5mg	24/26		Erturk;jnci,47,437-445;1971/1970a	
a	1073	10.2mg	42.6mg	0/28	57.5mg	14/26			
b	1073	17.1mg	92.9mg	0/29	57.5mg	10/29			
c	1073	20.8mg	151.mg	0/29	57.5mg	8/29			
d	1073	20.4mg	177.mg	0/28	57.5mg	7/26			
e	1073	26.4mg	690.mg	0/28	57.5mg	5/26			
f	1073	n.s.s.	6.71mg	0/29	57.5mg	29/29			
1-FORMYL-3-THIOSEMICARBAZIDE				2302-84-3					
1319	1073	151.mg	n.s.s.	0/29	71.9mg	0/27		Erturk;jnci,47,437-445;1971/1970a	
a	1073	38.6mg	n.s.s.	2/29	71.9mg	5/27			
FORMYLHYDRAZINE				624-84-0					
1320	397	19.5mg	64.9mg	15/96	250.mg	47/49		Toth;b ca,37,960-964;1978	
a	397	292.mg	n.s.s.	3/33	250.mg	2/19			
1321	397	n.s.s.	36.9mg	22/92	208.mg	50/50			
a	397	316.mg	n.s.s.	3/69	208.mg	5/43			
2-FURALDENHYDE SEMICARBAZONE				2411-74-7					
1322	1120	15.1mg	n.s.s.	2/29	26.8mg	6/30		Erturk;canr,30,1409-1412;1970	
FURFURAL				98-01-1					
1323	1078	92.4mg	n.s.s.	0/6	123.mg	0/6		Feron;txcy,11,127-144;1978	
a	1078	216.mg	n.s.s.	0/14	123.mg	0/14			
1324	1078	81.3mg	n.s.s.	0/6	108.mg	0/6			
a	1078	203.mg	n.s.s.	0/15	108.mg	0/15			
GERMANATE, SODIUM				---					
1325	1512	7.48mg	n.s.s.	26/170	.877mg	14/131		Kanisawa;canr,27,1192-1195;1967	
a	1512	10.5mg	n.s.s.	7/170	.877mg	4/131			
b	1512	7.84mg	n.s.s.	55/170	.877mg	25/131			
c	1512	8.97mg	n.s.s.	29/170	.877mg	13/131			
d	1512	10.0mg	n.s.s.	15/170	.877mg	7/131			
1326	1036	6.82mg	n.s.s.	1/82	.265mg	1/98		Kanisawa;canr,29,892-895;1969	
a	1036	2.70mg	n.s.s.	31/82	.265mg	25/98			
b	1036	8.11mg	n.s.s.	9/82	.265mg	2/98			
GIBBERELIC ACID				77-06-5					
1327	1281	318.mg	n.s.s.	0/17	180.mg	0/16		Innes;ntis,1968/1969	
a	1281	318.mg	n.s.s.	1/17	180.mg	0/16			
b	1281	208.mg	n.s.s.	2/17	180.mg	1/16			
1328	1281	89.6mg	n.s.s.	1/18	168.mg	4/18			
a	1281	96.2mg	n.s.s.	2/18	168.mg	4/18			
b	1281	52.6mg	n.s.s.	3/18	168.mg	8/18			
1329	1281	357.mg	n.s.s.	0/16	180.mg	0/18			
a	1281	357.mg	n.s.s.	0/16	180.mg	0/18			
b	1281	188.mg	n.s.s.	0/16	180.mg	1/18			
1330	1281	113.mg	n.s.s.	0/16	168.mg	2/16			
a	1281	155.mg	n.s.s.	0/16	168.mg	1/16			
b	1281	73.3mg	n.s.s.	0/16	168.mg	4/16			
GLYCEROL alpha-MONOCHLOROHYDRIN				96-24-2					
1331	1112	24.2mg	n.s.s.	0/20	6.79mg	0/26	13.6mg	0/26	Weisburger;jnci,67,75-88;1981
1332	1112	35.1mg	n.s.s.	0/20	6.79mg	0/26	13.6mg	3/26	
GLYCIDALDENHYDE**				765-34-4					
1333	55	6.29mg	n.s.s.	0/5	13.5mg	0/5		Van Duuren;jnci,37,825-838;1966	
GLYCOL SULFITE				3741-38-6					
1334	1143	.385mg	n.s.s.	10/30	1.71mg	17/30		Van Duuren;jnci,53,695-700;1974	
FD & C GREEN NO. 1 (guinea green B)				4680-78-8					
1335	143	18.2gm	n.s.s.	1/101	1.30gm	1/53	2.60gm	1/49	Hansen;fctx,4,389-410;1966
a	143	18.2gm	n.s.s.	1/101	1.30gm	1/53	2.60gm	1/49	
b	143	4.84gm	n.s.s.	1/101	1.30gm	3/53	2.60gm	0/49	
c	143	16.5gm	n.s.s.	6/101	1.30gm	3/53	2.60gm	2/49	

Spe	Strain	Site	Xpo+Xpt	Notes	TD50	2Tailpvl
Sex	Route	Hist			DR	AuOp
1336	M m	cbj eat	liv mix	24m24	>	26.1gm * P<.5 -
a	M m	cbj eat	lun mix	24m24		59.2gm * P<.3 -
b	M m	cbj eat	tba mix	24m24		20.8gm * P<.4 -
c	M m	cbj eat	tba mal	24m24		no dre P=1. -
1337	R f	osm eat	liv mix	24m24 e	.	13.8gm * P<.003 +
a	R f	osm eat	tba mix	24m24 e		97.5gm * P<.1 -
b	R f	osm eat	tba mal	24m24 e		no dre P=1. -
1338	R m	osm eat	liv mix	24m24 e	.	5.98gm * P<.003 +
a	R m	osm eat	tba mix	24m24 e		11.4gm * P<.4 -
b	R m	osm eat	tba mal	24m24 e		no dre P=1. -
1339	R b	wis eat	mix mly	93w93 er	.	3.92gm P<.006 +
a	R b	wis eat	nds mly	93w93 er		8.37gm P<.05 +
b	R b	wis eat	abd mly	93w93 er		8.37gm P<.05 +
FD & C GREEN NO. 2					100ng...1ug...10...100...1mg...10...100...1g...10	
1340	M f	cbj eat	lun mix	24m24		43.8gm * P<.04 -
a	M f	cbj eat	liv mix	24m24		no dre P=1. -
b	M f	cbj eat	tba mix	24m24		148.gm * P<.9 -
c	M f	cbj eat	tba mal	24m24		152.gm * P<.8 -
1341	M m	cbj eat	liv mix	24m24	>	18.9gm \ P<.4 -
a	M m	cbj eat	lun mix	24m24		58.2gm * P<.3 -
b	M m	cbj eat	tba mal	24m24		49.3gm * P<.5 -
c	M m	cbj eat	tba mix	24m24		318.gm * P<.1 -
1342	R m	nas eat	liv tum	65w65 e	>	no dre P=1. -
a	R m	nas eat	tba tum	65w65 e		no dre P=1. -
1343	R f	osm eat	liv tum	24m24 e	>	no dre P=1. -
a	R f	osm eat	tba mix	24m24 e		no dre P=1. -
b	R f	osm eat	tba mal	24m24 e		no dre P=1. -
1344	R m	osm eat	liv hpa	24m24 e	>	no dre P=1. -
a	R m	osm eat	tba mix	24m24 e		no dre P=1. -
b	R m	osm eat	tba mal	24m24 e		no dre P=1. -
1345	R b	wis eat	cec mly	95w95 er	.	5.64gm P<.04 +
FD & C GREEN NO. 3					100ng...1ug...10...100...1mg...10...100...1g...10	
1346	M f	cbj eat	lun ade	24m24		133.gm * P<.5 -
a	M f	cbj eat	liv hpa	24m24		no dre P=1. -
b	M f	cbj eat	tba mal	24m24		no dre P=1. -
c	M f	cbj eat	tba mix	24m24		no dre P=1. -
1347	M m	cbj eat	liv mix	24m24		no dre P=1. -
a	M m	cbj eat	lun ade	24m24		no dre P=1. -
b	M m	cbj eat	tba mix	24m24		18.1gm \ P<.5 -
c	M m	cbj eat	tba mal	24m24		no dre P=1. -
1348	R f	osm eat	liv tum	24m24 e	>	no dre P=1. -
a	R f	osm eat	mgl fba	24m24 e		no dre P=1. -
b	R f	osm eat	tba mix	24m24 e		18.5gm * P<.8 -
c	R f	osm eat	tba mal	24m24 e		46.7gm * P<.9 -
1349	R m	osm eat	liv hpa	24m24 e		no dre P=1. -
a	R m	osm eat	tba mix	24m24 e		no dre P=1. -
b	R m	osm eat	tba mal	24m24 e		no dre P=1. -
GRISEOFULVIN					100ng...1ug...10...100...1mg...10...100...1g...10	
1350	H f	syg eat	lun tum	23m23 ae	>	no dre P=1. -
a	H f	syg eat	liv clc	23m23 ae		no dre P=1. -
b	H f	syg eat	liv mix	23m23 ae		no dre P=1. -
1351	H m	syg eat	liv tum	29m29 ae	>	no dre P=1. -
a	H m	syg eat	lun tum	29m29 ae		no dre P=1. -
1352	M f	swi eat	lun tum	27m27 e	>	no dre P=1. -
a	M f	swi eat	liv hem	27m27 e		no dre P=1. -
1353	M m	swi eat	liv hpt	27m27 e	>	1.66gm P<.2 +
a	M m	swi eat	liv hem	27m27 e		no dre P=1. -
b	M m	swi eat	lun tum	27m27 e		no dre P=1. -
HCDD MIXTURE					100ng...1ug...10...100...1mg...10...100...1g...10	
1354	M f	b6c gav	liv MXA	24m24	:	3.87ug * P<.005 c
a	M f	b6c gav	liv hpa	24m24	+	4.31ug * P<.005 c
b	M f	b6c gav	TBA MXB	24m24	:	6.60ug * P<.5
c	M f	b6c gav	liv MXB	24m24	:	3.87ug * P<.005
d	M f	b6c gav	lun MXB	24m24	:	63.0ug * P<.9
1355	M m	b6c gav	liv MXA	24m24	:	876.ng * P<.007 c
a	M m	b6c gav	liv hpa	24m24	+	1.26ug * P<.005 c
b	M m	b6c gav	TBA MXB	24m24	:	1.02ug * P<.2
c	M m	b6c gav	liv MXB	24m24	:	876.ng * P<.007
d	M m	b6c gav	lun MXB	24m24	:	40.1ug * P<.1
1356	R f	osm gav	liv MXA	24m24	:	596.ng * P<.0005c
a	R f	osm gav	TBA MXB	24m24	+	no dre P=1.
b	R f	osm gav	liv MXB	24m24	:	596.ng * P<.0005
1357	R m	osm gav	liv MXA	24m25	:	#2.30ug * P<.02 -
a	R m	osm gav	TBA MXB	24m25	±	no dre P=1.
b	R m	osm gav	liv MXB	24m25	:	2.30ug * P<.02

Spe	Strain	Site	Xpo+Xpt		TD50	2Tailprl	
Sex	Route	Hist	Notes		DR	AuOp	
HEMATOXYLIN 100ng...1ug...10...100...1mg...10...100...1g...10							
1358	R b wis	eat	mix mly 78w78 er			1.00gm P<.002 +	
a	R b wis	eat	fhd mly 78w78 er			2.41gm P<.02 +	
b	R b wis	eat	abd mly 78w78 er			2.41gm P<.02 +	
HEPTACHLOR 100ng...1ug...10...100...1mg...10...100...1g...10							
1359	M f b6c	eat	liv hpc 80w89 v	:	+	1.47mg / P<.0005c	
a	M f b6c	eat	TBA MXB 80w89 v			1.46mg / P<.007	
b	M f b6c	eat	liv MXB 80w89 v			1.47mg / P<.0005	
c	M f b6c	eat	lun MXB 80w89 v			26.5mg * P<.6	
1360	M f b6c	eat	liv hpc 80w89 v	pool	:	+	1.37mg / P<.0005c
1361	M m b6c	eat	liv hpc 73w89 av	:	+	1.09mg / P<.006 c	
a	M m b6c	eat	TBA MXB 73w89 av			1.35mg / P<.03	
b	M m b6c	eat	liv MXB 73w89 av			1.09mg / P<.006	
c	M m b6c	eat	lun MXB 73w89 av			7.15mg * P<.2	
1362	M m b6c	eat	liv hpc 73w89 av	pool	:	+	1.09mg / P<.0005c
1363	R f osm	eat	thy MXA 19m26 v	:	±	#4.11mg / P<.02 -	
a	R f osm	eat	TBA MXB 19m26 v			125.ug * P<.1	
b	R f osm	eat	liv MXB 19m26 v			no dre P=1.	
1364	R f osm	eat	thy MXA 19m25 v	pool	:	+	#4.05mg / P<.002 -
a	R f osm	eat	thy fcc 19m25 v			10.5mg * P<.04	
1365	R m osm	eat	TBA MXB 19m26 v		>	no dre P=1. -	
a	R m osm	eat	liv MXB 19m26 v			18.1mg * P<.5	
1366	R f cfr	eat	tba tum 26m26 r		>	1.25mg * P<.2 -	
a	R f cfr	eat	tba mal 26m26 r			1.87mg * P<.2 -	
b	R f cfr	eat	tba ben 26m26 r			3.07mg * P<.4 -	
1367	R m cfr	eat	tba tum 26m26 r		>	no dre P=1. -	
a	R m cfr	eat	tba mal 26m26 r			no dre P=1. -	
b	R m cfr	eat	tba ben 26m26 r			no dre P=1. -	
HEPTAMETHYLENIMINE 100ng...1ug...10...100...1mg...10...100...1g...10							
1368	R f mrc	wat	liv tum 17m24 e		>	no dre P=1.	
a	R f mrc	wat	tba mix 17m24 e			15.8mg P<.3	
1369	R m mrc	wat	liv tum 17m24 e		>	no dre P=1.	
a	R m mrc	wat	tba mix 17m24 e			6.37mg P<.07	
HEPTYLAMINE 100ng...1ug...10...100...1mg...10...100...1g...10							
1370	R m wis	wat	liv tum 61w61 e		>	no dre P=1.	
a	R m wis	wat	tba mix 61w61 e			no dre P=1. -	
HEXACHLOROBENZENE 100ng...1ug...10...100...1mg...10...100...1g...10							
1371	H f syg	eat	liv hpt 24m24		+	7.42mg * P<.0005+	
a	H f syg	eat	liv hae 24m24			125.ug * P<.003 +	
b	H f syg	eat	tba mix 24m24			7.68mg * P<.0005+	
1372	H m syg	eat	liv hpt 24m24		+	5.48mg * P<.0005+	
a	H m syg	eat	liv hae 24m24			32.3mg * P<.0005+	
b	H m syg	eat	thy ald 24m24			108.ug * P<.002 +	
c	H m syg	eat	tba mix 24m24			3.72mg * P<.0005+	
1373	M f swi	eat	liv lct 86w93 aes		+	46.4mg * P<.0005+	
a	M f swi	eat	lun tum 86w93 aes			no dre P=1.	
b	M f swi	eat	tba mix 86w93 aes			no dre P=1.	
1374	M m swi	eat	liv lct 23m25 aes		+	109.ug * P<.0005+	
a	M m swi	eat	lun tum 23m25 aes			no dre P=1.	
b	M m swi	eat	tba mix 23m25 aes			no dre P=1.	
1375	R f agu	eat	liv lct 90w90 r		<	noTD50 P<.0005+	
HEXACHLOROBUTADIENE 100ng...1ug...10...100...1mg...10...100...1g...10							
1376	R f sss	eat	kid mix 24m24 e		+	94.4mg * P<.0005+	
a	R f sss	eat	liv mht 24m24 e			no dre P=1. -	
b	R f sss	eat	tba mix 24m24 e			9.84mg * P<.1	
1377	R m sss	eat	kid mix 95w95 es		+	50.5mg * P<.0005+	
a	R m sss	eat	liv hpc 95w95 es			no dre P=1. -	
b	R m sss	eat	tba mix 95w95 es			no dre P=1.	
alpha-1,2,3,4,5,6-HEXACHLOROCYCLOHEXANE ...1ug...10...100...1mg...10...100...1g...10							
1378	M m ddy	eat	liv mix 36w72 okr		<	noTD50 P<.0005+	
1379	R m buf	eat	liv mix 35w65 okr		>	no dre P=1. -	
1380	R m wis	eat	liv nod 72w72 okr		+	11.2mg * P<.0005+	
a	R m wis	eat	liv hpc 72w72 okr			107.ug * P<.09 +	
beta-1,2,3,4,5,6-HEXACHLOROCYCLOHEXANE ...1ug...10...100...1mg...10...100...1g...10							
1381	M f cfl	eat	liv lct 26m26 e		+	139.ug P<.007 +	
a	M f cfl	eat	liv mix 26m26 e			64.3mg P<.07 +	
b	M f cfl	eat	lun tum 26m26 e			no dre P=1. -	
1382	M m cfl	eat	liv mix 26m26 e		+	17.7mg P<.0005+	
a	M m cfl	eat	liv lct 26m26 e			51.1mg P<.002 +	
b	M m cfl	eat	lun tum 26m26 e			no dre P=1. -	

Spe	Strain	Site	Xpo+Xpt		TD50	2Tailpvt
Sex	Route	Hist	Notes		DR	AuOp
gamma-1,2,3,4,5,6-HEXACHLOROCHLOROCYCLOHEXANE...1ug.....10.....100.....1mg.....10.....100.....1g.....10						
1383	M f	b6c eat	TBA MXB 80w90	=>	no dre	P=1, -
a	M f	b6c eat	liv MXB 80w90		no dre	P=1, -
b	M f	b6c eat	lun MXB 80w90		no dre	P=1, -
1384	M m	b6c eat	TBA MXB 80w90	=>	no dre	P=1, -
a	M m	b6c eat	liv MXB 80w90		no dre	P=1, -
b	M m	b6c eat	lun MXB 80w90		no dre	P=1, -
1385	M m	b6c eat	liv hpc 80w90	pool	#12.0mg \	P<.004 -
a	M m	b6c eat	liv MXA 80w90	:	15.3mg \	P<.04
1386	M f	cf1 eat	liv mix 26m26 e	.	43.7mg	P<.0005+
a	M f	cf1 eat	liv lct 26m26 e	.	94.3mg	P<.0005+
b	M f	cf1 eat	lun tum 26m26 e	.	no dre	P=1, -
1387	M m	cf1 eat	liv mix 26m26 e	.	15.4mg	P<.0005+
a	M m	cf1 eat	liv lct 26m26 e	.	48.6mg	P<.0005+
b	M m	cf1 eat	lun tum 26m26 e	.	no dre	P=1, -
1388	M f	nmr eat	liv mix 80w80 r	>	803.mg *	P=1, -
1389	M m	nmr eat	liv mix 80w80 r	>	no dre	P=1, -
a	M m	nmr eat	liv ret 80w80 r		no dre	P=1, -
1390	R f	osm eat	TBA MXB 19m25 sv	=>	no dre	P=1, -
a	R f	osm eat	liv MXB 19m25 sv		no dre	P=1, -
1391	R m	osm eat	TBA MXB 19m25 v	=>	38.4mg *	P<.6 -
a	R m	osm eat	liv MXB 19m25 v		143.mg *	P<.8
1392	R m	osm eat	ham 19m25 v	pool	#131.mg *	P<.03 -
HEXACHLOROETHANE 100ng.....1ug.....10.....100.....1mg.....10.....100.....1g.....10						
1393	M f	b6c gav	liv hpc 78w90 v	=>	873.mg *	P<.2 c
a	M f	b6c gav	TBA MXB 78w90 v		1.19gm *	P<.4
b	M f	b6c gav	liv MXB 78w90 v		873.mg *	P<.2
c	M f	b6c gav	lun MXB 78w90 v		6.95gm *	P<.4
1394	M f	b6c gav	liv hpc 78w90 v	pool	319.mg \	P<.0005c
1395	M m	b6c gav	liv hpc 78w90 v	:	585.mg *	P<.2 c
a	M m	b6c gav	TBA MXB 78w90 v	=>	675.mg *	P<.4
b	M m	b6c gav	liv MXB 78w90 v		585.mg *	P<.2
c	M m	b6c gav	lun MXB 78w90 v		23.6gm *	P<.1
1396	M m	b6c gav	liv hpc 78w90 v	pool	359.mg *	P<.0005c
1397	R f	osm gav	TBA MXB 18m26 dv	=>	no dre	P=1, -
a	R f	osm gav	liv MXB 18m26 dv		no dre	P=1, -
1398	R m	osm gav	TBA MXB 18m26 dv	=>	no dre	P=1, -
a	R m	osm gav	liv MXB 18m26 dv		no dre	P=1, -
HEXACHLOROPHENE 100ng.....1ug.....10.....100.....1mg.....10.....100.....1g.....10						
1399	M f	c5l eat	liv hpt 24m24	>	434.mg	P<.3 -
a	M f	c5l eat	tba mix 24m24		no dre	P=1, -
1400	M m	c5l eat	liv tum 24m24	>	no dre	P=1, -
a	M m	c5l eat	lun tum 24m24		no dre	P=1, -
b	M m	c5l eat	tba mix 24m24		900.mg	P<.1, -
1401	M f	xvi eat	lun tum 24m24	>	33.4mg	P<.2 -
a	M f	xvi eat	liv tum 24m24		no dre	P=1, -
b	M f	xvi eat	tba mix 24m24		39.4mg	P<.3 -
1402	M m	xvi eat	lun tum 24m24	.	17.8mg	P<.07 -
a	M m	xvi eat	liv ade 24m24	.	450.mg	P<.3 -
b	M m	xvi eat	tba mix 24m24		17.8mg	P<.07 -
1403	R f	f34 eat	TBA MXB 25m25	=>	no dre	P=1, -
a	R f	f34 eat	liv MXB 25m25		no dre	P=1, -
1404	R m	f34 eat	sub fbs 25m25	:	#41.3mg *	P<.02 -
a	R m	f34 eat	tnv aen 25m25		57.5mg *	P<.05
b	R m	f34 eat	TBA MXB 25m25		30.4mg *	P<.5
c	R m	f34 eat	liv MXB 25m25		no dre	P=1, -
3-(HEXAHYDRO-4,7-METHANOINDAN-5-YL)-1,1-DIMETHYLUREA..10.....100.....1mg.....10.....100.....1g.....10						
1405	M f	b6a orl	liv hpt 76w76 evx	>	no dre	P=1, -
a	M f	b6a orl	lun ade 76w76 evx		no dre	P=1, -
b	M f	b6a orl	tba mix 76w76 evx		no dre	P=1, -
1406	M m	b6a orl	lun ade 76w76 evx	>	no dre	P=1, -
a	M m	b6a orl	liv hpt 76w76 evx		no dre	P=1, -
b	M m	b6a orl	tba mix 76w76 evx		no dre	P=1, -
1407	M f	b6c orl	lun ade 76w76 evx	>	1.23gm	P<.3 -
a	M f	b6c orl	liv hpt 76w76 evx		no dre	P=1, -
b	M f	b6c orl	tba mix 76w76 evx		1.23gm	P<.3 -
1408	M m	b6c orl	liv hpt 76w76 evx	.	359.mg	P<.04 -
a	M m	b6c orl	lun mix 76w76 evx	.	no dre	P=1, -
b	M m	b6c orl	tba mix 76w76 evx		259.mg	P<.02 -
HEXAMETHYLENETETRAMINE 100ng.....1ug.....10.....100.....1mg.....10.....100.....1g.....10						
1409	M f	c3d wat	liv agm 14m24 e	>	51.9gm	P<.7 -
a	M f	c3d wat	liv hpt 14m24 e		no dre	P=1, -
b	M f	c3d wat	lun ade 14m24 e		no dre	P=1, -
c	M f	c3d wat	tba mix 14m24 e		no dre	P=1, -

RefNum	LoConf	UpConf	Cntrl	1Dose	1Inc	2Dose	2Inc	Citation or Pathology	Brkly Code
gamma-1,2,3,4,5,6-HEXACHLOROCYCLOHEXANE (Lindane) 58-89-9									
1383	c00204	46.4mg n.s.s.	4/10	9.20mg	7/50	18.5mg	8/50		
a	c00204	56.9mg n.s.s.	1/10	9.20mg	4/50	18.5mg	3/50		Liv:hpa,hpc,nnd.
b	c00204	86.0mg n.s.s.	1/10	9.20mg	1/50	18.5mg	2/50		Lun:a/a,a/c.
1384	c00204	19.9mg n.s.s.	4/10	8.50mg	21/50	17.0mg	15/50		
a	c00204	25.8mg n.s.s.	3/10	8.50mg	19/50	17.0mg	10/50		Liv:hpa,hpc,nnd.
b	c00204	65.5mg n.s.s.	2/10	8.50mg	2/50	17.0mg	3/50		Lun:a/a,a/c.
1385	c00204	5.84mg 95.4mg	5/50p	8.50mg	19/50	(17.0mg)	9/50		S
a	c00204	6.39mg n.s.s.	8/50p	8.50mg	19/50	(17.0mg)	10/50		Liv:hpc,nnd. S
1386	89	21.9mg 140.mg	10/44	52.0mg	20/29			Thorpe;fctx,11,433-442;1973	
a	89	45.6mg 243.mg	0/44	52.0mg	10/29				
b	89	133.mg n.s.s.	27/44	52.0mg	10/29				
1387	89	7.43mg 34.4mg	11/45	48.0mg	27/29				
a	89	25.8mg 114.mg	2/45	48.0mg	16/29				
b	89	95.0mg n.s.s.	27/45	48.0mg	12/29				
1388	1119	16.7mg n.s.s.	6/100	1.63mg	7/50	3.25mg	2/50	Herbat;txcy,4,91-96;1975	6.50mg 4/50
1389	1119	22.9mg n.s.s.	7/100	1.50mg	5/50	3.00mg	1/50		6.00mg 3/50
a	1119	25.2mg n.s.s.	0/100	1.50mg	3/50	3.00mg	0/50		6.00mg 0/50
1390	c00204	3.27mg n.s.s.	9/10	4.90mg	44/50	(9.80mg)	34/50		
a	c00204	24.7mg n.s.s.	0/10	4.90mg	4/50	9.80mg	2/50		Liv:hpa,hpc,nnd.
1391	c00204	7.29mg n.s.s.	3/10	6.90mg	21/50	13.6mg	19/50		
a	c00204	27.8mg n.s.s.	0/10	6.90mg	3/50	13.6mg	2/50		Liv:hpa,hpc,nnd.
1392	c00204	39.5mg n.s.s.	0/55p	6.90mg	0/50	13.6mg	3/50		S
HEXACHLOROETHANE 67-72-1									
1393	c04604	362.mg n.s.s.	2/20	361.mg	20/50	722.mg	15/50		
a	c04604	313.mg n.s.s.	8/20	361.mg	32/50	722.mg	26/50		
b	c04604	362.mg n.s.s.	2/20	361.mg	20/50	722.mg	15/50		Liv:hpa,hpc,nnd.
c	c04604	1.65gm n.s.s.	1/20	361.mg	1/50	722.mg	4/50		Lun:a/a,a/c.
1394	c04604	178.mg 760.mg	2/60p	361.mg	20/50	(722.mg)	15/50		
1395	c04604	236.mg n.s.s.	3/20	361.mg	15/50	722.mg	31/50		
a	c04604	216.mg n.s.s.	4/20	361.mg	17/50	722.mg	34/50		
b	c04604	236.mg n.s.s.	3/20	361.mg	15/50	722.mg	31/50		Liv:hpa,hpc,nnd.
c	c04604	883.mg n.s.s.	0/20	361.mg	2/50	722.mg	3/50		Lun:a/a,a/c.
1396	c04604	213.mg 958.mg	6/60p	361.mg	15/50	722.mg	31/50		
1397	c04604	169.mg n.s.s.	14/20	105.mg	33/50	210.mg	20/50		
a	c04604	n.s.s. n.s.s.	0/20	105.mg	0/50	210.mg	0/50		Liv:hpa,hpc,nnd.
1398	c04604	118.mg n.s.s.	9/20	105.mg	17/50	210.mg	11/50		
a	c04604	n.s.s. n.s.s.	0/20	105.mg	0/50	210.mg	0/50		Liv:hpa,hpc,nnd.
HEXACHLOROPHENE 70-30-4									
1399	706	70.7mg n.s.s.	0/25	19.5mg	1/33			Rudali;clct,5,325-332;1978	
a	706	31.2mg n.s.s.	7/25	19.5mg	9/33				
1400	706	130.mg n.s.s.	0/25	18.0mg	0/35				
a	706	130.mg n.s.s.	1/25	18.0mg	0/35				
b	706	37.0mg n.s.s.	4/25	18.0mg	6/35				
1401	706	10.7mg n.s.s.	21/38	19.5mg	28/40				
a	706	161.mg n.s.s.	0/38	19.5mg	0/40				
b	706	11.1mg n.s.s.	22/38	19.5mg	28/40				
1402	706	6.56mg n.s.s.	23/37	18.0mg	30/37				
a	706	73.3mg n.s.s.	0/37	18.0mg	1/37				
b	706	6.56mg n.s.s.	23/37	18.0mg	30/37				
1403	c02653	9.82mg n.s.s.	21/24	.850mg	17/24	2.50mg	21/24	7.50mg 13/24	
a	c02653	n.s.s. n.s.s.	0/24	.850mg	0/24	2.50mg	0/24	7.50mg 0/24	Liv:hpa,hpc,nnd.
1404	c02653	12.4mg n.s.s.	0/24	.680mg	0/24	2.00mg	0/24	6.00mg 3/24	S
a	c02653	14.1mg n.s.s.	0/24	.680mg	0/24	2.00mg	0/24	6.00mg 2/24	S
b	c02653	5.68mg n.s.s.	11/24	.680mg	5/24	2.00mg	7/24	6.00mg 11/24	
c	c02653	n.s.s. n.s.s.	0/24	.680mg	0/24	2.00mg	0/24	6.00mg 0/24	Liv:hpa,hpc,nnd.
3-(HEXAHYDRO-4,7-METHANOINDAN-5-YL)-1,1-DIMETHYLUREA (Hercules-7531) 2163-79-3									
1405	1277	383.mg n.s.s.	0/17	205.mg	0/17			Innes;ntis,1968/1969	
a	1277	383.mg n.s.s.	1/17	205.mg	0/17				
b	1277	253.mg n.s.s.	2/17	205.mg	1/17				
1406	1277	250.mg n.s.s.	2/18	190.mg	1/18				
a	1277	377.mg n.s.s.	1/18	190.mg	0/18				
b	1277	197.mg n.s.s.	3/18	190.mg	2/18				
1407	1277	201.mg n.s.s.	0/16	205.mg	1/17				
a	1277	383.mg n.s.s.	0/16	205.mg	0/17				
b	1277	201.mg n.s.s.	0/16	205.mg	1/17				
1408	1277	108.mg n.s.s.	0/16	190.mg	3/17				
a	1277	356.mg n.s.s.	0/16	190.mg	0/17				
b	1277	89.2mg n.s.s.	0/16	190.mg	4/17				
HEXAMETHYLENETETRAMINE 100-97-0									
1409	155m	4.76gm n.s.s.	2/63	1.14gm	2/43			Della Porta;fctx,6,707-715;1968	
a	155m	5.98gm n.s.s.	15/63	1.14gm	4/43				
b	155m	6.38gm n.s.s.	12/63	1.14gm	3/43				
c	155m	3.01gm n.s.s.	46/63	1.14gm	20/43				

RefNum	LoConf	UpConf	Cntrl	1Dose	1Inc	2Dose	2Inc	Citation or Pathology	Brkly Code
1410	155m	5.25gm	n.s.s.	0/30	952.mg	1/49			
a	155m	3.16gm	n.s.s.	3/30	952.mg	5/49			
b	155m	3.24gm	n.s.s.	20/30	952.mg	16/49			
c	155m	2.21gm	n.s.s.	21/30	952.mg	22/49			
1411	155m	9.06gm	n.s.s.	1/99	600.mg	1/48	1.20gm 6/102 3.00gm 4/50		
a	155m	9.65gm	n.s.s.	3/99	600.mg	4/48	1.20gm 1/102 3.00gm 7/50		
b	155m	8.34gm	n.s.s.	17/99	600.mg	10/48	1.20gm 21/102 3.00gm 8/50		
c	155m	14.7gm	n.s.s.	3/99	600.mg	2/48	1.20gm 7/102 3.00gm 1/50		
d	155m	1.97gm	n.s.s.	67/99	600.mg	36/48	1.20gm 77/102 3.00gm 36/50		
1412	155m	10.3gm	n.s.s.	19/99	500.mg	10/50	1.00gm 19/94 2.50gm 1/29		
a	155m	12.6gm	n.s.s.	9/99	500.mg	3/50	1.00gm 10/94 2.50gm 0/29		
b	155m	5.51gm	n.s.s.	55/99	500.mg	27/50	1.00gm 57/94 2.50gm 8/29		
1413	155m	1.77gm	n.s.s.	15/30	1.17gm	10/27			
a	155m	6.36gm	n.s.s.	0/30	1.17gm	0/27			
b	155m	1.61gm	n.s.s.	18/30	1.17gm	12/27			
1414	155m	1.33gm	n.s.s.	19/45	971.mg	11/29			
a	155m	5.69gm	n.s.s.	1/45	971.mg	0/29			
b	155m	1.34gm	n.s.s.	22/45	971.mg	12/29			
1415	155n	7.94gm	n.s.s.	0/48	407.mg	0/48			
a	155n	1.56gm	n.s.s.	37/48	407.mg	27/48			
1416	155n	6.94gm	n.s.s.	1/48	356.mg	0/48			
a	155n	627.mg	n.s.s.	39/48	356.mg	36/48			
HEXAMETHYLMELAMINE 531-18-0									
1417	200a	4.13mg	52.4mg	0/25	10.6mg	6/24		Cohen;jnci,51,403-417;1973	
a	200a	4.33mg	n.s.s.	1/25	10.6mg	6/24			
b	200a	8.27mg	n.s.s.	0/25	10.6mg	2/24			
c	200a	21.1mg	n.s.s.	0/25	10.6mg	0/24			
d	200a	3.01mg	40.7mg	1/25	10.6mg	9/24			
HEXANAMIDE 628-02-4									
1418	1343	2.69gm	n.s.s.	0/86p	978.mg	3/41	1.47gm 0/34	Fleischman;jept,3,149-170;1980	
a	1343	3.94gm	n.s.s.	2/89p	978.mg	0/41	1.47gm 2/37		
b	1343	2.09gm	n.s.s.	1/89p	978.mg	0/41	1.47gm 0/37		
1419	1343	1.00gm	4.56gm	0/95p	903.mg	6/35	1.35gm 6/39		
a	1343	1.08gm	5.28gm	0/95p	903.mg	6/35	1.35gm 5/39		
b	1343	1.25gm	7.72gm	0/91p	903.mg	5/35	1.35gm 4/39		
c	1343	952.mg	n.s.s.	1/87p	903.mg	3/35	(1.35gm 0/39)		
d	1343	4.11gm	n.s.s.	0/91p	903.mg	0/35	1.35gm 1/39		
e	1343	4.11gm	n.s.s.	0/91p	903.mg	0/35	1.35gm 1/39		
1420	1343	1.89gm	n.s.s.	0/49	564.mg	0/37			
1421	1343	655.mg	n.s.s.	0/50	452.mg	0/16			
HYDRAZINE 302-01-2									
1422	1095	1.71mg	n.s.s.	8/85	5.19mg	6/25		Roe;natu,216,375-376;1967	
1423	1117	1.45mg	5.59mg	14/108	2.00mg	27/50		Toth;jcn,9,109-118;1972/1969a	
a	1117	1.59mg	6.34mg	12/108	2.00mg	25/50			
b	1117	4.00mg	37.2mg	2/108	2.00mg	9/50			
c	1117	13.1mg	n.s.s.	3/88	2.00mg	1/41			
1424	1117	1.23mg	5.11mg	10/86	1.67mg	24/46			
a	1117	1.47mg	7.69mg	10/86	1.67mg	21/46			
b	1117	2.91mg	16.9mg	0/86	1.67mg	9/46			
c	1117	3.73mg	180.mg	2/86	1.67mg	7/46			
d	1117	4.90mg	n.s.s.	2/41	1.67mg	3/33			
HYDRAZINE SULFATE 10034-93-2									
1425	1108	39.6mg	813.mg	0/79	16.4mg	4/40		Toth;canr,32,804-807;1972/1967a	
a	1108	42.8mg	895.mg	0/84	16.4mg	4/43			
b	1108	156.mg	n.s.s.	0/84	16.4mg	0/43			
c	1108	156.mg	n.s.s.	0/84	16.4mg	0/43			
1426	1108	41.0mg	241.gm	0/64	14.4mg	3/33			
a	1108	23.3mg	n.s.s.	1/22	14.4mg	0/6			
b	1108	194.mg	n.s.s.	0/86	14.4mg	0/50			
1427	158	87.1mg	n.s.s.	0/30	24.0mg	0/40		Toth;jnci,42,469-475;1969a/1966a	
a	158	87.1mg	n.s.s.	0/30	24.0mg	0/40			
1428	158	22.9mg	n.s.s.	1/11	20.0mg	1/20			
a	158	52.6mg	n.s.s.	1/16	20.0mg	0/29			
1429	158	37.7mg	n.s.s.	0/22	24.0mg	4/36			
1430	1074	1.58mg	7.60mg	4/47	21.8mg	19/21		Biancifiiori;bjca,18,543-550;1964	
a	1074	3.19mg	14.5mg	2/47	21.8mg	15/21			
1431	1074	2.62mg	11.3mg	1/37	16.0mg	16/21			
a	1074	4.01mg	26.7mg	4/37	16.0mg	13/21			
1432	156	5.58mg	21.6mg	0/12	37.7mg	17/24		Bhide;jcn,18,530-535;1976	
a	156	91.9mg	n.s.s.	0/12	37.7mg	0/24			
1433	156	19.5mg	n.s.s.	0/12	31.4mg	2/16			
a	156	51.1mg	n.s.s.	0/12	31.4mg	0/16			
1434	158	13.1mg	57.1mg	14/109	24.0mg	24/47		Toth;jnci,42,469-475;1969a/1966a	
a	158	14.5mg	66.4mg	12/109	24.0mg	22/47			
b	158	49.0mg	n.s.s.	2/109	24.0mg	5/47			

Spe	Strain	Site	Xpo+Xpt	Notes	TD50	2Tailp1
Sex	Route	Hist			DR	AuOp
c	M f swa wat	liv hem	95w95 e		no dre	P=1. -
1435	M m swa wat	lun mix	94w94 e	. + .	18.7mg	P<.0005+
a	M m swa wat	lun ade	94w94 e		23.1mg	P<.0005
b	M m swa wat	lun adc	94w94 e		74.2mg	P<.0005
c	M m swa wat	liv mix	94w94 e		78.4mg	P<.2
1436	R f cbs gav	lun mix	68w94	. + .	42.4mg	P<.004 +
a	R f cbs gav	liv mix	68w94 e		no dre	P=1.
1437	R m cbs gav	liv mix	68w94 e	. + .	+historical	P<.002 +
a	R m cbs gav	lun mix	68w94		60.1mg	P<.009 +
2-HYDRAZINO-4-(p-AMINOPHENYL)THIAZOLE1ug101001mg101001g10						
1438	M f swi eat	--- lle	46w66 e	. + .	11.3mg	P<.04 +
a	M f swi eat	liv tum	46w66 e		no dre	P=1.
b	M f swi eat	lun tum	46w66 e		no dre	P=1.
c	M f swi eat	tba mix	46w66 e		11.3mg	P<.04
1439	R f sda eat	mgl adc	46w75 e	. + .	1.02mg	P<.0005
a	R f sda eat	mgl mix	46w75 e		1.03mg	P<.0005+
b	R f sda eat	--- lbl	46w75 e		+historical	P<.002 +
c	R f sda eat	liv tum	46w75 e		no dre	P=1.
d	R f sda eat	tba mix	46w75 e		.582mg	P<.0005
2-HYDRAZINO-4-(5-NITRO-2-FURYL)THIAZOLE1ug101001mg101001g10						
1440	M f swi eat	for sqp	46w55 e	. + .	16.4mg	P<.0005+
a	M f swi eat	liv tum	46w55 e		no dre	P=1.
b	M f swi eat	lun tum	46w55 e		no dre	P=1.
c	M f swi eat	tba mix	46w55 e		7.57mg	P<.0005
1441	R f sda eat	mgl mix	46w57 ev	. + .	2.83mg	P<.000f
a	R f sda eat	mgl adc	46w57 ev		7.79mg	P<.000f
b	R f sda eat	mgl adf	46w57 ev		25.2mg	P<.04
c	R f sda eat	kid mix	46w57 ev		36.8mg	P<.02
d	R f sda eat	liv tum	46w57 ev		no dre	P=1.
e	R f sda eat	tba mix	46w57 ev		2.83mg	P<.00f
1442	R f sda eat	mgl mix	46w66 e	. + .	3.66mg	P<.0f /5+
a	R f sda eat	mgl adc	46w66 e		10.9mg	P<.0f5+
b	R f sda eat	slg adc	46w66 e		145. mg	P<.f
c	R f sda eat	liv cye	46w66 e		295. mg	P<.f
d	R f sda eat	tba mix	46w66 e		noTD50	P<.0005
2-HYDRAZINO-4-(p-NITROPHENYL)THIAZOLE1ug101001mg101001g10						
1443	M f swi eat	--- lle	46w66 e	. + .	10.6mg	P<.03 +
a	M f swi eat	lun alc	46w66 e		25.0mg	P<.07
b	M f swi eat	liv tum	46w66 e		no dre	P=1.
c	M f swi eat	tba mix	46w66 e		8.33mg	P<.02
1444	R f sda eat	mgl mix	45w52 ev	. + .	8.66mg	P<.0005+
a	R f sda eat	mgl adc	45w52 ev		9.51mg	P<.0005+
b	R f sda eat	slg adc	45w52 ev		21.7mg	P<.0005
c	R f sda eat	liv tum	45w52 ev		no dre	P=1.
d	R f sda eat	tba mix	45w52 ev		noTD50	P<.0005
1445	R f sda eat	mgl mix	46w75 e	. + .	1.97mg	P<.002 +
a	R f sda eat	mgl adc	46w75 e		3.78mg	P<.004
b	R f sda eat	for sqp	46w75 e		9.00mg	P<.003
c	R f sda eat	liv tum	46w75 e		no dre	P=1.
d	R f sda eat	tba mix	46w75 e		.743mg	P<.0005
2-HYDRAZINO-4-PHENYLTHIAZOLE 100ng1ug101001mg101001g10						
1446	R f sda eat	liv tum	46w66 ev		>	no dre P=1.
a	R f sda eat	tba mix	46w66 ev		311. mg	P<.8 -
p-HYDRAZINOBENZOIC ACID 100ng1ug101001mg101001g10						
1447	M f swi gav	lun tum	40w55		>	no dre P=1. -
HYDRAZOBENZENE 100ng1ug101001mg101001g10						
1448	M f b6c eat	liv MXA	78w95	. + .	26.0mg	* P<.0005c
a	M f b6c eat	liv hpc	78w95		29.7mg	* P<.0005c
b	M f b6c eat	TBA MXB	78w95		31.5mg	* P<.0005
c	M f b6c eat	liv MXB	78w95		26.0mg	* P<.0005
d	M f b6c eat	lun MXB	78w95		8.76gm	* P<.1.
1449	M m b6c eat	TBA MXB	78w95 v	>	no dre	P=1. -
a	M m b6c eat	liv MXB	78w95 v		1.09gm	* P<.9
b	M m b6c eat	lun MXB	78w95 v		no dre	P=1.
1450	R f f34 eat	MXB MXB	18w25	. + .	6.74mg	* P<.0005
a	R f f34 eat	mgl acn	18w25		11.4mg	* P<.002 c
b	R f f34 eat	liv nnd	18w25		18.1mg	* P<.0005c
c	R f f34 eat	TBA MXB	18w25		4.50mg	* P<.2
d	R f f34 eat	liv MXB	18w25		18.1mg	* P<.0005
1451	R m f34 eat	MXB MXB	18w25 v	. + .	3.55mg	* P<.0005
a	R m f34 eat	liv MXA	18w25 v		3.70mg	* P<.0005c
b	R m f34 eat	liv hpc	18w25 v		4.67mg	/ P<.0005c
c	R m f34 eat	adr phe	18w25 v		16.2mg	* P<.007

RefNum	LoConf	UpConf	Cntrl	1Dose	1Inc	2Dose	2Inc	Citation or Pathology	Brkly Code
c	158	97.1mg	n.s.s.	3/78	24.0mg	1/36			
1435	158	10.8mg	39.8mg	10/110	20.0mg	25/50			
a	158	12.7mg	55.2mg	10/110	20.0mg	22/50			
b	158	32.0mg	237.mg	0/110	20.0mg	7/50			
c	158	18.7mg	n.s.s.	2/40	20.0mg	3/17			
1436	157	16.0mg	274.mg	0/22	24.7mg	5/18	Severi;jnci,41,331-349;1968		
a	157	54.0mg	n.s.s.	0/22	24.7mg	0/13			
1437	157	13.5mg	231.mg	0/28	25.9mg	4/13			
a	157	18.1mg	1.95gm	0/28	25.9mg	3/14			
2-HYDRAZINO-4-(p-AMINOPHENYL)THIAZOLE 26049-71-8									
1438	1076	3.84mg	n.s.s.	1/28	9.06mg	5/22	Cohen;canr,33,1593-1597;1973		
a	1076	16.5mg	n.s.s.	0/28	9.06mg	0/22			
b	1076	16.5mg	n.s.s.	0/28	9.06mg	0/22			
c	1076	3.84mg	n.s.s.	1/28	9.06mg	5/22			
1439	200a	.587mg	2.05mg	6/71	3.07mg	24/35	Cohen;jnci,51,403-417;1973		
a	200a	.548mg	2.56mg	18/71	3.07mg	26/35			
b	200a	2.69mg	31.4mg	0/71	3.07mg	5/35			
c	200a	11.5mg	n.s.s.	0/71	3.07mg	0/35			
d	200a	.315mg	1.21mg	18/71	3.07mg	31/35			
2-HYDRAZINO-4-(5-NITRO-2-FURYL)THIAZOLE (HNT) 26049-68-3									
1440	1076	7.27mg	48.5mg	0/29	54.4mg	8/17	Cohen;canr,33,1593-1597;1973		
a	1076	53.3mg	n.s.s.	0/29	54.4mg	0/17			
b	1076	53.3mg	n.s.s.	0/29	54.4mg	0/17			
c	1076	3.58mg	20.0mg	2/29	54.4mg	13/17			
1441	1073	1.09mg	7.37mg	2/29	37.1mg	15/16	Erturk;jnci,47,437-445;1971/1970a		
a	1073	3.64mg	20.5mg	0/29	37.1mg	10/16			
b	1073	8.18mg	n.s.s.	2/29	37.1mg	5/16			
c	1073	11.1mg	n.s.s.	0/29	37.1mg	3/16			
d	1073	36.8mg	n.s.s.	0/29	37.1mg	0/16			
e	1073	1.09mg	7.37mg	2/29	37.1mg	15/16			
1442	1121	2.00mg	7.00mg	4/35	31.0mg	32/35	Cohen;canr,30,897-901;1970		
a	1121	6.26mg	21.3mg	0/35	31.0mg	19/35			
b	1121	35.8mg	n.s.s.	0/35	31.0mg	2/35			
c	1121	48.1mg	n.s.s.	0/35	31.0mg	1/35			
d	1121	n.s.s.	3.77mg	4/35	31.0mg	35/35			
2-HYDRAZINO-4-(p-NITROPHENYL)THIAZOLE 26049-70-7									
1443	1076	3.63mg	n.s.s.	1/28	9.06mg	5/21	Cohen;canr,33,1593-1597;1973		
a	1076	6.14mg	n.s.s.	0/28	9.06mg	2/21			
b	1076	15.8mg	n.s.s.	0/28	9.06mg	0/21			
c	1076	3.13mg	n.s.s.	1/28	9.06mg	6/21			
1444	1121	4.95mg	17.3mg	4/35	73.8mg	27/34	Cohen;canr,30,897-901;1970		
a	1121	5.64mg	17.3mg	0/35	73.8mg	25/34			
b	1121	11.8mg	46.3mg	0/35	73.8mg	15/34			
c	1121	129.mg	n.s.s.	0/35	73.8mg	0/34			
d	1121	n.s.s.	5.63mg	4/35	73.8mg	34/34			
1445	200a	.917mg	11.6mg	18/71	3.07mg	20/35	Cohen;jnci,51,403-417;1973		
a	200a	1.62mg	34.6mg	6/71	3.07mg	11/35			
b	200a	3.11mg	61.2mg	0/71	3.07mg	4/35			
c	200a	11.5mg	n.s.s.	0/71	3.07mg	0/35			
d	200a	.406mg	1.62mg	18/71	3.07mg	29/35			
2-HYDRAZINO-4-PHENYLTHIAZOLE 34176-52-8									
1446	200a	70.9mg	n.s.s.	0/25	26.7mg	0/32	Cohen;jnci,51,403-417;1973		
a	200a	31.5mg	n.s.s.	1/25	26.7mg	2/32			
p-HYDRAZINOBENZOIC ACID 619-67-0									
1447	1095	21.7mg	n.s.s.	8/85	20.8mg	1/25	Roe;natu,216,375-376;1967		
HYDRAZOBENZENE (NCI uses CAS# 530-50-7) 122-66-7									
1448	c01854	15.2mg	53.2mg	3/100	4.30mg	4/47	42.2mg	22/50	liv:hpa,hpc.
a	c01854	16.9mg	63.7mg	3/100	4.30mg	4/47	42.2mg	20/50	
b	c01854	15.7mg	126.mg	29/100	4.30mg	19/47	42.2mg	29/50	
c	c01854	15.2mg	53.2mg	3/100	4.30mg	4/47	42.2mg	22/50	liv:hpa,hpc,nnd.
d	c01854	100.mg	n.s.s.	5/100	4.30mg	3/47	42.2mg	2/50	lun:a/a,e/c.
1449	c01854	49.6mg	n.s.s.	45/100	7.90mg	18/50	39.4mg	17/50	
a	c01854	61.0mg	n.s.s.	20/100	7.90mg	11/50	39.4mg	9/50	liv:hpa,hpc,nnd.
b	c01854	148.mg	n.s.s.	15/100	7.90mg	2/50	39.4mg	3/50	lun:a/a,e/c.
1450	c01854	3.58mg	15.9mg	1/100	1.40mg	3/50	3.60mg	12/50	liv:nnd; mgl:acn. C
a	c01854	5.11mg	50.7mg	1/100	1.40mg	3/50	3.60mg	6/50	
b	c01854	7.27mg	64.9mg	0/100	1.40mg	0/50	3.60mg	6/50	
c	c01854	1.61mg	n.s.s.	80/100	1.40mg	39/50	3.60mg	36/50	
d	c01854	7.27mg	64.9mg	0/100	1.40mg	0/50	3.60mg	6/50	liv:hpa,hpc,nnd.
1451	c01854	2.37mg	5.97mg	6/99	2.30mg	14/50	8.80mg	38/50	liv:hpc,nnd; zym:sgc. C
a	c01854	2.44mg	6.30mg	6/99	2.30mg	13/50	8.80mg	37/50	liv:hpc,nnd.
b	c01854	3.05mg	7.77mg	1/99	2.30mg	5/50	8.80mg	31/50	
c	c01854	7.08mg	323.mg	15/99	2.30mg	7/50	8.80mg	16/50	S

Spe	Strain	Site	Xpo + Xpt	Notes	TD50	2Tailpvl
Sex	Route	Hist			DR	AuOp
d	R m f34 eat	MXA MXA	18w25	v	35.8mg	* P<.003
e	R m f34 eat	zym sqc	18w25	v	38.5mg	* P<.0005c
f	R m f34 eat	T8A MXB	18w25	v	6.85mg	* P<.01
g	R m f34 eat	liv MXB	18w25	v	3.70mg	* P<.0005
HYDROCORTISONE					100ng.....1ug.....10.....100.....1mg.....10.....100.....1g.....10	
1452	R f sda gav	tba mal	26w26	e	>	no dre P=1. -
1453	R m sda gav	liv hae	24w24	e	>	no dre P=1. -
a	R m sda gav	tba mal	24w24	e		no dre P=1. -
HYDROGEN PEROXIDE					100ng.....1ug.....10.....100.....1mg.....10.....100.....1g.....10	
1454	M b c56 wat	duo car	23w23	er		+9.01gm * P<.006 +
HYDROQUINONE MONOBENZYL ETHER					100ng.....1ug.....10.....100.....1mg.....10.....100.....1g.....10	
1455	M f b6a orl	liv hpt	76w76	evx	>	no dre P=1. -
a	M f b6a orl	lun ade	76w76	evx		no dre P=1. -
b	M f b6a orl	tba mix	76w76	evx		no dre P=1. -
1456	M m b6a orl	lun ade	76w76	evx	>	no dre P=1. -
a	M m b6a orl	liv hpt	76w76	evx		no dre P=1. -
b	M m b6a orl	tba mix	76w76	evx		no dre P=1. -
1457	M f b6c orl	liv hpt	76w76	evx	>	no dre P=1. -
a	M f b6c orl	lun mix	76w76	evx		no dre P=1. -
b	M f b6c orl	tba mix	76w76	evx		1.23gm P<.3 -
1458	M m b6c orl	liv hpt	76w76	evx	*	382.mg P<.05 -
a	M m b6c orl	lun ade	76w76	evx		382.mg P<.05 -
b	M m b6c orl	tba mix	76w76	evx		141.mg P<.002 -
3-HYDROXY-4-ACETYLAMINOBIPHENYL					100ng.....1ug.....10.....100.....1mg.....10.....100.....1g.....10	
1459	R f nss eat	liv tum	43w65		>	no dre P=1. -
N-HYDROXY-2-ACETYLAMINOFLOURENE					100ng.....1ug.....10.....100.....1mg.....10.....100.....1g.....10	
1460	H m nss eat	for mix	32w56		.	2.10mg P<.0005+
a	H m nss eat	liv bda	32w56		.	20.8mg P<.05 +
1461	H m nss ipj	per fbs	34w69		.	2.20mg P<.03
a	H m nss ipj	for pam	34w69		.	no dre P=1. -
b	H m nss ipj	sai adc	34w69		.	no dre P=1. -
1462	R f nbr eat	liv mix	64w64		.	1.74ug P<.0005+
a	R f nbr eat	liv cho	64w64		.	2.03ug P<.0005+
1463	R m nbr eat	liv mix	64w64		.	690.ng P<.0005+
a	R m nbr eat	liv cho	64w64		.	16.2ug P<.3
3-HYDROXY-4-AMINOBIPHENYL					100ng.....1ug.....10.....100.....1mg.....10.....100.....1g.....10	
1464	R f nss eat	liv tum	43w65		>	no dre P=1. -
1-(2-HYDROXYETHYL)-3-[(5-NITROFURFURYLIDENE)AMINO]-2-IMIDAZOLIDINONE					100ng.....1ug.....10.....100.....1mg.....10.....100.....1g.....10	
1465	R f sda eat	agl adc	46w66	e	.	16.7mg P<.0005+
a	R f sda eat	liv tum	46w66	e	.	no dre P=1. -
b	R f sda eat	tba mix	46w66	e	.	18.0mg P<.0005
1-(2-HYDROXYETHYL)-1-NITROUREA					100ng.....1ug.....10.....100.....1mg.....10.....100.....1g.....10	
1466	R m nrw wat	bon oat	52w70		.	1.52mg P<.002 +
a	R m nrw wat	--- mly	52w70		.	2.03mg P<.0005+
b	R m nrw wat	--- lcl	52w70		.	2.03mg P<.0005
c	R m nrw wat	tba mix	52w70		.	.360mg P<.0005
4-(2-HYDROXYETHYLAMINO)-2-(5-NITRO-2-THIENYL)QUINAZOLINE					100ng.....1ug.....10.....100.....1mg.....10.....100.....1g.....10	
1467	R f sda eat	itn lei	46w66	e	.	3.84mg P<.0005
a	R f sda eat	liv bda	46w66	e	.	132.mg P<.1
b	R f sda eat	tba mix	46w66	e	.	1.87mg P<.0005+
2-HYDROXYETHYLHYDRAZINE					100ng.....1ug.....10.....100.....1mg.....10.....100.....1g.....10	
1468	H f syg wat	liv hpt	84w84	a	.	148.mg P<.02 -
a	H f syg wat	lun tum	84w84	a	.	no dre P=1. -
1469	H m syg wat	liv hpt	84w84	a	.	84.4mg P<.02 -
a	H m syg wat	lun tum	84w84	a	.	no dre P=1. -
1470	M f b6a orl	lun ade	78w78	evx	>	no dre P=1. -
a	M f b6a orl	liv hpt	78w78	evx		no dre P=1. -
b	M f b6a orl	tba mix	78w78	evx		5.34mg P<.8
1471	M m b6a orl	liv hpt	78w78	evx	.	.314mg P<.0005+
a	M m b6a orl	lun ade	78w78	evx	.	no dre P=1. -
b	M m b6a orl	lun mix	78w78	evx	.	no dre P=1. -
c	M m b6a orl	tba mix	78w78	evx	.	.404mg P<.02
1472	M f b6c orl	liv hpt	78w78	evx	>	4.77mg P<.3
a	M f b6c orl	lun ade	78w78	evx		4.77mg P<.3
b	M f b6c orl	tba mix	78w78	evx		4.77mg P<.6
1473	M m b6c orl	liv hpt	78w78	evx	.	.541mg P<.02 +
a	M m b6c orl	lun ade	78w78	evx	.	no dre P=1. -
b	M m b6c orl	tba mix	78w78	evx	.	.713mg P<.4

RefNum	LoConf	UpConf	Cntrl	1Dose	1Inc	2Dose	2Inc	Citation or Pathology	Brkly Code
d	c01854	14.8mg	258.mg	1/99	2.30mg	2/50	8.80mg	6/50	eac:aqc, aqp; zym:aqc. S
e	c01854	15.5mg	157.mg	0/99	2.30mg	1/50	8.80mg	5/50	
f	c01854	3.13mg	342.mg	62/99	2.30mg	36/50	8.80mg	43/50	
g	c01854	2.44mg	6.30mg	6/99	2.30mg	13/50	8.80mg	37/50	liv:hpa,hpc, nnd.
HYDROCORTISONE (cortisol) 50-23-7									
1452	1134	27.5mg	n.s.s.	3/33	5.36mg	2/40			Schmahl; zkk0, 86, 77-84; 1976
1453	1134	32.0mg	n.s.s.	1/36	5.36mg	0/29			
a	1134	32.0mg	n.s.s.	1/36	5.36mg	0/29			
HYDROGEN PEROXIDE 7722-84-1									
1454	1381	3.68gm	98.2gm	0/98	175.mg	1/101	702.mg	5/99	ito; gann, 72, 174-175; 1981
HYDROQUINONE MONOBENZYL ETHER (Aperite alba) 103-16-2									
1455	1308	383.mg	n.s.s.	0/17	205.mg	0/17			Innes; ntis, 1968/1969
a	1308	383.mg	n.s.s.	1/17	205.mg	0/17			
b	1308	180.mg	n.s.s.	2/17	205.mg	2/17			
1456	1308	178.mg	n.s.s.	2/18	190.mg	2/18			
a	1308	225.mg	n.s.s.	1/18	190.mg	1/18			
b	1308	150.mg	n.s.s.	3/18	190.mg	3/18			
1457	1308	383.mg	n.s.s.	0/16	205.mg	0/17			
a	1308	383.mg	n.s.s.	0/16	205.mg	0/17			
b	1308	201.mg	n.s.s.	0/16	205.mg	1/17			
1458	1308	115.mg	n.s.s.	0/16	190.mg	3/18			
a	1308	115.mg	n.s.s.	0/16	190.mg	3/18			
b	1308	60.3mg	576.mg	0/16	190.mg	7/18			
3-HYDROXY-4-ACETYLAMINOBIPHENYL 4463-22-3									
1459	1424	7.94mg	n.s.s.	0/15	12.3mg	0/8			Miller; jnci, 15, 1571-1590; 1955
N-HYDROXY-2-ACETYLAMINOFLUORENE (hydroxy-N-2-fluorenylacetamide) 53-95-2									
1460	308m	1.07mg	4.56mg	0/17	17.0mg	16/20			Miller; canr, 24, 2018-2026; 1964
a	308m	6.27mg	n.s.s.	0/17	17.0mg	3/20			
1461	308n	.652mg	n.s.s.	0/8	3.43mg	3/8			
a	308n	2.49mg	n.s.s.	0/8	3.43mg	0/8			
b	308n	2.49mg	n.s.s.	0/8	3.43mg	0/8			
1462	162a	805.ng	4.90ug	0/20	4.00ug	9/20			Yamamoto; ijcn, 2, 337-343; 1967
a	162a	908.ng	6.43ug	0/20	4.00ug	8/20			
1463	162a	352.ng	1.55ug	0/20	3.20ug	14/20			
a	162a	2.64ug	n.s.s.	0/20	3.20ug	1/20			
3-HYDROXY-4-AMINOBIPHENYL (4-amino-3-hydroxybiphenyl) 4363-03-5									
1464	1424	5.45mg	n.s.s.	0/15	9.67mg	0/7			Miller; jnci, 15, 1571-1590; 1955
1-(2-HYDROXYETHYL)-3-(5-NITROFURFURYLIDENE)AMINO-2-IMIDAZOLIDINONE 5036-03-3									
1465	200a	8.90mg	36.9mg	0/25	34.8mg	14/32			Cohen; jnci, 51, 403-417; 1973
a	200a	92.6mg	n.s.s.	0/25	34.8mg	0/32			
b	200a	9.19mg	56.5mg	1/25	34.8mg	14/32			
1-(2-HYDROXYETHYL)-1-NITROSOUREA 13743-07-2									
1466	1246	.786mg	5.40mg	1/26	2.10mg	15/40			BuLay; jnci, 62, 1523-1528; 1979
a	1246	1.02mg	5.89mg	0/26	2.10mg	11/40			
b	1246	1.02mg	5.89mg	0/26	2.10mg	11/40			
c	1246	.190mg	.903mg	10/26	2.10mg	36/40			
4-(2-HYDROXYETHYLAMINO)-2-(5-NITRO-2-THIENYL)QUINAZOLINE 33389-36-5									
1467	1390	2.16mg	7.49mg	0/84	17.4mg	20/28			Cohen; jnci, 57, 277-282; 1976
a	1390	21.5mg	n.s.s.	0/84	17.4mg	1/28			
b	1390	.939mg	3.79mg	6/84	17.4mg	26/28			
2-HYDROXYETHYLHYDRAZINE (BOH) 109-84-2									
1468	160	44.7mg	28.1gm	0/100	20.5mg	3/50			Shimizu; jnci, 52, 903-906; 1974
a	160	137.mg	n.s.s.	0/100	20.5mg	0/50			
1469	160	29.9mg	49.0gm	1/100	18.0mg	5/50			
a	160	121.mg	n.s.s.	0/100	18.0mg	0/50			
1470	159	.670mg	n.s.s.	2/15	.708mg	2/17			Innes; ntis, 1968/1969
a	159	1.39mg	n.s.s.	1/15	.708mg	0/17			
b	159	.508mg	n.s.s.	2/15	.708mg	3/17			
1471	159	.148mg	.820mg	0/18	.660mg	10/18			
a	159	.912mg	n.s.s.	2/18	.660mg	1/18			
b	159	.975mg	n.s.s.	3/18	.660mg	1/18			
c	159	.163mg	n.s.s.	3/18	.660mg	10/18			
1472	159	.777mg	n.s.s.	0/17	.708mg	1/18			
a	159	.777mg	n.s.s.	0/17	.708mg	1/18			
b	159	.628mg	n.s.s.	1/17	.708mg	2/18			
1473	159	.212mg	n.s.s.	1/17	.660mg	7/17			
a	159	.774mg	n.s.s.	1/17	.660mg	1/17			
b	159	.177mg	n.s.s.	7/17	.660mg	10/17			

Spe	Strain	Site	Xpo + Xpt		TD50	2Tailpvl
Sex	Route	Hist	Notes		DR	AuOp
1474	M f swi wat	lun tum	75w75 s			
a	M f swi wat	liv mix	75w75 s	>	no dre	P=1. -
1475	M m swi wat	lun tum	75w75 s			
a	M m swi wat	liv mix	75w75 s	>	no dre	P=1. -
HYDROXYPROPYL DISTARCH GLYCEROL				100ng...1ug...10...100...1mg...10...100...1g...10		
1476	R f wis eat	liv tum	24m24 e			
a	R f wis eat	tba mix	24m24 e		930. gm	P<. -
1477	R m wis eat	liv hpt	24m24 e		243. gm	P<.3 -
a	R m wis eat	tba mix	24m24 e		no dre	P=1. -
8-HYDROXYQUINOLINE				100ng...1ug...10...100...1mg...10...100...1g...10		
1478	R m f34 eat	liv tum	52w52 e			
1479	R m f34 eat	tes ldc	78w78	>	no dre	P=1. -
a	R m f34 eat	liv tum	78w78	±	398. mg	P<.02 -
					no dre	P=1. -
1'-HYDROXYSAFROLE				100ng...1ug...10...100...1mg...10...100...1g...10		
1480	M f cd1 eat	liv hpc	51w73 ev			
a	M f cd1 eat	sub ang	51w73 ev	+	68.0mg	P<.0005+
b	M f cd1 eat	lun tum	51w73 ev		1.55gm	P<.007
1481	M m cd1 eat	liv car	51w73 ev			
a	M m cd1 eat	lun tum	51w73 ev			
1482	M m cd1 eat	isp ang	56w69			
a	M m cd1 eat	lun ade	56w69	+	429. mg	* P<.0005+
b	M m cd1 eat	liv car	56w69		5.47gm	* P<.5
1483	R m cdr eat	liv hpc	58w95 ee			
1484	R m cdr eat	liv car	43w69			
a	R m cdr eat	for pam	43w69	+	18.9gm	* P<.9
1485	R m cdr eat	liv car	36w52			
a	R m cdr eat	for pam	36w52	+	47.8mg	* P<.0005+
				+	16.7mg	P<.0005+
				+	59.8mg	P<.002 +
				+	12.1mg	P<.0005+
				+	65.8mg	P<.003 +
ICRF-159				100ng...1ug...10...100...1mg...10...100...1g...10		
1486	M f b6c ipj	---	MXB 52w86			
a	M f b6c ipj	---	MXA 52w86	:	23.7mg	* P<.005
b	M f b6c ipj	---	lhc 52w86	:	23.7mg	* P<.005 c
c	M f b6c ipj	TBA	MXB 52w86		53.7mg	* P<.03 c
d	M f b6c ipj	liv	MXB 52w86		16.8mg	* P<.003
e	M f b6c ipj	lun	MXB 52w86		no dre	P=1.
1487	M f b6c ipj	---	MXA 52w86	pool		
a	M f b6c ipj	---	lhc 52w86	:	25.9mg	* P<.0005
1488	M m b6c ipj	TBA	MXB 52w86			
a	M m b6c ipj	liv	MXB 52w86	:	53.7mg	* P<.003 c
b	M m b6c ipj	lun	MXB 52w86	:	262. mg	* P<.8 -
1489	R f sda ipj	ute	acn 52w81			
a	R f sda ipj	TBA	MXB 52w81	:	212. mg	* P<.3
b	R f sda ipj	liv	MXB 52w81	:	11.3mg	* P<.002 c
1490	R f sda ipj	ute	acn 52w79	pool		
1491	R m sda ipj	TBA	MXB 52w81 s	:	6.48mg	* P<.005
a	R m sda ipj	liv	MXB 52w81 s	:	no dre	P=1.
				±	10.7mg	* P<.0005c
				±	9.55mg	* P<.03 -
					105. mg	* P<.5
3,3'-IMINOBIS-1-PROPANOL DIMETHANESULFONATE (ESTER).HCl (IPD)				100...1mg...10...100...1g...10		
1492	M f b6c ipj	TBA	MXB 52w86 e			
a	M f b6c ipj	liv	MXB 52w86 e	:	1.17mg	* P<.0005-
b	M f b6c ipj	lun	MXB 52w86 e	:	no dre	P=1.
1493	M m b6c ipj	---	lym 52w78			
a	M m b6c ipj	TBA	MXB 52w78	:	6.88mg	* P<.04
b	M m b6c ipj	liv	MXB 52w78	:	±37.7mg	* P<.04 -
c	M m b6c ipj	lun	MXB 52w78	:	2.07mg	/ P<.0005
1494	R f sda ipj	per	MXA 36w80 es			
a	R f sda ipj	TBA	MXB 36w80 es	:	no dre	P=1.
b	R f sda ipj	liv	MXB 36w80 es	:	no dre	P=1.
1495	R m sda ipj	per	MXA 36w80 es			
a	R m sda ipj	TBA	MXB 36w80 es	:	2.74mg	Z P<.003 a
b	R m sda ipj	liv	MXB 36w80 es	:	.616mg	* P<.006
				+	5.01mg	* P<.05
				+	.915mg	* P<.003 a
				+	1.30mg	* P<.0005
					no dre	P=1.
IMINODIACETIC ACID, MONOSODIUM				100ng...1ug...10...100...1mg...10...100...1g...10		
1496	R f mrc wat	tba mix	20m24 e			
1497	R m mrc wat	tba mix	20m24 e			
				±	143. mg	P<.03 -
				>	no dre	P=1. -
INDOLE-3-ACETIC ACID				100ng...1ug...10...100...1mg...10...100...1g...10		
1498	M f b6a orl	lun ade	76w76 evx			
a	M f b6a orl	liv hpt	76w76 evx	>	no dre	P=1. -
b	M f b6a orl	tba mix	76w76 evx		no dre	P=1. -
1499	M m b6a orl	liv hpt	76w76 evx			
a	M m b6a orl	lun ade	76w76 evx	>	no dre	P=1. -
b	M m b6a orl	tba mix	76w76 evx		no dre	P=1. -
1500	M f b6c orl	lun ade	76w76 evx			
a	M f b6c orl	liv hpt	76w76 evx	>	538. mg	P<.3 -
b	M f b6c orl	tba mix	76w76 evx		no dre	P=1. -
					538. mg	P<.3 -

RefNum	LoConf	UpConf	Cntrl	1Dose	1Inc	2Dose	2Inc	Citation or Pathology	Brkly Code
1474	160	65.1mg	n.s.s.	21/100	30.0mg	7/50		Shimizu;jnci,52,903-906;1974	
a	160	107.1mg	n.s.s.	3/100	30.0mg	1/50			
1475	160	84.2mg	n.s.s.	23/100	25.0mg	4/50			
a	160	100.1mg	n.s.s.	6/100	25.0mg	1/50			
HYDROXYPROPYL DISTARCH GLYCEROL ---									
1476	1407	80.4gm	n.s.s.	0/30	15.0gm	0/26		de Groot;fctx,12,651-663;1974	
a	1407	7.41gm	n.s.s.	23/30	15.0gm	20/26			
1477	1407	39.5gm	n.s.s.	0/23	12.0gm	1/30			
a	1407	14.8gm	n.s.s.	21/23	12.0gm	19/30			
8-HYDROXYQUINOLINE 148-24-3									
1478	166m	165.1mg	n.s.s.	0/10	320.1mg	0/10		Yamamoto;txep,19,687-698;1971	
1479	166n	136.1mg	n.s.s.	0/15	320.1mg	4/15			
a	166n	556.1mg	n.s.s.	0/15	320.1mg	0/15			
1'-HYDROXYSAFROLE 5208-87-7									
1480	1035c	37.7mg	125.1mg	0/53	483.1mg	30/33		Wislocki;canr,37,1883-1891;1977	
a	1035c	587.1mg	17.2gm	0/55	483.1mg	5/50			
b	1035c	2.45gm	n.s.s.	0/55	483.1mg	0/50			
1481	1035c	1.43gm	n.s.s.	0/44	446.1mg	0/25			
a	1035c	2.04gm	n.s.s.	0/55	446.1mg	0/45			
1482	1042a	245.1mg	972.1mg	1/50	429.1mg	7/25	536.1mg	13/40	Borchert;canr,33,590-600;1973
a	1042a	1.05gm	n.s.s.	1/50	429.1mg	1/25	536.1mg	2/40	
b	1042a	872.1mg	n.s.s.	4/50	429.1mg	3/25	536.1mg	3/40	
1483	1035c	28.2mg	88.3mg	0/18	77.3mg	7/18	100.1mg	16/18	Wislocki;canr,37,1883-1891;1977
1484	1042a	6.14mg	47.1mg	0/12	138.1mg	11/12			Borchert;canr,33,590-600;1973
a	1042a	23.7mg	269.1mg	0/12	138.1mg	6/12			
1485	1042c	5.64mg	27.7mg	0/18	156.1mg	16/18			
a	1042c	26.6mg	334.1mg	0/18	156.1mg	6/18			
ICRF-159 21416-87-5									
1486	c01627	12.7mg	187.1mg	0/15	10.0mg	5/35	21.0mg	9/35	---:leu,lhc,lym. C
a	c01627	12.7mg	187.1mg	0/15	10.0mg	5/35	21.0mg	9/35	---:leu,lym.
b	c01627	21.9mg	n.s.s.	0/15	10.0mg	1/35	21.0mg	5/35	
c	c01627	9.72mg	86.4mg	0/15	10.0mg	8/35	21.0mg	11/35	
d	c01627	n.s.s.	n.s.s.	0/15	10.0mg	0/35	21.0mg	0/35	liv:hpa,hpc,ndd.
e	c01627	n.s.s.	n.s.s.	0/15	10.0mg	0/35	21.0mg	0/35	lun:a/a,a/c.
1487	c01627	13.2mg	90.5mg	1/45p	10.0mg	5/35	21.0mg	9/35	---:leu,lym. S
a	c01627	21.9mg	268.1mg	0/45p	10.0mg	1/35	21.0mg	5/35	
1488	c01627	23.0mg	n.s.s.	2/15	10.0mg	2/35	21.0mg	3/35	
a	c01627	65.8mg	n.s.s.	2/15	10.0mg	0/35	21.0mg	0/35	liv:hpa,hpc,ndd.
b	c01627	34.5mg	n.s.s.	0/15	10.0mg	0/35	21.0mg	1/35	lun:a/a,a/c.
1489	c01627	6.67mg	34.9mg	0/10	13.0mg	10/34	26.0mg	11/35	
a	c01627	3.48mg	66.8mg	4/10	13.0mg	24/34	26.0mg	22/35	
b	c01627	n.s.s.	n.s.s.	0/10	13.0mg	0/34	26.0mg	0/35	liv:hpa,hpc,ndd.
1490	c01627	6.34mg	20.1mg	0/40p	13.0mg	10/34	26.0mg	11/35	
1491	c01627	4.34mg	n.s.s.	1/10	13.0mg	11/36	26.0mg	4/35	
a	c01627	17.2mg	n.s.s.	0/10	13.0mg	1/36	26.0mg	0/35	liv:hpa,hpc,ndd.
3,3'-IMINOBIS-1-PROPANOL DIMETHANESULFONATE (ESTER).HCL (IPD) 3458-22-8									
1492	c01547	.541mg	3.20mg	3/15	5.20mg	13/36	11.6mg	14/35	
a	c01547	n.s.s.	n.s.s.	0/15	5.20mg	0/36	11.6mg	0/35	liv:hpa,hpc,ndd.
b	c01547	1.77mg	n.s.s.	1/15	5.20mg	2/36	11.6mg	2/35	lun:a/a,a/c.
1493	c01547	9.01mg	n.s.s.	0/15	5.80mg	0/34	14.0mg	3/35	
a	c01547	.728mg	7.51mg	1/15	5.80mg	6/34	14.0mg	4/35	S
b	c01547	n.s.s.	n.s.s.	0/15	5.80mg	0/34	14.0mg	0/35	liv:hpa,hpc,ndd.
c	c01547	n.s.s.	n.s.s.	0/15	5.80mg	0/34	14.0mg	0/35	lun:a/a,a/c.
1494	c01547	.722mg	27.7mg	0/20	3.30mg	0/35	4.90mg	3/35	per: fbs,arn.
a	c01547	.228mg	9.06mg	12/20	3.30mg	8/35	4.90mg	3/35	21.0mg 0/35
b	c01547	.816mg	n.s.s.	0/20	3.30mg	0/35	4.90mg	1/35	21.0mg 0/35
1495	c01547	.160mg	23.9mg	0/20	4.90mg	3/70	21.0mg	0/35	liv:hpa,hpc,ndd.
a	c01547	.226mg	11.1mg	5/20	4.90mg	7/70	21.0mg	1/35	per: fbs, fib,arn.
b	c01547	n.s.s.	n.s.s.	0/20	4.90mg	0/70	21.0mg	0/35	liv:hpa,hpc,ndd.
IMINODIACETIC ACID, MONOSODIUM 32607-00-4									
1496	213	53.5mg	n.s.s.	4/15	165.1mg	10/15		Lijinsky;jnci,50,1061-1063;1973	
1497	213	134.1mg	n.s.s.	8/15	115.1mg	5/15			
INDOLE-3-ACETIC ACID (heteroauxin) 87-51-4									
1498	1280	99.3mg	n.s.s.	1/17	89.1mg	1/17		Innes;ntis,1968/1969	
a	1280	167.1mg	n.s.s.	0/17	89.1mg	0/17			
b	1280	78.3mg	n.s.s.	2/17	89.1mg	2/17			
1499	1280	98.0mg	n.s.s.	1/18	82.9mg	1/18			
a	1280	109.1mg	n.s.s.	2/18	82.9mg	1/18			
b	1280	65.2mg	n.s.s.	3/18	82.9mg	3/18			
1500	1280	87.5mg	n.s.s.	0/16	89.1mg	1/17			
a	1280	167.1mg	n.s.s.	0/16	89.1mg	0/17			
b	1280	87.5mg	n.s.s.	0/16	89.1mg	1/17			

Spe	Strain	Site	Xpo+Xpt	Notes	TD50	2Tailpvl
Sex	Route	Hist			DR	AuOp
1501	M m	b6c orl	liv hpt 76w76	evx	113.mg	P<.02 -
a	M m	b6c orl	lun ade 76w76	evx	500.mg	P<.3 -
b	M m	b6c orl	tba mix 76w76	evx	40.3mg	P<.0005-
10DOFORM				100ng.....1ug.....10.....100.....1mg.....10.....100.....1g.....10		
1502	M f	b6c gav	TBA MXB 78w90	v		no dre P=1. -
a	M f	b6c gav	liv MXB 78w90	v	>	no dre P=1. -
b	M f	b6c gav	lun MXB 78w90	v		no dre P=1. -
1503	M m	b6c gav	TBA MXB 78w90	v		73.8mg * P<.2 -
a	M m	b6c gav	liv MXB 78w90	v	>	1.66gm * P<.9 -
b	M m	b6c gav	lun MXB 78w90	v		630.mg * P<.7 -
1504	R f	oam gav	TBA MXB 18m26	v		11.3mg \ P<.05 -
a	R f	oam gav	liv MXB 18m26	v	:	no dre P=1. -
1505	R m	oam gav	thy MXA 18m26	v		#82.2mg * P<.02 -
a	R m	oam gav	TBA MXB 18m26	v	:	113.mg * P<.4 -
b	R m	oam gav	liv MXB 18m26	v		no dre P=1. -
1506	R m	oam gav	thy MXA 18m26	v	pool	#116.mg * P<.05 -
N-ISOBUTYL-N'-NITRO-N-NITROSOGUANIDINE			1ug.....10.....100.....1mg.....10.....100.....1g.....10		
1507	R m	wis wat	stg tum 52w78	er		no dre P=1. -
ISONIAZID				100ng.....1ug.....10.....100.....1mg.....10.....100.....1g.....10		
1508	H f	syg wat	for pam 28m28	e		575.mg P<.02 -
a	H f	syg wat	liv tum 28m28	e		no dre P=1. -
b	H f	syg wat	lun tum 28m28	e		no dre P=1. -
1509	H m	syg wat	liv hem 30m30	e		no dre P=1. -
a	H m	syg wat	lun tum 30m30	e	>	no dre P=1. -
1510	M f	akr wat	lun tum 70w70	e		89.6mg P<.4 -
a	M f	akr wat	liv tum 70w70	e	>	no dre P=1. -
1511	M m	akr wat	lun tum 59w59	e		202.mg P<.2 -
a	M m	akr wat	liv hem 59w59	e	>	no dre P=1. -
1512	M m	amg gav	liv car 79w79	r		159.mg \ P<.2 -
a	M m	amg gav	lun car 79w79	r	>	206.mg * P<.4 -
b	M m	amg gav	mix car 79w79	r		219.mg * P<.5 +
1513	M f	c3h wat	lun ade 72w72	e		755.mg P<.5 -
1514	M m	c3h wat	lun ade 72w72	e	>	219.mg P<.2 -
1515	M f	cbc gav	lun mix 36w84	e		11.2mg P<.0005+
a	M f	cbc gav	liv hpt 36w84	e	.	187.mg P<.4 -
1516	M m	cbc gav	lun mix 36w74	e	.	12.2mg P<.0005+
a	M m	cbc gav	liv hpt 36w74	e	.	165.mg P<.6 -
1517	M b	nas gav	lun ade 52w52	e	.	19.3mg P<.0005+
a	M b	nas gav	agl adc 52w52	e	.	80.9mg P<.06 +
b	M b	nas gav	tba mix 52w52	e	.	14.1mg P<.0005+
1518	M f	awa wat	lun mix 80w80	e	.	153.mg P<.0005+
a	M f	awa wat	lun ade 80w80	e	.	189.mg P<.0005+
b	M f	awa wat	lun adc 80w80	e	.	435.mg P<.01 -
c	M f	awa wat	liv hem 80w80	e	.	no dre P=1. -
1519	M f	awa wat	lun ade 23m25	ee	.	386.mg * P<.0005+
a	M f	awa wat	liv hem 23m25	ee	.	no dre P=1. -
1520	M m	awa wat	lun ade 80w80	e	.	124.mg P<.0005+
a	M m	awa wat	liv hem 80w80	e	.	no dre P=1. -
1521	M m	awa wat	lun ade 86w87	ees	.	104.mg \ P<.0005+
a	M m	awa wat	liv mix 86w87	ees	.	no dre P=1. -
1522	M f	awi gav	mix car 83w83	r	.	53.1mg P<.0005+
a	M f	awi gav	lun car 83w83	r	.	53.1mg P<.0005
b	M f	awi gav	liv car 83w83	r	.	no dre P=1. -
1523	M f	awi gav	mix car 81w83	gr	.	39.9mg P<.0005+
a	M f	awi gav	lun car 81w83	gr	.	88.6mg P<.008
b	M f	awi gav	liv car 81w83	gr	.	88.6mg P<.008
1524	M m	awi gav	mix car 85w85	r	.	24.0mg * P<.0005+
a	M m	awi gav	lun car 85w85	r	.	28.9mg * P<.0005
b	M m	awi gav	liv car 85w85	r	.	211.mg * P<.3 -
1525	M m	awi gav	mix car 79w79	fr	.	25.7mg * P<.003 +
a	M m	awi gav	lun car 79w79	fr	.	41.1mg * P<.007
b	M m	awi gav	liv car 79w79	fr	.	88.8mg * P<.3 -
1526	M m	awi gav	mix car 79w79	br	.	21.2mg P<.005 +
a	M m	awi gav	lun car 79w79	br	.	39.2mg P<.05 -
b	M m	awi gav	liv car 79w79	br	.	71.3mg P<.05 -
1527	R f	cbs wat	agl fba 48w64	s	.	120.mg P<.002 +
a	R f	cbs wat	lun tum 48w64	s	.	no dre P=1. -
b	R f	cbs wat	liv tum 48w64	s	.	no dre P=1. -
1528	R m	cbs wat	liv tum 48w84	es	.	199.mg P<.07 +
a	R m	cbs wat	lun mix 48w84	s	.	1.07gm P<.2 +
ISONICOTINIC ACID				100ng.....1ug.....10.....100.....1mg.....10.....100.....1g.....10		
1529	H f	syg wat	cec tum 28m28	e		±8.08gm P<.03 -
a	H f	syg wat	liv tum 28m28	e		no dre P=1. -
b	H f	syg wat	lun tum 28m28	e		no dre P=1. -

CARCINOGENIC POTENCY DATABASE

RefNum	LoConf	UpConf	Cntrl	1Dose	1Inc	2Dose	2Inc	Citation or Pathology	Brdly Code
1501	1280	38.9mg n.s.s.	0/16	82.9mg	4/17				
a	1280	81.5mg n.s.s.	0/16	82.9mg	1/17				
b	1280	18.5mg 114.mg	0/16	82.9mg	9/17				
IODOFORM (triiodomethane) 75-48-8									
1502	c04568	40.2mg n.s.s.	7/20	28.5mg	14/50	(56.3mg	5/50)		
a	c04568	418.mg n.s.s.	1/20	28.5mg	1/50	56.3mg	0/50		liv:hpa,hpc,nn-
b	c04568	418.mg n.s.s.	1/20	28.5mg	1/50	56.3mg	0/50		lun:o/a,e/f/c.
1503	c04568	30.0mg n.s.s.	5/20	28.5mg	14/50	56.9mg	23/50		
a	c04568	81.1mg n.s.s.	3/20	28.5mg	5/50	56.9mg	7/50		liv:hpa,hpc,nn-
b	c04568	91.4mg n.s.s.	1/20	28.5mg	4/50	56.9mg	4/50		lun:o/a,e/f/c.
1504	c04568	4.66mg n.s.s.	10/20	13.6mg	27/50	(27.1mg	23/50)		
a	c04568	241.mg n.s.s.	1/20	13.6mg	0/50	27.1mg	0/50		liv:hpa,hpc,nn-
1505	c04568	40.8mg n.s.s.	0/20	35.2mg	8/50	70.4mg	4/50		thy:fca,fcc. S
a	c04568	28.4mg n.s.s.	7/20	35.2mg	17/50	70.4mg	10/50		
b	c04568	n.s.s. n.s.s.	0/20	35.2mg	0/50	70.4mg	0/50		liv:hpa,hpc,nn-
1506	c04568	46.2mg n.s.s.	2/40p	35.2mg	8/50	70.4mg	4/50		thy:fca,fcc. S
N-ISOBUTYL-N'-NITRO-N-NITROSOGUANIDINE 5461-85-8									
1507	1082	2.24mg n.s.s.	0/9	2.14mg	0/9				Mataukura;gann,70,181-185;1979
ISONIAZID (INH) 54-85-3									
1508	170	195.mg n.s.s.	2/54	136.mg	5/22				Toth;ejca,5,165-171;1969
a	170	1.37gm n.s.s.	0/72	136.mg	0/36				
b	170	1.37gm n.s.s.	0/72	136.mg	0/36				
1509	170	425.mg n.s.s.	2/25	120.mg	0/11				
a	170	1.51gm n.s.s.	0/67	120.mg	0/39				
1510	169	13.2mg n.s.s.	0/1	200.mg	1/2				Toth;ijcn,2,413-420;1967
a	169	560.mg n.s.s.	0/30	200.mg	0/30				
1511	169	32.6mg n.s.s.	0/9	167.mg	1/6				
a	169	155.mg n.s.s.	1/14	167.mg	0/14				
1512	584m	48.2mg n.s.s.	0/20	31.4mg	3/40	(62.9mg	0/40)		Bhide;ijcn,21,381-386;1978
a	584m	64.0mg n.s.s.	1/20	31.4mg	7/40	62.9mg	6/40		
b	584m	55.8mg n.s.s.	1/20	31.4mg	10/40	62.9mg	6/40		
1513	1115	123.mg n.s.s.	0/4	200.mg	1/12				Toth;acie,152,1376-1377;1966a
1514	1115	71.3mg n.s.s.	1/12	167.mg	6/21				
1515	1074	5.26mg 29.8mg	4/47	34.1mg	13/17				Biancifiori;b jca,18,543-550;1964
a	1074	32.3mg n.s.s.	2/47	34.1mg	2/17				
1516	1074	5.80mg 32.7mg	1/37	32.2mg	11/18				
a	1074	22.1mg n.s.s.	4/37	32.2mg	3/18				
1517	1425	11.1mg 47.4mg	5/94	30.1mg	27/98				Pershin;vopr,XVIII,50-53;1972
a	1425	30.1mg n.s.s.	2/94	30.1mg	8/98				
b	1425	8.62mg 29.9mg	7/94	30.1mg	35/98				
1518	1127	82.3mg 426.mg	9/68	200.mg	23/47				Toth;canr,26,1473-1475;1966
a	1127	97.3mg 635.mg	8/68	200.mg	20/47				
b	1127	165.mg 27.1gm	1/48	200.mg	6/32				
c	1127	534.mg n.s.s.	3/48	200.mg	1/32				
1519	169	201.mg 1.37gm	14/108	100.mg	17/39	300.mg	13/32		Toth;ijcn,2,413-420;1967
a	169	413.mg n.s.s.	3/88	100.mg	0/30	300.mg	0/18		
1520	1127	67.5mg 311.mg	8/80	167.mg	21/44				Toth;canr,26,1473-1475;1966
a	1127	203.mg n.s.s.	2/35	167.mg	0/10				
1521	169	49.2mg 437.mg	10/90	83.3mg	15/38	(250.mg	3/14)		Toth;ijcn,2,413-420;1967
a	169	555.mg n.s.s.	2/85	83.3mg	1/38	250.mg	0/10		
1522	584m	23.9mg 174.mg	0/30	37.7mg	8/30				Bhide;ijcn,21,381-386;1978
a	584m	23.9mg 174.mg	0/30	37.7mg	8/30				
b	584m	149.mg n.s.s.	0/30	37.7mg	0/30				
1523	584n	19.3mg 105.mg	0/30	37.0mg	10/30				
a	584n	33.6mg 1.32gm	0/30	37.0mg	5/30				
b	584n	33.6mg 1.32gm	0/30	37.0mg	5/30				
1524	584m	13.9mg 53.4mg	1/30	15.7mg	6/30	31.4mg	16/30		
a	584m	16.2mg 70.0mg	1/30	15.7mg	4/30	31.4mg	15/30		
b	584m	63.8mg n.s.s.	0/30	15.7mg	2/30	31.4mg	1/30		
1525	584o	14.1mg 107.mg	0/15	15.7mg	6/25	31.4mg	9/25		
a	584o	20.0mg 420.mg	0/15	15.7mg	3/25	31.4mg	7/25		
b	584o	33.7mg n.s.s.	0/15	15.7mg	3/25	31.4mg	2/25		
1526	584r	10.1mg 158.mg	1/15	31.4mg	12/25				
a	584r	15.4mg n.s.s.	1/15	31.4mg	8/25				
b	584r	24.6mg n.s.s.	0/15	31.4mg	4/25				
1527	157	60.1mg 399.mg	0/22	149.mg	11/40				Severi;jnci,41,331-349;1968
a	157	465.mg n.s.s.	0/22	149.mg	0/40				
b	157	465.mg n.s.s.	0/22	149.mg	0/40				
1528	157	32.1mg n.s.s.	0/21	99.4mg	1/5				
a	157	262.mg n.s.s.	0/28	99.4mg	2/49				
ISONICOTINIC ACID 55-22-1									
1529	1108	1.99gm n.s.s.	0/66	682.mg	2/27				Toth;canr,32,804-807;1972/1967a
a	1108	6.36gm n.s.s.	0/72	682.mg	0/34				
b	1108	6.36gm n.s.s.	0/72	682.mg	0/34				

Spe	Strain	Site	Xpo+Xpt	Notes	TD50	2Tailpv!
Sex	Route	Hist			DR	AuOp
1530	M m	syg wat	liv lcc 28w28 e		± 6.95gm	P<.1 -
a	M m	syg wat	liv mix 28w28 e		10.3gm	P<.5 -
b	M m	syg wat	lun tum 28w28 e		no dre	P=1. -
1531	M f	cbc gav	liv hpt 36w89 e	>	612.mg	P<.8 -
a	M f	cbc gav	lun ade 36w89 e		no dre	P=1. -
1532	M m	cbc gav	lun ade 36w89 e	>	101.mg	P<.3 -
a	M m	cbc gav	liv hpt 36w89 e		no dre	P=1. -
ISONICOTINIC ACID VANILLYLIDENEHYDRAZIDE...1ug.....10.....100.....1mg.....10.....100.....1g.....10						
1533	M b	nss gav	lun adc 52w52 e	±	45.0mg	P<.03 +
a	M b	nss gav	agl adc 52w52 e		86.6mg	P<.07 +
b	M b	nss gav	tba mix 52w52 e		27.4mg	P<.003 +
ISOPHOSPHAMIDE 100ng.....1ug.....10.....100.....1mg.....10.....100.....1g.....10						
1534	M f	b6c ipj	--- lhc 52w79 s	: + :	5.06mg *	P<.0005c
a	M f	b6c ipj	TBA MXB 52w79 s		3.63mg *	P<.0005
b	M f	b6c ipj	liv MXB 52w79 s		no dre	P=1. -
c	M f	b6c ipj	lun MXB 52w79 s		no dre	P=1. -
1535	M f	b6c ipj	--- lhc 52w79 s	pool : + :	5.06mg *	P<.0005c
1536	M m	b6c ipj	TBA MXB 52w79 s	:>	no dre	P=1. -
a	M m	b6c ipj	liv MXB 52w79 s		no dre	P=1. -
b	M m	b6c ipj	lun MXB 52w79 s		37.6mg *	P<.5
1537	M m	b6c ipj	liv MXA 52w79 s	pool : ±	#2.42mg \	P<.02 -
1538	R f	ada ipj	MXB MXB 52w83 s	: + :	.284mg *	P<.0005
a	R f	ada ipj	agl fba 52w83 s		.301mg *	P<.0005a
b	R f	ada ipj	ute lei 52w83 s		.739mg *	P<.003 c
c	R f	ada ipj	TBA MXB 52w83 s		.383mg /	P<.009
d	R f	ada ipj	liv MXB 52w83 s		17.2mg *	P<.5
1539	R f	ada ipj	agl fba 52w80 s	pool : + :	.358mg *	P<.0005a
a	R f	ada ipj	ute lei 52w80 s		.814mg *	P<.0005c
b	R f	ada ipj	agl MXA 52w80 s		2.96mg *	P<.007
1540	R m	ada ipj	TBA MXB 52w79 s	: ±	1.01mg /	P<.02 -
a	R m	ada ipj	liv MXB 52w79 s		no dre	P=1. -
1541	R m	ada ipj	--- MXA 52w79 s	pool : + :	#3.23mg *	P<.0005-
p-ISOPROPOXYDIPHENYLAMINE 100ng.....1ug.....10.....100.....1mg.....10.....100.....1g.....10						
1542	M f	b6a orl	liv agm 76w76 evx	>	2.65gm	P<.3 -
a	M f	b6a orl	lun ade 76w76 evx		no dre	P=1. -
b	M f	b6a orl	tba mix 76w76 evx		1.20gm	P<.5 -
1543	M m	b6a orl	liv hpt 76w76 evx	>	1.13gm	P<.3 -
a	M m	b6a orl	lun ade 76w76 evx		2.18gm	P<.7 -
b	M m	b6a orl	tba mix 76w76 evx		985.mg	P<.5 -
1544	M f	b6c orl	liv hpt 76w76 evx	>	2.65gm	P<.3 -
a	M f	b6c orl	lun mix 76w76 evx		no dre	P=1. -
b	M f	b6c orl	tba mix 76w76 evx		1.29gm	P<.2 -
1545	M m	b6c orl	liv hpt 76w76 evx	±	679.mg	P<.04 -
a	M m	b6c orl	lun ade 76w76 evx		2.18gm	P<.3 -
b	M m	b6c orl	tba mix 76w76 evx		300.mg	P<.003 -
ISOPROPYL-N-(3-CHLOROPHENYL)CARBAMATE ...1ug.....10.....100.....1mg.....10.....100.....1g.....10						
1546	M f	syg eat	liv tum 33m33 e	>	no dre	P=1. -
a	M f	syg eat	lun sqc 33m33 e		no dre	P=1. -
1547	M m	syg eat	liv hpc 33m33 e	>	no dre	P=1. -
1548	M f	b6a orl	lun ade 76w76 evx	>	no dre	P=1. -
a	M f	b6a orl	liv hpt 76w76 evx		no dre	P=1. -
b	M f	b6a orl	tba mix 76w76 evx		no dre	P=1. -
1549	M m	b6a orl	liv hpt 76w76 evx	>	no dre	P=1. -
a	M m	b6a orl	lun ade 76w76 evx		no dre	P=1. -
b	M m	b6a orl	tba mix 76w76 evx		no dre	P=1. -
1550	M f	b6c orl	liv hpt 76w76 evx	>	no dre	P=1. -
a	M f	b6c orl	lun mix 76w76 evx		no dre	P=1. -
b	M f	b6c orl	tba tum 76w76 evx		no dre	P=1. -
1551	M m	b6c orl	liv hpt 76w76 evx	±	258.mg	P<.04 -
a	M m	b6c orl	lun ade 76w76 evx		830.mg	P<.3 -
b	M m	b6c orl	tba mix 76w76 evx		114.mg	P<.003 -
1552	M b	swi eat	lun ade 27m27 e	>	682.mg	P<.2 -
a	M b	swi eat	lun adc 27m27 e		4.95gm	P<.3 -
b	M b	swi eat	liv tum 27m27 e		no dre	P=1. -
1553	R f	alb eat	mix mly 24m24 e	>	no dre	P=1. -
1554	R m	alb eat	liv tum 24m24 s	>	no dre	P=1. -
a	R m	alb eat	ads mly 24m24 s		no dre	P=1. -
1-ISOPROPYL-3-METHYL-S-PYRAZOLYLDIMETHYL CARBAMATE...10.....100.....1mg.....10.....100.....1g.....10						
1555	M f	b6a orl	liv hpt 76w76 evx	>	no dre	P=1. -
a	M f	b6a orl	lun mix 76w76 evx		no dre	P=1. -
b	M f	b6a orl	tba mix 76w76 evx		23.0ug	P<.08 -
1556	M m	b6a orl	lun ade 76w76 evx	±	14.7ug	P<.04 -
a	M m	b6a orl	liv hpt 76w76 evx		41.9ug	P<.6 -
b	M m	b6a orl	tba mix 76w76 evx		12.4ug	P<.2 -

RefNum	LoConf	UpConf	Cntrl	1Dose	1Inc	2Dose	2Inc	Citation or Pathology	Brkly Code	
1530	1108	1.13gm	n.s.s.	0/39	600.mg	1/13				
a	1108	1.19gm	n.s.s.	1/39	600.mg	1/13				
b	1108	4.85gm	n.s.s.	0/64	600.mg	0/29				
1531	1074	31.4mg	n.s.s.	2/47	20.9mg	1/17		Biancifiiori;bjca,18,543-550;1964		
a	1074	32.6mg	n.s.s.	4/47	20.9mg	1/16				
1532	1074	16.3mg	n.s.s.	0/13	17.4mg	1/12				
a	1074	24.6mg	n.s.s.	4/27	17.4mg	2/18				
ISONICOTINIC ACID VANILLYLIDENEDRAZIDE (phthivazid) ---										
1533	1425	19.2mg	n.s.s.	5/94	30.1mg	14/90		Perahin;vopr,XVIII,50-53;1972		
a	1425	30.3mg	n.s.s.	2/94	30.1mg	7/90				
b	1425	13.6mg	174.mg	7/94	30.1mg	21/90				
ISOPHOSPHAMIDE 3778-73-2										
1534	c01638	2.81mg	14.1mg	0/15	2.80mg	3/35	5.60mg	13/35		
a	c01638	2.18mg	9.48mg	0/15	2.80mg	7/35	5.60mg	15/35		
b	c01638	n.s.s.	n.s.s.	0/15	2.80mg	1/35	5.60mg	0/35	liv:hpa,hpc,nnd. lun:a/a,e/c.	
c	c01638	n.s.s.	n.s.s.	0/15	2.80mg	0/35	5.60mg	0/35		
1535	c01638	2.81mg	10.9mg	0/30p	2.80mg	3/35	5.60mg	13/35		
1536	c01638	1.85mg	n.s.s.	0/15	2.80mg	6/35	5.60mg	4/35		
a	c01638	2.70mg	n.s.s.	0/15	2.80mg	5/35	5.60mg	2/35	liv:hpa,hpc,nnd. lun:a/a,e/c.	
b	c01638	6.13mg	n.s.s.	0/15	2.80mg	0/35	5.60mg	1/35		
1537	c01638	.900mg	n.s.s.	0/30p	2.80mg	5/35	(5.60mg)	2/35	liv:hpa,hpc. S	
1538	c01638	.152mg	.872mg	3/10	1.60mg	30/35	3.30mg	6/35	mgl:fb; utc:lei. T	
a	c01638	.158mg	1.01mg	3/10	1.60mg	28/35	3.30mg	6/35		
b	c01638	.375mg	3.07mg	0/10	1.60mg	15/35	3.30mg	1/35		
c	c01638	.175mg	17.4mg	9/10	1.60mg	32/35	3.30mg	9/35		
d	c01638	2.79mg	n.s.s.	0/10	1.60mg	1/35	3.30mg	0/35	liv:hpa,hpc,nnd.	
1539	c01638	.199mg	.841mg	8/30p	1.60mg	28/35	3.30mg	6/35		
a	c01638	.429mg	1.76mg	0/30p	1.60mg	15/35	3.30mg	1/35		
b	c01638	.977mg	49.3mg	0/30p	1.60mg	3/35	3.30mg	1/35	mgl:ccn,cyn. S	
1540	c01638	.476mg	n.s.s.	5/10	1.60mg	17/35	3.30mg	12/35		
a	c01638	n.s.s.	n.s.s.	0/10	1.60mg	0/35	3.30mg	0/35	liv:hpa,hpc,nnd. ---:leu,lym. S	
1541	c01638	1.37mg	11.2mg	0/30p	1.60mg	3/35	3.30mg	5/35		
p-ISOPROPOXYDIPHENYLAMINE (Agerite 150) 101-73-5										
1542	1306	431.mg	n.s.s.	0/17	414.mg	1/18			Innes;ntia,1968/1969	
a	1306	492.mg	n.s.s.	1/17	414.mg	1/18				
b	1306	239.mg	n.s.s.	2/17	414.mg	4/18				
1543	1306	252.mg	n.s.s.	1/18	385.mg	3/18				
a	1306	274.mg	n.s.s.	2/18	385.mg	3/18				
b	1306	196.mg	n.s.s.	3/18	385.mg	5/18				
1544	1306	431.mg	n.s.s.	0/16	414.mg	1/18				
a	1306	820.mg	n.s.s.	0/16	414.mg	0/18				
b	1306	316.mg	n.s.s.	0/16	414.mg	2/18				
1545	1306	205.mg	n.s.s.	0/16	385.mg	3/16				
a	1306	355.mg	n.s.s.	0/16	385.mg	1/16				
b	1306	121.mg	1.47gm	0/16	385.mg	6/16				
ISOPROPYL-N-(3-CHLOROPHENYL)CARBAMATE (CIPC, chlorpropham) 101-21-3										
1546	171a	2.12gm	n.s.s.	0/27	209.mg	0/26		Van Esch;fctx,10,373-381;1972		
a	171a	2.12gm	n.s.s.	1/27	209.mg	0/26				
1547	171a	1.65gm	n.s.s.	1/22	184.mg	0/23				
1548	1196	175.mg	n.s.s.	1/17	157.mg	1/17		Innes;ntia,1968/1969		
a	1196	294.mg	n.s.s.	0/17	157.mg	0/17				
b	1196	138.mg	n.s.s.	2/17	157.mg	2/17				
1549	1196	258.mg	n.s.s.	1/18	146.mg	0/16				
a	1196	258.mg	n.s.s.	2/18	146.mg	0/16				
b	1196	180.mg	n.s.s.	3/18	146.mg	1/16				
1550	1196	311.mg	n.s.s.	0/16	157.mg	0/18				
a	1196	311.mg	n.s.s.	0/16	157.mg	0/18				
b	1196	311.mg	n.s.s.	0/16	157.mg	0/18				
1551	1196	77.8mg	n.s.s.	0/16	146.mg	3/16				
a	1196	135.mg	n.s.s.	0/16	146.mg	1/16				
b	1196	45.9mg	559.mg	0/16	146.mg	6/16				
1552	171a	209.mg	n.s.s.	10/49	125.mg	15/47		Van Esch;fctx,10,373-381;1972		
a	171a	807.mg	n.s.s.	0/49	125.mg	1/47				
b	171a	1.51gm	n.s.s.	0/49	125.mg	0/47				
1553	170a	4.86gm	n.s.s.	1/25	10.0mg	0/25	100.mg	1/25	1.00gm	0/25
1554	170a	37.1mg	n.s.s.	0/25	8.00mg	0/25	80.0mg	0/25	800.mg	0/25
a	170a	3.11gm	n.s.s.	0/25	8.00mg	0/25	80.0mg	1/25	800.mg	0/25
1-ISOPROPYL-3-METHYL-5-PYRAZOLYLDIMETHYL CARBAMATE (isolen) 119-38-0										
1555	1247	14.7ug	n.s.s.	0/18	8.38ug	0/16			Innes;ntia,1968/1969	
a	1247	14.7ug	n.s.s.	0/18	8.38ug	0/16				
b	1247	5.63ug	n.s.s.	0/18	8.38ug	2/16				
1556	1247	4.43ug	n.s.s.	0/18	7.80ug	3/17				
a	1247	6.12ug	n.s.s.	1/18	7.80ug	2/17				
b	1247	3.44ug	n.s.s.	2/18	7.80ug	5/17				

Spe	Strain	Site	Xpo+Xpt	Notes	TD50	2Tailpvi
Sex	Route	Hist			DR	AuOp
1557	M f	b6c orl	liv hpt	76w76 evx	>	no dre P=1. -
a	M f	b6c orl	lun ade	76w76 evx		no dre P=1. -
b	M f	b6c orl	tba mix	76w76 evx		no dre P=1. -
1558	M m	b6c orl	lun ade	76w76 evx	.	15.6ug P<.06 -
a	M m	b6c orl	liv hpt	76w76 evx	.	no dre P=1. -
b	M m	b6c orl	tba mix	76w76 evx	.	41.3ug P<.8 -
ISOPROPYL-N-PHENYL CARBAMATE 100ng...1ug...10...100...1mg...10...100...1g...10						
1559	H f	syg eat	liv tum	33m33 e	>	no dre P=1. -
a	H f	syg eat	lun aqc	33m33 e		no dre P=1. -
1560	H m	syg eat	liv hpc	33m33 e	>	no dre P=1. -
1561	M f	b6a orl	lun ade	76w76 evx	>	444.mg P<.6 -
a	M f	b6a orl	liv hpt	76w76 evx		no dre P=1. -
b	M f	b6a orl	tba mix	76w76 evx		416.mg P<.7 -
1562	M m	b6a orl	liv hpt	76w76 evx	>	350.mg P<.5 -
a	M m	b6a orl	lun ade	76w76 evx		1.70gm P<.1 -
b	M m	b6a orl	tba mix	76w76 evx		254.mg P<.6 -
1563	M f	b6c orl	lun ade	76w76 evx	>	244.mg P<.2 -
a	M f	b6c orl	liv hpt	76w76 evx		502.mg P<.3 -
b	M f	b6c orl	tba mix	76w76 evx		88.1mg P<.009 -
1564	M m	b6c orl	liv hpt	76w76 evx	.	120.mg P<.04 -
a	M m	b6c orl	lun ade	76w76 evx	.	387.mg P<.3 -
b	M m	b6c orl	tba mix	76w76 evx	.	52.3mg P<.002 -
ISOSAFROLE** 100ng...1ug...10...100...1mg...10...100...1g...10						
1565	M f	b6a orl	liv hpt	81w81 evx	>	no dre P=1. -
a	M f	b6a orl	lun ade	81w81 evx		no dre P=1. -
b	M f	b6a orl	tba mix	81w81 evx		no dre P=1. -
1566	M m	b6a orl	liv hpt	81w81 evx	.	225.mg P<.09 -
a	M m	b6a orl	lun mix	81w81 evx		no dre P=1. -
b	M m	b6a orl	tba mix	81w81 evx		327.mg P<.7 -
1567	M f	b6c orl	liv hpt	81w81 evx	>	468.mg P<.3 -
a	M f	b6c orl	lun ade	81w81 evx		468.mg P<.3 -
b	M f	b6c orl	tba mix	81w81 evx		414.mg P<.6 -
1568	M m	b6c orl	liv hpt	81w81 evx	.	106.mg P<.08 -
a	M m	b6c orl	lun ade	81w81 evx	.	231.mg P<.4 -
b	M m	b6c orl	tba mix	81w81 evx	.	492.mg P<.9 -
KEPONE 100ng...1ug...10...100...1mg...10...100...1g...10						
1569	M f	b6c eat	liv hpc	80w90 v	:	1.62mg \ P<.003 c
a	M f	b6c eat	TBA MXB	80w90 v	:	1.57mg \ P<.003
b	M f	b6c eat	liv MXB	80w90 v	:	1.62mg \ P<.003
c	M f	b6c eat	lun MXB	80w90 v	:	no dre P=1. -
1570	M m	b6c eat	liv hpc	80w89 dv	:	.705mg * P<.0005c
a	M m	b6c eat	TBA MXB	80w89 dv	:	.705mg * P<.0005
b	M m	b6c eat	liv MXB	80w89 dv	:	.705mg * P<.0005
c	M m	b6c eat	lun MXB	80w89 dv	:	29.3mg * P<.3 -
1571	R f	oam eat	TBA MXB	19m25 v	>	1.83mg \ P<.5 -
a	R f	oam eat	liv MXB	19m25 v		2.96mg / P<.08
1572	R m	oam eat	TBA MXB	19m25 v	>	1.42mg * P<.4 -
a	R m	oam eat	liv MXB	19m25 v		2.49mg * P<.2
1573	R m	sda eat	liv nnd	91w91	>	.199mg P<.3
LASIOCARPINE 100ng...1ug...10...100...1mg...10...100...1g...10						
1574	R f	f34 eat	MXB MXA	21m24 as	:	.141mg Z P<.0005
a	R f	f34 eat	mul MXA	21m24 as	:	.325mg * P<.0005c
b	R f	f34 eat	liv ang	21m24 as	:	.355mg * P<.0005c
c	R f	f34 eat	mul MXA	21m24 as	:	.387mg * P<.0005c
d	R f	f34 eat	liv MXA	21m24 as	:	.453mg Z P<.0005c
e	R f	f34 eat	TBA MXB	21m24 as	:	.102mg Z P<.0005
f	R f	f34 eat	liv MXB	21m24 as	:	22.7mg * P<.2
1575	R m	f34 eat	liv MXB	23m24 as	:	.250mg Z P<.0005
a	R m	f34 eat	liv ang	23m24 as	:	.355mg Z P<.0005c
b	R m	f34 eat	--- MXA	23m24 as	:	.514mg Z P<.0005
c	R m	f34 eat	liv MXA	23m24 as	:	.908mg Z P<.0005c
d	R m	f34 eat	TBA MXB	23m24 as	:	.152mg Z P<.0005
e	R m	f34 eat	liv MXB	23m24 as	:	7.43mg Z P<.03
1576	R m	f34 ipj	liv mix	56w76 ev	.	.341mg P<.0005+
a	R m	f34 ipj	liv hpc	56w76 ev	.	.397mg P<.0005+
b	R m	f34 ipj	ski aqc	56w76 ev	.	.794mg P<.002 +
c	R m	f34 ipj	lun ade	56w76 ev	.	1.33mg P<.09
d	R m	f34 ipj	smi adc	56w76 ev	.	+historical P<.06 +
e	R m	f34 ipj	tba mix	56w76 ev	.	.152mg P<.0005
1577	R m	f34 eat	liv ang	55w59 e	.	.688mg P<.004 +
a	R m	f34 eat	liv car	55w59 e	.	.954mg P<.02 +
b	R m	f34 eat	tba mix	55w59 e	.	.217mg P<.0005
LEAD ACETATE 100ng...1ug...10...100...1mg...10...100...1g...10						
1578	M f	cd1 wet	lun tum	28m28 e	.	7.56mg P<.05 -
a	M f	cd1 wet	tba mix	28m28 e	.	45.3mg P<.9 -

RefNum	LoConf	UpConf	Cntrl	1Dose	1Inc	2Dose	2Inc	Citation or Pathology	Brkly Code
1557	1247	14.7ug n.s.s.	0/18	8.38ug	0/16				
a	1247	14.7ug n.s.s.	1/18	8.38ug	0/16				
b	1247	14.7ug n.s.s.	2/18	8.38ug	0/16				
1558	1247	4.72ug n.s.s.	0/14	7.80ug	3/18				
a	1247	11.2ug n.s.s.	3/14	7.80ug	1/18				
b	1247	3.81ug n.s.s.	4/14	7.80ug	6/18				
ISOPROPYL-N-PHENYL CARBAMATE (IPC) 122-42-9									
1559	171a	2.12gm n.s.s.	0/27	209.mg	0/26			Van Esch;fctx,10,373-381;1972	
a	171a	2.12gm n.s.s.	1/27	209.mg	0/26				
1560	171a	995.mg n.s.s.	1/22	184.mg	1/23				
1561	171	61.8mg n.s.s.	1/17	78.4mg	2/17			Innes;ntis,1968/1969	
a	171	147.mg n.s.s.	0/17	78.4mg	0/17				
b	171	52.4mg n.s.s.	2/17	78.4mg	3/17				
1562	171	53.4mg n.s.s.	1/18	73.0mg	2/16				
a	171	58.9mg n.s.s.	2/18	73.0mg	2/16				
b	171	38.6mg n.s.s.	3/18	73.0mg	4/16				
1563	171	59.8mg n.s.s.	0/16	78.4mg	2/18				
a	171	81.7mg n.s.s.	0/16	78.4mg	1/18				
b	171	33.2mg 1.93gm	0/16	78.4mg	5/18				
1564	171	36.1mg n.s.s.	0/16	73.0mg	3/15				
a	171	63.0mg n.s.s.	0/16	73.0mg	1/15				
b	171	21.0mg 236.mg	0/16	73.0mg	6/15				
ISOSAFROLE** 120-58-1									
1565	172	145.mg n.s.s.	1/15	72.7mg	0/16			Innes;ntis,1968/1969	
a	172	145.mg n.s.s.	2/15	72.7mg	0/16				
b	172	145.mg n.s.s.	2/15	72.7mg	0/16				
1566	172	55.2mg n.s.s.	0/18	67.7mg	2/17				
a	172	144.mg n.s.s.	3/18	67.7mg	0/17				
b	172	44.2mg n.s.s.	3/18	67.7mg	4/17				
1567	172	76.2mg n.s.s.	0/17	72.7mg	1/16				
a	172	76.2mg n.s.s.	0/17	72.7mg	1/16				
b	172	60.7mg n.s.s.	1/17	72.7mg	2/16				
1568	172	34.5mg n.s.s.	1/17	67.7mg	5/18				
a	172	50.4mg n.s.s.	1/17	67.7mg	3/18				
b	172	31.4mg n.s.s.	7/17	67.7mg	8/18				
KEPONE (chlordecone) 143-50-0									
1569	c00191	1.01mg 6.36mg	0/10	2.30mg	26/50 (4.70mg 23/50)				
a	c00191	.992mg 5.65mg	0/10	2.30mg	27/50 (4.70mg 25/50)				
b	c00191	1.01mg 6.36mg	0/10	2.30mg	26/50 (4.70mg 23/50)			liv:hpa,hpc,nd.	
c	c00191	n.s.s. n.s.s.	0/10	2.30mg	0/50 4.70mg 0/50			Lun:a/a,s/c.	
1570	c00191	.462mg 1.59mg	6/20	2.40mg	43/50 2.20mg 39/50				
a	c00191	.462mg 1.59mg	6/20	2.40mg	43/50 2.20mg 39/50			liv:hpa,hpc,nd.	
b	c00191	.462mg 1.59mg	6/20	2.40mg	43/50 2.20mg 39/50			Lun:a/a,s/c.	
c	c00191	7.21mg n.s.s.	0/20	2.40mg	2/50 2.20mg 0/50				
1571	c00191	.469mg n.s.s.	7/10	.640mg	29/50 .930mg 29/50				
a	c00191	1.30mg n.s.s.	1/10	.640mg	1/50 .930mg 12/50			liv:hpa,hpc,nd.	
1572	c00191	.459mg n.s.s.	3/15	.230mg	24/50 .690mg 16/50				
a	c00191	1.22mg n.s.s.	0/15	.230mg	3/50 .690mg 3/50			liv:hpa,hpc,nd.	
1573	1160	32.4ug n.s.s.	0/10	40.0ug	1/10			Chu;txep,59,268-278;1981	
LASILOCARPINE 303-34-4									
1574	c01478	85.9ug .247mg	2/24	.350mg	17/24 .750mg 19/24 1.50mg 8/24			liv:adn,ang,hpc; mul:grl,leu,lle,lym,ule. C	
a	c01478	.165mg .822mg	2/24	.350mg	9/24 .750mg 11/24 1.50mg 1/24			mul:leu,lym.	
b	c01478	.183mg .741mg	0/24	.350mg	8/24 .750mg 7/24 1.50mg 2/24				
c	c01478	.186mg 1.04mg	1/24	.350mg	7/24 .750mg 8/24 1.50mg 1/24			mul:grl,lle,ule.	
d	c01478	.195mg 1.26mg	0/24	.350mg	5/24 .750mg 1/24 1.50mg 7/24			liv:adn,hpc.	
e	c01478	60.1ug .205mg	18/24	.350mg	22/24 .750mg 22/24 1.50mg 8/24				
f	c01478	3.70mg n.s.s.	0/24	.350mg	0/24 .750mg 0/24 1.50mg 1/24			liv:hpa,hpc,nd.	
1575	c01478	.149mg .428mg	0/24	.280mg	5/24 .600mg 14/24 1.20mg 17/24			liv:adn,ang,hpc. C	
a	c01478	.208mg .621mg	0/24	.280mg	5/24 .600mg 11/24 1.20mg 13/24				
b	c01478	.256mg 1.45mg	4/24	.280mg	3/24 .600mg 11/24 1.20mg 7/24			---:leu,lym. S	
c	c01478	.329mg 3.21mg	0/24	.280mg	0/24 .600mg 3/24 1.20mg 5/24			liv:adn,hpc.	
d	c01478	97.2ug .257mg	7/24	.280mg	14/24 .600mg 22/24 1.20mg 23/24				
e	c01478	1.82mg n.s.s.	0/24	.280mg	0/24 .600mg 0/24 1.20mg 2/24			liv:hpa,hpc,nd.	
1576	1013	.165mg .851mg	0/25	.880mg	11/18			Svoboda;canr,32,908-911;1972	
a	1013	.188mg 1.04mg	0/25	.880mg	10/18				
b	1013	.321mg 3.10mg	0/25	.880mg	6/18				
c	1013	.406mg n.s.s.	2/25	.880mg	5/18				
d	1013	.671mg n.s.s.	0/25	.880mg	2/18				
e	1013	69.2ug .372mg	2/25	.880mg	16/18				
1577	390	.319mg 3.32mg	0/10	1.86mg	9/20			Rao;b]ca,37,289-293;1978	
a	390	.408mg 170.mg	0/10	1.86mg	7/20				
b	390	.108mg .469mg	0/10	1.86mg	17/20				
LEAD ACETATE 301-04-2									
1578	1395	2.54mg n.s.s.	1/45	1.00mg	5/37			Schroeder; jnut,105,452-458;1975	
a	1395	2.62mg n.s.s.	9/45	1.00mg	8/37				

Spe	Strain	Site	Xpo+Xpt	Notes	TD50	2Tailpvl
Sex	Route	Hist			DR	AuOp
b	M f cd1	wat tba mal	28m28	e	no dre	P=1. -
1579	M f cd1	wat lun tum	30m30	e	no dre	P=1. -
a	M f cd1	wat tba tum	30m30	e	51.5mg	P<.1. -
1580	M m cd1	wat lun tum	25m25	e	7.78mg	P<.4. -
a	M m cd1	wat tba mal	25m25	e	4.04mg	P<.04. -
b	M m cd1	wat tba mix	25m25	e	6.22mg	P<.5. -
1581	M m cd1	wat lun tum	29m29	e	no dre	P=1. -
a	M m cd1	wat liv sar	29m29	e	no dre	P=1. -
b	M m cd1	wat tba mix	29m29	e	no dre	P=1. -
1582	R m f34	eat kid adc	52w52	okr	993.mg	P<.3. -
a	R m f34	eat liv hpc	52w52	okr	no dre	P=1. -
1583	R b leb	wat liv tum	41m41	es	no dre	P=1. -
a	R b leb	wat tba tum	41m41	es	no dre	P=1. -
b	R b leb	wat tba mal	41m41	es	133.mg	P<.1. -
LEAD ACETATE, BASIC					100ng...1ug...10...100...1mg...10...100...1g...10	
1584	H f syg	eat liv tum	23m25	as	no dre	P=1. -
1585	H m syg	eat liv tum	24m24	s	no dre	P=1. -
1586	M f swi	eat kid car	24m24	sv	14.8gm *	P<.2. +
a	M f swi	eat kid ade	24m24	sv	no dre	P=1. +
b	M f swi	eat liv hpt	24m24	sv	no dre	P=1. -
c	M f swi	eat lun ade	24m24	sv	no dre	P=1. -
1587	M m swi	eat kid car	20m24	asv	472.mg \	P<.02. +
a	M m swi	eat kid ade	20m24	asv	986.mg \	P<.1. +
b	M m swi	eat liv hpt	20m24	asv	no dre	P=1. -
c	M m swi	eat lun ade	20m24	asv	no dre	P=1. -
1588	R f wis	eat kid mix	29m29	e	107.mg	P<.003. +
1589	R f wis	eat kid mix	24m24	e	339.mg	P<.0005. +
1590	R m wis	eat kid mix	29m29	e	107.mg	P<.008. +
1591	R m wis	eat kid mix	24m24	e	443.mg	P<.002. +
LEAD DIMETHYLDITHIOCARBAMATE					100ng...1ug...10...100...1mg...10...100...1g...10	
1592	M f b6c	eat TBA MXB	24m24		no dre	P=1. -
a	M f b6c	eat liv MXB	24m24		149.mg *	P<.6. -
b	M f b6c	eat lun MXB	24m24		no dre	P=1. -
1593	M f b6c	eat orl liv hpt	76w76	evx	no dre	P=1. -
a	M f b6c	eat orl lun mix	76w76	evx	no dre	P=1. -
b	M f b6c	eat orl tba mix	76w76	evx	116.mg	P<.3. -
1594	M m b6c	eat TBA MXB	24m24		no dre	P=1. -
a	M m b6c	eat liv MXB	24m24		no dre	P=1. -
b	M m b6c	eat lun MXB	24m24		no dre	P=1. -
1595	M m b6c	eat orl --- rts	76w76	evx	16.4mg	P<.006. -
a	M m b6c	eat orl liv hpt	76w76	evx	95.3mg	P<.3. -
b	M m b6c	eat orl lun mix	76w76	evx	no dre	P=1. -
c	M m b6c	eat orl tba mix	76w76	evx	10.7mg	P<.002. -
1596	M f b6a	eat orl liv hpt	76w76	evx	no dre	P=1. -
a	M f b6a	eat orl lun ade	76w76	evx	no dre	P=1. -
b	M f b6a	eat orl tba mix	76w76	evx	no dre	P=1. -
1597	M m b6a	eat orl lun ade	76w76	evx	833.mg	P<.1. -
a	M m b6a	eat orl liv hpt	76w76	evx	no dre	P=1. -
b	M m b6a	eat orl tba mix	76w76	evx	no dre	P=1. -
1598	R f f34	eat TBA MXB	24m24		27.8mg *	P<.9. -
a	R f f34	eat liv MXB	24m24		no dre	P=1. -
1599	R m f34	eat TBA MXB	24m24		no dre	P=1. -
a	R m f34	eat liv MXB	24m24		72.6mg *	P<.4. -
LEUPEPTIN					100ng...1ug...10...100...1mg...10...100...1g...10	
1600	M f ejj	eat lun mix	68w68	e	229.mg	P<.3. -
a	M f ejj	eat liv lpb	68w68	e	933.mg	P<.3. -
1601	M m ejj	eat liv mix	68w68	e	55.8mg	P<.006. +
a	M m ejj	eat lun mix	68w68	e	422.mg	P<.9. -
LITHOCHOLIC ACID					100ng...1ug...10...100...1mg...10...100...1g...10	
1602	M f b6c	eat TBA MXB	24m24		960.mg *	P<.8. -
a	M f b6c	eat liv MXB	24m24		1.14gm *	P<.2. -
b	M f b6c	eat lun MXB	24m24		1.03gm *	P<.2. -
1603	M m b6c	eat TBA MXB	24m24		no dre	P=1. -
a	M m b6c	eat liv MXB	24m24		no dre	P=1. -
b	M m b6c	eat lun MXB	24m24		834.mg *	P<.6. -
1604	R f f34	eat TBA MXB	24m24		686.mg *	P<.6. -
a	R f f34	eat liv MXB	24m24		1.89gm *	P<.3. -
1605	R m f34	eat TBA MXB	24m24		501.mg *	P<.3. -
a	R m f34	eat liv MXB	24m24		2.25gm *	P<.2. -
LUTEOSKYRIN					100ng...1ug...10...100...1mg...10...100...1g...10	
1606	M f ddn	eat liv mix	37m37	e	79.4mg	P<.3. +
a	M f ddn	eat liv lca	37m37	e	122.mg	P<.4. +
b	M f ddn	eat liv lcc	37m37	e	248.mg	P<.5. +
1607	M m ddn	eat liv mix	37m37	e	14.8mg	P<.0005. +
a	M m ddn	eat liv lca	37m37	e	83.7mg *	P<.03. +

RefNum	LoConf	UpConf	Cntrl	LDose	1Inc	2Dose	2Inc	Citation or Pathology	Brkly Code
b	1395	3.06mg	n.s.s.	9/45	1.00mg	7/37			
1579	56	3.58mg	n.s.s.	9/60	1.00mg	4/29		Schroeder;jnut,83,239-250;1964	
a	56	1.90mg	n.s.s.	22/60	1.00mg	11/29			
1580	1395	1.98mg	n.s.s.	4/43	.833mg	8/49		Schroeder;jnut,105,452-458;1975	
a	1395	1.59mg	n.s.s.	2/43	.833mg	9/49			
b	1395	1.39mg	n.s.s.	10/43	.833mg	15/49			
1581	56	8.23mg	n.s.s.	8/44	.833mg	1/39		Schroeder;jnut,83,239-250;1964	
a	56	9.99mg	n.s.s.	1/44	.833mg	0/39			
b	56	8.57mg	n.s.s.	11/44	.833mg	1/39			
1582	1150	162.mg	n.s.s.	0/15	400.mg	1/15		Hinton;bect,23,464-469;1979	
a	1150	309.mg	n.s.s.	0/15	400.mg	0/15			
1583	1036	5.00mg	n.s.s.	1/34	.265mg	0/32		Kanisawa;canr,29,892-895;1969	
a	1036	1.67mg	n.s.s.	10/34	.265mg	7/32			
b	1036	2.40mg	n.s.s.	2/34	.265mg	2/32			
LEAD ACETATE, BASIC 1335-32-6									
1584	176	456.mg	n.s.s.	0/23	105.mg	0/24	523.mg	0/24	Van Esch;b ca,23,765-771;1969
1585	176	348.mg	n.s.s.	0/22	92.0mg	0/22	460.mg	0/22	
1586	176	2.42gm	n.s.s.	0/25	130.mg	0/25	751.mg	1/25	
a	176	2.93gm	n.s.s.	0/25	130.mg	1/25	751.mg	0/25	
b	176	2.93gm	n.s.s.	0/25	130.mg	1/25	751.mg	0/25	
c	176	2.58gm	n.s.s.	3/25	130.mg	5/25	751.mg	1/25	
1587	176	163.mg	n.s.s.	0/25	120.mg	4/25	(713.mg)	0/25)	
a	176	242.mg	n.s.s.	0/25	120.mg	2/25	(713.mg)	0/25)	
b	176	529.mg	n.s.s.	0/25	120.mg	0/25	713.mg	0/25	
c	176	2.75gm	n.s.s.	3/25	120.mg	1/25	713.mg	1/25	
1588	175m	43.1mg	571.mg	0/15	50.0mg	6/16		Van Esch;b ca,16,289-297;1962	
1589	175n	138.mg	1.13gm	0/13	500.mg	7/11			
1590	175m	40.4mg	2.21gm	0/14	40.0mg	5/16			
1591	175n	176.mg	2.04gm	0/13	400.mg	6/13			
LEAD DIMETHYLDITHIOCARBAMATE (Leadate) 19010-66-3									
1592	c02891	11.9mg	n.s.s.	9/20	3.25mg	18/50	6.50mg	18/50	
a	c02891	36.6mg	n.s.s.	0/20	3.25mg	1/50	6.50mg	1/50	Liv:hpa,hpc,nnd. Lun:a/a,a/c.
b	c02891	23.0mg	n.s.s.	3/20	3.25mg	4/50	6.50mg	5/50	Innes;ntis,1968/1969
1593	1093	35.8mg	n.s.s.	0/16	18.1mg	0/18			
a	1093	35.8mg	n.s.s.	0/16	18.1mg	0/18			
b	1093	18.8mg	n.s.s.	0/16	18.1mg	1/18			
1594	c02891	5.92mg	n.s.s.	12/20	3.00mg	32/50	6.00mg	28/50	
a	c02891	16.0mg	n.s.s.	4/20	3.00mg	11/50	6.00mg	7/50	Liv:hpa,hpc,nnd. Lun:a/a,a/c.
b	c02891	12.0mg	n.s.s.	9/20	3.00mg	14/50	6.00mg	15/50	Innes;ntis,1968/1969
1595	1093	6.17mg	162.mg	0/16	16.8mg	5/16			
a	1093	15.5mg	n.s.s.	0/16	16.8mg	1/16			
b	1093	29.6mg	n.s.s.	0/16	16.8mg	0/16			
c	1093	4.54mg	39.0mg	0/16	16.8mg	7/16			
1596	1093	35.8mg	n.s.s.	0/17	18.1mg	0/18			
a	1093	35.8mg	n.s.s.	1/17	18.1mg	0/18			
b	1093	35.8mg	n.s.s.	2/17	18.1mg	0/18			
1597	1093	14.6mg	n.s.s.	2/18	16.8mg	2/17			
a	1093	31.4mg	n.s.s.	1/18	16.8mg	0/17			
b	1093	16.2mg	n.s.s.	3/18	16.8mg	2/17			
1598	c02891	1.82mg	n.s.s.	15/20	1.25mg	33/50	2.50mg	36/50	
a	c02891	16.3mg	n.s.s.	1/20	1.25mg	1/50	2.50mg	1/50	Liv:hpa,hpc,nnd.
1599	c02891	1.40mg	n.s.s.	17/20	1.00mg	40/50	2.00mg	37/50	
a	c02891	11.8mg	n.s.s.	0/20	1.00mg	0/50	2.00mg	1/50	Liv:hpa,hpc,nnd.
LEUPEPTIN ---									
1600	1432	59.6mg	n.s.s.	3/20	130.mg	7/25			Hosaka;gann,71,913-917;1980
a	1432	152.mg	n.s.s.	0/20	130.mg	1/25			
1601	1432	25.2mg	641.mg	4/23	120.mg	14/25			
a	1432	29.0mg	n.s.s.	15/23	120.mg	17/25			
LITHOCHOLIC ACID 434-13-9									
1602	c03861	111.mg	n.s.s.	6/20	52.5mg	20/50	105.mg	23/50	
a	c03861	392.mg	n.s.s.	0/20	52.5mg	1/50	105.mg	3/50	Liv:hpa,hpc,nnd. Lun:a/a,a/c.
b	c03861	357.mg	n.s.s.	0/20	52.5mg	1/50	105.mg	3/50	
1603	c03861	132.mg	n.s.s.	12/20	52.5mg	26/50	105.mg	20/50	
a	c03861	187.mg	n.s.s.	6/20	52.5mg	17/50	105.mg	9/50	Liv:hpa,hpc,nnd.
b	c03861	180.mg	n.s.s.	1/20	52.5mg	7/50	105.mg	5/50	Lun:a/a,a/c.
1604	c03861	129.mg	n.s.s.	14/20	106.mg	35/49	212.mg	35/50	
a	c03861	653.mg	n.s.s.	0/20	106.mg	2/49	212.mg	2/50	Liv:hpa,hpc,nnd.
1605	c03861	150.mg	n.s.s.	9/20	106.mg	26/50	212.mg	30/50	
a	c03861	778.mg	n.s.s.	0/20	106.mg	1/50	212.mg	3/50	Liv:hpa,hpc,nnd.
LUTEOSKYRIN 21884-44-6									
1606	1346m	24.0mg	n.s.s.	0/7	6.00mg	3/26			Uruguchi;fctx,10,193-207;1972
a	1346m	29.9mg	n.s.s.	0/7	6.00mg	2/26			
b	1346m	40.4mg	n.s.s.	0/7	6.00mg	1/26			
1607	1346m	7.71mg	45.5mg	0/10	1.67mg	2/18	5.00mg	11/24	(16.7mg 11/29)
a	1346m	42.0mg	n.s.s.	0/10	1.67mg	0/18	5.00mg	5/24	16.7mg 6/29

Spe	Strain	Site	Xpo+Xpt	Notes	TD50	2Tailpvl		
Sex	Route	Hist			DR	AnOp		
b	M	ddn	eat	liv	hpt	37m37 e	89.5mg * P<.08 +	
c	M	ddn	eat	liv	lcc	37m37 e	332.mg * P<.2 +	
d	M	ddn	eat	liv	akt	37m37 e	no dre P=1. +	
1608	M	ddn	eat	liv	lca	37m37 e	25.1mg P<.03 +	
a	M	ddn	eat	liv	hpt	37m37 e	74.3mg P<.2 +	
b	M	ddn	eat	liv	akt	37m37 e	113.mg P<.3 +	
1609	M	ddn	eat	liv	hpt	37m37 e	113.mg P<.3 +	
a	M	ddn	eat	liv	lca	37m37 e	231.mg P<.5 +	
LUTESTRAL					100ng.....1ug.....10.....100.....1mg.....10.....100.....1g.....10			
1610	M	f	c3h	eat	mam	tum	24m24 er	5.98mg P<.7 -
1611	M	f	crf	eat	mam	tum	24m24 er	no dre P=1. -
1612	M	m	crf	eat	mam	tum	24m24 r	1.76mg P<.0005
1613	M	f	r3m	eat	mam	tum	24m24 er	2.12mg P<.4 -
MALAOXON					100ng.....1ug.....10.....100.....1mg.....10.....100.....1g.....10			
1614	M	f	b6c	eat	T8A	MXB	24m24	no dre P=1. -
a	M	f	b6c	eat	liv	MXB	24m24	no dre P=1. -
b	M	f	b6c	eat	lun	MXB	24m24	2.76gm * P<.3
1615	M	m	b6c	eat	T8A	MXB	24m24	472.mg * P<.4 -
a	M	m	b6c	eat	liv	MXB	24m24	579.mg / P<.2
b	M	m	b6c	eat	lun	MXB	24m24	3.23gm * P<.8
1616	R	f	f34	eat	thy	MXA	24m24	#296.mg * P<.02 -
a	R	f	f34	eat	T8A	MXB	24m24	no dre P=1. -
b	R	f	f34	eat	liv	MXB	24m24	no dre P=1. -
1617	R	m	f34	eat	T8A	MXB	24m24	no dre P=1. -
a	R	m	f34	eat	liv	MXB	24m24	1.56gm * P<.3
MALATHION					100ng.....1ug.....10.....100.....1mg.....10.....100.....1g.....10			
1618	M	f	b6c	eat	T8A	MXB	80w94	no dre P=1. -
a	M	f	b6c	eat	liv	MXB	80w94	31.7gm * P<.3
b	M	f	b6c	eat	lun	MXB	80w94	no dre P=1. -
1619	M	m	b6c	eat	liv	nnd	80w94	#10.2gm * P<.04 -
a	M	m	b6c	eat	T8A	MXB	80w94	5.19gm * P<.3
b	M	m	b6c	eat	liv	MXB	80w94	4.40gm * P<.2
c	M	m	b6c	eat	lun	MXB	80w94	44.7gm * P<.8
1620	R	f	f34	eat	T8A	MXB	24m24	293.mg * P<.3 -
a	R	f	f34	eat	liv	MXB	24m24	no dre P=1. -
1621	R	m	f34	eat	adr	phe	24m24	#145.mg * P<.0005-
a	R	m	f34	eat	T8A	MXB	24m24	66.6mg * P<.002
b	R	m	f34	eat	liv	MXB	24m24	411.mg * P<.05
1622	R	f	osm	eat	T8A	MXB	19m25 v	434.mg * P<.2 -
a	R	f	osm	eat	liv	MXB	19m25 v	3.87gm * P<.2
1623	R	f	osm	eat	thy	MXA	19m25 v	#2.96gm * P<.03 -
1624	R	m	osm	eat	T8A	MXB	19m25 v	335.mg * P<.2 -
a	R	m	osm	eat	liv	MXB	19m25 v	3.07gm * P<.7
MALEIC HYDRAZIDE					100ng.....1ug.....10.....100.....1mg.....10.....100.....1g.....10			
1625	M	f	b6a	orl	liv	hpt	76w76 evx	2.35gm P<.3 -
a	M	f	b6a	orl	lun	ade	76w76 evx	38.7gm P<.1. -
b	M	f	b6a	orl	tba	mix	76w76 evx	932.mg P<.4 -
1626	M	m	b6a	orl	liv	hpt	76w76 evx	2.07gm P<.6 -
a	M	m	b6a	orl	lun	ade	76w76 evx	no dre P=1. -
b	M	m	b6a	orl	tba	mix	76w76 evx	11.9gm P<.1. -
1627	M	f	b6c	orl	liv	hpt	76w76 evx	no dre P=1. -
a	M	f	b6c	orl	lun	mix	76w76 evx	no dre P=1. -
b	M	f	b6c	orl	tba	mix	76w76 evx	no dre P=1. -
1628	M	m	b6c	orl	liv	hpt	76w76 evx	1.06gm P<.09 -
a	M	m	b6c	orl	lun	mix	76w76 evx	no dre P=1. -
b	M	m	b6c	orl	tba	mix	76w76 evx	679.mg P<.04 -
1629	R	f	nss	eat	liv	hpt	23m23 e	no dre P=1. -
a	R	f	nss	eat	tba	mix	23m23 e	3.72gm P<.8 -
1630	R	m	nss	eat	liv	hpt	23m23 e	no dre P=1. -
a	R	m	nss	eat	tba	mix	23m23 e	12.3gm P<.1. -
MANGANESE ETHYLENEBISTHIOCARBAMATE				1ug.....10.....100.....1mg.....10.....100.....1g.....10			
1631	M	f	b6a	orl	lun	ade	76w76 evx	no dre P=1. -
a	M	f	b6a	orl	liv	hpt	76w76 evx	no dre P=1. -
b	M	f	b6a	orl	tba	mix	76w76 evx	138.mg P<.7 -
1632	M	m	b6a	orl	lun	ade	76w76 evx	54.9mg P<.4 -
a	M	m	b6a	orl	liv	hpt	76w76 evx	no dre P=1. -
b	M	m	b6a	orl	tba	mix	76w76 evx	106.mg P<.7 -
1633	M	f	b6c	orl	liv	hpt	76w76 evx	no dre P=1. -
a	M	f	b6c	orl	lun	mix	76w76 evx	no dre P=1. -
b	M	f	b6c	orl	tba	tum	76w76 evx	no dre P=1. -
1634	M	m	b6c	orl	liv	hpt	76w76 evx	128.mg P<.3 -
a	M	m	b6c	orl	lun	ade	76w76 evx	128.mg P<.3 -
b	M	m	b6c	orl	tba	mix	76w76 evx	62.3mg P<.2 -
1635	R	b	mgr	gav	liv	tum	22m24 e	no dre P=1. -
a	R	b	mgr	gav	tba	mix	22m24 e	157.mg P<.02 +

RefNum	LoConf	UpConf	Cntrl	1Dose	1Inc	2Dose	2Inc	Citation or Pathology	Brkly Code	
b	1346n	34.0mg	n.s.s.	0/10	1.67mg	1/18	5.00mg	7/24	16.7mg	7/29
c	1346n	100.0mg	n.s.s.	0/10	1.67mg	0/18	5.00mg	1/24	16.7mg	2/29
d	1346n	108.0mg	n.s.s.	0/10	1.67mg	1/18	5.00mg	3/24	16.7mg	1/29
1608	1346n	11.3mg	n.s.s.	0/9	5.00mg		8/29			
a	1346n	22.5mg	n.s.s.	0/9	5.00mg		3/29			
b	1346n	27.9mg	n.s.s.	0/9	5.00mg		2/29			
1609	1346n	27.9mg	n.s.s.	0/10	5.00mg		2/29			
a	1346n	37.6mg	n.s.s.	0/10	5.00mg		1/29			
LUTESTRAL 8065-91-6										
1610	1175	.759mg	n.s.s.	54/92	1.04mg	19/30		Rudali;jnci,49,813-819;1972		
1611	1175	.487mg	n.s.s.	161/167p	1.04mg	28/31				
1612	1463	.851mg	4.52mg	0/76	.960mg	10/32		Rudali;gmcr,17,243-252;1975		
1613	1175	.531mg	n.s.s.	50/73	1.04mg	31/40		Rudali;jnci,49,813-819;1972		
MALADON (malathion-O-analog) 1634-78-2										
1614	c08628	265.0mg	n.s.s.	15/50	65.0mg	15/50	130.0mg	15/50		
a	c08628	263.0mg	n.s.s.	6/50	65.0mg	3/50	(130.0mg)	1/50	Liv:hpa,hpc,nnd.	
b	c08628	680.0mg	n.s.s.	0/50	65.0mg	1/50	130.0mg	1/50	Lun:a/a,a/c.	
1615	c08628	127.0mg	n.s.s.	23/50	59.4mg	18/50	119.0mg	26/50		
a	c08628	183.0mg	n.s.s.	12/50	59.4mg	5/50	119.0mg	17/50	Liv:hpa,hpc,nnd.	
b	c08628	315.0mg	n.s.s.	6/50	59.4mg	5/50	119.0mg	6/50	Lun:a/a,a/c.	
1616	c08628	120.0mg	n.s.s.	0/50	25.0mg	1/50	49.5mg	5/50	thy:cca,ccr.	S
a	c08628	41.9mg	n.s.s.	45/50	25.0mg	44/50	49.5mg	44/50		
b	c08628	n.s.s.	n.s.s.	0/50	25.0mg	3/50	49.5mg	0/50	Liv:hpa,hpc,nnd.	
1617	c08628	27.7mg	n.s.s.	44/50	20.0mg	43/50	40.0mg	40/50		
a	c08628	256.0mg	n.s.s.	0/50	20.0mg	0/50	40.0mg	1/50	Liv:hpa,hpc,nnd.	
MALATHION (c00215 is NCI TR# 24; c00216 is NCI TR# 192) 121-75-5										
1618	c00215	4.12gm	n.s.s.	1/10	884.0mg	5/50	1.75gm	5/50		
a	c00215	7.80gm	n.s.s.	0/10	884.0mg	0/50	1.75gm	2/50	Liv:hpa,hpc,nnd.	
b	c00215	n.s.s.	n.s.s.	0/10	884.0mg	0/50	1.75gm	0/50	Lun:a/a,a/c.	
1619	c00215	4.17gm	n.s.s.	0/10	816.0mg	0/50	1.62gm	6/50		S
a	c00215	1.66gm	n.s.s.	3/10	816.0mg	9/50	1.62gm	19/50		
b	c00215	1.74gm	n.s.s.	2/10	816.0mg	7/50	1.62gm	17/50	Liv:hpa,hpc,nnd.	
c	c00215	7.80gm	n.s.s.	0/10	816.0mg	1/50	1.62gm	1/50	Lun:a/a,a/c.	
1620	c00216	82.4mg	n.s.s.	43/50	97.2mg	45/50	194.0mg	45/50		
a	c00216	1.16gm	n.s.s.	2/50	97.2mg	0/50	194.0mg	1/50	Liv:hpa,hpc,nnd.	
1621	c00216	64.8mg	587.0mg	2/50	78.5mg	11/50	157.0mg	6/49		S
a	c00216	32.0mg	340.0mg	32/50	78.5mg	30/50	157.0mg	26/49		
b	c00216	101.0mg	n.s.s.	0/50	78.5mg	2/50	157.0mg	0/49	Liv:hpa,hpc,nnd.	
1622	c00215	175.0mg	n.s.s.	7/15	166.0mg	28/50	299.0mg	32/50		
a	c00215	1.17gm	n.s.s.	0/15	166.0mg	0/50	299.0mg	3/50	Liv:hpa,hpc,nnd.	
1623	c00215	1.02gm	n.s.s.	0/55p	166.0mg	0/50	299.0mg	4/50	thy:fca,fcc.	S
1624	c00215	139.0mg	n.s.s.	4/15	133.0mg	23/50	239.0mg	25/50		
a	c00215	851.0mg	n.s.s.	0/15	133.0mg	2/50	239.0mg	1/50	Liv:hpa,hpc,nnd.	
MALEIC HYDRAZIDE (1,2-dihydro-3,6-pyridazinedione) 123-33-1										
1625	1193	382.0mg	n.s.s.	0/17	414.0mg		1/16	Innes;ntis,1968/1969		
a	1193	431.0mg	n.s.s.	1/17	414.0mg		1/16			
b	1193	205.0mg	n.s.s.	2/17	414.0mg		4/16			
1626	1193	302.0mg	n.s.s.	1/18	385.0mg		2/17			
a	1193	721.0mg	n.s.s.	2/18	385.0mg		0/17			
b	1193	280.0mg	n.s.s.	3/18	385.0mg		3/17			
1627	1193	774.0mg	n.s.s.	0/16	414.0mg		0/17			
a	1193	774.0mg	n.s.s.	0/16	414.0mg		0/17			
b	1193	774.0mg	n.s.s.	0/16	414.0mg		0/17			
1628	1193	259.0mg	n.s.s.	0/16	385.0mg		2/16			
a	1193	678.0mg	n.s.s.	0/16	385.0mg		0/16			
b	1193	205.0mg	n.s.s.	0/16	385.0mg		3/16			
1629	1109	1.33gm	n.s.s.	0/9	500.0mg		0/14	Barnes;natu,180,62-64;1957		
a	1109	393.0mg	n.s.s.	2/9	500.0mg		4/14			
1630	1109	1.07gm	n.s.s.	0/8	400.0mg		0/14			
a	1109	467.0mg	n.s.s.	1/8	400.0mg		2/14			
MANGANESE ETHYLENEBISTHIOCARBAMATE (maneb) 12427-38-2										
1631	1214	25.6mg	n.s.s.	1/17	21.6mg		1/18	Innes;ntis,1968/1969		
a	1214	42.7mg	n.s.s.	0/17	21.6mg		0/18			
b	1214	15.5mg	n.s.s.	2/17	21.6mg		3/18			
1632	1214	11.5mg	n.s.s.	2/18	20.0mg		4/18			
a	1214	39.7mg	n.s.s.	1/18	20.0mg		0/18			
b	1214	12.4mg	n.s.s.	3/18	20.0mg		4/18			
1633	1214	40.3mg	n.s.s.	0/16	21.6mg		0/17			
a	1214	40.3mg	n.s.s.	0/16	21.6mg		0/17			
b	1214	40.3mg	n.s.s.	0/16	21.6mg		0/17			
1634	1214	20.9mg	n.s.s.	0/16	20.0mg		1/18			
a	1214	20.9mg	n.s.s.	0/16	20.0mg		1/18			
b	1214	15.3mg	n.s.s.	0/16	20.0mg		2/18			
1635	1426	109.0mg	n.s.s.	0/46	88.0mg		0/6	Andrianova;vpit,29,71-74;1970		
a	1426	36.3mg	n.s.s.	1/46	88.0mg		2/6			

Spe	Strain	Site	Xpo+Xpt	Notes	TD50	2Tailpvj
Sex	Route	Hist			DR	AuOp
MANNITOL NITROGEN MUSTARD				100ng...1ug...10...100...1mg...10...100...1g...10		
1636	R m b46	ivj	tba mix	12m24 es	>	3.11mg P<.5
a	R m b46	ivj	tba mal	12m24 es		3.85mg P<.5
b	R m b46	ivj	tba ben	12m24 es		23.5mg P<.9
MELPHALAN				100ng...1ug...10...100...1mg...10...100...1g...10		
1637	M f swi	ipj	lun mix	26w79 e	.	.165mg * P<.007 +
a	M f swi	ipj	agl ade	26w79 e	.	.617mg * P<.004
b	M f swi	ipj	--- lys	26w79 e	.	.702mg * P<.06
c	M f swi	ipj	adr fbs	26w79 e	.	1.26mg * P<.03
d	M f swi	ipj	liv lys	26w79 e	.	no dre P=1.
e	M f swi	ipj	tba mix	26w79 e	.	51.0ug * P<.0005
f	M f swi	ipj	tba mal	26w79 e	.	.104mg * P<.002
g	M f swi	ipj	tba ben	26w79 e	.	.365mg * P<.08
1638	M m swi	ipj	lun mix	26w77 e	.	.137mg P<.005 +
a	M m swi	ipj	--- lys	26w77 e	.	.302mg P<.02 +
b	M m swi	ipj	liv mix	26w77 e	.	no dre P=1.
c	M m swi	ipj	tba mix	26w77 e	.	91.4ug P<.02
d	M m swi	ipj	tba mal	26w77 e	.	.115mg P<.02
e	M m swi	ipj	tba ben	26w77 e	.	2.02mg P<.8
1639	R f cdr	ipj	per ear	26w78 e	.	.135mg * P<.0005+
a	R f cdr	ipj	pan adc	26w78 e	.	1.44mg * P<.02
b	R f cdr	ipj	lun a/a	26w78 e	.	1.44mg * P<.02
c	R f cdr	ipj	--- lys	26w78 e	.	1.54mg * P<.09
d	R f cdr	ipj	liv tum	26w78 e	.	no dre P=1.
e	R f cdr	ipj	tba mal	26w78 e	.	78.1ug * P<.0005
f	R f cdr	ipj	tba mix	26w78 e	.	.106mg * P<.07
g	R f cdr	ipj	tba ben	26w78 e	.	no dre P=1.
1640	R m cdr	ipj	per mix	26w67 e	.	71.9ug P<.0005+
a	R m cdr	ipj	--- lys	26w67 e	.	.359mg P<.003
b	R m cdr	ipj	liv tum	26w67 e	.	no dre P=1.
c	R m cdr	ipj	tba mix	26w67 e	.	23.6ug P<.0005
d	R m cdr	ipj	tba mal	26w67 e	.	47.0ug P<.0005
e	R m cdr	ipj	tba ben	26w67 e	.	.493mg P<.5
dl-MENTHOL				100ng...1ug...10...100...1mg...10...100...1g...10		
1641	M f b6c	eat	T8A MXB	24m24	>	no dre P=1. -
a	M f b6c	eat	liv MXB	24m24		5.19gm * P<.3
b	M f b6c	eat	lun MXB	24m24		3.17gm * P<.06
1642	M m b6c	eat	T8A MXB	24m24	>	2.75gm * P<.7 -
a	M m b6c	eat	liv MXB	24m24		1.96gm * P<.3
b	M m b6c	eat	lun MXB	24m24		no dre P=1.
1643	R f f34	eat	T8A MXB	24m24	>	no dre P=1. -
a	R f f34	eat	liv MXB	24m24		no dre P=1.
1644	R m f34	eat	T8A MXB	24m24	>	1.41gm * P<.7 -
a	R m f34	eat	liv MXB	24m24		5.69gm * P<.6
MER-25				100ng...1ug...10...100...1mg...10...100...1g...10		
1645	R f nsa	gav	mam tum	52w52 er	>	no dre P=1. -
2-MERCAPTOBENZOTHAZOLE				100ng...1ug...10...100...1mg...10...100...1g...10		
1646	M f b6a	orl	lun ade	76w76 evx	>	no dre P=1. -
a	M f b6a	orl	liv hpt	76w76 evx		no dre P=1. -
b	M f b6a	orl	tba mix	76w76 evx		no dre P=1. -
1647	M m b6a	orl	lun ade	76w76 evx	>	no dre P=1. -
a	M m b6a	orl	liv hpt	76w76 evx		no dre P=1. -
b	M m b6a	orl	tba mix	76w76 evx		105.mg P<.5 -
1648	M f b6c	orl	lun ade	76w76 evx	>	283.mg P<.3 -
a	M f b6c	orl	liv hpt	76w76 evx		no dre P=1. -
b	M f b6c	orl	tba mix	76w76 evx		283.mg P<.3 -
1649	M m b6c	orl	liv hpt	76w76 evx	.	56.2mg P<.02 -
a	M m b6c	orl	lun ade	76w76 evx	.	120.mg P<.1 -
b	M m b6c	orl	tba mix	76w76 evx	.	17.0mg P<.0005-
2-MERCAPTOBENZOTHAZOLE, ZINC				100ng...1ug...10...100...1mg...10...100...1g...10		
1650	M f b6a	orl	lun ade	76w76 evx	>	no dre P=1. -
a	M f b6a	orl	liv hpt	76w76 evx		no dre P=1. -
b	M f b6a	orl	tba mix	76w76 evx		no dre P=1. -
1651	M m b6a	orl	lun ade	76w76 evx	>	no dre P=1. -
a	M m b6a	orl	liv hpt	76w76 evx		no dre P=1. -
b	M m b6a	orl	tba mix	76w76 evx		no dre P=1. -
1652	M f b6c	orl	liv hpt	76w76 evx	>	no dre P=1. -
a	M f b6c	orl	lun mix	76w76 evx		no dre P=1. -
b	M f b6c	orl	tba mix	76w76 evx		2.79gm P<.3 -
1653	M m b6c	orl	liv hpt	76w76 evx	.	388.mg P<.004 -
a	M m b6c	orl	lun ade	76w76 evx	.	2.75gm P<.3 -
b	M m b6c	orl	tba mix	76w76 evx	.	319.mg P<.002 -
6-MERCAPTOPURINE				100ng...1ug...10...100...1mg...10...100...1g...10		
1654	R m b46	ivj	tba mix	12m24 es	>	58.1mg P<.9 -

RefNum	LoConf	UpConf	Cntrl	1Dose	1Inc	2Dose	2Inc	Citation or Pathology	Brkly Code
MANNITOL NITROGEN MUSTARD (Degranol) 576-68-1									
1636	1017	.583mg n.s.s.	7/65	.286mg	6/37			Schmahl;arzn,20,1461-1467;1970	
a	1017	.706mg n.s.s.	4/65	.286mg	4/37				
b	1017	1.05mg n.s.s.	3/65	.286mg	2/37				
MELPHALAN (L-sarcolysin) 148-82-3									
1637	1336n	61.7ug 4.11mg	20/154	.106mg	6/15	.212mg	3/8	Skipper;srfr;1976/Weisburger 1977/Prejean pers.com.	
a	1336n	.152mg 10.1mg	0/154	.106mg	1/15	.212mg	1/8		
b	1336n	.154mg n.s.s.	3/154	.106mg	0/15	.212mg	2/8		
c	1336n	.204mg n.s.s.	0/154	.106mg	0/15	.212mg	1/8		
d	1336n	97.5ug n.s.s.	1/154	.106mg	0/15	.212mg	0/8		
e	1336n	23.3ug .167mg	42/154	.106mg	10/15	.212mg	7/8		
f	1336n	43.4ug .617mg	29/154	.106mg	7/15	.212mg	5/8		
g	1336n	.100mg n.s.s.	13/154	.106mg	3/15	.212mg	2/8		
1638	1336m	54.6ug 1.57mg	9/101	.108mg	9/28				
a	1336m	94.4ug n.s.s.	2/101	.108mg	4/28				
b	1336m	.341mg n.s.s.	2/101	.108mg	0/28				
c	1336m	36.2ug n.s.s.	28/101	.108mg	15/28				
d	1336m	44.9ug n.s.s.	19/101	.108mg	12/28				
e	1336m	.140mg n.s.s.	9/101	.108mg	3/28				
1639	1336n	63.2ug .371mg	0/182	.129mg	8/16	.304mg	1/6		
a	1336n	.234mg n.s.s.	0/182	.129mg	0/16	.304mg	1/6		
b	1336n	.234mg n.s.s.	0/182	.129mg	0/16	.304mg	1/6		
c	1336n	.236mg n.s.s.	1/182	.129mg	0/16	.304mg	1/6		
d	1336n	.112mg n.s.s.	0/182	.129mg	0/16	.304mg	0/6		
e	1336n	35.2ug .310mg	44/182	.129mg	13/16	.304mg	3/6		
f	1336n	33.1ug n.s.s.	103/182	.129mg	14/16	.304mg	4/6		
g	1336n	.319mg n.s.s.	59/182	.129mg	1/16	.304mg	1/6		
1640	1336n	32.0ug .212mg	0/177	.149mg	8/18				
a	1336n	88.1ug 4.84mg	0/177	.149mg	2/18				
b	1336n	.229mg n.s.s.	0/177	.149mg	0/18				
c	1336n	9.76ug 77.1ug	59/177	.149mg	16/18				
d	1336n	20.7ug .171mg	32/177	.149mg	12/18				
e	1336n	74.1ug n.s.s.	27/177	.149mg	4/18				
dl-MENTHOL (NCI uses CAS# 89-78-1) 15356-70-4									
1641	c50000	723.mg n.s.s.	30/50	257.mg	20/50	515.mg	24/50		
a	c50000	1.54gm n.s.s.	1/50	257.mg	3/50	515.mg	3/50	liv:hpa,hpc,nnd.	
b	c50000	1.22gm n.s.s.	1/50	257.mg	3/50	515.mg	5/50	lun:a/a,a/c.	
1642	c50000	357.mg n.s.s.	29/50	238.mg	28/50	475.mg	33/50		
a	c50000	601.mg n.s.s.	8/50	238.mg	8/50	475.mg	14/50	liv:hpa,hpc,nnd.	
b	c50000	1.10gm n.s.s.	6/50	238.mg	7/50	475.mg	6/50	lun:a/a,a/c.	
1643	c50000	462.mg n.s.s.	41/50	184.mg	36/50	368.mg	32/50		
a	c50000	2.11gm n.s.s.	1/50	184.mg	1/50	368.mg	1/50	liv:hpa,hpc,nnd.	
1644	c50000	200.mg n.s.s.	32/50	147.mg	41/50	294.mg	37/50		
a	c50000	932.mg n.s.s.	1/50	147.mg	3/50	294.mg	2/50	liv:hpa,hpc,nnd.	
MER-25 67-98-1									
1645	481	13.9mg n.s.s.	0/9	12.2mg	0/22			Shay;mpoc,305-318;1962	
2-MERCAPTOBENZOTHAZOLE (Captax, rotax) 149-30-4									
1646	1302	49.3mg n.s.s.	1/17	44.3mg	1/17			Innes;ntis,1968/1969	
a	1302	82.8mg n.s.s.	0/17	44.3mg	0/17				
b	1302	54.8mg n.s.s.	2/17	44.3mg	1/17				
1647	1302	38.5mg n.s.s.	2/18	41.2mg	2/18				
a	1302	48.7mg n.s.s.	1/18	41.2mg	1/18				
b	1302	21.0mg n.s.s.	3/18	41.2mg	5/18				
1648	1302	46.1mg n.s.s.	0/16	44.3mg	1/18				
a	1302	87.7mg n.s.s.	0/16	44.3mg	0/18				
b	1302	46.1mg n.s.s.	0/16	44.3mg	1/18				
1649	1302	19.3mg n.s.s.	0/16	41.2mg	4/17				
a	1302	29.5mg n.s.s.	0/16	41.2mg	2/17				
b	1302	7.99mg 44.6mg	0/16	41.2mg	10/17				
2-MERCAPTOBENZOTHAZOLE, ZINC (zetax) 155-04-4									
1650	1300	515.mg n.s.s.	1/17	462.mg	1/17			Innes;ntis,1968/1969	
a	1300	864.mg n.s.s.	0/17	462.mg	0/17				
b	1300	572.mg n.s.s.	2/17	462.mg	1/17				
1651	1300	564.mg n.s.s.	2/18	430.mg	1/18				
a	1300	851.mg n.s.s.	1/18	430.mg	0/18				
b	1300	603.mg n.s.s.	3/18	430.mg	1/18				
1652	1300	864.mg n.s.s.	0/16	462.mg	0/17				
a	1300	864.mg n.s.s.	0/16	462.mg	0/17				
b	1300	454.mg n.s.s.	0/16	462.mg	1/17				
1653	1300	157.mg 2.37gm	0/16	430.mg	6/18				
a	1300	448.mg n.s.s.	0/16	430.mg	1/18				
b	1300	136.mg 1.30gm	0/16	430.mg	7/18				
6-MERCAPTOPYRIMINE 50-44-2									
1654	1017	2.51mg n.s.s.	7/65	1.18mg	3/25			Schmahl;arzn,20,1461-1467;1970	

Spe	Strain	Site	Xpo+Xpt	Notes	TD50	2Tailpvl
Sex	Route	Hist			DR	AuOp
MERCURIC CHLORIDE 100ng...1ug...10...100...1mg...10...100...1g...10						
1655	M f	cd1 wat	---	lkm 27m27 e	.	+
a	M f	cd1 wat	lun tum	27m27 e	.	.
b	M f	cd1 wat	tba mix	27m27 e	.	.
c	M f	cd1 wat	tba mal	27m27 e	.	.
1656	M m	cd1 wat	lun tum	28m28 e	.	>
a	M m	cd1 wat	tba mix	28m28 e	.	.
b	M m	cd1 wat	tba mal	28m28 e	.	.
MERCURY (II) ACETATE 100ng...1ug...10...100...1mg...10...100...1g...10						
1657	M f	b6a orl	liv hpt	76w76 evx	.	>
a	M f	b6a orl	lun ade	76w76 evx	.	.
b	M f	b6a orl	tba mix	76w76 evx	.	.
1658	M m	b6a orl	lun ade	76w76 evx	.	>
a	M m	b6a orl	liv hpt	76w76 evx	.	.
b	M m	b6a orl	tba mix	76w76 evx	.	.
1659	M f	b6c orl	liv hpt	76w76 evx	.	>
a	M f	b6c orl	lun ade	76w76 evx	.	.
b	M f	b6c orl	tba mix	76w76 evx	.	.
1660	M m	b6c orl	lun ade	76w76 evx	.	.
a	M m	b6c orl	liv hpt	76w76 evx	.	.
b	M m	b6c orl	tba mix	76w76 evx	.	.
MERCURY METHYLCHLORIDE 100ng...1ug...10...100...1mg...10...100...1g...10						
1661	M f	cd1 wat	lun tum	33m35 esv	.	>
a	M f	cd1 wat	tba mix	33m35 esv	.	.
b	M f	cd1 wat	tba mal	33m35 esv	.	.
1662	M m	cd1 wat	lun tum	31m37 esv	.	>
a	M m	cd1 wat	tba mix	31m37 esv	.	.
b	M m	cd1 wat	tba mal	31m37 esv	.	.
MESTRANOL** 100ng...1ug...10...100...1mg...10...100...1g...10						
1663	M f	cfl eat	liv hct	78w78 or	.	>
1664	M m	cfl eat	liv hct	78w78 or	.	>
1665	M f	crf eat	mam tum	24m24 r	.	>
1666	M f	r3m eat	mam tum	24m24 r	.	>
METEPA 100ng...1ug...10...100...1mg...10...100...1g...10						
1667	R m	she gav	---	lyk 60w60 e	.	.
METHIMAZOLE 100ng...1ug...10...100...1mg...10...100...1g...10						
1668	R f	hrl eat	thy foe	24m24 es	.	.
a	R f	hrl eat	thy fdc	24m24 es	.	.
1669	R m	hrl eat	thy foe	24m24 es	.	.
a	R m	hrl eat	thy fdc	24m24 es	.	.
METHOTREXATE 100ng...1ug...10...100...1mg...10...100...1g...10						
1670	M f	syg eat	liv hpc	23m24 es	.	>
a	M f	syg eat	liv mix	23m24 es	.	.
b	M f	syg eat	lun tum	23m24 es	.	.
c	M f	syg eat	tba mix	23m24 es	.	.
1671	M m	syg eat	liv tum	25m27 es	.	>
a	M m	syg eat	lun tum	25m27 es	.	.
b	M m	syg eat	tba mix	25m27 es	.	.
1672	M f	swi eat	liv hpc	28m28	.	>
a	M f	swi eat	lun mix	28m28	.	.
b	M f	swi eat	tba mix	28m28	.	.
1673	M m	swi eat	liv ham	27m28 a	.	>
a	M m	swi eat	lun mix	27m28 a	.	.
b	M m	swi eat	tba mix	27m28 a	.	.
1674	R m	b46 ivj	tba ben	12m24 es	.	.
a	R m	b46 ivj	tba mix	12m24 es	.	.
b	R m	b46 ivj	tba mal	12m24 es	.	.
1675	R f	sda ipj	tba mal	24m24 e	.	>
1676	R m	sda ipj	liv hae	24m24 e	.	>
a	R m	sda ipj	tba mal	24m24 e	.	.
2-METHOXY-3-AMINODIBENZOFURAN 100ng...1ug...10...100...1mg...10...100...1g...10						
1677	R f	fis eat	ubl mix	75w75 e	.	.
a	R f	fis eat	ubl tcc	75w75 e	.	.
b	R f	fis eat	auc sqc	75w75 e	.	.
c	R f	fis eat	agl adc	75w75 e	.	.
d	R f	fis eat	liv tum	75w75 e	.	.
e	R f	fis eat	tba mal	75w75 e	.	.
1678	R m	fis eat	ubl mix	75w75 e	.	.
a	R m	fis eat	ubl tcc	75w75 e	.	.
b	R m	fis eat	auc sqc	75w75 e	.	.
c	R m	fis eat	liv tum	75w75 e	.	.
d	R m	fis eat	tba mal	75w75 e	.	.

RefNum	LoConf	UpConf	Cntrl	1Dose	1Inc	2Dose	2Inc	Citation or Pathology				Brkly Code	
MERCURIC CHLORIDE 7487-94-7													
1655	1395	1.55mg	105.0mg	3/47	1.00mg	11/41		Schroeder; jnut, 105, 452-458; 1975					
a	1395	3.36mg	n.s.s.	9/47	1.00mg	7/41							
b	1395	.973mg	n.s.s.	14/47	1.00mg	21/41							
c	1395	1.95mg	n.s.s.	4/47	1.00mg	9/41							
1656	1395	2.25mg	n.s.s.	5/38	.833mg	9/48							
a	1395	1.09mg	n.s.s.	11/38	.833mg	21/48							
b	1395	7.43mg	n.s.s.	2/38	.833mg	1/48							
MERCURY (II) ACETATE (phenylmercuric acetate) 62-38-4													
1657	1286	6.34mg	n.s.s.	0/17	3.39mg	0/17		Innes; nti, 1968/1969					
a	1286	6.34mg	n.s.s.	1/17	3.39mg	0/17							
b	1286	6.34mg	n.s.s.	2/17	3.39mg	0/17							
1658	1286	3.89mg	n.s.s.	2/18	3.16mg	1/17							
a	1286	5.91mg	n.s.s.	1/18	3.16mg	0/17							
b	1286	3.04mg	n.s.s.	3/18	3.16mg	2/17							
1659	1286	3.53mg	n.s.s.	0/16	3.39mg	1/18							
a	1286	3.53mg	n.s.s.	0/16	3.39mg	1/18							
b	1286	2.59mg	n.s.s.	0/16	3.39mg	2/18							
1660	1286	2.27mg	n.s.s.	0/16	3.16mg	2/17							
a	1286	5.91mg	n.s.s.	0/16	3.16mg	0/17							
b	1286	2.27mg	n.s.s.	0/16	3.16mg	2/17							
MERCURY METHYLCHLORIDE (methylmercuric acetate) 115-09-3													
1661	1395	3.28mg	n.s.s.	9/47	.200mg	3/31	.253mg	3/40	Schroeder; jnut, 105, 452-458; 1975				
a	1395	.446mg	n.s.s.	14/47	.200mg	12/31	(.253mg	4/40)					
b	1395	4.64mg	n.s.s.	4/47	.200mg	2/31	.253mg	0/40					
1662	1395	1.57mg	n.s.s.	5/38	.167mg	4/25	.208mg	3/32					
a	1395	.727mg	n.s.s.	11/38	.167mg	9/25	.208mg	10/32					
b	1395	1.53mg	n.s.s.	2/38	.167mg	3/25	.208mg	2/32					
MESTRANOL** 72-33-3													
1663	1453	.551mg	n.s.s.	1/40	5.00ug	0/40	30.0ug	1/40	60.0ug	1/39	.200mg	1/39	Barrows; jtxe, 3, 219-230; 1977
1664	1453	.335mg	n.s.s.	2/40	5.00ug	4/40	30.0ug	4/40	60.0ug	0/40	.200mg	5/40	
1665	1174	60.3ug	n.s.s.	145/160	.130mg	30/34		Rudali; reec, 16, 425-429; 1971					
1666	1174	12.2ug	n.s.s.	12/15	13.0ug	26/40							
METEPA 57-39-6													
1667	179	1.35mg	n.s.s.	0/20	.625mg	0/20	2.50mg	3/20	Gaines; buho, 34, 317-320; 1966				
METHIMAZOLE 60-56-0													
1668	180	.834mg	3.46mg	0/50	.250mg	0/25	1.50mg	14/25	(9.00mg	12/25)	Owen; fctx, 11, 649-653; 1973		
a	180	2.86mg	150.0mg	0/50	.250mg	0/25	1.50mg	3/25	(9.00mg	2/25)			
1669	180	5.00mg	1.85mg	1/50	.200mg	1/25	1.20mg	17/25	(7.20mg	5/25)			
a	180	11.5mg	n.s.s.	1/50	.200mg	0/25	1.20mg	2/25	7.20mg	3/25			
METHOTREXATE 59-05-2													
1670	1324	8.32mg	n.s.s.	0/49	.261mg	0/42	.523mg	0/42	1.05mg	1/39	Rustia; txap, 26, 329-338; 1973		
a	1324	9.14mg	n.s.s.	1/49	.261mg	0/42	.523mg	0/42	1.05mg	1/39			
b	1324	1.30mg	n.s.s.	0/49	.261mg	0/42	.523mg	0/42	1.05mg	0/39			
c	1324	6.01mg	n.s.s.	7/49	.261mg	4/42	.523mg	2/42	1.05mg	3/39			
1671	1324	1.38mg	n.s.s.	0/49	.230mg	0/42	.460mg	0/42	.920mg	0/40			
a	1324	1.38mg	n.s.s.	0/49	.230mg	0/42	.460mg	0/42	.920mg	0/40			
b	1324	12.8mg	n.s.s.	8/49	.230mg	1/42	.460mg	0/42	.920mg	1/40			
1672	1324	10.6mg	n.s.s.	0/70	.195mg	0/36	.325mg	0/36	.520mg	1/42	.650mg	0/48	
a	1324	3.57mg	n.s.s.	14/70	.195mg	8/36	.325mg	8/36	.520mg	6/42	.650mg	8/48	
b	1324	1.35mg	n.s.s.	34/70	.195mg	21/36	.325mg	13/36	.520mg	19/42	.650mg	26/48	
1673	1324	3.20mg	n.s.s.	6/70	.180mg	2/36	.300mg	6/36	.480mg	1/42	(.600mg	0/48)	
a	1324	3.45mg	n.s.s.	13/70	.180mg	6/36	.300mg	3/36	.480mg	9/42	.600mg	6/48	
b	1324	1.99mg	n.s.s.	29/70	.180mg	15/36	.300mg	17/36	.480mg	18/42	.600mg	15/48	
1674	1017	.111mg	n.s.s.	3/65	71.4ug	4/26		Schmahl; arzn, 20, 1461-1467; 1970					
a	1017	90.2ug	n.s.s.	7/65	71.4ug	6/26							
b	1017	.181mg	n.s.s.	4/65	71.4ug	2/26							
1675	1134	.406mg	n.s.s.	3/33	89.3ug	1/31		Schmahl; zkk0, 86, 77-84; 1976					
1676	1134	.552mg	n.s.s.	1/36	89.3ug	0/30							
a	1134	.552mg	n.s.s.	1/36	89.3ug	0/30							
2-METHOXY-3-AMINODIBENZOFURAN 5834-17-3													
1677	183n	10.2mg	115.0mg	0/12	50.0mg	6/12		Radowski; jnci, 39, 1069-1080; 1967					
a	183n	15.0mg	n.s.s.	0/12	50.0mg	4/12							
b	183n	15.0mg	n.s.s.	0/12	50.0mg	4/12							
c	183n	33.3mg	n.s.s.	0/12	50.0mg	1/12							
d	183n	64.3mg	n.s.s.	0/12	50.0mg	0/12							
e	183n	12.3mg	265.0mg	0/12	50.0mg	5/12							
1678	183n	9.84mg	212.0mg	0/12	40.0mg	5/12							
a	183n	19.2mg	n.s.s.	0/12	40.0mg	2/12							
b	183n	19.2mg	n.s.s.	0/12	40.0mg	2/12							
c	183n	51.4mg	n.s.s.	0/12	40.0mg	0/12							
d	183n	19.2mg	n.s.s.	0/12	40.0mg	2/12							

Spe	Strain	Site	Xpo+Xpt	Notes	TD50	2Tailpvi
Sex	Route	Hist			DR	AuOp
1679	R f sda eat ubl mix 75w75 e			. *	43.9mg	P<.02 +
a	R f sda eat auc sqc 75w75 e				61.9mg	P<.04 +
b	R f sda eat apl adc 75w75 e				61.9mg	P<.04 +
c	R f sda eat ubl tcc 75w75 e				205.3mg	P<.3 +
d	R f sda eat liv tum 75w75 e				no dre	P=1.
e	R f sda eat tba mal 75w75 e				25.7mg	P<.002
1680	R m sda eat kid sqc 75w75 e			>	164.3mg	P<.3 +
a	R m sda eat ubl tpp 75w75 e				164.3mg	P<.3 +
b	R m sda eat liv tum 75w75 e				no dre	P=1.
c	R m sda eat tba mal 75w75 e				78.2mg	P<.09
1681	R f wis eat ubl mix 75w75 e			. *	43.9mg	P<.02 +
a	R f wis eat apl adc 75w75 e				97.7mg	P<.09 +
b	R f wis eat ubl tcc 75w75 e				97.7mg	P<.09 +
c	R f wis eat liv cye 75w75 e				205.3mg	P<.3
d	R f wis eat tba mal 75w75 e				43.9mg	P<.02
1682	R m wis eat ubl mix 84w84 e			<	noTD50	P<.004 +
a	R m wis eat tba mal 84w84 e				noTD50	P<.004 +
b	R m wis eat tba ben 84w84 e				53.3mg	P<.07
1683	R m wis eat ubl mix 75w75 e			. *	35.2mg	P<.02 +
a	R m wis eat auc sqc 75w75 e				78.2mg	P<.09 +
b	R m wis eat ubl tcc 75w75 e				78.2mg	P<.09 +
c	R m wis eat kid sqc 75w75 e				164.3mg	P<.3 +
d	R m wis eat liv tum 75w75 e				no dre	P=1.
e	R m wis eat tba mal 75w75 e				26.4mg	P<.005
METHOXYCHLOR 100ng...1ug...10...100...1mg...10...100...1g...10						
1684	M f b6c eat TBA MXB 78w92 v			>	no dre	P=1. -
a	M f b6c eat liv MXB 78w92 v				no dre	P=1.
b	M f b6c eat lun MXB 78w92 v				no dre	P=1.
1685	M m b6c eat TBA MXB 78w91 v			>	no dre	P=1. -
a	M m b6c eat liv MXB 78w91 v				no dre	P=1.
b	M m b6c eat lun MXB 78w91 v				no dre	P=1.
1686	R f osm eat TBA MXB 18m26 dv			>	no dre	P=1. -
a	R f osm eat liv MXB 18m26 dv				no dre	P=1.
1687	R f osm eat liv tum 27m27			>	no dre	P=1.
a	R f osm eat tba mix 27m27				no dre	P=1.
1688	R f osm eat liv tum 24m24			>	no dre	P=1. -
a	R f osm eat tba ben 24m24				no dre	P=1. -
b	R f osm eat tba mal 24m24				no dre	P=1. -
1689	R m osm eat TBA MXB 18m26 dv			>	no dre	P=1. -
a	R m osm eat liv MXB 18m26 dv				no dre	P=1.
1690	R m osm eat liv tum 27m27			>	no dre	P=1.
a	R m osm eat tba mix 27m27				234.3mg	P<.08
1691	R m osm eat liv tum 24m24			>	no dre	P=1. -
a	R m osm eat tba ben 24m24				31.8mg	P<.1 -
b	R m osm eat tba mal 24m24				no dre	P=1. -
METHOXYPHENYLACETIC ACID 100ng...1ug...10...100...1mg...10...100...1g...10						
1692	M f b6a orl lun ade 76w76 evx			>	236.3mg	P<.4 -
a	M f b6a orl liv hpt 76w76 evx				no dre	P=1. -
b	M f b6a orl tba mix 76w76 evx				227.3mg	P<.5 -
1693	M m b6a orl lun ade 76w76 evx			>	157.3mg	P<.3 -
a	M m b6a orl liv hpt 76w76 evx				3.62gm	P<.1 -
b	M m b6a orl tba mix 76w76 evx				139.3mg	P<.4 -
1694	M f b6c orl lun ade 76w76 evx			>	244.3mg	P<.2 -
a	M f b6c orl liv hpt 76w76 evx				no dre	P=1. -
b	M f b6c orl tba mix 76w76 evx				157.3mg	P<.05 -
1695	M m b6c orl --- rta 76w76 evx			. +	82.1mg	P<.009 -
a	M m b6c orl liv hpt 76w76 evx				227.3mg	P<.2 -
b	M m b6c orl lun mix 76w76 evx				no dre	P=1. -
c	M m b6c orl tba mix 76w76 evx				54.2mg	P<.002 -
METHYL CARBAZATE 100ng...1ug...10...100...1mg...10...100...1g...10						
1696	R f wis eat tba tum 24m24			>	no dre	P=1. -
1697	R m wis eat tba tum 24m24			>	no dre	P=1. -
1-METHYL-1,4-DIHYDRO-7-[2-(5-NITROFURYL)VINYL]-4-OXO-1,8-NAPHTHYRIDINE-3-CARBOXYLATE, POTASSIUM ...1g...10						
1698	M b icr eat lun ade 54w54 s			. +	8.03mg	P<.0005+
a	M b icr eat for sqc 54w54 s				10.3mg	P<.002 +
b	M b icr eat lun car 54w54 s				21.9mg	P<.03 +
c	M b icr eat thm lyk 54w54 s				26.5mg	P<.05 +
N-METHYL-N,4-DINITROSOANILINE 100ng...1ug...10...100...1mg...10...100...1g...10						
1699	R m cbr ipj pec mix 26w86 e			>	1.30mg	P<.2 +
a	R m cbr ipj liv hpt 26w86 e				1.50mg	P<.3 -
N-METHYL-N-FORMYLHYDRAZINE 100ng...1ug...10...100...1mg...10...100...1g...10						
1700	H f syg wat --- mhs 24m24 e			. +	4.71mg	P<.0005+
a	H f syg wat liv mix 24m24 e				11.3mg	P<.0005+

RefNum	LoConf	UpConf	Cntrl	1Dose	1Inc	2Dose	2Inc	Citation or Pathology	Brkly Code
1679	183m	15.0mg	n.s.s.	0/12	50.0mg	4/12			
a	183m	18.6mg	n.s.s.	0/12	50.0mg	3/12			
b	183m	18.6mg	n.s.s.	0/12	50.0mg	3/12			
c	183m	33.3mg	n.s.s.	0/12	50.0mg	1/12			
d	183m	64.3mg	n.s.s.	0/12	50.0mg	0/12			
e	183m	10.2mg	115.mg	0/12	50.0mg	6/12			
1680	183m	26.6mg	n.s.s.	0/12	40.0mg	1/12			
a	183m	26.6mg	n.s.s.	0/12	40.0mg	1/12			
b	183m	51.4mg	n.s.s.	0/12	40.0mg	0/12			
c	183m	19.2mg	n.s.s.	0/12	40.0mg	2/12			
1681	183n	15.0mg	n.s.s.	0/12	50.0mg	4/12			
a	183n	23.9mg	n.s.s.	0/12	50.0mg	2/12			
b	183n	23.9mg	n.s.s.	0/12	50.0mg	2/12			
c	183n	33.3mg	n.s.s.	0/12	50.0mg	1/12			
d	183n	15.0mg	n.s.s.	0/12	50.0mg	4/12			
1682	1420	n.s.s.	17.9mg	0/7	34.3mg	6/6		Hackmann;zkko,61,45-54;1956	
a	1420	n.s.s.	17.9mg	0/7	34.3mg	6/6			
b	1420	13.0mg	n.s.s.	0/9	34.3mg	2/8			
1683	183n	12.0mg	n.s.s.	0/12	40.0mg	4/12		Radomski;Jnci,39,1069-1080;1967	
a	183n	19.2mg	n.s.s.	0/12	40.0mg	2/12			
b	183n	19.2mg	n.s.s.	0/12	40.0mg	2/12			
c	183n	26.6mg	n.s.s.	0/12	40.0mg	1/12			
d	183n	51.4mg	n.s.s.	0/12	40.0mg	0/12			
e	183n	9.84mg	212.mg	0/12	40.0mg	5/12			
METHOXYCHLOR 72-43-5									
1684	c00497	828.mg	n.s.s.	3/20	109.mg	6/50	217.mg	3/50	
a	c00497	1.41gm	n.s.s.	0/20	109.mg	1/50	217.mg	0/50	liv:hpa,hpc,nnd.
b	c00497	n.s.s.	n.s.s.	0/20	109.mg	0/50	217.mg	0/50	Lun:a/a,a/c.
1685	c00497	466.mg	n.s.s.	3/20	178.mg	5/50	352.mg	9/50	
a	c00497	664.mg	n.s.s.	3/20	178.mg	3/50	352.mg	6/50	liv:hpa,hpc,nnd.
b	c00497	n.s.s.	n.s.s.	0/20	178.mg	0/50	352.mg	0/50	Lun:a/a,a/c.
1686	c00497	63.8mg	n.s.s.	12/20	26.4mg	30/50	48.2mg	30/50	
a	c00497	329.mg	n.s.s.	1/20	26.4mg	1/50	48.2mg	2/50	liv:hpa,hpc,nnd.
1687	21	391.mg	n.s.s.	0/30	50.0mg	0/30			Deichmann;txap,11,88-103;1967
a	21	181.mg	n.s.s.	13/30	50.0mg	6/30			
1688	84a	24.7mg	n.s.s.	1/30	4.00mg	0/30			Radomski;txap,7,652-656;1965
a	84a	7.36mg	n.s.s.	6/30	4.00mg	6/30			
b	84a	8.82mg	n.s.s.	6/30	4.00mg	5/30			
1689	c00497	44.6mg	n.s.s.	11/20	12.6mg	23/50	23.8mg	21/50	
a	c00497	145.mg	n.s.s.	0/20	12.6mg	2/50	23.8mg	0/50	liv:hpa,hpc,nnd.
1690	21	313.mg	n.s.s.	0/30	40.0mg	0/30			Deichmann;txap,11,88-103;1967
a	21	76.3mg	n.s.s.	1/30	40.0mg	5/30			
1691	84a	19.8mg	n.s.s.	0/30	3.20mg	0/30			Radomski;txap,7,652-656;1965
a	84a	7.81mg	n.s.s.	0/30	3.20mg	2/30			
b	84a	19.8mg	n.s.s.	3/30	3.20mg	0/30			
METHOXYPHENYLACETIC ACID 1701-77-5									
1692	1312	51.4mg	n.s.s.	1/17	78.4mg	3/18			Innes;ntis,1968/1969
a	1312	155.mg	n.s.s.	0/17	78.4mg	0/18			
b	1312	45.2mg	n.s.s.	2/17	78.4mg	4/18			
1693	1312	35.9mg	n.s.s.	2/18	73.0mg	4/16			
a	1312	n.s.s.	n.s.s.	1/18	73.0mg	1/16			
b	1312	31.5mg	n.s.s.	3/18	73.0mg	5/16			
1694	1312	59.8mg	n.s.s.	0/16	78.4mg	2/18			
a	1312	155.mg	n.s.s.	0/16	78.4mg	0/18			
b	1312	47.5mg	n.s.s.	0/16	78.4mg	3/18			
1695	1312	30.9mg	1.80gm	0/16	73.0mg	5/18			
a	1312	55.7mg	n.s.s.	0/16	73.0mg	2/18			
b	1312	145.mg	n.s.s.	0/16	73.0mg	0/18			
c	1312	23.1mg	221.mg	0/16	73.0mg	7/18			
METHYL CARBAZATE 6294-89-9									
1696	1389	8.26mg	n.s.s.	16/24	2.50mg	11/24	5.00mg	15/24	10.0mg
1697	1389	17.5mg	n.s.s.	7/24	2.50mg	6/24	5.00mg	8/24	10.0mg
1-METHYL-1,4-DIHYDRO-7-[2-(5-NITROFURYL)VINYL]-4-OXO-1,8-NAPHTHYRIDINE-3-CARBOXYLATE, POTASSIUM									
1698	211	4.40mg	19.9mg	0/30	12.5mg	15/60			Matsuzaki;gann,66,259-267;1975
a	211	5.33mg	34.8mg	0/30	12.5mg	12/60			
b	211	8.94mg	n.s.s.	0/30	12.5mg	6/60			
c	211	10.1mg	n.s.s.	0/30	12.5mg	5/60			
N-METHYL-N,4-DINITROSOANILINE 99-80-9									
1699	1258	.319mg	n.s.s.	0/10	.429mg	2/14			Boylard;ejca,4,233-239;1968
a	1258	.244mg	n.s.s.	0/7	.429mg	1/8			
N-METHYL-N-FORMYLHYDRAZINE 758-17-8									
1700	716	2.73mg	8.73mg	0/13	10.6mg	24/31			Toth;zkko,93,109-121;1979
a	716	6.50mg	21.9mg	0/79	10.6mg	19/41			

Spe	Strain	Site	Xpo+Xpt	Notes	TD50	2Tailpvl
Sex	Route	Hist			DR	AuOp
b	H f	syg wat	liv lcc 24m24	e	25.1mg	P<.0005
c	H f	syg wat	liv hpt 24m24	e	28.3mg	P<.0005
d	H f	syg wat	gal mix 24m24	e	29.1mg	P<.5 +
e	H f	syg wat	lun tum 24m24	e	no dre	P=1.
f	H f	syg wat	tba mix 24m24	e	6.04mg	P<.0005
1701	H m	syg wat	liv mix 24m24	e	7.55mg	P<.0005+
a	H m	syg wat	--- mha 24m24	e	12.7mg	* P<.002 +
b	H m	syg wat	liv hpt 24m24	e	13.3mg	P<.0005
c	H m	syg wat	bil mix 24m24	e	19.7mg	P<.007 +
d	H m	syg wat	gal mix 24m24	e	25.3mg	* P<.002 +
e	H m	syg wat	liv lcc 24m24	e	30.0mg	P<.0005
f	H m	syg wat	gal ppa 24m24	e	42.5mg	P<.01
g	H m	syg wat	lun tum 24m24	e	no dre	P=1.
h	H m	syg wat	tba mix 24m24	e	4.89mg	P<.0005
1702	M f	swa wat	lun mix 65w73	ees	6.44mg \	P<.0005+
a	M f	swa wat	liv mix 65w73	ees	10.4mg *	P<.0005+
b	M f	swa wat	liv hpt 65w73	ees	19.5mg *	P<.0005+
c	M f	swa wat	liv lcc 65w73	ees	19.9mg \	P<.0005+
d	M f	swa wat	gal ade 65w73	ees	31.5mg *	P<.008 +
1703	M f	swa wat	lun mix 23m23	ees	.921mg *	P<.0005+
a	M f	swa wat	blv mix 23m23	ees	6.04mg *	P<.0005+
b	M f	swa wat	gal mix 23m23	ees	57.9mg *	P<.02
c	M f	swa wat	liv bhp 23m23	ees	24.7mg *	P<.2
1704	M f	swa wat	lun mix 92w92	ees	2.16mg	P<.0005+
a	M f	swa wat	liv mix 92w92	ees	8.66mg	P<.0005+
b	M f	swa wat	blv mix 92w92	ees	12.2mg	P<.0005+
c	M f	swa wat	liv bhp 92w92	ees	17.5mg	P<.0005
d	M f	swa wat	liv lcc 92w92	ees	22.4mg	P<.0005
e	M f	swa wat	gal mix 92w92	ees	31.3mg	P<.003 +
f	M f	swa wat	gal ade 92w92	ees	39.7mg	P<.006
1705	M m	swa wat	liv mix 65w72	ees	16.8mg \	P<.0005+
a	M m	swa wat	bil mix 65w72	ees	36.2mg *	P<.003 +
b	M m	swa wat	gal ade 65w72	ees	38.0mg \	P<.002 +
c	M m	swa wat	lun mix 65w72	ees	14.2mg \	P<.02 +
1706	M m	swa wat	lun mix 22m23	ees	1.72mg *	P<.0005+
a	M m	swa wat	blv mix 22m23	ees	3.47mg \	P<.0005+
b	M m	swa wat	liv mix 22m23	ees	5.47mg *	P<.0005+
c	M m	swa wat	gal mix 22m23	ees	9.10mg *	P<.0005+
d	M m	swa wat	gal ade 22m23	ees	9.88mg *	P<.0005
1707	M m	swa wat	liv mix 82w82	ees	1.03mg	P<.0005+
a	M m	swa wat	lun mix 82w82	ees	1.87mg	P<.0005+
b	M m	swa wat	bil cho 82w82	ees	12.4mg	P<.0005+
c	M m	swa wat	gal ade 82w82	ees	15.2mg	P<.0005+
d	M m	swa wat	sev ade 82w82	ees	20.7mg	P<.009 -
METHYL METHANESULFONATE <u>100ng...1ug.....10.....100.....1mg.....10.....100.....1g.....10</u>						
1708	M m	rfa wat	lun ade 24m24	e	31.8mg	P<.0005+
a	M m	rfa wat	thm lym 24m24	e	185.mg	P<.02 +
b	M m	rfa wat	liv tum 24m24	e	3.98gm	P<.9 -
N-METHYL-N'-NITRO-N-NITROSOGUANIDINE <u>....1ug.....10.....100.....1mg.....10.....100.....1g.....10</u>						
1709	R m	bfa wat	stg ivc 52w52	er	no dre	P=1. -
a	R m	bfa wat	stg pvc 52w52	er	no dre	P=1. -
1710	R f	wis wat	bil cye 35w60	er	.178mg	P<.0005
a	R f	wis wat	stg cnd 35w60	er	2.38mg	P<.2 +
1711	R m	wis wat	stg cnd 35w60	er	2.09mg	P<.2 +
a	R m	wis wat	bil cye 35w60	er	no dre	P=1.
1712	R m	wis wat	stg mix 77w77	e	.693mg	P<.0005+
a	R m	wis wat	stg ade 77w77	e	1.13mg	P<.003 +
b	R m	wis wat	stg adc 77w77	e	3.06mg	P<.06 +
c	R m	wis wat	liv hpa 77w77	e	14.3mg	P<.4
1713	R m	wis wat	stg adc 30w65	er	.523mg	P<.002 +
1714	R m	waf wat	stg ivc 52w52	er	6.75mg	P<.2
1715	R m	war wat	stg ivc 52w52	er	1.03mg	P<.0005+
a	R m	war wat	stg pvc 52w52	er	2.72mg	P<.0005+
2-METHYL-1-NITROANTHRAQUINONE <u>100ng...1ug.....10.....100.....1mg.....10.....100.....1g.....10</u>						
1716	M f	b6c eat	sub hes 49w49		1.88mg *	P<.0005c
a	M f	b6c eat	TBA MXB 49w49		1.76mg *	P<.0005
b	M f	b6c eat	liv MXB 49w49		no dre	P=1.
c	M f	b6c eat	lun MXB 49w49		97.3mg *	P<.06
1717	M m	b6c eat	sub hes 46w46		1.34mg /	P<.0005c
a	M m	b6c eat	TBA MXB 46w46		1.02mg /	P<.0005
b	M m	b6c eat	liv MXB 46w46		no dre	P=1.
c	M m	b6c eat	lun MXB 46w46		45.5mg *	P<.08
1718	R f	f34 eat	MXB MXB 18m25	s	59.6mg /	P<.0005
a	R f	f34 eat	MXB MXB 18m25	s	70.3mg /	P<.0005
b	R f	f34 eat	sub fib 18m25	s	131.mg /	P<.0005a
c	R f	f34 eat	ubl MXA 18m25	s	224.mg *	P<.01 a
d	R f	f34 eat	pit ade 18m25	s	63.4mg *	P<.04

RefNum	LoConf	UpConf	Cntrl	1Dose	1Inc	2Dose	2Inc	Citation or Pathology	Brkly Code
b	716	12.2mg	64.5mg	0/79	10.6mg	10/41			
c	716	13.3mg	77.2mg	0/79	10.6mg	9/41			
d	716	8.75mg	n.s.s.	0/1	10.6mg	3/14			
e	716	92.8mg	n.s.s.	0/100	10.6mg	0/44			
f	716	3.63mg	11.3mg	13/100	10.6mg	32/44			
1701	716	4.57mg	13.6mg	0/65	9.36mg	24/43			
a	716	6.13mg	41.1mg	0/16	9.36mg	10/26			
b	716	7.35mg	27.4mg	0/65	9.36mg	16/43			
c	716	8.45mg	218.mg	0/16	9.36mg	7/26			
d	716	11.4mg	89.1mg	0/34	9.36mg	8/37			
e	716	13.5mg	88.4mg	0/65	9.36mg	8/43			
f	716	16.1mg	1.95gm	0/34	9.36mg	5/37			
g	716	85.4mg	n.s.s.	0/88	9.36mg	0/46			
h	716	3.04mg	8.58mg	7/88	9.36mg	34/46			
1702	1110	3.77mg	13.3mg	15/100	15.6mg	30/48	(31.2mg 9/37)	Toth;jnci,60,201-204;1978	
a	1110	6.44mg	18.8mg	0/33	15.6mg	22/43	31.2mg 3/11		
b	1110	10.7mg	47.2mg	0/33	15.6mg	12/43	31.2mg 3/11		
c	1110	9.67mg	59.0mg	0/33	15.6mg	10/43	(31.2mg 0/11)		
d	1110	11.9mg	510.mg	0/29	15.6mg	4/23	31.2mg 1/5		
1703	1265	.636mg	1.37mg	15/99	2.00mg	39/49	4.00mg 47/50	Toth;nplm,27,25-31;1980	
a	1265	3.49mg	14.5mg	8/95	2.00mg	10/44	4.00mg 20/48		
b	1265	17.5mg	n.s.s.	0/82	2.00mg	0/44	4.00mg 3/48		
c	1265	4.02mg	n.s.s.	0/32	2.00mg	1/10	4.00mg 0/5		
1704	1314	1.32mg	3.73mg	15/99	7.80mg	43/49		Toth;myco,68,121-128;1979	
a	1314	4.95mg	17.1mg	0/68	7.80mg	18/47			
b	1314	6.17mg	39.7mg	8/99	7.80mg	17/49			
c	1314	8.50mg	45.0mg	0/68	7.80mg	10/47			
d	1314	10.1mg	66.6mg	0/68	7.80mg	8/47			
e	1314	11.9mg	164.mg	0/63	7.80mg	5/40			
f	1314	13.7mg	449.mg	0/63	7.80mg	4/40			
1705	1110	8.19mg	48.2mg	1/81	13.0mg	11/47	(26.0mg 3/26)	Toth;jnci,60,201-204;1978	
a	1110	13.8mg	203.mg	0/75	13.0mg	5/29	26.0mg 0/8		
b	1110	14.4mg	186.mg	0/81	13.0mg	5/47	(26.0mg 0/26)		
c	1110	6.00mg	n.s.s.	22/98	13.0mg	20/47	(26.0mg 4/26)		
1706	1265	1.12mg	3.09mg	22/98	1.67mg	36/49	3.33mg 31/46	Toth;nplm,27,25-31;1980	
a	1265	1.64mg	14.5mg	5/78	1.67mg	13/42	(3.33mg 7/36)		
b	1265	3.10mg	12.2mg	2/78	1.67mg	6/42	3.33mg 14/36		
c	1265	4.90mg	20.0mg	0/90	1.67mg	6/46	3.33mg 8/43		
d	1265	5.21mg	22.8mg	0/90	1.67mg	6/46	3.33mg 7/43		
1707	1314	.527mg	1.99mg	1/69	6.50mg	28/30		Toth;myco,68,121-128;1979	
a	1314	1.07mg	3.78mg	22/88	6.50mg	34/41			
b	1314	5.05mg	44.5mg	0/69	6.50mg	6/30			
c	1314	5.75mg	64.6mg	0/69	6.50mg	5/30			
d	1314	6.27mg	618.mg	0/51	6.50mg	3/24			
METHYL METHANESULFONATE (MMS) 66-27-3									
1708	195	16.0mg	113.mg	63/162	33.3mg	33/47		Clapp;scie,161,913-914;1968	
a	195	67.5mg	n.s.s.	6/162	33.3mg	7/47			
b	195	160.mg	n.s.s.	6/162	33.3mg	2/47			
N-METHYL-N'-NITRO-N-NITROSOGUANIDINE (MNNG) 70-25-7									
1709	196	10.7mg	n.s.s.	0/20	4.15mg	0/50		Bralow;onco,27,168-180;1973	
a	196	10.7mg	n.s.s.	0/20	4.15mg	0/50			
1710	1105	73.1ug	.411mg	0/5	2.33mg	19/20		Tahara;zkko,100,1-12;1981	
a	1105	.821mg	n.s.s.	0/5	2.33mg	4/20			
1711	1105	.510mg	n.s.s.	0/5	2.04mg	2/10			
a	1105	1.40mg	n.s.s.	0/5	2.04mg	0/10			
1712	199	.289mg	2.05mg	0/6	3.30mg	10/12		Sugimura;canr,30,455-465;1970	
a	199	.480mg	5.31mg	0/6	3.30mg	8/12			
b	199	1.04mg	n.s.s.	0/6	3.30mg	4/12			
c	199	2.32mg	n.s.s.	0/6	3.30mg	1/12			
1713	435	.186mg	2.54mg	0/10	1.92mg	5/8		Matsukura;jnci,61,141-143;1978	
1714	196	1.66mg	n.s.s.	0/16	4.15mg	2/20		Bralow;onco,27,168-180;1973	
1715	196	.684mg	1.63mg	0/40	4.15mg	37/74			
a	196	1.54mg	5.91mg	0/40	4.15mg	17/74			
2-METHYL-1-NITROANTHRAQUINONE 129-15-7									
1716	c01923	1.12mg	3.17mg	0/50	32.0mg	29/50	64.0mg 38/50		
a	c01923	1.07mg	2.85mg	10/50	32.0mg	34/50	64.0mg 44/50		
b	c01923	n.s.s.	n.s.s.	1/50	32.0mg	0/50	64.0mg 0/50		liv:hpa,hpc,nnd.
c	c01923	15.9mg	n.s.s.	3/50	32.0mg	0/50	64.0mg 1/50		lun:a/s,s/c.
1717	c01923	.780mg	2.31mg	0/50	29.5mg	25/50	59.0mg 36/50		
a	c01923	.621mg	1.65mg	22/50	29.5mg	42/50	59.0mg 46/50		
b	c01923	n.s.s.	n.s.s.	8/50	29.5mg	0/50	59.0mg 0/50		liv:hpa,hpc,nnd.
c	c01923	7.41mg	n.s.s.	10/50	29.5mg	1/50	59.0mg 0/50		lun:a/s,s/c.
1718	c01923	36.0mg	119.mg	1/50	21.0mg	4/50	43.0mg 21/50	liv:hpc,nnd; sto:sgc; sub:fib; ubl:ppn,arn,ppp. T	
a	c01923	41.1mg	150.mg	1/50	21.0mg	3/50	43.0mg 19/50	sto:sgc; sub:fib; ubl:ppn,arn,ppp. A	
b	c01923	66.1mg	403.mg	1/50	21.0mg	0/50	43.0mg 13/50		
c	c01923	96.4mg	28.3gm	0/50	21.0mg	3/50	43.0mg 4/50		ubl:ppn,arn,ppp.
d	c01923	27.4mg	n.s.s.	17/50	21.0mg	26/50	43.0mg 25/50		S

Spe	Strain	Site	Xpo+Xpt	Notes	TD50	2Tailpvl
Sex	Route	Hist			DR	AuOp
e	R f	f34 eat	liv MXA	18m25 s	324.mg *	P<.02 c
f	R f	f34 eat	sto sqc	18m25 s	507.mg *	P<.03 s
g	R f	f34 eat	liv hpc	18m25 s	547.mg *	P<.04 c
h	R f	f34 eat	TBA MXB	18m25 s	47.1mg *	P<.08
i	R f	f34 eat	liv MXB	18m25 s	324.mg *	P<.02
1719	R m	f34 eat	MXB MXB	18m25	19.7mg /	P<.0005
a	R m	f34 eat	sub fib	18m25	25.8mg /	P<.0005a
b	R m	f34 eat	liv MXA	18m25	48.8mg *	P<.0005c
c	R m	f34 eat	liv hpc	18m25	89.2mg *	P<.005 c
d	R m	f34 eat	liv nnd	18m25	133.mg *	P<.004
e	R m	f34 eat	TBA MXB	18m25	31.9mg *	P<.05
f	R m	f34 eat	liv MXB	18m25	48.8mg *	P<.0005
4-METHYL-1-[(5-NITROFURFURYLIDENE)AMINO]-2-IMIDAZOLIDINONE.....100.....1mg.....10.....100.....1g.....10						
1720	R f	sda eat	mgl adc	46w66 e	5.34mg	P<.0005+
a	R f	sda eat	liv tum	46w66 e	no dre	P=1.
b	R f	sda eat	tba mix	46w66 e	5.59mg	P<.0005
4-(4-N-METHYL-N-NITROSAMINOSTYRYL)QUINOLINE.1ug.....10.....100.....1mg.....10.....100.....1g.....10						
1721	R f	fis eat	liv hnd	34w52	.468mg	P<.0005+
1722	R m	fis eat	liv hnd	34w52	1.38mg	P<.04 +
a	R m	fis eat	liv car	34w52	4.37mg	P<.3 +
N-METHYL-N-NITROSOBENZAMIDE 100ng.....1ug.....10.....100.....1mg.....10.....100.....1g.....10						
1723	R f	mrw wat	liv tum	12m30	no dre	P=1. -
a	R f	mrw wat	tba mix	12m30	11.2mg	P<.4 +
1724	R m	mrw wat	for mix	12m30	3.23mg	P<.0005+
a	R m	mrw wat	for sqp	12m30	7.73mg	P<.002
b	R m	mrw wat	for sqc	12m30	9.66mg	P<.003
c	R m	mrw wat	liv tum	12m30	no dre	P=1. -
d	R m	mrw wat	tba mix	12m30	2.49mg	P<.02
N-(N-METHYL-N-NITROSO-CARBOXYL)-L-ORNITHINE.1ug.....10.....100.....1mg.....10.....100.....1g.....10						
1725	R f	wal ipj	kid epn	26w52 es	.633mg	P<.0005+
a	R f	wal ipj	kid mnp	26w52 es	.633mg	P<.0005+
b	R f	wal ipj	ski neo	26w52 es	1.42mg	P<.002 +
c	R f	wal ipj	pan aca	26w52 es	11.0mg	P<.3 +
d	R f	wal ipj	mam mix	26w52 es	no dre	P=1. +
1726	R m	wal ipj	kid epn	26w52 es	1.04mg	P<.02 +
a	R m	wal ipj	ski neo	26w52 es	1.04mg	P<.02 +
b	R m	wal ipj	kid mnp	26w52 es	1.57mg	P<.06 +
c	R m	wal ipj	pan mix	26w52 es	5.25mg	P<.3 +
d	R m	wal ipj	pan adc	26w52 es	11.0mg	P<.5 +
e	R m	wal ipj	zym car	26w52 es	11.8mg	P<.5 +
R(-)-2-METHYL-N-NITROSOPIPERIDINE 100ng.....1ug.....10.....100.....1mg.....10.....100.....1g.....10						
1727	R b	sda wat	nol epd	24m24	22.1mg	P<.0005+
a	R b	sda wat	liv hpc	24m24	108.mg	P<.04
b	R b	sda wat	tba mal	24m24	20.4mg	P<.0005+
S(+)-2-METHYL-N-NITROSOPIPERIDINE 100ng.....1ug.....10.....100.....1mg.....10.....100.....1g.....10						
1728	R b	sda wat	mix epd	24m24	34.5mg	P<.0005+
a	R b	sda wat	liv mix	24m24	49.4mg	P<.003
b	R b	sda wat	liv lcc	24m24	61.2mg	P<.007
c	R b	sda wat	tba mal	24m24	13.2mg	P<.0005+
METHYL PARATHION 100ng.....1ug.....10.....100.....1mg.....10.....100.....1g.....10						
1729	M f	b6c eat	TBA MXB	24m24	no dre	P=1. -
a	M f	b6c eat	liv MXB	24m24	no dre	P=1.
b	M f	b6c eat	liv MXB	24m24	125.mg *	P<.5
1730	M m	b6c eat	TBA MXB	24m24 v	no dre	P=1. -
a	M m	b6c eat	liv MXB	24m24 v	no dre	P=1.
b	M m	b6c eat	liv MXB	24m24 v	58.1mg *	P<.5
1731	R f	f34 eat	TBA MXB	24m24 s	no dre	P=1. -
a	R f	f34 eat	liv MXB	24m24 s	no dre	P=1.
1732	R m	f34 eat	TBA MXB	24m24	no dre	P=1. -
a	R m	f34 eat	liv MXB	24m24	no dre	P=1.
(N-6)-METHYLADENINE 100ng.....1ug.....10.....100.....1mg.....10.....100.....1g.....10						
1733	M f	scd wat	liv tum	6m24 s	no dre	P=1. -
a	M f	scd wat	liv hct	6m24 s	no dre	P=1. -
1734	M m	scd wat	liv hct	6m25 s	no dre	P=1. -
a	M m	scd wat	liv tum	6m25 s	no dre	P=1. -
(N-6)-METHYLADENOSINE 100ng.....1ug.....10.....100.....1mg.....10.....100.....1g.....10						
1735	M f	scd wat	liv mix	8m27 s	364.mg	P<.9 -
a	M f	scd wat	liv tum	8m27 s	no dre	P=1. -
1736	M m	scd wat	liv tum	8m27 s	55.6mg	P<.6 -
a	M m	scd wat	liv mix	8m27 s	108.mg	P<.8 -

RefNum	LoConf	UpConf	Cntrl	1Dose	1Inc	2Dose	2Inc	Citation or Pathology	Brkly Code
e	c01923	123.mg n.s.s.	0/50	21.0mg	1/50	43.0mg	4/50		
f	c01923	154.mg n.s.s.	0/50	21.0mg	0/50	43.0mg	3/50		liv:hpc,nnd.
g	c01923	165.mg n.s.s.	0/50	21.0mg	0/50	43.0mg	3/50		
h	c01923	18.6mg n.s.s.	38/50	21.0mg	43/50	43.0mg	44/50		
i	c01923	123.mg n.s.s.	0/50	21.0mg	1/50	43.0mg	4/50		liv:hpa,hpc,nnd.
1719	c01923	13.1mg 35.5mg	4/49	16.8mg	17/50	34.4mg	38/50		liv:hpc,nnd; sub:fib. T
a	c01923	16.8mg 47.4mg	3/49	16.8mg	10/50	34.4mg	34/50		
b	c01923	28.0mg 130.mg	1/49	16.8mg	7/50	34.4mg	15/50		liv:hpc,nnd.
c	c01923	43.8mg 879.mg	1/49	16.8mg	5/50	34.4mg	9/50		
d	c01923	60.2mg 779.mg	0/49	16.8mg	2/50	34.4mg	6/50		S
e	c01923	13.6mg n.s.s.	32/49	16.8mg	41/50	34.4mg	47/50		
f	c01923	28.0mg 130.mg	1/49	16.8mg	7/50	34.4mg	15/50		liv:hpa,hpc,nnd.
4-METHYL-1-[(5-NITROFURFURYLIDENE)AMINO]-2-IMIDAZOLIDINONE 21638-36-8									
1720	200a	3.04mg 10.5mg	0/25	17.4mg	19/32			Cohen;jnci,51,403-417;1973	
a	200a	46.3mg n.s.s.	0/25	17.4mg	0/32				
b	200a	3.11mg 12.4mg	1/25	17.4mg	19/32				
4-(4-N-METHYL-N-NITROSAMINOSTYRYL)QUINOLINE 16699-10-8									
1721	1162	.217mg 1.32mg	0/20	1.63mg	9/20			Yamamoto;jnci,51,1313-1315;1973	
1722	1162	.416mg n.s.s.	0/20	1.31mg	3/20				
a	1162	.711mg n.s.s.	0/20	1.31mg	1/20				
N-METHYL-N-NITROSOBENZAMIDE 63412-06-6									
1723	1246	22.0mg n.s.s.	0/25	3.59mg	0/19			Bulay;jnci,62,1523-1528;1979	
a	1246	2.67mg n.s.s.	12/25	3.59mg	12/19				
1724	1246	1.55mg 8.10mg	0/22	3.14mg	11/17				
a	1246	3.12mg 31.1mg	0/22	3.14mg	6/17				
b	1246	3.64mg 56.4mg	0/22	3.14mg	5/17				
c	1246	17.2mg n.s.s.	0/22	3.14mg	0/17				
d	1246	.856mg n.s.s.	12/22	3.14mg	15/17				
N-(N-METHYL-N-NITROSOCARBAMOYL)-L-ORNITHINE (nitrosoaree amino acid) ---									
1725	1317	.271mg 1.81mg	0/14	5.12mg	9/12			Longnecker;jept,4,117-129;1980	
a	1317	.271mg 1.81mg	0/14	5.12mg	9/12				
b	1317	.565mg 6.13mg	0/14	5.12mg	6/13				
c	1317	1.78mg n.s.s.	0/14	5.12mg	1/13				
d	1317	1.88mg n.s.s.	5/14	5.12mg	3/15				
1726	1317	.452mg n.s.s.	0/4	5.12mg	8/14				
a	1317	.452mg n.s.s.	0/4	5.12mg	8/14				
b	1317	.628mg n.s.s.	0/4	5.12mg	6/14				
c	1317	1.29mg n.s.s.	0/4	5.12mg	2/13				
d	1317	1.78mg n.s.s.	0/4	5.12mg	1/13				
e	1317	1.93mg n.s.s.	0/4	5.12mg	1/14				
R(-)-2-METHYL-N-NITROSOPIPERIDINE 14026-03-0									
1727	1418	10.8mg 54.7mg	0/20	25.7mg	11/20			Wiessler;zkk,79,118-122;1973	
a	1418	32.7mg n.s.s.	0/20	25.7mg	3/20				
b	1418	9.83mg 61.1mg	1/20	25.7mg	12/20				
S(+)-2-METHYL-N-NITROSOPIPERIDINE 36702-44-0									
1728	1418	15.4mg 109.mg	0/20	25.7mg	8/20			Wiessler;zkk,79,118-122;1973	
a	1418	20.0mg 258.mg	0/20	25.7mg	6/20				
b	1418	23.1mg 706.mg	0/20	25.7mg	5/20				
c	1418	6.62mg 31.9mg	1/20	25.7mg	15/20				
METHYL PARATHION 298-00-0									
1729	c02971	7.79mg n.s.s.	14/20	8.10mg	30/50 (16.2mg	20/50)			
a	c02971	58.5mg n.s.s.	1/20	8.10mg	4/50	16.2mg	2/50		liv:hpa,hpc,nnd.
b	c02971	47.3mg n.s.s.	0/20	8.10mg	3/50	16.2mg	2/50		lun:a/a,a/c.
1730	c02971	10.0mg n.s.s.	13/20	4.20mg	31/50	9.20mg	28/50		
a	c02971	8.86mg n.s.s.	10/20	4.20mg	14/50 (9.20mg	12/50)			liv:hpa,hpc,nnd.
b	c02971	13.9mg n.s.s.	1/20	4.20mg	10/50	9.20mg	8/50		lun:a/a,a/c.
1731	c02971	1.49mg n.s.s.	18/20	1.00mg	33/50	2.00mg	20/50		
a	c02971	7.80mg n.s.s.	2/20	1.00mg	5/50	2.00mg	0/50		liv:hpa,hpc,nnd.
1732	c02971	1.52mg n.s.s.	16/20	.800mg	37/50	1.60mg	32/50		
a	c02971	19.7mg n.s.s.	2/20	.800mg	0/50	1.60mg	0/50		liv:hpa,hpc,nnd.
(N-6)-METHYLADENINE ---									
1733	1255	6.08mg n.s.s.	3/16	4.33mg	3/17			Anderson;jcn,24,319-322;1979	
a	1255	15.2mg n.s.s.	1/16	4.33mg	0/17				
1734	1255	5.70mg n.s.s.	5/21	3.52mg	3/17				
a	1255	6.92mg n.s.s.	4/21	3.52mg	2/17				
(N-6)-METHYLADENOSINE ---									
1735	1255	16.9mg n.s.s.	1/16	9.76mg	1/12			Anderson;jcn,24,319-322;1979	
a	1255	14.1mg n.s.s.	3/16	9.76mg	2/12				
1736	1255	8.65mg n.s.s.	4/21	7.89mg	4/14				
a	1255	9.22mg n.s.s.	5/21	7.89mg	4/14				

Spe	Strain	Site	Xpo+Xpt	Notes	TD50	2Tailpvl
Sex	Route	Hist			DR	AuOp
METHYLAZOXYMETHANOL ACETATE AND CYCASIN MIXTURE.....10.....100.....1mg.....10.....100.....1g.....10						
1737	P b rhe ipj	liv hpc	8y9	euw (+)	72.2ug	P<.0005+
a	P b rhe ipj	kid car	8y9	euw	.521mg	P<.05 +
b	P b rhe ipj	esq sqc	8y9	euw	.521mg	P<.05 +
c	P b rhe ipj	smi adc	8y9	euw	.521mg	P<.05 +
d	P b rhe ipj	tba mal	8y9	euw	77.0ug	P<.002
1738	P b rhe eat	kid adc	14y14	emuw *	25.3mg	P<.06 +
a	P b rhe eat	liv hpc	14y14	emuw	25.3mg	P<.06 +
b	P b rhe eat	kid car	14y14	emuw	25.3mg	P<.06 +
c	P b rhe eat	pen adc	14y14	emuw	25.3mg	P<.06 +
d	P b rhe eat	bil adc	14y14	emuw	31.9mg	P<.3 +
e	P b rhe eat	tba mal	14y14	emuw	16.4mg	P<.3
3-METHYLCHOLANTHRENE 100ng.....1ug.....10.....100.....1mg.....10.....100.....1g.....10						
1739	R f nas gav	mem tum	52w52	er	.506mg	P<.0005+
1740	R f wis gav	mgl adc	52w52	m	1.25mg	P<.0005+
1741	R f wis gav	mem tum	52w52	r	.669mg	P<.0005+
1742	R f wis gav	mgl adc	26w52	r	.202mg	P<.0005+
1743	R f wis gav	mgl adc	39w52	r	.304mg	P<.0005+
1744	R f wis gav	mgl adc	52w52	r	.764mg	P<.0005+
1745	R f wis gav	mgl adc	52w52	r	.506mg	P<.0005+
1746	R f wis gav	mgl adc	52w52	r	noTD50	P<.0005+
1747	R f wis gav	mgl adc	52w52	r	.714mg	P<.0005+
1748	R f wis gav	mgl adc	52w52	r	.689mg	P<.0005+
1749	R f wis gav	mgl adc	52w52	r	.590mg	P<.0005+
4,4'-METHYLENE-BIS(2-CHLOROANILINE)1ug.....10.....100.....1mg.....10.....100.....1g.....10						
1750	D f beg eat	ubl ptc	9y9	emv	2.12mg	P<.003 +
a	D f beg eat	liv hnd	9y9	emv	3.72mg	P<.02 +
b	D f beg eat	mgl mix	9y9	emv	no dre	P=1. -
1751	R f cdr eat	lun adc	67w67	ef	42.3mg	P<.003 +
a	R f cdr eat	mgl adc	67w67	ef	42.3mg	P<.003 +
b	R f cdr eat	liv hpa	67w67	ef	142. mg	P<.1 -
c	R f cdr eat	liv hpc	67w67	ef	291. mg	P<.3 -
1752	R f cdr eat	lun adc	24m24	e	34.7mg	P<.0005+
a	R f cdr eat	liv hpc	24m24	e	467. mg	P<.04 -
b	R f cdr eat	liv hpa	24m24	e	708. mg	P<.1 -
c	R f cdr eat	liv cho	24m24	e	1.43gm	P<.3 -
1753	R m cdr eat	lun neo	18m24	es	20.8mg *	P<.0005+
a	R m cdr eat	lun mix	18m24	es	29.2mg *	P<.0005+
b	R m cdr eat	mgl adc	18m24	es	87.6mg *	P<.0005+
c	R m cdr eat	liv hpc	18m24	es	92.2mg Z	P<.0005+
d	R m cdr eat	zym car	18m24	es	107. mg *	P<.0005+
e	R m cdr eat	--- ker	18m24	es	144. mg Z	P<.01
f	R m cdr eat	ski sqc	18m24	es	286. mg *	P<.2
g	R m cdr eat	tba mix	18m24	es	10.4mg *	P<.0005
1754	R m cdr eat	lun neo	18m24	efs	35.1mg *	P<.0005+
a	R m cdr eat	lun mix	18m24	efs	60.9mg *	P<.0005+
b	R m cdr eat	zym car	18m24	efs	112. mg *	P<.0005+
c	R m cdr eat	liv hpc	18m24	efs	124. mg Z	P<.0005+
d	R m cdr eat	mgl adc	18m24	efs	162. mg *	P<.006 +
e	R m cdr eat	--- hes	18m24	efs	138. mg *	P<.02 +
f	R m cdr eat	ski sqc	18m24	efs	263. mg *	P<.03
g	R m cdr eat	tba mix	18m24	efs	14.8mg *	P<.0005
1755	R m cdr eat	liv hpc	67w67	ef	15.3mg	P<.0005+
a	R m cdr eat	liv hpa	67w67	ef	41.8mg	P<.007 +
b	R m cdr eat	lun adc	67w67	ef	41.8mg	P<.007 +
1756	R m cdr eat	lun adc	24m24	e	42.3mg	P<.0005+
a	R m cdr eat	liv hpc	24m24	e	388. mg	P<.04 -
b	R m cdr eat	liv hpa	24m24	e	388. mg	P<.04 -
1757	R f wi2 eat	liv mix	16m28	e	15.8mg	P<.0005+
a	R f wi2 eat	mgl mix	16m28	e	51.4mg	P<.003
b	R f wi2 eat	lun mix	16m28	e	104. mg	P<.005 +
c	R f wi2 eat	tba mix	16m28	e	11.6mg	P<.0005+
1758	R m wi2 eat	liv mix	16m29	e	10.8mg	P<.0005+
a	R m wi2 eat	lun mix	16m29	e	59.5mg	P<.0005+
b	R m wi2 eat	tba mix	16m29	e	9.09mg	P<.0005+
4,4'-METHYLENE-BIS(2-CHLOROANILINE).2HCL.....1ug.....10.....100.....1mg.....10.....100.....1g.....10						
1759	M f chi eat	liv hpt	77w90		66.6mg /	P<.0005+
a	M f chi eat	liv mix	77w90		66.6mg /	P<.0005+
b	M f chi eat	lun mix	77w90		556. mg *	P<.4 -
c	M f chi eat	tba mix	77w90		52.8mg /	P<.0005
1760	M m chi eat	lun mix	77w94		342. mg *	P<.2 -
a	M m chi eat	liv mix	77w94		471. mg *	P<.4
b	M m chi eat	tba mix	77w94		97.9mg *	P<.02
1761	R m cdr eat	liv mix	77w98		70.1mg *	P<.2
a	R m cdr eat	tba mix	77w98		33.4mg *	P<.5

CARCINOGENIC POTENCY DATABASE

RefNum	LoConf	UpConf	Cntrl	1Dose	1Inc	2Dose	2Inc	Citation or Pathology	Brkly Code	
METHYLAZOXYMETHANOL ACETATE AND CYCASIN MIXTURE (CAS# 592-61-1 and 14901-08-7) mixture										
1737	2000	20.0ug	.403mg	0/32	.910mg	4/5		Adanson;ossc,129-156;1982/Sieber	pers.comm.	
a	2000	84.0ug	n.s.s.	0/32	.910mg	1/5				
b	2000	84.0ug	n.s.s.	0/32	.910mg	1/5				
c	2000	84.0ug	n.s.s.	0/32	.910mg	1/5				
d	2000	20.3ug	.693mg	3/32	.910mg	4/5				
1738	2000m	4.10mg	n.s.s.	0/32	11.1mg	1/7				
a	2000m	4.10mg	n.s.s.	0/32	11.1mg	1/7				
b	2000m	4.10mg	n.s.s.	0/32	11.1mg	1/7				
c	2000m	4.10mg	n.s.s.	0/32	11.1mg	1/7				
d	2000m	4.23mg	n.s.s.	1/32	11.1mg	1/7				
e	2000m	3.01mg	n.s.s.	3/32	11.1mg	2/7				
3-METHYLCHOLANTHRENE 56-49-5										
1739	481	.261mg	1.08mg	0/9	4.90mg	17/21		Shay;mpec,305-318;1962		
1740	1130m	.808mg	2.04mg	1/54	8.57mg	37/53		Gruenstein;cnr,24,1656-1658;1964		
1741	1130n	.363mg	1.39mg	1/54	4.90mg	18/25				
1742	188bm	91.4ug	.485mg	0/20	2.46mg	14/16		Shay;jnci,27,503-513;1961		
1743	188bn	.137mg	.727mg	0/20	3.69mg	14/16				
1744	188bo	.375mg	1.84mg	0/20	4.90mg	12/18				
1745	188br	.261mg	1.08mg	0/20	4.90mg	17/21				
1746	188bs	n.s.s.	.486mg	0/20	4.90mg	17/17				
1747	188bt	.343mg	1.53mg	0/20	9.80mg	19/21				
1748	188bu	.286mg	1.55mg	0/20	12.2mg	20/21				
1749	188bv	.336mg	1.12mg	0/20	4.90mg	22/29				
4,4'-METHYLENE-BIS(2-CHLOROANILINE) (3,3'-dichloro-4,4'-diaminodiphenylmethane, MOCA) 101-14-4										
1750	1030	.586mg	14.8mg	0/6	7.31mg	4/5		Stula;jept,1,31-50;1977		
a	1030	1.04mg	n.s.s.	0/6	7.31mg	3/5				
b	1030	2.29mg	n.s.s.	4/6	7.31mg	2/5				
1751	192m	17.1mg	223.mg	0/21	50.0mg	6/21		Stula;txap,31,159-176;1975/pers.comm.		
a	192m	17.1mg	223.mg	0/21	50.0mg	6/21				
b	192m	34.9mg	n.s.s.	0/21	50.0mg	2/21				
c	192m	47.4mg	n.s.s.	0/21	50.0mg	1/21				
1752	192n	21.4mg	60.5mg	0/44	50.0mg	27/44				
a	192n	141.mg	n.s.s.	0/44	50.0mg	3/44				
b	192n	174.mg	n.s.s.	0/44	50.0mg	2/44				
c	192n	233.mg	n.s.s.	0/44	50.0mg	1/44				
1753	1031m	15.7mg	28.6mg	1/100	7.53mg	23/100	15.1mg	28/75	34.0mg	35/50
a	1031m	21.5mg	41.1mg	0/100	7.53mg	14/100	15.1mg	20/75	34.0mg	31/50
b	1031m	53.7mg	174.mg	1/100	7.53mg	5/100	15.1mg	8/75	34.0mg	14/50
c	1031m	56.8mg	164.mg	0/100	7.53mg	3/100	15.1mg	3/75	34.0mg	18/50
d	1031m	61.4mg	288.mg	1/100	7.53mg	8/100	15.1mg	5/75	34.0mg	11/50
e	1031m	63.9mg	6.58gm	1/100	7.53mg	3/100	15.1mg	7/75	34.0mg	1/50
f	1031m	109.mg	n.s.s.	1/100	7.53mg	4/100	15.1mg	7/75	34.0mg	2/50
g	1031m	6.48mg	21.1mg	58/100	7.53mg	80/100	15.1mg	61/75	34.0mg	48/50
1754	1031n	22.7mg	58.9mg	0/100	3.76mg	6/100	7.53mg	11/75	15.1mg	13/50
a	1031n	35.0mg	127.mg	0/100	3.76mg	3/100	7.53mg	7/75	15.1mg	8/50
b	1031n	54.5mg	298.mg	0/100	3.76mg	0/100	7.53mg	4/75	15.1mg	6/50
c	1031n	58.3mg	337.mg	0/100	3.76mg	0/100	7.53mg	0/75	15.1mg	9/50
d	1031n	70.1mg	1.51gm	0/100	3.76mg	1/100	7.53mg	3/75	15.1mg	3/50
e	1031n	58.8mg	n.s.s.	1/100	3.76mg	2/100	7.53mg	4/75	15.1mg	4/50
f	1031n	90.3mg	n.s.s.	1/100	3.76mg	0/100	7.53mg	1/75	15.1mg	4/50
g	1031n	8.87mg	37.5mg	37/100	3.76mg	34/100	7.53mg	40/75	15.1mg	36/50
1755	192m	7.53mg	38.0mg	0/21	40.0mg	11/21		Stula;txap,31,159-176;1975/pers.comm.		
a	192m	15.8mg	498.mg	0/21	40.0mg	5/21				
b	192m	15.8mg	498.mg	0/21	40.0mg	5/21				
1756	192n	25.0mg	79.2mg	0/44	40.0mg	21/44				
a	192n	117.mg	n.s.s.	0/44	40.0mg	3/44				
b	192n	117.mg	n.s.s.	0/44	40.0mg	3/44				
1757	1018	8.23mg	32.9mg	0/25	29.9mg	18/22		Grundmann;zkk,74,28-39;1970		
a	1018	22.5mg	352.mg	2/25	29.9mg	10/22				
b	1018	39.4mg	827.mg	0/25	29.9mg	5/22				
c	1018	5.53mg	25.9mg	2/25	29.9mg	20/22				
1758	1018	5.69mg	21.6mg	0/25	22.5mg	22/25				
a	1018	26.8mg	192.mg	0/25	22.5mg	8/25				
b	1018	4.52mg	18.4mg	0/25	22.5mg	23/25				
4,4'-METHYLENE-BIS(2-CHLOROANILINE).2HCl 64049-29-2										
1759	191	35.3mg	147.mg	0/20	117.mg	9/21	246.mg	7/14	Russfield;txap,31,47-54;1975	
a	191	35.3mg	147.mg	0/20	117.mg	9/21	246.mg	7/14		
b	191	108.mg	n.s.s.	6/20	117.mg	3/21	246.mg	2/14		
c	191	26.1mg	196.mg	17/20	117.mg	16/21	246.mg	12/14		
1760	191	86.4mg	n.s.s.	5/18	108.mg	3/13	206.mg	4/20		
a	191	112.mg	n.s.s.	3/18	108.mg	4/13	206.mg	4/20		
b	191	28.0mg	n.s.s.	12/18	108.mg	7/13	206.mg	16/20		
1761	191	18.6mg	n.s.s.	1/22	18.0mg	1/22	31.3mg	4/19		
a	191	6.57mg	n.s.s.	14/22	18.0mg	13/22	31.3mg	14/19		

Spe	Strain	Site	Xpo + Xpt		TD50	2Tailpvl
Sex	Route	Hist	Notes		DR	AuOp
4,4'-METHYLENE-BIS(2-METHYLANILINE)						
1762	R f	cdr eat liv hpc	82w82 v1ug.....10.....100.....1mg.....10.....100.....1g.....10	7.92mg	P<.0005+
a	R f	cdr eat liv hpc	82w82 v	.	30.5mg	P<.004
b	R f	cdr eat liv clc	82w82 v	.	96.3mg	P<.1
1763	R m	cdr eat mgl fba	68w68 v10.....100.....1mg.....10.....100.....1g.....10	6.91mg	P<.0005+
a	R m	cdr eat ski fib	68w68 v	.	8.19mg	P<.002 +
b	R m	cdr eat liv hpc	68w68 v	.	12.4mg	P<.002 +
c	R m	cdr eat liv hpc	68w68 v	.	17.0mg	P<.004
d	R m	cdr eat liv hem	68w68 v	.	35.2mg	P<.04
4,4'-METHYLENEBIS(N,N-DIMETHYL)BENZENAMINE						
1764	M f	b6c eat liv MXA	78w911ug.....10.....100.....1mg.....10.....100.....1g.....10	207. mg	* P<.003 c
a	M f	b6c eat TBA MXB	78w91	.	280. mg	* P<.07
b	M f	b6c eat liv MXB	78w91	.	207. mg	* P<.003
c	M f	b6c eat lun MXB	78w91	.	1.08gm	\ P<.2
1765	M m	b6c eat TBA MXB	78w9110.....100.....1mg.....10.....100.....1g.....10	367. mg	* P<.2 -
a	M m	b6c eat liv MXB	78w91	.	558. mg	* P<.2
b	M m	b6c eat lun MXB	78w91	.	1.41gm	* P<.4
1766	R f	f34 eat thy MXA	14m2410.....100.....1mg.....10.....100.....1g.....10	16.4mg	/ P<.0005c
a	R f	f34 eat thy fcc	14m24	.	27.7mg	/ P<.0005c
b	R f	f34 eat liv nnd	14m24	.	203. mg	* P<.05
c	R f	f34 eat TBA MXB	14m24	.	41.7mg	/ P<.4
d	R f	f34 eat liv MXB	14m24	.	203. mg	* P<.05
1767	R m	f34 eat thy MXA	14m2410.....100.....1mg.....10.....100.....1g.....10	16.5mg	/ P<.0005c
a	R m	f34 eat thy fcc	14m24	.	28.6mg	/ P<.002 c
b	R m	f34 eat TBA MXB	14m24	.	42.9mg	* P<.5
c	R m	f34 eat liv MXB	14m24	.	no dre	P=1.
METHYLGUANIDINE						
1768	R m	wis eat liv hem	68w68 e100ng.....1ug.....10.....100.....1mg.....10.....100.....1g.....10	84.0mg	P<.2
7-METHYLGUANINE						
1769	R b	b46 ivj tba mal	25m29100ng.....1ug.....10.....100.....1mg.....10.....100.....1g.....10	8.24mg	P<.2 -
METHYLHYDRAZINE						
1770	H f	syg wat liv mhs	86w86 e100ng.....1ug.....10.....100.....1mg.....10.....100.....1g.....10	15.4mg	P<.0005+
a	H f	syg wat cec mix	86w86 e	.	25.8mg	P<.0005+
b	H f	syg wat cec pla	86w86 e	.	29.8mg	P<.002
c	H f	syg wat liv mix	86w86 e	.	30.8mg	P<.006
d	H f	syg wat lun ang	86w86 e	.	297. mg	P<.2 -
1771	H m	syg wat liv mhs	23m23 e100ng.....1ug.....10.....100.....1mg.....10.....100.....1g.....10	9.20mg	P<.0005+
a	H m	syg wat cec mix	23m23 e	.	42.1mg	P<.004 +
b	H m	syg wat cec pla	23m23 e	.	50.7mg	P<.01
c	H m	syg wat lun tum	23m23 e	.	no dre	P=1.
1772	M f	swi wat lun ade	62w62 es100ng.....1ug.....10.....100.....1mg.....10.....100.....1g.....10	19.6mg	P<.008
a	M f	swi wat bil mix	62w62 es	.	24.6mg	P<.003 +
b	M f	swi wat bil cho	62w62 es	.	29.2mg	P<.006
c	M f	swi wat lun mix	62w62 es	.	21.4mg	P<.02 +
d	M f	swi wat liv hpt	62w62 es	.	51.1mg	P<.05 +
1773	M m	swi wat liv mix	69w69 es100ng.....1ug.....10.....100.....1mg.....10.....100.....1g.....10	4.58mg	P<.0005+
a	M m	swi wat liv hpt	69w69 es	.	7.25mg	P<.0005
b	M m	swi wat lun ade	69w69 es	.	10.1mg	P<.0005
c	M m	swi wat bil mix	69w69 es	.	22.5mg	P<.002 +
METHYLHYDRAZINE SULFATE						
1774	M f	swi gev lun tum	40w55100ng.....1ug.....10.....100.....1mg.....10.....100.....1g.....10	no dre	P=1. -
1775	M f	swi wat lun mix	26m26 e100ng.....1ug.....10.....100.....1mg.....10.....100.....1g.....10	2.98mg	P<.0005+
a	M f	swi wat lun ade	26m26 e	.	4.02mg	P<.0005
b	M f	swi wat lun adc	26m26 e	.	5.63mg	P<.0005
c	M f	swi wat liv mix	26m26 e	.	47.2mg	P<.5
1776	M m	swi wat lun mix	26m26 e100ng.....1ug.....10.....100.....1mg.....10.....100.....1g.....10	2.51mg	P<.0005+
a	M m	swi wat lun ade	26m26 e	.	2.93mg	P<.0005
b	M m	swi wat lun adc	26m26 e	.	12.0mg	P<.002
c	M m	swi wat --- mly	26m26 e	.	7.85mg	P<.02
d	M m	swi wat liv mix	26m26 e	.	no dre	P=1.
(N-6)-(METHYLNITROSO)ADENINE						
1777	M f	scd wat liv mix	24m24100ng.....1ug.....10.....100.....1mg.....10.....100.....1g.....10	63.2mg	P<.2
a	M f	scd wat lun tum	24m24	.	909. mg	P<.1
1778	M m	scd wat lun tum	24m24100ng.....1ug.....10.....100.....1mg.....10.....100.....1g.....10	18.0mg	P<.02 +
a	M m	scd wat liv mix	24m24	.	62.6mg	P<.4
(N-6)-(METHYLNITROSO)ADENOSINE						
1779	M f	scd wat rep mix	24m24100ng.....1ug.....10.....100.....1mg.....10.....100.....1g.....10	15.8mg	P<.0005+
a	M f	scd wat lun tum	24m24	.	17.4mg	P<.0005+
b	M f	scd wat mgl car	24m24	.	28.7mg	P<.0005+
c	M f	scd wat ute tum	24m24	.	84.9mg	P<.02 +
d	M f	scd wat liv mix	24m24	.	no dre	P=1.
1780	M m	scd wat lun tum	24m24100ng.....1ug.....10.....100.....1mg.....10.....100.....1g.....10	21.6mg	P<.002 +
a	M m	scd wat liv mix	24m24	.	no dre	P=1.

RefNum	LoConf	UpConf	Cntrl	1Dose	1Inc	2Dose	2Inc	Citation or Pathology	Brkly Code	
4,4'-METHYLENE-BIS(2-METHYLANILINE) 838-88-0										
1762	192	4.58mg	15.4mg	0/44	10.5mg	19/44		Stula;txap,31,159-176;1975/pers.comm.		
a	192	12.4mg	187.mg	0/44	10.5mg	6/44				
b	192	23.7mg	n.s.s.	0/44	10.5mg	2/44				
1763	192	3.58mg	19.2mg	1/44	8.49mg	14/44				
a	192	3.97mg	37.4mg	2/44	8.49mg	13/44				
b	192	5.61mg	41.8mg	0/44	8.49mg	8/44				
c	192	6.92mg	104.mg	0/44	8.49mg	6/44				
d	192	10.7mg	n.s.s.	0/44	8.49mg	3/44				
4,4'-METHYLENEBIS(N,N-DIMETHYL)BENZENAMINE 101-61-1										
1764	c01990	126.mg	1.14gm	1/20	139.mg	19/50	278.mg		23/50	liv:hpa,hpc.
a	c01990	122.mg	n.s.s.	6/20	139.mg	26/50	278.mg	30/50		
b	c01990	126.mg	1.14gm	1/20	139.mg	19/50	278.mg	23/50	liv:hpa,hpc,nnd.	
c	c01990	328.mg	n.s.s.	0/20	139.mg	3/50	(278.mg	0/50)	lun:a/s,a/c.	
1765	c01990	140.mg	n.s.s.	7/20	128.mg	24/50	257.mg	31/50		
a	c01990	216.mg	n.s.s.	5/20	128.mg	12/50	257.mg	22/50	liv:hpa,hpc,nnd.	
b	c01990	437.mg	n.s.s.	1/20	128.mg	6/50	257.mg	7/50	lun:a/s,a/c.	
1766	c01990	11.2mg	25.8mg	0/20	11.0mg	4/50	21.0mg	36/50	thy:fcø,fcc.	
a	c01990	17.4mg	51.4mg	0/20	11.0mg	3/50	21.0mg	23/50		
b	c01990	70.2mg	n.s.s.	0/20	11.0mg	0/50	21.0mg	4/50		
c	c01990	10.8mg	n.s.s.	17/20	11.0mg	33/50	21.0mg	44/50		
d	c01990	70.2mg	n.s.s.	0/20	11.0mg	0/50	21.0mg	4/50	liv:hpa,hpc,nnd.	
1767	c01990	10.7mg	33.5mg	1/20	8.80mg	4/50	16.8mg	34/50	thy:fcø,fcc.	
a	c01990	16.5mg	117.mg	1/20	8.80mg	4/50	16.8mg	21/50		
b	c01990	10.2mg	n.s.s.	14/20	8.80mg	29/50	16.8mg	44/50		
c	c01990	76.0mg	n.s.s.	3/20	8.80mg	5/50	16.8mg	3/50	liv:hpa,hpc,nnd.	
METHYLGUANIDINE 471-29-4										
1768	1471	13.5mg	n.s.s.	0/10	64.0mg	1/5		Matsukura;zkko,90,87-94;1977		
7-METHYLGUANINE 578-76-7										
1769	1443	2.03mg	n.s.s.	0/20	.565mg	2/30		Kruger;zkko,75,253-254;1971		
METHYLHYDRAZINE 60-34-4										
1770	194	8.53mg	31.7mg	0/85	13.6mg	16/47		Toth;canr,33,2744-2753;1973		
a	194	11.7mg	93.3mg	1/67	13.6mg	9/39				
b	194	12.9mg	132.mg	1/67	13.6mg	8/39				
c	194	9.28mg	418.mg	0/39	13.6mg	3/16				
d	194	48.4mg	n.s.s.	0/85	13.6mg	1/47				
1771	194	5.72mg	16.0mg	0/72	12.0mg	27/48				
a	194	17.1mg	359.mg	1/59	12.0mg	7/39				
b	194	19.2mg	4.28gm	1/59	12.0mg	6/39				
c	194	110.mg	n.s.s.	0/87	12.0mg	0/48				
1772	1117	8.03mg	558.mg	12/107	20.0mg	12/39			Toth;ijcn,9,109-118;1972/1969a	
a	1117	10.6mg	119.mg	0/34	20.0mg	7/39				
b	1117	11.9mg	247.mg	0/34	20.0mg	6/39				
c	1117	8.30mg	n.s.s.	14/107	20.0mg	12/39				
d	1117	15.5mg	n.s.s.	0/31	20.0mg	3/33				
1773	1117	1.43mg	24.5mg	0/45	16.7mg	4/6				
a	1117	2.10mg	52.8mg	0/45	16.7mg	3/6				
b	1117	4.45mg	44.8mg	10/91	16.7mg	11/24				
c	1117	6.79mg	167.mg	0/64	16.7mg	3/15				
METHYLHYDRAZINE SULFATE 302-15-8										
1774	1095	10.8mg	n.s.s.	8/85	10.4mg	1/25		Roe;netu,216,375-376;1967 Toth;ijcn,9,109-118;1972/1969a		
1775	1117	1.58mg	8.60mg	14/88	2.00mg	23/45				
a	1117	1.99mg	15.7mg	12/88	2.00mg	19/45				
b	1117	2.78mg	16.3mg	2/88	2.00mg	12/45				
c	1117	8.16mg	n.s.s.	3/88	2.00mg	3/45				
1776	1117	1.37mg	6.32mg	10/86	1.67mg	23/48				
a	1117	1.54mg	8.52mg	10/86	1.67mg	21/48				
b	1117	4.57mg	57.4mg	0/86	1.67mg	5/48				
c	1117	3.12mg	n.s.s.	2/55	1.67mg	8/43				
d	1117	7.98mg	n.s.s.	2/41	1.67mg	2/41				
(N-6)-(METHYLNITROSO)ADENINE ---										
1777	1255	19.8mg	n.s.s.	1/16	20.6mg	5/20		Anderson;ijcn,24,319-322;1979		
a	1255	28.5mg	n.s.s.	3/16	20.6mg	4/20				
1778	1255	7.37mg	n.s.s.	4/21	17.1mg	11/19				
a	1255	13.8mg	n.s.s.	5/21	17.1mg	7/19				
(N-6)-(METHYLNITROSO)ADENOSINE ---										
1779	1255	7.88mg	38.3mg	1/16	35.7mg	16/20		Anderson;ijcn,24,319-322;1979		
a	1255	8.22mg	58.0mg	3/16	35.7mg	16/20				
b	1255	13.7mg	101.mg	1/16	35.7mg	12/20				
c	1255	32.1mg	n.s.s.	0/16	35.7mg	5/20				
d	1255	89.9mg	n.s.s.	1/16	35.7mg	1/20				
1780	1255	9.65mg	115.mg	4/21	29.7mg	13/19				
a	1255	54.0mg	n.s.s.	5/21	29.7mg	3/19				

Spe	Strain	Site	Xpo+Xpt	Notes	TD50	2Tailpvl
Sex	Route	Hist			DR	AuOp
METHYLTHIOURACIL						
1781	M f	nas	wet	thy mix 52w52 akr	100ng...1ug...10...100...1mg...10...100...1g...10	53.4mg P<.006 +
METIAPINE						
1782	R f	alb	eat	mgl fba 78w78 e	100ng...1ug...10...100...1mg...10...100...1g...10	no dre P=1. -
1783	R m	alb	eat	pit ade 78w78 a		no dre P=1. -
METRONIDAZOLE						
1784	M f	swi	eat	lun mix 28w30 e	100ng...1ug...10...100...1mg...10...100...1g...10	937.mg * P<.0005+
a	M f	swi	eat	--- mly 28w30 e		1.30gm * P<.002 +
b	M f	swi	eat	liv mix 28w30 e		24.2gm * P<.6 -
1785	M m	swi	eat	lun mix 27w29 e		347.mg * P<.0005+
a	M m	swi	eat	liv mix 27w29 e		20.7gm * P<.8 -
1786	R f	ada	eat	ute amy 66w75 e		180.mg P<.004 -
a	R f	ada	eat	liv tum 66w75 e		no dre P=1. -
b	R f	ada	eat	tba mix 66w75 e		61.1mg P<.03 -
1787	R f	smw	eat	mgl fba 34w35 ae		431.mg * P<.0005+
a	R f	smw	eat	mgl mix 34w35 ae		446.mg * P<.0005+
b	R f	smw	eat	liv hpc 34w35 ae		1.86gm * P<.0005+
c	R f	smw	eat	sub mix 34w35 a		4.05gm * P<.03
d	R f	smw	eat	ute mix 34w35 a		2.97gm * P<.2 -
e	R f	smw	eat	pit mix 34w35 a		no dre P=1. -
f	R f	smw	eat	tba mix 34w35 a		139.mg * P<.0005
1788	R m	smw	eat	pit mix 33w33 a		731.mg * P<.004 +
a	R m	smw	eat	tes mix 33w33 a		993.mg * P<.01 +
b	R m	smw	eat	sub mix 33w33 a		2.36gm * P<.06
c	R m	smw	eat	mgl fba 33w33 a		2.49gm Z P<.02
d	R m	smw	eat	liv hpc 33w33 a		45.9gm * P<.8
e	R m	smw	eat	tba mix 33w33 a		211.mg * P<.0005
MEZACARBATE						
1789	M f	b6c	eat	TBA MXB 78w92 v	100ng...1ug...10...100...1mg...10...100...1g...10	no dre P=1. -
a	M f	b6c	eat	liv MXB 78w92 v		no dre P=1. -
b	M f	b6c	eat	lun MXB 78w92 v		no dre P=1. -
1790	M f	b6c	orl	lun ade 76w76 evx		2.93mg P<.04
a	M f	b6c	orl	liv hpt 76w76 evx		no dre P=1. -
b	M f	b6c	orl	tba mix 76w76 evx		2.12mg P<.02
1791	M m	b6c	eat	liv MXA 78w91 esv		*76.4mg * P<.03 -
a	M m	b6c	eat	liv hpc 78w91 esv		85.5mg * P<.02
b	M m	b6c	eat	TBA MXB 78w91 esv		53.2mg * P<.3
c	M m	b6c	eat	liv MXB 78w91 esv		76.4mg * P<.03
d	M m	b6c	eat	lun MXB 78w91 esv		391.mg * P<.6
1792	M m	b6c	eat	sub fba 78w90 esv pool		*137.mg * P<.05 -
a	M m	b6c	eat	ski fib 78w90 esv		242.mg * P<.03
1793	M m	b6c	orl	liv hpt 76w76 evx		1.42mg P<.006
a	M m	b6c	orl	lun ade 76w76 evx		1.84mg P<.02
b	M m	b6c	orl	tba mix 76w76 evx		.642mg P<.0005
1794	M f	b6a	orl	liv hpt 76w76 evx		no dre P=1. -
a	M f	b6a	orl	lun ade 76w76 evx		no dre P=1. -
b	M f	b6a	orl	tba mix 76w76 evx		no dre P=1. -
1795	M m	b6a	orl	liv hpt 76w76 evx		7.80mg P<.6
a	M m	b6a	orl	lun ade 76w76 evx		no dre P=1. -
b	M m	b6a	orl	tba mix 76w76 evx		44.8mg P<.1
1796	R f	osm	eat	TBA MXB 18w26 v		no dre P=1. -
a	R f	osm	eat	liv MXB 18w26 v		1.06gm * P<.4
1797	R m	osm	eat	TBA MXB 18w26 v		24.7mg \ P<.8 -
a	R m	osm	eat	liv MXB 18w26 v		no dre P=1. -
MICHLER'S KETONE						
1798	M f	b6c	eat	liv MXA 78w91	100ng...1ug...10...100...1mg...10...100...1g...10	53.0mg * P<.0005c
a	M f	b6c	eat	liv hpc 78w91		111.mg / P<.0005c
b	M f	b6c	eat	TBA MXB 78w91		69.1mg * P<.0005
c	M f	b6c	eat	liv MXB 78w91		53.0mg * P<.0005
d	M f	b6c	eat	lun MXB 78w91		no dre P=1. -
1799	M m	b6c	eat	--- MXA 78w91		203.mg / P<.0005c
a	M m	b6c	eat	--- hes 78w91		233.mg / P<.0005c
b	M m	b6c	eat	MXA MXA 78w91		753.mg * P<.008
c	M m	b6c	eat	TBA MXB 78w91		99.3mg / P<.0005
d	M m	b6c	eat	liv MXB 78w91		459.mg * P<.07
e	M m	b6c	eat	lun MXB 78w91		1.14gm / P<.3
1800	R f	f34	eat	liv MXA 18w25		4.87mg / P<.0005c
a	R f	f34	eat	liv hpc 18w25		5.47mg / P<.0005c
b	R f	f34	eat	TBA MXB 18w25		5.97mg / P<.0005
c	R f	f34	eat	liv MXB 18w25		4.87mg / P<.0005
1801	R m	f34	eat	liv MXA 18w25		6.69mg / P<.0005c
a	R m	f34	eat	liv hpc 18w25		8.86mg / P<.0005c
b	R m	f34	eat	TBA MXB 18w25		7.29mg / P<.0005
c	R m	f34	eat	liv MXB 18w25		6.69mg / P<.0005

CARCINOGENIC POTENCY DATABASE

RefNum	LoConf	UpConf	Cntrl	1Dose	1Inc	2Dose	2Inc	Citation or Pathology	Brkly Code				
METHYLTHIOURACIL 56-04-2													
1781	1385	22.1mg	507.mg	0/6	273.mg	7/12		Christov;zkko,77,171-179;1972					
METIAPINE 5800-19-1													
1782	200	38.9mg	n.s.s.	1/22	3.00mg	6/20	10.0mg	1/21	30.0mg	2/20	Gibson;txap,25,220-229;1973		
1783	200	8.00mg	n.s.s.	3/18	3.00mg	7/20	10.0mg	3/19	(30.0mg	0/20)			
METRONIDAZOLE 443-48-1													
1784	201	498.mg	3.54gm	14/65	78.0mg	4/10	195.mg	10/20	390.mg	14/19	650.mg	16/32	Rustia;jnci,48,721-729;1972
a	201	654.mg	6.48gm	16/68	78.0mg	3/10	195.mg	5/20	390.mg	10/19	650.mg	18/34	
b	201	3.34gm	n.s.s.	2/53	78.0mg	0/10	195.mg	0/18	390.mg	2/19	650.mg	1/25	
1785	201	217.mg	635.mg	13/67	72.0mg	3/8	180.mg	11/15	360.mg	12/16	600.mg	27/34	
a	201	2.06gm	n.s.s.	6/64	72.0mg	0/8	180.mg	3/14	360.mg	3/16	600.mg	3/32	
1786	200a	62.0mg	1.27gm	0/71	59.4mg	4/36							Cohen;jnci,51,403-417;1973
a	200a	229.mg	n.s.s.	0/71	59.4mg	0/36							
b	200a	24.3mg	n.s.s.	18/71	59.4mg	17/36							
1787	1064	231.mg	1.25gm	30/95	30.0mg	17/29	150.mg	14/28	300.mg	23/29			Rustia;jnci,63,863-868;1979
a	1064	232.mg	1.46gm	34/95	30.0mg	17/29	150.mg	15/28	300.mg	23/29			
b	1064	842.mg	5.46gm	0/58	30.0mg	0/28	150.mg	1/21	300.mg	7/25			
c	1064	1.54gm	n.s.s.	0/100	30.0mg	1/30	150.mg	3/30	300.mg	1/30			
d	1064	855.mg	n.s.s.	13/100	30.0mg	9/30	150.mg	8/30	300.mg	7/30			
e	1064	761.mg	n.s.s.	61/100	30.0mg	24/30	150.mg	19/30	300.mg	17/30			
f	1064	53.2mg	720.mg	80/100	30.0mg	27/30	150.mg	28/30	300.mg	30/30			
1788	1064	338.mg	6.36gm	20/100	24.0mg	11/30	120.mg	10/30	240.mg	15/30			
a	1064	424.mg	178.mg	18/100	24.0mg	9/30	120.mg	6/30	240.mg	14/30			
b	1064	816.mg	n.s.s.	5/100	24.0mg	2/30	120.mg	5/30	240.mg	4/30			
c	1064	989.mg	n.s.s.	0/100	24.0mg	2/30	120.mg	1/30	240.mg	3/30			
d	1064	2.70gm	n.s.s.	2/100	24.0mg	0/30	120.mg	0/30	240.mg	1/30			
e	1064	112.mg	592.mg	47/100	24.0mg	22/30	120.mg	21/30	240.mg	27/30			
MEXACARBATE (Zectran) 315-18-4													
1789	c00544	11.2mg	n.s.s.	5/20	7.50mg	16/50	(14.9mg	13/50)					
a	c00544	57.7mg	n.s.s.	1/20	7.50mg	1/50	14.9mg	3/50					liv:hpa,hpc,nnd.
b	c00544	28.4mg	n.s.s.	1/20	7.50mg	2/50	(14.9mg	1/50)					lun:a/a,a/c.
1790	1102	.885mg	n.s.s.	0/16	1.56mg	3/17							Innes;ntis,1968/1969
a	1102	2.91mg	n.s.s.	0/16	1.56mg	0/17							
b	1102	.729mg	n.s.s.	0/16	1.56mg	4/17							
1791	c00544	45.5mg	n.s.s.	0/20	33.6mg	6/50	66.0mg	15/50					liv:hpa,hpc. S
a	c00544	49.8mg	n.s.s.	0/20	33.6mg	4/50	66.0mg	15/50					S
b	c00544	20.2mg	n.s.s.	0/20	33.6mg	24/50	66.0mg	28/50					
c	c00544	45.5mg	n.s.s.	0/20	33.6mg	6/50	66.0mg	15/50					liv:hpa,hpc,nnd.
d	c00544	109.mg	n.s.s.	0/20	33.6mg	3/50	66.0mg	4/50					lun:a/a,a/c.
1792	c00544	72.2mg	n.s.s.	0/40p	33.6mg	6/50	66.0mg	7/50					S
a	c00544	105.mg	n.s.s.	0/40p	33.6mg	1/50	66.0mg	6/50					S
1793	1102	.533mg	14.0mg	0/16	1.45mg	5/16							Innes;ntis,1968/1969
a	1102	.633mg	n.s.s.	0/16	1.45mg	4/16							
b	1102	.293mg	1.80mg	0/16	1.45mg	9/16							
1794	1102	2.91mg	n.s.s.	0/17	1.56mg	0/17							
a	1102	2.91mg	n.s.s.	1/17	1.56mg	0/17							
b	1102	1.93mg	n.s.s.	2/17	1.56mg	1/17							
1795	1102	1.14mg	n.s.s.	1/18	1.45mg	2/17							
a	1102	1.78mg	n.s.s.	2/18	1.45mg	1/17							
b	1102	1.06mg	n.s.s.	3/18	1.45mg	3/17							
1796	c00544	23.7mg	n.s.s.	12/20	11.9mg	33/50	23.6mg	28/50					
a	c00544	173.mg	n.s.s.	0/20	11.9mg	0/50	23.6mg	1/50					liv:hpa,hpc,nnd.
1797	c00544	3.26mg	n.s.s.	6/20	5.80mg	21/50	(11.8mg	16/50)					
a	c00544	n.s.s.	n.s.s.	0/20	5.80mg	0/50	11.8mg	0/50					liv:hpa,hpc,nnd.
MICHLER'S KETONE 90-94-8													
1798	c02006	40.5mg	77.0mg	0/20	139.mg	41/50	278.mg	49/50					liv:hpa,hpc.
a	c02006	79.2mg	168.mg	0/20	139.mg	16/50	278.mg	38/50					
b	c02006	45.6mg	159.mg	4/20	139.mg	43/50	278.mg	49/50					
c	c02006	40.5mg	77.0mg	0/20	139.mg	41/50	278.mg	49/50					liv:hpa,hpc,nnd.
d	c02006	n.s.s.	n.s.s.	0/20	139.mg	0/50	278.mg	0/50					lun:a/a,a/c.
1799	c02006	126.mg	349.mg	0/20	128.mg	5/50	257.mg	23/50					---:hem,hes.
a	c02006	141.mg	425.mg	0/20	128.mg	5/50	257.mg	20/50					
b	c02006	331.mg	13.1gm	0/20	128.mg	2/50	257.mg	6/50					ski:fbs; sub:fbs,arn. S
c	c02006	63.1mg	207.mg	7/20	128.mg	21/50	257.mg	39/50					
d	c02006	183.mg	n.s.s.	3/20	128.mg	8/50	257.mg	9/50					liv:hpa,hpc,nnd.
e	c02006	310.mg	n.s.s.	2/20	128.mg	2/50	257.mg	4/50					lun:a/a,a/c.
1800	c02006	3.53mg	6.86mg	0/20	18.0mg	46/50	37.0mg	48/50					liv:hpc,nnd.
a	c02006	3.93mg	7.81mg	0/20	18.0mg	41/50	37.0mg	44/50					
b	c02006	4.06mg	10.1mg	7/20	18.0mg	47/50	37.0mg	48/50					
c	c02006	3.53mg	6.86mg	0/20	18.0mg	46/50	37.0mg	48/50					liv:hpa,hpc,nnd.
1801	c02006	4.85mg	9.78mg	0/20	7.40mg	17/50	14.4mg	43/50					liv:hpc,nnd.
a	c02006	6.24mg	13.3mg	0/20	7.40mg	9/50	14.4mg	40/50					
b	c02006	4.74mg	16.3mg	5/20	7.40mg	26/50	14.4mg	48/50					
c	c02006	4.85mg	9.78mg	0/20	7.40mg	17/50	14.4mg	43/50					liv:hpa,hpc,nnd.

Spe	Strain	Site	Xpo+Xpt						TD50	ZTailpvl	
Sex	Route	Hist	Notes						DR	AuOp	
MIREX				100ng	1ug	10	100	1mg	10	100	1g
1802	M f	b6a orl	liv hpt 68w68 evx	.	+	.			1.10mg	P<.0005+	
a	M f	b6a orl	lun ade 68w68 evx						no dre	P=1.	
b	M f	b6a orl	tba mix 68w68 evx						1.26mg	P<.003	
1803	M m	b6a orl	liv hpt 58w58 evx	.	.	*			2.13mg	P<.04 +	
a	M m	b6a orl	lun ade 58w58 evx						no dre	P=1.	
b	M m	b6a orl	tba mix 58w58 evx						3.32mg	P<.3	
1804	M f	b6c orl	liv hpt 69w69 evx	.	+	.			1.60mg	P<.0005	
a	M f	b6c orl	lun mix 69w69 evx						no dre	P=1.	
b	M f	b6c orl	tba mix 69w69 evx						1.60mg	P<.0005	
1805	M m	b6c orl	liv mix 58w58 evx	.	+	.			1.50mg	P<.002	
a	M m	b6c orl	liv hpt 58w58 evx						1.83mg	P<.004	
b	M m	b6c orl	lun mix 58w58 evx						no dre	P=1.	
c	M m	b6c orl	tba mix 58w58 evx						1.50mg	P<.002	
1806	R m	sda eat	liv nnd 91w91	.	.	.			no dre	P=1.	
MIREX, PHOTO-				100ng	1ug	10	100	1mg	10	100	1g
1807	R m	sda eat	thy ade 91w91	.	+	.			1.46mg *	P<.007 +	
a	R m	sda eat	liv nnd 91w91						6.68mg *	P<.5	
MITOMYCIN-C				100ng	1ug	10	100	1mg	10	100	1g
1808	R f	cdr ipj	per sar 26w78 e	.	+	.			981.ng	P<.0005+	
a	R f	cdr ipj	liv tum 26w78 e						no dre	P=1.	
b	R f	cdr ipj	tba mal 26w78 e						1.13ug	P<.0005	
c	R f	cdr ipj	tba mix 26w78 e						1.23ug	P<.0005	
d	R f	cdr ipj	tba ben 26w78 e						no dre	P=1.	
1809	R m	cdr ipj	per sar 26w63 e	.	+	.			1.07ug	P<.0005+	
a	R m	cdr ipj	liv lys 26w63 e						39.3ug	P<.04	
b	R m	cdr ipj	tba mal 26w63 e						732.ng	P<.0005	
c	R m	cdr ipj	tba mix 26w63 e						805.ng	P<.0005	
d	R m	cdr ipj	tba ben 26w63 e						no dre	P=1.	
MONOCHLOROACETIC ACID				100ng	1ug	10	100	1mg	10	100	1g
1810	M f	b6a orl	lun ade 76w76 evx	.	.	*			59.7mg	P<.09 -	
a	M f	b6a orl	liv hpt 76w76 evx						no dre	P=1. -	
b	M f	b6a orl	tba mix 76w76 evx						38.5mg	P<.04 -	
1811	M m	b6a orl	lun ade 76w76 evx	.	.	.			115.mg	P<.3 -	
a	M m	b6a orl	liv hpt 76w76 evx						2.01gm	P<.1 -	
b	M m	b6a orl	tba mix 76w76 evx						942.mg	P<.1 -	
1812	M f	b6c orl	liv hpt 76w76 evx	.	.	.			no dre	P=1. -	
a	M f	b6c orl	lun ade 76w76 evx						no dre	P=1. -	
b	M f	b6c orl	tba mix 76w76 evx						1.01gm	P<.1 -	
1813	M m	b6c orl	lun ade 76w76 evx	.	.	.			122.mg	P<.3 -	
a	M m	b6c orl	liv hpt 76w76 evx						no dre	P=1. -	
b	M m	b6c orl	tba mix 76w76 evx						no dre	P=1. -	
4-MORPHOLINO-2-(5-NITRO-2-THIENYL)QUINAZOLINE				100ng	1ug	10	100	1mg	10	100	1g
1814	R f	sda eat	tba mix 46w66 e	.	+	.			5.03mg	P<.0005+	
L-5-MORPHOLINOMETHYL-3-[(5-NITROFURFURYLIDENE)AMINO]-2-OXAZOLIDINONE.HCl				100ng	1ug	10	100	1mg	10	100	1g
1815	R f	sda eat	mgl mix 46w66 e	.	+	.			2.81mg	P<.0005	
a	R f	sda eat	mgl adc 46w66 e						6.33mg	P<.0005+	
b	R f	sda eat	--- lbl 46w66 e						+historical	P<.004 +	
c	R f	sda eat	k/p tcc 46w66 e						+historical	P<.2 +	
d	R f	sda eat	liv tum 46w66 e						no dre	P=1.	
e	R f	sda eat	tba mix 46w66 e						2.81mg	P<.0005	
MYLERAN				100ng	1ug	10	100	1mg	10	100	1g
1816	R m	b46 gav	tba mix 12w24 es	.	.	.			93.1ug	P<.6	
a	R m	b46 gav	tba mal 12w24 es						.117mg	P<.5	
b	R m	b46 gav	tba ben 12w24 es						.642mg	P<.9	
1-NAPHTHALENE ACETAMIDE				100ng	1ug	10	100	1mg	10	100	1g
1817	M f	b6a orl	liv hpt 76w76 evx	.	.	.			no dre	P=1. -	
a	M f	b6a orl	lun ade 76w76 evx						no dre	P=1. -	
b	M f	b6a orl	tba mix 76w76 evx						956.mg	P<.7 -	
1818	M m	b6a orl	liv hpt 76w76 evx	.	.	.			no dre	P=1. -	
a	M m	b6a orl	lun ade 76w76 evx						no dre	P=1. -	
b	M m	b6a orl	tba mix 76w76 evx						no dre	P=1. -	
1819	M f	b6c orl	lun ade 76w76 evx	.	.	*			461.mg	P<.09 -	
a	M f	b6c orl	liv hpt 76w76 evx						956.mg	P<.3 -	
b	M f	b6c orl	tba mix 76w76 evx						213.mg	P<.02 -	
1820	M m	b6c orl	liv hpt 76w76 evx	.	.	*			316.mg	P<.04 -	
a	M m	b6c orl	lun ade 76w76 evx						1.01gm	P<.3 -	
b	M m	b6c orl	tba mix 76w76 evx						141.mg	P<.003 -	
1-NAPHTHALENE ACETIC ACID				100ng	1ug	10	100	1mg	10	100	1g
1821	M f	b6a orl	liv agm 76w76 evx	.	.	*			213.mg	P<.09 -	

CARCINOGENIC POTENCY DATABASE

RefNum	LoConf	UpConf	Cntrl	1Dose	1Inc	2Dose	2Inc	Citation or Pathology	Brkly Code
MIREX 2385-85-5									
1802	202	.512mg	2.89mg	0/17	3.67mg	10/16			Innes;ntis,1968/1969
a	202	5.18mg	n.s.s.	1/17	3.67mg	0/16			
b	202	.540mg	7.45mg	2/17	3.67mg	10/16			
1803	202	.718mg	n.s.s.	1/18	3.48mg	5/15			
a	202	3.34mg	n.s.s.	2/18	3.48mg	0/15			
b	202	.797mg	n.s.s.	3/18	3.48mg	5/15			
1804	202	.705mg	4.95mg	0/16	3.67mg	8/16			
a	202	5.32mg	n.s.s.	0/16	3.67mg	0/16			
b	202	.705mg	4.95mg	0/16	3.67mg	8/16			
1805	202	.641mg	6.13mg	0/16	3.48mg	7/18			
a	202	.738mg	11.2mg	0/16	3.48mg	6/18			
b	202	4.01mg	n.s.s.	0/16	3.48mg	0/18			
c	202	.641mg	6.13mg	0/16	3.48mg	7/18			
1806	1160	52.6ug	n.s.s.	0/10	40.0ug	0/10	.200mg	0/10	Chu;txap,59,268-278;1981
MIREX, PHOTO- 39801-14-4									
1807	1160	.474mg	28.7mg	1/10	8.00ug	0/10	40.0ug	0/10	.200mg 0/10 1.00mg 4/10 Chu;txap,59,268-278;1981
a	1160	1.06mg	n.s.s.	0/10	8.00ug	1/10	40.0ug	0/10	.200mg 1/10 1.00mg 1/10
MITOMYCIN-C 50-07-7									
1808	1336	516.ng	1.95ug	0/182	5.40ug	22/25			Skipper;srfr;1976/Weisburger 1977/Prejean pers.com.
a	1336	15.6ug	n.s.s.	0/182	5.40ug	0/25			
b	1336	553.ng	2.67ug	44/182	5.40ug	22/25			
c	1336	490.ng	5.41ug	103/182	5.40ug	23/25			
d	1336	13.8ug	n.s.s.	59/182	5.40ug	1/25			
1809	1336	575.ng	2.16ug	0/177	6.65ug	19/24			
a	1336	6.40ug	n.s.s.	0/177	6.65ug	1/24			
b	1336	346.ng	1.66ug	32/177	6.65ug	22/24			
c	1336	361.ng	2.11ug	59/177	6.65ug	22/24			
d	1336	12.1ug	n.s.s.	27/177	6.65ug	0/24			
MONOCHLOROACETIC ACID 79-11-8									
1810	1263	14.7mg	n.s.s.	0/18	20.4mg	2/17			Innes;ntis,1968/1969
a	1263	38.2mg	n.s.s.	0/18	20.4mg	0/17			
b	1263	11.6mg	n.s.s.	0/18	20.4mg	3/17			
1811	1263	18.7mg	n.s.s.	0/18	19.0mg	1/17			
a	1263	21.0mg	n.s.s.	1/18	19.0mg	1/17			
b	1263	16.9mg	n.s.s.	2/18	19.0mg	2/17			
1812	1263	38.2mg	n.s.s.	0/18	20.4mg	0/17			
a	1263	38.2mg	n.s.s.	1/18	20.4mg	0/17			
b	1263	17.8mg	n.s.s.	2/18	20.4mg	2/17			
1813	1263	19.8mg	n.s.s.	0/14	19.0mg	1/18			
a	1263	20.9mg	n.s.s.	3/14	19.0mg	2/18			
b	1263	11.3mg	n.s.s.	4/14	19.0mg	5/18			
4-MORPHOLINO-2-(5-NITRO-2-THIENYL)QUINAZOLINE 58139-48-3									
1814	1390	2.70mg	11.2mg	6/84	17.4mg	18/28			Cohen;jnci,57,277-282;1976
1-5-MORPHOLINOMETHYL-3-[(5-NITROFURFURYLIDENE)AMINO]-2-OXAZOLIDINONE.HCL 3031-51-4									
1815	200a	1.25mg	5.71mg	1/25	34.8mg	31/32			Cohen;jnci,51,403-417;1973
a	200a	3.70mg	11.6mg	0/25	34.8mg	25/32			
b	200a	16.8mg	219.mg	0/25	34.8mg	7/32			
c	200a	36.6mg	n.s.s.	0/25	34.8mg	2/32			
d	200a	92.6mg	n.s.s.	0/25	34.8mg	0/32			
e	200a	1.25mg	5.71mg	1/25	34.8mg	31/32			
MYLERAN (busulfen) 55-98-1									
1816	1017	12.7ug	n.s.s.	7/65	9.29ug	3/18			Schmahl;arzn,20,1461-1467;1970
a	1017	15.1ug	n.s.s.	4/65	9.29ug	2/18			
b	1017	20.6ug	n.s.s.	3/65	9.29ug	1/18			
1-NAPHTHALENE ACETAMIDE 86-86-2									
1817	1156	337.mg	n.s.s.	0/17	180.mg	0/17			Innes;ntis,1968/1969
a	1156	337.mg	n.s.s.	1/17	180.mg	0/17			
b	1156	120.mg	n.s.s.	2/17	180.mg	3/17			
1818	1156	314.mg	n.s.s.	1/18	168.mg	0/17			
a	1156	314.mg	n.s.s.	2/18	168.mg	0/17			
b	1156	314.mg	n.s.s.	3/18	168.mg	0/17			
1819	1156	113.mg	n.s.s.	0/16	180.mg	2/15			
a	1156	156.mg	n.s.s.	0/16	180.mg	1/15			
b	1156	73.0mg	n.s.s.	0/16	180.mg	4/15			
1820	1156	95.4mg	n.s.s.	0/16	168.mg	3/17			
a	1156	165.mg	n.s.s.	0/16	168.mg	1/17			
b	1156	56.9mg	765.mg	0/16	168.mg	6/17			
1-NAPHTHALENE ACETIC ACID (PAnofix) 86-87-3									
1821	1157	52.4mg	n.s.s.	0/17	73.0mg	2/17			Innes;ntis,1968/1969

Spe	Strain	Site	Xpo+ Xpt	Notes	TD50	2Tailpv1
Sex	Route	Hist			DR	AuOp
a	M f b6a	orl lun ade	76w76	evx	no dre	P=1. -
b	M f b6a	orl tba mix	76w76	evx	387.mg	P<.7 -
1822	M m b6a	orl liv hpt	76w76	evx	no dre	P=1. -
a	M m b6a	orl lun ade	76w76	evx	no dre	P=1. -
b	M m b6a	orl tba mix	76w76	evx	no dre	P=1. -
1823	M f b6c	orl liv hpt	76w76	evx	no dre	P=1. -
a	M f b6c	orl lun mix	76w76	evx	no dre	P=1. -
b	M f b6c	orl tba tum	76w76	evx	no dre	P=1. -
1824	M m b6c	orl liv hpt	76w76	evx	199.mg	P<.1 -
a	M m b6c	orl lun mix	76w76	evx	no dre	P=1. -
b	M m b6c	orl tba mix	76w76	evx	71.5mg	P<.007 -
1,5-NAPHTHALENEDIAMINE				100ng.....1ug.....10.....100.....1mg.....10.....100.....1g.....10		
1825	M f b6c	eat MXB MXB	24m24		66.6mg \	P<.0005
a	M f b6c	eat liv hpc	24m24		115.mg \	P<.0005c
b	M f b6c	eat liv MXA	24m24		129.mg *	P<.0005c
c	M f b6c	eat thy MXA	24m24		327.mg *	P<.002 c
d	M f b6c	eat lun MXA	24m24		331.mg \	P<.0005c
e	M f b6c	eat thy MXA	24m24		936.mg *	P<.002 c
f	M f b6c	eat thy ccr	24m24		1.32gm *	P<.005 c
g	M f b6c	eat TBA MXB	24m24		223.mg *	P<.03
h	M f b6c	eat liv MXB	24m24		129.mg *	P<.0005
i	M f b6c	eat lun MXB	24m24		331.mg \	P<.0005
1826	M m b6c	eat thy MXB	24m24		217.mg *	P<.0005
a	M m b6c	eat thy MXA	24m24		276.mg *	P<.0005c
b	M m b6c	eat thy MXA	24m24		1.26gm *	P<.02 c
c	M m b6c	eat thy ccr	24m24		1.91gm *	P<.02 c
d	M m b6c	eat TBA MXB	24m24		583.mg *	P<.5
e	M m b6c	eat liv MXB	24m24		1.64gm *	P<.6
f	M m b6c	eat lun MXB	24m24		no dre	P=1.
1827	R f f34	eat MXB MXB	24m25		50.8mg *	P<.002
a	R f f34	eat ute eap	24m25		69.6mg *	P<.009 c
b	R f f34	eat cli MXA	24m25		137.mg *	P<.009 c
c	R f f34	eat thy MXA	24m25		57.6mg \	P<.03
d	R f f34	eat TBA MXB	24m25		55.8mg *	P<.2
e	R f f34	eat liv MXB	24m25		236.mg *	P<.2
1828	R m f34	eat TBA MXB	24m25		48.1mg *	P<.2 -
a	R m f34	eat liv MXB	24m25		1.04gm *	P<.9
N-(1-NAPHTHYL)ETHYLENEDIAMINE.2HCl			1ug.....10.....100.....1mg.....10.....100.....1g.....10		
1829	M f b6c	eat TBA MXB	24m25	av	no dre	P=1. -
a	M f b6c	eat liv MXB	24m25	av	25.6gm *	P<.8
b	M f b6c	eat lun MXB	24m25	av	4.39gm *	P<.2
1830	M m b6c	eat TBA MXB	24m24		no dre	P=1. -
a	M m b6c	eat liv MXB	24m24		no dre	P=1. -
b	M m b6c	eat lun MXB	24m24		no dre	P=1. -
1831	R f f34	eat liv MXA	24m25		#93.5mg \	P<.02 -
a	R f f34	eat TBA MXB	24m25		no dre	P=1.
b	R f f34	eat liv MXB	24m25		93.5mg \	P<.02
1832	R m f34	eat TBA MXB	24m25		41.6mg \	P<.3 -
a	R m f34	eat liv MXB	24m25		no dre	P=1.
sym.-dibeta-NAPHTHYL-p-PHENYLENEDIAMINE.....1ug.....10.....100.....1mg.....10.....100.....1g.....10						
1833	M f b6a	orl lun ade	76w76	evx	221.mg	P<.6 -
a	M f b6a	orl liv hpt	76w76	evx	no dre	P=1. -
b	M f b6a	orl tba mix	76w76	evx	63.8mg	P<.2 -
1834	M m b6a	orl lun ade	76w76	evx	no dre	P=1. -
a	M m b6a	orl liv hpt	76w76	evx	no dre	P=1. -
b	M m b6a	orl tba mix	76w76	evx	no dre	P=1. -
1835	M f b6c	orl liv hpt	76w76	evx	no dre	P=1. -
a	M f b6c	orl lun mix	76w76	evx	no dre	P=1. -
b	M f b6c	orl tba mix	76w76	evx	235.mg	P<.3 -
1836	M m b6c	orl liv hpt	76w76	evx	59.4mg	P<.04 -
a	M m b6c	orl lun ade	76w76	evx	192.mg	P<.3 -
b	M m b6c	orl tba mix	76w76	evx	25.9mg	P<.002 -
1-(1-NAPHTHYL)-2-THIOUREA				100ng.....1ug.....10.....100.....1mg.....10.....100.....1g.....10		
1837	M f b6a	orl lun ade	76w76	evx	no dre	P=1. -
a	M f b6a	orl liv hpt	76w76	evx	no dre	P=1. -
b	M f b6a	orl tba mix	76w76	evx	no dre	P=1. -
1838	M m b6a	orl lun ade	76w76	evx	no dre	P=1. -
a	M m b6a	orl liv hpt	76w76	evx	no dre	P=1. -
b	M m b6a	orl tba mix	76w76	evx	no dre	P=1. -
1839	M f b6c	orl liv hpt	76w76	evx	no dre	P=1. -
a	M f b6c	orl lun mix	76w76	evx	no dre	P=1. -
b	M f b6c	orl tba mix	76w76	evx	5.36mg	P<.3 -
1840	M m b6c	orl lun ade	76w76	evx	1.27mg	P<.04 -
a	M m b6c	orl liv hpt	76w76	evx	no dre	P=1. -
b	M m b6c	orl tba mix	76w76	evx	.700mg	P<.005 -

RefNum	LoConf	UpConf	Cntrl	1Dose	1Inc	2Dose	2Inc	Citation or Pathology	Brkly Code
a	1157	81.4mg	n.s.s.	1/17	73.0mg	1/17			
b	1157	48.8mg	n.s.s.	2/17	73.0mg	3/17			
1822	1157	80.4mg	n.s.s.	1/18	68.0mg	1/18			
a	1157	89.3mg	n.s.s.	2/18	68.0mg	1/18			
b	1157	53.5mg	n.s.s.	3/18	68.0mg	3/18			
1823	1157	129.mg	n.s.s.	0/16	73.0mg	0/16			
a	1157	129.mg	n.s.s.	0/16	73.0mg	0/16			
b	1157	129.mg	n.s.s.	0/16	73.0mg	0/16			
1824	1157	48.8mg	n.s.s.	0/16	68.0mg	2/17			
a	1157	127.mg	n.s.s.	0/16	68.0mg	0/17			
b	1157	26.9mg	966.mg	0/16	68.0mg	5/17			
1,5-NAPHTHALENE-DIAMINE (1,5-diaminonaphthalene) 2243-62-1									
1825	c03021	42.1mg	129.mg	3/50	127.mg	38/50	(253.mg	34/50)	liv:hpa,hpc; lun:a/a,a/c; thy:cca,ccr,fca,pcy,ppa. C
a	c03021	69.5mg	236.mg	1/50	127.mg	25/50	(253.mg	16/50)	
b	c03021	89.8mg	223.mg	1/50	127.mg	28/50	253.mg	27/50	liv:hpa,hpc.
c	c03021	186.mg	1.46gm	2/50	127.mg	17/50	253.mg	14/50	thy:fca,pcy,ppa.
d	c03021	161.mg	1.00gm	0/50	127.mg	10/50	(253.mg	5/50)	lun:a/a,a/c.
e	c03021	455.mg	3.26gm	0/50	127.mg	2/50	253.mg	8/50	thy:cca,ccr.
f	c03021	571.mg	9.23gm	0/50	127.mg	1/50	253.mg	6/50	
g	c03021	102.mg	n.s.s.	21/50	127.mg	41/50	253.mg	37/50	
h	c03021	89.8mg	223.mg	1/50	127.mg	28/50	253.mg	27/50	liv:hpa,hpc,nnd.
i	c03021	161.mg	1.00gm	0/50	127.mg	10/50	(253.mg	5/50)	lun:a/a,a/c.
1826	c03021	139.mg	373.mg	0/50	118.mg	10/50	235.mg	19/50	thy:cca,ccr,fca,pcy,ppa. C
a	c03021	170.mg	510.mg	0/50	118.mg	8/50	235.mg	16/50	thy:fca,pcy,ppa.
b	c03021	515.mg	n.s.s.	0/50	118.mg	2/50	235.mg	4/50	thy:cca,ccr.
c	c03021	661.mg	n.s.s.	0/50	118.mg	0/50	235.mg	4/50	
d	c03021	131.mg	n.s.s.	24/50	118.mg	40/50	235.mg	25/50	
e	c03021	291.mg	n.s.s.	12/50	118.mg	13/50	235.mg	13/50	liv:hpa,hpc,nnd.
f	c03021	607.mg	n.s.s.	4/50	118.mg	9/50	235.mg	2/50	lun:a/a,a/c.
1827	c03021	29.5mg	242.mg	3/25	24.3mg	16/50	48.1mg	28/50	cli:adn,can; ute:osp. C
a	c03021	37.7mg	2.04gm	2/25	24.3mg	14/50	48.1mg	20/50	
b	c03021	69.1mg	4.53gm	1/25	24.3mg	3/50	48.1mg	13/50	cli:adn,can.
c	c03021	26.2mg	n.s.s.	1/25	24.3mg	12/50	(48.1mg	4/50)	thy:cca,ccr. S
d	c03021	19.7mg	n.s.s.	17/25	24.3mg	41/50	48.1mg	49/50	
e	c03021	107.mg	n.s.s.	0/25	24.3mg	4/50	48.1mg	4/50	liv:hpa,hpc,nnd.
1828	c03021	19.2mg	n.s.s.	10/25	19.4mg	32/50	38.9mg	38/50	
a	c03021	86.4mg	n.s.s.	1/25	19.4mg	7/50	38.9mg	4/50	liv:hpa,hpc,nnd.
N-(1-NAPHTHYL)ETHYLENE-DIAMINE, 2HCl 1465-25-4									
1829	c03281	851.mg	n.s.s.	21/50	253.mg	15/50	392.mg	9/50	
a	c03281	1.94gm	n.s.s.	1/50	253.mg	1/50	392.mg	1/50	liv:hpa,hpc,nnd.
b	c03281	1.33gm	n.s.s.	0/50	253.mg	2/50	392.mg	1/50	lun:a/a,a/c.
1830	c03281	119.mg	n.s.s.	24/50	60.0mg	19/50	(120.mg	16/50)	
a	c03281	368.mg	n.s.s.	12/50	60.0mg	5/50	120.mg	9/50	liv:hpa,hpc,nnd.
b	c03281	384.mg	n.s.s.	4/50	60.0mg	7/50	120.mg	3/50	lun:a/a,a/c.
1831	c03281	42.3mg	n.s.s.	0/25	25.0mg	8/50	(50.0mg	1/50)	liv:hpc,nnd. S
a	c03281	69.2mg	n.s.s.	17/25	25.0mg	36/50	50.0mg	30/50	
b	c03281	42.3mg	n.s.s.	0/25	25.0mg	8/50	(50.0mg	1/50)	liv:hpa,hpc,nnd.
1832	c03281	12.5mg	n.s.s.	10/25	20.0mg	35/50	(40.0mg	27/50)	
a	c03281	265.mg	n.s.s.	1/25	20.0mg	2/50	40.0mg	1/50	liv:hpa,hpc,nnd.
sym.-dibeta-NAPHTHYL-p-PHENYLENE-DIAMINE (Agerite white) 93-46-9									
1833	1305	30.7mg	n.s.s.	1/17	38.9mg	2/17			Innes;ntis,1968/1969
a	1305	72.8mg	n.s.s.	0/17	38.9mg	0/17			
b	1305	17.3mg	n.s.s.	2/17	38.9mg	5/17			
1834	1305	47.5mg	n.s.s.	2/18	36.2mg	1/18			
a	1305	71.7mg	n.s.s.	1/18	36.2mg	0/18			
b	1305	37.5mg	n.s.s.	3/18	36.2mg	2/18			
1835	1305	72.8mg	n.s.s.	0/16	38.9mg	0/17			
a	1305	72.8mg	n.s.s.	0/16	38.9mg	0/17			
b	1305	38.2mg	n.s.s.	0/16	38.9mg	1/17			
1836	1305	17.9mg	n.s.s.	0/16	36.2mg	3/15			
a	1305	31.2mg	n.s.s.	0/16	36.2mg	1/15			
b	1305	10.4mg	117.mg	0/16	36.2mg	6/15			
1-(1-NAPHTHYL)-2-THIOUREA (ANTU) 86-88-4									
1837	1155	.991mg	n.s.s.	1/17	.834mg	1/18			Innes;ntis,1968/1969
a	1155	1.65mg	n.s.s.	0/17	.834mg	0/18			
b	1155	1.10mg	n.s.s.	2/17	.834mg	1/18			
1838	1155	1.02mg	n.s.s.	2/18	.776mg	1/18			
a	1155	1.54mg	n.s.s.	1/18	.776mg	0/18			
b	1155	.803mg	n.s.s.	3/18	.776mg	2/18			
1839	1155	1.65mg	n.s.s.	0/16	.834mg	0/18			
a	1155	1.65mg	n.s.s.	0/16	.834mg	0/18			
b	1155	.869mg	n.s.s.	0/16	.834mg	1/18			
1840	1155	.383mg	n.s.s.	0/16	.776mg	3/15			
a	1155	1.28mg	n.s.s.	0/16	.776mg	0/15			
b	1155	.263mg	5.52mg	0/16	.776mg	5/15			

Spe	Strain	Site	Xpo + Xpt	Notes	TD50	2Tailpvl
Sex	Route	Hist			DR	AuOp
2-NAPHTHYLAMINE					100ng.....1ug.....10.....100.....1mg.....10.....100.....1g.....10	
1841	M f	bal eat	liv hnd 40w55	er		17.4mg P<.0005
a	M f	bal eat	liv ade 40w55	er		36.9mg P<.0005
b	M f	bal eat	liv mix 40w55	er		63.0mg P<.0005
c	M f	bal eat	liv hpt 40w55	er		175.8mg P<.04 +
d	M f	bal eat	ubl tum 40w55	er		no dre P=1. -
1842	M b	cba gev	liv hpt 79w79	a		20.5mg P<.002 +
1843	P f	rhe mix	ubl mix 60m60	emrv	(±)	5.74mg P<.06 +
a	P f	rhe mix	ubl pam 60m60	emrv		25.8mg P<.4 +
b	P f	rhe mix	ubl tcc 60m60	emrv		25.8mg P<.4 +
c	P f	rhe mix	ubl ppa 60m60	emrv		25.8mg P<.4 +
d	P f	rhe mix	ubl car 60m60	emrv		53.7mg P<.6 +
e	P f	rhe mix	ubl ppc 60m60	emrv		53.7mg P<.6 +
1844	R b	alb eat	ubl pam 24m24	r		no dre P=1. -
1845	R b	alb eat	ubl pam 24m24	er		9.68mg P<.2
1846	R b	alb eat	ubl pam 24m24	efr		35.4mg P<.4
NICKEL					100ng.....1ug.....10.....100.....1mg.....10.....100.....1g.....10	
1847	R f	leb wat	tba mix 43m43	e		no dre P=1. -
a	R f	leb wat	tba mal 43m43	e		no dre P=1. -
1848	R m	leb wat	tba mix 37m37	e		no dre P=1. -
a	R m	leb wat	tba mal 37m37	e		no dre P=1. -
NICKEL (II) ACETATE					100ng.....1ug.....10.....100.....1mg.....10.....100.....1g.....10	
1849	M f	cd1 wat	tba mix 29m29	e		29.0mg P<.8 -
1850	M f	cd1 wat	lun tum 33m33	e		no dre P=1. -
a	M f	cd1 wat	liv car 33m33	e		no dre P=1. -
b	M f	cd1 wat	tba mix 33m33	e		no dre P=1. -
1851	M m	cd1 wat	tba mix 32m32	e		no dre P=1. -
1852	M m	cd1 wat	lun tum 32m32	e		no dre P=1. -
e	M m	cd1 wat	tba tum 32m32	e		no dre P=1. -
NICKEL DIBUTYLDITHIOCARBAMATE					100ng.....1ug.....10.....100.....1mg.....10.....100.....1g.....10	
1853	M f	b6a orl	lun ade 76w76	evx		86.9ug P<.4 -
a	M f	b6a orl	liv hpt 76w76	evx		no dre P=1. -
b	M f	b6a orl	tba mix 76w76	evx		.185mg P<.7 -
1854	M m	b6a orl	lun ade 76w76	evx		.153mg P<.7 -
a	M m	b6a orl	liv hpt 76w76	evx		no dre P=1. -
b	M m	b6a orl	tba mix 76w76	evx		no dre P=1. -
1855	M f	b6c orl	lun ade 76w76	evx		.174mg P<.3 -
a	M f	b6c orl	liv hpt 76w76	evx		no dre P=1. -
b	M f	b6c orl	tba mix 76w76	evx		.174mg P<.3 -
1856	M m	b6c orl	liv hpt 76w76	evx		50.9ug P<.04 -
a	M m	b6c orl	lun ade 76w76	evx		.163mg P<.3 -
b	M m	b6c orl	tba mix 76w76	evx		28.3ug P<.007 -
NICOTINE					100ng.....1ug.....10.....100.....1mg.....10.....100.....1g.....10	
1857	R f	sda ipj	tba mal 24m24	ea		no dre P=1. -
1858	R m	sda ipj	liv hae 24m24	ea		no dre P=1. -
a	R m	sda ipj	tba mal 24m24	ea		6.38mg P<.6 -
NICOTINIC ACID HYDRAZIDE					100ng.....1ug.....10.....100.....1mg.....10.....100.....1g.....10	
1859	M f	sua wat	lun mix 24m24	e		145.8mg P<.0005+
a	M f	sua wat	lun ade 24m24	e		181.8mg P<.0005
b	M f	sua wat	lun adc 24m24	e		511.8mg P<.0005
c	M f	sua wat	liv ang 24m24	e		no dre P=1. -
d	M f	sua wat	liv agm 24m24	e		no dre P=1. -
1860	M m	sua wat	lun ade 23m23	e		428.8mg P<.004
a	M m	sua wat	lun mix 23m23	e		528.8mg P<.05 +
b	M m	sua wat	liv hpt 23m23	e		1.41gm P<.08 -
c	M m	sua wat	liv ang 23m23	e		no dre P=1. -
d	M m	sua wat	liv agm 23m23	e		no dre P=1. -
NIGROSINE					100ng.....1ug.....10.....100.....1mg.....10.....100.....1g.....10	
1861	R f	nss eat	liv tum 64w64	e		no dre P=1. -
a	R f	nss eat	tba mix 64w64	e		no dre P=1. -
1862	R m	nss eat	liv tum 64w64	e		no dre P=1. -
a	R m	nss eat	tba mix 64w64	e		no dre P=1. -
NIOBATE, SODIUM					100ng.....1ug.....10.....100.....1mg.....10.....100.....1g.....10	
1863	M b	cd1 wat	lun tum 31m31	e		no dre P=1. -
a	M b	cd1 wat	liv tum 31m31	e		no dre P=1. -
b	M b	cd1 wat	tba tum 31m31	e		no dre P=1. -
c	M b	cd1 wat	tba mal 31m31	e		no dre P=1. -
NITHIAZIDE					100ng.....1ug.....10.....100.....1mg.....10.....100.....1g.....10	
1864	M f	b6c eat	TBA MXB 22m24	v		1.40gm * P<.2 -
a	M f	b6c eat	liv MXB 22m24	v		2.72gm * P<.3 -
b	M f	b6c eat	lun MXB 22m24	v		no dre P=1. -

CARCINOGENIC POTENCY DATABASE

RefNum	LoConf	UpConf	Cntrl	1Dose	1Inc	2Dose	2Inc	Citation or Pathology	Brkly Code
2-NAPHTHYLAMINE 91-59-8									
1841	1446	7.87mg	41.7mg	0/17	189.mg	14/16		Yoshida;gann,70,645-652;1979	
a	1446	17.2mg	97.2mg	0/17	189.mg	10/16			
b	1446	26.7mg	223.mg	0/17	189.mg	7/16			
c	1446	52.6mg	n.s.s.	0/17	189.mg	3/16			
d	1446	174.mg	n.s.s.	0/17	189.mg	0/16			
1842	207	10.5mg	67.5mg	0/7	50.1mg	13/21		Bonser;bjca,6,412-424;1952	
1843	1470	2.42mg	n.s.s.	0/3	90.5mg	7/14		Conzelman;jnci,42,825-831;1969	
a	1470	6.34mg	n.s.s.	0/3	90.5mg	2/14			
b	1470	6.34mg	n.s.s.	0/3	90.5mg	2/14			
c	1470	6.34mg	n.s.s.	0/3	90.5mg	2/14			
d	1470	8.74mg	n.s.s.	0/3	90.5mg	1/14			
e	1470	8.74mg	n.s.s.	0/3	90.5mg	1/14			
1844	207m	15.8mg	n.s.s.	0/17	4.50mg	0/17		Bonser;bjca,6,412-424;1952	
1845	207n	2.90mg	n.s.s.	0/5	4.50mg	3/11			
1846	207o	5.76mg	n.s.s.	0/5	4.50mg	1/12			
NICKEL 7440-02-0									
1847	1464	1.29mg	n.s.s.	10/26	.286mg	9/27		Schroeder;jnut,104,239-243;1974	
a	1464	2.83mg	n.s.s.	7/26	.286mg	3/27			
1848	1464	.919mg	n.s.s.	9/23	.250mg	4/17			
a	1464	1.10mg	n.s.s.	4/23	.250mg	2/17			
NICKEL (II) ACETATE 373-02-4									
1849	1395	2.89mg	n.s.s.	9/45	1.00mg	10/44		Schroeder;jnut,105,452-458;1975	
1850	56	6.58mg	n.s.s.	9/60	1.00mg	3/33		Schroeder;jnut,83,239-250;1964	
a	56	12.7mg	n.s.s.	1/60	1.00mg	0/33			
b	56	8.98mg	n.s.s.	22/60	1.00mg	3/33			
1851	1395	5.82mg	n.s.s.	10/43	.833mg	4/37		Schroeder;jnut,105,452-458;1975	
1852	56	4.94mg	n.s.s.	8/44	.833mg	5/41		Schroeder;jnut,83,239-250;1964	
a	56	4.36mg	n.s.s.	11/44	.833mg	7/41			
NICKEL DIBUTYLDIETHIOCARBAMATE (Vanguard N) 13927-77-0									
1853	1357	19.0ug	n.s.s.	1/17	28.9ug	3/18		Innes;ntis,1968/1969	
a	1357	57.3ug	n.s.s.	0/17	28.9ug	0/18			
b	1357	20.8ug	n.s.s.	2/17	28.9ug	3/18			
1854	1357	19.2ug	n.s.s.	2/18	27.0ug	3/18			
a	1357	53.5ug	n.s.s.	1/18	27.0ug	0/18			
b	1357	21.2ug	n.s.s.	3/18	27.0ug	3/18			
1855	1357	28.4ug	n.s.s.	0/16	28.9ug	1/17			
a	1357	54.1ug	n.s.s.	0/16	28.9ug	0/17			
b	1357	28.4ug	n.s.s.	0/16	28.9ug	1/17			
1856	1357	15.3ug	n.s.s.	0/16	27.0ug	3/17			
a	1357	26.5ug	n.s.s.	0/16	27.0ug	1/17			
b	1357	10.7ug	.383mg	0/16	27.0ug	5/17			
NICOTINE 54-11-5									
1857	1134	1.00mg	n.s.s.	3/33	.286mg	2/32		Schmahl;zkko,86,77-84;1976	
1858	1134	2.06mg	n.s.s.	1/36	.286mg	0/35			
a	1134	.898mg	n.s.s.	1/36	.286mg	2/35			
NICOTINIC ACID HYDRAZIDE (3-pyridoyl hydrazine) 553-53-7									
1859	1084	85.8mg	294.mg	25/98	250.mg	38/50		Toth;onco,38,106-109;1981	
a	1084	106.mg	376.mg	20/98	250.mg	34/50			
b	1084	259.mg	1.57gm	6/98	250.mg	16/50			
c	1084	1.41gm	n.s.s.	3/71	250.mg	1/42			
d	1084	1.54gm	n.s.s.	5/71	250.mg	1/42			
1860	1084	197.mg	3.49gm	16/99	208.mg	19/49			
a	1084	203.mg	n.s.s.	26/99	208.mg	21/49			
b	1084	230.mg	n.s.s.	0/43	208.mg	1/11			
c	1084	1.30gm	n.s.s.	4/90	208.mg	0/32			
d	1084	1.01gm	n.s.s.	8/80	208.mg	0/25			
NIGROSINE ---									
1861	1372	89.3mg	n.s.s.	0/7	150.mg	0/9	1.50gm	0/5	Allmark;jph,9,622-628;1957
a	1372	586.mg	n.s.s.	1/7	150.mg	1/9	1.50gm	0/5	
1862	1372	4.26mg	n.s.s.	0/5	12.0mg	0/5	120.mg	0/5	
a	1372	4.26mg	n.s.s.	0/5	12.0mg	0/5	120.mg	0/5	
NIOBATE, SODIUM 12034-09-2									
1863	1036	7.82mg	n.s.s.	15/71	.877mg	11/79		Kanisawa;canr,29,892-895;1969	
a	1036	24.1mg	n.s.s.	4/71	.877mg	0/79			
b	1036	6.56mg	n.s.s.	24/71	.877mg	18/79			
c	1036	10.8mg	n.s.s.	8/71	.877mg	5/79			
NITHAZIDE 139-94-6									
1864	c03792	522.mg	n.s.s.	6/20	294.mg	13/50	587.mg	23/50	
a	c03792	924.mg	n.s.s.	3/20	294.mg	4/50	587.mg	12/50	liv:hpa,hpc,nnd.
b	c03792	3.71gm	n.s.s.	3/20	294.mg	1/50	587.mg	2/50	lun:a/a,e/c.

Spe	Strain	Site	Xpo+Xpt	Notes	TD50	2Tailpvl
Sex	Route	Hist			DR	AuOp
1865	M m b6c eat liv	MXA	22m24 v			758.mg * P<.05 c
a	M m b6c eat liv	hpc	22m24 v	: ±		1.90gm * P<.2 c
b	M m b6c eat TBA	MXB	22m24 v			4.75gm * P<.9
c	M m b6c eat liv	MXB	22m24 v			758.mg * P<.05
d	M m b6c eat lun	MXB	22m24 v			no dre P=1.
1866	R f f34 eat MXA	MXA	22m24 v	: ±		131.mg * P<.02 c
a	R f f34 eat TBA	MXB	22m24 v			175.mg * P<.6
b	R f f34 eat liv	MXB	22m24 v			no dre P=1.
1867	R m f34 eat TBA	MXB	22m24 v	:>		no dre P=1. -
a	R m f34 eat liv	MXB	22m24 v			508.mg * P<.3
NITRATE, SODIUM					100ng...1ug...10...100...1mg...10...100...1g...10	
1868	R f mrc wat pit	tum	20m24 e	.	+	103.mg P<.004 -
a	R f mrc wat tba	mix	20m24 e			86.9mg P<.004 -
1869	R m mrc wat tba	mix	20m24 e	.	>	750.mg P<.8 -
NITRIC OXIDE					100ng...1ug...10...100...1mg...10...100...1g...10	
1870	M f fjc inh	lun	ade 29m29	.	>	no dre P=1. -
NITRILOTRIACETIC ACID					100ng...1ug...10...100...1mg...10...100...1g...10	
1871	M f b6c eat kid	uac	77w91		:	13.8gm * P<.06 c
a	M f b6c eat TBA	MXB	77w91			3.95gm * P<.3
b	M f b6c eat liv	MXB	77w91			no dre P=1.
c	M f b6c eat lun	MXB	77w91			9.31gm * P<.2
1872	M m b6c eat MXA	MXA	77w91		++:	1.47gm / P<.0005c
a	M m b6c eat TBA	MXB	77w91			2.21gm / P<.09
b	M m b6c eat liv	MXB	77w91			no dre P=1.
c	M m b6c eat lun	MXB	77w91			no dre P=1.
1873	R f f34 eat liv	nnd	77w99		+::	810.mg * P<.004
a	R f f34 eat MXA	MXA	77w99			1.45gm * P<.002 c
b	R f f34 eat ubl	MXA	77w99			1.57gm * P<.002 c
c	R f f34 eat adr	phe	77w99			1.71gm / P<.005
d	R f f34 eat lun	a/c	77w99			2.25gm * P<.03
e	R f f34 eat TBA	MXB	77w99			631.mg * P<.2
f	R f f34 eat liv	MXB	77w99			810.mg * P<.004
1874	R m f34 eat MXA	MXA	18m24		: ±	446.mg \ P<.05
a	R m f34 eat MXA	MXA	18m24			2.26gm * P<.02 c
b	R m f34 eat TBA	MXB	18m24			7.12gm * P<.9
c	R m f34 eat liv	MXB	18m24			no dre P=1.
1875	R f mrc wat tba	mix	20m24	.	>	221.mg P<.2 -
1876	R m mrc wat tba	mix	20m24	.	>	248.mg P<.3 -
NITRILOTRIACETIC ACID, TRISODIUM SALT, MONOHYDRATE					10...100...1mg...10...100...1g...10	
1877	M f b6c eat TBA	MXB	78w91		:>	5.31gm * P<.8 -
a	M f b6c eat liv	MXB	78w91			no dre P=1.
b	M f b6c eat lun	MXB	78w91			61.8gm * P<.9
1878	M m b6c eat ---	MXA	78w91		: ±	#1.55gm * P<.02 -
a	M m b6c eat TBA	MXB	78w91			no dre P=1.
b	M m b6c eat liv	MXB	78w91			no dre P=1.
c	M m b6c eat lun	MXB	78w91			1.99gm \ P<.6
1879	R f f34 eat MXA	MXA	24m24		+::	783.mg * P<.0005c
a	R f f34 eat ubl	MXA	24m24			1.99gm * P<.002 c
b	R f f34 eat ure	tcc	24m24			2.28gm * P<.0005c
c	R f f34 eat kid	MXA	24m24			2.88gm * P<.002 c
d	R f f34 eat TBA	MXB	24m24			2.99gm * P<.6
e	R f f34 eat liv	MXB	24m24			no dre P=1.
1880	R f f34 eat TBA	MXB	18m25		:>	no dre P=1. -
a	R f f34 eat liv	MXB	18m25			12.0gm * P<.5
1881	R m f34 eat MXA	MXA	24m24		+::	511.mg * P<.0005c
a	R m f34 eat kid	MXA	24m24			826.mg * P<.0005c
b	R m f34 eat ure	tcc	24m24			965.mg * P<.0005c
c	R m f34 eat kid	tcc	24m24			2.53gm * P<.002 c
d	R m f34 eat TBA	MXB	24m24			329.mg Z P<.0005
e	R m f34 eat liv	MXB	24m24			2.20gm * P<.05
1882	R m f34 eat TBA	MXB	18m25		:>	2.63gm * P<.7 -
a	R m f34 eat liv	MXB	18m25			no dre P=1.
1883	R m cdr wat kid	ade	24m24 e	.	±	320.mg P<.02 +
a	R m cdr wat tba	mix	24m24 e	.	.	88.4mg P<.07
1884	R m cdr wat kid	ade	24m24 e	.	+	224.mg P<.0005+
a	R m cdr wat tba	mix	24m24 e	.	.	105.mg P<.2
NITRITE, SODIUM					100ng...1ug...10...100...1mg...10...100...1g...10	
1885	M f cb6 eat liv	hpc	52w69 e		.	no dre P=1. -
a	M f cb6 eat lun	ade	52w69 e		.	no dre P=1. -
b	M f cb6 eat tba	mix	52w69 e		.	no dre P=1. -
1886	M m cb6 eat lun	ade	52w69 e		.	1.61gm P<.2 -
a	M m cb6 eat liv	hpc	52w69 e		.	no dre P=1. -
b	M m cb6 eat tba	mix	52w69 e		.	1.21gm P<.4 -

RefNum	LoConf	UpConf	Cntrl	1Dose	1Inc	2Dose	2Inc	Citation or Pathology	Brkly Code
1865	c03792	349.mg n.s.s.	4/20	271.mg	15/50	542.mg	25/50		liv:hpa,hpc.
a	c03792	721.mg n.s.s.	2/20	271.mg	6/50	542.mg	12/50		
b	c03792	415.mg n.s.s.	10/20	271.mg	27/50	542.mg	28/50		
c	c03792	349.mg n.s.s.	4/20	271.mg	15/50	542.mg	25/50		liv:hpa,hpc,nnd.
d	c03792	874.mg n.s.s.	3/20	271.mg	4/50	542.mg	1/50)		lun:a/a,a/c.
1866	c03792	68.2mg n.s.s.	1/20	28.2mg	5/50	56.5mg	15/50	mgl:cyn, fba; ski:fba; sub:fba.	
a	c03792	36.5mg n.s.s.	13/20	28.2mg	28/50	56.5mg	38/50		
b	c03792	n.s.s. n.s.s.	0/20	28.2mg	0/50	56.5mg	0/50		liv:hpa,hpc,nnd.
1867	c03792	48.5mg n.s.s.	11/20	22.6mg	25/50	45.2mg	24/50		
a	c03792	154.mg n.s.s.	0/20	22.6mg	1/50	45.2mg	2/50		liv:hpa,hpc,nnd.
NITRATE, SODIUM 7631-99-4									
1868	213	42.8mg 764.mg	3/15	165.mg	11/15			Lijinsky;jnci,50,1061-1063;1973	
a	213	35.3mg 665.mg	4/15	165.mg	12/15				
1869	213	83.5mg n.s.s.	5/15	115.mg	6/15				
NITRIC OXIDE 10102-43-9									
1870	1388	38.4mg n.s.s.	6/64	5.19mg	5/65			Oda;envr,22,254-263;1980	
NITRILOTRIACETIC ACID 139-13-9									
1871	c02766	4.77gm n.s.s.	0/20	836.mg	0/50	1.67gm	4/50		
a	c02766	1.33gm n.s.s.	4/20	836.mg	13/50	1.67gm	19/50		
b	c02766	9.71gm n.s.s.	0/20	836.mg	1/50	1.67gm	0/50		liv:hpa,hpc,nnd.
c	c02766	3.80gm n.s.s.	0/20	836.mg	2/50	1.67gm	4/50		lun:a/a,a/c.
1872	c02766	1.04gm 2.17gm	0/20	771.mg	5/50	1.54gm	24/50		k/p:pam; kid:tla,uac.
a	c02766	1.06gm n.s.s.	10/20	771.mg	14/50	1.54gm	31/50		
b	c02766	9.66gm n.s.s.	3/20	771.mg	3/50	1.54gm	2/50		liv:hpa,hpc,nnd.
c	c02766	4.68gm n.s.s.	4/20	771.mg	5/50	1.54gm	6/50		lun:a/a,a/c.
1873	c02766	508.mg 2.19gm	2/20	281.mg	8/50	562.mg	22/50		
a	c02766	908.mg 2.72gm	0/20	281.mg	2/50	562.mg	13/50	kid:tla, tpp; ubl:sqc, tcc.	\$
b	c02766	967.mg 3.08gm	0/20	281.mg	2/50	562.mg	12/50	ubl:sqc, tcc.	
c	c02766	984.mg 4.86gm	1/20	281.mg	0/50	562.mg	14/50		\$
d	c02766	1.28gm 10.1gm	0/20	281.mg	3/50	562.mg	7/50		\$
e	c02766	278.mg n.s.s.	14/20	281.mg	33/50	562.mg	47/50		
f	c02766	508.mg 2.19gm	2/20	281.mg	8/50	562.mg	22/50		liv:hpa,hpc,nnd.
1874	c02766	234.mg 10.6gm	2/20	225.mg	16/50	450.mg	8/50)	adr:phe; pit:bae, cra; pni:isa; thy:fca, fcc.	\$
a	c02766	1.21gm 7.43gm	0/20	225.mg	1/50	450.mg	7/50	kid:tla, uac; ure:pam, ppa.	
b	c02766	442.mg n.s.s.	8/20	225.mg	26/50	450.mg	22/50		
c	c02766	3.30gm n.s.s.	3/20	225.mg	5/50	450.mg	2/50		liv:hpa,hpc,nnd.
1875	213	67.2mg n.s.s.	5/15	165.mg	9/15			Lijinsky;jnci,50,1061-1063;1973	
1876	213	64.2mg n.s.s.	4/15	115.mg	7/15				
NITRILOTRIACETIC ACID, TRISODIUM SALT, MONOHYDRATE 18662-53-8									
1877	c01446	667.mg n.s.s.	6/20	279.mg	11/50	557.mg	16/50		
a	c01446	2.31gm n.s.s.	2/20	279.mg	3/50	557.mg	2/50		liv:hpa,hpc,nnd.
b	c01446	2.72gm n.s.s.	1/20	279.mg	0/50	557.mg	2/50		lun:a/a,a/c.
1878	c01446	778.mg n.s.s.	0/20	257.mg	3/49	514.mg	8/50		---:leu, lym. \$
a	c01446	730.mg n.s.s.	7/20	257.mg	17/49	514.mg	14/50		
b	c01446	2.12gm n.s.s.	4/20	257.mg	4/49	514.mg	3/50		liv:hpa,hpc,nnd.
c	c01446	409.mg n.s.s.	2/20	257.mg	7/49	514.mg	0/50)		lun:a/a,a/c.
1879	c01445	417.mg 1.73gm	0/24	10.0mg	0/24	100.mg	1/24	1.00gm	13/24
a	c01445	808.mg 10.9gm	0/24	10.0mg	0/24	100.mg	1/24	1.00gm	5/24
b	c01445	919.mg 8.10gm	0/24	10.0mg	0/24	100.mg	0/24	1.00gm	6/24
c	c01445	994.mg 17.1gm	0/24	10.0mg	0/24	100.mg	0/24	1.00gm	4/24
d	c01445	481.mg n.s.s.	18/24	10.0mg	19/24	100.mg	17/24	1.00gm	20/24
e	c01445	2.37gm n.s.s.	1/24	10.0mg	3/24	100.mg	1/24	1.00gm	1/24
1880	c01446	559.mg n.s.s.	13/20	276.mg	36/50	552.mg	26/49		
a	c01446	2.96gm n.s.s.	0/20	276.mg	1/50	552.mg	1/49		liv:hpa,hpc,nnd.
1881	c01445	261.mg 1.10gm	0/24	8.00mg	0/24	80.0mg	0/24	800.mg	14/24
a	c01445	367.mg 2.13gm	0/24	8.00mg	0/24	80.0mg	0/24	800.mg	9/24
b	c01445	412.mg 2.66gm	0/24	8.00mg	0/24	80.0mg	0/24	800.mg	8/24
c	c01445	830.mg 13.7gm	0/24	8.00mg	0/24	80.0mg	0/24	800.mg	4/24
d	c01445	157.mg 1.21gm	8/24	8.00mg	15/24	80.0mg	10/24	800.mg	18/24
e	c01445	579.mg n.s.s.	2/24	8.00mg	0/24	80.0mg	1/24	800.mg	3/24
1882	c01446	409.mg n.s.s.	10/20	221.mg	26/50	441.mg	24/50		
a	c01446	3.59gm n.s.s.	1/20	221.mg	0/50	441.mg	1/50		liv:hpa,hpc,nnd.
1883	1089m	139.mg n.s.s.	4/101	50.0mg	13/96			Goyar;jnci,66,869-880;1981/pers.comm.	
a	1089m	35.5mg n.s.s.	61/101	50.0mg	70/96				
1884	1089n	113.mg 748.mg	1/85	50.0mg	13/87				
a	1089n	37.9mg n.s.s.	50/85	50.0mg	61/87				
NITRITE, SODIUM 7632-00-0									
1885	1361	532.mg n.s.s.	1/92	489.mg	0/12			Murthy;ijcn,23,253-259;1979	
a	1361	532.mg n.s.s.	2/92	489.mg	0/12				
b	1361	268.mg n.s.s.	17/92	489.mg	2/12				
1886	1361	236.mg n.s.s.	1/95	452.mg	1/11				
a	1361	451.mg n.s.s.	2/95	452.mg	0/11				
b	1361	185.mg n.s.s.	8/95	452.mg	2/11				

Spe	Strain	Site	Xpo+Xpt	Notes	TD50	2Tailpvl
Sex	Route	Hist			DR	AuOp
1887	M f scd wat	liv hct	8m29 s		744.mg	P<.7 -
a	M f scd wat	lun tum	8m29 s	>	no dre	P=1. -
1888	M m scd wat	lun tum	8m27 s		103.mg	P<.3 -
a	M m scd wat	liv hct	8m27 s	>	no dre	P=1. -
1889	R b cdr eat	---	mly 29m29		539.mg	P<.03 +
a	R b cdr eat	spl lym	29m29	+	601.mg	P<.04
b	R b cdr eat	liv eng	29m29		5.84gm	P<.3
c	R b cdr eat	liv mix	29m29		no dre	P=1. -
1890	R f f34 eat	liv tum	52w69 e		no dre	P=1. -
a	R f f34 eat	tba mix	52w69 e	>	no dre	P=1. -
1891	R m f34 eat	liv tum	52w69 e		no dre	P=1. -
a	R m f34 eat	tba mix	52w69 e	>	no dre	P=1. -
1892	R f mrc wat	liv tum	16m28 e		no dre	P=1. -
a	R f mrc wat	tba tum	16m28 e	>	no dre	P=1. -
1893	R f mrc wat	tba mix	20m24 e		57.3mg	P<.03 -
1894	R m mrc wat	liv tum	16m28 e		no dre	P=1. -
a	R m mrc wat	tba tum	16m28 e	>	no dre	P=1. -
1895	R m mrc wat	tba mix	20m24 e		61.9mg	P<.2 -
1896	R m wis eat	liv mix	92w92 e		155.mg *	P<.007 +
3-NITRO-p-ACETOPHENETIDE						
100ng.....1ug.....10.....100.....1mg.....10.....100.....1g.....10						
1897	M f b6c eat	TBA MXB	78w97 v		no dre	P=1. -
a	M f b6c eat	liv MXB	78w97 v	>	no dre	P=1. -
b	M f b6c eat	lun MXB	78w97 v		30.8gm *	P<.7
1898	M m b6c eat	liv MXA	78w98 v		2.27gm *	P<.03 c
a	M m b6c eat	TBA MXB	78w98 v		3.49gm *	P<.3
b	M m b6c eat	liv MXB	78w98 v		2.27gm *	P<.03
c	M m b6c eat	lun MXB	78w98 v		no dre	P=1. -
1899	R f f34 eat	TBA MXB	18m25 v		no dre	P=1. -
a	R f f34 eat	liv MXB	18m25 v	>	6.24gm *	P<.7
1900	R m f34 eat	TBA MXB	18m24 v		no dre	P=1. -
a	R m f34 eat	liv MXB	18m24 v	>	no dre	P=1. -
5-NITRO-o-ANISIDINE						
100ng.....1ug.....10.....100.....1mg.....10.....100.....1g.....10						
1901	M f b6c eat	---	MXA 78w96 v		2.33gm *	P<.04
a	M f b6c eat	liv hpc	78w96 v		3.72gm /	P<.06 c
b	M f b6c eat	TBA MXB	78w96 v		1.82gm *	P<.2
c	M f b6c eat	liv MXB	78w96 v		3.72gm /	P<.06
d	M f b6c eat	lun MXB	78w96 v		no dre	P=1. -
1902	M m b6c eat	liv hpc	78w95 v		#1.05gm \	P<.003 -
a	M m b6c eat	liv MXA	78w95 v		1.12gm \	P<.005
b	M m b6c eat	TBA MXB	78w95 v		1.69gm \	P<.2
c	M m b6c eat	liv MXB	78w95 v		1.12gm \	P<.005
d	M m b6c eat	lun MXB	78w95 v		no dre	P=1. -
1903	R f f34 eat	MXB MXB	18m25		170.mg *	P<.0005
a	R f f34 eat	mpl MXA	18m25	+	222.mg \	P<.0005
b	R f f34 eat	cli MXA	18m25		230.mg *	P<.0005c
c	R f f34 eat	mpl acn	18m25		254.mg \	P<.0005
d	R f f34 eat	lun MXA	18m25		280.mg \	P<.0005
e	R f f34 eat	MXA MXA	18m25		602.mg *	P<.0005c
f	R f f34 eat	cli MXA	18m25		966.mg *	P<.0005c
g	R f f34 eat	cli can	18m25		1.26gm /	P<.0005c
h	R f f34 eat	TBA MXB	18m25		73.4mg *	P<.0005
i	R f f34 eat	liv MXB	18m25		3.20gm *	P<.2
1904	R m f34 eat	MXB MXB	18m25		28.1mg *	P<.0005
a	R m f34 eat	ski MXA	18m25	+	30.5mg *	P<.0005c
b	R m f34 eat	ski tri	18m25		43.7mg *	P<.0005c
c	R m f34 eat	ski bcc	18m25		52.0mg /	P<.0005c
d	R m f34 eat	ski MXA	18m25		66.0mg *	P<.0005c
e	R m f34 eat	MXA MXA	18m25		105.mg /	P<.0005c
f	R m f34 eat	pit adn	18m25		115.mg *	P<.0005
g	R m f34 eat	ski sec	18m25		162.mg /	P<.0005c
h	R m f34 eat	pre MXA	18m25		196.mg *	P<.0005
i	R m f34 eat	ski eqc	18m25		252.mg /	P<.0005c
j	R m f34 eat	adr MXA	18m25		345.mg *	P<.0005
k	R m f34 eat	TBA MXB	18m25		12.8mg *	P<.0005
l	R m f34 eat	liv MXB	18m25		194.mg *	P<.002
5-NITRO-2-FURALDEHYDE SEMICARBAZONE						
.....1ug.....10.....100.....1mg.....10.....100.....1g.....10						
1905	R f hza eat	apl fba	36w54 es		6.52mg	P<.006 +
a	R f hza eat	liv tum	36w54 es	+	no dre	P=1. -
1906	R f hza eat	mam tum	44w60 es		noTD50	P<.0005+
a	R f hza eat	liv tum	44w60 es	<	no dre	P=1. -
1907	R f sda eat	mam tum	46w66 er		7.12mg	P<.0005+
5-NITRO-2-FURAMIDOXIME						
100ng.....1ug.....10.....100.....1mg.....10.....100.....1g.....10						
1908	R f sda eat	liv tum	46w66 e		no dre	P=1. -
a	R f sda eat	tba mix	46w66 e	>	42.0mg	P<.5 -

RefNum	LoConf	UpConf	Cntrl	1Dose	1Inc	2Dose	2Inc	Citation or Pathology	Brkly Code
1887	1255	79.3mg	n.s.s.	1/16	30.7mg	2/20		Anderson; jcn, 24, 319-322; 1979	
a	1255	132. mg	n.s.s.	3/16	30.7mg	1/20			
1888	1255	25.7mg	n.s.s.	4/21	27.7mg	6/17			
a	1255	52.8mg	n.s.s.	5/21	27.7mg	3/17			
1889	471	231. mg	n.s.s.	6/136	45.0mg	16/136		Newberne; scie, 204, 1079-1081; 1979	
a	471	246. mg	n.s.s.	6/136	45.0mg	15/136			
b	471	952. mg	n.s.s.	0/136	45.0mg	1/136			
c	471	1.08gm	n.s.s.	1/136	45.0mg	1/136			
1890	1361	273. mg	n.s.s.	0/44	188. mg	0/16		Murthy; jcn, 23, 253-259; 1979	
a	1361	88.4mg	n.s.s.	20/44	188. mg	6/16			
1891	1361	218. mg	n.s.s.	0/50	151. mg	0/16			
a	1361	58.8mg	n.s.s.	30/50	151. mg	8/16			
1892	1189	41.3mg	n.s.s.	0/20	11.2mg	0/13		Greenblatt; jnci, 50, 799-802; 1973	
a	1189	6.48mg	n.s.s.	14/20	11.2mg	9/13			
1893	213	21.4mg	n.s.s.	4/15	65.9mg	10/15		Lijinsky; jnci, 50, 1061-1063; 1973	
1894	1189	33.4mg	n.s.s.	0/20	7.85mg	0/15		Greenblatt; jnci, 50, 799-802; 1973	
a	1189	12.9mg	n.s.s.	7/20	7.85mg	4/15			
1895	213	18.8mg	n.s.s.	5/15	46.2mg	9/15		Lijinsky; jnci, 50, 1061-1063; 1973	
1896	1352	63.2mg	2.04gm	0/19	32.0mg	1/22	64.0mg	5/19	Aoyagi; jnci, 65, 411-414; 1980
3-NITRO-p-ACETOPHENETIDE 1777-84-0									
1897	c01978	1.44gm	n.s.s.	22/50	763. mg	17/50	(1.53gm	15/50)	
a	c01978	8.86gm	n.s.s.	4/50	763. mg	3/50	1.53gm	1/50	liv:hpa,hpc,nnd. lun:a/a,a/c.
b	c01978	4.33gm	n.s.s.	1/50	763. mg	4/50	1.53gm	2/50	liv:hpa,hpc.
1898	c01978	1.02gm	n.s.s.	10/50	697. mg	13/49	1.39gm	23/50	
a	c01978	989. mg	n.s.s.	21/50	697. mg	20/49	1.39gm	29/50	
b	c01978	1.02gm	n.s.s.	10/50	697. mg	13/49	1.39gm	23/50	liv:hpa,hpc,nnd. lun:a/a,a/c.
c	c01978	5.73gm	n.s.s.	11/50	697. mg	2/49	1.39gm	6/50	
1899	c01978	649. mg	n.s.s.	45/50	66.0mg	12/50	130. mg	15/50	
a	c01978	692. mg	n.s.s.	2/50	66.0mg	0/50	130. mg	3/50	liv:hpa,hpc,nnd.
1900	c01978	118. mg	n.s.s.	26/50	52.8mg	19/50	(105. mg	13/50)	
a	c01978	1.38gm	n.s.s.	3/50	52.8mg	0/50	105. mg	0/50	liv:hpa,hpc,nnd.
5-NITRO-o-ANISIDINE 99-59-2									
1901	c01934	917. mg	n.s.s.	9/100	836. mg	5/50	666. mg	10/50	---:leu,lym. S
a	c01934	1.32gm	n.s.s.	3/100	836. mg	0/50	666. mg	8/50	
b	c01934	632. mg	n.s.s.	29/100	836. mg	9/50	666. mg	22/50	
c	c01934	1.32gm	n.s.s.	3/100	836. mg	0/50	666. mg	8/50	liv:hpa,hpc,nnd. lun:a/a,a/c.
d	c01934	3.87gm	n.s.s.	5/100	836. mg	0/50	666. mg	2/50	
1902	c01934	504. mg	6.19gm	18/100	780. mg	25/50	(615. mg	3/50)	liv:hpa,hpc. S
a	c01934	518. mg	11.3gm	20/100	780. mg	25/50	(615. mg	3/50)	
b	c01934	516. mg	n.s.s.	45/100	780. mg	32/50	(615. mg	17/50)	
c	c01934	518. mg	11.3gm	20/100	780. mg	25/50	(615. mg	3/50)	liv:hpa,hpc,nnd. lun:a/a,a/c.
d	c01934	2.53gm	n.s.s.	15/100	780. mg	5/50	(615. mg	2/50)	
1903	c01934	107. mg	292. mg	3/100	147. mg	17/50	294. mg	22/50	cli:adn,can,ppa,sgc; ski:sec,sgc; zym:sec,sgc. C
a	c01934	102. mg	642. mg	2/100	147. mg	11/50	(294. mg	4/50)	agl:acn,adn,pac. S
b	c01934	133. mg	454. mg	3/100	147. mg	12/50	294. mg	14/50	cli:adn,can,ppa,sgc. S
c	c01934	117. mg	609. mg	0/100	147. mg	10/50	(294. mg	4/50)	
d	c01934	99.1 mg	1.63gm	1/100	147. mg	5/50	(294. mg	1/50)	lun:a/a,a/c. S
e	c01934	306. mg	1.23gm	0/100	147. mg	5/50	294. mg	10/50	ski:sec,sgc; zym:sec,sgc.
f	c01934	458. mg	2.42gm	0/100	147. mg	1/50	294. mg	9/50	cli:can,sgc.
g	c01934	529. mg	3.95gm	0/100	147. mg	0/50	294. mg	7/50	
h	c01934	44.8mg	154. mg	83/100	147. mg	45/50	294. mg	41/50	
i	c01934	589. mg	n.s.s.	2/100	147. mg	0/50	294. mg	2/50	liv:hpa,hpc,nnd.
1904	c01934	16.4mg	43.8mg	2/99	118. mg	36/50	235. mg	45/50	ski:bcc,cuc,sea,sec,sgc,eqc,tri; zym:cuc,sec,sgc. C
a	c01934	17.3mg	49.6mg	2/99	118. mg	30/50	235. mg	42/50	ski:bcc,sec,sgc,sgc,tri.
b	c01934	21.5mg	78.8mg	0/99	118. mg	20/50	235. mg	9/50	
c	c01934	22.7mg	105. mg	1/99	118. mg	7/50	235. mg	30/50	
d	c01934	27.1mg	113. mg	0/99	118. mg	14/50	235. mg	26/50	ski:sea,sec. S
e	c01934	61.3mg	176. mg	1/99	118. mg	10/50	235. mg	29/50	ski:cuc,sec,sgc; zym:cuc,sec,sgc.
f	c01934	38.0mg	528. mg	10/99	118. mg	8/50	235. mg	5/50	
g	c01934	87.7mg	286. mg	0/99	118. mg	5/50	235. mg	21/50	
h	c01934	45.7mg	1.17gm	2/99	118. mg	2/50	235. mg	5/50	pre:adn,can. S
i	c01934	107. mg	627. mg	1/99	118. mg	3/50	235. mg	12/50	
j	c01934	55.5mg	2.47gm	1/99	118. mg	1/50	235. mg	5/50	adr:coa,coc. S
k	c01934	7.94mg	21.3mg	58/99	118. mg	44/50	235. mg	48/50	
l	c01934	49.9mg	1.68gm	4/99	118. mg	3/50	235. mg	3/50	liv:hpa,hpc,nnd.
5-NITRO-2-FURALDENYDE SEMICARBAZONE 59-87-0									
1905	1063m	3.15mg	54.3mg	0/5	33.3mg	11/18			Morris; canr, 29, 2145-2156; 1969
a	1063m	33.3mg	n.s.s.	0/5	33.3mg	0/18			
1906	1063n	n.s.s.	4.64mg	3/16	36.8mg	24/24			
a	1063n	60.5mg	n.s.s.	0/16	36.8mg	0/24			
1907	1120	3.96mg	16.7mg	2/29	34.8mg	22/29			Enturk; canr, 30, 1409-1412; 1970
5-NITRO-2-FURAMIDOXIME 772-43-0									
1908	200a	18.5mg	n.s.s.	0/39	6.97mg	0/32			Cohen; jnci, 51, 403-417; 1973
a	200a	6.78mg	n.s.s.	2/39	6.97mg	3/32			

Spe	Strain	Site	Xpo+Xpt			TD50	ZTailpvl
Sex	Route	Hist	Notes			DR	AuOp
5-(5-NITRO-2-FURANMETHANEDIOL DIACETATE) <u>1</u> ug..... <u>10</u> <u>100</u> <u>1</u> mg..... <u>10</u> <u>100</u> <u>1</u> g..... <u>10</u>							
1909	R f hza eat	liv tum	36w54 es		>	no dre	P=1.
a	R f hza eat	mam tum	36w54 es			no dre	P=1. -
1910	R f hza eat	mam tum	44w60 es		>	105. mg	P<.5 -
a	R f hza eat	liv tum	44w60 es			no dre	P=1.
3-(5-NITRO-2-FURYL)-IMIDAZO(1,2-alpha)PYRIDINE <u>10</u> <u>100</u> <u>1</u> mg..... <u>10</u> <u>100</u> <u>1</u> g..... <u>10</u>							
1911	M f ctn eat	mix car	40w79 es		+ .	21.6mg Z	P<.0005+
a	M f ctn eat	mix pam	40w79 es			117. mg Z	P<.0005+
b	M f ctn eat	thy lys	40w79 es			781. mg *	P<.0005
c	M f ctn eat	lun tum	40w79 es			no dre	P=1. -
d	M f ctn eat	liv hpt	40w79 es			no dre	P=1. -
e	M f ctn eat	tba mix	40w79 es			noTD50	P<.0005+
1912	M m ctn eat	mix car	40w73 es		+ .	40.1mg Z	P<.0005+
a	M m ctn eat	mix pam	40w73 es			65.8mg Z	P<.0005+
b	M m ctn eat	lun tum	40w73 es			763. mg *	P<.2 -
c	M m ctn eat	liv hpt	40w73 es			no dre	P=1. -
d	M m ctn eat	tba mix	40w73 es			57.1mg *	P<.002 +
1913	R f wis eat	mix pam	40w89 es		+ .	27.5mg	P<.0005+
a	R f wis eat	mam tum	40w89 es			33.3mg	P<.0005+
b	R f wis eat	kid tum	40w89 es			116. mg	P<.0005+
c	R f wis eat	mix car	40w89 es			443. mg	P<.04 +
d	R f wis eat	liv hpt	40w89 es			644. mg	P<.3
e	R f wis eat	tba mix	40w89 es			15.8mg	P<.0005+
1914	R m wis eat	kid tum	40w83 es		+ .	21.4mg	P<.0005+
a	R m wis eat	mix pam	40w83 es			43.7mg	P<.0005+
b	R m wis eat	mix car	40w83 es			104. mg	P<.0005+
c	R m wis eat	liv hpt	40w83 es			959. mg	P<.3
d	R m wis eat	tba mix	40w83 es			11.9mg	P<.0005+
5-(5-NITRO-2-FURYL)-1,3,4-OXADIAZOLE-2-OL .. <u>1</u> ug..... <u>10</u> <u>100</u> <u>1</u> mg..... <u>10</u> <u>100</u> <u>1</u> g..... <u>10</u>							
1915	R f sda eat	mgl mix	46w66 e		+ .	8.61mg	P<.0005
a	R f sda eat	mgl adc	46w66 e			31.2mg	P<.006
b	R f sda eat	liv tum	46w66 e			no dre	P=1.
c	R f sda eat	tba mix	46w66 e			8.61mg	P<.0005+
N-[3-(5-NITRO-2-FURYL)-1,2,4-OXADIAZOLE-5-YL]-METHYL]ACETAMIDE. <u>100</u> <u>1</u> mg..... <u>10</u> <u>100</u> <u>1</u> g..... <u>10</u>							
1916	R f sda eat	mgl mix	46w66 e		+ .	6.35mg	P<.0005
a	R f sda eat	mgl adc	46w66 e			10.3mg	P<.0005
b	R f sda eat	lun alc	46w66 e			59.6mg	P<.2 +
c	R f sda eat	k/p tcc	46w66 e			+historical	P<.2 +
d	R f sda eat	liv tum	46w66 e			no dre	P=1.
e	R f sda eat	tba mix	46w66 e			5.20mg	P<.0005
N-[5-(5-NITRO-2-FURYL)-1,3,4-THIAZOL-2-YL]ACETAMIDE <u>100</u> <u>1</u> mg..... <u>10</u> <u>100</u> <u>1</u> g..... <u>10</u>							
1917	M f swi eat	for mix	46w55 e		+ .	6.74mg	P<.0005+
a	M f swi eat	for eqp	46w55 e			14.1mg	P<.0005
b	M f swi eat	for eqc	46w55 e			104. mg	P<.008
c	M f swi eat	liv tum	46w55 e			no dre	P=1.
d	M f swi eat	lun tum	46w55 e			no dre	P=1.
e	M f swi eat	tba mix	46w55 e			6.90mg	P<.0005
1918	R f sda eat	for mix	40w59 ev		+ .	8.84mg	P<.0005+
a	R f sda eat	mix has	40w59 ev			10.6mg	P<.0005+
b	R f sda eat	for eqp	40w59 ev			11.6mg	P<.0005
c	R f sda eat	lun alc	40w59 ev			15.3mg	P<.0005+
d	R f sda eat	k/p tcc	40w59 ev			+historical	P<.0005+
e	R f sda eat	itn has	40w59 ev			18.6mg	P<.0005+
f	R f sda eat	liv has	40w59 ev			22.9mg	P<.0005+
g	R f sda eat	mgl adc	40w59 ev			37.7mg	P<.002
h	R f sda eat	lun has	40w59 ev			52.3mg	P<.007 +
i	R f sda eat	mgl mix	40w59 ev			43.3mg	P<.05
j	R f sda eat	pan has	40w59 ev			81.6mg	P<.03 +
k	R f sda eat	--- lbl	40w59 ev			111. mg	P<.06 +
l	R f sda eat	ami adc	40w59 ev			111. mg	P<.06 +
m	R f sda eat	ami lei	40w59 ev			111. mg	P<.06 +
n	R f sda eat	tba mix	40w59 ev			noTD50	P<.0005
N-[4-(5-NITRO-2-FURYL)-2-THIAZOLYL]ACETAMIDE <u>10</u> <u>100</u> <u>1</u> mg..... <u>10</u> <u>100</u> <u>1</u> g..... <u>10</u>							
1919	H m syg eat	ubl mix	48w70 e		+ .	8.91mg	P<.0005+
a	H m syg eat	ubl eqc	48w70 e			60.2mg	P<.004 +
b	H m syg eat	for eqp	48w70 e			68.1mg	P<.003 +
c	H m syg eat	liv tum	48w70 e			no dre	P=1.
d	H m syg eat	lun tum	48w70 e			no dre	P=1.
1920	R f sda eat	mam mix	46w66 e		+ .	10.5mg	P<.0005+
a	R f sda eat	mgl adc	46w66 e			36.2mg	P<.0005+
b	R f sda eat	mgl fba	46w66 e			56.9mg	P<.0005
c	R f sda eat	liv tum	46w66 e			no dre	P=1.
d	R f sda eat	tba mix	46w66 e			7.25mg	P<.0005

RefNum	LoConf	UpConf	Cntrl	1Dose	1Inc	2Dose	2Inc	Citation or Pathology	Bkly Code
5-NITRO-2-FURANMETHANEDIOL DIACETATE ---									
1909	1063m	18.5mg	n.s.s.	0/5	66.7mg	0/5		Morris; canr, 29, 2145-2156; 1969	
a	1063m	18.5mg	n.s.s.	0/5	66.7mg	0/5			
1910	1063n	18.5mg	n.s.s.	3/16	73.6mg	4/13			
a	1063n	65.6mg	n.s.s.	0/16	73.6mg	0/13			
3-(5-NITRO-2-FURYL)-IMIDAZO(1,2-alpha)PYRIDINE (NFIP) 75198-31-1									
1911	1163	13.3mg	37.7mg	0/39	65.8mg	28/40	(160.mg 23/36 371.mg 35/44)	Cabral; tumo, 66, 131-144; 1980	
a	1163	68.0mg	329.mg	2/39	65.8mg	12/40	160.mg 16/39 (371.mg 15/50)		
b	1163	412.mg	2.15gm	0/39	65.8mg	0/40	160.mg 5/40 371.mg 8/50		
c	1163	704.mg	n.s.s.	6/39	65.8mg	6/40	160.mg 3/35 371.mg 6/43		
d	1163	138.mg	n.s.s.	1/37	65.8mg	0/36	160.mg 0/23 371.mg 0/16		
e	1163	n.s.s.	20.3mg	28/39	65.8mg	40/40	160.mg 40/40 371.mg 50/50		
1912	1163	26.8mg	63.3mg	0/39	65.8mg	19/35	143.mg 20/33 (409.mg 18/30)		
a	1163	39.4mg	174.mg	3/39	65.8mg	19/38	143.mg 17/37 (409.mg 18/30)		
b	1163	248.mg	n.s.s.	5/39	65.8mg	5/36	143.mg 8/35 409.mg 8/31		
c	1163	765.mg	n.s.s.	7/37	65.8mg	1/33	143.mg 1/28 409.mg 1/15		
d	1163	26.0mg	338.mg	21/39	65.8mg	38/38	143.mg 37/37 409.mg 38/42		
1913	1163	15.9mg	50.7mg	0/32	89.9mg	25/31			
a	1163	17.5mg	85.0mg	8/32	89.9mg	25/31			
b	1163	56.1mg	304.mg	0/32	89.9mg	10/31			
c	1163	134.mg	n.s.s.	0/32	89.9mg	3/31			
d	1163	145.mg	n.s.s.	1/32	89.9mg	3/31			
e	1163	6.29mg	43.0mg	14/32	89.9mg	30/31			
1914	1163	12.1mg	40.4mg	0/31	77.1mg	23/29			
a	1163	23.4mg	101.mg	1/31	77.1mg	16/29			
b	1163	47.0mg	331.mg	0/31	77.1mg	8/29			
c	1163	156.mg	n.s.s.	0/31	77.1mg	1/29			
d	1163	4.72mg	32.9mg	13/31	77.1mg	28/29			
5-(5-NITRO-2-FURYL)-1,3,4-OXADIAZOLE-2-OL 2122-86-3									
1915	1126	4.53mg	22.7mg	2/39	17.4mg	16/35		Cohen; jnci, 54, 841-850; 1975	
a	1126	11.8mg	302.mg	0/39	17.4mg	5/35			
b	1126	50.6mg	n.s.s.	0/39	17.4mg	0/35			
c	1126	4.53mg	22.7mg	2/39	17.4mg	16/35			
N-([3-(5-NITRO-2-FURYL)-1,2,4-OXADIAZOLE-5-YL]-METHYL)ACETAMIDE 36133-88-7									
1916	1126	3.24mg	22.9mg	2/24	13.9mg	16/32		Cohen; jnci, 54, 841-850; 1975	
a	1126	4.98mg	30.0mg	0/24	13.9mg	10/32			
b	1126	14.7mg	n.s.s.	0/24	13.9mg	2/32			
c	1126	14.7mg	n.s.s.	0/24	13.9mg	2/32			
d	1126	37.0mg	n.s.s.	0/24	13.9mg	0/32			
e	1126	2.76mg	14.7mg	2/24	13.9mg	18/32			
N-[5-(5-NITRO-2-FURYL)-1,3,4-THIADIAZOL-2-YL]ACETAMIDE 2578-75-8									
1917	1076	2.82mg	15.0mg	0/29	109.mg	21/22		Cohen; canr, 33, 1593-1597; 1973	
a	1076	7.41mg	29.6mg	0/29	109.mg	17/22			
b	1076	35.8mg	2.28gm	0/29	109.mg	4/22			
c	1076	138.mg	n.s.s.	0/29	109.mg	0/22			
d	1076	138.mg	n.s.s.	0/29	109.mg	0/22			
e	1076	2.85mg	15.9mg	2/29	109.mg	21/22			
1918	1126	5.08mg	16.7mg	0/24	53.0mg	22/30		Cohen; jnci, 54, 841-850; 1975	
a	1126	6.06mg	20.6mg	0/24	53.0mg	20/30			
b	1126	6.59mg	22.9mg	0/24	53.0mg	19/30			
c	1126	8.40mg	31.9mg	0/24	53.0mg	16/30			
d	1126	9.10mg	36.0mg	0/24	53.0mg	15/30			
e	1126	9.87mg	40.9mg	0/24	53.0mg	14/30			
f	1126	11.7mg	55.1mg	0/24	53.0mg	12/30			
g	1126	17.0mg	145.mg	0/24	53.0mg	8/30			
h	1126	21.3mg	561.mg	0/24	53.0mg	6/30			
i	1126	16.9mg	n.s.s.	2/24	53.0mg	9/30			
j	1126	28.2mg	n.s.s.	0/24	53.0mg	4/30			
k	1126	33.5mg	n.s.s.	0/24	53.0mg	3/30			
l	1126	33.5mg	n.s.s.	0/24	53.0mg	3/30			
m	1126	33.5mg	n.s.s.	0/24	53.0mg	3/30			
n	1126	n.s.s.	5.41mg	2/24	53.0mg	30/30			
N-[4-(5-NITRO-2-FURYL)-2-THIAZOLYL]ACETAMIDE (NFTA) 531-82-8									
1919	1077	4.14mg	20.3mg	0/22	63.1mg	16/18		Croft; jnci, 51, 941-949; 1973	
a	1077	22.7mg	388.mg	0/22	63.1mg	5/18			
b	1077	27.6mg	372.mg	0/24	63.1mg	6/24			
c	1077	141.mg	n.s.s.	0/24	63.1mg	0/24			
d	1077	141.mg	n.s.s.	0/24	63.1mg	0/24			
1920	1122	6.89mg	16.4mg	0/28	69.3mg	47/56		Erturk; canr, 30, 936-941; 1970	
a	1122	21.9mg	66.4mg	0/28	69.3mg	23/56			
b	1122	31.7mg	132.mg	0/28	69.3mg	16/56			
c	1122	322.mg	n.s.s.	0/28	69.3mg	0/56			
d	1122	4.51mg	11.6mg	0/28	69.3mg	52/56			

Spe	Strain	Site	Xpo+Xpt	Notes	TD50	ZTailpvl
Sex	Route	Hist			DR	AuOp
1921	R f sda eat	mgl fba	46w66 e	. + .	25.0mg	P<.0005+
a	R f sda eat	k/p tcc	46w66 e		316.mg	P<.09
b	R f sda eat	liv tum	46w66 e		no dre	P=1.
c	R f sda eat	tba mix	46w66 e		22.8mg	P<.0005
1922	R f sda eat	mgl fba	46w66 e	. + .	30.2mg	P<.0005+
a	R f sda eat	k/p tcc	46w66 e		660.mg	P<.3
b	R f sda eat	liv tum	46w66 e		no dre	P=1.
c	R f sda eat	tba mix	46w66 e		27.7mg	P<.0005
M-[4-(5-NITRO-2-FURYL)-2-THIAZOLYL]FORMAMIDE10.....100.....1mg.....10.....100.....1g.....10						
1923	H m syg eat	ubl mix	48w70 e	<+	noTD50	P<.0005+
a	H m syg eat	ubl eqc	48w70 e		54.0mg	P<.003 +
b	H m syg eat	for eqp	48w70 e		83.8mg	P<.007 +
c	H m syg eat	liv tum	48w70 e		no dre	P=1.
d	H m syg eat	lun tum	48w70 e		no dre	P=1.
1924	M f swi eat	ubl tum	46w53	. + .	18.2mg	P<.0005+
a	M f swi eat	--- leu	46w53		55.4mg	P<.03 +
b	M f swi eat	lun car	46w53		163.mg	P<.03 +
1925	M f swi eat	ubl tcc	46w66 e	. + .	7.72mg	P<.0005+
a	M f swi eat	lun slc	46w66 e		86.4mg	P<.003
b	M f swi eat	--- lle	46w66 e		78.3mg	P<.02 +
c	M f swi eat	for eqp	46w66 e		235.mg	P<.07 +
d	M f swi eat	liv tum	46w66 e		no dre	P=1.
e	M f swi eat	tba mix	46w66 e		noTD50	P<.0005
1926	M f swi eat	ubl car	33w52	. + .	19.8mg	P<.0005+
a	M f swi eat	--- leu	33w52		47.6mg	P<.08
b	M f swi eat	lun ala	33w52		208.mg	P<.3
c	M f swi eat	liv tum	33w52		no dre	P=1.
1927	R m f34 eat	ubl mix	30w52 e	. + .	1.31mg *	P<.0005+
a	R m f34 eat	ubl ppc	30w52 e		5.92mg *	P<.0005
b	R m f34 eat	liv tum	30w52 e		no dre	P=1.
1928	R f sda eat	ubl mix	46w63	. + .	5.07mg	P<.0005+
1929	R f sda eat	ubl mix	26w70 er	<+	noTD50	P<.0005+
a	R f sda eat	ubl tcc	26w70 er		noTD50	P<.0005+
b	R f sda eat	ubl ppc	26w70 er		48.6mg	P<.003 +
1930	R f sda eat	ubl mix	46w70 er	<+	noTD50	P<.0005+
a	R f sda eat	ubl tcc	46w70 er		noTD50	P<.0005+
b	R f sda eat	ubl ppc	46w70 er		82.7mg	P<.003 +
1931	R m sda eat	ubl tcc	26w52 er	<+	noTD50	P<.0005+
1932	R m sda eat	ubl tcc	46w52 er	<+	noTD50	P<.0005+
1933	R f wis eat	ubl tcc	34w52 er	<+	noTD50	P<.0005+
M,N'-[6-(5-NITRO-2-FURYL)-s-TRIAZINE-2,4-DIYL]BISACETAMIDE100.....1mg.....10.....100.....1g.....10						
1934	R f sda eat	mgl mix	46w66 e	. + .	14.1mg	P<.0005+
a	R f sda eat	mgl adc	46w66 e		29.0mg	P<.0005
b	R f sda eat	liv tum	46w66 e		no dre	P=1.
c	R f sda eat	tba mix	46w66 e		12.8mg	P<.0005
3-NITRO-3-HEXENE 100ng.....1ug.....10.....100.....1mg.....10.....100.....1g.....10						
1935	M b swi inh	lun adc	62w62	. + .	.346mg	P<.02 +
1936	M f swi inh	lun adc	62w62 r	. + .	.363mg	P<.09
a	M f swi inh	lun mix	62w62 r		.687mg	P<.6
1937	M f swi inh	lun adc	62w62 r	. >	.768mg	P<.3
1938	R b cfn inh	lun ulc	37m37 e	. + .	8.66mg *	P<.0005+
NITRO-4-HYDROXYPHENYLARSONIC ACID 100ng.....1ug.....10.....100.....1mg.....10.....100.....1g.....10						
1939	M f asw eat	tba tum	24m24 e	. >	no dre	P=1. -
a	M f asw eat	tba mal	24m24 e		93.6mg *	P<.8 -
1940	M m asw eat	liv hpt	24m24 e	. >	185.mg *	P<.3 -
a	M m asw eat	tba mal	24m24 e		85.6mg *	P<.7 -
b	M m asw eat	tba tum	24m24 e		no dre	P=1. -
1941	R f asd eat	tba tum	24m24 e	. >	no dre	P=1. -
a	R f asd eat	tba mal	24m24 e		no dre	P=1. -
1942	R m asd eat	tba tum	24m24 e	. >	no dre	P=1. -
a	R m asd eat	tba mal	24m24 e		1.30gm *	P<.1. -
2-NITRO-p-PHENYLENEDIAMINE 100ng.....1ug.....10.....100.....1mg.....10.....100.....1g.....10						
1943	M f b6c eat	liv MXA	78w90	. + .	614.mg *	P<.006 c
a	M f b6c eat	TBA MXB	78w90		468.mg *	P<.02
b	M f b6c eat	liv MXB	78w90		614.mg *	P<.006
c	M f b6c eat	lun MXB	78w90		1.98gm *	P<.3
1944	M m b6c eat	TBA MXB	78w90	. >	no dre	P=1. -
a	M m b6c eat	liv MXB	78w90		no dre	P=1. -
b	M m b6c eat	lun MXB	78w90		945.mg \	P<.3
1945	R f f34 eat	--- MXA	18m24	. + .	#892.mg *	P<.05 -

RefNum	LoConf	UpConf	Cntrl	1Dose	1Inc	2Dose	2Inc	Citation or Pathology	Brkly Code
1921	1126m	13.4mg	66.1mg	4/35	69.3mg	20/34		Cohen;jnci,54,841-850;1975	
a	1126m	77.6mg	n.s.s.	0/35	69.3mg	2/34			
b	1126m	196.0mg	n.s.s.	0/35	69.3mg	0/34			
c	1126m	12.4mg	56.4mg	4/35	69.3mg	21/34			
1922	1126n	16.5mg	70.4mg	1/32	69.3mg	17/35			
a	1126n	108.0mg	n.s.s.	0/32	69.3mg	1/35			
b	1126n	201.0mg	n.s.s.	0/32	69.3mg	0/35			
c	1126n	15.3mg	61.8mg	1/32	69.3mg	18/35			
N-[4-(5-NITRO-2-FURYL)-2-THIAZOLYL]FORMAMIDE (FANFT) 24554-26-5									
1923	1077	n.s.s.	9.77mg	0/20	63.1mg	23/23		Croft;jnci,51,941-949;1973	
a	1077	23.2mg	238.0mg	0/20	63.1mg	7/23			
b	1077	31.7mg	1.09gm	0/24	63.1mg	5/24			
c	1077	141.0mg	n.s.s.	0/24	63.1mg	0/24			
d	1077	141.0mg	n.s.s.	0/24	63.1mg	0/24			
1924	1068	11.5mg	30.6mg	0/56	106.0mg	31/48		Erturk;canr,30,1309-1311;1970	
a	1068	23.4mg	n.s.s.	15/56	106.0mg	23/48			
b	1068	60.3mg	n.s.s.	1/56	106.0mg	6/48			
1925	1076	3.21mg	17.4mg	0/28	85.2mg	20/21		Cohen;canr,33,1593-1597;1973	
a	1076	32.7mg	508.0mg	0/28	85.2mg	5/21			
b	1076	29.4mg	n.s.s.	1/28	85.2mg	6/21			
c	1076	57.7mg	n.s.s.	0/28	85.2mg	2/21			
d	1076	148.0mg	n.s.s.	0/28	85.2mg	0/21			
e	1076	n.s.s.	12.5mg	1/28	85.2mg	21/21			
1926	1118	9.28mg	57.1mg	0/30	41.3mg	9/30		Cohen;canr,38,1398-1405;1978	
a	1118	15.6mg	n.s.s.	1/30	41.3mg	5/30			
b	1118	33.9mg	n.s.s.	0/30	41.3mg	1/30			
c	1118	63.8mg	n.s.s.	0/30	41.3mg	0/30			
1927	727	.739mg	2.38mg	0/20	.115mg	0/16	.231mg 0/15 1.15mg 0/16 2.31mg 1/15 11.5mg 13/14	Arai;jnci,62,1013-1016;1979	
a	727	3.09mg	13.4mg	0/20	.115mg	0/16	.231mg 0/15 1.15mg 0/16 2.31mg 0/15 11.5mg 4/14		
b	727	55.80mg	n.s.s.	0/20	.115mg	0/16	.231mg 0/15 1.15mg 0/16 2.31mg 0/15 11.5mg 0/14		
1928	1124	2.24mg	10.3mg	0/30	68.6mg	29/30		Erturk;canr,27,1998-2002;1967	
1929	1125m	n.s.s.	4.81mg	0/34	34.9mg	30/30		Erturk;canr,29,2219-2228;1969	
a	1125m	n.s.s.	5.30mg	0/27	34.9mg	24/24			
b	1125m	19.8mg	234.0mg	0/34	34.9mg	6/30			
1930	1125n	n.s.s.	8.63mg	0/34	61.8mg	29/29			
a	1125n	n.s.s.	9.56mg	0/27	61.8mg	23/23			
b	1125n	33.6mg	383.0mg	0/34	61.8mg	6/29			
1931	1125m	n.s.s.	3.99mg	0/30	37.6mg	15/15			
1932	1125n	n.s.s.	6.07mg	0/30	66.5mg	20/20			
1933	1123	n.s.s.	4.76mg	0/15	62.7mg	30/30		Adolphs;unre,6,19-27;1978	
N,N'-[6-(5-NITRO-2-FURYL)-s-TRIAZINE-2,4-DIYL]BISACETAMIDE 51325-35-0									
1934	200a	8.17mg	27.0mg	2/39	69.7mg	25/33		Cohen;jnci,51,403-417;1973	
a	200a	16.0mg	60.3mg	0/39	69.7mg	16/33			
b	200a	191.0mg	n.s.s.	0/39	69.7mg	0/33			
c	200a	7.44mg	24.3mg	2/39	69.7mg	26/33			
3-NITRO-3-HEXENE 4812-22-0									
1935	1360	.131mg	n.s.s.	0/21	.291mg	5/27		Deichmann;imed,34,800-807;1965	
1936	1366m	88.60mg	n.s.s.	0/10	.332mg	2/10		Deichmann;txap,5,445-456;1963	
a	1366m	97.10mg	n.s.s.	1/10	.332mg	2/10			
1937	1366n	.125mg	n.s.s.	0/10	.332mg	1/10			
1938	1360	4.91mg	19.8mg	0/100	.326mg	6/100	.651mg 11/100	Deichmann;imed,34,800-807;1965	
NITRO-4-HYDROXYPHENYLARSONIC ACID 121-19-7									
1939	213b	6.88mg	n.s.s.	14/16	6.50mg	20/30	13.0mg 27/33	Prier;txap,5,526-542;1963	
a	213b	10.9mg	n.s.s.	6/16	6.50mg	16/30	13.0mg 15/33		
1940	213b	30.1mg	n.s.s.	0/10	6.00mg	0/22	12.0mg 1/12		
a	213b	12.5mg	n.s.s.	1/10	6.00mg	5/22	12.0mg 2/12		
b	213b	12.6mg	n.s.s.	4/10	6.00mg	6/22	12.0mg 4/12		
1941	213b	15.2mg	n.s.s.	14/27	2.50mg	18/28	10.0mg 11/28		
a	213b	45.4mg	n.s.s.	4/27	2.50mg	2/28	10.0mg 1/28		
1942	213b	21.7mg	n.s.s.	4/24	2.00mg	2/24	8.00mg 2/22		
a	213b	22.9mg	n.s.s.	1/24	2.00mg	1/24	8.00mg 1/22		
2-NITRO-p-PHENYLENEDIAMINE 5307-14-2									
1943	c02222	346.0mg	6.17gm	1/20	248.0mg	10/50	490.0mg 17/50		liv:hpa,hpc.
a	c02222	244.0mg	n.s.s.	4/20	248.0mg	18/50	490.0mg 27/50		
b	c02222	346.0mg	6.17gm	1/20	248.0mg	10/50	490.0mg 17/50		liv:hpa,hpc,nn.
c	c02222	898.0mg	n.s.s.	0/20	248.0mg	5/50	490.0mg 3/50		lun:#/a,a/c.
1944	c02222	326.0mg	n.s.s.	9/20	229.0mg	17/50	(457.0mg 7/50)		
a	c02222	1.60gm	n.s.s.	3/20	229.0mg	7/50	457.0mg 3/50		liv:hpa,hpc,nn.
b	c02222	318.0mg	n.s.s.	1/20	229.0mg	8/50	(457.0mg 2/50)		lun:#/a,a/c.
1945	c02222	308.0mg	n.s.s.	0/20	41.0mg	0/50	82.0mg 4/50		---:leu,lym. S

Spe	Strain	Site	Xpo+Xpt	Notes	TD50	ZTailpvl
Sex	Route	Hist			DR	AuOp
a	R f	f34 eat	TBA MXB	18m24	no dre	P=1.
b	R f	f34 eat	liv MXB	18m24	no dre	P=1.
1946	R m	f34 eat	thy MXA	18m24	: ±	#224.mg * P<.03 -
a	R m	f34 eat	TBA MXB	18m24	no dre	P=1.
b	R m	f34 eat	liv MXB	18m24	no dre	P=1.
4-NITRO-o-PHENYLENEDIAMINE				100ng...1ug...10...100...1mg...10...100...1g...10		
1947	M f	b6c eat	TBA MXB	24m24	>	no dre P=1. -
a	M f	b6c eat	liv MXB	24m24		no dre P=1.
b	M f	b6c eat	lun MXB	24m24		no dre P=1.
1948	M m	b6c eat	TBA MXB	24m24	>	no dre P=1. -
a	M m	b6c eat	liv MXB	24m24		no dre P=1.
b	M m	b6c eat	lun MXB	24m24		no dre P=1.
1949	R f	f34 eat	TBA MXB	24m24	>	no dre P=1. -
a	R f	f34 eat	liv MXB	24m24		no dre P=1.
1950	R m	f34 eat	TBA MXB	24m24	>	no dre P=1. -
a	R m	f34 eat	liv MXB	24m24		no dre P=1.
5-NITRO-o-TOLUIDINE				100ng...1ug...10...100...1mg...10...100...1g...10		
1951	M f	b6c eat	MXB MXB	78w96 v	: + :	242.mg * P<.0005
a	M f	b6c eat	liv hpc	78w96 v		288.mg / P<.0005c
b	M f	b6c eat	--- hes	78w96 v		+historical * P<.4 c
c	M f	b6c eat	TBA MXB	78w96 v		989.mg * P<.5
d	M f	b6c eat	liv MXB	78w96 v		288.mg / P<.0005
e	M f	b6c eat	lun MXB	78w96 v		no dre P=1.
1952	M m	b6c eat	liv hpc	78w95 v	: + :	266.mg / P<.005 c
a	M m	b6c eat	MXB MXB	78w95 v		269.mg / P<.005
b	M m	b6c eat	--- MXA	78w95 v		+historical * P<.2 c
c	M m	b6c eat	TBA MXB	78w95 v		431.mg * P<.2
d	M m	b6c eat	liv MXB	78w95 v		266.mg / P<.005
e	M m	b6c eat	lun MXB	78w95 v		no dre P=1.
1953	R f	f34 eat	TBA MXB	18m25 v	>	no dre P=1. -
a	R f	f34 eat	liv MXB	18m25 v		43.0mg * P<.3
1954	R m	f34 eat	liv hpc	18m25 v	: ±	#27.7mg * P<.04 -
a	R m	f34 eat	TBA MXB	18m25 v		43.7mg * P<.9
b	R m	f34 eat	liv MXB	18m25 v		no dre P=1.
5-NITROACENAPHTHENE				100ng...1ug...10...100...1mg...10...100...1g...10		
1955	H f	syg eat	bil cho	26w71	: + :	354.mg P<.003
1956	M f	b6c eat	MXB MXB	78w96 ev	: + :	45.3mg * P<.0005
a	M f	b6c eat	liv hpc	78w96 ev		45.8mg * P<.0005c
b	M f	b6c eat	ova MXA	78w96 ev		217.mg * P<.0005c
c	M f	b6c eat	ova tua	78w96 ev		395.mg * P<.005 c
d	M f	b6c eat	TBA MXB	78w96 ev		90.4mg * P<.02
e	M f	b6c eat	liv MXB	78w96 ev		45.8mg * P<.0005
f	M f	b6c eat	lun MXB	78w96 ev		1.32gm * P<.5
1957	M m	b6c eat	TBA MXB	78w95 es	>	no dre P=1. -
a	M m	b6c eat	liv MXB	78w95 es		no dre P=1.
b	M m	b6c eat	lun MXB	78w95 es		no dre P=1.
1958	R f	f34 eat	MXB MXB	18m23 e	: + :	5.98mg / P<.0005
a	R f	f34 eat	lun MXA	18m23 e		9.63mg * P<.0005c
b	R f	f34 eat	oac MXA	18m23 e		14.9mg / P<.0005c
c	R f	f34 eat	oac cuc	18m23 e		17.4mg * P<.0005c
d	R f	f34 eat	cli can	18m23 e		52.2mg * P<.0005c
e	R f	f34 eat	mgl MXA	18m23 e		77.9mg * P<.0005c
f	R f	f34 eat	mgl acn	18m23 e		81.7mg * P<.0005c
g	R f	f34 eat	oac sqc	18m23 e		90.5mg / P<.0005c
h	R f	f34 eat	TBA MXB	18m23 e		6.44mg / P<.0005
i	R f	f34 eat	liv MXB	18m23 e		no dre P=1.
1959	R m	f34 eat	MXB MXB	17m23 ae	: + :	6.45mg / P<.0005
a	R m	f34 eat	oac MXA	17m23 ae		7.88mg * P<.0005c
b	R m	f34 eat	oac cuc	17m23 ae		8.92mg * P<.0005c
c	R m	f34 eat	lun MXA	17m23 ae		29.9mg * P<.0005c
d	R m	f34 eat	lun a/c	17m23 ae		35.1mg * P<.0005c
e	R m	f34 eat	thy MXA	17m23 ae		37.7mg / P<.0005
f	R m	f34 eat	kid MXA	17m23 ae		42.9mg * P<.0005
g	R m	f34 eat	thy MXA	17m23 ae		58.5mg * P<.0005
h	R m	f34 eat	oac sqc	17m23 ae		68.2mg * P<.0005c
i	R m	f34 eat	TBA MXB	17m23 ae		5.58mg / P<.0005
j	R m	f34 eat	liv MXB	17m23 ae		71.4mg * P<.08
4-NITROANTHRANILIC ACID				100ng...1ug...10...100...1mg...10...100...1g...10		
1960	M f	b6c eat	TBA MXB	78w93	>	no dre P=1. -
a	M f	b6c eat	liv MXB	78w93		no dre P=1.
b	M f	b6c eat	lun MXB	78w93		2.56gm \ P<.05
1961	M m	b6c eat	--- MXA	78w93	:	#12.6gm * P<.02 -
a	M m	b6c eat	TBA MXB	78w93		1.66gm \ P<.4
b	M m	b6c eat	liv MXB	78w93		no dre P=1.
c	M m	b6c eat	lun MXB	78w93		no dre P=1.

RefNum	LoConf	UpConf	Cntrl	1Dose	1Inc	2Dose	2Inc	Citation or Pathology	Brkly Code
a	c02222	153.mg	n.s.s.	11/20	41.0mg	12/50	82.0mg	17/50	
b	c02222	666.mg	n.s.s.	1/20	41.0mg	0/50	82.0mg	1/50	
1946	c02222	96.6mg	n.s.s.	0/20	16.0mg	1/50	32.8mg	6/50	liv:hpa,hpc,nnd. thy:cca,ccr. S
a	c02222	90.8mg	n.s.s.	9/20	16.0mg	15/50	32.8mg	13/50	
b	c02222	489.mg	n.s.s.	1/20	16.0mg	0/50	32.8mg	0/50	liv:hpa,hpc,nnd.
4-NITRO-o-PHENYLENEDIAMINE			99-56-9						
1947	c03941	924.mg	n.s.s.	8/20	478.mg	18/50	(956.mg)	11/50	
a	c03941	2.64gm	n.s.s.	1/20	478.mg	9/50	956.mg	3/50	liv:hpa,hpc,nnd. lun:a/a,a/c.
b	c03941	3.79gm	n.s.s.	3/20	478.mg	5/50	956.mg	4/50	
1948	c03941	539.mg	n.s.s.	12/20	441.mg	25/50	(883.mg)	12/50	
a	c03941	3.51gm	n.s.s.	4/20	441.mg	5/50	883.mg	4/50	liv:hpa,hpc,nnd. lun:a/a,a/c.
b	c03941	1.96gm	n.s.s.	3/20	441.mg	13/50	883.mg	6/50	
1949	c03941	36.0mg	n.s.s.	15/20	18.4mg	31/50	36.8mg	33/50	
a	c03941	217.mg	n.s.s.	0/20	18.4mg	2/50	36.8mg	0/50	liv:hpa,hpc,nnd.
1950	c03941	47.2mg	n.s.s.	9/20	14.7mg	26/50	29.4mg	19/50	
a	c03941	147.mg	n.s.s.	1/20	14.7mg	2/50	29.4mg	2/50	liv:hpa,hpc,nnd.
5-NITRO-o-TOLUIDINE			99-55-8						
1951	c01843	142.mg	698.mg	3/50	125.mg	12/50	240.mg	22/50	---:hes; liv:hpc. C
a	c01843	168.mg	787.mg	2/50	125.mg	7/50	240.mg	20/50	
b	c01843	529.mg	n.s.s.	1/50	125.mg	5/50	240.mg	3/50	
c	c01843	205.mg	n.s.s.	19/50	125.mg	19/50	240.mg	25/50	
d	c01843	168.mg	787.mg	2/50	125.mg	7/50	240.mg	20/50	liv:hpa,hpc,nnd. lun:a/a,a/c.
e	c01843	1.36gm	n.s.s.	2/50	125.mg	3/50	240.mg	0/50	
1952	c01843	135.mg	2.35gm	12/50	115.mg	12/49	224.mg	29/50	
a	c01843	135.mg	2.90gm	13/50	115.mg	12/49	224.mg	30/50	---:hes,hes; liv:hpc. C
b	c01843	718.mg	n.s.s.	1/50	115.mg	0/49	224.mg	4/50	---:hes,hes.
c	c01843	146.mg	n.s.s.	23/50	115.mg	20/49	224.mg	31/50	
d	c01843	135.mg	2.35gm	12/50	115.mg	12/49	224.mg	29/50	liv:hpa,hpc,nnd. lun:a/a,a/c.
e	c01843	1.03gm	n.s.s.	5/50	115.mg	3/49	224.mg	2/50	
1953	c01843	3.72mg	n.s.s.	42/50	1.80mg	33/50	3.60mg	35/50	
a	c01843	13.0mg	n.s.s.	0/50	1.80mg	2/50	3.60mg	1/50	liv:hpa,hpc,nnd.
1954	c01843	8.39mg	n.s.s.	0/50	1.40mg	0/50	2.90mg	3/50	S
a	c01843	2.67mg	n.s.s.	30/50	1.40mg	20/50	2.90mg	27/50	
b	c01843	9.23mg	n.s.s.	5/50	1.40mg	1/50	2.90mg	4/50	liv:hpa,hpc,nnd.
5-NITROACENAPHTHENE			602-87-9						
1955	1091	152.mg	1.66gm	0/20	382.mg	7/24			Takemura;bjca,30,481-483;1974
1956	c01967	29.3mg	87.4mg	2/50	53.3mg	23/50	127.mg	19/50	liv:hpc; ova:gct,lut,tua. C
a	c01967	29.5mg	90.3mg	2/50	53.3mg	23/50	127.mg	18/50	
b	c01967	108.mg	623.mg	0/50	53.3mg	4/50	127.mg	7/50	ova:gct,lut,tua.
c	c01967	161.mg	3.08gm	0/50	53.3mg	2/50	127.mg	4/50	
d	c01967	40.3mg	n.s.s.	19/50	53.3mg	29/50	127.mg	21/50	
e	c01967	29.5mg	90.3mg	2/50	53.3mg	23/50	127.mg	18/50	liv:hpa,hpc,nnd. lun:a/a,a/c.
f	c01967	232.mg	n.s.s.	2/50	53.3mg	3/50	127.mg	2/50	
1957	c01967	74.6mg	n.s.s.	23/50	58.8mg	15/50	140.mg	1/50	
a	c01967	132.mg	n.s.s.	12/50	58.8mg	7/50	140.mg	0/50	liv:hpa,hpc,nnd. lun:a/a,a/c.
b	c01967	152.mg	n.s.s.	5/50	58.8mg	4/50	140.mg	0/50	
1958	c01967	1.96mg	11.3mg	1/100	43.0mg	37/50	87.0mg	38/50	cli:can; eac:caa,cuc,sgc; lun:a/a,a/c; mgl:acn,pcn. C
a	c01967	2.18mg	44.5mg	1/100	43.0mg	8/50	87.0mg	3/50	lun:a/a,a/c.
b	c01967	7.28mg	24.8mg	0/100	43.0mg	27/50	87.0mg	35/50	eac:caa,cuc,sgc.
c	c01967	7.85mg	30.9mg	0/100	43.0mg	25/50	87.0mg	26/50	
d	c01967	18.7mg	143.mg	0/100	43.0mg	6/50	87.0mg	5/50	
e	c01967	31.5mg	198.mg	0/100	43.0mg	6/50	87.0mg	5/50	mgl:acn,pcn.
f	c01967	32.1mg	220.mg	0/100	43.0mg	5/50	87.0mg	5/50	
g	c01967	29.9mg	230.mg	0/100	43.0mg	3/50	87.0mg	9/50	
h	c01967	3.78mg	10.5mg	83/100	43.0mg	46/50	87.0mg	45/50	
i	c01967	n.s.s.	n.s.s.	2/100	43.0mg	0/50	87.0mg	0/50	liv:hpa,hpc,nnd.
1959	c01967	1.67mg	17.7mg	1/99	34.4mg	25/50	62.4mg	21/50	eac:cuc,sgc; lun:a/a,a/c. C
a	c01967	1.71mg	27.8mg	0/99	34.4mg	21/50	62.4mg	20/50	eac:cuc,sgc.
b	c01967	1.75mg	45.4mg	0/99	34.4mg	14/50	62.4mg	18/50	s
c	c01967	9.96mg	93.8mg	1/99	34.4mg	7/50	62.4mg	3/50	lun:a/a,a/c.
d	c01967	10.4mg	171.mg	1/99	34.4mg	5/50	62.4mg	0/50	
e	c01967	10.6mg	210.mg	0/99	34.4mg	4/50	62.4mg	1/50	thy:fcc,pec. S
f	c01967	13.5mg	204.mg	0/99	34.4mg	4/50	62.4mg	0/50	kid:tlc,uac. S
g	c01967	15.4mg	323.mg	0/99	34.4mg	4/50	62.4mg	0/50	thy:fca,ppa. S
h	c01967	27.4mg	188.mg	0/99	34.4mg	7/50	62.4mg	2/50	
i	c01967	2.91mg	10.1mg	58/99	34.4mg	39/50	62.4mg	30/50	
j	c01967	5.92mg	n.s.s.	4/99	34.4mg	1/50	62.4mg	0/50	liv:hpa,hpc,nnd.
4-NITROANTHRANILIC ACID			619-17-0						
1960	c01945	1.35gm	n.s.s.	39/100	502.mg	18/50	1.09gm	18/50	
a	c01945	6.86gm	n.s.s.	8/100	502.mg	1/50	1.09gm	1/50	liv:hpa,hpc,nnd.
b	c01945	824.mg	n.s.s.	2/100	502.mg	5/50	(1.09gm)	1/50	lun:a/a,a/c.
1961	c01945	3.81gm	n.s.s.	0/100	463.mg	0/50	1.01gm	3/50	---:hes,hes. S
a	c01945	381.mg	n.s.s.	40/100	463.mg	30/50	(1.01gm)	15/50	
b	c01945	2.25gm	n.s.s.	22/100	463.mg	16/50	1.01gm	9/50	liv:hpa,hpc,nnd.
c	c01945	4.11gm	n.s.s.	18/100	463.mg	10/50	1.01gm	4/50	lun:a/a,a/c.

Spe	Strain	Site	Xpo + Xpt	Notes	TD50	2Tailpvl
Sex	Route	Hist			DR	AuOp
1962	R f f34	eat	TBA MXB 18m24	v	>	no dre P=1. -
a	R f f34	eat	liv MXB 18m24	v		11.8gm * P<.6
1963	R m f34	eat	TBA MXB 18m24	v	>	no dre P=1. -
a	R m f34	eat	liv MXB 18m24	v		3.71gm * P<.09
6-NITROBENZIMIDAZOLE						
				100ng...1ug...10...100...1mg...10...100...1g...10		
1964	M f b6c	eat	liv MXA 78w95	v	: + :	354.mg / P<.0005c
a	M f b6c	eat	liv hpc 78w95	v		762.mg * P<.002 c
b	M f b6c	eat	pit MXA 78w95	v		335.mg \ P<.03
c	M f b6c	eat	TBA MXB 78w95	v		429.mg * P<.05
d	M f b6c	eat	liv MXB 78w95	v		354.mg / P<.0005
e	M f b6c	eat	lun MXB 78w95	v		no dre P=1.
1965	M m b6c	eat	liv MXA 78w95	v	: ±	392.mg * P<.02 c
a	M m b6c	eat	liv hpc 78w95	v		423.mg * P<.02
b	M m b6c	eat	TBA MXB 78w95	v		1.98gm * P<.8
c	M m b6c	eat	liv MXB 78w95	v		392.mg * P<.02
d	M m b6c	eat	lun MXB 78w95	v		no dre P=1.
1966	R f f34	eat	TBA MXB 18m24	v	>	no dre P=1. -
a	R f f34	eat	liv MXB 18m24	v		no dre P=1.
1967	R m f34	eat	TBA MXB 18m24	v	>	no dre P=1. -
a	R m f34	eat	liv MXB 18m24	v		8.83gm * P<.7
NITROFEN*						
				100ng...1ug...10...100...1mg...10...100...1g...10		
1968	M f b6c	eat	liv MXA 78w91		: + :	406.mg * P<.0005c
a	M f b6c	eat	liv hpc 78w91			1.20gm * P<.008 c
b	M f b6c	eat	TBA MXB 78w91			606.mg * P<.05
c	M f b6c	eat	liv MXB 78w91			406.mg * P<.0005
d	M f b6c	eat	lun MXB 78w91			4.73gm * P<.3
1969	M f b6c	eat	liv hpc 78w92	v	: + :	64.2mg \ P<.0005c
a	M f b6c	eat	TBA MXB 78w92	v		74.6mg \ P<.0005
b	M f b6c	eat	liv MXB 78w92	v		64.2mg \ P<.0005
c	M f b6c	eat	lun MXB 78w92	v		no dre P=1.
1970	M f b6c	eat	liv hpc 78w90	v	pool : + :	67.7mg \ P<.0005c
a	M f b6c	eat	--- has 78w90	v		2.84gm * P<.02 a
1971	M m b6c	eat	liv MXA 78w91		: + :	204.mg * P<.0005c
a	M m b6c	eat	liv hpc 78w91			540.mg * P<.0005c
b	M m b6c	eat	TBA MXB 78w91			310.mg * P<.003
c	M m b6c	eat	liv MXB 78w91			204.mg * P<.0005
d	M m b6c	eat	lun MXB 78w91			no dre P=1.
1972	M m b6c	eat	liv hpc 78w92	v	: + :	133.mg * P<.007 c
a	M m b6c	eat	TBA MXB 78w92	v		167.mg * P<.04
b	M m b6c	eat	liv MXB 78w92	v		133.mg * P<.007
c	M m b6c	eat	lun MXB 78w92	v		no dre P=1.
1973	M m b6c	eat	liv hpc 78w90	v	pool : + :	85.3mg * P<.0005c
a	M m b6c	eat	--- has 78w90	v		1.49gm * P<.005 c
b	M m b6c	eat	sub MXA 78w90	v		481.mg \ P<.03
1974	R f f34	eat	TBA MXB 18m24		>	no dre P=1. -
a	R f f34	eat	liv MXB 18m24			no dre P=1. -
1975	R m f34	eat	TBA MXB 18m24		>	no dre P=1. -
a	R m f34	eat	liv MXB 18m24			no dre P=1.
1976	R f osm	eat	pan can 18m26		: ±	459.mg * P<.02 -
a	R f osm	eat	ova gct 18m26			827.mg * P<.04
b	R f osm	eat	--- lym 18m26			934.mg * P<.05
c	R f osm	eat	TBA MXB 18m26			100.mg / P<.07
d	R f osm	eat	liv MXB 18m26			no dre P=1.
1977	R f osm	eat	pan can 18m24		pool : + :	420.mg * P<.0005c
a	R f osm	eat	ova MXA 18m24			820.mg * P<.03
b	R f osm	eat	ova gct 18m24			1.02gm * P<.04
c	R f osm	eat	--- lym 18m24			1.06gm * P<.04
1978	R m osm	eat	TBA MXB 18m26	sv	>	202.mg * P<.5
a	R m osm	eat	liv MXB 18m26	sv		no dre P=1.
1-(5-NITROFURFURYLIDENE)AMINO)HYDANTOIN...1ug...10...100...1mg...10...100...1g...10						
1979	R f hza	eat	mgl fba 36w54	es	>	120.mg P<.3 -
a	R f hza	eat	liv tum 36w54	es		no dre P=1.
1980	R f hza	eat	mam tum 44w60	es	>	214.mg P<.6 -
a	R f hza	eat	liv tum 44w60	es		no dre P=1.
1981	R f sda	eat	liv tum 75w80	ev	>	no dre P=1.
a	R f sda	eat	tba mix 75w80	ev		185.mg P<.7 -
1-(5-NITROFURFURYLIDENE)AMINO)-2-IMIDAZOLIDINONE...10...100...1mg...10...100...1g...10						
1982	R f sda	eat	mgl mix 46w66	e	<	noTD50 P<.0005
a	R f sda	eat	mgl adc 46w66	e		5.26mg P<.0005+
b	R f sda	eat	--- lbl 46w66	e		+historical P<.02 +
c	R f sda	eat	liv tum 46w66	e		no dre P=1.
d	R f sda	eat	tba mix 46w66	e		noTD50 P<.0005
NITROGEN MUSTARD						
				100ng...1ug...10...100...1mg...10...100...1g...10		
1983	R m b46	iv]	tba mix 12m24	ea	+	11.4ug P<.0005+

RefNum	LoConf	UpConf	Cntrl	LDose	LInc	2Dose	2Inc	Citation or Pathology	Brkly Code
1962	c01945	411.mg n.s.s.	57/75	170.mg	35/50	557.mg	22/50		
a	c01945	1.31gm n.s.s.	3/75	170.mg	0/50	557.mg	2/50		liv:hpa,hpc,nnd.
1963	c01945	353.mg n.s.s.	40/75	136.mg	24/50	446.mg	15/50		
a	c01945	911.mg n.s.s.	0/75	136.mg	1/50	446.mg	1/50		liv:hpa,hpc,nnd.
6-NITROBENZIMIDAZOLE 94-52-0									
1964	c01912	206.mg 769.mg	3/100	127.mg	4/50	253.mg	20/50		liv:hpa,hpc.
a	c01912	359.mg 3.92gm	3/100	127.mg	2/50	253.mg	11/50		
b	c01912	131.mg n.s.s.	8/100	127.mg	12/50	(253.mg)	0/50)		pit:edn,cra. S
c	c01912	176.mg n.s.s.	29/100	127.mg	22/50	253.mg	25/50		
d	c01912	206.mg 769.mg	3/100	127.mg	4/50	253.mg	20/50		liv:hpa,hpc,nnd.
e	c01912	870.mg n.s.s.	5/100	127.mg	4/50	253.mg	2/50		lun:a/a,a/c.
1965	c01912	180.mg n.s.s.	20/100	118.mg	19/50	234.mg	22/50		liv:hpa,hpc.
a	c01912	194.mg n.s.s.	18/100	118.mg	16/50	234.mg	21/50		S
b	c01912	229.mg n.s.s.	45/100	118.mg	29/50	234.mg	25/50		
c	c01912	180.mg n.s.s.	20/100	118.mg	19/50	234.mg	22/50		liv:hpa,hpc,nnd.
d	c01912	901.mg n.s.s.	15/100	118.mg	8/50	234.mg	4/50		lun:a/a,a/c.
1966	c01912	55.8mg n.s.s.	70/100	45.0mg	31/50	(182.mg)	26/50)		
a	c01912	1.92gm n.s.s.	2/100	45.0mg	0/50	182.mg	0/50		liv:hpa,hpc,nnd.
1967	c01912	247.mg n.s.s.	54/102	36.0mg	22/50	146.mg	22/50		
a	c01912	797.mg n.s.s.	1/102	36.0mg	0/50	146.mg	1/50		liv:hpa,hpc,nnd.
NITROFEN* (c00420 is NCI TR# 184; c00421 is NCI TR# 26) 1836-75-5									
1968	c00420	282.mg 942.mg	0/20	334.mg	14/50	668.mg	30/50		liv:hpa,hpc.
a	c00420	692.mg 20.6gm	0/20	334.mg	5/50	668.mg	13/50		
b	c00420	287.mg n.s.s.	3/20	334.mg	23/50	668.mg	33/50		
c	c00420	282.mg 942.mg	0/20	334.mg	14/50	668.mg	30/50		liv:hpa,hpc,nnd.
d	c00420	1.80gm n.s.s.	0/20	334.mg	2/50	668.mg	3/50		lun:a/a,a/c.
1969	c00421	42.8mg 102.mg	0/20	264.mg	42/50	(529.mg)	44/50)		
a	c00421	46.4mg 157.mg	3/20	264.mg	43/50	(529.mg)	44/50)		
b	c00421	42.8mg 102.mg	0/20	264.mg	42/50	(529.mg)	44/50)		liv:hpa,hpc,nnd.
c	c00421	n.s.s. n.s.s.	0/20	264.mg	1/50	529.mg	0/50		lun:a/a,a/c.
1970	c00421	45.2mg 108.mg	1/80p	264.mg	42/50	(529.mg)	44/50)		
a	c00421	993.mg n.s.s.	1/80p	264.mg	0/50	529.mg	5/50		
1971	c00420	144.mg 401.mg	1/20	308.mg	31/50	617.mg	40/50		liv:hpa,hpc.
a	c00420	355.mg 1.20gm	0/20	308.mg	13/50	617.mg	20/50		
b	c00420	175.mg 1.70gm	7/20	308.mg	31/50	617.mg	43/50		
c	c00420	144.mg 401.mg	1/20	308.mg	31/50	617.mg	40/50		liv:hpa,hpc,nnd.
d	c00420	2.90gm n.s.s.	3/20	308.mg	0/50	617.mg	3/50		lun:a/a,a/c.
1972	c00421	73.0mg 1.86gm	4/20	244.mg	38/50	488.mg	46/50		
a	c00421	78.7mg n.s.s.	6/20	244.mg	40/50	488.mg	46/50		
b	c00421	73.0mg 1.86gm	4/20	244.mg	38/50	488.mg	46/50		liv:hpa,hpc,nnd.
c	c00421	1.40gm n.s.s.	1/20	244.mg	1/50	488.mg	1/50		lun:a/a,a/c.
1973	c00421	60.9mg 129.mg	5/80p	244.mg	38/50	488.mg	46/50		
a	c00421	566.mg 13.6gm	0/80p	244.mg	1/50	488.mg	4/50		
b	c00421	193.mg n.s.s.	3/80p	244.mg	10/50	(488.mg)	0/50)		sub:fbn, fib. S
1974	c00420	206.mg n.s.s.	15/20	113.mg	21/50	(225.mg)	15/50)		
a	c00420	n.s.s. n.s.s.	0/20	113.mg	0/50	225.mg	0/50		liv:hpa,hpc,nnd.
1975	c00420	441.mg n.s.s.	10/20	90.4mg	20/50	180.mg	14/50		
a	c00420	n.s.s. n.s.s.	0/20	90.4mg	0/50	180.mg	0/50		liv:hpa,hpc,nnd.
1976	c00421	215.mg n.s.s.	0/20	46.1mg	2/50	92.0mg	7/50		S
a	c00421	286.mg n.s.s.	0/20	46.1mg	0/50	92.0mg	4/50		S
b	c00421	320.mg n.s.s.	0/20	46.1mg	0/50	92.0mg	4/50		S
c	c00421	42.4mg n.s.s.	14/20	46.1mg	31/50	92.0mg	42/50		
d	c00421	n.s.s. n.s.s.	0/20	46.1mg	0/50	92.0mg	0/50		liv:hpa,hpc,nnd.
1977	c00421	197.mg 1.17gm	0/110p	46.1mg	2/50	92.0mg	7/50		
a	c00421	281.mg n.s.s.	1/110p	46.1mg	1/50	92.0mg	4/50		ova:gcc,gct. S
b	c00421	321.mg n.s.s.	1/110p	46.1mg	0/50	92.0mg	4/50		S
c	c00421	333.mg n.s.s.	1/110p	46.1mg	0/50	92.0mg	4/50		S
1978	c00421	45.9mg n.s.s.	10/20	65.3mg	30/50	136.mg	4/50		
a	c00421	n.s.s. n.s.s.	0/20	65.3mg	0/50	136.mg	0/50		liv:hpa,hpc,nnd.
1-[(5-NITROFURFURYLIDENE)AMINO]HYDANTOIN 67-20-9									
1979	1063m	19.4mg n.s.s.	0/5	100.mg	1/7			Morris;canr,29,2145-2156;1969	
a	1063m	38.9mg n.s.s.	0/5	100.mg	0/7				
1980	1063n	35.8mg n.s.s.	3/16	110.mg	5/18				
a	1063n	136.mg n.s.s.	0/16	110.mg	0/18				
1981	200a	244.mg n.s.s.	0/30	55.6mg	0/36			Cohen;jnci,51,403-417;1973	
a	200a	28.6mg n.s.s.	14/30	55.6mg	19/36				
1-[(5-NITROFURFURYLIDENE)AMINO]-2-IMIDAZOLIDINONE 555-84-0									
1982	200a	n.s.s. 6.44mg	1/25	52.3mg	31/31			Cohen;jnci,51,403-417;1973	
a	200a	2.72mg 10.0mg	0/25	52.3mg	29/31				
b	200a	31.1mg n.s.s.	0/25	52.3mg	5/31				
c	200a	134.mg n.s.s.	0/25	52.3mg	0/31				
d	200a	n.s.s. 6.44mg	1/25	52.3mg	31/31				
NITROGEN MUSTARD (2,2'-dichloro-N-methyl-diethylamine) 51-75-2									
1983	1017	5.13ug 51.5ug	7/65	7.86ug	12/27			Schmahl;arzn,20,1461-1467;1970	

Spe	Strain	Site	Xpo+Xpt	Notes	TD50	2Tailpvl
Sex	Route	Hist			DR	AuOp
a	R m b46	ivj tba mal	12m24	es	22.8ug	P<.02 +
b	R m b46	ivj tba ben	12m24	es	34.2ug	P<.05
NITROGEN MUSTARD N-OXIDE					100ng.....1ug.....10.....100.....1mg.....10.....100.....1g.....10	
1984	R m b46	ivj --- mix	12m24	es	1.40mg	P<.002
a	R m b46	ivj tba mix	12m24	es	.764mg	P<.008 +
b	R m b46	ivj tba mal	12m24	es	.806mg	P<.003 +
c	R m b46	ivj tba ben	12m24	es	no dre	P=1.
1-NITRONAPHTHALENE					100ng.....1ug.....10.....100.....1mg.....10.....100.....1g.....10	
1985	M f b6c	eat TBA	MXB 78w96		>	no dre P=1. -
a	M f b6c	eat liv	MXB 78w96			no dre P=1. -
b	M f b6c	eat lun	MXB 78w96			682.mg * P<.2
1986	M m b6c	eat TBA	MXB 78w96		>	no dre P=1. -
a	M m b6c	eat liv	MXB 78w96			no dre P=1. -
b	M m b6c	eat lun	MXB 78w96			no dre P=1. -
1987	R f f34	eat TBA	MXB 18m25	v	>	no dre P=1. -
a	R f f34	eat liv	MXB 18m25	v		no dre P=1. -
1988	R m f34	eat TBA	MXB 18m25	v	>	no dre P=1. -
a	R m f34	eat liv	MXB 18m25	v		509.mg * P<.2
2-NITROPROPANE**					100ng.....1ug.....10.....100.....1mg.....10.....100.....1g.....10	
1989	R f sda	inh liv tum	95w95	e	>	293.mg P<.2 -
a	R f sda	inh tba ben	95w95	e		no dre P=1. -
b	R f sda	inh tba mal	95w95	e		no dre P=1. -
1990	R f sda	inh liv tum	52w52	ek	>	no dre P=1. -
a	R f sda	inh tba ben	52w52	ek		no dre P=1. -
b	R f sda	inh tba mal	52w52	ek		no dre P=1. -
1991	R f sda	inh liv tum	52w95	ek	>	no dre P=1. -
a	R f sda	inh tba ben	52w95	ek		no dre P=1. -
b	R f sda	inh tba mal	52w95	ek		no dre P=1. -
1992	R m sda	inh liv agm	95w95	e	>	no dre P=1. -
a	R m sda	inh tba ben	95w95	e		no dre P=1. -
b	R m sda	inh tba mal	95w95	e		no dre P=1. -
1993	R m sda	inh liv tum	52w52	ek	>	no dre P=1. -
a	R m sda	inh tba ben	52w52	ek		9.06mg P<.3 -
b	R m sda	inh tba mal	52w52	ek		no dre P=1. -
1994	R m sda	inh liv agm	52w95	ek	>	no dre P=1. -
a	R m sda	inh tba ben	52w95	ek		7.78mg P<.6 -
b	R m sda	inh tba mal	52w95	ek		23.6mg P<.4 -
3-NITROPROPIONIC ACID					100ng.....1ug.....10.....100.....1mg.....10.....100.....1g.....10	
1995	M f b6c	gav TBA	MXB 24m24		>	no dre P=1. -
a	M f b6c	gav liv	MXB 24m24			337.mg * P<.5
b	M f b6c	gav lun	MXB 24m24			499.mg * P<.8
1996	M m b6c	gav TBA	MXB 24m24		>	no dre P=1. -
a	M m b6c	gav liv	MXB 24m24			no dre P=1. -
b	M m b6c	gav lun	MXB 24m24			no dre P=1. -
1997	R f f34	gav TBA	MXB 26m26		>	43.8mg * P<.1 -
a	R f f34	gav liv	MXB 26m26			29.0mg * P<.3
1998	R m f34	gav MXB	MXB 26m26		: + :	2.31mg * P<.003
a	R m f34	gav liv	MXA 26m26			4.41mg * P<.004 e
b	R m f34	gav liv	nnd 26m26			5.03mg * P<.008 a
c	R m f34	gav pni	1sa 26m26			4.53mg * P<.06 a
d	R m f34	gav TBA	MXB 26m26			7.02mg * P<.7
e	R m f34	gav liv	MXB 26m26			4.41mg * P<.004
NITROSO-BAYGON					100ng.....1ug.....10.....100.....1mg.....10.....100.....1g.....10	
1999	R m sda	gav for tum	31w90	erv	.	.364mg P<.0005+
a	R m sda	gav for car	31w90	erv	.	.434mg P<.0005+
1-NITROSO-5,6-DIHYDROURACIL					100ng.....1ug.....10.....100.....1mg.....10.....100.....1g.....10	
2000	R f mrw	wat liv hpc	41w70		.	.104mg P<.0005+
a	R f mrw	wat liv mix	41w70		.	.104mg P<.0005+
b	R f mrw	wat tba mix	41w70		.	.130mg P<.0005
2001	R m mrw	wat liv hpc	41w70		.	93.2ug P<.0005+
a	R m mrw	wat liv mix	41w70		.	93.2ug P<.0005+
b	R m mrw	wat tba mix	41w70		.	.125mg P<.002
NITROSO-2,6-DIMETHYLMORPHOLINE					100ng.....1ug.....10.....100.....1mg.....10.....100.....1g.....10	
2002	H f syg	gav trh ppp	59w83	a	.	6.40mg * P<.0005+
a	H f syg	gav mix mix	59w83	a	.	9.17mg * P<.0005
b	H f syg	gav liv mix	59w83	a	.	11.0mg * P<.0005
c	H f syg	gav mix mix	59w83	a	.	16.9mg * P<.008
d	H f syg	gav pen mix	59w83	a	.	5.75mg * P<.02 +
e	H f syg	gav pdu ade	59w83	a	.	6.99mg * P<.02
f	H f syg	gav for mix	59w83	a	.	9.45mg * P<.03
g	H f syg	gav gel mix	59w83	a	.	12.9mg Z P<.04
h	H f syg	gav pdu car	59w83	a	.	32.1mg * P<.3 +

RefNum	LoConf	UpConf	Cntrl	1Dose	1Inc	2Dose	2Inc	Citation or Pathology	Brkly Code			
a	1017	8.41ug	n.s.s.	4/65	7.86ug	7/27						
b	1017	10.8ug	n.s.s.	3/65	7.86ug	5/27						
NITROGEN MUSTARD N-OXIDE (mitomen)				126-85-2								
1984	1017	.571mg	5.62mg	0/65	.300mg	6/44		Schmahl;arzn,20,1461-1467;1970				
a	1017	.335mg	15.9mg	7/65	.300mg	14/44						
b	1017	.364mg	5.46mg	4/65	.300mg	12/44						
c	1017	1.36mg	n.s.s.	3/65	.300mg	2/44						
1-NITRONAPHTHALENE				86-57-7								
1985	c01956	230.mg	n.s.s.	42/100	63.7mg	12/50	127.mg	20/50				
a	c01956	1.01gm	n.s.s.	5/100	63.7mg	0/50	127.mg	1/50	liv:hpa,hpc,nnd.			
b	c01956	231.mg	n.s.s.	5/100	63.7mg	4/50	127.mg	7/50	lun:a/a,a/c.			
1986	c01956	168.mg	n.s.s.	38/100	58.8mg	19/50	118.mg	21/50				
a	c01956	323.mg	n.s.s.	17/100	58.8mg	8/50	118.mg	8/50	liv:hpa,hpc,nnd.			
b	c01956	290.mg	n.s.s.	17/100	58.8mg	8/50	118.mg	9/50	lun:a/a,a/c.			
1987	c01956	72.0mg	n.s.s.	51/75	21.0mg	32/50	66.0mg	34/50				
a	c01956	346.mg	n.s.s.	4/75	21.0mg	0/50	66.0mg	2/50	liv:hpa,hpc,nnd.			
1988	c01956	23.4mg	n.s.s.	36/75	16.8mg	21/50	(52.8mg	19/50)				
a	c01956	175.mg	n.s.s.	0/75	16.8mg	2/50	52.8mg	2/50	liv:hpa,hpc,nnd.			
2-NITROPROPANE**				79-46-9								
1989	1444	47.8mg	n.s.s.	0/85	7.96mg	1/65			Griffin;eas,5,194-201;1981			
a	1444	24.1mg	n.s.s.	66/85	7.96mg	32/65						
b	1444	45.9mg	n.s.s.	18/85	7.96mg	6/65						
1990	1444n	4.10mg	n.s.s.	0/10	7.96mg	0/10						
a	1444n	2.38mg	n.s.s.	1/10	7.96mg	1/10						
b	1444n	4.10mg	n.s.s.	0/10	7.96mg	0/10						
1991	1444n	7.46mg	n.s.s.	0/48	4.34mg	0/10						
a	1444n	1.43mg	n.s.s.	36/48	4.34mg	7/10						
b	1444n	4.83mg	n.s.s.	7/48	4.34mg	1/10						
1992	1444	62.2mg	n.s.s.	1/85	5.57mg	0/65						
a	1444	12.2mg	n.s.s.	42/85	5.57mg	26/65						
b	1444	21.1mg	n.s.s.	11/85	5.57mg	7/65						
1993	1444n	2.87mg	n.s.s.	0/10	5.57mg	0/10						
a	1444n	1.47mg	n.s.s.	0/10	5.57mg	1/10						
b	1444n	2.87mg	n.s.s.	0/10	5.57mg	0/10						
1994	1444n	5.22mg	n.s.s.	1/64	3.04mg	0/10						
a	1444n	1.02mg	n.s.s.	32/64	3.04mg	6/10						
b	1444n	2.81mg	n.s.s.	2/64	3.04mg	1/10						
3-NITROPROPIONIC ACID				504-88-1								
1995	c03076	22.1mg	n.s.s.	26/50	8.80mg	32/50	17.7mg	26/50				
a	c03076	65.8mg	n.s.s.	2/50	8.80mg	1/50	17.7mg	4/50	liv:hpa,hpc,nnd.			
b	c03076	49.0mg	n.s.s.	2/50	8.80mg	6/50	17.7mg	3/50	lun:a/a,a/c.			
1996	c03076	17.9mg	n.s.s.	39/50	8.80mg	28/50	17.7mg	38/50				
a	c03076	39.7mg	n.s.s.	20/50	8.80mg	10/50	17.7mg	16/50	liv:hpa,hpc,nnd.			
b	c03076	49.1mg	n.s.s.	14/50	8.80mg	8/50	17.7mg	10/50	lun:a/a,a/c.			
1997	c03076	1.43mg	n.s.s.	40/50	.850mg	30/50	1.70mg	39/50				
a	c03076	7.14mg	n.s.s.	0/50	.850mg	1/50	1.70mg	1/50	liv:hpa,hpc,nnd.			
1998	c03076	1.20mg	14.5mg	4/50	.600mg	8/50	1.20mg	17/50	liv:hpc,nnd; pni:isa. A			
a	c03076	2.08mg	27.1mg	0/50	.600mg	3/50	1.20mg	6/50	liv:hpc,nnd.			
b	c03076	2.28mg	87.3mg	0/50	.600mg	3/50	1.20mg	5/50				
c	c03076	1.85mg	n.s.s.	4/50	.600mg	6/50	1.20mg	11/50				
d	c03076	.998mg	n.s.s.	36/50	.600mg	31/50	1.20mg	38/50				
e	c03076	2.08mg	27.1mg	0/50	.600mg	3/50	1.20mg	6/50	liv:hpa,hpc,nnd.			
NITROSO-BAYGON				38777-13-8								
1999	1409	.173mg	.891mg	0/40	.984mg	12/16			Lijinsky;eas,2,413-419;1978			
a	1409	.206mg	1.10mg	0/40	.984mg	11/16						
1-NITROSO-5,6-DIHYDROURACIL				16813-36-8								
2000	1246	44.5ug	.222mg	0/25	1.08mg	24/25			Bulay;inci,62,1523-1528;1979			
a	1246	44.5ug	.222mg	0/25	1.08mg	24/25						
b	1246	48.6ug	.458mg	12/25	1.08mg	24/25						
2001	1246	39.4ug	.204mg	0/22	.941mg	22/23						
a	1246	39.4ug	.204mg	0/22	.941mg	22/23						
b	1246	43.9ug	.639mg	12/22	.941mg	22/23						
NITROSO-2,6-DIMETHYLMORPHOLINE				1456-28-6								
2002	430	3.54mg	21.8mg	0/15	1.31mg	2/15	2.63mg	3/15	10.5mg	8/15	Reznik;inci,60,371-378;1978	
a	430	4.70mg	27.7mg	0/15	1.31mg	0/15	2.63mg	1/15	5.24mg	7/15	10.5mg	4/15
b	430	5.34mg	32.0mg	0/15	1.31mg	0/15	2.63mg	1/15	5.24mg	3/15	10.5mg	6/15
c	430	7.29mg	279.mg	0/15	1.31mg	0/15	2.63mg	0/15	5.24mg	5/15	10.5mg	2/15
d	430	2.77mg	n.s.s.	0/15	1.31mg	3/15	2.63mg	7/15	5.24mg	6/15	10.5mg	6/15
e	430	3.39mg	n.s.s.	0/15	1.31mg	2/15	2.63mg	6/15	5.24mg	5/15	10.5mg	5/15
f	430	4.86mg	n.s.s.	0/15	1.31mg	1/15	2.63mg	3/15	5.24mg	5/15	10.5mg	3/15
g	430	6.07mg	n.s.s.	0/15	1.31mg	0/15	2.63mg	5/15	5.24mg	0/15	10.5mg	4/15
h	430	8.48mg	n.s.s.	0/15	1.31mg	1/15	2.63mg	2/15	5.24mg	1/15	10.5mg	2/15

CARCINOGENIC POTENCY DATABASE

RefNum	LoConf	UpConf	Cntrl	1Dose	1Inc	2Dose	2Inc	Citation or Pathology				Brkly Code		
i	430	5.06mg	n.s.s.	0/15	1.31mg	3/15	2.63mg	5/15	5.24mg	5/15	10.5mg	2/15		
j	430	16.5mg	n.s.s.	0/15	1.31mg	3/15	2.63mg	2/15	5.24mg	0/15	10.5mg	1/15		
k	430	.987mg	4.99mg	0/15	1.31mg	8/15	2.63mg	12/15	5.24mg	14/15	10.5mg	10/15		
2003	430	.659mg	2.72mg	0/15	1.31mg	7/15	2.63mg	9/15	(5.24mg	5/15	10.5mg	5/15)		
a	430	1.58mg	7.41mg	0/15	1.31mg	2/15	2.63mg	10/15	5.24mg	6/15	(10.5mg	9/15)		
b	430	1.31mg	10.6mg	0/15	1.31mg	1/15	2.63mg	7/15	(5.24mg	3/15	10.5mg	4/15)		
c	430	3.75mg	18.8mg	0/15	1.31mg	0/15	2.63mg	5/15	5.24mg	6/15	10.5mg	6/15		
d	430	5.16mg	38.4mg	0/15	1.31mg	0/15	2.63mg	3/15	5.24mg	4/15	10.5mg	5/15		
e	430	4.25mg	n.s.s.	0/15	1.31mg	4/15	2.63mg	3/15	5.24mg	3/15	10.5mg	6/15		
f	430	5.29mg	n.s.s.	0/15	1.31mg	2/15	2.63mg	7/15	5.24mg	1/15	10.5mg	4/15		
g	430	7.74mg	n.s.s.	0/15	1.31mg	2/15	2.63mg	1/15	5.24mg	3/15	10.5mg	2/15		
h	430	1.07mg	2.90mg	0/15	1.31mg	5/15	2.63mg	10/15	5.24mg	12/15	10.5mg	13/15		
NITROSO-N-METHYL-N-(2-PHENYL)ETHYLAMINE				13256-11-6										
2004	1374m	4.57ug	17.1ug	0/20	2.92ug	9/20	8.10ug	11/20	(44.6ug	16/20	.197mg	19/20	.600mg	19/20)
											Lijinsky; fctx,20,393-399;1982			
a	1374m	22.3ug	80.6ug	0/20	2.92ug	1/20	8.10ug	2/20	44.6ug	15/20	(.197mg	13/20	.600mg	16/20)
b	1374m	.424mg	n.s.s.	0/20	2.92ug	6/20	8.10ug	1/20	44.6ug	1/20	.197mg	4/20	(.600mg	5/20)
c	1374m	.666mg	n.s.s.	0/20	2.92ug	4/20	8.10ug	7/20	44.6ug	15/20	.197mg	4/20	.600mg	9/20)
d	1374m	4.94mg	n.s.s.	0/20	2.92ug	0/20	8.10ug	5/20	44.6ug	0/20	.197mg	0/20	.600mg	0/20)
e	1374m	4.81mg	n.s.s.	9/20	2.92ug	16/20	8.10ug	13/20	44.6ug	9/20	.197mg	0/20	.600mg	0/20)
f	1374m	3.60mg	n.s.s.	0/20	2.92ug	0/20	8.10ug	0/20	44.6ug	6/20	.197mg	0/20	.600mg	0/20)
2005	1374n	6.49ug	35.5ug	0/20	9.22ug		10/20							
a	1374n	14.5ug	n.s.s.	0/20	9.22ug		4/20							
b	1374n	14.5ug	n.s.s.	0/20	9.22ug		4/20							
c	1374n	9.81ug	n.s.s.	9/20	9.22ug		10/20							
d	1374n	29.9ug	n.s.s.	0/20	9.22ug		1/20							
e	1374n	29.9ug	n.s.s.	0/20	9.22ug		1/20							
N-NITROSO-N-METHYLUREA (MNU)				684-93-5										
2006	2000	.565mg	n.s.s.	0/38	10.4mg		1/7	Adamson;ossc,129-156;1982/Sieber pers.comm.						
a	2000	.565mg	n.s.s.	0/38	10.4mg		1/7							
b	2000	1.13mg	n.s.s.	0/38	10.4mg		0/7							
c	2000	.580mg	n.s.s.	1/38	10.4mg		1/7							
2007	2000	1.18mg	10.9mg	0/32	10.6mg		6/11							
a	2000	1.78mg	27.3mg	0/32	10.6mg		4/11							
b	2000	2.89mg	n.s.s.	0/32	10.6mg		2/11							
c	2000	4.04mg	n.s.s.	0/32	10.6mg		1/11							
d	2000	4.04mg	n.s.s.	0/32	10.6mg		1/11							
e	2000	4.04mg	n.s.s.	0/32	10.6mg		1/11							
f	2000	7.83mg	n.s.s.	0/32	10.6mg		0/11							
g	2000	.991mg	13.5mg	3/32	10.6mg		7/11							
N-NITROSO-N-METHYLURETHAN				615-53-2										
2008	1181	n.s.s.	.127mg	0/16	.629mg		16/16	Herrold;jnci,37,389-394;1966						
a	1181	59.7ug	.305mg	0/16	.629mg		13/16							
NITROSO-1,2,3,6-TETRAHYDROPYRIDINE				55556-92-8										
2009	1375m	76.3ug	.350mg	0/20	7.94ug	6/20	20.6ug	1/20	50.8ug	4/20	.140mg	15/20	(.785mg	17/20)
											Lijinsky;eas,6,513-527;1982/pers.comm.			
a	1375m	.129mg	.378mg	0/20	7.94ug	0/20	20.6ug	0/20	50.8ug	1/20	.140mg	16/20	.785mg	19/20)
											(2.83mg 15/20)			
b	1375m	.141mg	.614mg	0/20	7.94ug	0/20	20.6ug	0/20	50.8ug	0/20	.140mg	13/20	(.785mg	10/20)
											(2.83mg 8/20)			
c	1375m	2.14mg	8.91mg	0/20	7.94ug	0/20	20.6ug	0/20	50.8ug	0/20	.140mg	0/20	.785mg	0/20)
											(2.83mg 14/20)			
d	1375m	12.8mg	n.s.s.	0/20	7.94ug	2/20	20.6ug	6/20	50.8ug	4/20	.140mg	2/20	.785mg	0/20)
											(2.83mg 2/20)			
e	1375m	14.4mg	n.s.s.	0/20	7.94ug	6/20	20.6ug	0/20	50.8ug	2/20	.140mg	4/20	.785mg	1/20)
											(2.83mg 1/20)			
f	1375m	8.09mg	n.s.s.	1/20	7.94ug	4/20	20.6ug	9/20	50.8ug	6/20	.140mg	5/20	.785mg	0/20)
											(2.83mg 5/20)			
2010	1375n	n.s.s.	62.0ug	0/20	.184mg		20/20							
a	1375n	49.3ug	.217mg	0/20	.184mg		14/20							
b	1375n	63.3ug	.303mg	0/20	.184mg		12/20							
c	1375n	.298mg	n.s.s.	1/20	.184mg		2/20							
2011	1375o	22.0ug	66.7ug	0/20	31.8ug	10/20	82.6ug		19/20					
a	1375o	25.6ug	.156mg	0/20	31.8ug	9/20	(82.6ug		3/20)					
b	1375o	37.6ug	.131mg	0/20	31.8ug	0/20	82.6ug		20/20)					
c	1375o	47.9ug	.171mg	0/20	31.8ug	2/20	82.6ug		16/20)					
d	1375o	66.5ug	.852mg	1/20	31.8ug	7/20	82.6ug		9/20)					
e	1375o	.163mg	3.43mg	0/20	31.8ug	0/20	82.6ug		5/20)					
f	1375o	.115mg	n.s.s.	1/20	31.8ug	3/20	82.6ug		6/20)					
N-NITROSO-2,2,4-TRIMETHYL-1,2-DIHYDROQUINOLINE POLYMER				29929-77-9										
2012	1258	1.34mg	15.4mg	0/22	1.86mg		6/20	Boyland;bjca,4,233-239;1968						
NITROSOANABASINE				1133-64-8										
2013	1260	4.84mg	35.9mg	0/5	98.0mg		12/13	Boyland;bjca,18,265-270;1964						

Spe	Strain	Site	Xpo+Xpt	Notes	TD50	2Tailpvl
Sex	Route	Hist			DR	AuOp
a	R f cbt wat	eso ben	73w73	e	17.7mg	P<.0005+
b	R f cbt wat	eso sqc	73w73	e	413.mg	P<.5 +
c	R f cbt wat	liv tum	73w73	e	no dre	P=1.
2014	R m cbt wat	eso mix	73w73	e	11.0mg	P<.002 +
a	R m cbt wat	eso ben	73w73	e	28.1mg	P<.03 +
b	R m cbt wat	eso sqc	73w73	e	86.0mg	P<.2 +
c	R m cbt wat	liv tum	73w73	e	no dre	P=1.
N-NITROSOBENZTHIAZURON					100ng...1ug.....10.....100.....1mg.....10.....100.....1g.....10	
2015	R b wis gav	for mix	51w58	e	1.13mg	* P<.0005+
a	R b wis gav	for sqc	51w58	e	1.48mg	* P<.0005+
b	R b wis gav	for pam	51w58	e	3.75mg	\ P<.0005
c	R b wis gav	liv mix	51w58	e	11.3mg	* P<.03
N-NITROSOBIS(2-HYDROXYPROPYL)AMINE				1ug.....10.....100.....1mg.....10.....100.....1g.....10	
2016	R m wis wat	lun ade	45w52	es	.881mg	* P<.0005+
a	R m wis wat	lun adc	45w52	es	3.36mg	* P<.0005
b	R m wis wat	liv hem	45w52	es	4.55mg	* P<.0005
c	R m wis wat	lun crt	45w52	es	9.48mg	* P<.003
d	R m wis wat	liv hpc	45w52	es	2.40mg	\ P<.03
N-NITROSOBIS(2,2-TRIFLUOROETHYL)AMINE				1ug.....10.....100.....1mg.....10.....100.....1g.....10	
2017	R f f34 wat	liv mal	7m30	e	4.98mg	P<.3 -
2018	R m sda wat	mix mal	7m26	e	no dre	P=1. -
a	R m sda wat	liv tum	7m26	e	no dre	P=1.
NITROSOCHLORDIAZEPoxide					100ng...1ug.....10.....100.....1mg.....10.....100.....1g.....10	
2019	M f c7b wat	lun tum	17m25	e	no dre	P=1. -
a	M f c7b wat	liv tum	17m25	e	no dre	P=1. -
b	M f c7b wat	tba mix	17m25	e	no dre	P=1. -
2020	M m c7b wat	lun tum	17m25	e	no dre	P=1. -
a	M m c7b wat	tba mix	17m25	e	no dre	P=1. -
NITROSOBIBUTYLAMINE					100ng...1ug.....10.....100.....1mg.....10.....100.....1g.....10	
2021	M m icr eat	for mix	52w65	e	.686mg	P<.0005
a	M m icr eat	for sqc	52w65	e	1.09mg	P<.0005+
b	M m icr eat	liv mix	52w65	e	2.65mg	P<.0005+
c	M m icr eat	liv ade	52w65	e	4.34mg	P<.0005
d	M m icr eat	for sqp	52w65	e	7.69mg	P<.008
e	M m icr eat	lun ade	52w65	e	8.00mg	P<.1 +
f	M m icr eat	eso pam	52w65	e	11.9mg	P<.03 +
N-NITROSOETHYLAMINE					100ng...1ug.....10.....100.....1mg.....10.....100.....1g.....10	
2022	N b bbb ipj	nac nec	27m29	e	noTD50	P<.0005+
a	N b bbb ipj	liv car	27m29	e	.246mg	P<.06 +
b	N b bbb ipj	tba mal	27m29	e	noTD50	P<.0005
2023	P b cym eat	liv hpc	11y11	euw	noTD50	P<.0005+
a	P b cym eat	tba mal	11y11	euw	noTD50	P<.0005
2024	P b cym ipj	liv hpc	45m63	ew	21.1ug	* P<.0005+
a	P b cym ipj	tba mal	45m63	ew	21.4ug	* P<.0005
2025	P b rhe eat	liv hpc	12y12	euw	noTD50	P<.0005+
a	P b rhe eat	tba mal	12y12	euw	noTD50	P<.002
2026	P b rhe ipj	liv hpc	37m73	ew	15.8ug	* P<.0005+
a	P b rhe ipj	tba mal	37m73	ew	16.6ug	* P<.0005
2027	R f f34 wat	eso mix	7m30	e	25.5ug	2 P<.0005+
a	R f f34 wat	liv hpc	7m30	e	no dre	P=1. +
b	R f f34 wat	ton bcc	7m30	e	no dre	P=1. +
2028	R f f34 wat	liv mix	14m30	e	7.87ug	\ P<.0005+
a	R f f34 wat	eso mix	14m30	e	20.7ug	/ P<.0005+
2029	R f f34 wat	mix mix	24m30	e	13.1ug	P<.0005+
a	R f f34 wat	eso mix	24m30	e	15.0ug	P<.0005+
b	R f f34 wat	for bcp	24m30	e	54.9ug	P<.007 +
c	R f f34 wat	liv mix	24m30	e	41.6ug	P<.02 +
2030	R f f34 wat	mix mal	7m30	e	30.8ug	* P<.0005+
2031	R f fis wat	liv hpt	86w86	e	no dre	P=1. -
a	R f fis wat	tba mix	86w86	e	no dre	P=1. -
2032	R m fis wat	liv hpt	86w86	e	no dre	P=1. -
a	R m fis wat	tba tum	86w86	e	no dre	P=1. -
2033	R m sda wat	mix tum	27m27	e	70.6ug	P<.0005+
a	R m sda wat	liv tum	27m27	e	.119mg	P<.0005+
b	R m sda wat	eso tum	27m27	e	.133mg	P<.0005+
2034	R f wio wat	liv hpt	60w63	e	49.3ug	P<.0005+
a	R f wio wat	tba mix	60w63	e	53.7ug	P<.002
2035	R m wio wat	liv hpt	60w63	e	.104mg	P<.02 +
a	R m wio wat	tba mix	60w63	e	.104mg	P<.02
2036	R f wis gav	mpl adc	28m28	e	.127mg	P<.08 -
a	R f wis gav	liv hnd	28m28	e	31.3mg	P<.1 -
b	R f wis gav	tba ben	28m28	e	35.5ug	P<.08 -

	RefNum	LoConf	UpConf	Cntrl	1Dose	1Inc	2Dose	2Inc	Citation or Pathology	Brkly Code
a	1260	7.54mg	53.0mg	0/5	98.0mg	11/13				
b	1260	67.2mg	n.s.s.	0/5	98.0mg	1/13				
c	1260	129.mg	n.s.s.	0/5	98.0mg	0/13				
2014	1260	4.19mg	37.0mg	0/3	85.7mg	13/14				
a	1260	12.6mg	n.s.s.	0/3	85.7mg	9/14				
b	1260	29.5mg	n.s.s.	0/3	85.7mg	4/14				
c	1260	122.mg	n.s.s.	0/3	85.7mg	0/14				
N-NITROSOBENZTHIAZURON (1-(2'-benzothiazolyl)-3-methyl-3-nitrosourea) 51542-33-7										
2015	1422	.746mg	1.74mg	0/22	7.14mg	27/30	14.3mg	25/30	Ungerer;zkko,81,217-224;1974	
a	1422	.984mg	2.31mg	0/22	7.14mg	21/30	14.3mg	25/30		
b	1422	1.82mg	11.0mg	0/22	7.14mg	10/30	(14.3mg)	4/30)		
c	1422	5.67mg	n.s.s.	0/22	7.14mg	6/30	14.3mg	5/30		
N-NITROSOBIS(2-HYDROXYPROPYL)AMINE 53609-64-6										
2016	1191	.358mg	2.34mg	0/12	5.00mg	6/10	25.0mg	9/9	Konishi;gann,69,573-577;1978	
a	1191	1.51mg	12.6mg	0/12	5.00mg	3/10	25.0mg	6/9		
b	1191	1.88mg	15.8mg	0/12	5.00mg	1/10	25.0mg	6/9		
c	1191	3.22mg	61.8mg	0/12	5.00mg	0/10	25.0mg	4/9		
d	1191	.718mg	n.s.s.	0/12	5.00mg	3/10	(25.0mg)	1/9)		
N-NITROSOBIS(2,2,2-TRIFLUOROETHYL)AMINE (6-F-DEN) ---										
2017	1342	.931mg	n.s.s.	1/20	.610mg	2/12			Preussmann;carc,2,753-756;1981	
2018	1342	2.36mg	n.s.s.	2/35	.561mg	2/35				
a	1342	4.86mg	n.s.s.	0/35	.561mg	0/35				
NITROSOCHLORDIAZEPOXIDE ---										
2019	1257	5.85mg	n.s.s.	14/43	4.02mg	6/21			Giner-Sorolla;fctx,18,81-83;1980	
a	1257	18.1mg	n.s.s.	0/43	4.02mg	0/21				
b	1257	8.43mg	n.s.s.	24/43	4.02mg	6/21				
2020	1257	3.32mg	n.s.s.	15/18	3.35mg	14/23				
a	1257	3.12mg	n.s.s.	16/18	3.35mg	15/23				
NITROSDIBUTYLAMINE 924-16-3										
2021	1434	.416mg	1.18mg	0/30	4.80mg	33/39			Takayama;gann,60,353;1969	
a	1434	.666mg	1.92mg	0/30	4.80mg	27/39				
b	1434	1.44mg	5.65mg	0/30	4.80mg	15/39				
c	1434	2.11mg	12.7mg	0/30	4.80mg	10/39				
d	1434	3.13mg	122.mg	0/30	4.80mg	6/39				
e	1434	2.82mg	n.s.s.	2/30	4.80mg	8/39				
f	1434	4.10mg	n.s.s.	0/30	4.80mg	4/39				
N-NITROSDIETHYLAMINE (DEN) 55-18-5										
2022	2000n	n.s.s.	43.5ug	0/13	1.33mg	10/10			Adamsen;ossc,129-156;1982/Sieber pers.comm.	
a	2000n	60.2ug	n.s.s.	0/13	1.33mg	2/10				
b	2000n	n.s.s.	43.5ug	0/13	1.33mg	10/10				
2023	2000	n.s.s.	4.05mg	0/38	28.6mg	14/14				
a	2000	n.s.s.	4.13mg	1/38	28.6mg	14/14				
2024	2000o	5.95ug	81.8ug	0/38	.714mg	4/5	2.65mg	5/5		
a	2000o	5.97ug	85.9ug	1/38	.714mg	4/5	2.65mg	5/5		
2025	2000	n.s.s.	5.20mg	0/32	28.4mg	12/12				
a	2000	n.s.s.	5.62mg	3/32	28.4mg	12/12				
2026	2000o	6.02ug	41.4ug	0/32	.357mg	4/6	.675mg	5/5	1.33mg	6/6
a	2000o	6.15ug	46.8ug	3/32	.357mg	4/6	.675mg	5/5	1.33mg	6/6
2027	1173m	14.7ug	48.3ug	0/20	4.40ug	0/20	10.4ug	3/20	26.4ug	18/19
									(.119mg)	13/20
a	1173m	1.53mg	n.s.s.	0/20	4.40ug	1/20	10.4ug	5/20	26.4ug	5/19
b	1173m	2.24mg	n.s.s.	0/20	4.40ug	0/20	10.4ug	1/20	26.4ug	6/19
2028	1173n	3.92ug	20.0ug	1/20	8.48ug	14/20	(20.7ug)	5/20)		
a	1173n	11.7ug	40.8ug	0/20	8.48ug	2/20	20.7ug	17/20		
2029	1173o	6.70ug	29.5ug	0/20	14.8ug	14/20				
a	1173o	7.61ug	34.8ug	0/20	14.8ug	13/20				
b	1173o	20.7ug	.633mg	0/20	14.8ug	5/20				
c	1173o	16.4ug	n.s.s.	1/20	14.8ug	7/20				
2030	1342	14.7ug	65.0ug	1/20	65.9ug	18/20	.170mg	12/12	Preussmann;carc,2,753-756;1981	
2031	1041	.109mg	n.s.s.	0/15	51.6ug	0/15			Nixon;jnci,53,453-458;1974	
a	1041	.109mg	n.s.s.	3/15	51.6ug	0/15				
2032	1041	84.3ug	n.s.s.	0/16	46.0ug	0/13				
a	1041	84.3ug	n.s.s.	0/16	46.0ug	0/13				
2033	1303	49.8ug	.104mg	0/90	71.4ug	52/90			Habs;onco,37,259-265;1980	
a	1303	79.4ug	.190mg	0/90	71.4ug	36/90				
b	1303	87.4ug	.217mg	0/90	71.4ug	33/90				
2034	1041	23.5ug	.131mg	0/18	.136mg	10/20			Nixon;jnci,53,453-458;1974	
a	1041	24.3ug	.262mg	1/18	.136mg	10/20				
2035	1041	35.9ug	n.s.s.	0/17	.104mg	4/18				
a	1041	35.9ug	n.s.s.	0/17	.104mg	4/18				
2036	1399	41.5ug	n.s.s.	1/59	10.2ug	5/58			Kroes;fctx,12,671-679;1974	
a	1399	98.7ug	n.s.s.	1/59	10.2ug	1/58				
b	1399	13.6ug	n.s.s.	18/59	10.2ug	27/58				

Spe	Strain	Site	Xpo+Xpt	Notes	Sex	Route	Hist	TD50		2Tailpvl	
								DR	AuOp		
c	R f wis gav	tba mal	28m28	e				4.01mg	P<.1	-	
2037	R m wis gav	liv tum	28m28	e			>	no dre	P=1.	-	
a	R m wis gav	tba mal	28m28	e				77.4ug	P<.4	-	
b	R m wis gav	tba ben	28m28	e				.257mg	P<.9	-	
N-NITROSODIMETHYLAMINE								100ng...1ug...10...100...1mg...10...100...1g...10			
2038	M f bal wat	lun ade	85w85	gs			.	.324mg	P<.0005+		
a	M f bal wat	tba mix	85w85	gs			.	.396mg	P<.3		
2039	R f por eat	liv tum	25m28	ar			.	1.40mg	* P<.0005+		
2040	R f por eat	liv tum	12m28	r			.	.443mg	P<.01		
2041	R m por eat	liv tum	28m28	r			.	1.18mg	* P<.2	+	
2042	R f wis eat	liv nod	96w96				.	.113mg	Z P<.002	+	
a	R f wis eat	--- lau	96w96				.	1.46mg	* P<.005		
b	R f wis eat	liv hae	96w96				.	1.83mg	* P<.03	+	
c	R f wis eat	liv hpc	96w96				.	4.10mg	* P<.4	+	
2043	R m wis eat	liv nod	96w96				.	.782mg	* P<.0005+		
a	R m wis eat	liv hae	96w96				.	1.95mg	* P<.007	+	
b	R m wis eat	liv hpc	96w96				.	5.52mg	* P<.4	+	
2044	R m wis eat	tes ldc	54w69	er			.	.136mg	P<.0005+		
a	R m wis eat	liv car	54w69	er			.	no dre	P=1.	-	
N-NITROSODIPHENYLAMINE								100ng...1ug...10...100...1mg...10...100...1g...10			
2045	M f b6c eat	TBA MXB	23m23	v			.	no dre	P=1.	-	
a	M f b6c eat	liv MXB	23m23	v			.	no dre	P=1.		
b	M f b6c eat	lun MXB	23m23	v			.	no dre	P=1.		
2046	M f b6c orl	liv hpt	76w76	evx			.	no dre	P=1.		
a	M f b6c orl	lun ade	76w76	evx			.	no dre	P=1.		
b	M f b6c orl	tba mix	76w76	evx			.	no dre	P=1.		
2047	M m b6c eat	TBA MXB	23m23				.	no dre	P=1.	-	
a	M m b6c eat	liv MXB	23m23				.	no dre	P=1.		
b	M m b6c eat	lun MXB	23m23				.	no dre	P=1.		
2048	M m b6c orl	liv hpt	76w76	evx			.	385.mg	P<.02		
a	M m b6c orl	lun ade	76w76	evx			.	9.67mg	P<.9		
b	M m b6c orl	tba mix	76w76	evx			.	897.mg	P<.6		
2049	M f b6a orl	lun ade	76w76	evx			.	1.02gm	P<.04		
a	M f b6a orl	liv hpt	76w76	evx			.	no dre	P=1.		
b	M f b6a orl	tba mix	76w76	evx			.	3.26gm	P<.7		
2050	M m b6a orl	lun ade	76w76	evx			.	no dre	P=1.		
a	M m b6a orl	liv hpt	76w76	evx			.	no dre	P=1.		
b	M m b6a orl	tba mix	76w76	evx			.	no dre	P=1.		
2051	R f f34 eat	ubl tcc	23m23				.	116.mg /	P<.0005c		
a	R f f34 eat	TBA MXB	23m23				.	159.mg /	P<.008		
b	R f f34 eat	liv MXB	23m23				.	no dre	P=1.		
2052	R m f34 eat	ubl tcc	23m23				.	299.mg /	P<.0005c		
a	R m f34 eat	--- fib	23m23				.	537.mg	* P<.01		
b	R m f34 eat	TBA MXB	23m23				.	136.gm	* P<.1		
c	R m f34 eat	liv MXB	23m23				.	5.45gm	* P<.3		
2053	R m cbr ipj	liv hpt	6m23	e			.	18.9mg	P<.1	-	
p-NITROSODIPHENYLAMINE								100ng...1ug...10...100...1mg...10...100...1g...10			
2054	M f b6c eat	TBA MXB	53w92	esv			.	2.17gm	* P<.5	-	
a	M f b6c eat	liv MXB	53w92	esv			.	2.25gm	* P<.2		
b	M f b6c eat	lun MXB	53w92	esv			.	5.41gm	* P<.4		
2055	M m b6c eat	liv MXA	53w92	esv			.	340.mg \	P<.02 c		
a	M m b6c eat	liv hpc	53w92	esv			.	661.mg \	P<.02 c		
b	M m b6c eat	TBA MXB	53w92	esv			.	260.mg \	P<.03		
c	M m b6c eat	liv MXB	53w92	esv			.	340.mg \	P<.02		
d	M m b6c eat	lun MXB	53w92	esv			.	3.52gm	* P<.7		
2056	R f f34 eat	TBA MXB	18m24				.	no dre	P=1.	-	
a	R f f34 eat	liv MXB	18m24				.	1.21gm	* P<.06		
2057	R m f34 eat	liv MXA	18m24				.	201.mg	* P<.0005c		
a	R m f34 eat	TBA MXB	18m24				.	no dre	P=1.		
b	R m f34 eat	liv MXB	18m24				.	201.mg	* P<.0005		
N-NITROSOEPHEDRINE								100ng...1ug...10...100...1mg...10...100...1g...10			
2058	R m sda gav	liv mix	24m24				.	95.2mg	P<.0005+		
a	R m sda gav	liv hpc	24m24				.	138.mg	P<.004		
b	R m sda gav	lun mix	24m24				.	217.mg	P<.1	+	
c	R m sda gav	for pem	24m24				.	239.mg	P<.03	+	
d	R m sda gav	for sqc	24m24				.	740.mg	P<.3	+	
e	R m sda gav	tba mix	24m24				.	40.0mg	P<.0005		
NITROSOHEPTAMETHYLENEIMINE								100ng...1ug...10...100...1mg...10...100...1g...10			
2059	R m f34 wat	ugi car	6m27	esv			.	36.3ug	Z P<.0005+		
a	R m f34 wat	ugi mix	6m27	esv			.	51.2ug	Z P<.0005+		
b	R m f34 wat	eso mix	6m27	esv			.	.118mg	Z P<.0005+		
c	R m f34 wat	liv hem	6m27	esv			.	no dre	P=1.		
2060	R m f34 wat	ugi mix	12m29	es			.	57.1ug	* P<.0005+		

RefNum	LoConf	UpConf	Cntri	1Dose	1Inc	2Dose	2Inc	Citation or Pathology	Brkly Code
c	1399	47.3ug n.s.s.	7/59	10.2ug	7/58				
2037	1399	78.4ug n.s.s.	0/39	7.14ug	0/40				
a	1399	18.1ug n.s.s.	4/39	7.14ug	7/40				
b	1399	18.2ug n.s.s.	8/39	7.14ug	9/40				
N-NITROSODIMETHYLAMINE (DMN) 62-75-9									
2038	88	.186mg .824mg	20/62	.600mg	44/62			Terracini;ijcn,11,747-764;1973	
a	88	97.8ug n.s.s.	56/62	.600mg	59/62				
2039	122a	.893mg 2.36mg	0/29	100.ug	0/18	.250mg	4/62	.500mg 2/5 1.00mg 15/23 2.50mg 10/12	Terracini;bjca,20,559-565;1967
2040	122n	.133mg 23.7mg	0/29	.108mg	3/15				
2041	122a	.289mg n.s.s.	0/12	80.0ug	1/19	.200mg	1/6		
2042	1201	46.0ug .439mg	0/18	5.00ug	0/24	50.0ug	6/24 (.500mg 4/24)	Arai;gann,70,549-558;1979	
a	1201	.546mg 16.3mg	0/18	5.00ug	1/24	50.0ug	0/24 .500mg 5/24		
b	1201	.631mg n.s.s.	0/18	5.00ug	0/24	50.0ug	1/24 .500mg 3/24		
c	1201	.666mg n.s.s.	0/18	5.00ug	0/24	50.0ug	3/24 .500mg 2/24		
2043	1201	.337mg 3.05mg	0/18	4.00ug	0/24	40.0ug	1/24 .400mg 6/24		
a	1201	.591mg 32.7mg	0/18	4.00ug	0/24	40.0ug	0/24 .400mg 3/24		
b	1201	.780mg n.s.s.	0/18	4.00ug	0/24	40.0ug	1/24 .400mg 1/24		
2044	707	57.3ug .441mg	0/29	.313mg	7/14			Terao;fctx,16,591-596;1978	
a	707	.398mg n.s.s.	0/29	.313mg	0/14				
N-NITROSODIPHENYLAMINE (redax, diphenylnitrosamine) 86-30-6									
2045	c02880	912.mg n.s.s.	9/20	322.mg	24/50	798.mg	15/50		
a	c02880	1.89gm n.s.s.	3/20	322.mg	7/50	798.mg	4/50		liv:hpa,hpc,nnd. lun:a/a,e/c.
b	c02880	1.48gm n.s.s.	3/20	322.mg	11/50	798.mg	5/50		Innes;ntis,1968/1969
2046	1094	842.mg n.s.s.	0/18	510.mg	0/15				
a	1094	842.mg n.s.s.	1/18	510.mg	0/15				
b	1094	582.mg n.s.s.	3/18	510.mg	1/15				
2047	c02880	2.44gm n.s.s.	10/20	1.20gm	29/50	2.40gm	22/50		
a	c02880	6.54gm n.s.s.	6/20	1.20gm	12/50	2.40gm	7/50		liv:hpa,hpc,nnd. lun:a/a,e/c.
b	c02880	5.78gm n.s.s.	4/20	1.20gm	9/50	2.40gm	7/50		Innes;ntis,1968/1969
2048	1094	142.mg n.s.s.	1/17	474.mg	6/15				
a	1094	356.mg n.s.s.	2/17	474.mg	2/15				
b	1094	154.mg n.s.s.	6/17	474.mg	7/15				
2049	1094	309.mg n.s.s.	0/17	510.mg	3/18				
a	1094	1.01gm n.s.s.	0/17	510.mg	0/18				
b	1094	366.mg n.s.s.	2/17	510.mg	3/18				
2050	1094	443.mg n.s.s.	2/18	474.mg	2/18				
a	1094	939.mg n.s.s.	3/18	474.mg	0/18				
b	1094	445.mg n.s.s.	5/18	474.mg	3/18				
2051	c02880	78.4mg 181.mg	0/20	50.0mg	0/50	200.mg	40/50		
a	c02880	76.7mg 3.27gm	13/20	50.0mg	23/50	200.mg	43/50		
b	c02880	n.s.s. n.s.s.	0/20	50.0mg	0/50	200.mg	0/50		liv:hpa,hpc,nnd.
2052	c02880	167.mg 616.mg	0/20	40.0mg	0/50	160.mg	16/50		
a	c02880	242.mg 24.5gm	1/20	40.0mg	1/50	160.mg	10/50		S
b	c02880	137.mg n.s.s.	16/20	40.0mg	29/50	160.mg	33/50		
c	c02880	887.mg n.s.s.	0/20	40.0mg	0/50	160.mg	1/50		liv:hpa,hpc,nnd.
2053	1258	.441mg n.s.s.	1/24	.186mg	1/21			Boylard;ejca,4,233-239;1968	
p-NITROSODIPHENYLAMINE 156-10-5									
2054	c02244	493.mg n.s.s.	4/20	343.mg	16/50	636.mg	9/50		
a	c02244	974.mg n.s.s.	0/20	343.mg	5/50	636.mg	2/50		liv:hpa,hpc,nnd. lun:a/a,e/c.
b	c02244	1.64gm n.s.s.	0/20	343.mg	2/50	636.mg	1/50		liv:hpa,hpc.
2055	c02244	172.mg n.s.s.	2/20	316.mg	22/50	587.mg	12/50		
a	c02244	323.mg n.s.s.	0/20	316.mg	10/50	587.mg	1/50		
b	c02244	128.mg n.s.s.	4/20	316.mg	30/50	587.mg	17/50		
c	c02244	172.mg n.s.s.	2/20	316.mg	22/50	587.mg	12/50		liv:hpa,hpc,nnd. lun:a/a,e/c.
d	c02244	711.mg n.s.s.	1/20	316.mg	10/50	587.mg	4/50		
2056	c02244	195.mg n.s.s.	11/20	92.9mg	36/50	186.mg	28/50		
a	c02244	522.mg n.s.s.	0/20	92.9mg	2/50	186.mg	5/50		liv:hpa,hpc,nnd.
2057	c02244	129.mg 547.mg	0/20	74.3mg	10/50	149.mg	19/50		liv:hpc,nnd.
a	c02244	129.mg n.s.s.	13/20	74.3mg	34/50	149.mg	33/50		
b	c02244	129.mg 547.mg	0/20	74.3mg	10/50	149.mg	19/50		liv:hpa,hpc,nnd.
N-NITROSOEPHEDRINE 17608-59-2									
2058	1259	41.0mg 332.mg	0/40	34.3mg	7/32			Eisenbrand;clat,5,103-106;1978	
a	1259	52.4mg 974.mg	0/40	34.3mg	5/32				
b	1259	64.1mg n.s.s.	1/40	34.3mg	4/32				
c	1259	72.2mg n.s.s.	0/40	34.3mg	3/32				
d	1259	120.mg n.s.s.	0/40	34.3mg	1/32				
e	1259	20.1mg 129.mg	4/40	34.3mg	16/32				
NITROSOHEPTAMETHYLENIMINE 20917-49-1									
2059	1376m	18.1ug 86.7ug	0/20	39.8ug	12/20	.197mg	11/20	.733mg 10/20	Lijinsky;inci,69,1127-1133;1982/pers.com.
a	1376m	30.3ug 96.3ug	0/20	39.8ug	15/20	.197mg	17/20	.733mg 15/20	
b	1376m	66.9ug .233mg	0/20	39.8ug	5/20	.197mg	15/20	.733mg 10/20	
c	1376m	.160mg n.s.s.	1/20	39.8ug	0/20	.197mg	0/20	.733mg 0/20	
2060	1376n	35.3ug 99.6ug	0/20	11.4ug	2/20	31.5ug	13/20	.125mg 16/20	

Spe	Strain	Site	Xpo + Xpt	Notes	TD50	2Tailpvi
Sex	Route	Hist			DR	AuOp
a	R m	f34 wat	eso bcc	12m29 es		.159mg * P<.0005+
b	R m	f34 wat	ton bcc	12m29 es		.171mg * P<.0005+
c	R m	f34 wat	liv hpc	12m29 es		no dre P=1. +
2061	R m	f34 wat	ugi mix	23m27 e	. + .	29.2ug * P<.0005+
a	R m	f34 wat	eso mix	23m27 e		73.5ug * P<.0005+
b	R m	f34 wat	ton bcc	23m27 e		.105mg * P<.004 +
c	R m	f34 wat	liv mix	23m27 e		.198mg \ P<.1 +
1-NITROSOHYDANTOIN						
2062	R f	mrw wat	liv tum	12m26	100ng...1ug...10...100...1mg...10...100...1g...10	no dre P=1.
a	R f	mrw wat	tba mix	12m26		19.6mg P<.2 +
2063	R m	mrw wat	for aqp	12m26	. +	27.8mg P<.005
a	R m	mrw wat	phr aqc	12m26		43.8mg P<.03 +
b	R m	mrw wat	liv tum	12m26		no dre P=1.
c	R m	mrw wat	tba mix	12m26		7.31mg P<.03
NITROSOHYDROXYPROLINE						
2064	R f	mrc wat	liv tum	17m24	100ng...1ug...10...100...1mg...10...100...1g...10	no dre P=1.
a	R f	mrc wat	tba mix	17m24		3.84mg P<.03 -
2065	R m	mrc wat	liv tum	17m24		no dre P=1.
a	R m	mrc wat	tba mix	17m24		no dre P=1. -
NITROSOIMINODIACETIC ACID						
2066	R f	mrc wat	tba mix	17m24 e	100ng...1ug...10...100...1mg...10...100...1g...10	63.9mg P<.07 -
2067	R m	mrc wat	pit tum	17m24 e	. +	66.9mg P<.006 -
a	R m	mrc wat	tba mix	17m24 e		76.0mg P<.3 -
2-NITROSOMETHYLAMINOPYRIDINE						
2068	R f	bdg gav	eso mix	72w72 e	100ng...1ug...10...100...1mg...10...100...1g...10	.214mg P<.003 +
a	R f	bdg gav	liv mix	72w72 e		no dre P=1.
b	R f	bdg gav	tba mal	72w72 e		.668mg P<.08
c	R f	bdg gav	tba mix	72w72 e		.280mg P<.2
d	R f	bdg gav	tba ben	72w72 e		3.05mg P<.9
3-NITROSOMETHYLAMINOPYRIDINE						
2069	R f	bdg gav	liv mix	27m27 e	100ng...1ug...10...100...1mg...10...100...1g...10	no dre P=1. -
a	R f	bdg gav	tba mix	27m27 e		no dre P=1. -
b	R f	bdg gav	tba mal	27m27 e		6.09mg P<.4 -
c	R f	bdg gav	tba ben	27m27 e		no dre P=1. -
4-NITROSOMETHYLAMINOPYRIDINE						
2070	R f	bdg gav	liv mix	23m23 e	100ng...1ug...10...100...1mg...10...100...1g...10	no dre P=1. -
a	R f	bdg gav	tba mix	23m23 e		no dre P=1. -
b	R f	bdg gav	tba ben	23m23 e		no dre P=1. -
c	R f	bdg gav	tba mal	23m23 e		26.8mg P<.5 -
NITROSOMETHYLANILINE						
2071	R f	cbt wat	eso mix	67w67 ev	100ng...1ug...10...100...1mg...10...100...1g...10	noTD50 P<.0005+
a	R f	cbt wat	eso aqc	67w67 ev		26.4mg P<.02 +
b	R f	cbt wat	eso ben	67w67 ev		32.0mg P<.03 +
c	R f	cbt wat	liv tum	67w67 ev		no dre P=1. -
2072	R m	cbt wat	eso mix	60w60 ev	. + .	5.27mg P<.002 +
a	R m	cbt wat	eso aqc	60w60 ev		10.5mg P<.009 +
b	R m	cbt wat	eso ben	60w60 ev		70.4mg P<.3 +
c	R m	cbt wat	liv tum	60w60 ev		no dre P=1. -
2073	R b	sda wat	eso mix	24m24 e	. + .	34.3ug \ P<.0005+
NITROSOMETHYLPHENIDATE						
2074	M f	c7b wat	liv tum	17m25	100ng...1ug...10...100...1mg...10...100...1g...10	no dre P=1. -
a	M f	c7b wat	liv tum	17m25		no dre P=1. -
b	M f	c7b wat	tba mix	17m25		no dre P=1. -
2075	M m	c7b wat	liv tum	17m25		no dre P=1. -
a	M m	c7b wat	tba mix	17m25		no dre P=1. -
NITROSOMETHYLUNDECYLAMINE						
2076	R m	f34 gav	liv hpc	30w65	100ng...1ug...10...100...1mg...10...100...1g...10	2.37mg P<.0005+
a	R m	f34 gav	liv hpc	30w65	. + .	2.38mg P<.0005+
b	R m	f34 gav	liv ald	30w65		2.41mg P<.0005+
c	R m	f34 gav	liv ctc	30w65		3.18mg P<.0005+
d	R m	f34 gav	liv ala	30w65		4.99mg P<.0005
e	R m	f34 gav	eso aqc	30w65		15.4mg P<.002
f	R m	f34 gav	stn pam	30w65		15.4mg P<.002
NITROSOPIPECOLIC ACID						
2077	R f	mrc wat	liv tum	17m24 e	100ng...1ug...10...100...1mg...10...100...1g...10	no dre P=1. -
a	R f	mrc wat	tba mix	17m24 e		4.99mg P<.07 -
2078	R m	mrc wat	liv tum	17m24 e		no dre P=1. -
a	R m	mrc wat	tba mix	17m24 e		3.82mg P<.07 -

RefNum	LoConf	UpConf	Cntrl	1Dose	1Inc	2Dose	2Inc		Citation or Pathology	Brkly Code
a	1376n	85.8ug .340mg	0/20	11.4ug	0/20	31.5ug	2/20	.125mg		13/20
b	1376n	92.7ug .410mg	0/20	11.4ug	1/20	31.5ug	4/20	.125mg		10/20
c	1376n	.729mg n.s.s.	0/20	11.4ug	5/20	31.5ug	0/20	.125mg		0/20
2061	1376o	17.4ug 52.1ug	0/20	24.8ug	10/20	64.6ug	17/20			
a	1376o	39.7ug .158mg	0/20	24.8ug	3/20	64.6ug	12/20			
b	1376o	53.7ug .736mg	0/20	24.8ug	6/20	64.6ug	6/20			
c	1376o	48.5ug n.s.s.	0/20	24.8ug	2/20	(64.6ug	0/20)			
1-NITROSDHYDANTOIN 42579-28-2										
2062	1246	63.0mg n.s.s.	0/25	11.4mg	0/24				Bulay;jnci,62,1523-1528;1979	
a	1246	5.90mg n.s.s.	12/25	11.4mg	16/24					
2063	1246	11.3mg 198.mg	0/22	9.96mg	6/25					
a	1246	15.1mg n.s.s.	0/22	9.96mg	4/25					
b	1246	57.4mg n.s.s.	0/22	9.96mg	0/25					
c	1246	2.84mg n.s.s.	12/22	9.96mg	21/25					
NITROSDYDROXYPROLINE 30310-80-6										
2064	216	13.6mg n.s.s.	0/15	4.42mg	0/15				Garcia;zkko,79,141-144;1973	
a	216	1.43mg n.s.s.	4/15	4.42mg	10/15					
2065	216	11.9mg n.s.s.	0/15	3.86mg	0/15					
a	216	3.47mg n.s.s.	5/15	3.86mg	5/15					
NITROSDIMINDIACETIC ACID 25081-31-6										
2066	213	22.0mg n.s.s.	4/15	56.5mg	9/15				Lijinsky;jnci,50,1061-1063;1973	
2067	213	25.1mg 631.mg	0/15	39.6mg	5/15					
a	213	19.4mg n.s.s.	3/15	39.6mg	8/15					
2-NITROSDMETHYLAMINOPYRIDINE 16219-98-0										
2068	1261	.118mg .826mg	0/5	.714mg	18/27				Preussmann;jnci,62,153-156;1979	
a	1261	.964mg n.s.s.	1/5	.714mg	2/27					
b	1261	.301mg n.s.s.	0/5	.714mg	8/27					
c	1261	.112mg n.s.s.	2/5	.714mg	20/27					
d	1261	.263mg n.s.s.	2/5	.714mg	12/27					
3-NITROSDMETHYLAMINOPYRIDINE 69658-91-0										
2069	1261	1.92mg n.s.s.	1/5	.571mg	2/26				Preussmann;jnci,62,153-156;1979	
a	1261	1.10mg n.s.s.	2/5	.571mg	6/26					
b	1261	1.50mg n.s.s.	0/5	.571mg	2/26					
c	1261	1.51mg n.s.s.	2/5	.571mg	4/26					
4-NITROSDMETHYLAMINOPYRIDINE 16219-99-1										
2070	1261	8.33mg n.s.s.	1/5	2.86mg	0/15				Preussmann;jnci,62,153-156;1979	
a	1261	2.85mg n.s.s.	2/5	2.86mg	4/15					
b	1261	3.56mg n.s.s.	2/5	2.86mg	3/15					
c	1261	4.35mg n.s.s.	0/5	2.86mg	1/15					
NITROSDMETHYLAMILINE 614-00-6										
2071	1260	n.s.s. 12.4mg	0/5	70.7mg	15/15				Boylend;bjca,18,265-270;1964	
a	1260	11.6mg n.s.s.	0/5	70.7mg	8/15					
b	1260	13.3mg n.s.s.	0/5	70.7mg	7/15					
c	1260	90.7mg n.s.s.	0/5	70.7mg	0/15					
2072	1260	2.07mg 16.2mg	0/3	64.1mg	15/16					
a	1260	5.02mg 241.mg	0/3	64.1mg	12/16					
b	1260	21.2mg n.s.s.	0/3	64.1mg	3/16					
c	1260	70.4mg n.s.s.	0/3	64.1mg	0/16					
2073	1264	22.0ug 55.7ug	0/48	83.8ug	39/48	(.319mg	42/48)		Schmahl;clet,1,215-218;1976	
NITROSDMETHYLPHENIDATE 55557-03-4										
2074	1257	19.3mg n.s.s.	14/43	8.05mg	7/31				Giner-Sorolla;fctx,18,81-83;1980	
a	1257	53.4mg n.s.s.	0/43	8.05mg	0/31					
b	1257	10.6mg n.s.s.	24/43	8.05mg	15/31					
2075	1257	4.69mg n.s.s.	15/18	6.70mg	17/24					
a	1257	3.59mg n.s.s.	16/18	6.70mg	19/24					
NITROSDMETHYLUNDECYLAMINE 68107-26-6										
2076	1207	1.12mg 6.28mg	2/260	6.07mg	10/20				Lijinsky;clet,5,209-213;1978	
a	1207	1.13mg 6.38mg	3/260	6.07mg	10/20					
b	1207	1.13mg 6.59mg	5/260	6.07mg	10/20					
c	1207	1.42mg 9.37mg	0/260	6.07mg	8/20					
d	1207	1.91mg 24.9mg	8/260	6.07mg	6/20					
e	1207	3.79mg 205.mg	0/260	6.07mg	2/20					
f	1207	3.79mg 205.mg	0/260	6.07mg	2/20					
NITROSDPIPECOLIC ACID 4515-18-8										
2077	216	13.6mg n.s.s.	0/15	4.42mg	0/15				Garcia;zkko,79,141-144;1973	
a	216	1.72mg n.s.s.	4/15	4.42mg	9/15					
2078	216	11.9mg n.s.s.	0/15	3.86mg	0/15					
a	216	1.30mg n.s.s.	5/15	3.86mg	10/15					

Spe	Strain	Site	Xpo+Xpt		TD50	2Tailpvl
Sex	Route	Hist	Notes		DR	AuOp
N-NITROSOPIPERAZINE				100ng...1ug...10...100...1mg...10...100...1g...10		
2079	R f mrc	wat liv tum	14m29 e	>	no dre	P=1.
a	R f mrc	wat tba mix	14m29 e		5.51mg *	P<.2 +
2080	R m mrc	wat liv hpt	14m29 e	.	6.52mg \	P<.05
a	R m mrc	wat tba mix	14m29 e	.	21.6mg *	P<.5 +
N-NITROSOPIPERIDINE				100ng...1ug...10...100...1mg...10...100...1g...10		
2081	M m icm	eat for sqc	52w52	.	1.30mg	P<.0005+
a	M m icm	eat liv mix	52w52	.	2.53mg	P<.0005+
b	M m icm	eat liv ade	52w52	.	5.12mg	P<.005
c	M m icm	eat lun ade	52w52	.	3.52mg	P<.02 +
2082	P b cym	eat liv hpc	90m92 ew		noTD50	P<.003 +
a	P b cym	eat tba mal	90m92 ew		noTD50	P<.02
2083	P b rhe	eat liv hpc	8y9 ew	.	18.7mg	P<.0005+
a	P b rhe	eat tba mal	8y9 ew	.	19.7mg	P<.0005
2084	P b rhe	ipj liv hpc	91m93 euw	.	.635mg	P<.0005+
a	P b rhe	ipj tba mal	91m93 euw	.	.712mg	P<.02
NITROSOPROLINE				100ng...1ug...10...100...1mg...10...100...1g...10		
2085	R f mrc	wat liv tum	17m24 e	>	no dre	P=1.
a	R f mrc	wat tba mix	17m24 e		6.69mg	P<.2 -
2086	R m mrc	wat liv tum	17m24 e	>	no dre	P=1.
a	R m mrc	wat tba mix	17m24 e		no dre	P=1. -
N-NITROSOPYRROLIDINE				100ng...1ug...10...100...1mg...10...100...1g...10		
2087	R f mrc	wat liv adc	16m28 e	.	2.10mg	P<.0005+
a	R f mrc	wat tba tum	16m28 e	.	5.21mg	P<.3
2088	R f mrc	wat liv hpc	67w90 e	<	noTD50	P<.0005+
a	R f mrc	wat tba mix	67w90 e		noTD50	P<.07
2089	R m mrc	wat tba tum	16m28 e	.	2.51mg	P<.008
2090	R m mrc	wat liv hpc	67w90 e	<	noTD50	P<.0005+
a	R m mrc	wat tes pms	67w90 e		5.38mg	P<.002
b	R m mrc	wat tba mix	67w90 e		noTD50	P<.008
2091	R b sda	wat liv hpc	23m30 as	.	3.26mg Z	P<.0005
a	R b sda	wat liv hpa	23m30 as		55.5mg *	P<.005
b	R b sda	wat tba mal	23m30 as		2.37mg Z	P<.0005+
c	R b sda	wat tba ben	23m30 as		71.1mg *	P<.2
N-NITROSOTHIOMORPHOLINE				100ng...1ug...10...100...1mg...10...100...1g...10		
2092	R f mrc	wat eso mix	9m24 e	.	7.69mg *	P<.002 +
a	R f mrc	wat ton sqc	9m24 e	.	22.0mg *	P<.3 +
b	R f mrc	wat liv tum	9m24 e		no dre	P=1.
c	R f mrc	wat tba mix	9m24 e		7.38mg *	P<.2
2093	R m mrc	wat eso mix	38w95 e	.	4.15mg *	P<.0005+
a	R m mrc	wat liv tum	38w95 e		no dre	P=1.
b	R m mrc	wat tba mix	38w95 e		2.29mg *	P<.02
NORETHYNODREL				100ng...1ug...10...100...1mg...10...100...1g...10		
2094	M f c3h	eat mam tum	24m24 er	>	no dre	P=1. -
2095	M f cfl	eat liv hct	78w78 er	.	49.1mg *	P<.04 -
2096	M m cfl	eat liv hct	78w78 er	.	no dre	P=1. -
2097	M f crf	eat mam tum	24m24 er	pool	2.13mg	P<.6 -
2098	M f r3m	eat mam tum	24m24 er	>	no dre	P=1. -
2099	M f swv	gav liv hct	65w80 er	>	no dre	P=1. -
NORHARMAN				100ng...1ug...10...100...1mg...10...100...1g...10		
2100	R m wis	eat for pam	80w80	>	191.mg	P<.3 -
a	R m wis	eat ubl tum	80w80		no dre	P=1. -
NORLESTRIN				100ng...1ug...10...100...1mg...10...100...1g...10		
2101	M f c7l	gav pit tum	89w89 e	>	1.34mg *	P<.2 +
2102	M f csc	gav lun tum	69w69 ek	>	no dre	P=1. -
a	M f csc	gav tba mix	69w69 ek		no dre	P=1. -
2103	M f csc	gav tba mix	69w82 ek	>	no dre	P=1. -
2104	R b asd	eat liv hnd	24m24 e	.	1.94mg \	P<.0005+
a	R b asd	eat pit cra	24m24 e		5.31mg /	P<.0005+
b	R b asd	eat mgl mix	24m24 e		6.66mg *	P<.0005+
c	R b asd	eat mgl ade	24m24 e		14.8mg *	P<.0005+
d	R b asd	eat ute sep	24m24 e		27.4mg *	P<.002 +
e	R b asd	eat liv hpa	24m24 e		7.59mg \	P<.02 +
f	R b asd	eat mgl adc	24m24 e		76.8mg *	P<.05 +
g	R b asd	eat mgl fap	24m24 e		21.0mg *	P<.2 +
h	R b asd	eat tba mix	24m24 e		14.2mg *	P<.6
NOVADELOX				100ng...1ug...10...100...1mg...10...100...1g...10		
2105	M b alb	eat lun ade	80w80 e		no dre	P=1. -
a	M b alb	eat lun mix	80w80 e		no dre	P=1. -
b	M b alb	eat liv hpt	80w80 e		no dre	P=1. -

CARCINOGENIC POTENCY DATABASE

RefNum	LoConf	UpConf	Cntrl	1Dose	1Inc	2Dose	2Inc	Citation or Pathology	Brkly Code
M-NITROSOPIPERAZINE 5632-47-3									
2079	229	2.48mg	n.s.s.	0/13	.964mg	0/10	4.90mg	0/10	Garcia;zkko,74,179-184;1970
a	229	1.55mg	n.s.s.	4/13	.964mg	8/10	4.90mg	7/10	
2080	229	1.06mg	n.s.s.	0/57	.672mg	1/10	(3.30mg)	0/10)	
a	229	3.16mg	n.s.s.	12/57	.672mg	4/10	3.30mg	3/10	
M-NITROSOPIPERIDINE (PIP) 100-75-4									
2081	225	.736mg	2.60mg	0/30	6.00mg	18/33			Takayama;nawi,56,142;1969
a	225	1.26mg	6.36mg	0/30	6.00mg	11/33			
b	225	2.09mg	36.6mg	0/30	6.00mg	6/33			
c	225	1.49mg	n.s.s.	2/30	6.00mg	10/33			
2082	2000	n.s.s.	39.3mg	0/38	279.mg	5/5			Adamsen;osscc,129-156;1982/Sieber pers.comm.
a	2000	n.s.s.	n.s.s.	1/38	279.mg	5/5			
2083	2000	5.89mg	74.6mg	0/32	280.mg	6/7			
a	2000	5.99mg	97.6mg	3/32	280.mg	6/7			
2084	2000m	.177mg	4.69mg	0/32	5.59mg	3/5			
a	2000m	.182mg	n.s.s.	3/32	5.59mg	3/5			
NITROSOPROLINE 7519-36-0									
2085	216	13.6mg	n.s.s.	0/15	4.42mg	0/15			Garcia;zkko,79,141-144;1973
a	216	2.05mg	n.s.s.	4/15	4.42mg	8/15			
2086	216	11.9mg	n.s.s.	0/15	3.86mg	0/15			
a	216	4.39mg	n.s.s.	5/15	3.86mg	4/15			
N-NITROSOPYRROLIDINE 930-55-2									
2087	1189	.932mg	5.18mg	0/20	4.48mg	13/15			Greenblatt;jnci,50,799-802;1973
a	1189	1.23mg	n.s.s.	14/20	4.48mg	13/15			
2088	228	n.s.s.	2.09mg	0/33	6.08mg	13/13			Greenblatt;jnci,48,1687-1696;1972
a	228	n.s.s.	n.s.s.	14/33	6.08mg	13/13			
2089	1189	.959mg	58.3mg	7/20	3.14mg	12/15			Greenblatt;jnci,50,799-802;1973
2090	228	n.s.s.	1.54mg	0/34	4.25mg	12/12			Greenblatt;jnci,48,1687-1696;1972
a	228	1.84mg	28.3mg	0/34	4.25mg	4/12			
b	228	n.s.s.	1.80mg	6/34	4.25mg	12/12			
2091	371	2.23mg	5.01mg	0/61	.300mg	0/60	1.00mg	13/62	3.00mg 30/58 (10.0mg 9/24)
a	371	20.9mg	857.mg	0/61	.300mg	3/60	1.00mg	4/62	3.00mg 1/38 10.0mg 5/24
b	371	1.60mg	3.90mg	6/61	.300mg	12/60	1.00mg	20/62	3.00mg 32/38 (10.0mg 11/24)
c	371	20.9mg	n.s.s.	5/61	.300mg	7/60	1.00mg	9/62	3.00mg 3/38 10.0mg 6/24
N-NITROSOETHIOMORPHOLINE 26541-51-5									
2092	229	3.11mg	34.4mg	0/13	.739mg	0/10	4.25mg	6/17	Garcia;zkko,74,179-184;1970
a	229	5.31mg	n.s.s.	0/13	.739mg	1/10	4.25mg	2/17	
b	229	1.41mg	n.s.s.	0/13	.739mg	0/10	4.25mg	0/17	
c	229	2.22mg	n.s.s.	4/13	.739mg	3/10	4.25mg	9/17	
2093	229	1.42mg	21.5mg	0/57	.571mg	0/11	2.90mg	4/10	
a	229	.888mg	n.s.s.	0/57	.571mg	0/11	2.90mg	0/10	
b	229	.794mg	n.s.s.	12/57	.571mg	4/11	2.90mg	6/10	
NORETHYNDREL 68-23-5									
2094	1175	2.48mg	n.s.s.	54/92	1.76mg	45/77			Rudali;jnci,49,813-819;1972
2095	1453m	12.1mg	n.s.s.	0/39	.125mg	0/39	1.50mg	0/40	5.00mg 2/39
2096	1453m	16.3mg	n.s.s.	6/39	.125mg	7/40	1.50mg	1/40	5.00mg 3/40
2097	1175	.243mg	n.s.s.	161/167p	1.76mg	48/49			Rudali;jnci,49,813-819;1972
2098	1175	1.86mg	n.s.s.	50/73	1.76mg	19/31			
2099	1453	6.19mg	n.s.s.	1/50	1.02mg	0/50			Barrows;jtxe,3,219-230;1977
NORHARMAN 244-63-3									
2100	1460	31.0mg	n.s.s.	0/28	20.0mg	1/24			Hagiwara;txlt,6,71-75;1980
a	1460	58.5mg	n.s.s.	0/28	20.0mg	0/24			
NORLESTRIN 8015-12-1									
2101	230	.347mg	n.s.s.	1/8	.200mg	7/15	2.00mg	5/8	Poel;scie,154,402-403;1966
2102	585m	.194mg	n.s.s.	0/15	.143mg	0/15			Poel;canr,28,845-859;1968
a	585m	83.4ug	n.s.s.	4/15	.143mg	3/15			
2103	585n	57.2ug	n.s.s.	8/15	.120mg	7/15			
2104	1403	.941mg	6.88mg	4/200	.338mg	13/100(3.38mg	10/100)		Schardein;txep,16,10-23;1970
a	1403	3.07mg	13.3mg	64/200	.338mg	19/100	3.38mg	55/100	
b	1403	3.47mg	27.9mg	61/200	.338mg	34/100	3.38mg	51/100	
c	1403	7.91mg	37.3mg	5/200	.338mg	2/100	3.38mg	17/100	
d	1403	12.0mg	164.mg	4/200	.338mg	2/100	3.38mg	10/100	
e	1403	2.30mg	37.2gm	0/200	.338mg	3/100(3.38mg	4/100)		
f	1403	22.9mg	n.s.s.	2/200	.338mg	0/100	3.38mg	4/100	
g	1403	6.38mg	n.s.s.	58/200	.338mg	33/100	3.38mg	37/100	
h	1403	2.59mg	n.s.s.	159/200	.338mg	82/100	3.38mg	83/100	
NOVADELOX ---									
2105	1345	9.23gm	n.s.s.	0/41	19.6mg	1/42	196.mg	1/42	1.96gm 0/42
a	1345	9.85gm	n.s.s.	1/41	19.6mg	1/42	196.mg	1/42	1.96gm 0/42
b	1345	11.0gm	n.s.s.	1/41	19.6mg	1/42	196.mg	0/42	1.96gm 0/42

Spe	Strain	Site	Xpo+Xpt	TD50	2Tailpvl
Sex	Route	Hist	Notes	DR	AuOp
2106	R b alb eat	liv mhp	28m28 e	>no dre	P=1. -
a	R b alb eat	tba ben	28m28 e	6.48gm *	P<.04 -
b	R b alb eat	tba mal	28m28 e	15.6gm *	P<.5 -
OCHRATOXIN A				100ng...1ug.....10.....100.....1mg.....10.....100.....1g.....10	
2107	R b wis gev	liv tum	12m26 e	no dre	P=1. -
a	R b wis gav	tba tum	12m26 e	no dre	P=1. -
OVULEN				100ng...1ug.....10.....100.....1mg.....10.....100.....1g.....10	
2108	M f crf eat	mam tum	24m24 r	.858mg	P<.8 -
2109	M m crf eat	mam tum	24m24 r	.300mg	P<.0005
N-(9-OXO-2-FLUORENYL)ACETAMIDE				100ng...1ug.....10.....100.....1mg.....10.....100.....1g.....10	
2110	R f buf eat	mgl adc	86w86 e	6.17mg	P<.0005+
a	R f buf eat	edu sqc	86w86 e	32.0mg	P<.04 +
b	R f buf eat	liv hpt	86w86 e	102.mg	P<.3 +
1'-OXOSAFROLE				100ng...1ug.....10.....100.....1mg.....10.....100.....1g.....10	
2111	R m cdr eat	liv car	73w95 e	no dre	P=1. -
OXPRENOLOL.HCl				100ng...1ug.....10.....100.....1mg.....10.....100.....1g.....10	
2112	M f cf1 eat	liv car	78w91 e	2.40gm *	P<.2 -
a	M f cf1 eat	lun ade	78w91 e	no dre	P=1. -
b	M f cf1 eat	lun nfs	78w91 e	no dre	P=1. -
2113	M f cf1 eat	lun car	78w78 e	425.mg	P<.2 -
a	M f cf1 eat	liv tum	78w78 e	no dre	P=1. -
2114	M m cf1 eat	liv pce	78w91 e	2.12gm *	P<.5 -
a	M m cf1 eat	lun ade	78w91 e	no dre	P=1. -
2115	M m cf1 eat	liv car	78w78 e	2.62gm *	P<.7 -
a	M m cf1 eat	lun ade	78w78 e	no dre	P=1. -
b	M m cf1 eat	lun car	78w78 e	no dre	P=1. -
2116	R f cdr eat	liv tum	78w78 e	no dre	P=1. -
2117	R m cdr eat	liv hps	78w78 e	1.68gm *	P<.3 -
N-OXYDIETHYLENEBENZOTHAZOLE-2-SULFENAMIDE				1ug.....10.....100.....1mg.....10.....100.....1g.....10	
2118	M f b6a orl	lun ade	76w76 evx	no dre	P=1. -
a	M f b6a orl	liv hpt	76w76 evx	no dre	P=1. -
b	M f b6a orl	tba mix	76w76 evx	1.31gm	P<.7 -
2119	M m b6a orl	liv hpt	76w76 evx	20.1gm	P<.1 -
a	M m b6a orl	lun ade	76w76 evx	no dre	P=1. -
b	M m b6a orl	tba mix	76w76 evx	no dre	P=1. -
2120	M f b6c orl	lun ade	76w76 evx	598.mg	P<.1 -
a	M f b6c orl	liv hpt	76w76 evx	1.23gm	P<.3 -
b	M f b6c orl	tba mix	76w76 evx	386.mg	P<.04 -
2121	M m b6c orl	liv hpt	76w76 evx	359.mg	P<.04 -
a	M m b6c orl	lun ade	76w76 evx	556.mg	P<.1 -
b	M m b6c orl	tba mix	76w76 evx	200.mg	P<.007 -
PARATHION				100ng...1ug.....10.....100.....1mg.....10.....100.....1g.....10	
2122	M f b6c eat	TBA MXB	80w89	no dre	P=1. -
a	M f b6c eat	liv MXB	80w89	no dre	P=1. -
b	M f b6c eat	lun MXB	80w89	no dre	P=1. -
2123	M m b6c eat	TBA MXB	67w89 a	75.1gm *	P<.7 -
a	M m b6c eat	liv MXB	67w89 a	111.mg *	P<.7 -
b	M m b6c eat	lun MXB	67w89 a	52.5mg *	P<.2 -
2124	R f oam eat	TBA MXB	19m26 v	no dre	P=1. -
a	R f oam eat	liv MXB	19m26 v	16.4gm *	P<.2 -
2125	R f oam eat	mgl fba	19m25 v	2.07mg \	P<.004
a	R f oam eat	adr MXA	19m25 v	3.93mg *	P<.0005a
b	R f oam eat	adr coa	19m25 v	5.31gm *	P<.004 a
2126	R m oam eat	TBA MXB	19m26 v	3.65gm *	P<.4 -
a	R m oam eat	liv MXB	19m26 v	17.7mg *	P<.09
2127	R m oam eat	adr MXA	19m25 v	5.22mg *	P<.005 a
a	R m oam eat	adr coa	19m25 v	6.39mg *	P<.007 a
b	R m oam eat	pni isc	19m25 v	19.2mg *	P<.03
PATULIN				100ng...1ug.....10.....100.....1mg.....10.....100.....1g.....10	
2128	R f sde gev	liv mhs	17m37 v	no dre	P=1. -
a	R f sde gev	tba mix	17m37 v	no dre	P=1. -
b	R f sde gev	tba ben	17m37 v	no dre	P=1. -
c	R f sde gev	tba mal	17m37 v	no dre	P=1. -
PENTACHLORONITROBENZENE				100ng...1ug.....10.....100.....1mg.....10.....100.....1g.....10	
2129	M f b6c eat	TBA MXB	78w91 v	3.32gm *	P<.2 -
a	M f b6c eat	liv MXB	78w91 v	9.69gm *	P<.09
b	M f b6c eat	lun MXB	78w91 v	30.7gm *	P<.4
2130	M f b6c orl	liv hpt	77w77 evx	252.mg	P<.02
a	M f b6c orl	lun ade	77w77 evx	1.11gm	P<.3
b	M f b6c orl	tba mix	77w77 evx	195.mg	P<.009

RefNum	LoConf	UpConf	Cntrl	1Dose	1Inc	2Dose	2Inc	Citation or Pathology	Brkly Code
2106	1345	6.57gm n.s.s.	0/46	7.07mg	0/47	70.7mg	1/47	707.mg	0/45
a	1345	2.16gm n.s.s.	3/46	7.07mg	1/47	70.7mg	1/47	707.mg	6/45
b	1345	2.84gm n.s.s.	6/46	7.07mg	2/47	70.7mg	1/47	707.mg	5/45
OCHRATOXIN A 303-47-9									
2107	1365	.132mg n.s.s.	0/10	76.4ug	0/10	.229mg	0/10		
a	1365	.132mg n.s.s.	0/10	76.4ug	0/10	.229mg	0/10	Purchase;fctx,9,681-682;1971	
OVULEN (ethynodiol diacetate/ethinyl estradiol [10:1]) 8056-92-6									
2108	1463	57.0ug n.s.s.	161/167	.390mg	37/38				
2109	1463	.158mg .664mg	0/76	.360mg	14/25			Rudali;gmc,17,243-252;1975	
N-(9-OXO-2-FLUORENYL)ACETAMIDE 3096-50-2									
2110	144	2.98mg 15.4mg	0/18	12.4mg	11/18				
a	144	9.65mg n.s.s.	0/18	12.4mg	3/18			Morris;jnci,24,149-180;1960	
b	144	16.6mg n.s.s.	0/18	12.4mg	1/18				
1'-OXOSAFROLE ---									
2111	1035d	239.mg n.s.s.	0/18	77.3mg	0/18				
								Wislocki;canr,37,1883-1891;1977	
OPRENOLOL.HCL 6452-73-9									
2112	469m	391.mg n.s.s.	0/24	12.9mg	0/28	42.9mg	0/28	129.mg	1/24
a	469m	464.mg n.s.s.	5/49	12.9mg	6/49	42.9mg	4/49	129.mg	4/50
b	469m	529.mg n.s.s.	0/24	12.9mg	1/28	42.9mg	0/28	129.mg	0/24
2113	469n	143.mg n.s.s.	1/25	150.mg	6/37				
a	469n	939.mg n.s.s.	0/40	150.mg	0/54				
2114	469m	366.mg n.s.s.	0/49	12.9mg	4/49	42.9mg	1/49	129.mg	3/49
a	469m	453.mg n.s.s.	4/49	12.9mg	7/49	42.9mg	3/49	129.mg	4/49
2115	469n	279.mg n.s.s.	1/29	150.mg	2/36				
a	469n	316.mg n.s.s.	2/29	150.mg	2/36				
b	469n	291.mg n.s.s.	9/44	150.mg	7/48				
2116	469m	37.3mg n.s.s.	0/30	15.0mg	0/30	50.0mg	0/30	150.mg	0/30
2117	469m	317.mg n.s.s.	1/29	15.0mg	0/30	50.0mg	0/30	150.mg	2/30
N-OXYDIETHYLENEBENZOTHAZOLE-2-SULFENAMIDE (amax) 102-77-2									
2118	1298	243.mg n.s.s.	1/17	205.mg	1/18				
a	1298	405.mg n.s.s.	0/17	205.mg	0/18				
b	1298	147.mg n.s.s.	2/17	205.mg	3/18				
2119	1298	211.mg n.s.s.	1/18	190.mg	1/17				
a	1298	356.mg n.s.s.	2/18	190.mg	0/17				
b	1298	250.mg n.s.s.	3/18	190.mg	1/17				
2120	1298	147.mg n.s.s.	0/16	205.mg	2/17				
a	1298	201.mg n.s.s.	0/16	205.mg	1/17				
b	1298	116.mg n.s.s.	0/16	205.mg	3/17				
2121	1298	108.mg n.s.s.	0/16	190.mg	3/17				
a	1298	137.mg n.s.s.	0/16	190.mg	2/17				
b	1298	75.3mg 2.70gm	0/16	190.mg	5/17				
PARATHION 56-38-2									
2122	c00226	33.0mg n.s.s.	3/10	9.40mg	12/50	18.5mg	9/50		
a	c00226	107.mg n.s.s.	1/10	9.40mg	1/50	18.5mg	1/50		
b	c00226	94.0mg n.s.s.	1/10	9.40mg	0/50	18.5mg	2/50		
2123	c00226	12.6mg n.s.s.	2/10	7.70mg	14/50	13.2mg	12/50		
a	c00226	19.6mg n.s.s.	2/10	7.70mg	6/50	13.2mg	9/50		
b	c00226	23.8mg n.s.s.	0/10	7.70mg	3/50	13.2mg	5/50		
2124	c00226	1.57mg n.s.s.	10/10	.820mg	34/50	1.60mg	32/50		
a	c00226	5.67mg n.s.s.	0/10	.820mg	1/50	1.60mg	3/50		
2125	c00226	.947mg 16.4mg	9/90p	.820mg	16/50	(1.60mg	8/50)		
a	c00226	2.01mg 15.0mg	4/90p	.820mg	6/50	1.60mg	13/50		
b	c00226	2.48mg 38.8mg	4/90p	.820mg	4/50	1.60mg	11/50		
2126	c00226	1.03mg n.s.s.	5/10	.900mg	25/50	1.80mg	35/50		
a	c00226	6.12mg n.s.s.	0/10	.900mg	0/50	1.80mg	4/50		
2127	c00226	2.54mg 54.3mg	3/90p	.900mg	7/50	1.80mg	11/50		
a	c00226	2.99mg 111.mg	2/90p	.900mg	5/50	1.80mg	9/50		
b	c00226	6.62mg n.s.s.	0/90p	.900mg	1/50	1.80mg	3/50		
PATULIN 149-29-1									
2128	393	7.80mg n.s.s.	1/50	.316mg	0/50				
a	393	.809mg n.s.s.	42/50	.316mg	37/50				
b	393	1.23mg n.s.s.	29/50	.316mg	25/50				
c	393	1.80mg n.s.s.	13/50	.316mg	12/50				
PENTACHLORONITROBENZENE (PCNB) 82-68-8									
2129	c00419	1.22gm n.s.s.	2/20	446.mg	5/50	893.mg	10/50		
a	c00419	2.93gm n.s.s.	0/20	446.mg	0/50	893.mg	3/50		
b	c00419	5.00gm n.s.s.	0/20	446.mg	0/50	893.mg	1/50		
2130	1101	86.7mg n.s.s.	0/16	169.mg	4/18				
a	1101	180.mg n.s.s.	0/16	169.mg	1/18				
b	1101	73.4mg 4.27gm	0/16	169.mg	5/18				
PATULIN 149-29-1									
2128	393	7.80mg n.s.s.	1/50	.316mg	0/50				
a	393	.809mg n.s.s.	42/50	.316mg	37/50				
b	393	1.23mg n.s.s.	29/50	.316mg	25/50				
c	393	1.80mg n.s.s.	13/50	.316mg	12/50				
PENTACHLORONITROBENZENE (PCNB) 82-68-8									
2129	c00419	1.22gm n.s.s.	2/20	446.mg	5/50	893.mg	10/50		
a	c00419	2.93gm n.s.s.	0/20	446.mg	0/50	893.mg	3/50		
b	c00419	5.00gm n.s.s.	0/20	446.mg	0/50	893.mg	1/50		
2130	1101	86.7mg n.s.s.	0/16	169.mg	4/18				
a	1101	180.mg n.s.s.	0/16	169.mg	1/18				
b	1101	73.4mg 4.27gm	0/16	169.mg	5/18				

Spe	Strain	Site	Xpo+Xpt		TD50	2Tailpvl
Sex	Route	Hist	Notes		DR	AuOp
2131	M m b6c eat	TBA	MXB 78w91 v		no dre	P=1. -
a	M m b6c eat	liv	MXB 78w91 v	>	no dre	P=1. -
b	M m b6c eat	lun	MXB 78w91 v		no dre	P=1. -
2132	M m b6c orl	liv	hpt 77w77 evx	>	501.mg	P<.2
a	M m b6c orl	lun	ade 77w77 evx		501.mg	P<.2
b	M m b6c orl	tba	mix 77w77 evx		181.mg	P<.009
2133	M f b6a orl	liv	hpt 77w77 evx	>	1.05gm	P<.3
a	M f b6a orl	lun	ade 77w77 evx		no dre	P=1. -
b	M f b6a orl	tba	mix 77w77 evx		no dre	P=1. -
2134	M m b6a orl	liv	hpt 77w77 evx	. + .	71.1mg	P<.0005+
a	M m b6a orl	lun	ade 77w77 evx		no dre	P=1. -
b	M m b6a orl	tba	mix 77w77 evx		68.7mg	P<.004
2135	R f oam eat	TBA	MXB 18m26 dv	>	no dre	P=1. -
a	R f oam eat	liv	MXB 18m26 dv		no dre	P=1. -
2136	R m oam eat	TBA	MXB 18m26 dv	>	no dre	P=1. -
a	R m oam eat	liv	MXB 18m26 dv		no dre	P=1. -
2,3,4,5,6-PENTACHLOROPHENOL				100ng...1ug...10...100...1mg...10...100...1g...10		
2137	M f b6a orl	liv	hpt 76w76 evx	>	no dre	P=1. -
a	M f b6a orl	lun	ade 76w76 evx		no dre	P=1. -
b	M f b6a orl	tba	mix 76w76 evx		no dre	P=1. -
2138	M m b6a orl	liv	mix 76w76 evx	>	90.4mg	P<.6
a	M m b6a orl	lun	ade 76w76 evx		no dre	P=1. -
b	M m b6a orl	tba	mix 76w76 evx		520.mg	P<.1
2139	M f b6c orl	liv	hpt 76w76 evx	>	56.1mg	P<.2
a	M f b6c orl	lun	ade 76w76 evx		no dre	P=1. -
b	M f b6c orl	tba	mix 76w76 evx		26.3mg	P<.02
2140	M m b6c orl	liv	hpt 76w76 evx	>	108.mg	P<.3
a	M m b6c orl	lun	ade 76w76 evx		108.mg	P<.3
b	M m b6c orl	tba	mix 76w76 evx		33.7mg	P<.05
2141	R f sas eat	tba	tum 24m24 e	>	no dre	P=1. -
2142	R m sas eat	tba	tum 95w95 e	>	no dre	P=1. -
N-PENTYL-N'-NITRO-N-NITROSOGUANIDINE				...1ug...10...100...1mg...10...100...1g...10		
2143	R m wis wat	atg	tum 52w78 er	>	no dre	P=1. -
n-PENTYLHYDRAZINE.HCl				100ng...1ug...10...100...1mg...10...100...1g...10		
2144	M f swa wat	lun	mix 94w94	. + .	5.87mg	P<.0005+
a	M f swa wat	lun	ade 94w94		7.95mg	P<.0005
b	M f swa wat	lun	adc 94w94		18.7mg	P<.0005
c	M f swa wat	blv	mix 94w94		35.5mg	P<.003 +
d	M f swa wat	blv	egm 94w94		71.9mg	P<.04
e	M f swa wat	blv	ang 94w94		82.2mg	P<.04
f	M f swa wat	liv	mix 94w94		223.mg	P<.4
2145	M m swa wat	lun	ade 94w94	. + .	30.0mg	P<.04
a	M m swa wat	lun	mix 94w94		46.9mg	P<.3
b	M m swa wat	blv	mix 94w94		65.6mg	P<.2
c	M m swa wat	liv	mix 94w94		271.mg	P<.7
PEPPERMINT OIL				100ng...1ug...10...100...1mg...10...100...1g...10		
2146	M m cfl gav	lun	tum 19m24 e	>	no dre	P=1. -
a	M m cfl gav	liv	tum 19m24 e		no dre	P=1. -
b	M m cfl gav	tba	mix 19m24 e		no dre	P=1. -
c	M m cfl gav	tba	mal 19m24 e		112.mg *	P<.6
PETASITENINE				100ng...1ug...10...100...1mg...10...100...1g...10		
2147	R f aci wat	liv	hms 68w68 er	. + .	+historical	P<.003 +
a	R f aci wat	liv	mix 68w68 er		+historical	P<.003 +
b	R f aci wat	liv	lca 68w68 er		+historical	P<.05 +
2148	R m aci wat	liv	mix 58w58 er	. + .	+historical	P<.0005+
a	R m aci wat	liv	lca 58w58 er		+historical	P<.005 +
b	R m aci wat	liv	hms 58w58 er		+historical	P<.2 +
PHENACETIN				100ng...1ug...10...100...1mg...10...100...1g...10		
2149	M f cb6 eat	liv	tum 77w77 e	>	no dre	P=1. -
2150	M m cb6 eat	liv	hnd 77w77 e	>	12.9gm *	P<.2 -
2151	R f sda eat	mgl	adc 26m26 e	. + .	1.38gm	P<.08 +
a	R f sda eat	edu	sqc 26m26 e		1.43gm	P<.02 +
2152	R f sda eat	---	myl 18m24	. + .	2.56gm *	P<.0005-
a	R f sda eat	mix	mix 18m24		2.73gm *	P<.0005+
b	R f sda eat	nas	adc 18m24		7.73gm *	P<.005 +
c	R f sda eat	ubl	tcc 18m24		11.7gm *	P<.02 +
d	R f sda eat	ubl	pam 18m24		23.8gm *	P<.08 +
e	R f sda eat	nas	tcc 18m24		23.8gm *	P<.2 +
f	R f sda eat	nas	sqc 18m24		48.0gm *	P<.7 +
g	R f sda eat	liv	tum 18m24		no dre	P=1. -
h	R f sda eat	tba	mix 18m24		1.21gm *	P<.0005
2153	R m sda eat	k/c	rct 27m27	. + .	+historical	P<.02 +
a	R m sda eat	for	sqp 27m27		+historical	P<.1 +

RefNum	LoConf	UpConf	Cntrl	1Dose	1Inc	2Dose	2Inc	Citation or Pathology	Brkly Code
2131	c00419	498.mg n.s.s.	6/20	265.mg	11/50	530.mg	12/50		
a	c00419	669.mg n.s.s.	2/20	265.mg	8/50	530.mg	4/50		Liv:hpa,hpc,nnd.
b	c00419	n.s.s. n.s.s.	0/20	265.mg	0/50	530.mg	0/50		Ln:a/a,e/c.
2132	1101	123.mg n.s.s.	0/16	157.mg	2/18				Innes;ntis,1968/1969
a	1101	123.mg n.s.s.	0/16	157.mg	2/18				
b	1101	68.4mg 3.98gm	0/16	157.mg	5/18				
2133	1101	170.mg n.s.s.	0/17	169.mg	1/17				
a	1101	324.mg n.s.s.	1/17	169.mg	0/17				
b	1101	152.mg n.s.s.	2/17	169.mg	2/17				
2134	1101	32.2mg 264.mg	1/18	157.mg	10/17				
a	1101	198.mg n.s.s.	2/18	157.mg	1/17				
b	1101	29.4mg 544.mg	3/18	157.mg	11/17				
2135	c00419	322.mg n.s.s.	14/20	272.mg	34/50	514.mg	20/50		
a	c00419	n.s.s. n.s.s.	0/20	272.mg	0/50	514.mg	0/50		Liv:hpa,hpc,nnd.
2136	c00419	409.mg n.s.s.	8/20	152.mg	20/50	280.mg	18/50		
a	c00419	1.67gm n.s.s.	0/20	152.mg	1/50	280.mg	0/50		Liv:hpa,hpc,nnd.
2,3,4,5,6-PENTACHLOROPHENOL (Dowicide-7, PCP) 87-86-5									
2137	1285	35.8mg n.s.s.	0/17	18.1mg	0/18				Innes;ntis,1968/1969
a	1285	35.8mg n.s.s.	1/17	18.1mg	0/18				
b	1285	17.0mg n.s.s.	2/17	18.1mg	2/18				
2138	1285	13.2mg n.s.s.	1/18	16.8mg	2/17				
a	1285	20.7mg n.s.s.	2/18	16.8mg	1/17				
b	1285	12.2mg n.s.s.	3/18	16.8mg	3/17				
2139	1285	13.8mg n.s.s.	0/16	18.1mg	2/18				
a	1285	35.8mg n.s.s.	0/16	18.1mg	0/18				
b	1285	9.04mg n.s.s.	0/16	18.1mg	4/18				
2140	1285	17.5mg n.s.s.	0/16	16.8mg	1/18				
a	1285	17.5mg n.s.s.	0/16	16.8mg	1/18				
b	1285	10.2mg n.s.s.	0/16	16.8mg	3/18				
2141	1401	10.0mg n.s.s.	27/27	1.00mg	26/27	3.00mg	25/27	10.0mg	25/27
2142	1401	33.4mg n.s.s.	11/27	1.00mg	13/26	3.00mg	13/27	10.0mg	11/27
Schwetz;pcpl,301-309;1978									
N-PENTYL-N'-NITRO-N-NITROSOQUANIDINE 13010-10-1									
2143	1082	1.60mg n.s.s.	0/9	2.30mg	0/6				Matsukura;gann,70,181-185;1979
n-PENTYLHYDRAZINE.HCL 1119-68-2									
2144	36	3.54mg 11.2mg	21/100	12.5mg	38/50				Shimizu;bjca,31,492-496;1975
a	36	4.69mg 16.3mg	18/100	12.5mg	33/50				
b	36	10.0mg 45.4mg	4/100	12.5mg	17/50				
c	36	15.6mg 245.mg	5/100	12.5mg	11/50				
d	36	24.4mg n.s.s.	3/100	12.5mg	6/50				
e	36	26.9mg n.s.s.	2/100	12.5mg	5/50				
f	36	39.3mg n.s.s.	3/100	12.5mg	3/50				
2145	36	11.6mg n.s.s.	15/100	10.4mg	15/50				
a	36	12.8mg n.s.s.	23/100	10.4mg	16/50				
b	36	19.8mg n.s.s.	6/100	10.4mg	7/50				
c	36	31.1mg n.s.s.	6/100	10.4mg	4/50				
PEPPERMINT OIL 8006-90-4									
2146	710	21.1mg n.s.s.	102/240	2.64mg	19/51	10.5mg	20/49		Roe;jept,2,799-819;1979
a	710	25.3mg n.s.s.	69/240	2.64mg	13/51	10.5mg	14/49		
b	710	11.0mg n.s.s.	170/240	2.64mg	37/51	10.5mg	34/49		
c	710	17.3mg n.s.s.	75/240	2.64mg	20/51	10.5mg	17/49		
PETASITENINE ---									
2147	427	.477mg 9.69mg	0/9	5.71mg	4/6				Hirono;jnci,58,1155-1157;1977
a	427	.477mg 9.69mg	0/9	5.71mg	4/6				
b	427	.994mg n.s.s.	0/9	5.71mg	2/6				
2148	427	.183mg 3.71mg	0/10	5.00mg	4/5				
a	427	.324mg 13.1mg	0/10	5.00mg	3/5				
b	427	.770mg n.s.s.	0/10	5.00mg	1/5				
PHENACETIN 62-44-2									
2149	1028	848.mg n.s.s.	0/36	268.mg	0/37	754.mg	0/41		Macklin;dact,3,135-163;1980
2150	1028	2.11gm n.s.s.	0/35	268.mg	0/40	754.mg	1/32		
2151	1449	451.mg n.s.s.	1/30	268.mg	5/30				Johansson;apms,84,375-383;1976
a	1449	494.mg n.s.s.	0/30	268.mg	4/30				
2152	708	1.45gm 5.32gm	0/65	469.mg	6/50	938.mg	11/50		Isaka;gann,70,29-36;1979
a	708	1.52gm 5.79gm	0/65	469.mg	5/50	938.mg	11/50		
b	708	3.15gm 58.5gm	0/65	469.mg	1/50	938.mg	5/50		
c	708	4.05gm n.s.s.	0/65	469.mg	0/50	938.mg	4/50		
d	708	5.85gm n.s.s.	0/65	469.mg	0/50	938.mg	2/50		
e	708	5.87gm n.s.s.	0/65	469.mg	1/50	938.mg	1/50		
f	708	7.82gm n.s.s.	0/65	469.mg	1/50	938.mg	0/50		
g	708	3.22gm n.s.s.	0/65	469.mg	0/50	938.mg	0/50		
h	708	728.mg 2.89gm	6/65	469.mg	19/50	938.mg	21/50		
2153	1459	447.mg n.s.s.	0/30	214.mg	4/30				Johansson;ijcn,27,521-529;1981
a	1459	661.mg n.s.s.	0/30	214.mg	2/30				

Spe	Strain	Site	Xpo + Xpt	Notes	TD50	2Tailpvl
Sex	Route	Hist			DR	AuOp
b	R m sda eat	ubl tum	27m27		1.64gm	P<.3 +
c	R m sda eat	k/p tum	27m27		+historical	P<.3 +
d	R m sda eat	liv hem	27m27		5.47gm	P<.3
2154	R m sda eat	mix mix	18m24		741.mg	* P<.0005+
a	R m sda eat	--- myl	18m24		2.38gm	* P<.0005-
b	R m sda eat	nas adc	18m24		2.38gm	* P<.0005+
c	R m sda eat	ubl tcc	18m24		2.71gm	/ P<.0005+
d	R m sda eat	nas tcc	18m24		4.05gm	* P<.002 +
e	R m sda eat	nas sqc	18m24		7.53gm	* P<.06 +
f	R m sda eat	k/p rcc	18m24		38.3gm	* P<.3 +
g	R m sda eat	liv tum	18m24		no dre	P=1.
h	R m sda eat	tba mix	18m24		631.mg	* P<.0005
PHENAZONE					100ng...:..1ug.....:..10.....:..100.....:..1mg.....:..10.....:..100.....:..1g.....:..10	
2155	R m sda eat	k/p mix	26m26		1.23gm	P<.02 +
a	R m sda eat	liv ccy	26m26		2.55gm	P<.1
b	R m sda eat	ubl tum	26m26		1.55gm	P<.3 +
PHENAZOPYRIDINE.HCl					100ng...:..1ug.....:..10.....:..100.....:..1mg.....:..10.....:..100.....:..1g.....:..10	
2156	M f b6c eat	liv MXA	19m24		71.1mg	* P<.007 c
a	M f b6c eat	liv hpc	19m24		132.mg	* P<.03 c
b	M f b6c eat	TBA MXB	19m24		89.7mg	* P<.2
c	M f b6c eat	liv MXB	19m24		71.1mg	* P<.007
d	M f b6c eat	lun MXB	19m24		4.65gm	* P<.9
2157	M m b6c eat	TBA MXB	19m24		496.mg	* P<.8 -
a	M m b6c eat	liv MXB	19m24		811.mg	* P<.9
b	M m b6c eat	lun MXB	19m24		1.30gm	* P<.8
2158	R f f34 eat	col acn	18m24		+historical	* P<.2 c
a	R f f34 eat	TBA MXB	18m24		no dre	P=1.
b	R f f34 eat	liv MXB	18m24		no dre	P=1.
2159	R m f34 eat	MXA MXA	18m24		303.mg	* P<.02 c
a	R m f34 eat	MXA MXA	18m24		333.mg	* P<.02 c
b	R m f34 eat	TBA MXB	18m24		no dre	P=1.
c	R m f34 eat	liv MXB	18m24		2.17gm	* P<.5
PHENESTERIN					100ng...:..1ug.....:..10.....:..100.....:..1mg.....:..10.....:..100.....:..1g.....:..10	
2160	M f b6c gav	MXB MXB	70w83	ses	.211mg	Z P<.0005
a	M f b6c gav	lun MXA	70w83	ses	.416mg	* P<.0005c
b	M f b6c gav	--- MXA	70w83	ses	.652mg	Z P<.0005c
c	M f b6c gav	ova tua	70w83	ses	.912mg	* P<.0005
d	M f b6c gav	myc arn	70w83	ses	.951mg	* P<.0005c
e	M f b6c gav	--- hes	70w83	ses	1.52mg	* P<.0005
f	M f b6c gav	TBA MXB	70w83	ses	.183mg	Z P<.0005
g	M f b6c gav	liv MXB	70w83	ses	no dre	P=1.
h	M f b6c gav	lun MXB	70w83	ses	.416mg	* P<.0005
2161	M f b6c gav	--- MXA	70w82	ses pool	2.07mg	* P<.0005c
2162	M m b6c gav	MXB	64w81	a	.757mg	* P<.0005
a	M m b6c gav	lun MXA	64w81	a	1.19mg	* P<.0005c
b	M m b6c gav	lun a/c	64w81	a	2.05mg	Z P<.0005c
c	M m b6c gav	--- MXA	64w81	a	2.13mg	* P<.0005c
d	M m b6c gav	myc arn	64w81	a	3.87mg	* P<.0005c
e	M m b6c gav	TBA MXB	64w81	a	.728mg	* P<.0005
f	M m b6c gav	liv MXB	64w81	a	32.9mg	* P<.9
g	M m b6c gav	lun MXB	64w81	a	1.19mg	* P<.0005
2163	M m b6c gav	--- MXA	64w81	a pool	1.89mg	* P<.0005c
a	M m b6c gav	--- hes	64w81	a	6.15mg	* P<.002
b	M m b6c gav	myc arn	64w81	a	6.28mg	* P<.003 c
2164	R f sda gav	TBA MXB	52w85		.271mg	* P<.0005-
a	R f sda gav	liv MXB	52w85		no dre	P=1.
2165	R f sda gav	agl acn	52w85	pool	.523mg	* P<.0005c
2166	R m sda gav	TBA MXB	52w84		.481mg	* P<.002 -
a	R m sda gav	liv MXB	52w84		no dre	P=1.
2167	R m sda gav	--- MXA	52w84	pool	#2.73mg	* P<.003 -
PHENFORMIN.HCl					100ng...:..1ug.....:..10.....:..100.....:..1mg.....:..10.....:..100.....:..1g.....:..10	
2168	M f b6c eat	TBA MXB	18m24		no dre	P=1. -
a	M f b6c eat	liv MXB	18m24		no dre	P=1.
b	M f b6c eat	lun MXB	18m24		no dre	P=1.
2169	M m b6c eat	TBA MXB	18m24	s	no dre	P=1. -
a	M m b6c eat	liv MXB	18m24	s	no dre	P=1.
b	M m b6c eat	lun MXB	18m24	s	no dre	P=1.
2170	R f f34 eat	TBA MXB	18m24		no dre	P=1. -
a	R f f34 eat	liv MXB	18m24		no dre	P=1.
2171	R m f34 eat	TBA MXB	18m24		36.4mg	/ P<.2 -
a	R m f34 eat	liv MXB	18m24		no dre	P=1.
PHENOBARBITAL					100ng...:..1ug.....:..10.....:..100.....:..1mg.....:..10.....:..100.....:..1g.....:..10	
2172	M f c3l eat	liv tum	52w52	r	noTD50	P<.0005+
2173	M f c3l eat	liv tum	52w52	r	12.2mg	P<.0005+

RefNum	LoConf	UpConf	Cntrl	1Dose	1Inc	2Dose	2Inc	Citation or Pathology	Brkly Code	
b	1459	435.mg n.s.s.	2/30	214.mg	5/30					
c	1459	891.mg n.s.s.	0/30	214.mg	1/30					
d	1459	891.mg n.s.s.	0/30	214.mg	1/30					
2154	708	503.mg 1.15gm	0/65	375.mg	17/50	750.mg	23/50	Iseoka;gann,70,29-36;1979		
a	708	1.30gm 6.32gm	0/65	375.mg	8/50	750.mg	7/50			
b	708	1.30gm 6.32gm	0/65	375.mg	8/50	750.mg	7/50			
c	708	1.43gm 6.12gm	0/65	375.mg	1/50	750.mg	12/50			
d	708	1.91gm 13.5gm	0/65	375.mg	2/50	750.mg	7/50			
e	708	2.86gm n.s.s.	0/65	375.mg	3/50	750.mg	2/50			
f	708	6.24gm n.s.s.	0/65	375.mg	0/50	750.mg	1/50			
g	708	2.58gm n.s.s.	0/65	375.mg	0/50	750.mg	0/50			
h	708	432.mg 990.mg	1/65	375.mg	20/50	750.mg	26/50			
PHENAZONE 60-80-0										
2155	1459	425.mg n.s.s.	0/30	214.mg	4/30			Johansson;ijcn,27,521-529;1981		
a	1459	628.mg n.s.s.	0/30	214.mg	2/30					
b	1459	413.mg n.s.s.	2/30	214.mg	5/30					
PHENAZOPYRIDINE.HCl 136-40-3										
2156	c01672	38.0mg 991.mg	2/15	41.6mg	11/35	84.5mg	19/35		liv:hpa,hpc.	
a	c01672	61.6mg n.s.s.	2/15	41.6mg	6/35	84.5mg	14/35			
b	c01672	34.1mg n.s.s.	8/15	41.6mg	20/35	84.5mg	27/35			
c	c01672	38.0mg 991.mg	2/15	41.6mg	11/35	84.5mg	19/35		liv:hpa,hpc,nnd.	
d	c01672	252.mg n.s.s.	1/15	41.6mg	1/35	84.5mg	2/35		lun:a/a,a/c.	
2157	c01672	51.8mg n.s.s.	7/15	39.6mg	17/35	78.0mg	20/35			
a	c01672	62.1mg n.s.s.	5/15	39.6mg	15/35	78.0mg	15/35		liv:hpa,hpc,nnd.	
b	c01672	144.mg n.s.s.	1/15	39.6mg	4/35	78.0mg	4/35		lun:a/a,a/c.	
2158	c01672	311.mg n.s.s.	0/15	98.0mg	3/34	199.mg	5/35			
a	c01672	232.mg n.s.s.	5/15	98.0mg	10/34	199.mg	13/35			
b	c01672	n.s.s. n.s.s.	0/15	98.0mg	0/34	199.mg	0/35		liv:hpa,hpc,nnd.	
2159	c01672	160.mg 43.4gm	0/15	78.4mg	4/35	161.mg	9/35		col:acn,adn; rec:acn.	
a	c01672	172.mg n.s.s.	0/15	78.4mg	4/35	161.mg	8/35		col:acn; rec:acn.	
b	c01672	210.mg n.s.s.	9/15	78.4mg	19/35	161.mg	14/35			
c	c01672	535.mg n.s.s.	0/15	78.4mg	1/35	161.mg	1/35		liv:hpa,hpc,nnd.	
PHENESTERIN 3456-10-9										
2160	c01558	.103mg .440mg	7/35	3.00mg	30/40	5.40mg	16/35	10.8mg	21/35	---:leu,lym; lun:a/a,a/c; myc:srn. C
a	c01558	.152mg 1.25mg	2/35	3.00mg	15/40	5.40mg	1/35	10.8mg	1/35	lun:a/a,a/c.
b	c01558	.288mg 1.65mg	5/35	3.00mg	12/40	5.40mg	14/35	10.8mg	17/35	---:leu,lym.
c	c01558	.273mg 3.43mg	0/35	3.00mg	8/40	5.40mg	0/35	10.8mg	0/35	S
d	c01558	.288mg 2.78mg	0/35	3.00mg	8/40	5.40mg	2/35	10.8mg	3/35	
e	c01558	.465mg 6.27mg	0/35	3.00mg	4/40	5.40mg	1/35	10.8mg	2/35	S
f	c01558	96.1ug .368mg	11/35	3.00mg	33/40	5.40mg	17/35	10.8mg	21/35	
g	c01558	n.s.s. n.s.s.	3/35	3.00mg	1/40	5.40mg	0/35	10.8mg	0/35	liv:hpa,hpc,nnd.
h	c01558	.152mg 1.25mg	2/35	3.00mg	15/40	5.40mg	1/35	10.8mg	1/35	lun:a/a,a/c.
2161	c01558	.862mg 3.97mg	0/31p	5.40mg	14/35	10.8mg	17/35		---:leu,lym.	
2162	c01558	.491mg 1.30mg	3/35	3.00mg	25/40	4.10mg	19/35	9.00mg	15/35	---:leu,lym; lun:a/a,a/c; myc:srn. C
a	c01558	.684mg 2.84mg	2/35	3.00mg	18/40	4.10mg	6/35	9.00mg	2/35	lun:a/a,a/c.
b	c01558	1.08mg 5.57mg	0/35	3.00mg	14/40	4.10mg	0/35	9.00mg	0/35	
c	c01558	1.20mg 4.46mg	1/35	3.00mg	11/40	4.10mg	9/35	9.00mg	11/35	---:leu,lym.
d	c01558	1.85mg 11.2mg	0/35	3.00mg	5/40	4.10mg	7/35	9.00mg	2/35	
e	c01558	.446mg 1.43mg	11/35	3.00mg	29/40	4.10mg	20/35	9.00mg	17/35	
f	c01558	2.07mg n.s.s.	7/35	3.00mg	10/40	4.10mg	2/35	9.00mg	0/35	liv:hpa,hpc,nnd.
g	c01558	.684mg 2.84mg	2/35	3.00mg	18/40	4.10mg	6/35	9.00mg	2/35	lun:a/a,a/c.
2163	c01558	.784mg 4.46mg	0/29p	4.10mg	9/35	9.00mg	11/35		---:leu,lym.	
a	c01558	1.99mg 36.3mg	0/29p	4.10mg	1/35	9.00mg	3/35		S	
b	c01558	2.64mg 30.5mg	0/29p	4.10mg	7/35	9.00mg	2/35			
2164	c01558	.137mg .880mg	7/10	1.30mg	28/35	2.60mg	22/35			
a	c01558	n.s.s. n.s.s.	0/10	1.30mg	0/35	2.60mg	0/35		liv:hpa,hpc,nnd.	
2165	c01558	.251mg 1.30mg	1/20p	1.30mg	12/35	2.60mg	12/35			
2166	c01558	.258mg 2.10mg	1/10	1.30mg	18/35	2.60mg	11/35			
a	c01558	n.s.s. n.s.s.	0/10	1.30mg	0/35	2.60mg	0/35		liv:hpa,hpc,nnd.	
2167	c01558	1.07mg 8.49mg	0/20p	1.30mg	2/35	2.60mg	5/35		---:leu,lym. S	
PHENFORMIN.HCl (NCI uses CAS# 114-86-3) 834-28-6										
2168	c01741	203.mg n.s.s.	7/15	117.mg	13/35	(244.mg	9/35)			
a	c01741	701.mg n.s.s.	1/15	117.mg	3/35	244.mg	2/35		liv:hpa,hpc,nnd.	
b	c01741	n.s.s. n.s.s.	0/15	117.mg	0/35	244.mg	0/35		lun:a/a,a/c.	
2169	c01741	266.mg n.s.s.	8/15	108.mg	10/35	226.mg	11/35			
a	c01741	262.mg n.s.s.	1/15	108.mg	6/35	226.mg	4/35		liv:hpa,hpc,nnd.	
b	c01741	376.mg n.s.s.	1/15	108.mg	4/35	226.mg	1/35		lun:a/a,a/c.	
2170	c01741	39.3mg n.s.s.	14/15	15.0mg	28/35	30.0mg	26/35			
a	c01741	n.s.s. n.s.s.	0/15	15.0mg	0/35	30.0mg	0/35		liv:hpa,hpc,nnd.	
2171	c01741	13.0mg n.s.s.	7/15	12.0mg	14/35	24.0mg	24/35			
a	c01741	n.s.s. n.s.s.	0/15	12.0mg	0/35	24.0mg	0/35		liv:hpa,hpc,nnd.	
PHENBARBITAL (phenobarbitone) 50-06-6										
2172	235m	n.s.s. 5.36mg	5/39	65.0mg	29/29				Peraino;jnci,51,1349-1350;1973	
2173	235n	5.45mg 46.2mg	1/16	65.0mg	10/16					

Spe	Strain	Site	Xpo+Xpt					TD50	2Tailpvl
Sex	Route	Hist	Notes					DR	AuOp
2174	M m c3l	eat	liv tum	52w52	r	.	+	4.18mg	P<.0005+
2175	M m c3l	eat	liv tum	52w52	r	.	+	4.46mg	P<.0005+
2176	R f aci	eat	liv tum	67w67		.		no dre	P=1. -
	a	R f aci	eat	tba mix	67w67	.		81.7mg	P<.3
2177	R m aci	eat	liv tum	67w67		.		no dre	P=1. -
	a	R m aci	eat	tba mix	67w67	.		no dre	P=1. -
2178	R f sda	ipj	tba mal	24m24	es	.	>	no dre	P=1. -
2179	R m sda	ipj	liv hae	24m24	es	.	>	no dre	P=1. -
	a	R m sda	ipj	tba mal	24m24	es		54.7mg	P<1. -
PHENOBARBITAL, SODIUM				100ng...1ug.....10.....100.....1mg.....10.....100.....1g.....10					
2180	M f cf1	wat	liv hpt	28m28	e	.	+	95.2mg	P<.0005+
	a	M f cf1	wat	lun ade	28m28	e		no dre	P=1. -
	b	M f cf1	wat	tba mix	28m28	e		no dre	P=1. -
2181	M f cf1	eat	liv mix	26m26	e	.	+	44.2mg	P<.0005+
	a	M f cf1	eat	liv lct	26m26	e		128.mg	P<.0005+
	b	M f cf1	eat	lun tum	26m26	e		no dre	P=1. -
2182	M m cf1	wat	liv hpt	28m28	e	.	+	62.2mg	P<.0005+
	a	M m cf1	wat	lun ade	28m28	e		no dre	P=1. -
	b	M m cf1	wat	tba mix	28m28	e		132.mg	P<.4
2183	M m cf1	eat	liv mix	26m26	e	.	+	34.6mg	P<.0005+
	a	M m cf1	eat	liv lct	26m26	e		174.mg	P<.006 +
	b	M m cf1	eat	lun tum	26m26	e		no dre	P=1. -
2184	R m cdr	wat	liv sad	95w95	e	.	>	500.mg	P<.3
2185	R m fis	eat	liv hnd	24m24	ev	.	+	67.3mg	P<.0005
2186	R f wis	wat	liv hpt	34m34	e	.	+	102.mg	P<.0005+
	a	R f wis	wat	tba tum	34m34	e		73.1mg	P<.2
2187	R m wis	wat	liv hpt	34m34	e	.	+	74.3mg	P<.0005+
	a	R m wis	wat	tba tum	34m34	e		206.mg	P<.6
PHENOTHIAZINE				100ng...1ug.....10.....100.....1mg.....10.....100.....1g.....10					
2188	M f b6a	orl	lun ade	76w76	evx	.	>	no dre	P=1. -
	a	M f b6a	orl	liv hpt	76w76	evx		no dre	P=1. -
	b	M f b6a	orl	tba mix	76w76	evx		no dre	P=1. -
2189	M m b6a	orl	liv hpt	76w76	evx	.	>	393.mg	P<.6 -
	a	M m b6a	orl	lun ade	76w76	evx		no dre	P=1. -
	b	M m b6a	orl	tba mix	76w76	evx		311.mg	P<.7 -
2190	M f b6c	orl	liv hpt	76w76	evx	.	>	no dre	P=1. -
	a	M f b6c	orl	lun mix	76w76	evx		no dre	P=1. -
	b	M f b6c	orl	tba tum	76w76	evx		no dre	P=1. -
2191	M m b6c	orl	liv hpt	76w76	evx	.	>	414.mg	P<.3 -
	a	M m b6c	orl	lun mix	76w76	evx		no dre	P=1. -
	b	M m b6c	orl	tba mix	76w76	evx		200.mg	P<.09 -
PHENOXYBENZAMINE.HCl				100ng...1ug.....10.....100.....1mg.....10.....100.....1g.....10					
2192	M f b6c	ipj	abc srn	52w84	s	.	+	5.85mg /	P<.0005c
	a	M f b6c	ipj	TBA MXB	52w84	s		3.08mg /	P<.0005
	b	M f b6c	ipj	liv MXB	52w84	s		no dre	P=1. -
	c	M f b6c	ipj	lun MXB	52w84	s		no dre	P=1. -
2193	M m b6c	ipj	abc srn	51w83	as	.	+	4.95mg /	P<.0005c
	a	M m b6c	ipj	TBA MXB	51w83	as		2.17mg /	P<.0005
	b	M m b6c	ipj	liv MXB	51w83	as		5.84mg *	P<.2
	c	M m b6c	ipj	lun MXB	51w83	as		63.0mg *	P<.9
2194	R f sda	ipj	per srn	52w83	s	.	+	2.36mg /	P<.0005c
	a	R f sda	ipj	TBA MXB	52w83	s		1.34mg *	P<.05
	b	R f sda	ipj	liv MXB	52w83	s		no dre	P=1. -
2195	R m sda	ipj	per srn	52w83	s	.	+	.710mg /	P<.0005c
	a	R m sda	ipj	TBA MXB	52w83	s		.555mg /	P<.0005
	b	R m sda	ipj	liv MXB	52w83	s		no dre	P=1. -
1-PHENYL-3,3-DIMETHYLTRIAZENE				100ng...1ug.....10.....100.....1mg.....10.....100.....1g.....10					
2196	R b bdr	gav	bra mix	24m24		.	+	5.81mg *	P<.0005+
	a	R b bdr	gav	tba mal	24m24			2.31mg *	P<.0005+
PHENYL ISOTHIOCYANATE				100ng...1ug.....10.....100.....1mg.....10.....100.....1g.....10					
2197	M f b6a	orl	liv hem	76w76	evx	.	>	138.mg	P<.3 -
	a	M f b6a	orl	lun ade	76w76	evx		no dre	P=1. -
	b	M f b6a	orl	tba mix	76w76	evx		39.4mg	P<.3 -
2198	M m b6a	orl	lun ade	76w76	evx	.	>	no dre	P=1. -
	a	M m b6a	orl	liv hpt	76w76	evx		no dre	P=1. -
	b	M m b6a	orl	tba mix	76w76	evx		no dre	P=1. -
2199	M f b6c	orl	liv hpt	76w76	evx	.	>	no dre	P=1. -
	a	M f b6c	orl	lun mix	76w76	evx		no dre	P=1. -
	b	M f b6c	orl	tba tum	76w76	evx		no dre	P=1. -
2200	M m b6c	orl	liv hpt	76w76	evx	.	>	128.mg	P<.3 -
	a	M m b6c	orl	lun ade	76w76	evx		128.mg	P<.3 -
	b	M m b6c	orl	tba mix	76w76	evx		40.2mg	P<.05 -
1-PHENYL-3-METHYL-5-PYRAZOLONE				100ng...1ug.....10.....100.....1mg.....10.....100.....1g.....10					
2201	M f b6c	eat	TBA MXB	24m24		.	>	no dre	P=1. -

RefNum	LoConf	UpConf	Cntrl	1Dose	1Inc	2Dose	2Inc	Citation or Pathology	Brkly Code
2174	235n	1.52mg	19.0mg	25/37	60.0mg	35/36			
2175	235n	1.56mg	21.4mg	7/17	60.0mg	16/17			
2176	1448	25.7mg	n.s.s.	0/10	25.0mg	0/12		Uchida;zkko,100,231-238;1981	
a	1448	13.3mg	n.s.s.	0/10	25.0mg	1/12			
2177	1448	20.5mg	n.s.s.	0/10	20.0mg	0/12			
a	1448	15.3mg	n.s.s.	4/10	20.0mg	1/12			
2178	1134	1.25mg	n.s.s.	3/33	.286mg	1/30		Schmahl;zkko,86,77-84;1976	
2179	1134	1.88mg	n.s.s.	1/36	.286mg	0/32			
a	1134	n.s.s.	n.s.s.	1/36	.286mg	1/32			
PHENOBARBITAL, SODIUM (phenobarbitone, sodium) 57-30-7									
2180	237	65.2mg	145.mg	0/47	100.mg	45/73		Ponomarkov;clet,1,165-172;1976	
a	237	338.mg	n.s.s.	15/47	100.mg	21/73			
b	237	93.4mg	n.s.s.	45/47	100.mg	65/73			
2181	89	22.5mg	122.mg	10/44	65.0mg	21/28		Thorpe;fctx,11,433-442;1973	
a	89	60.1mg	352.mg	0/44	65.0mg	9/28			
b	89	175.mg	n.s.s.	27/44	65.0mg	9/28			
2182	237	41.6mg	109.mg	12/44	83.3mg	77/98		Ponomarkov;clet,1,165-172;1976	
a	237	244.mg	n.s.s.	20/44	83.3mg	40/98			
b	237	33.0mg	n.s.s.	40/44	83.3mg	93/98			
2183	89	18.1mg	86.1mg	11/45	60.0mg	24/30		Thorpe;fctx,11,433-442;1973	
a	89	70.9mg	2.46gm	2/45	60.0mg	8/30			
b	89	86.7mg	n.s.s.	27/45	60.0mg	15/30			
2184	1035	81.4mg	n.s.s.	0/15	50.0mg	1/18		Wislocki;canr,37,1883-1891;1977	
2185	389	33.6mg	177.mg	0/25	39.8mg	11/33		Butler;bjca,37,418-423;1978	
2186	85	48.0mg	287.mg	0/32	28.6mg	9/29		Rossi;jcn,19,179-185;1977	
a	85	22.5mg	n.s.s.	19/32	28.6mg	22/29			
2187	85	38.9mg	168.mg	0/35	25.0mg	13/36			
a	85	35.8mg	n.s.s.	19/35	25.0mg	22/36			
PHENOTHIAZINE 92-84-2									
2188	1254	87.3mg	n.s.s.	1/17	78.4mg	1/17		Innes;ntis,1968/1969	
a	1254	147.mg	n.s.s.	0/17	78.4mg	0/17			
b	1254	68.9mg	n.s.s.	2/17	78.4mg	2/17			
2189	1254	57.3mg	n.s.s.	1/18	73.0mg	2/17			
a	1254	89.8mg	n.s.s.	2/18	73.0mg	1/17			
b	1254	41.9mg	n.s.s.	3/18	73.0mg	4/17			
2190	1254	155.mg	n.s.s.	0/16	78.4mg	0/18			
a	1254	155.mg	n.s.s.	0/16	78.4mg	0/18			
b	1254	155.mg	n.s.s.	0/16	78.4mg	0/18			
2191	1254	67.4mg	n.s.s.	0/16	73.0mg	1/16			
a	1254	129.mg	n.s.s.	0/16	73.0mg	0/16			
b	1254	49.1mg	n.s.s.	0/16	73.0mg	2/16			
PHENOXYBENZAMINE.HCL 63-92-3									
2192	c01661	3.11mg	12.0mg	0/15	3.30mg	0/35	10.3mg	16/35	
a	c01661	1.59mg	8.85mg	5/15	3.30mg	7/35	10.3mg	16/35	
b	c01661	7.21mg	n.s.s.	1/15	3.30mg	1/35	10.3mg	0/35	liv:hpa,hpc,nnd.
c	c01661	7.21mg	n.s.s.	1/15	3.30mg	1/35	10.3mg	0/35	lun:a/a,a/c.
2193	c01661	2.63mg	9.91mg	0/15	3.40mg	0/35	10.7mg	17/35	
a	c01661	1.17mg	4.88mg	3/15	3.40mg	7/35	10.7mg	18/35	
b	c01661	1.98mg	n.s.s.	1/15	3.40mg	6/35	10.7mg	0/35	liv:hpa,hpc,nnd.
c	c01661	3.24mg	n.s.s.	2/15	3.40mg	3/35	10.7mg	0/35	lun:a/a,a/c.
2194	c01661	1.30mg	5.16mg	0/10	1.30mg	0/35	2.70mg	16/35	
a	c01661	.610mg	n.s.s.	5/10	1.30mg	20/35	2.70mg	20/35	
b	c01661	n.s.s.	n.s.s.	0/10	1.30mg	0/35	2.70mg	0/35	liv:hpa,hpc,nnd.
2195	c01661	.403mg	1.31mg	0/10	1.30mg	11/35	3.80mg	16/35	
a	c01661	.303mg	1.35mg	3/10	1.30mg	15/35	3.80mg	16/35	
b	c01661	n.s.s.	n.s.s.	0/10	1.30mg	0/35	3.80mg	0/35	liv:hpa,hpc,nnd.
1-PHENYL-3,3-DIMETHYLTRIAZENE 7227-91-0									
2196	1467	2.65mg	16.1mg	0/120	3.57mg	1/7	7.14mg	8/12	Preussmann;zkko,81,285-310;1974
a	1467	1.10mg	5.34mg	2/120	3.57mg	4/7	7.14mg	11/12	
PHENYL ISOTHIOCYANATE 103-72-0									
2197	1304	22.5mg	n.s.s.	0/17	21.6mg	1/18			Innes;ntis,1968/1969
a	1304	25.6mg	n.s.s.	1/17	21.6mg	1/18			
b	1304	10.3mg	n.s.s.	2/17	21.6mg	5/18			
2198	1304	21.4mg	n.s.s.	2/18	20.0mg	1/15			
a	1304	33.1mg	n.s.s.	1/18	20.0mg	0/15			
b	1304	22.9mg	n.s.s.	3/18	20.0mg	1/15			
2199	1304	42.7mg	n.s.s.	0/16	21.6mg	0/18			
a	1304	42.7mg	n.s.s.	0/16	21.6mg	0/18			
b	1304	42.7mg	n.s.s.	0/16	21.6mg	0/18			
2200	1304	20.9mg	n.s.s.	0/16	20.0mg	1/18			
a	1304	20.9mg	n.s.s.	0/16	20.0mg	1/18			
b	1304	12.1mg	n.s.s.	0/16	20.0mg	3/18			
1-PHENYL-3-METHYL-5-PYRAZOLONE 89-25-8									
2201	c03952	2.85gm	n.s.s.	9/20	956.mg	19/50	1.91gm	15/50	

Spe	Strain	Site	Xpo+Xpt	Notes	TD50	2Tailpvl
Sex	Route	Hist			DR	AuOp
a	M f b6c eat liv	MXB	24m24		no dre	P=1.
b	M f b6c eat lun	MXB	24m24		no dre	P=1.
2202	M m b6c eat TBA	MXB	24m24		>	no dre P=1. -
a	M m b6c eat liv	MXB	24m24		no dre	P=1.
b	M m b6c eat lun	MXB	24m24		no dre	P=1.
2203	R f f34 eat TBA	MXB	24m24		>	no dre P=1. -
a	R f f34 eat liv	MXB	24m24		no dre	P=1.
2204	R m f34 eat TBA	MXB	24m24		>	no dre P=1. -
a	R m f34 eat liv	MXB	24m24		3.70gm *	P<.5
PHENYL-beta-NAPHTHYLAMINE				100ng.....1ug.....10.....100.....1mg.....10.....100.....1g.....10		
2205	H f syg gav liv	tum	84w84 e		>	no dre P=1.
a	H f syg gav lun	tum	84w84 e		no dre	P=1.
b	H f syg gav tba	mix	84w84 e		no dre	P=1. -
2206	H m syg gav liv	tum	84w84 e		>	no dre P=1.
a	H m syg gav lun	tum	84w84 e		no dre	P=1.
b	H m syg gav tba	mix	84w84 e		no dre	P=1. -
2207	M f b6a orl lun	ede	76w76 evx		>	no dre P=1.
a	M f b6a orl liv	hpt	76w76 evx		no dre	P=1.
b	M f b6a orl tba	mix	76w76 evx		1.08gm	P<.7
2208	M m b6a orl lun	ede	76w76 evx		>	431.mg P<.4
a	M m b6a orl liv	hpt	76w76 evx		460.mg	P<.3
b	M m b6a orl tba	mix	76w76 evx		186.mg	P<.2
2209	M f b6c orl liv	hpt	76w76 evx		>	1.08gm P<.3
a	M f b6c orl lun	mix	76w76 evx		no dre	P=1.
b	M f b6c orl tba	mix	76w76 evx		1.08gm	P<.3
2210	M m b6c orl liv	hpt	76w76 evx		.	165.mg P<.007
a	M m b6c orl lun	mix	76w76 evx		no dre	P=1.
b	M m b6c orl tba	mix	76w76 evx		108.mg	P<.002
N-PHENYL-p-PHENYLENEDIAMINE.HCl				100ng.....1ug.....10.....100.....1mg.....10.....100.....1g.....10		
2211	M f b6c eat TBA	MXB	48w91 sv		>	no dre P=1. -
a	M f b6c eat liv	MXB	48w91 sv		no dre	P=1.
b	M f b6c eat lun	MXB	48w91 sv		no dre	P=1.
2212	M m b6c eat TBA	MXB	48w91 sv		>	no dre P=1. -
a	M m b6c eat liv	MXB	48w91 sv		213.mg \	P<.06
b	M m b6c eat lun	MXB	48w91 sv		no dre	P=1.
2213	R f f34 eat TBA	MXB	18m24		>	no dre P=1. -
a	R f f34 eat liv	MXB	18m24		no dre	P=1.
2214	R m f34 eat TBA	MXB	18m24		>	161.mg * P<.5 -
a	R m f34 eat liv	MXB	18m24		no dre	P=1.
1-PHENYL-2-THIOUREA				100ng.....1ug.....10.....100.....1mg.....10.....100.....1g.....10		
2215	M f b6c eat TBA	MXB	78w91		>	133.mg * P<.4 -
a	M f b6c eat liv	MXB	78w91		268.mg *	P<.06
b	M f b6c eat lun	MXB	78w91		134.mg *	P<.07
2216	M m b6c eat TBA	MXB	78w91		>	no dre P=1. -
a	M m b6c eat liv	MXB	78w91		no dre	P=1.
b	M m b6c eat lun	MXB	78w91		no dre	P=1.
2217	R f f34 eat TBA	MXB	18m24		>	no dre P=1. -
a	R f f34 eat liv	MXB	18m24		no dre	P=1.
2218	R m f34 eat TBA	MXB	18m24		>	no dre P=1. -
a	R m f34 eat liv	MXB	18m24		no dre	P=1.
1-PHENYLAZO-2-NAPHTHOL				100ng.....1ug.....10.....100.....1mg.....10.....100.....1g.....10		
2219	M f cba eat liv	hpt	12m24		>	no dre P=1. -
2220	M m cba eat liv	hpt	12m24		>	no dre P=1. -
m-PHENYLENEDIAMINE.2HCl				100ng.....1ug.....10.....100.....1mg.....10.....100.....1g.....10		
2221	M f chi eat lun	mix	64w77 e		:	253.mg * P<.03 -
a	M f chi eat liv	mix	64w77 e		:	1.17gm * P<.3 -
b	M f chi eat tba	mix	64w77 e		:	370.mg * P<.3 -
2222	M m chi eat lun	mix	64w77 e		:	421.mg * P<.08 -
a	M m chi eat liv	mix	64w77 e		:	889.mg * P<.3 -
b	M m chi eat tba	mix	64w77 e		:	307.mg * P<.3 -
2223	R m cdr eat liv	mix	18m25		>	1.69gm * P<.9 -
a	R m cdr eat tba	mix	18m25		114.mg *	P<.3 -
o-PHENYLENEDIAMINE.2HCl				100ng.....1ug.....10.....100.....1mg.....10.....100.....1g.....10		
2224	M f chi eat liv	mix	77w90 v		:	507.mg * P<.002
a	M f chi eat liv	hpt	77w90 v		:	611.mg * P<.002 +
b	M f chi eat lun	mix	77w90 v		:	2.26gm * P<.3 -
c	M f chi eat tba	mix	77w90 v		:	676.mg * P<.07
2225	M f chi eat liv	hpt	77w90 v	pool	:	611.mg * P<.0005+
2226	M m chi eat liv	hpt	77w86 v		:	921.mg * P<.04 +
a	M m chi eat liv	mix	77w86 v		:	921.mg * P<.04 +
b	M m chi eat lun	mix	77w86 v		:	3.21gm * P<.6 -
c	M m chi eat tba	mix	77w86 v		:	1.97gm * P<.5 -
2227	M m chi eat liv	hpt	77w86 v	pool	:	1.11gm * P<.0005+

RefNum	LoConf	UpConf	Cntrl	1Dose	1Inc	2Dose	2Inc	Citation or Pathology	Brkly Code
a	c03952	14.2gm	n.s.s.	2/20	956.mg	2/50	1.91gm		liv:hpa,hpc,nnd.
b	c03952	8.43gm	n.s.s.	1/20	956.mg	3/50	1.91gm		lun:a/a,a/c.
2202	c03952	1.38gm	n.s.s.	11/20	883.mg	20/50	(1.77gm		
a	c03952	2.85gm	n.s.s.	8/20	883.mg	8/50	(1.77gm		liv:hpa,hpc,nnd.
b	c03952	3.62gm	n.s.s.	3/20	883.mg	3/50	(1.77gm		lun:a/a,a/c.
2203	c03952	115.mg	n.s.s.	12/20	123.mg	36/50	(245.mg		
a	c03952	n.s.s.	n.s.s.	0/20	123.mg	0/50	245.mg		liv:hpa,hpc,nnd.
2204	c03952	192.mg	n.s.s.	14/20	98.1mg	32/49	196.mg		
a	c03952	907.mg	n.s.s.	0/20	98.1mg	1/49	196.mg		liv:hpa,hpc,nnd.
PHENYL-beta-NAPHTHYLAMINE (Agerite powder)				135-88-6					
2205	1151	202.mg	n.s.s.	0/40	37.5mg	0/40			Green;zkko,95,51-55;1979
a	1151	202.mg	n.s.s.	0/40	37.5mg	0/40			
b	1151	72.3mg	n.s.s.	8/40	37.5mg	6/40			
2206	1151	202.mg	n.s.s.	0/40	37.5mg	0/40			
a	1151	202.mg	n.s.s.	0/40	37.5mg	0/40			
b	1151	84.5mg	n.s.s.	3/40	37.5mg	3/40			
2207	1153	201.mg	n.s.s.	1/17	169.mg	1/18			Innes;ntis,1968/1969
a	1153	334.mg	n.s.s.	0/17	169.mg	0/18			
b	1153	121.mg	n.s.s.	2/17	169.mg	3/18			
2208	1153	90.1mg	n.s.s.	2/18	157.mg	4/18			
a	1153	103.mg	n.s.s.	1/18	157.mg	3/18			
b	1153	57.2mg	n.s.s.	3/18	157.mg	7/18			
2209	1153	176.mg	n.s.s.	0/16	169.mg	1/18			
a	1153	334.mg	n.s.s.	0/16	169.mg	0/18			
b	1153	176.mg	n.s.s.	0/16	169.mg	1/18			
2210	1153	62.2mg	2.23gm	0/16	157.mg	5/17			
a	1153	294.mg	n.s.s.	0/16	157.mg	0/17			
b	1153	46.1mg	417.mg	0/16	157.mg	7/17			
N-PHENYL-p-PHENYLENEDIAMINE.HCl (NCI uses				CAS# 101-54-2)	2198-59-6				
2211	c02233	648.mg	n.s.s.	5/20	252.mg	4/50	(478.mg		2/50)
a	c02233	1.53gm	n.s.s.	1/20	252.mg	2/50	478.mg		liv:hpa,hpc,nnd.
b	c02233	n.s.s.	n.s.s.	0/20	252.mg	0/50	478.mg		lun:a/a,a/c.
2212	c02233	404.mg	n.s.s.	10/20	131.mg	25/49	260.mg		15/50)
a	c02233	96.5mg	n.s.s.	2/20	131.mg	18/49	(260.mg		10/50)
b	c02233	818.mg	n.s.s.	4/20	131.mg	4/49	260.mg		5/50)
2213	c02233	68.6mg	n.s.s.	13/20	22.5mg	26/50	45.0mg		24/50)
a	c02233	n.s.s.	n.s.s.	0/20	22.5mg	0/50	45.0mg		0/50)
2214	c02233	40.5mg	n.s.s.	6/20	18.0mg	17/50	36.0mg		20/50)
a	c02233	n.s.s.	n.s.s.	0/20	18.0mg	0/50	36.0mg		0/50)
1-PHENYL-2-THIOUREA				103-85-5					
2215	c02017	35.3mg	n.s.s.	4/20	16.9mg	11/50	33.8mg		15/50)
a	c02017	92.7mg	n.s.s.	0/20	16.9mg	0/50	33.8mg		4/50)
b	c02017	60.5mg	n.s.s.	0/20	16.9mg	3/50	33.8mg		5/50)
2216	c02017	49.0mg	n.s.s.	6/20	15.6mg	16/50	31.2mg		12/50)
a	c02017	74.6mg	n.s.s.	1/20	15.6mg	7/50	31.2mg		3/50)
b	c02017	73.7mg	n.s.s.	3/20	15.6mg	6/50	31.2mg		6/50)
2217	c02017	2.46mg	n.s.s.	12/20	2.30mg	37/50	(4.50mg		30/50)
a	c02017	n.s.s.	n.s.s.	0/20	2.30mg	0/50	4.50mg		0/50)
2218	c02017	2.71mg	n.s.s.	7/20	1.80mg	22/50	(3.60mg		22/50)
a	c02017	17.3mg	n.s.s.	0/20	1.80mg	2/50	3.60mg		1/50)
1-PHENYLAZO-2-NAPHTHOL				842-07-9					
2219	1165	348.mg	n.s.s.	0/18	64.9mg	0/26			Clayson;b]ca,19,297-310;1965/Williams 1962
2220	1165	150.mg	n.s.s.	2/15	59.9mg	1/18			
m-PHENYLENEDIAMINE.2HCl				541-69-5					
2221	381	87.6mg	n.s.s.	3/13	260.mg	4/13	520.mg		0/16)
a	381	190.mg	n.s.s.	0/13	260.mg	1/13	520.mg		0/16)
b	381	93.9mg	n.s.s.	9/13	260.mg	5/13	520.mg		1/16)
2222	381	104.mg	n.s.s.	2/16	240.mg	2/15	480.mg		0/10)
a	381	145.mg	n.s.s.	2/16	240.mg	1/15	480.mg		0/10)
b	381	77.9mg	n.s.s.	9/16	240.mg	5/15	480.mg		0/10)
2223	381	87.6mg	n.s.s.	1/17	30.0mg	1/17	60.0mg		1/15)
a	381	31.5mg	n.s.s.	13/17	30.0mg	7/17	60.0mg		6/15)
o-PHENYLENEDIAMINE.2HCl				615-28-1					
2224	381	236.mg	1.83gm	1/15	806.mg	7/18	1.70gm		6/15)
a	381	276.mg	2.46gm	1/15	806.mg	6/18	1.70gm		6/15)
b	381	522.mg	n.s.s.	5/15	806.mg	3/18	1.70gm		4/15)
c	381	233.mg	n.s.s.	10/15	806.mg	13/18	1.70gm		10/15)
2225	381	276.mg	1.49gm	1/102p	806.mg	6/18	1.70gm		6/15)
2226	381	406.mg	n.s.s.	0/14	783.mg	5/17	1.57gm		3/14)
a	381	406.mg	n.s.s.	1/14	783.mg	5/17	1.57gm		3/14)
b	381	643.mg	n.s.s.	3/14	783.mg	4/17	1.57gm		2/14)
c	381	381.mg	n.s.s.	7/14	783.mg	10/17	1.57gm		6/14)
2227	381	456.mg	4.81gm	7/99p	783.mg	5/17	1.57gm		3/14)

Spe	Strain	Site	Xpo + Xpt	Notes	TD50	2Tailpvl
Sex	Route	Hist			DR	AuOp
2228	R m cdr eat	liv hpt	18m25		248. mg *	P<.02 +
a	R m cdr eat	liv mix	18m25	:	248. mg *	P<.02 +
b	R m cdr eat	tba mix	18m25	:	no dre	P=1.
2229	R m cdr eat	liv hpt	18m25	pool	315. mg *	P<.02 +
p-PHENYLENEDIAMINE.2HCL				100ng...1ug.....10.....100.....1mg.....10.....100.....1g.....10		
2230	M f b6c eat	TBA MXB	24m24		1.50gm *	P<.8 -
a	M f b6c eat	liv MXB	24m24	:	1.37gm *	P<.5 -
b	M f b6c eat	lun MXB	24m24	:	1.39gm *	P<.2 -
2231	M m b6c eat	TBA MXB	24m24		no dre	P=1. -
a	M m b6c eat	liv MXB	24m24	:	no dre	P=1. -
b	M m b6c eat	lun MXB	24m24	:	no dre	P=1. -
2232	R f f34 eat	TBA MXB	24m27		247. mg *	P<.6 -
a	R f f34 eat	liv MXB	24m27	:	no dre	P=1. -
2233	R m f34 eat	TBA MXB	24m27		no dre	P=1. -
a	R m f34 eat	liv MXB	24m27	:	2.23gm *	P<.4 -
PHENYLETHYLHYDRAZINE SULFATE				100ng...1ug.....10.....100.....1mg.....10.....100.....1g.....10		
2234	M f swa wat	blv mix	93w93 e	.	14.6mg	P<.0005+
a	M f swa wat	sub ang	93w93 e	.	19.9mg	P<.0005
b	M f swa wat	blv ang	93w93 e	.	20.4mg	P<.0005
c	M f swa wat	mus ang	93w93 e	.	21.7mg	P<.0005
d	M f swa wat	fat ang	93w93 e	.	23.7mg	P<.0005
e	M f swa wat	lun ade	93w93 e	.	25.8mg	P<.0005
f	M f swa wat	lun mix	93w93 e	.	27.5mg	P<.0005+
g	M f swa wat	lun ang	93w93 e	.	123. mg	P<.0006
h	M f swa wat	liv mix	93w93 e	.	278. mg	P<.4 -
2235	M m swa wat	lun ade	99w99 e	.	30.0mg	P<.0005-
a	M m swa wat	lun mix	99w99 e	.	33.1mg	P<.004 -
b	M m swa wat	liv mix	99w99 e	.	no dre	P=1. -
PHENYLHYDRAZINE				100ng...1ug.....10.....100.....1mg.....10.....100.....1g.....10		
2236	M f sui gav	lun tum	39w55 v	.	no dre	P=1. -
PHENYLHYDRAZINE.HCL				100ng...1ug.....10.....100.....1mg.....10.....100.....1g.....10		
2237	M f swa wat	liv mix	26m26 e	.	68.6mg	P<.0005
a	M f swa wat	blv mix	26m26 e	.	72.1mg	P<.0005+
b	M f swa wat	blv agm	26m26 e	.	147. mg	P<.02
c	M f swa wat	liv agm	26m26 e	.	165. mg	P<.02
d	M f swa wat	blv ang	26m26 e	.	165. mg	P<.02
e	M f swa wat	liv ang	26m26 e	.	165. mg	P<.02
f	M f swa wat	lun mix	26m26 e	.	no dre	P=1. -
2238	M m swa wat	blv mix	26m26 e	.	70.6mg	P<.02 +
a	M m swa wat	liv mix	26m26 e	.	83.9mg	P<.04
b	M m swa wat	lun mix	26m26 e	.	no dre	P=1. -
o-PHENYLPHENATE, SODIUM				100ng...1ug.....10.....100.....1mg.....10.....100.....1g.....10		
2239	R m f3d eat	unt mix	91w91 er	.	414. mg *	P<.0005+
a	R m f3d eat	ubl mix	91w91 er	.	470. mg	P<.0005
b	R m f3d eat	k/l tcc	91w91 er	.	2.42gm *	P<.0005
o-PHENYLPHENOL				100ng...1ug.....10.....100.....1mg.....10.....100.....1g.....10		
2240	M f b6a orl	liv hpt	76w76 evx	.	no dre	P=1. -
a	M f b6a orl	lun ade	76w76 evx	.	no dre	P=1. -
b	M f b6a orl	tba mix	76w76 evx	.	no dre	P=1. -
2241	M m b6a orl	liv hpt	76w76 evx	.	1.80gm	P<.1. -
a	M m b6a orl	lun ade	76w76 evx	.	no dre	P=1. -
b	M m b6a orl	tba mix	76w76 evx	.	no dre	P=1. -
2242	M f b6c orl	lun ade	76w76 evx	.	221. mg	P<.3 -
a	M f b6c orl	liv hpt	76w76 evx	.	no dre	P=1. -
b	M f b6c orl	tba mix	76w76 evx	.	107. mg	P<.09 -
2243	M m b6c orl	liv hpt	76w76 evx	.	46.1mg	P<.02 -
a	M m b6c orl	lun ade	76w76 evx	.	205. mg	P<.3 -
b	M m b6c orl	tba mix	76w76 evx	.	35.4mg	P<.006 -
p-PHENYLPHENOL				100ng...1ug.....10.....100.....1mg.....10.....100.....1g.....10		
2244	M f b6a orl	lun ade	76w76 evx	.	no dre	P=1. -
a	M f b6a orl	liv hpt	76w76 evx	.	no dre	P=1. -
b	M f b6a orl	tba mix	76w76 evx	.	no dre	P=1. -
2245	M m b6a orl	liv hpt	76w76 evx	.	no dre	P=1. -
a	M m b6a orl	lun ade	76w76 evx	.	no dre	P=1. -
b	M m b6a orl	tba mix	76w76 evx	.	953. mg	P<.7 -
2246	M f b6c orl	liv hpt	76w76 evx	.	no dre	P=1. -
a	M f b6c orl	lun mix	76w76 evx	.	no dre	P=1. -
b	M f b6c orl	tba tum	76w76 evx	.	no dre	P=1. -

Spe	Strain	Site	Xpo+Xpt						TD50	2Tailpvl				
Sex	Route	Hist	Notes						DR	AnOp				
2247	M m b6c	orl	lun ade	76w76	evx	.	±		426.mg	P<.08	-			
a	M m b6c	orl	liv hpt	76w76	evx				no dre	P=1.	-			
b	M m b6c	orl	tba mix	76w76	evx				195.mg	P<.01	-			
PHORBOL				100ng	...	1ug	...	10	...	100	...	1g	...	10
2248	M f aka	ipj	lmr lyk	24m24	er		>		no dre	P=1.	-			
2249	M m aka	ipj	lmr lyk	24m24	er		>		8.26mg	P<.7	-			
2250	M f bal	ipj	lmr tum	24m24	er				no dre	P=1.	-			
2251	M m bal	ipj	lmr tum	24m24	er				no dre	P=1.	-			
2252	M f c3p	ipj	lmr tum	24m24	er				no dre	P=1.	-			
2253	M m c3p	ipj	lmr tum	24m24	er				no dre	P=1.	-			
2254	M f c5l	ipj	lmr tum	24m24	er				no dre	P=1.	-			
2255	M f sja	ipj	lmr rtb	24m24	er				92.6mg	P<.1	-			
2256	M f swr	ipj	lmr lyk	24m24	er		+		2.21mg	P<.0005+	-			
PHOSPHAMIDON*				100ng	...	1ug	...	10	...	100	...	1g	...	10
2257	M f b6c	eat	TBA MXB	80w90			>		215.mg	* P<.8	-			
a	M f b6c	eat	liv MXB	80w90					34.2mg	\ P<.2	-			
b	M f b6c	eat	lun MXB	80w90					no dre	P=1.	-			
2258	M m b6c	eat	TBA MXB	66w90			>		no dre	P=1.	-			
a	M m b6c	eat	liv MXB	66w90					no dre	P=1.	-			
b	M m b6c	eat	lun MXB	66w90					no dre	P=1.	-			
2259	R f osm	eat	TBA MXB	19m26			>		no dre	P=1.	-			
a	R f osm	eat	liv MXB	19m26					no dre	P=1.	-			
2260	R f osm	eat	thy MXA	19m25	pool		:	+						
2261	R m osm	eat	TBA MXB	19m26			>		#19.0mg	* P<.008	-			
a	R m osm	eat	liv MXB	19m26					no dre	P=1.	-			
2262	R m osm	eat	spl MXA	19m25	pool		:	±						
									#26.9mg	* P<.02	-			
PHOSPHATE DISTARCH PHOSPHATE				100ng	...	1ug	...	10	...	100	...	1g	...	10
2263	R f wis	eat	liv tum	24m24	e				no dre	P=1.	-			
a	R f wis	eat	tba mix	24m24	e				no dre	P=1.	-			
2264	R m wis	eat	liv tum	24m24	e				no dre	P=1.	-			
a	R m wis	eat	tba mix	24m24	e				24.4gm	P<.6	-			
PHTHALAMIDE				100ng	...	1ug	...	10	...	100	...	1g	...	10
2265	M f b6c	eat	TBA MXB	24m24	es				no dre	P=1.	-			
a	M f b6c	eat	liv MXB	24m24	es				no dre	P=1.	-			
b	M f b6c	eat	lun MXB	24m24	es				no dre	P=1.	-			
2266	M m b6c	eat	TBA MXB	24m24					>	1090.gm	P<.1			
a	M m b6c	eat	liv MXB	24m24					no dre	P=1.	-			
b	M m b6c	eat	lun MXB	24m24					35.8gm	* P<.5	-			
2267	R f f34	eat	TBA MXB	25m25					>	722.mg	* P<.3			
a	R f f34	eat	liv MXB	25m25					5.39gm	* P<.5	-			
2268	R m f34	eat	TBA MXB	25m25					>	no dre	P=1.			
a	R m f34	eat	liv MXB	25m25					16.6gm	* P<.3	-			
PHTHALIC ANHYDRIDE				100ng	...	1ug	...	10	...	100	...	1g	...	10
2269	M f b6c	eat	TBA MXB	24m24	v				>	no dre	P=1.			
a	M f b6c	eat	liv MXB	24m24	v				no dre	P=1.	-			
b	M f b6c	eat	lun MXB	24m24	v				no dre	P=1.	-			
2270	M m b6c	eat	TBA MXB	24m24	v				>	no dre	P=1.			
a	M m b6c	eat	liv MXB	24m24	v				7.46gm	\ P<.3	-			
b	M m b6c	eat	lun MXB	24m24	v				no dre	P=1.	-			
2271	R f f34	eat	lun a/a	24m24					:	± #6.23gm	* P<.03			
a	R f f34	eat	TBA MXB	24m24					4.50gm	* P<.8	-			
b	R f f34	eat	liv MXB	24m24					no dre	P=1.	-			
2272	R m f34	eat	TBA MXB	24m24					>	no dre	P=1.			
a	R m f34	eat	liv MXB	24m24					no dre	P=1.	-			
PICLORAM				100ng	...	1ug	...	10	...	100	...	1g	...	10
2273	M f b6c	eat	TBA MXB	80w90	v				>	no dre	P=1.			
a	M f b6c	eat	liv MXB	80w90	v				20.1gm	* P<.4	-			
b	M f b6c	eat	lun MXB	80w90	v				no dre	P=1.	-			
2274	M m b6c	eat	TBA MXB	80w90	v				>	no dre	P=1.			
a	M m b6c	eat	liv MXB	80w90	v				no dre	P=1.	-			
b	M m b6c	eat	lun MXB	80w90	v				no dre	P=1.	-			
2275	R f osm	eat	TBA MXB	19m26	v				>	no dre	P=1.			
a	R f osm	eat	liv MXB	19m26	v				1.64gm	* P<.09	-			
2276	R f osm	eat	liv nnd	19m26	v	pool		:	+	1.70gm	* P<.007			
2277	R m osm	eat	TBA MXB	19m26	v				>	2.93gm	* P<.8			
a	R m osm	eat	liv MXB	19m26	v				1.32gm	\ P<.3	-			
PILOCARPINE				100ng	...	1ug	...	10	...	100	...	1g	...	10
2278	R f sda	ipj	tba mal	24m24	e				>	98.4mg	P<.8			
2279	R m sda	ipj	liv hae	24m24	e				>	no dre	P=1.			
a	R m sda	ipj	tba mal	24m24	e				1.75gm	P<.1	-			
PIMARICIN				100ng	...	1ug	...	10	...	100	...	1g	...	10
2280	R f cfn	eat	liv mhp	24m24					>	no dre	P=1.	-		

RefNum	LoConf	UpConf	Cntrl	1Dose	1Inc	2Dose	2Inc	Citation or Pathology	Brkly Code	
2247	1309	105.mg	n.s.s.	0/16	180.mg	2/14				
a	1309	277.mg	n.s.s.	0/16	180.mg	0/14				
b	1309	66.9mg	13.2gm	0/16	180.mg	4/14				
PHORBOL 17673-25-5										
2248	1415	1.35mg	n.s.s.	15/15	4.16mg	11/13		Armuth;bjca,34,516-522;1976		
2249	1415	1.01mg	n.s.s.	10/14	3.47mg	11/14				
2250	1415	58.3mg	n.s.s.	0/53	4.16mg	0/68				
2251	1415	29.3mg	n.s.s.	0/58	3.47mg	0/41				
2252	1415	39.4mg	n.s.s.	0/61	4.16mg	0/46				
2253	1415	42.2mg	n.s.s.	0/41	3.47mg	0/59				
2254	1415	25.7mg	n.s.s.	0/20	4.16mg	0/30				
2255	1415	1.95mg	n.s.s.	26/32	4.16mg	27/33				
2256	1415	1.32mg	4.07mg	3/45	4.16mg	29/39				
PHOSPHAMIDON* 13171-21-6										
2257	c00588	22.4mg	n.s.s.	1/10	9.10mg	11/50	18.3mg	9/50		
a	c00588	14.0mg	n.s.s.	0/10	9.10mg	6/50	(18.3mg	1/50)	Liv:hpa,hpc,nnd.	
b	c00588	81.7mg	n.s.s.	1/10	9.10mg	3/50	18.3mg	1/50	Lun:a/a,a/c.	
2258	c00588	18.4mg	n.s.s.	3/10	7.60mg	14/50	13.2mg	11/50		
a	c00588	23.5mg	n.s.s.	2/10	7.60mg	9/50	13.2mg	7/50	Liv:hpa,hpc,nnd.	
b	c00588	47.9mg	n.s.s.	1/10	7.60mg	3/50	13.2mg	2/50	Lun:a/a,a/c.	
2259	c00588	6.09mg	n.s.s.	7/10	2.90mg	29/50	5.80mg	26/50		
a	c00588	47.0mg	n.s.s.	0/10	2.90mg	1/50	5.80mg	0/50	Liv:hpa,hpc,nnd.	
2260	c00588	9.26mg	361.mg	2/95p	2.90mg	9/50	5.80mg	8/50	thy:cca,ccr. S	
2261	c00588	5.55mg	n.s.s.	4/10	2.30mg	26/50	4.60mg	20/50		
a	c00588	30.2mg	n.s.s.	0/10	2.30mg	0/50	4.60mg	1/50	Liv:hpa,hpc,nnd.	
2262	c00588	10.9mg	n.s.s.	1/95p	2.30mg	3/50	4.60mg	5/50	spl:hem,hes. S	
PHOSPHATED DISTARCH PHOSPHATE ---										
2263	1407	89.6gm	n.s.s.	0/29	15.0gm	0/29			de Groot;fctx,12,651-663;1974	
a	1407	10.4gm	n.s.s.	25/29	15.0gm	22/29				
2264	1407	69.2gm	n.s.s.	0/28	12.0gm	0/28				
a	1407	4.43gm	n.s.s.	21/28	12.0gm	23/28				
PHTHALAMIDE 88-96-0										
2265	c03612	3.07gm	n.s.s.	19/40	806.mg	29/50	1.62gm	27/50	3.25gm	8/50
a	c03612	17.3gm	n.s.s.	4/40	806.mg	2/50	1.62gm	2/50	3.25gm	0/50
b	c03612	15.8gm	n.s.s.	3/40	806.mg	5/50	1.62gm	1/50	3.25gm	0/50
2266	c03612	4.34gm	n.s.s.	15/20	3.00gm	33/50	6.00gm	32/50		
a	c03612	10.8gm	n.s.s.	9/20	3.00gm	17/50	6.00gm	13/50	Liv:hpa,hpc,nnd.	
b	c03612	9.09gm	n.s.s.	3/20	3.00gm	7/50	6.00gm	10/50	Lun:a/a,a/c.	
2267	c03612	217.mg	n.s.s.	14/20	250.mg	39/50	500.mg	39/50		
a	c03612	1.25gm	n.s.s.	2/20	250.mg	2/50	500.mg	6/50	Liv:hpa,hpc,nnd.	
2268	c03612	1.06gm	n.s.s.	17/20	600.mg	43/50	1.20gm	34/50		
a	c03612	5.02gm	n.s.s.	0/20	600.mg	1/50	1.20gm	2/50	Liv:hpa,hpc,nnd.	
PHTHALIC ANHYDRIDE 85-44-9										
2269	c03601	5.42gm	n.s.s.	10/20	1.56gm	21/50	3.12gm	17/50		
a	c03601	25.9gm	n.s.s.	1/20	1.56gm	0/50	3.12gm	1/50	Liv:hpa,hpc,nnd.	
b	c03601	10.7gm	n.s.s.	1/20	1.56gm	6/50	3.12gm	2/50	Lun:a/a,a/c.	
2270	c03601	7.76gm	n.s.s.	11/20	1.96gm	22/50	3.92gm	18/50		
a	c03601	2.27gm	n.s.s.	3/20	1.96gm	12/50	(3.92gm	7/50)	Liv:hpa,hpc,nnd.	
b	c03601	13.3gm	n.s.s.	7/20	1.96gm	6/50	3.92gm	9/50	Lun:a/a,a/c.	
2271	c03601	2.37gm	n.s.s.	0/20	375.mg	0/50	750.mg	5/50		S
a	c03601	511.mg	n.s.s.	13/20	375.mg	37/50	750.mg	36/50	Liv:hpa,hpc,nnd.	
b	c03601	5.50gm	n.s.s.	0/20	375.mg	1/50	750.mg	0/50	Liv:hpa,hpc,nnd.	
2272	c03601	451.mg	n.s.s.	15/20	300.mg	37/50	600.mg	36/50		
a	c03601	4.79gm	n.s.s.	1/20	300.mg	2/50	600.mg	0/50	Liv:hpa,hpc,nnd.	
PICLORAM 1918-02-1										
2273	c00237	1.57gm	n.s.s.	1/10	292.mg	6/50	585.mg	3/50		
a	c00237	3.28gm	n.s.s.	0/10	292.mg	0/50	585.mg	1/50	Liv:hpa,hpc,nnd.	
b	c00237	1.25gm	n.s.s.	1/10	292.mg	1/50	(585.mg	0/50)	Lun:a/a,a/c.	
2274	c00237	688.mg	n.s.s.	5/10	270.mg	18/50	540.mg	14/50		
a	c00237	398.mg	n.s.s.	5/10	270.mg	13/50	(540.mg	8/50)	Liv:hpa,hpc,nnd.	
b	c00237	1.33gm	n.s.s.	1/10	270.mg	5/50	540.mg	3/50	Lun:a/a,a/c.	
2275	c00237	397.mg	n.s.s.	7/10	263.mg	32/50	527.mg	33/50		
a	c00237	864.mg	n.s.s.	0/10	263.mg	5/50	527.mg	8/50	Liv:hpa,hpc,nnd.	
2276	c00237	873.mg	23.4gm	0/40p	263.mg	5/50	527.mg	7/50		
2277	c00237	290.mg	n.s.s.	3/10	210.mg	28/50	422.mg	22/50		
a	c00237	456.mg	n.s.s.	0/10	210.mg	4/50	(422.mg	0/50)	Liv:hpa,hpc,nnd.	
PILOCARPINE 92-13-7										
2278	1134	10.1mg	n.s.s.	3/33	4.29mg	4/34			Schmahl;zkko,86,77-84;1976	
2279	1134	30.0mg	n.s.s.	1/36	4.29mg	0/34				
a	1134	18.1mg	n.s.s.	1/36	4.29mg	1/34				
PIMARICIN 7681-93-8										
2280	240	639.mg	n.s.s.	1/40	6.25mg	1/35	12.5mg	0/35	25.0mg	0/35
								50.0mg	0/40	Levinskas;txap,8,97-109;1966

Spe	Strain	Site	Xpo+Xpt		TD50	2Tailpvl
Sex	Route	Hist	Notes		DR	AuOp
2281	R m cfn eat	lun lys	24m24	>	1.97gm *	P<.5 -
a	R m cfn eat	thm tms	24m24		no dre	P=1. -
PIPERAZINE				100ng...1ug...10...100...1mg...10...100...1g...10		
2282	R f mrc wat	liv tum	17m24 e	>	no dre	P=1.
a	R f mrc wat	tba mix	17m24 e		11.2mg	P<.2
2283	R m mrc wat	liv tum	17m24 e	>	no dre	P=1.
a	R m mrc wat	tba mix	17m24 e		no dre	P=1.
PIPERIDINE				100ng...1ug...10...100...1mg...10...100...1g...10		
2284	R f mrc wat	liv tum	17m24 e	>	no dre	P=1.
a	R f mrc wat	tba mix	17m24 e		63.3mg	P<.3
2285	R m mrc wat	liv tum	17m24 e	>	no dre	P=1.
a	R m mrc wat	tba mix	17m24 e		no dre	P=1.
PIPERONYL BUTOXIDE				100ng...1ug...10...100...1mg...10...100...1g...10		
2286	M f b6c eat	TBA MXB	26m26 v	>	no dre	P=1. -
a	M f b6c eat	liv MXB	26m26 v		3.26gm *	P<.3
b	M f b6c eat	lun MXB	26m26 v		no dre	P=1.
2287	M f b6c orl	liv hpt	76w76 evx	>	no dre	P=1.
a	M f b6c orl	lun mix	76w76 evx		no dre	P=1.
b	M f b6c orl	tba mix	76w76 evx		83.1mg	P<.05
2288	M m b6c eat	TBA MXB	26m26 v	>	no dre	P=1. -
a	M m b6c eat	liv MXB	26m26 v		no dre	P=1.
b	M m b6c eat	lun MXB	26m26 v		no dre	P=1.
2289	M m b6c orl	--- rts	76w76 evx	.	34.8mg	P<.005
a	M m b6c orl	liv hpt	76w76 evx	.	98.5mg	P<.09
b	M m b6c orl	lun mix	76w76 evx		no dre	P=1.
c	M m b6c orl	tba mix	76w76 evx		22.4mg	P<.0005
2290	M f b6a orl	lun ade	76w76 evx	>	265. mg	P<.6
a	M f b6a orl	liv hpt	76w76 evx		no dre	P=1.
b	M f b6a orl	tba mix	76w76 evx		265. mg	P<.7
2291	M m b6a orl	lun ade	76w76 evx	>	no dre	P=1.
a	M m b6a orl	liv hpt	76w76 evx		no dre	P=1.
b	M m b6a orl	tba mix	76w76 evx		no dre	P=1.
2292	R f f34 eat	--- lym	25m25	.	#1.18gm *	P<.008 -
a	R f f34 eat	TBA MXB	25m25	.	7.82gm *	P<.9
b	R f f34 eat	liv MXB	25m25		no dre	P=1.
2293	R m f34 eat	TBA MXB	25m25	>	no dre	P=1. -
a	R m f34 eat	liv MXB	25m25		no dre	P=1.
2294	R b wis eat	liv hpt	22m24 sv	>	22.5gm *	P<.5 -
a	R b wis eat	liv hpc	22m24 sv		26.1gm *	P<.2 -
PIPERONYL BUTOXIDE IN SOLVENT				100ng...1ug...10...100...1mg...10...100...1g...10		
2295	M f b6a orl	lun ade	76w76 evx	>	no dre	P=1. -
a	M f b6a orl	liv hpt	76w76 evx		no dre	P=1. -
b	M f b6a orl	tba mix	76w76 evx		1.01gm	P<.7 -
2296	M m b6a orl	liv hpt	76w76 evx	>	no dre	P=1. -
a	M m b6a orl	lun ade	76w76 evx		no dre	P=1. -
b	M m b6a orl	tba mix	76w76 evx		no dre	P=1. -
2297	M f b6c orl	liv hpt	76w76 evx	>	no dre	P=1. -
a	M f b6c orl	lun mix	76w76 evx		no dre	P=1. -
b	M f b6c orl	tba tum	76w76 evx		no dre	P=1. -
2298	M m b6c orl	liv hpt	76w76 evx	.	186. mg	P<.02 -
a	M m b6c orl	lun mix	76w76 evx		no dre	P=1. -
b	M m b6c orl	tba mix	76w76 evx		93.1mg	P<.002 -
PIPERONYL SULFOXIDE				100ng...1ug...10...100...1mg...10...100...1g...10		
2299	M f b6c eat	TBA MXB	24m24 av	>	no dre	P=1. -
a	M f b6c eat	liv MXB	24m24 av		725. mg *	P<.3
b	M f b6c eat	lun MXB	24m24 av		no dre	P=1.
2300	M f b6c orl	liv hpt	76w76 evx	>	no dre	P=1.
a	M f b6c orl	lun mix	76w76 evx		no dre	P=1.
b	M f b6c orl	tba mix	76w76 evx		100. mg	P<.3
2301	M m b6c eat	liv hpc	24m24 a	.	62.2mg *	P<.02 c
a	M m b6c eat	TBA MXB	24m24 a	.	423. mg *	P<.8
b	M m b6c eat	liv MXB	24m24 a		62.2mg *	P<.02
c	M m b6c eat	lun MXB	24m24 a		no dre	P=1.
2302	M m b6c orl	--- rts	76w76 evx	.	9.10mg	P<.0005
a	M m b6c orl	liv hpt	76w76 evx		45.4mg	P<.2
b	M m b6c orl	lun mix	76w76 evx		no dre	P=1.
c	M m b6c orl	tba mix	76w76 evx		7.72mg	P<.0005
2303	M f b6a orl	lun ade	76w76 evx	>	no dre	P=1.
a	M f b6a orl	liv hpt	76w76 evx		no dre	P=1.
b	M f b6a orl	tba mix	76w76 evx		no dre	P=1.
2304	M m b6a orl	liv hpt	76w76 evx	>	88.2mg	P<.6
a	M m b6a orl	lun ade	76w76 evx		no dre	P=1.
b	M m b6a orl	tba mix	76w76 evx		no dre	P=1.

CARCINOGENIC POTENCY DATABASE

RefNum	LoConf	UpConf	Cntrl	1Dose	1Inc	2Dose	2Inc	Citation or Pathology	Brkly Code
2281	240	320.mg n.s.s.	0/40	5.00mg	0/35	10.0mg	0/35	20.0mg 1/35 40.0mg 0/40	
a	240	350.mg n.s.s.	0/40	5.00mg	0/35	10.0mg	1/35	20.0mg 0/35 40.0mg 0/40	
PIPERAZINE 110-85-0									
2282	216	22.7mg n.s.s.	0/15	7.36mg	0/15			Garcia;zkko,79,141-144;1977	
a	216	3.42mg n.s.s.	4/15	7.36mg	8/15				
2283	216	19.9mg n.s.s.	0/15	6.44mg	0/15				
a	216	5.79mg n.s.s.	5/15	6.44mg	5/15				
PIPERIDINE 110-89-4									
2284	216	91.0mg n.s.s.	0/15	29.4mg	0/15			Garcia;zkko,79,141-144;1973	
a	216	16.4mg n.s.s.	4/15	29.4mg	7/15				
2285	216	79.6mg n.s.s.	0/15	25.8mg	0/15				
a	216	29.2mg n.s.s.	5/15	25.8mg	4/15				
PIPERONYL BUTOXIDE 51-03-6									
2286	c02813	241.mg n.s.s.	15/20	135.mg	22/50	(364.mg	20/50)		
a	c02813	929.mg n.s.s.	1/20	135.mg	2/50	364.mg	5/50	liv:hpa,hpc,nnd.	
b	c02813	1.49gm n.s.s.	2/20	135.mg	6/50	364.mg	2/50	lun:a/a,a/c.	
2287	1096	82.0mg n.s.s.	0/16	41.4mg	0/18			Innes;ntis,1968/1969	
a	1096	82.0mg n.s.s.	0/16	41.4mg	0/18				
b	1096	25.1mg n.s.s.	0/16	41.4mg	3/18				
2288	c02813	406.mg n.s.s.	16/20	124.mg	32/50	336.mg	31/50		
a	c02813	528.mg n.s.s.	10/20	124.mg	17/50	336.mg	20/50	liv:hpa,hpc,nnd.	
b	c02813	998.mg n.s.s.	5/20	124.mg	6/50	336.mg	8/50	lun:a/a,a/c.	
2289	1096	13.1mg 274.mg	0/16	38.5mg	5/15			Innes;ntis,1968/1969	
a	1096	24.2mg n.s.s.	0/16	38.5mg	2/15				
b	1096	63.6mg n.s.s.	0/16	38.5mg	0/15				
c	1096	9.48mg 78.6mg	0/16	38.5mg	7/15				
2290	1096	34.8mg n.s.s.	1/17	41.4mg	2/18				
a	1096	82.0mg n.s.s.	0/17	41.4mg	0/18				
b	1096	29.7mg n.s.s.	2/17	41.4mg	3/18				
2291	1096	50.5mg n.s.s.	2/18	38.5mg	1/18				
a	1096	76.3mg n.s.s.	1/18	38.5mg	0/18				
b	1096	54.0mg n.s.s.	3/18	38.5mg	1/18				
2292	c02813	631.mg 27.1gm	1/20	250.mg	7/50	500.mg	15/50		S
a	c02813	422.mg n.s.s.	15/20	250.mg	33/50	500.mg	33/50		
b	c02813	n.s.s. n.s.s.	0/20	250.mg	0/50	500.mg	0/50	liv:hpa,hpc,nnd.	
2293	c02813	384.mg n.s.s.	14/20	200.mg	34/50	400.mg	32/50		
a	c02813	5.20gm n.s.s.	2/20	200.mg	0/50	400.mg	0/50	liv:hpa,hpc,nnd.	
2294	241	3.48gm n.s.s.	1/24	4.50mg	0/24	45.0mg	0/24	450.mg 1/24 1.11gm 1/24	Sarles;atmh,1,862-883;1952
a	241	4.25gm n.s.s.	0/24	4.50mg	0/24	45.0mg	0/24	450.mg 0/24 1.11gm 1/24	
PIPERONYL BUTOXIDE IN SOLVENT (butoxide) ---									
2295	1097	187.mg n.s.s.	1/17	157.mg	1/18			Innes;ntis,1968/1969	
a	1097	311.mg n.s.s.	0/17	157.mg	0/18				
b	1097	113.mg n.s.s.	2/17	157.mg	3/18				
2296	1097	173.mg n.s.s.	1/18	146.mg	1/18				
a	1097	192.mg n.s.s.	2/18	146.mg	1/18				
b	1097	115.mg n.s.s.	3/18	146.mg	3/18				
2297	1097	311.mg n.s.s.	0/16	157.mg	0/18				
a	1097	311.mg n.s.s.	0/16	157.mg	0/18				
b	1097	311.mg n.s.s.	0/16	157.mg	0/18				
2298	1097	63.9mg n.s.s.	0/16	146.mg	4/16				
a	1097	258.mg n.s.s.	0/16	146.mg	0/16				
b	1097	39.5mg 340.mg	0/16	146.mg	7/16				
PIPERONYL SULFOXIDE 120-62-7									
2299	c02824	110.mg n.s.s.	10/20	38.3mg	23/50	98.0mg	25/50		
a	c02824	215.mg n.s.s.	1/20	38.3mg	3/50	98.0mg	6/50	liv:hpa,hpc,nnd.	
b	c02824	523.mg n.s.s.	2/20	38.3mg	2/50	98.0mg	2/50	lun:a/a,a/c.	
2300	1099	31.1mg n.s.s.	0/16	15.7mg	0/18			Innes;ntis,1968/1969	
a	1099	31.1mg n.s.s.	0/16	15.7mg	0/18				
b	1099	16.3mg n.s.s.	0/16	15.7mg	1/18				
2301	c02824	31.0mg n.s.s.	6/20	42.2mg	31/50	84.0mg	46/50		
a	c02824	46.4mg n.s.s.	14/20	42.2mg	39/50	84.0mg	47/50		
b	c02824	31.0mg n.s.s.	6/20	42.2mg	31/50	84.0mg	46/50	liv:hpa,hpc,nnd.	
c	c02824	106.mg n.s.s.	6/20	42.2mg	10/50	(84.0mg	7/50)	lun:a/a,a/c.	
2302	1099	4.05mg 29.9mg	0/16	14.6mg	8/18			Innes;ntis,1968/1969	
a	1099	11.2mg n.s.s.	0/16	14.6mg	2/18				
b	1099	29.0mg n.s.s.	0/16	14.6mg	0/18				
c	1099	3.56mg 22.2mg	0/16	14.6mg	9/18				
2303	1099	17.5mg n.s.s.	1/17	15.7mg	1/17				
a	1099	29.3mg n.s.s.	0/17	15.7mg	0/17				
b	1099	13.8mg n.s.s.	2/17	15.7mg	2/17				
2304	1099	12.3mg n.s.s.	1/18	14.6mg	2/18				
a	1099	29.0mg n.s.s.	2/18	14.6mg	0/18				
b	1099	15.1mg n.s.s.	3/18	14.6mg	2/18				

Spe	Strain	Site	Xpo+Xpt	Notes	TD50	2Tailpvl
Sex	Route	Hist			DR	AuOp
2305	R f	f34 eat	TBA MXB 24m24			2.30gm * P<.8 -
a	R f	f34 eat	liv MXB 24m24	>		no dre P=1.
2306	R m	f34 eat	TBA MXB 24m24			no dre P=1. -
a	R m	f34 eat	liv MXB 24m24	>		2.65gm * P<.6
PIVALOLACTONE						
2307	M f	b6c gav	TBA MXB 24m24		100ng...1ug...10...100...1mg...10...100...1g...10	179.mg * P<.3 -
a	M f	b6c gav	liv MXB 24m24	>		no dre P=1.
b	M f	b6c gav	lun MXB 24m24			482.mg * P<.6
2308	M m	b6c gav	TBA MXB 24m24			no dre P=1. -
a	M m	b6c gav	liv MXB 24m24	>		no dre P=1.
b	M m	b6c gav	lun MXB 24m24			435.mg * P<.5
2309	R f	f34 gav	sto MXA 24m24			333.mg / P<.002 c
a	R f	f34 gav	TBA MXB 24m24		: + :	200.mg * P<.3
b	R f	f34 gav	liv MXB 24m24			no dre P=1.
2310	R m	f34 gav	sto MXA 24m24			154.mg * P<.0005c
a	R m	f34 gav	sto sqc 24m24		: + :	532.mg * P<.009 c
b	R m	f34 gav	TBA MXB 24m24			181.mg * P<.2
c	R m	f34 gav	liv MXB 24m24			850.mg * P<.3
POLYBROMINATED BIPHENYLS						
2311	R f	sss eat	liv tum 57w57		100ng...1ug...10...100...1mg...10...100...1g...10	no dre P=1. -
a	R f	sss eat	tba mix 57w57	>		5.91mg P<.4 -
POLYVINYLPIRIDINE-N-OXIDE						
2312	M f	ici ivj	lun ade 17m24		100ng...1ug...10...100...1mg...10...100...1g...10	no dre P=1. -
a	M f	ici ivj	tba mal 17m24	>		no dre P=1. -
b	M f	ici ivj	tba ben 17m24			1.69gm P<.1. -
2313	R f	wis ivj	tba mal 17m24			175.mg P<.8 -
a	R f	wis ivj	tba ben 17m24	>		no dre P=1. -
PREMARIN						
2314	R f	cdr eat	liv tum 24m24 e		100ng...1ug...10...100...1mg...10...100...1g...10	no dre P=1. -
2315	R m	cdr eat	liv hpt 24m24 e	>		no dre P=1. -
PROCARBAZINE						
2316	R m	b46 ivj	tba mix 12m24		100ng...1ug...10...100...1mg...10...100...1g...10	4.01mg P<.002 +
a	R m	b46 ivj	tba mal 12m24			3.93mg P<.0005
b	R m	b46 ivj	tba ben 12m24			no dre P=1.
PROCARBAZINE.HCL						
2317	M f	b6c ipj	MXB MXB 52w85 s		100ng...1ug...10...100...1mg...10...100...1g...10	.194mg / P<.0005
a	M f	b6c ipj	ute acn 52w85 s			.253mg / P<.0005c
b	M f	b6c ipj	--- MXA 52w85 s			.758mg * P<.0005c
c	M f	b6c ipj	--- lym 52w85 s			.908mg * P<.002 c
d	M f	b6c ipj	lun a/a 52w85 s			3.83mg / P<.002 c
e	M f	b6c ipj	bra oln 52w85 s			6.34mg / P<.0005c
f	M f	b6c ipj	TBA MXB 52w85 s			.193mg / P<.0005
g	M f	b6c ipj	liv MXB 52w85 s			no dre P=1.
h	M f	b6c ipj	lun MXB 52w85 s			3.83mg / P<.002
2318	M f	b6c ipj	ute acn 52w80 s	pool		.411mg / P<.0005c
a	M f	b6c ipj	--- MXA 52w80 s		: + :	.690mg * P<.0005c
b	M f	b6c ipj	--- lym 52w80 s			.855mg * P<.0005c
c	M f	b6c ipj	lun a/a 52w80 s			3.39mg / P<.0005c
d	M f	b6c ipj	bra oln 52w80 s			5.62mg / P<.0005c
2319	M m	b6c ipj	MXB MXB 52w85 s			.511mg / P<.0005
a	M m	b6c ipj	lun MXA 52w85 s		: + :	.623mg / P<.0005c
b	M m	b6c ipj	lun a/a 52w85 s			.721mg / P<.0005c
c	M m	b6c ipj	--- MXA 52w85 s			3.34mg * P<.009 c
d	M m	b6c ipj	bra MXA 52w85 s			4.51mg / P<.0005c
e	M m	b6c ipj	bra oln 52w85 s			5.19mg / P<.0005c
f	M m	b6c ipj	TBA MXB 52w85 s			.464mg / P<.0005
g	M m	b6c ipj	liv MXB 52w85 s			3.28mg / P<.01
h	M m	b6c ipj	lun MXB 52w85 s			.623mg / P<.0005
2320	M m	b6c ipj	lun MXA 52w85 s	pool		.623mg / P<.0005c
a	M m	b6c ipj	lun a/a 52w85 s		: + :	.721mg / P<.0005c
b	M m	b6c ipj	--- MXA 52w85 s			3.34mg * P<.002 c
c	M m	b6c ipj	bra MXA 52w85 s			4.51mg / P<.0005c
d	M m	b6c ipj	bra oln 52w85 s			5.19mg / P<.0005c
2321	M f	swi ipj	lun mix 26w76 e			1.05mg P<.0005+
a	M f	swi ipj	--- lau 26w76 e			3.72mg P<.0005
b	M f	swi ipj	ute car 26w76 e			5.75mg P<.004
c	M f	swi ipj	ute ear 26w76 e			6.11mg P<.03
d	M f	swi ipj	--- lys 26w76 e			6.99mg P<.09 +
e	M f	swi ipj	liv lys 26w76 e			no dre P=1.
f	M f	swi ipj	tba mix 26w76 e			.244mg P<.0005
g	M f	swi ipj	tba mal 26w76 e			.391mg P<.0005
h	M f	swi ipj	tba ben 26w76 e			27.8mg P<.8

RefNum	LoConf	UpConf	Cntrl	1Dose	1Inc	2Dose	2Inc	Citation or Pathology	Brkly Code
2305	c02824	283.mg n.s.s.	12/20	150.mg	24/50	300.mg	27/50		
a	c02824	n.s.s. n.s.s.	0/20	150.mg	0/50	300.mg	0/50		liv:hpa,hpc,nnd.
2306	c02824	60.1mg n.s.s.	15/20	60.0mg	32/50	(120.mg	22/50)		
a	c02824	651.mg n.s.s.	0/20	60.0mg	1/50	120.mg	1/50		liv:hpa,hpc,nnd.
PIVALOLACTONE 1955-45-9									
2307	c04126	55.7mg n.s.s.	6/20	31.8mg	20/50	63.7mg	22/50		
a	c04126	340.mg n.s.s.	0/20	31.8mg	2/50	63.7mg	0/50		liv:hpa,hpc,nnd.
b	c04126	161.mg n.s.s.	0/20	31.8mg	4/50	63.7mg	2/50		lun:a/a,a/c.
2308	c04126	97.0mg n.s.s.	12/20	31.8mg	24/50	63.7mg	25/50		
a	c04126	64.1mg n.s.s.	4/20	31.8mg	10/50	(63.7mg	4/50)		liv:hpa,hpc,nnd.
b	c04126	114.mg n.s.s.	2/20	31.8mg	6/50	63.7mg	10/50		lun:a/a,a/c.
2309	c04126	175.mg 1.03gm	0/20	63.1mg	2/50	126.mg	11/50		sto:sgc,sgp.
a	c04126	62.5mg n.s.s.	14/20	63.1mg	35/50	126.mg	34/50		
b	c04126	n.s.s. n.s.s.	0/20	63.1mg	0/50	126.mg	0/50		liv:hpa,hpc,nnd.
2310	c04126	96.7mg 293.mg	0/20	63.1mg	6/50	126.mg	21/50		sto:sgc,sgp.
a	c04126	241.mg 12.5gm	0/20	63.1mg	1/50	126.mg	7/50		
b	c04126	66.4mg n.s.s.	11/20	63.1mg	29/50	126.mg	34/50		
c	c04126	323.mg n.s.s.	0/20	63.1mg	3/50	126.mg	2/50		liv:hpa,hpc,nnd.
POLYBROMINATED BIPHENYLS 59536-61-1									
2311	1061	1.86mg n.s.s.	0/8	2.50mg	0/12			Schwartz;jnci,64,63-67;1980	
a	1061	.962mg n.s.s.	0/8	2.50mg	1/12				
POLYVINYLPIRIDINE-N-OXIDE ---									
2312	1419	48.0mg n.s.s.	3/39	8.24mg	2/50			Schmahl;arzn,19,1313-1314;1969	
a	1419	14.9mg n.s.s.	14/39	8.24mg	17/50				
b	1419	30.9mg n.s.s.	3/39	8.24mg	4/50				
2313	1419	18.2mg n.s.s.	4/48	5.89mg	5/48				
a	1419	21.8mg n.s.s.	4/48	5.89mg	4/48				
PREMARIN (conjugated equine estrogens) ---									
2314	108	.262mg n.s.s.	0/20	70.0ug	0/20	.700mg	0/20	Gibson;txep,11,489-510;1967	
2315	108	2.32mg n.s.s.	0/20	70.0ug	1/20	.700mg	0/20		
PROCARBAZINE 671-16-9									
2316	1017	1.92mg 17.2mg	7/89	1.71mg	15/48			Schmahl;arzn,20,1461-1467;1970	
a	1017	1.95mg 12.4mg	4/89	1.71mg	14/48				
b	1017	11.4mg n.s.s.	3/89	1.71mg	1/48				
PROCARBAZINE.HCl 366-70-1									
2317	c01810	65.1ug .432mg	0/15	2.00mg	19/35	5.20mg	18/35	---:leu,lym; bra:oln; lun:a/a; ute:acn. C	
a	c01810	68.9ug .728mg	0/15	2.00mg	14/35	5.20mg	8/35		
b	c01810	.289mg 2.96mg	0/15	2.00mg	8/35	5.20mg	2/35		---:leu,lym.
c	c01810	.308mg 5.34mg	0/15	2.00mg	6/35	5.20mg	2/35		
d	c01810	1.05mg 19.5mg	0/15	2.00mg	1/35	5.20mg	6/35		
a	c01810	2.93mg 16.6mg	0/15	2.00mg	0/35	5.20mg	11/35		
f	c01810	65.0ug .422mg	0/15	2.00mg	19/35	5.20mg	20/35		
g	c01810	n.s.s. n.s.s.	0/15	2.00mg	0/35	5.20mg	0/35		liv:hpa,hpc,nnd.
h	c01810	1.05mg 19.5mg	0/15	2.00mg	1/35	5.20mg	6/35		lun:a/a,a/c.
2318	c01810	.203mg .834mg	0/45p	2.00mg	14/35	5.20mg	8/35		
a	c01810	.258mg 2.69mg	1/45p	2.00mg	8/35	5.20mg	2/35		---:leu,lym.
b	c01810	.283mg 4.57mg	1/45p	2.00mg	6/35	5.20mg	2/35		
c	c01810	.927mg 13.6mg	0/45p	2.00mg	1/35	5.20mg	6/35		
d	c01810	2.60mg 13.2mg	0/45p	2.00mg	0/35	5.20mg	11/35		
2319	c01810	.289mg .947mg	0/15	1.90mg	14/35	4.80mg	19/35	---:leu,lym; bra:oln,ulc; lun:a/a,a/c. C	
a	c01810	.323mg 1.39mg	0/15	1.90mg	11/35	4.80mg	10/35		lun:a/a,a/c.
b	c01810	.369mg 1.63mg	0/15	1.90mg	10/35	4.80mg	10/35		
c	c01810	1.36mg 135.mg	0/15	1.90mg	4/35	4.80mg	4/35		---:leu,lym.
d	c01810	2.07mg 13.1mg	0/15	1.90mg	0/35	4.80mg	10/35		bra:oln,ulc.
e	c01810	2.28mg 17.1mg	0/15	1.90mg	0/35	4.80mg	9/35		
f	c01810	.271mg .821mg	0/15	1.90mg	18/35	4.80mg	20/35		
g	c01810	1.27mg 222.mg	0/15	1.90mg	3/35	4.80mg	3/35		liv:hpa,hpc,nnd.
h	c01810	.323mg 1.39mg	0/15	1.90mg	11/35	4.80mg	10/35		lun:a/a,a/c.
2320	c01810	.323mg 1.31mg	0/45p	1.90mg	11/35	4.80mg	10/35		lun:a/a,a/c.
a	c01810	.369mg 1.53mg	0/45p	1.90mg	10/35	4.80mg	10/35		
b	c01810	1.36mg 13.8mg	0/45p	1.90mg	4/35	4.80mg	4/35		---:leu,lym.
c	c01810	2.07mg 11.7mg	0/45p	1.90mg	0/35	4.80mg	10/35		bra:oln,ulc.
d	c01810	2.28mg 14.6mg	0/45p	1.90mg	0/35	4.80mg	9/35		
2321	1336	.446mg 4.68mg	20/154	1.75mg	10/19			Skipper;arfr;1976/Weisburger 1977/Prejean pers.comm.	
a	1336	1.12mg 26.7mg	0/154	1.75mg	3/19				
b	1336	1.41mg 82.8mg	0/154	1.75mg	2/19				
c	1336	1.43mg n.s.s.	1/154	1.75mg	2/19				
d	1336	1.47mg n.s.s.	3/154	1.75mg	2/19				
e	1336	3.66mg n.s.s.	1/154	1.75mg	0/19				
f	1336	92.6ug .683mg	42/154	1.75mg	18/19				
g	1336	.181mg 1.03mg	29/154	1.75mg	16/19				
h	1336	1.74mg n.s.s.	13/154	1.75mg	2/19				

Spe	Strain	Site	Xpo+Xpt		TD50	ZTallpvl
Sex	Route	Hist	Notes		DR	AuOp
2322	M m swi ipj	lun mix	26w78 e	.	1.53mg	P<.0005+
a	M m swi ipj	liv mix	26w78 e	.	no dre	P=1.
b	M m swi ipj	tba mix	26w78 e	.	1.15mg	P<.004
c	M m swi ipj	tba msl	26w78 e	.	1.74mg	P<.009
d	M m swi ipj	tba ben	26w78 e	.	9.84mg	P<.4
2323	P b cym mix	---	ost 12y13 emuw	.	8.70mg	P<.02 +
a	P b cym mix	---	lka 12y13 emuw	.	8.70mg	P<.02 +
b	P b cym mix	---	mlk 12y13 emuw	.	18.2mg	P<.1 +
c	P b cym mix	---	lcl 12y13 emuw	.	18.2mg	P<.1 +
d	P b cym mix	---	ule 12y13 emuw	.	18.2mg	P<.1 +
e	P b cym mix	spl	hes 12y13 emuw	.	18.2mg	P<.1 +
f	P b cym mix	hum	ost 12y13 emuw	.	18.2mg	P<.1 +
g	P b cym mix	jaw	ost 12y13 emuw	.	18.2mg	P<.1 +
h	P b cym mix	liv	aal 12y13 emuw	.	no dre	P=1.
i	P b cym mix	tba	aal 12y13 emuw	.	3.17mg	P<.002
2324	P b rhe mix	---	lka 14y14 emuw	.	9.50mg	P<.002 +
a	P b rhe mix	---	mlk 14y14 emuw	.	9.50mg	P<.002 +
b	P b rhe mix	---	ost 14y14 emuw	.	53.3mg	P<.2 +
c	P b rhe mix	hum	ost 14y14 emuw	.	53.3mg	P<.2 +
d	P b rhe mix	kid	has 14y14 emuw	.	53.3mg	P<.2 +
e	P b rhe mix	liv	aal 14y14 emuw	.	no dre	P=1.
f	P b rhe mix	tba	aal 14y14 emuw	.	5.35mg	P<.0005
2325	R f sda ipj	MXB MXB	26w86 s	:	.337mg	/ P<.0005
a	R f sda ipj	MXA MXA	26w86 s	:	.416mg	* P<.0005c
b	R f sda ipj	bra	oln 26w86 s	:	.418mg	* P<.0005c
c	R f sda ipj	mgl	MXA 26w86 s	:	.458mg	/ P<.0005c
d	R f sda ipj	mgl	acn 26w86 s	:	.459mg	/ P<.0005c
e	R f sda ipj	---	lym 26w86 s	:	5.18mg	/ P<.0005c
f	R f sda ipj	TBA	MXB 26w86 s	:	.329mg	/ P<.0005
g	R f sda ipj	liv	MXB 26w86 s	:	no dre	P=1.
2326	R f sda ipj	MXA MXA	26w80 s	:	.360mg	* P<.0005c
a	R f sda ipj	bra	oln 26w80 s	:	.361mg	* P<.0005c
b	R f sda ipj	mgl	MXA 26w80 s	:	.396mg	/ P<.0005c
c	R f sda ipj	mgl	acn 26w80 s	:	.397mg	/ P<.0005c
d	R f sda ipj	---	lym 26w80 s	:	4.48mg	/ P<.0005c
2327	R m sda ipj	MXB MXB	26w61 s	:	.284mg	* P<.0005
a	R m sda ipj	MXA MXA	26w61 s	:	.343mg	* P<.0005c
b	R m sda ipj	---	MXA 26w61 s	:	2.10mg	* P<.0005c
c	R m sda ipj	mgl	MXA 26w61 s	:	4.50mg	* P<.003 c
d	R m sda ipj	mgl	acn 26w61 s	:	4.85mg	* P<.004 c
e	R m sda ipj	TBA	MXB 26w61 s	:	.186mg	/ P<.0005
f	R m sda ipj	liv	MXB 26w61 s	:	no dre	P=1.
2328	R m sda ipj	MXA MXA	26w61 s	:	.343mg	* P<.0005c
a	R m sda ipj	---	MXA 26w61 s	:	2.10mg	* P<.0005c
b	R m sda ipj	---	lym 26w61 s	:	2.51mg	* P<.0005c
c	R m sda ipj	mgl	MXA 26w61 s	:	4.50mg	* P<.0005c
d	R m sda ipj	olb	acn 26w61 s	:	4.67mg	* P<.003
e	R m sda ipj	mgl	acn 26w61 s	:	4.85mg	* P<.0005c
f	R m sda ipj	---	leu 26w61 s	:	13.3mg	* P<.02
PROFLAVINE.HCL HEMIHYDRATE*				100ng...1ug...10...100...1mg...10...100...1g...10		
2329	M f b6c eat	liv	MXA 24m24	:	#26.4mg	\ P<.0005
a	M f b6c eat	TBA	MXB 24m24	:	86.2mg	* P<.3
b	M f b6c eat	liv	MXB 24m24	:	26.4mg	\ P<.0005
c	M f b6c eat	lun	MXB 24m24	:	487.mg	* P<.5
2330	M m b6c eat	TBA	MXB 24m24	>	no dre	P=1.
a	M m b6c eat	liv	MXB 24m24	>	248.mg	* P<.7
b	M m b6c eat	lun	MXB 24m24	>	no dre	P=1.
2331	R f f34 eat	TBA	MXB 25m25	>	no dre	P=1.
a	R f f34 eat	liv	MXB 25m25	>	no dre	P=1.
2332	R m f34 eat	MXA MXA	25m25	:	#213.mg	* P<.02
a	R m f34 eat	liv	MXA 25m25	:	254.mg	* P<.05
b	R m f34 eat	TBA	MXB 25m25	:	no dre	P=1.
c	R m f34 eat	liv	MXB 25m25	:	254.mg	* P<.05
PRONETHALOL				100ng...1ug...10...100...1mg...10...100...1g...10		
2333	M f nsa eat	thm	tum 64w64 r	>	408.mg	* P<.3
2334	M m nsa eat	thm	tum 64w64 r	>	1.93gm	* P<.7
PRONETHALOL.HCL				100ng...1ug...10...100...1mg...10...100...1g...10		
2335	M f cf1 eat	lun	ade 78w78 e	>	1.30gm	P<.6 -
a	M f cf1 eat	liv	tum 78w78 e	>	no dre	P=1. -
2336	M m cf1 eat	lun	ade 78w78 e	>	931.mg	P<.5 -
a	M m cf1 eat	liv	ade 78w78 e	>	1.82gm	P<.3 -
b	M m cf1 eat	liv	car 78w78 e	>	no dre	P=1. -
PROPANE SULTONE				100ng...1ug...10...100...1mg...10...100...1g...10		
2337	R f cdr gav	crb	mag 46w60 ees	.	4.06mg	* P<.1 +
a	R f cdr gav	mgl	adc 46w60 ees	.	4.13mg	* P<.02 +

RefNum	LoConf	UpConf	Cntrl	1Dose	1Inc	2Dose	2Inc	Citation or Pathology	Brkly Code		
2322	1336	.683mg	6.43mg	9/101	1.71mg	11/27					
a	1336	5.35mg	n.s.s.	2/101	1.71mg	0/27					
b	1336	.492mg	9.99mg	28/101	1.71mg	16/27					
c	1336	.689mg	94.8mg	19/101	1.71mg	12/27					
d	1336	1.74mg	n.s.s.	9/101	1.71mg	4/27					
2323	2000	2.13mg	n.s.s.	0/38	4.68mg	2/13		Adams;ogsc,129-156;1982/Sieber pers.com.			
a	2000	2.13mg	n.s.s.	0/38	4.68mg	2/13					
b	2000	2.95mg	n.s.s.	0/38	4.68mg	1/13					
c	2000	2.95mg	n.s.s.	0/38	4.68mg	1/13					
d	2000	2.95mg	n.s.s.	0/38	4.68mg	1/13					
e	2000	2.95mg	n.s.s.	0/38	4.68mg	1/13					
f	2000	2.95mg	n.s.s.	0/38	4.68mg	1/13					
g	2000	2.95mg	n.s.s.	0/38	4.68mg	1/13					
h	2000	5.68mg	n.s.s.	0/38	4.68mg	0/13					
i	2000	1.14mg	21.2mg	1/38	4.68mg	5/13					
2324	2000	3.59mg	46.3mg	0/32	8.17mg	5/20					
a	2000	3.59mg	46.3mg	0/32	8.17mg	5/20					
b	2000	8.68mg	n.s.s.	0/32	8.17mg	1/20					
c	2000	8.68mg	n.s.s.	0/32	8.17mg	1/20					
d	2000	8.68mg	n.s.s.	0/32	8.17mg	1/20					
e	2000	16.4mg	n.s.s.	0/32	8.17mg	0/20					
f	2000	2.39mg	15.8mg	0/32	8.17mg	8/20					
2325	c01810	.106mg	.701mg	0/10	3.15mg	25/36	10.8mg	30/35	---:lym; bra:oln; crb:mae; mgl:scn,adn. C		
a	c01810	.112mg	1.47mg	0/10	3.15mg	17/36	10.8mg	3/35	bra:oln; crb:mae.		
b	c01810	.112mg	1.51mg	0/10	3.15mg	17/36	10.8mg	2/35			
c	c01810	.112mg	1.37mg	0/10	3.15mg	17/36	10.8mg	25/35	mgl:scn,adn.		
d	c01810	.112mg	1.37mg	0/10	3.15mg	16/36	10.8mg	25/35			
e	c01810	2.79mg	9.68mg	0/10	3.15mg	0/36	10.8mg	20/35			
f	c01810	.105mg	.668mg	4/10	3.15mg	27/36	10.8mg	30/35			
g	c01810	n.s.s.	n.s.s.	0/10	3.15mg	0/36	10.8mg	0/35	liv:hpa,hpc,nod.		
2326	c01810	96.8mg	1.10mg	0/40p	3.15mg	17/36	10.8mg	3/35	bra:oln; crb:mae.		
a	c01810	96.9mg	1.11mg	0/40p	3.15mg	17/36	10.8mg	2/35			
b	c01810	96.7mg	1.14mg	3/40p	3.15mg	17/36	10.8mg	25/35	mgl:scn,adn.		
c	c01810	96.8mg	1.15mg	2/40p	3.15mg	16/36	10.8mg	25/35			
d	c01810	2.41mg	8.16mg	0/40p	3.15mg	0/36	10.8mg	20/35			
2327	c01810	.104mg	.627mg	1/10	2.20mg	16/34	6.20mg	24/35	---:leu,lym; bra:can,oln; mgl:scn,adn; olb:scn. C		
a	c01810	.110mg	1.13mg	0/10	2.20mg	12/34	6.20mg	9/35	bra:can,oln; olb:scn.		
b	c01810	1.00mg	5.59mg	1/10	2.20mg	3/34	6.20mg	12/35	---:leu,lym.		
c	c01810	1.93mg	20.1mg	0/10	2.20mg	1/34	6.20mg	8/35	mgl:scn,adn.		
d	c01810	2.00mg	29.1mg	0/10	2.20mg	1/34	6.20mg	7/35			
e	c01810	84.2mg	36.1mg	4/10	2.20mg	19/34	6.20mg	30/35			
f	c01810	n.s.s.	n.s.s.	0/10	2.20mg	0/34	6.20mg	0/35	liv:hpa,hpc,nod.		
2328	c01810	.110mg	.885mg	0/40p	2.20mg	12/34	6.20mg	9/35	bra:can,oln; olb:scn.		
a	c01810	1.00mg	6.63mg	1/40p	2.20mg	3/34	6.20mg	12/35	---:leu,lym.		
b	c01810	1.10mg	6.37mg	1/40p	2.20mg	3/34	6.20mg	9/35			
c	c01810	1.93mg	12.8mg	1/40p	2.20mg	1/34	6.20mg	8/35	mgl:scn,adn.		
d	c01810	1.22mg	50.7mg	0/40p	2.20mg	0/34	6.20mg	3/35	S		
e	c01810	2.00mg	15.3mg	1/40p	2.20mg	1/34	6.20mg	7/35			
f	c01810	3.78mg	n.s.s.	0/40p	2.20mg	0/34	6.20mg	3/35	S		
PROFLAVINE.HCL HEMIHYDRATE*				952-23-8							
2329	c04137	13.6mg	89.3mg	5/49	26.0mg	20/50	(52.0mg)	22/50)	liv:hpa,hpc. S		
a	c04137	26.0mg	n.s.s.	36/49	26.0mg	37/50	52.0mg	41/50			
b	c04137	13.6mg	89.3mg	5/49	26.0mg	20/50	(52.0mg)	22/50)	liv:hpa,hpc,nod.		
c	c04137	107.mg	n.s.s.	4/49	26.0mg	3/50	52.0mg	6/50	lun:a/s,a/c.		
2330	c04137	35.5mg	n.s.s.	39/50	24.0mg	38/50	48.0mg	39/50			
a	c04137	34.1mg	n.s.s.	26/50	24.0mg	28/50	48.0mg	30/50	liv:hpa,hpc,nod.		
b	c04137	95.5mg	n.s.s.	9/50	24.0mg	11/50	48.0mg	8/50	lun:a/s,a/c.		
2331	c04137	21.2mg	n.s.s.	48/50	15.0mg	42/50	(30.0mg)	35/50)			
a	c04137	157.mg	n.s.s.	1/50	15.0mg	2/50	30.0mg	1/50	liv:hpa,hpc,nod.		
2332	c04137	80.8mg	25.0pm	0/50	12.0mg	0/50	24.0mg	5/50	lgi:arn; smi:scn,lgi. S		
a	c04137	87.8mg	n.s.s.	0/50	12.0mg	1/50	24.0mg	3/50	liv:hpc,nod. S		
b	c04137	35.6mg	n.s.s.	36/50	12.0mg	30/50	24.0mg	32/50			
c	c04137	87.8mg	n.s.s.	0/50	12.0mg	1/50	24.0mg	3/50	liv:hpa,hpc,nod.		
PROMETHALOL (alderlin) 54-80-8											
2333	20	147.mg	n.s.s.	0/25	65.0mg	3/25	130.mg	4/25	260.mg	2/25	Howe;ratu,207,594-595;1965
2334	20	266.mg	n.s.s.	1/25	60.0mg	0/25	120.mg	3/25	240.mg	1/25	
PROMETHALOL.HCL (alderlin.HCL) 51-02-5											
2335	469	239.mg	n.s.s.	3/40	150.mg			6/52			Newbarna;txep,41,535-546;1977
a	469	904.mg	n.s.s.	0/40	150.mg			0/52			
2336	469	174.mg	n.s.s.	2/29	150.mg			4/32			
a	469	297.mg	n.s.s.	0/29	150.mg			1/32			
b	469	340.mg	n.s.s.	1/29	150.mg			1/32			
PROPANE SULFONE 1120-71-4											
2337	1112	2.02mg	n.s.s.	1/7	8.00mg	12/26	8.53mg	12/26			Weisburger;Inci,67,75-88;1981
a	1112	2.40mg	n.s.s.	0/7	8.00mg	6/26	8.53mg	13/26			

Spe	Strain	Site	Xpo+Xpt	Notes	TD50	2Tailpvl
Sex	Route	Hist			DR	AuOp
b	R f cdr	gav	crl	meg 46w60 aes	7.20mg	* P<.08 +
c	R f cdr	gav	---	grl 46w60 aes	+historical	* P<.3 +
d	R f cdr	gav	smi	adc 46w60 aes	+historical	* P<.5 +
2338	R m cdr	gav	crb	meg 46w60 aes	3.64mg	* P<.02 +
a	R m cdr	gav	crl	meg 46w60 aes	4.75mg	* P<.03 +
b	R m cdr	gav	smi	adc 46w60 aes	+historical	* P<.3 +
c	R m cdr	gav	---	grl 46w60 aes	+historical	* P<.3 +
PROPRAZINE					100ng.....1ug.....10.....100.....1mg.....10.....100.....1g.....10	
2339	M f b6a	orl	lun	ade 76w76 evx	82.6mg	P<.6 -
a	M f b6a	orl	liv	hpt 76w76 evx	no dre	P=1. -
b	M f b6a	orl	tba	mix 76w76 evx	37.2mg	P<.4 -
2340	M m b6a	orl	liv	hpt 76w76 evx	73.1mg	P<.6 -
a	M m b6a	orl	lun	ade 76w76 evx	673.mg	P<.1. -
b	M m b6a	orl	tba	mix 76w76 evx	57.8mg	P<.7 -
2341	M f b6c	orl	liv	hpt 76w76 evx	no dre	P=1. -
a	M f b6c	orl	lun	mix 76w76 evx	no dre	P=1. -
b	M f b6c	orl	tba	mix 76w76 evx	93.2mg	P<.3 -
2342	M m b6c	orl	liv	hpt 76w76 evx	39.7mg	P<.1 -
a	M m b6c	orl	lun	ade 76w76 evx	82.0mg	P<.3 -
b	M m b6c	orl	tba	mix 76w76 evx	11.4mg	P<.003 -
beta-PROPIOLACTONE					100ng.....1ug.....10.....100.....1mg.....10.....100.....1g.....10	
2343	M f hic	gav	for	tum 77w77	1.33mg	P<.0005+
a	M f hic	gav	for	sqc 77w77	1.47mg	P<.0005
2344	M m hic	gav	for	tum 83w83	1.16mg	P<.0005+
a	M m hic	gav	for	sqc 83w83	1.43mg	P<.0005
2345	R f ead	gav	sto	sqc 69w69	1.34mg	P<.02 +
PROPYL N-ETHYL-N-BUTYLTHIOCARBAMATE				1ug.....10.....100.....1mg.....10.....100.....1g.....10	
2346	M f b6a	orl	lun	ade 76w76 evx	113.mg	P<.09 -
a	M f b6a	orl	liv	hpt 76w76 evx	no dre	P=1. -
b	M f b6a	orl	tba	mix 76w76 evx	219.mg	P<.6 -
2347	M m b6a	orl	liv	hpt 76w76 evx	no dre	P=1. -
a	M m b6a	orl	lun	ade 76w76 evx	no dre	P=1. -
b	M m b6a	orl	tba	mix 76w76 evx	no dre	P=1. -
2348	M f b6c	orl	liv	hpt 76w76 evx	267.mg	P<.6 -
a	M f b6c	orl	lun	ade 76w76 evx	no dre	P=1. -
b	M f b6c	orl	tba	mix 76w76 evx	251.mg	P<.7 -
2349	M m b6c	orl	liv	hpt 76w76 evx	no dre	P=1. -
a	M m b6c	orl	lun	ade 76w76 evx	no dre	P=1. -
b	M m b6c	orl	tba	mix 76w76 evx	no dre	P=1. -
N-N'-PROPYL-N-FORMYLHYDRAZINE					100ng.....1ug.....10.....100.....1mg.....10.....100.....1g.....10	
2350	M f swa	wat	lun	mix 75w79 ae	8.74mg	\ P<.0005+
a	M f swa	wat	liv	mix 75w79 ae	215.mg	* P<.0005+
b	M f swa	wat	gal	mix 75w79 ae	444.mg	* P<.006 +
c	M f swa	wat	gal	ade 75w79 ae	497.mg	* P<.02
2351	M m swa	wat	lun	mix 51w61 aes	8.84mg	\ P<.0005+
a	M m swa	wat	pre	mix 51w61 aes	60.4mg	\ P<.0005+
b	M m swa	wat	pre	sqc 51w61 aes	75.7mg	\ P<.002
c	M m swa	wat	liv	hpt 51w61 aes	no dre	P=1.
N-PROPYL ISOME					100ng.....1ug.....10.....100.....1mg.....10.....100.....1g.....10	
2352	M f b6a	orl	liv	hpt 76w76 evx	4.69gm	P<.6 -
a	M f b6a	orl	lun	ade 76w76 evx	no dre	P=1. -
b	M f b6a	orl	tba	mix 76w76 evx	4.39gm	P<.7 -
2353	M m b6a	orl	liv	hpt 76w76 evx	no dre	P=1. -
a	M m b6a	orl	lun	ade 76w76 evx	no dre	P=1. -
b	M m b6a	orl	tba	mix 76w76 evx	no dre	P=1. -
2354	M f b6c	orl	liv	hpt 76w76 evx	no dre	P=1. -
a	M f b6c	orl	lun	mix 76w76 evx	no dre	P=1. -
b	M f b6c	orl	tba	tum 76w76 evx	no dre	P=1. -
2355	M m b6c	orl	liv	hpt 76w76 evx	1.05gm	P<.02 -
a	M m b6c	orl	lun	ade 76w76 evx	4.65gm	P<.3 -
b	M m b6c	orl	tba	mix 76w76 evx	374.mg	P<.0005-
N-PROPYL-N'-NITRO-N-NITROSOGUANIDINE				1ug.....10.....100.....1mg.....10.....100.....1g.....10	
2356	R m wis	wat	stg	ade 34w65 er	1.90mg	P<.04
2357	R m wis	wat	stg	ade 52w65 er	.919mg	P<.002 +
a	R m wis	wat	stg	adc 52w65 er	2.85mg	P<.05 +
2358	R m wis	wat	stg	adc 52w78 er	2.27mg	P<.06 +
a	R m wis	wat	stg	ade 52w78 er	2.27mg	P<.06
PROPYLENE GLYCOL					100ng.....1ug.....10.....100.....1mg.....10.....100.....1g.....10	
2359	R f cdr	eat	liv	nod 24m24 e	no dre	P=1. -
2360	R m cdr	eat	liv	nod 24m24 e	no dre	P=1. -
PROPYLHYDRAZINE.HCl					100ng.....1ug.....10.....100.....1mg.....10.....100.....1g.....10	
2361	M f swa	wat	lun	mix 99w99 e	41.4mg	P<.0005+

RefNum	LoConf	UpConf	Cntrl	1Dose	1Inc	2Dose	2Inc	Citation or Pathology	Brkly Code				
b	1112	3.70mg	n.s.s.	0/7	8.00mg	8/26	8.53mg	4/26					
c	1112	7.07mg	n.s.s.	0/7	8.00mg	2/26	8.53mg	3/26					
d	1112	9.60mg	n.s.s.	0/7	8.00mg	2/26	8.53mg	1/26					
2338	1112	2.16mg	n.s.s.	0/6	8.00mg	10/26	8.53mg	11/26					
a	1112	2.68mg	n.s.s.	0/6	8.00mg	6/26	8.53mg	11/26					
b	1112	6.27mg	n.s.s.	0/6	8.00mg	3/26	8.53mg	3/26					
c	1112	8.12mg	n.s.s.	0/6	8.00mg	0/26	8.53mg	4/26					
PROPАЗINE (Gesamil) 139-40-2													
2339	1242	11.5mg	n.s.s.	1/17	14.6mg	2/17		Innes;ntis,1968/1969					
a	1242	27.2mg	n.s.s.	0/17	14.6mg	0/17							
b	1242	7.81mg	n.s.s.	2/17	14.6mg	4/17							
2340	1242	10.7mg	n.s.s.	1/18	13.6mg	2/17							
a	1242	11.8mg	n.s.s.	2/18	13.6mg	2/17							
b	1242	7.80mg	n.s.s.	3/18	13.6mg	4/17							
2341	1242	28.8mg	n.s.s.	0/16	14.6mg	0/18							
a	1242	28.8mg	n.s.s.	0/16	14.6mg	0/18							
b	1242	15.2mg	n.s.s.	0/16	14.6mg	1/18							
2342	1242	9.75mg	n.s.s.	0/16	13.6mg	2/17							
a	1242	13.3mg	n.s.s.	0/16	13.6mg	1/17							
b	1242	4.61mg	61.9mg	0/16	13.6mg	6/17							
beta-PROPIOLACTONE 57-57-8													
2343	1011	.765mg	2.49mg	0/30	5.71mg	24/30		Van Duuren;Jnci,63,1433-1439;1979					
a	1011	.848mg	2.77mg	0/30	5.71mg	23/30							
2344	1011	.660mg	2.16mg	0/30	4.76mg	25/30							
a	1011	.821mg	2.68mg	0/30	4.76mg	23/30		Van Duuren;Jnci,37,825-838;1966					
2345	55	.374mg	n.s.s.	0/5	4.08mg	3/5							
PROPYL N-ETHYL-N-BUTYLTHIOCARBAMATE (Tillam-6-E) 1114-71-2													
2346	1223	27.8mg	n.s.s.	0/15	44.3mg	2/15		Innes;ntis,1968/1969					
a	1223	73.1mg	n.s.s.	0/15	44.3mg	0/15							
b	1223	30.5mg	n.s.s.	1/15	44.3mg	2/15							
2347	1223	33.8mg	n.s.s.	3/18	41.2mg	2/15							
a	1223	68.0mg	n.s.s.	0/18	41.2mg	0/15							
b	1223	33.8mg	n.s.s.	3/18	41.2mg	2/15							
2348	1223	37.1mg	n.s.s.	1/18	44.3mg	2/18							
a	1223	87.7mg	n.s.s.	0/18	44.3mg	0/18							
b	1223	31.5mg	n.s.s.	2/18	44.3mg	3/18							
2349	1223	48.2mg	n.s.s.	2/15	41.2mg	1/16							
a	1223	51.5mg	n.s.s.	3/15	41.2mg	1/16							
b	1223	43.8mg	n.s.s.	5/15	41.2mg	2/16							
N-N'-PROPYL-N-FORMYLHYDRAZINE 77337-54-3													
2350	1053	3.99mg	17.1mg	25/99	80.0mg	49/50	(160.mg	22/49)	Toth;bjca,42,922-928;1980				
a	1053	108.mg	653.mg	0/38	80.0mg	6/45	160.mg	5/19					
b	1053	216.mg	3.77gm	0/54	80.0mg	5/50	160.mg	5/49					
c	1053	234.mg	n.s.s.	0/54	80.0mg	5/50	160.mg	4/49					
2351	1053	5.21mg	16.5mg	26/100	66.7mg	42/48	(133.mg	6/37)					
a	1053	30.2mg	172.mg	0/33	66.7mg	11/48	(133.mg	1/37)					
b	1053	35.6mg	294.mg	0/33	66.7mg	9/48	(133.mg	1/37)					
c	1053	304.mg	n.s.s.	0/28	66.7mg	2/50	133.mg	0/50					
N-PROPYL ISOME 83-59-0													
2352	1252	653.mg	n.s.s.	1/17	828.mg	2/17		Innes;ntis,1968/1969					
a	1252	1.55gm	n.s.s.	0/17	828.mg	0/17							
b	1252	553.mg	n.s.s.	2/17	828.mg	3/17							
2353	1252	720.mg	n.s.s.	2/18	770.mg	2/18							
a	1252	1.53gm	n.s.s.	1/18	770.mg	0/18							
b	1252	797.mg	n.s.s.	3/18	770.mg	2/18							
2354	1252	1.64gm	n.s.s.	0/16	828.mg	0/18							
a	1252	1.64gm	n.s.s.	0/16	828.mg	0/18							
b	1252	1.64gm	n.s.s.	0/16	828.mg	0/18							
2355	1252	361.mg	n.s.s.	0/16	770.mg	4/17							
a	1252	757.mg	n.s.s.	0/16	770.mg	1/17							
b	1252	172.mg	1.06gm	0/16	770.mg	9/17							
N-PROPYL-N'-NITRO-N-NITROSOGUANIDINE 13010-07-6													
2356	1081n	.573mg	n.s.s.	0/15	1.59mg	3/15		Sasa;Jime;zkko,94,201-206;1979					
2357	1081n	.338mg	4.24mg	0/15	2.38mg	5/10							
a	1081n	.698mg	n.s.s.	0/15	2.38mg	2/10							
2358	1082	.551mg	n.s.s.	0/9	1.98mg	2/7		Matsukura;gann,70,181-185;1979					
a	1082	.551mg	n.s.s.	0/9	1.98mg	2/7							
PROPYLENE GLYCOL 57-55-6													
2359	1351	8.74gm	n.s.s.	4/28	313.mg	5/25	625.mg	2/27	1.25gm	4/28	2.50gm	2/27	Gaunt;fctx,10,151-162;1972
2360	1351	9.11gm	n.s.s.	2/26	250.mg	4/27	500.mg	3/27	1.00gm	0/23	2.00gm	1/24	
PROPYLHYDRAZINE.HCL 56795-66-5													
2361	252	22.6mg	104.mg	21/99	50.0mg	27/43		Nagel;ejca,11,473-478;1975/Toth 1974					

Spe	Strain	Site	Xpo+Xpt	Notes	TD50	2Tailpvl
Sex	Route	Hist			DR	AuOp
a	M f swa	wat	lun	ade 99w99 e	42.7mg	P<.0005
b	M f swa	wat	lun	adc 99w99 e	109.mg	P<.0005
c	M f swa	wat	liv	mix 99w99 e	no dre	P=1.
2362	M m swa	wat	lun	ade 93w93 e	41.3mg	P<.0005
a	M m swa	wat	lun	mix 93w93 e	50.5mg	P<.002 +
b	M m swa	wat	liv	lcc 93w93 e	102.mg	P<.006 -
c	M m swa	wat	liv	mix 93w93 e	80.8mg	P<.06
PROPYLTHIOURACIL					100ng...1ug...10...100...1mg...10...100...1g...10	
2363	M b c5l	eat	pit	ade 73w73 er	409.mg *	P<.0005+
2364	R m lev	eat	thy	ade 52w52 ers	10.3mg	P<.0005+
2365	R f wal	wat	thy	ade 78w78 erv	15.8mg	P<.0005+
a	R f wal	wat	thy	car 78w78 erv	115.mg	P<.04 +
2366	R m wal	wat	thy	ade 78w78 erv	17.2mg	P<.002 +
a	R m wal	wat	thy	car 78w78 erv	79.3mg	P<.03 +
2367	R m wis	wat	thy	ade 6m24 rs	noTD50	P<.2 -
PRORESID					100ng...1ug...10...100...1mg...10...100...1g...10	
2368	R m b46	ivj	tba	mix 12m24 es	no dre	P=1. -
SX PURPLE					100ng...1ug...10...100...1mg...10...100...1g...10	
2369	R b non	eat	liv	tum 33m33	no dre	P=1.
a	R b non	eat	tba	mix 33m33	24.5gm	P<.1 +
2370	R f nss	eat	liv	tum 64w64 e	no dre	P=1. -
2371	R m nss	eat	liv	tum 64w64 e	no dre	P=1. -
a	R m nss	eat	tba	tum 64w64 e	no dre	P=1. -
PYRAZINAMIDE*					100ng...1ug...10...100...1mg...10...100...1g...10	
2372	M f b6c	eat	TBA	MXB 18m24 s	3.43gm *	P<.7
a	M f b6c	eat	liv	MXB 18m24 s	10.7gm *	P<.5
b	M f b6c	eat	lun	MXB 18m24 s	no dre	P=1.
2373	M m b6c	eat	TBA	MXB 18m24 s	546.mg *	P<.2 -
a	M m b6c	eat	liv	MXB 18m24 s	5.18gm *	P<.4
b	M m b6c	eat	lun	MXB 18m24 s	no dre	P=1.
2374	R f f34	eat	pit	MXA 18m24	#178.mg \	P<.03 -
a	R f f34	eat	TBA	MXB 18m24	182.mg \	P<.4 -
b	R f f34	eat	liv	MXB 18m24	no dre	P=1.
2375	R m f34	eat	TBA	MXB 18m24	284.mg \	P<.4 -
a	R m f34	eat	liv	MXB 18m24	no dre	P=1.
PRYIMETHAMINE*					100ng...1ug...10...100...1mg...10...100...1g...10	
2376	M f b6c	eat	TBA	MXB 18m24	315.mg *	P<.8 -
a	M f b6c	eat	liv	MXB 18m24	no dre	P=1.
b	M f b6c	eat	lun	MXB 18m24	405.mg *	P<.4
2377	M m b6c	eat	TBA	MXB 18m24 s	419.mg *	P<.9
a	M m b6c	eat	liv	MXB 18m24 s	no dre	P=1.
b	M m b6c	eat	lun	MXB 18m24 s	no dre	P=1.
2378	R f f34	eat	TBA	MXB 18m24	27.8mg *	P<.5 -
a	R f f34	eat	liv	MXB 18m24	no dre	P=1.
2379	R m f34	eat	TBA	MXB 18m24	no dre	P=1. -
a	R m f34	eat	liv	MXB 18m24	no dre	P=1.
QUERCETIN					100ng...1ug...10...100...1mg...10...100...1g...10	
2380	M f ddy	eat	lun	mix 28m28 e	4.24gm	P<.05 -
a	M f ddy	eat	liv	tum 28m28 e	no dre	P=1. -
2381	M m ddy	eat	liv	mix 27m27 e	15.1gm	P<.09 -
a	M m ddy	eat	lun	mix 27m27 e	5.46gm	P<.2 -
b	M m ddy	eat	hea	sca 27m27 e	73.4gm	P<.4 -
2382	R f nra	eat	ilm	mix 58w58 er	5.12mg	P<.0005+
a	R f nra	eat	ilm	adc 58w58 er	15.4mg	P<.003
b	R f nra	eat	ubl	mix 58w58 er	51.3mg	P<.09 +
2383	R m nra	eat	ilm	mix 58w58 er	noTD50	P<.004 +
a	R m nra	eat	ubl	tcc 58w58 er	21.0mg	P<.06 +
QUERCETIN DIHYDRATE					100ng...1ug...10...100...1mg...10...100...1g...10	
2384	R f aci	eat	adr	coa 77w77	no dre	P=1. -
a	R f aci	eat	pit	ade 77w77	no dre	P=1. -
2385	R f aci	eat	thi	sar 28m28	90.4gm	P<.2 -
a	R f aci	eat	adr	coa 28m28	226.gm	P<.8 -
b	R f aci	eat	pit	ade 28m28	461.gm	P<.1 -
2386	R m aci	eat	tes	ict 77w77	2.29gm *	P<.09 -
a	R m aci	eat	cec	ade 77w77	7.13gm *	P<.08 -
b	R m aci	eat	adr	phe 77w77	7.13gm *	P<.08 -
2387	R m aci	eat	cec	adc 28m28	35.2gm	P<.05 -
a	R m aci	eat	cec	ade 28m28	72.3gm	P<.2 -
b	R m aci	eat	pan	exe 28m28	72.3gm	P<.2 -
QUILLAIA EXTRACT					100ng...1ug...10...100...1mg...10...100...1g...10	
2388	M f the	eat	lun	ppa 84w84 e	no dre	P=1. -

RefNum	LoConf	UpConf	Cntrl	1Dose	1Inc	2Dose	2Inc	Citation or Pathology	Brkly Code
a	252	23.5mg	103.mg	18/99	50.0mg	26/43			
b	252	51.8mg	367.mg	4/99	50.0mg	12/43			
c	252	18.7mg	n.s.s.	2/43	50.0mg	0/2			
2362	252	21.8mg	116.mg	15/99	41.7mg	22/43			
a	252	23.9mg	281.mg	23/99	41.7mg	22/43			
b	252	25.0mg	2.02gm	0/56	41.7mg	2/10			
c	252	20.3mg	n.s.s.	4/56	41.7mg	3/10			
PROPYLTHIOURACIL 51-52-5									
2363	257	266.mg	663.mg	0/28	1.25gm	15/24	1.50gm	21/29	
2364	254	5.69mg	21.5mg	0/68	40.0mg	16/33			King;pseb,112,365-366;1963
2365	256	8.77mg	34.7mg	1/20	42.9mg	20/30			Lindsay;arpa,81,308-316;1966
a	256	39.8mg	n.s.s.	0/20	42.9mg	4/30			Willis;jpat,82,23-27;1961
2366	256	7.77mg	73.3mg	2/20	37.5mg	11/18			
a	256	23.9mg	n.s.s.	0/20	37.5mg	3/18			
2367	1273	n.s.s.	n.s.s.	3/8	7.50mg	5/5			Stoll;bdca,50,389-398;1963
PRORESID 1508-45-8									
2368	1017	2.58mg	n.s.s.	7/65	.714mg	1/24			Schmahl;arzn,20,1461-1467;1970
SX PURPLE (ponceau 4R) 2611-82-7									
2369	1429	15.0gm	n.s.s.	0/50	771.mg	0/50			
a	1429	6.02gm	n.s.s.	0/50	771.mg	2/50			Andrianova;vpit,29,61-65;1970
2370	1372	819.mg	n.s.s.	0/7	1.50gm	0/7			
2371	1372	562.mg	n.s.s.	0/5	1.20gm	0/6			Altmark;jphp,9,622-628;1957
a	1372	562.mg	n.s.s.	0/5	1.20gm	0/6			
PYRAZINAMIDE* 98-96-4									
2372	c01785	575.mg	n.s.s.	1/15	348.mg	5/35	697.mg	9/35	
a	c01785	1.75gm	n.s.s.	0/15	348.mg	0/35	697.mg	1/35	
b	c01785	2.62gm	n.s.s.	1/15	348.mg	0/35	697.mg	1/35	liv:hpa,hpc,nnd. lun:a/a,a/c.
2373	c01785	105.mg	n.s.s.	2/15	322.mg	5/35	726.mg	6/35	
a	c01785	956.mg	n.s.s.	1/15	322.mg	0/35	726.mg	3/35	
b	c01785	n.s.s.	n.s.s.	0/15	322.mg	0/35	726.mg	0/35	liv:hpa,hpc,nnd. lun:a/a,a/c.
2374	c01785	78.9mg	n.s.s.	2/15	134.mg	14/35	(268.mg	7/34)	pit:cra,crc. S
a	c01785	50.4mg	n.s.s.	11/15	134.mg	26/35	(268.mg	19/34)	
b	c01785	n.s.s.	n.s.s.	0/15	134.mg	0/35	268.mg	0/34	liv:hpa,hpc,nnd.
2375	c01785	79.4mg	n.s.s.	4/15	107.mg	17/35	(214.mg	8/36)	
a	c01785	n.s.s.	n.s.s.	0/15	107.mg	0/35	214.mg	0/36	liv:hpa,hpc,nnd.
PYRIMETHAMINE* (Daraprin) 58-14-0									
2376	c01683	44.2mg	n.s.s.	1/15	34.7mg	5/35	69.5mg	9/35	
a	c01683	n.s.s.	n.s.s.	0/15	34.7mg	0/35	69.5mg	0/35	
b	c01683	99.6mg	n.s.s.	0/15	34.7mg	0/35	69.5mg	2/35	liv:hpa,hpc,nnd. lun:a/a,a/c.
2377	c01683	30.1mg	n.s.s.	0/15	32.0mg	1/35	64.2mg	1/35	
a	c01683	n.s.s.	n.s.s.	0/15	32.0mg	0/35	64.2mg	0/35	
b	c01683	n.s.s.	n.s.s.	0/15	32.0mg	0/35	64.2mg	0/35	liv:hpa,hpc,nnd. lun:a/a,a/c.
2378	c01683	7.01mg	n.s.s.	7/15	5.30mg	16/35	10.7mg	26/35	
a	c01683	n.s.s.	n.s.s.	0/15	5.30mg	0/35	10.7mg	0/35	liv:hpa,hpc,nnd.
2379	c01683	14.9mg	n.s.s.	8/15	4.20mg	17/35	8.60mg	11/35	
a	c01683	n.s.s.	n.s.s.	0/15	4.20mg	0/35	8.60mg	0/35	liv:hpa,hpc,nnd.
QUERCETIN 117-39-5									
2380	1146	1.82gm	n.s.s.	4/15	2.60gm	18/31			
a	1146	23.5gm	n.s.s.	0/15	2.60gm	0/33			Saito;tcam,1,213-221;1980
2381	1146	5.20gm	n.s.s.	0/14	2.40gm	4/32			
a	1146	1.87gm	n.s.s.	6/16	2.40gm	21/37			
b	1146	12.0gm	n.s.s.	0/16	2.40gm	1/37			
2382	1392	2.31mg	12.3mg	0/9	50.0mg	14/16			
a	1392	6.79mg	76.3mg	0/9	50.0mg	8/16			Panukcu;canr,40,3468-3472;1980
b	1392	15.5mg	n.s.s.	0/9	50.0mg	3/16			
2383	1392	n.s.s.	9.97mg	0/8	40.0mg	6/6			
a	1392	5.06mg	n.s.s.	0/8	40.0mg	2/6			
QUERCETIN DIHYDRATE 5117-01-1									
2384	1145m	462.mg	n.s.s.	0/22	500.mg	0/10	2.50gm	0/9	
a	1145m	462.mg	n.s.s.	0/22	500.mg	0/10	2.50gm	0/9	
2385	1145n	14.7gm	n.s.s.	0/33	5.00gm	1/20			
a	1145n	16.0gm	n.s.s.	1/33	5.00gm	1/20			
b	1145n	13.2gm	n.s.s.	3/33	5.00gm	2/20			
2386	1145m	593.mg	n.s.s.	3/30	400.mg	1/10	2.00gm	3/8	
a	1145m	1.16gm	n.s.s.	0/30	400.mg	0/10	2.00gm	1/8	
b	1145m	1.16gm	n.s.s.	0/30	400.mg	0/10	2.00gm	1/8	
2387	1145n	8.65gm	n.s.s.	0/33	4.00gm	2/20			
a	1145n	11.8gm	n.s.s.	0/33	4.00gm	1/20			
b	1145n	11.8gm	n.s.s.	0/33	4.00gm	1/20			
QUILLAIA EXTRACT (spray-dried aqueous extract of quillaja bark) ---									
2388	1404	5.84gm	n.s.s.	9/44	130.mg	5/43	650.mg	4/43	1.95gm 5/46
									Phillips;fctx,17,23-27;1979

Spe	Strain	Site	Xpo+Xpt	Notes	TD50	2Tailpvl
Sex	Route	Hist			DR	AuOp
a	M f	the eat	liv hnd	84w84 e		no dre P=1. -
2389	M m	the eat	lun ppa	84w84 e	.	4.09gm * P<.03 -
a	M m	the eat	liv mhp	84w84 e		no dre P=1. -
b	M m	the eat	liv hnd	84w84 e		no dre P=1. -
p-QUINONE DIOXIME				100ng...1ug.....10.....100.....1mg.....10.....100.....1g.....10		
2390	M f	b6c eat	TBA MXB	24m24		6.71gm * P<.1. -
a	M f	b6c eat	liv MXB	24m24	>	656.mg * P<.02 -
b	M f	b6c eat	lun MXB	24m24		6.66gm * P<.8 -
2391	M m	b6c eat	TBA MXB	24m24		936.mg * P<.6 -
a	M m	b6c eat	liv MXB	24m24	>	1230.gm P<.1. -
b	M m	b6c eat	lun MXB	24m24		no dre P=1. -
2392	R f	f34 eat	ubl MXA	24m24	:	106.mg * P<.003 c
a	R f	f34 eat	ubl tcc	24m24	+	182.mg * P<.02 c
b	R f	f34 eat	TBA MXB	24m24		no dre P=1. -
c	R f	f34 eat	liv MXB	24m24		no dre P=1. -
2393	R m	f34 eat	TBA MXB	24m24	>	349.mg * P<.9 -
a	R m	f34 eat	liv MXB	24m24		1.13gm * P<.4 -
C.I. FOOD RED 3				100ng...1ug.....10.....100.....1mg.....10.....100.....1g.....10		
2394	M f	asp eat	lun ppa	80w80 e		32.9gm * P<.9 -
a	M f	asp eat	liv tum	80w80 e	>	no dre P=1. -
2395	M m	asp eat	lun ppa	80w80 e		12.3gm * P<.7 -
a	M m	asp eat	liv nod	80w80 e		no dre P=1. -
b	M m	asp eat	liv ade	80w80 e		no dre P=1. -
D & C RED NO. 5				100ng...1ug.....10.....100.....1mg.....10.....100.....1g.....10		
2396	M f	ddy eat	liv hpc	81w81 erv	.	784.mg Z P<.0005+
a	M f	ddy eat	liv hpa	81w81 erv	+	21.5gm * P<.2 +
2397	M m	ddy eat	liv hpc	81w81 erv	.	659.mg Z P<.0005+
a	M m	ddy eat	liv hpa	81w81 erv	+	8.79gm * P<.06 +
2398	R f	cfe eat	liv nod	24m24 e	.	704.mg * P<.0005
2399	R m	cfe eat	liv nod	24m24 e	.	2.91gm * P<.02
2400	R m	wis eat	liv lca	65w65 es	.	1.13gm * P<.06 +
D & C RED NO. 9				100ng...1ug.....10.....100.....1mg.....10.....100.....1g.....10		
2401	R f	osm eat	pit ade	25m25 e		no dre P=1. -
2402	R m	osm eat	tes ica	25m25 e	>	28.6gm * P<.8 -
a	R m	osm eat	--- fbs	25m25 e		no dre P=1. -
D & C RED NO. 10				100ng...1ug.....10.....100.....1mg.....10.....100.....1g.....10		
2403	R f	osm eat	pit ade	24m24 e		3.56gm * P<.5 -
a	R f	osm eat	liv ade	24m24 e	>	no dre P=1. -
2404	R m	osm eat	liv hpa	24m24 e		no dre P=1. -
FD & C RED NO. 1				100ng...1ug.....10.....100.....1mg.....10.....100.....1g.....10		
2405	R b	bbl eat	liv mix	24m24	.	746.mg P<.0005
a	R b	bbl eat	liv car	24m24	+	2.48gm P<.0005+
b	R b	bbl eat	liv nod	24m24		3.04gm P<.003
c	R b	bbl eat	liv bht	24m24		3.54gm P<.002 +
2406	R f	nss eat	bil ade	65w65 r	.	1.57gm * P<.002
a	R f	nss eat	liv car	65w65 r	+	1.99gm * P<.003 +
2407	R m	nss eat	bil ade	65w65 r	.	755.mg * P<.0005
a	R m	nss eat	liv car	65w65 r	+	1.24gm * P<.0005+
2408	R b	osm eat	liv nod	24m24	.	639.mg Z P<.0005
a	R b	osm eat	liv bht	24m24	+	909.mg Z P<.0005+
b	R b	osm eat	liv car	24m24		7.54gm * P<.0005+
c	R b	osm eat	tba mal	24m24		12.9gm * P<.2
2409	R b	wis eat	liv tum	65w65 ekr	.	225.mg P<.0005+
2410	R b	wis eat	liv tum	65w65 ekr	+	394.mg P<.006 +
2411	R b	wis eat	liv tum	70w70 er	.	314.mg P<.0005+
2412	R b	wis eat	liv tum	70w70 er	+	420.mg P<.0005+
FD & C RED NO. 2				100ng...1ug.....10.....100.....1mg.....10.....100.....1g.....10		
2413	R b	mgr eat	liv tum	25m25 e		no dre P=1. -
a	R b	mgr eat	tba mix	25m25 e	>	632.mg P<.0005+
2414	R b	non eat	liv hpt	33m33		49.5gm P<.3
a	R b	non eat	tba mix	33m33		3.32gm P<.0005+
2415	R f	nss eat	liv tum	64w64 e	>	no dre P=1. -
a	R f	nss eat	tba mix	64w64 e		1.64gm * P<.6 -
2416	R m	nss eat	liv tum	64w64 e	>	no dre P=1. -
a	R m	nss eat	tba mix	64w64 e		no dre P=1. -
2417	R b	wis eat	abd mly	91w91 er	.	6.13gm P<.04 +
FD & C RED NO. 3				100ng...1ug.....10.....100.....1mg.....10.....100.....1g.....10		
2418	R b	osm gav	--- lys	20m24 e	.	122.mg Z P<.004 -
a	R b	osm gav	liv tum	20m24 e	+	no dre P=1. -
b	R b	osm gav	tba mal	20m24 e		no dre P=1. -
2419	R b	osm eat	liv hpt	20m24 e		84.9gm * P<.4 -

RefNum	LoConf	UpConf	Cntrl	1Dose	1Inc	2Dose	2Inc		Citation or Pathology	Brkly Code
a	1404	12.1gm n.s.s.	1/44	130.mg	2/43	650.mg	1/43	1.95gm	0/46	
2389	1404	1.64gm n.s.s.	7/45	120.mg	3/42	600.mg	7/41	1.80gm	12/43	
a	1404	8.58gm n.s.s.	5/45	120.mg	1/42	600.mg	2/41	1.80gm	1/43	
b	1404	3.93gm n.s.s.	8/45	120.mg	4/42	600.mg	3/41	1.80gm	6/43	
p-QUINONE DIOXIME 105-11-3										
2390	c03850	252.mg n.s.s.	7/20	96.6mg	14/50	193.mg	17/50			
a	c03850	329.mg n.s.s.	0/20	96.6mg	3/50	193.mg	8/50			liv:hpa,hpc,nnd. lun:a/a,e/c.
b	c03850	664.mg n.s.s.	1/20	96.6mg	2/50	193.mg	3/50			
2391	c03850	178.mg n.s.s.	5/18	89.2mg	20/50	178.mg	22/50			
a	c03850	398.mg n.s.s.	5/18	89.2mg	6/50	178.mg	12/50			liv:hpa,hpc,nnd. lun:a/a,e/c.
b	c03850	466.mg n.s.s.	2/18	89.2mg	7/50	178.mg	6/50			
2392	c03850	57.2mg 514.mg	0/20	18.6mg	3/49	37.1mg	11/50			ubl:sqc,tcc,ttp.
a	c03850	82.6mg n.s.s.	0/20	18.6mg	1/49	37.1mg	7/50			
b	c03850	39.7mg n.s.s.	14/20	18.6mg	30/49	37.1mg	28/50			
c	c03850	204.mg n.s.s.	0/20	18.6mg	2/49	37.1mg	0/50			liv:hpa,hpc,nnd.
2393	c03850	31.3mg n.s.s.	11/20	14.9mg	21/50	29.7mg	24/50			
a	c03850	184.mg n.s.s.	0/20	14.9mg	0/50	29.7mg	1/50			liv:hpa,hpc,nnd.
C.1. FOOD RED 3 (carmoisine) 3567-69-9										
2394	1325	1.65gm n.s.s.	4/55	13.0mg	2/23	65.0mg	4/26	325.mg	4/27	1.63gm 2/19
a	1325	29.9mg n.s.s.	0/55	13.0mg	0/23	65.0mg	0/26	325.mg	0/27	1.63gm 0/19
2395	1325	1.33gm n.s.s.	13/48	12.0mg	5/26	60.0mg	7/26	300.mg	4/24	1.50gm 8/28
a	1325	3.17gm n.s.s.	6/48	12.0mg	1/26	60.0mg	0/26	300.mg	0/24	1.50gm 2/28
b	1325	30.4mg n.s.s.	1/48	12.0mg	0/26	60.0mg	0/26	300.mg	0/24	1.50gm 0/28
D & C RED NO. 5 (ponceau MX) 3761-53-3										
2396	244	365.mg 2.43gm	0/34	260.mg	4/27	1.27gm	5/11	(6.22gm	5/12)	
a	244	4.19gm n.s.s.	1/34	260.mg	2/27	1.27gm	0/11	6.22gm	2/12	
2397	244	218.mg 3.45gm	0/31	240.mg	0/8	1.18gm	4/6	(5.74gm	6/12)	
a	244	2.47gm n.s.s.	1/31	240.mg	1/8	1.18gm	1/6	5.74gm	3/12	
2398	242	414.mg 1.34gm	0/30	62.5mg	1/30	125.mg	0/29	250.mg	5/28	500.mg 14/25
2399	242	1.10gm n.s.s.	0/30	50.0mg	0/30	100.mg	1/29	200.mg	1/30	400.mg 3/29
2400	243	368.mg n.s.s.	0/12	80.0mg	4/15	400.mg	4/12	2.00gm	6/14	
D & C RED NO. 9 (brilliant red) 5160-02-1										
2401	262a	998.mg n.s.s.	4/25	5.00mg	1/25	25.0mg	9/25	125.mg	6/25	500.mg 4/25
2402	262a	1.65gm n.s.s.	0/25	4.00mg	2/25	20.0mg	0/25	100.mg	0/25	400.mg 1/25
a	262a	1.68gm n.s.s.	0/25	4.00mg	1/25	20.0mg	1/25	100.mg	2/25	400.mg 0/25
D & C RED NO. 10 ---										
2403	263	666.mg n.s.s.	2/25	5.00mg	5/25	25.0mg	9/25	125.mg	3/25	500.mg 7/25
a	263	21.0mg n.s.s.	0/25	5.00mg	0/25	25.0mg	0/25	125.mg	0/25	500.mg 0/25
2404	263	2.70gm n.s.s.	1/25	4.00mg	1/25	20.0mg	0/25	100.mg	0/25	400.mg 0/25
FD & C RED NO. 1 (ponceau 3R) 3564-09-8										
2405	246	460.mg 1.36gm	2/50	900.mg	29/50					
a	246	1.24gm 6.19gm	0/50	900.mg	11/50					
b	246	1.40gm 17.3gm	1/50	900.mg	10/50					
c	246	1.60gm 12.0gm	0/50	900.mg	8/50					
2406	245	596.mg 8.52gm	0/45	150.mg	0/15	500.mg	2/15	1.50gm	3/15	
a	245	684.mg 13.2gm	0/45	150.mg	0/15	500.mg	1/15	1.50gm	3/15	
2407	245	340.mg 2.92gm	0/45	120.mg	1/15	400.mg	3/15	1.20gm	4/15	
a	245	468.mg 5.35gm	0/45	120.mg	0/15	400.mg	1/15	1.20gm	4/15	
2408	246	411.mg 1.08gm	0/49	225.mg	12/50	450.mg	18/50	(900.mg	9/50	2.25gm 4/49)
a	246	616.mg 1.69gm	1/49	225.mg	12/50	450.mg	17/50	900.mg	22/50	(2.25gm 25/49)
b	246	4.21gm 19.9gm	0/49	225.mg	1/50	450.mg	2/50	900.mg	4/50	2.25gm 9/49
c	246	4.09gm n.s.s.	10/49	225.mg	8/50	450.mg	7/50	900.mg	7/50	2.25gm 14/49
2409	247m	88.2mg 785.mg	0/6	1.35gm	8/10					
2410	247n	153.mg 4.09gm	0/6	1.35gm	6/10					
2411	247o	158.mg 711.mg	0/23	1.35gm	14/19					
2412	247r	208.mg 1.00gm	0/24	1.35gm	12/19					
FD & C RED NO. 2 (amaranth) 915-67-3										
2413	1427	3.03gm n.s.s.	0/35	758.mg	0/18					
a	1427	295.mg 1.87gm	2/35	758.mg	11/18					
2414	1429	8.06gm n.s.s.	0/50	771.mg	1/50					
a	1429	1.75gm 7.50gm	0/50	771.mg	13/50					
2415	1358	14.4gm n.s.s.	0/10	15.0mg	0/14	150.mg	0/13	750.mg	0/9	
a	1358	192.mg n.s.s.	2/10	15.0mg	1/14	150.mg	4/13	750.mg	2/9	
2416	1358	8.41gm n.s.s.	0/11	12.0mg	0/10	120.mg	0/11	600.mg	0/9	
a	1358	8.41gm n.s.s.	1/11	12.0mg	0/10	120.mg	0/11	600.mg	0/9	
2417	1136	993.mg n.s.s.	0/50	1.80gm	1/7					
FD & C RED NO. 3 (erythrosine) 16423-68-0										
2418	130m	49.8mg 759.mg	0/49	23.3mg	6/49	(54.7mg	3/47	175.mg	2/46	349.mg 1/43)
a	130m	141.mg n.s.s.	0/49	23.3mg	0/49	54.7mg	0/47	175.mg	0/46	349.mg 0/43
b	130m	1.36gm n.s.s.	5/49	23.3mg	12/49	54.7mg	6/47	175.mg	9/46	349.mg 4/43
2419	130n	13.8gm n.s.s.	0/89	185.mg	0/48	371.mg	0/41	742.mg	1/45	1.48gm 0/45

Spe	Strain	Site	Xpo+Xpt	Notes	TD50	2Tailpvl
Sex	Route	Hist			DR	AuOp
a	R b osm eat	tba mal	20m24	e	14.1gm	* P<.5 -
2420	R f osm eat	liv tum	24m24	e	>	no dre P=1. -
a	R f osm eat	tba mix	24m24	e	no dre	P=1. -
2421	R m osm eat	liv tum	24m24	e	>	no dre P=1. -
a	R m osm eat	tba mix	24m24	e	4.81gm	* P<.2 -
FD & C RED NO. 4				100ng...1ug...10...100...1mg...10...100...1g...10		
2422	D f beg eat	adr wda	85m85	e	>	316.mg P<.2 -
a	D f beg eat	mgl adc	85m85	e		316.mg P<.2 -
b	D f beg eat	liv nod	85m85	e		no dre P=1. -
c	D f beg eat	tba mix	85m85	e		670.mg P<.9 -
2423	M b che eat	liv hpt	24m24	e		>57.1gm * P<.7 -
a	M b che eat	tba mix	24m24	e		20.3gm * P<.3 -
2424	M b chj eat	liv hpt	24m24	e		>no dre P=1. -
a	M b chj eat	tba mix	24m24	e		no dre P=1. -
2425	R b non eat	liv hpt	33m33	e		49.5gm P<.3 -
a	R b non eat	tba mix	33m33	e		12.0gm P<.02 +
2426	R b osm eat	liv ade	24m24	e		59.8gm * P<.2 -
a	R b osm eat	tba mix	24m24	e		no dre P=1. -
2427	R b osm eat	--- tba	24m24	e		20.3gm * P<.006 -
a	R b osm eat	tba mix	24m24	e		no dre P=1. -
2428	R b sda eat	tba mix	24m24	e	>	no dre P=1. -
2429	R b wis eat	abd mly	91w91	er		± 6.13gm P<.04 +
RESERPINE				100ng...1ug...10...100...1mg...10...100...1g...10		
2430	M f b6c eat	mgl ---	24m24	e		3.58gm * P<.002 c
a	M f b6c eat	T8A MXB	24m24	e		6.42gm * P<.5 -
b	M f b6c eat	liv MXB	24m24	e		no dre P=1. -
c	M f b6c eat	lun MXB	24m24	e		54.5gm * P<.9 -
2431	M m b6c eat	sav ulc	24m24	e		8.39gm * P<.01 c
a	M m b6c eat	T8A MXB	24m24	e		no dre P=1. -
b	M m b6c eat	liv MXB	24m24	e		5.46gm \ P<.6 -
c	M m b6c eat	lun MXB	24m24	e		no dre P=1. -
2432	M f c3h eat	mgl car	24m24	e	>	34.2ug P<.6 +
2433	R f f34 eat	T8A MXB	24m24	e		.727gm * P<.3 -
a	R f f34 eat	liv MXB	24m24	e		no dre P=1. -
2434	R m f34 eat	adr MXA	24m24	e		.306gm * P<.0005c
a	R m f34 eat	T8A MXB	24m24	e		no dre P=1. -
b	R m f34 eat	liv MXB	24m24	e		6.77gm * P<.4 -
2435	R f wis eat	pit mix	75w75	e		no dre P=1. -
a	R f wis eat	mgl tba	75w75	e	>	no dre P=1. -
2436	R m wis eat	pit ade	75w75	e	>	38.3gm * P<.8 -
RIFAMPICIN				100ng...1ug...10...100...1mg...10...100...1g...10		
2437	M f bal wat	lun tum	14m26	e	>	1.01gm * P<.8 -
a	M f bal wat	liv hpt	14m26	e		3.18gm * P<.6 -
b	M f bal wat	tba mix	14m26	e		no dre P=1. -
2438	M m bal wat	lun tum	14m26	es	>	320.mg * P<.3 -
a	M m bal wat	liv hpt	14m26	es		3.00gm * P<.6 -
b	M m bal wat	tba mix	14m26	es		509.mg * P<.6 -
2439	M f c3d wat	liv hpt	14m25	e		33.6gm * P<.0005+
a	M f c3d wat	lun tum	14m25	e		no dre P=1. -
b	M f c3d wat	tba mix	14m25	e		39.3gm * P<.0005
2440	M m c3d wat	lun tum	14m25	e	>	356.mg * P<.2 -
a	M m c3d wat	liv hpt	14m25	e		1.05gm * P<.9 -
b	M m c3d wat	tba mix	14m25	e		474.mg * P<.9 -
2441	R f wis wat	liv hpt	24m32	e		436.mg * P<.09 -
a	R f wis wat	tba mix	24m32	e		no dre P=1. -
2442	R m wis wat	liv hpt	24m32	e	>	no dre P=1. -
a	R m wis wat	tba mix	24m32	e		1.38gm * P<.1. -
ROSANILINE.HCl				100ng...1ug...10...100...1mg...10...100...1g...10		
2443	H f syg gav	liv tum	68w68	e	>	no dre P=1. -
a	H f syg gav	lun tum	68w68	e		no dre P=1. -
b	H f syg gav	tba mix	68w68	e		no dre P=1. -
2444	H m syg gav	lun b/a	84w84	e	>	2.02gm P<.3 -
a	H m syg gav	liv tum	84w84	e		no dre P=1. -
b	H m syg gav	tba mix	84w84	e		no dre P=1. -
p-ROSANILINE.HCl				100ng...1ug...10...100...1mg...10...100...1g...10		
2445	H f syg gav	liv tum	84w84	e	>	no dre P=1. -
a	H f syg gav	lun tum	84w84	e		no dre P=1. -
b	H f syg gav	tba mix	84w84	e		no dre P=1. -
2446	H m syg gav	liv tum	84w84	e	>	no dre P=1. -
a	H m syg gav	lun tum	84w84	e		no dre P=1. -
b	H m syg gav	tba mix	84w84	e		no dre P=1. -
ROTENONE				100ng...1ug...10...100...1mg...10...100...1g...10		
2447	M f b6a orl	lun ade	76w76	evx	>	2.65gm P<.6 -

CARCINOGENIC POTENCY DATABASE

RefNum	LoConf	UpConf	Cntrl	1Dose	1Inc	2Dose	2Inc	Citation or Pathology				Brkly Code	
a	130n	3.08gm	n.s.s.	20/89	185.mg	6/48	371.mg	8/41	742.mg	9/45	1.48gm	12/45	
2420	1371	334.mg	n.s.s.	0/12	250.mg	0/12	500.mg	0/12	1.00gm	0/12	2.50gm	0/12	Hansen;fctx,11,527-534;1973
a	1371	7.16gm	n.s.s.	5/12	250.mg	4/12	500.mg	1/12	1.00gm	2/12	2.50gm	0/12	
2421	1371	267.mg	n.s.s.	0/12	200.mg	0/12	400.mg	0/12	800.mg	0/12	2.00gm	0/12	
a	1371	1.42gm	n.s.s.	2/12	200.mg	0/12	400.mg	2/12	800.mg	5/12	2.00gm	3/12	
FD & C RED NO. 4 (ponceau SX) 4548-53-2													
2422	248m	51.0mg	n.s.s.	0/9	250.mg		1/5						Davis;txap,8,306-317;1966
a	248m	51.0mg	n.s.s.	0/9	250.mg		1/5						
b	248m	106.mg	n.s.s.	1/9	250.mg		0/5						
c	248m	39.1mg	n.s.s.	3/9	250.mg		2/5						
2423	248m	7.69gm	n.s.s.	12/91	1.25gm	6/47	2.50gm		9/56				
a	248m	5.60gm	n.s.s.	13/91	1.25gm	8/47	2.50gm		12/56				
2424	248m	6.80gm	n.s.s.	0/66	1.25gm	0/50	2.50gm		0/28				
a	248m	6.80gm	n.s.s.	5/66	1.25gm	0/50	2.50gm		0/28				
2425	1429	8.06gm	n.s.s.	0/50	771.mg		1/50						Andrianova;vpit,29,61-65;1970
a	1429	4.14gm	n.s.s.	0/50	771.mg		4/50						
2426	248m	9.74gm	n.s.s.	0/16	225.mg	0/19	450.mg	0/23	900.mg	0/22	2.25gm	1/24	Davis;txap,8,306-317;1966
a	248m	5.14gm	n.s.s.	7/16	225.mg	10/19	450.mg	8/23	900.mg	10/22	2.25gm	5/24	
2427	248n	7.00gm	239.gm	0/171	450.mg		0/89		900.mg		4/89		
a	248n	3.48gm	n.s.s.	67/171	450.mg	23/89	900.mg	32/89					
2428	248m	4.95gm	n.s.s.	38/147	450.mg	16/83	900.mg	14/74					
2429	1136	993.mg	n.s.s.	0/50	1.80gm		1/7						Willheim;gaga,23,1-19;1953
RESERPINE 50-55-5													
2430	c50157	1.92mg	12.2mg	0/50	.650mg	7/50	1.30mg	7/50					
a	c50157	1.44mg	n.s.s.	21/50	.650mg	19/50	1.30mg	23/50					
b	c50157	10.1mg	n.s.s.	2/50	.650mg	0/50	1.30mg	1/50					Liv:hpa,hpc,nnd. Lun:a/a,a/c.
c	c50157	4.03mg	n.s.s.	4/50	.650mg	4/50	1.30mg	4/50					
2431	c50157	3.42mg	947.mg	0/50	.600mg	1/50	1.20mg	5/50					
a	c50157	1.78mg	n.s.s.	30/50	.600mg	34/50	1.20mg	25/50					
b	c50157	.868mg	n.s.s.	12/50	.600mg	14/50	(1.20mg)	4/50					Liv:hpa,hpc,nnd. Lun:a/a,a/c.
c	c50157	3.89mg	n.s.s.	9/50	.600mg	9/50	1.20mg	6/50					
2432	1187	5.54ug	n.s.s.	12/22	9.60ug	15/24							Lacassagne;adac,810-812;1959
2433	c50157	.216mg	n.s.s.	42/50	.250mg	45/50	.500mg	45/50					
a	c50157	6.05mg	n.s.s.	1/50	.250mg	0/50	.500mg	0/50					Liv:hpa,hpc,nnd. adr:phe,phs.
2434	c50157	.181mg	1.01mg	3/50	.200mg	18/50	.400mg	24/50					
a	c50157	.367mg	n.s.s.	43/50	.200mg	42/50	.400mg	42/50					
b	c50157	1.64mg	n.s.s.	0/50	.200mg	1/50	.400mg	1/50					Liv:hpa,hpc,nnd.
2435	1008	5.14mg	n.s.s.	1/22	1.50mg	1/18	3.00mg	1/24					Tatematsu;txlt,1,201-205;1978
a	1008	7.52mg	n.s.s.	1/22	1.50mg	1/18	3.00mg	0/24					
2436	1008	2.81mg	n.s.s.	1/22	1.20mg	1/18	2.40mg	1/15					
RIFAMPICIN 13292-46-1													
2437	400	115.mg	n.s.s.	13/37	10.7mg	10/36	32.1mg	10/37	64.3mg	14/38			Della Porta;txap,43,293-302;1978
a	400	518.mg	n.s.s.	0/37	10.7mg	0/36	32.1mg	1/37	64.3mg	0/38			
b	400	84.1mg	n.s.s.	26/37	10.7mg	30/36	32.1mg	25/37	64.3mg	25/38			
2438	400	88.4mg	n.s.s.	6/42	8.93mg	9/41	26.8mg	14/42	53.6mg	10/43			
a	400	489.mg	n.s.s.	0/42	8.93mg	0/41	26.8mg	1/42	53.6mg	0/43			
b	400	88.5mg	n.s.s.	11/42	8.93mg	13/41	26.8mg	15/42	53.6mg	14/43			
2439	400	21.6mg	63.7mg	8/40	11.3mg	16/40	34.0mg	27/44	67.9mg	29/36			
a	400	244.mg	n.s.s.	3/40	11.3mg	6/40	34.0mg	2/44	67.9mg	4/36			
b	400	21.0mg	148.mg	18/40	11.3mg	27/40	34.0mg	30/44	67.9mg	31/36			
2440	400	114.mg	n.s.s.	3/30	9.43mg	5/40	28.3mg	3/40	56.6mg	9/40			
a	400	59.8mg	n.s.s.	18/30	9.43mg	20/40	28.3mg	21/40	56.6mg	23/40			
b	400	38.5mg	n.s.s.	20/30	9.43mg	30/40	28.3mg	29/40	56.6mg	29/40			
2441	400	107.mg	n.s.s.	0/20	12.9mg	0/20	25.8mg	2/19					
a	400	22.0mg	n.s.s.	17/20	12.9mg	19/20	25.8mg	14/19					
2442	400	130.mg	n.s.s.	1/19	11.3mg	1/21	22.6mg	1/22					
a	400	26.2mg	n.s.s.	12/19	11.3mg	12/21	22.6mg	14/22					
ROSANILINE.HCl (magenta I) 632-99-5													
2443	1151	403.mg	n.s.s.	0/40	114.mg		0/40						Green;zkko,95,51-55;1979
a	1151	403.mg	n.s.s.	0/40	114.mg		0/40						
b	1151	248.mg	n.s.s.	5/40	114.mg		2/40						
2444	1151	329.mg	n.s.s.	0/40	114.mg		1/40						
a	1151	615.mg	n.s.s.	0/40	114.mg		0/40						
b	1151	331.mg	n.s.s.	3/40	114.mg		2/40						
p-ROSANILINE.HCl (p-magenta) 569-61-9													
2445	1151	461.mg	n.s.s.	0/40	85.7mg		0/40						Green;zkko,95,51-55;1979
a	1151	461.mg	n.s.s.	0/40	85.7mg		0/40						
b	1151	187.mg	n.s.s.	5/40	85.7mg		4/40						
2446	1151	461.mg	n.s.s.	0/40	85.7mg		0/40						
a	1151	461.mg	n.s.s.	0/40	85.7mg		0/40						
b	1151	331.mg	n.s.s.	3/40	85.7mg		1/40						
ROTENONE (tubetoxin) 83-79-4													
2447	1253	.348mg	n.s.s.	1/17	.414mg		2/18						Innes;ntis,1968/1969

Spe	Strain	Site	Xpo+Xpt	Notes	TD50	ZTailpvl
Sex	Route	Hist			DR	AuOp
a	M f b6a	orl	liv	hpt 76w76 evx	no dre	P=1. -
b	M f b6a	orl	tba	mix 76w76 evx	no dre	P=1. -
2448	M m b6a	orl	liv	hpt 76w76 evx	no dre	P=1. -
a	M m b6a	orl	lun	ade 76w76 evx	no dre	P=1. -
b	M m b6a	orl	tba	mix 76w76 evx	no dre	P=1. -
2449	M f b6c	orl	liv	hpt 76w76 evx	2.65mg	P<.3 -
a	M f b6c	orl	lun	car 76w76 evx	2.65mg	P<.3 -
b	M f b6c	orl	tba	mix 76w76 evx	.831mg	P<.05 -
2450	M m b6c	orl	liv	mix 76w76 evx	.773mg	P<.05 -
a	M m b6c	orl	lun	ade 76w76 evx	2.47mg	P<.3 -
b	M m b6c	orl	tba	mix 76w76 evx	.433mg	P<.009 -
RUTIN TRIHYDRATE					100ng...1ug...10...100...1mg...10...100...1g...10	
2451	R f aci	eat	pit	ade 77w77	8.91gm	P<.2 -
a	R f aci	eat	ubl	pam 77w77	8.91gm	P<.2 -
2452	R f aci	eat	adr	phe 28m28	90.4gm	P<.2 -
a	R f aci	eat	hea	sar 28m28	90.4gm	P<.2 -
2453	R m aci	eat	tes	ict 77w77	3.53gm	P<.2 -
a	R m aci	eat	adr	coa 77w77	5.71gm	P<.3 -
2454	R m aci	eat	col	ade 28m28	72.3gm	P<.2 -
a	R m aci	eat	ila	ade 28m28	72.3gm	P<.2 -
SACCHARIN					100ng...1ug...10...100...1mg...10...100...1g...10	
2455	M f swa	eat	lun	tum 76w76 e	>56.3gm	P<.7 -
a	M f swa	eat	liv	hpt 76w76 e	no dre	P=1. -
2456	M f swi	eat	ubl	apc 91w91 eg	no dre	P=1. -
2457	M m swi	eat	ubl	tcc 91w91 e	no dre	P=1. -
SACCHARIN, SODIUM					100ng...1ug...10...100...1mg...10...100...1g...10	
2458	M f chi	eat	liv	tum 24m24 e	no dre	P=1. -
a	M f chi	eat	lun	tum 24m24 e	no dre	P=1. -
b	M f chi	eat	tba	mix 24m24 e	26.1gm *	P<.7 -
2459	M m chi	eat	lun	tum 24m24 e	1.36gm \	P<.002 -
a	M m chi	eat	liv	hpt 24m24 e	no dre	P=1. -
b	M m chi	eat	tba	mix 24m24 e	881.4gm \	P<.002 -
2460	R f cdr	eat	liv	clc 26m26 e	78.2gm *	P<.03 -
a	R f cdr	eat	liv	nod 26m26 e	98.4gm *	P<.2 -
2461	R f cdr	eat	liv	bic 33m33 eg	155.5gm	P<.6 -
a	R f cdr	eat	liv	nnd 33m33 eg	155.5gm	P<.3 -
2462	R m cdr	eat	liv	hpc 26m26 e	no dre	P=1. -
2463	R m cdr	eat	pty	ade 33m33 e	23.2gm	P<.008
a	R m cdr	eat	ubl	tcc 33m33 e	31.1gm	P<.05 +
b	R m cdr	eat	liv	bic 33m33 e	60.0gm	P<.1 -
c	R m cdr	eat	ubl	tpp 33m33 e	30.8gm	P<.2 +
2464	R m cdr	eat	tba	mix 24m24 e	no dre	P=1. -
2465	R b sde	eat	ubl	tum 30m30 e	no dre	P=1. -
e	R b sde	eat	tba	mal 30m30 e	4.10gm *	P<.4 -
2466	R b wis	eat	ubl	tum 24m24 er	no dre	P=1. -
2467	R b wis	eat	ubl	tum 24m24 er	125.5gm	P<.08
SAFROLE					100ng...1ug...10...100...1mg...10...100...1g...10	
2468	M f b6a	orl	liv	mix 81w81 evx	23.5mg	P<.0005
a	M f b6a	orl	liv	hpt 81w81 evx	31.4mg	P<.0005+
b	M f b6a	orl	lun	ade 81w81 evx	no dre	P=1. -
c	M f b6a	orl	tba	mix 81w81 evx	24.2mg	P<.0005
2469	M m b6a	orl	liv	hpt 81w81 evx	312.4mg	P<.04
a	M m b6a	orl	lun	mix 81w81 evx	no dre	P=1. -
b	M m b6a	orl	tba	mix 81w81 evx	5.12gm	P<.1 -
2470	M f b6c	gav	liv	mix 90w90 e	27.0mg	P<.0005+
a	M f b6c	gav	liv	hpc 90w90 e	33.0mg	P<.0005+
b	M f b6c	gav	lun	tum 90w90 e	no dre	P=1. -
2471	M f b6c	orl	liv	hpt 81w81 evx	noTD50	P<.0005
a	M f b6c	orl	lun	mix 81w81 evx	no dre	P=1. -
b	M f b6c	orl	tba	mix 81w81 evx	noTD50	P<.0005
2472	M m b6c	gav	liv	mix 90w90 e	178.4mg	P<.07 -
a	M m b6c	gav	liv	hpc 90w90 e	281.4mg	P<.02 -
b	M m b6c	gav	lun	mix 90w90 e	no dre	P=1. -
2473	M m b6c	orl	liv	hpt 81w81 evx	61.7mg	P<.0005+
a	M m b6c	orl	lun	ade 81w81 evx	no dre	P=1. -
b	M m b6c	orl	tba	mix 81w81 evx	119.4mg	P<.2 -
2474	M f cd1	eat	liv	hpc 51w73 ev	125.4mg	P<.0005+
a	M f cd1	eat	lun	tum 51w73 ev	no dre	P=1. -
2475	M m cd1	eat	liv	car 51w73 ev	24.9mg	P<.0005+
a	M m cd1	eat	lun	tum 51w73 ev	no dre	P=1. -
2476	M m cd1	eat	liv	hpc 56w69	731.4mg *	P<.03
a	M m cd1	eat	lun	ade 56w69	no dre	P=1. -
2477	M m cd1	eat	liv	car 56w69	3.71gm	P<.7 -
a	M m cd1	eat	tba	mix 56w69	3.71gm	P<.7 -
2478	R m cdr	eat	liv	hpc 73w95 e	no dre	P=1. -

RefNum	LoConf	UpConf	Cntrl	1Dose	1Inc	2Dose	2Inc	Citation or Pathology	Brkly Code				
a	1253	.820mg	n.s.s.	0/17	.414mg	0/18							
b	1253	.391mg	n.s.s.	2/17	.414mg	2/18							
2448	1253	.455mg	n.s.s.	1/18	.385mg	1/18							
a	1253	.505mg	n.s.s.	2/18	.385mg	1/18							
b	1253	.303mg	n.s.s.	3/18	.385mg	3/18							
2449	1253	.431mg	n.s.s.	0/16	.414mg	1/18							
a	1253	.431mg	n.s.s.	0/16	.414mg	1/18							
b	1253	.251mg	n.s.s.	0/16	.414mg	3/18							
2450	1253	.233mg	n.s.s.	0/16	.385mg	3/18							
a	1253	.401mg	n.s.s.	0/16	.385mg	1/18							
b	1253	.163mg	9.50mg	0/16	.385mg	5/18							
RUTIN TRIHYDRATE 153-18-4													
2451	1145m	1.45gm	n.s.s.	0/22	2.50gm	1/10		Hirano;clet,13,15-21;1981					
a	1145m	1.45gm	n.s.s.	0/22	2.50gm	1/10							
2452	1145n	14.7gm	n.s.s.	0/33	5.00gm	1/20							
a	1145n	14.7gm	n.s.s.	0/33	5.00gm	1/20							
2453	1145m	777.mg	n.s.s.	3/30	2.00gm	3/11							
a	1145m	990.mg	n.s.s.	2/30	2.00gm	2/11							
2454	1145n	11.8gm	n.s.s.	0/33	4.00gm	1/20							
a	1145n	11.8gm	n.s.s.	0/33	4.00gm	1/20							
SACCHARIN 81-07-2													
2455	1090	7.21gm	n.s.s.	7/45	6.50gm	8/42		Roe;fctx,8,135-145;1970					
a	1090	21.4gm	n.s.s.	3/45	6.50gm	1/42							
2456	1349	1.12gm	n.s.s.	1/41	260.mg	0/37	650.mg	0/42	Kroes;txcy,8,285-300;1977				
2457	1349	3.40gm	n.s.s.	0/40	240.mg	1/39	600.mg	0/48					
SACCHARIN, SODIUM 128-44-9													
2458	1450	6.49gm	n.s.s.	0/17	1.30gm	0/28	6.50gm	0/36	Homburger;ctxf,359-373;1978				
a	1450	18.9gm	n.s.s.	4/17	1.30gm	6/28	6.50gm	5/36					
b	1450	4.12gm	n.s.s.	11/17	1.30gm	16/28	6.50gm	24/36					
2459	1450	686.mg	4.99gm	1/19	1.20gm	14/29	(6.00gm	9/34)					
a	1450	19.6gm	n.s.s.	1/19	1.20gm	5/29	6.00gm	2/34					
b	1450	442.mg	3.79gm	4/19	1.20gm	20/29	(6.00gm	21/34)					
2460	1114	19.2gm	n.s.s.	0/56	90.0mg	0/56	270.mg	0/52	810.mg	0/56	2.43gm	2/54	Munro;txap,32,513-526;1975
a	1114	20.1gm	n.s.s.	1/56	90.0mg	0/56	270.mg	0/52	810.mg	0/56	2.43gm	2/54	
2461	1398	20.8gm	n.s.s.	1/48	2.50gm	2/49							Arnold;txap,52,113-152;1980
a	1398	25.2gm	n.s.s.	0/48	2.50gm	1/49							
2462	1114	31.5gm	n.s.s.	0/57	90.0mg	0/51	270.mg	1/54	810.mg	0/52	2.43gm	0/54	Munro;txap,32,513-526;1975
2463	1398	8.81gm	378.gm	0/49	2.00gm	5/48							Arnold;txap,52,113-152;1980
a	1398	9.40gm	n.s.s.	0/36	2.00gm	3/38							
b	1398	14.8gm	n.s.s.	0/49	2.00gm	2/48							
c	1398	8.50gm	n.s.s.	1/36	2.00gm	4/38							
2464	1450	1.96gm	n.s.s.	11/16	400.mg	21/28	2.00gm	15/26					Homburger;ctxf,359-373;1978
2465	1416	1.94gm	n.s.s.	0/98	90.0mg	0/94	225.mg	0/93					Schmehl;erzn,23,1466-1470;1973
a	1416	1.11gm	n.s.s.	13/98	90.0mg	11/94	225.mg	17/93					
2466	1465	47.4gm	n.s.s.	0/98	2.00gm	0/115							Hicks;carc,2,475-489;1978
2467	1465m	37.8gm	n.s.s.	0/98	4.00gm	3/138							
SAFROLE 94-59-7													
2468	267	9.22mg	60.3mg	1/15	156.mg	16/17							Innes;ntis,1968/1969
a	267	14.1mg	79.3mg	1/15	156.mg	15/17							
b	267	332.mg	n.s.s.	2/15	156.mg	0/17							
c	267	9.32mg	66.2mg	2/15	156.mg	16/17							
2469	267	94.1mg	n.s.s.	0/18	146.mg	3/17							
a	267	310.mg	n.s.s.	3/18	146.mg	0/17							
b	267	120.mg	n.s.s.	3/18	146.mg	3/17							
2470	1039	16.2mg	49.9mg	0/98	34.3mg	22/46			Vesselinovitch;canr,39,4378-4380;1979				
a	1039	19.1mg	64.0mg	0/98	34.3mg	19/46							
b	1039	243.mg	n.s.s.	0/98	34.3mg	0/46							
2471	267	n.s.s.	38.8mg	0/17	156.mg	16/16							Innes;ntis,1968/1969
a	267	313.mg	n.s.s.	0/17	156.mg	0/16							
b	267	n.s.s.	40.5mg	1/17	156.mg	16/16							
2472	1039	50.7mg	n.s.s.	3/100	34.3mg	4/33			Vesselinovitch;canr,39,4378-4380;1979				
a	1039	69.2mg	n.s.s.	0/100	34.3mg	2/33							
b	1039	185.mg	n.s.s.	3/100	34.3mg	0/35							
2473	267	28.6mg	202.mg	1/17	146.mg	11/17							Innes;ntis,1968/1969
a	267	310.mg	n.s.s.	1/17	146.mg	0/17							
b	267	35.3mg	n.s.s.	7/17	146.mg	11/17							
2474	1035a	74.9mg	225.mg	0/53	439.mg	25/36							Wislocki;canr,37,1883-1891;1977
a	1035a	2.23gm	n.s.s.	0/55	439.mg	0/50							
2475	1035a	123.mg	612.mg	0/44	405.mg	11/26							
a	1035a	1.07gm	n.s.s.	0/44	405.mg	0/26							
2476	1042a	335.mg	n.s.s.	4/50	390.mg	11/40	488.mg	8/40					Borchert;canr,33,590-600;1973
a	1042a	786.mg	n.s.s.	1/50	390.mg	0/40	488.mg	0/40					
2477	1042b	417.mg	n.s.s.	3/35	390.mg	4/35							
a	1042b	417.mg	n.s.s.	3/35	390.mg	4/35							
2478	1035a	210.mg	n.s.s.	0/18	68.0mg	0/18							Wislocki;canr,37,1883-1891;1977

Spe	Strain	Site	Xpo+Xpt	Notes	TD50	2Tailpvl
Sex	Route	Hist			DR	AuOp
2479	R m	cdr eat	liv hpc 95w95 e		627.mg	P<.05 +
2480	R m	cdr eat	liv tum 43w69	>	no dre	P=1.
a	R m	cdr eat	tba tum 43w69		no dre	P=1.
2481	R m	cdr eat	liv mix 47w69	>	576.mg *	P<.2
a	R m	cdr eat	tba mix 47w69		1.32gm *	P<.7
2482	R m	cdr eat	liv car 36w52	>	425.mg	P<.3 +
a	R m	cdr eat	tba mix 36w52		425.mg	P<.3
2483	R b	osm eat	liv hpc 24m24 s	.	250.mg Z	P<.004
a	R b	osm eat	liv mix 24m24 s	.	340.mg *	P<.0005+
b	R b	osm eat	liv mal 24m24 s		624.mg *	P<.0005+
c	R b	osm eat	liv hpc 24m24 s		921.mg *	P<.0005
d	R b	osm eat	liv hpc 24m24 s		1.96gm *	P<.0005
2484	R f	osm eat	liv tum 24m24 s	.	231.mg *	P<.0005
2485	R m	osm eat	liv tum 24m24 s	.	593.mg *	P<.02
SELENIUM				100ng...1ug...10...100...1mg...10...100...1g...10		
2486	M f	c3s eat	mgl adc 81w81 r	>	no dre	P=1. -
2487	M f	c3s eat	mgl adc 53w81 r	>	no dre	P=1. -
SELENIUM DIETHYLDITHIOCARBAMATE				100ng...1ug...10...100...1mg...10...100...1g...10		
2488	M f	b6a orl	liv hpt 81w81 evx	>	no dre	P=1.
a	M f	b6a orl	liv hpt 81w81 evx		no dre	P=1.
b	M f	b6a orl	tba mix 81w81 evx		10.5mg	P<.4
2489	M m	b6a orl	liv hpt 81w81 evx	>	10.2mg	P<.3
a	M m	b6a orl	liv hpt 81w81 evx		18.4mg	P<.6
b	M m	b6a orl	tba mix 81w81 evx		8.45mg	P<.4
2490	M f	b6c orl	liv hpt 81w81 evx	.	7.76mg	P<.04
a	M f	b6c orl	liv hpt 81w81 evx	.	no dre	P=1.
b	M f	b6c orl	tba mix 81w81 evx	.	3.46mg	P<.003
2491	M m	b6c orl	liv mix 81w81 evx	.	1.28mg	P<.0005
a	M m	b6c orl	liv hpt 81w81 evx	.	1.49mg	P<.0005+
b	M m	b6c orl	liv hpt 81w81 evx	.	no dre	P=1.
c	M m	b6c orl	tba mix 81w81 evx	.	.638mg	P<.0005
SELENIUM DIMETHYLDITHIOCARBAMATE				100ng...1ug...10...100...1mg...10...100...1g...10		
2492	M f	b6a orl	liv hpt 76w76 evx	>	no dre	P=1. -
a	M f	b6a orl	liv hpt 76w76 evx		no dre	P=1. -
b	M f	b6a orl	tba mix 76w76 evx		no dre	P=1. -
2493	M m	b6a orl	liv hpt 76w76 evx	>	no dre	P=1. -
a	M m	b6a orl	liv hpt 76w76 evx		no dre	P=1. -
b	M m	b6a orl	tba mix 76w76 evx		no dre	P=1. -
2494	M f	b6c orl	liv hpt 76w76 evx	>	no dre	P=1. -
a	M f	b6c orl	liv hpt 76w76 evx		no dre	P=1. -
b	M f	b6c orl	tba mix 76w76 evx		no dre	P=1. -
2495	M m	b6c orl	liv hpt 76w76 evx	>	26.0mg	P<.3 -
a	M m	b6c orl	liv hpt 76w76 evx		no dre	P=1. -
b	M m	b6c orl	tba mix 76w76 evx		5.88mg	P<.02 -
SELENIUM SULFIDE				100ng...1ug...10...100...1mg...10...100...1g...10		
2496	M f	b6c gav	MXB 24m24	:+ :	46.8mg *	P<.0005
a	M f	b6c gav	liv MXA 24m24		69.3mg *	P<.0005c
b	M f	b6c gav	liv hpc 24m24		85.2mg *	P<.0005c
c	M f	b6c gav	liv MXA 24m24		137.mg *	P<.0005c
d	M f	b6c gav	liv MXA 24m24		433.mg *	P<.02 c
e	M f	b6c gav	TBA MXB 24m24		69.7mg *	P<.02
f	M f	b6c gav	liv MXB 24m24		69.3mg *	P<.0005
g	M f	b6c gav	liv MXB 24m24		137.mg *	P<.0005
2497	M m	b6c gav	TBA MXB 24m24	>	735.mg *	P<.9 -
a	M m	b6c gav	liv MXB 24m24		202.mg *	P<.3
b	M m	b6c gav	liv MXB 24m24		183.mg *	P<.07
2498	R f	f34 gav	liv MXA 24m24	:+ :	6.14mg /	P<.0005c
a	R f	f34 gav	liv hpc 24m24		13.2mg /	P<.0005c
b	R f	f34 gav	liv hpc 24m24		19.3mg *	P<.3
c	R f	f34 gav	liv MXB 24m24		6.14mg /	P<.0005
2499	R m	f34 gav	liv MXA 24m24	:+ :	11.5mg /	P<.0005c
a	R m	f34 gav	liv hpc 24m24		21.0mg *	P<.0005c
b	R m	f34 gav	liv hpc 24m24		25.0mg *	P<.4
c	R m	f34 gav	liv MXB 24m24		11.5mg /	P<.0005
SENKIRKINE				100ng...1ug...10...100...1mg...10...100...1g...10		
2500	R m	eci ipj	liv lca 56w92 ev	.	1.70mg	P<.0005+
SIMAZINE				100ng...1ug...10...100...1mg...10...100...1g...10		
2501	M f	b6a orl	liv hpt 76w76 evx	>	no dre	P=1. -
a	M f	b6a orl	liv hpt 76w76 evx		no dre	P=1. -
b	M f	b6a orl	tba mix 76w76 evx		no dre	P=1. -
2502	M m	b6a orl	liv hpt 76w76 evx	>	442.mg	P<.7 -
a	M m	b6a orl	liv hpt 76w76 evx		no dre	P=1. -
b	M m	b6a orl	tba mix 76w76 evx		199.mg	P<.5 -

RefNum	LoConf	UpConf	Cntrl	1Dose	1Inc	2Dose	2Inc	Citation or Pathology	Brkly Code		
2479	1035b	189.mg	n.s.s.	0/15	200.mg	3/18					
2480	1042a	136.mg	n.s.s.	0/12	125.mg	0/12		Borchert;canr,33,590-600;1973			
	a	1042a	136.mg	n.s.s.	0/12	125.mg	0/12				
2481	1042b	142.mg	n.s.s.	0/18	82.5mg	0/18	138.mg	2/18			
	a	1042b	157.mg	n.s.s.	1/18	82.5mg	0/18	138.mg	2/18		
2482	1042c	69.1mg	n.s.s.	0/18	142.mg	1/18					
	a	1042c	69.1mg	n.s.s.	0/18	142.mg	1/18				
2483	268	113.mg	1.90gm	1/50	4.50mg	1/50	22.5mg	2/50	45.0mg		
	a	268	199.mg	736.mg	3/50	4.50mg	1/50	22.5mg	3/50	45.0mg	
	b	268	331.mg	1.53gm	2/50	4.50mg	0/50	22.5mg	2/50	45.0mg	
	c	268	433.mg	3.23gm	2/50	4.50mg	0/50	22.5mg	2/50	45.0mg	
	d	268	743.mg	8.16gm	0/50	4.50mg	0/50	22.5mg	0/50	45.0mg	
2484	268	133.mg	457.mg	0/25	5.00mg	0/25	25.0mg	1/25	50.0mg		
2485	268	221.mg	n.s.s.	3/25	4.00mg	1/25	20.0mg	2/25	40.0mg		
									8/50 (225.mg	6/50)	Long;arpa,75,595-604;1963
										19/50	
										14/50	
										10/50	
										5/50	
										12/25	
										7/25	
SELENIUM 7782-49-2											
2486	1431	.218mg	n.s.s.	20/30	.111mg	7/30		Schrauzer;carc,1,199-201;1980			
2487	1431m	40.4ug	n.s.s.	20/30	72.1ug	18/30					
SELENIUM DIETHYLDITHIOCARBAMATE (ethyl selenac) 5456-28-0											
2488	1211	4.59mg	n.s.s.	1/17	3.63mg	1/17		Innes;ntis,1968/1969			
	a	1211	7.70mg	n.s.s.	0/17	3.63mg	0/17				
	b	1211	2.21mg	n.s.s.	2/17	3.63mg	4/17				
2489	1211	2.34mg	n.s.s.	1/18	3.37mg	3/17					
	a	1211	2.54mg	n.s.s.	2/18	3.37mg	3/17				
	b	1211	1.80mg	n.s.s.	3/18	3.37mg	5/17				
2490	1211	2.34mg	n.s.s.	0/16	3.63mg	3/17					
	a	1211	7.70mg	n.s.s.	0/16	3.63mg	0/17				
	b	1211	1.40mg	18.8mg	0/16	3.63mg	6/17				
2491	1211	.627mg	3.07mg	0/16	3.37mg	12/18					
	a	1211	.718mg	3.71mg	0/16	3.37mg	11/18				
	b	1211	7.59mg	n.s.s.	0/16	3.37mg	0/18				
	c	1211	.296mg	1.45mg	0/16	3.37mg	16/18				
SELENIUM DIMETHYLDITHIOCARBAMATE (methyl selenac) 144-34-3											
2492	1205	8.68mg	n.s.s.	0/17	4.64mg	0/17		Innes;ntis,1968/1969			
	a	1205	8.68mg	n.s.s.	1/17	4.64mg	0/17				
	b	1205	4.08mg	n.s.s.	2/17	4.64mg	2/17				
2493	1205	8.54mg	n.s.s.	1/18	4.31mg	0/18					
	a	1205	8.54mg	n.s.s.	2/18	4.31mg	0/18				
	b	1205	6.05mg	n.s.s.	3/18	4.31mg	1/18				
2494	1205	8.68mg	n.s.s.	0/16	4.64mg	0/17					
	a	1205	8.68mg	n.s.s.	0/16	4.64mg	0/17				
	b	1205	8.68mg	n.s.s.	0/16	4.64mg	0/17				
2495	1205	4.24mg	n.s.s.	0/16	4.31mg	1/17					
	a	1205	8.07mg	n.s.s.	0/16	4.31mg	0/17				
	b	1205	2.02mg	n.s.s.	0/16	4.31mg	4/17				
SELENIUM SULFIDE 7446-34-6											
2496	c50033	31.4mg	74.2mg	0/50	14.1mg	5/50	70.7mg	32/50	Liv:hpa,hpc; Lun:a/a,e/c. C		
	a	c50033	43.7mg	119.mg	0/50	14.1mg	2/50	70.7mg	25/50		
	b	c50033	51.8mg	154.mg	0/50	14.1mg	1/50	70.7mg	22/50		
	c	c50033	74.9mg	338.mg	0/50	14.1mg	3/50	70.7mg	12/50		
	d	c50033	164.mg	n.s.s.	0/50	14.1mg	1/50	70.7mg	4/50		
	e	c50033	31.5mg	n.s.s.	24/50	14.1mg	31/50	70.7mg	42/50		
	f	c50033	43.7mg	119.mg	0/50	14.1mg	2/50	70.7mg	25/50		
	g	c50033	74.9mg	338.mg	0/50	14.1mg	3/50	70.7mg	12/50		
2497	c50033	53.5mg	n.s.s.	29/50	14.1mg	35/50	70.7mg	36/50	Liv:hpa,hpc,nnd.		
	a	c50033	59.9mg	n.s.s.	15/50	14.1mg	14/50	70.7mg	23/50		
	b	c50033	68.1mg	n.s.s.	4/50	14.1mg	10/50	70.7mg	14/50		
2498	c50033	4.08mg	10.1mg	1/50	2.10mg	0/50	10.6mg	37/50	Liv:hpc,nnd.		
	a	c50033	7.90mg	24.7mg	0/50	2.10mg	0/50	10.6mg	21/50		
	b	c50033	5.48mg	n.s.s.	38/50	2.10mg	37/50	10.6mg	47/50		
	c	c50033	4.08mg	10.1mg	1/50	2.10mg	0/50	10.6mg	37/50		
2499	c50033	6.96mg	22.1mg	1/50	2.10mg	0/50	10.6mg	24/50	Liv:hpa,hpc,nnd.		
	a	c50033	11.3mg	45.8mg	0/50	2.10mg	0/50	10.6mg	14/50		
	b	c50033	6.01mg	n.s.s.	33/50	2.10mg	40/50	10.6mg	43/50		
	c	c50033	6.96mg	22.1mg	1/50	2.10mg	0/50	10.6mg	24/50		
SELENIUM SULFIDE 7446-34-6											
									Liv:hpa,hpc,nnd.		
SENKIRKINE (renardine) 2318-18-5											
2500	1396	.784mg	4.77mg	0/19	2.03mg	9/19		Hirono;jnci,63,469-472;1979			
SIMAZINE (CDT) 122-34-9											
2501	1243	166.mg	n.s.s.	0/17	83.8mg	0/18		Innes;ntis,1968/1969			
	a	1243	166.mg	n.s.s.	1/17	83.8mg	0/18				
	b	1243	166.mg	n.s.s.	2/17	83.8mg	0/18				
2502	1243	55.5mg	n.s.s.	2/18	78.0mg	3/18					
	a	1243	154.mg	n.s.s.	1/18	78.0mg	0/18				
	b	1243	39.7mg	n.s.s.	3/18	78.0mg	5/18				

Spe	Strain	Site	Xpo + Xpt	Notes	TD50	2Tailpvl
Sex	Route	Hist			DR	AuOp
2503	M f b6c	orl lun	ade 76w76	evx		
	a M f b6c	orl liv	hpt 76w76	evx	>	536.mg P<.3 -
	b M f b6c	orl tba	mix 76w76	evx		no dre P=1. -
2504	M m b6c	orl liv	hpt 76w76	evx		260.mg P<.2 -
	a M m b6c	orl lun	mix 76w76	evx	.	106.mg P<.02 -
	b M m b6c	orl tba	mix 76w76	evx	±	no dre P=1. -
						65.5mg P<.003 -
SODIUM BITHIONOLATE					100ng...1ug...10...100...1mg...10...100...1g...10	
2505	M f b6a	orl liv	hpt 76w76	evx		no dre P=1. -
	a M f b6a	orl lun	ade 76w76	evx	>	no dre P=1. -
	b M f b6a	orl tba	mix 76w76	evx		5.08mg P<.7 -
2506	M m b6a	orl lun	ade 76w76	evx		no dre P=1. -
	a M m b6a	orl liv	hpt 76w76	evx	>	no dre P=1. -
	b M m b6a	orl tba	mix 76w76	evx		no dre P=1. -
2507	M f b6c	orl liv	hpt 76w76	evx		no dre P=1. -
	a M f b6c	orl lun	mix 76w76	evx	>	no dre P=1. -
	b M f b6c	orl tba	tum 76w76	evx		no dre P=1. -
2508	M m b6c	orl liv	mix 76w76	evx		2.28mg P<.09 -
	a M m b6c	orl lun	mix 76w76	evx	.	no dre P=1. -
	b M m b6c	orl tba	mix 76w76	evx	±	.805mg P<.005 -
SODIUM DIETHYLDITHIOCARBAMATE TRIHYDRATE					100ng...1ug...10...100...1mg...10...100...1g...10	
2509	M f b6c	eat TBA	MXB 25m25	a		no dre P=1. -
	a M f b6c	eat liv	MXB 25m25	a	>	27.0gm * P<.8
	b M f b6c	eat lun	MXB 25m25	a		4.76gm * P<.5
2510	M f b6c	orl liv	hpt 76w76	evx		no dre P=1. -
	a M f b6c	orl lun	ade 76w76	evx	>	no dre P=1. -
	b M f b6c	orl tba	mix 76w76	evx		no dre P=1. -
2511	M m b6c	eat TBA	MXB 25m25	a		no dre P=1. -
	a M m b6c	eat liv	MXB 25m25	a	>	no dre P=1. -
	b M m b6c	eat lun	MXB 25m25	a		10.3gm * P<.9
2512	M m b6c	orl liv	hpt 76w76	evx		68.7mg P<.02
	a M m b6c	orl lun	ade 76w76	evx	.	468.mg P<.7
	b M m b6c	orl tba	mix 76w76	evx	±	71.4mg P<.2
2513	M f b6a	orl lun	ade 76w76	evx		607.mg P<.3
	a M f b6a	orl liv	hpt 76w76	evx	>	no dre P=1. -
	b M f b6a	orl tba	mix 76w76	evx		no dre P=1. -
2514	M m b6a	orl lun	ade 76w76	evx		155.mg P<.3
	a M m b6a	orl liv	hpt 76w76	evx	>	no dre P=1. -
	b M m b6a	orl tba	mix 76w76	evx		403.mg P<.8
2515	R f f34	eat TBA	MXB 24m24	a		no dre P=1. -
	a R f f34	eat liv	MXB 24m24	a	>	no dre P=1. -
2516	R m f34	eat TBA	MXB 24m24	a		no dre P=1. -
	a R m f34	eat liv	MXB 24m24	a	>	no dre P=1. -
SORBIC ACID					100ng...1ug...10...100...1mg...10...100...1g...10	
2517	M f asp	eat liv	hnd 80w80	e		362.gm * P<.2 -
	a M f asp	eat lun	ade 80w80	e		no dre P=1. -
2518	M m asp	eat liv	hnd 80w80	e		> no dre P=1. -
	a M m asp	eat lun	ade 80w80	e		no dre P=1. -
2519	R f wis	eat liv	hem 24m24	e		34.0gm * P<.2 -
	a R f wis	eat tba	mal 24m24	e		no dre P=1. -
	b R f wis	eat tba	mix 24m24	e		no dre P=1. -
2520	R m wis	eat liv	hem 24m24	e		no dre P=1. -
	a R m wis	eat tba	mix 24m24	e		33.9gm * P<.7 -
	b R m wis	eat tba	mal 24m24	e		51.4gm * P<.5 -
SOYBEAN LECITHIN					100ng...1ug...10...100...1mg...10...100...1g...10	
2521	R f wis	eat liv	nod 24m24	e		no dre P=1. -
2522	R m wis	eat liv	cho 24m24	e		>42.2gm P<.3 -
STARCH ACETATE					100ng...1ug...10...100...1mg...10...100...1g...10	
2523	R f wis	eat liv	tum 24m24	e		no dre P=1. -
	a R f wis	eat tba	mix 24m24	e		no dre P=1. -
2524	R m wis	eat liv	tum 24m24	e		no dre P=1. -
	a R m wis	eat tba	mix 24m24	e		no dre P=1. -
STERIGMATOCYSTIN					100ng...1ug...10...100...1mg...10...100...1g...10	
2525	R m ain	eat liv	mix 28m28	ee		+historical * P<.003 +
	a R m ain	eat liv	hnd 28m28	ee	.	+historical * P<.008 +
	b R m ain	eat liv	hes 28m28	ee	.	+historical * P<.03 +
	c R m ain	eat liv	hpc 28m28	ee	.	+historical * P<.2 +
	d R m ain	eat tba	mix 28m28	ee	.	no dre P=1. -
2526	R m don	eat liv	mix 23m23	ee	.	82.5ug * P<.0005+
	a R m don	eat liv	ade 23m23	ee	.	.727mg * P<.007
	b R m don	eat liv	hes 23m23	ee	.	1.57mg * P<.07
2527	R b wis	gav liv	hpc 12m29	ev	.	.322mg * P<.0005+
2528	R b wis	eat liv	hpc 12m29	ev	.	.124mg Z P<.0005+
2529	R m wis	eat liv	car 54w69	er	.	.111mg P<.0005+

RefNum	LoConf	UpConf	Cntrl	1Dose	1Inc	2Dose	2Inc	Citation or Pathology	Brkly Code
2503	1243	87.3mg	n.s.s.	0/16	83.8mg	1/18			
a	1243	166.mg	n.s.s.	0/16	83.8mg	0/18			
b	1243	63.9mg	n.s.s.	0/16	83.8mg	2/18			
2504	1243	36.5mg	n.s.s.	0/16	78.0mg	4/17			
a	1243	146.mg	n.s.s.	0/16	78.0mg	0/17			
b	1243	26.4mg	355.mg	0/16	78.0mg	6/17			
SODIUM BITHIONOLATE (Vancide BN) 6385-58-6									
2505	1284	1.79mg	n.s.s.	0/17	.959mg	0/17		Innes;ntis,1968/1969	
a	1284	1.79mg	n.s.s.	1/17	.959mg	0/17			
b	1284	.641mg	n.s.s.	2/17	.959mg	3/17			
2506	1284	.833mg	n.s.s.	2/18	.891mg	2/18			
a	1284	1.77mg	n.s.s.	1/18	.891mg	0/18			
b	1284	.922mg	n.s.s.	3/18	.891mg	2/18			
2507	1284	1.90mg	n.s.s.	0/16	.959mg	0/18			
a	1284	1.90mg	n.s.s.	0/16	.959mg	0/18			
b	1284	1.90mg	n.s.s.	0/16	.959mg	0/18			
2508	1284	.559mg	n.s.s.	0/16	.891mg	2/15			
a	1284	1.47mg	n.s.s.	0/16	.891mg	0/15			
b	1284	.302mg	6.34mg	0/16	.891mg	5/15			
SODIUM DIETHYLDITHIOCARBAMATE TRIHYDRATE (SPDC) 148-18-5									
2509	c02835	774.mg	n.s.s.	13/20	65.0mg	20/50	520.mg	26/50	
a	c02835	1.98gm	n.s.s.	0/20	65.0mg	2/50	520.mg	2/50	liv:hpa,hpc,nnd. lun:a/a,a/c.
b	c02835	941.mg	n.s.s.	0/20	65.0mg	7/50	520.mg	8/50	Innes;ntis,1968/1969
2510	273	188.mg	n.s.s.	0/18	94.9mg	0/18			
a	273	188.mg	n.s.s.	1/18	94.9mg	0/18			
b	273	133.mg	n.s.s.	3/18	94.9mg	1/18			
2511	c02835	530.mg	n.s.s.	13/20	60.0mg	37/50	480.mg	30/50	
a	c02835	1.01gm	n.s.s.	7/20	60.0mg	11/50	480.mg	11/50	liv:hpa,hpc,nnd. lun:a/a,a/c.
b	c02835	742.mg	n.s.s.	6/20	60.0mg	14/50	480.mg	14/50	Innes;ntis,1968/1969
2512	273	27.0mg	n.s.s.	1/17	88.2mg	7/17			
a	273	58.9mg	n.s.s.	2/17	88.2mg	3/17			
b	273	21.3mg	n.s.s.	6/17	88.2mg	10/17			
2513	273	98.9mg	n.s.s.	0/17	94.9mg	1/18			
a	273	188.mg	n.s.s.	0/17	94.9mg	0/18			
b	273	89.6mg	n.s.s.	2/17	94.9mg	2/18			
2514	273	42.0mg	n.s.s.	2/18	88.2mg	5/18			
a	273	175.mg	n.s.s.	3/18	88.2mg	0/18			
b	273	43.4mg	n.s.s.	5/18	88.2mg	6/18			
2515	c02835	146.mg	n.s.s.	17/20	62.5mg	26/50	125.mg	34/50	
a	c02835	1.79gm	n.s.s.	1/20	62.5mg	0/50	125.mg	0/50	liv:hpa,hpc,nnd.
2516	c02835	88.9mg	n.s.s.	14/16	50.0mg	38/50	100.mg	34/50	
a	c02835	684.mg	n.s.s.	0/16	50.0mg	1/50	100.mg	0/50	liv:hpa,hpc,nnd.
SORBIC ACID 110-44-1									
2517	409	58.9gm	n.s.s.	0/48	1.30gm	0/46	6.50gm	0/43	13.0gm 1/43
a	409	32.3gm	n.s.s.	14/48	1.30gm	5/46	6.50gm	10/43	13.0gm 5/43
2518	409	5.10gm	n.s.s.	1/44	1.20gm	0/46	6.00gm	0/43	12.0gm 0/43
a	409	14.6gm	n.s.s.	19/44	1.20gm	16/46	6.00gm	16/43	12.0gm 15/43
2519	412	10.9gm	n.s.s.	3/42	750.mg	2/45	5.00gm	7/46	
a	412	44.7gm	n.s.s.	3/42	750.mg	3/45	5.00gm	0/46	Gaunt;fctx,13,31-45;1975
b	412	1.02gm	n.s.s.	35/42	750.mg	30/45	(5.00gm)	17/46)	
2520	412	25.8gm	n.s.s.	0/43	600.mg	1/43	4.00gm	0/41	
a	412	4.11gm	n.s.s.	20/43	600.mg	21/43	4.00gm	21/41	
b	412	9.48gm	n.s.s.	5/43	600.mg	3/43	4.00gm	6/41	
SOYBEAN LECITHIN 8002-43-5									
2521	1359	19.4gm	n.s.s.	1/47	2.00gm	0/47			
2522	1359	6.87gm	n.s.s.	0/41	1.60gm	1/39			Brantom;fctx,11,755-769;1973
STARCH ACETATE ---									
2523	1407	92.7gm	n.s.s.	0/30	15.0gm	0/30			
a	1407	19.4gm	n.s.s.	23/30	15.0gm	17/30			de Groot;fctx,12,651-663;1974
2524	1407	66.8gm	n.s.s.	0/23	12.0gm	0/27			
a	1407	3.91gm	n.s.s.	21/23	12.0gm	24/27			
STERIGMATOCYSTIN 10046-13-2									
2525	1184	.679mg	10.4mg	0/11	4.00ug	0/27	40.0ug	1/29	.400mg 5/26
a	1184	1.05mg	91.1mg	0/11	4.00ug	0/27	40.0ug	0/29	.400mg 3/26
b	1184	.898mg	n.s.s.	0/11	4.00ug	0/27	40.0ug	1/29	.400mg 3/26
c	1184	1.76mg	n.s.s.	0/11	4.00ug	0/27	40.0ug	0/29	.400mg 1/26
d	1184	.753mg	n.s.s.	7/11	4.00ug	13/27	40.0ug	6/29	.400mg 10/26
2526	392	42.6ug	.166mg	0/17	.200mg	11/13	.400mg	12/13	
a	392	.295mg	9.46mg	0/17	.200mg	2/13	.400mg	4/13	Ohtaubo;fctx,16,143-149;1978
b	392	.474mg	n.s.s.	0/17	.200mg	1/13	.400mg	2/13	
2527	275m	.165mg	.982mg	0/10	.107mg	4/10	.213mg	5/10	1.07mg 9/10
2528	275n	53.6ug	.286mg	0/10	.239mg	8/10	.477mg	10/10	(.239mg 3/10)
2529	707	48.6ug	.333mg	0/25	.313mg	8/14			Terao;fctx,16,591-596;1978

Spe	Strain	Site	Xpo+Xpt	Notes	TD50	2Tailpvl						
Sex	Route	Hist			DR	AuOp						
STREPTOZOTOCIN												
			100ng	1ug	10	100	1mg	10	100	1g	10	
2530	M f	swi ipj	lun mix	26w78 e								.193mg \ P<.0005+
a	M f	swi ipj	kid ade	26w78 e								1.39mg \ P<.0005+
b	M f	swi ipj	ute sar	26w78 e								13.9mg * P<.04
c	M f	swi ipj	liv lys	26w78 e								no dre P=1.
d	M f	swi ipj	tba ben	26w78 e								.188mg \ P<.0005
e	M f	swi ipj	tba mix	26w78 e								.486mg * P<.0005
f	M f	swi ipj	tba mal	26w78 e								6.32mg / P<.2
2531	M m	swi ipj	lun mix	26w72 e								.462mg \ P<.0005+
a	M m	swi ipj	kfd tla	26w72 e								2.44mg \ P<.006 +
b	M m	swi ipj	liv mix	26w72 e								27.3mg * P<.6
c	M m	swi ipj	tba mix	26w72 e								.217mg \ P<.0005
d	M m	swi ipj	tba ben	26w72 e								.698mg \ P<.003
e	M m	swi ipj	tba mal	26w72 e								3.53mg * P<.3
2532	R f	cdr ipj	kid mix	26w78 e								1.27mg * P<.0005+
a	R f	cdr ipj	mgl car	26w78 e								1.41mg \ P<.009
b	R f	cdr ipj	ute sar	26w78 e								2.46mg \ P<.003
c	R f	cdr ipj	liv mix	26w78 e								4.43mg * P<.0005
d	R f	cdr ipj	liv cvh	26w78 e								5.63mg * P<.0005
e	R f	cdr ipj	tba mal	26w78 e								.363mg \ P<.0005
f	R f	cdr ipj	tba mix	26w78 e								1.14mg * P<.06
g	R f	cdr ipj	tba ben	26w78 e								no dre P=1.
2533	R m	cdr ipj	kid mix	26w78 e								.776mg * P<.0005+
a	R m	cdr ipj	liv lcc	26w78 e								20.4mg * P<.2
b	R m	cdr ipj	tba mix	26w78 e								.751mg * P<.0005
c	R m	cdr ipj	tba mal	26w78 e								1.03mg * P<.0005
d	R m	cdr ipj	tba ben	26w78 e								16.8mg * P<.7
STROBANE												
			100ng	1ug	10	100	1mg	10	100	1g	10	
2534	M f	b6a orl	liv hpt	79w79 evx								no dre P=1.
a	M f	b6a orl	lun ade	79w79 evx								no dre P=1.
b	M f	b6a orl	tba mix	79w79 evx								no dre P=1.
2535	M m	b6a orl	liv hpt	79w79 evx								.644mg P<.0005+
a	M m	b6a orl	lun ade	79w79 evx								no dre P=1.
b	M m	b6a orl	tba mix	79w79 evx								.750mg P<.006
2536	M f	b6c orl	lun ade	79w79 evx								10.7mg P<.3
a	M f	b6c orl	liv hpt	79w79 evx								no dre P=1.
b	M f	b6c orl	tba mix	79w79 evx								3.37mg P<.05
2537	M m	b6c orl	--- rts	79w79 evx								1.41mg P<.005 +
a	M m	b6c orl	liv hpt	79w79 evx								4.00mg P<.09
b	M m	b6c orl	lun ade	79w79 evx								8.29mg P<.3
c	M m	b6c orl	tba mix	79w79 evx								.750mg P<.0005
STYRENE												
			100ng	1ug	10	100	1mg	10	100	1g	10	
2538	M f	b6c gav	liv hpa	78w91								#905. mg * P<.04 -
a	M f	b6c gav	TBA MXB	78w91								625. mg * P<.4
b	M f	b6c gav	liv MXB	78w91								905. mg * P<.04
c	M f	b6c gav	lun MXB	78w91								1.38gm * P<.2
2539	M m	b6c gav	lun MXA	78w91								360. mg * P<.007 a
a	M m	b6c gav	TBA MXB	78w91								659. mg * P<.5
b	M m	b6c gav	liv MXB	78w91								895. mg * P<.5
c	M m	b6c gav	lun MXB	78w91								360. mg * P<.007
2540	R f	f34 gav	TBA MXB	90w97 as								no dre P=1. -
a	R f	f34 gav	liv MXB	90w97 as								25.2gm * P<.4
2541	R m	f34 gav	TBA MXB	90w97 as								3.41gm Z P<.5 -
a	R m	f34 gav	liv MXB	90w97 as								no dre P=1.
STYRENE AND beta-NITROSTYRENE MIXTURE												
			100ng	1ug	10	100	1mg	10	100	1g	10	
2542	M f	b6c gav	TBA MXB	78w92								216. mg * P<.3 -
a	M f	b6c gav	liv MXB	78w92								no dre P=1.
b	M f	b6c gav	lun MXB	78w92								no dre P=1.
2543	M m	b6c gav	lun MXA	79w92								#61.5mg \ P<.007 -
a	M m	b6c gav	TBA MXB	79w92								no dre P=1.
b	M m	b6c gav	liv MXB	79w92								no dre P=1.
c	M m	b6c gav	lun MXB	79w92								61.5mg \ P<.007
2544	R f	f34 gav	TBA MXB	18m25								no dre P=1. -
a	R f	f34 gav	liv MXB	18m25								no dre P=1.
2545	R m	f34 gav	TBA MXB	18m25								no dre P=1. -
a	R m	f34 gav	liv MXB	18m25								1.57gm * P<.4
SUCROSE												
			100ng	1ug	10	100	1mg	10	100	1g	10	
2546	M f	swa eat	lun mix	76w76 e								129. gm P<.8 -
a	M f	swa eat	liv hpt	76w76 e								no dre P=1. -
SULFALLATE												
			100ng	1ug	10	100	1mg	10	100	1g	10	
2547	M f	b6c eat	mgl MXA	78w90 dv								27.3mg * P<.0005c
a	M f	b6c eat	mgl acn	78w90 dv								39.3mg * P<.0005c
b	M f	b6c eat	lun MXA	78w90 dv								87.5mg * P<.007
c	M f	b6c eat	mgl esw	78w90 dv								98.3mg * P<.0005c

CARCINOGENIC POTENCY DATABASE

RefNum	LoConf	UpConf	Cntrl	1Dose	1Inc	2Dose	2Inc	Citation or Pathology	Brkly Code	
STREPTOZOTOCIN 18883-66-4										
2530	1336m	91.5ug .477mg	20/154	.855mg	16/19	(2.50mg	14/21)	Skipper;arfr;1976/Weisburger 1977/Prejean pers.com.		
a	1336m	.480mg 7.18mg	0/154	.855mg	4/19	(2.50mg	2/21)			
b	1336m	3.19mg n.s.s.	1/154	.855mg	0/19	2.50mg	2/21			
c	1336m	1.44mg n.s.s.	1/154	.855mg	0/19	2.50mg	0/21			
d	1336m	90.2ug .443mg	13/154	.855mg	16/19	(2.50mg	9/21)			
e	1336m	.263mg 1.09mg	42/154	.855mg	16/19	2.50mg	17/21			
f	1336m	1.66mg n.s.s.	29/154	.855mg	0/19	2.50mg	8/21			
2531	1336m	.197mg 1.82mg	9/101	.930mg	9/17	(2.08mg	5/16)			
a	1336m	.599mg 47.1mg	0/101	.930mg	2/17	(2.08mg	0/16)			
b	1336m	2.74mg n.s.s.	2/101	.930mg	0/17	2.08mg	1/16			
c	1336m	92.5ug .761mg	28/101	.930mg	14/17	(2.08mg	6/16)			
d	1336m	.264mg 5.53mg	9/101	.930mg	7/17	(2.08mg	2/16)			
e	1336m	.890mg n.s.s.	19/101	.930mg	7/17	2.08mg	4/16			
2532	1336n	.693mg 2.70mg	0/182	.859mg	5/23	1.82mg	10/23			
a	1336n	.487mg 65.7mg	12/182	.859mg	6/23	(1.82mg	1/23)			
b	1336n	.724mg 30.7mg	1/182	.859mg	3/23	(1.82mg	0/23)			
c	1336n	1.68mg 18.4mg	0/182	.859mg	1/23	1.82mg	4/23			
d	1336n	1.94mg 29.0mg	0/182	.859mg	1/23	1.82mg	3/23			
e	1336n	.169mg 1.22mg	44/182	.859mg	16/23	(1.82mg	8/23)			
f	1336n	.410mg n.s.s.	103/182	.859mg	21/23	1.82mg	15/23			
g	1336n	2.05mg n.s.s.	59/182	.859mg	5/23	1.82mg	7/23			
2533	1336n	.446mg 1.51mg	0/177	.859mg	7/22	1.72mg	12/20			
a	1336n	3.31mg n.s.s.	0/177	.859mg	1/22	1.72mg	0/20			
b	1336n	.365mg 2.94mg	59/177	.859mg	15/22	1.72mg	13/20			
c	1336n	.504mg 3.83mg	32/177	.859mg	14/22	1.72mg	8/20			
d	1336n	1.86mg n.s.s.	27/177	.859mg	1/22	1.72mg	5/20			
STROBANE (dichloricide mothproof) 8001-50-1										
2534	277	3.32mg n.s.s.	0/17	1.55mg	0/18			Innes;ntis,1968/1969		
a	277	3.32mg n.s.s.	1/17	1.55mg	0/18					
b	277	3.32mg n.s.s.	2/17	1.55mg	0/18					
2535	277	.300mg 2.14mg	1/18	1.45mg	11/18					
a	277	3.10mg n.s.s.	2/18	1.45mg	0/18					
b	277	.319mg 9.63mg	3/18	1.45mg	11/18					
2536	277	1.75mg n.s.s.	0/16	1.55mg	1/18					
a	277	3.32mg n.s.s.	0/16	1.55mg	0/18					
b	277	1.02mg n.s.s.	0/16	1.55mg	3/18					
2537	277	.530mg 11.1mg	0/16	1.45mg	5/15					
a	277	.980mg n.s.s.	0/16	1.45mg	2/15					
b	277	1.35mg n.s.s.	0/16	1.45mg	1/15					
c	277	.330mg 2.28mg	0/16	1.45mg	8/15					
STYRENE 100-42-5										
2538	c02200	369.mg n.s.s.	0/20	92.0mg	1/50	184.mg	5/50		S liv:hpa,hpc,nnd. Lun:a/a,a/c. Lun:a/a,a/c. Lun:a/a,a/c. Lun:a/a,a/c. Lun:a/a,a/c. Lun:a/a,a/c. Lun:a/a,a/c. Lun:a/a,a/c. Lun:a/a,a/c. Lun:a/a,a/c. Lun:a/a,a/c. Lun:a/a,a/c. Lun:a/a,a/c. Lun:a/a,a/c. Lun:a/a,a/c. Lun:a/a,a/c. Lun:a/a,a/c. Lun:a/a,a/c.	
a	c02200	188.mg n.s.s.	2/20	92.0mg	11/50	184.mg	10/50			
b	c02200	369.mg n.s.s.	0/20	92.0mg	1/50	184.mg	5/50			
c	c02200	477.mg n.s.s.	0/20	92.0mg	1/50	184.mg	3/50			
2539	c02200	198.mg 4.60gm	0/20	92.0mg	6/49	184.mg	9/50			
a	c02200	154.mg n.s.s.	9/20	92.0mg	14/49	184.mg	21/50			
b	c02200	219.mg n.s.s.	5/20	92.0mg	8/49	184.mg	13/50			
c	c02200	198.mg 4.60gm	0/20	92.0mg	6/49	184.mg	9/50			
2540	c02200	1.08gm n.s.s.	23/40	354.mg	25/50	530.mg	17/50	1.06gm 3/50		
a	c02200	4.11gm n.s.s.	0/40	354.mg	0/50	530.mg	1/50	1.06gm 0/50		
2541	c02200	765.mg n.s.s.	14/40	354.mg	14/50	530.mg	15/50	1.06gm 4/50		
a	c02200	6.85gm n.s.s.	1/40	354.mg	0/50	530.mg	0/50	1.06gm 0/50		
STYRENE AND beta-NITROSTYRENE MIXTURE (CAS# 100-42-5 and 102-96-5) mixture										
2542	c02211	70.1mg n.s.s.	2/20	31.8mg	10/50	63.6mg	10/50	S liv:hpa,hpc,nnd. Lun:a/a,a/c. Lun:a/a,a/c. Lun:a/a,a/c. Lun:a/a,a/c. Lun:a/a,a/c. Lun:a/a,a/c. Lun:a/a,a/c. Lun:a/a,a/c. Lun:a/a,a/c. Lun:a/a,a/c. Lun:a/a,a/c. Lun:a/a,a/c. Lun:a/a,a/c. Lun:a/a,a/c. Lun:a/a,a/c. Lun:a/a,a/c. Lun:a/a,a/c. Lun:a/a,a/c.		
a	c02211	467.mg n.s.s.	1/20	31.8mg	1/50	63.6mg	0/50			
b	c02211	288.mg n.s.s.	0/20	31.8mg	2/50	63.6mg	0/50			
2543	c02211	30.8mg 556.mg	0/20	31.8mg	11/50	(63.6mg	2/50)			
a	c02211	72.9mg n.s.s.	8/20	31.8mg	19/50	63.6mg	12/50			
b	c02211	118.mg n.s.s.	6/20	31.8mg	6/50	63.6mg	8/50			
c	c02211	30.8mg 556.mg	0/20	31.8mg	11/50	(63.6mg	2/50)			
2544	c02211	34.7mg n.s.s.	12/20	23.5mg	34/50	47.0mg	30/50			
a	c02211	270.mg n.s.s.	0/20	23.5mg	1/50	47.0mg	0/50			
2545	c02211	198.mg n.s.s.	10/20	47.0mg	18/50	94.0mg	11/50			
a	c02211	387.mg n.s.s.	0/20	47.0mg	1/50	94.0mg	1/50			
SUCROSE 57-50-1										
2546	1090	14.9gm n.s.s.	7/45	13.0gm	8/43				Roe;fctx,8,135-145;1970	
a	1090	32.9gm n.s.s.	3/45	13.0gm	2/43					
SULFALLATE 95-06-7										
2547	c00453	18.4mg 41.6mg	0/20	73.1mg	33/50	146.mg	27/50		mgL:acn,asm. Lun:a/a,a/c. S	
a	c00453	24.0mg 72.5mg	0/20	73.1mg	23/50	146.mg	11/50			
b	c00453	42.8mg 1.16gm	1/20	73.1mg	13/50	146.mg	4/50			
c	c00453	57.4mg 190.mg	0/20	73.1mg	10/50	146.mg	16/50			

Spe	Strain	Site	Xpo + Xpt	Notes	TD50	2Tailpvl
Sex	Route	Hist			DR	AnOp
d	M f b6c eat	liv hpc	78w90	dv	107.mg *	P<.0005
e	M f b6c eat	TBA MXB	78w90	dv	21.3mg *	P<.0005
f	M f b6c eat	liv MXB	78w90	dv	107.mg *	P<.0005
g	M f b6c eat	lun MXB	78w90	dv	87.5mg *	P<.007
2548	M m b6c eat	lun MXA	78w91	dv	92.5mg *	P<.0005c
a	M m b6c eat	lun a/c	78w91	dv	269.mg *	P<.006
b	M m b6c eat	--- hes	78w91	dv	539.mg *	P<.03
c	M m b6c eat	TBA MXB	78w91	dv	65.5mg *	P<.03
d	M m b6c eat	liv MXB	78w91	dv	188.mg *	P<.3
e	M m b6c eat	lun MXB	78w91	dv	92.5mg *	P<.0005
2549	R f oam eat	mpl acn	18m24	dv	17.2mg *	P<.0005c
a	R f oam eat	TBA MXB	18m24	dv	9.06mg *	P<.03
b	R f oam eat	liv MXB	18m24	dv	69.1mg *	P<.2
2550	R m oam eat	thy MXA	18m24	dv	24.0mg *	P<.007
a	R m oam eat	sto MXA	18m24	dv	53.9mg /	P<.007 c
b	R m oam eat	TBA MXB	18m24	dv	12.6mg *	P<.3
c	R m oam eat	liv MXB	18m24	dv	no dre	P=1.
SULFATE, SODIUM				100ng...:1ug...:10...:100...:1mg...:10...:100...:1g...:10		
2551	M f awi eat	--- leu	32w52	v	3.96gm	P<.6
a	M f awi eat	liv tum	32w52	v	no dre	P=1.
b	M f awi eat	lun tum	32w52	v	no dre	P=1.
SULFISOXAZOLE				100ng...:1ug...:10...:100...:1mg...:10...:100...:1g...:10		
2552	M f b6c eat	liv hpc	24m24		#2.65gm \	P<.008 -
a	M f b6c eat	lun MXA	24m24		11.9gm *	P<.007
b	M f b6c eat	TBA MXB	24m24		8.18gm *	P<.5
c	M f b6c eat	liv MXB	24m24		2.65gm \	P<.008
d	M f b6c eat	lun MXB	24m24		11.9gm *	P<.007
2553	M m b6c eat	TBA MXB	24m24		no dre	P=1. -
a	M m b6c eat	liv MXB	24m24		6.91gm *	P<.3
b	M m b6c eat	lun MXB	24m24		49.5gm \	P<.1
2554	R f f34 eat	TBA MXB	24m25		no dre	P=1. -
a	R f f34 eat	liv MXB	24m25		no dre	P=1. -
2555	R m f34 eat	TBA MXB	24m24		135.mg \	P<.09 -
a	R m f34 eat	liv MXB	24m24		26.3gm *	P<.9
SULFITE, POTASSIUM METABI-				100ng...:1ug...:10...:100...:1mg...:10...:100...:1g...:10		
2556	M f icr wat	lun ade	24m24		.33.6gm \	P<.1 -
a	M f icr wat	lun adc	24m24		100.gm *	P<.4 -
b	M f icr wat	liv hms	24m24		204.gm *	P<.3 -
2557	M m icr wat	lun ade	24m24		84.8gm *	P<.3 -
a	M m icr wat	lun adc	24m24		84.8gm *	P<.3 -
b	M m icr wat	liv tum	24m24		no dre	P=1. -
3-SULFOLENE				100ng...:1ug...:10...:100...:1mg...:10...:100...:1g...:10		
2558	M f b6c gav	TBA MXB	78w90	sv	no dre	P=1. -
a	M f b6c gav	liv MXB	78w90	sv	no dre	P=1. -
b	M f b6c gav	lun MXB	78w90	sv	1.94gm *	P<.4
2559	M m b6c gav	TBA MXB	78w90	sv	631.mg *	P<.5 -
a	M m b6c gav	liv MXB	78w90	sv	415.mg *	P<.09
b	M m b6c gav	lun MXB	78w90	sv	882.mg *	P<.2
2560	R f oam gav	TBA MXB	18m26	dv	5.37gm *	P<.1 -
a	R f oam gav	liv MXB	18m26	dv	no dre	P=1. -
2561	R m oam gav	TBA MXB	16m26	adv	30.8mg *	P<.04 -
a	R m oam gav	liv MXB	16m26	adv	no dre	P=1. -
4,4'-SULFONYLBISACETANILIDE				100ng...:1ug...:10...:100...:1mg...:10...:100...:1g...:10		
2562	R f buf eat	mpl adc	43w92	e	55.6mg	P<.3 +
SYMPHYTINE				100ng...:1ug...:10...:100...:1mg...:10...:100...:1g...:10		
2563	R m aci ipj	liv mix	56w92	ev	1.91mg	P<.02 +
a	R m aci ipj	tba mix	56w92	ev	4.50mg	P<.5
TACE				100ng...:1ug...:10...:100...:1mg...:10...:100...:1g...:10		
2564	R f cdr eat	liv tum	24m24	e	no dre	P=1. -
2565	R m cdr eat	liv tum	24m24	e	no dre	P=1. -
TELODRIN				100ng...:1ug...:10...:100...:1mg...:10...:100...:1g...:10		
2566	M f b6a orl	lun ade	76w76	evx	no dre	P=1. -
a	M f b6a orl	liv hpt	76w76	evx	no dre	P=1. -
b	M f b6a orl	tba mix	76w76	evx	no dre	P=1. -
2567	M m b6a orl	lun ade	76w76	evx	.146mg	P<.3 -
a	M m b6a orl	liv hpt	76w76	evx	no dre	P=1. -
b	M m b6a orl	tba mix	76w76	evx	.136mg	P<.3 -
2568	M f b6c orl	lun ade	76w76	evx	.571mg	P<.3 -
a	M f b6c orl	liv hpt	76w76	evx	no dre	P=1. -
b	M f b6c orl	tba mix	76w76	evx	.277mg	P<.2 -

RefNum	LoConf	UpConf	Cntrl	1Dose	1Inc	2Dose	2Inc	Citation or Pathology	Brkly Code	
d	c00453	53.4mg	272.mg	0/20	73.1mg	5/50	146.mg	8/50		S
e	c00453	13.7mg	39.2mg	7/20	73.1mg	42/50	146.mg	37/50		
f	c00453	53.4mg	272.mg	0/20	73.1mg	5/50	146.mg	8/50		
g	c00453	42.8mg	1.16gm	1/20	73.1mg	13/50	146.mg	4/50		
2548	c00453	59.6mg	276.mg	0/20	69.6mg	14/50	140.mg	17/50		
a	c00453	138.mg	2.29gm	0/20	69.6mg	3/50	140.mg	9/50		S
b	c00453	230.mg	n.s.s.	0/20	69.6mg	1/50	140.mg	6/50		S
c	c00453	31.1mg	n.s.s.	8/20	69.6mg	37/50	140.mg	39/50		
d	c00453	62.4mg	n.s.s.	7/20	69.6mg	22/50	140.mg	24/50		
e	c00453	59.6mg	276.mg	0/20	69.6mg	14/50	140.mg	17/50		
2549	c00453	9.63mg	34.8mg	0/50	6.70mg	7/50	10.8mg	11/50		
a	c00453	4.01mg	n.s.s.	36/50	6.70mg	37/50	10.8mg	30/50		
b	c00453	21.4mg	n.s.s.	1/50	6.70mg	3/50	10.8mg	2/50		
2550	c00453	9.75mg	321.mg	0/50	5.40mg	4/50	8.80mg	2/50		
a	c00453	18.7mg	703.mg	0/50	5.40mg	0/50	8.80mg	5/50		
b	c00453	3.94mg	n.s.s.	28/50	5.40mg	27/50	8.80mg	19/50		
c	c00453	n.s.s.	n.s.s.	0/50	5.40mg	0/50	8.80mg	0/50		
SULFATE, SODIUM (disodium sulfate) 7757-82-6										
2551	1118	544.mg	n.s.s.	1/30	811.mg			2/30		
a	1118	1.25gm	n.s.s.	0/30	811.mg			0/30		
b	1118	1.25gm	n.s.s.	0/30	811.mg			0/30		
SULFISOXAZOLE 127-69-5										
2552	c50022	1.01gm	11.0gm	0/50	490.mg	5/50	(1.96gm	2/50)		S
a	c50022	4.84gm	161.gm	0/50	490.mg	1/50	1.96gm	5/50		
b	c50022	1.71gm	n.s.s.	24/50	490.mg	29/50	1.96gm	31/50		
c	c50022	1.01gm	11.0gm	0/50	490.mg	5/50	(1.96gm	2/50)		
d	c50022	4.84gm	161.gm	0/50	490.mg	1/50	1.96gm	5/50		
2553	c50022	2.17gm	n.s.s.	29/50	495.mg	31/50	1.98gm	28/50		
a	c50022	1.87gm	n.s.s.	15/50	495.mg	13/50	1.98gm	21/50		
b	c50022	1.30gm	n.s.s.	4/50	495.mg	5/50	(1.98gm	0/50)		
2554	c50022	470.mg	n.s.s.	38/50	97.2mg	37/50	389.mg	35/50		
a	c50022	4.33gm	n.s.s.	1/50	97.2mg	0/50	389.mg	0/50		
2555	c50022	50.6mg	n.s.s.	28/50	97.2mg	36/50	(392.mg	31/50)		
a	c50022	1.10gm	n.s.s.	1/50	97.2mg	4/50	392.mg	2/50		
SULFITE, POTASSIUM METABI- ---										
2556	1391	8.26gm	n.s.s.	0/50	2.00gm	2/50	(4.00gm	0/50)		
a	1391	22.0gm	n.s.s.	1/50	2.00gm	0/50	4.00gm	3/50		
b	1391	33.3gm	n.s.s.	0/50	2.00gm	0/50	4.00gm	1/50		
2557	1391	20.9gm	n.s.s.	0/50	1.67gm	1/50	3.33gm	1/50		
a	1391	20.9gm	n.s.s.	0/50	1.67gm	1/50	3.33gm	1/50		
b	1391	11.4gm	n.s.s.	0/50	1.67gm	0/50	3.33gm	0/50		
3-SULFOLENE 77-79-2										
2558	c04557	426.mg	n.s.s.	4/20	235.mg	10/50	470.mg	1/50		
a	c04557	n.s.s.	n.s.s.	0/20	235.mg	1/50	470.mg	0/50		
b	c04557	480.mg	n.s.s.	1/20	235.mg	5/50	470.mg	1/50		
2559	c04557	152.mg	n.s.s.	5/20	190.mg	20/50	381.mg	8/50		
a	c04557	179.mg	n.s.s.	1/20	190.mg	11/50	381.mg	5/50		
b	c04557	350.mg	n.s.s.	0/20	190.mg	4/50	381.mg	2/50		
2560	c04557	60.1mg	n.s.s.	14/20	52.5mg	39/50	105.mg	21/50		
a	c04557	n.s.s.	n.s.s.	0/20	52.5mg	2/50	105.mg	0/50		
2561	c04557	8.90mg	n.s.s.	9/20	88.5mg	13/50	249.mg	1/50		
a	c04557	n.s.s.	n.s.s.	0/20	88.5mg	1/50	249.mg	0/50		
4,4'-SULFONYLBISACETANILIDE 77-46-3										
2562	144	9.05mg	n.s.s.	0/18	5.93mg			1/18		
SYMPHYTINE 22571-95-5										
2563	1396	.655mg	n.s.s.	0/13	1.20mg			4/14		
a	1396	.895mg	n.s.s.	3/18	1.20mg			5/18		
TACE (chlorotrianiene) 569-57-3										
2564	108	.162mg	n.s.s.	0/20	50.0ug	0/20	.200mg	0/20	2.00mg	0/20
2565	108	.162mg	n.s.s.	0/20	50.0ug	0/20	.200mg	0/20	2.00mg	0/20
TELODRIM (isobenzan) 297-78-9										
2566	1249	.106mg	n.s.s.	1/17	89.1ug			1/18		
a	1249	.177mg	n.s.s.	0/17	89.1ug			0/18		
b	1249	84.1ug	n.s.s.	2/17	89.1ug			2/18		
2567	1249	39.4ug	n.s.s.	2/18	82.9ug			5/18		
a	1249	98.0ug	n.s.s.	1/18	82.9ug			1/18		
b	1249	35.4ug	n.s.s.	3/18	82.9ug			6/18		
2568	1249	92.9ug	n.s.s.	0/16	89.1ug			1/18		
a	1249	.177mg	n.s.s.	0/16	89.1ug			0/18		
b	1249	68.0ug	n.s.s.	0/16	89.1ug			2/18		

Spe	Strain	Site	Xpo+Xpt		TD50	2Tailpvl
Sex	Route	Hist	Notes		DR	AuOp
2569	M	m b6c	ori liv hpt 76w76 evx	>	.500mg	P<.3 -
a	M	m b6c	ori lun ade 76w76 evx		.500mg	P<.3 -
b	M	m b6c	ori tba mix 76w76 evx		.242mg	P<.1 -
3,3',4,4'-TETRAAMINOBIPHENYL-4HCl 100ng...1ug...10...100...1mg...10...100...1g...10						
2570	M	f chi	eat lun mix 77w98		1.03gm	* P<.07 -
a	M	f chi	eat liv mix 77w98		1.69gm	* P<.03 -
b	M	f chi	eat tba mix 77w98		599.mg	* P<.05 -
2571	M	m chi	eat lun mix 77w94		288.mg	\ P<.003 +
a	M	m chi	eat liv mix 77w94		4.17gm	* P<.7 -
b	M	m chi	eat tba mix 77w94		224.mg	\ P<.003
2572	R	m cdr	eat liv mix 18m25		259.mg	* P<.02
a	R	m cdr	eat tba mix 18m25		200.mg	* P<.2
2573	R	m cdr	eat liv hpt 18m25	pool	395.mg	* P<.02 +
2,3,5,6-TETRACHLORO-4-NITROANISOLE ...1ug...10...100...1mg...10...100...1g...10						
2574	M	f b6c	eat TBA MXB 24m24	>	61.7mg	* P<.6 -
a	M	f b6c	eat liv MXB 24m24		no dre	P=1.
b	M	f b6c	eat lun MXB 24m24		1.77gm	* P<.1.
2575	M	m b6c	eat TBA MXB 24m24	>	no dre	P=1. -
a	M	m b6c	eat liv MXB 24m24		no dre	P=1.
b	M	m b6c	eat lun MXB 24m24		215.mg	* P<.8
2576	R	f f34	eat ute esp 24m24		#19.1mg	* P<.05 -
a	R	f f34	eat liv MXA 24m24		45.8mg	* P<.02
b	R	f f34	eat TBA MXB 24m24		106.mg	* P<.9
c	R	f f34	eat liv MXB 24m24		45.8mg	* P<.02
2577	R	m f34	eat liv MXA 24m24		#20.0mg	* P<.03 -
a	R	m f34	eat TBA MXB 24m24		no dre	P=1.
b	R	m f34	eat liv MXB 24m24		20.0mg	* P<.03
2,2',5,5'-TETRACHLOROBENZIDINE 100ng...1ug...10...100...1mg...10...100...1g...10						
2578	M	f ddx	eat --- mly 24m24 e		109.mg	P<.0005
a	M	f ddx	eat tba mal 24m24 e		87.2mg	P<.0005
2579	R	f wis	eat liv hpt 24m24 e	>	735.mg	P<.2
a	R	f wis	eat ubl tcc 24m24 e		2.31gm	P<.4
2580	R	m wis	eat ubl tcc 24m24 e	>	561.mg	P<.2
a	R	m wis	eat liv tum 24m24 e		no dre	P=1.
2,3,7,8-TETRACHLORODIBENZO-p-DIOXIN ...1ug...10...100...1mg...10...100...1g...10						
2581						
a	M	f b6c	gav MXB MXB 24m24		526.ng	Z P<.002
b	M	f b6c	gav --- lhc 24m24		705.ng	* P<.008
c	M	f b6c	gav liv MXA 24m24		756.ng	* P<.008 c
d	M	f b6c	gav --- lym 24m24		682.ng	* P<.04
e	M	f b6c	gav --- MXA 24m24		709.ng	* P<.05
f	M	f b6c	gav liv hpc 24m24		1.30ug	* P<.02 c
g	M	f b6c	gav thy fca 24m24		1.59ug	* P<.03 c
h	M	f b6c	gav sub fba 24m24		1.72ug	* P<.02
i	M	f b6c	gav TBA MXB 24m24		494.ng	* P<.06
j	M	f b6c	gav liv MXB 24m24		756.ng	* P<.008
k	M	f b6c	gav lun MXB 24m24		no dre	P=1.
2582						
a	M	m b6c	gav liv MXA 24m24		86.8ng	* P<.003 c
b	M	m b6c	gav liv hpc 24m24		147.ng	* P<.02 c
c	M	m b6c	gav lun MXA 24m24		198.ng	* P<.02
d	M	m b6c	gav lun a/a 24m24		219.ng	* P<.02
e	M	m b6c	gav liv hpa 24m24		271.ng	* P<.07 c
f	M	m b6c	gav TBA MXB 24m24		141.ng	* P<.2
g	M	m b6c	gav liv MXB 24m24		86.8ng	* P<.003
h	M	m b6c	gav lun MXB 24m24		198.ng	* P<.02
2583						
a	M	m shr	gav lun tum 12m24 e	>	no dre	P=1. -
b	M	m shr	gav liv mix 12m24 e		no dre	P=1. +
c	M	m shr	gav tba mix 12m24 e		no dre	P=1.
2584						
a	R	f osm	gav liv MXA 24m24		127.ng	* P<.0005c
b	R	f osm	gav liv nnd 24m24		154.ng	* P<.003 c
c	R	f osm	gav TBA MXB 24m24		1.58ug	* P<.1.
d	R	f osm	gav liv MXB 24m24		127.ng	* P<.0005
2585						
a	R	m osm	gav thy MXA 24m24		101.ng	* P<.002 c
b	R	m osm	gav thy fca 24m24		113.ng	* P<.003 c
c	R	m osm	gav liv MXA 24m24		391.ng	* P<.004
d	R	m osm	gav liv nnd 24m24		391.ng	* P<.004
e	R	m osm	gav adr coa 24m24		12.1ng	Z P<.04
f	R	m osm	gav sub fib 24m24		169.ng	* P<.02
g	R	m osm	gav TBA MXB 24m24		133.ng	* P<.3
h	R	m osm	gav liv MXB 24m24		391.ng	* P<.004
2586						
a	R	m sda	eat lun sqe 78w95		79.6ng	* P<.0005
b	R	m sda	eat liv mix 78w95		83.1ng	* P<.0005
2587						
a	R	f sds	eat liv hph 24m24		6.67ng	Z P<.0005+
b	R	f sds	eat liv hpc 24m24		65.1ng	* P<.0005+

RefNum	LoConf	UpConf	Cntrl	1Dose	1Inc	2Dose	2Inc	Citation or Pathology	Brkly Code
2569	1249	81.5ug	n.s.s.	0/16	82.9ug	1/17			
a	1249	81.5ug	n.s.s.	0/16	82.9ug	1/17			
b	1249	59.5ug	n.s.s.	0/16	82.9ug	2/17			
3,3',4,4'-TETRAAMINOBIPHENYL.4HCL (3,3'-diaminobenzidine.4HCl) 7411-49-6									
2570	381	377.mg	n.s.s.	4/17	468.mg	6/19	851.mg	4/17	Weisburger;jept,2,325-356;1978/pers.comm./Russfield 1973
a	381	526.mg	n.s.s.	0/17	468.mg	1/19	851.mg	3/17	
b	381	231.mg	n.s.s.	11/17	468.mg	9/19	851.mg	11/17	
2571	381	117.mg	1.52gm	1/19	432.mg	6/18	(785.mg	7/22)	
a	381	321.mg	n.s.s.	1/19	432.mg	1/18	785.mg	1/22	
b	381	95.1mg	1.50gm	4/19	432.mg	9/18	(785.mg	13/22)	
2572	381	89.7mg	n.s.s.	0/16	120.mg	1/16	240.mg	3/15	
a	381	63.4mg	n.s.s.	11/16	120.mg	8/16	240.mg	12/15	
2573	381	115.mg	n.s.s.	2/111p	120.mg	1/16	240.mg	3/15	
2,3,5,6-TETRACHLORO-4-NITROANISOLE 2438-88-2									
2574	c03032	11.8mg	n.s.s.	34/55	7.70mg	37/55	15.5mg	38/55	
a	c03032	83.1mg	n.s.s.	11/55	7.70mg	3/55	15.5mg	5/55	liv:hpa,hpc,nnd. lun:a/a,a/c.
b	c03032	43.3mg	n.s.s.	4/55	7.70mg	8/55	15.5mg	4/55	
2575	c03032	16.9mg	n.s.s.	43/55	7.20mg	38/55	14.3mg	36/55	
a	c03032	17.9mg	n.s.s.	28/55	7.20mg	16/55	(14.3mg	10/55)	liv:hpa,hpc,nnd. lun:a/a,a/c.
b	c03032	22.9mg	n.s.s.	12/55	7.20mg	17/55	14.3mg	13/55	
2576	c03032	8.30mg	n.s.s.	2/50	3.00mg	9/50	5.90mg	8/50	S
a	c03032	17.4mg	n.s.s.	0/50	3.00mg	1/50	5.90mg	4/50	liv:hpc,nnd. S
b	c03032	5.10mg	n.s.s.	27/50	3.00mg	34/50	5.90mg	28/50	
c	c03032	17.4mg	n.s.s.	0/50	3.00mg	1/50	5.90mg	4/50	liv:hpa,hpc,nnd. liv:hpc,nnd. S
2577	c03032	9.41mg	n.s.s.	0/50	2.40mg	5/50	4.70mg	1/25	4.60mg 3/24
a	c03032	6.57mg	n.s.s.	28/50	2.40mg	27/50	4.70mg	12/25	4.60mg 14/24
b	c03032	9.41mg	n.s.s.	0/50	2.40mg	5/50	4.70mg	1/25	4.60mg 3/24
2,2',5,5'-TETRACHLOROBENZIDINE 15721-02-5									
2578	558	57.0mg	240.mg	0/20	130.mg	16/25			Yoshimoto;jkaj,25,123-128;1978
a	558	47.0mg	184.mg	0/20	130.mg	16/25			
2579	558	222.mg	n.s.s.	0/10	150.mg	3/23			
a	558	376.mg	n.s.s.	0/10	150.mg	1/23			
2580	558	169.mg	n.s.s.	0/11	120.mg	3/22			
a	558	544.mg	n.s.s.	0/11	120.mg	0/22			
2,3,7,8-TETRACHLORODIBENZO-p-DIOXIN (TCDD, dioxin) 1746-01-6									
2581	c03714	236.ng	2.99ug	3/75	5.55ng	9/50	27.8ng	7/50	278.ng 15/50
a	c03714	294.ng	19.3ug	9/75	5.55ng	4/50	27.8ng	8/50	278.ng 14/50
b	c03714	303.ng	20.5ug	3/75	5.55ng	6/50	27.8ng	6/50	278.ng 11/50
c	c03714	262.ng	n.s.s.	18/75	5.55ng	11/50	27.8ng	13/50	278.ng 20/50
d	c03714	266.ng	n.s.s.	18/75	5.55ng	12/50	27.8ng	13/50	278.ng 20/50
e	c03714	466.ng	n.s.s.	1/75	5.55ng	2/50	27.8ng	2/50	278.ng 6/50
f	c03714	523.ng	n.s.s.	0/75	5.55ng	3/50	27.8ng	1/50	278.ng 5/50
g	c03714	594.ng	n.s.s.	1/75	5.55ng	1/50	27.8ng	1/50	278.ng 5/50
h	c03714	184.ng	n.s.s.	36/75	5.55ng	25/50	27.8ng	28/50	278.ng 34/50
i	c03714	303.ng	20.5ug	3/75	5.55ng	6/50	27.8ng	6/50	278.ng 11/50
j	c03714	956.ng	n.s.s.	2/75	5.55ng	3/50	27.8ng	4/50	278.ng 2/50
2582	c03714	40.6ng	613.ng	15/75	1.39ng	12/50	6.94ng	13/50	69.4ng 27/50
a	c03714	59.8ng	n.s.s.	8/75	1.39ng	9/50	6.94ng	8/50	69.4ng 17/50
b	c03714	78.4ng	n.s.s.	10/75	1.39ng	2/50	6.94ng	4/50	69.4ng 13/50
c	c03714	84.1ng	n.s.s.	7/75	1.39ng	2/50	6.94ng	4/50	69.4ng 11/50
d	c03714	90.3ng	n.s.s.	7/75	1.39ng	3/50	6.94ng	5/50	69.4ng 10/50
e	c03714	43.3ng	n.s.s.	40/75	1.39ng	25/50	6.94ng	27/50	69.4ng 37/50
f	c03714	40.6ng	613.ng	15/75	1.39ng	12/50	6.94ng	13/50	69.4ng 27/50
g	c03714	78.4ng	n.s.s.	10/75	1.39ng	2/50	6.94ng	4/50	69.4ng 13/50
2583	383a	105.ng	n.s.s.	15/38	.502ng	27/44	50.2ng	18/44	(502.ng 11/43)
a	383a	890.ng	n.s.s.	7/38	.502ng	13/44	50.2ng	21/44	502.ng 13/43
b	383a	899.ng	n.s.s.	27/38	.502ng	39/44	50.2ng	36/44	502.ng 27/43
2584	c03714	60.1ng	520.ng	5/75	1.39ng	1/50	6.94ng	3/50	69.4ng 14/50
a	c03714	67.7ng	1.05ug	5/75	1.39ng	1/50	6.94ng	3/50	69.4ng 12/50
b	c03714	52.1ng	n.s.s.	54/75	1.39ng	40/50	6.94ng	36/50	69.4ng 43/50
c	c03714	60.1ng	520.ng	5/75	1.39ng	1/50	6.94ng	3/50	69.4ng 14/50
2585	c03714	41.9ng	664.ng	1/75	1.39ng	5/50	6.94ng	6/50	69.4ng 11/50
a	c03714	45.9ng	875.ng	1/75	1.39ng	5/50	6.94ng	4/50	69.4ng 10/50
b	c03714	110.ng	3.83ug	0/75	1.39ng	0/50	6.94ng	0/50	69.4ng 3/50
c	c03714	110.ng	3.83ug	0/75	1.39ng	0/50	6.94ng	0/50	69.4ng 3/50
d	c03714	4.62ng	n.s.s.	6/75	1.39ng	9/50	6.94ng	12/50	(69.4ng 9/50)
e	c03714	60.1ng	n.s.s.	3/75	1.39ng	1/50	6.94ng	3/50	69.4ng 7/50
f	c03714	33.8ng	n.s.s.	40/75	1.39ng	29/50	6.94ng	33/50	69.4ng 32/50
g	c03714	110.ng	3.83ug	0/75	1.39ng	0/50	6.94ng	0/50	69.4ng 3/50
2586	377	17.5ng	545.ng	0/9	.035ng	0/9	.117ng	0/10	1.17ng 0/9
a	377	26.4ng	360.ng	0/9	.035ng	0/9	.117ng	0/10	1.17ng 0/9
248.ng 4/10 Van Miller;cmep,10,625-632;1977/pers.comm.									
2587	366	3.26ng	22.5ng	8/86	1.00ng	3/50	10.0ng	18/50	(100.ng 23/50)
a	366	28.9ng	173.ng	1/86	1.00ng	0/50	10.0ng	2/50	100.ng 11/50
Kociba;txap,46,279-303;1978/pers.comm.									

Spe	Strain	Site	Xpo+Xpt							TD50	2Tailpvl
Sex	Route	Hist	Notes							DR	AuOp
b										R f sds eat lun sqk 24m24	192.ng * P<.0005+
c										R f sds eat hnt sqs 24m24	205.ng * P<.0005+
2588				:	+	:				R m sds eat adr coa 24m24	217.ng * P<.002
a										R m sds eat hnt sqs 24m24	393.ng * P<.002 +
b										R m sds eat ton sqs 24m24	628.ng * P<.04 +
2,4,5,4'-TETRACHLORODIPHENYL SULFONE1ug.10.100.1mg.10.100.1g.10											
2589	M f	b6a	orl	liv	hpt	76w76	evx		>		233.mg P<.3 -
a	M f	b6a	orl	lun	ade	76w76	evx				no dre P=1. -
b	M f	b6a	orl	tba	mix	76w76	evx				233.mg P<.7 -
2590	M m	b6a	orl	lun	ade	76w76	evx		>		no dre P=1. -
a	M m	b6a	orl	liv	hpt	76w76	evx				no dre P=1. -
b	M m	b6a	orl	tba	mix	76w76	evx				no dre P=1. -
2591	M f	b6c	orl	liv	hpt	76w76	evx		>		no dre P=1. -
a	M f	b6c	orl	lun	mix	76w76	evx				no dre P=1. -
b	M f	b6c	orl	tba	mix	76w76	evx				220.mg P<.3 -
2592	M m	b6c	orl	liv	hpt	76w76	evx		±		46.2mg P<.02 -
a	M m	b6c	orl	lun	ade	76w76	evx				205.mg P<.3 -
b	M m	b6c	orl	tba	mix	76w76	evx				35.6mg P<.007 -
1,1,2,2-TETRACHLOROETHANE 100ng.1ug.10.100.1mg.10.100.1g.10											
2593	M f	b6c	gav	liv	hpc	78w92	v		+	:	35.4mg / P<.0005c
a	M f	b6c	gav	TBA	MXB	78w92	v				37.2mg * P<.0005
b	M f	b6c	gav	liv	MXB	78w92	v				35.4mg / P<.0005
c	M f	b6c	gav	lun	MXB	78w92	v				1.91gm * P<.3
2594	M f	b6c	gav	liv	hpc	78w91	v	pool	+	:	35.8mg * P<.0005c
2595	M m	b6c	gav	liv	hpc	78w92	av		+	:	41.6mg / P<.0005c
a	M m	b6c	gav	TBA	MXB	78w92	av				38.7mg / P<.0005
b	M m	b6c	gav	liv	MXB	78w92	av				41.6mg / P<.0005
c	M m	b6c	gav	lun	MXB	78w92	av				895.mg * P<.5
2596	M m	b6c	gav	liv	hpc	78w91	av	pool	+	:	45.4mg / P<.0005c
2597	R f	oam	gav	TBA	MXB	18m26	adv		>		84.2mg * P<.5 -
a	R f	oam	gav	liv	MXB	18m26	adv				no dre P=1. -
2598	R m	oam	gav	TBA	MXB	18m26	adv		>		no dre P=1. -
a	R m	oam	gav	liv	MXB	18m26	adv				624.mg * P<.2
TETRACHLOROETHYLENE+ 100ng.1ug.10.100.1mg.10.100.1g.10											
2599	M f	b6c	gav	liv	hpc	78w90	v		+	:	75.6mg * P<.0005c
a	M f	b6c	gav	TBA	MXB	78w90	v				98.1mg * P<.0005
b	M f	b6c	gav	liv	MXB	78w90	v				75.6mg * P<.0005
c	M f	b6c	gav	lun	MXB	78w90	v				2.95gm * P<.2
2600	M m	b6c	gav	liv	hpc	78w90	v		+	:	123.mg * P<.0005c
a	M m	b6c	gav	TBA	MXB	78w90	v				160.mg * P<.002
b	M m	b6c	gav	liv	MXB	78w90	v				123.mg * P<.0005
c	M m	b6c	gav	lun	MXB	78w90	v				no dre P=1. -
2601	R f	oam	gav	TBA	MXB	18m26	dev		>		1.71gm * P<.7
a	R f	oam	gav	liv	MXB	18m26	dev				no dre P=1. -
2602	R m	oam	gav	TBA	MXB	18m26	dev		>		3.02gm * P<.9
a	R m	oam	gav	liv	MXB	18m26	dev				no dre P=1. -
TETRACHLORVINPHOS 100ng.1ug.10.100.1mg.10.100.1g.10											
2603	M f	b6c	eat	liv	MXA	80w92			±		905.mg \ P<.02 a
a	M f	b6c	eat	TBA	MXB	80w92					7.88gm * P<.8
b	M f	b6c	eat	liv	MXB	80w92					905.mg \ P<.02
c	M f	b6c	eat	lun	MXB	80w92					7.79gm * P<.5
2604	M f	b6c	eat	liv	MXA	80w90	pool		+	:	1.07gm \ P<.002 a
a	M f	b6c	eat	liv	nnd	80w90					1.38gm \ P<.0005a
2605	M m	b6c	eat	liv	MXA	80w92			+	:	228.mg \ P<.0005c
a	M m	b6c	eat	liv	hpc	80w92					466.mg * P<.002 c
b	M m	b6c	eat	TBA	MXB	80w92					295.mg \ P<.007
c	M m	b6c	eat	liv	MXB	80w92					228.mg \ P<.0005
d	M m	b6c	eat	lun	MXB	80w92					401.gm * P<.1
2606	M m	b6c	eat	liv	MXA	80w90	pool		+	:	280.mg \ P<.0005c
a	M m	b6c	eat	liv	hpc	80w90					534.mg * P<.0005c
b	M m	b6c	eat	liv	nnd	80w90					1.77gm \ P<.02 a
2607	R f	oam	eat	pit	cre	19m26	v		±		#1.58gm * P<.03 -
a	R f	oam	eat	TBA	MXB	19m26	v				no dre P=1. -
b	R f	oam	eat	liv	MXB	19m26	v				no dre P=1. -
2608	R f	oam	eat	thy	cca	19m25	v	pool	±		1.92gm * P<.05 a
a	R f	oam	eat	adr	coa	19m25	v				2.28gm * P<.4 a
2609	R m	oam	eat	TBA	MXB	19m26	v		>		no dre P=1. -
a	R m	oam	eat	liv	MXB	19m26	v				no dre P=1. -
TETRAETHYLTHIURAM DISULFIDE 100ng.1ug.10.100.1mg.10.100.1g.10											
2610	M f	b6c	eat	TBA	MXB	25m25			>		no dre P=1. -
a	M f	b6c	eat	liv	MXB	25m25					120.mg \ P<.2
b	M f	b6c	eat	lun	MXB	25m25					323.mg * P<.2
2611	M f	b6c	orl	lun	mix	76w76	evx		>		138.mg P<.2
a	M f	b6c	orl	liv	hpt	76w76	evx				283.mg P<.3

RefNum	LoConf	UpConf	Cntrl	1Dose	1Inc	2Dose	2Inc	Citation or Pathology	Brkly Code	
b	366	66.7ng	559.ng	0/86	1.00ng	0/50	10.0ng	0/50	100.ng	7/50
c	366	73.9ng	972.ng	0/86	1.00ng	0/50	10.0ng	1/50	100.ng	4/50
2588	366	81.1ng	1.27ug	0/86	1.00ng	0/50	10.0ng	2/50	100.ng	5/50
a	366	126.ng	2.05ug	0/86	1.00ng	0/50	10.0ng	0/50	100.ng	4/50
b	366	161.ng	n.s.s.	0/86	1.00ng	1/50	10.0ng	1/50	100.ng	3/50
2,4,5,4'-TETRACHLORODIPHENYL SULFONE (tetrafidon) 116-29-0										
2589	1282	37.9mg	n.s.s.	0/17	36.4mg	1/18			Innea;ntis,1968/1969	
a	1282	43.3mg	n.s.s.	1/17	36.4mg	1/18				
b	1282	26.1mg	n.s.s.	2/17	36.4mg	3/18				
2590	1282	31.7mg	n.s.s.	2/18	33.9mg	2/18				
a	1282	67.2mg	n.s.s.	1/18	33.9mg	0/18				
b	1282	35.1mg	n.s.s.	3/18	33.9mg	2/18				
2591	1282	68.1mg	n.s.s.	0/16	36.4mg	0/17				
a	1282	68.1mg	n.s.s.	0/16	36.4mg	0/17				
b	1282	35.8mg	n.s.s.	0/16	36.4mg	1/17				
2592	1282	15.9mg	n.s.s.	0/16	33.9mg	4/17				
a	1282	33.3mg	n.s.s.	0/16	33.9mg	1/17				
b	1282	13.4mg	481.mg	0/16	33.9mg	5/17				
1,1,2,2-TETRACHLOROETHANE 79-34-5										
2593	c03554	25.9mg	50.2mg	0/20	87.7mg	30/50	175.mg	43/50		
a	c03554	26.1mg	61.6mg	2/20	87.7mg	33/50	175.mg	43/50		
b	c03554	25.9mg	50.2mg	0/20	87.7mg	30/50	175.mg	43/50	liv:hpa,hpc,ndd.	
c	c03554	449.mg	n.s.s.	0/20	87.7mg	1/50	175.mg	1/50	lun:a/a,a/c.	
2594	c03554	26.2mg	50.3mg	0/40p	87.7mg	30/50	175.mg	43/50		
2595	c03554	27.4mg	66.8mg	1/20	87.7mg	13/50	175.mg	44/50		
a	c03554	25.2mg	66.6mg	4/20	87.7mg	17/50	175.mg	45/50		
b	c03554	27.4mg	66.8mg	1/20	87.7mg	13/50	175.mg	44/50	liv:hpa,hpc,ndd.	
c	c03554	162.mg	n.s.s.	1/20	87.7mg	2/50	175.mg	2/50	lun:a/a,a/c.	
2596	c03554	29.7mg	75.1mg	3/40p	87.7mg	13/50	175.mg	44/50		
2597	c03554	20.7mg	n.s.s.	12/20	21.9mg	28/50	39.0mg	23/50		
a	c03554	n.s.s.	n.s.s.	0/20	21.9mg	0/50	39.0mg	0/50	liv:hpa,hpc,ndd.	
2598	c03554	60.2mg	n.s.s.	11/20	31.6mg	17/50	55.2mg	20/50		
a	c03554	185.mg	n.s.s.	0/20	31.6mg	0/50	55.2mg	3/50	liv:hpa,hpc,ndd.	
TETRACHLOROETHYLENE* 127-18-4										
2599	c04580	47.1mg	130.mg	0/20	240.mg	19/50	478.mg	19/50		
a	c04580	54.1mg	259.mg	5/20	240.mg	19/50	478.mg	19/50		
b	c04580	47.1mg	130.mg	0/20	240.mg	19/50	478.mg	19/50	liv:hpa,hpc,ndd.	
c	c04580	480.mg	n.s.s.	0/20	240.mg	0/50	478.mg	1/50	lun:a/a,a/c.	
2600	c04580	79.5mg	260.mg	2/20	332.mg	32/50	663.mg	27/50		
a	c04580	90.1mg	622.mg	6/20	332.mg	33/50	663.mg	27/50		
b	c04580	79.5mg	260.mg	2/20	332.mg	32/50	663.mg	27/50	liv:hpa,hpc,ndd.	
c	c04580	n.s.s.	n.s.s.	0/20	332.mg	3/50	663.mg	0/50	lun:a/a,a/c.	
2601	c04580	263.mg	n.s.s.	7/20	240.mg	17/50	480.mg	15/50		
a	c04580	n.s.s.	n.s.s.	0/20	240.mg	0/50	480.mg	0/50	liv:hpa,hpc,ndd.	
2602	c04580	239.mg	n.s.s.	5/20	238.mg	5/50	477.mg	5/50		
a	c04580	n.s.s.	n.s.s.	0/20	238.mg	0/50	477.mg	0/50	liv:hpa,hpc,ndd.	
TETRACHLORVINPHOS 961-11-5										
2603	c00168	528.mg	n.s.s.	0/9	904.mg	19/50	(1.81gm)	11/49)		liv:hpc,ndd.
a	c00168	1.04gm	n.s.s.	1/9	904.mg	25/50	1.81gm	19/49		
b	c00168	528.mg	n.s.s.	0/9	904.mg	19/50	(1.81gm)	11/49)	liv:hpa,hpc,ndd.	
c	c00168	2.87gm	n.s.s.	0/9	904.mg	5/50	1.81gm	5/49	lun:a/a,a/c.	
2604	c00168	558.mg	4.20gm	3/49p	904.mg	19/50	(1.81gm)	11/49)		liv:hpc,ndd.
a	c00168	705.mg	4.79gm	1/49p	904.mg	14/50	(1.81gm)	9/49)		
2605	c00168	158.mg	432.mg	0/10	835.mg	47/50	(1.67gm)	42/50)		liv:hpc,ndd.
a	c00168	348.mg	1.93gm	0/10	835.mg	36/50	1.67gm	40/50		
b	c00168	175.mg	3.98gm	2/10	835.mg	47/50	(1.67gm)	42/50)		
c	c00168	158.mg	432.mg	0/10	835.mg	47/50	(1.67gm)	42/50)	liv:hpa,hpc,ndd.	
d	c00168	3.40gm	n.s.s.	0/10	835.mg	4/50	1.67gm	2/50	lun:a/a,a/c.	
2606	c00168	176.mg	541.mg	8/50p	835.mg	47/50	(1.67gm)	42/50)		liv:hpc,ndd.
a	c00168	371.mg	905.mg	5/50p	835.mg	36/50	1.67gm	40/50		
b	c00168	737.mg	n.s.s.	3/50p	835.mg	11/50	(1.67gm)	2/50)		
2607	c00168	743.mg	n.s.s.	0/10	153.mg	1/50	306.mg	8/50		S
a	c00168	454.mg	n.s.s.	7/10	153.mg	23/50	306.mg	25/50		
b	c00168	2.01gm	n.s.s.	0/10	153.mg	2/50	306.mg	0/50	liv:hpa,hpc,ndd.	
2608	c00168	775.mg	n.s.s.	1/55p	153.mg	2/50	306.mg	7/50		
a	c00168	667.mg	n.s.s.	2/55p	153.mg	7/50	306.mg	6/50		
2609	c00168	226.mg	n.s.s.	6/10	122.mg	24/50	245.mg	18/50		
a	c00168	1.10gm	n.s.s.	0/10	122.mg	2/50	245.mg	0/50	liv:hpa,hpc,ndd.	
TETRAETHYLTHIURAM DISULFIDE (ethyl tuads) 97-77-8										
2610	c02959	99.5mg	n.s.s.	8/20	13.0mg	18/50	65.0mg	20/50		
a	c02959	36.4mg	n.s.s.	0/20	13.0mg	3/50	(65.0mg)	0/50)	liv:hpa,hpc,ndd.	
b	c02959	111.mg	n.s.s.	1/20	13.0mg	4/50	65.0mg	9/50	lun:a/a,a/c.	
2611	1100	33.8mg	n.s.s.	0/16	44.3mg	2/18			Innea;ntis,1968/1969	
a	1100	46.1mg	n.s.s.	0/16	44.3mg	1/18				

Spe	Strain	Site	Xpo+Xpt				TD50	ZTailpvl
Sex	Route	Hist	Notes				DR	AuOp
b	M f b6c	orl lun	car 76w76	evx			283.mg	P<.3
c	M f b6c	orl lun	ade 76w76	evx			283.mg	P<.3
d	M f b6c	orl tba	mix 76w76	evx			64.5mg	P<.02
2612	M m b6c	eat TBA	MXB 25m25		:	>	no dre	P=1. -
a	M m b6c	eat liv	MXB 25m25				no dre	P=1.
b	M m b6c	eat lun	MXB 25m25				no dre	P=1.
2613	M m b6c	orl liv	hpt 76w76	evx	.	+ .	23.7mg	P<.0005
a	M m b6c	orl lun	ade 76w76	evx			43.2mg	P<.007
b	M m b6c	orl tba	mix 76w76	evx			17.0mg	P<.0005
2614	M f b6a	orl lun	ade 76w76	evx		:	4.14gm	P<.1.
a	M f b6a	orl liv	hpt 76w76	evx			no dre	P=1.
b	M f b6a	orl tba	mix 76w76	evx			1.94gm	P<.1.
2615	M m b6a	orl sub	fbx 76w76	evx	.	+ .	15.4mg	P<.0005
a	M m b6a	orl liv	hpt 76w76	evx			197.mg	P<.5
b	M m b6a	orl lun	ade 76w76	evx			no dre	P=1.
c	M m b6a	orl tba	mix 76w76	evx			10.1mg	P<.0005
2616	R f f34	eat TBA	MXB 25m25			:	no dre	P=1. -
a	R f f34	eat liv	MXB 25m25				1.43gm *	P<.4
2617	R m f34	eat TBA	MXB 25m25		:	>	no dre	P=1. -
a	R m f34	eat liv	MXB 25m25				no dre	P=1.
2618	R f cdr	eat mgl	mix 78w78	e	.	±	68.9mg	P<.04
a	R f cdr	eat liv	ham 78w78	e			no dre	P=1.
b	R f cdr	eat liv	hct 78w78	e			no dre	P=1.
c	R f cdr	eat tba	mix 78w78	e			193.mg	P<.6
2619	R m cdr	eat liv	hct 78w78	e		:	366.mg	P<.3
a	R m cdr	eat tba	mix 78w78	e			no dre	P=1.
TETRAFLUORO-m-PHENYLENEDIAMINE.2HCl					...	1ug.....10.....100.....1mg.....10.....100.....1g.....10		
2620	M f chi	eat liv	mix 77w94			:	6.50gm *	P<.1. -
a	M f chi	eat lun	mix 77w94				no dre	P=1. -
b	M f chi	eat tba	mix 77w94				no dre	P=1. -
2621	M m chi	eat liv	mix 77w94		:	±	78.3mg *	P<.02
a	M m chi	eat liv	hpt 77w94				86.3mg *	P<.02 +
b	M m chi	eat lun	mix 77w94				1.13gm *	P<.7 -
c	M m chi	eat tba	mix 77w94				331.mg *	P<.7
2622	M m chi	eat liv	hpt 77w94	pool	:	+ :	109.mg *	P<.0005+
2623	R m cdr	eat liv	mix 77w98	v			no dre	P=1. -
a	R m cdr	eat tba	mix 77w98	v			14.6mg *	P<.003 -
TETRAHYDRO-2-NITROSO-2H-1,2-OXAZINE					...	1ug.....10.....100.....1mg.....10.....100.....1g.....10		
2624	R b sda	wat lun	mix 66w82		.	+	46.1mg	P<.007
a	R b sda	wat tba	mix 66w82				17.6mg	P<.004
b	R b sda	wat tba	mal 66w82				24.3mg	P<.003 +
TETRAMETHYLTHIURAM DISULFIDE					100ng.....1ug.....10.....100.....1mg.....10.....100.....1g.....10			
2625	M f b6a	orl lun	ade 76w76	evx		:	159.mg	P<.1. -
a	M f b6a	orl liv	hpt 76w76	evx			no dre	P=1. -
b	M f b6a	orl tba	mix 76w76	evx			no dre	P=1. -
2626	M m b6a	orl lun	ade 76w76	evx		:	no dre	P=1. -
a	M m b6a	orl liv	hpt 76w76	evx			no dre	P=1. -
b	M m b6a	orl tba	mix 76w76	evx			no dre	P=1. -
2627	M f b6c	orl liv	hpt 76w76	evx		:	no dre	P=1. -
a	M f b6c	orl lun	mix 76w76	evx			no dre	P=1. -
b	M f b6c	orl tba	mix 76w76	evx			no dre	P=1. -
2628	M m b6c	orl liv	hpt 76w76	evx	.	±	9.91mg	P<.1 -
a	M m b6c	orl lun	mix 76w76	evx			no dre	P=1. -
b	M m b6c	orl tba	mix 76w76	evx			6.39mg	P<.04 -
TETRAMETHYLTHIURAM MONOSULFIDE					100ng.....1ug.....10.....100.....1mg.....10.....100.....1g.....10			
2629	M f b6a	orl liv	hpt 76w76	evx		:	327.mg	P<.3 -
a	M f b6a	orl lun	ade 76w76	evx			no dre	P=1. -
b	M f b6a	orl tba	mix 76w76	evx			148.mg	P<.5 -
2630	M m b6a	orl lun	ade 76w76	evx		:	no dre	P=1. -
a	M m b6a	orl liv	hpt 76w76	evx			no dre	P=1. -
b	M m b6a	orl tba	mix 76w76	evx			no dre	P=1. -
2631	M f b6c	orl liv	hpt 76w76	evx		:	no dre	P=1. -
a	M f b6c	orl lun	mix 76w76	evx			no dre	P=1. -
b	M f b6c	orl tba	tum 76w76	evx			no dre	P=1. -
2632	M m b6c	orl lun	ade 76w76	evx	.	±	89.3mg	P<.04 -
a	M m b6c	orl liv	hpt 76w76	evx			139.mg	P<.1 -
b	M m b6c	orl tba	mix 76w76	evx			49.8mg	P<.007 -
THIO-TEPA					100ng.....1ug.....10.....100.....1mg.....10.....100.....1g.....10			
2633	M f b6c	ipj ---	MXA 47w86	as	:	+ :	.216mg /	P<.0005c
a	M f b6c	ipj TBA	MXB 47w86	as			85.5ug /	P<.0005
b	M f b6c	ipj liv	MXB 47w86	as			1.12mg *	P<.2
c	M f b6c	ipj lun	MXB 47w86	as			.408mg *	P<.02
2634	M f b6c	ipj ---	MXA 47w86	as	pool	:	.210mg /	P<.0005c
a	M f b6c	ipj lun	a/a 47w86	as			.408mg *	P<.003

RefNum	LoConf	UpConf	Cntrl	1Dose	1Inc	2Dose	2Inc	Citation or Pathology	Brkly Code
b	1100	46.1mg	n.s.s.	0/16	44.3mg	1/18			
c	1100	46.1mg	n.s.s.	0/16	44.3mg	1/18			
d	1100	22.2mg	n.s.s.	0/16	44.3mg	4/18			
2612	c02959	110.0mg	n.s.s.	11/20	60.0mg	21/50	(240.0mg 18/50)		
a	c02959	232.0mg	n.s.s.	5/20	60.0mg	6/50	(240.0mg 4/50)		liv:hpa,hpc,nnd. lun:a/a,a/c.
b	c02959	127.0mg	n.s.s.	4/20	60.0mg	11/50	(240.0mg 4/50)		Innes;ntis,1968/1969
2613	1100	10.5mg	75.4mg	0/16	41.2mg	8/17			
a	1100	16.3mg	585.0mg	0/16	41.2mg	5/17			
b	1100	7.99mg	44.6mg	0/16	41.2mg	10/17			
2614	1100	46.0mg	n.s.s.	1/17	44.3mg	1/16			
a	1100	77.9mg	n.s.s.	0/17	44.3mg	0/16			
b	1100	36.1mg	n.s.s.	2/17	44.3mg	2/16			
2615	1100	7.17mg	40.4mg	0/18	41.2mg	10/16			
a	1100	30.1mg	n.s.s.	1/18	41.2mg	2/16			
b	1100	47.2mg	n.s.s.	2/18	41.2mg	1/16			
c	1100	4.45mg	34.4mg	3/18	41.2mg	13/16			
2616	c02959	49.6mg	n.s.s.	19/20	15.0mg	28/50	30.0mg 33/50		
a	c02959	232.0mg	n.s.s.	0/20	15.0mg	0/50	30.0mg 1/50		liv:hpa,hpc,nnd.
2617	c02959	13.2mg	n.s.s.	15/20	12.0mg	33/50	(24.0mg 24/50)		
a	c02959	164.0mg	n.s.s.	0/20	12.0mg	1/50	24.0mg 0/50		liv:hpa,hpc,nnd.
2618	1032	26.1mg	n.s.s.	2/48	25.0mg	8/48			Wong;txap,63,155-165;1982/Plotnick pers.comm.
a	1032	139.0mg	n.s.s.	0/48	25.0mg	0/48			
b	1032	139.0mg	n.s.s.	0/48	25.0mg	0/48			
c	1032	30.7mg	n.s.s.	7/48	25.0mg	9/48			
2619	1032	59.6mg	n.s.s.	0/48	20.0mg	1/48			
a	1032	55.5mg	n.s.s.	8/48	20.0mg	4/48			
TETRAFLUORO- α -PHENYLENEDIAMINE.2HCl				63886-77-1					
2620	381	221.0mg	n.s.s.	1/15	106.0mg	2/20	213.0mg 2/15		Weisburger;jept,2,325-356;1978/pers.comm./Russfield 1973
a	381	94.8mg	n.s.s.	5/15	106.0mg	5/20	(213.0mg 1/15)		
b	381	53.6mg	n.s.s.	10/15	106.0mg	14/20	(213.0mg 7/15)		
2621	381	42.7mg	n.s.s.	1/14	103.0mg	8/18	206.0mg 7/16		
a	381	46.1mg	n.s.s.	0/14	103.0mg	7/18	206.0mg 7/16		
b	381	160.0mg	n.s.s.	3/14	103.0mg	2/18	206.0mg 4/16		
c	381	51.1mg	n.s.s.	7/14	103.0mg	13/18	206.0mg 10/16		
2622	381	53.0mg	324.0mg	7/99p	103.0mg	7/18	206.0mg 7/16		
2623	381	n.s.s.	n.s.s.	0/16	19.1mg	0/16	38.2mg 0/15		
a	381	6.81mg	101.0mg	10/16	19.1mg	8/16	38.2mg 12/15		
TETRAHYDRO-2-NITROSO-2H-1,2-OXAZINE				40548-68-3					
2624	1417	17.4mg	531.0mg	0/20	31.1mg	5/20			Wiesler;zkko,79,114-117;1973
a	1417	7.81mg	123.0mg	3/20	31.1mg	12/20			
b	1417	10.6mg	142.0mg	1/20	31.1mg	9/20			
TETRAETHYLTHIURAN DISULFIDE (TMTD, thiram)				137-26-8					
2625	1194	3.52mg	n.s.s.	1/17	3.64mg	1/15			Innes;ntis,1968/1969
a	1194	6.01mg	n.s.s.	0/17	3.64mg	0/15			
b	1194	3.90mg	n.s.s.	2/17	3.64mg	1/15			
2626	1194	3.17mg	n.s.s.	2/18	3.39mg	2/18			
a	1194	4.01mg	n.s.s.	1/18	3.39mg	1/18			
b	1194	2.67mg	n.s.s.	3/18	3.39mg	3/18			
2627	1194	7.21mg	n.s.s.	0/16	3.64mg	0/18			
a	1194	7.21mg	n.s.s.	0/16	3.64mg	0/18			
b	1194	7.21mg	n.s.s.	0/16	3.64mg	0/18			
2628	1194	2.43mg	n.s.s.	0/16	3.39mg	2/17			
a	1194	6.34mg	n.s.s.	0/16	3.39mg	0/17			
b	1194	1.93mg	n.s.s.	0/16	3.39mg	3/17			
TETRAMETHYLTHIURAN MONOSULFIDE (unads)				97-74-5					
2629	1199	53.2mg	n.s.s.	0/17	51.0mg	1/18			Innes;ntis,1968/1969
a	1199	101.0mg	n.s.s.	1/17	51.0mg	0/18			
b	1199	29.4mg	n.s.s.	2/17	51.0mg	4/18			
2630	1199	58.3mg	n.s.s.	2/18	47.4mg	1/17			
a	1199	88.7mg	n.s.s.	1/18	47.4mg	0/17			
b	1199	62.3mg	n.s.s.	3/18	47.4mg	1/17			
2631	1199	89.8mg	n.s.s.	0/16	51.0mg	0/16			
a	1199	89.8mg	n.s.s.	0/16	51.0mg	0/16			
b	1199	89.8mg	n.s.s.	0/16	51.0mg	0/16			
2632	1199	26.9mg	n.s.s.	0/16	47.4mg	3/17			
a	1199	34.0mg	n.s.s.	0/16	47.4mg	2/17			
b	1199	18.8mg	673.0mg	0/16	47.4mg	5/17			
THIO-TEPA				52-24-4					
2633	c01649	.133mg	.352mg	0/15	.300mg	5/35	1.00mg 32/35		---:lle,lym.
a	c01649	53.3ug	.142mg	0/15	.300mg	17/35	1.00mg 32/35		
b	c01649	.277mg	n.s.s.	0/15	.300mg	2/35	1.00mg 0/35		liv:hpa,hpc,nnd. lun:a/a,a/c.
c	c01649	.155mg	n.s.s.	0/15	.300mg	5/35	1.00mg 0/35		---:lle,lym.
2634	c01649	.127mg	.357mg	1/30p	.300mg	5/35	1.00mg 32/35		
a	c01649	.155mg	2.35mg	0/30p	.300mg	5/35	1.00mg 0/35		

Spe	Strain	Site	Xpo+Xpt	Notes	TD50	ZTailpvl
Sex	Route	Hist			DR	AuOp
2635	M m b6c	ipj	--- sqc 52w83	s		.102mg / P<.0005
a	M m b6c	ipj	--- MXA 52w83	s	:	.241mg / P<.0005c
b	M m b6c	ipj	--- MXB 52w83	s	+	.241mg / P<.0005
c	M m b6c	ipj	--- MXA 52w83	s	:	.265mg / P<.0005c
d	M m b6c	ipj	TBA MXB 52w83	s	:	69.0ug / P<.0005
e	M m b6c	ipj	liv MXB 52w83	s	:	1.12mg * P<.6
f	M m b6c	ipj	lun MXB 52w83	s	:	.584mg * P<.4
2636	M m b6c	ipj	--- sqc 52w83	s pool	:	.102mg / P<.0005
a	M m b6c	ipj	--- MXA 52w83	s	:	.238mg / P<.0005c
b	M m b6c	ipj	--- MXA 52w83	s	:	.262mg / P<.0005c
c	M m b6c	ipj	ski sqc 52w83	s	:	.280mg * P<.003 c
d	M m b6c	ipj	pre sqc 52w83	s	:	.300mg / P<.002 c
2637	R f sda	ipj	MXB MXB 36w81	ees	:	.172mg / P<.0005
a	R f sda	ipj	MXA MXA 36w81	ees	:	.217mg / P<.0005c
b	R f sda	ipj	ute acn 36w81	ees	:	.243mg / P<.002
c	R f sda	ipj	MXA MXA 36w81	ees	:	+historical * P<.07 a
d	R f sda	ipj	TBA MXB 36w81	ees	:	40.4ug / P<.0005
e	R f sda	ipj	liv MXB 36w81	ees	:	no dre P=1.
2638	R f sda	ipj	agl acn 36w79	as pool	:	.182mg * P<.0005
a	R f sda	ipj	MXA MXA 36w79	as	:	.214mg / P<.0005c
b	R f sda	ipj	ute acn 36w79	as	:	.236mg / P<.0005
c	R f sda	ipj	esc sqc 36w79	as	:	.327mg / P<.0005c
2639	R m sda	ipj	MXB MXB 32w82	ees	:	.149mg * P<.0005
a	R m sda	ipj	--- leu 32w82	ees	:	.312mg * P<.002 c
b	R m sda	ipj	MXA MXA 32w82	ees	:	+historical * P<.03 a
c	R m sda	ipj	TBA MXB 32w82	ees	:	33.2ug / P<.0005
d	R m sda	ipj	liv MXB 32w82	ees	:	no dre P=1.
2640	R m sda	ipj	MXA MXA 32w79	ees pool	:	.122mg * P<.0005c
a	R m sda	ipj	ski sqc 32w79	ees	:	.155mg * P<.0005c
b	R m sda	ipj	sub ern 32w79	ees	:	.220mg * P<.0005
c	R m sda	ipj	--- MXA 32w79	ees	:	.224mg * P<.0005c
d	R m sda	ipj	--- leu 32w79	ees	:	.290mg * P<.0005c
e	R m sda	ipj	--- lle 32w79	ees	:	.374mg * P<.0005c
2641	R m b46	ivj	tba mix 12m24		.	.186mg P<.002 +
a	R m b46	ivj	tba mal 12m24		.	.303mg P<.009
b	R m b46	ivj	tba ben 12m24		.	.646mg P<.2
THIOACETAMIDE				100ng...:..1ug...:..10...:..100...:..1mg...:..10...:..100...:..1g...:..10		
2642	M f swi	eat	liv hpt 65w65	kr	.	5.36mg P<.0005+
2643	M m swi	eat	liv hpt 65w65	kr	<+	noTD50 P<.005 +
2,2-THIOBIS(4,6-DICHLOROPHENOL)				100ng...:..1ug...:..10...:..100...:..1mg...:..10...:..100...:..1g...:..10		
2644	M f b6a	orl	lun ade 76w76	evx	>	100. mg P<.6
a	M f b6a	orl	liv hpt 76w76	evx	>	no dre P=1.
b	M f b6a	orl	tba mix 76w76	evx	>	28.7mg P<.3
2645	M m b6a	orl	liv hpt 76w76	evx	>	no dre P=1.
a	M m b6a	orl	lun ade 76w76	evx	>	no dre P=1.
b	M m b6a	orl	tba mix 76w76	evx	>	no dre P=1.
2646	M f b6c	orl	liv hpt 76w76	evx	>	no dre P=1.
a	M f b6c	orl	lun mix 76w76	evx	>	no dre P=1.
b	M f b6c	orl	tba mix 76w76	evx	>	43.0mg P<.09
2647	M m b6c	orl	liv agm 76w76	evx	>	88.2mg P<.3
a	M m b6c	orl	lun ade 76w76	evx	>	88.2mg P<.3
b	M m b6c	orl	tba mix 76w76	evx	>	10.1mg P<.002
4,4'-THIODIANILINE				100ng...:..1ug...:..10...:..100...:..1mg...:..10...:..100...:..1g...:..10		
2648	M f b6c	eat	MXB MXB 78w91	a	:	33.2mg * P<.0005
a	M f b6c	eat	liv hpc 78w91	a	:	33.3mg * P<.0005c
b	M f b6c	eat	thy MXA 78w91	a	:	88.4mg * P<.0005c
c	M f b6c	eat	thy fcc 78w91	a	:	165. mg / P<.0005c
d	M f b6c	eat	TBA MXB 78w91	a	:	33.2mg * P<.0005
e	M f b6c	eat	liv MXB 78w91	a	:	33.3mg * P<.0005
f	M f b6c	eat	lun MXB 78w91	a	:	no dre P=1.
2649	M m b6c	eat	MXB MXB 78w91	a	:	32.7mg * P<.0005
a	M m b6c	eat	liv MXA 78w91	a	:	33.2mg * P<.0005c
b	M m b6c	eat	liv hpc 78w91	a	:	33.8mg * P<.0005c
c	M m b6c	eat	thy MXA 78w91	a	:	51.8mg / P<.0005c
d	M m b6c	eat	thy fcc 78w91	a	:	70.7mg / P<.0005c
e	M m b6c	eat	TBA MXB 78w91	a	:	32.7mg * P<.0005
f	M m b6c	eat	liv MXB 78w91	a	:	33.2mg * P<.0005
g	M m b6c	eat	lun MXB 78w91	a	:	1.07gm * P<.3
2650	R f f34	eat	MXB MXB 16m24	s	:	8.53mg * P<.0005
a	R f f34	eat	ute acn 16m24	s	:	8.79mg * P<.0005c
b	R f f34	eat	thy fcc 16m24	s	:	11.5mg / P<.0005c
c	R f f34	eat	esc MXA 16m24	s	:	+historical * P<.006 c
d	R f f34	eat	TBA MXB 16m24	s	:	8.35mg * P<.0005
e	R f f34	eat	liv MXB 16m24	s	:	42.0mg * P<.0005
2651	R m f34	eat	MXB MXB 16m24		:	5.52mg \ P<.0005
a	R m f34	eat	thy MXA 16m24		:	5.59mg \ P<.0005c

RefNum	LoConf	UpConf	Cntrl	1Dose	1Inc	2Dose	2Inc	Citation or Pathology	Brkly Code
2635	c01649	55.1ug .281mg	0/15	.300mg	15/34	.900mg	1/35		S
a	c01649	.133mg .461mg	1/15	.300mg	3/34	.900mg	26/35	---	leu,lym.
b	c01649	.133mg .461mg	1/15	.300mg	3/34	.900mg	26/35	---	leu,lle,lym.
c	c01649	.146mg .506mg	1/15	.300mg	2/34	.900mg	26/35	---	lle,lym.
d	c01649	40.6ug .137mg	4/15	.300mg	19/34	.900mg	27/35		
e	c01649	.187mg n.s.s.	1/15	.300mg	4/34	.900mg	0/35		liv:hpa,hpc,nnd.
f	c01649	.140mg n.s.s.	1/15	.300mg	5/34	.900mg	0/35		lun:a/a,s/c.
2636	c01649	55.1ug .218mg	0/30p	.300mg	15/34	.900mg	1/35		S
a	c01649	.134mg .441mg	1/30p	.300mg	3/34	.900mg	26/35	---	leu,lym.
b	c01649	.146mg .485mg	1/30p	.300mg	2/34	.900mg	26/35	---	lle,lym.
c	c01649	.119mg 1.28mg	0/30p	.300mg	7/34	.900mg	0/35		
d	c01649	.126mg 1.25mg	0/30p	.300mg	6/34	.900mg	1/35		
2637	c01649	87.7ug .412mg	0/20	.190mg	4/31	.250mg	10/35	bra:oln; eac:sgc; nes:can; ski:sgc.	T
a	c01649	.101mg .666mg	0/20	.190mg	2/31	.250mg	8/35	eac:sgc; ski:sgc.	
b	c01649	.107mg .868mg	0/20	.190mg	2/31	.250mg	7/35		S
c	c01649	.260mg n.s.s.	0/20	.190mg	2/31	.250mg	2/35	bra:oln; nes:can.	
d	c01649	24.2ug 88.2ug	8/20	.190mg	26/31	.250mg	26/35		
e	c01649	n.s.s. n.s.s.	0/20	.190mg	0/31	.250mg	0/35		liv:hpa,hpc,nnd.
2638	c01649	89.5ug .491mg	2/60p	.190mg	7/31	.250mg	8/35		S
a	c01649	.101mg .537mg	0/60p	.190mg	2/31	.250mg	8/35	eac:sgc; ski:sgc.	
b	c01649	.105mg .637mg	0/60p	.190mg	2/31	.250mg	7/35		S
c	c01649	.138mg 1.05mg	0/60p	.190mg	2/31	.250mg	5/35		
2639	c01649	57.9ug .412mg	0/20	.190mg	8/39	.270mg	6/35	---	leu; bra:neu,oln; nes:can.
a	c01649	.144mg 1.14mg	0/20	.190mg	5/39	.270mg	6/35		
b	c01649	68.7ug n.s.s.	0/20	.190mg	3/39	.270mg	0/35	bra:neu,oln; nes:can.	
c	c01649	17.6ug 75.6ug	8/20	.190mg	27/39	.270mg	14/35		
d	c01649	n.s.s. n.s.s.	0/20	.190mg	0/39	.270mg	0/35		liv:hpa,hpc,nnd.
2640	c01649	52.4ug .317mg	0/60p	.190mg	7/39	.270mg	3/35	eac:sgc; ski:sgc.	
a	c01649	59.5ug .482mg	0/60p	.190mg	5/39	.270mg	3/35		
b	c01649	68.9ug 1.07mg	0/60p	.190mg	5/39	.270mg	0/35		S
c	c01649	91.5ug .674mg	1/60p	.190mg	6/39	.270mg	6/35	---	leu,lym.
d	c01649	.134mg .708mg	0/60p	.190mg	5/39	.270mg	6/35		
e	c01649	.153mg 1.15mg	0/60p	.190mg	3/39	.270mg	5/35		
2641	1017	86.1ug 1.02mg	7/89	71.4ug	14/48			Schmahl; arzn, 20, 1461-1467; 1970	
a	1017	.122mg 13.2mg	4/89	71.4ug	9/48				
b	1017	.188mg n.s.s.	3/89	71.4ug	5/48				
THIODACETAMIDE 62-55-5									
2642	282	1.69mg 22.6mg	0/6	39.0mg	6/7			Gothoaker; bjca, 24, 498-503; 1970	
2643	282	n.s.s. 11.3mg	0/6	36.0mg	6/6				
2,2-THIOBIS(4,6-DICHLOROPHENOL) (TBP, Vancide BL) 97-18-7									
2644	1283	13.2mg n.s.s.	1/17	15.7mg	2/18			Innes; ntis, 1968/1969	
a	1283	31.1mg n.s.s.	0/17	15.7mg	0/18				
b	1283	7.51mg n.s.s.	2/17	15.7mg	5/18				
2645	1283	27.4mg n.s.s.	1/18	14.6mg	0/17				
a	1283	27.4mg n.s.s.	2/18	14.6mg	0/17				
b	1283	19.2mg n.s.s.	3/18	14.6mg	1/17				
2646	1283	27.6mg n.s.s.	0/16	15.7mg	0/16				
a	1283	27.6mg n.s.s.	0/16	15.7mg	0/16				
b	1283	10.6mg n.s.s.	0/16	15.7mg	2/16				
2647	1283	14.4mg n.s.s.	0/16	14.6mg	1/17				
a	1283	14.4mg n.s.s.	0/16	14.6mg	1/17				
b	1283	4.29mg 38.7mg	0/16	14.6mg	7/17				
4,4'-THIODIANILINE 139-65-1									
2648	c01707	18.5mg 60.2mg	0/14	232. mg	33/35	464. mg	30/35	liv:hpc; thy:fca, fcc.	C
a	c01707	18.5mg 60.5mg	0/14	232. mg	32/35	464. mg	30/35		
b	c01707	45.5mg 178. mg	0/14	232. mg	11/35	464. mg	18/35	thy:fca, fcc.	
c	c01707	72.9mg 386. mg	0/14	232. mg	3/35	464. mg	15/35		
d	c01707	18.5mg 60.2mg	2/14	232. mg	33/35	464. mg	30/35		
e	c01707	18.5mg 60.5mg	0/14	232. mg	32/35	464. mg	30/35	liv:hpa,hpc,nnd.	
f	c01707	n.s.s. n.s.s.	0/14	232. mg	0/35	464. mg	0/35	lun:a/a,s/c.	
2649	c01707	20.1mg 54.0mg	4/14	214. mg	34/35	428. mg	24/35	liv:hpa,hpc; thy:fca, fcc.	C
a	c01707	20.3mg 55.3mg	4/14	214. mg	33/35	428. mg	23/35	liv:hpa,hpc.	
b	c01707	20.5mg 56.9mg	1/14	214. mg	32/35	428. mg	22/35		
c	c01707	30.7mg 88.8mg	0/14	214. mg	22/35	428. mg	20/35	thy:fca, fcc.	
d	c01707	40.7mg 125. mg	0/14	214. mg	15/35	428. mg	20/35		
e	c01707	20.1mg 54.0mg	4/14	214. mg	34/35	428. mg	24/35		
f	c01707	20.3mg 55.3mg	4/14	214. mg	33/35	428. mg	23/35	liv:hpa,hpc,nnd.	
g	c01707	174. mg n.s.s.	0/14	214. mg	1/35	428. mg	0/35	lun:a/a,s/c.	
2650	c01707	4.53mg 15.2mg	0/15	53.5mg	32/35	107. mg	33/35	eac:sgc, sqp; thy:fcc; ute:acn.	C
a	c01707	4.61mg 16.0mg	0/15	53.5mg	31/35	107. mg	23/35		
b	c01707	6.13mg 20.2mg	0/15	53.5mg	24/35	107. mg	32/35		
c	c01707	49.8mg 1.34gm	0/15	53.5mg	6/35	107. mg	3/35	eac:sgc, sqp.	
d	c01707	4.44mg 16.1mg	6/15	53.5mg	32/35	107. mg	33/35		
e	c01707	15.9mg 137. mg	0/15	53.5mg	6/35	107. mg	3/35	liv:hpa,hpc,nnd.	
2651	c01707	2.00mg 11.7mg	0/15	42.8mg	32/35	(85.6mg)	33/35	col:acn; eac:sgc, sqp; liv:hpa,hpc; thy:fca, fcc.	C
a	c01707	2.01mg 12.2mg	0/15	42.8mg	30/35	(85.6mg)	32/35	thy:fca, fcc.	

Spe	Strain	Site	Xpo + Xpt	Notes	TD50	2Tailpvl
Sex	Route	Hist			DR	AuOp
b	R m f34	eat thy fcc	16m24		6.36mg \	P<.0005c
c	R m f34	eat liv MXA	16m24		7.18mg \	P<.0005c
d	R m f34	eat liv hpc	16m24		7.31mg \	P<.0005c
e	R m f34	eat eac MXA	16m24		20.3mg \	P<.0005c
f	R m f34	eat col acn	16m24		+historical \	P<.02 c
g	R m f34	eat TBA MXB	16m24		5.96mg \	P<.0005
h	R m f34	eat liv MXB	16m24		7.18mg \	P<.0005
beta-THIOGUANINE DEOXYRIBOSIDE*					100ng...1ug...10...100...1mg...10...100...1g...10	
2652	M f b6c	ipj TBA MXB	43w77	as		4.48mg z P<.1.
a	M f b6c	ipj liv MXB	43w77	as		no dre P=1.
b	M f b6c	ipj lun MXB	43w77	as		6.87mg * P<.3
2653	M m b6c	ipj TBA MXB	38w77	as		no dre P=1.
a	M m b6c	ipj liv MXB	38w77	as		no dre P=1.
b	M m b6c	ipj lun MXB	38w77	as		no dre P=1.
2654	R f sda	ipj eac MXA	52w78	es	:	2.10mg / P<.005 c
a	R f sda	ipj eac	52w78	es	:	2.31mg / P<.008
b	R f sda	ipj TBA MXB	52w78	es	:	4.11mg / P<.7
c	R f sda	ipj liv MXB	52w78	es	:	no dre P=1.
2655	R f sda	ipj eac MXA	52w78	es	:	2.10mg / P<.0005c
a	R f sda	ipj eac	52w78	es	:	2.31mg / P<.002
2656	R m sda	ipj eac MXA	52w78	es	:	4.38mg * P<.08 a
a	R m sda	ipj TBA MXB	52w78	es	:	no dre P=1.
b	R m sda	ipj liv MXB	52w78	es	:	no dre P=1.
2657	R m sda	ipj eac MXA	52w78	es	:	4.38mg * P<.02 a
a	R m sda	ipj --- lym	52w78	es	:	5.75mg * P<.03
THIOSEMICARBAZIDE					100ng...1ug...10...100...1mg...10...100...1g...10	
2658	R f cdr	eat mgl tum	18m24	e	:	3.07mg * P<.2
THIOURACIL					100ng...1ug...10...100...1mg...10...100...1g...10	
2659	M f c3h	eat liv hpt	73w73	r	.	63.3mg P<.0005+
2660	M m c3h	eat liv hpt	73w73	r	.	48.6mg P<.0005+
2661	M f tmw	eat liv hpt	73w73	r	.	no dre P=1. -
2662	M m tmw	eat liv hpt	73w73	r	.	no dre P=1. -
THIOUREA					100ng...1ug...10...100...1mg...10...100...1g...10	
2663	M f c3h	wat lun tum	6m24	e	.	no dre P=1. -
2664	R m hew	mix aur epc	95w95	emv	.	104. mg P<.0005+
a	R m hew	mix epc	95w95	emv	.	225. mg P<.02 +
b	R m hew	mix tba mix	95w95	emv	.	50.8mg P<.0005
2665	R m hew	wat aur epc	26m26	e	.	93.5mg P<.0005+
a	R m hew	wat epc	26m26	e	.	93.5mg P<.0005+
b	R m hew	wat tba mix	26m26	e	.	27.5mg P<.0005
2666	R f osm	eat liv tum	26m26	e	.	no dre P=1. -
a	R f osm	eat tba mix	26m26	e	.	16.2mg P<.7 -
2667	R f osm	eat liv tum	24m24	e	.	no dre P=1. -
a	R f osm	eat tba ben	24m24	e	.	15.0mg P<.3 -
b	R f osm	eat tba mal	24m24	e	.	no dre P=1. -
2668	R m osm	eat liv tum	26m26	e	.	no dre P=1. -
a	R m osm	eat tba mix	26m26	e	.	46.1mg P<.6 -
2669	R m osm	eat liv tum	24m24	e	.	no dre P=1. -
a	R m osm	eat tba ben	24m24	e	.	64.7mg P<.3 -
b	R m osm	eat tba mal	24m24	e	.	no dre P=1. -
TIN (II) CNLORIDE					100ng...1ug...10...100...1mg...10...100...1g...10	
2670	M b cd1	wat lun mix	24m24	e	.	no dre P=1. -
a	M b cd1	wat lun ade	24m24	e	.	no dre P=1. -
b	M b cd1	wat tba mix	24m24	e	.	no dre P=1. -
c	M b cd1	wat tba mal	24m24	e	.	no dre P=1. -
d	M b cd1	wat tba ben	24m24	e	.	no dre P=1. -
2671	R b leb	wat liv tum	36m36	e	.	no dre P=1. -
a	R b leb	wat tba tum	36m36	e	.	no dre P=1. -
b	R b leb	wat tba mal	36m36	e	.	no dre P=1. -
TITANIUM DIOXIDE					100ng...1ug...10...100...1mg...10...100...1g...10	
2672	M f b6c	eat TBA MXB	24m24	e	.	>55.8gm * p<.8 -
a	M f b6c	eat liv MXB	24m24	e	.	55.5gm * p<.2 -
b	M f b6c	eat lun MXB	24m24	e	.	50.4gm * p<.1 -
2673	M m b6c	eat TBA MXB	24m24	e	.	:no dre P=1. -
a	M m b6c	eat liv MXB	24m24	e	.	38.7gm * p<.4 -
b	M m b6c	eat lun MXB	24m24	e	.	no dre P=1. -
2674	R f f34	eat thy MXA	24m24	e	.	: #17.2gm / P<.04 -
a	R f f34	eat TBA MXB	24m24	e	.	5.01gm * p<.4 -
b	R f f34	eat liv MXB	24m24	e	.	no dre P=1. -
2675	R m f34	eat --- ker	24m24	e	.	:#25.9gm * p<.05 -
a	R m f34	eat TBA MXB	24m24	e	.	23.0gm * p<.9 -
b	R m f34	eat liv MXB	24m24	e	.	no dre P=1. -

RefNum	LoConf	UpConf	Cntrl	1Dose	1Inc	2Dose	2Inc	Citation or Pathology	Brkly Code
b	c01707	2.08mg	15.3mg	0/15	42.8mg	28/35	(85.6mg 32/35)		
c	c01707	2.15mg	18.5mg	0/15	42.8mg	23/35	(85.6mg 12/35)		liv:hpa,hpc.
d	c01707	2.16mg	19.3mg	0/15	42.8mg	21/35	(85.6mg 10/35)		
e	c01707	6.42mg	57.0mg	0/15	42.8mg	15/35	(85.6mg 8/35)		oac:sgc,sqp.
f	c01707	38.5mg	n.s.s.	0/15	42.8mg	6/35	(85.6mg 1/35)		
g	c01707	2.28mg	13.6mg	4/15	42.8mg	32/35	(85.6mg 33/35)		
h	c01707	2.15mg	18.5mg	0/15	42.8mg	23/35	(85.6mg 12/35)		liv:hpa,hpc,nnd.
beta-THIOGUANINE DEOXYRIBOSIDE* (beta-TGdR. NCI uses CAS# 789-61-7) 64039-27-6									
2652	c01581	.150mg	n.s.s.	21/30	.300mg	20/35	.600mg 21/35	(1.70mg 1/35)	
a	c01581	n.s.s.	n.s.s.	0/30	.300mg	0/35	.600mg	0/35	liv:hpa,hpc,nnd.
b	c01581	1.12mg	n.s.s.	0/30	.300mg	0/35	.600mg	1/35	1.70mg 0/35
2653	c01581	.173mg	n.s.s.	20/30	.300mg	19/35	.600mg 19/35	1.70mg 0/35	
a	c01581	.421mg	n.s.s.	2/30	.300mg	1/35	.600mg	1/35	1.70mg 0/35
b	c01581	n.s.s.	n.s.s.	0/30	.300mg	0/35	.600mg	0/35	1.70mg 0/35
2654	c01581	.938mg	14.3mg	0/10	1.00mg	2/35	2.00mg	6/35	
a	c01581	.990mg	44.0mg	0/10	1.00mg	2/35	2.00mg	5/35	
b	c01581	.572mg	n.s.s.	9/10	1.00mg	17/35	2.00mg	10/35	
c	c01581	n.s.s.	n.s.s.	0/10	1.00mg	0/35	2.00mg	0/35	liv:hpa,hpc,nnd.
2655	c01581	.938mg	6.68mg	0/30p	1.00mg	2/35	2.00mg	6/35	oac:can,sgc.
a	c01581	.990mg	8.66mg	0/30p	1.00mg	2/35	2.00mg	5/35	
2656	c01581	1.32mg	n.s.s.	0/10	1.00mg	1/35	2.00mg	2/35	oac:can,sgc.
a	c01581	.839mg	n.s.s.	7/10	1.00mg	9/35	2.00mg	5/35	
b	c01581	n.s.s.	n.s.s.	0/10	1.00mg	0/35	2.00mg	0/35	liv:hpa,hpc,nnd.
2657	c01581	1.32mg	n.s.s.	0/30p	1.00mg	1/35	2.00mg	2/35	oac:can,sgc.
a	c01581	1.73mg	n.s.s.	0/30p	1.00mg	1/35	2.00mg	2/35	
THIOSEMICARBAZIDE 79-19-6									
2658	1112	1.11mg	n.s.s.	3/10	1.41mg	19/26	2.81mg	16/26	Weisburger;jnci,67,75-88;1981
THIOURACIL 141-90-2									
2659	284	28.6mg	152.mg	0/24	390.mg	14/16			Casas;pseb,113,493-494;1963
2660	284	17.9mg	139.mg	2/32	360.mg	12/13			
2661	284	871.mg	n.s.s.	0/20	390.mg	0/22			
2662	284	804.mg	n.s.s.	0/20	360.mg	0/22			
THIOUREA 62-56-6									
2663	1135	331.mg	n.s.s.	1/94	25.1mg	0/64			Vazquez-Lopez;b ca,3,401-414;1949
2664	288a	43.0mg	363.mg	0/12	159.mg	7/12			Rosin;canr,17,302-305;1957
a	288a	76.6mg	n.s.s.	0/12	159.mg	4/12			
b	288a	21.2mg	141.mg	0/12	159.mg	10/12			
2665	288b	45.5mg	249.mg	0/12	100.mg	11/19			
a	288b	45.5mg	249.mg	0/12	100.mg	11/19			
b	288b	11.2mg	64.0mg	0/12	100.mg	18/19			
2666	21	18.2mg	n.s.s.	0/30	2.50mg	0/30			Deichmann;txap,11,88-103;1967
a	21	2.51mg	n.s.s.	13/30	2.50mg	15/30			
2667	84a	24.7mg	n.s.s.	1/30	4.00mg	0/30			Radomski;txap,7,652-656;1965
a	84a	4.19mg	n.s.s.	6/30	4.00mg	10/30			
b	84a	19.7mg	n.s.s.	6/30	4.00mg	1/30			
2668	21	14.6mg	n.s.s.	0/30	2.00mg	0/30			Deichmann;txap,11,88-103;1967
a	21	6.34mg	n.s.s.	1/30	2.00mg	2/30			
2669	84a	19.8mg	n.s.s.	0/30	3.20mg	0/30			Radomski;txap,7,652-656;1965
a	84a	10.5mg	n.s.s.	0/30	3.20mg	1/30			
b	84a	19.8mg	n.s.s.	3/30	3.20mg	0/30			
TIN (II) CHLORIDE (stannous chloride) 7772-99-8									
2670	1512	5.26mg	n.s.s.	26/170	.877mg	10/86			Kanisawa;canr,27,1192-1195;1967
a	1512	12.0mg	n.s.s.	7/170	.877mg	1/86			
b	1512	3.83mg	n.s.s.	55/170	.877mg	22/86			
c	1512	6.06mg	n.s.s.	15/170	.877mg	6/86			
d	1512	6.42mg	n.s.s.	29/170	.877mg	9/86			
2671	1036	11.5mg	n.s.s.	1/82	.265mg	0/94			Kanisawa;canr,29,892-895;1969
a	1036	2.08mg	n.s.s.	31/82	.265mg	29/94			
b	1036	5.54mg	n.s.s.	9/82	.265mg	5/94			
TITANIUM DIOXIDE 13463-67-7									
2672	c04240	6.64gm	n.s.s.	30/50	3.22gm	24/50	6.44gm	26/50	
a	c04240	17.0gm	n.s.s.	1/50	3.22gm	3/50	6.44gm	3/50	liv:hpa,hpc,nnd.
b	c04240	16.9gm	n.s.s.	1/50	3.22gm	2/50	6.44gm	4/50	liv:hpa,hpc,nnd.
2673	c04240	9.26gm	n.s.s.	29/50	2.97gm	25/50	5.94gm	28/50	
a	c04240	9.45gm	n.s.s.	8/50	2.97gm	9/50	5.94gm	14/50	liv:hpa,hpc,nnd.
b	c04240	24.2gm	n.s.s.	6/50	2.97gm	3/50	5.94gm	5/50	liv:hpa,hpc,nnd.
2674	c04240	6.25gm	n.s.s.	1/50	1.24gm	0/50	2.48gm	6/50	thy:cca,ccr.
a	c04240	1.23gm	n.s.s.	41/50	1.24gm	43/50	2.48gm	46/50	
b	c04240	28.2gm	n.s.s.	1/50	1.24gm	0/50	2.48gm	0/50	liv:hpa,hpc,nnd.
2675	c04240	7.81gm	n.s.s.	0/50	990.mg	0/50	1.98gm	3/50	
a	c04240	1.54gm	n.s.s.	32/50	990.mg	40/50	1.98gm	36/50	
b	c04240	16.7gm	n.s.s.	1/50	990.mg	1/50	1.98gm	0/50	liv:hpa,hpc,nnd.

Spe	Strain	Site	Xpo + Xpt	Notes	TD50	2Tailpvl	DR	AuOp
Sex	Route	Hist						
TITANIUM OXALATE, POTASSIUM					100ng...1ug.....10.....100.....1mg.....10.....100.....1g.....10			
2676	M f	cd1	wat	tba mix 26m26 e	>	3.66mg	P<.2	-
2677	M f	cd1	wat	lun tum 31m31 e	>	150.mg	P<.1	-
	a	M f	cd1	wat	tba tum 31m31 e		no dre	P=1.
2678	M m	cd1	wat	tba mix 28m28 e	>	3.62mg	P<.2	-
2679	M m	cd1	wat	lun tum 25m25 e	>	no dre	P=1.	-
	a	M m	cd1	wat	tba tum 25m25 e		no dre	P=1.
TOLAZAMIDE					100ng...1ug.....10.....100.....1mg.....10.....100.....1g.....10			
2680	M f	b6c	eat	TBA MXB 24m24	>	no dre	P=1.	-
	a	M f	b6c	eat	liv MXB 24m24		no dre	P=1.
	b	M f	b6c	eat	lun MXB 24m24		no dre	P=1.
2681	M m	b6c	eat	TBA MXB 24m24	>	no dre	P=1.	-
	a	M m	b6c	eat	liv MXB 24m24		no dre	P=1.
	b	M m	b6c	eat	lun MXB 24m24		24.6gm *	P<.9
2682	R f	f34	eat	TBA MXB 24m24	>	no dre	P=1.	-
	a	R f	f34	eat	liv MXB 24m24		no dre	P=1.
2683	R m	f34	eat	TBA MXB 24m24	>	no dre	P=1.	-
	a	R m	f34	eat	liv MXB 24m24		no dre	P=1.
TOLBUTAMIDE					100ng...1ug.....10.....100.....1mg.....10.....100.....1g.....10			
2684	M f	b6c	eat	TBA MXB 18m24	>	24.2gm \	P<.9	-
	a	M f	b6c	eat	liv MXB 18m24		no dre	P=1.
	b	M f	b6c	eat	lun MXB 18m24		no dre	P=1.
2685	M m	b6c	eat	TBA MXB 18m24	>	no dre	P=1.	-
	a	M m	b6c	eat	liv MXB 18m24		no dre	P=1.
	b	M m	b6c	eat	lun MXB 18m24		no dre	P=1.
2686	R f	f34	eat	TBA MXB 18m25	>	no dre	P=1.	-
	a	R f	f34	eat	liv MXB 18m25		no dre	P=1.
2687	R m	f34	eat	TBA MXB 18m25	>	no dre	P=1.	-
	a	R m	f34	eat	liv MXB 18m25		no dre	P=1.
o-TOLUENESULFONAMIDE					100ng...1ug.....10.....100.....1mg.....10.....100.....1g.....10			
2688	R f	cdr	eat	agl adc 33m33 eg	*	12.2mg Z	P<.02	-
	a	R f	cdr	eat	liv kcs 33m33 eg		8.52gm *	P<.03
	b	R f	cdr	eat	liv nnd 33m33 eg		21.7gm *	P<.6
2689	R m	cdr	eat	ang 33m33 e	>	17.2gm *	P<.2	-
	a	R m	cdr	eat	liv nnd 33m33 e		35.9gm *	P<.7
	b	R m	cdr	eat	liv blc 33m33 e		no dre	P=1.
2690	R b	ada	eat	--- leu 31m33 a	+	.375.mg \	P<.009	-
	a	R b	ada	eat	ubl mix 31m33 a		3.96gm *	P<.06
	b	R b	ada	eat	liv car 31m33 a		no dre	P=1.
	c	R b	ada	eat	tba mal 31m33 a		13.3gm *	P<.9
2691	R f	wis	wat	liv hpc 24m24 e	>	no dre	P=1.	-
m-TOLUIDINE.HCl					100ng...1ug.....10.....100.....1mg.....10.....100.....1g.....10			
2692	M f	chi	eat	liv mix 77w90 v	>	9.99gm	P<.6	-
	a	M f	chi	eat	lun mix 77w90 v		no dre	P=1.
	b	M f	chi	eat	tba mix 77w90 v		no dre	P=1.
2693	M f	chi	eat	lun mix 77w81 v	>	no dre	P=1.	-
	a	M f	chi	eat	liv mix 77w81 v		no dre	P=1.
	b	M f	chi	eat	tba mix 77w81 v		1.95gm	P<.09
2694	M m	chi	eat	liv mix 77w90 v	>	6.77gm *	P<.7	-
	a	M m	chi	eat	lun mix 77w90 v		no dre	P=1.
	b	M m	chi	eat	tba mix 77w90 v		no dre	P=1.
2695	M m	chi	eat	liv hpt 77w90 v	pool	1.44gm \	P<.2	+
2696	R m	cdr	eat	liv mix 77w98 v		no dre	P=1.	-
	a	R m	cdr	eat	tba mix 77w98 v		98.4mg \	P<.2
o-TOLUIDINE.HCl					100ng...1ug.....10.....100.....1mg.....10.....100.....1g.....10			
2697	M f	b6c	eat	liv MXA 24m24	: + :	754.mg *	P<.002	c
	a	M f	b6c	eat	liv hpc 24m24		1.52gm *	P<.02
	b	M f	b6c	eat	TBA MXB 24m24		1.35gm *	P<.4
	c	M f	b6c	eat	liv MXB 24m24		754.mg *	P<.002
	d	M f	b6c	eat	lun MXB 24m24		no dre	P=1.
2698	M m	b6c	eat	--- MXA 24m24 a	: +	:926.mg *	P<.005	c
	a	M m	b6c	eat	--- hes 24m24 a		1.22gm /	P<.01
	b	M m	b6c	eat	TBA MXB 24m24 a		no dre	P=1.
	c	M m	b6c	eat	liv MXB 24m24 a		12.7gm *	P<.1
	d	M m	b6c	eat	lun MXB 24m24 a		no dre	P=1.
2699	M f	chi	eat	liv mix 68w90 av	: +	1.65gm *	P<.008	-
	a	M f	chi	eat	lun mix 68w90 av		no dre	P=1.
	b	M f	chi	eat	tba mix 68w90 av		699.mg *	P<.007
2700	M f	chi	eat	--- vac 68w90 av	pool	1.24gm *	P<.0005+	-
2701	M m	chi	eat	--- vac 68w90 av	: + :	646.mg /	P<.0005+	-
	a	M m	chi	eat	liv mix 68w90 av		1.40gm *	P<.005
	b	M m	chi	eat	lun mix 68w90 av		1.16gm *	P<.1
	c	M m	chi	eat	tba mix 68w90 av		325.mg /	P<.0005
2702	M m	chi	eat	--- vac 68w90 av	pool	660.mg /	P<.0005+	-

RefNum	LoConf	UpConf	Cntrl	1Dose	1Inc	2Dose	2Inc	Citation or Pathology	Brkly Code
TITANIUM OXALATE, POTASSIUM ---									
2676	1395	1.24mg n.s.s.	9/45	1.00mg	13/36			Schroeder; jnut, 105,452-458;1975	
2677	56	3.59mg n.s.s.	9/60	1.00mg	5/32			Schroeder; jnut, 83,239-250;1964	
a	56	4.45mg n.s.s.	22/60	1.00mg	7/32				
2678	1395	1.23mg n.s.s.	10/43	.833mg	17/45			Schroeder; jnut, 105,452-458;1975	
2679	56	6.12mg n.s.s.	8/44	.833mg	1/40			Schroeder; jnut, 83,239-250;1964	
a	56	4.09mg n.s.s.	11/44	.833mg	4/40				
TOLAZAMIDE 1156-19-0									
2680	c03327	867.mg n.s.s.	8/15	455.mg	6/35	919.mg	9/34		
a	c03327	1.61gm n.s.s.	1/15	455.mg	1/35	919.mg	1/34		liv:hpa,hpc,nnd. lun:a/a,a/c.
b	c03327	3.33gm n.s.s.	1/15	455.mg	0/35	919.mg	1/34		
2681	c03327	643.mg n.s.s.	8/15	420.mg	11/35	(848.mg	5/35)		
a	c03327	2.87gm n.s.s.	3/15	420.mg	2/35	848.mg	3/35		liv:hpa,hpc,nnd. lun:a/a,a/c.
b	c03327	2.07gm n.s.s.	0/15	420.mg	2/35	848.mg	1/35		
2682	c03327	214.mg n.s.s.	13/15	175.mg	23/35	354.mg	20/35		
a	c03327	n.s.s. n.s.s.	0/15	175.mg	1/35	354.mg	0/35		liv:hpa,hpc,nnd.
2683	c03327	277.mg n.s.s.	9/15	140.mg	19/35	283.mg	20/35		
a	c03327	n.s.s. n.s.s.	0/15	140.mg	0/35	283.mg	0/35		liv:hpa,hpc,nnd.
TOLBUTAMIDE 64-77-7									
2684	c01763	1.63gm n.s.s.	3/15	1.76gm	11/35	(3.52gm	3/35)		
a	c01763	10.6gm n.s.s.	1/15	1.76gm	2/35	3.52gm	1/35		liv:hpa,hpc,nnd. lun:a/a,a/c.
b	c01763	10.3gm n.s.s.	0/15	1.76gm	2/35	3.52gm	0/35		
2685	c01763	1.16gm n.s.s.	8/15	1.62gm	13/35	(3.28gm	2/35)		
a	c01763	1.96gm n.s.s.	3/15	1.62gm	4/35	(3.28gm	1/35)		liv:hpa,hpc,nnd. lun:a/a,a/c.
b	c01763	9.12gm n.s.s.	1/15	1.62gm	2/35	3.28gm	0/35		
2686	c01763	662.mg n.s.s.	13/15	315.mg	15/35	631.mg	16/35		
a	c01763	n.s.s. n.s.s.	0/15	315.mg	0/35	631.mg	0/35		liv:hpa,hpc,nnd.
2687	c01763	654.mg n.s.s.	8/15	252.mg	13/35	505.mg	17/35		
a	c01763	n.s.s. n.s.s.	0/15	252.mg	0/35	505.mg	0/35		liv:hpa,hpc,nnd.
o-TOLUENESULFONAMIDE 88-19-7									
2688	1398	5.34mg n.s.s.	6/48	2.50mg	16/49	(25.0mg	6/49	250.mg	5/49)
a	1398	2.10gm n.s.s.	0/48	2.50mg	0/49	25.0mg	0/49	250.mg	2/49
b	1398	2.01gm n.s.s.	0/48	2.50mg	0/49	25.0mg	2/49	250.mg	1/49
2689	1398	2.81gm n.s.s.	0/49	2.50mg	0/49	25.0mg	0/50	250.mg	1/49
a	1398	4.05gm n.s.s.	0/49	2.50mg	1/49	25.0mg	1/50	250.mg	1/49
b	1398	5.04gm n.s.s.	0/49	2.50mg	1/49	25.0mg	0/50	250.mg	0/49
2690	1397	143.mg 8.60gm	0/76	20.0mg	5/76	(200.mg	3/76)		Schmahl; ztko, 91, 19-22; 1978
a	1397	1.26gm n.s.s.	0/76	20.0mg	3/76	200.mg	5/76		
b	1397	531.mg n.s.s.	1/76	20.0mg	0/76	200.mg	0/76		
c	1397	1.02gm n.s.s.	13/76	20.0mg	20/76	200.mg	17/76		
2691	1433	544.mg n.s.s.	1/50	57.1mg	0/48				Hooon; bjca, 42, 129-147; 1980
m-TOLUIDINE.HCl 638-03-9									
2692	381	1.29gm n.s.s.	1/22	1.14gm	2/18				Weisburger; jept, 2, 325-356; 1978/pers.com./Russfield 1973
a	381	1.04gm n.s.s.	5/22	1.14gm	4/18				
b	381	919.mg n.s.s.	18/22	1.14gm	10/18				
2693	381a	2.75gm n.s.s.	8/15	2.66gm	2/19				
a	381a	n.s.s. n.s.s.	0/15	2.66gm	0/19				
b	381a	410.mg n.s.s.	11/15	2.66gm	7/19				
2694	381	1.06gm n.s.s.	1/18	754.mg	4/16	1.51gm	2/16		
a	381	1.45gm n.s.s.	8/18	754.mg	2/16	1.51gm	5/16		
b	381	751.mg n.s.s.	13/18	754.mg	10/16	1.51gm	10/16		
2695	381	368.mg n.s.s.	7/99p	754.mg	4/16	(1.51gm	1/16)		
2696	381	n.s.s. n.s.s.	0/16	146.mg	0/20	292.mg	0/18		
a	381	31.7mg n.s.s.	9/16	146.mg	17/20	(292.mg	9/18)		
o-TOLUIDINE.HCl 636-21-5									
2697	c02335	428.mg 2.86gm	0/20	130.mg	4/50	390.mg	13/50		liv:hpa,hpc.
a	c02335	716.mg n.s.s.	0/20	130.mg	2/50	390.mg	7/50		
b	c02335	344.mg n.s.s.	8/20	130.mg	19/50	390.mg	26/50		
c	c02335	428.mg 2.86gm	0/20	130.mg	4/50	390.mg	13/50		liv:hpa,hpc,nnd. lun:a/a,a/c.
d	c02335	1.66gm n.s.s.	1/20	130.mg	2/50	390.mg	2/50		---:hem,hes.
2698	c02335	453.mg 8.19gm	1/20	120.mg	2/50	360.mg	12/50		
a	c02335	554.mg 80.1gm	1/20	120.mg	1/50	360.mg	10/50		
b	c02335	304.mg n.s.s.	17/20	120.mg	28/50	360.mg	30/50		
c	c02335	404.mg n.s.s.	5/20	120.mg	19/50	360.mg	14/50		liv:hpa,hpc,nnd. lun:a/a,a/c.
d	c02335	473.mg n.s.s.	5/20	120.mg	5/50	(360.mg	3/50)		
2699	381	544.mg 46.2gm	0/15	1.09gm	3/18	2.50gm	2/21		Weisburger; jept, 2, 325-356; 1978/pers.com./Russfield 1973
a	381	1.18gm n.s.s.	8/15	1.09gm	3/18	2.50gm	0/21		
b	381	283.mg 12.1gm	11/15	1.09gm	12/18	2.50gm	8/21		
2700	381	513.mg 3.75gm	8/102p	1.09gm	4/18	2.50gm	8/21		
2701	381	300.mg 1.75gm	0/14	1.01gm	4/14	2.30gm	8/11		
a	381	474.mg 12.0gm	1/14	1.01gm	2/14	2.30gm	4/11		
b	381	353.mg n.s.s.	4/14	1.01gm	5/14	2.30gm	2/11		
c	381	154.mg 1.13gm	8/14	1.01gm	10/14	2.30gm	11/11		
2702	381	301.mg 1.84gm	5/99p	1.01gm	4/14	2.30gm	8/11		

Spe	Strain	Site	Xpo + Xpt	Notes	TD50	2Tailpvl
Sex	Route	Hist	AuOp		DR	AuOp
2703	R f f34	eat	MXB MXB 24m24 s			77.9mg / P<.0005
a	R f f34	eat	mgl fba 24m24 s	:+ :		115.mg / P<.0005c
b	R f f34	eat	mgl MXA 24m24 s			119.mg / P<.0005c
c	R f f34	eat	ubl MXA 24m24 s			175.mg / P<.0005c
d	R f f34	eat	ubl tcc 24m24 s			185.mg / P<.0005c
e	R f f34	eat	mul MXA 24m24 s			332.mg / P<.0005c
f	R f f34	eat	spl MXA 24m24 s			337.mg * P<.0005c
g	R f f34	eat	mul ost 24m24 s			423.mg / P<.0005c
h	R f f34	eat	spl ang 24m24 s			450.mg * P<.002 c
i	R f f34	eat	TBA MXB 24m24 s			75.8mg * P<.0005
j	R f f34	eat	liv MXB 24m24 s			no dre P=1.
2704	R m f34	eat	MXB MXB 24m24 as	: + :		23.3mg / P<.0005
a	R m f34	eat	sub fib 24m24 as			33.3mg / P<.0005c
b	R m f34	eat	mul MXA 24m24 as			93.2mg / P<.0005c
c	R m f34	eat	MXA MXA 24m24 as			97.4mg * P<.0005c
d	R m f34	eat	spl fib 24m24 as			134.mg * P<.0005c
e	R m f34	eat	mul fbs 24m24 as			184.mg / P<.0005c
f	R m f34	eat	mul srn 24m24 as			394.mg / P<.0005c
g	R m f34	eat	TBA MXB 24m24 as			24.4mg / P<.0005
h	R m f34	eat	liv MXB 24m24 as			645.mg / P<.06
2705	R m cdr	eat	sub mix 64u68 v	: + :		36.7mg * P<.0005+
a	R m cdr	eat	liv mix 64u68 v			2.96gm * P<.3 -
b	R m cdr	eat	tba mix 64u68 v			36.1mg * P<.0005
2706	R m cdr	eat	sub mix 64u68 v	pool : + :		38.8mg * P<.0005+
a	R m cdr	eat	ubl mix 64u68 v			131.mg * P<.0005+
p-TOLUIDINE-HCl				100ng.....1ug.....10.....100.....1mg.....10.....100.....1g.....10		
2707	M f chi	eat	liv mix 77u98 v			256.mg * P<.06
a	M f chi	eat	lun mix 77u98 v			400.mg * P<.5 -
b	M f chi	eat	tba mix 77u98 v			no dre P=1.
2708	M f chi	eat	liv hpt 77u98 v	pool : +		278.mg * P<.01 +
2709	M m chi	eat	liv hpt 77u98 v	: ±		49.1mg / P<.02 +
a	M m chi	eat	liv mix 77u98 v			49.1mg \ P<.02 +
b	M m chi	eat	lun mix 77u98 v			78.6mg \ P<.06 -
c	M m chi	eat	tba mix 77u98 v			49.4mg \ P<.06
2710	M m chi	eat	liv hpt 77u98 v	pool : + :		50.1mg \ P<.0005+
2711	R m cdr	eat	liv mix 77u98			no dre P=1. -
a	R m cdr	eat	tba mix 77u98			no dre P=1. -
p-TOLYLUREA				100ng.....1ug.....10.....100.....1mg.....10.....100.....1g.....10		
2712	M f cb6	eat	liv hpc 52u69 e	pool >		no dre P=1. -
a	M f cb6	eat	lun a/a 52u69 e			no dre P=1. -
2713	M m cb6	eat	--- mly 52u69 e	pool . + .		206.mg P<.0005+
a	M m cb6	eat	--- mlh 52u69 e			265.mg P<.0005
b	M m cb6	eat	mul mlh 52u69 e			441.mg P<.002
c	M m cb6	eat	mln mlh 52u69 e			626.mg P<.009
d	M m cb6	eat	liv hpc 52u69 e			722.mg P<.08 -
e	M m cb6	eat	lun a/a 52u69 e			no dre P=1. -
2714	R f f34	eat	liv tum 52u69 e			no dre P=1. -
2715	R m f34	eat	liv hpc 52u69 e			699.mg P<.2 -
TOXAPHENE				100ng.....1ug.....10.....100.....1mg.....10.....100.....1g.....10		
2716	M f b6c	eat	liv MXA 80u90 v	:+ :		8.78mg / P<.0005c
a	M f b6c	eat	liv hpc 80u90 v			15.2mg / P<.0005c
b	M f b6c	eat	TBA MXB 80u90 v			9.19mg * P<.0005
c	M f b6c	eat	liv MXB 80u90 v			8.78mg / P<.0005
d	M f b6c	eat	lun MXB 80u90 v			no dre P=1.
2717	M f b6c	eat	liv MXA 80u90 v	pool : + :		9.10mg / P<.0005c
a	M f b6c	eat	liv hpc 80u90 v			15.2mg / P<.0005c
2718	M m b6c	eat	liv hpc 80u90 v	: + :		4.08mg * P<.0005c
a	M m b6c	eat	liv MXA 80u90 v			4.23mg * P<.0005c
b	M m b6c	eat	TBA MXB 80u90 v			4.13mg * P<.0005
c	M m b6c	eat	liv MXB 80u90 v			4.23mg * P<.0005
d	M m b6c	eat	lun MXB 80u90 v			1.13gm * P<.9
2719	M m b6c	eat	liv MXA 80u90 v	pool : + :		4.46mg * P<.0005c
a	M m b6c	eat	liv hpc 80u90 v			4.79mg * P<.0005c
2720	R f osm	eat	TBA MXB 19m25 v			596.mg * P<.1. -
a	R f osm	eat	liv MXB 19m25 v			no dre P=1.
2721	R f osm	eat	thy fca 19m25 v	pool : ±		209.mg * P<.03 a
2722	R m osm	eat	TBA MXB 19m25 v			1.02gm * P<.1. -
a	R m osm	eat	liv MXB 19m25 v			949.mg * P<.1.
2723	R m osm	eat	thy MXA 19m25 v	pool : + :		58.9mg * P<.002 a
a	R m osm	eat	liv nnd 19m25 v			92.1mg * P<.03
TRENIMON				100ng.....1ug.....10.....100.....1mg.....10.....100.....1g.....10		
2724	R m b46	ivj	liv lcc 12m24 es	>		65.3ug P<.2
a	R m b46	ivj	tba mix 12m24 es			5.04ug P<.005 +
b	R m b46	ivj	tba mel 12m24 es			6.77ug P<.007 +
c	R m b46	ivj	tba ben 12m24 es			32.0ug P<.4

RefNum	LoConf	UpConf	Cntrl	1Dose	1Inc	2Dose	2Inc	Citation or Pathology	Brkly Code
2703	c02335	51.9mg	141.mg	7/20	150.mg	32/50	300.mg	48/50	mgl:edn, fba; mul:ang, fbs, ost, srn; spl:ang, ost, srn; ubl:tcc, tpp. C
a	c02335	72.0mg	244.mg	6/20	150.mg	20/50	300.mg	35/50	
b	c02335	73.4mg	268.mg	7/20	150.mg	20/50	300.mg	35/50	mgl:edn, fba.
c	c02335	111.mg	299.mg	0/20	150.mg	10/50	300.mg	22/50	ubl:tcc, tpp.
d	c02335	116.mg	318.mg	0/20	150.mg	9/50	300.mg	22/50	
e	c02335	199.mg	605.mg	0/20	150.mg	3/50	300.mg	21/50	mul:ang, fbs, ost, srn.
f	c02335	193.mg	610.mg	0/20	150.mg	9/50	300.mg	12/50	spl:ang, ost, srn.
g	c02335	236.mg	844.mg	0/20	150.mg	0/50	300.mg	18/50	
h	c02335	239.mg	1.53gm	0/20	150.mg	7/50	300.mg	9/50	
i	c02335	47.1mg	174.mg	13/20	150.mg	43/50	300.mg	48/50	
j	c02335	n.s.s.	n.s.s.	0/20	150.mg	2/50	300.mg	0/50	liv:hpa, hpc, nnd.
2704	c02335	15.5mg	35.3mg	0/20	120.mg	44/50	240.mg	48/50	mul:ang, fbs, mso, ost, srn; spl:fib; sub:fib; tnv:mso. C
a	c02335	20.9mg	54.6mg	0/20	120.mg	28/50	240.mg	27/50	
b	c02335	59.7mg	140.mg	0/20	120.mg	15/50	240.mg	37/50	mul:ang, fbs, ost, srn.
c	c02335	53.3mg	189.mg	0/20	120.mg	17/50	240.mg	9/50	mul:mso; tnv:mso.
d	c02335	64.1mg	355.mg	0/20	120.mg	10/50	240.mg	2/50	
e	c02335	99.1mg	336.mg	0/20	120.mg	8/50	240.mg	20/50	
f	c02335	192.mg	981.mg	0/20	120.mg	3/50	240.mg	11/50	
g	c02335	15.8mg	40.6mg	10/20	120.mg	50/50	240.mg	48/50	
h	c02335	169.mg	n.s.s.	1/20	120.mg	1/50	240.mg	3/50	liv:hpa, hpc, nnd.
2705	381	22.4mg	62.5mg	0/16	192.mg	18/23	384.mg	21/24	Weisburger; jept, 2, 325-356; 1978/pers. comm./Russfield 1973
a	381	482.mg	n.s.s.	0/16	192.mg	0/23	384.mg	1/24	
b	381	20.2mg	82.4mg	9/16	192.mg	19/23	384.mg	23/24	
2706	381	23.6mg	65.9mg	18/111p	192.mg	18/23	384.mg	21/24	
a	381	48.9mg	535.mg	5/111p	192.mg	3/23	384.mg	4/24	
p-TOLUIDINE.HCl 540-23-8									
2707	381	93.6mg	n.s.s.	0/20	74.3mg	2/21	142.mg	3/17	Weisburger; jept, 2, 325-356; 1978/pers. comm./Russfield 1973
a	381	86.3mg	n.s.s.	6/20	74.3mg	3/21	142.mg	7/17	
b	381	97.1mg	n.s.s.	17/20	74.3mg	6/21	142.mg	10/17	
2708	381	94.7mg	29.2gm	1/102p	74.3mg	2/21	142.mg	3/17	
2709	381	19.3mg	n.s.s.	3/18	68.6mg	8/17	(131.mg	9/18)	
a	381	19.3mg	n.s.s.	3/18	68.6mg	8/17	(131.mg	9/18)	
b	381	26.8mg	n.s.s.	5/18	68.6mg	6/17	(131.mg	8/18)	
c	381	17.2mg	n.s.s.	12/18	68.6mg	12/17	(131.mg	14/18)	
2710	381	20.2mg	212.mg	7/99p	68.6mg	8/17	(131.mg	9/18)	
2711	381	116.mg	n.s.s.	1/22	31.3mg	1/22	62.6mg	1/21	
a	381	42.9mg	n.s.s.	14/22	31.3mg	12/22	62.6mg	12/21	
p-TOLYLUREA 622-51-5									
2712	1343	674.mg	n.s.s.	1/89p	196.mg	0/38			Fleischman; jept, 3, 149-170; 1980
a	1343	674.mg	n.s.s.	2/89p	196.mg	0/38			
2713	1343	100.mg	529.mg	0/95p	181.mg	10/43			
a	1343	120.mg	776.mg	0/95p	181.mg	8/43			
b	1343	167.mg	1.93gm	0/91p	181.mg	5/43			
c	1343	189.mg	17.3gm	0/79p	181.mg	3/36			
d	1343	207.mg	n.s.s.	2/91p	181.mg	4/43			
e	1343	705.mg	n.s.s.	1/87p	181.mg	0/43			
2714	1343	287.mg	n.s.s.	0/49	75.3mg	0/42			
2715	1343	114.mg	n.s.s.	0/50	60.2mg	1/39			
TOXAPHENE 8001-35-2									
2716	c00259	6.34mg	14.8mg	0/10	11.3mg	18/50	22.9mg	40/50	liv:hpc, nnd.
a	c00259	10.3mg	24.9mg	0/10	11.3mg	5/50	22.9mg	34/50	
b	c00259	6.22mg	22.7mg	1/10	11.3mg	22/50	22.9mg	40/50	
c	c00259	6.34mg	14.8mg	0/10	11.3mg	18/50	22.9mg	40/50	liv:hpa, hpc, nnd.
d	c00259	217.mg	n.s.s.	1/10	11.3mg	0/50	22.9mg	0/50	lun:a/a, a/c.
2717	c00259	6.48mg	13.9mg	1/49p	11.3mg	18/50	22.9mg	40/50	liv:hpc, nnd.
a	c00259	10.3mg	23.7mg	0/49p	11.3mg	5/50	22.9mg	34/50	
2718	c00259	3.04mg	6.21mg	0/10	10.4mg	34/50	21.1mg	45/50	
a	c00259	2.88mg	9.30mg	2/10	10.4mg	40/50	21.1mg	45/50	liv:hpc, nnd.
b	c00259	2.79mg	9.59mg	2/10	10.4mg	44/50	21.1mg	45/50	
c	c00259	2.88mg	9.30mg	2/10	10.4mg	40/50	21.1mg	45/50	liv:hpa, hpc, nnd.
d	c00259	56.5mg	n.s.s.	1/10	10.4mg	1/50	21.1mg	2/50	lun:a/a, a/c.
2719	c00259	3.09mg	7.36mg	9/50p	10.4mg	40/50	21.1mg	45/50	liv:hpc, nnd.
a	c00259	3.37mg	7.58mg	6/50p	10.4mg	34/50	21.1mg	45/50	
2720	c00259	22.5mg	n.s.s.	6/10	20.0mg	31/50	40.0mg	40/50	
a	c00259	106.mg	n.s.s.	1/10	20.0mg	5/50	40.0mg	4/50	liv:hpa, hpc, nnd.
2721	c00259	84.2mg	n.s.s.	1/55p	20.0mg	1/50	40.0mg	7/50	
2722	c00259	17.2mg	n.s.s.	7/10	16.5mg	33/50	33.0mg	24/50	
a	c00259	46.9mg	n.s.s.	1/10	16.5mg	6/50	33.0mg	4/50	liv:hpa, hpc, nnd.
2723	c00259	29.3mg	298.mg	2/55p	16.5mg	7/50	33.0mg	9/50	thy:fca, fcc.
a	c00259	39.4mg	n.s.s.	1/55p	16.5mg	6/50	33.0mg	4/50	S
TRENIMON 68-76-8									
2724	1017	10.6ug	n.s.s.	0/65	2.14ug	1/45			Schmahl; arzn, 20, 1461-1467; 1970
a	1017	2.29ug	48.2ug	7/65	2.14ug	15/45			
b	1017	2.91ug	117mg	4/65	2.14ug	11/45			
c	1017	6.37ug	n.s.s.	3/65	2.14ug	4/45			

Spe	Strain	Site	Xpo+Xpt		TD50	2Tailpvl
Sex	Route	Hist	Notes		DR	AuOp
1,2,3-TRICHLORO-4,6-DINITROBENZENE				... <u>1ug</u> <u>10</u> <u>100</u> <u>1mg</u> <u>10</u> <u>100</u> <u>1g</u> <u>10</u>		
2725	M f	b6a orl	lun ade 76w76 evx	>	108.mg	P<.3
a	M f	b6a orl	liv hpt 76w76 evx		no dre	P=1.
b	M f	b6a orl	tba mix 76w76 evx		52.6mg	P<.09
2726	M m	b6a orl	lun ade 76w76 evx	.	49.0mg	P<.09
a	M m	b6a orl	liv hpt 76w76 evx	*	no dre	P=1.
b	M m	b6a orl	tba mix 76w76 evx		no dre	P=1.
2727	M f	b6c orl	liv hpt 76w76 evx	>	no dre	P=1.
a	M f	b6c orl	lun ade 76w76 evx		no dre	P=1.
b	M f	b6c orl	tba mix 76w76 evx		no dre	P=1.
2728	M m	b6c orl	liv hpt 76w76 evx	>	no dre	P=1.
a	M m	b6c orl	lun mix 76w76 evx		no dre	P=1.
b	M m	b6c orl	tba mix 76w76 evx		19.8mg	P<.4
2,4,6-TRICHLOROANILINE				<u>100ng</u> <u>1ug</u> <u>10</u> <u>100</u> <u>1mg</u> <u>10</u> <u>100</u> <u>1g</u> <u>10</u>		
2729	M f	chi eat	liv mix 68w77 a	:	927.mg *	P<.02 -
a	M f	chi eat	lun mix 68w77 a	*	1.37gm *	P<.02 -
b	M f	chi eat	tba mix 68w77 a		914.mg *	P<.06 -
2730	M m	chi eat	--- vsc 68w77 a	:	273.mg *	P<.0005+
a	M m	chi eat	lun mix 68w77 a	+	385.mg *	P<.0005-
b	M m	chi eat	liv mix 68w77 a	:	452.mg *	P<.004
c	M m	chi eat	tba mix 68w77 a	:	206.mg *	P<.0005
2731	M m	chi eat	--- vsc 68w77 a	:	259.mg *	P<.0005+
a	M m	chi eat	liv hpt 68w77 a	+	560.mg *	P<.0005+
2732	R m	cdr eat	liv mix 18m27 v	>	no dre	P=1. -
a	R m	cdr eat	tba mix 18m27 v		45.9mg \	P<.01 -
1,1,1-TRICHLOROETHANE*				<u>100ng</u> <u>1ug</u> <u>10</u> <u>100</u> <u>1mg</u> <u>10</u> <u>100</u> <u>1g</u> <u>10</u>		
2733	M f	b6c gav	TBA MXB 78w90 sv	:	>	no dre P=1.
a	M f	b6c gav	liv MXB 78w90 sv	:	no dre	P=1.
b	M f	b6c gav	lun MXB 78w90 sv	:	260.gm *	P<.9
2734	M m	b6c gav	TBA MXB 78w90 sv	>	30.5gm *	P<.8
a	M m	b6c gav	liv MXB 78w90 sv		39.7gm /	P<.8
b	M m	b6c gav	lun MXB 78w90 sv		5080.gm	P<1.
2735	R f	osm gav	TBA MXB 18m26 a	:	226.mg *	P<.0005
a	R f	osm gav	liv MXB 18m26 s	+	no dre	P=1.
2736	R m	osm gav	TBA MXB 18m25 a	:	950.mg \	P<.009
a	R m	osm gav	liv MXB 18m25 s	+	no dre	P=1.
1,1,2-TRICHLOROETHANE				<u>100ng</u> <u>1ug</u> <u>10</u> <u>100</u> <u>1mg</u> <u>10</u> <u>100</u> <u>1g</u> <u>10</u>		
2737	M f	b6c gav	MXB MXB 78w90 v	+	47.6mg *	P<.0005
a	M f	b6c gav	liv hpc 78w90 v	:	47.6mg *	P<.0005c
b	M f	b6c gav	adr phe 78w90 v	:	248.mg /	P<.0005c
c	M f	b6c gav	TBA MXB 78w90 v	:	52.9mg *	P<.0005
d	M f	b6c gav	liv MXB 78w90 v	:	47.6mg *	P<.0005
e	M f	b6c gav	lun MXB 78w90 v	:	787.mg *	P<.2
2738	M m	b6c gav	MXB MXB 78w90 v	:	65.0mg /	P<.0005
a	M m	b6c gav	liv hpc 78w90 v	:	65.0mg /	P<.0005c
b	M m	b6c gav	adr phe 78w90 v	:	588.mg /	P<.007 c
c	M m	b6c gav	TBA MXB 78w90 v	:	79.5mg *	P<.006
d	M m	b6c gav	liv MXB 78w90 v	:	65.0mg /	P<.0005
e	M m	b6c gav	lun MXB 78w90 v	:	1.56gm *	P<.8
2739	R f	osm gav	TBA MXB 18m26 v	>	no dre	P=1. -
a	R f	osm gav	liv MXB 18m26 v		771.mg *	P<.7
2740	R m	osm gav	TBA MXB 18m26 v	>	no dre	P=1. -
a	R m	osm gav	liv MXB 18m26 v		no dre	P=1.
TRICHLOROETHYLENE				<u>100ng</u> <u>1ug</u> <u>10</u> <u>100</u> <u>1mg</u> <u>10</u> <u>100</u> <u>1g</u> <u>10</u>		
2741	H f	syg inh	tba mal 18m30 e	>	9.22gm *	P<.8 -
a	H f	syg inh	tba ben 18m30 e		no dre	P=1. -
2742	H m	syg inh	tba mal 18m30 e	>	no dre	P=1. -
a	H m	syg inh	tba ben 18m30 e		5.64gm *	P<.4 -
2743	M f	b6c gav	liv hpc 78w90 sv	:	1.93gm *	P<.004 c
a	M f	b6c gav	TBA MXB 78w90 sv	+	1.85gm *	P<.2
b	M f	b6c gav	liv MXB 78w90 sv	:	1.93gm *	P<.004
c	M f	b6c gav	lun MXB 78w90 sv	:	4.35gm *	P<.2
2744	M m	b6c gav	liv hpc 78w90 sv	:	421.mg *	P<.0005c
a	M m	b6c gav	TBA MXB 78w90 sv	+	553.mg *	P<.01
b	M m	b6c gav	liv MXB 78w90 sv	:	421.mg *	P<.0005
c	M m	b6c gav	lun MXB 78w90 sv	:	7.16gm *	P<.7
2745	M f	hic gav	for tum 88w88 r	>	41.3mg	P<.3 -
2746	M m	hic gav	for tum 88w88 r	.	16.9mg	P<.1 -
2747	M f	nmh inh	--- mly 18m30 e	.	846.mg *	P<.03
a	M f	nmh inh	tba mal 18m30 e	*	573.mg *	P<.03 -
b	M f	nmh inh	tba ben 18m30 e		no dre	P=1. -
2748	M m	nmh inh	--- mly 18m30 e	>	no dre	P=1. -
a	M m	nmh inh	tba mal 18m30 e		no dre	P=1. -
b	M m	nmh inh	tba ben 18m30 e		no dre	P=1. -
2749	R f	osm gav	TBA MXB 18m26 dav	>	5.62gm *	P<.9 -
a	R f	osm gav	liv MXB 18m26 dav		no dre	P=1.

RefNum	LoConf	UpConf	Cntrl	1Dose	1Inc	2Dose	2Inc	Citation or Pathology	Brkly Code
1,2,3-TRICHLORO-4,6-DINITROBENZENE (Vancide PB) 6379-49-0									
2725	1262	17.6mg	n.s.s.	0/18	16.9mg	1/18		Innes;ntis,1968/1969	
a	1262	33.5mg	n.s.s.	0/18	16.9mg	0/18			
b	1262	12.9mg	n.s.s.	0/18	16.9mg	2/18			
2726	1262	12.0mg	n.s.s.	0/18	15.8mg	2/18			
a	1262	31.2mg	n.s.s.	1/18	15.8mg	0/18			
b	1262	14.7mg	n.s.s.	2/18	15.8mg	2/18			
2727	1262	33.5mg	n.s.s.	0/18	16.9mg	0/18			
a	1262	33.5mg	n.s.s.	1/18	16.9mg	0/18			
b	1262	22.2mg	n.s.s.	2/18	16.9mg	1/18			
2728	1262	18.5mg	n.s.s.	3/14	15.8mg	1/15			
a	1262	26.0mg	n.s.s.	0/14	15.8mg	0/15			
b	1262	4.75mg	n.s.s.	4/14	15.8mg	7/15			
2,4,6-TRICHLOROANILINE 634-93-5									
2729	381	369.mg	n.s.s.	0/13	780.mg	5/21	1.56gm	Weisburger;jept,2,325-356;1978/pers.com./Russfield 1973	
a	381	490.mg	n.s.s.	3/13	780.mg	3/21	1.56gm		
b	381	333.mg	n.s.s.	9/13	780.mg	7/21	1.56gm		
2730	381	140.mg	725.mg	2/16	720.mg	8/18	1.44gm		
a	381	166.mg	1.45gm	2/16	720.mg	6/18	1.44gm		
b	381	178.mg	3.14gm	2/16	720.mg	5/18	1.44gm		
c	381	104.mg	590.mg	9/16	720.mg	12/18	1.44gm		
2731	381	137.mg	537.mg	5/99p	720.mg	8/18	1.44gm		
a	381	202.mg	2.72gm	7/99p	720.mg	5/18	1.44gm		
2732	381	462.mg	n.s.s.	1/17	57.5mg	0/18	102.mg		
a	381	18.7mg	3.80gm	13/17	57.5mg	13/18	(102.mg	10/16)	
1,1,1-TRICHLOROETHANE* 71-55-6									
2733	c04626	6.79gm	n.s.s.	7/20	1.72gm	2/50	3.44gm		
a	c04626	13.6gm	n.s.s.	1/20	1.72gm	0/50	3.44gm		liv:hpa,hpc,nnd.
b	c04626	7.97gm	n.s.s.	1/20	1.72gm	0/50	3.44gm		lun:a/a,a/c.
2734	c04626	3.09gm	n.s.s.	5/20	1.74gm	2/50	3.48gm		
a	c04626	4.18gm	n.s.s.	3/20	1.74gm	0/50	3.48gm		liv:hpa,hpc,nnd.
b	c04626	5.52gm	n.s.s.	1/20	1.74gm	1/50	3.48gm		lun:a/a,a/c.
2735	c04626	81.4mg	685.mg	10/20	380.mg	6/50	760.mg		
a	c04626	n.s.s.	n.s.s.	1/20	380.mg	0/50	760.mg		liv:hpa,hpc,nnd.
2736	c04626	334.mg	22.2gm	7/20	380.mg	6/50	(760.mg	4/50)	
a	c04626	n.s.s.	n.s.s.	0/20	380.mg	0/50	760.mg		liv:hpa,hpc,nnd.
1,1,2-TRICHLOROETHANE 79-00-5									
2737	c04579	33.3mg	70.8mg	0/20	119.mg	16/50	239.mg		adr:phe; liv:hpc. C
a	c04579	33.3mg	70.8mg	0/20	119.mg	16/50	239.mg		
b	c04579	127.mg	611.mg	0/20	119.mg	0/50	239.mg		
c	c04579	33.9mg	106.mg	5/20	119.mg	20/50	239.mg		
d	c04579	33.3mg	70.8mg	0/20	119.mg	16/50	239.mg		liv:hpa,hpc,nnd.
e	c04579	287.mg	n.s.s.	0/20	119.mg	3/50	239.mg		lun:a/a,a/c.
2738	c04579	42.2mg	146.mg	2/20	121.mg	18/50	239.mg		adr:phe; liv:hpc. C
a	c04579	42.2mg	146.mg	2/20	121.mg	18/50	239.mg		
b	c04579	263.mg	6.05gm	0/20	121.mg	0/50	239.mg		
c	c04579	42.3mg	872.mg	6/20	121.mg	28/50	239.mg		
d	c04579	42.2mg	146.mg	2/20	121.mg	18/50	239.mg		liv:hpa,hpc,nnd.
e	c04579	338.mg	n.s.s.	0/20	121.mg	3/50	239.mg		lun:a/a,a/c.
2739	c04579	31.0mg	n.s.s.	4/20	23.0mg	34/50	45.5mg		
a	c04579	182.mg	n.s.s.	0/20	23.0mg	1/50	45.5mg		liv:hpa,hpc,nnd.
2740	c04579	11.8mg	n.s.s.	6/20	23.0mg	21/50	(45.9mg	11/50)	
a	c04579	436.mg	n.s.s.	1/20	23.0mg	0/50	45.9mg		liv:hpa,hpc,nnd.
TRICHLOROETHYLENE 79-01-6									
2741	1010	821.mg	n.s.s.	2/30	46.1mg	3/29	230.mg		Henschler;artx,43,237-248;1980
a	1010	2.14gm	n.s.s.	1/30	46.1mg	1/29	230.mg		
2742	1010	863.mg	n.s.s.	6/30	40.5mg	2/30	203.mg		
a	1010	999.mg	n.s.s.	1/30	40.5mg	0/30	203.mg		
2743	c04546	1.06gm	9.81gm	0/20	538.mg	4/50	1.08gm		
a	c04546	716.mg	n.s.s.	4/20	538.mg	14/50	1.08gm		
b	c04546	1.06gm	9.81gm	0/20	538.mg	4/50	1.08gm		liv:hpa,hpc,nnd.
c	c04546	1.55gm	n.s.s.	1/20	538.mg	4/50	1.08gm		lun:a/a,a/c.
2744	c04546	277.mg	1.13gm	1/20	724.mg	26/50	1.45gm		
a	c04546	288.mg	28.9gm	5/20	724.mg	30/50	1.45gm		
b	c04546	277.mg	1.13gm	1/20	724.mg	26/50	1.45gm		liv:hpa,hpc,nnd.
c	c04546	1.79gm	n.s.s.	0/20	724.mg	5/50	1.45gm		lun:a/a,a/c.
2745	1011	6.75mg	n.s.s.	0/30	2.86mg	1/30			
2746	1011	4.16mg	n.s.s.	0/30	2.38mg	2/30			Van Duuren;jnci,63,1433-1439;1979
2747	1010	339.mg	n.s.s.	9/29	102.mg	17/30	509.mg		Henschler;artx,43,237-248;1980
a	1010	230.mg	n.s.s.	13/29	102.mg	22/30	509.mg		
b	1010	2.03gm	n.s.s.	6/29	102.mg	1/30	509.mg		
2748	1010	1.33gm	n.s.s.	7/30	84.8mg	7/29	424.mg		
a	1010	1.12gm	n.s.s.	11/30	84.8mg	10/29	424.mg		
b	1010	2.37gm	n.s.s.	8/30	84.8mg	6/29	424.mg		
2749	c04546	302.mg	n.s.s.	7/20	242.mg	12/50	484.mg		
a	c04546	n.s.s.	n.s.s.	0/20	242.mg	0/50	484.mg		liv:hpa,hpc,nnd.

Spe	Strain	Site	Xpo + Xpt		TD50	2Tailpvl
Sex	Route	Hist	Notes		DR	AuOp
2750	R m osm gav	TBA MXB	18m26	dsv	>	16.0gm * P<.1. -
a	R m osm gav	liv MXB	18m26	dsv		no dre P=.1. -
2751	R f wsh inh	tba mal	18m36	e	>	no dre P=.1. -
a	R f wsh inh	tba ben	18m36	e		2.12gm * P<.4 -
2752	R m wsh inh	tba mal	18m36	e	±	351.mg * P<.03 -
a	R m wsh inh	tba ben	18m36	e		no dre P=.1. -
TRICHLOROFLUOROMETHANE*				100ng...1ug.....10.....100.....1mg.....10.....100.....1g.....10		
2753	M f b6c gav	TBA MXB	78w91	sv	>	11.5gm * P<.6 -
a	M f b6c gav	liv MXB	78w91	sv		no dre P=.1. -
b	M f b6c gav	lun MXB	78w91	sv		111.gm * P<.8 -
2754	M m b6c gav	TBA MXB	78w91	sv	>	5.81gm * P<.6 -
a	M m b6c gav	liv MXB	78w91	sv		15.0gm * P<.8 -
b	M m b6c gav	lun MXB	78w91	sv		no dre P=.1. -
2755	R f osm gav	TBA MXB	18m26	sv	±	326.mg * P<.09 -
a	R f osm gav	liv MXB	18m26	sv		no dre P=.1. -
2756	R m osm gav	TBA MXB	18m26	sv	>	no dre P=.1. -
a	R m osm gav	liv MXB	18m26	sv		no dre P=.1. -
N-(TRICHLOROMETHYLTHIO)PHthalimide				...1ug.....10.....100.....1mg.....10.....100.....1g.....10		
2757	M f b6a orl	liv hpt	76w76	evx	>	no dre P=.1. -
a	M f b6a orl	lun ade	76w76	evx		no dre P=.1. -
b	M f b6a orl	tba mix	76w76	evx		no dre P=.1. -
2758	M m b6a orl	liv hpt	76w76	evx	>	8.23gm P<.1. -
a	M m b6a orl	lun ade	76w76	evx		no dre P=.1. -
b	M m b6a orl	tba mix	76w76	evx		no dre P=.1. -
2759	M f b6c orl	liv hpt	76w76	evx	>	no dre P=.1. -
a	M f b6c orl	lun mix	76w76	evx		no dre P=.1. -
b	M f b6c orl	tba mix	76w76	evx		260.mg P<.2 -
2760	M m b6c orl	lun ade	76w76	evx	±	156.mg P<.05 -
a	M m b6c orl	liv hpt	76w76	evx		242.mg P<.2 -
b	M m b6c orl	tba mix	76w76	evx		87.7mg P<.009 -
2,4,6-TRICHLOROPHENOL				100ng...1ug.....10.....100.....1mg.....10.....100.....1g.....10		
2761	M f b6c eat	liv MXA	24m24	v	+	1.41gm * P<.0005c
a	M f b6c eat	TBA MXB	24m24	v		1.51gm * P<.05
b	M f b6c eat	liv MXB	24m24	v		1.41gm * P<.0005
c	M f b6c eat	lun MXB	24m24	v		114.gm * P<.1.
2762	M f b6c orl	liv hpt	76w76	evx	>	113.mg P<.2
a	M f b6c orl	lun ade	76w76	evx		113.mg P<.2
b	M f b6c orl	tba mix	76w76	evx		27.0mg P<.002
2763	M m b6c eat	liv MXA	24m24		+	856.mg * P<.01 c
a	M m b6c eat	TBA MXB	24m24			10.7gm * P<.9
b	M m b6c eat	liv MXB	24m24			856.mg * P<.01
c	M m b6c eat	lun MXB	24m24			no dre P=.1.
2764	M m b6c orl	liv hpt	76w76	evx	±	68.0mg P<.05
a	M m b6c orl	lun ade	76w76	evx		105.mg P<.2
b	M m b6c orl	tba mix	76w76	evx		17.9mg P<.0005
2765	M f b6a orl	liv hpt	76w76	evx	>	220.mg P<.3
a	M f b6a orl	lun ade	76w76	evx		no dre P=.1.
b	M f b6a orl	tba mix	76w76	evx		no dre P=.1.
2766	M m b6a orl	lun ade	76w76	evx	>	1.68gm P<.1.
a	M m b6a orl	liv hpt	76w76	evx		3.58gm P<.1.
b	M m b6a orl	tba mix	76w76	evx		1.05gm P<.1.
2767	R f f34 eat	TBA MXB	25m25	a	>	no dre P=.1. -
a	R f f34 eat	liv MXB	25m25	a		no dre P=.1. -
2768	R m f34 eat	--- mte	25m25		+	:405.mg * P<.008 c
a	R m f34 eat	--- MXA	25m25			445.mg * P<.02 c
b	R m f34 eat	--- MXB	25m25			445.mg * P<.02
c	R m f34 eat	TBA MXB	25m25			1.43gm * P<.7
d	R m f34 eat	liv MXB	25m25			no dre P=.1.
2-(2,4,5-TRICHLOROPHENOXY)PROPIONIC ACID				...1ug.....10.....100.....1mg.....10.....100.....1g.....10		
2769	M f b6a orl	liv hpt	76w76	evx	>	no dre P=.1. -
a	M f b6a orl	lun ade	76w76	evx		no dre P=.1. -
b	M f b6a orl	tba mix	76w76	evx		no dre P=.1. -
2770	M m b6a orl	lun ade	76w76	evx	>	no dre P=.1. -
a	M m b6a orl	liv hpt	76w76	evx		no dre P=.1. -
b	M m b6a orl	tba mix	76w76	evx		no dre P=.1. -
2771	M f b6c orl	liv hpt	76w76	evx	>	no dre P=.1. -
a	M f b6c orl	lun mix	76w76	evx		no dre P=.1. -
b	M f b6c orl	tba mix	76w76	evx		52.6mg P<.2 -
2772	M m b6c orl	liv hpt	76w76	evx	+	16.6mg P<.007 -
a	M m b6c orl	lun ade	76w76	evx		95.2mg P<.3 -
b	M m b6c orl	tba mix	76w76	evx		9.07mg P<.0005-
2,4,5-TRICHLOROPHENOXYACETIC ACID				100ng...1ug.....10.....100.....1mg.....10.....100.....1g.....10		
2773	M f b6a orl	liv hpt	76w76	evx	>	no dre P=.1. -
a	M f b6a orl	lun ade	76w76	evx		no dre P=.1. -
b	M f b6a orl	tba mix	76w76	evx		no dre P=.1. -

RefNum	LoConf	UpConf	Cntrl	1Dose	1Inc	2Dose	2Inc	Citation or Pathology	Brkly Code
2750	c04546	305.mg n.s.s.	5/20	242.mg	7/50	484.mg	5/50		
a	c04546	n.s.s. n.s.s.	0/20	242.mg	0/50	484.mg	0/50		liv:hpa,hpc,nnd.
2751	1010	277.mg n.s.s.	16/28	20.1mg	12/30	101.mg	14/30	Henschler;artx,43,237-248;1980	
a	1010	448.mg n.s.s.	2/28	20.1mg	2/30	101.mg	4/30		
2752	1010	141.mg n.s.s.	4/29	14.1mg	5/30	70.4mg	11/30		
a	1010	385.mg n.s.s.	7/29	14.1mg	2/30	70.4mg	5/30		
TRICHLOROFUOROMETHANE* 75-69-4									
2753	c04637	2.49gm n.s.s.	3/20	1.20gm	11/50	2.40gm	9/50		
a	c04637	5.59gm n.s.s.	1/20	1.20gm	4/50	2.40gm	2/50		liv:hpa,hpc,nnd.
b	c04637	9.23gm n.s.s.	1/20	1.20gm	0/50	2.40gm	2/50		lun:a/a,a/c.
2754	c04637	1.14gm n.s.s.	7/20	1.20gm	22/50	2.40gm	16/49		
a	c04637	1.54gm n.s.s.	5/20	1.20gm	15/50	2.40gm	10/49		liv:hpa,hpc,nnd.
b	c04637	10.3gm n.s.s.	2/20	1.20gm	0/50	2.40gm	1/49		lun:a/a,a/c.
2755	c04637	91.0mg n.s.s.	7/20	270.mg	4/50	540.mg	7/50		
a	c04637	n.s.s. n.s.s.	0/20	270.mg	0/50	540.mg	0/50		liv:hpa,hpc,nnd.
2756	c04637	117.mg n.s.s.	5/20	257.mg	4/50	490.mg	1/50		
a	c04637	n.s.s. n.s.s.	0/20	257.mg	0/50	490.mg	0/50		liv:hpa,hpc,nnd.
N-(TRICHLOROMETHYLTHIO)PHTHALIMIDE (folpet) 133-07-3									
2757	1239	138.mg n.s.s.	0/17	83.8mg	0/15				Innes;ntis,1968/1969
a	1239	138.mg n.s.s.	1/17	83.8mg	0/15				
b	1239	89.8mg n.s.s.	2/17	83.8mg	1/15				
2758	1239	86.4mg n.s.s.	1/18	78.0mg	1/17				
a	1239	95.9mg n.s.s.	2/18	78.0mg	1/17				
b	1239	75.1mg n.s.s.	3/18	78.0mg	2/17				
2759	1239	166.mg n.s.s.	0/16	83.8mg	0/18				
a	1239	166.mg n.s.s.	0/16	83.8mg	0/18				
b	1239	63.9mg n.s.s.	0/16	83.8mg	2/18				
2760	1239	47.2mg n.s.s.	0/16	78.0mg	3/18				
a	1239	59.5mg n.s.s.	0/16	78.0mg	2/18				
b	1239	33.1mg 1.92gm	0/16	78.0mg	5/18				
2,4,6-TRICHLOROPHENOL (Dowicide-2S) 88-06-2									
2761	c02904	874.mg 4.56gm	1/20	678.mg	12/50	1.36gm	24/50		liv:hpa,hpc.
a	c02904	686.mg n.s.s.	6/20	678.mg	30/50	1.36gm	33/50		
b	c02904	874.mg 4.56gm	1/20	678.mg	12/50	1.36gm	24/50		liv:hpa,hpc,nnd.
c	c02904	4.39gm n.s.s.	1/20	678.mg	4/50	1.36gm	3/50		lun:a/a,a/c.
2762	292	27.8mg n.s.s.	0/16	36.4mg	2/18				Innes;ntis,1968/1969
a	292	27.8mg n.s.s.	0/16	36.4mg	2/18				
b	292	11.5mg 110.mg	0/16	36.4mg	7/18				
2763	c02904	457.mg 66.3gm	4/20	600.mg	32/50	1.20gm	39/50		liv:hpa,hpc.
a	c02904	708.mg n.s.s.	14/20	600.mg	42/50	1.20gm	42/50		
b	c02904	457.mg 66.3gm	4/20	600.mg	32/50	1.20gm	39/50		liv:hpa,hpc,nnd.
c	c02904	2.89gm n.s.s.	3/20	600.mg	13/50	1.20gm	7/50		lun:a/a,a/c.
2764	292	20.5mg n.s.s.	0/16	33.9mg	3/18				Innes;ntis,1968/1969
a	292	25.9mg n.s.s.	0/16	33.9mg	2/18				
b	292	8.25mg 51.6mg	0/16	33.9mg	9/18				
2765	292	35.8mg n.s.s.	0/17	36.4mg	1/17				
a	292	68.1mg n.s.s.	1/17	36.4mg	0/17				
b	292	32.0mg n.s.s.	2/17	36.4mg	2/17				
2766	292	29.5mg n.s.s.	2/18	33.9mg	2/17				
a	292	37.6mg n.s.s.	1/18	33.9mg	1/17				
b	292	24.7mg n.s.s.	3/18	33.9mg	3/17				
2767	c02904	301.mg n.s.s.	16/20	250.mg	32/50	(500.mg	27/50)		
a	c02904	n.s.s. n.s.s.	0/20	250.mg	0/50	500.mg	0/50		liv:hpa,hpc,nnd.
2768	c02904	222.mg 8.89gm	3/20	200.mg	23/50	400.mg	28/50		
a	c02904	227.mg n.s.s.	4/20	200.mg	25/50	400.mg	29/50		---:leu,lym.
b	c02904	227.mg n.s.s.	4/20	200.mg	25/50	400.mg	29/50		---:leu,lym,ale. C
c	c02904	229.mg n.s.s.	16/20	200.mg	40/50	400.mg	41/50		
d	c02904	3.93gm n.s.s.	1/20	200.mg	1/50	400.mg	0/50		liv:hpa,hpc,nnd.
2-(2,4,5-TRICHLOROPHENOXY)PROPIONIC ACID 93-72-1									
2769	1234	29.8mg n.s.s.	0/17	16.9mg	0/16				Innes;ntis,1968/1969
a	1234	29.8mg n.s.s.	1/17	16.9mg	0/16				
b	1234	19.6mg n.s.s.	2/17	16.9mg	1/16				
2770	1234	20.7mg n.s.s.	2/18	15.8mg	1/18				
a	1234	31.2mg n.s.s.	1/18	15.8mg	0/18				
b	1234	22.1mg n.s.s.	3/18	15.8mg	1/18				
2771	1234	33.5mg n.s.s.	0/16	16.9mg	0/18				
a	1234	33.5mg n.s.s.	0/16	16.9mg	0/18				
b	1234	12.9mg n.s.s.	0/16	16.9mg	2/18				
2772	1234	6.24mg 224.mg	0/16	15.8mg	5/17				
a	1234	15.5mg n.s.s.	0/16	15.8mg	1/17				
b	1234	4.03mg 28.9mg	0/16	15.8mg	8/17				
2,4,5-TRICHLOROPHENOXYACETIC ACID (2,4,5-T) 93-76-5									
2773	1233	16.5mg n.s.s.	0/17	8.34mg	0/18				Innes;ntis,1968/1969
a	1233	16.5mg n.s.s.	1/17	8.34mg	0/18				
b	1233	7.87mg n.s.s.	2/17	8.34mg	2/18				

Spe	Strain	Site	Xpo+Xpt	Notes	TD50	2Tailpvl
Sex	Route	Hist			DR	AuOp
2774	M m b6a	orl liv	hpt 76w76	evx	no dre	P=1. -
a	M m b6a	orl lun	ade 76w76	evx	no dre	P=1. -
b	M m b6a	orl tba	mix 76w76	evx	no dre	P=1. -
2775	M f b6c	orl lun	ade 76w76	evx	53.4mg	P<.3 -
a	M f b6c	orl liv	hpt 76w76	evx	no dre	P=1. -
b	M f b6c	orl tba	mix 76w76	evx	53.4mg	P<.3 -
2776	M m b6c	orl liv	hpt 76w76	evx	11.3mg	P<.02 -
a	M m b6c	orl lun	ade 76w76	evx	49.7mg	P<.3 -
b	M m b6c	orl tba	mix 76w76	evx	7.00mg	P<.004 -
2777	R f sda	eat thy	cca 24m24	e	488. mg Z	P<.5 -
a	R f sda	eat liv	hnd 24m24	e	no dre	P=1. -
b	R f sda	eat tba	mix 24m24	e	10.6mg	* P<.2 -
2778	R m sda	eat liv	hpc 24m24	e	no dre	P=1. -
a	R m sda	eat tba	mix 24m24	e	no dre	P=1. -
TRIETHANOLAMINE				100ng...1ug...10...100...1mg...10...100...1g...10		
2779	M f icr	eat ---	mix 25m25	e	1.29mg	* P<.04
a	M f icr	eat liv	tum 25m25	e	no dre	P=1.
b	M f icr	eat lun	ade 25m25	e	no dre	P=1.
c	M f icr	eat tba	mix 25m25	e	88.8mg	\ P<.003
d	M f icr	eat tba	mal 25m25	e	100. mg	\ P<.002 +
2780	M m icr	eat liv	tum 26m27	e	no dre	P=1.
a	M m icr	eat lun	mix 26m27	e	no dre	P=1.
b	M m icr	eat tba	mal 26m27	e	no dre	P=1. +
c	M m icr	eat tba	mix 26m27	e	no dre	P=1.
TRIETHYLENE GLYCOL				100ng...1ug...10...100...1mg...10...100...1g...10		
2781	R m osm	eat ubl	tum 24m24	r	no dre	P=1.
2,2,2-TRIFLUORO-N-[4-(5-NITRO-2-FURYL)-2-THIAZOLYL]ACETAMIDE				100...1ug...10...100...1mg...10...100...1g...10		
2782	M f swi	eat for	mix 46w55	e	9.98mg	P<.0005+
a	M f swi	eat for	sqc 46w55	e	38.6mg	P<.0005
b	M f swi	eat for	sqp 46w55	e	43.5mg	P<.0005
c	M f swi	eat liv	tum 46w55	e	no dre	P=1.
d	M f swi	eat lun	tum 46w55	e	no dre	P=1.
e	M f swi	eat tba	mix 46w55	e	8.01mg	P<.0005
2783	R f sda	eat mgl	mix 46w66	e	6.79mg	P<.0005+
a	R f sda	eat mgl	adc 46w66	e	7.27mg	P<.0005
b	R f sda	eat liv	tum 46w66	e	no dre	P=1.
c	R f sda	eat tba	mix 46w66	e	5.58mg	P<.0005
TRIFLURALIN				100ng...1ug...10...100...1mg...10...100...1g...10		
2784	M f b6c	eat liv	MXA 78w90	dv	330. mg	* P<.0005c
a	M f b6c	eat liv	hpc 78w90	dv	368. mg	* P<.0005c
b	M f b6c	eat TBA	MXB 78w90	dv	263. mg	* P<.0005
c	M f b6c	eat liv	MXB 78w90	dv	330. mg	* P<.0005
d	M f b6c	eat lun	MXB 78w90	dv	1.36gm	* P<.08
2785	M f b6c	eat liv	MXA 78w90	dv pool	330. mg	* P<.0005c
a	M f b6c	eat liv	hpc 78w90	dv	368. mg	* P<.0005c
b	M f b6c	eat lun	MXA 78w90	dv	1.36gm	* P<.003 c
c	M f b6c	eat lun	s/a 78w90	dv	1.52gm	* P<.003 c
d	M f b6c	eat sto	sqc 78w90	dv	3.09gm	* P<.05 c
2786	M m b6c	eat TBA	MXB 78w90	dv	1.50gm	* P<.8 -
a	M m b6c	eat liv	MXB 78w90	dv	1.50gm	* P<.8
b	M m b6c	eat lun	MXB 78w90	dv	5.44gm	* P<.4
2787	R f osm	eat thy	MXA 18m26	dv	#663. mg	\ P<.03 -
a	R f osm	eat TBA	MXB 18m26	dv	2.64gm	\ P<.1
b	R f osm	eat liv	MXB 18m26	dv	no dre	P=1.
2788	R m osm	eat TBA	MXB 18m26	dv	no dre	P=1. -
a	R m osm	eat liv	MXB 18m26	dv	no dre	P=1.
2,4,5-TRIMETHYLANILINE				100ng...1ug...10...100...1mg...10...100...1g...10		
2789	M f b6c	eat liv	hpc 23m23		6.13mg	* P<.0005c
a	M f b6c	eat TBA	MXB 23m23		22.4mg	* P<.4
b	M f b6c	eat liv	MXB 23m23		6.13mg	* P<.0005
c	M f b6c	eat lun	MXB 23m23		47.6mg	* P<.09
2790	M m b6c	eat TBA	MXB 23m23		52.5mg	* P<.7 -
a	M m b6c	eat liv	MXB 23m23		14.4mg	* P<.08
b	M m b6c	eat lun	MXB 23m23		no dre	P=1.
2791	R f f34	eat MXB	MXB 23m23		20.4mg	* P<.0005
a	R f f34	eat liv	MXA 23m23		27.2mg	* P<.0005c
b	R f f34	eat lun	MXA 23m23		88.1mg	* P<.003 c
c	R f f34	eat liv	hpc 23m23		142. mg	* P<.002 c
d	R f f34	eat TBA	MXB 23m23		396. mg	* P<.9
e	R f f34	eat liv	MXB 23m23		27.2mg	* P<.0005
2792	R m f34	eat liv	MXA 23m23		43.8mg	* P<.002 c
a	R m f34	eat liv	hpc 23m23		71.8mg	* P<.004 c
b	R m f34	eat lun	MXA 23m23		180. mg	* P<.05
c	R m f34	eat liv	bdc 23m23		268. mg	* P<.03
d	R m f34	eat TBA	MXB 23m23		138. mg	* P<.7
e	R m f34	eat liv	MXB 23m23		43.8mg	* P<.002

RefNum	LoConf	UpConf	Cntrl	1Dose	1Inc	2Dose	2Inc	Citation or Pathology	Brkly Code
2774	1233	9.17mg n.s.s.	1/18	7.76mg	1/18				
a	1233	15.4mg n.s.s.	2/18	7.76mg	0/18				
b	1233	6.10mg n.s.s.	3/18	7.76mg	3/18				
2775	1233	8.69mg n.s.s.	0/16	8.34mg	1/18				
a	1233	16.5mg n.s.s.	0/16	8.34mg	0/18				
b	1233	8.69mg n.s.s.	0/16	8.34mg	1/18				
2776	1233	3.89mg n.s.s.	0/16	7.76mg	4/18				
a	1233	8.09mg n.s.s.	0/16	7.76mg	1/18				
b	1233	2.83mg 42.8mg	0/16	7.76mg	6/18				
2777	1353	87.9mg n.s.s.	3/86	3.00mg	10/50	10.0mg	2/50	30.0mg	6/50
a	1353	208. mg n.s.s.	4/86	3.00mg	2/50	10.0mg	3/50	30.0mg	1/50
b	1353	2.34mg n.s.s.	83/86	3.00mg	48/50	10.0mg	48/50	30.0mg	50/50
2778	1353	279. mg n.s.s.	3/86	3.00mg	1/50	10.0mg	0/50	30.0mg	1/50
a	1353	17.5mg n.s.s.	76/86	3.00mg	44/50	10.0mg	40/50	30.0mg	44/50
TRIETHANOLAMINE 102-71-6									
2779	550	471. mg n.s.s.	1/36	39.0mg	7/37	390. mg	9/36		
a	550	291. mg n.s.s.	0/36	39.0mg	0/37	390. mg	0/36		
b	550	2.52gm n.s.s.	0/36	39.0mg	1/37	390. mg	0/36		
c	550	42.2mg 371. mg	1/36	39.0mg	11/37	(390. mg)	13/36)		
d	550	46.1mg 559. mg	1/36	39.0mg	10/37	(390. mg)	13/36)		
2780	550	277. mg n.s.s.	0/35	36.0mg	0/33	360. mg	0/28		
a	550	2.38gm n.s.s.	1/35	36.0mg	2/33	360. mg	0/28		
b	550	1.53gm n.s.s.	1/35	36.0mg	3/33	360. mg	1/28		
c	550	1.70gm n.s.s.	2/35	36.0mg	4/33	360. mg	1/28		
TRIETHYLENE GLYCOL 112-27-6									
2781	105	565. mg n.s.s.	0/12	400. mg	0/12	800. mg	0/12	1.60gm	0/12
2,2,2-TRIFLUORO-N-[4-(5-NITRO-2-FURYL)-2-THIAZOLYL]ACETANIDE 42011-48-3									
2782	1076	4.97mg 20.2mg	0/29	132. mg	23/25				
a	1076	19.5mg 91.1mg	0/29	132. mg	12/25				
b	1076	21.5mg 107. mg	0/29	132. mg	11/25				
c	1076	190. mg n.s.s.	0/29	132. mg	0/25				
d	1076	190. mg n.s.s.	0/29	132. mg	0/25				
e	1076	3.39mg 17.7mg	2/29	132. mg	24/25				
2783	1126	3.55mg 20.5mg	2/24	17.4mg	17/31				
a	1126	3.93mg 15.5mg	0/24	17.4mg	15/31				
b	1126	44.8mg n.s.s.	0/24	17.4mg	0/31				
c	1126	3.01mg 14.2mg	2/24	17.4mg	19/31				
TRIFLURALIN 1582-09-8									
2784	c00442	220. mg 577. mg	0/20	309. mg	15/50	585. mg	21/50		liv:hpa,hpc.
a	c00442	242. mg 648. mg	0/20	309. mg	12/50	585. mg	21/50		
b	c00442	170. mg 639. mg	2/20	309. mg	24/50	585. mg	26/50		
c	c00442	220. mg 577. mg	0/20	309. mg	15/50	585. mg	21/50		liv:hpa,hpc,nnd.
d	c00442	664. mg n.s.s.	0/20	309. mg	7/50	585. mg	3/50		Lun:a/a,a/c.
2785	c00442	220. mg 526. mg	0/60p	309. mg	15/50	585. mg	21/50		liv:hpa,hpc.
a	c00442	242. mg 600. mg	0/60p	309. mg	12/50	585. mg	21/50		
b	c00442	664. mg 5.71gm	0/60p	309. mg	7/50	585. mg	3/50		Lun:a/a,a/c.
c	c00442	718. mg 7.46gm	0/60p	309. mg	6/50	585. mg	3/50		
d	c00442	1.17gm n.s.s.	0/60p	309. mg	4/50	585. mg	1/50		
2786	c00442	170. mg n.s.s.	9/20	208. mg	20/50	389. mg	17/50		
a	c00442	195. mg n.s.s.	4/20	208. mg	14/50	389. mg	9/50		liv:hpa,hpc,nnd.
b	c00442	886. mg n.s.s.	0/20	208. mg	0/50	389. mg	1/50		Lun:a/a,a/c.
2787	c00442	255. mg n.s.s.	1/50	145. mg	7/50	(278. mg)	0/50)		thy:faa,fcc. S
a	c00442	118. mg n.s.s.	36/50	145. mg	39/50	(278. mg)	22/50)		
b	c00442	3.39gm n.s.s.	1/50	145. mg	0/50	278. mg	0/50		liv:hpa,hpc,nnd.
2788	c00442	410. mg n.s.s.	28/50	116. mg	22/50	225. mg	22/50		
a	c00442	n.s.s. n.s.s.	0/50	116. mg	0/50	225. mg	0/50		liv:hpa,hpc,nnd.
2,4,5-TRIMETHYLANILINE 137-17-7									
2789	c02299	4.44mg 9.97mg	0/20	6.50mg	18/50	13.0mg	40/50		
a	c02299	5.84mg n.s.s.	12/20	6.50mg	41/50	13.0mg	45/50		
b	c02299	4.44mg 9.97mg	0/20	6.50mg	18/50	13.0mg	40/50		liv:hpa,hpc,nnd.
c	c02299	23.9mg n.s.s.	0/20	6.50mg	5/50	13.0mg	6/50		Lun:a/a,a/c.
2790	c02299	7.35mg n.s.s.	12/20	6.00mg	34/50	12.0mg	32/50		
a	c02299	6.14mg n.s.s.	5/20	6.00mg	26/50	12.0mg	27/50		liv:hpa,hpc,nnd.
b	c02299	13.1mg n.s.s.	4/20	6.00mg	9/50	(12.0mg)	1/50)		Lun:a/a,a/c.
2791	c02299	13.8mg 54.5mg	0/20	10.0mg	14/50	40.0mg	33/50		liv:hpc,nnd; Lun:a/a,a/c. C
a	c02299	17.3mg 88.2mg	0/20	10.0mg	12/50	40.0mg	27/50		liv:hpc,nnd.
b	c02299	47.4mg 545. mg	0/20	10.0mg	3/50	40.0mg	11/50		Lun:a/a,a/c.
c	c02299	67.0mg 388. mg	0/20	10.0mg	0/50	40.0mg	9/50		
d	c02299	23.8mg n.s.s.	17/20	10.0mg	39/50	40.0mg	45/50		
e	c02299	17.3mg 88.2mg	0/20	10.0mg	12/50	40.0mg	27/50		liv:hpa,hpc,nnd.
2792	c02299	23.9mg 205. mg	1/20	8.00mg	6/50	32.0mg	20/50		liv:hpc,nnd.
a	c02299	38.7mg 497. mg	0/20	8.00mg	3/50	32.0mg	11/50		
b	c02299	68.2mg n.s.s.	1/20	8.00mg	0/50	32.0mg	7/50		Lun:a/a,a/c. S
c	c02299	92.5mg n.s.s.	0/20	8.00mg	0/50	32.0mg	4/50		S
d	c02299	19.2mg n.s.s.	17/20	8.00mg	33/50	32.0mg	45/50		
e	c02299	23.9mg 205. mg	1/20	8.00mg	6/50	32.0mg	20/50		liv:hpa,hpc,nnd.

Spe	Strain	Site	Xpo+Xpt						TD50	2Tailpvl	
Sex	Route	Hist	Notes						DR	AuOp	
2,4,5-TRIMETHYLANILINE.HCl											
				100ng	1ug	10	100	1mg	10	100	1g
2793	M f	chi eat	lun mix 77w98								52.8mg * P<.0005+
a	M f	chi eat	liv mix 77w98								60.4mg / P<.0005
b	M f	chi eat	liv hpt 77w98								62.9mg / P<.0005+
c	M f	chi eat	tba mix 77w98								47.2mg / P<.002
2794	M f	chi eat	liv hpt 77w98	pool							62.3mg / P<.0005+
a	M f	chi eat	lun mix 77w98								64.7mg * P<.0005+
2795	M m	chi eat	liv mix 77w98								35.4mg / P<.0005
a	M m	chi eat	lun mix 77w98								40.0mg * P<.0005+
b	M m	chi eat	liv hpt 77w98								46.2mg / P<.0005+
c	M m	chi eat	tba mix 77w98								40.3mg / P<.0005
2796	M m	chi eat	liv hpt 77w98	pool							44.2mg / P<.0005+
a	M m	chi eat	lun mix 77w98								63.0mg * P<.0005+
b	M m	chi eat	--- vac 77w98								260.mg * P<.02 +
2797	R m	cdr eat	liv mix 77w98								47.9mg * P<.08
a	R m	cdr eat	liv hpt 77w98								98.5mg * P<.2 +
b	R m	cdr eat	sub mix 77w98								no dre P=1. +
c	R m	cdr eat	tba mix 77w98								37.2mg * P<.3
2,4,6-TRIMETHYLANILINE.HCl											
				100ng	1ug	10	100	1mg	10	100	1g
2798	M f	chi eat	liv hpt 77w94 v								34.6mg / P<.0005+
a	M f	chi eat	liv mix 77w94 v								34.6mg / P<.0005+
b	M f	chi eat	lun mix 77w94 v								23.9mg * P<.04 -
c	M f	chi eat	tba mix 77w94 v								20.6mg * P<.02
2799	M f	chi eat	liv hpt 77w94 v	pool							34.6mg / P<.0005+
2800	M m	chi eat	liv mix 77w94 v								18.2mg / P<.0005
a	M m	chi eat	liv hpt 77w94 v								19.3mg * P<.0005+
b	M m	chi eat	lun mix 77w94 v								38.2mg * P<.05 -
c	M m	chi eat	tba mix 77w94 v								18.4mg * P<.009
2801	M m	chi eat	liv hpt 77w94 v	pool							22.7mg * P<.0005+
a	M m	chi eat	--- vac 77w94 v								120.mg * P<.005 +
2802	R m	cdr eat	lun mix 73w77 v								5.17mg * P<.002 +
a	R m	cdr eat	liv mix 73w77 v								6.15mg * P<.002 +
b	R m	cdr eat	liv hpt 73w77 v								6.15mg * P<.002 +
c	R m	cdr eat	tba mix 73w77 v								2.15mg * P<.0005
2803	R m	cdr eat	lun mix 73w77 v	pool							5.27mg * P<.0005+
a	R m	cdr eat	liv hpt 73w77 v								6.22mg * P<.0005+
b	R m	cdr eat	sto mix 73w77 v								22.0mg * P<.002 +
TRIMETHYLPHOSPHATE											
				100ng	1ug	10	100	1mg	10	100	1g
2804	M f	b6c gav	utm acn 24m24								335.mg * P<.002 c
a	M f	b6c gav	TBA MXB 24m24								385.mg * P<.3
b	M f	b6c gav	liv MXB 24m24								6.39gm / P<.1
c	M f	b6c gav	lun MXB 24m24								3.90gm / P<.7
2805	M m	b6c gav	TBA MXB 24m24								no dre P=1. -
a	M m	b6c gav	liv MXB 24m24								no dre P=1. -
b	M m	b6c gav	lun MXB 24m24								61.3gm * P<.1
2806	R f	f34 gav	TBA MXB 24m24								73.0mg * P<.4 -
a	R f	f34 gav	liv MXB 24m24								no dre P=1. -
2807	R m	f34 gav	sub fib 24m24								123.mg * P<.005 a
a	R m	f34 gav	TBA MXB 24m24								54.5mg * P<.3
b	R m	f34 gav	liv MXB 24m24								485.mg * P<.5
TRIMETHYLTHIOUREA											
				100ng	1ug	10	100	1mg	10	100	1g
2808	M f	b6c eat	TBA MXB 77w91								1.97gm * P<.8 -
a	M f	b6c eat	liv MXB 77w91								no dre P=1. -
b	M f	b6c eat	lun MXB 77w91								1.26gm * P<.3
2809	M m	b6c eat	TBA MXB 77w91								no dre P=1. -
a	M m	b6c eat	liv MXB 77w91								no dre P=1. -
b	M m	b6c eat	lun MXB 77w91								478.mg * P<.3
2810	R f	f34 eat	thy MXA 18m25								25.8mg / P<.0005c
a	R f	f34 eat	thy fcc 18m25								45.0mg / P<.0005c
b	R f	f34 eat	TBA MXB 18m25								17.4mg * P<.005
c	R f	f34 eat	liv MXB 18m25								no dre P=1. -
2811	R m	f34 eat	TBA MXB 18m25								no dre P=1. -
a	R m	f34 eat	liv MXB 18m25								no dre P=1. -
TRIPHENYLTIIN ACETATE											
				100ng	1ug	10	100	1mg	10	100	1g
2812	M f	b6a orl	lun ade 76w76 evx								964.mg P<.6 -
a	M f	b6a orl	liv hpt 76w76 evx								no dre P=1. -
b	M f	b6a orl	tba mix 76w76 evx								437.mg P<.5 -
2813	M m	b6a orl	liv hpt 76w76 evx								241.mg P<.2 -
a	M m	b6a orl	lun ade 76w76 evx								no dre P=1. -
b	M m	b6a orl	tba mix 76w76 evx								307.mg P<.4 -
2814	M f	b6c orl	lun ade 76w76 evx								440.mg P<.1 -
a	M f	b6c orl	liv hpt 76w76 evx								909.mg P<.3 -
b	M f	b6c orl	tba mix 76w76 evx								284.mg P<.04 -
2815	M m	b6c orl	lun ade 76w76 evx								262.mg P<.04 -
a	M m	b6c orl	liv hpt 76w76 evx								407.mg P<.1 -
b	M m	b6c orl	tba mix 76w76 evx								117.mg P<.003 -

RefNum	LoConf	UpConf	Cntrl	1Dose	1Inc	2Dose	2Inc	Citation or Pathology	Brkly Code
2,4,5-TRIMETHYLANILINE.HCl 21436-97-5									
2793	381	24.8mg	182.mg	6/20	106.mg	11/15	246.mg	12/22	Weisburger;jept,2,325-356;1978/pers.comm./Russfield 1973
a	381	31.9mg	123.mg	0/20	106.mg	6/15	246.mg	15/22	
b	381	32.6mg	131.mg	0/20	106.mg	6/15	246.mg	14/22	
c	381	21.2mg	255.mg	17/20	106.mg	15/15	246.mg	19/22	
2794	381	32.1mg	134.mg	1/102p	106.mg	6/15	246.mg	14/22	
a	381	31.3mg	184.mg	31/102p	106.mg	11/15	246.mg	12/22	
2795	381	19.1mg	83.5mg	3/18	98.2mg	11/14	227.mg	19/21	
a	381	19.4mg	136.mg	5/18	98.2mg	11/14	227.mg	10/21	
b	381	24.3mg	115.mg	3/18	98.2mg	9/14	227.mg	18/21	
c	381	19.3mg	140.mg	12/18	98.2mg	13/14	227.mg	19/21	
2796	381	24.4mg	91.2mg	7/99p	98.2mg	9/14	227.mg	18/21	
a	381	28.8mg	216.mg	23/99p	98.2mg	11/14	227.mg	10/21	
b	381	78.1mg	n.s.s.	5/99p	98.2mg	3/14	227.mg	3/21	
2797	381	15.0mg	n.s.s.	1/22	31.3mg	5/17	68.6mg	2/25	
a	381	23.5mg	n.s.s.	1/22	31.3mg	3/17	68.6mg	2/25	
b	381	27.3mg	n.s.s.	4/22	31.3mg	7/17	68.6mg	1/25	
c	381	9.25mg	n.s.s.	14/22	31.3mg	15/17	68.6mg	13/25	
2,4,6-TRIMETHYLANILINE.HCl 6334-11-8									
2798	381	15.9mg	107.mg	1/15	37.1mg	1/12	78.0mg	12/16	Weisburger;jept,2,325-356;1978/pers.comm./Russfield 1973
a	381	15.9mg	107.mg	1/15	37.1mg	1/12	78.0mg	12/16	
b	381	7.63mg	n.s.s.	5/15	37.1mg	7/12	78.0mg	7/16	
c	381	7.27mg	n.s.s.	10/15	37.1mg	10/12	78.0mg	16/16	
2799	381	15.9mg	73.9mg	1/102p	37.1mg	1/12	78.0mg	12/16	
2800	381	9.03mg	43.4mg	1/14	34.3mg	5/15	75.8mg	11/13	
a	381	9.31mg	51.4mg	0/14	34.3mg	5/15	75.8mg	9/13	
b	381	12.9mg	n.s.s.	3/14	34.3mg	5/15	75.8mg	5/13	
c	381	7.34mg	966.mg	7/14	34.3mg	11/15	75.8mg	12/13	
2801	381	10.5mg	60.0mg	7/99p	34.3mg	5/15	75.8mg	9/13	
a	381	36.5mg	1.84gm	5/99p	34.3mg	1/15	75.8mg	4/13	
2802	381	2.64mg	17.7mg	0/16	5.90mg	5/20	11.8mg	8/21	
a	381	3.07mg	21.1mg	0/16	5.90mg	4/20	11.8mg	8/21	
b	381	3.07mg	21.1mg	0/16	5.90mg	4/20	11.8mg	8/21	
c	381	1.21mg	6.38mg	10/16	5.90mg	13/20	11.8mg	18/21	
2803	381	2.65mg	12.9mg	1/111p	5.90mg	5/20	11.8mg	8/21	
a	381	3.06mg	15.7mg	2/111p	5.90mg	4/20	11.8mg	8/21	
b	381	6.57mg	159.mg	2/111p	5.90mg	0/20	11.8mg	3/21	
TRIMETHYLPHOSPHATE 512-56-1									
2804	c03781	197.mg	995.mg	0/20	107.mg	7/50	214.mg	13/49	
a	c03781	125.mg	n.s.s.	11/20	107.mg	29/50	214.mg	30/49	
b	c03781	258.mg	n.s.s.	2/20	107.mg	4/50	(214.mg	0/49)	liv:hpa,hpc,nnd.
c	c03781	599.mg	n.s.s.	3/20	107.mg	0/50	214.mg	6/49	lun:a/a,a/c.
2805	c03781	227.mg	n.s.s.	11/20	107.mg	26/50	214.mg	26/49	
a	c03781	471.mg	n.s.s.	4/20	107.mg	10/50	214.mg	8/49	liv:hpa,hpc,nnd.
b	c03781	381.mg	n.s.s.	3/20	107.mg	11/50	214.mg	9/49	lun:a/a,a/c.
2806	c03781	20.1mg	n.s.s.	15/20	21.2mg	40/50	42.5mg	42/49	
a	c03781	n.s.s.	n.s.s.	0/20	21.2mg	0/50	42.5mg	0/49	liv:hpa,hpc,nnd.
2807	c03781	60.4mg	850.mg	0/20	21.2mg	2/50	42.5mg	9/49	
a	c03781	16.4mg	n.s.s.	12/20	21.2mg	38/50	42.5mg	38/49	
b	c03781	119.mg	n.s.s.	0/20	21.2mg	1/50	42.5mg	1/49	liv:hpa,hpc,nnd.
TRIMETHYLTHIOUREA 2489-77-2									
2808	c02186	274.mg	n.s.s.	1/20	54.6mg	3/50	110.mg	4/50	
a	c02186	n.s.s.	n.s.s.	0/20	54.6mg	0/50	110.mg	0/50	liv:hpa,hpc,nnd.
b	c02186	381.mg	n.s.s.	0/20	54.6mg	1/50	110.mg	2/50	lun:a/a,a/c.
2809	c02186	174.mg	n.s.s.	8/20	50.4mg	11/50	102.mg	15/50	
a	c02186	244.mg	n.s.s.	6/20	50.4mg	2/50	(102.mg	2/50)	liv:hpa,hpc,nnd.
b	c02186	165.mg	n.s.s.	1/20	50.4mg	5/50	102.mg	8/50	lun:a/a,a/c.
2810	c02186	15.8mg	47.4mg	0/20	9.10mg	1/50	18.0mg	23/50	thy:fca,fcc.
a	c02186	24.5mg	114.mg	0/20	9.10mg	1/50	18.0mg	14/50	
b	c02186	9.35mg	169.mg	7/20	9.10mg	20/50	18.0mg	37/50	
c	c02186	143.mg	n.s.s.	2/20	9.10mg	2/50	18.0mg	0/50	liv:hpa,hpc,nnd.
2811	c02186	33.7mg	n.s.s.	9/20	7.30mg	13/50	14.4mg	16/50	
a	c02186	128.mg	n.s.s.	1/20	7.30mg	0/50	14.4mg	1/50	liv:hpa,hpc,nnd.
TRIPHENYLTIW ACETATE 900-95-8									
2812	295	127.mg	n.s.s.	1/17	151.mg	2/18			Innes;nt is,1968/1969
a	295	298.mg	n.s.s.	0/17	151.mg	0/18			
b	295	86.9mg	n.s.s.	2/17	151.mg	4/18			
2813	295	69.2mg	n.s.s.	1/18	139.mg	4/17			
a	295	171.mg	n.s.s.	2/18	139.mg	1/17			
b	295	65.4mg	n.s.s.	3/18	139.mg	5/17			
2814	295	108.mg	n.s.s.	0/16	151.mg	2/17			
a	295	148.mg	n.s.s.	0/16	151.mg	1/17			
b	295	85.6mg	n.s.s.	0/16	151.mg	3/17			
2815	295	79.1mg	n.s.s.	0/16	139.mg	3/17			
a	295	99.8mg	n.s.s.	0/16	139.mg	2/17			
b	295	47.2mg	634.mg	0/16	139.mg	6/17			

Spe	Strain	Site	Xpo+Xpt	Notes	TD50	2Tailpvl	DR	AuOp
Sex	Route	Hist						
TRIPHENYLITIN HYDROXIDE				100ng...1ug...10...100...1mg...10...100...1g...10				
2816	M f	b6c eat	TBA MXB 18m24				no dre	P=1. -
a	M f	b6c eat	liv MXB 18m24	>			136.mg *	P<.7
b	M f	b6c eat	lun MXB 18m24				90.9mg *	P<.3
2817	M m	b6c eat	TBA MXB 18m24				31.1mg *	P<.6 -
a	M m	b6c eat	liv MXB 18m24	>			112.mg *	P<.8
b	M m	b6c eat	lun MXB 18m24				147.mg *	P<.8
2818	R f	f34 eat	TBA MXB 18m24				2.36mg \	P<.3 -
a	R f	f34 eat	liv MXB 18m24	>			no dre	P=1.
2819	R m	f34 eat	TBA MXB 18m24				no dre	P=1. -
a	R m	f34 eat	liv MXB 18m24	>			no dre	P=1.
TRIS-1,2,3-(CHLOROMETHOXY)PROPANE				100ng...1ug...10...100...1mg...10...100...1g...10				
2820	M f	hic ipj	abd sar 76w76				3.44mg	P<.008 +
TRIS(2,3-DIBROMOPROPYL)PHOSPHATE				100ng...1ug...10...100...1mg...10...100...1g...10				
2821	M f	b6c eat	MXB MXB 24m24				80.1mg *	P<.0005
a	M f	b6c eat	liv MXA 24m24				95.0mg *	P<.0005c
b	M f	b6c eat	sto MXA 24m24				127.mg *	P<.0005c
c	M f	b6c eat	liv hpc 24m24				221.mg *	P<.005 c
d	M f	b6c eat	lun MXA 24m24				225.mg *	P<.002 c
e	M f	b6c eat	ute esp 24m24				264.mg \	P<.003
f	M f	b6c eat	sto sqc 24m24				611.mg *	P<.02 c
g	M f	b6c eat	TBA MXB 24m24				148.mg *	P<.09
h	M f	b6c eat	liv MXB 24m24				95.0mg *	P<.0005
i	M f	b6c eat	lun MXB 24m24				225.mg *	P<.002
2822	M m	b6c eat	MXB MXB 24m24				103.mg *	P<.0005
a	M m	b6c eat	sto MXA 24m24				197.mg *	P<.0005c
b	M m	b6c eat	kid MXA 24m24				256.mg *	P<.0005c
c	M m	b6c eat	kid uac 24m24				822.mg *	P<.009 c
d	M m	b6c eat	lun MXA 24m24				211.mg *	P<.03 c
e	M m	b6c eat	lun e/c 24m24				449.mg *	P<.1 c
f	M m	b6c eat	TBA MXB 24m24				2.22gm *	P<.1
g	M m	b6c eat	liv MXB 24m24				172.mg \	P<.4
h	M m	b6c eat	lun MXB 24m24				211.mg *	P<.03
2823	R f	f34 eat	kid tla 24m24				13.8mg *	P<.0005c
a	R f	f34 eat	ova sct 24m24				66.4mg *	P<.05
b	R f	f34 eat	TBA MXB 24m24				23.0mg *	P<.8
c	R f	f34 eat	liv MXB 24m24				2.82gm *	P<.1
2824	R m	f34 eat	kid tla 24m24				1.57mg \	P<.0005c
a	R m	f34 eat	kid MXA 24m24				1.57mg \	P<.0005c
b	R m	f34 eat	pre MXA 24m24				20.3mg *	P<.03
c	R m	f34 eat	liv MXA 24m24				34.3mg *	P<.02
d	R m	f34 eat	kid uac 24m24				63.3mg *	P<.05 c
e	R m	f34 eat	TBA MXB 24m24				8.31mg *	P<.4
f	R m	f34 eat	liv MXB 24m24				34.3mg *	P<.02
L-TRYPTOPHAN				100ng...1ug...10...100...1mg...10...100...1g...10				
2825	M f	b6c eat	TBA MXB 18m24				no dre	P=1. -
a	M f	b6c eat	liv MXB 18m24				30.2gm *	P<.6
b	M f	b6c eat	lun MXB 18m24				no dre	P=1.
2826	M m	b6c eat	TBA MXB 18m24				1.47gm \	P<.2 -
a	M m	b6c eat	liv MXB 18m24				no dre	P=1.
b	M m	b6c eat	lun MXB 18m24				no dre	P=1.
2827	R f	f34 eat	TBA MXB 18m24				no dre	P=1. -
a	R f	f34 eat	liv MXB 18m24				no dre	P=1.
2828	R m	f34 eat	TBA MXB 18m24				no dre	P=1. -
a	R m	f34 eat	liv MXB 18m24				no dre	P=1.
TUNGSTATE, SODIUM				100ng...1ug...10...100...1mg...10...100...1g...10				
2829	R f	leb wat	tba mix 35m35 e				no dre	P=1. -
a	R f	leb wat	tba eal 35m35 e	>			no dre	P=1. -
2830	R m	leb wat	tba mix 32m32 es				40.1mg	P<.1 -
a	R m	leb wat	tba eal 32m32 es	>			87.7mg	P<.1 -
UREA				100ng...1ug...10...100...1mg...10...100...1g...10				
2831	M f	cb6 eat	liv mlh 52w69 e				40.4gm *	P<.03
a	M f	cb6 eat	--- mly 52w69 e				19.5gm *	P<.5
b	M f	cb6 eat	liv mix 52w69 e				50.1gm *	P<.2
c	M f	cb6 eat	lun a/a 52w69 e				no dre	P=1. -
2832	M m	cb6 eat	liv fba 52w69 e				70.8gm *	P<.2 -
a	M m	cb6 eat	liv mix 52w69 e				275.gm *	P<.9
b	M m	cb6 eat	lun a/a 52w69 e				no dre	P=1. -
2833	R f	f34 eat	liv tum 52w69 e				no dre	P=1. -
2834	R m	f34 eat	tes ica 52w69 e				684.mg *	P<.009
a	R m	f34 eat	liv tum 52w69 e				no dre	P=1. -
URETHANE				100ng...1ug...10...100...1mg...10...100...1g...10				
2835	H f	syg wat	for pam 90w90 e				44.5mg	P<.0005+
a	H f	syg wat	der mlc 90w90 e				74.4mg	P<.0005+

RefNum	LoConf	UpConf	Cntrl	1Dose	1Inc	2Dose	2Inc	Citation or Pathology	Brkly Code	
TRIPHENYLTIIN HYDROXIDE 76-87-9										
2816	c00260	12.9mg	n.s.s.	10/20	3.60mg	15/50	7.30mg	18/50		
a	c00260	22.4mg	n.s.s.	1/20	3.60mg	2/50	7.30mg	4/50	liv:hpa,hpc,nnd.	
b	c00260	27.5mg	n.s.s.	0/20	3.60mg	1/50	7.30mg	2/50	lun:a/a,a/c.	
2817	c00260	6.34mg	n.s.s.	10/20	3.40mg	19/50	6.70mg	22/50		
a	c00260	12.9mg	n.s.s.	5/20	3.40mg	6/50	6.70mg	10/50	liv:hpa,hpc,nnd.	
b	c00260	14.3mg	n.s.s.	3/20	3.40mg	5/50	6.70mg	6/50	lun:a/a,a/c.	
2818	c00260	.753mg	n.s.s.	12/20	1.40mg	39/50	(2.80mg)	31/50)		
a	c00260	21.2mg	n.s.s.	0/20	1.40mg	1/50	2.80mg	0/50	liv:hpa,hpc,nnd.	
2819	c00260	4.24mg	n.s.s.	9/20	1.10mg	22/50	2.20mg	16/50		
a	c00260	12.2mg	n.s.s.	0/20	1.10mg	2/50	2.20mg	0/50	liv:hpa,hpc,nnd.	
TRIS-1,2,3-(CHLOROMETHOXY)PROPANE 38571-73-2										
2820	582	1.30mg	51.1mg	0/30	1.71mg	5/30			Van Duuren;cnr,35,2553-2557;1975	
TRIS(2,3-DIBROMOPROPYL)PHOSPHATE (TRIS) 126-72-7										
2821	c03270	51.3mg	171.mg	16/55	64.3mg	34/50	129.mg	40/50	liv:hpa,hpc; lun:a/a,a/c; sto:scq,scp. C	
a	c03270	62.2mg	188.mg	11/55	64.3mg	23/50	129.mg	35/50	liv:hpa,hpc.	
b	c03270	88.1mg	212.mg	2/55	64.3mg	14/50	129.mg	22/50	sto:scq,scp.	
c	c03270	128.mg	692.mg	7/55	64.3mg	12/50	129.mg	20/50		
d	c03270	135.mg	576.mg	4/55	64.3mg	9/50	129.mg	17/50	lun:a/a,a/c.	
e	c03270	130.mg	682.mg	0/55	64.3mg	6/50	(129.mg)	(22/50)	S	
f	c03270	328.mg	2.15gm	0/55	64.3mg	4/50	129.mg	4/50		
g	c03270	67.7mg	n.s.s.	34/55	64.3mg	42/50	129.mg	44/50		
h	c03270	55.7mg	268.mg	11/55	64.3mg	23/50	129.mg	35/50	liv:hpa,hpc,nnd.	
i	c03270	119.mg	1.13gm	4/55	64.3mg	9/50	129.mg	17/50	lun:a/a,a/c.	
2822	c03270	58.7mg	336.mg	12/55	59.0mg	23/50	119.mg	37/50	kid:tla,uac; lun:a/a,a/c; sto:scq,scp. C	
a	c03270	120.mg	406.mg	0/55	59.0mg	10/50	119.mg	13/50	sto:scq,scp.	
b	c03270	147.mg	531.mg	0/55	59.0mg	4/50	119.mg	14/50	kid:tla,uac.	
c	c03270	335.mg	25.7gm	0/55	59.0mg	1/50	119.mg	5/50		
d	c03270	95.1mg	n.s.s.	12/55	59.0mg	18/50	119.mg	25/50	lun:a/a,a/c.	
e	c03270	170.mg	n.s.s.	6/55	59.0mg	8/50	119.mg	13/50		
f	c03270	86.1mg	n.s.s.	43/55	59.0mg	41/50	119.mg	43/50		
g	c03270	43.2mg	n.s.s.	28/55	59.0mg	31/50	(119.mg)	(23/50)	liv:hpa,hpc,nnd.	
h	c03270	95.1mg	n.s.s.	12/55	59.0mg	18/50	119.mg	25/50	lun:a/a,a/c.	
2823	c03270	7.41mg	35.7mg	0/55	2.50mg	4/55	4.95mg	10/55		
a	c03270	20.1mg	n.s.s.	0/55	2.50mg	0/55	4.95mg	3/55	S	
b	c03270	2.88mg	n.s.s.	52/55	2.50mg	47/55	4.95mg	54/55		
c	c03270	29.8mg	n.s.s.	1/55	2.50mg	1/55	4.95mg	1/55	liv:hpa,hpc,nnd.	
2824	c03270	.975mg	2.75mg	0/55	2.00mg	26/55	(4.00mg)	(26/55)		
a	c03270	.975mg	2.75mg	0/55	2.00mg	26/55	(4.00mg)	(29/55)	kid:tla,uac.	
b	c03270	8.69mg	n.s.s.	1/55	2.00mg	3/55	4.00mg	7/55	pre:acn,adn,can. S	
c	c03270	13.0mg	n.s.s.	0/55	2.00mg	1/55	4.00mg	4/55	liv:hpc,nnd. S	
d	c03270	18.9mg	n.s.s.	0/55	2.00mg	0/55	4.00mg	3/55		
e	c03270	2.31mg	n.s.s.	39/55	2.00mg	44/55	4.00mg	48/55		
f	c03270	13.0mg	n.s.s.	0/55	2.00mg	1/55	4.00mg	4/55	liv:hpa,hpc,nnd.	
L-TRYPTOPHAN 73-22-3										
2825	c01729	5.55gm	n.s.s.	3/15	1.74gm	11/35	3.48gm	3/35		
a	c01729	7.40gm	n.s.s.	0/15	1.74gm	1/35	3.48gm	1/35	liv:hpa,hpc,nnd.	
b	c01729	11.9gm	n.s.s.	1/15	1.74gm	0/35	3.48gm	1/35	lun:a/a,a/c.	
2826	c01729	602.mg	n.s.s.	1/15	1.61gm	15/35	(3.21gm)	(12/33)		
a	c01729	3.33gm	n.s.s.	1/15	1.61gm	5/35	3.21gm	7/33	liv:hpa,hpc,nnd.	
b	c01729	4.66gm	n.s.s.	0/15	1.61gm	4/35	3.21gm	2/33	lun:a/a,a/c.	
2827	c01729	1.53gm	n.s.s.	11/15	690.mg	24/35	1.33gm	19/35		
a	c01729	n.s.s.	n.s.s.	0/15	690.mg	0/35	1.33gm	0/35	liv:hpa,hpc,nnd.	
2828	c01729	560.mg	n.s.s.	11/15	552.mg	21/35	(1.07gm)	(14/35)		
a	c01729	n.s.s.	n.s.s.	0/15	552.mg	0/35	1.07gm	0/35	liv:hpa,hpc,nnd.	
TUNGSTATE, SODIUM 13472-45-2										
2829	1456	.380mg	n.s.s.	17/24	.286mg	13/20			Schroeder;jnut,105,421-427;1975	
a	1456	.884mg	n.s.s.	8/24	.286mg	5/20				
2830	1456	.780mg	n.s.s.	4/26	.250mg	4/25				
a	1456	1.05mg	n.s.s.	2/26	.250mg	2/25				
UREA 57-13-6										
2831	1343	9.95gm	n.s.s.	0/89p	440.mg	0/43	881.mg	0/38	4.40gm	2/50
a	1343	3.90gm	n.s.s.	10/92p	440.mg	7/43	881.mg	10/38	4.40gm	9/50
b	1343	10.4gm	n.s.s.	1/89p	440.mg	0/43	881.mg	0/38	4.40gm	2/50
c	1343	646.mg	n.s.s.	2/89p	440.mg	0/28	881.mg	0/23	4.40gm	0/23
2832	1343	11.5gm	n.s.s.	0/91p	406.mg	0/41	813.mg	0/36	4.06gm	1/47
a	1343	12.9gm	n.s.s.	2/91p	406.mg	0/41	813.mg	0/36	4.06gm	1/47
b	1343	8.00gm	n.s.s.	1/87p	406.mg	0/27	813.mg	1/21	4.06gm	0/24
2833	1343	473.mg	n.s.s.	0/49	169.mg	0/50	339.mg	0/48	1.69gm	0/48
2834	1343	305.mg	36.6gm	21/50	135.mg	27/48	271.mg	25/47	1.35gm	35/50
a	1343	369.mg	n.s.s.	0/50	135.mg	0/48	271.mg	0/48	1.35gm	0/48
URETHANE 51-79-6										
2835	170	27.9mg	74.7mg	1/67	136.mg	35/44			Toth;ejca,5,165-171;1969	
a	170	45.2mg	133.mg	0/62	136.mg	25/41				

Spe	Strain	Site	Xpo + Xpt	Notes	TD50	2Tailpvi
Sex	Route	Hist			DR	AuOp
b	H f syg wat	cec adp	90w90	e	294. mg	P<.0005+
c	H f syg wat	vag car	90w90	e	314. mg	P<.002
d	H f syg wat	adr mix	90w90	e	318. mg	P<.003 +
e	H f syg wat	adr coc	90w90	e	349. mg	P<.0005
f	H f syg wat	for car	90w90	e	374. mg	P<.0005+
g	H f syg wat	thy mix	90w90	e	538. mg	P<.003 +
h	H f syg wat	gal pam	90w90	e	682. mg	P<.007
i	H f syg wat	ova car	90w90	e	682. mg	P<.007
j	H f syg wat	lun ade	90w90	e	1.36gm	P<.2
k	H f syg wat	liv tum	90w90	e	no dre	P=1.
2836	H f syg wat	for pam	55w55	e	102. mg	P<.005 +
a	H f syg wat	ski mlt	55w55	e	496. mg	P<.2
2837	H m syg wat	for pam	24m24	e	64.2mg	P<.0005+
a	H m syg wat	der mtc	24m24	e	109. mg	P<.0005+
b	H m syg wat	for car	24m24	e	135. mg	P<.0005+
c	H m syg wat	cec adp	24m24	e	765. mg	P<.009 +
d	H m syg wat	liv mix	24m24	e	1.28gm	P<.03
e	H m syg wat	adr coa	24m24	e	564. mg	P<.2
f	H m syg wat	lun ade	24m24	e	927. mg	P<.2
2838	H m syg wat	ski mlt	76w76	e	74.2mg	P<.0005+
a	H m syg wat	for pam	76w76	e	95.8mg	P<.0005+
2839	M f b6a orl	lun mix	73w73	evx	12.5mg	P<.0005+
a	M f b6a orl	lun ade	73w73	evx	29.3mg	P<.0005
b	M f b6a orl	--- agm	73w73	evx	31.7mg	P<.0005
c	M f b6a orl	hag ade	73w73	evx	59.7mg	P<.002
d	M f b6a orl	lun car	73w73	evx	89.9mg	P<.009
e	M f b6a orl	liv hpt	73w73	evx	89.9mg	P<.009
f	M f b6a orl	tba mix	73w73	evx	9.73mg	P<.0005
2840	M m b6a orl	lun mix	72w72	evx	24.2mg	P<.0005+
a	M m b6a orl	liv mix	72w72	evx	26.0mg	P<.0005
b	M m b6a orl	lun ade	72w72	evx	27.8mg	P<.0005
c	M m b6a orl	hag ade	72w72	evx	35.8mg	P<.0005
d	M m b6a orl	liv hpt	72w72	evx	39.0mg	P<.002 +
e	M m b6a orl	--- rts	72w72	evx	77.9mg	P<.006 +
f	M m b6a orl	tba mix	72w72	evx	11.2mg	P<.0005
2841	M f b6c orl	liv mix	68w68	evx	32.4mg	P<.0005
a	M f b6c orl	liv hpt	68w68	evx	55.9mg	P<.003
b	M f b6c orl	lun mix	68w68	evx	79.0mg	P<.009 +
c	M f b6c orl	lun ade	68w68	evx	97.4mg	P<.02
d	M f b6c orl	tba mix	68w68	evx	13.7mg	P<.0005
2842	M m b6c orl	liv mix	70w70	evx	46.0mg	P<.002
a	M m b6c orl	lun mix	70w70	evx	65.9mg	P<.006 +
b	M m b6c orl	lun ade	70w70	evx	81.7mg	P<.02
c	M m b6c orl	liv hpt	70w70	evx	81.7mg	P<.02 +
d	M m b6c orl	tba mix	70w70	evx	22.4mg	P<.0005
2843	M f cf1 wat	lun tum	31m31	eg	23.8mg	P<.0005+
a	M f cf1 wat	liv hpt	31m31	eg	no dre	P=1. -
b	M f cf1 wat	tba mix	31m31	eg	23.3mg	P<.09
2844	M m cf1 wat	lun tum	29m29	e	13.2mg	P<.0005+
a	M m cf1 wat	liv hpt	29m29	e	no dre	P=1. -
b	M m cf1 wat	tba mix	29m29	e	12.1mg	P<.04
2845	M b nar wat	tba ben	23m24	ae	.434mg Z	P<.004
a	M b nar wat	tba mal	23m24	ae	14.7mg *	P<.0005+
2846	M b swi eat	lun ade	27m27	e	36.1mg	P<.0005+
a	M b swi eat	lun ade	27m27	e	36.1mg	P<.0005+
b	M b swi eat	lun adc	27m27	e	5.06gm	P<.3
c	M b swi eat	liv tum	27m27	e	no dre	P=1.
2847	P b rhe eat	jaj adc	5y19	euw	166. mg	P<.06 +
a	P b rhe eat	liv hpc	5y19	euw	166. mg	P<.06 +
b	P b rhe eat	tba mal	5y19	euw	98.7mg	P<.2
2848	R b sda wat	tba mal	23m24	ae	41.3mg *	P<.0005+
a	R b sda wat	tba ben	23m24	ae	91.2mg *	P<.02
VANADYL SULFATE					100ng.....1ug.....10.....100.....1mg.....10.....100.....1g.....10	
2849	M b cd1 wat	lun mix	24m24	e	29.2mg	P<.8 -
a	M b cd1 wat	liv ade	24m24	e	no dre	P=1. -
b	M b cd1 wat	tba mal	24m24	e	5.00mg	P<.06 -
c	M b cd1 wat	tba ben	24m24	e	no dre	P=1. -
d	M b cd1 wat	tba mix	24m24	e	no dre	P=1. -
2850	M f cd1 wat	tba mix	33m33	e	5.11mg	P<.07 -
2851	M m cd1 wat	tba mix	31m31	e	no dre	P=1. -
VANGUARD GF					100ng.....1ug.....10.....100.....1mg.....10.....100.....1g.....10	
2852	M f b6a orl	lun ade	76w76	evx	170. mg	P<.6 -
a	M f b6a orl	liv hpt	76w76	evx	no dre	P=1. -
b	M f b6a orl	tba mix	76w76	evx	150. mg	P<.6 -
2853	M m b6a orl	lun mix	76w76	evx	1.57gm	P<.1. -
a	M m b6a orl	liv hpt	76w76	evx	no dre	P=1. -
b	M m b6a orl	tba mix	76w76	evx	no dre	P=1. -

RefNum	LoConf	UpConf	Cntrl	1Dose	1Inc	2Dose	2Inc	Citation or Pathology	Brkly Code
b	170	126.mg	949.mg	0/55	136.mg	7/33			
c	170	108.mg	1.77gm	0/49	136.mg	4/20			
d	170	130.mg	2.05gm	1/55	136.mg	7/33			
e	170	142.mg	1.31gm	0/55	136.mg	6/33			
f	170	161.mg	1.23gm	0/62	136.mg	7/41			
g	170	204.mg	2.94gm	0/62	136.mg	5/41			
h	170	235.mg	8.99gm	0/62	136.mg	4/41			
i	170	235.mg	8.99gm	0/62	136.mg	4/41			
j	170	222.mg	n.s.s.	0/49	136.mg	1/20			
k	170	926.mg	n.s.s.	0/67	136.mg	0/44			
2836	297a	34.6mg	965.mg	0/14	273.mg	4/10		Pietra;jnci,25,627-630;1960	
a	297a	80.6mg	n.s.s.	0/14	273.mg	1/10			
2837	170	40.5mg	110.mg	6/88	120.mg	36/49		Toth;ejca,5,165-171;1969	
a	170	66.7mg	197.mg	1/62	120.mg	26/49			
b	170	76.8mg	267.mg	0/53	120.mg	18/40			
c	170	264.mg	25.2gm	0/53	120.mg	4/40			
d	170	386.mg	n.s.s.	0/62	120.mg	3/49			
e	170	114.mg	n.s.s.	1/26	120.mg	2/12			
f	170	151.mg	n.s.s.	0/26	120.mg	1/12			
2838	297a	29.2mg	260.mg	1/49	240.mg	7/10		Pietra;jnci,25,627-630;1960	
a	297a	37.1mg	352.mg	0/49	240.mg	6/10			
2839	297	5.80mg	29.5mg	1/17	81.3mg	17/19		Innes;ntis,1968/1969	
a	297	14.0mg	92.3mg	1/17	81.3mg	12/19			
b	297	15.4mg	79.1mg	0/17	81.3mg	11/19			
c	297	25.5mg	245.mg	0/17	81.3mg	7/19			
d	297	33.9mg	2.02gm	0/17	81.3mg	5/19			
e	297	33.9mg	2.02gm	0/17	81.3mg	5/19			
f	297	3.86mg	24.8mg	2/17	81.3mg	18/19			
2840	297	11.9mg	76.3mg	2/18	75.6mg	15/22			
a	297	13.1mg	72.1mg	1/18	75.6mg	14/22			
b	297	13.4mg	103.mg	2/18	75.6mg	14/22			
c	297	17.6mg	90.2mg	0/18	75.6mg	11/22			
d	297	18.2mg	174.mg	1/18	75.6mg	11/22			
e	297	31.6mg	645.mg	0/18	75.6mg	6/22			
f	297	5.20mg	27.7mg	3/18	75.6mg	20/22			
2841	297	16.3mg	79.2mg	0/16	81.5mg	12/23			
a	297	25.1mg	238.mg	0/16	81.5mg	8/23			
b	297	32.1mg	1.76gm	0/16	81.5mg	6/23			
c	297	36.9mg	n.s.s.	0/16	81.5mg	5/23			
d	297	7.21mg	28.0mg	0/16	81.5mg	19/23			
2842	297	20.6mg	165.mg	0/16	75.7mg	8/20			
a	297	26.7mg	555.mg	0/16	75.7mg	6/20			
b	297	30.8mg	n.s.s.	0/16	75.7mg	5/20			
c	297	30.8mg	n.s.s.	0/16	75.7mg	5/20			
d	297	11.3mg	51.7mg	0/16	75.7mg	13/20			
2843	90	13.1mg	59.4mg	13/56	20.0mg	28/40		Tomatis;jcn,10,489-506;1972	
a	90	175.mg	n.s.s.	2/56	20.0mg	1/40			
b	90	7.51mg	n.s.s.	45/56	20.0mg	37/40			
2844	90	7.18mg	34.6mg	23/55	16.7mg	40/48			
a	90	78.0mg	n.s.s.	12/55	16.7mg	8/48			
b	90	4.11mg	n.s.s.	46/55	16.7mg	46/48			
2845	298	.198mg	3.14mg	2/74	100.ug	11/65	(.500mg 12/69 2.50mg 21/59 12.5mg 30/65)	Schmahl;jcn,19,77-80;1977	
a	298	8.61mg	32.7mg	6/74	100.ug	11/65	.500mg 17/69 2.50mg 21/59 12.5mg 32/65		
2846	171a	19.3mg	66.9mg	10/49	125.mg	46/48		Van Esch;fctx,10,373-381;1972	
a	171a	19.3mg	66.9mg	10/49	125.mg	46/48			
b	171a	824.mg	n.s.s.	0/49	125.mg	1/48			
c	171a	1.54gm	n.s.s.	0/49	125.mg	0/48			
2847	2000	26.9mg	n.s.s.	0/32	46.6mg	1/6		Adamsen;ossc,129-156;1982/Sieber pers. comm.	
a	2000	26.9mg	n.s.s.	0/32	46.6mg	1/6			
b	2000	19.0mg	n.s.s.	3/32	46.6mg	2/6			
2848	298	21.4mg	129.mg	2/74	100.ug	2/70	.500mg 4/65 2.50mg 7/70 12.5mg 15/74	Schmahl;jcn,19,77-80;1977	
a	298	35.6mg	n.s.s.	1/74	100.ug	3/70	.500mg 2/65 2.50mg 5/70 12.5mg 8/74		
VANADYL SULFATE 27774-13-6									
2849	1512	2.33mg	n.s.s.	26/170	.877mg	8/47		Kanisawa;canr,27,1192-1195;1967	
a	1512	6.00mg	n.s.s.	7/170	.877mg	1/47			
b	1512	1.65mg	n.s.s.	15/170	.877mg	9/47			
c	1512	4.10mg	n.s.s.	29/170	.877mg	5/47			
d	1512	1.79mg	n.s.s.	55/170	.877mg	15/47			
2850	1395	2.01mg	n.s.s.	9/45	1.00mg	19/51		Schroeder;jnut,105,452-458;1975	
2851	1395	4.93mg	n.s.s.	10/43	.833mg	5/38			
VANGUARD GF (ferric nitrosodimethylthiocarbamate and tetramethylthiurem disulfide. CAS# --- and 137-26-8) mixture									
2852	1356	24.9mg	n.s.s.	1/17	33.9mg	2/16		Innes;ntis,1968/1969	
a	1356	59.7mg	n.s.s.	0/17	33.9mg	0/16			
b	1356	21.0mg	n.s.s.	2/17	33.9mg	3/16			
2853	1356	27.5mg	n.s.s.	2/18	31.6mg	2/17			
a	1356	59.1mg	n.s.s.	1/18	31.6mg	0/17			
b	1356	30.4mg	n.s.s.	3/18	31.6mg	2/17			

Spe	Strain	Site	Xpo+Xpt	Notes	TD50	2Tailpvl
Sex	Route	Hist			DR	AuOp
2854	M f b6c	orl lun	ade 76w76	evx	99.1mg	P<.1 -
a	M f b6c	orl liv	hpt 76w76	evx	no dre	P=1. -
b	M f b6c	orl tba	mix 76w76	evx	99.1mg	P<.1 -
2855	M m b6c	orl lun	car 76w76	evx	179.mg	P<.3 -
a	M m b6c	orl lun	ade 76w76	evx	179.mg	P<.3 -
b	M m b6c	orl liv	hpt 76w76	evx	no dre	P=1. -
c	M m b6c	orl tba	mix 76w76	evx	40.2mg	P<.02 -
VINBLASTINE					100ng...1ug.....10.....100.....1mg.....10.....100.....1g.....10	
2856	R m b46	ivj tba	mix 12m24	es	no dre	P=1. -
VINYL BROMIDE					100ng...1ug.....10.....100.....1mg.....10.....100.....1g.....10	
2857	R f sda	inh liv	nnd 19m24	ees	18.9mg	Z P<.003
a	R f sda	inh mix	ang 19m24	ees	19.2mg	Z P<.0005+
b	R f sda	inh zym	sqc 19m24	ees	2.24gm	* P<.0005
c	R f sda	inh liv	mix 19m24	ees	433.mg	Z P<.04 +
d	R f sda	inh liv	hpc 19m24	ees	749.mg	Z P<.04 +
2858	R m sda	inh mix	ang 18m24	ees	17.9mg	Z P<.0005+
a	R m sda	inh zym	sqc 18m24	ees	409.mg	* P<.0005
b	R m sda	inh zym	pam 18m24	ees	2.76gm	* P<.004
c	R m sda	inh liv	mix 18m24	ees	303.mg	Z P<.02 +
d	R m sda	inh liv	hpc 18m24	ees	387.mg	Z P<.02 +
e	R m sda	inh liv	nnd 18m24	ees	no dre	P=1.
VINYL CHLORIDE					100ng...1ug.....10.....100.....1mg.....10.....100.....1g.....10	
2859	H m syg	inh for	mix 7m25	ez	126.mg	Z P<.0005+
a	H m syg	inh adu	epo 7m25	ez	3.42gm	Z P<.2
b	H m syg	inh ski	epo 7m25	ez	15.4gm	Z P<.7
c	H m syg	inh liv	ang 7m25	ez	no dre	P=1. +
2860	M f cd1	inh liv	hes 26w58	es	98.9mg	* P<.0005+
a	M f cd1	inh lun	a/t 26w58	es	142.mg	* P<.02
b	M f cd1	inh mgl	mix 26w58	es	142.mg	* P<.02
2861	M m cd1	inh liv	hes 26w78	es	32.0mg	Z P<.0005+
a	M m cd1	inh lun	a/t 26w78	es	88.7mg	* P<.004
2862	M b swi	inh lun	tum 30w81	ez	21.1mg	Z P<.0005+
a	M b swi	inh liv	ang 30w81	ez	59.4mg	Z P<.0005+
b	M b swi	inh liv	agm 30w81	ez	99.8mg	Z P<.0005
c	M b swi	inh mgl	car 30w81	ez	5.04gm	Z P<.009 +
d	M b swi	inh ski	epo 30w81	ez	5.99gm	* P<.0005
e	M b swi	inh ehp	agm 30w81	ez	22.4gm	* P<.3 +
f	M b swi	inh ehp	ang 30w81	ez	no dre	P=1. +
2863	R f cdr	inh liv	mix 26w78	es	75.5mg	* P<.04
2864	R f cdr	inh liv	hes 43w95	es	69.5mg	* P<.0005
2865	R m cdr	inh liv	nnd 26w78	es	11.5mg	Z P<.02
a	R m cdr	inh liv	hpc 26w78	es	52.9mg	* P<.04
2866	R m cdr	inh liv	hes 43w95	es	103.mg	* P<.002
2867	R b sda	inh liv	hpt 12m31	ez	+historical	Z P<.003 +
a	R b sda	inh liv	ang 12m31	ez	843.mg	Z P<.0005+
b	R b sda	inh zym	car 12m31	ez	1.70gm	Z P<.0005+
c	R b sda	inh bra	neu 12m31	ez	+historical	* P<.0005+
d	R b sda	inh ehp	ang 12m31	ez	9.60gm	* P<.1 +
e	R b sda	inh kid	nep 12m31	ez	+historical	* P<.3 +
2868	R b sda	gav liv	ang 12m32	ez	54.1mg	* P<.0005+
a	R b sda	gav kid	nep 12m32	ez	+historical	* P<.05 +
b	R b sda	gav ehp	ang 12m32	ez	1.14gm	* P<.5
c	R b sda	gav zym	car 12m32	ez	1.97gm	* P<.8
2869	R b sda	inh mgl	adc 12m34	ez	3.69gm	Z P<.008 +
a	R b sda	inh liv	ang 12m34	ez	+historical	* P<.002 +
b	R b sda	inh zym	car 12m34	ez	64.5mg	* P<.2 +
c	R b sda	inh ehp	ang 12m34	ez	124.mg	* P<.4 +
d	R b sda	inh kid	nep 12m34	ez	+historical	* P<.2 +
2870	R b sda	inh kid	nep 12m33	ez	+historical	* P<.0005+
a	R b sda	inh liv	ang 12m33	ez	136.mg	* P<.0005+

CARCINOGENIC POTENCY DATABASE

RefNum	LoConf	UpConf	Cntrl	1Dose	1Inc	2Dose	2Inc	Citation or Pathology	Brkly Code
2854	1356	24.3mg n.s.s.	0/16	33.9mg	2/17				
a	1356	63.4mg n.s.s.	0/16	33.9mg	0/17				
b	1356	24.3mg n.s.s.	0/16	33.9mg	2/17				
2855	1356	29.2mg n.s.s.	0/16	31.6mg	1/16				
a	1356	29.2mg n.s.s.	0/16	31.6mg	1/16				
b	1356	55.6mg n.s.s.	0/16	31.6mg	0/16				
c	1356	13.8mg n.s.s.	0/16	31.6mg	4/16				
VINBLASTINE 865-21-4									
2856	1017	37.8ug n.s.s.	7/65	10.0ug	1/25			Schwahl;arzn,20,1461-1467;1970	
VINYL BROMIDE 593-60-2									
2857	1466	8.74mg 107.mg	3/142	2.95mg	12/101(14.4mg	9/113 63.5mg	10/118 343.mg	5/112)	Benja;txap,64,367-379;1982
a	1466	13.9mg 27.9mg	1/144	2.95mg	10/120 14.4mg	50/120(63.5mg	61/120 343.mg	41/120)	
b	1466	1.12gm 6.44gm	0/139	2.95mg	0/99 14.4mg	3/113 63.5mg	2/119 343.mg	11/114	
c	1466	175.mg n.s.s.	7/142	2.95mg	18/101 14.4mg	12/113 63.5mg	21/118(343.mg	9/112)	
d	1466	282.mg n.s.s.	4/142	2.95mg	6/101 14.4mg	3/113 63.5mg	11/118(343.mg	4/112)	
2858	1466	12.3mg 27.2mg	0/144	2.11mg	7/120 8.88mg	36/120(38.9mg	61/120 232.mg	43/120)	
a	1466	281.mg 647.mg	2/142	2.11mg	1/99 8.88mg	1/112 38.9mg	13/114 232.mg	35/116	
b	1466	1.14gm 27.3gm	0/142	2.11mg	0/99 8.88mg	1/112 38.9mg	3/114 232.mg	5/116	
c	1466	129.mg n.s.s.	4/143	2.11mg	5/103 8.88mg	10/119 38.9mg	13/120(232.mg	5/119)	
d	1466	161.mg n.s.s.	3/143	2.11mg	1/103 8.88mg	7/119 38.9mg	9/120(232.mg	3/119)	
e	1466	2.91gm n.s.s.	1/143	2.11mg	4/103 8.88mg	3/119 38.9mg	4/120 232.mg	2/119	
VINYL CHLORIDE 75-01-4									
2859	1878	72.9mg 274.mg	3/60	2.95mg	3/30 14.7mg	4/30 29.5mg	9/30 147.mg	17/30 (354.mg 10/30	
					590.mg 10/30)			Maltoni;enhp,41,3-29;1981/1977a	
a	1878	872.mg n.s.s.	0/60	2.95mg	0/30 14.7mg	0/30 29.5mg	3/30 147.mg	1/30 354.mg 2/30	
					(590.mg 1/30)				
b	1878	1.73gm n.s.s.	3/60	2.95mg	9/30 14.7mg	3/30 29.5mg	7/30 147.mg	3/30 354.mg 1/30	
					590.mg 7/30				
c	1878	4.04gm n.s.s.	0/60	2.95mg	0/30 14.7mg	0/30 29.5mg	2/30 147.mg	0/30 354.mg 1/30	
					590.mg 0/30				
2860	1113m	45.2mg 316.mg	1/28	17.9mg	1/8 161.mg	2/8 459.mg	8/12		Hong;jtxe,7,909-924;1981
a	1113m	52.4mg n.s.s.	7/28	17.9mg	1/8 161.mg	4/8 459.mg	7/12		
b	1113m	52.4mg n.s.s.	7/28	17.9mg	1/8 161.mg	4/8 459.mg	7/12		
2861	1113m	13.4mg 104.mg	0/28	11.2mg	0/8 60.9mg	7/12 (244.mg	5/12)		
a	1113m	37.3mg 927.mg	4/28	11.2mg	2/8 60.9mg	8/12 244.mg	7/12		
2862	1874	15.6mg 29.5mg	15/150	8.70mg	6/60 43.5mg	41/60 87.0mg	50/60 (435.mg	40/59 1.04gm 47/60	
					1.74gm 46/56)			Maltoni;enhp,41,3-29;1981/1977a	
a	1874	34.6mg 115.mg	0/150	8.70mg	1/60 43.5mg	18/60 (87.0mg	14/60 435.mg	16/59 1.04gm 13/60	
					1.74gm 10/56)				
b	1874	51.4mg 234.mg	0/150	8.70mg	1/60 43.5mg	11/60 (87.0mg	5/60 435.mg	5/59 1.04gm 7/60	
					1.74gm 6/56)				
c	1874	2.21gm 235.gm	1/150	8.70mg	12/60 43.5mg	12/60 87.0mg	8/60 435.mg	8/59 1.04gm 8/60	
					1.74gm 13/56				
d	1874	2.91gm 25.3gm	2/150	8.70mg	0/60 43.5mg	1/60 87.0mg	2/60 435.mg	4/59 1.04gm 7/60	
					1.74gm 4/56				
e	1874	5.45gm n.s.s.	1/150	8.70mg	5/60 43.5mg	3/60 87.0mg	3/60 435.mg	1/59 1.04gm 3/60	
					1.74gm 4/56				
f	1874	7.81gm n.s.s.	1/150	8.70mg	1/60 43.5mg	3/60 87.0mg	7/60 435.mg	8/59 1.04gm 1/60	
					1.74gm 1/56				
2863	1113m	22.7mg n.s.s.	0/8	3.19mg	0/8 15.9mg	1/8 63.8mg	2/8		Hong;jtxe,7,909-924;1981
2864	1113n	34.4mg 195.mg	0/16	4.35mg	0/16 21.7mg	4/12 87.0mg	7/16		
2865	1113m	3.43mg n.s.s.	0/8	2.23mg	0/8 11.2mg	3/8 (44.6mg	1/8)		
a	1113m	15.9mg n.s.s.	0/8	2.23mg	0/8 11.2mg	1/8 44.6mg	2/8		
2866	1113n	41.7mg 483.mg	0/16	3.04mg	0/10 15.2mg	1/16 60.9mg	5/16		
2867	1871	147.mg 1.82gm	0/58	2.02mg	0/60 10.1mg	1/59 20.2mg	5/60 (101.mg	2/60 243.mg 1/59	
					405.mg 1/60)			Maltoni;enhp,41,3-29;1981/1977a	
a	1871	528.mg 1.94gm	0/58	2.02mg	1/60 10.1mg	3/59 20.2mg	6/60 101.mg	13/60 243.mg 13/59	
					(405.mg 7/60)				
b	1871	1.08gm 3.29gm	0/58	2.02mg	0/60 10.1mg	0/59 20.2mg	4/60 101.mg	2/60 243.mg 7/59	
					405.mg 16/60				
c	1871	1.98gm 8.17gm	0/58	2.02mg	0/60 10.1mg	0/59 20.2mg	0/60 101.mg	4/60 243.mg 3/59	
					405.mg 7/60				
d	1871	3.07gm n.s.s.	0/58	2.02mg	1/60 10.1mg	2/59 20.2mg	1/60 101.mg	3/60 243.mg 3/59	
					405.mg 3/60				
e	1871	2.44gm n.s.s.	0/58	2.02mg	1/60 10.1mg	5/59 20.2mg	6/60 101.mg	6/60 243.mg 5/59	
					405.mg 5/60				
2868	18711	34.2mg 93.0mg	0/80	.819mg	0/80 4.09mg	10/80 12.3mg	17/80		
a	18711	121.mg n.s.s.	0/80	.819mg	0/80 4.09mg	3/80 12.3mg	2/80		
b	18711	177.mg n.s.s.	0/80	.819mg	2/80 4.09mg	0/80 12.3mg	2/80		
c	18711	192.mg n.s.s.	1/80	.819mg	0/80 4.09mg	2/80 12.3mg	1/80		
2869	18715	1.79mg 83.2mg	7/120	37.2ug	15/118 .186mg	22/119 .372mg	21/119(.929mg	17/120)	
a	18715	16.7mg 167.mg	0/120	37.2ug	0/118 .186mg	0/119 .372mg	1/119 .929mg	5/120	
b	18715	17.9mg n.s.s.	2/120	37.2ug	1/118 .186mg	1/119 .372mg	2/119 .929mg	4/120	
c	18715	30.6mg n.s.s.	0/120	37.2ug	0/118 .186mg	0/119 .372mg	2/119 .929mg	0/120	
d	18715	40.5mg n.s.s.	0/120	37.2ug	0/118 .186mg	0/119 .372mg	0/119 .929mg	1/120	
2870	1872	58.3mg 170.mg	0/185	3.82mg	10/120 5.73mg	11/119 7.64mg	7/120		
a	1872	79.2mg 264.mg	0/185	3.82mg	1/120 5.73mg	6/119 7.64mg	12/120		

Spe	Strain	Site	Xpo+Xpt	Notes	TD50	2Tailpvl	DR	AuOp
Sex	Route	Hist						
b	R b sda inh mgl adc	12m33	ez		216.mg	* P<.02	+	
c	R b sda inh liv agm	12m33	ez		528.mg	* P<.02	+	
d	R b sda inh liv hpt	12m33	ez		+historical	* P<.05	+	
e	R b sda inh zym car	12m33	ez		447.mg	* P<.2	+	
2871	R b sda gav zym car	14m32	ez	.	14.2mg	* P<.02	+	
a	R b sda gav liv ang	14m32	ez		+historical	* P<.02	+	
b	R b sda gav liv hpt	14m32	ez		+historical	* P<.2	+	
c	R b sda gav ehp ang	14m32	ez		64.5mg	* P<.2	+	
2872	R b sda inh liv ang	12m33	ez	.	50.4mg	P<.005	+	
a	R b sda inh mgl adc	12m33	ez		19.0mg	P<.02	+	
b	R b sda inh ehp agm	12m33	ez		64.4mg	P<.02	+	
c	R b sda inh ehp ang	12m33	ez		79.0mg	P<.03	+	
d	R b sda inh zym car	12m33	ez		79.0mg	P<.03	+	
e	R b sda inh liv agm	12m33	ez		89.1mg	P<.04	+	
f	R b sda inh kid nep	12m33	ez		+historical	P<.5	+	
2873	R b sda inh zym car	6m36	eyz	.	672.mg	* P<.0005	+	
a	R b sda inh liv ang	6m36	eyz		2.41gm	* P<.05	+	
b	R b sda inh ehp ang	6m36	eyz		4.85gm	* P<.3	+	
2874	R b sda inh zym car	6m36	eyz	.	555.mg	* P<.0005	+	
a	R b sda inh mam mal	6m36	eyz		569.mg	* P<.02	+	
b	R b sda inh kid nep	6m36	eyz		4.87gm	* P<.2	+	
c	R b sda inh liv ang	6m36	eyz		4.87gm	* P<.2	+	
d	R b sda inh liv hpt	6m36	eyz		4.88gm	* P<.3	+	
e	R b sda inh bra neu	6m36	eyz		9.76gm	* P<.2	+	
f	R b sda inh ehp ang	6m36	eyz		9.77gm	* P<.4	+	
2875	R f wis inh liv ang	52w52	ek	.	209.mg	* P<.002	+	
a	R f wis inh nas oec	52w52	ek		276.mg	P<.004	+	
b	R f wis inh zym sqc	52w52	ek		857.mg	P<.09	+	
c	R f wis inh lun ppa	52w52	ek		1.81gm	P<.3	+	
d	R f wis inh liv nnd	52w52	ek		1.81gm	P<.3	+	
e	R f wis inh liv hpc	52w52	ek		1.81gm	P<.3	+	
2876	R m wis inh ehp agm	12m31	ez	.	.761mg	P<.01	+	
a	R m wis inh ehp ang	12m31	ez		1.28mg	P<.05	+	
b	R m wis inh liv agm	12m31	ez		3.88mg	P<.3	+	
c	R m wis inh liv hpt	12m31	ez		3.88mg	P<.3	+	
d	R m wis inh zym car	12m31	ez		no dre	P=1.	+	
e	R m wis inh liv ang	12m31	ez		no dre	P=1.	+	
2877	R m wis inh liv ang	12m38	ez	.	1.55gm	* P<.0005+	+	
a	R m wis inh bra neu	12m38	ez		4.77gm	* P<.003	+	
b	R m wis inh zym car	12m38	ez		6.00gm	* P<.004	+	
c	R m wis inh liv hpt	12m38	ez		8.14gm	* P<.07	+	
d	R m wis inh kid nep	12m38	ez		13.6gm	* P<.4	+	
e	R m wis inh ehp ang	12m38	ez		no dre	P=1.	+	
2878	R m wis inh zym sqc	52w52	ek	.	330.mg	P<.03	+	
a	R m wis inh liv ang	52w52	ek		330.mg	P<.03	+	
b	R m wis inh nas oec	52w52	ek		533.mg	P<.08	+	
c	R m wis inh liv hpc	52w52	ek		1.14gm	P<.3	+	
d	R m wis inh lun ppa	52w52	ek		no dre	P=1.	+	
VINYLIDENE CHLORIDE				100ng...1ug.....10.....100.....1mg.....10.....100.....1g.....10				
2879	M f cd1 inh lab tum	26w78	e	.	no dre	P=1.	-	
a	M f cd1 inh liv hct	26w78	e		no dre	P=1.	-	
b	M f cd1 inh liv hes	26w78	e		no dre	P=1.	-	
2880	M f cd1 inh liv hes	52w52	e	.	170.mg	P<.3	+	
a	M f cd1 inh liv hpt	52w52	e		170.mg	P<.3	+	
b	M f cd1 inh lun tum	52w52	e		no dre	P=1.	-	
2881	M m cd1 inh lab tum	26w78	e	.	no dre	P=1.	-	
a	M m cd1 inh liv hct	26w78	e		no dre	P=1.	-	
2882	M m wi inh kid adc	52w82	eu	.	23.6mg	* P<.0005+	+	
2883	R f cdr inh liv mix	26w78	e	.	no dre	P=1.	-	
2884	R f cdr inh liv mix	43w95	e	.	no dre	P=1.	-	
2885	R f cdr inh liv hes	52w52	e	.	no dre	P=1.	-	
2886	R m cdr inh liv mix	26w78	e	.	no dre	P=1.	-	
2887	R m cdr inh liv mix	43w95	e	.	no dre	P=1.	-	
FD & C VIOLET NO. 1				100ng...1ug.....10.....100.....1mg.....10.....100.....1g.....10				
2888	M f asp eat lun ade	80w80	e	.	1.91gm	* P<.3	-	
a	M f asp eat liv tum	80w80	e		no dre	P=1.	-	
2889	M m asp eat lun adc	80w80	e	.	4.66gm	* P<.3	-	
a	M m asp eat liv tum	80w80	e		no dre	P=1.	-	
b	M m asp eat lun ade	80w80	e		no dre	P=1.	-	
2890	R f asd eat mgl car	52w52	e	.	1.14gm	P<.02	+	
a	R f asd eat edu car	52w52	e	.	1.60gm	P<.05	+	

RefNum	LoConf	UpConf	Cntri	1Dose	1Inc	2Dose	2Inc	Citation or Pathology	Brkly Code
b	18T2	101.mg n.s.s.	2/185	3.82mg	4/120	5.73mg	6/119	7.64mg	6/120
c	18T2	201.mg n.s.s.	0/185	3.82mg	1/120	5.73mg	0/119	7.64mg	4/120
d	18T2	267.mg n.s.s.	0/185	3.82mg	0/120	5.73mg	0/119	7.64mg	3/120
e	18T2	157.mg n.s.s.	2/185	3.82mg	1/120	5.73mg	4/119	7.64mg	4/120
2871	18T27	5.01mg n.s.s.	1/150	8.37ug	0/150	83.7ug	0/148	.279mg	5/149
a	18T27	5.54mg n.s.s.	0/150	8.37ug	0/150	83.7ug	1/148	.279mg	3/149
b	18T27	7.93mg n.s.s.	0/150	8.37ug	0/150	83.7ug	1/148	.279mg	1/149
c	18T27	10.5mg n.s.s.	0/150	8.37ug	0/150	83.7ug	0/148	.279mg	1/149
2872	18T9	27.1mg 305.mg	0/98	1.92mg	14/294				
a	18T9	10.2mg n.s.s.	10/98	1.92mg	62/294				
b	18T9	32.4mg n.s.s.	0/98	1.92mg	11/294				
c	18T9	37.2mg n.s.s.	0/98	1.92mg	9/294				
d	18T9	37.2mg n.s.s.	0/98	1.92mg	9/294				
e	18T9	40.3mg n.s.s.	0/98	1.92mg	8/294				
f	18T9	117.mg n.s.s.	0/98	1.92mg	1/294				
2873	18T10m	362.mg 1.47gm	0/227	20.5mg	5/118	34.1mg	9/119		
a	18T10m	834.mg n.s.s.	0/227	20.5mg	3/118	34.1mg	1/119		
b	18T10m	1.19gm n.s.s.	0/227	20.5mg	2/118	34.1mg	0/119		
2874	18T10n	315.mg 1.13gm	0/227	20.5mg	9/120	34.1mg	8/119		
a	18T10n	261.mg n.s.s.	17/227	20.5mg	12/120	34.1mg	20/119		
b	18T10n	1.20gm n.s.s.	0/227	20.5mg	1/120	34.1mg	1/119		
c	18T10n	1.20gm n.s.s.	0/227	20.5mg	1/120	34.1mg	1/119		
d	18T10n	1.20gm n.s.s.	0/227	20.5mg	2/120	34.1mg	0/119		
e	18T10n	1.59gm n.s.s.	0/227	20.5mg	0/120	34.1mg	1/119		
f	18T10n	1.59gm n.s.s.	0/227	20.5mg	1/120	34.1mg	0/119		
2875	1170	80.8mg 884.mg	0/10	1.12gm	6/10			Feron;txcy,13,131-141;1979/1979a	
a	1170	101.mg 1.93gm	0/10	1.12gm	5/10				
b	1170	209.mg n.s.s.	0/10	1.12gm	2/10				
c	1170	295.mg n.s.s.	0/10	1.12gm	1/10				
d	1170	295.mg n.s.s.	0/10	1.12gm	1/10				
e	1170	295.mg n.s.s.	0/10	1.12gm	1/10				
2876	18T17	.289mg 48.8mg	0/94	34.6ug	5/99			Maltoni;enhp,41,3-29;1981/1977a	
a	18T17	.388mg n.s.s.	0/94	34.6ug	3/99				
b	18T17	.632mg n.s.s.	0/94	34.6ug	1/99				
c	18T17	.632mg n.s.s.	0/94	34.6ug	1/99				
d	18T17	.647mg n.s.s.	3/94	34.6ug	2/99				
e	18T17	1.17mg n.s.s.	0/94	34.6ug	0/99				
2877	18T7	762.mg 5.08gm	0/38	1.41mg	0/28	7.03mg	1/27	14.1mg	3/28
				281.mg 8/27				70.3mg	3/25
a	18T7	1.81gm 27.0gm	0/38	1.41mg	0/28	7.03mg	0/27	14.1mg	0/28
				281.mg 3/27				70.3mg	1/25
b	18T7	2.07gm 43.5gm	0/38	1.41mg	0/28	7.03mg	0/27	14.1mg	0/28
				281.mg 2/27				70.3mg	0/25
c	18T7	2.46gm n.s.s.	0/38	1.41mg	0/28	7.03mg	0/27	14.1mg	0/28
				281.mg 0/27				70.3mg	1/25
d	18T7	2.46gm n.s.s.	0/38	1.41mg	1/28	7.03mg	0/27	14.1mg	2/28
				281.mg 1/27				70.3mg	0/25
e	18T7	3.86gm n.s.s.	1/38	1.41mg	0/28	7.03mg	1/27	14.1mg	0/28
				281.mg 0/27				70.3mg	1/25
2878	1170	98.3mg n.s.s.	0/10	781.mg	3/9			Feron;txcy,13,131-141;1979/1979a	
a	1170	98.3mg n.s.s.	0/10	781.mg	3/9				
b	1170	130.mg n.s.s.	0/10	781.mg	2/9				
c	1170	185.mg n.s.s.	0/10	781.mg	1/9				
d	1170	362.mg n.s.s.	0/10	781.mg	0/9				
VINYLIDENE CHLORIDE 75-35-4									
2879	1113m	31.8mg n.s.s.	7/28	22.9mg	0/12			Hong;jtxe,7,909-924;1981	
a	1113m	31.8mg n.s.s.	1/28	22.9mg	0/12				
b	1113m	31.8mg n.s.s.	1/28	22.9mg	0/12				
2880	357	27.7mg n.s.s.	0/16	68.6mg	1/15			Lee;jtxe,4,15-30;1978	
a	357	27.7mg n.s.s.	0/16	68.6mg	1/15				
b	357	53.0mg n.s.s.	0/16	68.6mg	0/15				
2881	1113m	17.5mg n.s.s.	4/28	19.0mg	1/12			Hong;jtxe,7,909-924;1981	
a	1113m	17.5mg n.s.s.	4/28	19.0mg	1/12				
2882	18T402	13.2mg 50.0mg	0/70	9.88mg	16/98			Maltoni;ludi,64,241-262;1977/pars.com.	
2883	1113m	5.05mg n.s.s.	0/8	5.44mg	0/8			Hong;jtxe,7,909-924;1981	
2884	1113n	20.4mg n.s.s.	0/16	7.42mg	0/16				
2885	357	12.6mg n.s.s.	0/15	16.3mg	0/15			Lee;jtxe,4,15-30;1978	
2886	1113m	3.53mg n.s.s.	0/8	3.81mg	0/8			Hong;jtxe,7,909-924;1981	
2887	1113n	12.5mg n.s.s.	1/16	5.19mg	0/14				
FD & C VIOLET NO. 1 1964-09-3									
2888	1354	480.mg n.s.s.	8/42	9.10mg	7/43	91.0mg	7/42	455.mg	12/48
a	1354	42.6mg n.s.s.	0/42	9.10mg	0/43	91.0mg	0/42	455.mg	0/48
2889	1354	1.15gm n.s.s.	0/42	8.40mg	0/45	84.0mg	1/42	420.mg	1/46
a	1354	40.9mg n.s.s.	0/42	8.40mg	0/45	84.0mg	0/42	420.mg	0/46
b	1354	519.mg n.s.s.	18/42	8.40mg	13/45	84.0mg	18/42	420.mg	15/46
2890	1364	430.mg n.s.s.	0/10	2.50gm	5/16			Uematsu;jnci,51,1337-1338;1973	
a	1364	549.mg n.s.s.	0/10	2.50gm	4/17				

Spe	Strain	Site	Xpo+Xpt	Notes	TD50	2Tailpvl
Sex	Route	Hist			DR	AuOp
b	R f	asd eat	tba mal	52w52 e	568.mg	P<.002
c	R f	asd eat	tba mix	52w52 e	660.mg	P<.02
2891	R m	asd eat	tba tum	52w52	>	no dre P=1.
VITAMIN D2					100ng...1ug...10...100...1mg...10...100...1g...10	
2892	M f	c3h eat	mgl adc	24m24 r	>	39.6mg Z P<.1. +
VITAMIN A ACID					100ng...1ug...10...100...1mg...10...100...1g...10	
2893	R f	sda ipj	tba mal	24m24 e	>	no dre P=1. -
2894	R m	sda ipj	liv hae	24m24 e	>	no dre P=1. -
a	R m	sda ipj	tba mal	24m24 e		188.mg P<.1. -
2,4-XYLIDINE.HCL					100ng...1ug...10...100...1mg...10...100...1g...10	
2895	M f	chi eat	lun mix	77w90	:	12.4mg / P<.004 +
a	M f	chi eat	liv mix	77w90	:	no dre P=1. -
b	M f	chi eat	tba mix	77w90	:	12.2mg / P<.08
2896	M f	chi eat	lun mix	77w90	pool	13.5mg / P<.002 +
2897	M m	chi eat	liv mix	77w90	>	65.4mg * P<.5 -
a	M m	chi eat	lun mix	77w90		no dre P=1. -
b	M m	chi eat	tba mix	77w90		646.mg * P<.1. -
2898	R m	cdr eat	liv mix	77w98 v	>	260.mg * P<.4 -
a	R m	cdr eat	tba mix	77w98 v		16.8mg \ P<.02 -
2,5-XYLIDINE.HCL					100ng...1ug...10...100...1mg...10...100...1g...10	
2899	M f	chi eat	liv hpt	68w94 a	:	552.mg * P<.003 +
a	M f	chi eat	liv mix	68w94 a	:	552.mg * P<.003 +
b	M f	chi eat	lun mix	68w94 a	:	1.29mg * P<.006 -
c	M f	chi eat	tba mix	68w94 a	:	475.mg * P<.003
2900	M f	chi eat	liv hpt	68w94 a	pool	552.mg * P<.0005+
2901	M m	chi eat	lun mix	68w94 a	:	765.mg * P<.005 -
a	M m	chi eat	liv mix	68w94 a	:	805.mg * P<.01
b	M m	chi eat	tba mix	68w94 a	:	321.mg / P<.002
2902	M m	chi eat	--- vsc	68w94 a	pool	723.mg * P<.0005+
2903	R m	cdr eat	liv mix	18m24 v	>	3.26gm * P<.8 -
a	R m	cdr eat	tba mix	18m24 v		67.2mg \ P<.005
2904	R m	cdr eat	sub mix	18m24 v	pool	152.mg * P<.0005+
C.I. PIGMENT YELLOW 12					100ng...1ug...10...100...1mg...10...100...1g...10	
2905	M f	b6c eat	TBA MXB	78w96		no dre P=1. -
a	M f	b6c eat	liv MXB	78w96		no dre P=1. -
b	M f	b6c eat	lun MXB	78w96		no dre P=1. -
2906	M m	b6c eat	TBA MXB	78w96		no dre P=1. -
a	M m	b6c eat	liv MXB	78w96		no dre P=1. -
b	M m	b6c eat	lun MXB	78w96		no dre P=1. -
2907	M b	nmr eat	tba tum	24m24	>	9.11gm * P<.3 -
2908	R f	f34 eat	TBA MXB	18m25	>	4.14gm * P<.4 -
a	R f	f34 eat	liv MXB	18m25		71.9gm * P<.6
2909	R m	f34 eat	TBA MXB	18m25	>	no dre P=1. -
a	R m	f34 eat	liv MXB	18m25		no dre P=1. -
2910	R b	sda eat	tba tum	24m24	>	5.33gm Z P<.6 -
C.I. PIGMENT YELLOW 16					100ng...1ug...10...100...1mg...10...100...1g...10	
2911	M b	nmr eat	tba tum	24m24 e	>	11.7gm * P<.5 -
2912	R b	sda eat	tba tum	24m24 e	>	13.7gm Z P<.8 -
C.I. PIGMENT YELLOW 83					100ng...1ug...10...100...1mg...10...100...1g...10	
2913	M b	nmr eat	tba tum	24m24 e	>	no dre P=1. -
2914	R b	sda eat	tba tum	24m24 e	>	3.56gm Z P<.4 -
C.I. VAT YELLOW 4					100ng...1ug...10...100...1mg...10...100...1g...10	
2915	M f	b6c eat	TBA MXB	25m25	>	no dre P=1. -
a	M f	b6c eat	liv MXB	25m25		23.9gm * P<.5
b	M f	b6c eat	lun MXB	25m25		no dre P=1. -
2916	M m	b6c eat	--- lym	25m25	:	10.9gm * P<.009 c
a	M m	b6c eat	TBA MXB	25m25		4.41gm * P<.05
b	M m	b6c eat	liv MXB	25m25		8.61gm * P<.07
c	M m	b6c eat	lun MXB	25m25		19.1gm * P<.4
2917	R f	f34 eat	TBA MXB	24m24	>	no dre P=1. -
a	R f	f34 eat	liv MXB	24m24		no dre P=1. -
2918	R m	f34 eat	TBA MXB	24m24	>	787.mg * P<.5 -
a	R m	f34 eat	liv MXB	24m24		2.79gm * P<.2
FD & C YELLOW NO. 5					100ng...1ug...10...100...1mg...10...100...1g...10	
2919	R f	nas eat	liv tum	64w64 e	>	no dre P=1. -
a	R f	nas eat	tba mix	64w64 e		no dre P=1. -
2920	R m	nas eat	liv tum	64w64 e	>	no dre P=1. -
a	R m	nas eat	tba mix	64w64 e		no dre P=1. -
2921	R b	osm eat	liv ade	24m24 e	>	231.gm * P<.9 -
a	R b	osm eat	tba mal	24m24 e		no dre P=1. -
b	R b	osm eat	tba mix	24m24 e		no dre P=1. -

RefNum	LoConf	UpConf	Cntrl	LDose	LDnc	LDose	LDnc	Citation or Pathology	Brkly Code
b	1364	261.mg	2.03gm	0/10	2.50gm	9/17			
c	1364	274.mg	n.s.s.	1/10	2.50gm	9/17			
2891	1364	2.06gm	n.s.s.	0/10	2.00gm	0/20			
VITAMIN D2 50-14-6									
2892	1131	.889mg	n.s.s.	16/64	65.0ug	18/68	.130mg	23/46	.260mg 17/66 .520mg 9/31 (1.04mg 0/7) Gass;obgy,5,477;1977
VITAMIN A ACID 302-79-4									
2893	1134	2.80mg	n.s.s.	3/33	.714mg	2/35			Schmahl;zkko,86,77-84;1976
2894	1134	4.86mg	n.s.s.	1/36	.714mg	0/33			
a	1134	2.91mg	n.s.s.	1/36	.714mg	1/33			
2,4-XYLIDINE.HCL 21436-96-4									
2895	381	5.45mg	103.mg	5/22	13.9mg	5/18	29.3mg	11/19	Weisburger;jept,2,325-356;1978/pers.comm./Russfield 1973
a	381	122.mg	n.s.s.	1/22	13.9mg	0/18	29.3mg	0/19	
b	381	4.28mg	n.s.s.	18/22	13.9mg	11/18	29.3mg	16/19	
2896	381	5.74mg	89.6mg	31/102p	13.9mg	5/18	29.3mg	11/19	
2897	381	9.11mg	n.s.s.	1/18	12.9mg	2/20	27.0mg	1/19	
a	381	14.5mg	n.s.s.	8/18	12.9mg	2/20	27.0mg	3/19	
b	381	8.40mg	n.s.s.	13/18	12.9mg	8/20	27.0mg	9/19	
2898	381	63.9mg	n.s.s.	0/16	23.6mg	1/20	47.3mg	1/24	
a	381	6.86mg	n.s.s.	9/16	23.6mg	14/20	47.3mg	15/24	
2,5-XYLIDINE.HCL 51786-53-9									
2899	381	217.mg	3.20gm	0/13	669.mg	5/16	1.56gm	2/20	Weisburger;jept,2,325-356;1978/pers.comm./Russfield 1973
a	381	217.mg	3.20gm	0/13	669.mg	5/16	1.56gm	2/20	
b	381	403.mg	15.3gm	3/13	669.mg	2/16	1.56gm	4/20	
c	381	196.mg	3.12gm	9/13	669.mg	8/16	1.56gm	7/20	
2900	381	217.mg	2.01gm	1/102p	669.mg	5/16	1.56gm	2/20	
2901	381	294.mg	6.83gm	2/16	617.mg	4/18	1.44gm	3/19	
a	381	299.mg	48.4gm	2/16	617.mg	4/18	1.44gm	2/19	
b	381	149.mg	1.55gm	9/16	617.mg	12/18	1.44gm	12/19	
2902	381	324.mg	2.11gm	5/99p	617.mg	5/18	1.44gm	7/19	
2903	381	272.mg	n.s.s.	1/17	120.mg	1/17	240.mg	1/17	
a	381	19.1mg	747.mg	13/17	120.mg	12/17	240.mg	12/17	
2904	381	69.6mg	475.mg	18/111p	120.mg	7/17	240.mg	9/17	
C.I. PIGMENT YELLOW 12 (diarylanilide yellow) 6358-85-6									
2905	c03269	10.1gm	n.s.s.	12/50	2.61gm	10/50	5.23gm	9/50	
a	c03269	51.7gm	n.s.s.	2/50	2.61gm	0/50	5.23gm	0/50	Liv:hpa,hpc,nnd. Lun:a/a,a/c.
b	c03269	25.5gm	n.s.s.	4/50	2.61gm	3/50	5.23gm	1/50	
2906	c03269	8.17gm	n.s.s.	20/50	2.44gm	21/50	4.82gm	13/50	
a	c03269	5.41gm	n.s.s.	15/50	2.44gm	11/50	4.82gm	4/50	Liv:hpa,hpc,nnd. Lun:a/a,a/c.
b	c03269	16.6gm	n.s.s.	7/50	2.44gm	5/50	4.82gm	4/50	
2907	1021	2.46gm	n.s.s.	33/100	125.mg	21/100	375.mg	26/100	1.12gm 34/100
2908	c03269	1.13gm	n.s.s.	31/50	920.mg	40/50	1.84gm	34/50	Leuschner;txlt,2,253-260;1978
a	c03269	10.4gm	n.s.s.	1/50	920.mg	0/50	1.84gm	2/50	Liv:hpa,hpc,nnd.
2909	c03269	2.64gm	n.s.s.	31/50	736.mg	25/50	1.47gm	23/50	
a	c03269	n.s.s.	n.s.s.	0/50	736.mg	1/50	1.47gm	0/50	Liv:hpa,hpc,nnd.
2910	1021	1.03gm	n.s.s.	43/100	45.0mg	20/100	135.mg	18/100	405.mg 37/100
C.I. PIGMENT YELLOW 16 5979-28-2									
2911	1021	2.50gm	n.s.s.	33/100	125.mg	22/100	375.mg	33/100	1.13gm 33/100
2912	1021	1.19gm	n.s.s.	43/100	45.0mg	24/100	135.mg	16/100	405.mg 36/100
C.I. PIGMENT YELLOW 83 5567-15-7									
2913	1021	4.66gm	n.s.s.	33/100	125.mg	23/100	375.mg	19/100	1.13gm 26/100
2914	1021	897.mg	n.s.s.	43/100	45.0mg	23/100	135.mg	20/100	405.mg 40/100
C.I. VAT YELLOW 4 128-66-5									
2915	c03565	3.77gm	n.s.s.	13/20	1.62gm	29/50	3.25gm	29/50	
a	c03565	5.84gm	n.s.s.	2/20	1.62gm	6/50	3.25gm	9/50	Liv:hpa,hpc,nnd. Lun:a/a,a/c.
b	c03565	11.6gm	n.s.s.	2/20	1.62gm	5/50	3.25gm	3/50	
2916	c03565	5.66gm	333.gm	3/20	3.00gm	7/50	6.00gm	22/50	
a	c03565	1.94gm	n.s.s.	12/20	3.00gm	42/50	6.00gm	48/50	
b	c03565	3.87gm	n.s.s.	3/20	3.00gm	22/50	6.00gm	21/50	Liv:hpa,hpc,nnd.
c	c03565	5.69gm	n.s.s.	4/20	3.00gm	14/50	6.00gm	15/50	Lun:a/a,a/c.
2917	c03565	474.mg	n.s.s.	9/20	175.mg	26/50	350.mg	23/50	
a	c03565	n.s.s.	n.s.s.	0/20	175.mg	0/50	350.mg	0/50	Liv:hpa,hpc,nnd.
2918	c03565	185.mg	n.s.s.	11/20	140.mg	32/50	280.mg	31/50	
a	c03565	963.mg	n.s.s.	0/20	140.mg	1/50	280.mg	3/50	Liv:hpa,hpc,nnd.
FD & C YELLOW NO. 5 (tartrazine) 1934-21-0									
2919	1358	13.6mg	n.s.s.	0/10	15.0mg	0/13	150.mg	0/14	750.mg 0/10
a	1358	273.mg	n.s.s.	2/10	15.0mg	4/13	150.mg	5/14	750.mg 2/10
2920	1358	11.4mg	n.s.s.	0/11	12.0mg	0/14	120.mg	0/12	600.mg 0/9
a	1358	439.mg	n.s.s.	1/11	12.0mg	2/14	120.mg	1/12	600.mg 0/9
2921	305a	7.86gm	n.s.s.	0/18	225.mg	2/22	450.mg	0/21	900.mg 0/24 2.25gm 1/23
a	305a	4.76gm	n.s.s.	6/18	225.mg	4/22	450.mg	6/21	900.mg 6/24 2.25gm 4/23
b	305a	5.13gm	n.s.s.	8/18	225.mg	9/22	450.mg	9/21	900.mg 8/24 2.25gm 5/23

Spe	Strain	Site	Xpo+Xpt	Notes	TD50	2Tailpvl
Sex	Route	Hist			DR	AuOp
FD & C YELLOW NO. 6				100ng...1ug...10...100...1mg...10...100...1g...10		
2922	M f	cdr eat	liv tum	80w80 e	>	no dre P=1. -
a	M f	cdr eat	lun ade	80w80 e		no dre P=1. -
2923	M m	cdr eat	liv tum	80w80 e	>	no dre P=1. -
a	M m	cdr eat	lun ade	80w80 e		no dre P=1. -
2924	R f	nss eat	liv tum	64w64 e	>	no dre P=1. -
a	R f	nss eat	tba mix	64w64 e		87.4mg Z P<.02 -
2925	R m	nss eat	liv tum	64w64 e	>	no dre P=1. -
a	R m	nss eat	tba mix	64w64 e		14.0gm * P<.1. -
ZINC DIBUTYL DITHIOCARBAMATE				100ng...1ug...10...100...1mg...10...100...1g...10		
2926	M f	b6a orl	lun ade	76w76 evx	>	1.09gm P<.4 -
a	M f	b6a orl	liv hpt	76w76 evx		no dre P=1. -
b	M f	b6a orl	tba mix	76w76 evx		2.33gm P<.7 -
2927	M m	b6a orl	lun ade	76w76 evx	>	no dre P=1. -
a	M m	b6a orl	liv hpt	76w76 evx		no dre P=1. -
b	M m	b6a orl	tba mix	76w76 evx		no dre P=1. -
2928	M f	b6c orl	lun ade	76w76 evx	>	2.33gm P<.3 -
a	M f	b6c orl	liv hpt	76w76 evx		no dre P=1. -
b	M f	b6c orl	tba mix	76w76 evx		731.mg P<.05 -
2929	M m	b6c orl	liv hpt	76w76 evx	*	680.mg P<.05 -
a	M m	b6c orl	lun ade	76w76 evx		1.05gm P<.2 -
b	M m	b6c orl	tba mix	76w76 evx		252.mg P<.002 -
ZINC DIETHYL DITHIOCARBAMATE				100ng...1ug...10...100...1mg...10...100...1g...10		
2930	M f	b6a orl	liv hpt	76w76 evx	>	no dre P=1. -
a	M f	b6a orl	lun ade	76w76 evx		no dre P=1. -
b	M f	b6a orl	tba mix	76w76 evx		no dre P=1. -
2931	M m	b6a orl	liv hpt	76w76 evx	>	205.mg P<.6 -
a	M m	b6a orl	lun ade	76w76 evx		no dre P=1. -
b	M m	b6a orl	tba mix	76w76 evx		86.7mg P<.5 -
2932	M f	b6c orl	liv hpt	76w76 evx	>	no dre P=1. -
a	M f	b6c orl	lun mix	76w76 evx		no dre P=1. -
b	M f	b6c orl	tba tum	76w76 evx		no dre P=1. -
2933	M m	b6c orl	lun ade	76w76 evx	*	46.2mg P<.02 -
a	M m	b6c orl	liv hpt	76w76 evx		no dre P=1. -
b	M m	b6c orl	tba mix	76w76 evx		28.5mg P<.003 -
ZINC DIMETHYL DITHIOCARBAMATE				100ng...1ug...10...100...1mg...10...100...1g...10		
2934	M f	b6a orl	liv hpt	76w76 evx	>	no dre P=1. -
a	M f	b6a orl	lun ade	76w76 evx		no dre P=1. -
b	M f	b6a orl	tba mix	76w76 evx		no dre P=1. -
2935	M m	b6a orl	lun ade	76w76 evx	>	9.15gm P<.6 -
a	M m	b6a orl	liv hpt	76w76 evx		202.mg P<.1. -
b	M m	b6a orl	tba mix	76w76 evx		4.21gm P<.4 -
2936	M f	b6c orl	lun ade	76w76 evx	>	13.1gm P<.3 -
a	M f	b6c orl	liv hpt	76w76 evx		no dre P=1. -
b	M f	b6c orl	tba mix	76w76 evx		13.1gm P<.3 -
2937	M m	b6c orl	lun mix	76w76 evx	*	5.23gm P<.09 -
a	M m	b6c orl	liv hpt	76w76 evx		10.8gm P<.3 -
b	M m	b6c orl	tba mix	76w76 evx		3.37gm P<.04 -
2938	R b	mgr gav	liv mhp	22w24 e	+	56.5mg P<.008 -
a	R b	mgr gav	tba mix	22w24 e		25.8mg P<.002 +
ZINC ETHYLENEBISTHIOCARBAMATE				100ng...1ug...10...100...1mg...10...100...1g...10		
2939	M f	b6a orl	lun ade	76w76 evx	>	1.15gm P<.6 -
a	M f	b6a orl	liv hpt	76w76 evx		no dre P=1. -
b	M f	b6a orl	tba mix	76w76 evx		1.15gm P<.7 -
2940	M m	b6a orl	liv hpt	76w76 evx	>	903.mg P<.6 -
a	M m	b6a orl	lun ade	76w76 evx		no dre P=1. -
b	M m	b6a orl	tba mix	76w76 evx		715.mg P<.7 -
2941	M f	b6c orl	lun ade	76w76 evx	>	1.15gm P<.3 -
a	M f	b6c orl	liv hpt	76w76 evx		no dre P=1. -
b	M f	b6c orl	tba mix	76w76 evx		1.15gm P<.3 -
2942	M m	b6c orl	liv hpt	76w76 evx	*	244.mg P<.02 -
a	M m	b6c orl	lun mix	76w76 evx		no dre P=1. -
b	M m	b6c orl	tba mix	76w76 evx		189.mg P<.009 -
2943	R b	mgr gav	liv tum	22w24 e	>	no dre P=1. -
a	R b	mgr gav	tba mix	22w24 e		255.mg P<.06 +
ZIRCONIUM (IV) SULFATE				100ng...1ug...10...100...1mg...10...100...1g...10		
2944	M b	cd1 wat	lun tum	32w32 e	>	no dre P=1. -
a	M b	cd1 wat	liv tum	32w32 e		no dre P=1. -
b	M b	cd1 wat	tba tum	32w32 e		no dre P=1. -
c	M b	cd1 wat	tba mal	32w32 e		no dre P=1. -

RefNum	LoConf	UpConf	Cntrl	1Dose	1Inc	2Dose	2Inc	Citation or Pathology	Brkly Code			
FD & C YELLOW NO. 6 (sunset yellow FCF) 2783-94-0												
2922	1355	476.mg n.s.s.	0/47	260.mg	0/29	520.mg	0/27	1.04gm	0/27	2.08gm	0/29	Gaunt;fctx,12,1-10;1974
a	1355	6.02gm n.s.s.	12/47	260.mg	6/29	520.mg	3/27	1.04gm	2/27	2.08gm	3/29	
2923	1355	412.mg n.s.s.	0/50	240.mg	0/26	480.mg	0/30	960.mg	0/27	1.92gm	0/19	
a	1355	2.34gm n.s.s.	7/50	240.mg	2/26	480.mg	8/30	960.mg	2/27	1.92gm	3/19	
2924	1358	15.3mg n.s.s.	0/10	15.0mg	0/15	150.mg	0/13	750.mg	0/9			Mennell;jphp,10,625-634;1958
a	1358	31.1mg n.s.s.	2/10	15.0mg	0/15	150.mg	6/13	(750.mg	2/9)			
2925	1358	6.91mg n.s.s.	0/11	12.0mg	0/8	120.mg	0/12	600.mg	0/9			
a	1358	264.mg n.s.s.	1/11	12.0mg	1/8	120.mg	1/12	600.mg	1/9			
ZINC DIBUTYLDITHIOCARBAMATE (butyl zimate) 136-23-2												
2926	1220	239.mg n.s.s.	1/17	364.mg	3/18							Innes;ntis,1968/1969
a	1220	721.mg n.s.s.	0/17	364.mg	0/18							
b	1220	261.mg n.s.s.	2/17	364.mg	3/18							
2927	1220	317.mg n.s.s.	2/18	339.mg	2/18							
a	1220	672.mg n.s.s.	1/18	339.mg	0/18							
b	1220	351.mg n.s.s.	3/18	339.mg	2/18							
2928	1220	379.mg n.s.s.	0/16	364.mg	1/18							
a	1220	721.mg n.s.s.	0/16	364.mg	0/18							
b	1220	220.mg n.s.s.	0/16	364.mg	3/18							
2929	1220	205.mg n.s.s.	0/16	339.mg	3/18							
a	1220	259.mg n.s.s.	0/16	339.mg	2/18							
b	1220	107.mg 1.03gm	0/16	339.mg	7/18							
ZINC DIETHYLDITHIOCARBAMATE (ethyl zimate) 14324-55-1												
2930	1210	68.1mg n.s.s.	0/17	36.4mg	0/17							Innes;ntis,1968/1969
a	1210	68.1mg n.s.s.	1/17	36.4mg	0/17							
b	1210	32.0mg n.s.s.	2/17	36.4mg	2/17							
2931	1210	28.4mg n.s.s.	1/18	33.9mg	2/18							
a	1210	31.7mg n.s.s.	2/18	33.9mg	2/18							
b	1210	17.3mg n.s.s.	3/18	33.9mg	5/18							
2932	1210	68.1mg n.s.s.	0/16	36.4mg	0/17							
a	1210	68.1mg n.s.s.	0/16	36.4mg	0/17							
b	1210	68.1mg n.s.s.	0/16	36.4mg	0/17							
2933	1210	15.9mg n.s.s.	0/16	33.9mg	4/17							
a	1210	63.4mg n.s.s.	0/16	33.9mg	0/17							
b	1210	11.5mg 155.mg	0/16	33.9mg	6/17							
ZINC DIMETHYLDITHIOCARBAMATE (methyl zimate) 137-30-4												
2934	1204	4.07mg n.s.s.	0/17	2.05mg	0/18							Innes;ntis,1968/1969
a	1204	4.07mg n.s.s.	1/17	2.05mg	0/18							
b	1204	4.07mg n.s.s.	2/17	2.05mg	0/18							
2935	1204	1.27mg n.s.s.	2/18	1.91mg	3/17							
a	1204	2.12mg n.s.s.	1/18	1.91mg	1/17							
b	1204	.898mg n.s.s.	3/18	1.91mg	5/17							
2936	1204	2.14mg n.s.s.	0/16	2.05mg	1/18							
a	1204	4.07mg n.s.s.	0/16	2.05mg	0/18							
b	1204	2.14mg n.s.s.	0/16	2.05mg	1/18							
2937	1204	1.28mg n.s.s.	0/16	1.91mg	2/16							
a	1204	1.76mg n.s.s.	0/16	1.91mg	1/16							
b	1204	1.01mg n.s.s.	0/16	1.91mg	3/16							
2938	1426	13.8mg 1.94gm	0/46	18.4mg	2/10							Andrianova;vpit,29,71-74;1970
a	1426	8.47mg 198.mg	1/46	18.4mg	4/10							
ZINC ETHYLENEBISTHIOCARBAMATE (zineb) 12122-67-7												
2939	1213	152.mg n.s.s.	1/17	180.mg	2/18							Innes;ntis,1968/1969
a	1213	357.mg n.s.s.	0/17	180.mg	0/18							
b	1213	130.mg n.s.s.	2/17	180.mg	3/18							
2940	1213	132.mg n.s.s.	1/18	168.mg	2/17							
a	1213	206.mg n.s.s.	2/18	168.mg	1/17							
b	1213	96.4mg n.s.s.	3/18	168.mg	4/17							
2941	1213	188.mg n.s.s.	0/16	180.mg	1/18							
a	1213	357.mg n.s.s.	0/16	180.mg	0/18							
b	1213	188.mg n.s.s.	0/16	180.mg	1/18							
2942	1213	84.0mg n.s.s.	0/16	168.mg	4/18							
a	1213	333.mg n.s.s.	0/16	168.mg	0/18							
b	1213	71.2mg 4.14gm	0/16	168.mg	5/18							
2943	1426	154.mg n.s.s.	0/46	74.9mg	0/10							Andrianova;vpit,29,71-74;1970
a	1426	57.5mg n.s.s.	1/46	74.9mg	2/10							
ZIRCONIUM (IV) SULFATE 14644-61-2												
2944	1036	8.41mg n.s.s.	15/71	.877mg	9/72							Kanisawa;canr,29,892-895;1969
a	1036	10.4mg n.s.s.	4/71	.877mg	3/72							
b	1036	7.10mg n.s.s.	24/71	.877mg	15/72							
c	1036	9.64mg n.s.s.	8/71	.877mg	5/72							

APPENDIX 1: CHEMICAL NAMES AND SYNONYMS

CAS NUMBER*	CHEMICAL NAME	CAS NUMBER*	CHEMICAL NAME
60-35-5	ACETAMIDE	1336-21-6	AMMONIUM HYDROXIDE
103-90-2	ACETAMINOPHEN	10589-74-9	1-AMYL-1-NITROSOUREA
968-81-0	ACETOHEXAMIDE	1119-68-2	n-AMYLHYDRAZINE.HCl (see n-PENTYLHYDRAZINE.HCl)
18523-69-8	ACETONE[4-(5-NITRO-2-FURYL)-2-THIAZOLYL]HYDRAZONE	15879-93-3	ANHYDROGLUCOCHLORAL
34627-78-6	1'-ACETOXYSAFROLE	101-05-3	ANILAZINE
65734-38-5	N'-ACETYL-4-(HYDROXYMETHYL)PHENYLHYDRAZINE	62-53-3	ANILINE
1078-38-2	1-ACETYL-2-ISONICOTINOYLHYDRAZINE	142-04-1	ANILINE.HCl
520-46-5	3-ACETYL-6-METHYL-2,4-PYRANDIONE	134-29-2	o-ANISIDINE.HCl
114-83-0	1-ACETYL-2-PHENYLHYDRAZINE	20265-97-8	p-ANISIDINE.HCl
4075-79-0	4-ACETYLAMINOBIHENYL	118-92-3	ANTHRANILIC ACID
28314-03-6	1-ACETYLAMINOFLUORENE	84-65-1	9,10-ANTHRAQUINONE
53-96-3	2-ACETYLAMINOFLUORENE	28300-74-5	ANTIMONY POTASSIUM TARTRATE
28322-02-3	4-ACETYLAMINOFLUORENE	60-80-0	ANTIPYRINE (see PHENAZONE)
---	ACETYLATED DIAMYLOPECTIN PHOSPHATE	86-88-4	ANTU (see 1-(1-NAPHTHYL)-2-THIOUREA)
---	ACETYLATED DISTARCH ADIPATE	8003-03-0	APC (see ASPIRIN, PHENACETIN, AND CAFFEINE)
---	ACETYLATED DISTARCH GLYCEROL	140-57-8	ARAMITE
---	ACETYLATED DISTARCH PHOSPHATE	27323-18-8	AROCLOR 1254
7008-42-6	ACRONYCINE	11096-82-5	AROCLOR 1260
107-13-1	ACRYLONITRILE	7631-89-2	ARSENATE, SODIUM
8052-16-2	ACTINOMYCIN C	1327-53-3	ARSENIC TRIOXIDE (see ARSENIUS OXIDE)
50-76-0	ACTINOMYCIN D	1327-53-3	ARSENIUS OXIDE
628-94-4	ADIPAMIDE	7784-46-8	ARSENITE, SODIUM
3688-53-7	AF-2	22839-47-0	ASPARTAME
29611-03-8	AFLATOXICOL	50-78-2	ASPIRIN
1162-65-8	AFLATOXIN B1	8003-03-0	ASPIRIN, PHENACETIN, AND CAFFEINE
---	AFLATOXIN, CRUDE	1912-24-9	ATRAZINE
101-73-5	AGERITE 150 (see p-ISOPROPOXYDIPHENYLAMINE)	51-55-8	ATROPINE
103-16-2	AGERITE ALBA (see HYDROQUINONE MONOBENZYL ETHER)	2465-27-2	AURAMINE-O
74-31-7	AGERITE DPPD (see DIPHENYL-p-PHENYLENEDIAMINE)	2303-16-4	AVADEX (see DIALLATE)
135-88-6	AGERITE POWDER (see PHENYL-beta-NAPHTHYLAMINE)	320-67-2	5-AZACYTIDINE
93-46-9	AGERITE WHITE (see sym.-dibeta-NAPHTHYL-p-PHENYLENEDIAMINE)	115-02-6	AZASERINE
54-80-8	ALDERLIN (see PRONETHALOL)	26628-22-8	AZIDE, SODIUM
51-02-5	ALDERLIN.HCl (see PRONETHALOL.HCl)	86-50-0	AZINPHOSMETHYL
116-06-3	ALDICARB	103-33-3	AZO BENZENE
309-00-2	ALDRIN	543-80-6	BARIUM ACETATE
---	ALKYLBENZENESULFONATE, LINEAR	542-88-1	BCME (see BIS-(CHLOROMETHYL) ETHER)
107-05-1	ALLYL CHLORIDE	71-43-2	BENZENE
52207-83-7	ALLYLHYDRAZINE.HCl	319-84-6	alpha-BENZENE HEXACHLORIDE (see alpha-1,2,3,4,5,6-HEXACHLOROCYCLOHEXANE)
120-78-5	ALTAX (see BENZOTHIAZYL DISULFIDE)	5351-65-5	BENZENESULFONOHYDRAZIDE
---	ALUMINUM POTASSIUM SULFATE	613-94-5	BENZHYDRAZIDE (see BENZOYL HYDRAZINE)
915-67-3	AMARANTH (see FD & C RED NO. 2)	92-87-5	BENZIDINE
102-77-2	AMAX (see N-OXYDIETHYLENEBENZOTHIAZOLE-2-SULFENAMIDE)	50-32-8	BENZO(a)PYRENE
97-56-3	2-AMINO-5-AZOTOLUENE (see o-AMINOAZOTOLUENE)	532-32-1	BENZOATE, SODIUM
75104-43-7	3-AMINO-1,4-DIMETHYL-5H-PYRIDO[4,3-b]INDOLE ACETATE	91-76-9	BENZOGUANAMINE
97-56-3	4-AMINO-2,3-DIMETHYLAZOBENZENE (see o-AMINOAZOTOLUENE)	91-64-5	1,2-BENZOPYRONE
17026-81-2	3-AMINO-4-ETHOXYACETANILIDE	51542-33-7	1-(2'-BENZOTHIAZOLYL)-3-METHYL-3-NITROSOUREA (see N-NITROSOBENZTHIAZURON)
6109-97-3	3-AMINO-9-ETHYLCARBAZOLE.HCl	120-78-5	BENZOTHIAZYL DISULFIDE
mixture	3-AMINO-9-ETHYLCARBAZOLE MIXTURE (3-amino-9-ethylcarbazole and 3-amino-9-ethylcarbazole.HCl. CAS NUMBER 132-32-1 and 6109-97-3)	95-14-7	1H-BENZOTRIAZOLE
4363-03-5	4-AMINO-3-HYDROXYBIPHENYL (see 3-HYDROXY-4-AMINOBIHENYL)	613-94-5	BENZOYL HYDRAZINE
59-05-2	4-AMINO-N10-METHYL-PTEROYLGLUTAMIC ACID (see METHOTREXATE)	50-32-8	BENZPYRENE (see BENZO(a)PYRENE)
72254-58-1	3-AMINO-1-METHYL-5H-PYRIDO[4,3-b]INDOLE ACETATE	50-32-8	3,4-BENZOPYRENE (see BENZO(a)PYRENE)
82-28-0	1-AMINO-2-METHYLANTHRAQUINONE	20570-96-1	BENZYLHYDRAZINE.2HCl
3775-55-1	2-AMINO-5-(5-NITRO-2-FURYL)-1,3,4-OXADIAZOLE	13510-49-1	BERYLLIUM SULFATE
712-68-5	2-AMINO-5-(5-NITRO-2-FURYL)-1,3,4-THIADIAZOLE	64039-27-6	beta-TGdR (see beta-THIOGUANINE DEOXYRIBOSIDE)
38514-71-5	2-AMINO-4-(5-NITRO-2-FURYL)THIAZOLE	128-37-0	BHT (see BUTYLATED HYDROXYTOLUENE)
119-34-6	4-AMINO-2-NITROPHENOL	92-52-4	BIPHENYL
2104-09-8	2-AMINO-4-(p-NITROPHENYL)THIAZOLE	108-60-1	BIS(2-CHLORO-1-METHYLETHYL) ETHER
121-66-4	2-AMINO-5-NITROTHIAZOLE	111-44-4	BIS-2-CHLOROETHYLETHETHER
18968-99-5	2-AMINO-5-PHENYL-2-OXAZOLIN-4-ONE + Mg(OH)2	---	BIS-1,4-(CHLOROMETHOXY)BUTANE
117-79-3	2-AMINOANTHRAQUINONE	13483-18-6	BIS-1,2-(CHLOROMETHOXY)ETHANE
97-56-3	o-AMINOAZOTOLUENE	---	BIS-1,6-(CHLOROMETHOXY)HEXANE
118-92-3	AMINOBENZOIC ACID (see ANTHRANILIC ACID)	56894-91-8	BIS-1,4-(CHLOROMETHOXY)-p-XYLENE
92-67-1	p-AMINOBIHENYL (see 4-AMINODIPHENYL)	542-88-1	BIS-(CHLOROMETHYL) ETHER
92-67-1	4-AMINODIPHENYL	---	4-BIS(2-HYDROXYETHYL)AMINO-2-(5-NITRO-2-THIENYL)QUINAZOLINE
3693-22-9	2-AMINODIPHENYLENE OXIDE	---	4-BIS(2-HYDROXYETHYL)AMINO-2-(2-THIENYL)QUINAZOLINE
119-34-6	p-AMINONITROPHENOL (see 4-AMINO-2-NITROPHENOL)	23746-34-1	BIS-2-HYDROXYETHYLDITHIOCARBAMIC ACID, POTASSIUM
61-82-5	3-AMINOTRIAZOLE	53609-64-6	N-BIS(2-HYDROXYPROPYL)NITROSAMINE (see N-NITROSOBIS(2-HYDROXYPROPYL)AMINE)
61-82-5	AMITROL (see 3-AMINOTRIAZOLE)	21260-46-8	BISMATE (see BISMUTH DIMETHYLDITHIOCARBAMATE)
12125-02-9	AMMONIUM CHLORIDE	21260-46-8	BISMUTH DIMETHYLDITHIOCARBAMATE
3012-65-5	AMMONIUM CITRATE	7787-59-9	BISMUTH OXYCHLORIDE
		2519-30-4	BLACK PN
		1937-37-7	C.I. DIRECT BLACK 38
		2602-46-2	C.I. DIRECT BLUE 6

CAS NUMBER*	CHEMICAL NAME	CAS NUMBER*	CHEMICAL NAME
3844-45-9	FD & C BLUE NO. 1	---	4-CHLORO-6-(2,3-XYLIDINO)-2-PYRIMIDINYLTHIO(N-beta-HYDROXYETHYL) ACETAMIDE
860-22-0	FD & C BLUE NO. 2	107-20-0	CHLOROACETALDEHYDE
109-84-2	BOF (see 2-HYDROXYETHYLHYDRAZINE)	140-49-8	4'-(CHLOROACETYL)-ACETANILIDE
99-30-9	BOTRAN (see 2,6-DICHLORO-4-NITROANILINE)	106-47-8	p-CHLOROANILINE
2519-30-4	BRILLIANT BLACK BN (see BLACK PN)	510-15-6	CHLOROBENZILATE
3844-45-9	BRILLIANT BLUE FCF (see FD & C BLUE NO. 1)	54749-90-5	2-[3-(2-CHLOROETHYL)-3-NITROSOUREIDO]-D-GLUCOPYRANOSE (see CHLOROZOTOCIN)
5160-02-1	BRILLIANT RED (see D & C RED NO. 9)	999-81-5	(2-CHLOROETHYL)TRIMETHYLAMMONIUM CHLORIDE
7758-01-2	BROMATE, POTASSIUM	67-66-3	CHLOROFORM
77-65-6	BROMODIETHYLACETYLUREA (see CARBROMAL)	107-30-2	CHLOROMETHYL METHYL ETHER
16071-86-6	C.I. DIRECT BROWN 95	6959-47-3	2-(CHLOROMETHYL)PYRIDINE.HCl
5351-65-5	BSH (see BENZENESULPHONOHYDRAZIDE)	6959-48-4	3-(CHLOROMETHYL)PYRIDINE.HCl
55-98-1	BUSULFAN (see MYLERAN)	56-75-7	CHLOROMYCETIN (see CHLORAMPHENICOL)
---	BUTACIDE (see PIPERONYL BUTOXIDE IN SOLVENT)	100-00-5	p-CHLORONITROBENZENE (see 1-CHLORO-4-NITROBENZENE)
3817-11-6	BUTYL-BUTANOL-NITROSAMINE (see N-BUTYL-N-(4-HYDROXYBUTYL)NITROSAMINE)	80-33-1	p-CHLOROPHENYL-p-CHLOROBENZENE SULFONATE
88-85-7	2-sec-BUTYL-4,6-DINITROPHENOL	150-68-5	3-(p-CHLOROPHENYL)-1,1-DIMETHYLUREA
---	N-N-BUTYL-N-FORMYLHYDRAZINE	10473-70-8	1-(4-CHLOROPHENYL)-1-PHENYL-2-PROPYNYL CARBAMATE
3817-11-6	N-BUTYL-N-(4-HYDROXYBUTYL)NITROSAMINE	2227-13-6	p-CHLOROPHENYL-2,4,5-TRICHLOROPHENYL SULFIDE
---	DI-tert-BUTYL-4-HYDROXYMETHYL PHENOL	94-20-2	1-(p-CHLOROPHENYLSULFONYL)-3-PROPYLUREA (see CHLOROPROPAMIDE)
13010-08-7	N-BUTYL-N-NITRO-N-NITROSOGUANIDINE	76-06-2	CHLOROPICRIN
136-23-2	BUTYL ZIMATE (see ZINC DIBUTYLDITHIOCARBAMATE)	683-50-1	2-CHLOROPROPANAL
128-37-0	BUTYLATED HYDROXYTOLUENE	107-05-1	CHLOROPROPENE (see ALLYL CHLORIDE)
---	1,1-DI-n-BUTYLHYDRAZINE	590-21-6	1-CHLOROPROPENE
7422-80-2	1,2-DI-n-BUTYLHYDRAZINE.2HCl	1897-45-6	CHLOROTHALONIL
56795-65-4	n-BUTYLHYDRAZINE.HCl	54749-90-5	CHLOROZOTOCIN
592-31-4	N-BUTYLUREA	94-20-2	CHLORPROPAMIDE
3068-88-0	beta-BUTYROLACTONE	101-21-3	CHLORPROPAM (see ISOPROPYL-N-(3-CHLOROPHENYL)CARBAMATE)
75-60-5	CACODYLIC ACID (see DIMETHYLARSINIC ACID)	2921-88-2	CHLORPYRIFOS (see O,O-DIETHYL-O-(3,5,6-TRICHLORO-2-PYRIDYL) PHOSPHOROTHIOATE)
543-90-8	CADMIUM ACETATE	12236-46-3	CHOCOLATE BROWN FB
35658-65-2	CADMIUM CHLORIDE MONOHYDRATE	4553-89-3	CHOCOLATE BROWN HT
14239-68-0	CADMIUM DIETHYLDITHIOCARBAMATE	1308-39-9	CHROMIC OXIDE PIGMENT
7790-84-3	CADMIUM SULPHATE	1066-30-4	CHROMIUM (III) ACETATE
58-08-2	CAFFEINE	101-21-3	CIPC (see ISOPROPYL-N-(3-CHLOROPHENYL)CARBAMATE)
8003-03-0	CAFFEINE, ASPIRIN, AND PHENACETIN (see ASPIRIN, PHENACETIN, AND CAFFEINE)	---	CLIVORINE
156-62-7	CALCIUM CYANAMIDE (see CYANAMIDE, CALCIUM)	637-07-0	CLOFIBRATE
133-06-2	CAPTAN	43054-45-1	CLOMIPHENE CITRATE
149-30-4	CAPTAX (see 2-MERCAPTOBENZOTHAZOLE)	1420-04-8	CLONITRALID
563-41-7	CARBAMYL HYDRAZINE.HCl	107-30-2	CMME (see CHLOROMETHYL METHYL ETHER)
103-03-7	1-CARBAMYL-2-PHENYLHYDRAZINE	477-30-5	COLCEMID
121-59-5	CARBARSONE	---	CONJUGATED EQUINE ESTROGENS (see PREMARIN)
63-25-2	CARBARYL	137-29-1	COPPER DIMETHYLDITHIOCARBAMATE
56-23-5	CARBON TETRACHLORIDE	10380-28-6	COPPER-8-HYDROXYQUINOLINE
60391-92-6	CARBOXYMETHYLNITROSOUREA	56-72-4	COUMAPHOS
77-65-6	CARBROMAL	91-64-5	COUMARIN (see 1,2-BENZOPYRONE)
3567-69-9	CARMOISINE (see C.I. FOOD RED 3)	102-50-1	m-CRESIDINE
---	CARRAGEENAN, ACID-DEGRADED	120-71-8	p-CRESIDINE
9000-07-1	CARRAGEENAN, NATIVE	137-29-1	CUMATE (see COPPER DIMETHYLDITHIOCARBAMATE)
999-81-5	CCC (see (2-CHLOROETHYL)TRIMETHYLAMMONIUM CHLORIDE)	135-20-6	CUPFERRON
122-34-9	CDT (see SIMAZINE)	156-62-7	CYANAMIDE, CALCIUM
9004-32-4	CELLULOSE CARBOXYMETHYL ETHER, SODIUM (see EDIFAS B)	139-05-9	CYLAMATE, SODIUM
474-25-9	CHENODEOXYCHOLIC ACID	12663-46-6	CYCLOCHLOROTINE
15879-93-3	alpha-CHLORALOSE (see ANHYDROGLUCOCHLORAL)	95-33-0	N-CYCLOHEXYL-2-BENZOTHAZOLE SULFENAMIDE
133-90-4	CHLORAMBEN	4998-76-9	CYCLOHEXYLAMINE.HCl
305-03-3	CHLORAMBUCIL	19834-02-7	CYCLOHEXYLAMINE SULFATE
56-75-7	CHLORAMPHENICOL	50-18-0	CYCLOPHOSPHAMIDE
118-75-2	CHLORANIL	60-11-7	DAB (see N,N-DIMETHYL-4-AMINOAZOBENZENE)
106-47-8	4-CHLORANILIC (see p-CHLOROANILINE)	4342-03-4	DACARBAZINE
57-74-9	CHLORDANE	1897-45-6	DACONIL (see CHLOROTHALONIL)
143-50-0	CHLORDECONE (see KEPONE)	1596-84-5	DAMINOZIDE
80-33-1	CHLORFENSON (see p-CHLOROPHENYL-p-CHLOROBENZENE SULFONATE)	80-08-0	DAPSONE
7782-50-5	CHLORINE	58-14-0	DARAPRIN (see PYRIMETHAMINE)
302-22-7	CHLORMADINONE ACETATE	96-12-8	DBCP (see 1,2-DIBROMO-3-CHLOROPROPANE)
101-79-1	4-CHLORO-4'-AMINODIPHENYLETHER	488-41-5	DBM (see DIBROMOMANNITOL)
---	2-CHLORO-5-(3,5-DIMETHYLPYPERIDINOSULFONYL)BENZOIC ACID	91-94-1	DCB (see 3,3'-DICHLOROBENZIDINE)
97-00-7	1-CHLORO-2,4-DINITROBENZENE	33857-26-0	DCDD (see 2,7-DICHLORODIBENZO-p-DIOXIN)
88-73-3	1-CHLORO-2-NITROBENZENE	53-19-0	o,p'-DDD
100-00-5	1-CHLORO-4-NITROBENZENE	72-54-8	p,p'-DDD
5131-60-2	4-CHLORO-m-PHENYLENEDIAMINE	72-55-9	p,p'-DDE
95-83-0	4-CHLORO-o-PHENYLENEDIAMINE	50-29-3	DDT
61702-44-1	2-CHLORO-p-PHENYLENEDIAMINE SULFATE	62-73-7	DDVP (see DICHLORVOS)
95-74-9	3-CHLORO-p-TOLUIDINE	576-68-1	DEGRANOL (see MANNITOL NITROGEN MUSTARD)
95-79-4	5-CHLORO-o-TOLUIDINE	520-46-5	DEHYDROACETIC ACID (see 3-ACETYL-6-METHYL-2,4-PYRANDIONE)
3165-93-3	4-CHLORO-o-TOLUIDINE.HCl	55-18-5	DEN (see N-NITROSODIETHYLAMINE)
50892-23-4	[4-CHLORO-6-(2,3-XYLIDINO)-2-PYRIMIDINYLTHIO]ACETIC ACID	64039-27-6	beta-2'-DEOXY-6-THIOGUANOSINE MONOHYDRATE (see beta-THIOGUANINE DEOXYRIBOSIDE)

CAS NUMBER ^a	CHEMICAL NAME	CAS NUMBER ^a	CHEMICAL NAME
56-53-1	DES (see DIETHYLSTILBESTROL)	94-58-6	DIHYDROSAFROLE
131-01-1	DESERPIDINE	60-51-5	DIMETHOATE
---	N-1-DIACETAMIDOFLUORENE	828-00-2	DIMETHOXANE
2303-16-4	DIALATE	5803-51-0	2,5-DIMETHOXY-4'-AMINOSTILBENE
720-69-4	4,6-DIAMINO-2-(5-NITRO-2-FURYL)-s-TRIAZINE	54150-69-5	2,4-DIMETHOXYANILINE.HCl
39156-41-7	2,4-DIAMINOANISOLE SULFATE	91-93-0	3,3'-DIMETHOXYBENZIDINE-4,4'-DIISOCYANATE
7411-49-6	3,3'-DIAMINO BENZIDINE.4HCl (see 3,3',4,4'-TETRAAMINOBIPHENYL.4HCl)	1146-71-0	5,7-DIMETHOXYCYCLOPENTENE[c]COUMARIN
2243-62-1	1,5-DIAMINONAPHTHALENE (see 1,5-NAPHTHALENE DIAMINE)	---	5,7-DIMETHOXYCYCLOPENTENONE[2,3-c]COUMARIN
95-80-7	2,4-DIAMINOTOLUENE	---	5,7-DIMETHOXYCYCLOPENTENONE[3,2-c]COUMARIN
636-23-7	2,4-DIAMINOTOLUENE.2HCl	60-11-7	N,N-DIMETHYL-4-AMINOAZOBENZENE
6369-59-1	2,5-DIAMINOTOLUENE SULFATE	57-97-6	9,10-DIMETHYL-1,2-BENZANTHRACENE (see 7,12-DIMETHYLBENZ(a)ANTHRACENE)
6358-85-6	DIARYLANILIDE YELLOW (see C.I. PIGMENT YELLOW 12)	3851-16-9	N,N'-DIMETHYL-N,N'-DINITROSOPHTHALAMIDE
333-41-5	DIAZINON	59-35-8	4,6-DIMETHYL-2-(5-NITRO-2-FURYL)PYRIMIDINE
53-70-3	DIBENZ(a,h)ANTHRACENE	551-92-8	1,2-DIMETHYL-5-NITROIMIDAZOLE
262-12-4	DIBENZO-p-DIOXIN	120-61-6	DIMETHYL TEREPHTHALATE
4106-66-5	3-DIBENZOFURANAMINE	55738-54-0	trans-2-[(DIMETHYLAMINO)METHYLIMINO]-5-[2-(5-NITRO-2-FURYL)VINYL]-1,3,4-OXADIAZOLE
96-12-8	1,2-DIBROMO-3-CHLOROPROPANE	6120-10-1	4-DIMETHYLAMINO-3,5-XYLENOL
10318-26-0	DIBROMODULCITOL	75-60-5	DIMETHYLARSINIC ACID
106-93-4	1,2-DIBROMOETHANE	57-97-6	7,12-DIMETHYLBENZ(a)ANTHRACENE
488-41-5	DIBROMOMANNITOL	79-44-7	DIMETHYLCARBAMOYL CHLORIDE (see DIMETHYLCARBAMYL CHLORIDE)
56654-52-5	1,3-DIBUTYL-1-NITROSOUREA	79-44-7	DIMETHYLCARBAMYL CHLORIDE
924-16-3	DIBUTYLNITROSAMINE (see NITROSODIBUTYLAMINE)	598-64-1	DIMETHYLDITHIOCARBAMIC ACID, DIMETHYLAMINE
1067-33-0	DIBUTYLTIN DIACETATE	57-14-7	1,1-DIMETHYLHYDRAZINE
4342-03-4	DIC (see DACARBAZINE)	306-37-6	1,2-DIMETHYLHYDRAZINE.2HCl
117-80-6	DICHLONE (see 2,3-DICHLORO-1,4-NAPHTHOQUINONE)	26049-69-4	2-(2,2-DIMETHYLHYDRAZINO)-4-(5-NITRO-2-FURYL)THIAZOLE
51-75-2	DICHLOREN (see NITROGEN MUSTARD)	4164-28-7	DIMETHYLNITRAMINE
8001-50-1	DICHLORICIDE MOTHPROOFER (see STROBANE)	62-75-9	DIMETHYLNITROSAMINE (see N-NITROSODIMETHYLAMINE)
101-14-4	3,3'-DICHLORO-4,4'-DIAMINODIPHENYLMETHANE (see 4,4'-METHYLENE-BIS(2-CHLOROANILINE))	62-75-9	N,N-DIMETHYLNITROSAMINE (see N-NITROSODIMETHYLAMINE)
3883-43-0	2,3-DICHLORO-p-DIOXANE	6119-92-2	DINITRO(1-METHYLHEPTYL)PHENYL CROTONATE
87-56-9	alpha,beta-DICHLORO-beta-FORMYLACRYLIC ACID	51-28-5	2,4-DINITROPHENOL
2164-09-2	3,4'-DICHLORO-2-METHYLACRYLANILIDE	55557-00-1	DINITROSOHOMOPIPERAZINE
51-75-2	2,2'-DICHLORO-N-METHYLETHYLAMINE (see NITROGEN MUSTARD)	101-25-7	N,N-DINITROSOPENTAMETHYLENETETRAMINE
117-80-6	2,3-DICHLORO-1,4-NAPHTHOQUINONE	140-79-4	DINITROSOPIPERAZINE
99-30-9	2,6-DICHLORO-4-NITROANILINE	121-14-2	2,4-DINITROTOLUENE
91-94-1	3,3'-DICHLOROBENZIDINE	123-91-1	1,4-DIOXANE
110-57-6	trans-1,4-DICHLOROBUTENE-2	123-91-1	p-DIOXANE (see 1,4-DIOXANE)
33857-26-0	2,7-DICHLORODIBENZO-p-DIOXIN	78-34-2	DIOXATHION
75-34-3	1,1-DICHLOROETHANE	1746-01-6	DIOXIN (see 2,3,7,8-TETRACHLORODIBENZO-p-DIOXIN)
107-06-2	1,2-DICHLOROETHANE	---	DIPENTAMETHYLENETHIURAM HEXASULFIDE
120-36-5	2-(2,4-DICHLOROPHENOXY)PROPIONIC ACID (see alpha-(2,4-DICHLOROPHENOXY)PROPIONIC ACID)	74-31-7	DIPHENYL-p-PHENYLENEDIAMINE
120-36-5	alpha-(2,4-DICHLOROPHENOXY)PROPIONIC ACID	86-29-3	DIPHENYLACETONITRILE
6965-71-6	alpha-(2,5-DICHLOROPHENOXY)PROPIONIC ACID	102-09-0	DIPHENYLCARBONATE
94-75-7	2,4-DICHLOROPHENOXYACETIC ACID	57-41-0	5,5-DIPHENYLHYDANTOIN
94-80-4	2,4-DICHLOROPHENOXYACETIC ACID, n-BUTYL ESTER	86-30-6	DIPHENYLNITROSAMINE (see N-NITROSODIPHENYLAMINE)
25168-26-7	2,4-DICHLOROPHENOXYACETIC ACID, ISOCTYL ESTER	---	N,N-DIPROPYL-4-(4'-PYRIDYL-1'-OXIDE)AZOANILINE
94-11-1	2,4-DICHLOROPHENOXYACETIC ACID, ISOPROPYL ESTER	142-59-6	DISODIUM ETHYLENEBISDITHIOCARBAMATE (see ETHYLENEBISDITHIOCARBAMATE, DISODIUM)
330-54-1	3-(3,4-DICHLOROPHENYL)-1,1-DIMETHYLUREA	7757-82-6	DISODIUM SULFATE (see SULFATE, SODIUM)
97-16-5	2,4-DICHLOROPHENYLBENZENE SULFONATE	97-77-8	DISULFIRAM (see TETRAETHYLTHIURAM DISULFIDE)
62-73-7	DICHLORVOS	142-59-6	DITHANE (see ETHYLENEBISDITHIOCARBAMATE, DISODIUM)
115-32-2	DICOPOL	142-46-1	2,5-DITHIOBIUREA
2164-09-2	DICRYL (see 3,4'-DICHLORO-2-METHYLACRYLANILIDE)	79-40-3	DITHIOOXAMIDE
1212-29-9	N,N'-DICYCLOHEXYLTHIOUREA	330-54-1	DIURON (see 3-(3,4-DICHLOROPHENYL)-1,1-DIMETHYLUREA)
81-21-0	DICYCLOPENTADIENE DIOXIDE	1596-84-5	DMASA (see DAMINOZIDE)
60-57-1	DIELDRIN	57-97-6	DMBA (see 7,12-DIMETHYLBENZ(a)ANTHRACENE)
13366-73-9	DIELDRIN, PHOTO-	62-75-9	DMN (see N-NITROSODIMETHYLAMINE)
298-18-0	D,L-DIEPOXYBUTANE	120-61-6	DMT (see DIMETHYL TEREPHTHALATE)
7316-37-2	DIETHYL-beta,gamma-EPOXYPROPYLPHOSPHONATE	2439-10-3	n-DODECYLGUANIDINE ACETATE
7347-49-1	N,N-DIETHYL-4-(4'-PYRIDYL-1'-OXIDE)AZOANILINE	2439-10-3	DODINE (see n-DODECYLGUANIDINE ACETATE)
2921-88-2	O,O-DIETHYL-O-(3,5,6-TRICHLORO-2-PYRIDYL)PHOSPHOROTHIOATE	90-43-7	DOWICIDE-1 (see o-PHENYLPHENOL)
685-91-6	DIETHYLACETAMIDE	88-06-2	DOWICIDE-2S (see 2,4,6-TRICHLOROPHENOL)
148-18-5	DIETHYLDITHIOCARBAMATE TRIHYDRATE, SODIUM (see SODIUM DIETHYLDITHIOCARBAMATE TRIHYDRATE)	87-86-5	DOWICIDE-7 (see 2,3,4,5,6-PENTACHLOROPHENOL)
111-46-6	DIETHYLENE GLYCOL	95-33-0	DURAX (see N-CYCLOHEXYL-2-BENZOTHAZOLE SULFENAMIDE)
617-84-5	DIETHYLFORMAMIDE	106-93-4	EDB (see 1,2-DIBROMOETHANE)
55-18-5	DIETHYLNITROSAMINE (see N-NITROSODIETHYLAMINE)	107-06-2	EDC (see 1,2-DICHLOROETHANE)
55-18-5	N,N-DIETHYLNITROSAMINE (see N-NITROSODIETHYLAMINE)	9004-59-5	EDIFAS A
56-53-1	DIETHYLSTILBESTROL	9004-32-4	EDIFAS B
105-55-5	N,N'-DIETHYLTHIOUREA	150-38-9	EDTA (see EDTA, TRISODIUM SALT TRIHYDRATE)
628-36-4	1,2-DIFORMYLHYDRAZINE	150-38-9	EDTA, TRISODIUM SALT TRIHYDRATE
33389-33-2	1,2-DIHYDRO-2-(5-NITRO-2-THIENYL)QUINAZOLIN-4(3H)-ONE	316-42-7	EMETINE.2HCl
3276-41-3	3,6-DIHYDRO-2-NITROSO-2H-1,2-OXAZINE	55965-13-4	EMULSIFIER YN
123-33-1	1,2-DIHYDRO-3,6-PYRIDAZINEDIONE (see MALEIC HYDRAZIDE)	115-29-7	ENDOSULFAN
		50-18-0	ENDOXAN (see CYCLOPHOSPHAMIDE)

CAS NUMBER ^a	CHEMICAL NAME	CAS NUMBER ^a	CHEMICAL NAME
72-20-8	ENDRIN	77-06-5	GIBBERELIC ACID
8015-30-3	ENOVID	96-24-2	GLYCEROL alpha-MONOCHLOROHYDRIN
---	ENOVID-E	765-34-4	GLYCIDALDEHYDE
106-89-8	EPICHLOROXYDRIN	1072-53-3	GLYCOL SULFATE (see ETHYLENE GLYCOL)
16423-68-0	ERYTHROSINE (see FD & C RED NO. 3)	3741-38-6	GLYCOL SULFITE
50-28-2	ESTRADIOL	4680-78-8	FD & C GREEN NO. 1
50-28-2	ESTRADIOL-17beta (see ESTRADIOL)	5141-20-8	FD & C GREEN NO. 2
22966-79-6	ESTRADIOL MUSTARD	2353-45-9	FD & C GREEN NO. 3
536-33-4	ETHIONAMIDE	126-07-8	GRISOFULVIN
13073-35-3	ETHIONINE	4680-78-8	GUINEA GREEN B (see FD & C GREEN NO. 1)
64-17-6	ETHYL ALCOHOL	86-50-0	GUSATHION (see AZINPHOSMETHYL)
105-36-2	ETHYL BROMOACETATE	118-74-1	HCB (see HEXACHLOROBENZENE)
14239-68-0	ETHYL CADMATE (see CADMIUM DIETHYLDITHIOCARBAMATE)	mixture	HCDD MIXTURE (1,2,3,7,8,9-hexachlorodibenzo-p-dioxin and 1,2,3,6,7,8-isomer. CAS NUMBER 19408-74-3 and 57653-86-7)
637-07-0	ETHYL-alpha-p-CHLOROPHENOXYISOBUTYRATE (see CLOFIBRATE)	517-28-2	HEMATOXYLIN
2629-59-6	S-ETHYL-L-CYSTEINE	76-44-8	HEPTACHLOR
72-56-0	p,p'-ETHYL-DDD	1121-92-2	HEPTAMETHYLENEIMINE
74920-78-8	N-ETHYL-N-FORMYLHYDRAZINE	1241-27-6	HEPTYLAMINE
---	N-ETHYL-N'-NITRO-N-NITROSOGUANIDINE	2163-79-3	HERCULES-7531 (see 3-(HEXAHYDRO-4,7-METHANOINDAN-5-YL)-1,1-DIMETHYLUREA)
5456-28-0	ETHYL SELENAC (see SELENIUM DIETHYLDITHIOCARBAMATE)	87-51-4	HETEROAUXIN (see INDOLE-3-ACETIC ACID)
20941-65-5	ETHYL TELLURAC	118-74-1	HEXACHLOROBENZENE
97-77-8	ETHYL TUADS (see TETRAETHYLTHIURAM DISULFIDE)	87-68-3	HEXACHLOROBUTADIENE
14324-55-1	ETHYL ZIMATE (see ZINC DIETHYLDITHIOCARBAMATE)	319-84-6	alpha-1,2,3,4,5,6-HEXACHLOROCYCLOHEXANE
106-93-4	ETHYLENE DIBROMIDE (see 1,2-DIBROMOETHANE)	319-85-7	beta-1,2,3,4,5,6-HEXACHLOROCYCLOHEXANE
107-06-2	ETHYLENE DICHLORIDE (see 1,2-DICHLOROETHANE)	58-89-9	gamma-1,2,3,4,5,6-HEXACHLOROCYCLOHEXANE
1072-53-3	ETHYLENE GLYCOL	67-72-1	HEXACHLOROETHANE
151-56-4	ETHYLENE IMINE	70-30-4	HEXACHLOROPHENE
96-45-7	ETHYLENE THIOUREA	2163-79-3	3-(HEXAHYDRO-4,7-METHANOINDAN-5-YL)-1,1-DIMETHYLUREA
120-93-4	ETHYLENE UREA	100-97-0	HEXAMETHYLENETETRAMINE
142-59-6	ETHYLENEBISDITHIOCARBAMATE, DISODIUM	531-18-0	HEXAMETHYLMELAMINE
106-87-6	1-ETHYLENEOXY-3,4-EPOXYCYCLOHEXANE	628-02-4	HEXANAMIDE
18413-14-4	ETHYLHYDRAZINE.HCl	26049-68-3	HNT (see 2-HYDRAZINO-4-(5-NITRO-2-FURYL)THIAZOLE)
38434-77-4	ETHYLNITROSOXYANAMIDE	302-01-2	HYDRAZINE
842-00-2	4-ETHYLSULPHONYLNAPHTHALENE-1-SULFONAMIDE	10034-93-2	HYDRAZINE SULFATE
297-76-7	ETHYNODIOL DIACETATE	26049-71-8	2-HYDRAZINO-4-(p-AMINOPHENYL)THIAZOLE
8056-92-6	ETHYNODIOL DIACETATE/ETHINYL ESTRADIOL [10:1] (see OVULEN)	26049-68-3	2-HYDRAZINO-4-(5-NITRO-2-FURYL)THIAZOLE
96-45-7	ETU (see ETHYLENE THIOUREA)	26049-70-7	2-HYDRAZINO-4-(p-NITROPHENYL)THIAZOLE
470-82-6	EUCALYPTOL	34176-52-8	2-HYDRAZINO-4-PHENYLTHIAZOLE
24554-26-5	FANFT (see N-[4-(5-NITRO-2-FURYL)-2-THIAZOLYL]FORMAMIDE)	619-67-0	p-HYDRAZINOBENZOIC ACID
2353-45-9	FAST GREEN FCF (see FD & C GREEN NO. 3)	122-66-7	HYDRAZOBENZENE
140-56-7	FENAMINOSULF, FORMULATED	50-23-7	HYDROCORTISONE
55-38-9	FENTHION	7722-84-1	HYDROGEN PEROXIDE
14484-64-1	FERBAM (see FERRIC DIMETHYLDITHIOCARBAMATE)	103-16-2	HYDROQUINONE MONOBENZYL ETHER
14484-64-1	FERRIC DIMETHYLDITHIOCARBAMATE	53-95-2	N-HYDROXY-N-ACETYL-2-AMINOFLUORENE (see N-HYDROXY-2-ACETYLAMINOFLUORENE)
mixture	FERRIC NITROSODIMETHYLDITHIOCARBAMATE AND TETRAMETHYLTHIURAM DISULFIDE (see VANGUARD GF)	4463-22-3	3-HYDROXY-4-ACETYLAMINOBIOPHENYL
363-17-7	N-(2-FLUORENYL)-2,2,2-TRIFLUOROACETAMIDE	53-95-2	N-HYDROXY-2-ACETYLAMINOFLUORENE
53-96-3	FLUORENYLACETAMIDE (see 2-ACETYLAMINOFLUORENE)	4363-03-5	3-HYDROXY-4-AMINOBIOPHENYL
28314-03-6	N-1-FLUORENYLACETAMIDE (see 1-ACETYLAMINOFLUORENE)	53-95-2	HYDROXY-N-2-FLUORENYLACETAMIDE (see N-HYDROXY-2-ACETYLAMINOFLUORENE)
53-96-3	N-2-FLUORENYLACETAMIDE (see 2-ACETYLAMINOFLUORENE)	103-90-2	p-HYDROXYACETANILIDE (see ACETAMINOPHEN)
28322-02-3	N-4-FLUORENYLACETAMIDE (see 4-ACETYLAMINOFLUORENE)	5036-03-3	1-(2-HYDROXYETHYL)-3-[(5-NITROFURFURYLIDENE)AMINO]-2-IMIDAZOLIDINONE
---	N-1-FLUORENYLDIACETAMIDE (see N-1-DIACETAMIDOFLUORENE)	13743-07-2	1-(2-HYDROXYETHYL)-1-NITROSOUREA
7681-49-4	FLUORIDE, SODIUM	33389-36-5	4-(2-HYDROXYETHYLAMINO)-2-(5-NITRO-2-THIENYL)QUINAZOLINE
324-93-6	4'-FLUORO-4-AMINODIPHENYL	109-84-2	2-HYDROXYETHYLHYDRAZINE
398-32-3	N-(4'-FLUORO-4-BIPHENYLYL)ACETAMIDE (see N-4-(4'-FLUOROBIPHENYL)ACETAMIDE)	---	HYDROXYPROPYL DISTARCH GLYCEROL
398-32-3	N-4-(4'-FLUOROBIPHENYL)ACETAMIDE	148-24-3	8-HYDROXYQUINOLINE
51-21-8	5-FLUOROURACIL	5208-87-7	1'-HYDROXYSAFROLE
3570-75-0	FNT [†] (see FORMIC ACID 2-[4-(5-NITRO-2-FURYL)-2-THIAZOLYL]HYDRAZIDE)	21416-87-5	ICRF-159
133-07-3	POLPET (see N-(TRICHLOROMETHYLTHIO)PHTHALIMIDE)	120-93-4	2-IMIDAZOLIDINONE (see ETHYLENE UREA)
31873-81-1	FORMIC ACID 2-[4-(2-FURYL)-2-THIAZOLYL]HYDRAZIDE	3458-22-8	3,3'-IMINOBIS-1-PROPANOL DIMETHANESULFONATE (ESTER).HCl (IPD)
32852-21-4	FORMIC ACID 2-(4-METHYL-2-THIAZOLYL)HYDRAZIDE	32807-00-4	IMINODIACETIC ACID, MONOSODIUM
3570-75-0	FORMIC ACID 2-[4-(5-NITRO-2-FURYL)-2-THIAZOLYL]HYDRAZIDE	860-22-0	INDIGO CARMINE (see FD & C BLUE NO. 2)
140-56-7	FORMULATED FENAMINOSULF (see FENAMINOSULF, FORMULATED)	87-51-4	INDOLE-3-ACETIC ACID
2302-84-3	1-FORMYL-3-THIOSEMICARBAZIDE	54-85-3	INH (see ISONIAZID)
624-84-0	FORMYLHYDRAZINE	75-48-8	IODIFORM
2411-74-7	2-FURALDEHYDE SEMICARBAZONE	122-42-9	IPC (see ISOPROPYL-N-PHENYL CARBAMATE)
98-01-1	FURFURAL	3458-22-8	IPD (see 3,3'-IMINOBIS-1-PROPANOL DIMETHANESULFONATE (ESTER).HCl (IPD))
3688-53-7	2-(2-FURYL)-3-(5-NITRO-2-FURYL)ACRYLAMIDE (see AF-2)	297-78-9	ISOBENZAN (see TELDRIN)
3688-53-7	FURYLURAMIDE (see AF-2)	5461-85-8	N-ISOBUTYL-N'-NITRO-N-NITROSOGUANIDINE
97-16-5	GENITE-R99 (see 2,4-DICHLOROPHENYLBENZENE SULFONATE)	1.19-38-0	ISOLAN (see 1-ISOPROPYL-3-METHYL-8-PYRAZOLYLDIMETHYL CARBAMATE)
---	GERMANATE, SODIUM	54-85-3	ISONIAZID
139-40-2	GESAMIL (see PROPANINE)	55-22-1	ISONICOTINIC ACID

CAS NUMBER*	CHEMICAL NAME	CAS NUMBER*	CHEMICAL NAME
54-85-3	ISONICOTINIC ACID HYDRAZIDE (see ISONIAZID)	137-30-4	METHYL ZIMATE (see ZINC DIMETHYLDITHIOCARBAMATE)
---	ISONICOTINIC ACID VANILLYLDIENEHYDRAZIDE	---	(N-6)-METHYLADENINE
3778-73-2	ISOPHOSPHAMIDE	---	(N-6)-METHYLADENOSINE
101-73-5	p-ISOPROPOXYDIPHENYLAMINE	mixture	METHYLAZOXYMETHANOL ACETATE AND CYCASIN MIXTURE (CAS NUMBER 592-61-1 and 14901-08-7)
101-21-3	ISOPROPYL-N-(3-CHLOROPHENYL)CARBAMATE	56-49-5	METHYLCHOLANTHRENE (see 3-METHYLCHOLANTHRENE)
119-38-0	1-ISOPROPYL-3-METHYL- <i>s</i> -PYRAZOLYLDIMETHYL CARBAMATE	56-49-5	3-METHYLCHOLANTHRENE
122-42-9	ISOPROPYL-N-PHENYL CARBAMATE	101-14-4	4,4'-METHYLENE-BIS(2-CHLOROANILINE)
120-58-1	ISOSAFROLE	64049-29-2	4,4'-METHYLENE-BIS(2-CHLOROANILINE).2HCI
6119-92-2	KARATHANE (see DINITRO(1-METHYLHEPTYL)PHENYL CROTONATE)	838-88-0	4,4'-METHYLENE-BIS(2-METHYLANILINE)
330-54-1	KARMEX (see 3-(3,4-DICHLOROPHENYL)-1,1-DIMETHYLUREA)	101-61-1	4,4'-METHYLENEBIS(N,N-DIMETHYL)BENZENAMINE
115-32-2	KELTHANE (see DICOFOL)	471-29-4	METHYLGUANIDINE
143-50-0	KEPONE	578-76-7	7-METHYLGUANINE
303-34-4	LASIOCARPINE	60-34-4	METHYLHYDRAZINE
301-04-2	LEAD ACETATE	302-15-8	METHYLHYDRAZINE SULFATE
1335-32-6	LEAD ACETATE, BASIC	115-09-3	METHYLMERCURIC ACETATE (see MERCURYMETHYLCHLORIDE)
19010-66-3	LEAD DIMETHYLDITHIOCARBAMATE	115-09-3	METHYLMERCURY CHLORIDE (see MERCURYMETHYLCHLORIDE)
1335-32-6	LEAD SUBACETATE (see LEAD ACETATE, BASIC)	---	(N-6)-(METHYLNITROSO)ADENINE
19010-66-3	LEDATE (see LEAD DIMETHYLDITHIOCARBAMATE)	---	(N-6)-(METHYLNITROSO)ADENOSINE
---	LEUPEPTIN	56-04-2	METHYLTHIOURACIL
5141-20-8	LIGHT GREEN SF YELLOWISH (see FD & C GREEN NO. 2)	5800-19-1	METIAPINE
58-89-9	LINDANE (see gamma-1,2,3,4,5,6-HEXACHLOROCYCLOHEXANE)	443-48-1	METRONIDAZOLE
434-13-9	LITHOCHOLIC ACID	315-18-4	MEXACARBATE
21884-44-6	LUTROSKYRIN	90-94-8	MICHLER'S KETONE
8065-91-6	LUTESTRAL	137-30-4	MILBAM (see ZINC DIMETHYLDITHIOCARBAMATE)
632-99-5	MAGENTA I (see ROSANILINE.HCl)	2385-85-5	MIREX
569-61-9	p-MAGENTA (see p-ROSANILINE.HCl)	39801-14-4	MIREX, PHOTO-
18968-99-5	MAGNESIUM PEMOLINE (see 2-AMINO-5-PHENYL-2-OXAZOLIN-4-ONE + Mg(OH) ₂)	126-85-2	MITOMEN (see NITROGEN MUSTARD N-OXIDE)
1634-78-2	MALAOXON	50-07-7	MITOMYCIN-C
121-75-5	MALATHION	66-27-3	MMS (see METHYL METHANESULFONATE)
1634-78-2	MALATHION-O-ANALOG (see MALAOXON)	70-25-7	MNNG (see N-METHYL-N'-NITRO-N-NITROSOGUANIDINE)
123-33-1	MALEIC HYDRAZIDE	684-93-5	MNU (see N-NITROSO-N-METHYLUREA)
mixture	MAM ACETATE AND CYCASIN MIXTURE (see METHYLAZOXYMETHANOL ACETATE AND CYCASIN MIXTURE)	101-14-4	MOCA (see 4,4'-METHYLENE-BIS(2-CHLOROANILINE))
12427-38-2	MANEB (see MANGANESE ETHYLENEBISTHIOCARBAMATE)	79-11-8	MONOCHLOROACETIC ACID
12427-38-2	MANGANESE ETHYLENEBISTHIOCARBAMATE	32607-00-4	MONOSODIUM IMINODIACETIC ACID (see IMINODIACETIC ACID, MONOSODIUM)
576-68-1	MANNITOL NITROGEN MUSTARD	150-68-5	MONURON (see 3-(p-CHLOROPHENYL)-1,1-DIMETHYLUREA)
148-82-3	MELPHALAN	58139-48-3	4-MORPHOLINO-2-(5-NITRO-2-THIENYL)QUINAZOLINE
15356-70-4	dl-MENTHOL	3031-51-4	1-5-MORPHOLINOMETHYL-3-[(5-NITROFURFURYLIDENE)AMINO]-2-OXAZOLIDINONE.HCl
67-98-1	MER-25	87-56-9	MUCOCHLORIC ACID (see alpha,beta-DICHLORO-beta-FORMYLACRYLIC ACID)
149-30-4	2-MERCAPTOBENZOTHAZOLE	55-98-1	MYLERAN
155-04-4	2-MERCAPTOBENZOTHAZOLE, ZINC	142-59-6	NABAM (see ETHYLENEBISDITHIOCARBAMATE, DISODIUM)
50-44-2	6-MERCAPTOPYRURINE	86-86-2	1-NAPHTHALENE ACETAMIDE
7487-94-7	MERCURIC CHLORIDE	86-87-3	1-NAPHTHALENE ACETIC ACID
62-38-4	MERCURY (II) ACETATE	2243-62-1	1,5-NAPHTHALENEDIAMINE
115-09-3	MERCURYMETHYLCHLORIDE	1465-25-4	N-(1-NAPHTHYL)ETHYLENEDIAMINE.2HCI
72-33-3	MESTRANOL	93-46-9	sym.-dibeta-NAPHTHYL-p-PHENYLENEDIAMINE
57-39-6	METEPA	86-88-4	1-(1-NAPHTHYL)-2-THIOUREA
60-56-0	METHIMAZOLE	91-59-8	2-NAPHTHYLAMINE
59-05-2	METHOTREXATE	91-59-8	beta-NAPHTHYLAMINE (see 2-NAPHTHYLAMINE)
5834-17-3	2-METHOXY-3-AMINODIBENZOFURAN	2611-82-7	NEW COCCINE (see SX PURPLE)
5834-17-3	2-METHOXY-3-DIBENZOFURANAMINE (see 2-METHOXY-3-AMINODIBENZOFURAN)	531-82-8	NFTA (see N-[4-(5-NITRO-2-FURYL)-2-THIAZOLYL]ACETAMIDE)
72-43-5	METHOXYCHLOR	7440-02-0	NICKEL
1701-77-5	METHOXYPHENYLACETIC ACID	373-02-4	NICKEL (II) ACETATE
6294-89-9	METHYL CARBAZATE	13927-77-0	NICKEL DIBUTYLDITHIOCARBAMATE
---	1-METHYL-1,4-DIHYDRO-7-[2-(5-NITROFURYL)VINYLY]-4-OXO-1,8-NAPHTHYRIDINE-3-CARBOXYLATE, POTASSIUM	1420-04-8	NICLOSAMIDE (see CLONITRALID)
99-80-9	N-METHYL-N,4-DINITROSOANILINE	54-11-5	NICOTINE
9004-59-5	METHYL ETHYL CELLULOSE (see EDIFAS A)	553-53-7	NICOTINIC ACID HYDRAZIDE
758-17-8	N-METHYL-N-FORMYLHYDRAZINE	---	NIGROSINE
66-27-3	METHYL METHANESULFONATE	12034-09-2	NIOBATE, SODIUM
70-25-7	N-METHYL-N'-NITRO-N-NITROSOGUANIDINE	139-94-6	NITHAZIDE
129-15-7	2-METHYL-1-NITROANTHRAQUINONE	7631-99-4	NITRATE, SODIUM
21638-36-8	4-METHYL-1-[(5-NITROFURFURYLIDENE)AMINO]-2-IMIDAZOLIDINONE	10102-43-9	NITRIC OXIDE
16899-10-8	4-(4-N-METHYL-N-NITROSAMINOSTYRYL)QUINOLINE	139-13-9	NITRILOTRIACETIC ACID
83412-06-6	N-METHYL-N-NITROSOBENZAMIDE	18662-53-8	NITRILOTRIACETIC ACID, TRISODIUM SALT, MONOHYDRATE
---	N-(N-METHYL-N-NITROSOCARBAMOYL)-L-ORNITHINE	7632-00-0	NITRITE, SODIUM
14026-03-0	R(-)-2-METHYL-N-NITROSOPIPERIDINE	1777-84-0	3-NITRO-p-ACETOPHENETIDE
36702-44-0	S(+)-2-METHYL-N-NITROSOPIPERIDINE	99-59-2	5-NITRO-o-ANISIDINE
684-93-5	N-METHYL-N-NITROSOUREA (see N-NITROSO-N-METHYLUREA)	59-87-0	5-NITRO-2-FURALDEHYDE SEMICARBAZONE
140-56-7	METHYL ORANGE B (see FENAMINOSULF, FORMULATED)	772-43-0	5-NITRO-2-FURAMIDOXIME
298-00-0	METHYL PARATHION	---	5-NITRO-2-FURANMETHANEDIOL DIACETATE
614-00-6	METHYL-PHENYL-NITROSAMINE (see NITROSOMETHYLANILINE)	75198-31-1	3-(5-NITRO-2-FURYL)-IMIDAZO(1,2-alpha)PYRIDINE
144-34-3	METHYL SELENAC (see SELENIUM DIMETHYLDITHIOCARBAMATE)	2122-86-3	5-(5-NITRO-2-FURYL)-1,3,4-OXADIAZOLE-2-OL
		36133-88-7	N-[3-(5-NITRO-2-FURYL)-1,2,4-OXADIAZOLE-5-YL]-METHYLACETAMIDE

CAS NUMBER*	CHEMICAL NAME	CAS NUMBER*	CHEMICAL NAME
2578-75-8	N-[5-(5-NITRO-2-FURYL)-1,3,4-THIAZOL-2-YL]ACETAMIDE	8056-92-6	OVULEN
531-82-8	N-[4-(5-NITRO-2-FURYL)-2-THIAZOLYL]ACETAMIDE	3096-50-2	N-(9-OXO-2-FLUORENYL)ACETAMIDE
24554-26-5	N-[4-(5-NITRO-2-FURYL)-2-THIAZOLYL]FORMAMIDE	---	1'-OXOSAFROLE
51325-35-0	N,N'-[6-(5-NITRO-2-FURYL)-s-TRIAZINE-2,4-DIYL]BISACETAMIDE	6452-73-9	OXPRENOLOL.HCl
4812-22-0	3-NITRO-3-HEXENE	102-77-2	N-OXYDIETHYLENEBENZOTHAZOLE-2-SULFENAMIDE
121-19-7	NITRO-4-HYDROXYPHENYLARSONIC ACID	103-90-2	PARACETAMOL (see ACETAMINOPHEN)
5307-14-2	2-NITRO-p-PHENYLENEDIAMINE	56-38-2	PARATHION
99-58-9	4-NITRO-o-PHENYLENEDIAMINE	92-69-3	PARAXENOL (see p-PHENYLPHENOL)
99-55-8	5-NITRO-o-TOLUIDINE	149-29-1	PATULIN
602-87-9	5-NITROACENAPHTHENE	11096-82-5	PCB (see AROCLOR 1260)
619-17-0	4-NITROANTHRANILIC ACID	27323-18-8	PCB (see AROCLOR 1254)
94-62-0	6-NITROBENZIMIDAZOLE	82-68-8	PCNB (see PENTACHLORONITROBENZENE)
1836-75-5	NITROFEN	87-86-5	PCP (see 2,3,4,5,6-PENTACHLOROPHENOL)
67-20-9	1-[5-NITROFURFURYLIDENE]AMINO]HYDANTOIN	82-68-8	PENTACHLORONITROBENZENE
555-84-0	1-[5-NITROFURFURYLIDENE]AMINO]-2-IMIDAZOLIDINONE	87-86-5	2,3,4,5,6-PENTACHLOROPHENOL
51-75-2	NITROGEN MUSTARD	13010-10-1	N-PENTYL-N'-NITRO-N-NITROSOGUANIDINE
126-85-2	NITROGEN MUSTARD N-OXIDE	1119-68-2	n-PENTYLHYDRAZINE.HCl
86-57-7	1-NITRONAPHTHALENE	8006-90-4	PEPPERMINT OIL
56-75-7	D-(-)-threo-1-(p-NITROPHENYL)-2-DICHLOROACETAMIDO-1,3-PROPANEDIOL (see CHLORAMPHENICOL)	72-56-0	PERTHANE (see p,p'-ETHYL-DDD)
79-46-9	2-NITROPROPANE	---	PETASITENINE
504-88-1	3-NITROPROPIONIC ACID	62-44-2	PHENACETIN
38777-13-8	NITROSO-BAYGON	8003-03-0	PHENACETIN, ASPIRIN, AND CAFFEINE (see ASPIRIN, PHENACETIN, AND CAFFEINE)
3276-41-3	N-NITROSO-3,6-DIHYDROOXAZINE-1,2 (see 3,6-DIHYDRO-2-NITROSO-2H-1,2-OXAZINE)	60-80-0	PHENAZONE
16813-36-8	1-NITROSO-5,6-DIHYDROURACIL	136-40-3	PHENAZOPYRIDINE.HCl
1456-28-6	NITROSO-2,6-DIMETHYLMORPHOLINE	3456-10-9	PHENESTERIN
13256-11-6	NITROSO-N-METHYL-N-(2-PHENYL)ETHYLAMINE	834-28-6	PHENFORMIN.HCl
684-93-5	N-NITROSO-N-METHYLUREA	50-06-6	PHENOBARBITAL
615-53-2	N-NITROSO-N-METHYLURETHAN	57-30-7	PHENOBARBITAL, SODIUM
55556-92-8	NITROSO-1,2,3,6-TETRAHYDROPYRIDINE	50-06-6	PHENOBARBITONE (see PHENOBARBITAL)
29929-77-9	N-NITROSO-2,2,4-TRIMETHYL-1,2-DIHYDROQUINOLINE POLYMER	92-84-2	PHENOTHIAZINE
1133-64-8	NITROSOANABASINE	63-92-3	PHENOXYBENZAMINE.HCl
51542-33-7	N-NITROSOBENZTHIAZURON	7227-91-0	1-PHENYL-3,3-DIMETHYLTRIAZENE
53609-64-6	N-NITROSOBIS(2-HYDROXYPROPYL)AMINE	103-72-0	PHENYL ISOTHIOCYANATE
---	N-NITROSOBIS(2,2,2-TRIFLUOROETHYL)AMINE	89-25-8	1-PHENYL-3-METHYL-5-PYRAZOLONE
---	NITROSOCHLORDIAZEPoxide	135-88-6	PHENYL-beta-NAPHTHYLAMINE
924-16-3	NITROSODIBUTYLAMINE	2198-69-6	N-PHENYL-p-PHENYLENEDIAMINE.HCl
55-18-5	N-NITROSODIETHYLAMINE	103-85-5	1-PHENYL-2-THIOUREA
62-75-9	N-NITROSODIMETHYLAMINE	4075-79-0	4'-PHENYLACETANILIDE (see 4-ACETYLAMINOBIIPHENYL)
86-30-6	N-NITROSODIPHENYLAMINE	842-07-9	1-PHENYLazo-2-NAPHTHOL
156-10-5	p-NITROSODIPHENYLAMINE	541-69-5	m-PHENYLENEDIAMINE.2HCl
17608-59-2	N-NITROSOEPHEDRINE	615-28-1	o-PHENYLENEDIAMINE.2HCl
38434-77-4	NITROSOETHANECARBAMONITRILE (see ETHYLNITROSOCYANAMIDE)	624-18-0	p-PHENYLENEDIAMINE.2HCl
20917-49-1	NITROSOHEPTAMETHYLENEMINE	50-06-6	PHENYLETHYLBARBITURIC ACID (see PHENOBARBITAL)
42579-28-2	1-NITROSOHYDANTOIN	156-51-4	PHENYLETHYLHYDRAZINE SULFATE
30310-80-6	NITROSOHYDROXYPROLINE	100-63-0	PHENYLHYDRAZINE
25081-31-6	NITROSOIMINODIACETIC ACID	59-88-1	PHENYLHYDRAZINE.HCl
16219-98-0	2-NITROSOMETHYLAMINOPYRIDINE	62-38-4	PHENYLMERCURIC ACETATE (see MERCURY (II) ACETATE)
69658-91-0	3-NITROSOMETHYLAMINOPYRIDINE	132-27-4	o-PHENYLPHENATE, SODIUM
16219-99-1	4-NITROSOMETHYLAMINOPYRIDINE	90-43-7	o-PHENYLPHENOL
614-00-6	NITROSOMETHYLANILINE	92-69-3	p-PHENYLPHENOL
55557-03-4	NITROSOMETHYLPHENIDATE	17673-25-5	PHORBOL
68107-26-6	NITROSOMETHYLUNDECYLAMINE	18171-21-6	PHOSPHAMIDON
684-93-5	NITROSOMETHYLUREA (see N-NITROSO-N-METHYLUREA)	---	PHOSPHATED DISTARCH PHOSPHATE
4515-18-8	NITROSOPIPECOLIC ACID	12366-73-9	PHOTODIELDRIN (see DIELDRIN, PHOTO-)
5632-47-3	NITROSOPIPERAZINE (see N-NITROSOPIPERAZINE)	39801-14-4	PHOTOMIREX (see MIREX, PHOTO-)
5632-47-3	1-NITROSOPIPERAZINE (see N-NITROSOPIPERAZINE)	88-96-0	PHTHALAMIDE
5632-47-3	N-NITROSOPIPERAZINE	85-44-9	PHTHALIC ANHYDRIDE
100-75-4	N-NITROSOPIPERIDINE	---	PHTIVAZID (see ISONICOTINIC ACID VANILLYLIDENEHYDRAZIDE)
7519-36-0	NITROSOPROLINE	1918-02-1	PICLORAM
930-55-2	NITROSOPYRROLIDINE (see N-NITROSOPYRROLIDINE)	92-13-7	PILOCARPINE
930-55-2	N-NITROSOPYRROLIDINE	7681-93-8	PIMARICIN
28541-51-5	N-NITROSOTHOMORPHOLINE	100-75-4	PIP (see N-NITROSOPIPERIDINE)
mixture	beta-NITROSTYRENE AND STYRENE MIXTURE (see STYRENE AND beta-NITROSTYRENE MIXTURE)	110-85-0	PIPERAZINE
68-23-5	NORETHYNODREL	110-89-4	PIPERIDINE
---	NORETHYNODREL/MESTRANOL [25:1] (see ENOVID-E)	51-03-6	PIPERONYL BUTOXIDE
8015-30-3	NORETHYNODREL/MESTRANOL [66:1] (see ENOVID)	---	PIPERONYL BUTOXIDE IN SOLVENT
244-63-3	NORHARMAN	120-62-7	PIPERONYL SULFOXIDE
8015-12-1	NORLESTRIN	1955-45-9	PIVALOLACTONE
---	NOVADELOX	86-87-3	PLANOFIX (see 1-NAPHTHALENE ACETIC ACID)
303-47-9	OCHRATOXIN A	59536-61-1	POLYBROMINATED BIPHENYLS
50-28-2	17beta-OESTRADIOL (see ESTRADIOL)	---	POLYVINYLPIRIDINE-N-OXIDE
90-43-7	ORTHOXENOL (see o-PHENYLPHENOL)	3564-09-8	PONCEAU 3R (see FD & C RED NO. 1)
80-33-1	OVEX (see p-CHLOROPHENYL-p-CHLOROBENZENE SULFONATE)	2311-82-7	PONCEAU 4R (see SX PURPLE)
		3761-53-3	PONCEAU MX (see D & C RED NO. 5)
		4548-53-2	PONCEAU SX (see FD & C RED NO. 4)
		7758-01-2	POTASSIUM BROMATE (see BROMATE, POTASSIUM)
		---	POTASSIUM METABISULFITE (see SULFITE, POTASSIUM METABI-)

CAS NUMBER ^a	CHEMICAL NAME	CAS NUMBER ^a	CHEMICAL NAME
---	PREMARIN	57-50-1	SUCROSE
671-16-9	PROCARBAZINE	---	SULFADS (see DIPENTAMETHYLENETHIURAM HEXASULFIDE)
366-70-1	PROCARBAZINE.HCl	95-06-7	SULFALLATE
952-23-8	PROFLAVINE.HCl HEMIHYDRATE	7767-82-6	SULFATE, SODIUM
54-80-8	PRONETHALOL	127-69-5	SULFISOXAZOLE
51-02-5	PRONETHALOL.HCl	---	SULFITE, POTASSIUM METABI-
1120-71-4	PROPANE SULTONE	77-79-2	3-SULFOLENE
139-40-2	PROPABINE	77-46-3	4,4'-SULFONYLBISACETANILIDE
57-57-8	beta-PROPIOLACTONE	2783-94-0	SUNSET YELLOW FCF (see FD & C YELLOW NO. 6)
1114-71-2	PROPYL N-ETHYL-N-BUTYLTHIOCARBAMATE	22571-95-5	SYMPHYTINE
77337-54-3	N-N'-PROPYL-N-FORMYLHYDRAZINE	569-57-3	TACE
83-59-0	N-PROPYL ISOME	1934-21-0	TARTRAZINE (see FD & C YELLOW NO. 5)
13010-07-6	N-PROPYL-N'-NITRO-N-NITROSOGUANIDINE	97-18-7	TBP (see 2,2-THIOBIS(4,6-DICHLOROPHENOL))
57-55-6	PROPYLENE GLYCOL	1746-01-6	TCDD (see 2,3,7,8-TETRACHLORODIBENZO-p-DIOXIN)
56795-66-5	PROPYLHYDRAZINE.HCl	72-54-8	TDE (see p,p'-DDD)
51-52-5	PROPYLTHIOURACIL	297-78-9	TELODRIN
1508-45-8	PRORESID	150-68-5	TELVAR (see 3-(p-CHLOROPHENYL)-1,1-DIMETHYLUREA)
2611-82-7	SX PURPLE	116-06-3	TEMIK (see ALDICARB)
98-96-4	PYRAZINAMIDE	7411-49-6	3,3',4,4'-TETRAAMINOBIPHENYL.4HCl
553-53-7	3-PYRIDOYL HYDRAZINE (see NICOTINIC ACID HYDRAZIDE)	118-75-2	TETRACHLORO-p-BENZOQUINONE (see CHLORANIL)
58-14-0	PYRIMETHAMINE	2438-88-2	2,3,5,6-TETRACHLORO-4-NITROANISOLE
117-39-5	QUERCETIN	15721-02-5	2,2',5,5'-TETRACHLOROBENZIDINE
5117-01-1	QUERCETIN DIHYDRATE	1746-01-6	2,3,7,8-TETRACHLORODIBENZO-p-DIOXIN
---	QUILLAIA EXTRACT	116-29-0	2,4,5,4'-TETRACHLORODIPHENYL SULFONE
105-11-3	p-QUINONE DIOXIME	79-34-5	1,1,2,2-TETRACHLOROETHANE
82-68-8	QUINTOZINE (see PENTACHLORONITROBENZENE)	127-18-4	TETRACHLOROETHYLENE
3567-69-9	C.I. FOOD RED 3	961-11-5	TETRACHLORVINPHOS
3761-53-3	D & C RED NO. 5	97-77-8	TETRAETHYLTHIURAM DISULFIDE
5160-02-1	D & C RED NO. 9	116-29-0	TETRAFIDON (see 2,4,5,4'-TETRACHLORODIPHENYL SULFONE)
---	D & C RED NO. 10	63886-77-1	TETRAFLUORO-m-PHENYLENEDIAMINE.2HCl
3564-09-8	FD & C RED NO. 1	40548-68-3	TETRAHYDRO-2-NITROSO-2H-1,2-OXAZINE
915-87-3	FD & C RED NO. 2	137-26-8	TETRAMETHYLTHIURAM DISULFIDE
16423-68-0	FD & C RED NO. 3	mixture	TETRAMETHYLTHIURAM DISULFIDE AND FERRIC NITROSODIMETHYLDITHIOCARBAMATE (see VANGUARD GF)
4548-53-2	FD & C RED NO. 4	97-74-5	TETRAMETHYLTHIURAM MONOSULFIDE
86-30-6	REDAX (see N-NITROSODIPHENYLAMINE)	2227-13-6	TETRASUL (see p-CHLOROPHENYL-2,4,5-TRICHLOROPHENYL SULFIDE)
2318-18-5	RENARDINE (see SENKIRKINE)	52-24-4	THIO-TEPA
50-55-5	RESERPINE	62-55-5	THIOACETAMIDE
13292-46-1	RIFAMPICIN	97-18-7	2,2-THIOBIS(4,6-DICHLOROPHENOL)
632-99-5	ROSANILINE.HCl	115-29-7	THIODAN (see ENDOSULFAN)
569-61-9	p-ROSANILINE.HCl	139-65-1	4,4'-THIODIANILINE
149-30-4	ROTAX (see 2-MERCAPTOBENZOTHAZOLE)	64039-27-6	beta-THIOGUANINE DEOXYRIBOSIDE (beta-TGdR. NCI uses CAS NUMBER 789-61-7)
83-79-4	ROTENONE	79-19-6	THIOSEMICARBAZIDE
153-18-4	RUTIN (see RUTIN TRIHYDRATE)	141-90-2	THIOURACIL
153-18-4	RUTIN TRIHYDRATE	62-56-6	THIOUREA
81-07-2	SACCHARIN	137-26-8	THIRAM (see TETRAMETHYLTHIURAM DISULFIDE)
128-44-9	SACCHARIN, SODIUM	1114-71-2	TILLAM-6-E (see PROPYL N-ETHYL-N-BUTYLTHIOCARBAMATE)
94-59-7	SAFROLE	7772-99-8	TIN (II) CHLORIDE
8052-16-2	SANAMYCIN (see ACTINOMYCIN C)	13463-67-7	TITANIUM DIOXIDE
148-82-3	L-SARCOSYLIN (see MELPHALAN)	---	TITANIUM OXALATE, POTASSIUM
148-18-5	SDDC (see SODIUM DIETHYLDITHIOCARBAMATE TRIHYDRATE)	137-26-8	TMTD (see TETRAMETHYLTHIURAM DISULFIDE)
7782-49-2	SELENIUM	1156-19-0	TOLAZAMIDE
5456-28-0	SELENIUM DIETHYLDITHIOCARBAMATE	64-77-7	TOLBUTAMIDE
144-34-3	SELENIUM DIMETHYLDITHIOCARBAMATE	636-23-7	2,4-TOLUENEDIAMINE.2HCl (see 2,4-DIAMINOTOLUENE.2HCl)
7446-34-6	SELENIUM SULFIDE	6369-59-1	2,5-TOLUENEDIAMINE SULFATE (see 2,5-DIAMINOTOLUENE SULFATE)
2318-18-5	SENKIRKINE	88-19-7	o-TOLUENESULFONAMIDE
63-25-2	SEVIN (see CARBARYL)	638-03-9	m-TOLUIDINE.HCl
122-34-9	SIMAZINE	636-21-5	o-TOLUIDINE.HCl
7784-46-5	SODIUM ARSENITE (see ARSENITE, SODIUM)	540-23-8	p-TOLUIDINE.HCl
26628-22-8	SODIUM AZIDE (see AZIDE, SODIUM)	622-51-5	p-TOLYLUREA
532-32-1	SODIUM BENZOATE (see BENZOATE, SODIUM)	8001-35-2	TOXAPHENE
6385-58-6	SODIUM BITHIONOLATE	68-76-8	TRENIMON
139-05-9	SODIUM CYCLAMATE (see CYCLAMATE, SODIUM)	6379-49-0	1,2,3-TRICHLORO-4,6-DINITROBENZENE
148-18-5	SODIUM DIETHYLDITHIOCARBAMATE TRIHYDRATE	634-93-5	2,4,6-TRICHLOROANILINE
7681-49-4	SODIUM FLUORIDE (see FLUORIDE, SODIUM)	71-55-6	1,1,1-TRICHLOROETHANE
12034-09-2	SODIUM NIOBATE (see NIOBATE, SODIUM)	79-00-5	1,1,2-TRICHLOROETHANE
7631-99-4	SODIUM NITRATE (see NITRATE, SODIUM)	79-01-6	TRICHLOROETHYLENE
7757-82-6	SODIUM SULFATE (see SULFATE, SODIUM)	75-69-4	TRICHLOROFLUOROMETHANE
13472-45-2	SODIUM TUNGSTATE (see TUNGSTATE, SODIUM)	133-07-3	N-(TRICHLOROMETHYLTHIO)PHTHALIMIDE
110-44-1	SORBIC ACID	88-06-2	2,4,6-TRICHLOROPHENOL
8002-43-5	SOYBEAN LECITHIN	93-72-1	2-(2,4,5-TRICHLOROPHENOXY)PROPIONIC ACID
7772-99-8	STANNOUS CHLORIDE (see TIN (II) CHLORIDE)	93-76-5	2,4,5-TRICHLOROPHENOXYACETIC ACID
---	STARCH ACETATE	102-71-6	TRITHANOLAMINE
10048-13-2	STERIGMATOCYSTIN	112-27-6	TRIETHYLENE GLYCOL
18683-66-4	STREPTOZOTOCIN		
8001-50-1	STROBANE		
100-42-5	STYRENE		
mixture	STYRENE AND beta-NITROSTYRENE MIXTURE (CAS NUMBER 100-42-5 and 102-96-5)		
1596-84-5	SUCCINIC ACID 2,2-DIMETHYLHYDRAZIDE (see DAMINOZIDE)		

CAS NUMBER ^a	CHEMICAL NAME
42011-48-3	2,2,2-TRIFLUORO-N-[4-(5-NITRO-2-FURYL)-2-THIAZOLYL]ACETAMIDE
1582-09-8	TRIFLURALIN
75-48-8	TRIODOMETHANE (see IODOFORM)
137-17-7	2,4,5-TRIMETHYLANILINE
21436-97-5	2,4,5-TRIMETHYLANILINE.HCl
6334-11-8	2,4,6-TRIMETHYLANILINE.HCl
512-56-1	TRIMETHYLPHOSPHATE
2489-77-2	TRIMETHYLTHIOUREA
900-95-8	TRIPHENYL TIN ACETATE
76-87-9	TRIPHENYL TIN HYDROXIDE
126-72-7	TRIS (see TRIS(2,3-DIBROMOPROPYL)PHOSPHATE)
38571-73-2	TRIS-1,2,3-(CHLOROMETHOXY)PROPANE
126-72-7	TRIS(2,3-DIBROMOPROPYL)PHOSPHATE
150-38-9	TRISODIUM ETHYLENEDIAMINETETRAACETATE TRIHYDRATE (see EDTA, TRISODIUM SALT TRIHYDRATE)
75104-43-7	TRP-P-1 ACETATE (see 3-AMINO-1,4-DIMETHYL-5H-PYRIDO[4,3-b]INDOLE ACETATE)
72254-58-1	TRP-P-2 ACETATE (see 3-AMINO-1-METHYL-5H-PYRIDO[4,3-b]INDOLE ACETATE)
73-22-3	L-TRYPTOPHAN
83-79-4	TUBATOXIN (see ROTENONE)
13472-45-2	TUNGSTATE, SODIUM
103-90-2	TYLENOL (see ACETAMINOPHEN)
97-74-5	UNADS (see TETRAMETHYLTHURAM MONOSULFIDE)
57-13-6	UREA
51-79-6	URETHANE
27774-13-6	VANADYL SULFATE
97-18-7	VANCIDE BL (see 2,2-THIOBIS(4,6-DICHLOROPHENOL))
6385-58-6	VANCIDE BN (see SODIUM BITHIONOLATE)
6379-49-0	VANCIDE PB (see 1,2,3-TRICHLORO-4,6-DINITROBENZENE)

CAS NUMBER ^a	CHEMICAL NAME
13927-77-0	VANGUARD N (see NICKEL DIBUTYLDITHIOCARBAMATE) mixture
62-73-7	VANGUARD GF (ferric nitrosodimethyldithiocarbamate and tetramethylthiuram disulfide, CAS NUMBER --- and 137-26-8)
865-21-4	VAPONA (see DICHLORVOS)
593-60-2	VINBLASTINE
75-01-4	VINYL BROMIDE
75-35-4	VINYL CHLORIDE
1964-09-3	VINYLDENE CHLORIDE
50-14-6	FD & C VIOLET NO. 1
302-79-4	VITAMIN D2
21436-96-4	VITAMIN A ACID
51786-53-9	2,4-XYLIDINE.HCl
6358-85-6	2,5-XYLIDINE.HCl
5979-28-2	C.I. PIGMENT YELLOW 12
5567-15-7	C.I. PIGMENT YELLOW 16
128-66-5	C.I. PIGMENT YELLOW 83
6358-85-6	C.I. VAT YELLOW 4
1934-21-0	DIARYLANILIDE YELLOW (see C.I. PIGMENT YELLOW 12)
2783-94-0	FD & C YELLOW NO. 5
315-18-4	FD & C YELLOW NO. 6
155-04-4	ZECTRAN (see MEXACARBATE)
136-23-2	ZETAX (see 2-MERCAPTOBENZOTHAZOLE, ZINC)
14324-55-1	ZINC DIBUTYLDITHIOCARBAMATE
137-30-4	ZINC DIETHYLDITHIOCARBAMATE
12122-67-7	ZINC DIMETHYLDITHIOCARBAMATE
12122-67-7	ZINC ETHYLENEBISTHIOCARBAMATE
137-30-4	ZINEB (see ZINC ETHYLENEBISTHIOCARBAMATE)
14644-61-2	ZIRAM (see ZINC DIMETHYLDITHIOCARBAMATE)
	ZIRCONIUM (IV) SULFATE

^aCAS NUMBER = Chemical Abstracts Service registry number

APPENDIX 2: CHEMICAL NAMES LISTED BY CAS NUMBER

CAS NUMBER ^a	CHEMICAL NAME
mixture	3-AMINO-9-ETHYL CARBAZOLE MIXTURE (3-amino-9-ethylcarbazole and 3-amino-9-ethylcarbazole.HCl. CAS NUMBER 132-32-1 and 6109-97-3)
mixture	HCDD MIXTURE (1,2,3,7,8,9-hexachlorodibenzo-p-dioxin and 1,2,3,6,7,8-isomer. CAS NUMBER 19408-74-3 and 57853-85-7)
mixture	STYRENE AND beta-NITROSTYRENE MIXTURE (CAS NUMBER 100-42-5 and 102-96-5)
mixture	VANGUARD GF (ferric nitrosodimethyldithiocarbamate and tetramethylthiuram disulfide, CAS NUMBER --- and 137-26-8)
mixture	METHYL AZOXYMETHANOL ACETATE AND CYCASIN MIXTURE (CAS NUMBER 592-81-1 and 14901-08-7)
50-06-6	PHENOBARBITAL (phenobarbitone)
50-07-7	MITOMYCIN-C
50-14-6	VITAMIN D2
50-18-0	CYCLOPHOSPHAMIDE (Endoxan)
50-23-7	HYDROCORTISONE (cortisol)
50-28-2	ESTRADIOL (estradiol-17beta)
50-29-3	DDT
50-32-8	BENZO(a)PYRENE
50-44-2	6-MERCAPTOPYRIMIDINE
50-65-6	RESERPINE
50-78-0	ACTINOMYCIN D
50-78-2	ASPIRIN
61-02-5	PRONETHALOL.HCl (alderlin.HCl)
51-03-8	PIPERONYL BUTOXIDE
51-21-8	6-FLUOROURACIL
51-28-5	2,4-DINITROPHENOL
51-52-6	PROPYLTHIOURACIL
51-65-8	ATROPINE
51-75-2	NITROGEN MUSTARD (2,2'-dichloro-N-methyldiethylamine)
51-79-6	URETHANE
52-24-4	THIO-TEPA
53-19-0	o,p'-DDD
53-70-3	DIBENZ(a,h)ANTHRACENE
53-96-2	N-HYDROXY-2-ACETYLAMINOFLUORENE (hydroxy-N-2-fluorenylacetamide)
53-96-3	2-ACETYLAMINOFLUORENE (N-2-fluorenylacetamide)
54-11-6	NICOTINE
54-80-8	PRONETHALOL (alderlin)
54-85-3	ISONIAZID (INH)

CAS NUMBER ^a	CHEMICAL NAME
55-18-6	N-NITROSODIETHYLAMINE (DEN)
55-22-1	ISONICOTINIC ACID
55-38-9	FENTHION
55-98-1	MYLERAN (busulfan)
56-04-2	METHYLTHIOURACIL
56-23-5	CARBON TETRACHLORIDE
56-38-2	PARATHION
56-49-5	3-METHYLCHOLANTHRENE
56-53-1	DIETHYLSTILBESTROL (DES)
56-72-4	COUMAPHOS
56-75-7	CHLORAMPHENICOL (Chloromycetin)
57-13-6	UREA
57-14-7	1,1-DIMETHYLHYDRAZINE
57-30-7	PHENOBARBITAL, SODIUM (phenobarbitone, sodium)
57-39-6	METEPA
57-41-0	5,5-DIPHENYLHYDANTOIN
57-50-1	SUCROSE
57-55-6	PROPYLENE GLYCOL
57-67-8	beta-PROPIOLACTONE
57-74-9	CHLORDANE
57-97-6	7,12-DIMETHYLBENZ(a)ANTHRACENE
58-08-2	CAFFEINE
58-14-0	PYRIMETHAMINE (Daraprin)
58-89-9	gamma-1,2,3,4,5,6-HEXACHLOROXYCLOHEXANE (lindane)
59-05-2	METHOTREXATE
59-35-8	4,6-DIMETHYL-2-(5-NITRO-2-FURYL)PYRIMIDINE
59-87-0	5-NITRO-2-FURALDEHYDE SEMICARBAZONE
59-88-1	PHENYLHYDRAZINE.HCl
60-11-7	N,N-DIMETHYL-4-AMINOAZOBENZENE (DAB)
60-34-4	METHYLHYDRAZINE
60-35-5	ACETAMIDE
60-51-6	DIMETHOATE
60-56-0	METHIMAZOLE
60-57-1	DIELDRIN (HEOD)
60-80-0	PHENAZONE
61-82-6	3-AMINOTRIAZOLE (amitrol)
62-38-4	MERCURY (II) ACETATE (phenylmercuric acetate)
62-44-2	PHENACETIN
62-53-3	ANILINE
62-55-6	THIOACETAMIDE

CAS NUMBER*	CHEMICAL NAME	CAS NUMBER*	CHEMICAL NAME
62-56-6	THIOUREA	91-64-5	1,2-BENZOPYRONE (coumarin)
62-73-7	DICHLORVOS (DDVP, Vapona)	91-76-9	BENZOGUANAMINE
62-75-9	N-NITROSODIMETHYLAMINE (DMN)	91-93-0	3,3'-DIMETHOXYBENZIDINE-4,4'-DIISOCYANATE
63-25-2	CARBARYL (Sevin)	91-94-1	3,3'-DICHLOROBENZIDINE (DCB)
63-92-3	PHENOXYBENZAMINE.HCl	92-13-7	PILOCARPINE
64-17-5	ETHYL ALCOHOL	92-52-4	BIPHENYL
64-77-7	TOLBUTAMIDE	92-67-1	4-AMINODIPHENYL
66-27-3	METHYL METHANESULFONATE (MMS)	92-69-3	p-PHENYLPHENOL (paraxenol)
67-20-9	1-(5-NITROFURFURYLIDENE)AMINOHYDANTOIN	92-84-2	PHENOTHIAZINE
67-66-3	CHLOROFORM	92-87-5	BENZIDINE
67-72-1	HEXACHLOROETHANE	93-46-9	sym.-dibeta-NAPHTHYL-p-PHENYLENEDIAMINE (Agerite white)
67-98-1	MER-25	93-72-1	2-(2,4,5-TRICHLOROPHENOXY)PROPIONIC ACID
68-23-5	NORETHYNODREL	93-76-5	2,4,6-TRICHLOROPHENOXYACETIC ACID (2,4,5-T)
68-76-8	TRENIMON	94-11-1	2,4-DICHLOROPHENOXYACETIC ACID, ISOPROPYL ESTER
70-25-7	N-METHYL-N'-NITRO-N-NITROSOGUANIDINE (MNNG)	94-20-2	CHLORPROPAMIDE
70-30-4	HEXACHLOROPHENE	94-52-0	6-NITROBENZIMIDAZOLE
71-43-2	BENZENE	94-58-6	DIHYDROSAPROLE
71-55-6	1,1,1-TRICHLOROETHANE	94-59-7	SAPROLE
72-20-8	ENDRIN	94-75-7	2,4-DICHLOROPHENOXYACETIC ACID (2,4-D)
72-33-3	MESTRANOL	94-80-4	2,4-DICHLOROPHENOXYACETIC ACID, n-BUTYL ESTER
72-43-5	METHOXYCHLOR	95-06-7	SULFALLATE
72-54-8	p,p'-DDD (TDE)	95-14-7	1H-BENZOTRIAZOLE
72-55-9	p,p'-DDE	95-33-0	N-CYCLOHEXYL-2-BENZOTHAZOLE SULFENAMIDE (Durax)
72-56-0	p,p'-ETHYL-DDD (Perthane)	95-74-9	3-CHLORO-p-TOLUIDINE
73-22-3	L-TRYPTOPHAN	95-79-4	5-CHLORO-o-TOLUIDINE
74-31-7	DIPHENYL-p-PHENYLENEDIAMINE (Agerite DPPD)	95-80-7	2,4-DIAMINOTOLUENE
75-01-4	VINYL CHLORIDE	95-83-0	4-CHLORO-o-PHENYLENEDIAMINE
75-34-3	1,1-DICHLOROETHANE	96-12-8	1,2-DIBROMO-3-CHLOROPROPANE (DBCP, NCI uses CAS NUMBER 1836-75-5)
75-35-4	VINYLDENE CHLORIDE	96-24-2	GLYCEROL alpha-MONOCHLOROHYDRIN
75-48-8	IODOFORM (triiodomethane)	96-45-7	ETHYLENE THIOUREA (ETU)
75-60-5	DIMETHYLARSINIC ACID (cacodylic acid)	97-00-7	1-CHLORO-2,4-DINITROBENZENE
75-69-4	TRICHLOROFLUOROMETHANE	97-16-5	2,4-DICHLOROPHENYLBENZENE SULFONATE (Genite-R99)
76-06-2	CHLOROPICRIN	97-18-7	2,2-THIOBIS(4,6-DICHLOROPHENOL) (TBP, Vancide BL)
76-44-8	HEPTACHLOR	97-56-3	o-AMINOAZOTOLUENE
76-87-9	TRIPHENYLITIN HYDROXIDE	97-74-5	TETRAMETHYLTHIURAM MONOSULFIDE (unada)
77-06-5	GIBBERELIC ACID	97-77-8	TETRAETHYLTHIURAM DISULFIDE (ethyl unada)
77-46-3	4,4'-SULFONYLBISACETANILIDE	98-01-1	FURFURAL
77-65-6	CARBROMAL (bromodiethylacetylurea)	98-96-4	PYRAZINAMIDE
77-79-2	3-SULFOLENE	99-30-9	2,6-DICHLORO-4-NITROANILINE (Botran)
78-34-2	DIOXATHION	99-55-8	5-NITRO-o-TOLUIDINE
79-00-5	1,1,2-TRICHLOROETHANE	99-56-9	4-NITRO-o-PHENYLENEDIAMINE
79-01-6	TRICHLOROETHYLENE	99-59-2	5-NITRO-o-ANISIDINE
79-11-8	MONOCHLOROACETIC ACID	99-80-9	N-METHYL-N,4-DINITROSOANILINE
79-19-6	THIOSEMICARBAZIDE	100-00-5	1-CHLORO-4-NITROBENZENE
79-34-5	1,1,2,2-TETRACHLOROETHANE	100-42-5	STYRENE
79-40-3	DITHIOXAMIDE	100-63-0	PHENYLHYDRAZINE
79-44-7	DIMETHYLCARBAMYL CHLORIDE	100-75-4	N-NITROSOPIPERIDINE (PIP)
79-46-9	2-NITROPROPANE	100-97-0	HEXAMETHYLENETETRAMINE
80-08-0	DAPSONE	101-05-3	ANILAZINE
80-33-1	p-CHLOROPHENYL-p-CHLOROBENZENE SULFONATE (ovex)	101-14-4	4,4'-METHYLENE-BIS(2-CHLOROANILINE) (3,3'-dichloro-4,4'-diaminodiphenylmethane, MOCA)
81-07-2	SACCHARIN	101-21-3	ISOPROPYL-N-(3-CHLOROPHENYL)CARBAMATE (CIPC, chlorpropham)
81-21-0	DICYCLOPENTADIENE DIOXIDE	101-25-7	N,N-DINITROSO-PENTAMETHYLENETETRAMINE
82-28-0	1-AMINO-2-METHYLANTHRAQUINONE	101-61-1	4,4'-METHYLENEBIS(N,N-DIMETHYL)BENZENAMINE
82-68-8	PENTACHLORONITROBENZENE (PCNB)	101-73-5	p-ISOPROPOXYDIPHENYLAMINE (Agerite 150)
83-59-0	N-PROPYL ISOME	101-79-1	4-CHLORO-4'-AMINODIPHENYLETHER
83-79-4	ROTENONE (tubetoxin)	102-09-0	DIPHENYLCARBONATE
84-65-1	9,10-ANTHRAQUINONE	102-50-1	m-CRESIDINE
85-44-9	PHTHALIC ANHYDRIDE	102-71-6	TRIETHANOLAMINE
86-29-3	DIPHENYLACETONITRILE	102-77-2	N-OXYDIETHYLENEBENZOTHAZOLE-2-SULFENAMIDE (amax)
86-30-6	N-NITROSODIPHENYLAMINE (redax, diphenylnitrosamine)	103-03-7	1-CARBAMYL-2-PHENYLHYDRAZINE
86-50-0	AZINPHOSMETHYL (Gusathion)	103-16-2	HYDROQUINONE MONOBENZYL ETHER (Agerite alba)
86-57-7	1-NITRONAPHTHALENE	103-33-3	AZOBENZENE
86-86-2	1-NAPHTHALENE ACETAMIDE	103-72-0	PHENYL ISOTHIOCYANATE
86-87-3	1-NAPHTHALENE ACETIC ACID (Planofix)	103-85-5	1-PHENYL-2-THIOUREA
86-88-4	1-(1-NAPHTHYL)-2-THIOUREA (ANTU)	103-90-2	ACETAMINOPHEN (Tylenol, paracetamol)
87-51-4	INDOLE-3-ACETIC ACID (heteroauxin)	105-11-3	p-QUINONE DIOXIME
87-56-9	alpha,beta-DICHLORO-beta-FORMYLACRYLIC ACID (mucochloric acid)	105-36-2	ETHYL BROMOACETATE
87-68-3	HEXACHLOROBTADIENE	106-55-5	N,N'-DIETHYLTHIOUREA
87-96-5	2,3,4,5,6-PENTACHLOROPHENOL (Dowicide-7, PCP)	106-47-8	p-CHLOROANILINE
88-06-2	2,4,6-TRICHLOROPHENOL (Dowicide-2S)	106-87-6	1-ETHYLENEOXY-3,4-EPOXYCYCLOHEXANE
88-19-7	o-TOLUENESULFONAMIDE	106-89-8	EPICHLOROHYDRIN
88-73-3	1-CHLORO-2-NITROBENZENE	106-93-4	1,2-DIBROMOETHANE (ethylene dibromide, EDB)
88-85-7	2-sec-BUTYL-4,6-DINITROPHENOL	107-05-1	ALLYL CHLORIDE (chloropropene)
88-96-0	PHTHALAMIDE	107-06-2	1,2-DICHLOROETHANE (ethylene dichloride, EDC)
89-25-8	1-PHENYL-3-METHYL-5-PYRAZOLONE	107-13-1	ACRYLONITRILE
90-43-7	o-PHENYLPHENOL (orthozenol, Dowicide-1)		
90-94-8	MICHLER'S KETONE		
91-59-8	2-NAPHTHYLAMINE		

CAS NUMBER*	CHEMICAL NAME
107-20-0	CHLOROACETALDEHYDE
107-30-2	CHLOROMETHYL METHYL ETHER (CMME)
108-60-1	BIS(2-CHLORO-1-METHYLETHYL) ETHER
109-84-2	2-HYDROXYETHYLHYDRAZINE (BOH)
110-44-1	SORBIC ACID
110-57-6	trans-1,4-DICHLOROBUTENE-2
110-85-0	PIPERAZINE
110-89-4	PIPERIDINE
111-44-4	BIS-2-CHLOROETHYLETHER
111-46-6	DIETHYLENE GLYCOL
112-27-6	TRIETHYLENE GLYCOL
114-83-0	1-ACETYL-2-PHENYLHYDRAZINE
115-02-6	AZASERINE
115-09-3	MERCURYMETHYLCHLORIDE (methylmercuric acetate)
115-29-7	ENDOSULFAN (Thiodan)
115-32-2	DICOPOL (Kethane)
116-06-3	ALDICARB (Temik)
116-29-0	2,4,5,4'-TETRACHLORODIPHENYL SULFONE (tetradifon)
117-39-5	QUERCETIN
117-79-3	2-AMINOANTHRAQUINONE
117-80-6	2,3-DICHLORO-1,4-NAPHTHOQUINONE (dichlone)
118-74-1	HEXACHLOROBENZENE (HCB)
118-75-2	CHLORANIL (tetrachloro-p-benzoquinone)
118-92-3	ANTHRANILIC ACID
119-34-6	4-AMINO-2-NITROPHENOL
119-38-0	1-ISOPROPYL-3-METHYL-5-PYRAZOLYLDIMETHYL CARBAMATE (isolan)
120-36-6	alpha-(2,4-DICHLOROPHENOXY)PROPIONIC ACID (2-(2,4-dichlorophenoxy) propionic acid)
120-58-1	ISOSAFROLE
120-61-6	DIMETHYL TEREPHTHALATE (DMT)
120-62-7	PIPERONYL SULFOXIDE
120-71-5	p-CRESIDINE
120-78-5	BENZOTHAZYL DISULFIDE (Altax)
120-93-4	ETHYLENE UREA (2-imidazolidinone)
121-14-2	2,4-DINITROTOLUENE
121-19-7	NITRO-4-HYDROXYPHENYLARSONIC ACID
121-69-6	CARBARSONE
121-68-4	2-AMINO-6-NITROTHIAZOLE
121-75-5	MALATHION
122-34-9	SIMAZINE (CDT)
122-42-9	ISOPROPYL-N-PHENYL CARBAMATE (IPC)
122-66-7	HYDRAZOBENZENE (NCI uses CAS NUMBER 530-50-7)
123-33-1	MALEIC HYDRAZIDE (1,2-dihydro-3,6-pyridazinedione)
123-91-1	1,4-DIOXANE (p-dioxane)
126-07-8	GRISOPFULVIN
126-72-7	TRIS(2,3-DIBROMOPROPYL)PHOSPHATE (TRIS)
126-85-2	NITROGEN MUSTARD N-OXIDE (mitomen)
127-18-4	TETRACHLOROETHYLENE
127-69-5	SULFISOXAZOLE
128-37-0	BUTYLATED HYDROXYTOLUENE (BHT)
128-44-9	SACCHARIN, SODIUM
128-66-5	C.I. VAT YELLOW 4
129-15-7	2-METHYL-1-NITROANTHRAQUINONE
131-01-1	DESERPIDINE
132-27-4	o-PHENYLPHENATE, SODIUM
133-06-2	CAPTAN
133-07-3	N-(TRICHLOROMETHYLTHIO)PHTHALIMIDE (folpet)
133-90-4	CHLORAMBEN
134-29-2	o-ANISIDINE.HCl (NCI uses CAS NUMBER 134-29-0)
135-20-6	CUPFERRON
135-88-6	PHENYL-beta-NAPHTHYLAMINE (Agerite powder)
136-23-2	ZINC DIBUTYLDITHIOCARBAMATE (butyl zimate)
136-40-3	PHENAZOPYRIDINE.HCl
137-17-7	2,4,5-TRIMETHYLANILINE
137-26-8	TETRAMETHYLTHIURAM DISULFIDE (TMTD, thiram)
137-29-1	COPPER DIMETHYLDITHIOCARBAMATE (cumate)
137-30-4	ZINC DIMETHYLDITHIOCARBAMATE (methyl zimate)
139-06-9	CYCLAMATE, SODIUM
139-13-9	NITRILOTRIACETIC ACID
139-40-2	PROPAZINE (Gesamil)
139-65-1	4,4'-THIODIANILINE
139-94-6	NITHIAZIDE
140-49-8	4-(CHLOROACETYL)-ACETANILIDE
140-56-7	FENAMINOSULF, FORMULATED (methyl orange B)
140-57-8	ARAMITE
140-79-4	DINITROSOPIPERAZINE
141-90-2	THIOURACIL
142-04-1	ANILINE.HCl

CAS NUMBER*	CHEMICAL NAME
142-46-1	2,5-DITHIOBIUREA
142-59-6	ETHYLENEBISDITHIOCARBAMATE, DISODIUM (Dithane, nabam)
143-50-0	KEPONE (chlordecone)
144-34-3	SELENIUM DIMETHYLDITHIOCARBAMATE (methyl selenac)
148-18-5	SODIUM DIETHYLDITHIOCARBAMATE TRIHYDRATE (SDDC)
148-24-3	8-HYDROXYQUINOLINE
148-82-3	MELPHALAN (L-sarcosylin)
149-29-1	PATULIN
149-30-4	2-MERCAPTOBENZOTHAZOLE (Captax, rotax)
150-38-9	EDTA, TRISODIUM SALT TRIHYDRATE (EDTA)
150-68-5	3-(p-CHLOROPHENYL)-1,1-DIMETHYLUREA (Telvar, monuron)
151-56-4	ETHYLENE IMINE
153-18-4	RUTIN TRIHYDRATE
155-04-4	2-MERCAPTOBENZOTHAZOLE, ZINC (zetax)
156-10-5	p-NITROSODIPHENYLAMINE
156-51-4	PHENYLETHYLHYDRAZINE SULFATE
156-62-7	CYANAMIDE, CALCIUM
244-63-3	NORHARMAN
262-12-4	DIBENZO-p-DIOXIN
297-78-7	ETHYNYDIOL DIACETATE
297-78-9	TELODRIN (isobenzan)
298-00-0	METHYL PARATHION
298-18-0	D,L-DIEPOXYBUTANE
301-04-2	LEAD ACETATE
302-01-2	HYDRAZINE
302-15-8	METHYLHYDRAZINE SULFATE
302-22-7	CHLORMADINONE ACETATE
302-79-4	VITAMIN A ACID
303-34-4	LASIOCARPINE
303-47-9	OCHRATOXIN A
306-03-3	CHLORAMBUCIL
306-37-6	1,2-DIMETHYLHYDRAZINE.2HCl
309-00-2	ALDRIN
315-18-4	MEKACARBATE (Zectran)
316-42-7	EMETINE.2HCl (NCI uses CAS NUMBER 483-18-1)
319-84-8	alpha-1,2,3,4,5,8-HEXACHLOROCYCLOHEXANE (alpha-lindane)
319-85-7	beta-1,2,3,4,5,6-HEXACHLOROCYCLOHEXANE (beta-lindane)
320-67-2	5-AZACYTIDINE
324-93-6	4'-FLUORO-4-AMINODIPHENYL
330-54-1	3-(3,4-DICHLOROPHENYL)-1,1-DIMETHYLUREA (Karnex, diuron)
333-41-6	DIAZINON
363-17-7	N-(2-FLUORENYL)-2,2,2-TRIFLUOROACETAMIDE
366-70-1	PROCARBAZINE.HCl
373-02-4	NICKEL (II) ACETATE
398-32-3	N-4-(4'-FLUOROBIPHENYL)ACETAMIDE
434-13-9	LITHOCHOLIC ACID
443-48-1	METRONIDAZOLE
470-82-6	EUCALYPTOL
471-29-4	METHYLGUANIDINE
474-25-9	CHENODEOXYCHOLIC ACID
477-30-5	COLCEMID
488-41-5	DIBROMOMANNITOL (DBM)
504-88-1	3-NITROPROPIONIC ACID
510-15-8	CHLOROBENZILATE
512-56-1	TRIMETHYLPHOSPHATE
517-28-2	HEMATOXYLIN
520-46-5	3-ACETYL-6-METHYL-2,4-PYRANDIONE (dehydroacetic acid)
531-18-0	HEXAMETHYLMELAMINE
531-82-8	N-[4-(6-NITRO-2-FURYL)-2-THIAZOLYL]ACETAMIDE (NPTA)
532-32-1	BENZOATE, SODIUM
536-33-4	ETHIONAMIDE
540-23-8	p-TOLUIDINE.HCl
541-69-5	m-PHENYLENEDIAMINE.2HCl
542-88-1	BIS-(CHLOROMETHYL) ETHER (BCME)
543-80-6	BARIUM ACETATE
543-90-8	CADMIUM ACETATE
551-92-8	1,2-DIMETHYL-5-NITROIMIDAZOLE
553-53-7	NICOTINIC ACID HYDRAZIDE (3-pyridoyl hydrazine)
556-84-0	1-[6-NITROFURFURYLIDENE]AMINO]-2-IMIDAZOLIDINONE
563-41-7	CARBAMYL HYDRAZINE.HCl
569-57-3	TACE (chlorotriane)
569-61-9	p-ROSANILINE.HCl (p-magenta)
576-68-1	MANNITOL NITROGEN MUSTARD (Degranol)
578-78-7	7-METHYLGUANINE
590-21-6	1-CHLOROPROPENE
592-31-4	N-BUTYLUREA
593-60-2	VINYL BROMIDE
598-84-1	DIMETHYLDITHIOCARBAMIC ACID, DIMETHYLAMINE

CAS NUMBER*	CHEMICAL NAME	CAS NUMBER*	CHEMICAL NAME
602-87-9	5-NITROACENAPHTHENE	1955-46-9	PIVALOLACTONE
613-94-5	BENZOYL HYDRAZINE	1964-09-3	FD & C VIOLET NO. 1
614-00-6	NITROSOMETHYLANILINE	2104-09-8	2-AMINO-4-(p-NITROPHENYL)THIAZOLE
615-28-1	o-PHENYLENEDIAMINE.2HCl	2122-86-3	5-(5-NITRO-2-FURYL)-1,3,4-OXADIAZOLE-2-OL
615-53-2	N-NITROSO-N-METHYLURETHAN	2163-79-3	3-(HEXAHYDRO-4,7-METHANOINDAN-5-YL)-1,1-DIMETHYLUREA (Hercules-7531)
617-84-5	DIETHYLFORMAMIDE	2164-09-2	3,4'-DICHLORO-2-METHYLACRYLANILIDE (dicryl)
619-17-0	4-NITROANTHRANILIC ACID	2198-59-6	N-PHENYL-p-PHENYLENEDIAMINE.HCl (NCI uses CAS NUMBER 101-54-2)
619-67-0	p-HYDRAZINO BENZOIC ACID	2227-13-6	p-CHLOROPHENYL-2,4,6-TRICHLOROPHENYL SULFIDE (tetrasul)
622-51-5	p-TOLYLUREA	2243-62-1	1,5-NAPHTHALENEDIAMINE (1,5-diaminonaphthalene)
624-19-0	p-PHENYLENEDIAMINE.2HCl	2302-84-3	1-FORMYL-3-THIOSEMICARBAZIDE
624-84-0	FORMYLHYDRAZINE	2303-16-4	DIALLATE (Avadex)
628-02-4	HEXANAMIDE	2318-18-5	SENKIRKINE (renardine)
628-36-4	1,2-DIFORMYLHYDRAZINE	2353-45-9	FD & C GREEN NO. 3 (fast green FCF)
628-94-4	ADIPAMIDE	2385-86-5	MIREX
632-99-5	ROSANILINE.HCl (magenta 1)	2411-74-7	2-FURALDEHYDE SEMICARBAZONE
634-93-5	2,4,6-TRICHLOROANILINE	2438-88-2	2,3,5,6-TETRACHLORO-4-NITROANISOLE
636-21-5	o-TOLUIDINE.HCl	2439-10-3	n-DODECYLGUANIDINE ACETATE
636-23-7	2,4-DIAMINOTOLUENE.2HCl (2,4-toluediamine.2HCl)	2465-27-2	AURAMINE-O
637-07-0	CLOFIBRATE	2489-77-2	TRIMETHYLTHIOUREA
638-03-9	m-TOLUIDINE.HCl	2519-30-4	BLACK PN (brilliant black BN)
671-16-9	PROCARBAZINE	2578-75-8	N-[5-(5-NITRO-2-FURYL)-1,3,4-THIAZOL-2-YL]ACETAMIDE
683-50-1	2-CHLOROPROPAÑAL	2602-46-2	C.I. DIRECT BLUE 6
684-93-5	N-NITROSO-N-METHYLUREA (MNU)	2611-82-7	SK PURPLE (ponceau 4R)
685-91-6	DIETHYLACETAMIDE	2629-69-6	S-ETHYL-L-CYSTEINE
712-68-5	2-AMINO-5-(5-NITRO-2-FURYL)-1,3,4-THIAZOLE	2783-94-0	FD & C YELLOW NO. 6 (sunset yellow FCF)
720-69-4	4,6-DIAMINO-2-(5-NITRO-2-FURYL)-s-TRIAZINE	2921-88-2	O,O-DIETHYL-O-(3,5,6-TRICHLORO-2-PYRIDYL) PHOSPHOROTHIOATE
758-17-8	N-METHYL-N-FORMYLHYDRAZINE	3012-85-5	AMMONIUM CITRATE
765-34-4	GLYCIDALDEHYDE	3031-51-4	1-5-MORPHOLINOMETHYL-3-[(5-NITROFURFURYLIDENE) AMINO]-2-OXAZOLIDINONE.HCl
772-43-0	5-NITRO-2-FURAMIDOXIME	3068-88-0	beta-BUTYROLACTONE
828-00-2	DIMETHOXANE	3096-50-2	N-(9-OXO-2-FLUORENYL)ACETAMIDE
834-28-6	PHENFORMIN.HCl (NCI uses CAS NUMBER 114-86-3)	3166-93-3	4-CHLORO-o-TOLUIDINE.HCl
838-88-0	4,4'-METHYLENE-BIS(2-METHYLANILINE)	3276-41-3	3,6-DIHYDRO-2-NITROSO-2H-1,2-OXAZINE (N-nitroso-3,6-dihydrooxazine-1,2)
842-00-2	4-ETHYLSULPHONYLNAPHTHALENE-1-SULFONAMIDE	3456-10-9	PHENESTERIN
842-07-8	1-PHENYLAZO-2-NAPHTHOL	3458-22-8	3,3'-IMINO BIS-1-PROPANOL DIMETHANESULFONATE (ESTER).HCl (IPD)
860-22-0	FD & C BLUE NO. 2 (indigo carmine)	3564-09-8	FD & C RED NO. 1 (ponceau 3R)
865-21-4	VINBLASTINE	3567-69-9	C.I. FOOD RED 3 (carmoisine)
900-96-8	TRIPHENYL TIN ACETATE	3570-75-0	FORMIC ACID 2-[4-(5-NITRO-2-FURYL)-2-THIAZOLYL] HYDRAZIDE (FNT)
915-67-3	FD & C RED NO. 2 (amaranth)	3688-53-7	AF-2 (furyfuramide)
924-16-3	NITROSODIBUTYLAMINE	3693-22-9	2-AMINODIPHENYLENE OXIDE
930-55-2	N-NITROSOPYRROLIDINE	3741-38-6	GLYCOL SULFITE
952-23-8	PROFLAVINE.HCl HEMIHYDRATE	3761-53-3	D & C RED NO. 5 (ponceau MX)
961-11-5	TETRACHLORVINPHOS	3775-55-1	2-AMINO-5-(5-NITRO-2-FURYL)-1,3,4-OXADIAZOLE
968-81-0	ACETOHEXAMIDE	3778-73-2	ISOPHOSPHAMIDE
989-81-5	(2-CHLOROETHYL)TRIMETHYLAMMONIUM CHLORIDE (CCC)	3817-11-6	N-BUTYL-N-(4-HYDROXYBUTYL)NITROSAMINE
1066-30-4	CHROMIUM (III) ACETATE	3844-45-9	FD & C BLUE NO. 1 (brilliant blue FCF)
1067-33-0	DIBUTYL TIN DIACETATE	3851-16-9	N,N'-DIMETHYL-N,N'-DINITROSOPHTHALAMIDE
1072-53-3	ETHYLENE GLYCOL (glycol sulfate)	3883-43-0	2,3-DICHLORO-p-DIOXANE
1078-38-2	1-ACETYL-2-ISONICOTINOYLHYDRAZINE	4075-79-0	4-ACETYLAMINOBIIPHENYL (4'-phenylacetanilide)
1114-71-2	PROPYL N-ETHYL-N-BUTYLTHIOCARBAMATE (Tillam-6-E)	4106-86-5	3-DIBENZOFURANAMINE
1119-68-2	n-PENTYLHYDRAZINE.HCl	4164-28-7	DIMETHYLNITRAMINE
1120-71-4	PROPANE SULTONE	4342-03-4	DACARBAZINE (DIC)
1121-92-2	HEPTAMETHYLENIMINE	4363-03-5	3-HYDROXY-4-AMINOBIIPHENYL (4-amino-3-hydroxybiphenyl)
1133-64-8	NITROSOANABASINE	4483-22-3	3-HYDROXY-4-ACETYLAMINOBIIPHENYL
1146-71-0	5,7-DIMETHOXYCYCLOPENTENE]cCOUMARIN	4515-18-8	NITROSOPIPECOLIC ACID
1156-19-0	TOLAZAMIDE	4548-53-2	FD & C RED NO. 4 (ponceau SX)
1182-65-8	AFLATOXIN B1	4553-89-3	CHOCOLATE BROWN HT
1212-29-9	N,N'-DICYCLOHEXYLTHIOUREA	4680-78-8	FD & C GREEN NO. 1 (guinea green B)
1241-27-6	HEPTYLAMINE	4812-22-0	3-NITRO-3-HEXENE
1309-39-9	CHROMIC OXIDE PIGMENT	4998-76-9	CYCLOHEXYLAMINE.HCl
1327-53-3	ARSENIOUS OXIDE	5038-03-3	1-(2-HYDROXYETHYL)-3-[(5-NITROFURFURYLIDENE) AMINO]-2-IMIDAZOLIDINONE
1336-32-6	LEAD ACETATE, BASIC	5117-01-1	QUERCETIN DIHYDRATE
1338-21-6	AMMONIUM HYDROXIDE	5131-90-2	4-CHLORO-m-PHENYLENEDIAMINE
1420-04-8	CLONITRALID (niclosamide)	5141-20-8	FD & C GREEN NO. 2 (light green SF yellowish)
1466-28-6	NITROSO-2,6-DIMETHYLMORPHOLINE	5160-02-1	D & C RED NO. 9 (brilliant red)
1465-25-4	N-(1-NAPHTHYL)ETHYLENEDIAMINE.2HCl	5208-87-7	1'-HYDROXYSAFROLE
1508-45-8	PRORESID	5307-14-2	2-NITRO-p-PHENYLENEDIAMINE
1562-09-8	TRIFLURALIN	5351-66-5	BENZENESULPHONOHYDRAZIDE (BSH)
1596-84-6	DAMINOZIDE (succinic acid 2,2-dimethyl hydrazide, DMSA)	5456-28-0	SELENIUM DIETHYLDITHIOCARBAMATE (ethyl selenac)
1834-78-2	MALAOXON (malathion-O-analog)		
1701-77-5	METHOXYPHENYLACETIC ACID		
1746-01-6	2,3,7,8-TETRACHLORODIBENZO-p-DIOXIN (TCDD, dioxin)		
1777-84-0	3-NITRO-p-ACETOPHENETIDE		
1836-75-5	NITROFEN		
1887-46-6	CHLOROTHALONIL		
1912-24-9	ATRAZINE		
1918-02-1	PICLORAM		
1934-21-0	FD & C YELLOW NO. 5 (tartrazine)		
1937-37-7	C.I. DIRECT BLACK 38		

CAS NUMBER*	CHEMICAL NAME
5461-85-8	N-ISOBUTYL-N'-NITRO-N-NITROSOGUANIDINE
5667-15-7	C.I. PIGMENT YELLOW 83
5632-47-3	N-NITROSOPIPERAZINE
5800-19-1	METIAPINE
5803-51-0	2,5-DIMETHOXY-4'-AMINOSTILBENE
5834-17-3	2-METHOXY-3-AMINODIBENZOFURAN
5979-28-2	C.I. PIGMENT YELLOW 16
6109-97-3	3-AMINO-9-ETHYLCARBAZOLE.HCl
6119-92-2	DINITRO(1-METHYLHEPTYL)PHENYL CROTONATE (Karathane)
6120-10-1	4-DIMETHYLAMINO-3,5-XYLENOL
6294-89-9	METHYL CARBAZATE
6334-11-8	2,4,6-TRIMETHYLANILINE.HCl
6358-85-8	C.I. PIGMENT YELLOW 12 (diarylanilide yellow)
6369-59-1	2,5-DIAMINOTOLUENE SULFATE (2,5-toluenediamine sulfate)
6379-49-0	1,2,3-TRICHLORO-4,6-DINITROBENZENE (Vancide PB)
6386-58-6	SODIUM BITHIONOLATE (Vancide BN)
6452-73-9	OXPRENOLOL.HCl
6859-47-3	2-(CHLOROMETHYL)PYRIDINE.HCl
6969-48-4	3-(CHLOROMETHYL)PYRIDINE.HCl
6965-71-6	alpha-(2,5-DICHLOROPHENOXY)PROPIONIC ACID
7008-42-8	ACRONYCINE
7227-91-0	1-PHENYL-3,3-DIMETHYLTRIAZENE
7316-37-2	DIETHYL-beta,gamma-EPOXYPROPYLPHOSPHONATE
7347-49-1	N,N-DIETHYL-4-(4'-PYRIDYL-1'-OXIDE(AZO)ANILINE
7411-49-6	3,3',4,4'-TETRAAMINOBIIPHENYL.4HCl (3,3'-diaminobenzidine.4HCl)
7422-80-2	1,2-DI-n-BUTYLHYDRAZINE.2HCl
7440-02-0	NICKEL
7446-34-6	SELENIUM SULFIDE
7487-94-7	MERCURIC CHLORIDE
7519-36-0	NITROSOPROLINE
7631-89-2	ARSENATE, SODIUM
7631-99-4	NITRATE, SODIUM
7632-00-0	NITRATE, SODIUM
7681-49-4	FLUORIDE, SODIUM
7681-93-8	PIMARICIN
7722-84-1	HYDROGEN PEROXIDE
7757-82-6	SULFATE, SODIUM (disodium sulfate)
7768-01-2	BROMATE, POTASSIUM
7772-99-8	TIN (II) CHLORIDE (stannous chloride)
7782-49-2	SELENIUM
7782-60-5	CHLORINE
7784-46-5	ARSENITE, SODIUM
7787-59-9	BISMUTH OXYCHLORIDE
7790-84-3	CADMIUM SULPHATE
8001-35-2	TOXAPHENE
8001-50-1	STROBANE (dichloride mothproof)
8002-43-5	SOYBEAN LECITHIN
8003-03-0	ASPIRIN, PHENACETIN, AND CAFFEINE (APC)
8006-90-4	PEPPERMINT OIL
8015-12-1	NORLESTRIN
8015-30-3	ENOVID (norethynodrel/mestranol [86:1])
8062-16-2	ACTINOMYCIN C (kanamycin)
8066-92-6	OVULEN (ethynodiol diacetate/ethinyl estradiol [10:1])
8066-91-6	LUTESTRAL
9000-07-1	CARRAGEENAN, NATIVE
9004-32-4	EDIFAS B (cellulose carboxymethyl ether, sodium)
9004-59-5	EDIFAS A (methyl ethyl cellulose)
10034-93-2	HYDRAZINE SULFATE
10048-13-2	STERIGMATOCYSTIN
10102-43-9	NITRIC OXIDE
10318-26-0	DIBROMODULCITOL
10360-28-6	COPPER-8-HYDROXYQUINOLINE
10473-70-8	1-(4-CHLOROPHENYL)-1-PHENYL-2-PROPYNYL CARBAMATE
10689-74-9	1-AMYL-1-NITROSOUREA
11096-82-5	AROCCLOR 1260 (PCB)
12034-09-2	NIOBATE, SODIUM
12122-87-7	ZINC ETHYLENEBISTHIOCARBAMATE (zineb)
12125-02-9	AMMONIUM CHLORIDE
12236-46-3	CHOCOLATE BROWN FB
12427-38-2	MANGANESE ETHYLENEBISTHIOCARBAMATE (maneb)
12663-46-6	CYCLOCHLOROTINE
13010-07-8	N-PROPYL-N'-NITRO-N-NITROSOGUANIDINE
13010-08-7	N-BUTYL-N'-NITRO-N-NITROSOGUANIDINE
13010-10-1	N-PENTYL-N'-NITRO-N-NITROSOGUANIDINE
13073-35-3	ETHIONINE
13171-21-6	PHOSPHAMIDON

CAS NUMBER*	CHEMICAL NAME
13256-11-6	NITROSO-N-METHYL-N-(2-PHENYL)ETHYLAMINE
13292-46-1	RIFAMPICIN
13366-73-9	DIELDRIN, PHOTO-
13483-87-7	TITANIUM DIOXIDE
13472-45-2	TUNGSTATE, SODIUM
13483-18-6	BIS-1,2-(CHLOROMETHOXY)ETHANE
13510-49-1	BERYLLIUM SULFATE
13743-07-2	1-(2-HYDROXYETHYL)-1-NITROSOUREA
13927-77-0	NICKEL DIBUTYLDITHIOCARBAMATE (Vanguard N)
14026-03-0	R(-)-2-METHYL-N-NITROSOPIPERIDINE
14238-68-0	CADMIUM DIETHYLDITHIOCARBAMATE (ethyl cadmate)
14324-55-1	ZINC DIETHYLDITHIOCARBAMATE (ethyl zimate)
14484-64-1	FERRIC DIMETHYLDITHIOCARBAMATE (ferbam)
14644-61-2	ZIRCONIUM (IV) SULFATE
15356-70-4	dl-MENTHOL (NCI uses CAS NUMBER 88-78-1)
15721-02-5	2,2',5,5'-TETRACHLOROENZIDINE
15878-93-3	ANHYDROGLUCOCHLORAL (alpha-chloralose)
16071-86-6	C.I. DIRECT BROWN 95
18219-98-0	2-NITROSOMETHYLAMINOPYRIDINE
18219-99-1	4-NITROSOMETHYLAMINOPYRIDINE
16423-68-0	FD & C RED NO. 3 (erythrosine)
16899-10-8	4-(4-N-METHYL-N-NITROSAMINOSTYRYL)QUINOLINE
16813-36-8	1-NITROSO-5,6-DIHYDROURACIL
17326-81-2	3-AMINO-4-ETHOXYACETANILIDE
17308-59-2	N-NITROSOEPHEDRINE
17573-25-5	PHORBOL
18413-14-4	ETHYLHYDRAZINE.HCl
18523-69-8	ACETONE4-(5-NITRO-2-FURYL)-2-THIAZOLYLHYDRAZONE
18382-53-8	NITRILOTRIACETIC ACID, TRISODIUM SALT, MONOHYDRATE
18383-66-4	STREPTOZOTOCIN
18968-99-5	2-AMINO-5-PHENYL-2-OXAZOLIN-4-ONE + Mg(OH)2 (magnesium pemoline)
19010-66-3	LEAD DIMETHYLDITHIOCARBAMATE (ledate)
19334-02-7	CYCLOHEXYLAMINE SULFATE
20265-97-8	p-ANISIDINE.HCl
20570-96-1	BENZYLHYDRAZINE.2HCl
20917-49-1	NITROSOHEPTAMETHYLENEIMINE
20941-65-5	ETHYL TELLURAC
21280-46-8	BISMUTH DIMETHYLDITHIOCARBAMATE (biamate)
21416-87-5	ICRF-159
21436-96-4	2,4-XYLIDINE.HCl
21436-97-5	2,4,5-TRIMETHYLANILINE.HCl
21638-36-8	4-METHYL-1-[(5-NITROFURFURYLIDENE)AMINO]-2-IMIDAZOLIDINONE
21884-44-6	LUTEOSKYRIN
22571-95-5	SYMPHYTINE
22839-47-0	ASPARTAME
22866-79-6	ESTRADIOL MUSTARD
23746-34-1	BIS-2-HYDROXYETHYLDITHIOCARBAMIC ACID, POTASSIUM
24554-26-5	N-[4-(5-NITRO-2-FURYL)-2-THIAZOLYL]FORMAMIDE (FANFT)
25081-31-6	NITROSOIMINODIACETIC ACID
25168-26-7	2,4-DICHLOROPHENOXYACETIC ACID, ISOCTYL ESTER
26049-68-3	2-HYDRAZINO-4-(5-NITRO-2-FURYL)THIAZOLE (HNT)
26049-69-4	2-(2,2-DIMETHYLHYDRAZINO)-4-(5-NITRO-2-FURYL)THIAZOLE
26049-70-7	2-HYDRAZINO-4-(p-NITROPHENYL)THIAZOLE
26049-71-8	2-HYDRAZINO-4-(p-AMINOPHENYL)THIAZOLE
26541-51-5	N-NITROSOTHIOMORPHOLINE
26628-22-8	AZIDE, SODIUM
27323-18-8	AROCCLOR 1254 (PCB)
27774-13-6	VANADYL SULFATE
28300-74-5	ANTIMONY POTASSIUM TARTRATE
28314-03-6	1-ACETYLAMINOFLUORENE (N-1-fluorenylacetylamine)
28322-02-3	4-ACETYLAMINOFLUORENE (N-4-fluorenylacetylamine)
29611-03-8	AFLATOXICOL
29929-77-9	N-NITROSO-2,2,4-TRIMETHYL-1,2-DIHYDROQUINOLINE POLYMER
30310-80-6	NITROSOHYDROXYPROLINE
31873-81-1	FORMIC ACID 2-[4-(2-FURYL)-2-THIAZOLYL]HYDRAZIDE
32827-00-4	IMINODIACETIC ACID, MONOSODIUM
32852-21-4	FORMIC ACID 2-(4-METHYL-2-THIAZOLYL)HYDRAZIDE
33339-33-2	1,2-DIHYDRO-2-(5-NITRO-2-THIENYL)QUINAZOLIN-4(3H)-ONE
33339-36-5	4-(2-HYDROXYETHYLAMINO)-2-(5-NITRO-2-THIENYL)QUINAZOLINE
33857-26-0	2,7-DICHLORODIBENZO-p-DIOXIN (DCDD)
34176-62-8	2-HYDRAZINO-4-PHENYLTHIAZOLE
34627-78-6	1'-ACETOXYSAFROLE
35658-65-2	CADMIUM CHLORIDE MONOHYDRATE

CAS NUMBER ^a	CHEMICAL NAME
38133-88-7	N-[3-(5-NITRO-2-FURYL)-1,2,4-OXADIAZOLE-5-YL]-METHYLACETAMIDE
38702-44-0	S(+)-2-METHYL-N-NITROSOPIPERIDINE
38434-77-4	ETHYLNITROSOCYANAMIDE (nitrosoethanecarbonitrile)
38514-71-5	2-AMINO-4-(5-NITRO-2-FURYL)THIAZOLE
38571-73-2	TRIS-1,2,3-(CHLOROMETHOXY)PROPANE
38777-13-8	NITROSO-BAYGON
39156-41-7	2,4-DIAMINOANISOLE SULFATE (NCI uses CAS NUMBER 616-05-4)
39801-14-4	MIREX, PHOTO-
40549-68-3	TETRAHYDRO-2-NITROSO-2H-1,2-OXAZINE
42011-48-3	2,2,2-TRIFLUORO-N-[4-(5-NITRO-2-FURYL)-2-THIAZOLYL]ACETAMIDE
42579-28-2	1-NITROSOHYDANTOIN
43054-45-1	CLOMIPHENE CITRATE
50892-23-4	[4-CHLORO-6-(2,3-XYLIDINO)-2-PYRIMIDINYLTHIO]ACETIC ACID
51325-35-0	N,N'-[6-(5-NITRO-2-FURYL)-a-TRIAZINE-2,4-DIYL]BISACETAMIDE
51542-33-7	N-NITROSOBENZTHIAZURON (1-(2'-benzothiazolyl)-3-methyl-3-nitrosourea)
51786-53-9	2,5-XYLIDINE.HCl
52207-83-7	ALLYLHYDRAZINE.HCl
53809-64-6	N-NITROSOBIS(2-HYDROXYPROPYL)AMINE
54150-89-5	2,4-DIMETHOXYANILINE.HCl
54749-90-5	CHLOROZOTOCIN
55556-92-8	NITROSO-1,2,3,6-TETRAHYDROPYRIDINE
55557-00-1	DINITROSOHOMOPIPERAZINE
55557-03-4	NITROSOMETHYLPHENIDATE
55738-54-0	trans-2-[(DIMETHYLAMINO)METHYLIMINO]-5-[2-(5-NITRO-2-FURYL)VINYL]-1,3,4-OXADIAZOLE
55965-13-4	EMULSIFIER YN
56654-52-5	1,3-DIBUTYL-1-NITROSUREA
56795-65-4	n-BUTYLHYDRAZINE.HCl
56795-66-5	PROPYLHYDRAZINE.HCl
56894-91-8	BIS-1,4-(CHLOROMETHOXY)-p-XYLENE
58139-48-3	4-MORPHOLINO-2-(5-NITRO-2-THIENYL)QUINAZOLINE
59536-61-1	POLYBROMINATED BIPHENYLS
60391-92-6	CARBOXYMETHYLNITROSUREA (CMNU)
61702-44-1	2-CHLORO-p-PHENYLENEDIAMINE SULFATE
63412-06-6	N-METHYL-N-NITROSOBENZAMIDE
63886-77-1	TETRAFLUORO-m-PHENYLENEDIAMINE.2HCl
64039-27-6	beta-THIOGUANINE DEOXYRIBOSIDE (beta-TGdR. NCI uses CAS NUMBER 789-61-7)
64049-29-2	4,4'-METHYLENE-BIS(2-CHLOROANILINE).2HCl
65734-38-5	N'-ACETYL-4-(HYDROXYMETHYL)PHENYLHYDRAZINE
68107-26-8	NITROSOMETHYLNUNDECYLAMINE
69658-91-0	3-NITROSOMETHYLAMINOPYRIDINE
72254-58-1	3-AMINO-1-METHYL-5H-PYRIDO[4,3-b]INDOLE ACETATE (trp-P-2 acetate)
74920-78-8	N-ETHYL-N-FORMYLHYDRAZINE
75104-43-7	3-AMINO-1,4-DIMETHYL-5H-PYRIDO[4,3-b]INDOLE ACETATE (trp-P-1 acetate)
75198-31-1	3-(5-NITRO-2-FURYL)-IMIDAZO(1,2-alpha)PYRIDINE (NFIP)
77337-54-3	N-N'-PROPYL-N-FORMYLHYDRAZINE
...	1'-OXOSAFROLE

CAS NUMBER ^a	CHEMICAL NAME
...	1,1-DI-n-BUTYLHYDRAZINE
...	1-METHYL-1,4-DIHYDRO-7-[2-(5-NITROFURYL)VINYL]-4-OXO-1,8-NAPHTHYRIDINE-3-CARBOXYLATE, POTASSIUM
...	2-CHLORO-5-(3,5-DIMETHYLPYPERIDINOSULFONYL)BENZOIC ACID
...	4-BIS(2-HYDROXYETHYL)AMINO-2-(2-THIENYL)QUINAZOLINE
...	4-BIS(2-HYDROXYETHYL)AMINO-2-(5-NITRO-2-THIENYL)QUINAZOLINE
...	4-CHLORO-6-(2,3-XYLIDINO)-2-PYRIMIDINYLTHIO(N-beta-HYDROXYETHYL)ACETAMIDE
...	5,7-DIMETHOXYCYCLOPENTENONE[2,3-c]COUMARIN
...	5,7-DIMETHOXYCYCLOPENTENONE[3,2-c]COUMARIN
...	5-NITRO-2-FURANMETHANEDIOL DIACETATE
...	ACETYLATED DIAMYLOPECTIN PHOSPHATE
...	ACETYLATED DISTARCH ADIPATE
...	ACETYLATED DISTARCH GLYCEROL
...	ACETYLATED DISTARCH PHOSPHATE
...	AFLATOXIN, CRUDE
...	ALKYLBENZENESULFONATE, LINEAR
...	ALUMINUM POTASSIUM SULFATE
...	CARRAGEENAN, ACID-DEGRADED
...	CLIVORINE
...	D & C RED NO. 10
...	DI-tert-BUTYL-4-HYDROXYMETHYL PHENOL
...	DIPENTAMETHYLENETHIURAM HEXASULFIDE (sulfide)
...	ENOVID-E (norethynodrel/mestranol [25:1])
...	GERMANATE, SODIUM
...	HYDROXYPROPYL DISTARCH GLYCEROL
...	ISONICOTINIC ACID VANILLYLIDENEHYDRAZIDE (phthivazid)
...	LEUPEPTIN
...	N,N-DIPROPYL-4-(4'-PYRIDYL-1'-OXIDE)AZOANILINE
...	N-(N-METHYL-N-NITROSO-CARBAMOYL)-L-ORNITHINE (nitrosourea amino acid)
...	N-ETHYL-N'-NITRO-N-NITROSOGUANIDINE
...	N-N-BUTYL-N-FORMYLHYDRAZINE
...	N-NITROSOBIS(2,2,2-TRIFLUOROETHYL)AMINE (6-F-DEN)
...	NIGROSINE
...	NITROSOCHLORDIAZEPOXIDE
...	NOVADELOX
...	PETASITENINE
...	PHOSPHATED DISTARCH PHOSPHATE
...	PIPERONYL BUTOXIDE IN SOLVENT (butoxide)
...	POLYVINYLPIRIDINE-N-OXIDE
...	PREMARIN (conjugated equine estrogens)
...	QUILLAJA EXTRACT (spray-dried aqueous extract of quillaja bark)
...	STARCH ACETATE
...	SULFITE, POTASSIUM METABI-
...	TITANIUM OXALATE, POTASSIUM
...	BIS-1,4-(CHLOROMETHOXY)BUTANE
...	BIS-1,6-(CHLOROMETHOXY)HEXANE
...	N-1-DIACETAMIDOFLOURENE
...	(N-6)-(METHYLNITROSO)ADENINE
...	(N-6)-(METHYLNITROSO)ADENOSINE
...	(N-6)-METHYLADENINE
...	(N-6)-METHYLADENOSINE

^aCAS NUMBER = Chemical Abstracts Service registry number

APPENDIX 3: STRAIN CODES AND DEFINITIONS

Code	Strain
aah	A/He
abi	Ab X IF
aci	ACI
afr	African green (<i>Cercopithecus aethiops</i>)
agu	AGUS
aif	A X IF
ain	ACI/n
ajj	A/JJms
akr	AKR
aks	AKR/J
alb	albino
amm	A
aps	Alderly Park
asd	Sprague-Dawley albino

Code	Strain
asp	ASH-CS1
asw	Swiss-Webster albino
b46	BR 46
b6a	B6AKF1
b6c	B6C3F1
baj	BALB/cJ
bal	BALB/c
bbb	Bush babies (<i>Galago crassicaudatus</i>)
bbi	Bethesda black
bce	BALB/cHe
bcn	BALB/c StCrIfC3Hf/Netr
bd2	BD II
bdf	BD VI
bdr	BD

Code	Strain
beg	beagle
bfm	Buffalo-Mai
buf	Buffalo
c17	C17
c3c	C3H/AnCum
c3d	C3H/Dp
c3e	C3HeB/Fe
c3h	C3H
c3j	C3H/HeJ
c3l	C3H (C3H/Anl) (Anl 70)
c3p	C3HeB
c3s	C3H/St
c56	C57BL/6J
c5l	C57BL
c7b	(C57BL/6 X BALB/c)F1
c7l	C57L
cb6	C57BL/6
cba	CBA
cbe	CBA/Cb/Se
ebh	CBA/H-T6
cbj	C3HeB/FeJ
cbo	C.B. hooded
cbr	CB
cbs	Cb/Sc
cbt	Chester Beatty albino
cd1	Charles River CD1
cdf	CDF1
cdr	Charles River CD
cf1	CF-1
cfe	CFE
cf1	CF1P
cfn	CFN
cfr	CF
che	C57BL/He
chf	C3HfB
chh	C3H/He
chi	CD-1 HaM/ICR
chj	C3HeB/Jax
chm	Charles River
cif	(C57 x IF)F1
crf	(C3H x RIII)F1
csa	Charles River albino
csb	CSb
csc	C57L/He x 129/Rr x C3HeB/De x SWR/Ly (hybrid of these parent strains)
ctn	CTM
ewf	Carworth Farms
ews	CFW
cym	Cynomolgus (<i>Macaca fascicularis</i>)
dba	DBA/2
ddn	ddNi
ddx	dd
ddy	DDY
don	Donryu
esd	Eastern Sprague-Dawley
f34	Fischer 344
f3d	F344/DuCrj
fdr	FDRL
fds	Food and Drug Research Laboratories stock rats
fis	Fischer
hew	Hebrew University
hic	Ha/ICR
hrl	Harlan
hza	Holtzman albino (Sprague-Dawley derived)
ic3	ICRC x C3h (Jax)
ici	ICI
icm	ICR
icr	ICR/Jcl
ife	IF x C57
ifm	IF

Code	Strain
jic	JCL: ICR
leb	Long-Evans BLU: (LE)
lev	Long-Evans
mgr	mongrel
mrc	MRC
mrw	MRC-Wistar
nbr	NBR
nbw	NZBW (hooded black and white strain)
nmh	Han: NMRI
nmr	NMRI
non	non-inbred
nra	Norwegian albino
nss	not specified
nzd	NZR/Gd
ofs	OFA (Sprague-Dawley derived)
osm	Osborne-Mendel
por	MRC Porton (Wistar derived)
r3m	RIII
r1m	RF
r1e	Rhesus (<i>Macaca mulatta</i>)
scd	Swiss CD-1
sda	Sprague-Dawley
shc	Sherman COBS
she	Sherman
shr	Swiss/H/Riop
sjs	SJL/J
sls	Slc-Wistar
smw	Sas: MRC(W1)BR
sss	Sprague-Dawley Spartan
swa	Swiss albino
swi	Swiss
swr	SWR
sww	Swiss Webster
syg	Syrian Golden
tfl	Tuck
the	Theiller's Original
tmm	TM
tst	Tree shrew (<i>Tupaia glis</i>)
wag	WAG
wal	Wistar albino
wi2	Wistar II
wid	Wistar/FDRL
wio	Wistar-OSU
wis	Wistar
wmf	Wistar-Mai-Furth
wsh	Han: WIST
wsr	Wistar-random
wsw	Wilmslow Wistar
wws	Wistar W.74
xvi	XVII/G

APPENDIX 4: ROUTE OF ADMINISTRATION CODES AND DEFINITIONS

Code	Route of Administration
cap	gelatin capsule, p.o.
eat	diet
gav	gavage
inh	inhalation
ipj	intraperitoneal injection
ivj	intravenous injection
mix	multiple routes Used for two compounds: 1)thiourea (rats): intraperitoneal injection followed by water; 2) procarbazine-HCl (monkeys): a variety of combinations of diet, subcutaneous, intraperitoneal, and intravenous injection.
orl	gavage preweaning, followed by diet
wat	water

APPENDIX 5: SITE CODES AND DEFINITIONS

Code	Site	Code	Site
---	all target sites	mix	more than one site; sites specified in published paper
abc	abdominal cavity	mln	mesenteric lymph node
abd	abdomen	mth	mouth
adr	adrenal gland	mul	multiple organs
adu	acoustic duct	mus	muscle
auc	external auditory canal	MXA	more than one site, combined by NCI/NTP
aur	auricular region	MXB	more than one site, combined by Berkeley
b/l	lung/bronchiole	myc	myocardium
bcm	buccal mucosa	nac	nasal mucosa
bil	bile duct	nap	nasal passageway
blv	blood vessels	nas	nasal cavity
bod	body cavities	nol	n. olfactorius
bom	bone marrow	nse	nose
bon	bone	nsm	nasal septum
bra	brain	nsp	nasopharynx
brs	brain stem	ntu	nasal turbinate
ccx	cerebral cortex	oes	oesophagus
cec	cecum	olb	olfactory bulb
cli	clitoral gland	opx	oropharynx
clr	colorectum	ova	ovary
cns	central nervous system	pae	pancreas, exocrine
col	colon	pan	pancreas
crb	cerebrum	pdu	pancreatic duct
cri	cerebellum	pec	peritoneal cavity
der	dermis	pep	paraepididymal tissue
dgt	digestive tract	per	peritoneum
duo	duodenum	phr	pharynx
eac	ear canal	pit	pituitary gland
ear	ear	pls	palate, soft
edu	ear duct	pni	pancreatic islets
ehp	extrahepatic tissue	prn	peripheral nervous system
eld	eyelid	pre	preputial gland
epi	epidermis	prn	pararenal tissue
eso	esophagus	pty	parathyroid
eye	eye	rec	rectum
fat	fat	rel	reticuloendothelium
fhd	forehead	rep	reproductive tract
for	forestomach	res	respiratory system
g/b	gall bladder/bile duct	sev	seminal vesicle
gal	gall bladder	sft	skin of foot and toe
gnv	gingiva	skb	skin of back
hag	Harderian gland	skf	skin of flank
hea	heart	ski	skin
hnt	hard palate/nasal turbinates	slg	salivary gland
hpl	hypophysis	smi	small intestine
hum	humerus	spe	splenic capsule
ilm	ileum	spd	spinal cord
isp	interscapulum	spl	spleen
itl	intestinal tract	stg	stomach, glandular
itn	intestine	stn	stomach, nonglandular
jaw	jaw	sto	stomach
jej	jejunum	sub	subcutaneous tissue
k/c	kidney/cortex	tba	all tumor bearing animals
k/l	kidney/papilla	tes	testis
k/p	kidney/pelvis	thi	thigh
kid	kidney	thm	thymus gland
ktu	kidney tubule	thy	thyroid gland
l/b	lung/bronchus	tnv	tunica vaginalis
lab	lung/alveoli/bronchioles	ton	tongue
lar	larynx	trh	trachea
lgi	large intestine	tyf	thyroid follicle
liv	liver	ubl	urinary bladder
lmr	lymphoreticular system	ugi	upper gastrointestinal tract
lun	lung	unt	urinary tract
lyd	lymph node	ure	ureter
mam	mammary tissue (other than or including more than mammary gland)	ute	uterus
mds	mediastinum	utm	uterus/endometrium
mei	mesenteric intestine	vag	vagina
mey	mesentery	ver	vertebra
mgl	mammary gland	zym	Zymbal's gland

APPENDIX 6:
HISTOPATHOLOGY CODES AND DEFINITIONS

Code	Histopathology	Code	Histopathology
---	all tumors	esp	endometrial stromal polyp
a/a	alveolar/bronchiolar adenoma	ess	endometrial stromal sarcoma
a/c	alveolar/bronchiolar carcinoma	exa	exocrine adenoma
a/t	alveolar/bronchiolar tumor	fba	fibroadenoma
aca	adenocarcinoma in adenomatous polyp	fbs	fibrosarcoma
acc	acinar-cell carcinoma	fca	follicular-cell adenoma
acn	adenocarcinoma, NOS ^a	fcc	follicular-cell carcinoma
ace	acidophil adenoma	fdc	follicular adenocarcinoma
adc	adenocarcinoma	fep	fibroepithelial tumor
ade	adenoma	fib	fibroma
adf	adenofibroma	fih	fibrous histiocytoma
adm	adenomatous polyp, NOS or adenocarcinoma in adenomatous polyp	foa	follicular adenoma
adn	adenoma, NOS	gcc	granulosa-cell carcinoma
adp	adenomatous polyp	gct	granulosa-cell tumor
aep	adenomatous endometrial polyp	gln	glioma, NOS
aff	adenofibroma/fibroadenoma	grl	granulocytic leukemia
agm	angioma	gsa	granulocytic sarcoma
akt	adenoma-like tumor	hae	hemangioendothelioma
ala	alveolar-cell adenoma	hct	hepatocellular tumor
alc	alveolar-cell carcinoma	hem	hemangioma
ald	alveolar adenoma	hes	hemangiosarcoma
aml	acute myeloblastic leukemia	hms	hemangioendothelial sarcoma
amy	adenomyoma	hnd	hyperplastic nodules
ane	angio-endothelioma, malignant	hpa	hepatocellular adenoma
ang	angiosarcoma	hpc	hepatocellular carcinoma
apc	anaplastic carcinoma	hph	hepatocellular hyperplastic nodule
apn	adenomatous polyp, NOS	hpm	hemangiopericytoma, malignant
asm	adenocarcinoma with squamous metaplasia	hpn	hepatocellular neoplastic nodule
ast	astrocytoma	hpt	hepatoma
b/a	bronchiolar adenoma	ica	interstitial-cell adenoma
bcc	basal-cell carcinoma	iet	interstitial-cell tumor
bcp	basal-cell papilloma	ile	leukemia, indeterminate type
bct	basal-cell tumor	isa	islet-cell adenoma
bda	bile duct adenoma	isc	islet-cell carcinoma
bde	bile duct carcinoma	ivc	carcinoma, invasive
bdt	bile duct tumor	kes	Kupffer-cell sarcoma
ben	benign tumor	ker	keratoacanthoma
bhp	hepatoma, benign	lbl	lymphoblastic lymphoma
bht	hepatocellular tumor, benign	lca	liver-cell adenoma
blc	biliary cystadenoma	lcc	liver-cell carcinoma
bro	bronchogenic carcinoma	lcl	lymphocytic lymphoma
bsa	basophil adenoma	lct	liver-cell tumor
cac	cholangioadenocarcinoma	ldc	Leydig-cell tumor
can	carcinoma, NOS	lei	leiomyosarcoma
car	carcinoma	leu	leukemia
cas	carcinosarcoma	lhc	lymphoma, histiocytic type
cca	c-cell adenoma	lip	lipoma
ccn	cystadenocarcinoma, NOS	lka	acute leukemia
cer	c-cell carcinoma	lkm	lymphoma/leukemia
ccy	cholangioma, cystic	lle	lymphocytic leukemia
cho	cholangioma	lpb	liver-cell tumor, type B
clc	cholangiocarcinoma	lps	liposarcoma
cnd	carcinoid	lut	luteoma
coa	cortical adenoma	lyk	lymphatic leukemia
coc	cortical carcinoma	lym	lymphoma
cra	chromophobe adenoma	lys	lymphosarcoma
cre	chromophobe carcinoma	mag	malignant glioma
crt	carcinoma, combined glandular and squamous type	mal	malignant tumor
cuc	ceruminous carcinoma	mda	medullary adenoma
cvh	cavernous hemangioma	mec	muco-epidermoid carcinoma
cye	cystadenoma	men	mesothelioma, NOS
cyn	cystadenoma, NOS	mhe	mixed hepato/cholangio carcinoma
eal	leukemia, early	mhp	malignant hepatoma
ene	esthesioneuroepithelioma	mhs	histiocytoma, malignant
epc	epidermoid carcinoma	mht	hepatocellular tumor, malignant
epd	ependyoblastoma	mix	more than one tumor type; tumor types specified in published paper
epn	epithelial neoplasm	mle	melanocytoma
epo	epithelioma	mle	monocytic leukemia

Code	Histopathology
mlh	malignant lymphoma, histiocytic type
mlk	myelogenous leukemia
mlt	melanotic tumor
mly	malignant lymphoma
mng	meningioma
mno	malignant lymphoma, NOS
mnp	mesenchymal neoplasm
msm	mesothelioma, malignant
mso	mesothelioma
mua	mucinous adenocarcinoma
muc	mucinous cystadenocarcinoma
MXA	more than one tumor type, combined by NCI/NTP
MXB	more than one tumor type, combined by Berkeley
mye	myelocytic leukemia
myl	myeloid leukemia
nen	neoplasm, NOS
neo	neoplasm
nep	nephroblastoma
neu	neuroblastoma
nfs	neurofibrosarcoma
nnd	neoplastic nodule
nod	nodular hyperplasia
npm	neoplasm, NOS, malignant
oec	olfactory epithelial carcinoma
olc	olfactory carcinoma
oli	oligodendroglioma
oln	olfactory neuroblastoma
ost	osteosarcoma
pac	papillary adenocarcinoma
pam	papilloma
pas	papillomatosis
pca	parenchymal adenoma
pcn	papillary cystadenocarcinoma, NOS
pcy	papillary cystadenoma, NOS
phe	pheochromocytoma
phm	pheochromocytoma, malignant
pla	polypoid adenoma
plc	plasmacytoma
pms	papillary mesothelioma
pol	polyp
ppa	papillary adenoma
ppc	papillary carcinoma
ppn	papilloma, NOS
ppp	papillary polyp
ptc	papillary transitional-cell carcinoma
ptm	papillary tumor
pvc	carcinoma, preinvasive
rec	renal-cell carcinoma
ret	renal-cell tumor
ret	reticulum-cell tumor
rhb	rhabdomyosarcoma
rna	reticulum-cell neoplasm, type A
rsc	respiratory epithelial carcinoma
rtb	reticulum-cell sarcoma, type B
rts	reticulum-cell sarcoma
sad	scirrhous adenocarcinoma
sar	sarcoma
sea	solid-cell adenoma
ses	spindle-cell sarcoma
set	Sertoli-cell tumor
sea	sebaceous adenoma
seb	sebaceous adenoma and adenocarcinoma
sec	sebaceous adenocarcinoma
sgc	sweat gland carcinoma
sqa	squamous-cell tumor
sqc	squamous-cell carcinoma
sqk	squamous-cell carcinoma, keratinized
sqp	squamous-cell papilloma
sqc	squamous-cell carcinoma, stratified

Code	Histopathology
srn	sarcoma, NOS
ssc	sebaceous squamous-cell carcinoma
tec	transitional-cell carcinoma
tla	tubular-cell adenoma
tma	thymoma
tpp	transitional-cell papilloma
tri	trichoeplithelioma
tua	tubular adenoma
tum	tumor or more than one tumor type; tumor types not specified in published paper
uac	tubular-cell adenocarcinoma
ule	undifferentiated carcinoma
ule	undifferentiated leukemia
vsc	all vascular tumors

*NOS = not otherwise specified.

APPENDIX 7: NOTECODES AND DEFINITIONS

Code	Definition
a	The exposure time reported on the plot is an average of the different exposure times of the individual dose groups in the experiment. In addition, for NCI/NTP bioassays an "a" may indicate that all animals in one group were dead long before those in another group, and therefore the experiment time on the plot is an average of experiment times for the different dose groups. (In the TD ₅₀ calculation for the NCI/NTP bioassays, full lifetable data have been used.)
b	Diet was specially prepared to be deficient in one or more vitamins.
d	A cyclic dosing schedule was followed for part of the exposure time, with at least one week between cycles, e.g., 3 weeks dosed, one week not dosed.
e	For the general literature we have used an effective number of animals in a group whenever possible. This effective number is either: (1) the number of animals examined, or (2) the number of animals alive at the time of appearance of the first tumor. For some NCI/NTP bioassays the Technical Report includes both time-adjusted and unadjusted statistical analyses. Effective number indicates that some sites in these experiments have been included in the plot on the basis of the time-adjusted analysis.
f	Diet was specially prepared to have a lower than average protein level.
g	Some or all of the animals were used as breeders during the course of the experiment.
k	For interim and serial sacrifice experiments, we have reported each sacrifice time as a separate experiment. The k notecode identifies these sacrificed groups. Unscheduled deaths have been included with the terminal sacrifice data, wherever possible and do not receive a notecode.
m	The calculated dose level for a group is an average of either (1) different doses administered to individual animals, or (2) the range of doses administered.
r	Authors either examined or chose to report data for only a few selected tissues. Therefore, this is a restricted site analysis.
s	Authors noted that survival was decreased due to toxicity or disease.
u	Tests in monkeys are still in progress. The vinylidene chloride experiment in mice has been completed, but the final report has not yet been published.
v	Variable or irregular dosing schedules have been used, e.g., dose level changed during the experiment.
w	Monkey control animals are from a colony which includes both vehicle and untreated controls. Some animals have been used as breeders. Seventy percent of the animals are born in the colony; thirty percent are brought in from the wild as adults. The age of controls ranges from neonate to greater than 16 years. Only controls which have died are included in the TD ₅₀ calculations.
x	Exposure began before the animals were weaned.

Code	Definition
y	In experiments from two papers, animals were dosed for only 25 weeks; one week short of the standard criterion. Due to rounding, 6 months is reported as the exposure time on the plot.
z	In a report of these vinyl chloride experiments (20), the author notes "All the animals exposed to the highest doses (30,000 and 10,000 ppm for 52 weeks), with or without tumors, were examined radiologically during treatment and/or at death; moreover, radiologic examinations have also been made on several animals bearing tumors even though these animals had been exposed to the lower doses." The experiment at the highest dose (30,000 ppm) is not included in the database. The reported data include the 10,000 ppm or lower doses.

APPENDIX 8: DOSE-RESPONSE CURVE SYMBOLS AND DEFINITIONS

Symbol	Dose-Response Curve
*	consistent with linearity
/	significant departure from linearity, upward curvature
\	significant departure from linearity, downward curvature
Z	significant departure from linearity, more than three dose groups including controls
blank	either no dose-related effect, or only two dose groups including controls, so not enough information to determine a curve shape

APPENDIX 9: REFERENCE CODES AND DEFINITIONS

Code	Reference
adsc	Academie des Sciences, Memoires et Communications des Membres et des Correspondants de l'Academie
aenh	Archives of Environmental Health (formerly A.M.A. Archives of Industrial Health, prior to July 1, 1960)
agfc	Agricultural and Food Chemistry: Past, Present, Future (R. Teranishi, Ed.), Avi Publishing Company, Inc., Westport, Conn., 1978
ajpa	American Journal of Pathology
amih	American Industrial Hygiene Association Journal (formerly American Industrial Hygiene Association Quarterly, prior to Feb. 1958)
anoh	The Annals of Occupational Hygiene
apms	Acta Pathologica et Microbiologica Scandinavica Section A. Pathology
arpa	Archives of Pathology and Laboratory Medicine (formerly Archives of Pathology, Mar. 1928-Sept. 1950; A.M.A. Archives of Pathology, Oct. 1950- June 1960)
artx	Archives of Toxicology
arzn	Arzneimittel-Forschung
atmh	American Journal of Tropical Medicine and Hygiene (formerly American Journal of Tropical Medicine, 1921-1951)
banb	Banbury Report 5 Ethylene Dichloride: A Potential Health Risk? (B. Ames, P. Infante and R. Reitz, Eds.), Cold Spring Harbor Laboratory, 1980.
beer	N.C.I. Brief Communication
bdca	Bulletin du Cancer
bebm	Byulleten' Eksperimental'noi Biologii i Meditsiny
beet	Bulletin of Environmental Contamination and Toxicology
bjca	British Journal of Cancer
bmjl	British Medical Journal
bwho	Bulletin W.H.O. (World Health Organization)

Code	Reference
canc	Cancer
canr	Cancer Research
carc	Carcinogenesis
carml	Carcinogenesis, Vol. 2. Mechanisms of Tumor Promotion and Cocarcinogenesis (T. J. Slaga, A. Sivak, and R. K. Boutwell, Eds.), Raven Press, New York, 1978
clet	Cancer Letters
cmosp	Chemosphere
ctxf	Chemical Toxicology of Food. Proceedings of the International Symposium on Chemical Toxicology of Food, Milan, June 8-10, 1978 (C. L. Galli, R. Paoletti and G. Vettorazzi, Eds.), Elsevier/North-Holland Biomedical Press, New York, 1978
daet	Drug and Chemical Toxicology
defr	A Two-year Toxicity and Oncogenicity Study with Acrylonitrile Incorporated in the Drinking Water of Rats. (J. F. Quast, C. E. Wade, C. G. Humiston, R. M. Carreon, E. A. Hermann, C. N. Park and B. A. Schwetz). Final Report. Dow Chemical U.S.A., Midland, MI, 1980
derp	A Two-year Toxicity and Oncogenicity Study with Acrylonitrile Following Inhalation Exposure of Rats (J. F. Quast, D. J. Schuetz, M. F. Balmer, T. S. Gushow, C. N. Park and M. J. McKenna). Final Report. Dow Chemical U.S.A., Midland, MI, 1980
eaes	Ecotoxicology and Environmental Safety
ejca	European Journal of Cancer (European Journal of Cancer and Clinical Oncology since 1982)
enhp	Environmental Health Perspectives
envr	Environmental Research
expa	Experientia
ftcx	Food and Cosmetics Toxicology (Food and Chemical Toxicology since 1982)
gaga	Gastroenterology
gann	Gann
gmer	Gann Monograph on Cancer Research
ijcn	International Journal of Cancer (formerly International Union Against Cancer. Acta. Vols. 1-20, 1936-64)
imed	International Journal of Occupational Health and Safety (formerly Industrial Medicine and Surgery of Trauma, June-July 1949; Industrial Medicine and Surgery, Aug. 1949-73)
jept	Journal of Environmental Pathology and Toxicology
jiht	Journal of Industrial Hygiene and Toxicology (formerly Journal of Industrial Hygiene, 1919-35)
jkmj	Jikeikai Medical Journal
jnci	Journal of the National Cancer Institute (U.S. National Cancer Institute. Journal)
jnut	Journal of Nutrition
jpat	Journal of Pathology (formerly Journal of Pathology and Bacteriology, prior to 1969)
jphp	Journal of Pharmacy and Pharmacology
jtxe	Journal of Toxicology and Environmental Health
lapp	Lavori dell Istituto di Anatomia e Istologia Patologica, Universita degli Studi, Perugia, Italy
livt	Laboratory Investigation
lmdl	La Medicina del Lavoro
mpoc	Morphological Precursors of Cancer (L. Severi, Ed.) Division of Cancer Research, Perugia, Italy, 1962
myco	Mycopathologia
natu	Nature
nawi	Naturwissenschaften
nplm	Neoplasma
ntis	National Technical Information Service. Evaluation of Carcinogenic, Teratogenic, and Mutagenic Activities of Selected Pesticides and Industrial Chemicals. Vol. 1: Carcinogenic Study. NTIS, Springfield, VA, 1968
obgy	Obstetrics and Gynecology
onco	Oncology
osse	Organ and Species Specificity in Chemical Carcinogenesis. (R. Langenbach, S. Nesnow, and J. M. Rice, Eds.), Plenum Press, New York, 1982

Code	Reference
pcpl	Pentachlorophenol (K. Ranga Rao, Ed.), Plenum Press, New York, 1978
pseb	Proceedings of the Society for Experimental Biology and Medicine (New York)
reec	Revue Europeen d'Etudes Cliniques et Biologiques
sabo	Sabouraudia
scie	Science
srfr	Booklet 1, 1976. Phase I Studies on the Carcinogenic Activity of Anticancer Drugs in Mice and Rats (H. E. Skipper) Final Report. Southern Research Institute. Birmingham, AL, 1976
stev	Science of the Total Environment
tcam	Teratogenesis, Carcinogenesis, and Mutagenesis
tjem	Tohoku Journal of Experimental Medicine
tumo	Tumori
txap	Toxicology and Applied Pharmacology
txcy	Toxicology
txlt	Toxicology Letters
txoc	Toxicology and Occupational Medicine. Proceedings of the 10th Inter-American Conference on Toxicology and Occupational Medicine. Oct. 22nd-25th, 1978. Miami, FL (W. Deichmann, Ed.), Developments in Toxicology and Environmental Science, Vol. 4. Elsevier/North-Holland, New York, 1979
urre	Urological Research
vopr	Voprosy Onkologii (Problems in Oncology)
vpit	Voprosy Pitaniya (Problems in Nutrition)
yjbm	Yale Journal of Biology and Medicine
zkko	Journal of Cancer Research and Clinical Oncology (formerly Zeitschrift fur Krebsforschung und Klinische Onkologie, prior to Vol. 92, 1979)

APPENDIX 10: NCI/NTP BIOASSAYS WITH COMBINED CONTROLS

Chemical Name	Experiments with Combined Controls
ACRONYCINE	rats, female mice
3-AMINO-4-ETHOXYACETANILIDE	rats, mice
2-AMINOANTHRAQUINONE	mice
2,4-DIAMINOANISOLE SULFATE	rats, mice
2,5-DIAMINOTOLUENE SULFATE	rats, mice
2,4-DINITROTOLUENE	rats, mice
FENAMINOSULF FORMULATED	female mice
HYDRAZOBENZENE	rats, mice
5-NITRO- <i>o</i> -ANISIDINE	rats, mice
5-NITROACENAPHTHENE	rats
4-NITROANTHRANILIC ACID	rats, mice
6-NITROBENZIMIDAZOLE	rats, mice
1-NITRONAPHTHALENE	rats, mice
PHENESTERIN	mice
STYRENE	rats
THIO-TEPA	rats

APPENDIX 11: NCI/NTP BIOASSAYS WITH REVISED DATA

Chemical Name	Experiments with Revised Data
2-AMINOANTHRAQUINONE	rats, mice
AZINPHOSMETHYL	rats, mice
CAPTAN	rats
CHLORAMBEN	rats

Chemical Name	Experiments with Revised Data
1,2-DICHLOROETHANE	rats
DICOFOL	mice
DIELDRIN, PHOTO-	rats
1,4-DIOXANE	mice
DIOXATHION	rats, mice
ENDRIN	rats, mice
HYDRAZOBENZENE	rats, mice
2-METHYL-1-NITROANTHRAQUINONE	mice
5-NITRO- <i>o</i> -TOLUIDINE	rats, mice
PHOSPHAMIDON	rats
PICLORAM	rats

APPENDIX 12: NCI/NTP BIOASSAYS EVALUATED AS INADEQUATE IN TECHNICAL REPORTS

Chemical Name	Experiments Evaluated as Inadequate
ACRONYCINE	mice
ALLYL CHLORIDE	rats
5-AZACYTIDINE	rats, male mice
CHLOROPICRIN	rats
CLONITRALID	male mice
<i>m</i> -CRESIDINE	male mice
DIBUTYL TIN DIACETATE	female rats
EMETINE·2HCl	rats, mice
ENDOSULFAN	male rats, male mice
NITROFEN	male rats (C00421 only)
PHOSPHAMIDON	rats
PROFLAVINE·HCl HEMIHYDRATE	rats, mice
PYRAZINAMIDE	female mice
PYRIMETHAMINE	male mice
TETRACHLOROETHYLENE	rats
β -THIOGUANINE DEOXYRIBOSIDE	mice
1,1,1-TRICHLOROETHANE	rats, mice
TRICHLOROFLUOROMETHANE	rats

APPENDIX 13: NONHUMAN PRIMATES

A special literature search was conducted for chemical carcinogenesis experiments in nonhuman primates. While many research reports were identified, few fit the standard inclusion criteria used for the rest of the database. Most of the tests did not meet the inclusion rules for one of the following reasons: (1) fewer than five dosed animals; (2) no control group; or (3) short experiment time.

We subsequently relaxed the standard criteria in order to include tests from which a reasonable estimate of TD₅₀ could be made. The major change has been to reduce the required experiment length from half the standard lifespan to 3 years for monkeys and 2 years for bush babies, if the author evaluated the compound as carcinogenic in that short time. The TD₅₀ values from these shorter tests have been calculated with an extrapolation factor greater than that for other tests in the database, and are therefore less reliable. These cases are flagged in the plot with parentheses around the TD₅₀.

Most of the experiments on nonhuman primates in the database are from the Laboratory of Chemical Pharmacology, National Cancer Institute (NCI). Several of these experiments are still in progress and have been included in the database only if the researchers have already reported that the test compound is carcinogenic. We have excluded experiments still in progress and without evidence of carcinogenicity because tumor induction may still occur (For example, the test of saccharin is excluded.) The TD₅₀ calculations for the experiments still in progress are based only on dosed and control animals which have already died.

Some special considerations about these tests from the Laboratory of Chemical Pharmacology, (NCI) are as follows: (1) Data for males and females have been combined because the results for both sexes of control animals were reported together. (2) Histopathology was reported only for malignant neoplasms. (3) The first dose was usually administered at birth; however, in some experiments, the age at first dose ranged from neonate to adult. (4) Dosing may have been as infrequent as one time per month. (5) Monkey control animals are from a colony which includes both vehicle and untreated controls. Some animals have been used as breeders. Seventy percent of the animals are born in the colony, 30% are brought in from the wild as adults. The age of controls ranges from neonate to greater than 16 years. Only controls which have died are included in the TD₅₀ calculations. (6) For one compound, procarbazine-HCl, we accepted subcutaneous injection as a route of administration when given in combination with either diet or intraperitoneal injection.

APPENDIX 14

Bibliography: General Literature

- Adamson, R. H., and Sieber, S. M. Chemical carcinogenesis studies in nonhuman primates. In: *Organ and Species Specificity in Chemical Carcinogenesis*. (R. Langenback and S. Newnow, Eds.), Plenum Press, New York and London, 1982 pp. 129-156.
- Adolphs, H. D., Thiele, J., Kiel, H., and Steffens, L. Induction of transitional cell carcinoma of the urinary bladder in rats by feeding *N*-[4-(5-nitro-2-furyl)-2-thiazolyl]formamide. *Urol. Res.* 6: 19-27(1978).
- Agthe, C., Garcia, H., Shubik, P., Tomatis, L., and Wenyon, E. Study of the potential carcinogenicity of DDT in the Syrian golden hamster (34740). *Proc. Soc. Exptl. Biol. Med.* 134: 113-116(1970).
- Allmark, M. G., Grice, H. C., and Mannell, W. A. Chronic toxicity studies on food colours. Part II. Observations on the toxicity of FD&C Green No. 2 (light green SF yellowish), FD&C Orange No. 2 (orange SS) and FD&C Red No. 32 (oil red XO) in rats. *J. Pharm. Pharmacol.* 8: 417-424(1956).
- Allmark, M. G., Mannell, W. A., and Grice, H. C. Chronic toxicity studies on food colours. Part III. Observations on the toxicity of malachite green, new cocine and nigrosine in rats. *J. Pharm. Pharmacol.* 9: 622-628(1957).
- Anderson, L. M., Giner-Sorolla, A., Greenbaum, J. H., Last-Barney, K., and Budinger, J. M. Induction of reproductive system tumors in mice by *N*6-(methylnitroso)-adenosine and a tumorigenic effect of its combined precursors. *Int. J. Cancer* 24: 319-322(1979).
- Andrianova, M. M. Carcinogenic properties of red food pigments—amaranth, SX purple and ponceau 4R. *Vopr. Pitan.* 29: 61-65(1970).
- Andrianova, M. M., and Alekscev, I. V. On carcinogenic properties of the pesticides Sevin, maneb, ziram and zineb. *Vopr. Pitan.* 29: 71-74(1970).
- Angsubhakorn, S., Bhamarapravati, N., Romruen, K., Saha-phong, S., Thamavit, W., and Miyamoto, M. Further study of alpha benzene hexachloride inhibition of aflatoxin B1 hepatocarcinogenesis in rats. *Brit. J. Cancer* 43: 881-883(1981).
- Aoyagi, M., Matsukura, N., Uchida, E., Kawachi, T., Sugimura, T., Takayama, S., and Matsui, M. Induction of liver tumors in Wistar rats by sodium nitrite given in pellet diet. *J. Natl. Cancer Inst.* 65: 411-414(1980).
- Arai, M., Aoki, Y., Nakanishi, K., Miyata, Y., Mori, T., and Ito, N. Long-term experiment of maximal non-carcinogenic dose of dimethylnitrosamine for carcinogenesis in rats. *Gann* 70: 549-558(1979).
- Arai, M., Cohen, S. M., Jacobs, J. B., and Friedell, G. H. Effect of dose on urinary bladder carcinogenesis induced in F344 rats by *N*-[4-(5-nitro-2-furyl)-2-thiazolyl]formamide. *J. Natl. Cancer Inst.* 62: 1013-1016(1979).
- Argus, M. F., Arcos, J. C., and Hoch-Ligeti, C. Studies on the carcinogenic activity of protein-denaturing agents: hepatocarcinogenicity of dioxane. *J. Natl. Cancer Inst.* 35: 949-958(1965).
- Argus, M. F., White, L. E., Bryant, G. M., Arcos, J. C., and Hoch-Ligeti, C. Molecular specificity of the tumorigenic action of ethionine: the inactivity of *S*-ethylcysteine. Action on respiratory parameters. *Cancer Res. Clin. Oncol.* 75: 201-208(1971).
- Armuth, V. Leukaemogenic action of phorbol in intact and thymectomized mice of different strains. *Brit. J. Cancer* 34: 516-522(1976).
- Arnold, D. L., Moodie, C. A., Grice, H. C., Charbonneau, S. M., Stavric, B., Collins, B. T., McGuire, P. F., Zawidzka, Z. Z., and Munro, I. C. Long-term toxicity of ortho-toluenesulfonamide and sodium saccharin in the rat. *Toxicol. Appl. Pharmacol.* 52: 113-152(1980).
- Baigusheva, M. M. Carcinogenic properties of the amaranth paste. *Vopr. Pitan.* 27: 46-50(1968).
- Barnes, J. M., Magee, P. N., Boyland, E., Haddow, A., Passey, R. D., Bullough, W. S., Cruickshank, C. N. D., Salaman, M. H., and Williams, R. T. The non-toxicity of maleic hydrazide for mammalian tissues. *Nature* 180: 62-64(1957).
- Barrows, G. H., Christopherson, W. M., and Drill, V. A. Liver lesions and oral contraceptive steroids. *J. Toxicol. Environ. Health* 3: 219-230(1977).
- Baroni, C., van Esch, G. J., and Saffiotti, U. Carcinogenesis tests of two inorganic arsenicals. *Arch. Environ. Health* 7: 668-674(1963).
- Beal, D. D., Skibba, J. L., Croft, W. A., Cohen, S. M., and Bryan, G. T. Carcinogenicity of the antineoplastic agent, 5-(3,3-dimethyl-1-triazeno)-imidazole-4-carboxamide, and its metabolites in rats. *J. Natl. Cancer Inst.* 54: 951-957(1975).
- Benya, T. J., Busey, W. M., Dorato, M. A., and Berteau, P. E. Inhalation carcinogenicity of vinyl bromide in rats. *Toxicol. Appl. Pharmacol.* 64: 367-379(1982).
- Bhide, S. V., Maru, G. B., Sawai, M. M., and Ranadive, K. J. Isoniazid tumorigenicity in mice under different experimental conditions. *Int. J. Cancer* 21: 381-386(1978).
- Bhide, S. V., D'Souza, R. A., Sawai, M. M., and Ranadive, K. J. Lung tumour incidence in mice treated with hydrazine sulphate. *Int. J. Cancer* 18: 530-535(1976).
- Biancifiore, C., Bucciarelli, E., Clayson, D. B., and Santilli, F. E. Induction of hepatomas in CBA/Cb/Se mice by hydrazine sulphate and the lack of effect of croton oil on tumour induction in BALB/c/Cb/Se mice. *Brit. J. Cancer* 18: 543-550(1964).
- Biancifiore, C., Milia, U., and Di Leo, F. P. Tumori della tiroide indotti mediante etionamide (ET) in topi femmina vergini BALB/c/Cb/Se substrain. *Lav. Inst. Anat. Istol. Patol. Univ. Studi Perugia.* 24: 145-165(1964).
- Blair, D., Dix, K. M., Hunt, P. F., Thorpe, E., Stevenson, D. E., and Walker, A. I. T. A 2-year inhalation carcinogenesis study in rats. *Arch. Toxicol.* 35: 281-294(1976).
- Bonser, G. M., Clayson, D. B., Jull, J. W., and Pyrah, L. N. The carcinogenic properties of 2-amino-1-naphthol hydrochloride and its parent amine 2-naphthylamine. *Brit. J. Cancer* 6: 412-424(1952).
- Borchert, P., Miller, J. A., Miller, E. C., and Shires, T. K. 1'-Hydroxysafrole, a proximate carcinogenic metabolite of safrole in the rat and mouse. *Cancer Res.* 33: 590-600(1973).
- Borzsonyi, M., Torok, G., Pinter, A., Surjan, A., Nadasdi, L., and Roller, P. Carcinogenic effect of dinitrosopiperazine in adult Swiss mice and after transplacental or translactational exposure. *Cancer Res.* 40: 2925-2927(1980).
- Boyland, E., Carter, R. L., Gorrod, J. W., and Roe, F. J. C. Carcinogenic properties of certain rubber additives. *Eur. J. Cancer* 4: 233-239(1968).
- Boyland, E., Roe, F. J. C., Gorrod, J. W., and Mitchley, B. C. V. The carcinogenicity of nitrosoanabasine a possible constituent of tobacco smoke. *Brit. J. Cancer* 18: 265-270(1964).
- Bralow, S. P., Gruenstein, M., and Meranze, D. R. Host resistance to gastric adenocarcinomatosis in three strains of rats ingesting *N*-methyl-*N'*-nitro-*N*-nitrosoguanidine. *Oncology* 27: 168-180(1973).
- Brantom, P. G., Gaunt, I. F., and Grasso, P. Long-term toxicity of sodium cyclamate in mice. *Food Cosmet. Toxicol.* 11: 735-746(1973).

35. Brantom, P. G., Gaunt, I. F., Hardy, J., Grasso, P., and Gangolli, S. D. Long-term feeding and reproduction studies on emulsifier YN in rats. *Food Cosmet. Toxicol.* 11: 755-769(1973).
36. Brown, E. V., and Hamdan, A. A. Carcinogenic activity of analogues of *p*-dimethylaminoazobenzene. V. Effect of added methyl groups in the pyridine series. *J. Natl. Cancer Inst.* 37: 365-367(1966).
37. Bulay, O., Mirvish, S. S., Garcia, H., Pelfrene, A. F., Gold, B., and Eagen, M. Carcinogenicity test of six nitrosamides and a nitrosocyanamide administered orally to rats. *J. Natl. Cancer Inst.* 62: 1523-1528(1979).
38. Burtin, C., Scheinmann, P., Salomon, J. C., Lespinats, G., Frayssinet, C., Lebel, B., and Canu, P. Increased tissue histamine in tumour-bearing mice and rats. *Brit. J. Cancer* 43: 684-688(1981).
39. Butler, W. H. Long-term effects of phenobarbitone-Na on male Fischer rats. *Brit. J. Cancer* 37: 418-423(1978).
40. Butler, W. H., and Barnes, J. M. Carcinogenic action of groundnut meal containing aflatoxin in rats. *Food Cosmet. Toxicol.* 6: 135-141 (1968).
41. Byron, W. R., Bierbower, G. W., Brower, J. B., and Hansen, W. H. Pathologic changes in rats and dogs from two-year feeding of sodium arsenite or sodium arsenate. *Toxicol. Appl. Pharmacol.* 10: 132-147 (1967).
42. Cabral, J. R. P., Hall, R. K., Bronczyk, S. A., and Shubik, P. A carcinogenicity study of the pesticide dieldrin in hamsters. *Cancer Lett.* 6: 241-246 (1979).
43. Cabral, J. R. P., Hall, R. K., Bronczyk, S. A., and Shubik, P. Lack of carcinogenicity of DDT in hamsters. *Tumori* 68: 5-10 (1982).
44. Cabral, J. R. P., Hall, R. K., Rossi, L., Bronczyk, S. A., and Shubik, P. Effects of long-term DDT intake on rats. *Tumori* 68: 11-17 (1982).
45. Cabral, J. R. P., Mollner, T., Raitano, F., and Shubik, P. Carcinogenesis of hexachlorobenzene in mice. *Int. J. Cancer* 23: 47-51 (1979).
46. Cabral, J. R., Rossi, L., Dragani, T. A., and Della Porta, G. Carcinogenicity study of 3-(5-nitro-2-furyl)-imidazo(1,2- α)pyridine in mice and rats. *Tumori* 66: 131-144 (1980).
47. Cabral, J. R. P., Shubik, P., Mollner, T., and Raitano, F. Carcinogenic activity of hexachlorobenzene in hamsters. *Nature* 265: 510-511 (1977).
48. Cameron, G. R., and Cheng, K. K. Failure of oral D.D.T. to induce toxic changes in rats. *Brit. Med. J.* 2: 819-821 (1951).
49. Casas, C. B. Induction of hepatomas by thiouracil in inbred strains of mice. *Proc. Soc. Exptl. Biol. Med.* 113: 493-494 (1963).
50. Chouroulinkov, I., Gentil, A., and Guerin, M. Etude de l'activite carcinogene du 9,10-dimethyl-benzanthracene et du 3,4-benzopyrene administres par voie digestive. *Bull. Cancer* 54: 67-78 (1967).
51. Christov, K., and Raichev, R. Thyroid carcinogenesis in hamsters after treatment with 131-iodine and methylthiouracil. *Cancer Res. Clin. Oncol.* 77: 171-179(1972).
52. Chu, I., Villeneuve, D. C., Valli, V. E., Secours, V. E., and Becking, G. C. Chronic toxicity of photomirex in the rat. *Toxicol. Appl. Pharmacol.* 59: 268-278(1981).
53. Clapp, N. K., Craig, A. W., and Toya, R. E. Oncogenicity by methyl methanesulfonate in male RF mice. *Science* 161: 913-914 (1968).
54. Clapp, N. K., Tyndall, R. L., Cumming, R. B., and Otten, J. A. Effects of butylated hydroxytoluene alone or with diethylnitrosamine in mice. *Food Cosmet. Toxicol.* 12: 367-371(1974).
55. Clapp, N. K., Tyndall, R. L., Satterfield, L. C., Klima, W. C., and Bowles, N. D. Selective sex-related modification of diethylnitrosamine-induced carcinogenesis in BALB/c mice by concomitant administration of butylated hydroxytoluene. *J. Natl. Cancer Inst.* 61: 177-180(1978).
56. Clayson, D. B., Lawson, T. A., and Pringle, J. A. S. The carcinogenic action of 2-aminodiphenylene oxide and 4-aminodiphenyl on the bladder and liver of the C57 x IF mouse. *Brit. J. Cancer* 21: 755-762(1967).
57. Clayson, D. B., Lawson, T. A., Santana, S., and Bonser, G. M. Correlation between the chemical induction of hyperplasia and of malignancy in the bladder epithelium. *Brit. J. Cancer* 19: 297-310 (1965).
58. Cleveland, F. P. A summary of work on aldrin and dieldrin toxicity at the Kettering Laboratory. *Arch. Environ. Health* 13: 195-198(1966).
59. Cohen, S. M., and Bryan, G. T. Effect of *p*-hydroxyacetanilide, sodium sulfate, and L-methionine on the leukemogenicity of *N*-[4-(5-nitro-2-furyl)-2-thiazolyl]acetamide. *Cancer Res.* 38: 1398-1405(1978).
60. Cohen, S. M., Erturk, E., and Bryan, G. T. Comparative carcinogenicity of 5-nitrothiophenes and 5-nitrofurans in rats. *J. Natl. Cancer Inst.* 57: 277-282(1976).
61. Cohen, S. M., Erturk, E., Price, J. M., and Bryan, G. T. Comparative carcinogenicity in the rat of 2-hydrazinotiazoles with nitrofuryl, nitrophenyl, or aminophenyl substituents in the 4-position. *Cancer Res.* 30: 897-901(1970).
62. Cohen, S. M., Erturk, E., Von Esch, A. M., Crovetto, A. J., and Bryan, G. T. Carcinogenicity of 5-nitrofurans, 5-nitroimidazoles, 4-nitrobenzenes, and related compounds. *J. Natl. Cancer Inst.* 51: 403-417(1973).
63. Cohen, S. M., Erturk, E., Von Esch, A. M., Crovetto, A. J., and Bryan, G. T. Carcinogenicity of 5-nitrofurans and related compounds with amino-heterocyclic substituents. *J. Natl. Cancer Inst.* 54: 841-850(1975).
64. Cohen, S. M., Ichikawa, M., and Bryan, G. T. Carcinogenicity of 2-(2-furyl)-3-(5-nitro-2-furyl)acrylamide (AF-2) fed to female Sprague-Dawley rats. *Gann* 68: 473-476(1977).
65. Cohen, S. M., Lower, G. M., Erturk, E., and Bryan, G. T. Comparative carcinogenicity in Swiss mice of *N*-[4-(5-nitro-2-furyl)-2-thiazolyl]acetamide and structurally related 5-nitrofurans and 4-nitrobenzenes. *Cancer Res.* 33: 1593-1597(1973).
66. Conzelman, G. M., Moulton, J. E., Flanders, L. E., Springer, K., and Crout, D. W. Induction of transitional cell carcinoma of the urinary bladder in monkeys fed 2-naphthylamine. *J. Natl. Cancer Inst.* 42: 825-831(1969).
67. Cremlyn, R. J. W., and Roe, F. J. C. A study of certain substituted sulphonohydrazides for carcinogenicity in mice. *Food Cosmet. Toxicol.* 9: 319-321(1971).
68. Croft, W. A., and Bryan, G. T. Production of urinary bladder carcinomas in male hamsters by *N*-[4-(5-nitro-2-furyl)-2-thiazolyl]formamide, *N*-[4-(5-nitro-2-furyl)-2-thiazolyl]acetamide, or formic acid 2-[4-(5-nitro-2-furyl)-2-thiazolyl]hydrazide. *J. Natl. Cancer Inst.* 51: 941-949(1973).
69. Dacre, J. C. Toxicologic studies with 2,6-di-*tert*-butyl-4-hydroxymethylphenol in the rat. *Toxicol. Appl. Pharmacol.* 17: 669-678 (1970).
70. Davis, K. J., and Fitzhugh, O. G. Pathologic changes noted in rats fed D&C Red No. 9 for two years. *Toxicol. Appl. Pharmacol.* 4: 200-205(1962).
71. Davis, K. J., and Fitzhugh, O. G. Tumorigenic potential of aldrin and dieldrin for mice. *Toxicol. Appl. Pharmacol.* 4: 187-189(1962).
72. Davis, K. J., and Fitzhugh, O. G. Pathologic changes noted in rats fed D&C Red No. 10 [monosodium salt of 2-(2-hydroxy-1-naphthylazo)-1-naphthalenesulfonic acid] for two years. *Toxicol. Appl. Pharmacol.* 5: 728-734(1963).
73. Davis, K. J., Fitzhugh, O. G., and Nelson, A. A. Chronic rat and dog toxicity studies on tartrazine. *Toxicol. Appl. Pharmacol.* 6: 621-626(1964).
74. Davis, K. J., Nelson, A. A., Zwickley, R. E., Hansen, W. H., and Fitzhugh, O. G. Chronic toxicity of ponceau SX to rats, mice, and dogs. *Toxicol. Appl. Pharmacol.* 8: 306-317(1966).
75. De Groot, A. P., Til, H. P., Feron, V. J., Dreef-Van der Meulen, H. C., and Willems, M. I. Two-year feeding and multigeneration studies in rats on five chemically modified starches. *Food Cosmet. Toxicol.* 12: 651-663(1974).
76. Deichmann, W. B., Keplinger, M., Sala, F., and Glass, E. Synergism among oral carcinogens: IV. The simultaneous feeding of four tumorigens to rats. *Toxicol. Appl. Pharmacol.* 11: 88-103(1967).
77. Deichmann, W. B., MacDonald, W. E., Anderson, W. A. D., and Bernal, E. Adenocarcinoma in the lungs of mice exposed to vapors of 3-nitro-3-hexene. *Toxicol. Appl. Pharmacol.* 5: 445-456 (1963).

78. Deichmann, W. B., MacDonald, W. E., Blum, E., Bevilacqua, M., Radomski, J., Keplinger, M., and Balkus, M. Tumorigenicity of aldrin, dieldrin and endrin in the albino rat. *Ind. Med.* 39: 426-434(1970).
79. Deichmann, W. B., MacDonald, W. E., Lampe, K. F., Dressler, I., and Anderson, W. A. D. Nitro-olefins as potential carcinogens in air pollution. *Ind. Med.* 34: 800-807(1965).
80. Deichmann, W. B., MacDonald, W. E., and Lu, F. C. Effects of chronic aldrin feeding in two strains of female rats and a discussion on the risks of carcinogens in man. In: *Developments in Toxicology and Environmental Science*, Vol. 4 (W. Deichman, Ed.), Elsevier North Holland, Amsterdam, 1979, pp. 407-413.
81. Della Porta, G., Cabral, J. R., and Rossi, L. Carcinogenicity study of rifampicin in mice and rats. *Toxicol. Appl. Pharmacol.* 43: 293-302(1978).
82. Della Porta, G., Colnaghi, M. I., and Parmiani, G. Non-carcinogenicity of hexamethylenetetramine in mice and rats. *Food Cosmet. Toxicol.* 6: 707-715(1968).
83. Della Porta, G., Shubik, P., and Scortecchi, V. The action of *N*-2-fluorenylacetylamide in the Syrian golden hamster. *J. Natl. Cancer Inst.* 22: 463-471(1959).
84. Drake, J. J-P., Butterworth, K. R., Gaunt, I. F., and Grasso, P. Long-term toxicity study of black PN in mice. *Food Cosmet. Toxicol.* 15: 503-508(1977).
85. Drake, J. J-P., Butterworth, K. R., Gaunt, I. F., and Hardy, J. Long-term toxicity studies of chocolate brown HT in mice. *Toxicology* 10: 17-27(1978).
86. Druckrey, H. Chloriertes Trinkwasser, Toxizitäts-Prüfungen an Ratten über sieben Generationen. *Food Cosmet. Toxicol.* 6: 147-154 (1968).
87. Dunn, T. B. Cancer of the uterine cervix in mice fed a liquid diet containing an antifertility drug. *J. Natl. Cancer Inst.* 14: 671-692 (1969).
88. Eisenbrand, G., Preussmann, R., and Schmahl, D. Carcinogenicity of *N*-nitrosoephedrine in rats. *Cancer Lett.* 5: 103-106(1978).
89. Epstein, S. S. The carcinogenicity of dieldrin. Part 1. (Review of: Davis, H.J., Hansen, W., and Fitzhugh, O.G., Pathology report on mice for aldrin, dieldrin, heptachlor or heptachlor epoxide for two years [ref. 2, p. 341].) *Sci. Total Environ.* 4: 1-52(1975).
90. Epstein, S. S. Carcinogenicity of heptachlor and chlordane. (Review of: Witherup, S., Cleveland, F. P., Shaffer, F. G., Schlecht, H., and Muser, L., The physiological effects of introduction of heptachlor into de [sic] diet of experimental animals in varying levels of concentration [ref. 1, p. 341].) *Sci. Total Environ.* 6: 103-154(1976).
91. Epstein, S. S. Carcinogenicity of heptachlor and chlordane. (Review of: Eighteen month oral carcinogenic study in mice, report of the International Research and Development Corporation (IRDC) to Velsicol Corporation [ref. 1, p. 127].) *Sci. Total Environ.* 6: 103-154 (1976).
92. Erturk, E., Cohen, S. M., and Bryan, G. T. Carcinogenicity of *N*-[4-(5-nitro-2-furyl)-2-thiazolyl]acetamide in female rats. *Cancer Res.* 30: 936-941(1970).
93. Erturk, E., Cohen, S. M., and Bryan, G. T. Induction, histogenesis, and isotransplantability of renal tumors induced by formic acid 2-[4-(5-nitro-2-furyl)-2-thiazolyl]hydrazide in rats. *Cancer Res.* 30: 2098-2106(1970a).
94. Erturk, E., Cohen, S. M., and Bryan, G. T. Urinary bladder carcinogenicity of *N*-[4-(5-nitro-2-furyl)-2-thiazolyl]formamide in female Swiss mice. *Cancer Res.* 30: 1309-1311(1970).
95. Erturk, E., Cohen, S. M., Price, J. M., and Bryan, G. T. Pathogenesis, histology, and transplantability of urinary bladder carcinomas induced in albino rats by oral administration of *N*-[4-(5-nitro-2-furyl)-2-thiazolyl]formamide. *Cancer Res.* 29: 2219-2228(1969).
96. Erturk, E., Morris, J. E., Cohen, S. M., Price, J. M., and Bryan, G. T. Transplantable rat mammary tumors induced by 5-nitro-2-furaldehyde semicarbazone and by formic acid 2-[4-(5-nitro-2-furyl)-2-thiazolyl]hydrazide. *Cancer Res.* 30: 1409-1412(1970).
97. Erturk, E., Morris, J. E., Cohen, S. M., Von Esch, A. M., Croveti, A. J., Price, J. M., and Bryan, G. T. Comparative carcinogenicity of formic acid 2-[4-(5-nitro-2-furyl)-2-thiazolyl]hydrazide and related chemicals in the rat. *J. Natl. Cancer Inst.* 47: 437-445(1971).
98. Erturk, E., Price, J. M., Morris, J. E., Cohen, S., Leith, R. S., Von Esch, A. M., and Croveti, A. J. The production of carcinoma of the urinary bladder in rats by feeding *N*-[4-(5-nitro-2-furyl)-2-thiazolyl]formamide. *Cancer Res.* 27: 1998-2002(1967).
99. Evarts, R. P., and Brown, C. A. 2,4-Diaminoanisole sulfate: early effect on thyroid gland morphology and late effect on glandular tissue of Fischer 344 rats. *J. Natl. Cancer Inst.* 65: 197-204(1980).
100. Feron, V. J., and Kroes, R. One-year time-sequence inhalation toxicity study of vinyl chloride in rats. II. Morphological changes in the respiratory tract, ceruminous glands, brain, kidneys, heart and spleen. *Toxicology* 13: 131-141(1979).
101. Feron, V. J., and Kruyssen, A. Effects of exposure to furfural vapour in hamsters simultaneously treated with benzo[*a*]pyrene or diethylnitrosamine. *Toxicology* 11: 127-144(1978).
102. Feron, V. J., Spit, B. J., Immel, H. R., and Kroes, R. One-year time-sequence inhalation toxicity study of vinyl chloride in rats. III. Morphological changes in the livers. *Toxicology* 13: 143-154(1979).
103. Fitzhugh, O. G., and Nelson, A. A. Comparison of the chronic toxicity of triethylene glycol with that of diethylene glycol. *J. Ind. Hyg. Toxicol.* 28: 40-43(1946).
104. Fitzhugh, O. G., Nelson, A. A., and Quaife, M. L. Chronic oral toxicity of aldrin and dieldrin in rats and dogs. *Food Cosmet. Toxicol.* 2: 551-562(1964).
105. Flaks, A., and Clayson, D. B. The influence of ammonium chloride on the induction of bladder tumours by 4-ethylsulphonylnaphthalene-1-sulphonamide. *Brit. J. Cancer* 31: 585-587(1975).
106. Flaks, A., Hamilton, J. H., and Clayson, D. B. Effect of ammonium chloride on incidence of bladder tumors induced by 4-ethylsulfonylnaphthalene-1-sulfonamide. *J. Natl. Cancer Inst.* 51: 2007-2008(1973).
107. Flaks, A., Hamilton, J. M., Clayson, D. B., and Burch, P. R. J. The combined effect of radiation and chemical carcinogens in female A x IF mice. *Brit. J. Cancer* 28: 227-231(1973).
108. Fleischman, R. W., Baker, J. R., Hagopian, M., Wade, G. G., Hayden, D. W., Smith, E. R., Weisburger, J. H., and Weisburger, E. K. Carcinogenesis bioassay of acetamide, hexanamide, adipamide, urea and *p*-tolylurea in mice and rats. *Environ. Pathol. Toxicol.* 3: 149-170(1980).
109. Fong, L. Y. Y., and Chan, W. C. Long-term effects of feeding aflatoxin-contaminated market peanut oil to Sprague-Dawley rats. *Food Cosmet. Toxicol.* 19: 179-183(1981).
110. Fujii, K., Nakadate, M., Ogiu, T., and Odashima, S. Induction of digestive tract tumors and leukemias in Donryu rats by administration of 1-amylyl-1-nitrosourea in drinking water. *Gann* 71: 464-470(1980).
111. Gaines, T. B., and Kimbrough, R. D. The sterilizing, carcinogenic and teratogenic effects of MeTEPA in rats. *Bull. W.H.O.* 34: 317-320 (1966).
112. Garcia, H., Keefer, L., Lijinsky, W., and Wenyon, C. E. M. Carcinogenicity of nitrosothiomorpholine and 1-nitrosopiperazine in rats. *Cancer Res. Clin. Oncol.* 74: 179-184(1970).
113. Garcia, H., and Lijinsky, W. Studies of the tumorigenic effect in feeding of nitrosamino acids and of low doses of amines and nitrite to rats. *Cancer Res. Clin. Oncol.* 79: 141-144(1973).
114. Gass, G. H., and Allaben, W. T. Preliminary report on the carcinogenic dose-response curve to oral vitamin D₂. *Obstet. Gynecol.* 5: 477(1977).
115. Gass, G. H., Coats, D., and Graham, N. Carcinogenic dose-response curve to oral diethylstilbestrol. *J. Natl. Cancer Inst.* 33: 971-977(1964).
116. Gaunt, I. F., Brantom, P. G., Grasso, P., Creasey, M., and Gangolli, S. D. Long-term feeding study on Chocolate Brown FB in rats. *Food Cosmet. Toxicol.* 10: 3-15(1972).
117. Gaunt, I. F., Brantom, P. G., Grasso, P., and Kiss, I. S. Long-term toxicity studies of Chocolate Brown FB in mice. *Food Cosmet. Toxicol.* 11: 375-382(1973).
118. Gaunt, I. F., Butterworth, K. R., Grasso, P., and Ginocchio, A.

- V Long-term toxicity study of emulsifier YN in the mouse. *Food Cosmet. Toxicol.* 15: 1-5(1977).
119. Gaunt, I. F., Butterworth, K. R., Hardy, J., and Gangolli, S. D. Long-term toxicity of sorbic acid in the rat. *Food Cosmet. Toxicol.* 13: 31-45(1975).
 120. Gaunt, I. F., Carpanini, F. M. B., Grasso, P., Kiss, I. S., and Gangolli, S. D. Long-term feeding study on Black PN in rats. *Food Cosmet. Toxicol.* 10: 17-27(1972).
 121. Gaunt, I. F., Carpanini, F. M. B., Grasso, P., and Lansdown, A. B. G. Long-term toxicity of propylene glycol in rats. *Food Cosmet. Toxicol.* 10: 151-162(1972).
 122. Gaunt, I. F., Hardy, J., Grasso, P., Gangolli, S. D., and Butterworth, K. R. Long-term toxicity of cyclohexylamine hydrochloride in the rat. *Food Cosmet. Toxicol.* 14: 255-267(1976).
 123. Gaunt, I. F., Mason, P. L., Grasso, P., and Kiss, I. S. Long-term toxicity of Sunset Yellow FCF in mice. *Food Cosmet. Toxicol.* 12: 1-10(1974).
 124. Gibson, J. P., Newberne, J. W., Kuhn, W. L., and Elsea, J. R. Comparative chronic toxicity of three oral estrogens in rats. *Toxicol. Appl. Pharmacol.* 11: 489-510(1967).
 125. Gibson, J. P., Rohovsky, M. W., Newberne, J. W., and Larson, E. J. Toxicity studies with metiapine. *Toxicol. Appl. Pharmacol.* 25: 220-229(1973).
 126. Giner-Sorolla, A., Greenbaum, J., Last-Barney, K., Anderson, L. M., and Budinger, J. M. Lack of carcinogenic effect of nitroschloridiazepoxide and of nitrosomethylphenidate given orally to mice. *Food Cosmet. Toxicol.* 18: 81-83(1980).
 127. Ginocchio, A. V., Waite, V., Hardy, J., Fisher, N., Hutchinson, J. B., and Berry, R. Long-term toxicity and carcinogenicity studies of the bread improver potassium bromate. 2. Studies in mice. *Food Cosmet. Toxicol.* 17: 41-47(1979).
 128. Goodall, C. M., and Kennedy, T. H. Carcinogenicity of dimethylnitramine in NZR rats and NZO mice. *Cancer Lett.* 1: 295-298(1976).
 129. Gothoskar, S. V., Talwalkar, G. V., and Bhide, S. V. Tumorigenic effect of thioacetamide in Swiss strain mice. *Brit. J. Cancer* 24: 498-503(1970).
 130. Goyer, R. A., Falk, H. L., Hogan, M., Feldman, D. D., and Richter, W. Renal tumors in rats given trisodium nitrilotriacetic acid in drinking water for 2 years. *J. Natl. Cancer Inst.* 66: 869-880(1981).
 131. Graham, S. L., Davis, K. J., Hansen, W. H., and Graham, C. H. Effects of prolonged ethylene thiourea ingestion on the thyroid of the rat. *Food Cosmet. Toxicol.* 13: 493-499(1975).
 132. Grasso, P., Hardy, J., Gaunt, I. F., Mason, P. L., and Lloyd, A. G. Long-term toxicity of Violet 6B (FD & C Violet No. 1) in mice. *Food Cosmet. Toxicol.* 12: 21-31(1974).
 133. Grasso, P., Lansdown, A. B. G., Kiss, I. S., Gaunt, I. F., and Gangolli, S. D. Nodular hyperplasia in the rat liver following prolonged feeding of Ponceau MX. *Food Cosmet. Toxicol.* 7: 425-442 (1969).
 134. Green, U., Holste, J., and Spikermann, A. R. A comparative study of the chronic effects of magenta, paramagenta, and phenyl-beta-naphthylamine in Syrian golden hamsters. *Cancer Res. Clin. Oncol.* 95: 51-55(1979).
 135. Greenblatt, M., Kommineni, V. R. C., and Lijinsky, W. Null effect of concurrent feeding of sodium nitrite and amino acids to MRC rats. *J. Natl. Cancer Inst.* 50: 799-802(1973).
 136. Greenblatt, M., and Lijinsky, W. Nitrosamine studies: neoplasms of liver and genital mesothelium in nitrosopyrrolidine-treated MRC rats. *J. Natl. Cancer Inst.* 48: 1687-1696(1972).
 137. Grice, H. C., Mannell, W. A., and Allmark, M. G. Liver tumors in rats fed Ponceau 3R. *Toxicol. Appl. Pharmacol.* 3: 509-520 (1961).
 138. Griffin, T. B., Stein, A. A., and Coulston, F. Histologic study of tissues and organs from rats exposed to vapors of 2-nitropropane at 25 ppm. *Ecotoxicol. Environ. Saf.* 5: 194-201(1981).
 139. Gruenstein, M., Shay, H., and Shimkin, M. B. Lack of effect of orenethynodrel (Enovid) on methylcholanthrene-induced mammary carcinogenesis in female rats. *Cancer Res.* 24: 1656-1658 (1964).
 140. Grundmann, E., and Steinhoff, D. Leber- und Lungentumoren nach 3,3'-Dichlor-4,4'-diaminodiphenylmethan bei Ratten. *Cancer Res. Clin. Oncol.* 74: 28-39(1970).
 141. Habs, M., Eisenbrand, G., and Schmahl, D. Carcinogenic activity in Sprague-Dawley rats of 2[3-(2-chloroethyl)-3-nitrosoureido]-D-glucopyranose (chlorozotocin). *Cancer Lett.* 8: 133-137(1979).
 142. Habs, M., and Schmahl, D. Synergistic effects of N-nitroso compounds in experimental long-term carcinogenesis studies. *Oncology* 37: 259-265(1980).
 143. Hackmann, C. Erzeugung von Blasencarcinomen und Tumoren verschiedener Lokalisation bei Ratten durch Verfütterung von 2-Amino-3-methoxy-diphenylenoxyd und 2-Amino-diphenylenoxyd. *Cancer Res. Clin. Oncol.* 61: 45-54(1956).
 144. Hagan, E. C., Jenner, P. M., Jones, W. I., Fitzhugh, O. G., Long, E. L., Brouwer, J. G., and Webb, W. K. Toxic properties of compounds related to safrole. *Toxicol. Appl. Pharmacol.* 7: 18-24(1965).
 145. Hagiwara, A., Arai, M., Hirose, M., Nakanowatari, J., Tsuda, H., and Ito, N. Chronic effects of norharman in rats treated with aniline. *Toxicol. Lett.* 6: 71-75(1980).
 146. Hansen, W. H., Davis, K. J., Fitzhugh, O. G., and Nelson, A. A. Chronic oral toxicity of Ponceau 3R. *Toxicol. Appl. Pharmacol.* 5: 105-118(1963).
 147. Hansen, W. H., Davis, K. J., Graham, S. L., Perry, C. H., and Jacobson, K. H. Long-term toxicity studies of erythrosine. II. Effects on haematology and thyroxine and protein-bound iodine in rats. *Food Cosmet. Toxicol.* 11: 535-545(1973).
 148. Hansen, W. H., Fitzhugh, O. G., Nelson, A. A., and Davis, K. J. Chronic toxicity of two food colors, Brilliant Blue FCF and indigotine. *Toxicol. Appl. Pharmacol.* 8: 29-36(1966).
 149. Hansen, W. H., Long, E. L., Davis, K. J., Nelson, A. A., and Fitzhugh, O. G. Chronic toxicity of three food colourings: Guinea Green B, Light Green SF Yellowish and Fast Green FCF in rats, dogs and mice. *Food Cosmet. Toxicol.* 4: 389-410(1966).
 150. Hansen, W. H., Zwickey, R. E., Brouwer, J. B., and Fitzhugh, O. G. Long-term toxicity studies of erythrosine. I. Effects in rats and dogs. *Food Cosmet. Toxicol.* 11: 527-534(1973).
 151. Hardy, J., Gaunt, I. F., Hooson, J., Hendy, R. J., and Butterworth, K. R. Long-term toxicity of cyclohexylamine hydrochloride in mice. *Food Cosmet. Toxicol.* 14: 269-276(1976).
 152. Harris, P. N., Gibson, W. R., and Dillard, R. D. Oncogenicity of 1-(4-chlorophenyl)-1-phenyl-2-propynyl carbamate for rats. *Toxicol. Appl. Pharmacol.* 21: 414-418(1972).
 153. Hendy, R. J., Hardy, J., Gaunt, I. F., Kiss, I. S., and Butterworth, K. R. Long-term toxicity studies of sorbic acid in mice. *Food Cosmet. Toxicol.* 14: 181-186(1976).
 154. Henschler, D., Romen, W., Elsasser, H. M., Reichert, D., Eder, E., and Radwan, Z. Carcinogenicity study of trichloroethylene by long-term inhalation in three animal species. *Arch. Toxicol.* 43: 237-248(1980).
 155. Herbst, M., Weisse, I., and Koellmer, H. A contribution to the question of the possible hepatocarcinogenic effects of lindane. *Toxicology* 4: 91-96(1975).
 156. Herrold, K. M. Epidermoid carcinomas of esophagus and forestomach induced in Syrian hamsters by N-nitroso-N-methylurethan. *J. Natl. Cancer Inst.* 37: 389-394(1966).
 157. Heston, W. E., Vlahakis, G., and Desmukes, B. Effects of the antifertility drug Enovid in five strains of mice, with particular regard to carcinogenesis. *J. Natl. Cancer Inst.* 51: 209-224(1973).
 158. Heywood, R., Sortwell, R. J., Noel, P. R. B., Street, A. E., Prentice, D. E., Roe, F. J. C., Wadsworth, P. F., and Worden, A. N. Safety evaluation of toothpaste containing chloroform. III. Long-term study in beagle dogs. *Environ. Pathol. Toxicol.* 2: 835-851(1979).
 159. Hicks, R. M., Chowanec, J., and St J. Wakefield, J. Experimental induction of bladder tumors by a two-stage system. In: *Carcinogenesis: Mechanisms of Tumor Promotion and Cocarcinogenesis*, Vol. 2, (T. J. Slaga, A. Sivak and R. K. Boutwell, Eds.), Raven Press, New York, 1978, pp. 475-489.
 160. Highman, B., Greenman, D. L., Norvell, M. J., Farmer, J., and

- Shellenberger, T. E. Neoplastic and preneoplastic lesions induced in female C3H mice by diets containing diethylstilbestrol or 17-beta-estradiol. *Environ. Pathol. Toxicol.* 4: 81-95(1980).
161. Hinton, D. E., Lipsky, M. M., Heatfield, B. M., and Trump, B. F. Opposite effects of lead on chemical carcinogenesis in kidney and liver of rats. *Bull. Environ. Contam. Toxicol.* 23: 464-469 (1979).
162. Hiraga, K. Tumors of the preputial gland in rats. *Gann* 68: 369-370(1977).
163. Hiraga, K., and Fujii, T. Induction of tumours of the urinary system in F344 rats by dietary administration of sodium *o*-phenylphenate. *Food Cosmet. Toxicol.* 19: 303-310(1981).
164. Hirono, I., Haga, M., Fujii, M., Matsuura, S., Matsubara, N., Nakayama, M., Furuya, T., Hikichi, M., Takanashi, H., Uchida, E., Hosaka, S., and Ueno, I. Induction of hepatic tumors in rats by senkirkine and symphytine. *J. Natl. Cancer Inst.* 63: 469-472(1979).
165. Hirono, I., Mori, H., Yamada, K., Hirata, Y., Haga, M., Tatematsu, H., and Kanie, S. Carcinogenic activity of petasitenine, a new pyrrolizidine alkaloid isolated from *Petasites japonicus* Maxim. *J. Natl. Cancer Inst.* 58: 1155-1157(1977).
166. Hirono, I., Ueno, I., Hosaka, S., Takanashi, H., Matsushima, T., Sugimura, T., and Natori, S. Carcinogenicity examination of quercetin and rutin in ACI rats. *Cancer Lett.* 13: 15-21(1981).
167. Hirose, M., Shibata, M., Hagiwara, A., Imaida, K., and Ito, N. Chronic toxicity of butylated hydroxytoluene in Wistar rats. *Food Cosmet. Toxicol.* 19: 147-151(1981).
168. Hoch-Ligeti, C., Argus, M. F., and Arcos, J. C. Induction of carcinomas in the nasal cavity of rats by dioxane. *Brit. J. Cancer* 24: 164-167(1969).
169. Hoch-Ligeti, C., Argus, M. F., and Arcos, J. C. Oncogenic activity of an *m*-dioxane derivative: 2,6-dimethyl-*m*-dioxan-4-ol acetate (dimethoxane). *J. Natl. Cancer Inst.* 53: 791-793(1974).
170. Homburger, F. Negative lifetime carcinogen studies in rats and mice fed 50,000 ppm saccharin. In: *Chemical Toxicology of Food* (C. L. Galli, R. Paoletti and G. Vettorazzi, Eds.), Elsevier/North-Holland Biomedical Press, 1978, pp. 359-373.
171. Hong, C. B., Winston, J. M., Thornburg, L. P., Lee, C. C., and Woods, J. S. Follow-up study on the carcinogenicity of vinyl chloride and vinylidene chloride in rats and mice: tumor incidence and mortality subsequent to exposure. *J. Toxicol. Environ. Health* 7: 909-924(1981).
172. Hooson, J., Gaunt, I. F., Kiss, I. S., Grasso, P., and Butterworth, K. R. Long-term toxicity of indigo carmine in mice. *Food Cosmet. Toxicol.* 13: 167-176(1975).
173. Hooson, J., Hicks, R. M., Grasso, P., and Chowaniec, J. Ortho-toluene sulphonamide and saccharin in the promotion of bladder cancer in the rat. *Brit. J. Cancer* 42: 129-147(1980).
174. Horie, A., Kohchi, S., and Kuratsune, M. Carcinogenesis in the esophagus. II. Experimental production of esophageal cancer by administration of ethanolic solution of carcinogens. *Gann* 56: 429-441 (1965).
175. Horn, H. J., Black, Bruce R., and Paynter, O. E. Toxicology of chlorobenzilate. In: *Agricultural and Food Chemistry: Past, Present, Future*, Vol. 3 (R. Teranishi, Ed.), Avi Publishing Company, Inc., Westport, CT, 1955, pp. 752-756.
176. Hosaka, S., and Hirono, I. Effect of leupeptin, a protease inhibitor, on the development of spontaneous tumors in strain A mice. *Gann* 71: 913-917(1980).
177. Hosaka, S., Matsushima, T., Hirono, I., and Sugimura, T. Carcinogenic activity of 3-amino-1-methyl-5H-pyrido[4,3-b]indole (trp-P-2), a pyrolysis product of tryptophan. *Cancer Lett.* 13: 23-28(1981).
178. Hoshino, H., and Tanooka, H. Carcinogenicity of triethanolamine in mice and its mutagenicity after reaction with sodium nitrite in bacteria. *Cancer Res.* 38: 3918-3921(1978).
179. Howe, R. Carcinogenicity of 'alderlin' (pronethalol) in mice. *Nature* 207: 594-595(1965).
180. Hueper, W. C., and Payne, W. W. Experimental studies in metal carcinogenesis. Chromium, nickel, iron, arsenic. *Arch. Environ. Health* 5: 445-462(1962).
181. Ikeda, Y., Horiuchi, S., Furuya, T., and Omori, Y. Chronic toxicity of ponceau MX in the rat. *Food Cosmet. Toxicol.* 4: 485-492(1966).
182. Ikeda, Y., Horiuchi, S., Kobayashi, K., Furuya, T., and Kohgo, K. Carcinogenicity of ponceau MX in the mouse. *Food Cosmet. Toxicol.* 6: 591-598(1968).
183. Innes, J. R. M. Evaluation of Carcinogenic, Teratogenic, and Mutagenic Activities of Selected Pesticides and Industrial Chemicals. Volume 1: Carcinogenic Study. Bionetics Research Laboratories, Inc. Distributed by National Technical Information Service, Springfield, VA, 1968.
184. Innes, J. R. M., Ulland, B. M., Valerio, M. G., Petrucelli, L., Fishbein, L., Hart, E. R., Pallota, A. J., Bates, R. R., Falk, H. L., Gart, J. J., Klein, M., Mitchell I., and Peters, J. Bioassay of pesticides and industrial chemicals for tumorigenicity in mice: a preliminary note. *J. Natl. Cancer Inst.* 42: 1101-1114(1969).
185. Isaka, H., Yoshii, H., Otsuji, A., Koike, M., Nagai, Y., Koura, M., Sugiyasu, K., and Kanabayashi, T. Tumors of Sprague-Dawley rats induced by long-term feeding of phenacetin. *Gann* 70: 29-36(1979).
186. Ishii, H. Incidence of brain tumors in rats fed aspartame. *Toxicol. Lett.* 7: 433-437(1981).
187. Ito, A., Watanabe, H., Naito, M., and Naito, Y. Induction of duodenal tumors in mice by oral administration of hydrogen peroxide. *Gann* 72: 174-175(1981).
188. Ito, N., Hananouchi, M., Sugihara, S., Shirai, T., Tsuda, H., Fukushima, S., and Nagasaki, H. Reversibility and irreversibility of liver tumors in mice induced by the alpha isomer of 1,2,3,4,5,6-hexachlorocyclohexane. *Cancer Res.* 36: 2227-2234 (1976).
189. Ito, N., Nagasaki, H., Aoe, H., Sugihara, S., Miyata, Y., Arai, M., and Shirai, T. Development of hepatocellular carcinomas in rats treated with benzene hexachloride. *J. Natl. Cancer Inst.* 54: 801-804(1975).
190. Ivankovic, S., and Preussmann, R. Absence of toxic and carcinogenic effects after administration of high doses of chronic oxide pigment in subacute and long-term feeding experiments in rats. *Food Cosmet. Toxicol.* 13: 347-351(1975).
191. Johansson, S. L. Carcinogenicity of analgesics: long-term treatment of Sprague-Dawley rats with phenacetin, phenazone, caffeine and paracetamol (acetamidophen). *Int. J. Cancer* 27: 521-529(1981).
192. Johansson, S., and Angervall, L. Urothelial changes of the renal papillae in Sprague-Dawley rats induced by long term feeding of phenacetin. *Acta Pathol. Microbiol. Scand. Sect. A. Suppl.* 84: 375-383(1976).
193. Jukes, T. H., and Shaffer, C. B. Antithyroid effects of aminotriazole. *Science* 132: 296-297(1960).
194. Kanisawa, M., and Schroeder, H. A. Life term studies on the effects of arsenic, germanium, tin and vanadium on spontaneous tumors in mice. *Cancer Res.* 27: 1192-3195(1967).
195. Kanisawa, M., and Schroeder, H. A. Life term studies on the effect of trace elements on spontaneous tumors in mice and rats. *Cancer Res.* 29: 892-895(1969).
196. Kimbrough, R. D., and Linder, R. E. Induction of adenofibrosis and hepatomas of the liver in BALB/cJ mice by polychlorinated biphenyls (Aroclor 1254). *J. Natl. Cancer Inst.* 53: 547-549(1974).
197. Kimbrough, R. D., Squire, R. A., Linder, R. E., Strandberg, J. D., Montali, R. J., and Burse, V. W. Induction of liver tumors in Sherman strain female rats by polychlorinated biphenyl Aroclor 1260. *J. Natl. Cancer Inst.* 55: 1453-1456(1975).
198. Kinebuchi, M., Kawachi, T., Matsukura, N., and Sugimura, T. Further studies on the carcinogenicity of a food additive, AF-2, in hamsters. *Food Cosmet. Toxicol.* 17: 339-341(1979).
199. King, D. W., Bock, F. G., and Moore, G. E. Dinitrophenol inhibition of pituitary adenoma formation in mice fed propylthiouracil. *Proc. Soc. Exptl. Biol. Med.* 112: 365-366(1963).
200. Kirby, A. H. M., and Peacock, P. R. The induction of liver tumours by 4-aminoazobenzene and its *N,N*-dimethyl derivative in rats on a restricted diet. *J. Pathol.* 59: 1-18(1947).
201. Kociba, R. J., Keyes, D. G., Beyer, J. E., Carreon, R. M., Wade,

- C. E., Dittenber, D. A., Kalnins, R. P., Frauson, L. E., Park, C. N., Barnard, S. D., Hummel, R. A., and Humiston, C. G. Results of a two-year chronic toxicity and oncogenicity study of 2,3,7,8-tetrachlorodibenzo-*p*-dioxin in rats. *Toxicol. Appl. Pharmacol.* 46: 279-303(1978).
202. Kociba, R. J., Keyes, D. G., Jersey, G. C., Ballard, J. J., Dittenber, D. A., Quast, J. F., Wade, C. E., Humiston, C. G., and Schwetz, B. A. Results of a two year chronic toxicity study with hexachlorobutadiene in rats. *Am. Ind. Hyg. Assoc. J.* 38: 589-602(1977).
203. Kociba, R. J., Keyes, D. G., Lisowe, R. W., Kalnins, R. P., Dittenber, D. D., Wade, C. E., Gorzinski, S. J., Mahle, N. H., and Schwetz, B. A. Results of a two-year chronic toxicity and oncogenic study of rats ingesting diets containing 2,4,5-trichlorophenoxyacetic acid (2,4,5-T). *Food Cosmet. Toxicol.* 17: 205-221(1979).
204. Kociba, R. J., McCollister, S. B., Park, C., Torkelson, T. R., and Gehring, P. J. 1,4-Dioxane. I. Results of a 2-year ingestion study in rats. *Toxicol. Appl. Pharmacol.* 30: 275-286(1974).
205. Kommineni, C., Groth, D. H., Frockt, I. J., Voelker, R. W., and Stanovick, R. P. Determination of the tumorigenic potential of methylene-bis-ortho-chloroaniline. *Environ. Pathol. Toxicol.* 2: 149-171 (1979).
206. Konishi, Y., Kondo, H., Ikeda, T., Kawabata, A., Shoji, Y., and Denda, A. Effect of dose on the carcinogenic activity of orally administered *N*-bis(2-hydroxypropyl)nitrosamine in rats. *Gann* 69: 573-577(1978).
207. Kroes, R., Peters, P. W. J., Berkvens, J. M., Verschuuren, H. G., De Vries, T., and Van Esch, G. J. Long term toxicity and reproduction study (including a teratogenicity study) with cyclamate, saccharin and cyclohexylamine. *Toxicology* 8: 285-300 (1977).
208. Kroes, R., Van Logten, M. J., Berkvens, J. M., De Vries, T., and Van Esch, G. J. Study on the carcinogenicity of lead arsenate and sodium arsenate and on the possible synergistic effect of diethylnitrosamine. *Food Cosmet. Toxicol.* 12: 671-679 (1974).
209. Kruger, F. W., and Schmahl, D. Fehlen einer carcinogenen Wirkung von 7-Methylguanin bei Ratten. *Cancer Res. Clin. Oncol.* 75: 253-254(1971).
210. Kuhara, K., Takanashi, H., Hirono, I., Furuya, T., and Asada, Y. Carcinogenic activity of chlorine, a pyrrolizidine alkaloid isolated from *Ligularia dentata*. *Cancer Lett.* 10: 117-122(1980).
211. Lacassagne, A., and Duplan, J. F. *Cancerologie. Le mecanisme de la cancerisation de la mamelle chez la souris, considere d'apres les resultats d'experiences au moyen de la reserpine.* Academie des Sciences. Memoires et Communications des Membres et des Correspondants de l'Academie. 1959, pp. 810-812.
212. Lalwani, N. D., Reddy, M. K., Qureshi, S. A., and Reddy, J. K. Development of hepatocellular carcinomas and increased peroxisomal fatty acid beta-oxidation in rats fed [4-chloro-6-(2,3-xyldino)-2-pyrimidinylthio]acetic acid (WY-14,643) in the semipurified diet. *Carcinogenesis* 2: 645-650(1981).
213. Larson, P. S., Crawford, E. M., Blackwell Smith, R., Hennigar, G. R., Haag, H. B., and Finnegan, J. K. Chronic toxicologic studies on isopropyl *N*-(3-chlorophenyl) carbamate (CIPC). *Toxicol. Appl. Pharmacol.* 2: 659-673(1960).
214. Laskin, S., Drew, R. T., Cappiello, V., Kuschner, M., and Nelson, N. Inhalation carcinogenicity of alpha halo ethers. II. Chronic inhalation studies with chloromethyl methyl ether. *Arch. Environ. Health* 30: 70-72(1975).
215. Laskin, S., Sellakumar, A. R., Kuschner, M., Nelson, N., La Mendola, S., Rusch, G. M., Katz, G. V., Dulak, N. C., and Albert, R. E. Inhalation carcinogenicity of epichlorohydrin in noninbred Sprague-Dawley rats. *J. Natl. Cancer Inst.* 65: 751-757(1980).
216. Lee, C. C., Bhandari, J. C., Winston, J. M., House, W. B., Dixon, R. L., and Woods, J. S. Carcinogenicity of vinyl chloride and vinylidene chloride. *J. Toxicol. Environ. Health* 4: 15-30 (1978).
217. Lee, D. J., Wales, J. H., and Sinnhuber, R. O. Hepatoma and renal tubule adenoma in rats fed aflatoxin and cyclopropenoid fatty acids. *J. Natl. Cancer Inst.* 43: 1037-1041(1969).
218. Leong, B. K. J., Kociba, R. J., and Jersey, G. C. A lifetime study of rats and mice exposed to vapors of bis(chloromethyl) ether. *Toxicol. Appl. Pharmacol.* 58: 269-281(1981).
219. Leuschner, F. Carcinogenicity studies on different diarylide yellow pigments in mice and rats. *Toxicol. Lett.* 2: 253-260(1978).
220. Levinskas, G. J., Ribelin, W. E., and Shaffer, C. B. Acute and chronic toxicity of pimaricin. *Toxicol. Appl. Pharmacol.* 8: 97-109 (1966).
221. Levy, L. S., and Clack, J. Further studies on the effect of cadmium on the prostate gland. I. Absence of prostatic changes in rats given oral cadmium sulphate for two years. *Ann. Occup. Hyg.* 17: 205-211(1975).
222. Levy, L. S., Clack, J., and Roe, F. J. C. Further studies on the effect of cadmium on the prostate gland. II. Absence of prostatic changes in mice given oral cadmium sulphate for eighteen months. *Ann. Occup. Hyg.* 17: 213-220(1975).
223. Lijinsky, W., Greenblatt, M., and Kommineni, C. Feeding studies of nitrilotriacetic acid and derivatives in rats. *J. Natl. Cancer Inst.* 50: 1061-1063(1973).
224. Lijinsky, W., Reuber, M. D., Davies, T. C., and Riggs, C. W. Dose-response studies with nitroso-1,2,3,6-tetrahydropyridine and dinitrosohomopiperazine in F344 rats. *Ecotoxicol. Environ. Saf.* 6: 513-527(1982).
225. Lijinsky, W., Reuber, M. D., Davies, T. S., and Riggs, C. W. Dose-response studies with nitrosoheptamethyleneimine and its alpha-deuterium-labeled derivative in F344 rats. *J. Natl. Cancer Inst.* 69: 1127-1133(1982).
226. Lijinsky, W., Reuber, M. D., Davies, T. S., Saavedra, J. E., and Riggs, C. W. Dose-response studies in carcinogenesis by nitroso-*N*-methyl-*N*-(2-phenyl)ethylamine in rats and the effects of deuterium substitution. *Food Cosmet. Toxicol.* 20: 393-399 (1982).
227. Lijinsky, W., Reuber, M. D., and Riggs, C. W. Dose response studies of carcinogenesis in rats by nitrosodiethylamine. *Cancer Res.* 41: 4997-5003(1981).
228. Lijinsky, W., and Schmahl, D. Carcinogenicity of *N*-nitroso derivatives of *N*-methylcarbamate insecticides in rats. *Ecotoxicol. Environ. Saf.* 2: 413-419(1978).
229. Lijinsky, W., Taylor, H. W., Mangino, M., and Singer, G. M. Carcinogenesis of nitrosomethylundecylamine in Fischer rats. *Cancer Lett.* 5: 209-213(1978).
230. Lindsay, S., Nichols, C. W., and Chaikoff, I. L. Induction of benign and malignant thyroid neoplasms in the rat. Induction of thyroid neoplasms by injection of 131-I with or without the feeding of diets containing propylthiouracil and/or desiccated thyroid. *Arch. Pathol.* 81: 308-316(1966).
231. Littlefield, N. A., Farmer, J. H., Gaylor, D. W., and Sheldon, W. G. Effects of dose and time in a long-term, low-dose carcinogenic study. *Environ. Pathol. Toxicol.* 3: 17-34(1980).
232. Long, E. L., Nelson, A. A., Fitzhugh, O. G., and Hansen, W. H. Liver tumors produced in rats by feeding safrole. *Arch. Pathol.* 75: 595-604(1963).
233. Longnecker, D. S., Curphey, T. J., Lilja, H. S., French, J. I., and Daniel, D. S. Carcinogenicity in rats of the nitrosourea amino acid *N*-delta-(*N*-methyl-*N*-nitrosocarbamoyl)-*L*-ornithine. *Environ. Pathol. Toxicol.* 4: 117-129(1980).
234. Longnecker, D. S., Roebuck, B. D., Yager, J. D., Lilja, H. S., and Siegmund, B. Pancreatic carcinoma in azaserine-treated rats: induction, classification and dietary modulation of incidence. *Cancer* 47: 1562-1572(1981).
235. Loser, E. A 2 year oral carcinogenicity study with cadmium on rats. *Cancer Lett.* 9: 191-198(1980).
236. Louria, D. B., Finkel, G., Smith, J. K., and Buse, M. Aflatoxin-induced tumors in mice. *Sabouraudia* 12: 371-375(1974).
237. Macklin, A. W., and Sztot, R. J. Eighteen month oral study of aspirin, phenacetin and caffeine in C57BL/6 mice. *Drug Chem. Toxicol.* 3: 135-163(1980).
238. Maekawa, A., Kajiwarra, T., Odashima, S., and Kurata, H. Hepatic changes in male ACI/N rats on low dietary levels of stigmatocystin. *Gann* 70: 777-781(1979).
239. Maltoni, C. Vinyl chloride carcinogenicity: an experimental model for carcinogenesis studies. In: *Origins of Human Cancer, Book A, Vol. 4* (H. H. Hiatt, J. D. Watson and J. A. Winsten,

- Eds.), Cold Spring Harbor Laboratory, Cold Spring Harbor, NY, 1977, pp. 119-146.
240. Maltoni, C., Cotti, G., Morisi, L., and Chieco, P. Carcinogenicity bioassays of vinylidene chloride. Research plans and early results. *Med. Lavoro* 64: 241-262(1977).
 241. Maltoni, C., Lefemine, G., Ciliberti, A., Cotti, G., and Carretti, D. Carcinogenicity bioassays of vinyl chloride monomer: a model of risk assessment on an experimental basis. *Environ. Health Perspect.* 41: 3-29(1981).
 242. Maltoni, C., and Scarnato, C. First experimental demonstration of the carcinogenic effects of benzene. *Med. Lavoro* 70: 352-357(1979).
 243. Maltoni, C., Valgimigli, L., and Scarnato, C. Long-term carcinogenic bioassays on ethylene dichloride administered by inhalation to rats and mice. In: *Banbury Report 5 Ethylene Dichloride: A Potential Health Risk?* (B. Ames, P. Infante and R. Reitz, Eds.), Cold Spring Harbor Laboratory, 1980.
 244. Mannell, W. A. Further investigations on production of liver tumours in rats by ponceau 3R. *Food Cosmet. Toxicol.* 2: 169-174 (1964).
 245. Mannell, W. A., Grice, H. C., Lu, F. C., and Allmark, M. G. Chronic toxicity studies on food colours. Part IV. Observations on the toxicity of tartrazine, amaranth and sunset yellow in rats. *J. Pharm. Pharmacol.* 10: 625-634(1958).
 246. Martin, M. S., Justrabo, E., Jeannin, J. F., Leclerc, A., and Martin, F. Effect of dietary chenodeoxycholic acid on intestinal carcinogenesis induced by 1.2 dimethylhydrazine in mice and hamsters. *Brit. J. Cancer* 43: 884-886(1981).
 247. Mason, P. L., Gaunt, I. F., Butterworth, K. R., Hardy, J., Kiss, I. S., and Grasso, P. Long-term toxicity studies of carmoisine in mice. *Food Cosmet. Toxicol.* 12: 601-607(1974).
 248. Matsukura, N., Kawachi, T., Morino, K., Ohgaki, H., and Sugimura, T. Carcinogenicity in mice of mutagenic compounds from a tryptophan pyrolyzate. *Science* 213: 346-347(1981).
 249. Matsukura, N., Kawachi, T., Sasajima, K., Sano, T., Sugimura, T., and Hirota, T. Induction of intestinal metaplasia in the stomachs of rats by *N*-methyl-*N'*-nitro-*N*-nitrosoguanidine. *J. Natl. Cancer Inst.* 61: 141-143(1978).
 250. Matsukura, N., Kawachi, T., Sasajima, K., Sano, T., Sugimura, T., and Ito, N. Induction of liver tumors in rats by sodium nitrite and methylguanidine. *Cancer Res. Clin. Oncol.* 90: 87-94(1977).
 251. Matsukura, N., Kawachi, T., Sugimura, T., Nakadate, M., and Hirota, T. Induction of intestinal metaplasia and carcinoma in the glandular stomach of rats by *N*-alkyl-*N'*-nitro-*N*-nitrosoguanidines. *Gann* 70: 181-185(1979).
 252. Matsuzaki, O. Histogenesis and growing patterns of lung tumors induced by potassium 1-methyl-1,4-dihydro-7-[2-(5-nitrofuryl) vinyl]-4-oxo-1,8-naphthyridine-3-carboxylate in ICR mice. *Gann* 66: 259-267(1975).
 253. McCollister, S. B., Kociba, R. J., Humiston, C. G., McCollister, D. D., and Gehring, P. J. Studies of the acute and long-term oral toxicity of chlorpyrifos (O,O-diethyl-O-(3,5,6-trichloro-2-pyridyl) phosphorothioate). *Food Cosmet. Toxicol.* 12: 45-61(1974).
 254. McElligott, T. F., and Hurst, E. W. Long-term feeding studies of methyl ethyl cellulose ('edifas' A) and sodium carboxymethyl cellulose ('edifas' B) in rats and mice. *Food Cosmet. Toxicol.* 6: 449-460(1968).
 255. Merkow, L. P., Epstein, S. M., Slifkin, M., and Pardo, M. The ultrastructure of renal neoplasms induced by aflatoxin B1. *Cancer Res.* 33: 1608-1614(1973).
 256. Miller, E. C., and Miller, J. A. Biochemical investigations on hepatic carcinogenesis. *J. Natl. Cancer Inst.* 15: 1571-1590(1955).
 257. Miller, E. C., Miller, J. A., and Enomoto, M. The comparative carcinogenicities of 2-acetylaminofluorene and its *N*-hydroxy metabolite in mice, hamsters, and guinea pigs. *Cancer Res.* 24: 2018-2026 (1964).
 258. Miyaji, T. Acute and chronic toxicity of furylfuramide in rats and mice. *Tohoku J. Exp. Med.* 103: 331-369(1971).
 259. Morris, H. P., Velat, C. A., Wagner, B. P., Dahlgard, M., and Ray, F. E. Studies of carcinogenicity in the rate of derivatives of aromatic amines related to *N*-2-fluorenylacetylacetamide. *J. Natl. Cancer Inst.* 24: 149-180(1960).
 260. Morris, J. E., Price, J. M., Lalich, J. J., and Stein, R. J. The carcinogenic activity of some 5-nitrofurans derivatives in the rat. *Cancer Res.* 29: 2145-2156(1969).
 261. Munoz, M. Effect of herpes virus type 2 and hormonal imbalance on the uterine cervix of the mouse. *Cancer Res.* 33: 1504-1508 (1973).
 262. Munro, I. C., Moodie, C. A., Krewski, D., and Grice, H. C. A. A carcinogenicity study of commercial saccharin in the rat. *Toxicol. Appl. Pharmacol.* 32: 513-526(1975).
 263. Murthy, A. S. K., Baker, J. R., Smith, E. R., and Zepp, E. Neoplasms in rats and mice fed butylurea and sodium nitrite separately and in combination. *Int. J. Cancer* 23: 253-259(1979).
 264. Nagel, D., Shimizu, H., and Toth, B. Tumor induction studies with *n*-butyl- and *n*-propylhydrazine hydrochlorides in Swiss mice. *Eur. J. Cancer* 11: 473-478(1975).
 265. Nakamura, T., Matsuyama, M., and Kishimoto, H. Tumors of the esophagus and duodenum induced in mice by oral administration of *N*-ethyl-*N'*-nitro-*N*-nitrosoguanidine. *J. Natl. Cancer Inst.* 52: 519-522(1974).
 266. National Cancer Institute. Report on carcinogenesis bioassay of chloroform. N.C.I. Brief Communication. 1976.
 267. Newberne, J. W., Newberne, P. M., Gibson, J. P., Huffman, K. W., and Palopoli, F. P. Lack of carcinogenicity of oxprenolol, a beta-adrenergic blocking agent. *Toxicol. Appl. Pharmacol.* 41: 535-546(1977).
 268. Newberne, P. M. Nitrite promotes lymphoma incidence in rats. *Science* 204: 1079-1081(1979).
 269. Newberne, P. M., Harrington, D. H., and Wogan, G. N. Effects of cirrhosis and other liver insults on induction of liver tumors by aflatoxin in rats. *Lab. Invest.* 15: 962-969(1966).
 270. Newberne, P. M., and Rogers, A. E. Rat colon carcinomas associated with aflatoxin and marginal vitamin A. *J. Natl. Cancer Inst.* 50: 439-444(1973).
 271. Newberne, P. M., and Williams, G. Inhibition of aflatoxin carcinogenesis by diethylstilbestrol in male rats. *Arch. Environ. Health* 19: 489-498(1969).
 272. Nixon, J. E., Hendricks, J. D., Pawlowski, N. E., Loveland, P. M., and Sinnhuber, R. O. Carcinogenicity of aflatoxicol in Fischer 344 rats. *J. Natl. Cancer Inst.* 66: 1159-1163(1981).
 273. Nixon, J. E., Sinnhuber, R. O., Lee, D. J., Landers, M. K., and Harr, J. R. Effect of cyclopropenoid compounds on the carcinogenic activity of diethylnitrosamine and aflatoxin B1 in rats. *J. Natl. Cancer Inst.* 53: 453-458(1974).
 274. Oda, H., Nogami, H., Kusumoto, S., Nakajima, T., and Kurata, A. Lifetime exposure to 2.4 ppm nitric oxide in mice. *Environ. Res.* 22: 254-263(1980).
 275. Ogiu, T., Kajiwaru, T., Furuta, K., Takeuchi, M., Odashima, S., and Tada, K. Mammary tumorigenic effect of a new nitrosourea, 1,3-dibutyl-1-nitrosourea (B-BNU), in female Donryu rats. *Cancer Res. Clin. Oncol.* 96: 35-41(1980).
 276. Ohtsubo, K., Saito, M., Kimura, H., and Tsuruta, O. High incidence of hepatic tumours in rats fed mouldy rice contaminated with *Aspergillus versicolor* containing sterigmatocystin. *Food Cosmet. Toxicol.* 16: 143-149(1978).
 277. Okey, A. B., and Gass, G. H. Continuous versus cyclic estrogen administration: mammary carcinoma in C3H mice. *J. Natl. Cancer Inst.* 40: 225-230(1968).
 278. Oser, B. L., Carson, S., Cox, G. E., Vogin, E. E., and Sternberg, S. S. Long-term and multigenefaction toxicity studies with cyclohexylamine hydrochloride. *Toxicology* 6: 47-65(1976).
 279. Oser, B. L., Morgareidge, K., Weinberg, M. S., and Oser, M. Carcinogenicity study of carbarson. *Toxicol. Appl. Pharmacol.* 9: 528-535(1966).
 280. Oser, B. L., and Oser, M. 2-(*p*-*tert*-Butylphenoxy)isopropyl 2-chloroethyl sulfite (Aramite). 1. Acute, subacute, and chronic oral toxicity. *Toxicol. Appl. Pharmacol.* 2: 441-457(1960).
 281. Osswald, H., Frank, H. K., Komitowski, D., and Winter, H. Long-term testing of patulin administered orally to Sprague-Dawley rats and Swiss mice. *Food Cosmet. Toxicol.* 16: 243-247(1978).
 282. Owen, N. V., Worth, H. M., and Kiplinger, G. F. The effects of long-term ingestion of methimazole on the thyroids of rats. *Food Cosmet. Toxicol.* 11: 649-653(1973).
 283. Pai, S. R., Shirke, A. J., and Gothoskar, S. V. Long-term feeding

- study in C17 mice administered saccharin coated betel nut and 1,4-dinitrosopiperazine in combination. *Carcinogenesis* 2: 175-177 (1981).
284. Palmer, A. K., Street, A. E., Roe, F. J. C., Worden, A. N., and Van Abbe, N. J. Safety evaluation of toothpaste containing chloroform. II. Long term studies in rats. *Environ. Pathol. Toxicol.* 2: 821-833 (1979).
 285. Pamukcu, A. M., Yalciner, S., Hatcher, J. F., and Bryan, G. T. Quercetin, a rat intestinal and bladder carcinogen present in bracken fern (*Pteridium aquilinum*). *Cancer Res.* 40: 3468-3472 (1980).
 286. Peraino, C., Fry, R. J. M., and Staffeldt, E. Enhancement of spontaneous hepatic tumorigenesis in C3H mice by dietary phenobarbital. *J. Natl. Cancer Inst.* 51: 1349-1350 (1973).
 287. Pershin, G. N., Makeeva, O. O., Grushina, A. A., and Chernov, V. A. An experimental study of the carcinogenic effect of tubazid (isoniazid) and phtivazid. *Vopr. Onkol.* 18: 50-53 (1972).
 288. Phillips, J. C., Butterworth, K. R., Gaunt, I. F., Evans, J. G., and Grasso, P. Long-term toxicity study of quillaia extract in mice. *Food Cosmet. Toxicol.* 17: 23-27 (1979).
 289. Pietra, G., and Shubik, P. Induction of melanotic tumors in the Syrian golden hamster after administration of ethyl carbamate. *J. Natl. Cancer Inst.* 25: 627-630 (1960).
 290. Poel, W. E. Pituitary tumors in mice after prolonged feeding of synthetic progestins. *Science* 154: 402-403 (1966).
 291. Poel, W. E., Ciocco, A., and Doolittle, D. P. Unusual neoplasms and hyperplastic lesions in "random-bred" mice derived from four-way crossed inbred lines. *Cancer Res.* 28: 845-859 (1968).
 292. Ponomarkov, V., Tomatis, L., and Turusov, V. The effect of long-term administration of phenobarbitone in CF-1 mice. *Cancer Lett.* 1: 165-172 (1976).
 293. Popper, H., Sternberg, S. S., Oser, B. L., and Oser, M. The carcinogenic effect of aramite in rats. A study of hepatic nodules. *Cancer* 13: 1035-1046 (1960).
 294. Preussmann, R., Habs, M., and Pool, B. L. Carcinogenicity and mutagenicity testing of three isomeric *N*-nitroso-*N*-methylamino-pyridines in rats. *J. Natl. Cancer Inst.* 62: 153-156 (1979).
 295. Preussmann, R., Habs, M., Pool, B., Stummeyer, D., Lijinsky, W., and Reuber, M. D. Fluoro-substituted *N*-nitrosamines. I. Inactivity of *N*-nitroso-bis(2,2,2-trifluoroethyl)amine in carcinogenicity and mutagenicity tests. *Carcinogenesis* 2: 753-756 (1981).
 296. Preussmann, R., and Ivankovic, S. Absence of carcinogenic activity in BD rats after oral administration of high doses of bismuth oxychloride. *Food Cosmet. Toxicol.* 13: 543-544 (1975).
 297. Preussmann, R., Ivankovic, S., Landschutz, C., Gimmy, J., Flohr, E., and Griesbach, U. Carcinogene Wirkung von 13 Aryldialkyltriazenen an BD-Ratten. *Cancer Res. Clin. Oncol.* 81: 285-310 (1974).
 298. Preussmann, R., Schmahl, D., and Eisenbrand, G. Carcinogenicity of *N*-nitrosopyrrolidine: dose-response study in rats. *Cancer Res. Clin. Oncol.* 90: 161-166 (1977).
 299. Price, J. M., Biava, C. G., Oser, B. L., Vogin, E. E., Steinfeld, J., and Ley, H. L. Bladder tumors in rats fed cyclohexylamine or high doses of a mixture of cyclamate and saccharin. *Science* 167: 1131-1132 (1970).
 300. Prier, R. F., Nees, P. O., and Derse, P. H. The toxicity of an organic arsenical, 3-nitro-4-hydroxyphenylarsonic acid. II. Chronic toxicity. *Toxicol. Appl. Pharmacol.* 5: 526-542 (1963).
 301. Purchase, I. F. H., and van der Watt, J. J. Carcinogenicity of sterigmatocystin. *Food Cosmet. Toxicol.* 8: 289-295 (1970).
 302. Purchase, I. F. H., and van der Watt, J. J. The long-term toxicity of ochratoxin A to rats. *Food Cosmet. Toxicol.* 9: 681-682 (1971).
 303. Quast, J. F., Schuetz, D. J., Balmer, M. F., Gushow, T. S., Park, C. N., and McKenna, M. J. A Two-year Toxicity and Oncogenicity Study with Acrylonitrile Following Inhalation Exposure of Rats. Final Report. Dow Chemical U.S.A., Midland, MI, 1980.
 304. Quast, J. F., Wade, C. E., Humiston, C. G., Carreon, R. M., Hermann, E. A., Park, C. N., and Schwetz, B. A. A Two-year Toxicity and Oncogenicity Study with Acrylonitrile Incorporated in the Drinking Water of Rats. Final Report. Dow Chemical U.S.A., Midland, MI, 1980.
 305. Radomski, J. L., Brill, E., and Glass, E. M. Induction of bladder tumors and other malignancies in rats with 2-methoxy-3-aminodibenzofuran. *J. Natl. Cancer Inst.* 39: 1069-1080 (1967).
 306. Radomski, J. L., Deichmann, W. B., Macdonald, W. E., and Glass, E. M. Synergism among oral carcinogens: I. Results of the simultaneous feeding of four tumorigens to rats. *Toxicol. Appl. Pharmacol.* 7: 652-656 (1965).
 307. Rao, M. S., and Reddy, J. K. Malignant neoplasms in rats fed lasiocarpine. *Brit. J. Cancer* 37: 289-293 (1978).
 308. Reddy, J. K., Azarnoff, D. L., and Hignite, C. E. Hypolipidaemic hepatic peroxisome proliferators form a novel class of chemical carcinogens. *Nature* 283: 397-398 (1980).
 309. Reddy, J. K., and Qureshi, S. A. Tumorigenicity of the hypolipidaemic peroxisome proliferator ethyl-alpha-p-chlorophenoxyisobutyrate (clofibrate) in rats. *Brit. J. Cancer* 40: 476-482 (1979).
 310. Reddy, J. K., Svoboda, D. J., and Rao, M. S. Induction of liver tumors by aflatoxin B1 in the tree shrew (*Tupaia glis*) a nonhuman primate. *Cancer Res.* 36: 151-160 (1976).
 311. Reznik, G., Mohr, U., and Lijinsky, W. Carcinogenic effect of *N*-nitroso-2,6-dimethylmorpholine in Syrian golden hamsters. *J. Natl. Cancer Inst.* 60: 371-378 (1978).
 312. Roe, F. J. C., Grant, G. A., and Millican, D. M. Carcinogenicity of hydrazine and 1,1-dimethylhydrazine for mouse lung. *Nature* 216: 375-376 (1967).
 313. Roe, F. J. C., Levy, L. S., and Carter, R. L. Feeding studies on sodium cyclamate, saccharin and sucrose for carcinogenic and tumour-promoting activity. *Food Cosmet. Toxicol.* 8: 135-145 (1970).
 314. Roe, F. J. C., Palmer, A. K., Worden, A. N., and Van Abbe, N. J. Safety evaluation of toothpaste containing chloroform. I. Long-term studies in mice. *Environ. Pathol. Toxicol.* 2: 799-819 (1979).
 315. Rosin, A., and Ungar, H. Malignant tumors in the eyelids and the auricular region of thiourea-treated rats. *Cancer Res.* 17: 302-305 (1957).
 316. Rossi, L., Ravera, M., Repetti, G., and Santi, L. Long-term administration of DDT or phenobarbital-Na in Wistar rats. *Int. J. Cancer* 19: 179-185 (1977).
 317. Rudali, G. Induction of tumors in mice with synthetic sex hormones. *Gann Mono. Cancer Res.* 17: 243-252 (1975).
 318. Rudali, G., and Assa, R. Lifespan carcinogenicity studies with hexachlorophene in mice and rats. *Cancer Lett.* 5: 325-332 (1978).
 319. Rudali, G., Coezy, E., and Chemama, R. Mammary carcinogenesis in female and male mice receiving contraceptives or gestagens. *J. Natl. Cancer Inst.* 49: 813-819 (1972).
 320. Rudali, G., Coezy, E., Frederic, F., and Apiou, F. Susceptibility of mice of different strains to the mammary carcinogenic action of natural and synthetic oestrogens. *Rev. Eur. Etud. Clin. Biol.* 16: 425-429 (1971).
 321. Rudali, G., Coezy, E., and Muranyi-Kovacs, I. Cancerologie. -recherches sur l'action cancerigene du cyclamate de soude chez les souris. *Academie des Sciences, Memoires et Communications des Membres et des Correspondants de l'Academie.* 269: 1910-1913 (1969).
 322. Russfield, A. B., Homburger, F., Boger, E., Van Dongen, C. G., Weisburger, E. K., and Weisburger, J. H. Carcinogenicity of Chemicals in Man's Environment. Final Report. Contract No. NIH-NCI-E-68-1311. Bio-research Consultants, Inc., Cambridge, MA, 1973.
 323. Russfield, A. B., Homburger, F., Boger, E., Van Dongen, C. G., Weisburger, E. K., and Weisburger, J. H. The carcinogenic effect of 4,4'-methylene-bis-(2-chloroaniline) in mice and rats. *Toxicol. Appl. Pharmacol.* 31: 47-54 (1975).
 324. Rustia, M., and Shubik, P. Induction of lung tumors and malignant lymphomas in mice by metronidazole. *J. Natl. Cancer Inst.* 48: 721-729 (1972).
 325. Rustia, M., and Shubik, P. Life-span carcinogenicity tests with 4-amino-*N*-(10)-methylpteroylglutamic acid (methotrexate) in Swiss mice and Syrian golden hamsters. *Toxicol. Appl. Pharmacol.* 26: 329-338 (1973).
 326. Rustia, M., and Shubik, P. Thyroid tumours in rats and hepatomas in mice after griseofulvin treatment. *Brit. J. Cancer* 38: 237-249 (1978).
 327. Rustia, M., and Shubik, P. Experimental induction of hepatomas,

- mammary tumors, and other tumors with metronidazole in noninbred Sas:MRC(WI)BR rats. *J. Natl. Cancer Inst.* 63: 863-868(1979).
328. Rustia, M., Shubik, P., and Patil, K. Lifespan carcinogenicity tests with native carrageenan in rats and hamsters. *Cancer Lett.* 11: 1-10(1980).
329. Saito, D., Shirai, A., Matsushima, T., Sugimura, T., and Hirono, I. Test of carcinogenicity of quercetin, a widely distributed mutagen in food. *Teratog. Carcinog. Mutagen.* 1: 213-221(1980).
330. Sanderson, K. V. Arsenic as a co-carcinogen in mice. *British Empire Cancer Campaign, 39th Annual Report* 39: 628-629 (1961).
331. Sano, T., Kawachi, T., Matsukura, N., Sasajima, K., and Sugimura, T. Carcinogenicity of a food additive, AF-2, in hamsters and mice. *Cancer Res. Clin. Oncol.* 89: 61-68(1977).
332. Sarles, M. P., and Vandegrift, W. B. Chronic oral toxicity and related studies on animals with the insecticide and pyrethrum synergist, piperonyl butoxide. *Am. J. Trop. Med. Hyg.* 1: 862-883 (1952).
333. Sasajima, K., Kawachi, T., Matsukura, N., Sano, T., and Sugimura, T. Intestinal metaplasia and adenocarcinoma induced in the stomach of rats by *N*-propyl-*N'*-nitro-*N*-nitrosoguanidine. *Cancer Res. Clin. Oncol.* 94: 201-206(1979).
334. Schardein, J. L., Kaump, D. H., Woosley, E. T., and Jellema, M. M. Long-term toxicologic and tumorigenesis studies on an oral contraceptive agent in albino rats. *Toxicol. Appl. Pharmacol.* 16: 10-23(1970).
335. Schmahl, D. Prüfung von Polyvinylpyridin-*N*-oxid (PVNO) auf carcinogene Wirkung bei Ratten und Mäusen. *Arzneim.-Forsch.* 19: 1313-1314(1969).
336. Schmahl, D. Fehlen einer kanzerogenen Wirkung von Cyclamat, Cyclohexylamin und Saccharin bei Ratten. *Arzneim.-Forsch.* 23: 1466-1470(1973).
337. Schmahl, D. Investigations on esophageal carcinogenicity by methyl-phenyl-nitrosamine and ethyl alcohol in rats. *Cancer Lett.* 1: 215-218(1976).
338. Schmahl, D. Experiments on the carcinogenic effect of orthotoluol-sulfonamid (OTS). *Cancer Res. Clin. Oncol.* 91: 19-22 (1978).
339. Schmahl, D., and Habs, M. Life-span investigations for carcinogenicity of some immune-stimulating, immunodepressive and neurotropic substances in Sprague-Dawley-rats. *Cancer Res. Clin. Oncol.* 86: 77-84(1976).
340. Schmahl, D., and Habs, M. Experiments on the influence of an aromatic retinoid on the chemical carcinogenesis in rats by butyl-butanol-nitrosamine and 1,2-dimethylhydrazine. *Arzneim.-Forsch.* 23: 49-51(1978).
341. Schmahl, D., and Osswald, H. Experimentelle Untersuchungen über carcinogene Wirkungen von Krebs-Chemotherapeutica und Immunsuppressiva. *Arzneim.-Forsch.* 20: 1461-1467(1970).
342. Schmahl, D., Port, R., and Wahrendorf, J. A dose-response study on urethane carcinogenesis in rats and mice. *Int. J. Cancer* 19: 77-80(1977).
343. Schrauzer, G. N., McGinness, J. E., and Kuehn, K. Effects of temporary selenium supplementation on the genesis of spontaneous mammary tumors in inbred female C3H/St mice. *Carcinogenesis* 1: 199-201(1980).
344. Schroeder, H. A., Balassa, J. J., and Vinton, W. H. Chromium, lead, cadmium, nickel and titanium in mice: effect on mortality, tumors and tissue levels. *J. Nutr.* 83: 239-250(1964).
345. Schroeder, H. A., and Mitchener, M. Life-term effects of mercury, methyl mercury, and nine other trace metals on mice. *J. Nutr.* 105: 452-458(1975).
346. Schroeder, H. A., and Mitchener, M. Life-term studies in rats: effects of aluminum, barium, beryllium, and tungsten. *J. Nutr.* 105: 421-427(1975).
347. Schroeder, H. A., Mitchener, M., and Nason, A. P. Life-term effects of nickel in rats: survival, tumors, interactions with trace elements and tissue levels. *J. Nutr.* 104: 239-243(1974).
348. Schwartz, E. L., Kluwe, W. K., Sleight, S. D., Hook, J. B., and Goodman, J. I. Inhibition of *N*-2-fluorenylacetylacetamide-induced mammary tumorigenesis in rats by dietary polybrominated biphenyls. *J. Natl. Cancer Inst.* 64: 63-67(1980).
349. Schwetz, B. A., Quast, J. F., Keeler, P. A., Humiston, C. G., and Kociba, R. J. Results of two-year toxicity and reproduction studies on pentachlorophenol in rats. *Pentachlorophenol* (K. Ranga Rao, Ed.), Plenum Press, New York, 1978, pp. 301-309.
350. Sellakumar, A. R., Laskin, S., Kuschner, M., Rusch, G., Katz, G. V., Snyder, C. A., and Albert, R. E. Inhalation carcinogenesis by dimethylcarbamoyl chloride in Syrian golden hamsters. *Environ. Pathol. Toxicol.* 4: 107-115(1980).
351. Severi, L., and Biancifiore, C. Hepatic carcinogenesis in CBA/Cb/Se mice and Cb/Se rats by isonicotinic acid hydrazide and hydrazine sulfate. *J. Natl. Cancer Inst.* 41: 331-349(1968).
352. Sharratt, M., Frazer, A. C., and Forbes, O. C. Study of the biological effects of benzoyl peroxide. *Food Cosmet. Toxicol.* 2: 527-538(1964).
353. Shay, H., Gruenstein, M., and Kessler, W. B. Experimental mammary adenocarcinoma of rats: some considerations of methylcholanthrene dosage and hormonal treatment. *J. Natl. Cancer Inst.* 27: 503-513(1961).
354. Shay, H., Gruenstein, M., and Kessler, W. B. Methylcholanthrene induced breast cancer in the rat: studies on mechanism of inhibition by large doses of estrogen. *Morphological Precursors of Cancer*, (L. Severi, Ed.), Div. Canc. Res., Perugia, 1962, pp. 305-318.
355. Shimizu, H., Nagel, D., and Toth, B. Ethylhydrazine hydrochloride as a tumor inducer in mice. *Int. J. Cancer* 13: 500-505(1974).
356. Shimizu, H., Nagel, D., and Toth, B. Tumour induction study with *N*-amylhydrazine hydrochloride in Swiss mice. *Brit. J. Cancer* 31: 492-496(1975).
357. Shimizu, H., and Toth, B. Effect of lifetime administration of 2-hydroxyethylhydrazine on tumorigenesis in hamsters and mice. *J. Natl. Cancer Inst.* 52: 903-906(1974).
358. Skipper, H. E. Booklet 1, 1976. Phase I Studies on the Carcinogenic Activity of Anticancer Drugs in Mice and Rats. Final report. Southern Research Institute, Birmingham, AL, 1976.
359. Smith, A. G., and Cabral, J. R. Liver-cell tumours in rats fed hexachlorobenzene. *Cancer Lett.* 11: 169-172(1980).
360. Snell, K. C., and Stewart, H. L. Pulmonary adenomatosis induced in DBA/2 mice by oral administration of dibenz[*a,h*]anthracene. *J. Natl. Cancer Inst.* 28: 1043-1051(1962).
361. Snyder, C. A., Goldstein, B. D., Sellakumar, A. R., Bromberg, I., Laskin, S., and Albert, R. E. The inhalation toxicology of benzene: incidence of hematopoietic neoplasms and hematotoxicity in AKR/J and C57BL/6J mice. *Toxicol. Appl. Pharmacol.* 54: 323-331(1980).
362. Snyder, C. A., Goldstein, B. D., Sellakumar, A., Wolman, S. R., Bromberg, I., Erlichman, M. N., and Laskin, S. Hematotoxicity of inhaled benzene to Sprague-Dawley rats and AKR mice at 300 ppm. *J. Toxicol. Environ. Health* 4: 605-618(1978).
363. Sodemoto, Y., and Enomoto, M. Report of carcinogenesis bioassay of sodium benzoate in rats: absence of carcinogenicity of sodium benzoate in rats. *Environ. Pathol. Toxicol.* 4: 87-95(1980).
364. Stevenson, D. E., Thorpe, E., Hunt, P. F., and Walker, A. I. T. The toxic effects of dieldrin in rats: a reevaluation of data obtained in a two-year feeding study. *Toxicol. Appl. Pharmacol.* 36: 247-254(1976).
365. Stoll, R., and Maraud, R. Sur l'induction de tumeurs thyroïdiennes chez le rat traité par le propylthiouracil et le radio-iode. *Bull. Cancer* 50: 389-398(1963).
366. Stula, E. F., Barnes, J. R., Sherman, H., Reinhardt, C. F., and Zapp, J. A. Urinary bladder tumors in dogs from 4,4'-methylene-bis(2-chloroaniline) (MOCA). *Environ. Pathol. Toxicol.* 1: 31-50(1977).
367. Stula, E. F., Barnes, J. R., Sherman, H., Reinhardt, C. F., and Zapp, J. A. Liver and urinary bladder tumors in dogs from 3,3'-dichlorobenzidine. *Environ. Pathol. Toxicol.* 1: 475-490(1978).
368. Stula, E. F., Sherman, H., Zapp, J. A., and Clayton, J. W. Experimental neoplasia in rats from oral administration of 3,3'-dichlorobenzidine, 4,4'-methylene-bis(2-chloroaniline), and 4,4'-methylene-bis(2-methylaniline). *Toxicol. Appl. Pharmacol.* 31: 159-176 (1975).
369. Sugimura, T., Fujimura, S., and Baba, T. Tumor production in

- the glandular stomach and alimentary tract of the rat by *N*-methyl-*N'*-nitro-*N*-nitrosoguanidine. *Cancer Res.* 30: 455-465(1970).
370. Svoboda, D. J., and Reddy, J. K. Malignant tumors in rats given lasiocarpine. *Cancer Res.* 32: 908-911(1972).
 371. Tahara, E., Ito, H., Nakagami, K., and Shimamoto, F. Induction of carcinoids in the glandular stomach of rats by *N*-methyl-*N'*-nitro-*N*-nitrosoguanidine. *Cancer Res. Clin. Oncol.* 100: 1-12 (1981).
 372. Takayama, S. Induction of tumors in ICR mice with *N*-nitrosopiperidine, especially, in forestomach. *Naturwissenschaften* 56: 142 (1969).
 373. Takayama, S., and Imaizumi, T. Carcinogenic action of *N*-nitrosodibutylamine in mice. *Gann* 60: 353(1969).
 374. Takayama, S., and Kuwabara, N. Carcinogenic activity of 2-(2-furyl)-3-(5-nitro-2-furyl)acrylamide, a food additive, in mice and rats. *Cancer Lett.* 3: 115-120(1977).
 375. Takemura, N., Hashida, C., and Terasawa, M. Carcinogenic action of 5-nitroacenaphthene. *Brit. J. Cancer* 30: 481-483(1974).
 376. Tanaka, T., Fujii, M., Mori, H., and Hirono, I. Carcinogenicity test of potassium metabisulfite in mice. *Ecotoxicol. Environ. Saf.* 3: 451-453(1979).
 377. Tatematsu, M., Takahashi, M., Tsuda, H., Ogiso, T., and Ito, N. The administration of reserpine to rats for 75 weeks. *Toxicol. Lett.* 1: 201-205(1978).
 378. Terao, K., Aikawa, T., and Kera, K. A synergistic effect of nitrosodimethylamine on sterigmatocystin carcinogenesis in rats. *Food Cosmet. Toxicol.* 16: 591-596(1978).
 379. Terracini, B., Magee, P. N., and Barnes, J. M. Hepatic pathology in rats on low dietary levels of dimethylnitrosamine. *Brit. J. Cancer* 20: 559-565(1967).
 380. Terracini, B., Testa, M. C., Cabral, J. R., and Day, N. The effects of long-term feeding of DDT to BALB/c mice. *Int. J. Cancer* 11: 747-764(1973).
 381. Thorpe, E., and Walker, A. I. T. The toxicology of dieldrin (HEOD). II. Comparative long-term oral toxicity studies in mice with dieldrin, DDT, phenobarbitone, beta-BHC and gamma-BHC. *Food Cosmet. Toxicol.* 11: 433-442(1973).
 382. Tomatis, L., Turusov, V., Charles, R. T., and Boicchi, M. Effect of long-term exposure to 1,1-dichloro-2,2-bis(*p*-chlorophenyl)ethylene, to 1,1-dichloro-2,2-bis(*p*-chlorophenyl)ethane, and to the two chemicals combined on CF-1 mice. *J. Natl. Cancer Inst.* 52: 883-891(1974).
 383. Tomatis, L., Turusov, V., Charles, R. T., Boicchi, M., and Gati, E. Liver tumours in CF-1 mice exposed for limited periods to technical DDT. *Cancer Res. Clin. Oncol.* 82: 25-35(1974).
 384. Tomatis, L., Turusov, V., Day, N., and Charles, R. T. The effect of long-term exposure to DDT on CF-1 mice. *Int. J. Cancer* 10: 489-506(1972).
 385. Toth, B. Studies on the incidence, morphology, transplantation and cell-free filtration of malignant lymphomas in the Syrian golden hamster. *Cancer Res.* 27: 1430-1442(1967).
 386. Toth, B. Lung tumor induction and inhibition of breast adenocarcinomas by hydrazine sulfate in mice. *J. Natl. Cancer Inst.* 42: 469-475(1969).
 387. Toth, B. Benzoylhydrazine carcinogenesis in lungs and lymphoreticular tissues of Swiss mice. *Eur. J. Cancer* 8: 341-345(1972).
 388. Toth, B. Hydrazine, methylhydrazine and methylhydrazine sulfate carcinogenesis in Swiss mice. Failure of ammonium hydroxide to interfere in the development of tumors. *Int. J. Cancer* 9: 109-118(1972).
 389. Toth, B. Tumorigenesis studies with 1,2-dimethylhydrazine dihydrochloride, hydrazine sulfate, and isonicotinic acid in Golden hamsters. *Cancer Res.* 32: 804-807(1972).
 390. Toth, B. 1,1-Dimethylhydrazine (unsymmetrical) carcinogenesis in mice. Light microscopic and ultrastructural studies on neoplastic blood vessels. *J. Natl. Cancer Inst.* 50: 181-194(1973).
 391. Toth, B. Tumorigenicity of beta-phenylethylhydrazine sulfate in mice. *Cancer Res.* 36: 917-921(1976).
 392. Toth, B. The large bowel carcinogenic effects of hydrazines and related compounds occurring in nature and in the environment. *Cancer* 40: 2427-2431(1977).
 393. Toth, B. Formylhydrazine carcinogenesis in mice. *Brit. J. Cancer* 37: 960-964(1978).
 394. Toth, B. 1-Acetyl-2-phenylhydrazine carcinogenesis in mice. *Brit. J. Cancer* 39: 584-587(1979).
 395. Toth, B. Nicotinic acid hydrazide carcinogenesis in mice. *Oncology* 38: 106-109(1981).
 396. Toth, B., and Boreisha, I. Tumorigenesis with isonicotinic acid hydrazide and urethan in the Syrian golden hamsters. *Eur. J. Cancer* 5: 165-171(1969).
 397. Toth, B., and Erickson, J. Lung tumorigenesis by 1,2-diformylhydrazine in mice. *Cancer Res. Clin. Oncol.* 92: 11-16(1973).
 398. Toth, B., and Nagel, D. Tumour induction study with allylhydrazine HCl in Swiss mice. *Brit. J. Cancer* 34: 90-93(1976).
 399. Toth, B., and Nagel, D. Tumors induced in mice by *N*-methyl-*N*-formylhydrazine of the false morel *Gyromitra esculenta*. *J. Natl. Cancer Inst.* 60: 201-204(1978).
 400. Toth, B., and Nagel, D. *N*-Ethyl-*N*-formylhydrazine tumorigenesis in mice. *Carcinogenesis* 1: 61-65(1980).
 401. Toth, B., and Nagel, D. 1,2-Di-*n*-butylhydrazine dihydrochloride carcinogenesis in mice. *Experientia* 37: 773-775(1981).
 402. Toth, B., Nagel, D., and Patil, K. Tumorigenesis by *N*-*N*-propyl-*N*-formylhydrazine in mice. *Brit. J. Cancer* 42: 922-928(1980).
 403. Toth, B., Nagel, D., and Patil, K. Tumorigenic action of *N*-*N*-butyl-*N*-formylhydrazine in mice. *Carcinogenesis* 1: 589-593(1980).
 404. Toth, B., Nagel, D., and Patil, K. Carcinogenic effects of 1,1-di-*n*-butylhydrazine in mice. *Carcinogenesis* 2: 651-654(1981).
 405. Toth, B., Nagel, D., Patil, K., Erickson, J., and Antonson, K. Tumor induction with the *N'*-acetyl derivative of 4-hydroxymethylphenylhydrazine, a metabolite of agaritine of *Agaricus bisporus*. *Cancer Res.* 38: 177-180(1978).
 406. Toth, B., and Patil, K. Carcinogenic effects in the Syrian golden hamster of *N*-methyl-*N*-formylhydrazine of the false morel mushroom *Gyromitra esculenta*. *Cancer Res. Clin. Oncol.* 93: 109-121(1979).
 407. Toth, B., and Patil, K. The tumorigenic effect of low dose levels of *N*-methyl-*N*-formylhydrazine in mice. *Neoplasma* 27: 25-31 (1980).
 408. Toth, B., Patil, K., Erickson, J., and Kupper, R. False morel mushroom *Gyromitra esculenta* toxin: *N*-methyl-*N*-formylhydrazine carcinogenesis in mice. *Mycopathologia* 68: 121-123(1979).
 409. Toth, B., and Rustja, M. The effect of isonicotinic acid hydrazide on the development of tumors. *Int. J. Cancer* 2: 413-420(1967).
 410. Toth, B., and Shimizu, H. Lung carcinogenesis with 1-acetyl-2-isonicotinoylhydrazine, the major metabolite of isoniazid. *Eur. J. Cancer* 9: 285-289(1973).
 411. Toth, B., and Shimizu, H. Methylhydrazine tumorigenesis in Syrian golden hamsters and the morphology of malignant histiocytes. *Cancer Res.* 33: 2744-2753(1973).
 412. Toth, B., and Shimizu, H. 1-Carbamyl-2-phenylhydrazine tumorigenesis in Swiss mice. Morphology of lung adenomas. *J. Natl. Cancer Inst.* 52: 241-251(1974).
 413. Toth, B., and Shimizu, H. Tumorigenic effects of chronic administration of benzylhydrazine dihydrochloride and phenylhydrazine hydrochloride in Swiss mice. *Cancer Res. Clin. Oncol.* 87: 267-273(1976).
 414. Toth, B., Shimizu, H., and Erickson, J. Carbamylhydrazine hydrochloride as a lung and blood vessel tumour inducer in Swiss mice. *Eur. J. Cancer* 11: 17-22(1975).
 415. Toth, B., and Shubik, P. Carcinogenesis in Swiss mice by isonicotinic acid hydrazide. *Cancer Res.* 26: 1473-1475(1966).
 416. Toth, B., and Shubik, P. Mammary tumor inhibition and lung adenoma induction by isonicotinic acid hydrazide. *Science* 152: 1376-1377(1966).
 417. Toth, B., Wallcave, L., Patil, K., Schmeltz, I., and Hoffmann, D. Induction of tumors in mice with the herbicide succinic acid 2,2-dimethylhydrazide. *Cancer Res.* 37: 3497-3500(1977).
 418. Toth, B., and Wilson, R. B. Blood vessel tumorigenesis by 1,2-dimethylhydrazine dihydrochloride (symmetrical). *Am. J. Pathol.* 64: 585-600(1971).
 419. Toth, K., Somfai-Relle, S., Sugar, J., and Bence, J. Carcinogenicity testing of herbicide 2,4,5-trichlorophenoxyethanol containing

- dioxin and of pure dioxin in Swiss mice. *Nature* 278: 548-549 (1979).
420. Tourkevitch, N. M., Gorevaia, A. N., Kounitsa, L. K., and Mao, L. S. Developpement des tumeurs des glandes mammaires chez les rats en cas de trouble de la regulation endocrine provoque par differentes actions. *Int. J. Cancer* 20: 1446-1449(1964).
421. Truhaut, R., Coquet, B., Fouillet, X., Galland, D., Guyot, D., Long, D., and Rouaud, J. L. Two-year oral toxicity and multi-generation studies in rats on two chemically modified maize starches. *Food Cosmet. Toxicol.* 17: 11-17(1979).
422. Truhaut, R., Ferrando, R., Faccini, J. M., and Monro, A. M. Negative results of carcinogenicity bioassay of methyl carbazate in rats: significance for the toxicological evaluation of carbadox. *Toxicology* 22: 219-221(1981).
423. Tsuda, H., Hananouchi, M., Tatematsu, M., Hirose, M., Hirao, K., Takahashi, M., and Ito, N. Tumorigenic effect of 3-amino-1H-1,2,4-triazole on rat thyroid. *J. Natl. Cancer Inst.* 57: 861-864(1976).
424. Tuchmann-Duplessis, H., and Mercier-Parot, L. Cancerologie. apparition de tumeurs malignes dans une lignee de rats "Wistar". *Academie des Sciences, Memoires et Communications des Membres et des Correspondants de l'Academie.* 254: 1535-1537 (1962).
425. Uchida, E., and Hirono, I. Effect of phenobarbital on the development of neoplastic lesions in the liver of cycasin-treated rats. *Cancer Res. Clin. Oncol.* 100: 231-238(1981).
426. Uematsu, K., and Miyaji, T. Induction of tumors in rats by oral administration of technical acid violet 6B. *J. Natl. Cancer Inst.* 51: 1337-1338(1973).
427. Ueno, I., and Hirono, I. Non-carcinogenic response to coumarin in Syrian golden hamsters. *Food Cosmet. Toxicol.* 19: 353-355 (1981).
428. Ulland, B. M., Weisburger, J. H., Weisburger, E. K., Rice, J. M., and Cypher, R. Brief communication: thyroid cancer in rats from ethylene thiourea intake. *J. Natl. Cancer Inst.* 49: 583-584(1972).
429. Ungerer, O., Eisenbrand, G., and Preussmann, R. Zur Reaktion von Nitrit mit Pestiziden. Bildung, chemische Eigenschaften und cancerogene Wirkung der *N*-Nitrosoverbindung des Herbizids *N*-Methyl-*N'*-(2-benzothiazolyl)-harnstoff(Benthiazuron). *Cancer Res. Clin. Oncol.* 81: 217-224(1974).
430. Uraguchi, K., Saito, M., Noguchi, Y., Takahashi, K., Enomoto, M., and Tatsuno, T. Chronic toxicity and carcinogenicity in mice of the purified mycotoxins, luteoskyrin and cyclochlorotine. *Food Cosmet. Toxicol.* 10: 193-207(1972).
431. Van Duuren, B. L., Goldschmidt, B. M., Katz, C., Seidman, I., and Paul, J. S. Carcinogenic activity of alkylating agents. *J. Natl. Cancer Inst.* 53: 695-700(1974).
432. Van Duuren, B. L., Goldschmidt, B. M., Loewengart, G., Smith, A. C., Melchionne, S., Seidman, I., and Roth, D. Carcinogenicity of halogenated olefinic and aliphatic hydrocarbons in mice. *J. Natl. Cancer Inst.* 63: 1433-1439(1979).
433. Van Duuren, B. L., Goldschmidt, B. M., and Seidman, I. Carcinogenic activity of di- and trifunctional alpha-chloro ethers and of 1,4-dichlorobutene-2 in ICR/Ha Swiss mice. *Cancer Res.* 35: 2553-2557(1975).
434. Van Duuren, B. L., Langseth, L., Orris, L., Teebor, G., Nelson, N., and Kuschner, M. Carcinogenicity of epoxides, lactones, and peroxy compounds. IV. Tumor response in epithelial and connective tissue in mice and rats. *J. Natl. Cancer Inst.* 37: 825-838(1966).
435. Van Esch, G. J., and Kroes, R. The induction of renal tumours by feeding basic lead acetate to mice and hamsters. *Brit. J. Cancer* 23: 765-771(1969).
436. Van Esch, G. J., and Kroes, R. Long-term toxicity studies of chlorpropham and propham in mice and hamsters. *Food Cosmet. Toxicol.* 10: 373-381(1972).
437. Van Esch, G. J., Van Genderen, H., and Vink, H. H. The induction of renal tumours by feeding of basic lead acetate to rats. *Brit. J. Cancer* 16: 289-297(1962).
438. Van Miller, J. P., Lalich, J. J., and Allen, J. R. Increased incidence of neoplasms in rats exposed to low levels of 2,3,7,8-tetrachlorodibenzo-*p*-dioxin. *Chemosphere* 10: 625-632(1977).
439. Vazquez-Lopez, E. The effects of thiourea on the development of spontaneous tumours on mice. *Brit. J. Cancer* 3: 401-414(1949).
440. Verschuuren, H. G., Kroes, R., and Van Esch, G. J. Toxicity studies on tetrasul. I. Acute, long-term and reproduction studies. *Toxicology* 1: 63-78(1973).
441. Vesselinovitch, S. D., Rao, K. V. N., and Mihailovich, N. Transplacental and lactational carcinogenesis by safrole. *Cancer Res.* 39: 4378-4380(1979).
442. Wakabayashi, K., Inagaki, T., Fujimoto, Y., and Fukuda, Y. Induction by degraded carrageenan of colorectal tumors in rats. *Cancer Lett.* 4: 171-176(1978).
443. Walker, A. I. T., Thorpe, E., and Stevenson, D. E. The toxicology of dieldrin (HEOD). I. Long-term oral toxicity studies in mice. *Food Cosmet. Toxicol.* 11: 415-432(1973).
444. Ward, J. M., Sontag, J. M., Weisburger, E. K., and Brown, C. A. Effect of lifetime exposure to aflatoxin B1 in rats. *J. Natl. Cancer Inst.* 55: 107-110(1975).
445. Waters, L. L. *o*-Aminoazotoluene as a carcinogenic agent. *Yale J. Biol. Med.* 10: 179-184(1978).
446. Weisburger, E. K. Bioassay program for carcinogenic hazards of cancer chemotherapeutic agents. *Cancer* 40: 1935-1949(1977).
447. Weisburger, E. K., Russfield, A. B., Homburger, F., Weisburger, J. H., Boger, E., Van Dongen, C. G., and Chu, K. Testing of twenty-one aromatic amines or derivatives for long-term toxicity or carcinogenicity. *J. Environ. Pathol. Toxicol.* 2: 325-356(1978).
448. Weisburger, E. K., Ulland, B. M., Nam, J., Gart, J. J., and Weisburger, J. H. Carcinogenicity tests of certain environmental and industrial chemicals. *J. Natl. Cancer Inst.* 67: 75-88(1981).
449. Weisburger, J. H., Yamamoto, R. S., Glass, R. M., and Frankel, H. H. Prevention by arginine glutamate of the carcinogenicity of acetamide in rats. *Toxicol. Appl. Pharmacol.* 14: 163-175(1969).
450. Wiessler, M., and Schmahl, D. Zur carcinogenen Wirkung von *N*-Nitroso-Verbindungen. 1. Mitteilung: *N*-Nitroso-3,6-dihydrooxazin-1,2 und *N*-Nitroso-tetrahydrooxazin-1,2. *Cancer Res. Clin. Oncol.* 79: 114-117 (1973).
451. Wiessler, M., and Schmahl, D. Zur carcinogenen Wirkung von *N*-Nitroso-Verbindungen. 2. Mitteilung: *S*(+) und *R*(-)-*N*-Nitroso-2-methyl-piperidin. *Cancer Res. Clin. Oncol.* 79: 118-122 (1973).
452. Willheim, R., and Ivy, A. C. A preliminary study concerning the possibility of dietary carcinogenesis. *Gastroenterology* 23: 1-19(1953).
453. Williams, M. H. C., and Bonser, G. M. Induction of hepatomas in rats and mice following the administration of auramine. *Brit. J. Cancer* 16: 87-91(1962).
454. Willis, J. The induction of malignant neoplasms in the thyroid gland of the rat. *J. Pathol.* 82: 23-27(1961).
455. Wislocki, P. G., Miller, E. C., Miller, J. A., McCoy, E. C., and Rosenkranz, H. S. Carcinogenic and mutagenic activities of safrole, 1'-hydroxysafrole, and some known or possible metabolites. *Cancer Res.* 37: 1883-1891(1977).
456. Wogan, G. N., Edwards, G. S., and Newberne, P. M. Structure-activity relationships in toxicity and carcinogenicity of aflatoxins and analogs. *Cancer Res.* 31: 1936-1942(1971).
457. Wogan, G. N., Paglialunga, S., and Newberne, P. M. Carcinogenic effects of low dietary levels of aflatoxin B1 in rats. *Food Cosmet. Toxicol.* 12: 681-685(1974).
458. Wong, L. C. K., Winston, J. M., Hong, C. B., and Plotnick, H. Carcinogenicity and toxicity of 1,2-dibromoethane in the rat. *Toxicol. Appl. Pharmacol.* 63: 155-165(1982).
459. Wood, M. Factors influencing the induction of tumours of the urinary bladder and liver by 2-acetylaminofluorene in the mouse. *Eur. J. Cancer* 5: 41-47(1969).
460. Wood, M., Flaks, A., and Clayson, D. B. The carcinogenic activity of dibutylnitrosamine in IF X C57 mice. *Eur. J. Cancer* 6: 433-440(1970).
461. Yamamoto, R. S., Korzis, J., and Weisburger, J. H. Chronic ethanol ingestion and the hepatocarcinogenicity of *N*-hydroxy-*N*-2-fluorenylacetamide. *Int. J. Cancer* 2: 337-343(1967).
462. Yamamoto, R. S., Richardson, H. L., Weisburger, E. K., Weisburger, J. H., Benjamin, T., and Bahner, C. T. Carcinogenicity of proposed cancer chemotherapeutic agents with stil-

- benearlynitrosamine structures. J. Natl. Cancer Inst. 51: 1313-1315(1973).
463. Yamamoto, R. S., Williams, G. M., Frankel, H. H., and Weisburger, J. H. 8-Hydroxyquinoline: chronic toxicity and inhibitory effect on the carcinogenicity of *N*-2-fluorenylaceta-
mide. Toxicol. Appl. Pharmacol. 19: 687-698(1971).
464. Yokoro, K., Kajihara, H., Kodama, Y., Nagao, K., Hamada, K., and Kinomura, A. Chronic toxicity of 2-(2-furyl)-3-(5-nitro-2-furyl)acrylamide (AF-2) in mice with special reference to carcinogenicity in the forestomach. Gann 68: 825-828(1977).
465. Yoshida, M., Numoto, S., and Otsuka, H. Histopathological changes induced in the urinary bladder and liver of female BALB/c mice treated simultaneously with 2-naphthylamine and cyclophosphamide. Gann 70: 645-652(1979).
466. Yoshimoto, S. Carcinogenicity and mutagenicity of tetrachloro-benzidine. Jikeikai Med. J. 25: 123-128(1978).
467. Zabezhinskii, M. A. Effectiveness of inhalation as a method of administration of atomized carcinogens. Byull. Eksp. Biol. Med. 69: 72-74(1970).

APPENDIX 15
BIBLIOGRAPHY
National Cancer Institute/National
Toxicology Program Technical Reports

All Technical Reports are entitled "Bioassay of [Chemical Name] for Possible Carcinogenicity"

CHEMICAL NAME	TECHNICAL REPORT NUMBER	PUBLICATION DATE
ACETOHEXAMIDE	50	1978
ACRONYCINE	49	1978
ALDICARB	136	1979
ALDRIN	21	1978
ALLYL CHLORIDE	73	1978
3-AMINO-4-ETHOXYACETANILIDE	112	1978
3-AMINO-9-ETHYLCARBAZOLE HYDROCHLORIDE	93	1978
1-AMINO-2-METHYLANTHRAQUINONE	111	1978
4-AMINO-2-NITROPHENOL	94	1978
2-AMINO-5-NITROTHIAZOLE	53	1978
2-AMINOANTHRAQUINONE	144	1978
ANILAZINE	104	1978
ANILINE HYDROCHLORIDE	130	1978
<i>o</i> -ANISIDINE HYDROCHLORIDE	89	1978
<i>p</i> -ANISIDINE HYDROCHLORIDE	116	1978
ANTHRANILIC ACID	36	1978
AROCLOR 1254	38	1978
5-AZACYTIDINE	42	1978
AZINPHOSMETHYL	69	1978
AZOBENZENE	154	1979
1H-BENZOTRIAZOLE	88	1978
beta-TGdR	57	1978
BIS(2-CHLORO-1-METHYLETHYL) ETHER	191	1979
BUTYLATED HYDROXYTOLUENE (BHT)	150	1979
C.I. VAT YELLOW 4	134	1979
CALCIUM CYANAMIDE	163	1979
CAPTAN	15	1977
CARBROMAL	173	1979
CHLORAMBEN	25	1977
CHLORDANE	8	1977
4-CHLORO- <i>m</i> -PHENYLENEDIAMINE	85	1978
4-CHLORO- <i>o</i> -PHENYLENEDIAMINE	63	1978
2-CHLORO- <i>p</i> -PHENYLENEDIAMINE SULFATE	113	1978
3-CHLORO- <i>p</i> -TOLUIDINE	145	1978
5-CHLORO- <i>o</i> -TOLUIDINE	187	1979
4-CHLORO- <i>o</i> -TOLUIDINE HYDROCHLORIDE	165	1979
4'-(CHLOROACETYL)-ACETANILIDE	177	1979
<i>p</i> -CHLOROANILINE	189	1979
CHLOROBENZILATE	75	1978
(2-CHLOROETHYL)TRIMETHYLAMMONIUM CHLORIDE (CCC)	158	1979
CHLOROFORM	A	1976
2-(CHLOROMETHYL)PYRIDINE HYDROCHLORIDE	178	1979
3-(CHLOROMETHYL)PYRIDINE HYDROCHLORIDE	95	1978

CHEMICAL NAME	TECHNICAL REPORT NUMBER	PUBLICATION DATE
CHLOROPICRIN	65	1978
CHLOROTHALONIL	41	1978
CHLORPROPAMIDE	45	1978
CLONITRALID	91	1978
COUMAPHOS	96	1979
<i>m</i> -CRESIDINE	105	1978
<i>p</i> -CRESIDINE	142	1979
CUPFERRON	100	1978
DAMINOZIDE	83	1978
DAPSONE	20	1977
<i>p,p'</i> -DDE	131	1978
DDT	131	1978
2,4-DIAMINOANISOLE SULFATE	84	1978
2,4-DIAMINOTOLUENE	162	1979
2,5-DIAMINOTOLUENE SULFATE	126	1978
DIARYLANILIDE YELLOW	30	1978
DIAZINON	137	1979
DIBENZO- <i>p</i> -DIOXIN	122	1979
DIBROMOCHLOROPROPANE	28	1978
DIBROMOCHLOROPROPANE (INHALATION)	206	1982
1,2-DIBROMOETHANE	86	1978
1,2-DIBROMOETHANE (INHALATION)	210	1982
DIBUTYLTIN DIACETATE	183	1979
2,7-DICHLORODIBENZO- <i>p</i> -DIOXIN (DCDD)	123	1979
1,1-DICHLOROETHANE	66	1978
1,2-DICHLOROETHANE	55	1978
DICHLORVOS	10	1977
DICOFOL	90	1978
<i>N,N'</i> -DICYCLOHEXYLTHIOUREA	56	1978
DIELDRIN	21	1978
DIELDRIN	22	1978
<i>N,N'</i> -DIETHYLTHIOUREA	149	1979
DIMETHOATE	4	1977
2,4-DIMETHOXYANILINE HYDROCHLORIDE	171	1979
3,3'-DIMETHOXYBENZIDINE-4,4'-DIISOCYANATE	128	1979
DIMETHYL TEREPHTHALATE	121	1979
2,4-DINITROTOLUENE	54	1978
1,4-DIOXANE	80	1978
DIOXATHION	125	1978
DIRECT BLACK 38	108	1978
DIRECT BLUE 6	108	1978
DIRECT BROWN 95	108	1978
2,5-DITHIOBIUREA	132	1979
EMETINE	43	1978
ENDOSULFAN	62	1978
ENDRIN	12	1979
ESTRADIOL MUSTARD	59	1978
ETHIONAMIDE	46	1978
<i>p,p'</i> -ETHYL-DDD	156	1979
ETHYL TELLURAC	152	1979
FENTHION	103	1979
FORMULATED FENAMINOSULF	101	1978
HEPTACHLOR	9	1977
HEXACHLOROETHANE	68	1978
HEXACHLOROPHENE	40	1978
HYDRAZOBENZENE	92	1978
ICRF-159	78	1978
3,3'-IMINOBIIS-1-PROPANOL DIMETHANESULFONATE (ESTER) HYDROCHLORIDE (IPD)	18	1978
IODOFORM	110	1978
ISOPHOSPHAMIDE	32	1977
KEPONE	B	1976
LASIOCARPINE	39	1978
LEAD DIMETHYLDITHIOCARBAMATE	151	1979

CHEMICAL NAME	TECHNICAL REPORT NUMBER	PUBLICATION DATE
LINDANE	14	1977
LITHOCHOLIC ACID	175	1979
MALAOXON	135	1979
MALATHION	24	1979
MALATHION	192	1979
dl-MENTHOL	98	1979
METHOXYCHLOR	35	1978
2-METHYL-1-NITROANTHRAQUINONE	29	1978
METHYL PARATHION	157	1979
4,4'-METHYLENEBIS(N,N-DIMETHYL)BENZENAMINE	186	1979
MEXACARBATE	147	1978
MICHLER'S KETONE	181	1979
A MIXTURE OF ASPIRIN, PHENACETIN, AND CAFFEINE	67	1978
MIXTURE OF 1,2,3,6,7,8-HEXACHLORODIBENZO- <i>p</i> -DIOXIN AND 1, 2,3,7,8,9-HEXACHLORODIBENZO- <i>p</i> -DIOXIN (GAVAGE)	198	1980
1,5-NAPHTHALENEDIAMINE	143	1978
N-(1-NAPHTHYL)ETHYLENEDIAMINE DIHYDROCHLORIDE	168	1979
NITHAZIDE	146	1979
NITRILOTRIACETIC ACID (NTA)	6	1977
NITRILOTRIACETIC ACID, TRISODIUM SALT, MONOHYDRATE (Na ₃ NTA H ₂ O)	6	1977
3-NITRO- <i>p</i> -ACETOPHENETIDE	133	1979
5-NITRO- <i>o</i> -ANISIDINE	127	1978
2-NITRO- <i>p</i> -PHENYLENEDIAMINE	169	1979
4-NITRO- <i>o</i> -PHENYLENEDIAMINE	180	1979
5-NITRO- <i>o</i> -TOLUIDINE	107	1978
5-NITROACENAPHTHENE	118	1978
4-NITROANTHRANILIC ACID	109	1978
6-NITROBENZIMIDAZOLE	117	1979
NITROFEN	26	1979
NITROFEN	184	1979
1-NITRONAPHTHALENE	64	1978
3-NITROPROPIONIC ACID	52	1978
N-NITROSODIPHENYLAMINE	164	1979
<i>p</i> -NITROSODIPHENYLAMINE	190	1979
PARATHION	70	1979
PENTACHLORONITROBENZENE	61	1978
PHENAZOPYRIDINE HYDROCHLORIDE	99	1978
PHENESTERIN	80	1978
PHENFORMIN	7	1977
PHENOXYBENZAMINE HYDROCHLORIDE	72	1978
1-PHENYL-3-METHYL-5-PYRAZOLONE	141	1978
N-PHENYL- <i>p</i> -PHENYLENEDIAMINE HYDROCHLORIDE	82	1978
1-PHENYL-2-THIOUREA	148	1978
<i>p</i> -PHENYLENEDIAMINE DIHYDROCHLORIDE	174	1979
PHOSPHAMIDON	16	1979
PHOTODIELDRIN	17	1977
PHTHALAMIDE	161	1979
PHTHALIC ANHYDRIDE	159	1979
PICLORAM	23	1978
PIPERONYL BUTOXIDE	120	1979
PIPERONYL SULFOXIDE	124	1979
PIVALOLACTONE	140	1978
PROCARBAZINE	19	1979
PROFLAVINE	5	1977
PYRAZINAMIDE	48	1978
PYRIMETHAMINE	77	1978
<i>p</i> -QUINONE DIOXIME	179	1979
RESERPINE	193	1980
SELENIUM SULFIDE	194	1980
SODIUM DIETHYLDITHIOCARBAMATE	172	1979
A SOLUTION OF beta-NITROSTYRENE AND STYRENE	170	1979
STYRENE	185	1979

CHEMICAL NAME	TECHNICAL REPORT NUMBER	PUBLICATION DATE
SULFALLATE	115	1978
SULFISOXAZOLE	138	1979
3-SULFOLENE	102	1978
TDE	131	1978
2,3,5,6-TETRACHLORO-4-NITROANISOLE	114	1978
2,3,7,8-TETRACHLORODIBENZO- <i>p</i> -DIOXIN IN OSBORNE-MENDEL RATS AND B6C3F1 MICE (GAVAGE STUDY)	209	1982
1,1,2,2-TETRACHLOROETHANE	27	1978
TETRACHLOROETHYLENE	13	1977
TETRACHLORVINPHOS	33	1978
TETRAETHYLTHIURAM DISULFIDE	166	1979
THIO-TEPA	58	1978
4,4'-THIODIANILINE	47	1978
TITANIUM DIOXIDE	97	1979
TOLAZAMIDE	51	1978
TOLBUTAMIDE	31	1977
<i>o</i> -TOLUIDINE HYDROCHLORIDE	153	1979
TOXAPHENE	37	1977
1,1,1-TRICHLOROETHANE	3	1977
1,1,2-TRICHLOROETHANE	74	1978
TRICHLOROETHYLENE	2	1976
TRICHLOROFLUOROMETHANE	106	1978
2,4,6-TRICHLOROPHENOL	155	1979
TRIFLURALIN	34	1978
2,4,5-TRIMETHYLANILINE	160	1979
TRIMETHYLPHOSPHATE	81	1978
TRIMETHYLTHIOUREA	129	1979
TRIPHENYLTIN HYDROXIDE	139	1978
TRIS(2,3-DIBROMOPROPYL)PHOSPHATE	76	1978
TRISODIUM ETHYLENEDIAMINETETRAACETATE TRIHYDRATE (EDTA)	11	1977
L-TRYPTOPHAN	71	1978

A - No Technical Report number assigned by NCI.

B - NCI (brief communication).